[{"article": ".\nThis takes a certain amount of time from the patient's symptom onset which prompted the 9-1-1 call.\nThis preliminary study showed that three months after stroke, 182 out of every 1,000 patients treated before arriving at hospital were less disabled, including 58 patients who had zero disability, compared to people who received treatment after reaching the hospital.\nThat is why patients need a CT scan to confirm the type of stroke before receiving tPA.\nBut tPA is not indicated and could hurt a patient's chances if they are having a hemorrhagic stroke, in which a blood vessel ruptures.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does raise risks in a meaningful way. It says:\n\u201cBut tPA is not indicated and could hurt a patient\u2019s chances if they are having a hemorrhagic stroke, in which a blood vessel ruptures. That is why patients need a CT scan to confirm the type of stroke before receiving tPA.\u201d\nHowever,\u00a0that statement could have gone further and noted that some patients with a negative CT scan may have a hemorrhage after getting tPA.  ", "answer": 1}, {"article": "It would be, they report in the Journal of the American Medical Association.\nTreating more Americans with statins is worth the small risk of side-effects and would be cost-effective, a new report finds.\nAnd if even more people were given statins -- if they were given to people with a 3 percent risk of developing heart disease over 10 years -\u2013 another 160,000 heart attacks and strokes would be prevented, they estimated.\nOne of the recommendations was that statins should be prescribed to anyone with a 7.5 percent risk or higher of developing heart disease over the next 10 years.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d Dr. Philip Greenland, an expert in preventive medicine at Northwestern University and a senior editor of the journal, and Dr. Michael Lauer of the National Heart, Lung and Blood Institute wrote in a commentary.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "NBC did a better job than the Times in answering the question about risks. NBC wrote that statins \u201ccan damage muscle in 5 to 15 percent of patients. In 2012, the Food and Drug Administration\u00a0updated labeling on statins to\u00a0include warnings about confusion and memory loss, elevated blood sugar leading to Type 2 diabetes, and muscle weakness.\u201d This is a nice addition to the overall coverage of the new statin studies and a step we wish more reporters had taken.", "answer": 1}, {"article": "\u201cA lot of preparations have added so many things that they aren\u2019t releasing zinc properly,\u201d said Dr. Ananda Prasad, professor in the department of oncology at Wayne State University School of Medicine in Detroit and an early pioneer of research into zinc as an essential mineral.\nThe Cochrane report did not review any studies of nasal zinc products.\nThe authors declined to make recommendations about the optimal dose, formulation or duration of zinc use, saying that more work was needed before they could make recommendations.\nA sweeping new review of the medical research on zinc shows that sniffing, sneezing, coughing and stuffy-headed cold sufferers finally have a better option than just tissue and chicken soup.\nIn some of the cited studies, the benefits of zinc were significant.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pointed out that nasal zinc products, associated with loss of smell, were not evaluated in the Cochrane review and it\u00a0quotes one of the authors of the study suggesting that the potential harms of zinc products are limited to a bad taste and some nausea. However, the full listing includes constipation, diarrhea, abdominal pain, dry mouth and oral irritation. \u00a0\u00a0 \n\u00a0", "answer": 0}, {"article": "[2] Quotes direct from author and cannot be found in text of Article.\n\"We have identified a cardiac troponin concentration (less than 5 nanograms per deciliter; <5 ng/L) below which patients are at very low risk of heart attack either during the admission or in the ensuing 30 days.\nThis study shows that low plasma cardiac troponin concentrations at presentation identify up to two-thirds of patients who are at very low risk of heart attack and could be safely discharged from the Emergency Department.\nThe test used in this study is more sensitive than the standard version and can detect far lower levels of troponin in the blood.\nUntil now, whether new high-sensitivity cardiac troponin tests could identify very low-risk patients who may be suitable for immediate and safe discharge from the emergency department was unknown.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms of this test \u2014 discharging a patient who may be having a heart attack and be at risk of dying \u2014 can only be adequately assessed in prospective evaluations using this new test as part of routine care. The release doesn\u2019t adequately address this or describe what might happen if the test is wrong. We also think that the release could have done a better job of explaining that this new test is only one part of the assessment of patients presenting with chest pain. Other factors that are likely to be important that could have been mentioned from the paper include changes in the EKG (electrical test of the heart) that is also part of standard care. In addition, the duration of symptoms is also important. For patients who have had pain for less than 2 hours, the test may not be as effective.", "answer": 0}, {"article": "Scientists have used a form of stem-cell therapy to improve survival rates for the most severely sick lupus patients, a group that usually has no remaining treatment options.\n\nLupus is an autoimmune disease that attacks an individual's own organs, causing symptoms that range from swollen joints and skin rashes to severe damage to kidneys, lungs and other parts of the body.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects of the \ntreatment were not mentioned", "answer": 0}, {"article": "\"This is the first study looking at women who have failed so many other treatments,\" Krop tells WebMD.\nAll the women, who had breast tumors for an average of three years, had cancer that had metastasized, or spread to other parts of the body.\nDec. 15, 2009 (San Antonio) -- A new targeted cancer drug has been shown to shrink tumors in women with metastatic breast cancer after an average of seven other drugs, including Herceptin, failed.\nIn another 12%, tumors stopped growing for at least six months.\nTumors shrank in one-third of women with metastatic breast cancer given T-DM1, says Ian Krop, MD, of the Dana-Farber Cancer Institute in Boston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does mention that all the women experienced side effects. It left out some potential harms and didn\u2019t quantify any specific adverse events, simply noting that side effects were \"typically the fatigue and nausea often seen with chemotherapy.\" The Genentech press release mentions and quantifies severe adverse events that were not mentioned here, including low platelet levels in about 6% of patients.\u00a0\nThe article does describe a death that occurred during the trial, although see the \"sources\" criterion for a comment about the outside source that provided the interpretation. Especially because it doesn\u2019t present how many women were enrolled in the trial, the article needs a truly outside expert\u2019s interpretation of this death. In general, more discussion and quantification of the harms would have matched the quantified benefits.\nAlso not noted are the potential risks associated with Herceptin, a component of T-DM1. For instance, this drug is associated with\u00a0cardiac toxicity;\u00a0while the risk of heart failure may at present not be a dominant concern in the treatment of metastatic breast cancer, the risk could become more relevant if T-DM1 were truly able to increase lifespan. Other\u00a0black box warnings\u00a0of Herception not mentioned include the potential for serious infusion reactions, sometimes fatal.", "answer": 0}, {"article": "Dr. David Rosenstreich, director of the division of allergy and immunology at Montefiore Medical Center in New York City, added: \"An objective and fast test for diagnosing asthma would be helpful, and this test seems to be a non-invasive way of sampling for the underlying problem.\nWhen combined with another test, called the fractional exhaled nitric oxide (FENO) test, the electronic nose did an even better job at detecting asthma, the study found.\nThose with asthma had a history of allergies, and none had been treated with corticosteroids for at least four weeks prior to the start of the study.\nThe electronic nose was able to correctly differentiate healthy people from those with physician-diagnosed asthma in 87.5 percent of the cases.\nWEDNESDAY, April 7, 2010 (HealthDay News) -- Using an artificial breath-sensor system dubbed the \"electronic nose,\" Italian researchers were able to spot more cases of asthma than with traditional diagnostic tools.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although there appears to be little risk of harm from the new\u00a0testing procedure itself, the\u00a0story makes no mention of the\u00a0downside that can accompany\u00a0a faulty diagnosis\u2013whether a false positive or negative. False positive tests (diagnosing asthma when the patient has another disease) and false negatives (failing to diagnose asthma) can have significant consequences.\u00a0A brief comment on the potential harms associated with a faulty test would have been helpful.", "answer": 0}, {"article": "The way it works: A doctor draws a vial of your blood and separates it into its key components, the red blood cells, the clear serum and the platelets. The physician then adds vitamins and amino acids to the mix, and the enriched serum is injected into your face.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms. ", "answer": 0}, {"article": "To view the abstract or the published article, visit http://www.lipidjournal.com/article/S1933-2874(15)00427-4/abstract.\nResearchers found avocado consumption (1 to 1.5 per day) significantly reduced total cholesterol (TC), \"bad\" low density lipoprotein cholesterol (LDL-C) and triglycerides (TG) when they were substituted for sources of saturated fat.\nAccording to the recently released 2015-2020 Dietary Guidelines for Americans, small shifts in food choices can make a big difference; including a shift from solid fats to oils, like the oil in fresh avocados.\n\"Fresh avocado, as part of a balanced diet, and as a cholesterol-free substitute for solid fats, can help be part of the solution for maintaining normal cholesterol levels,\" says Nikki Ford, PhD, Director of Nutrition, Hass Avocado Board.\nAdditionally, avocado consumption did not impact \"good\" high density lipoprotein cholesterol (HDL).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It could have been noted that adding an avocado or two a day to one\u2019s diet would also add to daily caloric intake. An average avocado has around 250 calories and 21 grams (about one-third of the recommended daily allowance) of fat.\u00a0Additional caloric intake can result in weight gain and stored fat, which in turn impacts metabolic markers (such as increased insulin production and inflammatory markers) and cardiovascular risk.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070805/13folate.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discussed the increase in colorectal cancer incidence that has been observed.", "answer": 1}, {"article": "Medical researchers are well aware that the dummy pills used in clinical trials often provide as much relief as the actual drugs being tested. This is what's known as the placebo effect, and it's quite common in people with Parkinson's, a movement disorder that causes tremors, stiffness and balance problems. A 2008 meta-analysis found that placebos used in clinical trials of Parkinson's treatments improved symptoms by an average of 16%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms. From a bioethics standpoint, there is concern that\u00a0the use of a placebo without the patient\u2019s knowledge may undermine trust between the physician and patient, thereby leading to medical harm. (More background on these concerns in this Science-Based Medicine post.) In addition, patients receiving placebo treatments in clinical studies commonly complain of adverse drug reactions. The story also could have discussed the potential for harm resulting from the participants\u2019 interruption of active drug therapy for the study.", "answer": 0}, {"article": "\u201cWe want to alleviate the suffering and get them back to their life,\u201d he said.\nIt\u2019s also a drug of abuse, at much higher doses than those used in Zarate\u2019s research; while patients in the current study received about 50 milligrams during a 40-minute period, a dose too low to induce anesthesia, recreational users of ketamine, known as \u201cSpecial K,\u201d may take hundreds of milligrams per week.\nBut, according to Zarate, more research is needed on how to use the drug in the safest and most effective way.\nRight now, medications available for treating either major depression or bipolar illness can take weeks, or even months, to work, notes Dr. Carlos A. Zarate Jr. of the National Institutes of Health in Bethesda, Maryland, one of the researchers on the study.\nAnd as a person waits for their medications to kick in, he added, they will continue to have difficulty working and coping with social and family life; they may even be having thoughts of suicide.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify the potential harms. In fact, it minimizes the potential harms by saying there were no \"serious adverse events,\" while listing side effects that\u00a0included anxiety, feeling woozy or loopy, headache, and dissociative symptoms, meaning a temporary sense of disconnection from reality.\" People on ketamine may have a different perception of what is serious. ", "answer": 0}, {"article": "Melanoma is one of the most common forms of cancer and the most serious type of skin cancer.\n\u201cThis test integrates anatomic pathology and analytical chemistry in a very useful and meaningful way.\u201d\n\nThe finding suggests that IMS analysis, based on proteomic signatures, may improve both diagnosis and prediction of outcomes for patients with ambiguous moles, the researchers said.\nThe test, which analyzes proteins in cells, could provide more reliable results for clinicians with patients who might be at risk for this deadly cancer.\nEarly diagnosis of melanoma is critical to cure and long term survival.\n\u200b\u200b\u200b\u200bCalifornia Skin Institute \u2014 A recently developed test for assessing suspicious moles for melanoma is more accurate than standard analyses, according to Dr. Rossitza Lazova, a former Yale investigator.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention potential harms. Like any diagnostic or screening test, IMS carries a risk of a false negative and false-positive tests that could lead to a false sense of security or anxiety/unnecessary treatment. In addition, a biopsy is required to test\u00a0a tissue sample (for both a standard evaluation and IMS). Though generally safe, a biopsy can result in scarring, bleeding, infection or allergic reaction to a topical antibiotic. The release could have mentioned these potential harms.", "answer": 0}, {"article": "On weekends, even though hospitals have lower levels of staffing, stroke patients arriving at the hospital may have greater access to equipment and doctors who might be busier during the week than they are on weekends.\nPutting those figures together could suggest that the clot-buster tPA wasn\u2019t doing much good.\nOverall, Kazley added, this study offers \u201cgood news that indicates that the quality of care is similar regardless of when patients present at the hospital for treatment.\n(See Reuters Health report, March 8, 2007).\n(See Reuters Health report, March 17, 2007).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story made no mention of the serious risks associated with tPA therapy.", "answer": 0}, {"article": "The observation was based on a national study launched at 118 hospitals across the United States.\nMore than half of those women who had been categorized as mastectomy-only patients were also able to go the lumpectomy route and experience a good outcome.\nThe most common form of breast cancer, ER+ accounts for about three-quarters of all breast cancer cases in the United States, the authors noted.\nAfter the four months of estrogen-lowering therapy, the research team found that 82 percent of those women in the marginal group were, in fact, able to undergo successful breast-conservation surgery.\n\"These results will encourage a change in practice across the country so that more women can benefit from the currently underutilized approach of administering estrogen-lowering agents before surgery.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no\u00a0discussion of any potential harms from\u00a0aromatase inhibitors.\u00a0These drugs can cause joint pain and sexual problems which lead many women to discontinue using them.\u00a0There also is concern that these estrogen-lowering drugs may decrease bone density and increase the risk of osteoporotic fractures.\u00a0This is an outcome\u00a0that\u00a0can\u00a0have severe health consequences for older women.", "answer": 0}, {"article": "Toenail fungus causes nails to become thick, yellow and brittle in a way that looks pretty ugly and can be painful.\nIn this case, there is a chance.\u201d\n\nEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\n\u201cI\u2019ve had patients come in who have had laser procedures and not seen long-term success.\u201d\n\nFirestone also says that over-the-counter antifungal nail creams and ointments rarely work because they can\u2019t penetrate the nail root.\nResearch done by PinPointe, which is based in Chico, Calif., identified more than 100 organisms, including fungi, yeast, mold and bacteria, that work together to cause toenail fungus.\nThe treatment, in which the podiatrist aims a laser beam at the patient\u2019s toenails to kill the organisms that cause the fungus, costs about $1,000 and is not covered by insurance because it is considered an aesthetic procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides absolutely no information on harms or potential harms of the laser approach. While the risk may be low, lasers do present risks. Instead, the story says, \u201cKominsky has treated 400 to 500 patients with the PinPointe laser. Compared with oral medication, he says, \u2018the odds of success are better with the laser; plus, there\u2019s no side effects.'\u201d A\u00a0doctor selling laser treatments should not be allowed to make these kinds of claims without proof. The folks at Novartis have every right to be miffed that they were held to a higher standard. We did appreciate that the story mentioned reinfection. \u201cEven John Strisower, the founder of PinPointe USA, says patients should expect at least a minimal reinfection within five years after laser treatment.\u201d", "answer": 0}, {"article": "But that's changing.\nWith the hip, however, doctors using arthroscopes discovered a host of conditions, including labrum tears and FAI, that had not been recognized.\nLeft untreated, labrum tears can lead to arthritis.\nThese tears are not detectable by X-ray, and though they usually can be seen by MRI, even those images can sometimes be inconclusive.\nIn the past 10 to 15 years, doctors have discovered one specific cause of hip pain: a tear in the acetabular labrum, a condition in which the cartilage that lines the hip socket is damaged.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe news story fails to mention potential harms of hip arthroscopy. A recent review suggests the rate of complications for all indications is \u201cgenerally less than 1.5%.\u201d (Clin Orthop Rel Res 2009;467:760-8) Various sources suggest complications include: scuffing of the articular cartilage and chondral surface from instrument breakage and inadequate distraction (separation of the femoral head from the hip socket); iatrogenic dislocation; nerve damage (sciatic, superior gluteal, lateral femorocutaneous); removal of too much labral tissue; removal of too much bone, thus weakening the bone and causing a fracture; damaging the blood supply to the femoral head, leading to avascular necrosis; temporary numbness of the perineum or foot (a distraction neuropraxia); and scrotal necrosis. Although an expert says that the procedure is meant to prevent future arthritis, this is not quantified; without good data on people who did not have the procedure, it is conceivable that arthroscopy could promote arthritis.", "answer": 0}, {"article": "Almost everyone suffering from back pain says something like, \"I want to feel better, I want to play golf again, or I want to be able to play baseball with my grandkids,\" anesthesiologist and lead author Steve P. Cohen tells Shots.\nPatients don't care much about the finer points of diagnostic accuracy.\nCoping with an aching back isn't easy.\nBut some pain experts defend the value of the diagnostic tests.\nDoctors may not change their approach anytime soon, however.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of harms incurred or avoided. ", "answer": 0}, {"article": "\"We know the earlier we begin interventions, the greater the likelihood of better outcome,\" he said.\nThere are important limitations to the study, Adesman said.\n\"There are questions about how this varies across the severity of autism.\n\"It is possible that children who have delayed language but not autism would also show the same pattern.\nTUESDAY, May 31, 2011 (HealthDay News) -- At the moment, a diagnosis of autism is based on subjective evaluations, but a new way of using MRI might be an objective way of spotting the disorder, Columbia University researchers report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms quantified or even mentioned, which is disappointing. The harms from an inaccurate diagnosis of autism or any other disorder can be real and devastating.", "answer": 0}, {"article": "He studied the extract puerarin.\nMay 17, 2012 -- An extract from the Chinese herb kudzu may help drinkers cut down on drinking, according to a new pilot study.\nThe study is published in Drug and Alcohol Dependence.\n\"It didn't stop the drinking,\" says researcher David M. Penetar, PhD, assistant professor of psychology at McLean Hospital and Harvard Medical School.\n\"They still drank, but they drank less.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were \u201cno serious side effects\u201d in the study, but one week of treatment in 10 people isn\u2019t going to provide an adequate picture of the potential harms \u2014 a shortcoming the story should have alerted readers to. In addition, we were a little concerned by the notion that this supplement \u201cmay deliver alcohol to the brain\u2019s reward center faster. So you get an effect sooner; therefore, you don\u2019t drink as much.\u201d Getting people drunker faster may well cut down on the amount of alcohol they consume in a night, but it might also result in unintended consequences like an increase in impaired driving or other risky behaviors. We think the story was too quick to give a free pass on safety without exploring some of these concerns.\nThe nature of a daily habit like drinking demands long-term treatment, thus increasing the time that side effect incidence could accumulate.", "answer": 0}, {"article": "scans on 991 people ages 50 to 90.\nFor example, they wrote, if a scan showed advanced disk deterioration, the report should say, \u201cRoughly 40 percent of patients with this finding do not have back pain so the finding may be unrelated.\u201d\n\nIt is an idea that only would work for back pain, because that is the one area where radiologists have enough data.\nHowever, Dr. Modic said, there was one effect of being told \u2014 patients felt worse about themselves when they knew they had a bulging disk.\nBut in many cases it is just not known whether what is seen on a scan is the cause of the pain.\nIt\u2019s one of only two body parts \u2014 the other is the back \u2014 where there are good data on abnormalities that turn up in people who feel just fine, indicating that the abnormalities may not be so abnormal after all.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions unnecessary surgery\u00a0as the most serious\u00a0harm of scanning, as well as needless worry and potentially, feeling worse about the diagnosis. The story could have mentioned more common problems with MRI (claustrophobia) and CT scans (radiation exposure), but the real concern is that the imaging test makes the patient and physician more likely to chose an invasive treatment such as surgery.", "answer": 1}, {"article": "Researchers conducted a randomized, double-blind, placebo-controlled study of 40 postmenopausal women ages 45 to 65 with high blood pressure.\nBut, they say, eating blueberries in larger amounts or for longer periods could increase the effect.\nThe lead author, Sarah A. Johnson, a postdoctoral researcher at Florida State University, said she saw no reason for people to radically change their diet, but that if they are not eating blueberries, they might want to try them.\nThe improvement, the scientists write, was moderate compared with that of blood pressure medicines.\nThere were no significant changes in the placebo group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention or discuss the potential harms of consuming a daily portion of blueberries or blueberry product. But since it\u2019s difficult to imagine what these would be, we\u2019ll rule this not applicable.", "answer": 2}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The study itself didn\u2019t include any discussion of potential harms that could be attributable to \u2018Mediterranean diet\u2019 adherence.", "answer": 2}, {"article": "Co-authors are: Leslie Donato, Ph.D.; Sandra Bryant; Grant Spears; Peter Berger, M.D.\nThe study found that individuals with the highest levels of blood ceramides were found to have a 3- to 4-times greater risk of having a cardiovascular event compared with those with the lowest ceramide score, regardless of their LDL cholesterol level or the presence of a blockage in the heart\u2019s arteries.\nBut when researchers examined cardiovascular disease in this population by ceramide scores, people with the highest levels of ceramides were four times more likely to have an event compared with those with the lowest (7.8 vs. 2.2 percent, respectively).\nEven individuals with normal levels of low-density lipoprotein (LDL), known as the so-called \u201cbad\u201d cholesterol, but still at risk, seem to be identified, according to Mayo Clinic research being presented at the American College of Cardiology\u2019s 66th Annual Scientific Session.\nBut the risk of having an event became higher as ceramide level increased; for each 1-point increase in the ceramide risk score, the risk rose by 9 percent.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Presumably, there is little risk to individuals from the blood test itself. However, it\u2019s important to note that among individuals with low LDL and the highest levels of blood ceramides, 83.6% did not experience cardiovascular disease. This raises the concern that use of the blood ceramide test might increase overtreatment, depending on what a patient\u2019s doctor recommends if the test reveals high ceramide levels. It is not clear what, if anything, individuals can do to reduce their blood ceramide levels. While there\u2019s certainly no harm in encouraging people to change their lifestyles to reduce their risk of heart disease and stroke, some health experts now argue that statins, often prescribed to decrease patients\u2019 cholesterol levels, might do more harm than good for individuals at lower risk of heart disease.", "answer": 0}, {"article": "Individuals with panic chronically hyperventilate, even when not experiencing a panic attack.\nFreespira is commercially available throughout the U.S. To learn more, visit http://www.freespira.com or contact info@pahealthsciences.com.\nFreespira is both easy to use and effective.\nDANVILLE, Calif., April 11, 2018 /PRNewswire/ -- Palo Alto Health Sciences, Inc. (PAHS), developer of the drug-free Freespira\u00ae treatment for panic attacks and other symptoms of panic disorder, today announced that another study has demonstrated clinically significant symptom improvement, with 80% of patients panic attack free one year after treatment.\nAbout Freespira\n\nFreespira is an FDA-cleared, drug-free, four-week at-home treatment for panic attacks and other panic symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms.\n(For a tutorial on how unsafe medical devices have been allowed into the marketplace, see our toolkit article.)", "answer": 0}, {"article": "More than six million children in the United States have asthma, according to the Centers for Disease Control and Prevention, as do more than 330 million children and adults worldwide, according to the Global Asthma Network.\nThe author of that editorial, Dr. Christopher E. Ramsden, from the National Institutes of Health, said the findings would help doctors develop a \u201cprecision medicine\u201d approach in which fish-oil treatment could be tailored to women who are most likely to benefit.\nDr. Bisgaard said it was not possible to tell from the study whether pregnant women could benefit from simply eating more fish.\nAn editorial in the same journal by an expert who was not part of the study praised the research, saying it was well designed and carefully performed.\nThe scientists bought fish oil from a company that makes it, but they said the company had no role in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that no adverse events were associated with the intervention. However, the harms assessed by the researchers were things like maternal or infant death, emergency caesarean delivery, and preterm birth. They didn\u2019t assess (and the story didn\u2019t mention) less serious harms like fishy taste, nausea, belching, and heartburn that are commonly associated with fish oil capsules and which might make this regimen burdensome for pregnant women.\nMoreover, it would have been useful if the story had also noted that the reason researchers want to replicate the results in a larger group of women is to make sure these very high doses of fish oil are indeed safe.", "answer": 0}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nFagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\n\u201cThe results were pretty encouraging and there is great potential here,\u201d Fagerholm said in a telephone interview.\nThe biosynthetic corneas also became sensitive to touch and the treated eyes began producing normal tears, the researchers said.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The last sentence of the story says, \"Fagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\" This is about as much space as any of the stories devoted to the harms. It would have been nice to see a little more detail here, but, if after two years there were not any side effects, this is a satisfactory quantification.", "answer": 1}, {"article": "\u201cFor moving your system to a later time, such as would be necessary when traveling East-to-West, light during the first few hours of the night is ideal,\u201d he said.\nMistiming light therapy can make jet lag worse, cautioned Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland, who was not part of the new study.\nA series of flashes similar to a camera flash delivered every 10 seconds over a 60-minute period delayed sleepiness by two hours, compared to a 36-minute delay for those exposed to continuous light for an hour, according to the results published in the Journal of Clinical Investigation.\nThe study included 39 people, 31 of whom were exposed to a series of two-millisecond light flashes with changing intervals while sleeping, and eight of whom were exposed to 60 minutes of continuous bright light.\nIn experiments, the technique \u2013 which is based on the way non-visual parts of the brain respond to light \u2013 was much more effective than sustained bright light similar to that from devices sometimes used to combat sleep disorders or seasonal depression.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report indicated there was no harm involved: \u00a0\u201cIn a previous study, the short flashes of light at night did not interrupt sleep or reduce its quality.\u201d This report also indicated helpful additional information from an outside observer, Anna Wirz-Justice, professor emeritus at the Center for Chronobiology at the University of Basel in Switzerland, who was not part of the new study, who said: \u201cMistiming light therapy can make jet lag worse.\u201d", "answer": 1}, {"article": "Androgens, including testosterone, are thought to contribute to the growth and development of prostate cancer.\nThe results were especially dramatic for men who had prostate-specific antigen (PSA) levels above .07 ng/ml when they started the trial.\nThe effect of the newer-generation medications, gonadotropin-releasing hormones, is similar to bicalutamide, according to other trials.\nThe specific ADT drug used in the study, bicalutamide, has since been largely replaced by another kind of drug that decreases the amount of testosterone the body produces.\nA commonly used drug could dramatically increase survival rates for men who have to fight prostate cancer twice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "STAT does not mention any negative side effects (including hot flashes and sexual problems).", "answer": 0}, {"article": "Wisdom teeth, also called the third molars, are four teeth that grow at the very back of each corner of the mouth.\nThe question comes down to which side of the fence medical professionals fall on\n\nIt's worth noting that oral surgeons make a good chunk of their paychecks by removing wisdom teeth, so there is a financial incentive involved.\nThat's because the tooth is easier to remove if its roots aren't fully developed.\n(The same thing happened with tonsils, which doctors no longer remove just to get rid of the chance of infection later on.)\nSo the question comes down to which side of the fence medical professionals fall on, and what works best for their patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks associated with wisdom tooth extraction are clearly spelled out in the story. These include \u201cpoor wound healing, infection, pain, and uncontrolled bleeding\u201d along with nerve injury which can, in rare cases, leave people with permanent facial numbness. As noted above, some quantification of these results would have been ideal.", "answer": 1}, {"article": "\"Additional research will be needed to fully answer this question in the future.\"\nThe new drug, while promising, is of concern because of its potential to lower blood sodium levels in the elderly, one doctor said.\nIn the United States there's no approved drug to treat the problem, the study authors said.\nGriebling said the American Geriatrics Society includes desmopressin in the Beers Criteria for potentially inappropriate medications for older adults, primarily because of concerns about resulting low blood sodium levels.\nKnown as SER-120, the nasal spray contains desmopressin, a low-dose synthetic version of the naturally occurring hormone vasopressin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes risks of\u00a0using this drug in the elderly, and mentions that it is already on a list of drugs not to be given to the elderly.\u00a0 The story also discusses incidences of low blood sodium levels that sometimes occur with this drug.", "answer": 1}, {"article": "As the ovaries curb production of the hormones estrogen and progesterone in the years leading up to menopause and afterward, women can experience symptoms ranging from irregular periods and vaginal dryness to mood swings and insomnia.\nTaking a combination of estrogen and progestin is associated with an increased risk of breast cancer, but advances in screening and treatment since the WHI started now mean these tumors are unlikely to be fatal, McNeil said by email.\nStill, the current study should ease concerns raised by earlier results from the WHI trials that an increased risk of breast cancer or heart attacks might translate into higher long-term mortality rates, said Dr. Melissa McNeil, author of an accompanying editorial and a women\u2019s health researcher at the University of Pittsburgh.\nWith additional years of follow-up, it also appears that the increased heart attack risk associated with HRT in the initial results from the WHI trials is limited to older women, McNeil added.\nFor women who started hormones in their 60s or 70s, however, there wasn\u2019t a meaningful difference in death rates according to whether they got the treatment or a placebo during the initial years of the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of outlining the complicated history of findings from hormone replacement studies, and the harms and risks, and uses numbers to explain the risks.\nThere is great nuance in the findings, which can be interpreted differently for women of different ages seeking HRT. Women bring different life risks of cardiovascular disease or breast cancer with them into any discussion of HRT.\nThe conclusion quoted in the story may be less-than-reassuring, but is here:\n\u201cHormone therapy has been in and out of favor \u2013 first it was good for all menopausal women, then it was dangerous for all women,\u201d McNeil said. \u201cThe take-home message now is that for the right patient, hormone therapy is safe and effective.\u201d", "answer": 1}, {"article": "Using the gentler technique, called laparoscopy, a surgeon makes small cuts in the abdomen before inserting a tiny camera inside, then performing the operation by watching a television monitor.\nYet again, the patients who had laparoscopy fared much better than those who had conventional surgery.\nOn average, it cost $17,594, compared to $12,125 for the laparoscopic surgery.\n\u201cSubstantial savings could be seen if open surgery is done in a laparoscopic fashion.\u201d\n\nBut he acknowledged that the study has major limitations.\n\u201cIn healthy individuals, the death rate is very (small) for all groups of patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job comparing death rate, readmission rate and hospital stays between the two procedures.", "answer": 1}, {"article": "While many commercial health plans provide comprehensive coverage for home infusion services, Medicare has limited reimbursement for this type of care, and Congress is discussing how to implement a comprehensive home infusion benefit for Medicare beneficiaries.\nThe research showed that patients receiving intravenous therapy at home had as good or better clinical outcomes as those patients who received the same therapy in a traditional health care setting.\nCare is administered by experienced infusion nurses and pharmacists, and in addition, patients receive additional disease management education and support throughout their treatment.\n\"In fact, our patients report high satisfaction with our Coram home infusion services, citing convenience and comfort as key elements that improved their overall experience.\"\nDespite this, clinical outcomes and quality of care have not previously been systematically evaluated.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The word \u201charms\u201d does not appear in the news release. During intravenous infusions there are complications that may arise. The release does not mention harm, even to dismiss the probability as rare.", "answer": 0}, {"article": "Screening patients for heart disease with a heart-imaging test prompted greater follow-up care but had little to no effect on the number of heart attacks and other cardiovascular events in those patients, a new study found.\n\nResearchers at Johns Hopkins Hospital in Baltimore led the study, which was published online Monday in the Archives of Internal Medicine.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The CCTA test was reported as a non-invasive alternative to angiography. \u00a0But there was no mention of the harms associated with this test which includes radiation exposure, which is higher than that associated with angiography; the potential for allergic reaction to the material injected to allow the vessels to be seen; and the potential for there to be harms from following up on something seen on the CCTA which turns out to be nothing.\n(A sad, but fascinating case report can be found in the Archives of Internal Medicine Dec 14, 2010)", "answer": 0}, {"article": "For men with advanced prostate cancer, the news for decades has been mostly bleak. Until recently, only two treatments had been shown to prolong survival.\n\nResearchers reported Monday that the drug abiraterone, being developed by Johnson & Johnson, extended survival by an average of 3.9 months among men with cancer that has spread beyond the prostate and for whom other treatments have failed. Among men, prostate cancer is the second-leading cancer killer, behind only lung cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nSome harms were mentioned, but oddly the story then referred to this hormone therapy not causing harms associated with chemotherapy. The story does not mention other harms linked to hormone therapy, such as osteoporosis, fractures, diabetes, and heart disease.  We aren\u2019t provided any information on these outcomes or cause of death. Since these results were presented at a medical meeting (which means it is likely the full data have not been reviewed by independent experts) and because the trial was halted early, there is much that remains unknown.", "answer": 0}, {"article": "Gluck et al.\nObesity 4 Nov.\n\nNIDDK Research Clinical Psychologist Marci Gluck, Ph.D., is available to comment on this study.\nBut the five people who got inactive stimulation on the first visit, and active tDCS at the brain target on the second visit, consumed an average of 700 fewer calories and lost an average of 0.8 pounds on the second visit.\nNext, the researchers will compare a group getting only active tDCS with a separate group getting only sham stimulation.\nThen for three days, they unknowingly received either active or sham (fake) transcranial direct current stimulation, or tDCS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not contain a single sentence regarding whether there might be harms if this technique were expanded and used in a wider setting as a treatment for obesity. We wondered: Would people get used to the stimulation if it were used on a long-term basis and stop showing the \u201cbenefit?\u201d Are there other cognitive abilities that are in any way muffled by the stimulation? The release should at least acknowledge that there could be potential harms uncovered in further study. The limitations section of the paper itself even states that is was not entirely clear that the treatment reached the targeted brain areas and not other areas. We find this concerning if not a bit alarming.", "answer": 0}, {"article": "\"It's clearly muddying the waters,\" he said.\nMaybe Not and Here's Why, suggested that with better treatment and increased awareness of the importance of seeking care for breast abnormalities, screening mammography may be less important now than in the past.\nBut Kopans noted that mammography is still the only test that has been proven to reduce the death rate from breast cancer and that this study should not divert attention away from that fact.\nWEDNESDAY, Sept. 22, 2010 (HealthDay News) -- Routine mammograms account for only about one-third of the decline in breast cancer death rates, according to a large new analysis of data from Norway's expansive breast cancer screening program.\nBut since the advent of routine mammograms in the 1990s, the rate of death from breast cancer has dropped 30 percent, he observed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the fourth graph, we are given this great quote from the lead author, Dr. Mette Kalager, an epidemiologist with the Cancer Registry of Norway in Oslo and a visiting scientist at the Harvard School of Public Health in Boston. \"Women should be informed that the benefit is smaller than expected, and there should be a balanced discussion on the benefit and the possible harms of screening, such as overdiagnosis, false-negative and -positive tests and psychological distress.\" Given how thorough the story was\u00a0in other areas, we hoped to see some of these potential\u00a0harms actually broken down later in the story.\u00a0What\u00a0has research shown to be the estimated\u00a0amount of overdiagnosis, false-negatives and false-positives? Some of\u00a0these numbers would have been a nice counterpoint to some of the statements\u00a0elsewhere in the story touting\u00a0the benefits\u00a0of mammograms.\u00a0", "answer": 0}, {"article": "Rising levels of PSA (prostate-specific antigen) are a sign that prostate cancer may be getting worse.\nHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\nAt the start of the study, the men's PSA levels were doubling every 12 months.\nThe new study involved 92 men with cancer that had not spread beyond the prostate and rising PSA levels.\nThe study is the latest to demonstrate pomegranate's promising antitumor effects, says study head Michael Carducci, MD, professor of oncology and urology at Johns Hopkins Medical Institutes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated: \u201cHowever, men who took three pills daily were more likely to suffer mild to moderate diarrhea: 14% vs. 2% of those who took one pill.\u201d", "answer": 1}, {"article": "Low sperm count, or oligospermia, is a main cause of male infertility.\nFor women who are having trouble getting pregnant, the test may very well be one they \u2014 and not their squeamish partners \u2014 snap up along with over-the-counter ovulation kits.\nAs SpermCheck\u2019s website puts it, a \u201ctrip to a fertility clinic for a semen analysis is not for everyone.\nStores will begin stocking the $39.99 test in April; until then, men \u2014 or their partners \u2014 can find it online at www.Walgreens.com and www.CVS.com.\n\u201cMen don\u2019t say, \u2018Let me go to the urologist and give a semen sample.\u2019\u201d That reluctance has created a $440 million-a-year market for male fertility tests in the U.S., Lopez says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The specificity of the test was not discussed; it was 94% according to FDA documents. It\u2019s only half the story to tell what the sensitivity was.\u00a0 Sensitivity doesn\u2019t tell you about false-positive results, and specificity does not tell you about false-negative results. Why not report both?\nIn addition, a test that tells you about sperm count doesn\u2019t necessarily tell you anything about sperm quality \u2013 another part of the picture. So any man who truly wants the complete picture would need to see the doctor anyway.\u00a0 This isn\u2019t exactly a \u201charm\u201d but it is part of the reality that a news story should have reported \u2013 or else men may feel drawn in by the story\u2019s promotional tone, not realizing the full ramifications of the \u201cdebut\u201d of this \u201cfirst at-home test.\u201d\n\u00a0", "answer": 0}, {"article": "Curcumin is an ingredient found in the common spice turmeric.\nThe author of the study believes that the effectiveness of curcumin gel on the skin - or topical curcumin - is related to its potent anti-inflammatory activity.\nDr. Heng reports her experience using curcumin gel on such injuries using three examples of patients treated after burns and scalds, and provides a detailed explanation why topical curcumin may work on such injuries.\n\"Curcumin gel appears to work much better when used on the skin because the gel preparation allows curcumin to penetrate the skin, inhibit phosphorylase kinase and reduce inflammation,\" explains Dr Heng.\n\"When taken by mouth, curcumin is very poorly absorbed into the body, and may not work as well,\" notes Dr. Heng.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Curcumin, the active ingredient of tumeric, is considered to be an alternative therapy. Neither turmeric nor curcumin has been extensively studied in clinical trials, but animal studies have shown that chronic use could lead to stomach ulcers. In addition, the American Herbal Products Association classifies turmeric as a menstrual stimulant. Turmeric should be avoided in patients with bleeding disorders and bile duct obstruction.\nExperts believe tumeric is generally safe, although the quality of the available clinical studies is questionable.\nAn additional potential harm is failure to be treated with appropriate care. We would not want parents of kids with severe burns to forgo appropriate, evidence-based medical care in favor of an alternative over-the-counter product with no scientific evidence to support its use. The last sentence of the news release states that the doctor uses curcumin gel in addition to standard medical treatment. That important bit of information should have been highlighted more prominently in the release so that people skimming the release wouldn\u2019t assume they could attempt to self-treat burns or scalds with curcumin alone.\nSince harms weren\u2019t mentioned in the news release we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "But this is important.\nA new study has found, however, that AA, the original 12-step program, and others like it don\u2019t have to be the only answer for people seeking out mutual help groups to deal with alcohol addiction.\nGroups like SMART and LifeRing, meanwhile, can be friendlier to the idea of members moderating their drinking but not quitting altogether.\nResearchers have long suspected, though, that the benefits found in 12-step treatment programs are not exclusive to the 12 steps.\nBy showing that there really might be other effective options out there, the research provides hope that there may be a better \u2014 or at least more complete \u2014 solution out there for alcohol addiction.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While there is no well-established quantification of harms of mutual-help groups, we feel this potential should be borne in mind, just as we would expect reports of negative side effects and adverse events in a medication study. The story doesn\u2019t mention potential downsides to any of these programs.\nFor example, as a ProPublica investigation\u00a0pointed out in 2014, some who participate in AA meetings are forced to do so by the criminal justice system. This group of mandatory members may include violent felons who are trading attendance for a lighter sentence. ProPublica noted that in some cases, this can create \u201ca combustible mix of violent ex-felons and newcomers who assume that others \u2018in the rooms\u2019 are there voluntarily.\u201d\u00a0 These conditions may increase the potential for sexual and financial abuse of AA members.", "answer": 0}, {"article": "\u201cThis is great news,\u201d says Kay Dickersin, PhD, an epidemiologist with the Johns Hopkins School of Public Health and director of the U.S. Cochrane Center.\nIt updates a 1999 Cochrane review that found no strong evidence to recommend zinc as a help for colds.\n\u201cThe evidence from the recent trials does support the use of zinc lozenges in treatment of common cold,\u201d says study researcher Meenu Singh, MD, a pediatric pulmonologist at the Post Graduate Institute of Medical Research in Chandigarh, India.\nFeb. 15, 2011 -- Taking zinc, either as a syrup or lozenge, through the first few days of a cold may shorten the misery of an upper respiratory infection, a new research review shows.\nThe review also found that zinc cut the number of days that kids missed school because of being sick and reduced the use of antibiotics by cold sufferers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify the potential harms, but did an adequate job mentioning the harms from zinc. This story did an especially good job providing a range of side effects. \u201cExperts stress that more research is needed before the most effective kind of zinc can be determined, and they caution that in high doses \u2014 more than 40 milligrams per day \u2014 zinc can cause dizziness, headache, drowsiness, increased sweating, loss of muscle coordination, alcohol intolerance, hallucinations, and anemia.\u201d", "answer": 1}, {"article": "Hialeah bucket list: All the things you need to do in Hialeah before you die\n\nYou can spend your whole life working on this list.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0mentions potential harms from screening, namely \"serious health risks from examining and treating tumors that may not be harmful.\"\u00a0 The story could have been clearer about what some of these risks are (like undergoing unnecessary surgery with all of its risks and anxiety to the patient), but it appropriately mentions that screening may have harms, which is often overlooked.\u00a0 ", "answer": 1}, {"article": "The Food and Drug Administration approved a new drug on Tuesday to treat serious cases of eczema.\n\u201cThe most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u201d the FDA notes.\nThe agency gave it both priority review and breakthrough therapy status, speeding it through the approval process.\n\u201cThe Wholesale Acquisition Cost (WAC) of Dupixent in the United States is $37,000 annually.\n\u201cBy binding to this protein, Dupixent is able to inhibit the inflammatory response that plays a role in the development of atopic dermatitis,\u201d the FDA said in a statement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cthe drug can cause serious allergic reactions and eye inflammation. \u2018The most common side effects include injection site reactions; cold sores in the mouth or on the lips; and eye and eyelid inflammation, including redness, swelling and itching,\u2019 the FDA notes.\u201d\nThis is sufficient, but one important detail we think is worth noting: The FDA gave the drug \u201cbreakthrough therapy status,\u201d meaning that long-term impacts were not studied.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does note the potential harms of treatment, such as dry and irritated eyes and blurry vision, but we are not told how often these happens. The story only provides one patient's anecdotal evidence that the surgery did not work well for him due to lasting uncomfortable side effects. \n\u00a0\n\u00a0", "answer": 1}, {"article": "In Rothwell\u2019s study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for oesophageal cancer in those taking aspirin.\nThe findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.\nPeter Elwood, an expert on aspirin from Cardiff University\u2019s medical school who was not involved in this study, described aspirin as \u201ca remarkable drug.\u201d\n\n\u201cThis risk of a bleed is so small compared to the benefits,\u201d he told reporters.\n\u201cYes, okay, it\u2019s a tragedy if a person is rushed into hospital and given a transfusion (because of a stomach bleed) but in relation to the things we are preventing, that is trivial.\u201d\n\u201cPrevious guidelines have rightly cautioned that in healthy middle-aged people the small risk of bleeding on aspirin partly offsets the benefit from prevention of strokes and heart attacks, but the reductions in deaths due to several common cancers will now alter this balance for many people,\u201d he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story dismisses concerns about ulcers and other bleeding caused by aspirin. Indeed, the last sentence of the story in fact says the risk is trivial. ", "answer": 0}, {"article": "In people with atrial fibrillation, disorganized electrical activity causes ineffective contraction of the upper chambers of the heart.\nThe study was published online Oct. 1 in The Lancet.\nThe drug has not yet been approved by the U.S. Food and Drug Administration.\n\"This analysis provides further support for the benefit of apixaban, but given the very low risk of bleeding with apixaban, it also suggests that the current stroke and bleeding risk scores may not be sensitive enough to tease out those patients with the very lowest risk of stroke who might benefit from apixaban therapy,\" said Ansell, who is chairman of the department of medicine at Lenox Hill Hospital in New York City and a consultant to Bristol-Myers Squibb and Pfizer, the companies that are marketing the drug as Eliquis.\n\"The benefits of apixaban are preserved, regardless of the risk score used and regardless of the patient risk category,\" study author and cardiologist Dr. Renato Lopes said in a Duke news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms from long term or short term use of apixaban.", "answer": 0}, {"article": "In an outpatient procedure under local anesthesia, doctors funneled a catheter into the patient's heart and removed peppercorn-sized bits of tissue from the part of the patient's heart that was unaffected by the heart attack.\nThis could change in the future if larger clinical trials and longer patient outcomes confirm the results of this early research published Monday in the journal The Lancet.\nThe study authors say based on these results, further research is warranted.\nShe cautions that this procedure has to be tested on many more patients and they have to be observed for longer periods than in the current study, but she says these results are all very positive.\nMarb\u00e1n says when the first patient data came in, he and his colleagues were relieved to see the procedure was safe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story at least mentioned harms. Another story on the study, by WebMD, did not. This one says, \u201cAfter 12 months, researchers report only one patient appeared to have a serious side effect that may have been connected to the experimental cells.\u201d Competing coverage discussed a broader group of patients who had bad outcomes, although it is not clear that all of those outcomes were a result of the treatment. Pinpointing the cause of a side effect can be tricky, and given the lead researcher\u2019s financial interest in this stem cell therapy, we think stories should err on the side of providing more information about potential harms.", "answer": 1}, {"article": "She\u2019s healed, basically,\u201d she said.\nThis patient is at a late stage of her disease.\n\u201cSix weeks into her treatment, the skin lesions were gone, her itchiness went away.\nReferred to City of Hope by her physician at Davis, she began responding to the experimental treatment right away, Yuan said, her skin tumors disappearing and the latest biopsies showing no cancer.\nShe had exhausted all of her chemotherapy options, and this experimental treatment was her last hope.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of side effects of the combination treatment and only a brief mention that this drug combination showed no clinical benefit in other patients.", "answer": 0}, {"article": "increases at age 4, although no cognitive benefit was seen in infants or 7-year-olds.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nDr. Jatinder Bhatia, a neonatologist heading the nutrition committee of the American Academy of Pediatrics, said that unless further studies showed no benefit as children got older, he would continue recommending DHA, now in many prenatal vitamins, because \u201cI\u2019m not convinced at this time that we should reverse course.\u201d\n\nMuch about DHA is unknown.\nShe said babies in her study might have received more DHA than those in this study.\nDr. Oken said the new study might have shown no benefit in 18-month-olds because effects in infants might be \u201chard to measure\u201d or \u201cit may be that the benefit of DHA is not as important as when you\u2019re 4.\u201d\n\nDr. Makrides\u2019s team plans assessments at 4 and 7.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story used terms like \"no harm\u2026safe\u2026and apparently has few downsides.\"\u00a0 Well, which is it?\u00a0 No harm or few downsides?\u00a0 And if the latter, then how few and of what kind?\u00a0 This is too vague and confusing. \nThis may also be an area in which products that are not as tightly regulated as prescription drugs carry a potential downside.\u00a0 Again, it\u2019s hard to get real information about purity, quality standards and bioavailability for supplements.\u00a0 ", "answer": 0}, {"article": "But high blood pressure also appears to increase a person's risk of developing Alzheimer's disease, which is associated with the accumulation of plaques and tangles in the brain.\nAnd he says other people with high blood pressure should follow his lead.\nKoroshetz's campaign is getting some help from the Alzheimer's Association.\nAt least two large studies have revealed an alarming trend among stroke patients, Koroshetz says.\nAnd the group is encouraging people to control high blood pressure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with costs, we wouldn\u2019t expect a story like this to cover all the side effects of the myriad treatments.\nBut we do think it could have noted that one reason blood pressure drugs are prescription-only is because they can cause side effects that may need medical management. Unlike what the story said, it is not as simple and carefree as taking \u201ca pill\u2026 to help keep [your] brain healthy and sharp.\u201d", "answer": 2}, {"article": "LONDON (Reuters) - First results from a human trial of an Ebola vaccine from GlaxoSmithKline show it is safe and generates an immune response, scientists said on Wednesday, but larger trials are needed to see if it protects and if a booster is needed.\nThe volunteers got one of three doses - low, medium, or high - and data from 28 days after vaccination showed the shot was safe at these doses, with only mild side effects.\n\u201cPeople typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish,\u201d Hill said.\nThe data, published in the New England Journal of Medicine, were from 60 healthy volunteers given the vaccine in Britain between Sept. 17 and Nov. 18 last year.\nThe early-stage Phase I trial of GSK\u2019s vaccine was primarily designed to test safety, but Adrian Hill, who led the work at Oxford\u2019s Jenner Institute, said it was \u201cencouraging\u201d that the shot also prompted responses from the immune system.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides just enough information to get a flavor for the potential harms without overly dramatizing them. Example: \u201cThe volunteers got one of three doses \u2013 low, medium, or high \u2013 and data from 28 days after vaccination showed the shot was safe at these doses, with only mild side effects.\u201d And: \u201cPeople typically experienced mild symptoms that lasted for one or maybe two days, such as pain or reddening at the injection site, and occasionally people felt feverish.\u201d", "answer": 1}, {"article": "For more about cryoablation, visit the U.S. National Cancer Institute.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nBut they acknowledged that more research needs to be done to track the treatment's impact over the long haul.\nThe study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease.\nThe team concluded that cryoablation appears to be both safe and effective, at least in the short-term.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was cautious in reporting:\n\u201cThe authors noted that side effects were minimal, typically involving air or fluid around the lungs after the procedure, and in all cases were resolved quickly.\nThe team concluded that cryoablation appears to be both safe and effective, at least in the short-term. But they acknowledged that more research needs to be done to track the treatment\u2019s impact over the long haul.\u201d\nA further caution could have been that we don\u2019t know what patients think about such side effects being described as \u201cminimal\u201d and that we were only hearing this from the researchers announcing their findings.", "answer": 1}, {"article": "\"The truth is that quit smoking programs, like other programs that treat addictions, often have fairly low success rates. But that doesn't mean they're not worthwhile or that you should be discouraged. Your own success in quitting and staying that way is what really counts, and you have some control over that. Even if you don't succeed the first few times, keep trying. You can learn from your mistakes so that you'll be ready for those pitfalls next time.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When quitting, heavy smokers can experience\u00a0withdrawal symptoms\u2013such as depression, insomnia and decreased heart rate\u2013even if they use nicotine replacement products.\nThe article did refer to \u201cwithdrawal\u201d and \u201curge intensities\u201d and so we\u2019ll considered that sufficient.\u00a0However, the piece would have been stronger had it specifically discussed the withdrawal symptoms mentioned above.", "answer": 1}, {"article": "Uterine fibroids are benign tumors that grow in and around the uterus.\nThe drugs, experts say, would provide a new treatment option for a condition most commonly treated with a hysterectomy, or removal of the uterus.\nTwo other oral medications indicated to treat uterine fibroids are also in development.\nWhile the company has done studies of women taking the drug up to a year, some experts believe the long-term health profile of a drug needs to be evaluated up to seven years, Dr. Jacoby says.\nShao-Lee Lin, vice president of therapeutic areas and international development at AbbVie , says the company is testing a twice daily dosing of elagolix.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes the side effects of UA and potentially two other similar drugs in the pipeline. The main concern about these agents is the effects they may have on the endometrium (uterine lining) over time.", "answer": 1}, {"article": "For that reason, UV devices are often used for sterilization \u2014 for medical equipment in hospitals, for example, or drinking water for backcountry campers.\n\u201cThink about doctor\u2019s waiting rooms, schools, airports and airplanes\u2014any place where there\u2019s a likelihood for airborne viruses.\u201d And unlike the flu vaccine, he says, far-UVC light is likely to be effective against all airborne microbes, including newly emerging virus strains.\n\u201cIf you have a lamp over the surgical site that can sterilize the air, you can prevent the bacteria from floating down and contaminating the wound.\u201d\n\nBrenner can\u2019t predict how long it might take for these lamps to be commercially available, but he says he\u2019s \u201cextremely optimistic\u201d about the technology.\n\u201cWe don\u2019t see cost as being a limiting factor here.\u201d\n\nUVC lamps could also have potential implications in clinical settings, as well \u2014 in the operating room during surgeries, for example.\n\u201cThere has been no way of killing viruses in the air in public spaces, and this is an approach that may solve that problem.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms of far-UVC light are mentioned; in fact, in the opening sentence we read:\u00a0 \u201cresearchers have developed an ultraviolet (UV) lamp that kills influenza virus but isn\u2019t harmful to human skin or eyes\u2026.\u201d\nBut, again, we\u2019re given no data regarding safety.\u00a0We are not told if the previous skin or eye studies (which we\u2019re told prove the safety of this approach) were done in the laboratory or on real humans.", "answer": 0}, {"article": "In one study, the number of daily hot flashes experienced by postmenopausal women taking 1,800 milligrams of the drug per day declined from around 10 to around 2.\nThe study was presented in Chicago at the annual meeting of the North American Menopause Society (NAMS).\nBut side effects, including dizziness and daytime sleepiness, were commonly reported by users.\n\u201cThis drug was about 60% to 65% effective, which is about the same efficacy that has been reported with antidepressants [for treatment of hot flashes].\u201d\nAbout 60% of women who took the experimental drug in one study reported side effects, compared to about 50% of women taking placebo pills.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "had lower HDL-cholesterol, lower income, and less education,\u201d in comparison to participants who did not consume red chili peppers.\n\u201cFor those who are affected by digestive disorders such as a stomach ulcer, I would be cautious about eating spicy foods,\u201d Lu Qi, of Harvard\u2019s T. H. Chan School of Public Health and Brigham and Women\u2019s Hospital in Boston, and lead author of The BMJ study, told CBS News.\nStill, the authors say the study strengthens the growing body of evidence that spicy food may have protective health properties that can lead to a longer life.\nFor the study, researchers at the Larner College of Medicine at the University of Vermont analyzed data on more than 16,000 Americans using the National Health and Nutritional Examination Survey (NHANES).\n\u201cSuch evidence may lead to new insights into the relationships between diet and health, updated dietary recommendations, and the development of new therapies,\u201d they write.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0addresses potential harms from eating red hot chili peppers, by quoting\u00a0an expert source warning about discomfort and worsening symptoms\u00a0in people with\u00a0digestive disorders such as stomach ulcers.", "answer": 1}, {"article": "Dr. Andrew Adesman is chief of developmental and behavioral pediatrics at Cohen Children's Medical Center of New York, in New Hyde Park, N.Y.\nTwo experts agreed that early intervention is key.\nHe was cautiously optimistic about the promise of the video feedback approach.\n\"Although it would be wonderful if a relatively simple, video-based intervention could reduce the recurrence risk of autism spectrum disorder in later offspring, further studies are needed to examine this very issue,\" he said.\nThe goal of the therapy -- delivered over five months while the infants were ages 7 to 10 months -- was to improve the infant's attention, communication, early language development, and social engagement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of this intervention could include the time and expense of an experimental approach whose benefits were not shown to be statistically significant in the one study reported on herein. The study abstract notes the possibility of negative effects\u00a0in language and responsivity to vowel change. The story didn\u2019t touch on any of this.\u00a0 It emphasized potential benefits and ignored potential harms.\u00a0 In our view, there is a harm in this kind of reporting.", "answer": 0}, {"article": "Hot flashes, which mostly affect women transitioning to menopause and already in that phase of life, involve a sudden sensation of heat, sometimes accompanied by sweating or visible reddening of the skin.\nFreedman said that the overall research on antidepressants and hot flashes is still inconsistent.\nAnd for now, he noted, it\u2019s also not clear why antidepressants would have effects on hot flashes.\nThose findings appear in a separate report in the journal Menopause.\n\u201cBut my feeling is that it\u2019s the placebo effect,\u201d Freedman said, referring to the phenomenon of study participants on placebos improving because they believe they are getting a real treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did discuss some of the side effects of antidepressants.", "answer": 1}, {"article": "\"This is really the gold standard.\nThe downside is that the test is expensive, about $300 to $400, but is covered by most insurers.\nPhysicians say the test is accurate and the most comprehensive available, but some say its long processing time limits usefulness in emergency rooms.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nThe test is expected to be used mainly in hospitals and emergency rooms, but doctors can send the swab to a local lab.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The two\u00a0main drawbacks of the xTag test, that it is expensive and can\u00a0take up to a day or two to get the results, are presented.\u00a0\u00a0Expense is an important\u00a0issue given the volume of acute febrile illnesses in children, particularly if this test were given routinely in an outpatient setting.\u00a0 In addition, if the processing time at the specific location is is too long, the test may not have any practical benefit in the treatment decision window.\u00a0\u00a0 ", "answer": 1}, {"article": "It didn\u2019t work miracles.\nRelated: More U.S. Moms are Breastfeeding Their Babies\n\n\u201cThe effects of kangaroo mother care at one year on IQ and home environment were still present 20 years later in the most fragile individuals, and kangaroo mother care parents were more protective and nurturing,\u201d Dr. Nathalie Charpak and colleagues at the Kangaroo Foundation in Bogota, Colombia, wrote in their report.\nRelated: Too Many Babies Die on Their First Day\n\nCharpak\u2019s team found the babies randomly assigned to get this treatment were 39 percent more likely to live into adulthood.\n\u201cAt 20 years, the young ex-kangaroo mother care participants, especially in the poorest families, had less aggressive drive and were less impulsive and hyperactive.\nThey found that babies held upright and close to bare skin and breastfed, instead of being left in incubators, grew up with fewer social problems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There aren\u2019t any obvious harms from this intervention, although the story does note the finding that children given standard incubator care had higher math and language scores in school even though IQ levels were similar in both groups.\nA 2012 Cochrane review of multiple studies found no negative outcomes associated with skin-to-skin contact for healthy newborns except for one study\u2019s report of longer duration of breastfeeding in a control group.", "answer": 1}, {"article": "\"Certainly, however, this solid paper adds to the literature and paves the way for additional research on this interesting topic.\"\nBut Rabin, who was not involved in the study, did add a few caveats about the findings.\nWEDNESDAY, Sept. 5, 2018 (HealthDay News) -- Taking fish oil supplements during pregnancy might translate into healthier growth in children during their first six years of life, a new study suggests.\nThose whose mothers took the fish oil supplements during pregnancy sustained a higher body mass index (BMI) from the age of 1 to 6 years.\nHowever, the findings only showed an association and did not prove that fish oil pills caused healthier growth in children.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss any risks of taking fish oil. But these include belching, bad breath, heartburn, nausea, loose stools, rash, and nosebleeds. For pregnant women who have to be vigilant about even seemingly harmless side effects (nausea can be a serious symptom in the third trimester, for example), these details are important.", "answer": 0}, {"article": "Prescribing testosterone for age-related deficiency \u2014 which is only vaguely defined \u2014 took off in 2000. The trend was driven not by solid scientific evidence, but by the introduction of convenient, rub-on testosterone products, the first being Androgel. Many men are put on testosterone with no tests of their levels or despite tests showing normal levels, a study of Medicare claims found.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author of this story makes possible harms of the therapy clear: testosterone therapy\u00a0increased fatty plaque in coronary arteries, a risk factor for heart disease. It also talked about the possible risk of stroke in a subset of men.", "answer": 1}, {"article": "Dr. Gheorghe Doros has received payment for statistical analysis from Bayer Pharma.\n\"The low CV events observed in the T-group compared to the untreated (control) group strongly suggest that TTh is protective.\nThese findings appear online in the Journal of Cardiovascular Pharmacology and Therapeutics.\nInsufficient levels of circulating T in men, contributes to frailty and bone loss.\nIn addition, T is essential for overall health and well-being and for the prevention of osteoporosis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not on this text\u2019s radar screen. Testosterone treatment does have a few side effects including sleep apnea, stimulation of benign growths in the prostate, enlarged breasts and increased risk of blood clots. The study on which this release was based does not appear to discuss these outcomes either, but their inclusion here would have been helpful.", "answer": 0}, {"article": "Now, she said, \u201cI\u2019m out walking my Lab about five miles a day, every day.\nLast year, the average salary for joint-replacement specialists topped $575,000, reported the Dallas consulting firm Merritt Hawkins & Associates, compared with just over $230,000 for family doctors.\nIn patient-reported surveys, some still complain of pain and tissue inflammation after their procedures.\nWhile physical activity obviously plays a role in joint deterioration, genetics may be the biggest factor in determining who needs a replacement and when, he said.\nSome took multiple cortisone shots, hoping to avoid surgeries.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned at least some potential harms:\nIn patient-reported surveys, some still complain of pain and tissue inflammation after their procedures. Smaller numbers suffer serious complications, ranging from blood clotting to hospital-acquired infections.\nStill, it could have devoted more attention to risks, including the lax regulation of implantable devices.", "answer": 1}, {"article": "2011.\nThe researchers found that incorporating SelectMDx resulted in an average gain of 0.045 life years, or approximately 16 days, in full health gained at a cost-savings of $1,694 for each patient undergoing biopsy.\nExtrapolating these data to a conservative estimate of 311,879 patients per year undergoing biopsy resulted in 14,035 life years in full health gained with an annual cost saving of more than $500 million for each cohort.\n\"This study demonstrated that routine use of SelectMDx to guide biopsy decision-making improves health outcomes and lowers healthcare costs associated with prostate cancer risk assessment in a population of U.S. men,\" said Dr. Matthew Resnick from the departments of Urologic Surgery and Health Policy at Vanderbilt University Medical Center, Nashville, TN.\nThe study published in The Journal of Urology, led by researchers at the Vanderbilt University Medical Center, was designed to elucidate the cost-effectiveness of SelectMDx in a population of U.S. men with elevated PSA, a marker of prostate cancer risk.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although providing urine for the test involves little to no risk, choosing not to move forward with a biopsy as a result of the test does bring with it a risk of being wrong, should the cancer be aggressive (a false negative). The likelihood of that error would be an important piece of information.\nThe study cites a reference suggesting that the sensitivity for detecting high-risk cancers was 95.7%.", "answer": 0}, {"article": "The researchers added up how often people in those studies got colds, and how long those colds tended to last.\nFor adult males, the recommended amount is 90 milligrams per day.\nVitamin C is also an antioxidant, which means it's believed to help prevent or minimize conditions that include cancer, heart disease, and inflammatory conditions such as arthritis.\nThe researchers found that these people were 50 percent less likely to catch cold if they took vitamin C daily.\nShe explained that a review of numerous studies concluded that vitamin C isn't what it's cracked up to be, failing to help prevent the common cold in any meaningful way, except in some people exposed to extremely high stress.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report fails to indicate that taking high levels of vitamin C, as some advocates\u00a0suggest, can have serious health consequences, from dental erosion to kidney toxicity. It can also interact with aspirin and other drugs.\u00a0 ", "answer": 0}, {"article": "Decipher is a Medicare-covered genomic test capable of predicting tumor aggressiveness in men following prostate surgery.\nThe test provided a more accurate and precise estimate of a patient's risk of recurrence.\nAdding truly unique information to the treatment decision-making process, Decipher generates a risk result that is completely independent and distinct from PSA, Gleason score and other clinical risk factors.\nThe Decipher test results altered 45% and 35% of treatment recommendations made by urologists and radiation oncologists, respectively.\nUse of this test therefore has the potential to assist clinicians to better direct utilization of secondary therapy after surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t explain what sorts of risks a patient faces from radiation, hormone, and other \u201cadjuvant\u201d therapies after surgery, and avoiding these seems to be a key point of the Decipher test.\u00a0We also don\u2019t get\u00a0any words on how reliable the test actually test is and how often it might return inaccurate results, which is its own kind of risk.", "answer": 0}, {"article": "Diabetes, high cholesterol, high blood pressure, stroke and being overweight jeopardize vascular health.\nRobert Nagele, PhD, presented his team's most recent findings October 18 at OMED 15 in Orlando.\nPeople found to have preclinical disease can take steps to improve their vascular health, including watching their diet, exercising and managing any weight and blood pressure issues to help stave off or slow disease progression,\" Nagele said.\nIt is among the top 10 causes of death in America.\nOMED 15 is a five-day event offering clinical and research updates in 15 specialties, with an emphasis on osteopathic principles and practices.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Without discussing sensitivity or specificity, the news release gives no picture of the potential for false positives or false negatives \u2013 always potential harms with any test.", "answer": 0}, {"article": "The GI tract is also home to the intestinal microbiome, a complex population of roughly 100 trillion microorganisms (more than ten times the number of cells that make up the human body) that interacts with the mucosal lining of the GI tract.\nThe patients were randomly selected to receive either the probiotic supplement or a placebo in addition to their usual medications.\nThe beneficial effects were most pronounced in those patients who exhibited abnormally high levels of inflammation at the beginning of the study.\nAnd a new study from Baltimore's Sheppard Pratt Health System, conducted by a research team led by Faith Dickerson, finds that a probiotic supplement may reduce inflammation of the gut, which is known to exacerbate bipolar disorder.\nThe results showed that the group receiving the probiotic supplement, on average, didn't return to the hospital as quickly and required less in-patient treatment time compared to the placebo group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms of probiotics nor the fact that they are not regulated for safety and effectiveness.", "answer": 0}, {"article": "It may actually help you live longer, according to new research from the Harvard T.H.\n\u201cIf you\u2019re more optimistic, you tend to have healthier behaviors.\n\u201cSo you think about your different domains of life, whether it\u2019s your personal relationship, your spouse, your career, your friendships, and in each of those domains you think about the best possible outcome.\u201d\n\nHagan had some suggestions, too.\nHaving an optimistic outlook on life may do more than just boost your mood.\n\u201cOne is called \u2018best possible self,\u2019\u201d Eric Kim, who also co-led the study, told CBS News.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Being\u00a0overly\u00a0optimistic\u00a0can\u00a0put\u00a0people\u00a0into\u00a0harm\u2019s way \u2014 say, thinking they\u2019re better drivers than they really are, and upping the risk of an accident. (There are a number of studies about this very thing.) But that\u2019s a kind of common sense we don\u2019t think needs calling out in a story.", "answer": 2}, {"article": "Switching to AstraZeneca PLC's breast-cancer drug Arimidex after treatment with older drug tamoxifen not only helps women live longer, but also increases their chances of staying cancer-free after initial therapy for breast cancer, according to a study in the online edition of the Lancet Oncology medical journal.\n\nThe data, which come from more than 4,000 patients in three clinical trials, have shown that switching treatment from tamoxifen to Arimidex reduces the risk of dying by 29%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential side effects of aromatase inhibitors. Both hormone therapies may increase menopausal symptoms such as hot flashes or vaginal discomfort, though\u00a0anstrozole slightly less so than tamoxifen.\u00a0 Anastrozole may increase the risk of bone or joint pain and\u00a0possibly may increase cholesterol. ", "answer": 0}, {"article": "But it may be too early to call this a cure.\nBut the new findings provide even more evidence that using peanuts to treat peanut allergy, and to re-train the immune system to be less allergic, can be effective.\nFewer children in the treated group had an allergic reaction to the peanuts, and they also showed smaller reactions to skin prick tests with peanut allergen.\nMORE: Babies Should Eat Eggs and Peanuts Early to Avoid Food Allergies\n\nIn the follow-up, which tracked the children for four years after they were treated with the combination therapy, 67% of those who got the combination probiotic and peanut therapy were comfortable eating peanuts, compared to only 4% of those who did not get the treatment.\nCompared to 4% of children who didn\u2019t get any treatment, 82% of those receiving the combination therapy significantly reduced their allergic reactions to peanuts.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t mentioned, which is problematic. The type of immunotherapy used in conjunction with probiotics for this study is called peanut oral immunotherapy. In a 2016 research summary document, the American Academy of Allergy, Asthma & Immunology describe this type of immunotherapy as \u201cone of the more promising new treatments\u201d for peanut allergies. Specifically, the summary noted that \u201cMultiple studies have now shown [oral immunotherapy] to be efficacious at desensitizing peanut-allergic children, but this efficacy comes at the expense of high rates of allergic adverse events, and the risk/benefit ratio of [oral immunotherapy] is an area requiring more study.\u201d This is a complex area, and the research summary is worth reading, but the key point here is that there are risks associated with oral immunotherapy \u2014 and this story doesn\u2019t acknowledge them.", "answer": 0}, {"article": "After all, our immune system evolved over millions of years to respond to infections of injured skin, not vaccines delivered by hypodermic syringe into muscle,\" he noted.\n\"We should also continue to explore the implications for developing powerful cancer vaccines, like the one demonstrated by melanoma vaccine results in this study.\"\nNearly all modern vaccines are given via injection, according to background information in a news release about the study, which is published in the Jan. 17 issue of Nature Medicine.\n\"This research illustrates the remarkable capacity of the most superficial layer of skin to generate powerful protective immune responses after vaccination,\" study senior researcher Dr. Thomas Kupper, chairman of the dermatology department at the hospital, said in a news release from the hospital.\nThey also found that a melanoma vaccine delivered by scarification was much more effective than injected vaccines in protecting animals against melanoma tumor growth.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms of this approach to vaccination. ", "answer": 0}, {"article": "Supplements may be an additional source of DHA, but an editorial in the same issue, by Dr. Martha Clare Morris, an associate professor of medicine at Rush University Medical Center in Chicago, points out that there are no published human studies of the effects of omega-3 fatty acid supplementation.\nThe study was financed in part by Martek, a concern that manufactures DHA, and one author received a grant from Pfizer, France.\n\u201cThis study doesn\u2019t prove that eating fish oil prevents dementia,\u201d he said.\nEating fish is not a guarantee of having high levels of DHA.\nBut, she adds, epidemiological studies consistently show positive health effects from fish consumption on mortality, cardiovascular risk factors and, now, dementia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned potential harms from fish oil consumption and included speculation on potential harms from fish consumption.", "answer": 1}, {"article": "Flare-ups , which involve excruciating joint pain, redness, swelling and warmth, can last days or weeks.\nThe study appeared online Jan. 5 in the journal Arthritis & Rheumatism.\nDr. Michael A. Becker, a professor emeritus of medicine at the University of Chicago, described the findings as \"very promising.\"\n\"(And) this trial provides well-controlled evidence that this IL-1 blocker is effective in preventing acute gout flares in this setting,\" he added.\nTHURSDAY, Jan. 5, 2012 (HealthDay News) -- Preliminary findings suggest a drug used to treat another disease might also reduce painful flare-ups in gout patients starting new medication regimens.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The standard line about \u201cappears safe and well tolerated\u201d is all we hear about harms.\nEven the news release did better than that, stating: \u201d Common adverse events included infections reported in 15% of the rilonacept group compared with 26% with the placebo.\u201d", "answer": 0}, {"article": "That number was the same in younger people who had large waistlines, and even lower in those with metabolic syndrome, a combination of risk factors including belly fat, high blood pressure and high blood sugar.\nA camera at the tip shows the inside of the gut, so that unusual cell clumps can be found and removed.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nAs part of their employer-provided health benefits, each participant in the study underwent screening colonoscopy at Konkuk University, which also sponsored the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential harms of colonoscopy, such as bleeding and perforation.", "answer": 1}, {"article": "When all seizures were taken into account, children who did not have surgery were four times more likely to have a seizure during that year than youngsters in the surgery group, the researchers calculated.\nThey are left with this minor deficit.\nThe only thing that does not improve is the wrist and the fingers.\nHe was not involved in the research.\nBehavior and quality of life also improved.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained but again without much quantification.", "answer": 1}, {"article": "Thanks to members Drs.\nHowever, certain aspects of treatment for knee OA are controversial.\nThe lifetime risk of suffering symptomatic knee OA is estimated to be 44.7% and approximately 1 in 11 of the US population is diagnosed with symptomatic knee OA by age 60.\nThere is a general consensus that the initial management of knee OA treatment should include weight loss and strengthening exercises.\nThis is different than studies recently published that say the average response differs.\u201d The full report, published ahead of print in the Clinical Journal of Sport Medicince (CJSM) and will appear in the (British Journal of Sports Medicine) BJSM, entitled, AMSSM Scientific Statement Concerning Viscosupplementation Injections for Knee Osteoarthritis Importance for Individual Patient Outcomes, includes the following notable AMSSM recommendations and one suggestion:\n\u2022 AMSSM RECOMMENDS viscosupplementation injections for Kellgren and Lawrence (KL) grade II-III knee osteoarthritis in those patients above the age of 60 based on HIGH quality evidence demonstrating benefit using OMERACT-OARSI Responder Rating but the evidence should be downgraded due to indirectness for those under 60 years of age.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It seems intuitive that injection of a solution into the joint space of the knee should have some downsides. Indeed, a 2012 meta-analysis of 89 clinical trials involving over 12,000 subjects published in Annals of Internal Medicine concluded, \u201cIn patients with knee osteoarthritis, viscosupplementation is associated with a small and clinically irrelevant benefit and an increased risk for serious adverse events.\u201d\nCommon side effects of short duration following viscosupplementation include swelling, and feelings of pain and warmth at the injection site. Serious but rare complications include infection, allergic reaction and bleeding.", "answer": 0}, {"article": "It may also improve vision in those with mild myopia (nearsightedness).\nIf we haven\u2019t yet processed the prior set of information, we can\u2019t understand it.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine what harms there might be, but it would have been helpful to know something about the drop-out rate that would have done at least a bit of financial damage to the trainees.", "answer": 2}, {"article": "The active ingredients in Salonpas are methyl salicylate and menthol, common components of pain-relieving gels and creams, such as Bengay.\nOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\nPain patches have a number of benefits, Rosenquist and Dombrowski said, not the least of which is convenience.\nThe main downside to pain patches, however, apparently comes from their effect on the skin.\nAnd, because patches release their medication slowly into the body through the skin, people also should get more consistent pain relief than they do with pills.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are quantified. Instead, the story relies on quotes that merely mention side effects. Interestingly, the story gives more space to the possibility of a skin reaction from the patches than it does the more serious potential harm. In one sentence it says, \u201cOn the other hand, people have to be sure to carefully follow instructions for using the patches, to avoid overdose.\u201d\u00a0 The story should have given some estimate of how often that\u2019s happened.", "answer": 0}, {"article": "The thought that you could lose your vision is very, very depressing,\" Daniel says.\nThere are some rare side effects, including severe inflammation, infection and detached retina.\nHe was diagnosed with wet macular degeneration, the most acute form, affecting 1.7 million Americans.\nTwo studies out Wednesday in the New England Journal of Medicine report on patients given monthly injections for two years.\n\"These symptoms were these wavy lines \u2014 and especially on the periphery of your vision,\" says macular generation patient Daniel Davison.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention side effects, such as inflammation, infection, and detached retina.", "answer": 1}, {"article": "On average, using probiotics reduced a bout of diarrhea by more than a day, and reduced the risk of a prolonged diarrhea episode -- four days or more -- by 59 percent.\nAllen says that since the original review, there's been increasing interest in probiotics and, therefore, more research.\nEven so, Allen says more research is needed to determine the specific strains of bacteria that are most effective.\nAnd, he says, researchers need to take a look at probiotic regimes that could best target different cases of acute diarrhea in both developed and developing countries.\nHowever, the impact of the probiotics varied greatly from study to study, researcher found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that there were \u201cno negative side effects\u201d in the literature review. So, for that, we\u2019ll give it a satisfactory score.\u00a0 But a broader perspective on this issue could have addressed the potential for harm in hospitalization-associated diarrhea.", "answer": 1}, {"article": "\"We're kind of on the edge of this becoming more accepted.\"\nUp to now, however, there's been little evidence showing that a calcium scan can provide a solid assessment of a person's long-term health risk, the study authors said in background information.\nThe test, called a coronary calcium scan, uses a regular CT scan to look for calcium deposits in the three major arteries that carry blood away from the heart, said lead author Leslee Shaw, a professor of cardiology at Emory University in Atlanta.\nIn this new study, doctors referred 9,715 healthy patients in the Nashville area between 1996 and 1999 to a cardiology outreach screening program provided by the military's Tricare Healthcare System.\nMONDAY, July 6, 2015 (HealthDay News) -- A scan of calcium deposits inside your arteries can help doctors deduce how long you're likely to live, a new study has found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss any potential harms of CAC testing. It fails to tell readers that the researchers noted in their article that for every 10,000 people screened, about 12 would develop cancer. That means that subjecting 100 million adults to this test would be expected to result in 120,000 additional cancers.\nEven if that cancer burden were deemed acceptable, patients sent for additional testing (such as catheter imaging) or prescribed drugs or procedures would be exposed to the risks and costs of those tests and treatments.", "answer": 0}, {"article": "Laparoscopic surgery, in which a surgeon performs the operation through small incisions, usually with the help of a surgical robot, has been touted as carrying a lower risk of incontinence and impotence than the standard \u201copen\u201d form of the surgery.\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nLack of information on outcomes isn\u2019t only a problem for robot-assisted surgery, but \u201cbedevils\u201d the scientific literature on prostate removal overall, the researchers note in the journal European Urology.\nFinally, the researchers note, expenses associated with the procedure\u2014the robot costs at least 1.8 million ($2.6 million) to install, 100,000 ($145,000) a year to run, and 1,500 ($2,200) extra for each surgical case-mean the procedure is \u201cprohibitively\u201d expensive \u201cfor many hospitals and indeed many countries.\u201d\n\nThe researchers conclude: \u201cThe significant learning curve should not be understated, and the expense of this technology continues to restrict access to many patients.\u201d\nThere was also a lack of data on how well patients functioned after surgery, and how patients with high-risk prostate cancer fared long-term.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story provides readers with some potentially interesting questions to raise with a doctor (e.g. how many of these surgeries have you done using this equipment; is this approach the best for the type of cancer I have, i.e. early or more advanced). \u00a0The story mentions in passing potential harms such as impotence and incontinence, referencing a study published in October. \u00a0\nHowever \u2013 the story did not really follow-up on one of the key issues it raised. \u00a0For example, the story mentioned that a surgeon will have to do 80 procedures with this equipment to ensure that they don\u2019t leave any cancerous tissue behind. \u00a0The story could have completed this thought and indicated the ramifications of leaving cancerous tissue behind in terms of health consequences.", "answer": 1}, {"article": "But researchers controlled for these and many other factors, and found that compared with women who ate no walnuts, those who consumed 8 ounces of walnuts or more a month reduced their risk for Type 2 diabetes by 24 percent.\nWalnuts may have some unique benefits.\u201d\n\nThe study was supported with grants from the National Institutes of Health and the California Walnut Commission.\n\u201cThere\u2019s been a lot of research on nuts in general in relation to cardiovascular health,\u201d said the senior author, Dr. Frank B. Hu, a professor of medicine at Harvard.\n\u201cThis is the first on walnuts and diabetes.\nThough the findings are correlational, walnuts are uniquely high in omega-3 and omega-6 fatty acids, which may be of particular value in Type 2 diabetes prevention.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms.\u00a0 Aside from the fact that walnuts carry a significant amount of fat and protein and should be eaten in moderation, we don\u2019t know of other harms worthy of mention.", "answer": 2}, {"article": "Robotic-assisted surgery is similar to laparoscopy, only the instruments and cameras are integrated into robotic arms, which the surgeon operates through a control console.\nNo differences between the three methods were seen in the numbers of complications, report the researchers in the journal Obstetrics & Gynecology.\nMore research is needed to be able to compare long-term outcomes, wrote the researchers.\nThe robotic equipment provides better three-dimensional vision, increased range of motion and intuitive, downscaled movements, while adding a few thousand more dollars to the procedure\u2019s price tag, the authors note.\n\u201cHowever, if the surgeon is skilled enough to do the hysterectomy without the robot by laparoscopy then the outcomes will be similar.\u201d\n\nNezhat further noted that while robotic assistance can be a good \u201cenabler\u201d for a minimally invasive approach, surgeons should have at least the basic knowledge of regular laparoscopy too, as there may be times when the robotic equipment doesn\u2019t work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that \u201cNo differences between the three methods were seen in the numbers of complications, report the researchers in the journal Obstetrics & Gynecology.\u201d\u00a0 The researchers reported a very complete breakdown of intraoperative and post-operative complications \u2013 including what differences were statistically significant or not.\u00a0 We\u2019ll give the story the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Currently, the most popular drugs to treat depression are called selective serotonin reuptake inhibitors, or SSRIs.\nAn advantage is that the drug doesn't have the side effects of other drugs that target these same areas, such as hallucinations and schizophrenia-like symptoms, the researchers noted.\nFor his part, Bruno cautioned that the long-term effects of the drug need to be studied before it can be used regularly in clinical practice.\nBecause the drug targets these areas of the brain it might also help people with other problems such as schizophrenia, bipolar disorder, anxiety and Alzheimer's disease, the researchers suggested.\nThe effect of the drug was substantially better than seen with other antidepressants, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The lead researcher is quoted as saying, \u201cIn addition, we have shown little or no side effects with our compound.\u201d And the story does caution that many unknowns remain about GLYX-13, including its long-term effects and the effects of stopping its use. The story also adds that the drug does not display side effects of hallucinations and schizophrenia-like symptoms.\nHowever, here\u2019s why we rule this one unsatisfactory on the harms criterion:\u00a0 A single dose of a medication (which appears to be the design here) can\u2019t establish harms.\u00a0 The story should have been less accepting of the statement that there were no side effects.\u00a0 The compare-and-contrast to other drugs targeting the same receptors and the apparent lack of short-term and severe side effects (e.g., hallucinations) was useful but not close to the whole story.", "answer": 0}, {"article": "Eliquis is scheduled to be submitted for F.D.A.\nIn the first seven months on market, about four in five cardiologists and two in five primary care doctors had prescribed it to more than 250,000 people, Wa\u2019el Hashad, Boehringer\u2019s vice president for cardiovascular marketing, said in an interview last week.\nevent of the year.\u201d\n\n\u201cIf everything checks out,\u201d Jami Rubin of Goldman Sachs said in an interview, \u201cthat will confirm in our minds that Eliquis has potential to take a majority share of the $10 billion anticoagulation market.\u201d\n\nMore than 2.6 million people have atrial fibrillation in the United States, according to the Centers for Disease Control and Prevention.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned some of the disadvantages associated with this use of the medication reported on. \u00a0It did not specifically detail whether there were any harms associated with this medication or how well people in the study were able to stick with the dosing schedule.\nOn this issue, this story was not as complete as its HealthDay competition, which reported:\n\u201cThe new trial comes on the heels of another study on apixaban that was stopped early due to safety concerns. In that trial, published in July in the New England Journal of Medicine, apixaban\u2019s use was associated with raised odds for bleeding \u2014 without providing patients with any reduction in heart attack risk.However, \u201cin that case, apixaban was given to patients with coronary artery disease who were also taking two other blood thinners,\u201d Ansell noted. \u201cThe three of them together showed that the risk of bleeding was just too high and there was no real benefit in that population. But, that\u2019s an entirely different problem, compared with atrial fibrillation,\u201d he said.\u201d ", "answer": 0}, {"article": "A next-generation visor from eSight can improve vision for many legally blind people.\nGeoffrey A. Fowler discusses the headset with Yvonne Felix, a blind artist and supporter of the technology.\nPhoto/Video: Emily Prapuolenis/The Wall Street Journal\n\nYvonne Felix\u2019s eyes don\u2019t work well enough on their own for her to read, recognize faces or cross the street without help.\nBut when the Toronto-based artist and mother puts on a new kind of camera-equipped headgear, she looks at me like no one has before.\nThe visor that allows legally blind people to see is no longer Star Trek fiction.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s\u00a0no\u00a0discussion of risks here. Does an eSight cause eye strain? What about headaches? Nausea? Does all-day use impact sleep quality? Is there a feeling of detachment or foggy-headedness that sometimes accompanies use of the virtual reality headsets it takes after? These are but a few of the questions we had on the drawbacks.", "answer": 0}, {"article": "About the Alzheimer's Research and Prevention Foundation\n\nThe Alzheimer's Research and Prevention Foundation is a non-profit organization dedicated to reducing the incidence of Alzheimer's disease by conducting clinical research and providing educational outreach about the lifestyle changes that can help prevent Alzheimer's disease.\nThe print edition is scheduled to be published in August.\nThe full text of \"Stress, Meditation, and Alzheimer's Prevention: Where the Evidence Stands\" can be accessed at http://content.iospress.com/articles/journal-of-alzheimers-disease/jad142766.\nKhalsa's article highlights the principles and practices of this 12-minute meditation, with corresponding SPECT scans showing how it successfully activates the posterior cingulate gyrus, an important region of the brain that helps regulate memory and emotional function.\nWhile preliminary studies have suggested a link between meditation, a sense of spirituality or faith and the risk of Alzheimer's disease, the article's author, Dharma Singh Khalsa, M.D., states that a cultivation of higher levels of psycho-social well-being, such as independence, resilience and life purpose represents \"an important new frontier that deserves further research as it is freely available to anyone, anytime, anywhere.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not addressed in the release but meditation is not associated with any common health risks. We\u2019ll rule this Not Applicable.", "answer": 2}, {"article": "While Drs.\nThe present analysis was not supported by industry funding.\nThe trial was initially sponsored by St. Jude Medical, a global medical device company, until the three-year follow-up.\nThe FAME 2 trial was supported by St. Jude Medical.\nThe medication used in the FAME 2 trial consisted of a combination of aspirin, cholesterol-lowering and blood pressure-lowering drugs as required by current treatment guidelines.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms of the PCI procedure. According to the NIH these include:", "answer": 0}, {"article": "According to the Skin Cancer Foundation, metastatic melanoma accounts for only about 1 percent of skin cancer cases but causes the majority of skin cancer deaths.\nAnd at 18 months, the rate was 66 percent for Opdivo and 53 percent for Yervoy, the findings showed.\n\"With these advanced melanomas -- that have high risks of recurrences and have poor outcomes -- it is vital to look at alternative treatments.\n\"Based on this study, it appears that patients with advanced melanoma who have their disease completely removed by surgery should go on to receive additional therapy with Opdivo,\" said Dr. Gary Deutsch.\n\"Results like this will change how we practice medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the most common side effects were fatigue and diarrhea. But the story also offers information about how common any adverse side effects were \u2014 for both Opdivo and Yervoy. That\u2019s valuable information. What\u2019s more, the story notes that Opdivo was less likely to cause adverse side effects than Yervoy, and that those side effects were less severe. Again, that\u2019s useful context.", "answer": 1}, {"article": "The U.S. Centers for Disease Control and Prevention has more on cervical cancer screening.\nThe HPV test should become the screening tool of choice for women 35 and older, the researchers said.\nIt could be done less frequently than the Pap test, which could be used only in women who have tested positive for HPV, they said.\nThe HPV test works a step further back in the process, looking to see if women are infected with HPV.\nThis results in many more callbacks for women to undergo further testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes the potential harms of HPV DNA testing, most notably the high false positive rate \u2013 or the high number of tests that come back positive that would never progress on to cancer. Positive results require additional testing and follow-up, which in itself isn\u2019t particularly dangerous, but could cause anxiety and requires time off work and additional costs.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070225/5disease.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention the increased risk of strokes with Lucentis. The story should have also mentioned risk of inflammation and infection from injection into the eye.", "answer": 1}, {"article": "People taking resveratrol also showed suppression of the inflammatory protein tumor necrosis factor, or TNF, and other compounds that increase blood vessel inflammation and interfere with insulin action, causing insulin resistance and the risk of developing diabetes.\nThe volunteers took pills once a day for six weeks.\nStudy author Husam Ghanim, PhD, of the University of Buffalo says the popular plant extract has been shown to prolong life and reduce the rate of aging in roundworms, fruit flies, and yeast, apparently because resveratrol affects a gene associated with longevity.\nNow, Ghanim and colleagues say they have found that resveratrol reduces inflammation in humans that could lead to heart disease, stroke, and type 2 diabetes.\nBlood samples from those on placebo showed no significant change in pro-inflammatory markers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Anything we put in our mouths has the potential to cause harm \u2013 a concept not recognized in this story. ", "answer": 0}, {"article": "\"I think this may be changing in health care,\" said Spears, \"but because migraine affects women more than men, there is a stigma around the stereotype of a patient who comes in with multiple complaints, calls frequently and wants to see the doctor frequently.\" Men, on the other hand, have been stereotyped as going to the doctor \"only when something he has is real.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Similarly, this story doesn\u2019t discuss harms.", "answer": 0}, {"article": "Why Biogen is breathing a sigh of relief with the latest Alzheimer\u2019s data\n\nWe already know Eli Lilly\u2019s big bet on Alzheimer\u2019s disease didn\u2019t work. But a deep dive into just how it failed has provided a bit of encouragement to Biogen and the many companies still hoping to succeed where their rival fell short.\n\nLilly\u2019s treatment, solanezumab, had no significant effect on the buildup of toxic brain plaques believed by many to be responsible for Alzheimer\u2019s neuron-destroying effects. The company had already disclosed that the treatment failed to improve patients\u2019 cognition and function, but the new data, released Thursday night, shed some important light on the underlying biology.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not cover harms.\u00a0A problem with these drugs is that they can cause amyloid-related imaging abnormalities (ARIAs), which are findings on brain scans that indicate swelling and small hemorrhages in portions of the brain. These were the most frequent adverse events in the Biogen study and occurred in a lot of people, especially at the higher doses.", "answer": 0}, {"article": "For women age 55 to 79, aspirin is recommended to prevent strokes, with the same caveat.\n\u201cIt refines our knowledge of how beneficial aspirin is,\u201d Dr. Graham Nichol, an expert in emergency care at the University of Washington in Seattle, said about the study.\n\u201cI like to say you have to make the recommendation about aspirin one patient at a time,\u201d Dr. Michael L. LeFevre, who was not linked to the study, told Reuters Health.\n\u201cThere is not universal agreement on what is high risk,\u201d he told Reuters Health.\nLeFevre added that while the new study did add extra evidence compared with earlier work, it failed to analyze the effects on men and women separately.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated \u201caspirin increased the rate of bleeding from 0.7 to 1 per 1,000 people per year, making the authors conclude the drug was of \u201cuncertain net value.\u201d", "answer": 1}, {"article": "The monthly, peer-reviewed Journal of Clinical Sleep Medicine is the official publication of the American Academy of Sleep Medicine, a professional membership society that improves sleep health and promotes high quality, patient-centered care through advocacy, education, strategic research, and practice standards.\nResults show that there were significant and clinically meaningful improvements in general quality of life and sleep-related quality of life measures after the initiation of PAP therapy for sleep apnea.\nThe improvements were more robust in those who were adherent to PAP therapy.\nThe study involved 2,027 patients with sleep apnea who began PAP therapy between Jan. 1, 2010, and Dec. 31, 2014.\nThe study is published in the Nov. 15 issue of the Journal of Clinical Sleep Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While CPAP therapy is relatively safe, there are still common side effects that were not mentioned in the news release. According to the National Sleep Foundation, most CPAP users will experience some mild side effects including congestion, runny nose, or stomach bloating. Though the harms are only mildly irritating, it would have been helpful if they were included in the release.", "answer": 0}, {"article": "That 1.7 percent difference is not considered statistically significant.\nAbbott Laboratories' newly approved Absorb stent comes with one important caveat: it hasn't yet been shown to be safer than older metal implants.\n\"We have good theoretical reasons to believe that by getting rid of the stent, and allowing the coronary artery to restore its normal shape, that will prevent many of those late events,\" said Dr. Gregg Stone, of Columbia University Medical Center, who helped conduct the pivotal trial of Absorb.\nIn the company study submitted to the FDA, patients who got Absorb fared about as well as those receiving Abbott's older metal stent after one year.\nHe says a \"perfect storm of events,\" including safety concerns and the economic downturn led Abbott and competitors Medtronic Inc. and Boston Scientific Corp. to slash prices in recent years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text offers a list of complications found with the new device, apparently recorded in the clinical trial: allergic reactions, infections, internal bleeding. And it gives us quantified information on \u201cheart-related complications\u201d for both the dissolvable and metal stents.\nBut the story\u2019s main message is that we simply do not know if these stents cause complications over the long term.\u00a0 It does quote a source who helped conduct the clinical trial for Abbott and who describes the \u201ctheoretical\u201d reason for the new stents as allowing arteries to return to their \u201cnormal\u201d shapes after the stents dissolve and, thus, prevent the kinds of problems that afflict permanent mesh stents, including a higher risk of blood clots.\u00a0 But the only study mentioned by the story, and by Abbot Labs in a news release, lasted a single year, while the stents are designed to completely dissolve over the course of three years.", "answer": 1}, {"article": "In a study recently published in the European Journal of Applied Physiology, Seeley and a group of BYU colleagues, as well as Dr. Eric Robinson from Intermountain Healthcare, measured inflammation markers in the knee joint fluid of several healthy men and women aged 18-35, both before and after running.\nSpecifically, they're looking to do similar tests on people who have suffered ACL injuries.\nHyldahl said the study results indicate running is chondroprotective, which means exercise may help delay the onset of joint degenerative diseases such as osteoarthritis.\nThis is potentially great news, since osteoarthritis--the painful disease where cartilage at the end of bones wears down and gradually worsens over time--affects about 27 million people in the United States.\n\"Instead, this study suggests exercise can be a type of medicine.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms are not discussed. The release hints that this benefit is there for \u201chealthy\u201d joints, but says nothing about joints with torn cartilage, already degrading joint surfaces or substantial osteoarthritis. The release notes that researchers plan more do more study of those with anterior cruciate ligament (ACL) injuries, but that is a tendon injury, not a joint injury.\nThere\u2019s a concern that this release could send the wrong message to some runners. What about people who experience pain when they run? Should they continue to run, despite the pain, because running might be \u201cchondroprotective.\u201d", "answer": 0}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms. For example, the story does not mention how many calories are in the drinks and that overconsumption by non-elite athletes could contribute to weight gain.", "answer": 0}, {"article": "A 6-month supply of vitamin D supplements can be bought for less than $10, and many multivitamins contain the recommended daily dose of vitamin D.\n\nAs for calcium, the NIH advises 1,000 mg per day for men ages19-70, and then 1,200 mg per day for men older than 70.\nAdding the supplements to the exercise program provided no extra benefit, hinting that the men already had enough vitamin D and calcium in their diets to be able to boost their bone strength through exercise alone.\n\u201cIt\u2019s like the four legs of the stool: vitamin D and calcium, exercise, medications if a person is losing bone, and the fourth leg is telling people how to prevent fractures,\u201d Zaidi said.\nHowever, there isn\u2019t enough data to say if vitamin D can help treat or prevent these diseases, Zaidi said.\nDespite the findings, people still need to get enough calcium and vitamin D to reduce the risk of osteoporosis, or bone thinning, said Dr. Mone Zaidi, an osteoporosis researcher at the Mount Sinai School of Medicine in New York, who was not involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a sense, the story was all about a finding that might help people avoid the \u201charm\u201d\u00a0of thinking that supplements do more for them than they actually do.", "answer": 1}, {"article": "When treating a patient suffering from depression, Brent Forester considers which anti-depressant to prescribe\u2014ideally, one that will ease psychic pain without side effects.\n\nIt can be a tough call.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The test itself \u2014 using DNA taken from a cheek swab \u2014 carries no physical risks.\nBut the story needed more detail about the potential downsides. As noted in more detail in the TIME coverage of the story, the various \u201cscales\u201d that are used to assess drugs aren\u2019t organized by how effective the drugs might be based on genetics, but instead how many adverse events they might cause. So, a person is told to take certain drugs not because they\u2019ll be more effective than other drugs, they\u2019re just less likely to cause problems.\nCould selecting drugs based on how many problems they cause lead some people to choose drugs that aren\u2019t as effective for treating depression? That would seem to be biggest issue in terms of harms \u2014 that the test would simply be wrong for some people.\nAlso, the test appears to show results for drugs beyond antidepressants \u2014 including some drugs that are known to cause dependency or can be deadly when taken alone, mixed together or with other drugs, such as hypnotics and benzodiazepines (Ambien and Xanax, for example). This is important to consider in a group of people already at higher risk for suicide.\nAll of this means adverse event data is vital \u2014 was it indeed lower in the gene-tested group?\nIf adverse event data were not available from the company or the investigators at the University of Michigan who led the study, the article could have noted the fact.", "answer": 0}, {"article": "Lauren Gravitz is a science writer and editor in Hershey, Penn.\nRight now, the longest patients have been on one of these new therapies is one to two years.\nSo for those of us who get numerous migraines each month, the prospect of a new approach feels almost life-changing.\nAll of that could change in a few months when the Food and Drug Administration is expected to announce its decision about new therapies that have the potential to turn migraine treatment on its head.\nYet, despite decades of research, there isn't a drug on the market today that prevents them by targeting the underlying cause.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Initially the story says patients \u201creport limited side effects that consist mostly of pain at the injection site. Unlike the current preventive medications, there is no nausea, no fuzzy thinking, no nerve pain, no weight loss or gain.\u201d\nBut it also notes a lack of long-term safety data and \u201cpotential long-term effects on blood pressure or other cardiovascular function\u201d as well as potential effects on fertility or placental function.\nIn the end, the reporter reflects on her own migraines and her own choices: \u201cI think about my two young children and my risk tolerance. Perhaps in ten years I\u2019ll feel differently. For now, however, I pick up the phone and cancel my clinical trial appointment.\u201d\nWe also like this cautionary sentence: \u201cRight now, the longest patients have been on one of these new therapies is one to two years.\u201d", "answer": 1}, {"article": "Harder\u2019s PSA was 9.\nAn MRI can also help determine how aggressive a tumor is, Yu said, and indicates if the tumor extends outside of the prostate and involves other areas \u2014 all information that helps urologists and radiation oncologists determine the best course of treatment.\nYu credits the technology and also having a dedicated team that can perform multiparametric-MRI, read the MRI scans and conduct biopsies with a very high success rate.\nOther patients who continue to hit a brick wall with negative results from TRUS biopsies yet persistently high PSA levels may not be as fortunate.\nHe estimates the volume will continue to increase because VCU will attract patients not only from the Greater Richmond area but also patients such as Grandon from other parts of the country.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention possible side effects of biopsies such as serious infections, pain, and bleeding. There\u2019s also no mention of the\u00a0 harms that can come from a false-positive test that can lead to more tests, mental anguish and unnecessary procedures.\nAlso, it does not mention that MRIs may be inappropriate for patients with kidney disease or implanted devices such as pacemakers, stents and inner ear implants, due to the strong magnetic field used.", "answer": 0}, {"article": "\"We adjusted for as many of those differences as we could,\" Wong said.\nOther experts expressed skepticism, saying the study's design may have missed another explanation for the lower death rate among men who were treated: They were probably healthier in ways that doctors can tell only by examining them, not by looking at their medical records, which is what the study's authors did.\nSome experts said they hope the findings will encourage more doctors to consider treating elderly men.\nThe research, published in today's Journal of the American Medical Association, is the first to directly examine what has become conventional wisdom: that many older men need not treat early prostate cancer because it tends to grow so slowly that they will probably die of something else first.\nBut she said she and her colleagues analyzed the data carefully to account for factors that could have influenced the findings, such as the subjects' ages and whether they had other health problems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the article does mention some harms of aggressive treatment, impotence and incontinence, it doesn't provide readers with any context around how often these occur or how troubling men may find these.\u00a0 There are qualitative statements telling readers that\u00a0quality of life can be affected, but overall, the seriousness of treatment side effects seems to be minimized.\u00a0 ", "answer": 0}, {"article": "First published on March 28, 2007 at 12:00 am\nAGH doctors have used the procedure in cardiac arrest victims five times since November, and three of those patients survived the procedure.\nAnother University of Pittsburgh Medical Center study also is using hypothermia to treat victims of head trauma.\nDr. Ashis Tayal, an AGH stroke neurologist, said trials are under way to use the therapy to help stroke victims.\nAlthough the cases are few, AGH's success rate points to the value of the therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms associated with this treatment or the frequency with which these are typically observed.\nThe person used as an example of the benefits of the treatment developed pneumonia in the course of his recovery from his cardiac arrest and his hypothemia treatment, which may be a side-effect of the treatment. ", "answer": 0}, {"article": "Baltimore, Md.\nTo be clear, other PSMA-based theranostics have reached the research bench, but previous contenders had too many limitations in terms of instability in live subjects, a lack of imaging contrast between targeted tissue and background signal and increased PSMA-associated binding to normal organs such as the kidneys.\n\"Prostate cancer still represents one of the main causes for cancer-related deaths among men,\" said Matthias Eder, PhD, co-author of the study and a researcher in the division of radiopharmaceutical chemistry at the German Cancer Research Center in Heidelberg, Germany.\n\"The diagnosis and therapy of metastatic prostate cancer is still challenging.\nScientific Paper 63: \"PSMA-617 - a novel theranostic PSMA inhibitor for both diagnosis and endoradiotherapy of prostate cancer,\" M. Benesova, M. Sch\u00e4fer, U. Bauder-W\u00fcst, K. Kopka, M. Eder, Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany; C. Kratochwil, A. Afshar-Oromieh, W. Mier, U. Haberkorn, Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany; SNMMI's 62nd Annual Meeting, June 6-10, 2015, Baltimore, Md.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is not really addressed \u2014 or addressable \u2014 given that only one patient has been treated. The release discusses previous drugs of this type that had problems, and mentions \u201cadverse effects\u201d associated with existing therapies. The suggestion is that this drug does not have those problems and would be a safer alternative to existing therapies. But there\u2019s no way we can assess the safety of this approach based on results in only patient. So the release is incomplete and potentially misleading in its discussion on this point.", "answer": 0}, {"article": "Stroke is the single largest cause of adult disability and the third-largest cause of death in the developed world.\nThere were also more independent patients and depression was less common in the Prozac group than in the placebo group, and side effects of the drug were rare and mild, researchers said.\nRoger Bonomo, director of stroke care at Lenox Hill Hospital in New York, said another way to look at the implications of this trial would be as justification for treatment of post-stroke depression before it progresses.\nExperts commenting on the findings said they had \u201cenormous potential to change clinical practice\u201d and raised the question of whether most stroke patients with motor skill problems should be treated with this relatively cheap type of antidepressant.\n\u201cThe positive effect of the drug on motor function... suggests that the neuronal ... action of SSRIs provides a new pathway that should be explored further,\u201d said Francois Chollet of Toulouse University Hospital, who led this research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Generally this isn\u2019t a risky medicine, but we ding the story here for not only failing to quantify harms, but perhaps mischaracterizing the safety data from the study. It quotes the researchers as stating that side effects were rare and mild. But in the actual study,\u00a025% of those taking fluoxetine had transient digestive problems (compared to 11% receiving placebo), and there were two serious side effects, a partial seizure and a serious case of low\u00a0sodium.\u00a0A more accurate summary would\u2019ve been the softer statement that MOST side effects were rare OR mild.", "answer": 0}, {"article": "They collected blood from 584 people coming to the Orlando Regional Medical Center, which is a Level 1 Trauma Center, for trauma-related injuries.\nIt might also help coaches or athletic trainers are sports events to determine which athletes who have had a concussion are able to return to the game and which, if they have higher levels of the blood marker, should not.\nBut there aren\u2019t good ways to distinguish between mild blows that don\u2019t require additional care and mild to moderate traumatic brain injury (TBI), which could have more serious consequences.\nCurrently, CT scans of the brain are the standard way of diagnosing TBI, but they can\u2019t pick up every case.\nAnd because the expose patients to radiation, doctors are often reluctant to use them on every patient, especially young children, who come to the emergency room with a head injury.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention any harms, but all screening tests have harms associated with false positive and negative results. In athletes, for example, a false positive test keeps you off the field and creates\u00a0unnecessary anxiety. A false negative result\u00a0means you go back on the field with a concussion and potentially suffer another head injury that could have catastrophic consequences.", "answer": 0}, {"article": "Deaths from adenomatous lung cancer were cut 30 percent, those from colorectal cancer 40 percent, and those from prostate cancer 10 percent.\nBut Rothwell says this bleeding hazard is \"drowned out\" by the cancer benefit.\nRothwell says the \"sensible time\" to start taking aspirin \"would be before the risk of cancer starts to rise, at about 45.\"\nTo be sure, the U.S. Preventive Services Task Force's currently recommends against taking aspirin to prevent colorectal cancer, the type of cancer for which there is the largest body of scientific work.\nYes, scientists have already published strong evidence suggesting aspirin can cut bowel cancer and deaths.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is one of the few stories to put a number to the potential harms. \u201cBut aspirin carries risks. The biggest is stomach bleeding, although it also raises the risk of brain hemorrhage. Daily aspirin doubles a person\u2019s gastrointestinal bleeding risk to about 2 in every 1,000 people a year. But Rothwell says this bleeding hazard is \u201cdrowned out\u201d by the cancer benefit.\u201d", "answer": 1}, {"article": "Then at 9 to 10 weeks the mother's blood takes over to feed the embryo,\" said Kliman.\nFor women who suffer multiple pregnancy losses in the first four to six weeks of gestation, the hormone progesterone could offer hope for a successful birth, according to a new study by Yale School of Medicine researchers and their colleagues at University of Illinois at Chicago.\nWomen in the study with an abnormal nCyclinE level were prescribed progesterone two days after ovulation, when the uterine lining matures in preparation for a possible pregnancy.\nThe researchers believe that the progesterone caused the patients' endometrium to produce more endometrial secretions.\nWhen we give progesterone back to these women, the endometrium makes more nutrients and prevents their pregnancy loss.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "With any drug treatment related to pregnancy it is absolutely essential to discuss the effects of the drug on both mother and child. This news release doesn\u2019t address safety risks to either.\nThe Mayo Clinic\u2019s website for patients offers a long list of possible side effects from progesterone in adults. Much less information is available about progesterone\u2019s risk to a developing fetus. ", "answer": 0}, {"article": "The results of the Women's Health Initiative (WHI)--the largest, most scientifically rigorous study of older women's medical issues ever conducted--continue to startle researchers, confuse the public and frustrate headline writers. Case in point: last week's report that taking estrogen for seven years does not increase the risk of breast cancer for many women. There is a lot of good news in that finding, as well as some important caveats.\n\nIn many ways, the story began four years ago when researchers halted a different part of the WHI--one that looked at the long-term health effects of taking the hormone combination estrogen and progestin...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the estrogen-only part of the Women\u2019s Health Initiative was stopped early because the women taking estrogen had an increased risk of stroke. (But it also could have mentioned that possible harm again as a factor that women should consider when deciding about therapy for their menopausal symptoms.) Blood clots, another possible side effect of estrogen therapy, are mentioned only briefly.", "answer": 1}, {"article": "\"Nobody wants to sedate a healthy infant,\" says Dawson.\nDoctors and scientists not connected to the study are intrigued by the results but caution that this is very early research and not something concerned parents can be looking for as a screening tool for their babies any time soon.\nWiznitzer \u2013 a pediatric neurologist at Rainbow Babies & Children's Hospital in Cleveland, Ohio \u2013 notes that what the study can't tell us is what the differences in brain activity between the two groups of babies actually mean.\nBosl acknowledges that if this is very early research, but he believes if the results are confirmed, it may lead to a safe and inexpensive way to detect autism, which would allow intervention before any autistic behaviors appear.\nThe EEG technique is much easier to use because the baby can be awake and moving and wiggling around, says Dr. Geraldine Dawson, chief science officer for the advocacy group Autism Speaks, which partially funded this research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story quantified the harms.\u00a0The obvious harm is parental anxiety and labeling an infant as having autism when there must be at least some risk of false positives.\nThis was framed as a potential screening test.\u00a0 All screening tests carry potential harms.\u00a0 Journalists often report only on screening tests\u2019 potential benefits.", "answer": 0}, {"article": "Women who carry these mutations have a lifetime risk of breast cancer of anywhere between 56 percent to 84 percent, according to the researchers, whereas the risk for ovarian cancer ranges from 36 percent to 63 percent for BRCA1 mutation carriers and 10 percent to 27 percent for BRCA2 mutation carriers.\nTUESDAY, Aug. 31, 2010 (HealthDay News) -- Women who carry genetic mutations that boost their odds of breast and ovarian cancer can live longer and reduce their cancer risk by having preventive surgery, a new study suggests.\nThe surgery in question is drastic: removal of the breasts or ovaries before any signs of cancer have arisen.\n\"These findings really emphasize how important it is for all women with a family history of early breast or ovarian cancer to undergo genetic testing,\" said Dr. Virginia Kaklamani, co-author of an editorial that accompanied the study.\nSilver added that women who are found to carry one of these genetic mutations face \"a very complex set of considerations, so the more hard facts you can give them, the better.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story calls preventive surgery \u201cdrastic,\u201d but it doesn\u2019t provide any details about harms of the procedures. Also, the description of laparoscopic ovary removal makes the procedure seem entirely benign. No mention of how women might think about potential harms such as premature menopause, heart disease, osteoporosis, etc. ", "answer": 0}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the harms of hormone pills. ", "answer": 1}, {"article": "For more information on stroke, visit the U.S. National Library of Medicine.\nAmong those in the study, 38 percent had the fattier-than-normal plaque, 17 percent had signs of blood clots and 27 percent had both the fattier plaque and blood clots, the researchers found.\nWEDNESDAY, Aug. 17, 2011 (HealthDay News) -- People who have narrowed carotid arteries in the neck and show no symptoms may be at risk for stroke and not know it, but a simple ultrasound test can identify the problem, a new study suggests.\nIn addition, over the two years of the study, 10 people had TIAs.\nMoreover, people with the fattier plaque were more than six times more likely to have a stroke than those people without the plaque, and those with the fattier plaque and clots had a risk that was 10 times higher, Topakian's team found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported that 10 individuals in the study of 435 had TIAs. \u00a0While transient ischemic attacks is one outcome of interest, the study presented the number of study participants that had strokes, and died of either stroke or cardiovascular death.\nThe story reported the likelihood that individuals with one or another of the problems visualized with ultrasound would have a stroke \u2013 but did not report the absolute increase in stroke that was actually observed. \u00a0This information is essential for understanding the magnitude of benefit possible. \u00a0And although the story included quotes from clinicians indicating that the risk of stroke is higher with carotid endarterectomy, there should have been some number provided to enable readers to understand the risks associated with the intervention that might result from having undergone the tests.", "answer": 0}, {"article": "... Then a lot of guys eventually were like, 'I'll go.\n'Medical mistrust has been an important barrier'\n\nThe study had some limitations, including that it was not blind, because both participants and researchers knew who was assigned to the pharmacist-led program and who was in the control group.\nAdditionally, more research is needed to determine whether similar study results would occur on a national level, since the study was conducted only in the Los Angeles area.\nOn the other hand, the barbershop represents a safe haven in the black community -- a no-judgment zone -- where conversations about health and other personal topics are commonplace.\n\"To a certain extent, I was surprised by the magnitude of the effect of the intervention,\" said Ciantel Blyler, a clinical pharmacist at Cedars-Sinai Medical Center in Los Angeles who was a co-author of the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough one to rate. On one hand, It is hard to envision harms arising from men participating in what appeared to be a safe screening and treatment program for high blood pressure. On the other, the journal paper about this study reported that three individuals experienced acute kidney injury, although that problem disappeared once medications were altered. So, there are risks, and the story would have been stronger had it included them.", "answer": 0}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nThe Penn-led team administered a once-daily dose of LDX for four weeks to 32 healthy, non-ADHD-diagnosed women between the ages of 45 and 60 experiencing difficulties with executive functions as a result of mid-life onset menopause, and as measured using the Brown Attention Deficit Disorder Scale (BADDS).\nResults of the study are published online today in the journal Psychopharmacology.\nThis project was funded in part by Shire Pharmaceuticals, the National Institute of Mental Health, the National Institute on Aging, and the National Institute on Drug Abuse.\nThe researchers found a 41 percent overall improvement in executive functions for women receiving LDX, compared to a 17 percent improvement when taking placebo medication.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release fails to mention any harms in this release, although the paper mentions that this drug can raise both heart rate and blood pressure, although not precipitously.", "answer": 0}, {"article": "Benign prostate hyperplasia, also known as enlarged prostate, is a non-cancerous condition familiar to millions of aging males.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\nAnd while this study showed some symptomatic improvement, it didn't have enough objective data to show that the new technique would surpass surgery, she said.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\nAfter nine months, none had experienced sexual dysfunction and 25 percent still reported improvements.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not report on any harms observed in the 67 men who took part in the study reported on.", "answer": 0}, {"article": "Nerve cells that communicate and control the voluntary muscles of the body (such as those in the arms, legs and face) degenerate or die.\nThe results of one new study may be less than hoped for, but the science is sound: The study concluded that injecting stem cells into the spinal cords of patients with amyotrophic lateral sclerosis is safe in most, though not all, cases.\nIn Pharr's opinion, this and other stem cell studies are certainly fair from a participant's perspective, since beforehand, \"patients are presented with all the risk factors involved so they can make an informed decision.\"\nWhat he discovered during that experiment was that none of the patients suffered long-term effects (from either the surgical procedure or the implantation of stem cells), and no unusual acceleration of disease occurred.\nImportantly, one patient showed some improvement, though he and his colleagues noted that this outcome \"must be interpreted with caution\" since the study wasn't designed to measure effectiveness of the treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided a lot of detail on the harms noted in the study, earning it\u00a0a Satisfactory rating in this criterion, albeit with caveats.\nCertainly, the bar for safety may be lower for ALS than for other diseases, but we think the story misleads by calling the treatment \u201cgenerally safe.\u201d As the story explains,\u00a0two of the 15 patients developed \u201csevere complications,\u201d including partial paralysis and \u201cincapacitating pain.\u201d More detail is warranted here. In fact, the 15 patients in the study experienced\u00a0a total of 81 adverse events\u00a0that researchers said were probably or definitely related to the treatment, mainly surgery. While most of these were not serious, they may\u00a0have reduced the quality of life at least temporarily for patients who probably have little time left to live. In addition, these patients spent several days in a hospital going through an uncomfortable procedure.", "answer": 1}, {"article": ".\nThis is an evolving field, and our goal is to better discern who is at high and low risk of breast cancer and develop a greater range of prevention strategies.\u201d\n\nAn individual risk analysis should prompt conversation between doctor and patient about the potential benefits and the risk of the therapy.\nBut few women are opting for this protection, which goes by the name chemoprevention.\nAt that point, the panel said, women \u201care likely to have more benefit than harm from using tamoxifen or raloxifene.\u201d\n\nASCO\u2019s lower cutoff worries some experts.\nIt is important to realize, she adds, that \u201cas the risk increases, the benefits tend to be greater.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We grant a passing grade for the inclusion of statements about increased risk of uterine cancer and other serious side effects. But we have to wish for some discussion of sexual side effects in more common language. Not everyone knows that \u201chot flashes\u201d and \u201cvaginal dryness\u201d are part of the menopause-like state that chemoprevention creates in some women. We suspect those potential side effects influence women\u2019s decisions.", "answer": 1}, {"article": "And the warriors had a 40 percent lower risk of cardiovascular death and an 18 percent lower risk for cancer-related death.\nAnd vigorous activity makes you fit, and fitness reduces your risk of disease and death,\u201d says Gary O\u2019Donovan, a researcher in physical activity and sedentary behavior at England\u2019s Loughborough University and lead author of the paper.\n\u201cI would be more concerned about what\u2019s happening at the point of exercise\u2014not the long-term benefits,\u201d says Dr. Howard Andrew Selinger, chair of family medicine at Quinnipiac University.\n\u201cIn theory, someone who did one bout of 150 minutes of moderate exercise is a weekend warrior,\u201d says O\u2019Donovan.\nHe says middle-aged adults should exercise moderately during the first 12 weeks and then slowly build up to more vigorous activity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job highlighting some of the potential harms associated with vigorous physical activity: \u201cHowever, experts caution that it is possible to overdo it\u201d \u00a0and \u201cmore exercise than two and a half hours a week can actually be unhelpful and even harmful.\u201d\nAn expert in the field not associated with the study provides a bit of common sense to the discussion; \u201cThere are risks that come with a\u00a0weekend warrior exercise schedule, especially for people who aren\u2019t used to being active. \u201cI would be more concerned about what\u2019s happening at the point of exercise\u2014not the long-term benefits,\u201d says Dr. Howard Andrew Selinger, chair of family medicine at Quinnipiac\u00a0University.", "answer": 1}, {"article": "Dr Joanna Bowtell, head of Sport and Health Sciences at the University of Exeter, said: \"Our cognitive function tends to decline as we get older, but previous research has shown that cognitive function is better preserved in healthy older adults with a diet rich in plant-based foods.\nThere was also evidence suggesting improvement in working memory.\n\"In this study we have shown that with just 12 weeks of consuming 30ml of concentrated blueberry juice every day, brain blood flow, brain activation and some aspects of working memory were improved in this group of healthy older adults.\"\nThe study was also supported by the charity BRACE, which raises funds to support dementia research.\nBefore and after the 12-week period, participants took a range of cognitive tests while an MRI scanner monitored their brain function and resting brain blood flow was measured.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no statement about harms, not even a statement declaring there are none.", "answer": 0}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nThe study earlier this year also found that women who took supplements regularly reduced their chance of fracture more than those who didn't.\nThese women showed about a 10 percent chance of fracture, compared with 15 percent.\nResearchers studied the effect of 600-milligram calcium supplements twice a day on women over 70 and found that only those women who took 80 percent or more of their pills were less likely to experience fractures.\nNow, says Senay, a study in the Archives of Internal Medicine shows calcium supplements do reduce the risk of fractures in elderly women, but only among those who take them regularly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. In the study, the researchers found that constipation was a side effect of taking the calcium supplement", "answer": 0}, {"article": "A tiny but promising study suggests that a medicine used for immune disorders may offer long-term benefits to Alzheimer's patients\u2014a result likely to spur demand for the treatment even though it is in limited supply and isn't approved for the memory-debilitating disease.\n\nThe treatment, intravenous immunoglobulin therapy, or IVIG, is made from the blood plasma of healthy young adults. Since 2004 it had shown early promise for Alzheimer's, which afflicts some five million Americans.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t report on what side effects were observed in the study.\u00a0 But we\u2019ll give it the benefit of the doubt for at least citing the experience of one doctor who has used the drug:\nSeveral of her patients have exhibited side effects. One developed a serious allergic reaction, two had kidney insufficiencies that reversed when they stopped and a few have had mild skin rashes that went away as they stayed on the treatment.", "answer": 1}, {"article": "Symptoms include recurring headaches, loss of appetite, blurred vision, vomiting, shifts in personality and the ability to learn, seizures and the gradual loss of speech.\nShi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\n\u201cFor example, we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.\u201d\n\nDr. Harry Bulstrode, brain tumor expert funded by the charity Cancer Research U.K. who is researching how Zika could be used to treat aggressive brain tumors, who was not involved in the study, told Newsweek: \"This study is another interesting piece in the jigsaw, but it is never going to demonstrate what we believe to be the really exciting properties of the virus.\n\u201cWe still need to further improve the specificity of the cancer-killing ability, while retain the safety of the vaccine strain,\u201d Shi explained.\nThe study showed that a live-attenuated Zika vaccine (containing a weakened version of the virus that does not cause disease in humans) could selectively infect and kill human glioblastoma stem cells, explained Shi.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that the Zika virus had no adverse health effects in mice, but that it is possible it might destroy healthy neural tissue in humans. Again, the story needed to caution that we have no idea how this might help\u2013or hurt\u2013humans.", "answer": 0}, {"article": "\u201cThey\u2019ll feel measurably better.\u201d\n\n\u201cThe patient population was really quite ill and had very high disease activity, and despite that we saw nice response rates,\u201d Sandborn said.\nThe rate of infections and other serious side effects was similar in the Stelara and placebo groups, researchers said.\nClinical remission was defined as a CDAI score down to 150.\nCommon symptoms are abdominal pain and diarrhea, and it can lead to bowel perforations.\nThat compared with a response rate of 23.5 percent of patients who received a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Unlike common polyps, they tend to be flat and the same color as the colon lining.\nThe DNA stool test methods were developed at the Mayo Clinic.\nTUESDAY, May 4, 2010 (HealthDay News) -- Noninvasive stool DNA testing can detect two types of colorectal precancers and could play a larger role in colon cancer prevention, say two new studies.\nSome of the study authors and the Mayo Clinic have a financial interest related to technology used with this research.\n\"The 90 percent detection rate by stool DNA testing is remarkable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of false positives with this method. ", "answer": 0}, {"article": "They found that Chinese women who ate the most soy were also less likely to die of lung cancer, the No.\n\u201cThis finding, along with our previous observation of an approximately 40 percent reduction in risk of incident lung cancer associated with high intake of soy food, provides further support for the role of soy food intake in lung cancer development and prognosis,\u201d the researchers wrote.\nThe findings, published in the Journal of Clinical Oncology, lends support to the idea that adding soy foods to the diet can help people in multiple ways, says Dr. Jyoti Patel, a lung cancer specialist at Northwestern University in Chicago, who was not involved in the study.\n\u201cIt may be that we do need to change our diets a little bit and eat more of these soy-based diets.\nMost of the women in the study had never been smokers, and there\u2019s a lot of evidence to suggest that lung cancer is a different disease in smokers versus non-smokers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t address harms, but we\u2019re not sure that there are any harms worth mentioning when it comes to soy foods eaten in moderate amounts.\u00a0Hypothetical concerns that soy may promote estrogen-sensitive cancers have not been confirmed in large studies. And the story correctly\u00a0advises readers not to take soy supplements, which deliver a higher dose of soy isoflavones that might potentially increase\u00a0cancer risk. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "Smokers who count on nicotine patches or gum to help them quit may want to reconsider: A new study finds that these and other nicotine replacement products aren't effective at preventing former smokers from relapsing in real-world conditions.\nBut the latest results are in line with other studies that have found little \u2014 if any \u2014 benefit from the products when used by smokers in real life.\nThose who had used nicotine patches, gum, inhalers or nasal sprays were just as likely to relapse as those who had quit without them, researchers from Harvard University and the University of Massachusetts found.\nThe findings run counter to the results of several randomized clinical trials conducted before the Food and Drug Administration gave the thumbs-up to these nicotine replacement products in the 1990s.\nIn those trials, volunteers using such products were up to three times more likely to kick the smoking habit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of the potential harms from taking nicotine, as opposed to quitting without drug therapy. There\u2019s also the question of whether people are doing themselves more harm by continuing to smoke because they failed to quit with the help of a nicotine replacement product. If they had been able to more effectively quit earlier, would they live longer?", "answer": 0}, {"article": "Phentermine quickly suppresses appetite, while the controlled-release topiramate decreases appetite and increases satiety throughout the day.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\nThe new analysis of three separate studies included more than 4,500 people.\n\u201cWhen the hunger comes back, the topiramate kicks in,\u201d says study author Suzanne Oparil, MD, a professor of medicine, physiology, and biophysics and director of the vascular biology and hypertension program at the University of Alabama at Birmingham.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned specific side effects of this particular medication combination. \nTo be most informative to readers, the story should have mentioned that the potential for long-term harm is not known. \u00a0And the rate at which people stopped taking the drug due to side effects should have been included.", "answer": 1}, {"article": "As a nicotine-gum addict, Mike Metzger used to worry about the warning on its label: \"Stop using the nicotine gum at the end of 12 weeks.\"\n\nBut that was before a prominent smoking-cessation scientist, K. Michael Cummings, told him to keep chewing the gum as long as it helped him stay off cigarettes. So 15 years after quitting smoking, Mr. Metzger, a 63-year old retired New York telephone worker, still chews 16 pieces of nicotine gum a day.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although some potential harms are mentioned, none are quantified.\nThe story states that NRT products \u201chave amassed a strong safety record\u201d but we never get any details on that record.\nWe wish the story had delivered a deeper exploration than one health behavior specialist saying, \u201cThere really doesn\u2019t appear to be any great harm.\u201d And a British regulatory proclamation that \u201cthere are no grounds to suspect appreciable long-term adverse effects.\u201d\u00a0 Statements like \u201cdoesn\u2019t appear to be\u201d and \u201cno grounds to suspect\u201d could be haunting some day.", "answer": 0}, {"article": "Ketamine infusion therapy, the controversial treatment for depression, has been resisted by many physicians due to concerns about short-lived benefits, risks of addiction, and the lack of large scale studies.\nPatients in the study completed the Quick Inventory of Depressive Symptoms (QIDS-SR), among other scales, and 80% showed persistent positive response to the ketamine infusions treatments.\nThe study also challenges concerns about neurotoxicity and a recent hypothesis that patients must experience hallucinations during ketamine infusion in order to have an anti-depressant benefit.\nIn contrast, this retrospective study of over three years of clinical experience, shows lasting benefits for many patients, with no apparent risk of addiction.\nWhile controversial in academic settings, Dr. Henderson said his direct experience supports a different strategy for multiple-infusion treatment regimens and his clinical experience shows ketamine can invoke long-lasting effects often with less than six infusions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible side effects in the news release, other than to challenge the broader psychiatric community\u2019s belief that ketamine is addictive. The author is quoted saying, \u201cOur patients get better after a few infusions and from there treatments can be discontinued.\u201d\nIn contrast to the release, the study did point out some side effects, which should have been included in the PR release. It states, \u201cThe most common side effects in doses used for depression treatment include: dizziness, nausea, and a slight sense of dissociation. The side effects clear generally within 15-30 minutes after the infusion.\u201d", "answer": 0}, {"article": "Some prostate cancers evolve to use energy from lipids (fat).\n\u201cSince the drugs are clinically safe, a clinical trial can be designed in patients for whom enzalutamide is prescribed.\u201d\nA University of Colorado Cancer Center study published today [May 3] in Oncotarget shows that combining a CPT1A inhibitors with anti-androgen therapy increases the cancer\u2019s sensitivity to the anti-androgen drug enzalutamide.\nThe drug ranolazine is a fat oxidation inhibitor that earned FDA approval in 2006 to treat angina.\n\u201cThis finding may have a huge impact on patients with CRPC that had very few options before,\u201d says Schlaepfer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The drug\u2019s potential harms to people are known and reported in the New England Journal of Medicine. They include \u201cfatigue, constipation, and back and joint pain as well as hypertension.\u201d\nThe release doesn\u2019t tell us if the mice in the study experienced any side effects from the drug.  ", "answer": 0}, {"article": "\"Even a small, straightforward, relatively inexpensive policy intervention was associated with a small but statistically significant drop,\" Elbel told CBS News.\nThe editorial, entitled \"Power of a Simple Intervention to Improve Student Health: Just Add Water,\" said the study's findings are significant.\nThe study, published in JAMA Pediatrics, analyzed data collected from 1,227 elementary and middle schools across New York City - some with and some without \"water jets.\"\n\"The study by Schwartz and colleagues in this issue of JAMA Pediatrics adds to a growing body of evidence supporting the importance of providing drinking water access in schools.\nGiving school children access to chilled, self-serve water may help chip away at childhood obesity, a new study of more than one million New York City school students suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Students in New York City schools had access to water through drinking fountains before this intervention study. This study looked at a new way to deliver New York city tap water to kids, which may have encouraged them to opt for water instead of sugary beverages, like soda.\nWe rate this one Not Applicable.", "answer": 2}, {"article": "They found it would be.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\nHowever, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nThey did not study actual people eating actual chocolate.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quoted the Harvard expert:\n\u201cThe researchers are ignoring some downsides, he says. \u201cThey are ignoring the dangers of too many calories and too much fat and sugar from the chocolate bar,\u201d he says.\u201d\nBut somewhere in this review, we must criticize the story for never offering any detailed analysis of the researcher\u2019s \u201cmodel.\u201d We could do it in the Evidence criterion, but we\u2019ll choose to do it here.\nSurprisingly the model used by these researchers did not account for the adverse effects (weight gain, etc) that might accrue from adding a daily 100 g chocolate bar, which might contain as much as 600 calories (!), to your diet for 10 years.\u00a0 Since the entire underpinning of the story was the validity of the model, this is a weakness in the story. ", "answer": 0}, {"article": "Sept. 17, 2010 -- The FDA has approved Krystexxa (pegloticase) for the treatment of gout.\nThe drug is associated with some serious side effects.\nThe drug is administered to patients every two weeks as an intravenous infusion.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did explain: ", "answer": 1}, {"article": "\u201cIt\u2019s easier to pop a pill,\u201d Dr. Altman said.\nThe topical painkillers are not for everyone.\n\u201cFuture research needs to be done using patients with co-morbidities to know that these agents are safe in the highest-risk population,\u201d said the author of the analysis, Dr. Una Makris, an associate research scientist at the Yale School of Medicine.\n\u201cI think many people are not aware of topical Nsaids, or there is a perception that they don\u2019t work well, or people confuse topical Nsaids with other topical drugs, like the topical salicylates or capsaicin,\u201d Dr. Chou said.\nBut for immediate relief of my tennis-related muscle pull, the cream was handy and helpful.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story summarizes the reported side effects of topical NSAIDS. What\u2019s more, the reporter points out that the potential risks in people who have other health problems or are taking other drugs have not been well studied. That insight is something we see too rarely.", "answer": 1}, {"article": "Here's why.\nAfter a median follow-up time of 10.5 months, Gandhi said, the patients in the combination group were 51 percent less likely to die, compared with patients in the chemo-only arm.\nThe estimated proportion of patients in the combination therapy group who were alive and whose disease had not gotten worse at a year was about 34 percent, about double the proportion for the chemo-only group.\nThe patients experienced a significantly longer period during which their disease did not worsen, compared with people who received only chemotherapy, said Memorial Sloan Kettering Cancer Center oncologist Matthew Hellmann, who led the study.\nResearchers at Johns Hopkins and Memorial Sloan Kettering gave patients two doses of Opdivo \u2014 the first a month before surgery, the second two weeks before the operation \u2014 to try to stimulate anti-tumor activity and reduce the risk of relapse.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects were not addressed. About 14% of the patients in the combination group dropped out of the trial due to adverse events, versus about 8% of those in the chemo-only group.\nAcute kidney injury and fever relating to neutropenia, a low white blood cell count, occurred more frequently in patients who received Keytruda.", "answer": 0}, {"article": "He noted that the technology's cost \"is not prohibitive, and it is safe.\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\nIn prior studies, they found that far-UVC light killed methicillin-resistant S. aureus (MRSA) bacteria -- a common and dangerous \"superbug\" -- without harming human or mouse skin.\nThe disinfecting success of initial experiments still need to be confirmed, said lead research David Brenner.\nResearchers say a certain spectrum of ultraviolet light -- called far-UVC -- easily kills airborne flu viruses while posing no risk to people.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Based on earlier in vitro studies by the same authors, it\u2019s mentioned the antiviral effect can be achieved without harming human or mouse skin, or causing cataracts (cataracts and skin cancer are a\u00a0 well-documented side effect of full spectrum UVC exposure). It\u2019s not clear if these results would hold up in live subjects. No other side effects of far-UVC spectrum light are mentioned.", "answer": 0}, {"article": "The participants were randomly assigned to one of two groups.\nProf. Ahluwalia advises that people looking to increase their daily nitrate intake should avoid boiling vegetables, as the nitrate dissolves in water.\nBeetroot contains high levels of dietary nitrate (NO3), which the body converts into biologically active nitrite (NO2) and nitric oxide (NO).\nResearchers have concluded that one glass of beetroot juice a day is enough to significantly reduce blood pressure in people with high blood pressure.\nOther leafy vegetables, such as lettuce and cabbage, also have high levels of the compound.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It may be reasonable to think that taking large amounts of nitrates for long periods of time is safe, but are we really sure? It\u2019s perhaps also worth mentioning that people should get their nitrate from foods, not supplements.\u00a0Cases in the medical literature have documented confusion between inorganic nitrate (found in beets) and \u00a0synthetic organic nitrate or nitrite (e.g. nitroglycerin or amyl nitrate). The latter agents cause potent dilation of the blood vessels at low doses and can precipitate fatal cardiovascular collapse.", "answer": 0}, {"article": "Breast cancer has a high rate of metastasis to bone, lung, liver, lymph nodes, and the brain.\n\u201cWe think this targeted approach holds great promise for earlier imaging of high-risk cancers in the clinic.\nTherefore, they expect it will be safe if ultimately developed for clinical use.\nIt could also become useful as a non-invasive way to assess breast cancer treatment progress.\u201d\n\nThe team plans to complete safety testing of the imaging agent during the next three years.\n\u201cThe technique used by researchers in this study enables very early detection of metastatic spread, which would allow adaptation of treatment more quickly and hopefully lead to better outcomes in the future.\u201d\n\nThe study, published online in the Aug. 12, 2015, issue of Nature Communications, was led by Zheng-Rong Lu, Ph.D., CWRU M. Frank Rudy and Margaret Domiter Rudy Professor of biomedical engineering and an expert in molecular imaging for cancer and other diseases.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release seems overly optimistic here. It says testing by the researchers \u201cshowed that the agent is readily cleared from the body and has a low level of retention in tissues. Therefore, they expect it will be safe if ultimately developed for clinical use.\u201d \u00a0We think it would be best to conduct the necessary studies before commenting optimistically on the potential safety of the agent \u2014 after all, the point of conducting the studies is that we don\u2019t know yet if the agent is safe or not. And even if it does turn out to be safe, there could be potential side effects that patients should know about. Also, the experiments involved mice, and it\u2019s not clear if this technique would require a patient to submit to a whole body MRI in order to find metastases.", "answer": 0}, {"article": "\u201cSome men go to the bathroom several times a night, get right back to sleep and are not bothered,\u201d he said.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\nNor does it lead to cancer.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm associated with any of the treatments was the possible need for additional treatment some time in the future for the minimally invasive and surgical options mentioned. \u00a0However \u2013 there was no mention of the sexual function and incontinence issues that may accompany these invasive treatments; nor was there discussion of the side effects associated with medication use.", "answer": 0}, {"article": "Differences in mean changes in swallowing at radiotherapy week 4 (\u221215 in the CRT group and \u221225 in the radiotherapy alone group, P = .02), loss of appetite at radiotherapy week 4 (\u221211 in the CRT group and \u221218 in the radiotherapy alone group, P = .03), nausea at week 8 after radiotherapy (\u22127.3 in the CRT group and 0.3 in the radiotherapy alone group, P = .04), coughing at radiotherapy week 4 (7.4 in the CRT group and \u22125.6 in the radiotherapy alone group, P = .02) and at week 8 after radiotherapy (\u22123.2 in the CRT group and 1.1 in the radiotherapy alone group, P = .04), constipation at month 8 (2.6 in the CRT group and \u221219 in the radiotherapy alone group, P < .001), and cognitive functioning at month 12 (\u22127.0 in the CRT group and 4.6 in the radiotherapy alone group, P = .04) were not seen at the other time points.\nIt is noteworthy that this randomized clinical trial was not designed to enroll a sufficient number of patients to definitively and prospectively address the subject of the analysis reported herein.\nA pharmacologic profile was also performed weekly on patients receiving cetuximab infusion (CRT group).\nOne of the largest randomized clinical trials was designed to evaluate laryngeal preservation compared with radiotherapy alone, concomitant chemoradiotherapy, and induction chemotherapy followed by radiotherapy.13,14 Each treatment group included at least 180 patients, thus providing much greater statistical power than the current communication.\nMeaning The results of this secondary subset analysis reveal a possible cetuximab-related benefit in laryngeal preservation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This comes back to cetuximab. As noted above, cetuximab is already sold under the trade name Erbitux. And Erbitux\u2019s own website notes that it can cause significant adverse health effects, including heart attacks and allergic reactions that resulted in death. We don\u2019t expect a news release to include a thorough recounting of every possible adverse health effect associated with a treatment, but we do expect there to be at least an acknowledgment of known health risks \u2014 and especially so when the relevant risks are so severe.", "answer": 0}, {"article": "Another person said of their pet birds: \"If I didn't have my pets I think I would be on my own.\nThis may be especially true for people with serious mental illness, a study finds.\nThe social workers at McLean also incorporate pets into their aftercare planning, encouraging patients to make walking and grooming their pets a part of their routine.\nPatients with pets often say the animals help keep them from following through on suicidal thinking, because they know their pets depend on them.\nThe animals also could distract them from their illness, even from severe psychosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. It is important to recognize that the patients reporting positive influences of pets are having a good experience already. Giving a pet to someone with a major mental illness, who has not previously cared for an animal, could go very poorly without the right support systems in place.", "answer": 0}, {"article": "Autologous CD34?\nOutcomes from the \"ACT-34-CMI\" study, a two-year, phase II, randomized, double-blind, placebo-controlled clinical trial, will be published in an upcoming cardiac issue of Cell Transplantation.\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\nThe patients, who were unresponsive to other treatments, were considered to have no other options (refractory).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential risks associated with CD34+ treatment. The Cell Transplantation paper did not report significant adverse effects associated with the treatment, but noted that \u201cthe longer-term effects of this treatment are unknown.\u201d Even if there are no additional risks associated with a treatment, a release needs to tell readers that \u2014 and, in this case, the researchers themselves make clear that they do not yet have a clear assessment of potential risks.", "answer": 0}, {"article": "Please see paper for the complete list.\n\u201cEven though we see the far-reaching implications of this success, we also realize that this is a very small study that needs to be replicated in larger numbers at various sites.\u201d Plans for larger studies are underway.\nWithout effective prevention and treatment, the prospects for the future are bleak.\nNow we\u2019re recommending that people find out their genetic status as early as possible so they can go on prevention.\u201d Sixty-five percent of the Alzheimer\u2019s cases in this country involve APOE4; with seven million people carrying two copies of the ApoE4 allele.\n\u201cWe think addressing multiple targets within the molecular network may be additive, or even synergistic, and that such a combinatorial approach may enhance drug candidate performance, as well.\u201d\n\nWhile encouraged by the results of the study, Bredesen admits more needs to be done.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any potential risks of any aspect of the protocol. Since we do not really know what the protocol consists of we have no way of assessing potential risk.", "answer": 0}, {"article": "The study found that test subjects given 5-Hour Energy experienced \u201cenergy\u201d for about 40 minutes longer than when given Red Bull or Monster Energy, though it was not clear from court papers whether that difference reflected the energy shot\u2019s higher levels of caffeine.\nShe added that another study showing the benefits of 5-Hour Energy was undergoing \u201cpeer review\u201d for possible publication in a scientific journal.\nAsked whether consumers mistakenly believe that the shot does not produce a caffeine-related crash, Ms. Lutz said that the use of the special mark and its explanation were clear.\nThat mark, which also appears on the back label, explains in fine print that \u201cno crash means no sugar crash.\u201d\n\nThat is hardly surprising, because 5-Hour Energy does not contain sugar.\n\u201cI don\u2019t believe that it is misleading,\u201d said Ms. Lutz, who added that the advertising division of the Council of Better Business Bureaus had approved the \u201cNo Crash Later\u201d claim.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly\u00a0acknowledges that energy drinks have been linked to\u00a0reports of deaths and\u00a0injuries that may be related\u00a0to their high caffeine content, and there was an online link in the text to a previous story about these concerns. We\u2019ll call this good enough for a satisfactory. However,\u00a0considering that FDA reports\u00a0suggest that 18 deaths and more than 150 injuries\u00a0may be related to energy drinks, we don\u2019t think the story captures the full scope of the potential problem.\u00a0This deficiency was nicely described by Paul Raeburn at the Knight Science Journalism Tracker, who\u00a0noted that\u00a0in a 2,000-word piece, there was ample room\u00a0to do \u201ca more thorough job of reminding offline readers why these drinks have provoked concern.\u201d\nAdditional comment about kids and teens and use of these drinks along with alcohol would have strengthened the article.", "answer": 1}, {"article": "Some people (about 1 percent of whites; fewer of minorities) lack both copies of the CCR5 gene and are naturally resistant to HIV.\nThe only side effect was two days of flulike symptoms.\nThe sixth man also had modified cells, but fewer than expected.\n\"It's an overreach of the data.\nThere are a lot of people out there with hopes and dreams around the C-word,\" so caution is needed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job in saying:\u00a0\u201cThe only side effect was two days of flulike symptoms. It will take longer to determine safety\u201d", "answer": 1}, {"article": "on Sept. 2.\nMr. Schimmer\u2019s note was entitled \u201cFolotyn Prices High, Reiterate Outperform.\u201d He estimated annual sales of the drug in the United States reaching about $300 million by 2014.\n\u201cA peripheral T-cell lymphoma patient,\u201d he said, \u201cat first blush will see this therapy as a very good thing.\u201d\n\nAllos, which is still unprofitable, has lost $350 million since its founding in 1992 and failed to win approval of a previous drug.\nIn the prospectus for that offering, the company said that one of the risks for investors was \u201cthe relative price of Folotyn as compared to alternate treatment options.\u201d It said there was a risk it might have to lower the price or offer discounts to successfully market Folotyn.\nIn the clinical trial, the median duration of use was 70 days, which would cost roughly $70,000 to $80,000.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms of Folotyn. Although the primary focus of the story realtes to the drug\u2019s cost, it would have desriable to provide a brief comment on the toxicity of the drug as well.\u00a0 The addition of the information would help the reader place the value of the drug into a better perspective.\u00a0 According to the package insert, 44% of patients treated in the clinical trial suffered from a serious side effect of the drug", "answer": 0}, {"article": "I'm proof.\"\nWe can anticipate challenges by practicing the procedure beforehand.\u201d\n\nSo far doctors at Mayo Clinic have done this personalized procedure on more than 450 patients.\n\"The data shows that similar clinical outcomes are had when you look at the traditional open approach versus the endovascular approach but the endovascular approach provides the added benefit of shorter hospital stays and a faster recovery.\"\nUsing a minimally invasive endoscopic vascular surgical technique, patient recovery times are quicker.\nThe cardiology community now prefers the endovascular approach.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential risks associated with this procedure or any stent insertions for abdominal aortic aneurysms. Further, there\u2019s no discussion of whether the procedures and devices involved have undergone safety trials.", "answer": 0}, {"article": "In their study, published in the Feb. 23 issue of the Journal of the American Medical Association, Miglioretti and her colleagues found that false positives and interval cancers were both higher in women with a history of breast cancer than in those without such history.\nDr. William Audeh, medical director of the Samuel Oschin Cancer Center and the Wasserman Breast Cancer Risk Reduction Program at Cedars-Sinai Medical Center in Los Angeles, described the findings as \"not at all surprising.\"\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nAnd though mammography did not catch all cancers in the women with a breast cancer history, the study still points out the value of the test, he said.\nWomensHealth.gov has more on mammograms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0discusses false positives & interval cancers & provides explanations of both of these problems associated with screening mammography.", "answer": 1}, {"article": "Then President Richard Nixon declared drugs \u201cpublic enemy No.\n\u201cWith even minor mental health conditions like minor depression or anxiety...or more serious problems like addiction, the existing paradigm is to frame these as chronic, lifelong diseases\u201d that require continuous medication with drugs like serotonin-specific reuptake inhibitors, Wood says.\nIn the past 20 years or so, a small amount of research has once again begun to focus on these chemicals, showing that they have promise for treating a range of conditions, from addiction to depression and anxiety, says Evan Wood, a psychiatric researcher at the University of British Columbia.\nThat said, when studied under controlled and supervised conditions, these chemicals have not been found to cause lasting negative health consequences, the Canadian Medical Association Journal review noted.\nThe idea that you can take a medicine one or a few times and become \u201ccured,\u201d or at least significantly helped, conflicts with current standard practices, which often involve taking medications every day for years, or life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Obviously the harm potential of these drugs is probably what gave them a bad reputation in the first place\u2013particularly in their potential for abuse\u2013so it would have been useful to hear which adverse effects were experienced by these users in these small experiments. It was good that the story stipulated that the drugs were used under controlled and supervised conditions, and so the obvious question arises: is that how these drugs would be used in the wider population, and if not, would that not alter the harm/benefit potential of the drug?\nAs we circle back to re-evaluating these drugs, focusing on one specific area (anxiety/depression), it seems a little too easy to forget they are powerful drugs that affect multiple chemical and who knows what other\u00a0systems in the brain. Informed consent documents for future studies will be tricky.", "answer": 0}, {"article": "A lot changed in between the births of my second and third daughters. For one thing, this time around I really am getting no sleep; for another, the pediatrician recommended something for our 1-month-old that is different from what had been suggested for our other children. She said we needed to pick up a liquid multivitamin that contains 400 international units (IUs) of vitamin D. It was a little confusing, because with our first daughter, now almost 4, the doctor told us to simply get her out in the sun from time to time to let her body produce vitamin D,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although this story did mention two side effects of excessive intake of vitamin D, this list downplays the consequence of overdose. \u00a0For this, they could have simply gone to the Time archives and unearthed their piece from 1992: \u00a0http://www.time.com/time/magazine/article/0,9171,975464,00.html\u00a0\nThis is not a trivial point, especially since the clinician quoted in the piece mentioned personal consumption levels above those recommended. \u00a0Taking a supplement to match the intake mentioned, in concert with vitamin D containing foods, multivitamins, and exposure to sunlight \u2013 could result in people ending up with higher than intended levels.\nThere is also no mention of the lack of long term data on supra-therapeutic levels of the vitamin, and we can assume that the effects, good or bad, may be magnified by the longer duration of exposure and more sensitive developing body in the children and adolescents that were the focus of the piece.", "answer": 0}, {"article": "The CHEO Research Institute makes discoveries today for healthier kids tomorrow.\nTwo other practices - receiving an opioid prior to sedation and having a laceration repair - were associated with the occurrence of vomiting, oxygen desaturation and need for significant interventions.\nThe overall incidence of adverse events in the study population was 11.7%.\nThe results of the study show that choice of sedation medication had the biggest impact on the incidence of adverse events and need for significant interventions in response to those events.\nSignificant interventions in response to an adverse event were rare, occurring in only 1.4% of children.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did a good job of explaining possible harms that occur in relation to different types of sedation. A few words about the specific adverse events seen with ketamine would have been of value. \u00a0As a dissociative agent, ketamine is known for its ability to produce bizarre dreams, and hallucination as well as excessive salivation.\nHere is an excerpt from the release:\n\u201cThe overall incidence of adverse events in the study population was 11.7%. The most common events were a decrease in oxygen saturation (5.6%) and vomiting (5.2%). Significant interventions in response to an adverse event were rare, occurring in only 1.4% of children. Two other practices \u2013 receiving an opioid prior to sedation and having a laceration repair \u2013 were associated with the occurrence of vomiting, oxygen desaturation and need for significant interventions.\u201d", "answer": 1}, {"article": "The U.S. Food and Drug Administration has not yet approved its use.\nIf it is applicable, it could mean patients need not take blood-pressure drugs, Esler suggested.\nThe procedure is safe as well as effective, the study authors said.\nThere is thus an important, but currently unmet, need for additional therapies to effectively control hypertension.\"\nSingh also noted that although this procedure is used in other countries it is not yet approved in the United States.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not sufficient to simply act as stenographer when study authors say \u201cthe procedure is safe as well as effective.\u201d In fact, a careful review of the actual journal paper contradicts the safety statement.\u00a0One subject in the crossover group suffered a renal artery dissection (tear) during placement of the guide catheter that required urgent repair. Not important enough to report?\nAnd it certainly isn\u2019t adequate to quote from a news release that \u201cparticipants\u2019 kidneys were not damaged or functionally impaired.\u00a0 We also found no ill effects on long-term health from the procedure.\u201d\u00a0 Would most blood pressure experts consider 6-12 months as \u201clong-term health\u201d?\nCan a procedure be proclaimed \u201csafe\u201d in the hands of one experienced team?\u00a0 What might the learning curve be for this approach?\nThese are not merely academic questions when a researcher \u2013 and a story \u2013 proclaim a tiny study as proof of safety.", "answer": 0}, {"article": "According to Dr. Anthony L. Komaroff, a Harvard internist and epidemiologist who has written a commentary to accompany the study, \"For many years medical scientists have speculated that the symptoms of ME/CFS might be caused by cytokines, molecules that the immune system use to wage war against foreign invaders of the body.\nOut of 51 cytokines investigated via sophisticated fluorescence-based testing, only two of the cytokines differed, in their total concentrations, between the ME/CFS and control groups.\nTwo classic laboratory measures of inflammation are sedimentation rate \u2014 the ability of red blood cells to clump together, which isn't a factor in ME/CFS \u2014 and C-reactive protein, which reflects levels of a single cytokine that wasn't one of those linked to severity in this study.\nBut, levels of 17 of the cytokines varied dramatically between the patients with mild versus severe ME/CFS symptoms.\nThe link to gradation in severity, rather than simply seeking a positive versus negative result, represents a new approach to the search for biological markers for the illness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms of testing. Notably, since the researchers noted broad overlaps between cases and healthy controls in the levels of almost all the cytokines measured, it seems likely that test results could be easily misinterpreted to either label healthy people as sick or sick people as health.", "answer": 0}, {"article": "This measure of metabolic health is called \u201cinsulin sensitivity,\u201d and it is one of many metabolic functions that goes awry in people with obesity. In those who develop type 2 diabetes, sensitivity to insulin becomes so impaired that the body is tricked into believing less insulin is needed, and it pares back its production. The insulin-producing cells in the pancreas will often atrophy and die in response. As a person\u2019s insulin production declines, an external supply of insulin is needed to control blood sugar and deliver fuel to muscles and organs.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not mention side effects of deep brain stimulation, which may include brain bleeding, stroke, seizure, and mood and cognitive changes.", "answer": 0}, {"article": "Among 46 chronic pain sufferers, those who spent time each day in a sauna for four weeks enjoyed a 54% improvement in sleep quality and were 27% more likely to return to work compared to a no-sauna group.\nWhile there\u2019s not a ton of published research looking specifically at infrared saunas, Beever has published a review of all the existing studies he could turn up on the subject.\nBeever says infrared heat may damage sperm as do other forms of heat, but at this point there\u2019s no data on those risks.)\nBeever\u2019s review also looked at some of the other purported health benefits of infrared saunas\u2014including pain management.\nHealthy sperm and heat don\u2019t play well together.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Effect on sperm count is mentioned. But that\u2019s far from the only risk.\u00a0There are large segments of the population who are generally told not to use saunas\u2013such as pregnant women or people with chronic diseases.\u00a0What makes saunas inherently dangerous for them? Is it also true for infrared saunas?\u00a0We don\u2019t know or learn in this article.", "answer": 0}, {"article": "They also lost substantial inches from their waistlines, which may be an important consideration for heart health, said Shane Phillips, an assistant professor in the department of physical therapy at the University of Illinois at Chicago.\nThe study did not include a control group of men and women who performed no exercise, making it impossible to tease out the exact physiological role that exercise played, Dr. Stewart said.\n\u201cIt took people less time to lose 10 pounds\u201d on a high-fat diet-and-exercise program, about 45 days on average, than the 70 days it took for those who exercised and followed a high-carbohydrate, low-fat diet constructed using guidelines from the American Heart Association, said Kerry J. Stewart, director of clinical and research exercise physiology at Johns Hopkins University School of Medicine and lead author of the report.\n\u201cBut what about in 5 or 10 years, if they remain on the diet?\u201d\n\nThis study also reported on a single marker of cardiovascular health, she continued.\nThe full study will monitor the volunteers for six months and include additional measures of cardiovascular health after both diets.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that there were no harmful effects on the blood vessels observed in either group. \u00a0However \u2013 since people in the study were reported to have healthy vessels to begin with, combined with the short amount of time they were followed, it is very unlikely that any change would be seen. \u00a0So it is really insufficient evidence about lack of harm.\nThe story lacks perspective on the problem of knowing whether a treatment is safe or not. We need thousands of people in a clinical trial to determine cardiovascular safety, not 46.", "answer": 0}, {"article": "The Claim: Red palm oil, a deep orange fat pressed from the palm tree fruit, is a superfood\u2014packed with healthy antioxidants and good for the heart, say companies who sell it.\n\nThe Verdict: The colorful oil is rich in tocotrienols, nutrients in the vitamin E family, and carotenoids, which the body converts into vitamin A. Several studies suggest possible benefits in stroke and liver disease from vitamin extracts made from the oil, but so far there isn\u2019t proof that consuming the oil can ward off disease, scientists say.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with benefits, the potential harms of red palm oil are just generally summarized. Still, the story points out that this oil and others like it can produce harm (and clearly contain plenty of calories). A nice touch is that the potential harms addressed by the story include environmental damage caused by poor agricultural practices, as well as potential exploitation of workers in developing nations. While those domains are typically outside our scope, they are clearly relevant to consumers looking to make informed purchases.", "answer": 1}, {"article": "Immunotherapy is one of medicine's most promising \u2014 and most problematic \u2014 approaches to cancer treatment.\nIn six of the 11 patients in the trial, the melanoma stopped progressing for 12 to 19 weeks.\nThe researchers hoped that by choosing T cells more selectively and cloning only those judged most likely to vanquish their foe, the treatment would be more effective.\nBut they also noted that the trial involved only 11 patients and said the therapy was less effective than in other published trials.\nThe approach outlined in the new study by researchers from the Fred Hutchinson Cancer Research Center in Seattle identifies several ways to make it better, said Dr. Cassian Yee, the study's senior author.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\n\u201cCurrently, the T cells have limited staying power and often die off before their work is done. Doctors give them a boost by administering a growth factor called interleukin-2. But at high doses, it can cause dangerously low blood pressure, breathing problems, kidney failure and heart arrhythmias.\nYee\u2019s group showed that by choosing T cells more selectively, patients can get by with much lower doses of interleukin-2, making the treatment less toxic.\u201d\nBut we\u2019re not told what side effects were observed in the 11 patients in the study. In reality the study originally involved a high dose (3 subjects) and low dose (8 subjects) IL-2 arm.\u00a0 The high dose arm was closed by the Data and Safety Monitoring Board prematurely due to unacceptable toxicity.\n\u00a0", "answer": 0}, {"article": "Related: New Test Detects Heart Disease Risk, Especially for Black Women\n\nIt\u2019s not just the fat cells that lead to heart disease, the No.\nIf the method holds up, doctors could start patients on drugs such as statins far earlier than they do now \u2014 in time to save them from ever developing serious heart disease, the researchers report in the journal Science Translational Medicine.\nResearchers say they\u2019ve developed a better way of scanning someone\u2019s heart to predict who is most at risk of a heart attack or stroke \u2014 long before conventional imaging methods can do it.\nRelated: Why Young Women are Having Heart Attacks\n\nThe team studied more than 450 people having heart bypass surgery, removing some of the fat clogging their arteries.\n\u201cWe are now further validating our method in larger numbers of patients in large prospective clinical studies to document and confirm the predictive value of this method for future heart attacks,\u201d Antoniades said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because there is so little information about the imaging technique and what it requires, it\u2019s hard to say what the harms or benefits might be, but certainly the story might have mentioned the potential risk of drug intervention (or non-intervention) if the inflammatory cell \u201cmarker\u201d is valid as a predictor of heart attack risk.\nAlso, it would have been worth discussing if the new imaging technique exposes patients to radiation, which has been shown to increase the risk of cancer if used repeatedly.", "answer": 0}, {"article": "The company\u2019s consolidated revenues for fiscal 2014 (ended March 31, 2015) totaled 9,761 billion yen ($81.3 billion).\nThree primary benefits are: (1) more accurate irradiation which reduces the side effects to healthy tissues surrounding the tumor compared with irradiation from conventional double scattering irradiation; (2) patient-specific collimators and boluses become obsolete, shortening set up times for patients; and (3) high proton beam usage factor reducing unnecessary secondary radiation.\nUnlike conventional scattering technology, spot scanning technology delivers narrow beams to the tumor and the complex tumor shape can be irradiated through repetitive beam delivery with quick position change.\nPBT improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared with that of traditional radiotherapy.\nThe same spot scanning system has already been installed at Nagoya Proton Therapy Center and Hokkaido University in Japan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release gives the briefest mention of side effects, but we\u2019ll give it the benefit of the doubt.\u00a0The statement that PBT brings \u201cvery few side effects\u201d is understood to be true since proton beams deposit less radiation outside the tumor area than do photon-based treatments. However, there are few (if any) reports of clinical studies comparing the side effects of protons with those from photon treatments.\nIn addition, claiming that patients \u201cexperience no pain\u201d when undergoing proton therapy is slightly misleading, since the same can be said for photon-based radiation therapy.\nIt\u2019s important to point out that proton facilities don\u2019t typically use an advanced imaging technique (such as CT or MR) to verify the patient\u2019s position prior to administering radiation; whereas this is standard practice for photon IMRT techniques. That is troublesome, because the consequences of a geometric miss in proton therapy are expected to be greater than they would be for photon IMRT.", "answer": 1}, {"article": "For further information please visit www.gsk.com.\nIn addition, a pooled analysis of data from the ZOE-70 and ZOE-50 trials showed that the candidate vaccine effectively reduced the risk of subsequent chronic neuropathic pain, also known as postherpetic neuralgia (PHN)1 which is the most common, and often severe, complication of shingles3,4.\nA pooled analysis of data from both trials showed the vaccine demonstrated 91% efficacy against shingles (95% confidence interval: 86-95%) in adults aged 70 years and older compared to placebo1.\nThe study, from which headline results were reported in October 2015, showed that the two-dose candidate shingles vaccine had 90% efficacy (95% confidence interval: 84-94%) compared to placebo in people over 70 years old.\nThe candidate vaccine was shown to be 89% (95% confidence interval: 68-97%) efficacious in preventing PHN in people aged 70 years and older and 91% efficacious (95% confidence interval: 75-98%) in people aged 50 years and over1.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release notes that serious adverse reactions occurred with about equal frequency among study participants who received the vaccine and those who had placebo injections.\u00a0Although the release acknowledges the most common injection site\u00a0and systemic adverse reactions, most commonly mild-to-moderate\u00a0pain at the injection site and fatigue, it could have been more forthcoming about how common these reactions were. The article on which the release is based states that 79% of participants who received the vaccine, versus 29.5% of placebo recipients, reported local and/or systemic side effects.", "answer": 1}, {"article": "CNN Films Presents:\" Glen Campbell ...\n\"The study is encouraging enough that we should certainly go ahead and do a [larger] clinical trial because we showed that it is safe and does have significant effects on Alzheimer's biomarkers,\" said Dr. R. Scott Turner, professor of neurology at Georgetown University Medical Center and lead investigator of the study, which was published on Friday in the journal Neurology.\nThe only small concern they found was that patients taking resveratrol lost about two pounds during the one-year study, and weight loss is already a problem with Alzheimer's, Turner said.\nIf resveratrol does pan out in further research, it may add to the medications that are currently available, such as Aricept and Exelon, which slow, but do not halt, progression of the disease, Hendrix said.\nMuch more research is needed\n\nThe study was not big enough to answer some important questions, such as whether patients taking resveratrol actually had lower levels of amyloid-beta plaques in their brain, and most importantly, whether they experienced less decline in their mental faculties.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story specifically discusses the safety of resveratrol, noting that the one concern researchers found was that there appeared to be a slight weight loss (two pounds) in patients taking resveratrol over the course of the one-year study, compared to a one pound weight gain in patients taking placebo. This is significant because weight loss can be a problem for Alzheimer\u2019s patients. The story could also have addressed the concerns raised in some quarters that resveratrol may affect blood clotting, which would be important information for patients taking blood thinners.", "answer": 1}, {"article": ".\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\nATLANTA--A novel class of antimicrobials that inhibits the function of a key disease-causing component of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial pathogens, according to researchers at Georgia State University.\nThe best inhibitor in this group, SCA-50, showed strong activity against MRSA Mu50 strain and an inhibitory effect on MRSA Mu50 that was two-to-60 times more potent than all commonly used antibiotics, including vancomycin, the last resort option for treating MRSA-related infections.\nHe co-led the study with Phang C. Tai, Regents' Professor of Biology at Georgia State, who is an expert on the functions of SecA in bacteria.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Any new drug developed from this research would have side effects. But whereas the release is optimistic in forecasting that such drugs would be effective treatments for MRSA, it doesn\u2019t also caution that such drugs might cause harm. At the very least, a statement about the fact that potential harms are unknown would have been helpful.", "answer": 0}, {"article": "\"Blueberries are one of the more potent foods in terms of protecting the brain,\" Morris said.\nThe MIND diet recommends limiting yourself to no more than five of these treats per week.\nThe MIND diet recommends frequent servings of green leafy vegetables.\nThe MIND diet recommends eating berries at least twice a week.\nThe Mediterranean and DASH diets do not specifically recommend these types of vegetables, but the MIND diet study found that including greens in addition to other veggies made a difference in reducing the risk of Alzheimer's.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Following any of these three diets is better than the normal, high fat, salt and red meat standard American diet and even moderate adherence to these diets is thought to be heart healthy and perhaps brain healthy, too.", "answer": 2}, {"article": "An estimated 5 million people in the world have an eye disease called trachoma that affects the cornea, and another 1.5 million to 2 million are thought to have developed cornea-related blindness through other diseases or trauma.\nThe researchers went one step further and gave contact lenses to the patients.\nThe study appears in the Aug. 25 issue of Science Translational Medicine.\nThe mock corneas were then placed into the eyes of 10 patients after the diseased corneas were removed.\nGriffith said a German study recently found that donated corneas cost about $2,500.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that there were no adverse side effects. It should have been clear that the patients were followed for two years.", "answer": 1}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets credit for noting that DXA scans involve radiation, and for explaining exactly how much radiation one may be exposed to during a scan. However, that information could have been placed in a more health-relevant context. The DXA scan, the story says, exposes someone to \u201cabout the same as one day of background radiation\u201d and compares the dose to chest x-rays and mammograms. The story would have have stronger if it had explained whether that means low risk or high. A few more details would have been helpful here.", "answer": 1}, {"article": "To find out more about the activities of EULAR, visit: http://www.\n\"Findings from our study have shown that adopting a TNFi dose reduction strategy can still meet this objective, with no compromise on symptom control for the patient and offering a more cost-effective option by substantially reducing the high drug costs associated with TNFi maintenance therapy.\"\nFor those patients who either fail to respond, or who develop an inadequate response to these drugs over time, a biologic DMARD is an effective add-on treatment option.2 The first choice of biologic therapy is usually a TNFi2 and currently identical dosing regimens of TNFi are used both to induce and then maintain a clinical response.1\n\nOver the first six months of the study, flares (exacerbations of symptoms and signs) occurred in 14% of patients who stayed on the same TNFi dose, compared to a similar figure of 13% in those patients for whom the dose was reduced by one-third.\nRome, Italy, 13 June 2015: The results of a study presented today at the European League Against Rheumatism Annual Congress (EULAR 2015) showed that, in rheumatoid arthritis (RA) patients, a good clinical response to maintenance treatment with a tumour necrosis factor inhibitor (TNFi) was maintained even when the dose was reduced by one-third.\nOf the 47 patients who reduced, then stopped their TNFi after six months, 45% (21/47) succeeded without flaring, and their final mean DAS28 score after stopping treatment was 2.2, demonstrating low disease activity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release says: \u201cThere were no significant differences in self-reported measures of disability (Health Assessment Questionnaire score) with either dose reduction strategy at six months.\u201d\u00a0But it is not clear whether self-reported measures of disability are limited to the effects of rheumatoid arthritis, or whether they also include side effects that may have been caused by the drug.\u00a0According to the American College of Rheumatology, those side effects can include \u201can increased risk for all types of infections, including tuberculosis (TB) and fungal infections. Some of these infections may be severe.\u201d\nWhile the potential for side effects should have been mentioned, we\u2019d note that reducing the TNFi dose should theoretically reduce harms. But that is an assumption that needs to be studied. This study is too small to do that.", "answer": 0}, {"article": "Clostridium novyi flourishes in low-oxygen environments.\nThe strain used in this clinical trial, Clostridium novyi-NT, had been weakened to prevent it from producing its toxin, which can be lethal in humans, Janku said.\nResearchers have moved on to the next phase, in which patients taking the immunotherapy drug pembrolizumab (Keytruda) will also be treated with a single injection of Clostridium novyi-NT, Janku said.\nPatients also could be susceptible to immune response side effects, such as low blood pressure or fever, he added.\nWhen both injected and uninjected lesions were included, the stable disease rate was 86 percent, the researchers reported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that two patients in the trial who received the highest doses fell ill with sepsis and gangrene. It also mentioned a need to \u201ckeep an eye on potential side effects\u201d in future trials.", "answer": 1}, {"article": "\"It's odd and it's tough and people say, 'I'm sorry.'\nMore research will be needed to try to establish whether they actually repair damage to the spinal cord.\nAnd for one patient, it is promising.\nToday, the company sponsoring the trial reported four of the six patients experienced improvement in both motor strength and function.\nAn experimental procedure aimed at repairing spinal cord injuries is showing promise.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. Any surgical procedure presents a risk. Since clinical trials of stem cell procedures for spinal cord injury are just beginning, they carry a risk of unforeseen adverse effects.", "answer": 0}, {"article": "Their median age was 63.\nWith better drugs and radiation techniques available, the proportion of women with Stage 4 breast cancer who had surgery dropped from 67.8 percent in 1988 to 25.1 percent in 2011, according to a study published Wednesday in the journal JAMA Surgery.\nIn a Stage 4 case, cancer cells have left the breast, metastizing to bones or other organs, which presents a more dire and immediate threat to a woman's survival than the presence of the original tumor.\nThat would include younger women whose cancers have not spread in great volume to other organs and who have certain kinds of cancers that respond better to drugs, Lisa Newman, medical director of the Henry Ford Health System's International Center for the Study of Breast Cancer Subtypes, said in an e-mail.\nOver the past few decades, as breast cancer has increasingly been treated as a systemic disease, the number of surgeries performed on the most serious cases has plummeted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Breast surgery can lead to complications, such as bleeding and infection, like any major surgery. Patients usually choose between breast-sparing surgery (surgery that takes out the cancer and leaves most of the breast) and a mastectomy (surgery that removes the whole breast).\nAccording to cancer.gov, mastectomies can affect a woman\u2019s psychological well-being due to a change in body image and the loss of normal breast functions. Furthermore, women undergoing total mastectomies lose nipple sensation, which may impede sexual arousal.\nOther breast surgeries could lead to sudden drops in estrogen production, which could induce early menopause in premenopausal women.\nSince harms are not addressed, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "\"Amphibians, especially certain groups of frogs, produce and store large amounts of antimicrobial peptides in specialized granular glands in the skin,\" said Louise Rollins-Smith, associate professor of pathology, microbiology, and immunology at Vanderbilt University School of Medicine.\nIf those studies prove to be successful, human testing could be next.\nIf there is a similarity, it may explain why H1 viruses are vulnerable to urumin's wrath.\nThe urumin peptide could be a novel treatment since it targets the hemagglutinin, unlike current drugs on the market which target other parts of the virus, resulting in less impact, Jacob said.\n\"As an amphibian biologist concerned about the loss of amphibian species around the globe, it is important to note that they may hold important secrets useful for human medicine and they should be preserved,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given the early nature of the research\u2013which the story makes clear is preliminary\u2013we\u2019ll rate this N/A.\nIdeally, we\u2019d like a statement to the effect that the safety is totally unknown.\u00a0However\u00a0the story does establish that future research might better pin down the harms, i.e.,\u00a0\u201cIf further studies show it has a low level of cytotoxicity\u2026\u201d", "answer": 2}, {"article": "For more information, visit http://www.\nAs more and more handheld ultrasound machines come to market, these results suggest that lung ultrasound has the potential to become the preferred choice for the diagnosis of pneumonia in children.\nLung ultrasound has been shown to be highly effective and safe for diagnosing pneumonia in children and a potential substitute for chest X-ray, according to a study conducted at the Icahn School of Medicine at Mount Sinai.\nChest X-ray is considered the test of choice for diagnosing pneumonia in children, but the WHO estimates three-quarters of the world's population does not have access to radiography.\n\"In the era of precision medicine, lung ultrasound may also be an ideal imaging option in children who are at higher risk for radiation-induced cancers or have received multiple radiographic or CT imaging studies,\" says Dr. Tsung.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release points out that there was no increase in adverse events reported during the study, nor were there any cases where pneumonia was not appropriately diagnosed. There is the potential for some harms that aren\u2019t addressed, namely missed diagnosis and the identification of small pneumonias that don\u2019t need to be treated (overdiagnosis).\n\u201cIn the era of precision medicine, lung ultrasound may also be an ideal imaging option in children who are at higher risk for radiation-induced cancers or have received multiple radiographic or CT imaging studies,\u201d according to the lead study author. This benefit in terms of harms reduction might have been stressed even more. Ultrasound screening could be safer in the long run for children than X-ray since repeated exposure to radiation presents a cumulative risk for cancer. Radiation oncology experts and the FDA have long called for reduced reliance on routine X-ray and computerized tomography (CT) screening in children unless the benefits outweigh the risks. More than 100 professional organizations including pediatricians, radiation physicists and oncologists have signed on to the \u201cImage Gently\u201d campaign which urges the use of ultrasound instead of radiation when feasible.", "answer": 1}, {"article": "It employs more than 100 people and has government backing through Innovate UK but also gets private funding through partnerships.\nInsulin shots could become a thing of the past for type 1 diabetes patients thanks to a technology being developed by Cell and Gene Therapy Catapult, a London-based not-for-profit organisation, and Aberdeen University.\nIf clinical trials are successful, the technology means tens of thousands more people could live without the need for frequent insulin injections, although it will take a few years until the treatment is available.\nGrowing islets will \u201csignificantly increase the number of patients who can receive the treatment,\u201d Keith Thompson, CGT\u2019s chief executive, told the World Stem Cells and Regenerative Medicine congress in London on Wednesday.\nJohn Casey, consultant transplant surgeon at the Royal Infirmary of Edinburgh and lead clinician for the islet transplantation programme in Scotland, said: \u201cIslet transplantation can transform the lives of patients with type 1 diabetes, and in some cases can result in long-term freedom from insulin injections with excellent glucose control.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article\u00a0mentions a few times the benefits of being freed from insulin injections, but offers no information on the potential harms of any therapy, including the one being proposed here, which would be invasive. Current islet transplant treatments contain a number of risks.\nThere also should be some discussion about what percentage of transplanted patients would see benefit. The article makes it seem as if all of them would be free from using insulin.", "answer": 0}, {"article": "When planning a day at the beach, should you add Polypodium leucotomos to your picnic basket? The company that sells the natural fern extract says a daily dose can help protect against sunburn, sun-related aging and even genetic mutations that cause skin cancer. Dermatologists say preliminary evidence suggests the extract does protect against the sun -- but don't throw away your sunscreen yet.\n\nEvery year, 36% of U.S. adults get at least one sunburn, according to the federal Centers for Disease Control and Prevention....", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that \u201cso far no negative side effects have been reported.\u201d This is insufficient.", "answer": 0}, {"article": "Professor Marianne Thoresen said: \"Even if we account for a lesser severity of perinatal asphyxia, our research has shown that therapeutic hypothermia reduces the number of children who develop epilepsy later in childhood.\nEven if a lesser severity of perinatal asphyxia is accounted for, cooling therapy has increased the number of healthy survivors and there are very few children with epilepsy needing drug treatment.\nUntil recently, 20 to 30 per cent of these patients would develop epilepsy and many need regular antiepileptic treatment.\nThe patients' cognitive performance, life quality and life expectancy is also affected by having the condition.\nCooling treatment also reduces the number and severity of cerebral palsy and increases the number of patients who survive normally.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Therapeutic hypothermia is widely regarded as safe, if the treatment is provided by practitioners with the right expertise to patients who meet the relevant criteria.\nForcing the human body to the wrong temperature can cause many potentially serious side effects, including bleeding, infection, dehydration and low magnesium. It is relatively safe only because of expert management by ICU personnel familiar with the procedure.\nAll of that needs to be mentioned, whereas the release doesn\u2019t address the risks.", "answer": 0}, {"article": "This test is generally done at about 15 or 16 weeks gestation and involves taking amniotic fluid from the mother by inserting a hollow needle into the uterus.\nPhilippos Patsalis, medical director of the Cyprus Institute of Neurology and Genetics, who led the study, said the results were \u201cvery exciting\u201d and the test now needed to be trialed in a larger study of about 1,000 pregnancies, but could lead to changes in clinical practice within two years.\n\u201cSuch a non-invasive approach will avoid the risk of miscarriages of normal pregnancies caused by current, more invasive procedures,\u201d the scientists wrote in their paper.\nIn a small trial, Patsalis\u2019 team were able to correctly diagnose 14 cases where there were extra copies of the chromosome, and 26 normal fetuses \u2014 results they said highlighted its clinical potential.\nIn a study in the Nature Medicine journal researchers from Cyprus said a trial on 40 pregnancies using the test, which involves analyzing the woman\u2019s blood to detect DNA differences between the mother and the fetus, showed it accurately predicted which fetuses were at risk of developing the syndrome.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 of sensitivity and specificity issues that can only be established in a much larger trial.\u00a0 The need for a larger trial was mentioned, but no hint of unestablished potential harms.", "answer": 0}, {"article": "It also adds new information.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nOct. 10, 2011 -- A healthy chocolate habit -- about two chocolate bars a week -- appears to help women reduce their risk of stroke, according to new research.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story warns that milk chocolate may be \u201chigh in sugar, fat, and calories,\u201d it doesn\u2019t spell out the implications of eating too much milk chocolate in an attempt to reap health benefits. (To the contrary, the story suggests that eating larger amounts of U.S. milk chocolate with low cocoa content might yield the same result\u00a0as eating less of the higher-cocoa Swedish chocolate.)\u00a0Eating\u00a0more than a modest amount of chocolate is likely to cause weight gain,\u00a0which would probably negate any beneficial effects on stroke and increase the risk for other health problems.", "answer": 0}, {"article": "Back in April the WSJ wrote about the race to develop ways of detecting Alzheimer\u2019s disease using a brain scan. Currently only a post-mortem sampling of brain tissue can provide a definitive diagnosis. But the hope is that a technology that could be used in living patients could help rule out Alzheimer\u2019s in some patients and for those that have the disease, allow its \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of potential harms beyond mention that the tracer was radioactive.\u00a0 What is the radiation burden? ", "answer": 0}, {"article": "Dr. Roger Fielding (Tufts University) is partially supported by the U.S. Department of Agriculture, under agreement No.\nThe researchers acknowledge limitations of this study, including examining the different quantities of exercise participation achieved in the LIFE study participants and not specifically prescribing different amounts of exercise to different study groups.\nWe wanted the physical activity sessions to include exercise that participants could do outside of the study, and we hope that learning of these results might motivate others to try to make safe, incremental changes to their activity levels.\nThere was a continuous, graded effect with the greatest benefits seen in the participants who engaged in at least 48 minutes of physical activity per week.\nWhile the researchers saw improvements in all participants who added some physical activity to their routine, those who got more exercise saw greater changes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms. The release could have noted that harm scores were pretty even among all of the study participants, regardless of the duration of their physical activity, and that the protocol was designed to keep the regimen safe for older, sedentary people.", "answer": 0}, {"article": "So this is good as it gets.\"\nPatients who are older, overweight and male are generally most at-risk, reports CBS News correspondent David Begnaud.\nA study published in the New England Journal of Medicine found that 68 percent of patients experienced less sleep apnea after getting the implant.\nOn average, she stops breathing 53 times an hour, that's nearly once every minute during a night's sleep.\nAn estimated 22 million Americans suffer from sleep apnea, putting them at greater risk for diabetes, heart disease, stroke and memory loss.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that \u201clike any surgery, there is risk of infection\u201d when Inspire is implanted.\nThat isn\u2019t enough.\u00a0A check of FDA\u2019s MAUDE database reveals patient complaints of slurred speech, difficulty breathing, and the device suddenly activating itself, among other problems.\nIn addition, there are questions particular to the use of an electrical device implanted in the chest \u2014 especially for a condition that is most common among patients who are \u201colder, overweight and male\u201d (as the story puts it). For example, can patients with pacemakers also use Inspire, or would they interfere with each other?", "answer": 0}, {"article": "It includes top-ranked graduate schools of dentistry, medicine, nursing and pharmacy; a graduate division with nationally renowned programs in basic, biomedical, translational and population sciences; and a preeminent biomedical research enterprise.\nPreviously there has not been a way to predict whose symptoms will fade or persist following mTBI.\nFor concussion sufferers, even those who never lost consciousness, physicians may now be able to predict early on who is more likely to continue experiencing symptoms months or years after the head-jarring event, using a new non-invasive magnetic resonance imaging (MRI) method devised by a consortium of researchers led by UC San Francisco scientists.\nScientists refer to concussion as mild traumatic brain injury (mTBI), but for some patients the harmful, sometimes insidious effects are long lasting.\nIn comparison to the control subjects, who had never experienced TBI, mTBI patients displayed less connectivity in frontal areas of the \"default mode network,\" a set of brain regions that are particularly active in the resting brain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "MRIs are generally deemed to be a safe procedure, since no ionizing radiation is used. Adverse events for MRI scans are rare, but like any medical procedure, they do carry some risk, especially for patients with implants and external and accessory devices \u2014 like artificial joints, insulin pumps and\u00a0ventilators. For these patients, risks include device malfunction or heating of the implanted medical device and the surrounding tissue, which could lead to burns.\nAccording to the FDA, the use of gadolinium-based contrast agents (GBCAs) also carries some risk, including side effects such as allergic reactions. For patients with kidney disease, GBCAs could cause a rare and potentially fatal condition known as nephrogenic systemic fibrosis.\nSince harms are not mentioned, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": ".\nThe data suggest that abaloparatide appears to be an effective treatment for a broad group of postmenopausal women with osteoporosis.\nAt 18 months, abaloparatide-SC significantly increased bone mineral density from baseline at the lumbar spine by 9.2%, the total hip by 3.4% and the femoral neck by 2.9%, compared with placebo.\nThe researchers investigated patients enrolled in the randomized, double-blind, comparative, multicenter international phase 3 ACTIVE trial to evaluate the efficacy and safety of 80 micrograms of abaloparatide-SC in preventing fractures in otherwise healthy, ambulatory, postmenopausal women with osteoporosis.\nOverall, 2,463 patients between 49 and 86 years of age were randomized to one of three treatment arms for 18 months: double-blind 80 micrograms of abaloparatide-SC, blind-matched placebo, or open-label 20 micrograms of subcutaneous teriparatide (an FDA-approved prescription drug known to increase bone density and strength).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A serious omission, the release is essentially silent about potential harms, which, according to other sources, may include \u201cback pain, arthralgia, upper-respiratory-tract infection, hypercalciuria, and dizziness.\u201d A mid-term post-marketing surveillance study of Forteo (teriparatide), a related drug on the market, observed an association but not causation with osteosarcoma (a rare malignant bone cancer) in people taking the drug. Osteosarcoma had been observed in animal trials of the drug that were dependent on dose and treatment duration. ", "answer": 0}, {"article": "In general, though, \"the more options that are available to migraine headache patients, the better,\" Waltman said.\nPatients with heart disease or who are using antidepressants known as selective serotonin reuptake inhibitors should also be careful when taking sumatriptans, said Waltman, who added that she thought the patches \"are wonderful.\"\nOne study found that 18 percent of patients using the patch were headache-free after two hours, compared with 9 percent of those using an inactive placebo.\nAnd 84 percent of patients using the patch were relieved of their nausea, compared with 63 percent of those in the placebo group, according to a company news release.\nIt's not clear how much the patches will cost, but the class of medications known as triptans can be expensive, as much as $300 a month (although sumatriptan now has a generic version), Waltman said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the story, \u201cThe most frequent side effects were pain at the site of application along with tingling, itching, warmth and discomfort.\u201d We\u2019ll call this adequate for a satisfactory, but it would have been helpful to know how often these adverse effects occurred, especially since the FDA had previously delayed approval of the product based in part on safety concerns. In addition, there was no mention of other adverse effects\u00a0that have been associated with triptan use, such as atypical pain and pressure sensations (e.g. tightness in the chest and throat constriction). The story did mention that triptans can be harmful for\u00a0patients with heart disease or who are taking SSRI antidepressants.", "answer": 1}, {"article": "Sorry. The page you requested is not available", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article explores the issue of whether Rituxan may suppress the immune response too much, making the patient vulnerable to other diseases. It also explains how this effect has been observed in the drug Tysabri, a different immune suppressant used for MS.", "answer": 1}, {"article": "The Site is down for maintenance.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state \u201cPatients in the study experienced diarrhea, nausea, rash, fatigue decreased appetite, vomiting, itchiness and taste alteration.\u201d But we weren\u2019t told how many of the 97 experienced these.\u00a0 So the true scope of what was seen is not reported.", "answer": 0}, {"article": "\"It's premature to make any conclusions,\" he said.\nBut Dr. Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston, said that this study was too small to reach any definitive conclusion about the value of vitamin D in fighting prostate cancer.\nDoctors often recommend a \"watch and wait\" period for men with low-grade, or less aggressive, prostate tumors.\nWhen the prostate gland was examined after their surgery, researchers found that many who received vitamin D had improvements in their prostate tumors, while the tumors in the placebo group remained the same or got worse.\n\"Vitamin D decreases inflammation in tissues, and inflammation is a driver of cancer,\" explained Bruce Hollis, the study's lead researcher and a professor of pediatrics, biochemistry and molecular biology at the Medical University of South Carolina in Charleston.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms from taking vitamin D supplements were not mentioned (nor were those of surgery). \u00a0While toxicity is rare, studies suggest that long-term intakes of high doses are associated with adverse health effects. Perhaps more importantly, what about men possibly taking vitamin D when they really ought to have surgery because they have an aggressive tumor type?", "answer": 0}, {"article": "A vicious cycle ensues: The heart enlarges, so the mitral valve leaks.\nBut that research included many patients with less severe valve problems, the procedure was not performed as adeptly, and the patients\u2019 medications were not as well optimized as in the new study.\nIn the new trial, 614 patients with severe heart failure in the United States and Canada were randomly assigned to receive a MitraClip along with standard medical treatment or to continue with standard care alone.\nUntil today, researchers were not sure that fixing the mitral valve would do much to help these patients.\nIn the new study, a device called the MitraClip was used to repair the mitral valve by clipping its two flaps together in the middle.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not address potential harms of this device nor mention that medical devices are not required to provide robust safety data to go on the market in the U.S. According to the study, 3.4% of patients experienced complications related to the device within one year. It\u2019s important to keep in mind that this adverse event rate is under ideal conditions\u2013where patients are closely monitored by physicians because of clinical trial enrollment.\nWhile there may be smaller surgical incisions than standard surgery, is it still quite invasive to insert a metal clip into a heart valve. Post-surgery, the device can malfunction, and cause a host of problems, including death.", "answer": 0}, {"article": "During transcranial magnetic stimulation (TMS), a doctor places a large magnetic coil against the patient\u2019s scalp, which creates electric currents to stimulate nerve cells.\nDec. 14, 2011 -- It can be an all too common scenario for certain stroke survivors.\nThere were no improvements seen in test scores of those who got the other treatment.\nThe overactive brain circuits also improved among people who got the TMS treatment, the study showed.\nThis is often not enough to make a meaningful improvement.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although TMS used for depression is associated with a low rate of adverse effects (mostly headache), we don\u2019t know if other problems might emerge when using it on patients who\u2019ve had a stroke. The story didn\u2019t discuss the potential for adverse effects or mention whether any adverse effects were seen in this study. Any new treatment \u2013 however theoretically safe \u2013 may cause unexpected harms in such a clinically fragile population. That is one of the limitations of a study of such a small number of highly selected individuals.", "answer": 0}, {"article": "Michael Burk found walking increasingly painful last year. Crossing the street and tying his shoes became challenges, and colleagues noticed he was limping at work.\n\nOn a recent morning, Mr. Burk reported to the Hospital for Joint Diseases, part of NYU Langone Medical Center in New York City, for hip-replacement surgery. His surgeon had promised him a better quality of life, and said both the operation and recovery would be quick.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The anecdotes cited were all glowing. None included any mention of possible drawbacks. This surgery is associated with very significant risks, including risk of death\u2013typically from a blood clot. Now, those risks are with all hip replacements\u2013same day discharge and not\u2013but they are never mentioned and should have been.\nThe story leaves readers with the impression that they might all be going home maybe 10-12 hours after surgery as the 54-year old patient profiled did (no exact timing of his day was provided in the story). How representative was that? Didn\u2019t the age and conditioning of a 54-year old play a big factor here? What might change if he were a 64-year old or 74-year old reader of the WSJ? Or is this what gets hidden when joint replacement surgeries are increasingly marketed to younger and younger people? And when journalism fails to scrutinize that factor?", "answer": 0}, {"article": "Children who ate a diet high in processed foods at age 3 had a lower IQ at 8.5 years than kids with a healthy diet.\nChildren should be encouraged to eat healthy foods from an early age, she said.\nA more health-conscious diet was associated with small increases in IQ, she said.\nCommenting on the study, Samantha Heller, a dietitian, nutritionist and exercise physiologist in Fairfield, Conn., said that \"most of us do not realize that the foods we eat have direct consequences on brain growth, function and performance.\"\nHowever, to truly understand the effect of diet on children's intelligence, further studies are needed, they said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In a sense, this story is all about the potential developmental harms of a high-calorie, nutrient poor diet.", "answer": 1}, {"article": "\u201cWe need at least 1 \u00bd to 2 years\u2019 worth of data\u201d to make a meaningful judgment about how to proceed, Dr. Carter said.\nAside from cancer and prostatic growth with age, factors that can change PSA measurements include inflammation or infection of the prostate; a decline in testosterone levels or the drug finasteride, taken for hair loss, both of which lower the PSA; and variations in laboratory assays and in the inherent biology of a person.\nBiological variability can result in as much as a 15 percent difference between readings, and in nearly half of men with an abnormal PSA, the test will normalize in one to four years without any treatment.\nThe larger a man\u2019s prostate, the more PSA is produced, which makes the test very confusing in older men with benign enlargement of this gland.\nIf more than 25 percent of the PSA is free, chances are that it is being produced by a benignly enlarged prostate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Specific harms of screening and its downstream consequences are not mentioned.\u00a0 For instance, the article only states prostate cancer surgery is debilitating, without stating why or how and without recognizing that other prostate cancer treatments, like radiation, can also have debilitating side effects, like problems with erections, leaking urine, and problems with bowel function (which is not stated).\u00a0 The article doesn't tell readers how severe these problems could be or how frequently they might occur.\u00a0 There is also harm in managing the many false positive test results that occur, which is not mentioned; the biopsies can be painful, are often not definitive because they are random, and there are psychological consequences, like anxiety, that men endure.\u00a0 ", "answer": 0}, {"article": "Proton therapy is an advanced type of radiation treatment that uses a beam of protons to deliver radiation directly to the tumor, destroying cancer cells while sparing healthy tissues.\nOf note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\nThe findings are the final results of the single institution, Phase II study and represent the longest follow-up to date of stage 3 lung cancer patients who have received proton therapy, said Joe Y. Chang, M.D., professor, Radiation Oncology and the study's corresponding author.\nHealthy tissue surrounding the tumor is spared, and side effects are even more reduced than earlier proton delivery, said Chang.\nWhile the study's survival, recurrence rates and toxic effects are still favorable when compared to rates associated with the most advanced traditional photon radiation therapy, intensity modulated radiation therapy (IMRT), technology to diagnose and stage the disease, as well all treatment modalities have significantly improved.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says:\n\u201cAmong the acute and late toxic effects diagnosed in patients were: esophagitis, pneumonitis and cardiac arrhythmia. Of note, said Chang, no patients developed the most severe, or grade five, toxicities, as seen in patients who receive standard of care.\u201d\nSo we give the release credit for talking about harms. Some numbers to show how many of the 64 people enrolled had side effects would have been helpful.", "answer": 1}, {"article": "Transcendental meditation involves shutting out the outside world and focusing thoughts inward, or resting while remaining alert.\nStudies Say Meditation May Help\n\n\u201cThe main finding [of our research] is that, added on top of usual medical care, intervention with a mind-body technique \u2014 transcendental meditation \u2014 can have a major effect on cardiovascular events,\u201d says Robert Schneider, lead author on the study published in Circulation: Cardiovascular Quality and Outcomes and a professor at the Maharishi University of Management, an institution in Iowa that was founded by the creator of transcendental meditation.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nIn the past, these benefits have been hard to test scientifically, largely because study participants who volunteered for meditation programs may have been biased to see them succeed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Though it doesn\u2019t explicity report on harms, the story does imply that meditation \u201ccan\u2019t hurt you,\u201d which we\u2019ll agree is an accurate sentiment. Any harms are likely to be indirect \u2014 i.e. choosing meditation (a possibly ineffective treatment) over something that is more proven.\nHowever, the story whiffed on the important indirect harm of \u201copportunity costs.\u201d\u00a0 Training and ongoing programming in TM is expensive especially given the mean household income of the participants.\nAll interventions have costs.\u00a0 All interventions have harms.\u00a0\u00a0 All health care new stories \u2013 in our opinion \u2013 need to report on both.", "answer": 0}, {"article": "An inexpensive drug therapy far surpassed a conventional laser procedure in fixing a leading cause of blindness in babies born prematurely, according to a new study.\n\nThe results of the study, to be published this week in the New England Journal of Medicine, were so significant that the 15 hospitals participating in the research have stopped using lasers in favor of the drug, Avastin, which is injected into the eyes of the affected newborns. Avastin, made by Roche Holding AG's Genentech unit, is designed to be used for treating...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Room for improvement. We give the article credit for noting that Avastin has limited safety information in this setting and that the investigator has noted no significant side effects in this cohort. It also gives some theoretical reasons to be optimistic. But what\u2019s missing from the story is the key line from the study: it \u201cwas too small to assess safety.\u201d You know the saying about absence of evidence and evidence of absence?\nAs noted, as readers we are unclear why Avastin is sparring with Lucentis. The article elevates Avastin because it \u201ccan\u2019t easily travel outside the eye,\u201d while Lucentis has a theoretical concern of systemic effects. That paragraph gave us several itches: \nThe article states that the 7 deaths in the study were unrelated to either treatment. We don\u2019t see that conclusion in the publication or editorial. Perhaps it was based on an interview with the lead researcher? If so we\u2019re unable to verify, since we can\u2019t interpret the raw\u00a0mortality\u00a0information on the 7 cases in the study report ourselves. With that caveat in mind, we note that, to us, the study report seems to suggest that their study was too small to determine whether Avastin is associated with more deaths than\u00a0is\u00a0laser therapy. Since there were more deaths in the Avastin group (5 vs 2), we would\u2019ve liked more clarity around this topic.", "answer": 0}, {"article": "LONDON (Reuters) - A non-surgical treatment for low-risk prostate cancer in which doctors inject a light-sensitive drug derived from deep-sea bacteria into a patient\u2019s bloodstream was shown in a trial to kill cancer cells without destroying healthy tissue.\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said.\nIn the trial, only 6 percent of patients treated with VTP needed radical therapy compared with 30 percent of patients in the control arm who were under active surveillance.\n\u201cThis is truly a huge leap forward.\u201d\n\nThe treatment, called vascular-targeted photodynamic therapy or VTP, was developed by scientists at the Weizmann Institute of Science in Israel in collaboration with the privately-owned STEBA Biotech.\nThe trial involved 47 treatment sites in 10 European countries, most of which were performing VTP for the first time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story regurgitates nearly word-for-word what\u2019s in the news release:\nWhile radical therapy causes lifelong erectile problems and incontinence, VTP only caused short-term urinary and erectile problems which resolved within three months, the researchers said. No significant side-effects remained after two years.\nAs we mentioned in our review of the news release, it\u2019s a disservice to patients to downplay harms with the word \u201conly.\u201d\nThe story does not give the proportion of patients on VTP who experienced adverse events, which was 80 percent. Nor does it mention that 30 percent of VTP patients versus 10 percent of those in the active surveillance group had serious adverse events.\nFinally, both the story and the news release gloss over the fact that over 1/3 of patients needed repeat treatment within 2 years, and that men undergoing VTP appear likely to need to be on the same monitoring protocol as those on active surveillance (meaning they will need biopsies, which carry risks). VTP and prostate biopsies can cause harms.", "answer": 0}, {"article": "\n\u2022 Detailed Results of Phase 2 Trial Presented at the American College of Gastroenterology 2016 Annual Scientific Meeting\n\u2022 93.3% of Patients Treated Using the Lead Formulation of Novel Prep Achieved a Colonoscopy Rating of Excellent or Good, Compared to 85.7% of Those Using Standard Prep Products in Colonoscopist-blinded Trial\n\u2022 More 'Patient-friendly,' Palatable Prep Could Help Increase Patient Acceptance of Colonoscopies for Colorectal Cancer Screening\n\nNewton, MA (October 17, 2016) - Detailed results from a Phase 2 study of a novel colonoscopy prep (ECP) under development by ColonaryConcepts, LLC show the investigational treatment to be at least as effective and safe as two currently available colonoscopy prep formulations, while offering a much higher level of patient satisfaction and preference than standard preps.\n\"Results from this study show that this innovative investigational product performed as well as or better at colon cleansing than two currently available colonoscopy prep formulations.\nMoreover, the higher levels of patient satisfaction reported by those who used the lead ECP formulation in the trial suggest this new approach to colonoscopy prep may have a positive impact on patient willingness to undergo this potentially life-saving colorectal cancer screening procedure.\"\nWith ColonaryConcepts' lead formulation, 93.3% (14 of 15) of patients had a rating of excellent or good, with 40 of 45 colon segments rated as excellent or good on the Ottawa scale.\n\"Patients participating in the study were nearly four times more likely to recommend ECP to their friends and family as compared to the standard colonoscopy prep.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the text notes that individuals involved in the study experienced no \u201cserious adverse effects,\u201d it doesn\u2019t define what \u201cserious\u201d means. The use of that adjective implies that participants may have experienced some side effects, however modest. And although this prep is too new to have gathered data over time about possible harms, the release claims it is as \u201csafe\u201d as some already available options. These standard preps are purgatives that often come with mild side effects such as stomach pain, nausea and syncope from induced bowel movements, and the inevitable damage to intestinal flora. Those side effects deserved a mention here.", "answer": 0}, {"article": "We are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\"\nThe clinical studies support powerful marketing claims.\nAt 72 hours, OsteoRx\u2122 results were nearly five and a half times better.\nAfter 14 days of treatment, the average improvement was still nearly twice as large as the competition.\n\"All HSRx OTC drug products are designed to become category leaders,\" noted Frank Parise, the company's Chief Financial Officer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss any potential harms of the topical cream or tablet \u2014 or whatever it truly is.", "answer": 0}, {"article": "In an analysis of 29 studies, they found people who got acupuncture typically reported more pain relief than those who didn\u2019t.\nBut, he added, \u201cI would sincerely say more than 75 percent of my patients will see improvement.\u201d\n\nVickers said people who are considering acupuncture should first make sure their acupuncturist is appropriately qualified and licensed.\nIn those cases, he said, acupuncture is very safe - and the main downsides are costs and the inconvenience of getting to a clinic.\nThat either means many of the three million Americans that get acupuncture every year are \u201cwasting their time\u201d - or others who forgo it are missing out on potential benefits, Vickers said.\nIt\u2019s usually \u201cnot their first approach to address the condition,\u201d he said - rather people seek acupuncture when traditional care fails to stop their pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that acupuncture is safe\u00a0when performed by a\u00a0qualified and licensed acupuncturist, which is true. The story didn\u2019t report on the flip side of this statement,\u00a0which was addressed by another\u00a0recent review of the evidence \u2014 i.e. that when acupuncture\u00a0is delivered by unqualified practitioners, there\u00a0are dozens of published cases of\u00a0severe adverse reactions including\u00a0death. Tough call here, but we think the story didn\u2019t quite meet our standard.", "answer": 0}, {"article": "Aug. 30, 2010 -- Three puffs a day of cannabis, better known as marijuana, helps people with chronic nerve pain due to injury or surgery feel less pain and sleep better, a Canadian team has found.\nThe research is published in CMAJ, the Canadian Medical Association Journal.\nBut Ware's study is more scientific -- a clinical trial in which his team compared placebo with three different doses of cannabis.\n\"About 10% to 15% of patients attending a chronic pain clinic use cannabis as part of their pain [control] strategy,\" he tells WebMD.\nThe new study ''adds to the trickle of evidence that cannabis may help some of the patients who are struggling [with pain] at present,\" Henry McQuay, DM, an emeritus fellow at Balliol College, Oxford University, England, writes in a commentary accompanying the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The I.V.\nAnd though the IV lends a medical air to the procedure, the infusions suffer from the same problem as many supplements taken orally \u2014 there isn\u2019t any robust evidence to back up their health claims.\nSchwartz, though, said the supplements are completely safe.\nOne didn\u2019t turn up any significant improvement in patients who received the infusions.\nThere is a published review on the use of Myers\u2019 cocktail \u2014 but it\u2019s just a collection of anecdotal evidence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The statement from the clinic that these IV infusions are safe was unchallenged. There is always a potential harm in an IV administration (infection, vein damage) and yes, receiving worthless treatments for what could be a serious condition is a potential. Also, there was no mention about what kind of testing is done before these treatments are administered, but it appeared to be minimal.", "answer": 0}, {"article": "That wouldn\u2019t be surprising.\nAmong others who might need a boost: Vegans, people with lactose intolerance and anyone who, for whatever reason, does not consume enough calcium, says Taylor Wallace, an affiliate professor of nutrition at George Mason University in Fairfax, Va., and a co-author of the new cardiovascular statement.\nBut the study, published in the Journal of the American Heart Association, was not designed in a way that could prove the supplements caused the artery changes.\nMany people get more than they realize, he says, not just from milk, cheese and yogurt, but from vegetables, grains, and, increasingly, fortified foods and beverages.\nTeen girls, who are in crucial bone-building years, often have diets that fall short of their needs, 1,300 mg a day, Wallace says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While we discussed benefits above, the focus of the story is primarily on potential harms. Namely, the story looks at potential risks to heart health associated with the use of calcium supplements. And the story does a fine job here, particularly given the fact that, as one source in the story notes, \u201cThe public has been receiving very confusing and alarming messages about calcium supplements.\u201d Specifically, the story explains that there is some concern that the use of calcium supplements may lead to a build-up of calcium in the arteries, which may contribute to risk of heart attack or stroke. The story then fleshes out the arguments of both sides in this debate, without making any sweeping judgments about which side of that argument is correct. In other words, the story gives readers information without telling readers what conclusions they should draw. In a case like this one, we think that\u2019s the responsible position to take.", "answer": 1}, {"article": "\u201cWe still found the same thing,\u201d Brandt said.\n\u201cHere we find on a population level when we restrict them, it benefits society by reducing heart attacks and strokes.\u201d\n\nThe findings suggest the FDA\u2019s action will lead to health benefits across the country, he added.\nBy 2018, those fats will be nearly eliminated from American diets, they add.\nBrandt and colleagues write that in 2015, the U.S. Food and Drug Administration (FDA) removed manufactured trans fats from its list of safe food additives.\n\u201cNew York City was progressive and they enacted restrictions on trans fats, but no one looked to see if this made measurable changes to outcomes,\u201d said study lead author Dr. Eric Brandt, of Yale University in New Haven, Connecticut.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of harm/side effects does not seem relevant here.\nHowever, we did want to note: When trans fats were first introduced, they were supposed to be a healthy alternative to tropical oils with lots of saturated fat. Now that they are being removed, it\u2019s worth discussing what they will be replaced with and whether that change could have negative health consequences, too.", "answer": 2}, {"article": "\"It may be that it helps with relaxation of muscles that are tense,\" Deyo says.\nAfter 10 weeks, the results were dramatic: Nearly two-thirds of the patients who received either type of weekly massage said their back pain was significantly improved or gone altogether.\nNo one knows exactly how massage works to relieve pain, says Dr. Richard Deyo of Oregon Health Sciences University, who also took part in the study.\nPrior studies of massage for back pain had tested only structural forms of massage, not relaxation massage.\nNow, a study in the July 5 issue of the Annals of Internal Medicine shows that massage is an effective treatment for lower back pain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms weren\u2019t mentioned but it would have been easy to cite what the study reported: that adverse events, mainly increased pain, was uncommon (4-7%) in those treated with massage. Even saying that massage is generally a safe treatment would have been fine.", "answer": 0}, {"article": "TMS treats conditions by delivering brief, powerful magnetic field pulses that stimulate nerve cells in the brain.\nOverall, 38% of the people with the real device responded to the treatment compared with 11% of those with the sham device.\nPeople who were taking medication for OCD continued to do so for the trial.\nThe approval was based on a clinical trial of 100 people with obsessive-compulsive disorder, where roughly half received treatment with TMS and the other half had a sham treatment that didn't deliver the electromagnetic pulses.\nA response was considered a 30% reduction in the Yale-Brown Obsessive Compulsive Scale (YBOCS) score, which is used to measure the severity of OCD symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article uses information from an FDA news release to discuss side effects:\nThe most common side effect in the clinical trial was headache, which occurred in 37.5% of the treatment group and 35.3% of the sham treatment group. Other possible side effects were mild, and included temporary jaw or face pain, muscle spasms or twitching, and neck pain.\nThis is enough to rate Satisfactory, but there is certainly more that could be said about side effects. We easily found evidence of short-term memory loss and patient complaints of significant\u00a0anxiety by doing a quick Google search.", "answer": 1}, {"article": "A new method for performing a \u201cvirtual\u201d colonoscopy that requires less unpleasant preparation was shown in a new study to accurately detect larger precancerous polyps\u2014and was a better experience for patients.\n\nThe second-leading cause of cancer deaths in the U.S., colon cancer can be prevented if precancerous polyps\u2014known as adenomas\u2014are found and removed during a colonoscopy\u2026.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We preferred the way the Boston Globe handled this question. It said:\n\u201cVirtual colonoscopy, with or without prep, has some limitations. About one in five patients must undergo a standard colonoscopy after the imaging procedure to have suspicious looking polyps snipped off and biopsied. The CT scan also delivers a dose of radiation that \u2014 while only one-fifth of the dose of an abdominal CT scan \u2014 was significant enough to raise the flags of the US Preventive Services Task Force.\u201d\nIn addition, MedPage Today reported:\nCT imaging picked up indeterminate or potentially clinically important findings outside the colon in 16% and 3% of patients, respectively. Medical record review showed that 5.5% of the cohort ended up getting additional diagnostic work-up due to such incidental findings.\nThat could be a good thing \u2013 but it could bring potential harm in additional workups for some incidentalomas \u2013 things you caught that you really didn\u2019t need to know about.", "answer": 0}, {"article": "This direct antiviral approach has been used with great success in treating H.I.V.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nBut in Vertex\u2019s trial, about 70 percent of those who achieved an effective cure were able to do so in 24 weeks, or about six months.\nIt is not quite clear how those drugs work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes the standard treatment sound terrible. But it glosses over the side effects of the new treatment, saying only that it causes a \"nasty rash.\" Where is the rash?\u00a0That can make a world of difference. Does it cause the skin to break and bleed? Does it interfere with basic functions like sight, breathing, eating? It says that 7% of the people in the drug group dropped out, while about half that percentage dropped out of the placebo group.\u00a0Again, some absolute numbers would be good here, as would some context about what percentage of patients experience side effects with the standard treatment or with the competing drug in the same family\u00a0of drugs\u00a0mentioned earlier in the story. And the story could have been more clear that all patients get the standard therapy, IFN and ribavirin. So they will face the side effects of the current regimen, PLUS the side effects of this new agent.", "answer": 0}, {"article": "But Johannesdottir added that \"we hope that our finding will inspire more research on skin cancer prevention.\nWhile the study found an association between skin cancer risk and NSAIDs, it did not prove a cause-and-effect relationship.\nOn that front, long-term users and those who took NSAIDs at relatively higher doses appeared to benefit from the strongest protective effect, suggesting that when it comes to skin cancer risk reduction, more NSAID use is better.\nBut taking NSAIDs for long periods of time, and at relatively high doses, was associated with a reduced risk (between 15 and 21 percent), specifically for basal cell cases that manifested in skin regions that typically experience relatively little sun exposure (areas other than the neck or head).\nSimilarly, malignant melanoma risk fell by nearly as much (13 percent) among those filling more than two NSAID prescriptions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of the harms associated with long-term use of aspirin, including bleeding in the gastrointestinal tract and brain. The suggestion that \u201cmost\u201d people are already taking aspirin for cardiovascular disease prevention is also potentially misleading, since regular aspirin use is recommended primarily for those at higher risk of heart disease.", "answer": 0}, {"article": "Dr. Scolnick has not seen the results of the Novartis trial, but was told of them and concluded that if the drugs work in fragile X, \u201cthere\u2019s nothing to say that they won\u2019t work in some cases of broader autism-spectrum disorders.\u201d\n\nThe roots for the Novartis results began in 1982 when Stephen T. Warren, then a graduate student in genetics at Michigan State University, was looking for a job and something to research.\nThe results of the trial were something of a jumble until Novartis scientists noticed that patients who had a particular, undisclosed biological trait improved far more than others.\nWhen a doctor finally thought to do a fragile X test, Ms. Clapp and her husband, Dr. Michael Tranfaglia \u2014 both Harvard graduates with post-graduate degrees \u2014 researched the disease and came to two conclusions: fragile X was potentially treatable; and only about five researchers in the world were working toward a cure.\nThe Novartis trial results were not published or peer reviewed, and for commercial reasons Dr. Fishman refused to divulge many details.\nSure enough, mice, fish and fruit flies that through genetic engineering were made to have fragile X seemed to become normal when given Dr. Bear\u2019s compound.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the big problems of reporting on research that hasn\u2019t been published or peer-reviewed is that harms don\u2019t get adequately quantified\u2013a\u00a0 drawback that was on\u00a0full display in this story. The report\u00a0didn\u2019t\u00a0even mention the possibility of patients being harmed by this experimental drug. \u00a0", "answer": 0}, {"article": "\"Your eyes look like they're responding beautifully!\"\nBefore the surgery, Manuela said she would most like to see her family and friends' faces clearly, particularly her sister's.\nBefore the surgery, Manuela's pupil gave no response to or recognition of light.\nIn Manuela's case, Maguire was concerned about the damage already done by the disease to her retina.\n\"It will succeed not only for me, but also for other people with visual problems so that they can have a hope for their future,\" said Manuela.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a small hole that formed in one eye, thought not to be clinically meaningful.\u00a0 There is also not enough emphasis that this is a short term (weeks to months) trial and that problems (or improvement)\u00a0may well develop after a delay. The story also did not mention the past history of deaths which have been associated with some gene therapy trials. \u00a0", "answer": 0}, {"article": "Performed through the urethra, an urologist uses the UroLift System to push aside the obstructive prostate lobes and positions small, tailored permanent UroLift implants to hold the prostate lobes in the retracted position.\n\"The UroLift System has an excellent safety profile and provides men suffering from an enlarged prostate a beneficial first-line treatment alternative to drug therapy or more invasive surgery.\nImportantly, the UroLift System provides fast and meaningful relief from BPH symptoms, improving overall quality of life for our patients.\"\nAdverse reactions associated with UroLift System treatment were comparable to other minimally invasive surgical therapies as well as standard cystoscopy.\nPatients recover from the procedure quickly, and return to their normal routines with minimal downtime.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We learn about a range of adverse effects ranging from blood in the urine to incontinence. \u201cMost symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure,\u201d we are told.\nWe\u2019ll award a satisfactory grade here because the release at least mentions some adverse effects associated with the procedure. But as with the benefits description, we again receive no sense of what this is compared to (drugs? surgery? watchful waiting?), how common these problems were, or what the release means when it describes them as \u201cmild to moderate in severity.\u201d\nUpdate: This rating has been changed to Not Satisfactory in order to be consistent with how this criterion has been applied in the past. As stated in the description of our review criteria, a news release or story may be rated Not Satisfactory if it:\u00a0", "answer": 0}, {"article": "\"The problem,\" Kohler noted, \"is that we don't want to make behavior changes.\nAnother sleep specialist said the findings show \"some potential benefit\" from suvorexant, but he cautioned insomnia sufferers against relying completely on any drug.\nThe effect was essentially comparable to what has been seen with other sleep medications, said Bazil, who was not involved in the research.\nThe study also excluded adults aged 65 or older -- an age group commonly affected by insomnia.\nAll of the patients spent four weeks on one of four doses of suvorexant and another four weeks on placebo pills.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\n\u201cthere were no serious side effects in this study.\nThe most common side effects were sleepiness (reported by about 10 percent of patients on the two higher doses of suvorexant), headache (reported by about 5 percent), dizziness and abnormal dreams (5 percent).\u201d", "answer": 1}, {"article": "People with painfully damaged knees and hips have increasingly turned to \"minimally invasive\" joint-replacement surgery. But these relatively new procedures, though they promise shorter recuperation times, are raising concerns about potential complications.\n\nMany surgeons in recent years have performed joint replacements with ever smaller incisions. In minimally invasive surgery, the incision is typically about three to four inches long, roughly half that of traditional surgery. By cutting less of the surrounding tissue...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article provides ample reporting on the potential harms of minimally invasive surgery (e.g., \u201cuneven leg lengths, broken hip bones, slightly off-kilter knee joints and pain in the knee because of hardened cement left in the wound\u201d).", "answer": 1}, {"article": "(Adenoids, glands at the roof of the mouth, are often removed along with tonsils.)\nThe researchers decided to review whether the throat infection guidelines are too stringent, ruling out patients who potentially could benefit but don't meet the high threshold of recurring infections, Chinnadurai said.\nTo qualify for the surgery, a child must have many recurring throat infections within a short span of time or severe sleep disturbances, said Dr. Sivakumar Chinnadurai, a co-author of the reviews.\nHowever, this strong benefit only applies to the first couple of years following surgery, Chinnadurai said.\nAbout 3 percent of kids who undergo the procedure experience bleeding during the two-week recovery period, Hackett said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story a satisfactory rating for including the following statements:\n\u201cAbout 3 percent of kids who undergo the procedure experience bleeding during the two-week recovery period, Hackett said. \u201cThough a tonsillectomy is low-risk, it is not risk-free, and those risks need to be weighed against the benefits for each individual child,\u201d Chinnadurai said.\nThe story would have been stronger if it had named the risk of infection following surgery and that general anesthesia carries its own important risks.", "answer": 1}, {"article": "And if you wake up in the middle of night and don\u2019t fall back asleep easily, get out of bed.\u201d\n\n\u201cYou don\u2019t want to have any linkage between the experience of lying in bed and being awake,\u201d he said.\nAnd the risks may be even more pronounced among older patients, added senior author Timothy Monk, also of the University of Pittsburgh.\nYet the time and resource-intense strategy \u2014 usually involving between six- and eight hour-long appointments with a clinical psychologist - is not widely available and its cost, generally hundreds of dollars, is prohibitive for many.\n\u201cMore consolidated sleep is more refreshing.\u201d\n\nBased on questionnaires and sleep diaries, the researchers found that two out of every three participants receiving the behavioral intervention responded favorably by the end of 4 weeks, while just one out of every four receiving the printed material experienced substantial improvement in their sleep.\nBuysse and his colleagues wondered if the pill-free treatment could be shortened and simplified, providing more rapid results at a lower cost.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nWe won\u2019t hold this story to this criterion because neither the journal article on the test nor an accompanying commentary noted any adverse events. However, the story could have pointed out that a trial this small generally would miss all but the most common problems. Also, the story could have pointed out that until further evidence is developed, it is not know for certain how this type of intervention compares with alternatives. If it turns out that for some people this treatment is less effective than alternatives, then prescribing it would mean leaving them at greater risk of being harmed by insomnia.", "answer": 2}, {"article": "\"That's the main natural compound in unroasted coffee, and roasted coffee has much, much less of it than unprocessed coffee,\" Vinson said.\nLona Sandon, a registered dietitian and assistant professor of clinical nutrition at the University of Texas Southwestern in Dallas, cautioned that the study is short on specifics, making it difficult to draw any conclusions.\nTUESDAY, March 27, 2012 (HealthDay News) -- When taken as a supplement, unroasted -- or green -- coffee-bean extract can help people shed pounds, according to a small preliminary study.\n\"This was indeed a small study,\" acknowledged corresponding study author Joe Vinson, a professor of chemistry at the University of Scranton, in Pennsylvania, but he noted that prior research has been conducted in both France and Japan.\nVinson said his team was not focused on the weight-loss impact of caffeine as much as that of unprocessed, unroasted coffee's primary ingredient: chlorogenic acid.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quotes a researcher who says weight loss in the study was achieved \u201cwithout side effects.\u201d That\u2019s not good enough \u2013 not without any acknowledgment that a 16-person study can\u2019t tell us very much about the adverse effects of any treatment.\nThe story does make the point that weight loss supplements are not necessarily tested for purity and have been found to contain undeclared ingredients in the past.\u00a0 Although we\u2019d like to see some more detail on what adverse effects might be cause by these spiked supplements (for example: kidney failure, heart problems, etc).\nThe LA Times\u2019 story, by comparison, quoted an expert on a specific concern about malabsorption within the gut \u2013 \u201ca condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems.\u201d", "answer": 0}, {"article": "Essential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study cites research dating back to 1983 examining such a possible link.\nThe study, authored by researchers from the Federal University of Pernambuco, is not the first to address the possible link between PMS and essential fatty acids, substances that play a complicated role in a woman's reproductive system.\nThe study, published Monday in the journal Reproductive Health, found that taking capsules containing about 1 gram of a blend of three essential fatty acids produced a significant reduction in PMS symptoms.\nAccording to the study, the 120 women who participated reported few side effects, and most of those were mild and may have been due to sensitivity to mineral oil, the placebo taken by some of the participants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions there were few side effects and mostly \u201cmild.\u201d But what were they?\u00a0 And what does \u201cmild\u201d mean?\u00a0 After all, PMS has a range of symptoms as well.\u00a0 So did this story really help women think about the tradeoffs?\u00a0 Nonetheless, since the story at least mentioned harms, we\u2019ll give it the benefit of the doubt \u2013 barely.", "answer": 1}, {"article": "Collaborating with Dr. De Giglio were Francesca Tona, M.D., Francesca De Luca, Psy.D., Nikolaos Petsas, M.D., Ph.D., Luca Prosperini, M.D., Ph.D., Valentina Bianchi, Psy.D., Carlo Pozzilli, M.D., Ph.D., and Patrizia Pantano, M.D.\nIn the future, the researchers hope to study whether the plasticity induced by video games in MS patients is also related to improvements in other aspects of their daily lives.\nThe modifications in functional connectivity shown in the video game group after training corresponded to significant improvements in test scores assessing sustained attention and executive function, the higher-level cognitive skills that help organize our lives and regulate our behavior.\n\"This means that even a widespread and common use tool like video games can promote brain plasticity and can aid in cognitive rehabilitation for people with neurological diseases, such as multiple sclerosis.\"\nThe results suggest that video-game-based brain training is an effective option to improve cognitive abilities of patients with MS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While there are no obvious harms that would come from playing the video game/training program used in the study we think addressing harms is applicable for this news release, and there was no mention. It is possible that focusing on training in one part of brain function may lead to lack of attention in other parts, and this imbalance may result in relative gains and losses in brain activity that may have negative impacts in certain cognitive or functional areas. It may also be worth noting that harm may come from overuse. In a controlled setting like this study, overuse may be preventable. But what if this was available at home and the person could use it 24/7?", "answer": 0}, {"article": "March 31, 2010 -- A widely prescribed drug used to shrink enlarged prostates appears to reduce the incidence of prostate cancer in men with an increased risk for the disease.\nBut none had evidence of cancer when biopsies were performed within six months of entering the trial.\nScheduled biopsies were performed two and four years after they entered the trial.\n\"But we don't have studies saying that they decrease the risk of death from prostate cancer.\"\nThe men were assigned to receive either placebo treatments or daily 0.5-milligram doses of Avodart for four years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing and quantifying the potential harms of the drug, which are significant.", "answer": 1}, {"article": "A new study has an intriguing finding: Advanced cancer patients who received early palliative care in conjunction with standard care for their disease not only reported better quality of life, but lived a few months longer than patients who received only standard care.\n\nThe research, published in the New England Journal of Medicine, included 151 patients diagnosed with metastatic non-small-cell lung cancer who were randomly assigned to one of those treatment plans. At 12 weeks, 86% of those who were still alive filled out assessments \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the competing coverage, we\u2019ll rule this one not applicable since the harms of palliative care are thought to be minimal.", "answer": 2}, {"article": "\"It doesn't take a lot,\" said Ross.\nBut there was also a benefit from going just a bit faster: Only participants in the higher-intensity group saw an improvement in glucose tolerance, a risk factor for heart disease.\nAt the end of the study, members of all three exercise groups lost an average of about 2 inches from their waist circumference.\nThe intensity was about equivalent to walking slowly, said study author Robert Ross, a kinesiologist at Queen's University.\nIn effect, those guidelines say there's no particular benefit from working out harder, other than saving time.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The high-intensity exercisers in this study had higher rates of musculoskeletal issues (cramping, strains, bone breaks \u2014 several of which required hospitalization) than other groups. Adverse effects caused more people to drop out of the study in the high-intensity group compared with the other groups. The story did not mention this.", "answer": 0}, {"article": "The National Fibromyalgia Association estimates that about 10 million Americans, mostly women, have fibromyalgia, an unexplained condition characterized by chronic pain and fatigue.\nMay 12, 2010 (Baltimore) -- The powerful sleeping medication Xyrem can help relieve the hallmark symptom of pain in people with fibromyalgia, suggests a study that pitted the drug against a placebo.\nXyrem, which is approved by the FDA for the treatment of narcolepsy, corrects the same disturbed sleep patterns that studies have shown are common in fibromyalgia patients, Jones says.\nXyrem also helped reduce fatigue, stiffness, and other symptoms, she tells WebMD.\nAlso, small, preliminary studies suggested the drug can reduce pain and fatigue in people with fibromyalgia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The most common side effects in the study were quantified for each Xyrem group. It also mentions the high potential for abuse and \"date rape drug\" association. While the story quotes a consultant to the drug manufacturer without support regarding the lesser abuse risks in narcolepsy, there\u2019s evidence in the literature, such as in this article, to support the anecdote.\u00a0\nIt would have been nice to read some of the important drug interactions that are possible with Xyrem. It has a boxed warning in its\u00a0prescribing information.", "answer": 1}, {"article": "Those patches of dry, red, itchy skin are at increased risk of infections, particularly from a worrisome germ known as Staphylococcus aureus.\nThe study couldn\u2019t address the bigger question of whether exposure to the right mix of protective bacteria might improve atopic dermatitis itself, cautioned Mount Sinai\u2019s Guttman-Yassky.\nGallo\u2019s team took a closer look at how microbes in healthy skin might be keeping that bad staph in check.\nIn one early test, those customized creams guarded five patients with a kind of itchy eczema against risky bacteria that were gathering on their cracked skin, researchers reported Wednesday.\nNow scientists are mixing the good bugs into lotions in hopes of spreading protection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have explained that the harms are unknown\u2013more testing must be done before a better understanding of the risks and benefits emerge.", "answer": 0}, {"article": "Prof Johann de Bono, Regius professor of cancer research at the ICR, and consultant medical oncologist at the Royal Marsden NHS foundation trust, said: \u201cOur study identifies, for the first time, genetic changes that allow prostate cancer cells to become resistant to the precision medicine olaparib.\n\u201cFrom these findings, we were able to develop a powerful, three-in-one test that could in future be used to help doctors select treatment, check whether it is working and monitor the cancer in the longer term.\nThirdly, they used the test to monitor a patient\u2019s blood throughout treatment to quickly pick up signs that the cancer was evolving genetically and might be becoming resistant to the drugs.\nWe think it could be used to make clinical decisions about whether a PARP-inhibitor is working within as little as four to eight weeks of starting therapy.\nHe said: \u201cBlood tests for cancer promise to be truly revolutionary.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made no mention of potential harms of the liquid biopsy itself or of guiding chemotherapeutic treatment decisions based on results of the liquid biopsy.\nWhat about false positives? And false negatives? Erroneous results from a \u201csimple\u201d blood test could lead to a patient stopping the drug prematurely or initiating erroneously. Stories about screening tests must include the false positive and false negative rates for these reasons\u2013they are a real risk.", "answer": 0}, {"article": "Although many patients take drugs like statins and medicine to reduce their risk of stroke, surgical treatment of severe blockages in the carotid artery has been shown to be more effective than medical therapy alone in preventing ischemic strokes caused by a buildup of plaque in the arteries.\nThe most important message is that the overall death rate was extremely low, 0.6 percent, said one of the study\u2019s principal investigators, Dr. Gary S. Roubin, the chairman of cardiovascular medicine at Lenox Hill Hospital in New York.\nThe death rate in the trial was very low, but risks varied depending on the procedure.\n\u201cWe had outstanding results, and our study, we think, is representative of these treatments in the and ,\u201d said Dr. Thomas G. Brott, director for research at the campus in , Fla., and lead author of the North American study, called Crest (for Carotid Revascularization Endarterectomy versus Stenting Trial).\n\u201cWhat this trial has done overwhelmingly,\u201d he said, \u201cis shown that in , with the very skilled surgeons and physicians performing stenting, the outcomes were extremely safe.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the LA Times coverage,\u00a0this story gives us the key\u00a0essentials regarding what happened to patients in both studies and their risk of major complications such as stroke or heart attack.", "answer": 1}, {"article": "Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.\n\u201cThese induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,\u201d said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study.\n\u201cThough additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.\u201d\n\nNext steps include testing the efficacy and safety of the stem cell injection in preclinical animal studies to provide information for applying for an investigational new drug.\n\u201cThis is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,\u201d said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.\nWhen animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release fails to mention any potential harms from the procedure, although it appears to involve\u00a0piercing of the eyeball and injecting cells inside.\u00a0 It would also appear that the procedure requires\u00a0a small slice through the cornea to release pressure within the eye from adding the stem cells.\u00a0 And while the eye is well-known to be one of the fastest healing of our organs, any surgery involves potential risks.\u00a0 While the release does point out that the cells, as they multiply, form a kind of protective layer in the back of the eye, it does not mention \u2014 as the actual research paper does \u2014 that that layer may interfere with the supply of nutrients to cells in the eye, leading to their death.\u00a0 Nor does the release mention the potential problem of rejection of the foreign cells, which the research paper explains.", "answer": 0}, {"article": "Dr. Michael Schwartz is director of laparoscopy and minimally invasive surgery at North Shore-LIJ Health System in Lake Success, N.Y.\nIf a treatment showed a marked change, it could continue to be used in that patient, hence \"personalized\" medicine.\nUsing positron emission tomography -- also known as a PET scan -- doctors are then able to better visualize tumors and tumor spread.\nIf used on people, the researchers claimed that the radiotracer might someday help doctors \"personalize\" treatment strategies for prostate cancer and better manage the disease.\nBoth methods have their limits and, \"while this study is very preliminary, if this radiotracer technology can prove to detect very early recurrence or metastasis in human patients, it could become extremely useful in either the pre- or post-treatment setting in selecting a treatment algorithm,\" Schwartz said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said nothing about potential harms.\nMedline Plus reminds consumers:\nThe amount of radiation used in a PET scan is low. It is about the same amount of radiation as in most CT scans. Also, the radiation doesn\u2019t last for very long in your body.\nIt is possible, although very unlikely, to have an allergic reaction to the radioactive substance. Some people have pain, redness, or swelling at the injection site.\nHarms also emerge from false positive and false negative test results \u2013 which could lead to unnecessary treatment or undertreatment.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of treatment, i.e. increased risk of advanced prostate cancer and fatal prostate cancer were mentioned.\u00a0 However, the source article for this story included estimates of the frequency with which these normally occur, so the story could have included this information and provided a more informative picture.", "answer": 1}, {"article": "Men and women with mildly high blood pressure who ate three kiwi fruits a day for eight weeks had systolic blood pressure levels that were 3.6 millimeters of mercury lower than those of volunteers who ate an apple a day.\nTUESDAY, Nov. 15, 2011 (HealthDay News) -- An apple a day won't necessarily keep the doctor away, but three kiwis just might help, at least according to a small study that showed that the brown, fuzzy fruit may lower blood pressure levels.\nDon't start popping lutein in supplement form based on these results, he noted.\nThe study was to be presented Tuesday at the American Heart Association's annual meeting in Orlando, Fla.\n\nCardiologists were quick to caution that there is no single magic food or ingredient that is the key to heart health, but they all agreed that kiwi may have a place in the five daily servings of fruit and vegetables that are currently recommended as part of a heart-healthy diet.\nModeration is the key with kiwis or any food, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s an odd cautionary quote that even 3 kiwis a day \u201cdoesn\u2019t sound like moderation and I would caution against eating that much.\u201d\u00a0 But the story never explains why.\u00a0 Is there a harm?\u00a0 This point was just left hanging unexplained.\nHere\u2019s some of the explanation that could have been given.\u00a0 Kiwi is rich in potassium, which may be one of the ways it helps lower blood pressure. People with kidney disease or other metabolic disorders predisposing them to high potassium could get into trouble with high intake of the fruit (theoretically). See Medlineplus for information about potassium-rich diets.", "answer": 0}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cWe have made a nano-sized device that we can put under the skin using an injection needle to recruit the cancer cells into a small area where we can treat them with less overall side effects to the whole body,\u201d Tang said.\n\u201cWe are putting biological agents in a cancer trap to attract and kill cancer cells.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not addressed. That may be for reasons that we\u2019ll address under \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "This news-agency article is no longer available on nytimes.com.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted privacy and data security concerns near the top and expanded on them in the body of the piece. The story would have been more balanced if it had declared more strongly that while these apps could be helpful, until studies are done, it is also just as possible that they could be useless or even harmful in ways that were not discussed in the story, such as diverting patients from proven interventions.", "answer": 1}, {"article": "1 Ward et al.\nThe safety profile of tramiprosate in 2,025 AD patients across the two studies was favorable and similar in the APOE4 carriers and non-carriers.\nIn these new subgroup analyses, the high dose of tramiprosate showed promising clinical effects in APOE4/4 homozygous AD patients already receiving maximal standard of care, and this dose was not associated with any events of vasogenic edema,\" said Susan Abushakra, MD, Chief Medical Officer of Alzheon and lead author on the JPAD publication.\nThe efficacy and safety analyses with tramiprosate published in JPAD reveal a therapeutic effect in patients who are carriers of APOE4 after segmenting them from the larger, non-genetically-defined study population in the Phase 3 clinical program, involving more than 2,000 AD patients in North America and Europe.\nIn the overall Mild and Moderate AD study population with baseline MMSE of 16-26 (and any APOE genotype), the North American study did not demonstrate a significant benefit with either of two tramiprosate doses (100 mg BID and 150 mg BID), compared to placebo, during the 78-week study period.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contained enough detail about safety issues to give it a satisfactory when it noted: \u201cThe safety profile of tramiprosate in 2,025 AD patients across the two studies was favorable and similar in the APOE4 carriers and non-carriers. The main adverse events were gastrointestinal (nausea, vomiting and weight loss), which were mild or moderate in severity.\u201d\nWe would have liked more discussion of how patients might use the drug and whether there are any other harms that could loom from treatment.", "answer": 1}, {"article": "On the flip side, a low-risk score \"doesn't give you a free pass,\" he added.\nFor example, when the researchers tested the system using a DNA database from Britain, less than 1 percent of people with the lowest risk scores were diagnosed with coronary artery disease, compared with 11 percent of people with the highest risk score.\nThe scoring system can also predict an increased risk of Type 2 diabetes, inflammatory bowel disease, breast cancer and an irregular heartbeat called atrial fibrillation, the team reported in the journal Nature Genetics \u2014 noting that next steps include learning what might likewise lower those risks.\n\"This is the first time polygenic scores have really been shown to reach the level of precision where they can have an impact\" on patient health.\nScores more than three times the average person's risk were deemed high.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention in the story about possible false positives or false negatives although both represent considerable concerns for individuals. False positives can cause patients unnecessary concern\u00a0while false negatives may embolden persons to be careless in controlling other risk factors that can lead to disease.\nFor example, people with a high score may want to take cholesterol-lowering medications, which will have costs and potential side effects, without knowing whether they are effective. There also can be psychological harms of telling someone that that they have a high risk for cardiovascular disease or other diseases.", "answer": 0}, {"article": "\"It can be extremely painful to pass these jagged little crystallized minerals and it's very common for sufferers to go to an emergency department for treatment.\nTrial leader and specialist emergency medicine physician at The Townsville Hospital, Dr Jeremy Furyk, said Tamsulosin was normally used to treat an enlarged prostate, but the research team found the treatment could also assist the passage of large kidney stones in the urine.\nPatients with kidney stones were treated with the drug Tamsulosin in an Emergency Medicine Foundation Australasia (EMF) funded clinical trial run across five Australian hospital emergency departments.\nMillions of Australians suffering from kidney stones could soon get relief, with researchers discovering a prostrate treatment can also help ease the painful condition.\nEMF Australasia Chair, Associate Professor Sally McCarthy said this research had the potential to help millions of Australians suffering with this extremely painful condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of potential harms from the use of tamsulosin mentioned in the news release, although a simple web search reveals a host of minor side effects \u2014 drowsiness, dizziness, blurred vision, lightheadedness, fainting, back pain, cough, decreased sexual ability, diarrhea, headache, runny or stuffy nose, sinus inflammation, trouble sleeping, or weakness \u2014 and possible severe side effects including severe allergic reactions, chest pain or irregular heartbeat, fever or chills, or other conditions.", "answer": 0}, {"article": "Omega-3 fatty acids are unsaturated fats found in most fish, but especially in fatty fish that live in cold seawater, such as salmon and herring.\nMight fish consumption help the brain, too?\nWHO MAY BE AFFECTED?\nTHE QUESTION Eating fish can be good for the heart, thanks to the presence of omega-3 fatty acids.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of eating fish are not in question \u2013 although the story could have mentioned concerns with mercury in some fish at some levels of consumption.", "answer": 2}, {"article": "DCIS affects one out of every five women diagnosed with breast cancer in the United States, and is often treated with surgery followed by radiation therapy and/or hormonal therapy.\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the benefits of the test to physicians, patients and payors.\nPhysicians in this study rated the DCIS Score as the most important factor in planning treatment compared with pathologic features, patient preference, patient age, comorbidities or consultation with other physicians.\n\"These results highlight the need to optimize treatment of this non-invasive, indolent form of breast disease, and the importance of Oncotype DX in helping physicians reduce over- and under-treatment of DCIS.\"\n\"The publication of this clinical utility study clearly demonstrates that the Oncotype DX DCIS Score can play a key role in enhancing cancer care for patients with DCIS, and we believe that these results will support expanded adoption of and access to the DCIS Score.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release emphasizes the potential beneficial effect of test results on refinement of treatment recommendations. It doesn\u2019t contemplate or even mention the possibility that an inaccurate test result could cause harm \u2014 for instance by recommending a conservative course of therapy when a more aggressive approach is warranted, or vice-versa. While the study itself didn\u2019t assess outcomes or potential for harm, as with Benefits we\u2019d expect some nod to the fact that this is an area of uncertainty that requires more research.", "answer": 0}, {"article": "\"We don't yet have a full understanding--nobody does--of how the bile acid actually does what it does in heart cells,\" explains Michalak.\nThe team is now pushing forward with additional studies to see if the same therapeutic effect can be achieved in humans.\nOnce that occurs, the team hopes to work with cardiologists to quickly move the research into clinical trials, involving chemotherapy and heart transplant patients.\nThe collaborative study, funded by the Canadian Institutes of Health Research and published in PLOS One, examined the molecular mechanisms that lead to cardiac fibrosis in a pre-clinical model.\nThe study discovered the specific triggers activating the development of fibrosis which accelerates heart failure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The research paper does not include any statement about potential toxicity other than to point out that none of the 162 mice died prior to the conclusion of the study. The release is silent on the issue. A\u00a0few words about the potential toxicity (or the absence of risk if that\u2019s the case) of TUDCA which is commercially available and has been studied\u00a0for the treatment of biliary cirrhosis would have been in order.", "answer": 0}, {"article": "The subjects were followed for 10 years.\nFor example, a person who, according to the current risk calculator, has a 12 percent risk of a heart attack in the next decade should take a statin, the guidelines say.\nIt turned out that the actual incidence of heart attacks or disabling chest pain in those with zero calcium was half or less than what the risk calculator predicted.\nFirst, he asks patients for whom statins are recommended according to the current guidelines if they would want to avoid taking the drugs if they turn out to have a calcium score of zero and an actual risk of less than 5 percent.\nDr. Krumholz and Dr. Khurram Nasir, a preventive cardiologist at Baptist Health South Florida, who conceived the new study, reasoned that research on heart scans had not been designed to help doctors make treatment decisions they face today.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly lays out some of the ways that testing can go awry. It reports that the CT scans expose people to about the same amount of radiation as a mammogram, implying a level that many people routinely accept, though it does not go into detail about potential radiation effects. The story also explains the risk of \u201cincidentalomas\u201d, things that can pop up on this sort of scan besides coronary artery calcium, such as nodules in lungs, that might lead a person down a path of further testing and treatment. And it spells out the potential consequences of having a scan that reveals high levels of calcium deposits, prompting further testing and treatments, perhaps leading to substantial harms.Overall, we think the harms are admirably covered.", "answer": 1}, {"article": "ASTRO publishes three medical journals, International Journal of Radiation Oncology\n\u2022 Biology\n\u2022 Physics (www.redjournal.org), Practical Radiation Oncology (www.practicalradonc.org) and Advances in Radiation Oncology (www.advancesradonc.org); developed and maintains an extensive patient website, RT Answers (www.rtanswers.org); and created the Radiation Oncology Institute (www.roinstitute.org), a nonprofit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment.\n\u201cAfter following patients for more than five years, we found that serious side effects from a brief course of SBRT were uncommon and that cancer control rates were very favorable compared to historical data.\nSpecifically in the low-risk group, the five-year RFS rate was 97.3 percent, which is superior to the 93 percent historical comparison DFS control rate (p = 0.014).\nIn low-risk patients, the cancer control rates was superior to historical controls.\nActuarial five-year nadir+2 RFS was 97.1 percent for all patients, representing 97.3 percent of low-risk and 97.1 of intermediate-risk patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states that between half and two-thirds of patients experienced low, \u201cusually temporary\u201d rates of toxicities. It also notes that \u201cfewer than 2 percent of patients experienced severe toxicities in their gastrointestinal, reproductive, and urinary systems, and no patients reported life-threatening or fatal toxicity.\u201d A few more details here would be helpful. For example, how many patients experienced a decline in urinary or sexual function, and for what period of time? And what are other potential risks of radiation therapy? The real question is how do these harms compare to other treatments? That was not assessed in this study.", "answer": 1}, {"article": "It's the No.\nNot all men with premature ejaculation suffer to the same degree as the men in the study, says researcher Ira Sharlip, MD, clinical professor of urology at the University of California, San Francisco.\nMen who sprayed the head of their penis with PSD502 five minutes before sex lasted an average of just over three minutes after three months of treatment, compared with just over 30 seconds before.\nPremature ejaculation can be devastating for both a man and his partner, triggering anxiety, depression, and relationship problems, says Goldstein, who heard the results presented at the annual meeting of the American Urological Association.\nA total of 358 of the men gave themselves three quick sprays of PSD502 to the head of the penis five minutes before sex and then wiped it off right before penetration.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, this was the most complete story of the three reviewed in discussing side effects: \n\"A total of 6.1% of the men and 6.7% of their partners suffered at least one side effect. In men, the most frequent side effect was loss of erection; it occurred at least once in 3.1% of men. In the partners, the most frequent side effect was burning in the vulvovaginal area; 5% of women reported it at least once.\"", "answer": 1}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nThe new product also contains pennywort, a plant found in Asia, Africa, and the Americas that has anti-inflammatory properties and is widely used in Indian naturopathic medicine for ulcer healing, she says.\nHe was not involved with the research.\n\"But [after several weeks of treatment], the cream made them look and feel better,\" she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that women experienced no side effects from the cream.", "answer": 1}, {"article": "In more than 22% of cases, implantable defibrillators are given to heart patients who don\u2019t meet the guidelines for receiving the pricey devices, according to a study just published in JAMA.\n\nThe research, based on 111,707 cases submitted to a national registry over a three-and-a-half-year period, also finds that those patients who didn\u2019t meet the guidelines had a higher risk of dying in the hospital and of complications from the implantation.\n\nICDs, which can cost north of $30,000, monitor the rhythm of the \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says up high that patients who fell outside the guidelines had a \u201chigher risk of dying in the hospital and of complications from the implantation.\u201d But there are no numbers provided. In fact, there are more percentages provided in this story about the stock prices of the various device makers involved than there are about the harms or benefits. This is the Wall Street Journal, of course, but we still thought some additional numbers about harms or benefits would have been helpful to any reader.", "answer": 0}, {"article": "\u201cBut now, we\u2019re seeing this whole new spectrum of treatments.\n\u201cI foresee that a lot of allergy therapies will become more and more specific and targeted, and more customizable to the individual patient,\u201d said Andrew Long, the lead investigational drug pharmacist at Stanford\u2019s Sean N. Parker Center for Allergy & Asthma Research.\n\u201cAt the end of the day, it\u2019s a fairly 19th-century approach,\u201d said Dr. Wayne Shreffler, a researcher at Massachusetts General Hospital who is working on the Broad Institute\u2019s Food Allergy Science Initiative.\nThis timeline becomes untenable for patients with multiple allergies \u2014 and about 70 percent of people who have an allergy to one type of food will also be allergic to another, Long said.\nIf it works, it\u2019d be fairly easy to swap out the cedar pollen DNA for a different allergen \u2014 for instance, the genetic material that codes for peanut or cat antigens \u2014 and tack it onto this vaccine template.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Particularly for the new-style food-desensitization therapies under development, the article explains potential (and even deadly) risks associated with them and it alludes to some of the downsides of immunotherapies (\u201callergy shots,\u201d for instance) that can take months or years to work. But it says essentially nothing about the potential or actual adverse effects of a DNA vaccine under development, noting only that it \u201chypothetically decreases the risk for adverse events.\u201d", "answer": 1}, {"article": "Inflammation is a sign of damage from cholesterol.\n\u201cIt appears to be safe and to not raise blood pressure,\u201d Shah told CNN, \u201cbut it\u2019s not a slam-dunk.\u201d For one thing, despite improved cholesterol levels, patients did not see less inflammation in their blood vessels.\nBy then, results will also be in on a large study of a similar drug, dalcetrapib, made by Merck\u2019s competitor, Roche.\nIf the same benefit were seen in all patients at risk of heart disease \u2013 far from a sure thing \u2013 it would translate to hundreds of thousands of fewer deaths and heart attacks over a five-year period, according to Dr. Christopher Cannon, the lead study author and a cardiologist at Brigham and Women\u2019s Hospital in Boston.\nLee Davies, a Merck spokesman, said the company is not likely to seek FDA approval until those results are in, most likely in 2015.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nReaders of this story are likely to conclude that anacetrapib is safe. They aren\u2019t told that what the researchers actually reported is that based on their statistical analysis, they are at least 94 percent sure that the drug doesn\u2019t cause the 25 percent increase in cardiovascular events that was seen in experiments with a similar drug, torcetrapib. That \u201cpromising\u201d drug was yanked from testing.\nThe story did report the dangerous turn taken in trials of torcetrapib, but it could have done a better job of explaining to readers that while researchers breathed a sigh of relief that the same sort of hazards weren\u2019t seen in this trial of anacetrapib, the safety picture is still only short-term and sketchy.", "answer": 0}, {"article": "It works like a lock on a canal, he said.\nSo, even older patients with limited mobility and balance don\u2019t have to negotiate getting down into a pool.\nWhether you call it water running, aqua jogging or hydrotherapy, you can\u2019t beat a workout in water for an array of health benefits, many experts say.\nAn alternative to a water treadmill: Some pool companies will install a water flow system you can work out against.\nBudd Coates, training director at Runner\u2019s World magazine, said runners don\u2019t just plunge into water\u200b therapy when they\u2019re injured; it\u2019s a great conditioning method for healthy athletes, too.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss harms. There don\u2019t appear to be any particular health risks associated with the use of underwater treadmills that wouldn\u2019t apply to beginning any exercise or rehabilitation regime \u2014 but that\u2019s actually a point worth making.\nHowever, exercising in a pool poses risks of its own \u2014 particularly for patients who may be recovering from surgery or stroke. As a result, it would be wise\u00a0to explain that these patients (or any patient who is not confident in the water) should have\u00a0supervision. And, this therapy may induce anxiety among people who can\u2019t swim or are anxious around water.", "answer": 0}, {"article": "\"Being impotent is no fun.\"\nBut he echoed the thought that a longer-term and larger test is needed to determine the incidence of some possible major side effects, such as impotence.\nIf eprotirome does pass all the anticipated tests successfully, its use at first probably would be in combination with a statin, Angelin said.\nWEDNESDAY, March 10, 2010 (HealthDay News) -- A thyroid-derived cholesterol-lowering drug that could be an alternative to the widely used statin medications has done well in a small, early trial, Swedish and American researchers report.\nAnd though statins are widely used and most often successful, an alternative to them would be welcome, Ladenson said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that the drug \" did not cause the feared side effects on the heart and other organs that have plagued similar thyroid-based treatments.\" But can these side effects be expected to show up in a small, short-term trial? \nNonetheless, because of the strength of the concluding comments by the independent expert \u2013 \"But if there is one thing we\u2019ve learned about drugs in this arena, it\u2019s that we need large trials to see how they measure up in terms of risk and benefit\u2026I\u2019m not sure I\u2019d want to sign up for that one before I had longer-term results. Being impotent is no fun.\"- we\u2019ll give this story the benefit of the doubt.\u00a0", "answer": 1}, {"article": "The page you are looking for has moved. Please go to the main EurekAlert! homepage to locate the section you are interested in and reset your bookmarks.\n\nFor further assistance, please contact webmaster@eurekalert.org.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of the potential side effects associated with daily use of a nonsteroidal anti-inflammatory drug. Potential harms of ibuprofen taken for years can be substantial and include increased risk of stroke, heart attack, gastrointestinal bleeding and kidney disease.\nNo mention is made of the potential harms associated with either false-positive, or false-negative, tests for Abeta42.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nNoctiva is being approved with a boxed warning and a Medication Guide because it can cause low sodium levels in the blood (hyponatremia).\nNoctiva\u2019s efficacy was established in two 12-week, randomized, placebo-controlled trials in 1,045 patients 50 years of age and older with nocturia due to nocturnal polyuria.\nNoctiva should also not be used in patients with symptomatic congestive heart failure or uncontrolled hypertension because fluid retention can worsen these underlying conditions.\nBecause Noctiva is approved only for adults with nocturia caused by nocturnal polyuria, health care providers should confirm overproduction of urine at night with a 24-hour urine collection, if one has not been obtained previously.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does well describing harms, providing extensive details on adverse effects, particularly warning that Noctiva can cause a potentially life-threatening drop in blood sodium and shouldn\u2019t be used by those at risk for that condition. The release says the drug will come with a boxed warning and a Medication Guide to draw attention to the risk. It also lists the most common side effects: nasal discomfort, cold symptoms, nasal congestion, sneezing, high or increased blood pressure, back pain, nose bleeds, bronchitis and dizziness.\nIt cautions against use in pregnant women and children as well as patients with symptomatic congestive heart failure or uncontrolled hypertension and patients with certain nasal conditions such as colds or allergies.\nWe would have liked to see the news release mention that 4 percent of patients in the trials stopped therapy due to adverse events. Also, an FDA document expressed concern that the drug could mask symptoms of underlying conditions, which was only alluded to in the news release with an advisory that doctors treat underlying conditions that could cause frequent urination.", "answer": 1}, {"article": "Stay out of the sun, or utilize a proper sunscreen.\nA few potential caveats to note include the reliance on self-reporting when it comes to a man's history of STIs, as well as his sexual partners.\nCircumcision, of course, removes this protective environment.\nA cursory review of the data suggests, for example, that the number of male sexual partners is greatly underreported.\nIt's important to note, right off the bat, that this study is not purporting to establish a cause and effect relationship.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms of circumcision, such as pain, are not discussed.", "answer": 0}, {"article": "\u201cI don\u2019t want to throw cold water on an interesting thing, but that\u2019s what it is \u2014 an interesting thing,\u201d Gallo said.\n\u201cIt is possibly a cure, that\u2019s for sure, you won\u2019t know for absolute sure until the person dies and undergoes extreme PCR (genetic) analysis of post-mortem tissue.\u201d\n\nThe mutation affects a receptor, a cellular doorway, called CCR5, that the AIDS virus uses to get into the cells it infects.\nSome researchers are working on the idea of gene therapy to treat or try to cure HIV, but the technology is still in experimental stages.\nAIDS researchers have rejected the approach on any kind of scale for patients with HIV.\n\u201cOur results strongly suggest that cure of HIV has been achieved in this patient,\u201d they wrote in the journal Blood.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that bone marrow transplants are risky and in fact , \u201c\u2026can kill people.\u201d But it should have told readers that for some types of leukemia, up to 40 percent of patients die have receiving a bone marrow transplant from a donor. What\u2019s more the list of serious complications is harrowing. According to the National Cancer Institute, leukemia patients treated with a bone marrow transplant may have less than a 50-50 chance of successful treatment and even when the treatment works, it is often very painful and may cause serious to kidneys, liver, heart and lungs. So even though this story does tell readers that transplants are risky, it fails to provide numbers that would make clear just how perilous this course of treatment is.", "answer": 0}, {"article": "In a twist in the debate about the safety of menopause hormones, new research suggests the real problem may not be the hormone itself, but the fact that it's typically swallowed as a pill.\n\nThis week, the medical journal Circulation offers some of the strongest evidence yet that the risks of hormones are dramatically reduced when the drugs are absorbed through the skin in patches and gels rather than taken as pills. The study by French researchers showed that one of the most serious risks associated with hormone use -- blood...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions blood clots, stroke and breast cancer as potential harms of hormone therapy. ", "answer": 1}, {"article": "The requested URL /usnews/health/articles/060723/31robot.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms of treatments mentioned. The article mentions in a general way that \u201cimpotence and incontinence are common following surgery to remove the prostate\u2026\u201d Yet presenting one person\u2019s very rosy experience with the new technology\u2013\u2026\u201dhad no difficulty with either incontinence or impotence\u201d\u2013seems unbalancing. ", "answer": 0}, {"article": "She lets her enthusiasm loose.\nThere are also costs in the sense of risks: Women who get a combo 2-D and 3-D mammogram, the protocol that confers the most dramatic jump in benefits, are exposed to twice as much X-ray radiation as the norm (albeit still an amount that\u2019s under the FDA\u2019s permitted limit).\nIn fact, technology developers had been trying in various ways for years to increase mammography\u2019s sensitivity (its ability to flag possible cases of cancer) while also increasing its specificity (its ability to filter out the false positives).\nBut 3-D mammography could become its flagship, because for the moment it owns the entire market \u2013 although other companies, including powerhouse GE, are developing their own 3-D machines, Hologic is the only one with FDA approval thus far.\nDigital mammography did seem to perform more accurately than film in women who were younger than 50, women who were pre- or perimenopausal, and women with dense breast tissue.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author does mention that a woman who has both 2-D and 3-D imaging, the protocol with the most benefit, would receive twice the radiation of 2-D imaging alone.\u00a0 While this is still under the FDA\u2019s permitted limit, the piece should also mention that patients need to consider\u00a0total radiation exposure from increased use of all high-tech diagnostic imaging equipment.\nIn addition to providing no evidence of improved sensitivity and specificity of 3-D imaging, the piece doesn\u2019t even mention the possibility of over-diagnosis and over-treatment of very early stage breast cancers that may never have needed treatment.\u00a0 Thus a woman may be harmed physically, emotionally\u00a0and financially because of over-treatment.", "answer": 0}, {"article": "\u201cDiet is a complicated business,\u201d he said.\nThe investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\n\u201cIf the goal is to prevent hypertension\u201d with lower sodium consumption, said the lead author, Dr. Jan A. Staessen, a professor of medicine at the University of Leuven, in Belgium, \u201cthis study shows it does not work.\u201d\n\nBut among the study\u2019s other problems, Dr. Briss said, its subjects who seemed to consume the smallest amount of sodium also provided less urine than those consuming more, an indication that they might not have collected all of their urine in an 24-hour period.\nAnd while those eating the most salt had, on average, a slight increase in systolic blood pressure \u2014 a 1.71-millimeter increase in pressure for each 2.5-gram increase in sodium per day \u2014 they were no more likely to develop hypertension.\n\u201cThey do not tell you what will happen if you change peoples\u2019 sodium intake.\u201d\n\nWhat is needed, Dr. Alderman said, is a large study in which people are randomly assigned to follow a low-sodium diet or not and followed for years to see if eating less salt improves health and reduces the death rate from cardiovascular disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of this story was avoiding harm by eating too much (or too little) salt. \u201cThe investigators found that the less salt people ate, the more likely they were to die of heart disease \u2014 50 people in the lowest third of salt consumption (2.5 grams of sodium per day) died during the study as compared with 24 in the medium group (3.9 grams of sodium per day) and 10 in the highest salt consumption group (6.0 grams of sodium per day).\u00a0And while those eating the most salt had, on average, a slight increase in systolic blood pressure \u2014 a 1.71-millimeter increase in pressure for each 2.5-gram increase in sodium per day \u2014 they were no more likely to develop hypertension.\u201d It does a great job presenting the numbers in absolute terms.", "answer": 1}, {"article": "MayoClinic: Find out more about melanoma\n\nOne study presented at the American Society of Clinical Oncology's (ASCO) conference on Sunday focused on the experimental drug vemurafenib.\nThis is very unusual in the world of drug development, he said.\nBut in many cases that are nine or 10 months they otherwise would not have had.\nNearly 90% benefited from this new targeted drug, Schuchter said.\nYervoy takes a while to work, and some patients may not have that time, study author Chapman said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not a single word about potential harms, as opposed to a New York Times story, which described \u2013 variously for the two drugs:\nAgain, is this not worthy of at least a line?", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to\u00a0point out\u00a0that in terms of serious side effects (renal, cardiovascular, or cerebrovascular events), or of people discontinuing treatment because of side effects \u2013 there was no difference between those being treated or those who received the placebo.\u00a0 The story neglected to discuss the side effects commonly seen in the study participants given the treatment; there was a higher incidence of fever and musculoskeletal pain in those infused with the drug.\u00a0 \n\u00a0", "answer": 0}, {"article": "\"In the short term, what it is designed for is treatment of withdrawal,\" he says.\nSmoking cessation experts and a maker of nicotine replacement therapies took issue with the findings.\nThe results of the new study are published online in Tobacco Control.\nRelapse rates of the quitters were similar during the study period, whether they used the products alone or with counseling, or they did not use them.\nBetter strategies are needed to prevent relapse, he tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the stories mentioned the potential harms from taking nicotine, as opposed to quitting cold turkey. Nor did they mention the additional risks associated with continuing to smoke instead of making use of a more successful smoking cessation program that would actually help a smoker quit. As the leading risk factor for early death, smoking should be stopped as quickly and effectively as possible.", "answer": 0}, {"article": "\"If someone really feels they need to take this and they need to try it, well go ahead and do it.\nIn a statement, Douglas MacKay, CRN's vice president of scientific and regulatory affairs, said that \"there is a large body of previously published evidence, as well as ongoing trials, which suggest that ginkgo biloba is effective for helping to improve cognitive impairment in older adults.\"\nHowever, ginkgo was safe and no serious side effects were noted, DeKosky added.\nAnother group, the Council for Responsible Nutrition (CRN), which represents the dietary supplement industry, also had reservations about the study.\nEarlier results from the same study found that ginkgo did not prevent or slow the development of Alzheimer's or other dementias, DeKosky said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the study found that ginkgo was safe and no serious side effects were noted. But it could have noted that the National Center for Complementary and Alternative Medicine states that \"Side effects of ginkgo may include headache, nausea, gastrointestinal upset, diarrhea, dizziness, or allergic skin reactions. More severe allergic reactions have occasionally been reported.\" ", "answer": 1}, {"article": "Their overall risk of death was 30% lower than the sedentary adults, with the risk of cardiovascular and cancer deaths lower by 40% and 18% respectively.\n\u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise,\u201d he said.\n\u201cMy take home message is that the greatest risk reduction and the greatest gain for the individual and for public health is if those who are physically inactive take up some activity,\u201d he added.\nFor those who have resolved to get fit in the New Year, O\u2019Donovan recommends to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury.\nThe findings will reassure people who find it hard to make time for a daily exercise routine and opt instead to break a sweat once or twice a week in the hope of keeping fit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not explicit the story does provide some information on the potential harms before embarking on a \u201cweekend warrior\u201d status. \u00a0The lead author of the paper recommended, \u201c\u2026\u00a0to start with moderate exercise, such as brisk walking, and then to set realistic, incremental goals to boost confidence without running the risk of setbacks due to injury. \u201cA middle aged or older person should do as much as 12 weeks of moderate exercise before introducing vigorous exercise.\u201d", "answer": 1}, {"article": "Anderson Cancer Center.\nThe new finding could lead to a blood test that would allow doctors to screen for pancreatic cancer much more effectively.\nIf it can be shown that screening improved outcomes, it could one day be used to screen the general population.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\nThat is due in part to the lack of any easy way to detect the cancer in its earliest stages.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the story neglect to mention harms, it asserts that the still-to-be-developed test is 100 percent accurate. But as the competing stories on this study pointed out, that figure is based on testing in a very small number of people under favorable conditions. We now know from many decades of increased use of screening tests that these tests are fallible and there\u2019s no reason to to expect a new test would not offer up false positives and negatives when used in a broader population. Inconclusive and incorrect tests can lead to more invasive tests, increased patient anxiety and expensive and debilitating surgeries.", "answer": 0}, {"article": "They\u2019re widely used in Europe and Australia.\nSince there are about 30 million people hospitalized in the U.S. alone each year, \u201cthere are tens or hundreds of thousands of patients who would be spared death or severe kidney problems by using balanced fluids instead of saline,\u201d said one study leader, Vanderbilt\u2019s Dr. Matthew Semler.\nThe fluids cost about the same \u2014 a dollar or two per IV \u2014 and many suppliers make both types, so switching should not be hard or expensive, doctors said.\n\u201cWe\u2019ve been sounding the alarm for 20 years\u201d about possible harms from saline, said Dr. John Kellum, a critical care specialist at the University of Pittsburgh.\nAfter seeing the results two months ago, Vanderbilt hospital officials decided to primarily use balanced fluids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that this study is all about safety, we think the story should have provided more detail on the known harms of saline vs balanced fluids. The AP story does mention the kidney disease risk with saline, but doesn\u2019t explore why physicians might be leery to use balanced fluids. As CNN explained:", "answer": 0}, {"article": "\"We found comparable detection between self-collection and physician-collection,\" Des Marais said.\nEarlier this year, the U.S. Preventive Services Task Force gave an \"A\" rating to HPV primary screening alone for women aged 30 to 65.\nOffering HPV testing using self-collection by mail has a lot of potential to reach women who are the highest risk of being screened: those who don't access regular medical care.\"\nThey reported this screening approach detected high-risk HPV in all of the cases of women who were found to have high-grade, abnormal cervical precancerous growths, showing that self-collection at home for HPV may be a viable method to identify women at high-risk for cervical cancer.\n\"We are already working on the next step, which is a clinical trial in which women who aren't up-to-date on screening get either a referral to a free clinic appointment to receive a screening, or receive a self-collection kit in the mail, followed by referral to a free clinic appointment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not address two key potential harms, namely the failure to identify someone who has high-risk HPV, and the \u201cfalse positive\u201d misdiagnosis of people who did not have high-risk HPV. This is the difference between \u201csensitivity\u201d and \u201cspecificity.\u201d\u00a0It\u2019s particularly relevant in this instance because HPV screening has a track record of problems with both specificity and sensitivity\u2014 and because the release itself makes clear that there were people diagnosed as at high risk in some of the screening tests, but not others. Missing someone who is at high risk is clearly problematic. But being told that one faces significant medical risks that one does not actually face can also have ramifications for future healthcare, with consequences both physical and financial.\nAnother potential harm could be having a certain rate of patients sending in the test but not following up, leaving clinicians with positive tests and patients lost to follow up which would skew the impact of the screening effort.", "answer": 0}, {"article": "BRCA mutations cause about 5 to 10 percent of breast cancers and 10 to 15 percent of ovarian cancers among white women in the United States.\n\u201cThere is no effective screening for ovarian cancer and too many women with advanced stage ovarian cancer die of their disease.\u201d\n\nWriting for The New York Times\u2019s Op-Ed page, Ms. Jolie Pitt, 39, said she had expected to have her ovaries and fallopian tubes removed, a procedure called a laparoscopic bilateral salpingo-oophorectomy, but that a cancer scare made her decide to undergo the procedure sooner.\n\u201cProphylactic removal of ovaries and fallopian tubes is strongly recommended in women before age 40 in BRCA1 and BRCA2 mutation carriers,\u201d said Dr. Susan Domchek, executive director of the University of Pennsylvania\u2019s Basser Research Center, which specializes in BRCA mutations.\nCancer experts said Tuesday that the actress and filmmaker Angelina Jolie Pitt was wise to have had her ovaries and fallopian tubes removed last week because she carries a genetic mutation, BRCA1, that significantly increases the risk of ovarian cancer, a disease so difficult to detect that it is often found only at an advanced, untreatable stage.\nIt is unclear how common the mutations are in other racial and ethnic groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does point out that a woman would be expected to suffer from post-menopausal symptoms after removal of her ovaries and that treatments are available. \u00a0However, no information is provided about the potential harms related to the surgical procedure.", "answer": 1}, {"article": "March 20, 2011 -- Elevated levels of a group of five amino acids may predict the development of diabetes years before any noticeable symptoms occur, according to a new study.\n\"They also raise the possibility that, in selected individuals, these measurements could identify those at highest risk of developing diabetes so that early preventive measures could be instituted.\"\n\"These findings could provide insight into metabolic pathways that are altered very early in the process leading to diabetes,\" says researcher Thomas Wang, MD, of Massachusetts General Hospital's Cardiovascular Research Center, in a news release.\nResearchers found that blood tests that screened for these amino acids accurately predicted risk of type 2 diabetes in otherwise healthy adults as well as in those with traditional risk factors such as obesity.\nFor example, insulin resistance, where the body does not use insulin effectively, occurs long before blood sugars reach the level seen in type 2 diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, Virginia, screening tests do have potential harms. If we\u2019re ready to raise the possibility of benefits of a hypothetical test, we need to raise the equally unknown possibilities of false positives and false negatives. The authors do not address the risk that follows from misclassification of non-high-risk patients as high risk. These risks include exposure to unnecessary medical interventions, difficulties getting insurance, and other potential impacts on the way they plan their lives.", "answer": 0}, {"article": "For more information, visit us at allinahealth.org, Facebook, Twitter, YouTube or Healthy Set Go.\nThe study, funded by Engelsma Family Foundation and Abbott Northwestern Hospital Foundation, was published recently in The Breast Journal, the official journal of the National Consortium of Breast Cancers.\nHow to treat patients who have microinvasive breast cancer - tumors that are 1 mm or less in size (the thickness of a dime) -- is somewhat controversial.\n\"These findings allow surgeons to select which patients with microinvasive tumors may actually benefit from lymph node sampling, while sparing other patients from this procedure,\" said Tamera Lillemoe, M.D, pathologist and a study co-author.\nAnd the only patients with positive lymph nodes had microinvasive tumors that were associated with relatively large non-invasive tumors (ductal carcinoma in situ or DCIS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The results of this study support forgoing routine axillary (armpit)\u00a0sentinel lymph node biopsy to evaluate for cancer spread in cases where the invasive breast cancer is less than 1mm in size.\nA potential harm of this approach is missing metastatic cancer. This is not mentioned in the release.\nApropos of this, how long the patients were followed (the mean follow-up was 4.6 years, according to the published study) is a key piece of information and was also not included in the release.", "answer": 0}, {"article": "\u201cBut we do expect the patients to have significant improvements in mobility.\u201d\n\nNearly 30,000 Asterias\u2019s shares were traded by 12:30 p.m.\nData showed that the severity of the spinal injury was reduced in the first patient and two other patients were able to resume their rehabilitation programs soon after being injected with the stem cells.\nIts success is a key step toward proving that embryonic stem cell research could cure diseases such as cancer, Parkinson\u2019s and serious health conditions such immune deficiencies, stroke and spinal injuries.\nThe early study tested the benefits of a smaller dose of 2 million stem cells that are tuned to develop into nerves.\nThe therapy, AST OPC-1, is the first product derived from human embryos to be tested on humans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "AST OPC-1 just completed its phase 1/2a clinical trial, which essentially evaluates the safety of the therapy. The three patients in the trial have not shown any serious adverse events, and the story reports this. However, we think the story could made it clearer that that is very early data, and that harms resulting from the therapy remain to be seen. This is the first stage of a three-step dose escalation trial and the dose used was the lowest envisioned. It\u2019s certainly possible that adverse events not seen at a low dose will occur more frequently with a higher dose of the therapy.", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story has many levels of harm to cover, and it does so in Satisfactory fashion. First, it identifies that a recent study published in JAMA of 309 cases of the use of the Lariat device showed urgent follow-up required in seven patients \u2013 2.3 percent of the cases, and one death. Second, the story explains how and why some physicians choose to use a device off-label, not for a purpose identified at the time of its limited approval by the FDA. One of the physicians calls this a \u201cregulatory loophole\u201d and the JAMA study recommends further research before other doctors use the Lariat device for this purpose.\nOur wish list for this story would have included some yardstick or context to help us understand these harms. How often would patients getting some alternative to the Lariat be expected to have a bad outcome? And in any group of\u00a0309 sick old people with failing hearts, how many bad outcomes should you expect, no matter what device is used? Another missing piece is one of the timing of the harms. Presumably these reports refer to short-term complications, most commonly within 30 days of the procedure, that can most directly be attributable to the device and/or its placement. What isn\u2019t mentioned and warrants comment is that these devices are meant to make permanent changes. And we really don\u2019t know what the long-term issues are with such devices.", "answer": 1}, {"article": "Foxman B, Barlow R, D'Arcy H, Gillespie B and Sobel JD.\nThe review explains that the medicinal properties of cranberries may be attributed to their unique polyphenol, proanthocyanidins - or PACs, for short.\nIt is estimated that one third of women in the United States will get a UTI by the age of 24.2\n\n\"Findings like this,\" adds Dr. Luis, \"give practitioners a viable, inexpensive, non-antibiotic option to help patients reduce the recurrence of an uncomfortable and potentially debilitating infection.\"\nThe industry appreciates the efforts of these researchers and takes pride in the healthy attributes that cranberry products provide to consumers around the world,\" comments Terry Humfeld, executive director of the non-profit research and education-focused organization, The Cranberry Institute.\n\"Our investigation supports that cranberry products can be a powerful tool to fight off frequent UTIs,\" explains lead author, Dr. \u00c2ngelo Lu\u00eds.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says only that taking cranberries as a health supplement is \u201clow risk.\u201d And that\u2019s true. But that doesn\u2019t mean that it\u2019s no risk. For example, the University of Maryland notes that one of the chemicals found in cranberries can increase the risk of kidney stones for some people \u2014 that\u2019s valuable information for readers who have a history of kidney stones. Even if the harms are minimal, it is important to note that fact explicitly.\u00a0", "answer": 0}, {"article": "Nov. 5, 2012 (Los Angeles) -- An IV infusion of \"good\" HDL cholesterol seems to rapidly remove cholesterol out of plaque-clogged arteries following a heart attack, a small, early study suggests.\nThe goal of the new treatment is to reduce the high risk of a second heart attack in people who have had a heart attack.\nHDL removes cholesterol from artery walls, but current HDL-boosting drugs, such as niacin and fibrates, take years to work, according to Gille.\nStandard heart attack medications, such as aspirin and anti-clotting drugs, prevent clotting but don\u2019t eliminate an underlying factor: cholesterol that has built up on artery walls, he says.\nAnd half of them happen in the first month, says researcher Andreas Gille, MD, PhD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It is ludicrous to simply report \u201cThere were no serious side effects\u201d when the only data you\u2019ve reported is two hours of observation of healthy volunteers!\nFirst, were there ANY side effects?\u00a0 If so, what?\nSecond, how many people with diseased arteries (not healthy volunteers) would have to be treated and followed for how long in order to be able to say ANYTHING meaningful about side effects?", "answer": 0}, {"article": "A study believed to be the largest of its kind suggests that the physical aspects of yoga are effective at relieving low back pain, but it didn't find any evidence that yoga provided broader mental benefits.\n\nThe study, funded by the National Institutes of Health's National Center for Complementary and Alternative Medicine, was published online Monday in the Archives of Internal Medicine. It was lead by researchers at Seattle's Group Health Research Institute.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t discuss adverse events related to yoga or intensive stretching. Yet the authors of the study reported on both. These are important issues, as many patients with chronic back pain fear that becoming physically active will exacerbate their symptoms.\n\n\n\n ", "answer": 0}, {"article": "\"Do I want to go back to where I was or do I want to maintain this level of quality of life?\"\nThere are no significant side effects to the surgery, and patients can return to work the day after they have the procedure.\nAfter the surgery, Watson says, patients report feeling fuller and less hungry and they ultimately gain greater control over what they are eating.\nThe problem is that over the years the stomach stretches, and when that happens, Watson says, \"Patients are able to eat more at one sitting and they feel hungrier more often.\"\nAbout one in three patients regain significant amounts of weight a few years after surgery to reduce the size of the stomach pouch.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects should be clearly stated. The randomized study notes that the majority of people who had the surgery (including, interestingly, those who underwent a sham procedure) had side effects including nausea and vomiting. The story states simply that there were \u201cno significant side effects.\u201d", "answer": 0}, {"article": "For more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\nIn the study, researchers examined 171 patients with chronic back or leg pain who were implanted at 10 comprehensive pain treatment centers.\nNone of the patients in the HF10 therapy group experienced paresthesia.\nHF10 therapy remained more effective than traditional SCS over the 12 month study period.\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms except to note that the high-frequency group had no paresthesia. The study that\u2019s the basis for the release noted that \u201cnon-serious\u201d study-related adverse events occurred in about 30% of patients in both groups. These included implant site pain and lead migration resulting in \u201csurgical\u00a0revision\u201d (i.e. a second operation). But that begs the question: How can a second surgery be considered \u201cnon-serious\u201d?", "answer": 0}, {"article": "Many Type 2 diabetics become resistant to insulin and have to inject additional amounts.\nExperts rightfully caution against relying on miracle diet drugs, but a new study offers a novel approach that bears watching.\nBetter yet, the drug, fexaramine, works only in the intestine, never entering the bloodstream.\nOther researchers are working on similar approaches, he said, but this drug, so far, passes harmlessly out of the intestine after doing its work.\nFor now, the new approach has been demonstrated only in mice, according to the research, published Monday in the journal Nature Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story passes along a claim that this drug would be safer than other treatments. This is irresponsible. Since the drug has yet to be tested in people, it is impossible to know what potential harms might be found later.", "answer": 0}, {"article": "1 Sperling RA, Aisen PS, Beckett LA, et al.\nIt is estimated that as many as 3 million cases of Alzheimer's dementia worldwide can be prevented with as little as a 10% reduction in the burden of preventable lifestyle.\nAmong the lifestyle and risk factors that can be altered to potentially prevent cognitive declines are obesity, diet, sleep, hypertension, diabetes, depression, supplementation, smoking and physical activity.\nArmed with new knowledge about how neurodegenerative diseases alter brain structures, increasing numbers of neurologists, psychiatrists and other clinicians are adopting quantitative brain imaging as a tool to measure and help manage cognitive declines in patients.\nAuthor Cyrus Raji, M.D., Ph.D., of UCLA and an international team suggest a framework in which neuroradiologists work as part of a team of clinical neuroscientists (neurologists, psychiatrists, neuropsychologists, etc.)\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Procedures almost always carry risks, and MRI is no exception. Some physicians are concerned with \u201cMRI abuse,\u201d pointing out that MRIs often pick up abnormal \u2013 but harmless \u2013 findings that muddy up the clinical picture. These so-called \u201cincidentalomas\u201d can lead to more tests and treatments that cause harm and add to costs. Unnecessary imaging is a major contributor to spiraling health care costs in the US, since a single scan on average in the US costs $2,611, according to Medicare data.", "answer": 0}, {"article": "When a person with asthma comes into contact with something that irritates their sensitive airways it causes the body to react in several ways which can include wheezing, coughing and can make breathing more difficult.\n\"Most treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all of the types of tests.\nThe study was designed primarily to examine the effects on inflammation in the airway by measuring the sputum eosinophil count.\nThe research was funded by Novartis Pharmaceuticals, National Institute for Health Research (NIHR) and the EU (AirPROM), and is described by the lead researcher as \"a game changer for future treatment of asthma.\"\n\"This new drug could be a game changer for future treatment of asthma\" - Professor Chris Brightling, NIHR Senior Research Fellow at the University of Leicester\n\nThe first new asthma pill for nearly 20 years has the power to significantly reduce the severity of the condition, a study led by the University of Leicester has found.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s particularly important to note side effects associated with new medications but the release makes no mention of any harms arising from the drug\u2019s use in the study. However, the full research paper (which unfortunately is behind a paywall) includes a table of adverse events experienced by both the experimental group and patients receiving a placebo that include problems such as infections, respiratory disorders, gastrointestinal and nervous system disorders. While these may ultimately have been minor problems, they deserve mentioning.", "answer": 0}, {"article": "Dec. 14, 2009 -- Every cup of coffee a person drinks per day may lower the risk of diabetes by 7%.\nOverall, the studies involved nearly a million participants.\n\u201cDespite considerable research attention, the role of specific dietary and lifestyle factors remains uncertain, although obesity and physical inactivity have consistently been reported to raise the risk of diabetes mellitus,\u201d write researcher Rachel Huxley, DPhil, of the George Institute for International Health, University of Sydney, Australia, and colleagues in the Archives of Internal Medicine.\nThey say several studies have suggested that drinking coffee may lower the risk of developing type 2 diabetes and others have shown that decaffeinated coffee and tea may offer similar benefits, but there has not been a recent review of the research on the issue.\nTea drinkers who drank more than three to four cups of tea per day had about a one-fifth lower risk of diabetes than those who didn\u2019t drink tea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of the potential harms of drinking large quantities of coffee or tea.\u00a0 ", "answer": 0}, {"article": "Hospitals have focused on marketing colonoscopies rather than alternative tests.\nBut if you prefer something less invasive but more frequent, you can test your poop every year without feeling like you\u2019re opting for, um, No.\nThere\u2019s a small but real risk of harm, such as a perforation.\nIn addition to its polyp-removing ability, if you have a negative test, you don\u2019t have to come back for another 10 years.\nBut that\u2019s not yet been proved by randomized controlled trials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets a Satisfactory rating here since it does mention that with colonoscopy, there\u2019s \u201ca small but real risk of harm, such as a perforation\u201d from the screening test.\nBut, as with all screening methods, there is the possibility of false positives or false negatives with the at-home tests which could produce either false confidence or needless worry, not insignificant issues.\u00a0 We would have liked the story even better had it mentioned these factors.\u00a0 \u00a0", "answer": 1}, {"article": "\"As soon as you stop the chemo, you feel stripped, and you think, 'Wow, what do I do now?'\nThen, he discovered in one of his own brain scanner experiments that he -- had brain cancer.\n\"\n\nServan-Schreiber did what he knew best -- he hit the books, and was surprised to find studies on how nutrition and exercise might help the body fight cancer -- information doctors never told him.\nTo read an excerpt, click here.\nHe has penned the best-selling book, \"Anti-Cancer: A New Way of Life,\" about his past and on-going battle, and offers suggestions to fellow cancer patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story rightly points out that there are few drawbacks to adopting a healthy lifestyle.", "answer": 1}, {"article": "Tamoxifen has side effects, including endometrial cancer, blood clots and hot flashes, which cause many women to stop taking the drug.\nThe new study, known as Atlas, included nearly 7,000 women with ER-positive disease who had completed five years of tamoxifen.\nMr. Peto said he thought the results of the Atlas study would \u201capply to endocrine therapy in general,\u201d meaning that 10 years of an aromatase inhibitor would be better than five years.\nIn the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\nAbout 12.2 percent of those in the 10-year treatment group died from breast cancer, compared with 15 percent for those in the control group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quantified the risk of endometrial cancer and pulmonary blood clots.\nThis was the only one of the three stories that we reviewed that picked up on the high dropout rate in the study \u2013 an important addition:\n\u201cIn the Atlas trial, it appears that roughly 40 percent of the patients assigned to take tamoxifen for the additional five years stopped prematurely.\u201d\n\u00a0", "answer": 1}, {"article": "During the last three months of 2008 \u2014 the most recent data available that allowed a comparison among robotic, open and laparoscopic surgeries \u2014 more than half of all prostate removals involved robot-assisted surgery.\nEmphasis should be lmited on procedure, he said, as opposed to surgical skill.\nDavid Penson, a surgeon at Vanderbilt University Medical Center who was not part of the study, said more consideration should have been given to the state of patients afterwards.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the benefits criterion above, the details provided were adequate.", "answer": 1}, {"article": "Co-authors include Loki Natarajan, Dorothy Sears and Sheri Hartman of UC San Diego; and Linda Gallo and Elva Arredondo of San Diego State University.\nThe data shows that each three hour increase in nighttime fasting was associated with a 4 percent lower postprandial glucose level, regardless of how much women ate.\n\u201cNew evidence suggests that when and how often people eat can also play a role in cancer risk.\u201d\n\nWomen in the study reported eating five times per day with a mean nighttime fasting of 12 hours.\nIt may have a big impact on public health without requiring complicated counting of calories or nutrients.\u201d\n\nWomen who fasted for longer periods of time overnight had significantly better control over blood glucose concentrations.\nThose who reported longer fast durations also indicated they consumed fewer calories per day, ate fewer calories after 10 p.m. and had fewer eating episodes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of any potential harms associated with increasing the time periods between eating and decreasing overall calorie consumption. The\u00a0mean duration of nighttime fasting in the study was 12 hours, with discussion of \u201ceach three hour increase in nighttime fasting\u201d being associated with a lower glucose level. \u00a0It makes one wonder \u2013 but the release doesn\u2019t address this \u2013 just how long some women in the study fasted.", "answer": 0}, {"article": "The beleaguered parent now drags hollering kid to the doctor's office, only to find the pediatrician reluctant to prescribe antibiotics.\nMoms have flooded https://www.facebook.com/ClearPop with glowing testimonials for this simple drug-free solution that:\n\n-can be given along with analgesics or antibiotics.\nFull study report at http://clearpop.com \n\n\n\nEAR INFECTION AND ANTIBIOTICS\n\nEar infections are the Number One reason kids aged 5 and under receive oral antibiotics.\nABOUT CLEARPOP\n\nClearPop for Rapid Earache Relief represents a simple, safe, pediatrician recommended, clinically effective and fun way to treat earaches.\nCLINICAL TESTS\n\nChildren diagnosed with Acute Otitis Media, or ear infection, consumed the xylitol and Vitamin C-based product in pediatric offices.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There were no risks mentioned for the lollipop device or for the ingredients but we give them a pass on this criteria since harms appear minimal. It\u2019s worth noting that there can be a harm if persistent ear pain that is not resolved by use of the lollipop is not given medical attention.", "answer": 1}, {"article": "Troponin I is a protein that is released into the bloodstream when the heart muscle has been damaged such as during a heart attack.\nThe issue with available troponin testing has been that they must be repeated two more times over the next 12 to 16 hours for accurate readings.\nThe troponin tests were more predictive than other biomarkers used to make the diagnosis, the study showed.\nThis means that if a test result is negative, the person is not having a heart attack.\nAnother measure, specificity, rules in disease with a high degree of confidence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Since the sensitivity and specificity of the new test was not quantified, the story provided only a glowing report of progress \u2013 of benefit.\u00a0 There was no discussion of potential harms.\nMost physicians and most organizations would frown on making a diagnosis of a heart attack based simply on a blood test.\u00a0 Up To Date, an authoritative resource suggests that patients with a suspicion of having a heart attack have an electrocardiogram, undergo a brief medical history, have a physical examination and have blood drawn for biologic markers.\u00a0 The story suggests that this new blood test can be used alone to make the diagnosis or rule it out.\u00a0 Exaggerating the benefits of a test without placing it into the context provides the readers with a false impression of the test and its utility.\u00a0 Making decisions on the basis of a single blood test could lead to patient harm.", "answer": 0}, {"article": "Evolve recently completed a $40M Series C round of funding co-led by the Bill & Melinda Gates Foundation and Horizons Ventures, the venture division of the Li Ka Shing Foundation.\nA stool sample containing high levels of these markers will be strong enough to change the test's liquid display from pink to yellow, indicating high levels of Bifidobacterium.\nIn the past, babies acquired Bifidobacterium from their mother during childbirth, but due to the increased use of modern medical practices such as antibiotics, C-sections and formula feeding, nine out of 10 babies born in the U.S. today no longer acquire it.\nEvivo's quick and non-invasive test measures the presence of markers that indicate low or high levels of good Bifidobacterium , such as acetate and lactate.\nThe generational loss of this good bacteria in the infant gut allows for potentially harmful bacteria such as E. Coli and Clostridia to thrive, which are linked to higher risk of short- and long-term health issues such as colic, eczema, allergies, diabetes, and obesity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The test itself is described as \u201cquick and non-invasive.\u201d However, the release transitions to the Evivo probiotic product, which is a live culture of Bifidobacterium\u00a0bacteria that\u2019s designed to augment such microbes in a baby\u2019s gut. There are no potential harms discussed here.\nHowever, the CDC\u2019s website states about probiotics (generally): \u201cIn healthy people, probiotics usually have only minor side effects, if any. However, in people with underlying health problems (for example, weakened immune systems), serious complications such as infections have occasionally been reported.\u201d", "answer": 0}, {"article": "The best moment in Rene\u00e9 Ford's life came the day her son Chase, then 2, tried to kick his doctor. It was July 2005, and that angry gesture marked the first time the boy had moved below the neck in more than a month.\n\nThese days when you look at Chase, you don't at first notice any sign of what happened to him that year--not the fall he took while jumping on the couch nor the paralyzing blow to the neck as he hit the wooden armrest. More and more, Chase can do the kinds of things any other 4-year-old can...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any possible harms of treatment. Specifically, it would be important to mention that in new spine injuries with fractures, there can be instability that needs to be treated first. Mobilization activities such as these could be harmful in that situation.", "answer": 0}, {"article": "Elective Caesarean-section deliveries can increase problems for a newborn if done too early -- even when the baby has technically reached full term, according to a large new study.\n\nThe findings could help diminish a widely popular practice -- now about one in every 14 births -- in which mothers choose to schedule c-sections, or surgical removal of the baby. The study, published in the New England Journal of Medicine, found that about a third of elective c-sections are done too early -- before 39 weeks. Although a fetus is considered...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The risk of harm in elective c-sections is the focus of the study, and the news report explains them well. ", "answer": 1}, {"article": "Malignant pleural mesothelioma is a rare and aggressive cancer that represents about 90 percent of all malignant mesothelioma cases.\nThere are multiple studies going on right now to confirm these findings, which the authors note is a necessary step before the drug can become a standard second-line therapy.\nIn fiscal year 2015, Penn Medicine provided $253.3 million to benefit our community.\n\"There have been a lot of studies looking at different drugs, but researchers have not seen positive results,\" said the study's lead author Evan Alley, MD, PhD, chief of Hematology and Medical Oncology at Penn Presbyterian Hospital.\nThe study, published this month in The Lancet Oncology, is the first to show a positive impact from checkpoint inhibitor immunotherapy drugs on this disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions that \u201cthe most common side-effects reported were fatigue, nausea, loss of appetite, and dry mouth,\u201d but we have no idea of magnitude of those effects or whether more serious, less common effects may have occurred.\nThe study reported that 64% of the patients had a treatment related adverse effect, but this wasn\u2019t mentioned in the news release. Side effects directly relate to quality of life and could be a deal-breaker for many patients. \nWe\u2019ve outlined some of the common challenges in writing about harms from immunotherapy drugs in this guide for journalists.", "answer": 1}, {"article": "Pneumonia is a leading cause of death for elderly patients, with over 90 percent of pneumonia-related deaths among those 65 and older.\nWhen appropriate, it can complement, and in some cases replace, medications or surgery.\nOMT also reduced the in-hospital mortality rates of those with the highest severity of illness.\nPrevious studies have also shown that OMT can improve the efficacy of antibiotics in pneumonia patients.\n\"This study should encourage physicians to use their osteopathic techniques when treating older patients with pneumonia.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although it\u2019s commonly accepted that osteopathic manipulation is \u201charmless,\u201d the release should have addressed any potential complications, discomforts, cost issues or other side effects.", "answer": 0}, {"article": "Of the men who had a raised platelet count of the same value or higher six months after being diagnosed with thrombocytosis, 18.1% developed cancer, while for women the figure was 10.1%.\nThat, say the researchers, makes testing for raised platelet count a valuable tool, and could speed up cancer diagnosis by at least three months for thousands of patients a year.\n\u201cThis is an excellent study that demonstrates the potential for a commonly used blood test to identify some patients with cancer earlier,\u201d he said.\n\u201cThis work should begin to change practice, so that GPs should be testing patients with raised platelet counts for cancer, especially those without other potential cancer symptoms,\u201d he added.\n\u201cThis is a clue which can be used in practice by GPs to help them select patients for further investigation \u2026 most excitingly in some patients who may not already have other symptoms of cancer to achieve earlier diagnosis,\u201d said Sarah Bailey, co-author of the research from the University of Exeter.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have stated more explicitly the significant potential downsides (clinical and financial) of mass use of primary thrombocytosis screening, and even the harm that can potentially occur when an \u201cincidental\u201d finding of elevated platelet levels must be further investigated in the absence of other cancer risk factors or symptoms. It could raise anxiety levels of people who may have elevated platelet counts due to other reasons or younger people feeling they need to be tested because the results by age weren\u2019t mentioned.", "answer": 0}, {"article": "Shingles is a viral disease produced by the chicken pox virus, a common childhood disease, and is characterized by pain and a blistering rash along the nerves that have housed the dormant virus.\nBut researchers cautioned that because they did not follow patients over the longer term, they didn\u2019t know how effective the vaccine is years later.\nEveryone in the study, published in the Journal of the American Medical Association, was at least 60 years old, and the researchers didn\u2019t include anybody for whom the live vaccine is not recommended.\n\u201cThe human cost of shingles is enormous,\u201d said Michael Oxman, who studies infectious diseases at the University of California, San Diego, and was involved in a previous study of the vaccine.\nDespite the FDA\u2019s approval, the vaccine has not caught on as much as some had hoped.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not address potential harms. This study did not report adverse events, but the clinical trial that led to approval of the vaccine reported more than a third of participants had redness and pain after getting a shot. Although the original clinical trial (partially funded by the vaccine maker) concluded that adverse events were generally mild, the story still should have addressed this point.\u00a0 ", "answer": 0}, {"article": "Kouzarides\u2019s team found that in the disease, the MLL-fusion proteins are targeted to leukemia-causing genes by proteins from the BET family, which recognize certain chemical \u201ctags\u201d on chromatin, the scaffold on which DNA is arranged.\n\u201cIt is important to remember we will need to be successful on a number of additional steps before we can move this from the lab to testing this compound in humans.\u201d\n\nMLL leukemia is thought to account for up to 80 percent of cases of acute leukemia in children below two years old, and up to one in 10 cases in adults.\n\u201cAlthough this research is only in the lab at the moment, we hope it will move quickly toward clinical trials in patients.\u201d\n\nLeukemia is the most commonly diagnosed cancer in children and accounts for a around a third of all cancers diagnosed in children.\nKevin Lee, head of epigenetics discovery research at GSK, who also worked on the study, said he too was excited about the findings, although it will probably be many years before the drug could potentially reach the market.\nUsing I-BET151 to treat leukaemias in mice and human cancer cells in a lab, the researchers found that the chemical could halt the disease, paving the way for more research to be done in first-stage, or so-called Phase I, human trials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a news story can speculate about \u201cearly potential\u201d benefits in a headline from such early laboratory results, it can also speculate about potential harms from the pathway this proposed intervention takes.\nWhat could go wrong with this approach?\nWhat will scientists be concerned about as they move into clinical trials?\nThe story talks only about potential benefits.\u00a0 There are always potential harms on the horizon.", "answer": 0}, {"article": "Pereira wrote about blood pressure reductions in a patient getting deep brain stimulation in the January 2010 issue of the Journal of Clinical Neuroscience.\nThe case study is published in the Jan. 25 issue of Neurology.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\n\u201cWhat their case report shows is that blood pressure can be reduced in a sustained fashion in a patient with unsuccessful deep brain stimulation for pain,\u201d says Erlick Pereira, MD, a neurosurgeon at the University of Oxford.\nPatel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A tough call here. While the report is much more detailed than HealthDay about the potential risks of treatment, it features a clumsily worded quote from an expert who calls the risks of this surgery \u201ctiny, but important.\u201d\u00a0The use of the word \u201ctiny\u201d here tends to minimize the risks associated with the\u00a0procedure, which can be very serious.\u00a0A 2% risk of stroke\u00a0in patients undergoing the procedure (as reported on this UCSF Dept of Neurosurgery\u00a0FAQ about DBS) strikes us as\u00a0somewhat\u00a0more than \u201ctiny.\u201d", "answer": 0}, {"article": "Will they be habit forming?\nThat means, theoretically, fewer side effects and perhaps less of a tendency to be habit forming, Thorpy explained.\nIn each case, the minimum dose to achieve sleep was compared with the minimum dose that altered memory and thinking.\nThis is the first time in years that scientists have targeted a totally different receptor in the quest to combat insomnia, said Dr. Alexandre Abreu, co-director of the UHealth Sleep Center at the University of Miami Miller School of Medicine.\nMore than 30 million Americans struggle to get a good night's sleep, and about one-third of these use drugs to help the process, the study authors pointed out.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag.\nWhile the study did not examine the effects of DORA-22 in any detail it did in fact look at level of cognition in the animals studied.\u00a0 While the story notes, \u201cDORA-22 did not lead to the same mental impairments as the other three drugs. Rhesus monkeys and rats performed just as well on memory and attention tasks shortly after being administered DORA-22 as they did on an inactive placebo,\u201d it fails to note that cognition was impaired at higher doses.\u00a0 This is a major error in interpretation of the study results.\nAlthough we would prefer to see potential harms mentioned as high up in stories as potential benefits, this story does highlight questions about harms at the end, so at least those who read the whole story are alerted to the many unknowns.\nBecause of that ending, we\u2019ll give it the benefit of the doubt and grade it satisfactory on this criterion.\n\u00a0", "answer": 1}, {"article": "A new study finds that supplementing the Mediterranean diet with more olive oil or more nuts helps diminish age-related decline in cognitive function. Photo: Getty Images\n\nThe Mediterranean diet, supplemented with a handful of nuts or a few tablespoons of olive oil a day, can counteract the effects of aging on the brain\u2019s ability to function, a new clinical study suggests.\n\nThe study, published online Monday in JAMA Internal Medicine, was unusual in that it employed rigorous scientific practices to test the effect of the diet on health. Most previous evidence showing benefits from the Mediterranean diet was gathered through observational studies, a less conclusive research technique.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The extra olive oil consumed by participants amounts to more than 500 kcal per day, which could cause weight gain if not balanced by a similar reduction in other food intake. Weight effects weren\u2019t reported here and may not have been a problem in this study. But these were Spaniards already accustomed to consuming a lot of olive oil, vegetables, fruits, and legumes. We don\u2019t know if adding a lot of olive oil to the diets of Americans would yield the same results.\nBut the story makes no mention of this or other possible harms linked to the diet. If there really are none, that would have been nice to know and would have strengthened the story.\nSo too would have been a discussion of why, according to the study, more than 25% of the 447 participants \u201crefused to undergo a second procedure or abandoned the study for different reasons.\u201d", "answer": 0}, {"article": "\"That's a very important message.\"\nAnywhere from 50 to 200 healthy people need to take a statin daily to prevent a single heart attack for five years, so even small harms may outweigh the potential benefits, the Swiss scientists say.\nHe notes that physician guidelines don't generally compare the relative value of these drugs, which are all available as inexpensive generics.\nThe study, in the Annals of Internal Medicine, argues that current medical guidelines haven't adequately considered the risks from these widely used drugs.\n\"Some harms are mentioned, but it's entirely unclear how they were considered when coming up with the recommendations,\" says Milo Puhan, a physician and epidemiologist at the University of Zurich and senior author of the new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a service by highlighting the harms of statins. It explains: \u201cThe most common side effect of these drugs is muscle pain, which usually goes away if patients stop taking the medicines. People taking statins are also at a higher risk of developing diabetes, which is harder to reverse.\u201d\nIt also mentions the potential for overtreatment with the use of coronary calcium scans.\nHowever, we wish it had included absolute numbers. The story says harms are \u201cuncommon,\u201d but provides no data to back that up.\nRates of adverse effects with statins have been measured at 1 to 10%, which makes them \u201ccommon\u201d in the definition of the European Medicines Agency. Also noteworthy is that some contend that adverse effects of statins have not been reliably reported.", "answer": 1}, {"article": "I think there is a greater capacity to be open-minded and let science dictate our conclusion, not politics,\u201d Grob said.\nPatients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.\nThey were told to lie still with their eyes closed as they wore headphones and listened to soothing music.\nFederal law prohibits the use of the magic mushroom compound for any purpose.\nThe treatments were given in random order and neither the doctors nor the patients were told which compound was administered.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Micro-RNA are small non-coding RNA that control many genes and processes vital for cellular life such as metabolism, development and the immune system.\nGiven exosomes can cross the blood-brain barrier, it is likely that some of the circulating exosomes in MS patients come from affected central nervous system cells or the associated inflammatory milieu.\nUsing next generation sequencing and integrative bioinformatics they found that serum exosome micro-RNA profiles not only distinguish MS from healthy controls, but also distinguish relapsing-remitting MS (RRMS) from progressive MS with high accuracy.\nMS is a chronic disease, so current diagnostic and monitoring tests are costly and still have limited utility to discriminate between different stages of the disease.\nThe researchers hypothesised that physiological changes associated with MS and its progression is reflected in differences in serum exosomal micro-RNAs.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The possible debits of this blood test\u2014false positives and false negatives, for example\u2014are not broached. These are very likely to occur in a larger group of subjects.", "answer": 0}, {"article": "\"All those things I'm able to do for myself now.\"\nUnder low-wear conditions, doctors expect joint prosthetics to last 10 to 15 years, another reason replacement might not be considered for younger people.\nPotential patients must be evaluated for other causes of pain, Collins noted, because problems with thumbs or other hand parts can make the wrist hurt.\nOlder prosthetics used in wrist replacement required removing significant amounts of bone, which made later fusion problematic if the surgery failed, Collins explained.\nThe wrist procedure replaces some of the small carpal bones altogether and sends as many as three screws into the hand.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions a single disadvantage of the operation\u2014that patients can\u2019t lift heavy objects. But any patient undergoing joint replacement faces potential complications such as infection. In one recent study, 52% of patients had a complication after wrist replacement and 44% reported pain one to five years after surgery. (J Hand Surg [Am]. 2003;28:570-6). There is also the possibility of undergoing a second operation for fusion if the implant fails\u2014a risk that persists with newer implant designs as well as old ones. The article does not cite a source for the projected 10- to 15-year life of the device.", "answer": 0}, {"article": "ET.\nAlthough the results provide evidence that PDE5 inhibitors may benefit heart health, the retrospective study design makes it impossible to ascertain direct cause and effect, Andersson noted.\n\"From the perspective of a doctor, if a patient asks about erectile dysfunction drugs after a heart attack and has no contraindications for PDE5 inhibitors, based on these results you can feel safe about prescribing it.\"\n\"This type of erectile dysfunction treatment is beneficial in terms of prognosis, and having an active sex life seems to be a marker for a decreased risk of death.\"\nEligible media should register for ACC.17 to receive access to the briefing.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study was designed to determine if there is an\u00a0association between treatment for ED and death or cardiovascular outcomes after a first heart attack. Other side effects more commonly seen were not measured.\nWe\u2019d still like to see at least some mention of the common harms from ED drugs in a news release distributed to a wide audience, particularly one that touts its safety and potential benefits.", "answer": 0}, {"article": "Some of the complaints related to the placement of the device.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nAll physicians who offer Essure are expected to be trained to perform the TVU confirmation test by mid-2016, the company said.\nA woman using Essure must do a test to confirm that the device is properly placed within three months of the procedure and until she receives a confirmation from her doctor, she must use alternate birth control methods, Bayer said in a statement on Wednesday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of TVU are not addressed. Unlike the HSG, TVU does not emit ionizing radiation, which could potentially make it safer. However, some women do not tolerate TVU, which can last 45 minutes long, well. In addition, as the news release (but not the Reuters story) acknowledged, some women experience spotting or infection following a TVU test.", "answer": 0}, {"article": "Follow us: twitter.com/CocoaHealthSci\n\nIn 1911, Frank C. Mars made the first Mars candies in his Tacoma, Washington kitchen and established Mars' first roots as a confectionery company.\nThis study, conducted by researchers from Italy's University of L'Aquila and Mars, Incorporated, reinforces the results of several recent cognitive studies--throwing more light on the important role diet plays in maintaining cognitive health.\nNote to Editors: This research trial was carried out with a special cocoa flavanol test product, designed to deliver a standardized amount of flavanols within a nutritionally suitable drink.\n\"Now we'd like to know how they work and how long the effects last.\nDr. Giovambattista Desideri, lead author on the paper, said, \"The results of this study are encouraging--they support the idea that diet, and specifically a diet rich in cocoa flavanols, can play an important role in maintaining cognitive health as we age.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no explanation of harms, potential or actual, in the release. Our main concern is that consumers will think these findings apply to your typical chocolate candy bar, which is full of sugar and fat. While the release notes dryly that commercially available chocolate, \u201cgiven its macronutrient profile \u2026 is not recommended as a health food,\u201d we don\u2019t think many readers will find this caveat that\u2019s buried in an editor\u2019s note at the end of the release. And even if they do, they might not understand what it\u2019s getting at.", "answer": 0}, {"article": "Dr. Gerald Bernstein coordinates the Friedman Diabetes Program at Lenox Hill Hospital in New York City.\nSelvin's group analyzed that data, and reported that a positive result for glucose and HbA1c from just a single blood sample can confirm type 2 diabetes.\n\"Doctors are already doing these [glucose and HbA1c] tests together -- if a patient is obese, for example, and has other risk factors for diabetes, the physician is likely to order tests for both glucose and HbA1c from a single blood sample.\nAccording to Bernstein, if only one diagnostic test were needed, \"this would mean that a follow-up visit would be a look at the treatment benefits -- rather than a confirmation of an abnormal glucose.\"\nCurrently, it's recommended that a blood test focused on elevated fasting levels of blood sugar (glucose) or a blood component called glycated hemoglobin (HbA1c) be confirmed with a second blood test at a follow-up visit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story would have benefited from an exploration of the harms of overdiagnosis and overtreatment. Many of the patients who tested positive in both tests didn\u2019t develop diabetes until a decade or two later. Potentially, patients like that could be treated overly aggressively with drugs that could do them harm.\nLikewise, an accompanying editorial notes that the criteria proposed by the study might miss more people with diabetes than the conventional method of repeated blood glucose tests. In the data studied, simultaneous A1C and blood glucose tests agreed only about 40% of the time, versus 70% agreement for successive blood sugar tests.", "answer": 0}, {"article": "In traditional Chinese medicine, acupuncture involves inserting long, very thin needles just beneath the skin's surface at specific points on the body to control pain or stress.\nScientists aren't sure what biological mechanism could explain how acupuncture might relieve pain, but the authors of the new study say the results suggest there's more involved than just a placebo effect.\nTheir study isn't proof, but it adds to evidence that acupuncture may benefit a range of conditions.\nAcupuncture skeptic Dr. Stephen Barrett said the study results are dubious.\nThe retired psychiatrist runs Quackwatch, a Web site on medical scams, and says studies of acupuncture often involve strict research conditions that don't mirror how the procedure is used in the real world.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says acupuncture is \u201crelatively safe,\u201d but doesn\u2019t specify that safety can be improved by selecting licensed\u00a0practitioners. It also does not mention\u00a0that acupuncture is associated with rare reports of serious adverse events, most of which seem to occur with unqualified practitioners.", "answer": 0}, {"article": "Antidepressants frequently prescribed to help treat bipolar depression do little to help patients recover, according to a new study that adds fuel to a long-running debate over how to best treat an affliction that affects an estimated eight million Americans.\n\nBipolar disorder, also known as manic depression, is a serious mental illness that involves dramatic swings in mood, including frequent and lengthy periods of depression. Along with mood-stabilizing drugs like lithium, many physicians also treat the disorder with common...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harm of triggering a manic episode and reports (accurately) that there was no observed difference in the groups studied. The story could have gone further and discussed common harms from antidepressants stacked up against this finding of no benefit \u2013 strong incentive to stop giving antidepressants for bipolar disorder.", "answer": 1}, {"article": "\"I had a really bad headache,\" Aldrich told Regan.\nBut, Regan adds, diagnosing them can be daunting: While there are some physical symptoms such as headaches, nausea, dizziness and blurred vision, concussions don't cause bleeding or swelling in the brain and don't show up on X-rays.\nTo avoid permanent injury, Aldrich will have to play it safe and wear a helmet on the field from now on.\nConcussions, once considered minor conditions, are now being recognized as serious medical problems with potentially permanent consequences, Regan says.\nOne expert says doctors have learned more about concussions in the past five years than in the previous 50.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe broadcast does not mention potential harms of using the Impact system. Testing could cause an athlete needless anxiety. Unnecessarily withholding an athlete from play increases inactivity and the risk of depression. It is unclear who owns the sensitive information and how it is protected.\u00a0 And it is unclear whether the recommendation to wear headgear might make head-to-head collisions more dangerous for other players. \n", "answer": 0}, {"article": "During a treatment, a patient sits in a chair like one in a dentist\u2019s office while an electromagnetic coil is placed against her head.\n\u201cThe majority of studies that evaluated rTMS failed to find evidence of an enduring treatment effect after the initial response .\nSupporters such as those at TMS NeuroHealth say they are seeing better results than that among their patients, who can continue taking antidepressants along with their treatment.\nBut she says questions remain about how long the effects last and how often a patient should return for additional sessions.\nMagnetic stimulation is aimed at patients with such \u201ctreatment-resistant depression.\u201d\n\nSupporters say rTMS is worth the cost \u2014 between $6,000 and $12,000 for the four-to-six-week treatment \u2014 because it enables people such as Curtis to resume productive lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately addresses adverse effects. It says, \u201cStudies have shown that side effects are few and generally minor, such as headaches and scalp irritations.\u201d In addition, \u201cA few small studies have looked at its effects on cognitive function and found either no effect or slight improvement.\u201d\nInteresting, in the AHRQ report, rTMS vs ECT had about the same number of withdrawals due to adverse effects, so despite the scarier sounding potential adverse effects from ECT, dropouts due to actual adverse effects were about the same.", "answer": 1}, {"article": "\"I don't think pregnancy should be the thing that tips the scale,\" said Caughey.\nBut Caughey, who wrote an editorial accompanying the new research, said women considering weight-loss surgery should make the decision based on the long-term health benefits of the procedure -- not on potential pregnancy-related benefits.\nAdditionally, the surgical group experienced a slight bump in the rate of stillbirths, the study found.\nBut Johannson said those outcomes might be due to reduced nutrient absorption resulting from the surgery, with a fetus not receiving sufficient nutrition.\nThe investigators didn't examine what might have caused smaller babies among bariatric surgery recipients, or higher stillbirths.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story uses relative ratios to express the possible negative effects of bariatric surgery (e.g. \u201cthe weight-loss surgery group was twice as likely to give birth to babies considered small for their gestational age, and their pregnancies were also of slightly shorter duration.\u201d), which misses critical information needed to understand the clinical or real world significance of these results. What was the overall percentage of babies considered small in each group, and was this a small or a large number? How worried should people be about this? Another concern is that the story didn\u2019t emphasize or quantify the more important harmful outcomes. There was a higher rate of stillbirths and neonatal deaths in the surgery group (1.7% in the postsurgery group and 0.7% in the control group) which, while not quite statistically significant, provides cause for concern. \u00a0We think readers would be most interested in this \u2014 more deaths among babies of women who had bariatric surgery. But the story mentions merely \u201ca slight bump in the rate of stillbirths.\u201d", "answer": 0}, {"article": "In traditional transplants, hair follicles are taken from an area that runs an inch or two above the ears and temples to the back of the head.\n\u201cHe had resorted to cropping his hair short to obscure the problem.\u201d\n\nWith the patients under local anesthesia, Dr. Umar used a device that creates microscopic wounds around hair follicles in the back of the leg; the follicles were then removed and transplanted to the hairline.\nAbout 75 to 80 percent of the transplanted leg hair grew successfully on the patients\u2019 heads after the operations, and both men were happy with the results, Dr. Umar said.\n\u201cThe hairline was fully grown and soft-looking by nine months\u201d in the 35-year-old, he wrote, \u201cat which time the patient started combing his hair backward and sporting a ponytail, exposing his hairline comfortably.\u201d\n\nSince then, Dr. Umar has done eight more of the procedures, including one in a woman.\nIn each case, Dr. Umar and his team extracted about 1,000 leg hair follicles and grafted them, one by one, to the patients\u2019 hairlines.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All surgeries carry the potential for harms. None of the harms were discussed in this story.\nThe story does not provide a true picture of the process involved in the two patients.\u00a0 Prior to the 8 hour transplant procedure, the patients underwent harvesting of leg hair, \u201c\u2026once or twice daily for a variable period of 6 weeks to 6 months before surgery.\u201d", "answer": 0}, {"article": "Mammograms, for example, prevent 25 percent of breast cancer deaths, and the PSA test for men has not been shown to prevent prostate cancer deaths.\nBut gastroenterologists say that, if nothing else, the study points up the paucity of evidence for the common suggestion that anyone who had a clean bill of health from a colonoscopy is almost totally protected for at least a decade.\nDr. Ransohoff and other screening experts say patients should continue to have the test, because it is still highly effective.\nBut, said Dr. Douglas K. Rex, director of endoscopy and professor of medicine at Indiana University, that cannot be the entire explanation because at least one study, as yet unpublished, involving California Medi-Cal patients also found the test missed many cancers on the right side of the colon.\nCancer may also be different in the right colon, researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the risk of perforations, missed cancers and \"unpleasant\" preparation as the risks/side effects of colonoscopy.", "answer": 1}, {"article": "Professor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nUniquely, this chemo-catalyst treatment can be recycled and reused within a cancer cell to attack it repeatedly.\nManipulating and applying well-established chemistry in a biological context provides a highly selective strategy for killing cancer cells.\nSince this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.\nThis unprecedented functional ability to recycle and reuse the compound within cancer cells could lead to future anticancer drugs being administered in smaller, more effective, and potentially less toxic doses - decreasing the side-effects of chemotherapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cthe development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched\u201d (emphasis added). What does \u201clargely untouched\u201d mean? Was there some level of harm or change induced in healthy cells? In the context of human health, vague statements like that make us nervous. That\u2019s particularly true when a release does not disclose what sort of testing has been done \u2014 and remains to be done \u2014 for a potential treatment. It\u2019s always a good idea to point out that in research this preliminary, we have almost no idea what kind of adverse effects might occur when the compound is actually administered to patients.\nThis also plays to the popularity of terms like \u201cprecision oncology\u201d and \u201cselective\u2019 or \u201ctargeted\u201d\u00a0 cancer treatment.\u201d We are finding more and more that lots of our targeted treatments still can and do have \u201coff target\u201d harms. Gleevec and subsequent generation molecules are examples (prototypes) of great \u201ctargeted therapies\u201d but they still have other common side effects. Also, always comparing targeted molecules to chemotherapy is becoming less fair these days given that we have a better understanding of how to anticipate and manage side effects in general.", "answer": 0}, {"article": "The latest health and science updates, breakthroughs, research, and the best in investigative and informative journalism.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided accurate information about a potential harm of excess consumption of vitamin B-6.", "answer": 1}, {"article": "Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.\nBased on reduction in pain and absence of complications at 6 months, treatment was rated successful in 81 percent of subjects assigned to the SIJ implant procedure, compared to 26 percent with nonsurgical treatment.\nAt 6 months, subjects in the nonsurgical group had the option to \"cross over\" to the implant procedure.\nGood Pain Relief and Other Outcomes with Implant Treatment for SIJ Dysfunction\n\nThe study included 148 patients with low back pain caused by confirmed SIJ dysfunction, treated at 19 US spine surgery clinics.\nThe results show \"clinically and statistically important\" improvements in clinical outcomes for patients undergoing the SIJ implant procedure, according to Dr. Cher and colleagues, with \"profound differences\" between the surgical and nonsurgical groups.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some harms are mentioned but in insufficient detail. The published study cites a small number of serious complications. Although the adverse events are rare, they should still be mentioned. The most common side effects among those receiving the procedure were leg and pelvic pain within the first year, according to the study.", "answer": 0}, {"article": "This was definitely worth it.\u201d\nResearch pharmacist, Krista Bohlen, director of personalized pharmaceutical medicine at the Avera Institute for Human Genetics, believes that genetics play a large role in how different individuals react to certain medications, but cautions doctors and patients against relying solely on this method for answers.\nWhile the results are striking, this technology is not a guarantee of complete resolution of depressive symptoms or medication side effects.\nIt's unclear how many patients have had to stop or chosen to stop treatment for depression due to side effects.\nDNA Tests May Be a Guide\n\n'One piece of the puzzle'\n\nAIHG\u2019s pharmacogenomics research has led to the development of Genefolio, a genetic test that uses an individual\u2019s unique DNA to predict how that individual will respond to medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of any potential harms of genetic testing, and the article also does not discuss the fact that some genetic tests may focus only on a single genetic marker, making them far less useful. Tests that are inaccurate may falsely suggest that patients will or will not respond to a specific drug, delaying effective treatment.\u00a0Moreover, genetic test results can have significant negative social, emotional and financial consequences for patients, including the possibility of employment and insurance discrimination based on the test results.", "answer": 0}, {"article": "But \"we could never get it to sustain beyond maybe a day,\" he says.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nBut the studies of ketamine have produced results so dramatic that some doctors, including Feifel, are bypassing the usual protocols.\nOthers have been started by entrepreneurial anesthesiologists and emergency room doctors, who are familiar with ketamine but may not know much about depression.\nInsurers don't cover the cost because the treatment is still considered experimental.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although there is a brief mention of possible harms, including abuse and hallucinations, the soft warnings in the story are undercut by statements such as, \u201cketamine\u2019s safety record is so good that it\u2019s often the painkiller of choice for children who arrive in the emergency room with a broken bone.\u201d Again, readers and listeners are given the impression that the drug has been scrutinized far more carefully that it actually has.\nThere is a final cautionary note from a proponent of ketamine treatment of depression that wider use could mean \u201csomething bad will happen to a depressed patient\u201d. However, this risk is cast not as a hazard inherent in the drug, but as worry that a careless doctor will tarnish the drug\u2019s good name.", "answer": 0}, {"article": "An enzyme is a protein that performs a chemical reaction.\nThe re-engineered enzyme, named KumaMax, appears to be highly effective, at least in a test tube.\nIdeally, the team could develop the enzyme into a food additive such as the gas remedies Beano or Gas-X and offer it without a prescription, said lead study author Justin Siegel, assistant professor of chemistry and biochemistry at the University of California, Davis.\nBut scientists anticipate that some day a simple pill could help prevent the digestive upsets caused by ingesting the gluten in wheat, rye or barley products.\nFRIDAY, Feb. 8, 2013 (HealthDay News) -- For people with celiac disease, everyday foods such as bread, pizza crust and muffins are potential enemies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harm, but in an unsatisfactory way, when it quotes a study author who says, \u201cIt shouldn\u2019t be toxic; it\u2019s just a protein you\u2019re eating.\u201d In fact, proteins can be plenty toxic, and until this new compound is tested in humans, we can\u2019t be certain of what its effects might be.\nAnd even if it\u2019s not directly toxic,\u00a0such a treatment might\u00a0give patients permission to indulge and overdo it with respect to gluten, a compensating behavior that might cancel out any benefit from neutralizing small amounts of dietary gluten.", "answer": 0}, {"article": "\u201cWomen really dread the axillary dissection,\u201d Dr. Giuliano said.\nThe results mean that women like those in the study will still have to have at least one removed, to look for cancer and decide whether they will need more treatment.\nIt is not known whether the findings also apply to women who do not have radiation and chemotherapy, or to those who have only part of the breast irradiated.\nOne potential weakness in the study is that there was not complete follow-up information on 166 women, about equal numbers from each group.\nIn 27 percent of the women who had additional nodes removed, those nodes were cancerous.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses several harms from lymph node removal, and shows that the difference in survival for women who had nodes removed and those who did not was not significant. \u201cIndeed, women in the study who had the nodes taken out were far more likely (70 percent versus 25 percent) to have complications like infections, abnormal sensations and fluid collecting in the armpit. They were also more likely to have lymphedema.\u201d", "answer": 1}, {"article": "Older adults who take college courses may increase their cognitive capacity and possibly reduce their risk for developing Alzheimer's disease or other forms of dementia, according to new research published by the American Psychological Association.\nFull text of the article is available from the APA Public Affairs Office and at\n\nThe American Psychological Association, in Washington, D.C., is the largest scientific and professional organization representing psychology in the United States.\nThe research was published online in the journal Neuropsychology.\nThe participants who took college classes volunteered for the study so they probably had a greater interest in continuing education that the general senior population, the journal article noted.\n\"It is possible that any mentally stimulating activity later in life may also enhance cognitive capacity, such as other adult-education classes or programs to increase social interaction,\" she said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were noted in the news release or the paper, and its hard to envision any, so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "For men, the difference came out to 103 fewer cancer deaths a year per 100,000 people; for women, the number was 42.\nDr. Kausik Ray of St. George\u2019s University of London, who has studied aspirin, said the new study did not look at overall death rates or side effects such as serious stomach bleeds.\nEarlier this year, Ray\u2019s team published an analysis of previous aspirin trials showing the medication did not prevent deaths from heart disease or cancer, and was likely to cause more harm than good.\nStill, Thun said the results would favor broadening the aspirin guidelines to include cancer prevention based on an individual risk-benefit assessment.\n\u201cNews about the cancer potential of aspirin use has been really encouraging lately,\u201d said Dr. Michael Thun of the American Cancer Society, who worked on the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged side effects such as serious stomach bleeds and pointed out that this study didn\u2019t look at overall death rates or side effects.", "answer": 1}, {"article": "Doctors usually try to start people off with lifestyle treatment, such as weight loss, drinking less caffeine and alcohol, and avoiding lifting heavy objects.\n\u201cWe are actually not surprised that there isn\u2019t a big difference between the two because both therapies are effective at relaxing the overactive bladder muscles.\u201d\n\nWomen can choose between a surgical procedure, which is more expensive at first, versus regular Botox injections, which are less costly and less invasive but which could add up over time, Amundsen said.\nIncontinence may sound funny, but it\u2019s no joke, the researchers said.\nIt\u2019s good news for women with severe urge incontinence, who can choose between treatments based on preference, said Dr. Cindy Amundsen of Duke University, who led the study.\n\u201cForty-six percent in the onabotulinumtoxinA (Botox) group and 26 percent in the sacral neuromodulation group had at least a 75 percent reduction in the number of episodes of urgency incontinence,\u201d they added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Urinary tract infections were three times more common in the women who received Botox shots, and the reader is informed of this. But a lot is left out. We would have also liked to see noted other side effects of Botox for urinary incontinence, such as blood in the urine, fatigue, insomnia, and\u00a0inability to completely empty the bladder (in about 17% of people) \u2014 and the need to self-catheterize to relieve the problem.\nAnd then there are the more general side effects left out of the story, including \u201cdry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, and eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, and dry eyes,\u201d according to botoxforincontinence.com. And what of the harms of a neurostimulator implant? There\u2019s no mention of this, and the side effects are numerous.", "answer": 0}, {"article": "Your office thermostat is set for men's comfort.\nBased on other studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations, the researchers had thought they might find some associations to disease or other health conditions.\nUpdate: The study's findings generated significant controversy along with requests for supplemental analysis, according to the editors of the Psychology of Addictive Behaviors.\nBechtold said the researchers wanted to \"help inform the debate about legalization of marijuana\" but that this is a very complicated issue and one, study, including his own, should not be taken in isolation and should be viewed in context of other studies on teenagers' marijuana use.\nIn a lengthy clarification issued in December 2015, the journal said that by applying different models to look at the data they confirmed that there did not appear to be any link between marijuana use and health issues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides\u00a0a list of the potential harms associated with marijuana use but it over-emphasizes the importance of this relatively small study in downplaying them \u2013 calling it \u201csurprising news\u201d that is \u201call good\u201d in the headline. And the second sentence says the study \u201cshould alleviate some of the worst fears.\u201d \u00a0That is too big a leap.\nThe story tried to describe the context of previous studies on marijuana but used this language \u201cother studies in the past that seemed to allude to marijuana use and later development of psychotic symptoms such as delusions or hallucinations.\u201d\u00a0As readers, we want to ask \u2013 did previous studies conclude there were risks? How can a study \u201cseem to allude?\u201d\nA recent review (N Engl J Med 2014; 370:2219-222) cited 69 publications examining the potential harms of marijuana use by the general population. \u00a0This one study is simply an addition to the growing body of evidence.", "answer": 0}, {"article": "Acupuncture, a popular form of alternative medicine, involves inserting ultra-thin needles into the skin.\nThe question is whether the acupuncture reduced the hot flashes or a placebo effect played a role, said Freedland, who's familiar with the study findings.\nIt's also possible, he said, that the symptoms went away on their own, which commonly happens to men on hormone therapy.\n\"We are now designing a randomized clinical trial to further evaluate acupuncture after prostate cancer treatment,\" Ashamalla added.\n\"The symptoms don't (normally) get better by that much that quickly.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms.\u00a0 Maybe none were found.\u00a0 Some past acupuncture studies report discomfort at the needling sites. One line could have easily addressed what was seen in this study or in related work.", "answer": 0}, {"article": "; Francesca Cesari, MSc., Ph.D.; Anna Maria Gori, MSc.\nIn an editorial accompanying the study, Cheryl A. M. Anderson, Ph.D., M.P.H., M.S., an associate professor of preventive medicine at the University of California, San Diego, in California, wrote that there were similarities between the two diets that may explain the results.\nMost participants were able to stay on both diets.\nAnderson, who was not involved in the study, added that promoting both diets by healthcare professionals \"offer a possible solution to the ongoing challenges to prevent and manage obesity and cardiovascular diseases.\"\nAuthors said they did find two differences between the diets that may be noteworthy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Both diets used in the study are generally safe for most people. Food intolerances aside, the only potential harm we could see in the diets used in the study is that the calorie quota (about 2100 calories per day) may not be appropriate for all people.", "answer": 2}, {"article": "More than 300 million people worldwide have depression, according to the World Health Organization, of which less than half recieve effective treatments.\nSome drugs more effective than others\n\nThe researchers analyzed existing studies of 21 different drugs, and found some were much more effective than others.\nPooling data from 522 trials including nearly 120,000 patients, researchers found all drugs analysed were more effective than placebos in the treatment of adults with acute depression.\n\u201cAlthough antidepressants are of proven benefit\u2014as this study shows,\u201d she said, \u201cno doctor wants their patients to become reliant on medication.\u201d\n\nCarmine Pariante, a professor at the UK\u2019s Institute of Psychiatry, Psychology and Neuroscience and spokesperson for the Royal College of Psychiatrists, said the study \"finally puts to bed the controversy on antidepressants.\"\nThe results add up to a complex treatment picture for what authors called \u201cone of the most common, burdensome, and costly psychiatric disorders worldwide in adults.\u201d\n\nAntidepressants do not improve symptoms in about 40 percent of people, study author Andrea Cipriani of Oxford University told a press briefing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of the various side effects that can occur with antidepressant medication, such as weight gain, insomnia, and loss of sexual desire.\nThe study authors looked at which drugs were more or less tolerated, and their analysis did not include adverse effects or withdrawal symptoms. Those facts weren\u2019t included in the story.", "answer": 0}, {"article": "Frailty predicts postoperative mortality and illness more than age alone, thus presenting opportunities to identify the highest-risk surgical patients and provide tailored clinical care to improve their outcomes.\n\u201cThe ultimate cause of the survival benefit is likely multifactorial, including changes in preoperative decision making, intraoperative management, and postoperative rescue,\u201d the authors write.\n\u201cThis study reveals the feasibility of facility-wide frailty screening in elective surgical populations.\nOn the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient\u2019s frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input.\nEMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, NOVEMBER 30, 2016\n\nAlso available at the For the Media website, the commentary \u201cA Call for Frailty Screening in the Preoperative Setting,\u201d by Anne M. Suskind, M.D., M.S., and Emily Finlayson, M.D., M.S., of the University of California, San Francisco.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that this was a study about a quality improvement initiative, we\u2019ll rate this N/A.\u00a0However, it might have been worth raising the question of whether the time and emphasis placed on this screening test by clinicians detracted from other work they could have been doing to improve patient care and outcomes.", "answer": 2}, {"article": ".\nThe number of cancers detected in women ages 40-49 was not significantly different from women ages 50-59 or 60-69.\nMore than 41,000 screening mammography exams were examined for callbacks and recall rate, biopsies performed, cancers detected, and sensitivity and specificity of screening mammography.\nLeesburg, VA, March 13, 2018 - When compared to the screening population ages 50 and over, screening mammography in women ages 40-49 detects 19.3% additional cancers at the expense of an overall 1.5% increase in callbacks and 0.1% in increased biopsies, according to a study to be presented at the ARRS 2018 Annual Meeting, set for April 22-27 in Washington, DC.\nBy adding the women ages 40-49 to the screening population of 50 and over, the overall callback rate increased 1.5%, the biopsy rate increased 0.1% and 19.3% more cancers were detected.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not explain additional harms of earlier mammogram screening, of which there are several. One is radiation exposure; though mammograms involve minimal radiation, the risk of exposure still exists. The larger harm, however, is the possibility of false-positives and false-negatives. Mammograms aren\u2019t foolproof tests; the American Cancer Society estimates that mammograms miss 1 in 5 breast cancers (false negatives). They also estimate that about half of women getting an annual mammogram over a 10-year period will have a false positive (where the screening indicates something abnormal, but in reality there is no cancer). False positives are more common in younger women, and can lead to additional tests, cost and anxiety for women when nothing is wrong. The higher rate of false positives in women ages 40-49 is one of the reasons that the mammogram age is so controversial. For the group 40-49 years of age about 3% of the callbacks resulted in an actual cancer detected while it was about 6% and 7% in the older age groups.", "answer": 0}, {"article": "For more information, visit www.aacc.org.\nThis test detects the presence of a protein in the blood produced by a specific variation of the apolipoprotein gene (ApoE4), which is associated with increased risk of developing Alzheimer's disease.\n\"Higher FT4 or TSH Below the Normal Range are Associated with an Increased Risk of Dementia: a Meta-analysis of 10 Studies\" (A-180)\n\nSession Information \n\nRegistration for the AACC Annual Scientific Meeting is free for members of the media.\nResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement.\n\"Cerebrospinal Fluid Angiotensin-Converting Enzyme Activity Levels of Patients With Alzheimer's and Parkinson's Disease\" (A-118)\n\u2022 Researchers have shown that a specific protein in blood plasma could serve as a biomarker for early detection of AD.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although there are likely no direct harms from drawing a blood sample, the release could have noted the potential harm of any screening tests for AD risk factors \u2014 such as anxiety, depression, misdiagnosis or over-diagnosis\u00a0 \u2014 particularly if screening is conducted on those at potentially very low risk. To its credit, the release includes a quote from one of the investigators who makes it pretty clear that the test is intended for those with probable symptoms and family histories of AD.", "answer": 0}, {"article": "\"There is a tremendous lack of kidneys for transplant,\" he explained.\nIn a study of 20 uninfected patients, researchers found that transplanting infected kidneys and then treating recipients for HCV resulted in a 100 percent cure rate.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\nAnd the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\nUsing hepatitis C-infected kidneys would expand the organ pool and save lives, said lead researcher Dr. Peter Reese.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged that \u201csome patients might not want to take the risk associated with an infected kidney,\u201d but we think the potential risks of this strategy warranted more discussion.\nHepatitis C causes inflammation of the liver that can lead to diminished liver function or failure of that organ. According to the study, one patient in the study experienced a serious adverse event, protein in the urine, which indicated liver malfunction and could have been triggered by the HCV infection. The condition improved after treatment, according to the published study.\nModern HCV treatments are not 100% effective at curing the disease and come with \u201cblack box warnings\u201d for side effects such as low blood cell count, nausea, flulike symptoms, feeling tired, headache, and reduced appetite.", "answer": 0}, {"article": "The women on low-fat diets had a 9 percent lower rate of breast cancer; the incidence was 42 per thousand per year in women in the low-fat diet group, compared with 45 per thousand per year in women consuming their regular diet.\nIn this case, the study addressed a tricky problem.\n\"It doesn't say that this diet is not beneficial.\"\nThat is also what the cancer society recommends.\nThese days, Dr. Libby said, most people have moved on from the idea of controlling total fat to the idea that people should eat different kinds of fat.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes many questions about whether a low-fat diet is worth the trouble.", "answer": 1}, {"article": "Software engineer Ben Wallace underwent subchondroplasty in November to help shore up a damaged hip.\nThe best candidates for the procedure are patients who still have some cartilage protecting their joint, but have somehow \"overloaded\" and injured the bone, causing swelling and pain, Hepinstall said.\nHowever, subchondroplasty is only feasible in a narrow range of patients.\nThe cement braces the bruised or injured joint bone from the inside, Vasileff explained, and eventually is replaced by new bone as part of the body's natural healing process.\nThose with full-blown bone-on-bone arthritis or joint pain caused by damage to the cartilage and ligaments will get little to no relief from the procedure, Vasileff said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned in the story is the harm of overselling the benefits of the procedure. There is no discussion of whether there are other significant harms to consider. Like all surgery, this procedure will have serious risks\u2013both within the joint that\u2019s being injected and throughout the body. (A similar injection into the spinal vertebrae, called vertebroplasty, comes with very serious potential risks.)", "answer": 0}, {"article": "2017.\n\u201cThe discovery made at IRB Barcelona and tested in the current study could be of great use to clinicians and would avoid unnecessary treatment of patients who would not benefit or could be harmed by the treatment,\" added Professor Roger Gomis, leader of the growth control and cancer metastasis group at IRB Barcelona, who was a co-author on the study.\n\u201cIt only seems to be effective in some patients, particularly older women, while others show no response and in some younger women it may even be harmful.\u201d\n\nThe new study, which is published in the journal Lancet Oncology, has shown it may be possible to identify women who will benefit from bisphosphonates by using a test that looks for a gene known as MAF.\nProfessor Coleman said: \"If the test is negative for this gene, then they can be offered this bone strengthening treatment, which can give them a better chance of surviving their cancer.\u201d\n\nA test for the gene, known as MAFTest, has been developed by a Spanish medical company called Inbiomotion following work conducted at the Institute for Research in Biomedicine (IRB) in Barcelona.\nThousands of breast cancer patients at risk of developing aggressive secondary tumours could benefit from a potential new genetic test.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any of the possible side effects of taking a bisphosphonate. For some women, those side effects are significant and thus they should be included.\nAdditionally, we\u2019re wondering how the genetic test is performed since there was no description offered. Is it a blood test or is it more invasive, complex and risky, requiring acquisition of tumor tissue?", "answer": 0}, {"article": "PD-1 acts as a brake, or checkpoint, to shut down activated T cells.\nLong-term follow up shows 22 percent of those treated with the drug survive 10 years or longer.\nThe immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.\nThis Phase I/II clinical trial treated 78 patients: five (6.4 percent) had complete responses, 14 (18 percent) had partial responses, in which tumor burden shrinks by at least 30 percent, and 22 (28.2 percent) had stable disease.\nThe U.S. FDA approved atezolizumab, which blocks PD-L1, for these patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states that \u201cTreatment-related side effects included mainly low-grade fatigue, itching, elevated lipase, rash, nausea, joint pain and anemia. Grade 3 or 4 side effects occurred in 20.5 percent of patients. Two patients discontinued therapy because of adverse events related to the drug.\u201d That\u2019s enough to earn a satisfactory rating. However, it could have been better. The release says adverse effects \u201cincluded mainly\u201d manageable problems. But more than 20 percent of patients had \u201cgrade 3 or 4\u201d side effects \u2014 and that is not trivial. The release would have been much stronger if it had offered some insight into those more severe effects, or even explained what \u201cgrade 3 or 4\u201d effects means. Grade 3 effects, according to the National Cancer Institute, are \u201csevere\u201d \u2014 while grade 4 effects are \u201clife-threatening or disabling.\u201d That merits more discussion than it got.", "answer": 1}, {"article": "Who and When: 8,385 obese patients in Israel who underwent bariatric surgery (laparoscopic banding, Roux-en-Y gastric bypass, or laparoscopic sleeve gastrectomy) from 2005-2014; 25,155 obese patients who received nonsurgical care for obesity management from primary care physicians that may have included dietary counseling and behavior modification.\nStudy Conclusions: The association between bariatric surgery and a lower rate of death from any cause adds to the limited literature describing the beneficial outcomes of these surgical procedures for obese patients.\nWhy The Research Is Interesting: Much is known about the short-term outcomes of bariatric surgery for weight loss but relatively little is known about its long-term effects.\nPlease see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.\nThe study is observational.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t discuss any potential harms associated with bariatric surgery \u2014 and there are several. While the focus of this study was on rates of death, not on other outcomes, any discussion of this surgery that might sway a reader to try it needs to include a summary of potential complications and risks.\nThe issue of harms might have been included in the \u201climitations\u201d section of the release.", "answer": 0}, {"article": "We're sorry, but Newspapers.com doesn't work properly without JavaScript enabled. You will need to enable Javascript by changing your browser settings. Learn how to enable it.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said the new drug was found to be \"safe and effective\" but provided no details on its potential harms and no detailed safety comparison with the current standard of treatment. \nIf the trial was small, it may be premature to assume cethromycin is as safe as Biaxin.\u00a0", "answer": 0}, {"article": "But on Oct. 23, the F.D.A.\nVirtually all the money to develop the drug comes from $180 million in grants from the Department of Health and Human Services.\nPeramivir, still being tested in clinical trials, is not approved by the Food and Drug Administration for general use.\nSome of the push to make the drug more widely available is coming from investors in BioCryst, including Kleiner Perkins Caufield & Byers, the prominent Silicon Valley venture capital firm.\nAnecdotes like Ms. Gurno\u2019s aside, the efficacy of peramivir is still in question, according to the government.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story should have mentioned the side effects seen in clinical trials so far, as well as the risk that patients could suffer harms like those sometimes seen in people who have been given similar antiviral drugs.\nThese side effects are clearly spelled out in an FDA fact sheet prepared for patients and caregivers:\n\u201cThe most common side effects of PERAMIVIR are:\n\u2022 diarrhea\n\u2022 nausea\n\u2022 vomiting\n\u2022 white blood cell count decreased\nThese side effects may go away after you stop receiving PERAMIVIR. These are not all the possible side effects of PERAMIVIR. Peramivir is still being studied so it is possible that all of the risks are not known at this time.\nOther medicines that are used to treat people with 2009 H1N1 flu have side effects that may also happen in people who receive PERAMIVIR. \nThese side effects include:\n\u2022 Signs of unusual behavior. People with the flu, especially children and adolescents, may be at a higher risk for seizures, confusion, or abnormal behavior early in their illness. These events may happen after starting PERAMIVIR or may happen if the flu is not treated. These events are not common. Patients should be watched for signs of unusual behavior.\n\u2022 Allergic reaction or severe rash\nNot a lot of people have taken PERAMIVIR for 5 days or longer. Serious and unexpected side effects may happen. The side effects of getting any medicine by vein are brief pain, bleeding, bruising of the skin where the needle enters, soreness and swelling at that spot, and possible infection at that spot.\u201d\n\n\n\n \nPatient fact sheet available at:\nhttp://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187799.pdf \nProvider fact sheet available at:\n http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf\u00a0 ", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\n\"In addition, the bother associated with the higher urine output, and feasibility of implementing this water intake strategy across a range of occupations and ages, requires further study as well,\" he said.\n\"It is the urine output which is of course the key factor leading to the effect seen in the study,\" said Wessells, chair of the department of urology at the University of Washington School of Medicine in Seattle.\nAnd while the study involved younger women, he said older women who experience recurrent UTIs may benefit from increasing their daily fluid intake as well.\nHooton noted that it's not clear exactly how much fluid intake must increase to deliver a benefit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Increasing intake of water carries a low risk of causing problems\u2013except for more bathroom trips. For women suffering from incontinence, this could be especially troublesome and a disincentive. The story indirectly addressed that, so we\u2019ll give credit:\n\u201cIn addition, the bother associated with the higher urine output, and feasibility of implementing this water intake strategy across a range of occupations and ages, requires further study as well,\u201d he said.", "answer": 1}, {"article": "Matthews: \u2018It\u2019s only going to get better\u2019\n\nIn his first game with the Pacers, he only made two shots but they came in the fourth quarter to pull out the victory vs. the Hornets.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms of this treatment.", "answer": 0}, {"article": "Weekly yoga classes relieve symptoms of low back pain about as well as intense, regular stretching sessions, a new study shows.\n\u201cCompared with self-care, yoga and stretching class participants were significantly more likely to rate their back pain as better, much better or completely gone at all follow-up times,\u201d the study noted.\nA number of earlier studies suggested that regular yoga classes might benefit back pain sufferers, though most were limited by small sample sizes, short study periods and other flaws.\nThis is a much larger study, and the findings are robust.\u201d\n\nAbout four out of five people experience low back pain at some point in their lives, prompting Americans to spend $50 billion a year on medications, physical therapy and related costs.\nThe study is the largest and most thorough to date to look at whether yoga has an effect on chronic low back pain, a problem that affects millions and has no surefire long-term remedy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not discuss adverse events in any of the groups, though the study reported on them. This is an important point, as the New York Times article observed that many people with back pain shy away from exercise programs for fear of exacerbating their symptoms.\n\n\n\n ", "answer": 0}, {"article": "\"But it's a slippery slope to saying 'OK, maybe two is better.'\nAnd heavy drinking is not good for anyone: It has long been linked with stroke, heart failure and many non-cardiovascular hazards, including car crashes.\nAnother consideration: even light drinking is associated with an increased risk of breast cancer, according the National Cancer Institute.\nHis editorial accompanies a British study that finds death rates among moderate drinkers and non-drinkers are not different enough to suggest any real health benefits for drinkers.\nBut he says some studies show moderate drinking can boost levels of \"good\" HDL cholesterol and a hormone key to blood sugar control.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes a variety of potential harms associated with moderate drinking: excess calorie intake, increased blood pressure (among those with hypertension), and increased breast cancer risk in women.\nThe article also pointed out that heavy drinking is not good for anyone: \u201cIt has long been linked with stroke, heart failure and many non-cardiovascular hazards, including car crashes.\u201d", "answer": 1}, {"article": "Acupuncture designed to treat depression appears to improve symptoms in pregnant women, suggesting it as an alternative to antidepressant medication during pregnancy, a study found.\n\nThe study, published Monday in the journal Obstetrics & Gynecology, is the largest to date examining the effectiveness of acupuncture to treat depression in pregnant women. It was funded by a grant from the government's Agency for Healthcare Research and Quality. \"Acupuncture that we have tested works for pregnant, depressed women,\"...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Acupuncture is very safe, however there are some potential undesirable side effects that were reported in the study and that should have been mentioned.", "answer": 0}, {"article": "\"That's what we set out to answer.\"\nIf proved effective, it could become the norm for identifying heart conditions that put one in 10,000 people at risk when doing top-level physical activities, researchers say.\nNational estimates are that roughly 1% of people are born with potentially life-threatening heart defects.\nBut the Children's Hospital study is showing more than twice that rate and a higher rate for more minor abnormalities as well, perhaps because of better technology, Grenier says.\nCurrently, an EKG and echocardiogram would cost parents a minimum of $2,500, Anderson says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does report that of the first 500 high school athletes enrolled in this heart screening study, four were advised to drop out of sports and 22 more were told they needed lifetime monitoring. However, the costs and consequences of these recommendations are not addressed. How much does reduce physical activity increase other health risks, including obesity? Does a detection of an \u201cabnormality\u201d on this sort of test mean that these children may have difficulty getting life or disability insurance\u2026 or even health care coverage, if pending insurance reforms are repealed? Will they be barred from certain careers because they have been labeled as having abnormal heart conditions?\nBased on figures from the National Federation of State High School Associations (NFSHSA), if the rate of abnormal test results reported by these researchers were applied nationally, about 100,000 teens a year would be told they need lifelong monitoring and another 15,000 would be kicked out of high school sports activities. These are important consequences that the story should have addressed.\nNote: the NFSHSA reports almost 8 million high school students participate in sports (which means about 2 million new students begin each year).", "answer": 0}, {"article": "\"For patients, the concept that psoriasis is 'just something you live with' is no longer appropriate,\" he said.\nA significantly higher proportion of patients in the guselkumab group had a score of 0 (cleared psoriasis) or 1 (minimal psoriasis) in both the short and long term periods compared to the adalimumab and placebo groups.\nAt week 40, for example, 81 percent of patients taking a 200-mg dose of guselkumab had a score of 0 or 1, compared to 49 percent of patients taking adalimumab.\nIn the multi-center trial, 293 adult patients with moderate-to-severe psoriasis (defined as covering 10 percent or more of the body) were randomly assigned to receive varying doses of one of the two drugs or a placebo over 52 weeks.\nIn the study, published in the New England Journal of Medicine, investigators compared guselkumab to adalimumab, the most common medication currently used to treat psoriasis.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss harms at all, which is problematic. The authors of the paper noted the difficulty in identifying true rates of adverse events in the study given the discrepancy in the number of subjects in each treatment group.\u00a0 There was a 6:1 ratio of guselkumab subjects compared to adalimumab in the post placebo phase of the trial.\u00a0 While the true incidence of harm is unclear at the moment, some comment is\u00a0necessary even in a press release.\u00a0 For example, according to the paper, 20 percent of patients who received guselkumab experienced \u201cadverse events of infection\u201d during the first 16 weeks of the trial, as compared to 14 percent among patients receiving a placebo and 12 percent of patients who received adalimumab. A higher rate of infection is certainly worth mentioning. Heck, even a comparable rate of infection is worth mentioning. Overall, patients who received guselkumab had lower rates of all \u201cadverse events\u201d compared to adalimumab over the first 16 weeks of treatment (50 percent versus 56 percent), and over weeks 16 through 52 of the study (49 percent versus 61 percent). But the rates of adverse events were still noteworthy, and the release should have addressed them.", "answer": 0}, {"article": "DOI: 10.1001/jamacardio.2016.4828\n\nCONTACT: For more information or to schedule an interview, please contact the NHLBI Office of Science Policy, Engagement, Education, and Communications at 301-496-5449 or nhlbi_news@nhlbi.nih.gov (link sends e-mail)\n\nPart of the National Institutes of Health, the National Heart, Lung, and Blood Institute (NHLBI) plans, conducts, and supports research related to the causes, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases; and sleep disorders.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nBut the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.\nThe study, funded by the National Heart, Lung, and Blood Institute (NHLBI), appears in the December 28 issue of JAMA Cardiology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "All drugs come with some kind of risk profile. And, in this case, we are talking about treating patients with diabetes who, presumably, already are managing that disease with prescription medication. At a minimum, the release should mention any side effects or harms observed in the study.", "answer": 0}, {"article": "Schizophrenia is a long-term mental health condition that causes a range of psychological symptoms, ranging from changes in behavior through to hallucinations and delusions.\n\u201cThis proof-of-concept study...demonstrates that the memory game can help where drugs have so far failed.\nThe game, \u201cWizard\u201d, is designed to help so-called episodic memory \u2014 the type of memory needed to remember where you left your keys several hours ago, or to remember a few hours later where you parked your car in a multi-storey car park.\n(And) because the game is interesting, even those patients with a general lack of motivation are spurred on to continue the training.\u201d\nThe researchers said this was important, since lack of motivation is a common feature of schizophrenia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear that there are any potential harms associated with playing the game. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "\"This is a small study, but also very intensive with direct, accurate pressure measurements,\" Moon said.\nIn addition to Moon, study authors include Stefanie D. Martina, Dionne F. Peacher, Jennifer F. Potter, Tracy E. Wester, Anne D. Cherry, Michael J. Natoli, Claire E. Otteni, Dawn N. Kernagis, William D. White, and John J. Freiberger.\n\"Some cases of SIPE appear to have been the result of cardiac problems,\" said Moon, who was lead author of the study published online February 16 in Circulation: Journal of the American Heart Association.\nDURHAM, N.C. -- Swimmers and divers who are prone to a sudden and potentially life-threatening form of pulmonary edema in cold water could benefit from a simple and readily available dose of sildenafil, according to findings from a small study by Duke Health researchers.\nWhen the SIPE participants were given sildenafil and then performed the same underwater exercise, the pressures were no longer as elevated.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study itself is silent on the potential harms seen in the subjects treated with sildenafil, we think that the story should have noted that explicitly. Are four-hour erections an issue that swimmers need to be concerned about? Harmful side effects of ingesting sildenafil certainly\u00a0exist but are not broached\u00a0here.", "answer": 0}, {"article": "The thought never crossed my mind.\nStudies show that for kids' ear infections, antibiotics work better than waiting\n\nBeing a parent these days sometimes entails this hypocrisy: Yes, I know overuse of antibiotics is creating superbugs that may soon conquer the universe.\nNow two new studies (bolstered by an accompanying editorial) in the New England Journal of Medicine demonstrate what we parents have suspected for years: When it comes to ear infections, antibiotics are in order.\nThe studies also noted that the use of antibiotics must be weighed against the risk of antimicrobial resistance, to which prescriptions for childhood maladies such as ear infections are thought to contribute mightily, and against antibiotics' side effects, which can include diarrhea and eczema.\nInterestingly, antibiotics were no more effective at reducing pain, as reported by parents or children, than placebos.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "To its credit, this blog mentions some of the\u00a0most common\u00a0side effects associated antibiotic use such as diarrhea and eczema, and it mentions antibiotic resistance as a problem. However, it failed to put these harms into terms that understandable and useful to readers.\u00a0Clearly, data about the frequency of adverse effects would help readers weigh these downsides against potential benefits. In addition, while the story\u00a0says\u00a0that overuse of antibiotics might be \u201ccreating superbugs that may soon conquer the universe\u201d (a characterization that we understand is meant to be humorous),\u00a0the story should have explained that antibiotic overuse may have\u00a0real implications for children\u00a0who get treated unnecessarily. For example, there is some evidence that the use of antibiotics can lead to colonization of the child\u2019s nasal passages with resistant bacteria which can cause future infections that are\u00a0more difficult to treat. Parents need this kind of information before deciding whether to use drugs\u00a0on an infection that will probably clear up on its own anyway in most children \u2014 and can be effectively treated after a few days with antibiotics if it doesn\u2019t.", "answer": 0}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThese trials employed a simple, economical design in which participants acted as their own controls (i.e., change in metabolic markers was measured before and after eating the bar).\nImproved metabolism resulting from eating the bar is also associated with a number of reports of feeling better (though this observation has not yet been formally tested), which the CHORI team predicts will help people transition to improved lifestyle habits.\nThe CHORI-team thinks the broad scale improvements observed with the CHORI-bar may be the result of \"oiling\" multiple joints by the complex nutrient mixture.\nAmes and McCann's work on vitamins and minerals, supports the idea that simply supplying missing or deficient dietary ingredients will improve metabolism (4-7).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text extols the benefits of the bars with no mention of possible harms. \u00a0We\u2019d suggest that there is possible harm in replacing actual foods containing a wide variety of nutrients (and many potentially beneficial compounds that we don\u2019t know anything about) with a supplement bar processed in a factory. The peer-reviewed rendition of the study also finds no clear downsides, although it did note that \u201cchronic inflammation [which\u00a0can accompany obesity] blunted most improvements,\u201d suggesting that some folks will be helped far less by the bars than will others.", "answer": 0}, {"article": "The study was supported by the Andrew Sabin Family Fellowship Program; the American Association for Cancer Research \u2013 Stand Up to Cancer; the National Institutes of Health (CA219896-01A1, HL124112); the Cancer Prevention & Research Institute of Texas; and the Melanoma Moon Shot\u2122, part of MD Anderson\u2019s Moon Shots Program\u2122, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients\u2019 lives\n\nIn addition to Wang, other MD Anderson authors include: Diana Wiesnoski, Christopher Sanchez, and Chia-Chi Chang, Ph.D., all of Genomic Medicine; Beth Helmink, M.D., Ph.D., and Vancheswaran Gopalakrishnan, Ph.D., both of Surgical Oncology; Hamzah Abu-Sbeih, M.D., Gottumukkala Raju, M.D., and John Stroehlein, M.D., all of Gastroenterology, Hepatology & Nutrition; Edwin Parra, M.D., Ph.D., and Alejandro Francisco-Cruz, Ph.D., both of Translational Molecular Pathology; Matthew Campbell, M.D., Jianjun Gao, M.D., Ph.D., and Sumit Subudhi, M.D., Ph.D., all of Genitourinary Medical Oncology; Dipen Maru, M.D., of Pathology; Jorge Blando, DVM, and James Allison, Ph.D., both of Immunology; Padmanee Sharma, M.D., Ph.D., of Genitourinary Medical Oncology and Immunology; Michael Tetzlaff, M.D., Ph.D., of Translational Molecular Pathology and Pathology; Jennifer Wargo, M.D., of Genomic Medicine and Surgical Oncology; and Robert Jenq, M.D., of Genomic Medicine and Stem Cell Transplantation.\nThe study from The University of Texas MD Anderson Cancer Center, which includes two patients, suggests fecal microbiota transplantation (FMT) is worth investigating in clinical trials as a therapy for this common side effect of immunotherapy.\nThese conditions typically are treated with steroids and targeted immunosuppressive agents, which result in additional severe side effects and can counteract the effects of immunotherapy.\nPre- and post-treatment stool analyses revealed patients\u2019 gut microbiomes to be most similar to the donor immediately after treatment, with less resemblance to the donor over time.\nHowever, these treatments are often associated with significant immune-related toxicities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Risks of these transplants are not mentioned.\u00a0 Fecal material produced without careful screening could introduce microbes, including those linked to MS and Parkinson\u2019s.", "answer": 0}, {"article": "This article has been updated to include additional comment from Kathryn Cullen.\nJames Stone, a clinical senior lecturer from the Institute of Psychiatry, Psychology and Neuroscience at King's College London, who was not involved in the study, told Newsweek that there is \"a lot of potential for the use of ketamine as a second or third line antidepressant where other treatments have failed.\"\nThe study serves to point out the need for further, rigorous, study designed to answer the many questions that remain about ketamine for TRD, such as optimal dosing and route of administration, dosing interval and treatment length, and long-term effects\u2014just to name a few.\"\nSeveral recent studies have shown that even a single dose in adults can lead to rapid reductions in depressive symptoms.\nResearchers from the University of Minnesota (UM) and the nonprofit Mayo Clinic found that ketamine caused an average decrease of 42 percent on the Children\u2019s Depression Rating Scale (CDRS)\u2014the most widely used rating scale in research trials for assessing the severity of depression and change in depressive symptoms among adolescents.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story brushed over significant potential harms, including the potential for misuse. It stated that researchers \u201cfound that the treatment was well tolerated,\u201d and contained a quote stating \u201cwe still don\u2019t know about the long-term safety.\u201d\nAccording to the research paper, there were some issues the story ignored.\u00a0 Three participants became nauseous during the infusions, while two others experienced dysphoria (profound unease).\u00a0 One participant reported hand pain from the intravenous site that persisted for several days.\nAlso, with any invasive procedure \u2014 even infusions \u2014 there is always the risk of infections.\nBut most importantly, ketamine use requires considerable caution. It is now considered a misused recreational drug and some research indicates it can cause complications when used long-term.\nIt seems such cautions are particularly warranted due to the existence of clinics where ketamine is used off-label to treat depression.", "answer": 0}, {"article": "A 33-year-old Queens woman who was treated by Batzofin last week fits that bill. Married for two years, she failed to get pregnant through intercourse, with and without drugs. When Batzofin told her about his new procedure, she said, \"Let's go for it.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not adequately list the harms of this treatment for women with and without polycystic ovarian syndrome (PCO). Instead the story focuses on the potential downsides of IVF and the risks of hormones for some women. \nThe target group, that is, women with subfertility, can enhance their likelihood of conceiving with modest weight loss and conventional medications as needed, but who might be lured into this \"tennis shoe\" treatment out of fear that they won\u2019t conceive rather than doing the harder thing of diet, activity, and physical activity. This is not dicussed. However, IVM requires egg retrieval and embryo transfer, the same as IVF, and these risks should be mentioned\u2013 the former with small risks of bleeding and infection and the latter with small risk of infection and poorer reproductive outcomes. ", "answer": 0}, {"article": "\"Parents often say that their biggest concern is, 'When is my child going to be back to normal again?'\nIn contrast, a concussion survey commonly used by doctors was right less than 70 percent of the time.\nSpit Test May Reveal The Severity Of A Child's Concussion\n\nA little spit may help predict whether a child's concussion symptoms will subside in days or persist for weeks.\nA reliable test would help overcome a major obstacle in assessing and treating concussions, which affect more than one million children and adolescents in the U.S. each year.\nIn most cases, concussion symptoms last only a few days.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms, which would include false positive and false negative results. For example, if a child\u2019s test result erroneously said he would have prolonged symptoms (a false positive result), he may miss out on school or activities, for no good reason. And if the result instead erroneously said the child wouldn\u2019t have prolonged symptoms (a false negative result), the child may resume school or activities too early.", "answer": 0}, {"article": "Ishdori A, Capps O, Murano PS.\nAn overarching conclusion from the various papers included in the supplement, \"Science and Policy: Adopting a Fruitful Vegetable Encounter for Our Children,\" is that potatoes are a vegetable that tend to be well-liked by young children and are a good source of potassium and provide 8 percent of the recommended daily value of fiber.\nHowever, plate waste for white potatoes was the lowest among any type of vegetables; thus, including potatoes in school meals is one important way to help ensure children receive those key nutrients of concern.\nIn fact, a study of elementary school students demonstrated that students are not consuming the majority of vegetables offered to them in school lunches.\n\"It's important that consumption of all vegetables, particularly those that are good sources of potassium and dietary fiber, be encouraged in children,\" says Theresa A. Nicklas, DrPH, USDA/ARS Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, and one of the supplement's authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The most troubling thing about this study and about the release is the inclusion of french fries and potato chips in the study as if they were equal in health value to other forms of potatoes. There is no discussion of the potential harms that come from foods high in sugar, salt, fat, and calories.", "answer": 0}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nIn a recent study from the Piglet Nutrition and Cognition Lab at U of I, scientists worked with piglets to show prebiotics included in infant formula can enhance memory and exploratory behavior.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\nAmong other things, breast milk contains natural sources of prebiotics: small, indigestible fiber molecules that promote the growth of good bacteria in the baby's gut.\nThe article, \"Dietary polydextrose and galactooligosaccharide increase exploratory behavior, improve recognition memory, and alter neurochemistry in the young pig,\" is published in Nutritional Neuroscience.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are known disadvantages of formula over breast milk so harms should be included in any discussion of changing infant nutrition patterns.", "answer": 0}, {"article": "The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery\u00ae brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues\n\nThe American Society of Plastic Surgeons is the largest organization of board-certified plastic surgeons in the world.\nWhile the EarWell system is not new, the report is the largest study of congenital ear malformations treated with this approach--including a standardized approach to treatment and assessment of the results.\nIn eight cases, treatment had to be stopped because of an allergic reaction to the adhesive tape used.\nDr. Byrd and colleagues present a classification system and technical details for plastic surgeons to follow in evaluating the best treatment for specific types of malformations.\nBut treatment must begin early--preferably within the first three weeks after birth, according to the study by ASPS Member Surgeon H. Steve Byrd, MD, and colleagues of Pediatric Plastic Surgery Institute, Dallas.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release clearly addresses the vast majority of the complications discussed in the journal article, which is enough to earn it a satisfactory rating. However, the release does not mention the possibility of infection. There was only one case identified in the article, but it is also the most significant of the complications that cropped up over the course of the (retrospective) study.", "answer": 1}, {"article": "GAITHERSBURG, Md.\nThe therapy is exciting, AIDS specialists say, even though it is at least three years from market, because it could offer a completely new tool to combat a 25-year-old foe.\nIf all goes well, the trial could enroll up to 144 patients.\nExperimental AIDS therapies in clinical trial or awaiting FDA approval hint at more life-saving benefits, like the once-a-day AIDS pill that the agency hailed last month as the ``holy grail\" of drug development because it simplifies drug delivery in developing nations.\nAs the International AIDS Conference convenes next week, there are more than 20 drugs available to suppress the virus and at least 82 additional HIV therapies in development.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not discuss the potential side effects of this new drug, nor does the story provide a caveat that the drug may not live up to its predicted effect in humans. The possibility of a negative interaction with other HIV drugs, or with drugs for co-existing medical conditions is also not mentioned. But this is one of the hazards of reporting on data that have not yet been peer-reviewed (Or have they? The story doesn\u2019t make it clear.) The company and the investigators certainly know what side effects have been experienced so far. Having the company president say that the drug has \u201ca great safety profile\u201d is inadequate. ", "answer": 0}, {"article": "Trisha Bradbury was one of the participants allocated to the FIT study, and she explains: \"I lost my mum at 60, and being 59 myself with a variety of health problems, my motivation was to be there for my daughter.\n\"As well as being delighted by the success of the study in the short term, there are very few studies that document weight loss past the end of treatment, so to see that people continued to lose weight despite not having any support shows the sustainability and effectiveness of this intervention.\"\nThe full study, entitled Functional Imagery Training versus Motivational Interviewing for Weight Loss: A randomised controlled trial of brief individual interventions for overweight and obesity is available to view in the International Journal of Obesity (doi: 10.1038/s41366-018-0122-1).\nIn addition, users of FIT lost 4.3cm more around their waist circumference in six months - and continued to lose weight after the intervention had finished.\nThe study showed how after six months people who used the FIT intervention lost an average of 4.11kg, compared with an average of 0.74kg among the MI group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some forms of weight loss can pose risks for patients, such as various fad diets or when people with a sedentary lifestyle suddenly begin engaging in rigorous exercise. But this study does not appear to have evaluated how people tried to lose weight, instead focusing on the extent to which they were motived to make changes based on the intervention. Because of the nature of the study, we\u2019ll rate this as not applicable. However, it would have been valuable to include language encouraging people to talk to a health care provider before making abrupt changes to their lifestyle.", "answer": 2}, {"article": "\"For black tea lovers, there may be a new reason to keep drinking it,\" she said.\nDr. Zhaoping Li, director of the UCLA Center for Human Nutrition, chief of the UCLA Division of Clinical Nutrition and the study's senior author, said the findings suggest that the health benefits of both green tea and black tea go beyond their antioxidant benefits, and that both teas have a strong impact on the gut microbiome.\n\"It was known that green tea polyphenols are more effective and offer more health benefits than black tea polyphenols since green tea chemicals are absorbed into the blood and tissue,\" said Susanne Henning, the study's lead author and an adjunct professor at the UCLA Center for Human Nutrition, which is part of the David Geffen School of Medicine at UCLA.\nBenefits of green tea were already known; new UCLA study shows that polyphenols in both varieties alter gut bacteria\n\nUCLA researchers have demonstrated for the first time that black tea may promote weight loss and other health benefits by changing bacteria in the gut.\nThe study was funded by the National Institutes of Health and the UCLA Center for Human Nutrition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms of consuming black tea were mentioned. Black tea contains caffeine, which can cause a range of adverse effects in high doses.\nOf course, the manuscript that\u2019s the basis of the release specifies that the study tested decaffeinated black tea. However, the release doesn\u2019t mention this. Clarifying this point would have been helpful.", "answer": 0}, {"article": "\u201cThe baby will grow and the biodegradable material will disappear,\u201d he said.\n\u201cThe trial\u2019s results would be equivalent to an excellent metallic stent - that type of performance,\u201d said Dr. Patrick Serruys, a cardiologist from Erasmus University Hospital in Rotterdam, who led the study.\nThe findings, which follow similarly promising 6-month and 9-month data on the plastic device, were described at the annual scientific sessions of the American College of Cardiology in New Orleans.\nSerruys said current stents are essentially \u201ccages\u201d that hamper the flexibility of arteries and make them more prone to reclogging as they develop scar tissue and plaque builds up.\nBut unlike the millions of metal stents that are implanted in patients each year, it does not remain fixed in the arteries for life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story simply stated:\u00a0\u201cAbbott said 6.9 percent of patients suffered major cardiac events \u2014 including heart attacks \u2014 over a 12-month period, which the device maker described as a low rate.\u201d\u00a0 Do independent experts consider that a low rate?\u00a0 We wouldn\u2019t know from the story.\u00a0 And is a 12-month period sufficient to call the device \u201cproven safe and effective\u201d as the opening sentence does?", "answer": 0}, {"article": "That helped keep our spirits high.\"\nCompared to X-ray beams, which pass through a patient, proton beams deliver targeted radiation to the tumor and then stop \u2013 resulting in no exit dose.\nWhile proton therapy is not effective against all cancers, it is effective in treating many solid and localized tumors.\nA scanning beam of proton radiation with online image guidance offers greater precision to destroy cancerous cells, sparing adjacent healthy tissue with fewer side effects.\nDr. Kabolizadeh explained, \"Image guidance allows doctors to visualize tumors during therapy to assess response and make sure the tumor is treated correctly every day.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release tells readers that proton beam treatment poses fewer risks than other forms of radiation therapy, but doesn\u2019t explain what those risks are \u2014 or what risks proton treatment does pose. As the Mayo Clinic notes on its site, \u201cProton therapy can cause side effects as the cancer cells die or when the energy from the proton beam damages healthy tissue.\u201d Common side effects range from headaches and fatigue to soreness and digestive problems.\nSide effects from proton beam are likely the same as photon beam radiation but the selling point of proton is that it is more precise and thus the overlapping side effects should be fewer. But there have been few, if any, trials to compare proton and photon therapies which would supply the needed evidence to support the claim.", "answer": 0}, {"article": "Researchers said they had identified a family of retroviruses in patients with chronic fatigue syndrome, opening up a potentially promising new avenue of treatment for a debilitating disease that afflicts as many as four million Americans and 17 million people world-wide.\n\nThe finding will likely spur patients with the condition to seek treatment with drugs used to fight HIV, the virus that causes AIDS. Although HIV and the newly identified virus group are different, they are both retroviruses.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The U.S. Food and Drug Administration approved the first therapy to treat an underlying cause of cystic fibrosis, a pill that targets a genetic mutation affecting a small minority of patients suffering from the life-threatening breathing disorder.\n\nThe drug, Kalydeco, from Vertex Pharmaceuticals Inc., will be among the most expensive therapies on the market, costing $294,000 a year.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from the drug.\nThe prescribing information for the drug states: \u201cOverall, the most common adverse reactions in 353 patients with CF were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).\u201d", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070520/28diet.b.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms of treatment in the news story or in the published study. Other research suggests that main harm of taking the supplements is kidney stones.", "answer": 0}, {"article": "For example, she says, someone might say, \" 'I find that I'm staying in my room, not answering the phone, not answering texts, not answering emails.'\nNow, a study shows that a simple intervention conducted by staff in emergency departments can reduce the risk of future attempts.\nThe provider also tries to persuade patients to remove or distance themselves from their means of suicide.\nAs part of the 2012 National Strategy For Suicide Prevention, many health care providers have adopted the approaches to prevention outlined in the Zero Suicide Initiative, which includes safety planning based on previous evidence showing it works.\nMany people who attempt suicide end up in an emergency room for immediate treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Patients could be potentially harmed if a hospital relies too heavily on the SPI instead of more thorough and immediate psychiatric care. For example, if a patient with a serious mental illness isn\u2019t diagnosed and treated promptly.", "answer": 0}, {"article": "Shares of Vanda, which has a market of about $116 million, closed at $4.12 on Tuesday on the Nasdaq.\nAn orphan drug, if approved, can usually fetch a premium pricing in the market.\nWhile the first two are efficacy studies, the remaining two are intended to establish the safety profile of the drug.\nThe drug is being tested for \u2018non-24-hour disorder\u2019 that has no approved treatment.\nTasimelteon received orphan drug status \u2014 which offers several years of marketing exclusivity for drugs developed for rare conditions \u2014 from the FDA in 2010 and from the European Commission in 2011.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms. Even a brief discussion with a specialist or generalist who prescribes the similar drug ramelteon would have yielded some information about possible harms.", "answer": 0}, {"article": "Adults with arm or leg pain caused by a sprain, strain or fracture.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nData on pain came from the participants' ratings; no information on side effects was collected.\nThe study did not assess longer-term pain reduction.\nThe drug industry\u2019s triumph over the DEA, even as opioid-related deaths rise\n\nShingles can be intensely painful; it may also mean health problems ahead\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not delve into potential harms \u2014 but it does note that the study itself did not collect information on side effects. In a case like this one, simply reminding readers that there are potential side effects for all the drugs studied, and that the study did not address them, is sufficient for a Satisfactory rating.", "answer": 0}, {"article": "But on the other hand we have to be realistic and in many countries you cannot just switch traffic overnight to electric cars and do other drastic things.\u201d\n\n\u201cIt will take many more years, especially in countries like China, and I think there is an ethical need to provide something to the general population to protect them,\u201d he said.\nRussell, who also lectures at Imperial College and Oxford University, said it might also be useful for the treatment of asthma, COPD and other lung diseases, not only prevention.\nEctoine does not interact with cell receptors, so it is classed as a medical device rather than a drug.\nA version of the product for use in nebulisers will be available this year in Germany and Poland, while an ectoine-based nasal spray for allergy relief is already available.\nAntioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not explained. The comments of one doctor in the story\u00a0suggest that the compound is inert, supporting the notion that there are no harms. But a quick check of a material safety data sheet reveals some concern about the potential for ectoine to produce pulmonary edema if inhaled, in addition to eye and skin irritation.", "answer": 0}, {"article": "In Britain, around 35,000 men are diagnosed with it and some 10,000 die from the disease.\nWhitaker said that while it could be around five years before the results of this study are translated into a test for doctors to use in clinics, she hoped it would then also help them to determine which patients have aggressive tumors.\n\u201cAt the moment, PSA testing is the best method we have to detect prostate cancer but it has significant limitations, so there is an urgent need to find new biomarkers such as MSMB that could be used in screening and diagnosis,\u201d said Rosalind Eeles of the ICR and The Royal Marsden Hospital, who also worked on the study.\nThe scientists took tissue and urine samples from around 350 men both with and without prostate cancer to test MSMB levels.\n\u201cThe protein is easy to detect because it is found in urine and would potentially be a very simple test to carry out on men to identify those most at risk of developing the disease,\u201d said Hayley Whitaker of the Cambridge institute, who led the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story detailed the harms associated with the current means of testing for prostate cancer. \u00a0While suggesting that the new MSMB test was able to distinguish between aggressive and non-aggressive prostate cancer, the story did not provide details about how well the test was able to do this. In a nutshell, the story mentioned (though it didn\u2019t quantify) the high false positive rate associated with PSA, but it provided no detail on the relative false positive rate of MSMB. It also failed to mention whether the test failed to pick up on a percentage of prostate cancers that were present. ", "answer": 0}, {"article": "Whitcomb, whose research on the determinants of fertility and pregnancy outcomes usually involves studying biomarkers at the molecular level, adds, \"Lifestyle is definitely relevant to these outcomes because it can have an effect at the molecular level.\nFurther study is necessary to clarify possible mechanisms through which walking and vigorous activity might affect time-to-pregnancy.\"\nWhitcomb says another way in which this study is distinct from other work in this area has to do with who was included in the study.\nThis is especially true for the results about walking for even limited blocks of time.\nModerate activity, sitting and other activity categories were not associated with fecundability overall or in BMI-stratified analyses, they add.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms from walking are likely not significant enough to warrant mention here.\nHere\u2019s a minor point:\u00a0 since vigorous activity is noted as beneficial to conception, this might warrant mention as something that a woman with other health concerns might consider consulting her doctor about.\nOtherwise, the issue of harms seems negligible enough to consider this N/A.", "answer": 2}, {"article": "Their average age was 69.\nAn editorial accompanying the study said which drug is selected may be less important than identifying and starting an approved treatment.\nAmong the nearly 2,000 women who completed the trial, increases in bone mineral density were greater with abaloparatide than placebo, the researchers found.\nThere needs to be a large head-to-head trial between Forteo and abaloparatide, she said, to really see which drug is better.\nHe predicts that when abaloparatide is on the market, it will compete with Forteo, driving down the price of both drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists nausea and heart palpitations among the serious side effects of both abaloparatide and Forteo.", "answer": 1}, {"article": "Antimicrobial resistance refers to infections that have evolved the ability to withstand drugs that ought to stop them.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\nThe mice got injections containing the bacteria with or without the plant extracts.\nHer lab at Emory is doing additional research to confirm the safest and most effective way of using the plant extract.\nInstead of destroying the bacteria, the ingredients in the fruit weakened the bacteria by preventing them from producing the toxins it uses as weapons to damage tissue.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that \u201cthe plant extracts didn\u2019t harm the skin tissues or the normal, healthy bacteria found on skin.\u201d It also wisely cautioned \u201cthe average person shouldn\u2019t try to use the weed to make their own medicine.\u201d\nWe\u2019ll award a satisfactory grade but note that the disclaimer could have been stronger, saying that the injections were prepared under laboratory conditions and could not be prepared by just crushing the berries. We also don\u2019t know how the extract might affect humans.", "answer": 1}, {"article": "\u2022 4.9 million babies are born with a serious birth defect worldwide every year\n\u2022 3.3 million children under five die from serious birth defects annually\n\u2022 Congenital heart disease is the most common form of birth defect, affecting 1 in 100 babies\n\u2022 42 babies are born with a heart defect in Australia every week\n\u2022 30 babies will undergo heart surgery in Australia every week\n\u2022 Heart defects account for 30% of deaths in children under five\n\n[1] Baker H, DeAngelis B, Holland B, Gittens-Williams L, Barrett T Jr. Vitamin Profile of 563 Gravidas during Trimesters of Pregnancy.\nWorld first research at the Victor Chang Institute has found that this deficiency can be particularly harmful during a pregnancy as it can cripple an embryo when it is forming.\nThis indicates pregnant women may require more vitamin B3 than is currently available in most vitamin supplements.\nScientists at the Victor Chang Institute have discovered simply boosting levels of this nutrient during pregnancy can potentially prevent recurrent miscarriages and birth defects.\nCrucially, Australian scientists have also demonstrated a potential cure, in the form of a common dietary supplement.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release made no mention of harms of niacin supplements. Niacin supplements are used clinically and have side effects when used in high doses. According to WebMD, these include a hot \u201cflush\u201d reaction that can be frightening. As dosage increases, other side effects may occur, including liver problems, ulcers, loss of vision, and irregular heartbeat. \nThere have been enough people worried about niacin side effects that the British Columbia Drug and Poison Information Centre has an FAQ page\u00a0about the supplement. ", "answer": 0}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nIn the study, investigators injected cardiosphere-derived cells, a specific type of stem cell, from newborn laboratory rats into the hearts of rats with an average age of 22 months, which is considered aged.\nThe CDCs, manufactured by Capricor Inc. (NASDAQ: CAPR) as their product CAP-1002, have been used in other human clinical trials.\nThe team is studying the use of stem cells to treat patients with Duchenne muscular dystrophy as well as patients with heart failure with preserved ejection fraction, a condition that affects more than 50 percent of all heart failure patients.\n\"Our previous lab studies and human clinical trials have shown promise in treating heart failure using cardiac stem cell infusions,\" said Eduardo Marb\u00e1n, MD, PhD, director of the Cedars-Sinai Heart Institute and the primary investigator of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of stem cell therapy are not mentioned, and it\u2019s impossible to know for sure what the risks of this intervention might be. Safety data appears to be limited. The published study states that cardiosphere-derived cells \u201care already in advanced clinical testing and have proven safe to date,\u201d but it cites just one article that was written by one of the same researchers, Eduardo Marban, who developed and owns a financial interest in the technology.", "answer": 0}, {"article": "And then there's the lengthy recovery ahead, a less than ideal situation to find yourself in.\"\nThe team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells.\nThere is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.\nThe researchers are continuing to investigate the use of this drug to treat Dupuytren's disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.\nResearchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren's disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren's disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s mentioned the researchers \u201cfound the drug to be safe and well tolerated.\u201d\u00a0 The associated research paper mentions \u201cthere were two serious adverse advents, both considered unrelated to the study drug.\u201d\u00a0 But no further information is provided. The release could have been more informative regarding potential harms from the drug.\nHumira has been documented to cause a host of side-effects. It carries a black box warning for compromising immunity, and has been reported to make people more prone to tuberculosis and skin cancer.\nOf note, these side effects were noted in patients given subcutaneous Humira. The Humira in this study was administered locally in the hand, which could be less likely to cause systemic side effects.", "answer": 0}, {"article": "The World Health Organisation predicts that by 2020, depression will rival heart disease as the health disorder with the highest disease burden in the world.\nHalf the patients received electroacupuncture nine times over three weeks, while the other half - the placebo group - only had needles inserted superficially into their heads.\nThey were later assessed by experts for their depression levels and the group that received genuine electroacupuncture was found to be a lot happier.\nZhang said his group may consider moving into another trial using only electroacupuncture on patients suffering milder depression.\nLed by Zhang Zhang-jin at the School of Chinese Medicine, University of Hong Kong, the researchers used electroacupuncture to stimulate seven spots on the heads of 73 participants, who had suffered several bouts of depression in the last 7 years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\nThe journal article explained that adverse events (including dizziness, tiredness, nausea, excessive sweating, headache, transient tachycardia, insomnia, vomiting, unsteadiness and somnolence) occurred in at least 5% of the patients in either group and that two patients discontinued due to intolerance of acupuncture stimulation.", "answer": 0}, {"article": "His doctor prescribed a C.P.A.P.\nNor will it work very well in someone who has severe nasal allergies and has a blocked nose at night, said one of the leaders of the Provent studies, Dr. Meir H. Kryger, a professor at Yale Medical School and founder of the National Sleep Foundation.\nLast year, in a large study of 250 apnea sufferers published in the medical journal Sleep and subsidized by Ventus, researchers found that those who used Provent devices over a three-month period saw their apnea episodes fall sharply, compared with people who were given a sham, or placebo, device.\nTests showed that in a typical night, Mr. Bleck, 47, awoke or stopped breathing 42 times an hour.\nDr. Lee A. Surkin, a cardiologist and sleep medicine specialist in Greenville, N.C., said patients typically start with a 10-day trial pack that costs $27.50.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in this story.\nBoth the Provent device and the sham device were very similar in design and use.\u00a0 Both were adhesive \u201cbandaids\u201d place over the nostrils and both restricted exhalation through the nose (although the sham device did so less).\u00a0 Although the device was shown to have no side effects in the published study, about 16% of those using the Provent device stopped doing so by month 3 (as compared to 13.6% who used the sham device).\u00a0 That means about 1 out of 6 patients using the nasal \u201cbandaids\u201d stopped doing so relatively soon.\u00a0 The reasons for stopping were not provided but we can assume that discomfort was at least one of the reasons.", "answer": 0}, {"article": "Compared with the 35 stroke patients who got clot-dissolving medicine alone, the 35 who got the two-pronged treatment were nearly twice as likely to regain some neurological function after three days. Imaging results revealed that for those who got both treatments, 100% of the brain tissue initially affected by a clot had blood flowing to it after 24 hours. Among the subjects who only got alteplase, the median level of restored blood flow was 37%.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is the one major flaw in the reporting from our perspective. Harms are not mentioned anywhere. Threading a catheter into a blood vessel in the brain to retrieve a clot and giving a clot buster are not totally benign procedures. The Australian study did not see any differences in the incidence of bleeding or worsening of symptoms whereas the second study saw a slight but statistically insignificant increase in bleeding in the group who received alteplase and the clot removal. \u00a0Importantly, the study was conducted in centers where there is considerable expertise and availability. \u00a0These results may not be transferable to all hospitals.", "answer": 0}, {"article": "Food sources of vitamin E include wheat germ, nuts such as almonds and hazelnuts, vegetable oils such as sunflower and safflower oils, and some green vegetables, such as spinach and broccoli.\nIt is unlikely that people could get too much vitamin E from food.\nExperts advise that adults consume no more than 1,000 mg of vitamin E per day.\nThe findings, reported in the Archives of Neurology, do not prove that vitamin E itself protects the aging brain.\nThe researchers acknowledge that they cannot exclude the possibility that factors other than vitamin E explain the connection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no known harms to eating a diet rich in foods containing vitamin E, but this story goes the extra mile and notes that high vitamin E intake from supplements can cause excessive bleeding.", "answer": 1}, {"article": "In another, ulipristal acetate was found to be as effective as monthly injections of the drug Lupron for reducing heavy bleeding in women with uterine fibroids.\nBoth studies appear in the Feb. 2 issue of The New England Journal of Medicine.\nUlipristal acetate is the active chemical in the emergency contraceptive sold in the U.S. as Ella, but the daily doses taken by the fibroid patients in the studies were much smaller than those in the contraceptive.\nIf trials now under way in the U.S. prove positive, New Jersey-based Watson Pharmaceuticals Inc. and Swiss-based PregLem hope to market ulipristal acetate as a fibroid treatment under the trade name Esmya, says Watson spokesman Charlie Mayr.\nIn one study, the drug ulipristal acetate proved to be much more effective than a placebo for shrinking the non-malignant uterine tumors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story at least mentioned potential harms and that \u201cit remains to be seen if the drug is safe for long-term, intermittent use.\u201d\nBut we think it is inadequate to simply state that those on the drug had \u201csignificantly fewer side effects.\u201d\u00a0 What does \u201csignificantly fewer\u201d mean?\u00a0 And what were they?\nBoth stories we reviewed could have talked a bit more about the experimental nature of this drug and the problems seen in the past with hormone-regulating drugs.", "answer": 0}, {"article": "A rare form of blindness inched closer to a cure, after two groups published preliminary studies on replacing the bad gene that causes the condition. The results are likely to boost the prospects of gene therapy, a technique that shows promise but has yet to prove it can be used to cure many diseases.\n\nAbout 2,000 people in the U.S. have Leber's congenital amaurosis No. 2, caused when a child inherits a certain flawed gene from both parents. Patients with the bad gene can't make a protein that is supposed to nourish the eye's...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states that none of the patients experienced serious side effects or adverse events.\u00a0 It could have emphasized that one can\u2019t draw much of a conclusion on safety after experiments in a few people. ", "answer": 1}, {"article": "Guadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\nDuring the study, 15 patients had at least one imaging scan to retest the extent and location of their cancers -- with 12 patients experiencing stable disease -- for more than the four-month period, on average, and one patient experiencing a partial response to the treatment (measured as at least a 30 percent reduction in the size of the tumors.)\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\nThe current study was based on previous studies in the laboratory of Nita Ahuja, M.D., director of the Sarcoma and Peritoneal Surface Malignancy Program and professor of surgery at the Johns Hopkins University School of Medicine, which showed that guadecitabine limited the growth of colorectal cancer cell lines when combined with irinotecan, says Azad.\nThe study also showed signs that guadecitabine reduced methylation among the cancer cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The headline is problematic, but we\u2019ll talk about that under the \u201cUnjustifiable Language\u201d criterion. The rest of the release does a good job of describing potential harms. The release discusses eight potential harms, defines them and offers numbers on all of them (e.g., \u201ctwo patients developed thrombocytopenia, a lowered count of blood-clotting platelets\u201d). That\u2019s very good. Two things would have made it even better. First, the release could have included an explanation of what the observed adverse effects actually mean. For example, how severe was the thrombocytopenia? And how much of a risk does that pose to a patient\u2019s health \u2014 are we talking about the potential for bruising easily? Or a high risk of bleeding to death? Second, it wasn\u2019t clear if the dose of guadecitabine was related to observed effects. I.e., were patients who received higher doses of guadecitabine more likely to exhibit adverse effects?", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070902/10healthwatch.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the potential harms of oophorectomy, including heart disease, hip fractures and now, potentially, neurological deficits.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070603/11back.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that surgery has risks, but does not explain what the risks are, whether the patients enrolled in the studies were harmed by the treatments they received, or whether other research has documented potential long-term harms not reported in the current studies. For example, fusion eliminates movement in the fused segment of the spine. This not only reduces instability (as intended), but can add extra stress to the segments above and below the fused segment. This added stress often creates its own problems and may trigger additional fusions. ", "answer": 0}, {"article": "Tiny channels collect perspiration and route it to different compartments where it interacts with chemicals that change color to reflect sweat loss, the perspiration\u2019s acidity level, and concentrations of chloride, glucose and lactate.\nWhile Wednesday\u2019s studies used an early version that analyzed sweat just once during the exercise, he\u2019s now testing a design capable of multiple measurements over time.\nThe experimental gadget goes well beyond activity monitors like the Fitbit.\nIf you think of perspiration as just a drippy nuisance, think again.\nA little larger than a quarter, it\u2019s almost like a tiny lab stuck to the skin \u2014 and a study published Wednesday found it worked on sweaty bicyclists, sticking even during a long-distance race in Arizona.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study doesn\u2019t contain data on adverse effects, and the story doesn\u2019t touch on potential harms. Have patches been tested for skin irritation, for example? More broadly, could skin patches give athletes a false sense of security, prompting them to ignore physical symptoms, or distract them from the basics of proper training, nutrition and hydration? That\u2019s not addressed.", "answer": 0}, {"article": "University of Eastern Finland, Institute of Public Health and Clinical Nutrition, tel.\nThe new study provides further evidence on the health benefits that fermented dairy products may have over non-fermented ones.\nHowever, the researchers found that a very high consumption on non-fermented dairy products was associated with an increased risk of incident coronary heart disease.\nA very high consumption of non-fermented dairy products, on the other hand, was associated with an increased risk of incident coronary heart disease.\nWhen the study participants were divided into four groups on the basis of their consumption of fermented dairy products with less than 3.5% fat, the risk of incident coronary heart disease was 26% lower in the highest consumption group compared to the lowest consumption group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Since readers might interpret this study\u2019s results as supporting consuming more fermented dairy (much of which contains saturated fats), not mentioning the potential harms of consuming too much saturated fats is a shortcoming.", "answer": 0}, {"article": "Surgery is considered by some to be the most definitive treatment, and there is evidence from other studies that it has better long-term cancer outcomes than radiation for higher-risk cancers, but it has more sexual and urinary side effects than radiation.\nThree-year survival from prostate cancer was excellent in the study at over 99 percent for patients regardless of whether they chose surgery, radiation or active surveillance.\nThe authors also reported that:\n\n- Surgery was associated with fewer urinary irritative symptoms, like weak urine stream or urinary frequency, compared to active surveillance.\nResearch reported in this article was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) award CE12-11-4667.\n\u201cThis study shows that, despite technological advances in the treatment of prostate cancer, both surgery and radiation still have a negative effect on quality of life,\u201d said co-author David Penson, M.D., MPH, Paul V. Hamilton, M.D., and Virginia E. Howd Professor of Urologic Oncology and professor and chair of the Department of Urologic Surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study compared benefits and harms for three different situations: surgery, radiation and surveillance.", "answer": 1}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was concerned primarily with the implications of a negative BRCA test result, so we won\u2019t fault it for not going into detail on the many potential harms of a positive or ambiguous test result. The story did stipulate that BRCA-negative women may still have an elevated risk of cancer if they have a family history of the condition, which is an important caveat.", "answer": 1}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are mentioned at different points in the report: maternal deaths; interventions and complications, such as cesarean sections, forceps delivery, infections and hemorrhage compared with hospital births; \u201ccomplications\u201d for the babies. But the story does not really explore the difference (if any) between risks that would be of potentially greater concern during home birth versus hospital birth \u2014 or vice versa. The story does note that the U.K. study behind the guidance found that there was a slightly increased risk of complications for babies born at home if it was the mother\u2019s first birth. We\u2019ll rule this Satisfactory with suggestions noted for next time.", "answer": 1}, {"article": "Steven Storey, who was diagnosed with MS in 2013, said: \u201cI went from running marathons to needing 24-hour acute care.\nThis is not a technology you can patent and we have achieved this without industry backing.\u201d\n\nEmma Gray, the head of clinical trials at the MS Society, said: \u201cOngoing research suggests stem cell treatments such as HSCT could offer hope, and it\u2019s clear that in the cases highlighted by Panorama, they\u2019ve had a life-changing impact.\nI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\n\nRichard Burt of Northwestern University in Chicago, who carried out the first HSCT for MS in 1995 and is coordinating the international trials, told the BBC: \u201cThere has been resistance to this in the pharma[ceutical] and academic world.\n\u201cWe want people to be aware that HSCT is an aggressive treatment that comes with significant risks.\n\u201cThe MS Society has recently funded a study looking into the impact of HSCT on the immune system and we\u2019d like to see larger trials in this area.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are left unexplained.\u00a0 One source notes that haematopoietic stem cell transplant (HSCT) \u201cis an aggressive treatment that comes with significant risks.\u201d\u00a0 And one patient who received the treatment noted that \u201cI\u2019d rather have done 10 rounds with Mike Tyson.\u201d\u00a0 But none of that illuminates the nature of the risks that someone would encounter.\nThis is the weakest point of the story. This is a treatment with real risks. They way it is presented gives very little insight to the reader about what these risks are.", "answer": 0}, {"article": "Paul J.D.\n\u201c\u2018Sonoillumination\u2019 will be extremely beneficial for clinicians and the ASLMS presentation allowed us to demonstrate the system to the people who actually will be using the technology once it\u2019s commercialized.\u201d\n\nNicholas Golda, associate professor of dermatology and director of dermatology surgery at the MU School of Medicine, echoed the merits of the sonoillumination system and the effect it will have on dermatology.\nEditor\u2019s Note: For more information on the patent application for sonoillumination, please see: https://www.google.com/patents/US20150351841\nWhiteside presented his technique to clinicians on April 9, 2017, at the annual conference of American Society for Laser Medicine and Surgery (ASLMS).\nThe techniques developed by the interdisciplinary team can be used by dermatologists and will reduce safety concerns in laser dermatology by improving laser transmission through surface layers of the skin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release refers to \u201csafety concerns\u201d of existing laser devices, including eye damage, but there are no details about the level of risk presented by this new device. Oddly, the abstract of the conference presentation and the upcoming journal article in Lasers in Surgery and Medicine that were mentioned in the release both highlighted concerns about discoloring or burning skin, something not mentioned at all in the release.\nNote: The conference abstract was behind a paywall which requires a journal subscription. A draft of the accepted journal article was provided upon request, but we urge those who send out news releases to automatically include primary source material.", "answer": 0}, {"article": "All participants passed safety tests including liver and kidney health checks.\nPage has high hopes for the results, calling them \u201cunprecedented in the development of a prototype male pill.\u201d Longer-term studies are the next step toward a once-daily male contraceptive pill, she said.\nMore attractive to many men than a long-acting injection or topical gel\u2014both of which are in development\u2014the prototype pill offers a \u201cmajor step forward\u201d in male contraception, Stephanie Page, a professor at the University of Washington in Seattle and senior investigator on the study, said in a statement.\nRead more: Male birth control pill could be made from heart-stopping poison in ancient African arrows\n\nThe once-daily prototype pill suppressed certain hormones to the low levels you'd expect to see with effective longer-term contraceptives, results from an ENDO 2018, the Endocrine Society\u2019s annual meeting in Chicago, abstract show.\nThere were no significant changes in mood or sexual function, but a minority of participants did experience decreased libido during the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes the range of side effects found among study participants, though some of the characterizations appear to lack context. For example, the story mentions that some subjects experienced \u201cmild weight gain.\u201d Based on information in the study abstract, the mean weight gain was 1.5 to 3.9 kilograms. Given that 3.9 kilograms is 8.5 pounds, that\u2019s not inconsiderable. i.e., many men may balk at the idea of gaining more than eight pounds in a month. It\u2019s also not clear what sort of weight we\u2019re talking about. Muscle? Fat? Water retention? This may be particularly relevant (and worth articulating clearly) for a medical intervention aimed specifically at sexually active adults.\nBy the same token, the story notes that \u201ca minority of participants did experience decreased libido during the study.\u201d According to the study abstract, eight of the study participants who received the drug experienced decreased libido. Given that only 83 people completed the study, and that some of those study participants received a placebo, that means that more than 10 percent of men who received the drug experienced decreased libido.\nAgain, this seems particularly relevant for a drug aimed solely at people who are planning to have sex. In short, the story did not overlook any of the potential harms discussed in the abstract, but could have done a better job of placing those potential harms in relevant context. How appealing is a birth control pill for men if it makes more than 10 percent of them less interested in sex in the first place?", "answer": 1}, {"article": "Varenicline contains no nicotine.\nAnd given how difficult it is to kick the habit, smokers need all the help they can get to succeed the first time they try, Lerman said.\nResearchers did not test nicotine gum because it delivers a less consistent flow of nicotine to the user, she said.\nIn some of the test groups, overall success rates were fairly low, Lerman noted, but the study was conducted during the Great Recession, a time when financial stress may have depressed the chances of succeeding for everyone, regardless of which approach was used.\nThis may seem like common sense, but no one had ever tested it before, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that side effects of\u00a0varenicline\u00a0include nausea, difficulty sleeping, and abnormal dreams. It also acknowledges that there is harm in pursuing a therapy that does not work if the quitter is discouraged. Excerpt: \u201cEach time somebody fails, it affects their self confidence,\u201d Lerman said. \u201cThe trial and error approach is not optimal.\u201d \u00a0We\u2019ll rate this borderline satisfactory, but ideally we would have liked to see some quantification of these side effects, especially since frequency of side effects is an important part of the rationale for choosing one approach over the other. Moreover, the story should have explored potential harms from the blood test used to classify nicotine metabolism. How accurate is it? And if the test is wrong, what does that mean for your chances of quitting successfully?", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that \u2018few side effects were reported\u2019.\u00a0 While it is true that \u2018few\u2019 is a subjective term, it would have been useful for readers to know that ~13% of those taking the 200 milligram dose experienced side effects; further \u2013 in order to have some idea about how to value the side effects, it would have been helpful to list that the side effects included fatigue, dry mouth, headache, and drowsiness.", "answer": 0}, {"article": "But 'fish oil supplements just don't cut it.'\nFor women in their 40s, the likelihood of benefit is less and the potential harms are proportionally greater, it said.\nThe task force's guidelines are important because insurers and government programs often follow the panel's recommendations in deciding whether to cover certain preventive services.\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\nAs a result of the congressional action, women in their 40s will continue to be able to get annual mammograms at no cost.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harms briefly in two places. In one place, the story refers to \u201cthe anxiety and potential harm caused by over-diagnosis and false positives,\u201d though it doesn\u2019t explain what over-diagnosis or false positives mean (potentially leaving many readers in the dark). The story also notes that \u201cThe most serious potential harm is unneeded treatment for a type of cancer that would not have become a threat to a woman\u2019s health during her lifetime.\u201d But it doesn\u2019t give readers any idea of how serious this harm might be, or how common this scenario is. In short, the story does enough to earn a Satisfactory rating, but could have (and should have) done more. It\u2019s worth noting that the New York Times piece did a top-notch job discussing harms.\nThe story does, however, make clear that women should be informed consumers, and that \u2014 if well-informed \u2014 women should have the authority to weigh potential benefits against potential harms and make their own decisions about when and how often to get screened. That\u2019s an important point, and one worth making.", "answer": 1}, {"article": "\u201cIf people paid more attention to guidelines, more people would be on the drug,\u201d Dr. Jacobson said.\nThere was a great need, the authors concluded, to \u201cimprove awareness of this important advice.\u201d\n\nThe fact that fish oil is also sold as a nutritional supplement has made it harder for some doctors to regard it as a powerful drug, experts said.\nMarylou Rowe, a spokeswoman for Reliant Pharmaceuticals, which owns the license for the drug in the United States, said that further trials of Omacor would be needed for it to be licensed for heart attack patients in the United States.\nThis summer, a critical review of existing research in BMJ, The British Medical Journal, \u201ccast doubt over the size of the effect of these medications\u201d for the general population, said Dr. Roger Harrison, an author of the paper, \u201cbut still suggested that they might benefit some people as a treatment.\u201d\n\nDr. Harrison said he believed that people should generally increase their intake of omega-3 acids, best done by eating more fish.\nThis meant that, despite impressive results, the trial did not meet the F.D.A.\u2019s standards for approval.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms, side effects, or anticoagulation effects with excess doses. The story also failed to mention that fish oil can be a source of mercury with its potential neurologic risks (although there was a brief mention of mercury without context). ", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were many stories about this study, and we could not find one that mentioned harms. This is unfortunate because screening tests do produce false positives and people do make choices based on those results. As a clinician in a New York Times piece about the relative weakness of treadmill tests as a predictor of health explained, \u201cIn my own practice I\u2019ve seen people who thought they shouldn\u2019t be exercising anymore because someone put them on a treadmill and got an abnormal test result when in fact there was nothing wrong with them.\u201d\nProviding this information could also be harmful in other ways. It might reassure someone that they\u2019re going to live a long time, and lead them to forego the things that they\u2019ve previously done to be healthy. Or for those at increased risk of dying, it might make them more fatalistic and less prone to take steps to improve their health.", "answer": 0}, {"article": "\"I've been through it, it was the past, time to move on,\" he said.\nIt was neuroblastoma, a rare but deadly form of childhood cancer.\nAfter several trips to the doctor, the Mullins received the worst possible news.\nThis new treatment is still experimental, but it's a step forward in the strategy of manipulating a person's own immune system to fight cancer.\nToday, there's no stopping 8-year-old Brian Mullin on the Wiffle ball field.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story failed to mention the side effects associated with the treatment. \u00a0This was a glaring omission. \u00a0The side effects of treatment includes pain, vascular leak syndrome, and allergic reaction. \u00a0", "answer": 0}, {"article": "Besides flavonoids, berries also are loaded with other nutrients, including vitamin C, potassium and folate.\nThe study included nearly 94,000 young and middle-aged women who took part in the Nurses' Health Study II.\nThe study was funded by the U.S. National Institutes of Health and the U.K. Biotechnology and Biological Sciences Research Council.\nAlthough more research is needed to confirm these benefits, \"these data are important from a public health perspective because these fruits can be readily incorporated into the habitual diet,\" the study concluded.\nDuring the study period, 405 participants had heart attacks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms, but all health interventions have harms, as well as benefits.", "answer": 0}, {"article": "People getting the combination of immunotherapy and chemotherapy were 51% less likely to die after 10.5 months than people receiving chemotherapy alone.\n\u201cTo give you some idea of how significant that is, with chemotherapy we normally see the same degree of response around 20% of the time.\u201d\n\nForde says that the strong response seen in people at the beginning of the disease could suggest that immunotherapies might be useful in re-training the immune system to fight cancer for long periods of time \u2014 possibly even a lifetime.\nWhat\u2019s more, say the study\u2019s authors, doctors may also figure out which people are most likely to respond to the two-drug combination of nivolumab (Opdivo) and ipilimumab (Yervoy) and which are not.\nAnd when the scientists studied the blood of the people receiving the immunotherapy, they discovered a close match between the types of immune cells in the blood and certain targets on the tumor cells, suggesting that nivolumab had released the immune system to pump out the appropriate cells it needed to tackle the cancer.\n\u201cAnd while our study is only with 21 patients, the early indications from this study are very positive.\u201d\n\nTaken together, the results could fundamentally change the way lung cancer is treated, significantly improving people\u2019s ability to both hold off lung cancer for longer periods of time, as well as live longer with the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No side effects are mentioned, and this is a major oversight of the story.\nFor example, it could have mentioned that in the Keytruda study of patients with a common type of advanced disease, called non-squamous non-small-cell lung cancer, those in the immunotherapy group experienced more of certain adverse events, such as kidney problems, and were more likely to drop out of treatment due to side effects that those receiving chemotherapy alone.\nNot to mention that in general, immunotherapy can lead to many inflammatory conditions that can occur throughout the body as a result of treatment, such as colitis.", "answer": 0}, {"article": "\"We think it will be a very important tool in the toolbag of surgeons and physicians treating obesity and its co-morbidities,\" said Gregory S. Lea, senior vice president and chief financial officer of EnteroMedics. \"When patients leave the diet, counseling and drug world and have nothing more, they turn to surgical procedures, and only 1% to 2% of patients who might be eligible for bariatric surgery are getting it.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms or potential drawbacks to the surgery, nor does it describe which patients should not get the surgery. The FDA announcement (from which this story is partially based) noted that serious side effects of the surgery included nausea, pain at the device implant site, vomiting, and surgical complications. Less severe side effects included pain, heartburn, problems swallowing, belching, mild nausea and chest pain. In addition, the company disclosed in its announcement that the therapy is not suitable for a wide swath of the patient population including those with cirrhosis of the liver, portal hypertension, enlarged esophageal veins, certain types of hiatal hernia; patients who may undergo magnetic resonance imaging (MRI) or diathermy; patients at high risk for surgical complications; and patients who have a other implanted medical devices such as pacemakers, implanted defibrillators and neurostimulators.\nWe would add that when you start tinkering with the vagus nerve, there could possibly be many adverse effects over time, especially cardiac-related. Twelve months is too short a timeframe to establish these types of harms.", "answer": 0}, {"article": "\u201cAre DORAs the perfect hypnotics?\nSo far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.\nFor this study, the team wanted to find out what would happen if someone is awakened on this drug and has a very high level of it in their system.\nMonkeys given GABA inhibitors were much slower in responding to the prompt, and in some cases, missed it altogether, while monkeys given a potent orexin blocker called DORA-22 did not show these attention issues, Renger said.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is one quote noting that further testing will need to be done to look for rare complications, including narcolepsy-like symptoms, but the story does not mention other side effects, such as sleep walking, balance issues, etc.\u00a0 About a similar drug, Suvorexant, it states that the most common side effects have been headache and sleepiness \u2013 but no data are provided.\nThroughout, the story is not clear in differentiating between Suvorexant and the similar drug tested in the latest trial \u2013 DORA-22.\u00a0 Suvorexant is mentioned in the second sentence but it is NOT the drug studied in the trial being reported on.", "answer": 0}, {"article": "\"... obesity, smoking, certain types of genetic predisposition,\" Devi said.\nAnd despite this study, there is not enough evidence to prescribe statins for the brain.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\nSince cholesterol is part of the tell-tale plaques on the brains of Alzheimer's patients, it made sense to think that statins might help.\nHigh cholesterol is one risk factor for dementia - but experts stress focusing on all risk factors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study should have mentioned whether the studied group that took statins showed any side effects compared to the group not taking the statins. \nThe story is implictly about the potential benefits of long-term, prophylactic use of statins for people at high risk for dementia and some vascular diseases. The possiblity of side effects in this group should have been mentioned.\u00a0\nThe journal\u2019s press release says \"the most common side effects of statins are headaches, nausea, fever and muscle pain.\" ", "answer": 0}, {"article": "Senator Arlen Specter, a Pennsylvania Democrat and longtime advocate for cancer screening, said in an interview: \u201cAnd this Pap smear guideline is yet another cut back in screening?\nThe doctors\u2019 group also felt it was safe to test women less often because cervical cancer grows slowly, so there is time to catch precancerous growths.\nIn addition, Dr. Saslow said, doctors in this country have been performing 15 million Pap tests a year to look for cervical cancer in women who have no cervix, because they have had hysterectomies.\nDr. Carol L. Brown, a gynecologic oncologist and surgeon at Memorial Sloan-Kettering Cancer Center, said the new guidelines should probably not be applied to all women, because there are some girls who begin having sex at 12 or 13 and may be prone to develop cervical cancer at an early age.\nDr. Kevin M. Holcomb, an associate professor of clinical obstetrics and gynecology at NewYork-Presbyterian/Weill Cornell hospital, said that when he heard the advice to delay Pap testing until 21, \u201cMy emotional response is \u2018Wow, that seems dangerous,\u2019 and yet I know the chances of an adolescent getting cervical cancer are really low.\u201d\n\nAs with the new mammogram recommendations, women may not readily give up a yearly cancer test.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the harms of not catching cervical cancers early. It devotes some attention to the harms of over-treatment that follow unnecessary screening, particularly in low-risk younger women. \nThe story should have mentioned the likelihood of these risks.\n\u00a0", "answer": 1}, {"article": "Visit the U.S. National Cancer Institute for more on aspirin and cancer risk.\nWhile not common, aspirin can cause serious, even occasionally fatal, stomach bleeding, even at low doses, he said.\nThe benefit was no longer seen within four years of stopping it, the researchers found.\nAmounts ranged from less than one aspirin a week to 15 or more, the researchers said.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes prominently the possible harms: \u201cWhile not common, aspirin can cause serious, even occasionally fatal, stomach bleeding, even at low doses, he said.\u201d", "answer": 1}, {"article": "WASHINGTON -- A new study shows patients taking the anticlotting drug Plavix along with a type of drug used to block stomach acid have an increased risk of a subsequent hospitalization for heart trouble.\n\nThe study, which is being published in this week's Journal of the American Medical Association, adds to other recent studies that suggest proton pump inhibitors like Aciphex, Nexium, Prevacid and Protonix reduce the effectiveness of Plavix, which is marketed by Bristol-Myers Squibb Co. and Sanofi-Aventis SA.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presented the data on the combined outcome of being re-hospitalized or dying from cardiovascular problems, indicating that this occurred in a higher percentage of patients taking the combination of a PPI and Plavix than in those taking Plavix alone. \u00a0The story then went on to say that it appeared that this was due to an increase in re-hospitalization rather than cardiovascular death.\nIt would have been more informative to simply present the data on the individual endpoints of rehospitalization and revascularization \u2013 both of which were higher in the group taking the medication combination; but that dying of any cause did not differ among the two groups.", "answer": 1}, {"article": "Symptoms of heart failure include fatigue, breathlessness and swelling in the limbs.\nThat's because the study didn't include a comparison group that did not receive stem cells.\nBut it's not clear whether the stem-cell tactic was actually effective, said Gorodeski, who was not involved in the study.\nBut the study was small, and the stem cells had only a minor impact on patients' heart function.\nThe patch tactic could have some advantages, said senior researcher Dr. Yoshiki Sawa, of Osaka University.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that the study was designed primarily to determine whether the technique was safe, and the researchers said it was. That\u2019s consistent with the relevant paper, which reports that patients showed \u201cno procedural-related complications.\u201d\nHowever, that does not mean the procedure is risk free and carries no harms. This is effectively heart surgery\u2013what are the risks? That needed at least a passing mention.", "answer": 0}, {"article": "People with cluster headaches can have as many as eight per day in bouts that last for weeks or months.\nTUESDAY, Dec. 8, 2009 (HealthDay News) -- High-flow oxygen appears to be an effective treatment for cluster headaches, British researchers have found.\n\"This work paves the way for further studies to optimize the administration of oxygen and its more widespread use as an acute attack treatment in cluster headache, offering an evidence-based alternative to those who cannot take triptan agents,\" they concluded.\n\"To our knowledge, this is the first adequately powered trial of high-flow oxygen compared with placebo, and it confirms clinical experience and current guidelines that inhaled oxygen can be used as an acute attack therapy for episodic and chronic cluster headache,\" wrote Anna S. Cohen, of the National Hospital for Neurology and Neurosurgery in London, and colleagues.\nNo serious harmful side effects were reported after high-flow oxygen treatment, according to the report published in the Dec. 9 issue of the Journal of the American Medical Association.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites the researchers\u2019 claim that there were no adverse effects to the oxygen treatment. \nBoth the study and the article fail to address potential future harms, and this should have been discussed. The story barely receives a \"satisfactory\" rating under this criterion. \nThis is one area where an independent perspective would have been helpful. ", "answer": 1}, {"article": "\u201cI\u2019d be very rich.\u201d\napproval was a belated triumph for the drug\u2019s original developer, BioSpecifics Technologies of Lynbrook, N.Y., on Long Island.\nBut work was slowed by lack of money, and by 2004, BioSpecifics was about out of cash.\nBut the drug did not reduce pain or discomfort during intercourse by a statistically significant amount.\nBut the company hopes to begin late-stage trials of Xiaflex for Peyronie\u2019s disease later this year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The sidebar mentions that Xiaflex can rupture tendons \"in rare circumstances\" and that the injections\u00a0\"often\" cause temporary pain\u00a0and bruising and \"sometimes\" cause allergic reactions.\u00a0\u00a0We wish that the story had been a bit more precise in its quantification of these adverse effects,\u00a0but we feel the descriptions provided are\u00a0enough to paint a reasonably accurate portrait of the drug\u2019s potential harms.", "answer": 1}, {"article": "\"This is a potentially life-saving discovery,\" Ginde said.\nHe cautioned that the study is not definitive proof that vitamin D can prevent ARI but it suggests that it can and at little risk to the patient.\nThe falls were lower in those given smaller doses rather than higher monthly doses of vitamin D.\n\nThe clinical trial, the first to examine vitamin D's impact on respiratory infections in nursing home residents, looked at 107 patients with an average age of 84 over a 12 month period.\nAt the same time, Ginde found that those who received higher doses of vitamin D also saw an increase in falls.\nBut Ginde said the primary finding that vitamin D can reduce ARI is a major step forward in treating these dangerous infections.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the higher doses of vitamin D also had unintended side effects. It reports that the number of falls in the high dose\u00a0group was significantly increased, although according to the study, the number of hip fractures was not different in the two groups.\nThe release meets our standard here, but the finding of more falls should arguably have received more emphasis. Falls might lead to more hip fractures, which could cancel out any \u201clifesaving\u201d benefits from reduced rates of respiratory infection. ", "answer": 1}, {"article": "Dry eye syndrome is a multifactorial disease of the tear film and ocular surface that produces symptoms of ocular discomfort, eyesight disorders, and tear film instability with potential damage to the ocular surface.\nIn this context, the phase III \"Helix\" study is being carried out in more than 30 hospitals in Spain, Germany, Estonia, Portugal, Slovakia and Italy, in 300 patients to evaluate the efficacy of this compound in the treatment of the sign and symptoms of dry eye syndrome.\nSylentis, Pharmaceutical Company belonging to the PharmaMar Group, has presented results from the clinical studies carried out with tivanisiran for the treatment of dry eye syndrome and that has enabled the start-up of the Phase III \"Helix\" clinical trial.\nNon-clinical studies conducted by Sylentis with SYL1001 have demonstrated it has high ability to inhibit this specific target and block the perception of ocular pain in animals3.\nWe currently have a robust therapeutic program in ophthalmology with two candidates under development in Phase II and III studies for glaucoma (bamosiran) and ocular pain (SYL1001) , respectively.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Likewise, there is no mention of potential harms that use of tivanisiran might cause to patients. Since one of the earlier studies was a safety trial it would have been appropriate to include those results in the release.\u00a0\u00a0", "answer": 0}, {"article": "But that\u2019s not enough.\nIn the 2009-10 National Health and Nutrition Examination Survey, about 0.6 percent of people without celiac disease or an allergy say their diet is gluten-free.\nIf you don\u2019t have celiac disease or a wheat allergy and are experiencing distressing gastrointestinal symptoms after eating gluten \u2014 lack of satisfaction with your stool consistency, for example \u2014 there is something like a 1 in 30 chance that the gluten is potentially responsible.\nThirty percent of Americans say they\u2019re trying to reduce or eliminate gluten in their diets.\nThere are two groups of people who should definitely avoid gluten: those diagnosed with wheat allergies and those who have celiac disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address the fact that adopting a gluten-free diet can pose nutritional risks. As a Harvard Medical School post notes, \u201ccutting out [gluten-containing] products may mean you\u2019re reducing your fiber intake from whole grains, or missing out on vitamins that you\u2019d normally get from fortified foods.\u201d For example, a 2000 study that compared the diets of a healthy control group with celiac disease patients who had gluten-free diets found that, among other things, \u201cthe diet of the [celiac] patients was unbalanced, with a higher percentage of energy as fat and a lower percentage of energy as carbohydrates.\u201d Children would likely be most impacted by nutritional deficits from a restrictive gluten-free diet.", "answer": 0}, {"article": "Since the 1990s, Japan has been an active center of research into the study of electrical motor cortex stimulation (EMCS) to treat post-stroke pain using surgically implanted devices.\nNone of the 18 patients reported any serious side effects from weekly sessions of 10 trains of 10-second 5Hz rTMS, at 90 percent of the active motor threshold.\nOf 18 patients in the open-label series, 11 patients achieved satisfactory-to-excellent pain relief.\nOverall, 8 patients who had severe stroke-caused dysesthesias, such as uncomfortable numbness or prickling, experienced less relief than patients without severe dysesthesias, suggesting possible neural circuit damage was inhibiting response to treatment.\nAll patients received repetitive transcranial magnetic stimulation (rTMS) to their primary motor cortex once a week for at least 12 weeks.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Quoting from the release: \u201cNone of the 18 patients reported any serious side effects from weekly sessions of 10 trains of 10-second 5Hz rTMS, at 90 percent of the active motor threshold. Two patients reported transient, slight scalp discomfort after rTMS.\u201d", "answer": 1}, {"article": "The women were then followed for an average of three years.\nActivities like these account for more than 55% of older adults\u2019 daily activity, says LaCroix, so the fact that they were protective in this study is very good news.\n\u201cBut what we have here is solid evidence that light physical activity reduces a woman\u2019s risk of dying over the next three to four years\u2014and we see the benefits are substantial and independent of moderate-to-vigorous physical activity.\u201d\n\nThe study could not show a cause-and-effect relationship between activity level and risk of death, only an association.\nLaCroix says her new study refutes that research and shows that older adults can still benefit at levels below the moderate-to-vigorous guidelines.\nQuestionnaires used in self-reported studies don\u2019t do a good job of encompassing all the ways people get physical activity throughout the day, she says, which may have skewed previous study results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the NIH has noted, the benefits of physical activity far outweigh the risks. For that reason, we won\u2019t ding this story for not going into details regarding the risks associated with light physical activity. Nonetheless, it would have been nice to see the story mention that older adults may want to consult with a health professional to determine what types of activity they should (or should not) engage in.", "answer": 2}, {"article": "Mayta-Apaza AC, Pottgen E, De Bodt J, et al.\nHowever, the new study does suggest that Montmorency tart cherries can be added to the list of gut-friendly foods.\nWhile more research is needed, these results suggest individuals consuming a more plant-based diet may have a mix of gut bacteria that responds more positively and/or rapidly to tart cherry consumption.\nWhile previous studies on Montmorency tart cherries have ranged from heart health and exercise recovery to sleep, this is the first study to explore the potential gut health benefits.\nIndividuals who ate a more Western diet (low in fruits, vegetables and fiber) potentially had a lower ability to metabolize polyphenols, thereby reducing bioavailability and any potential health benefits in the tart cherries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned.\nSeveral tart cherry juices on the market contain substantial amounts of sugar. This is germane since \u2014 among the host of diseases cherry juice is claimed to be good for \u2014 there are claims that tart cherry juice is actually \u201cgood for diabetes.\u201d\nAlthough the amounts used in this study were modest, it\u2019s worth noting that some readers might think \u201cmore is better\u201d and drink enough to substantially elevate their blood sugar.\nFurther, most physicians do not recommend juice as a source of nutrition, but rather the whole fruit.", "answer": 0}, {"article": "\u201cSo I ask them, \u2018What would you like to do?\u2019 And I explain the data and say it\u2019s a gray area, and I say we can decide together.\u2019\u2019\nA task force of specialists appointed by the American Society for Bone and Mineral Research reported last month that long-term use of bisphosphonates, typically beyond five years, may increase a patient\u2019s risk of an unusual but serious type of thigh fracture.\nIt also called on the US Food and Drug Administration to change medication labeling to alert physicians and patients to the possibility of these unusual fractures, and to urge awareness of possible warning signs: prolonged groin or thigh pain.\nIn August, a team of researchers reported in the Journal of the American Medical Association that bisphosphonate use was not linked to an increased risk of stomach or esophageal cancer.\nThe panel reviewed 310 such cases and concluded that they represent less than one-half of 1 percent of all American patients taking bisphosphonates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": " \nThe article provided substantial information about potential side effects such as cancer of the esophagus and thigh fractures related to the use of bisphosphonates. However, it would have been useful for the article to also report the conclusion of the US Preventive Services Task Force that bisphosphonates are not consistently associated with serious adverse events.\n  \u00a0", "answer": 1}, {"article": "In addition, Drs.\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\n\u201cWe hope that the breath analysis can serve as the primary screening tool for cancer recurrence and a CT scan ordered only if the breath test suggests that there has been a change,\u201d said Dr. van Berkel.\n\u201cThe great potential with breath analysis is detecting lung cancer at any point, both as a primary screening tool and to follow patients after disease has been treated,\u201d said Dr. van Berkel.\nOur next step is getting approval from the FDA.\u201d\n\nNote: This work was supported by the Coulter Foundation, V Foundation, National Science Foundation, and Bill and Melinda Gates Foundation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release points out that the test could potentially reduce harms by reducing a patient\u2019s repeat exposure to radiation from CT scans. However, the harms of the test itself \u2014 i.e. false positive screens that cause substantial anxiety and necessitate additional testing \u2014 are not addressed. \nAs noted above under \u201cWhy This Matters,\u201d the concern is that using this test to guide surveillance testing (whether to order the CT) could be a problem if the test is not actually very accurate when used in that role \u2014 false positive and particularly false negative results could lead to harms. We have no data (certainly not from the study in question) that could address these concerns.", "answer": 0}, {"article": "Examining more than 500,000 Facebook posts from both groups, researchers determined which words, post lengths, frequency of posting and timing of posts were most associated with a depression diagnosis. They found people with depression used the words \"I, my, and me,\" as well as such words as \"hurt, tired, and hospital,\" more often than others in the months preceding their diagnosis. Using indicators such as these, they built a computer model that could predict which people would receive a depression diagnosis with comparable accuracy to commonly used clinical surveys.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not address potential harms, which include not only the failure to identify someone who has depression, but also the \u201cfalse positive\u201d misdiagnosis of people who do not have depression. This is the difference between \u201csensitivity\u201d and \u201cspecificity\u201d \u2014 and it\u2019s important. Being told that one has a medical problem that one does not actually have can have implications in people\u2019s personal and professional lives. We did like that the story addressed privacy concerns, which can certainly lead to anxiety and other problems.", "answer": 0}, {"article": "Unfortunately, our previous study indicated that, despite their benefits, many patients on statins discontinue their treatment,\" Chodick said.\nThis work received no outside or corporate finding, the researchers noted.\nThe only way to prove the connection is with a clinical trial, Myerburg said.\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\nThe report was published online Sept. 7 in PLoS Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story does not mention any side effects of statins or other concerns about the long-term use of the drugs.", "answer": 0}, {"article": "He is a professor in the School of Health and Biomedical Sciences at RMIT University in Melbourne, Australia.\nBut he noted that more research is needed because some patients remained in pain no matter what treatment they received.\nThe study results suggest acupuncture would be especially beneficial for patients who can't use standard pain-relieving drugs because of other medical conditions, Cohen added.\n\"While acupuncture is widely used by practitioners in community settings for treating pain, it is rarely used in hospital emergency departments,\" said study lead investigator Marc Cohen.\nMONDAY, June 19, 2017 (HealthDay News) -- Acupuncture is a safe and effective alternative to pain medications for some emergency room patients, a new study reports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the story of possible harms from the use of acupuncture. While the risks may be slight in most cases, they are not negligible. Infection is always possible and some can be serious.\u00a0Also if a patient is not given an actual pain reliever and has to revisit the ER later, that is a harm.", "answer": 0}, {"article": "See original publication for details.\nThereafter, any woman who has been tested positive for a BRCA1 mutation could take RANKL blockade as prevention measure to reduce her dramatically increased breast cancer risk.\nScientists at the University of Maryland School of Medicine in Baltimore have already tried the preventive use of a RANKL blocking drug in mice.\nOn average, women with this mutation have an up to 87% lifetime risk of developing breast cancer.\nIn the human cell culture, too, RANKL inhibition led to a significant reduction of growth and spreading of breast tissue cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Denosumab \u2014 as well as carrying out genetic testing \u2014 comes with harms, none of which are mentioned in the release. Denosumab is described as \u201can antibody with very few side effects,\u201d but this does not accord with the results of a online drug database\u00a0which\u00a0shows a lengthy side\u00a0effects list, some of which are serious.\nDenosumab was approved by the FDA for osteoporosis in postmenopausal women in 2010 and for giant cell tumor of the bone in 2013. It carries an increased risk of osteonecrosis (a painful condition caused by reduced blood flow to the bone which causes it to die) of the jaw and femoral hip fractures, increased infection susceptibility, and low calcium levels in the blood, among others. Women at risk might be expected to take such a drug for decades.", "answer": 0}, {"article": "\"You've got to turn off all the stimulants and also get into a natural sleep cycle.\"\nShe says that people with certain health conditions, such as high blood pressure, should consult their physician before downing a can of Unwind or any of the other sleep beverages.\nThe number of nonalcoholic beverages making relaxation claims continues to rise; 40 new ones came on the market in 2010, according to Mintel.\nThe relaxation drink market is tiny compared with the energy drink market, says Garima Goel Lal, a senior analyst at the consumer research firm Mintel.\nJason Healy, the head of InterMark Brands, which markets Snooz'n, says he drinks his product on nights when he is stressed-out or when he is traveling internationally.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story raises the general issue of safety, suggests that\u00a0pregnant/nursing women\u00a0and children should not take\u00a0these drinks,\u00a0and warns against mixing these drinks with alcohol. It also suggests that people with certain health conditions check with their doctor before taking any of these drinks. We think that\u2019s thorough enough.", "answer": 1}, {"article": "\u2022 43% had at least 50% fewer arthritis symptoms, compared to 19% getting a placebo.\nIt's not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\nBut there's an overabundance of Syk in the fluid of arthritic joints, and the enzyme is part of the runaway immune machinery that increases joint inflammation.\n\"Inhibition of the Syk pathway offers a new drug target for rheumatoid arthritis,\" Weinblatt and colleagues conclude.\nNobody is exactly sure of the role Syk plays in rheumatoid arthritis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides more quantification of potential harms than most stories we review. It provides a point by point breakdown of the harms in the same way it breaks down the benefits. It also flags a potentially huge Achilles heel for the drug. \"There\u2019s at least one theoretical concern about R788. Normally, the Syk enzyme helps suppress tumors. Women with breast tumors have low levels of Syk. It\u2019s not clear whether long-term use of R788 will increase cancer risk; longer-term clinical trials will have to evaluate this risk.\" This is more than a theoretical concern. Inceased cancer risk is one of the big reasons that drugs end up being pulled from the market after approval.", "answer": 1}, {"article": "In addition, BCG alters metabolism so cells consume higher levels of glucose, drawing more of it out of the blood, in a process called aerobic glycolysis.\nThe new paper describes how the BCG vaccine, which has been used for nearly 100 years against tuberculosis and is considered extremely safe, might affect diabetes.\nThe experimental treatment, a decades-old generic vaccine for tuberculosis called bacillus Calmette-Gu\u00e9rin (BCG), seems to alter both cellular metabolism and the immune system, said Dr. Denise Faustman of Massachusetts General Hospital, senior author of the study published Thursday in npj Vaccines.\n\u201cThe clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system,\u201d said Dr. Mihai Netea of Radboud University Medical Center in the Netherlands, who was not involved in the study.\nWhile the results, from only nine patients, must be replicated in a larger study, said Dr. Joseph Bellanti of Georgetown University Medical Center, \u201cif what they found is true, they really have something here.\u201d Bellanti, who was not involved in the research, said the study\u2019s eight-year follow-up and use of a placebo control arm made him \u201ccautiously optimistic\u201d that two doses of the BCG vaccine \u201ccan decrease levels of A1c,\u201d a measure of blood glucose that predicts the likelihood of serious complications such as stroke and kidney failure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the BCG vaccine, an attenuated form of Mycobacterium bovis that has been used to treat tuberculosis for nearly 100 years, is considered extremely safe.\nThere are some rare side effects of the BCG vaccine (as for any medicine), so the article could have mentioned this, though.", "answer": 0}, {"article": "Scientists hypothesize that the electrical currents may disrupt bacteria in two ways: by interrupting the production of chemical messages that instruct bacteria to develop biofilms and by weakening the molecular structure of existing biofilms, potentially making them more susceptible to antibiotics or the body\u2019s natural immune response.\nThe team\u2019s next move is to focus on the bioelectric bandage as a treatment for chronic wounds in a patient population; however, the technology could also be used to treat acute injuries.\nThe patch\u2019s design significantly advances existing FDA-approved wireless electroceutical dressing (WED) that harnesses the body\u2019s innate response to injury to help wounds heal.\nMade of silk and silver, the experimental dressing includes a self-contained battery that delivers a continuous, safe, low-level electrical current to the injury.\nIt could be applied immediately to wounds help keep bacteria from mobilizing and start promoting healing until the soldier could be transported to a facility for more intensive medical care.\u201d\n\nThe team already has interest from several industry partners, and is hoping to begin testing the new technology in patients before the end of the year to determine optimal treatment duration and more about the healing effects of electrical fields on skin cells on a molecular level.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms from the technology.\nAccording to an article in DermatologyTimes, \u201cPatients who are allergic or sensitive to silver, zinc and/or polyester should avoid using Procellera. In addition, patients undergoing magnetic resonance imaging, electrocardiogram or electroencephalogram should avoid using Procellera.\u201d The information was provided by a physician-consultant to the manufacturer. ", "answer": 0}, {"article": "Whether you've been relatively inactive or fairly athletic, age is the enemy of one of the most important sets of muscles in the body: the group of four known as the rotator cuff that surround the ball of the shoulder joint.\n\nAbout 54% of adults older than 60 have a completely or partially torn rotator cuff, compared with just 4% of those between 40 and 60. But tears are most frequently caused by degeneration of the tendon due to age, rather than injury from sports or trauma. Studies show that tears can be managed without...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a credible job of explaining that there are complications with any surgery. They did not explore the potential of surgery \u2013 even without complications \u2013 to leave a patient with reduced range-of-motion or other results that are less than desired outcomes.", "answer": 1}, {"article": "A sunscreen pill?\nA cautionary note:The damning evidence against vitamin A, which has long been used as a skin-cancer treatment, came from experiments done on mice, which have a far higher susceptibility to skin cancers than humans.\nAnd though dermatologists who have experience with Fernblock think it offers a measure of protection, even the manufacturer warns it won't suffice alone.\nIf you're squeamish about vitamin A, there are a number of alternatives.\nWe've long assumed sunscreens will do the trick, but then came reports that the vitamin-A compound (retinyl palmitate) integral to many of them could actually be making us more melanoma-prone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms of Fernblock are mentioned. If the long-term safety is unknown, an acknowledgement of that or the potential harms of taking any herbal supplement would have sufficed.", "answer": 0}, {"article": "\"All living cells undergo cell division and palbociclib's unique capacity to halt the cell division process (also known as the 'cell cycle') therefore has potentially broad applicability,\" said the study's lead author Amy S. Clark, MD, MSCE, an assistant professor of Hematology/Oncology at Penn's Perelman School of Medicine and ACC.\nAt the recommended doses, evidence of the desired drug effect in tumors has been obtained using novel PET imaging at Penn.\nAnother phase 2 trial with 29 sarcoma patients treated with palbociclib showed a progression-free survival of 66 percent at 12 weeks.\nIt is the first CDK4/6 inhibitor to be approved for the treatment of breast cancer.\nIn such cases the drug is temporarily discontinued and reintroduced at a lower dose.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes the drug\u2019s side effects, including the most common one which renders patients more susceptible to infections. However, it needs to be pointed out that the studies involved very small numbers of patients and the emergence of more serious side effects may not be seen until the drug is observed in a larger population.", "answer": 1}, {"article": "\u201cIt\u2019s not going to be a panacea,\u201d says Thomas.\n\u201cWe believe this vaccine candidate will prove safe for human trials,\u201d said Janda in a statement.\nBut in light of the growing drug abuse epidemic, for which, he says, \u201cwe have so few tools,\u201d adding a vaccine to the available treatments could help.\n\u201cIt\u2019s an avenue that shows some promise.\u201d\n\nAlthough research on humans is not yet planned, study authors Kim Janda and Paul Bremer, chemists at the Scripps Research Institute, are encouraged about this next step.\nAll four monkeys responded to the vaccine, but the two that were receiving it a second time had a stronger response, hinting that their immune systems were already primed with the \u201cmemory\u201d of the compound.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes\u00a0\u201cThe researchers did not observe any harmful side effects from the intervention.\u201d Having said that, again the study was conducted in four monkeys under highly controlled lab conditions\u2013not in humans. The comment of one of the authors, \u201cWe believe this vaccine candidate will prove safe for human trials,\u201d feels premature. On what grounds does he believe this?\nTo have passed this criteria, the story should have said the harms are\u00a0unknown.", "answer": 0}, {"article": "Six patients were given a full series of vaccinations, including five priming injections and two booster vaccinations.\n\u201cThe data shows that it is a safe and well tolerated strategy that stimulates relevant anti-tumor immune responses.\u201d\n\nHowever, the treatment has its downsides: \u201cAs the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment\u2014approximately four months\u2014which may be too long from some patients with advanced cancer.\nAdditional clinical trials will be required to determine the utility of these individualised neoepitope vaccines.\u201d\n\nCatherine Pickworth, science communication officer at Cancer Research UK said: \u201cThe promising results from these two small, early-stage studies show that personalized cancer vaccines designed to treat skin cancer are safe to use, and that for some patients, they can successfully harness the power of the body\u2019s own immune system to kill cancer cells.\nHe added, however, that the studies confirm the potential of cancer vaccines.\nThese vaccines are not necessarily the future of personalized cancer treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story credit for making an important point that waiting for the vaccine to be made might be detrimental to patients with advanced cancer. It says, \u201cAs the vaccine therapies are designed and generated specifically for each individual there is a lag time from enrollment to commencement of treatment\u2014approximately four\u00a0months\u2014which may be too long from some patients with advanced cancer.\u201d\nThe story also notes that \u201cBoth vaccines were deemed safe\u201d but it doesn\u2019t discuss any side effects that may have shown up in the trials. What happened to the five patients who were not tumor free at 25 months?\nThe story does mention that more research is needed to identify potential harms.", "answer": 1}, {"article": "It's OK to ask the question,\" Hoberman said.\nBoth studies, which appear today in the New England Journal of Medicine, find these kids get over painful ear infections faster, and have less severe symptoms, if they get prompt treatment with Augmentin, an inexpensive antibiotic often used to treat respiratory infections.\nStudy authors and other experts say doctors should be sure the child really is suffering from an ear infection before writing that prescription.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nTo do a correct diagnosis, says Dr. Alejandro Hoberman of the University of Pittsburgh, the doctor needs to be able to see the child's eardrum, which may mean cleaning out earwax first.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The possibility of antibiotic resistance is raised but never quantified in any way. Other harms are not mentioned. This is a significant omission. Both studies list adverse events, and the Finnish study saw a large number of children with adverse events. As the authors note, \u201cAn adverse event occurred in 85 children (52.8%) in the amoxicillin\u2013clavulanate group and in 57 children (36.1%) in the placebo group (an increase of 16.7 percentage points with amoxicillin\u2013clavulanate\u201d. Of those who received the drug, 77 had diarrhea, 17 had vomiting and 14 had eczema. There also are harms from not taking the drugs, which were not mentioned.", "answer": 0}, {"article": "Researchers say surgical removal of tumors is the standard treatment for early-stage lung cancer, but some people are not candidates for surgery due to other coexisting illnesses such as emphysema and heart disease.\nThree years after the treatment, the study showed that 28 participants had a complete response to the therapy and 21 had a partial response.\n\"Conventional radiotherapy fails to durably control the primary lung tumor in 60 percent to 70 percent of patients.\nThe next step is a clinical trial to evaluate the therapy in a larger number of patients and determine the proper dosage for maximum benefit and minimal risk.\nOverall, the rate of complete plus partial response after therapy was 89%.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicates that 16% experienced significant but non-deadly side effects of treatment. But what were those side effects?\u00a0 How serious were they?\u00a0 Did they occur more or less often with SBRT than conventional radiation? ", "answer": 0}, {"article": "1.\nResearchers sought to determine the clinical effectiveness of acupuncture or Alexander Technique lessons compared with usual care for persons with chronic, nonspecific neck pain.\nBoth acupuncture and Alexander Technique prove effective for long-term relief of chronic neck pain\n\nIn a randomized, controlled trial, both acupuncture and the Alexander Technique led to long-term significant reductions in neck pain and associated disability compared with usual care alone.\nIn addition, persons with chronic neck pain often seek complimentary care to manage their condition, such as acupuncture or the Alexander Technique.\nThe researchers found that acupuncture and the Alexander Technique lessons both led to a significant reduction in neck pain at 12 months compared with usual care alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention the possible harms of each intervention. While these methods are generally considered safe, no treatment is without risk of harm so we would like to see some discussion.\u00a0 The risks associated with acupuncture generally rest with the acupuncturist and can include soreness, infection, and in rare cases, organ injury if the needle is pushed in too far. Because the Alexander Technique calls for changes to posture and movement, it may cause harms to people with specific spinal injuries that are better left treated by licensed medical experts.", "answer": 0}, {"article": "The researchers noted that thousands of people in this final group were participants in the Women\u2019s Health Initiative, a long-term study sponsored by the National Heart, Lung and Blood Institute in the U.S. Earlier reports based on data gathered by the Women\u2019s Health Initiative found that calcium and vitamin D supplements were associated with a lower risk of fractures, but only for women who took hormone therapy after menopause. To get a clearer picture of the direct link (if any) between supplements and fracture risk, Zhao and his colleagues opted not to include data from women on hormone therapy.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cited one instance of harms, saying: \u201c\u2026\u00a0for people who started out with at least 20 nanograms of vitamin D per milliliter of blood, adding more vitamin D through supplements was associated with a greater risk of hip fractures.\u201d\nWe also wanted to see a mention of potential harms of calcium, such as kidney stones. Another common side effect is excess gas and one potential harm of high doses is cardiovascular complications such as heart attack.", "answer": 0}, {"article": "[Watch how the body\u2019s \u2018serial killers\u2019 stalk and attack cancer cells]\n\n\"This is a first in class agent, a brand new therapy,\" Harrington said.\nNow that other therapies -- ones that target specific mutations in patients' cancer cells -- are showing more success than what was available when the trial was formed, researchers will have to see how T-VEC compares.\nWhen the latest trial was started, Harrington explained, there was no standard of treatment for melanoma -- so it's compared to a treatment that no one expected to outpace T-VEC.\nHarrington expects the FDA to clear T-VEC within the year, and it could potentially be available to patients right away.\nThis compared with an average survival of 21.5 months in the 66 earlier-stage patients who received the control immunotherapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harmful side effects, or side effects at all, is made. The original paper does indicate that side effects were minor and that most negative effects were either unrelated or due to disease progression rather than the treatment.\u00a0 However, a line indicating that most side effects were minimal would have been welcome. It would also have been reasonable to mention that virus- delivered therapies have been shown to have potential side effects that warrant caution, and that there is some worry that healthcare workers and others could be infected by these viruses. (though this one seems safe, at least from the studies performed to date).", "answer": 0}, {"article": "Lobular breast cancer forms in the milk glands.\nResearchers did not have information on the doses of fish oil that were taken by women in the study.\nThe new research is part of the Vitamins and Lifestyle (VITAL) study, which included data from women 50 to 76 years old from Washington state.\n\"If you are taking fish oil now for other reasons, this is reassuring that it may have beneficial effects beside what you are taking it for,\" she says.\nOther supplements were not linked to breast cancer risk in the new study, including black cohosh, dong quai, soy, and St. John's wort, which are often taken to relieve some of the symptoms of menopause.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No harms were discussed but this is not a serious issue in this case. ", "answer": 2}, {"article": "\"We need people to swim against the stream.\nStill, that means that 11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn't.\nThe new device was about that accurate at differentiating between severe and less severe heart failure patients.\n\"Still, much more work is needed before we will know if the electronic nose will make it to the clinic,\" says Ruschitzka, who moderated a news briefing to discuss the findings.\nThe electronic nose correctly identified 89% of the people who had heart failure and 84% of people that didn't have the condition.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that, \u201c11% of cases would have been missed and 16% of people would have been told they had a life-threatening condition when they didn\u2019t.\u201d There could have been a little more discussion of the ramifications of a test with this kind of error rate.", "answer": 1}, {"article": "Also some fancier CT studies, involving multiple \"slices\" through the body in a single examination, can be replaced by simpler CT tests, conventional X-rays or tests such as ultrasound or MRI that don't involve radiation.\nTo cut down on unnecessarily high radiation doses, Thrall says, the College of Radiology is also developing an \"alarm\" system that will alert hospitals when their CT scan exceeds an acceptable dose.\nShe says patients should start asking doctors if they really need a particular CT scan, and if so, whether it can be done with minimal radiation exposure.\nSmith-Bindman says neither doctors nor patients appreciate the amount of radiation exposure that U.S. patients are accumulating from CT scans.\nShe adds that a single CT scan can deliver about the same radiation dose that survivors of the atomic blasts at Nagasaki and Hiroshima endured.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of describing the harm of exposure to radiation due to CT scanning.\u00a0The story could\u00a0have also mentioned\u00a0other\u00a0harms from overuse of scanning, such as follow-up testing\u00a0and procedures to evaluate suspicious findings that\u00a0turn out to be benign.\u00a0", "answer": 1}, {"article": "Other types of retinal implants, known as epiretinal implants, sit outside the retina and because they bypass the intact light-sensitive structures in the eyes they require the patient to wear an external camera and processor unit.\nThe implant device, which sits completely within the eye, is a tiny plate, measuring just 3 mm squared and a 10th of a millimeter thick, which has around 1,500 tiny light sensors connected to amplifiers and electrodes.\nTests were conducted starting from seven to nine days after the device was implanted.\nZrenner said further trials of the implant should be completed in two to three years and if those proved successful the device could be on the market and available for thousands of patients in about five years\u2019 time.\nExperts described the study results as phenomenal and said the device, developed by German researchers, could eventually change the lives of up to 200,000 people worldwide who suffer from blindness due to a degenerative eye disease called retinitis pigmentosa.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides absolutely no information on the implant requirements for the device\u00a0nor the potential downsides associated with this surgical procedure.", "answer": 0}, {"article": "Dr. William Nelson, co-vice chair of the SU2C Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, said:\n\n\"Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families.\nFor enquiries out of hours, please call 07595 963 613.\nThe ICR has an outstanding record of achievement dating back more than 100 years.\nFor more information visit http://www.\nFor more information, click here.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned.", "answer": 0}, {"article": "One of the top research universities in the world, MSU focuses its vast resources on creating solutions to some of the world\u2019s most pressing challenges, while providing life-changing opportunities to a diverse and inclusive academic community through more than 200 programs of study in 17 degree-granting colleges.\n\u201cIt\u2019s believed that cognitive function decreases in many of those with HIV partly due to chronic inflammation that occurs in the brain,\u201d said Norbert Kaminski, lead author of the study, now published in the journal AIDS.\n\u201cWhat we learn from this could also have implications to other brain-related diseases like Alzheimer\u2019s and Parkinson\u2019s since the same inflammatory cells have been found to be involved.\u201d\n\nKnowing more about this interaction could ultimately lead to new therapeutic agents that could help HIV patients specifically maintain their mental function.\nNewswise \u2014 EAST LANSING, Mich. \u2014 A chemical found in marijuana, known as tetrahydrocannabinol, or THC, has been found to potentially slow the process in which mental decline can occur in up to 50 percent of HIV patients, says a new Michigan State University study.\n\u201cThis happens because the immune system is constantly being stimulated to fight off disease.\u201d\n\nKaminski and his co-author, Mike Rizzo, a graduate student in toxicology, discovered that the compounds in marijuana were able to act as anti-inflammatory agents, reducing the number of inflammatory white blood cells, called monocytes, and decreasing the proteins they release in the body.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is nothing in the release about the harms of ingesting or smoking marijuana. The release (nor the study) never mentions specifically how the HIV patients consumed their marijuana \u2014 whether through smoking, edibles, cannabis oil or other means, or any potential risks associated with any of the methods.\nAnytime we inhale smoke into our lungs we are taking a risk. At a minimum, some of those risks should be mentioned. And, better yet, if the study did not adequately track patients to assess the negative effects of marijuana smoking or otherwise ingesting, that should be acknowledged.\nIt\u2019s likely that the negative impact of marijuana was not mentioned because the study was in vitro (using blood samples). However, that underscores the fact that no true clinical correlation can reasonably be made from this study alone.", "answer": 0}, {"article": "After adjusting for factors that might play a role in dying, such as age, gender, ethnicity and common causes of death, the researchers found those taking statins lived longer than those who were not taking them.\nFRIDAY, July 8, 2016 (HealthDay News) -- Some cancer patients who take cholesterol-lowering statins may live longer than those not on these heart medications, a study from Britain suggests.\nThe database includes information on cancer and other medical conditions, including high cholesterol.\nOne expert doesn't think sufficient evidence exists yet to take statins to prevent or treat cancer.\nAt this time, people without high cholesterol should not be taking statins in the hope of warding off cancer or living longer with cancer, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Statins have been identified with some serious side effects, including memory loss, muscle pain, and a condition known as rhabdomyolysis, and the story should have made some reference to this. In this article, the FDA\u00a0explains risks.", "answer": 0}, {"article": "Flavonoids have been found to relax blood vessels and thereby improve blood flow, inhibit platelets from sticking together in the blood, and have a beneficial antioxidant effect. What still is not known is whether regularly eating dark chocolate, especially with its high sugar and fat content, eventually will lead to an unhealthy weight gain that would erase the beneficial effects of the flavonoids found in the cocoa.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that chocolate is laden with fat and calories, potentially harmful in people who are already overweight or obese.\n", "answer": 1}, {"article": "Hot flashes are a sudden rush of heat, followed by facial flushing and sweating, often followed by chills and clamminess.\n\u201cThere is certainly a need for non-pharmacologic treatments for hot flashes and night sweats,\u201d says North American Menopause Society (NAMS) Executive Director Margery Gass, MD.\nThe alternative therapy reduced hot flashes by as much as 74% in the study conducted by researchers at Baylor University\u2019s Mind-Body Medicine Research Laboratory and funded by the National Institutes of Health.\nIn the newly published study, they set out to determine if the alternative treatment would do the same in women whose symptoms were related to menopause.\nIn an earlier study, Elkins and his Baylor colleagues showed that hypnosis dramatically reduced hot flash and night sweat frequency in breast cancer patients with treatment-related symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any possible harms or side effects of the alternative therapy. It does, however, mention that hormone therapy comes with its own risks. The LA Times article, by comparison, correctly states there is no known risk of hypnosis.", "answer": 0}, {"article": "But in this case, if anything, we're taking money out of our own pockets.\"\nThe American Cancer Society, which has led the opposition to the mammography guidelines issued by the U.S. Preventive Services Task Force, was involved in the discussions leading up to the Pap test guidelines and will consider them in reevaluating its own recommendations, an official said.\n\"We are persuaded that the guidelines are really consistent with the evidence,\" said Robert Smith, the society's director of cancer screening.\nThe change comes amid sharp controversy over new recommendations from a federal task force that women wait until age 50 before they begin having routine mammograms and that women age 50 to 74 scale back to getting the exams routinely every two years.\nThe National Cervical Cancer Coalition, a patient advocacy group, endorsed the recommendations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes in paragraph two the potential harms of over-screening\u2013that the testing led to stress, anxiety and some unnecessary treatments. \nThis point is emphasized by a quote in the following paragraph.\u00a0 ", "answer": 1}, {"article": "Imaging equipment makers such as GE Healthcare, Siemens, Philips and Toshiba Medical Systems are working to develop low-dose CT scanners.\nThe findings, published in the Archives of Internal Medicine, add to mounting evidence that Americans are overexposed to radiation from diagnostic tests, especially from a specialized kind of X-ray called a computed tomography, or CT, scan.\nThe researchers said efforts need to be taken to minimize CT radiation exposure, including reducing the number of unnecessary tests, cutting the dose per study, and standardizing the doses across facilities.\nRedberg, who wrote a commentary on the studies, said U.S. doctors\u2019 enthusiasm for the tests has led to an explosion in their use that is putting patients at risk.\n\u201cWhat we learned is there is a significant amount of radiation with these CT scans, more than what we thought, and there is a significant number of cancers,\u201d said Dr. Rita Redberg, editor of the Archives of Internal Medicine, where the studies were published.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly describes the harm of radiation exposure from CT scanning. The story could have also mentioned that excessive CT scanning can also lead to unecessary follow-up testing and/or procedures for suspicious findings that turn out to be benign.", "answer": 1}, {"article": "He is vice president for health care outcomes and policy at Roswell Park Cancer Institute in Buffalo, N.Y.\nThe guidelines don't offer a single formula for which patients need radiation therapy, Edge noted.\nAndrews said that one take-home message for patients is to expect the surgeon to have consulted with the radiation oncologist and others on her team.\n\"In the past, if a woman had a small tumor, less than 5 centimeters, and not more than three or four positive lymph nodes, many doctors would say she does not need [post-mastectomy radiation therapy],\" she said.\n\"The new guidelines say there is clear evidence that the benefit of [post-mastectomy radiation therapy] extends to women with limited lymph node involvement,\" said Dr. Stephen Edge.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does address the need to \u201cweigh the risks and benefits.\u201d The story notes: \u201cSide effects can include redness of the skin, swelling and skin breakdown severe enough to compromise future breast reconstruction.\u201d Those are important points, and we\u2019re glad the story made them.\nWe wish the story had also discussed that there can also be more serious health effects from radiation, including the possibility of increased risk of a second cancer. Also, surgical complications may be increased in patients who require radiation therapy.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2009/11/02/financial/f035110S68.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study points out the potential adverse effects associated with this drug.\u00a0 ", "answer": 1}, {"article": "Dr. Gaetan Michel, Chief Executive Officer of Volition's wholly-owned subsidiary, Belgian Volition SPRL, commented, \"We would like to thank the Walloon Region for their continued support of the company.\nThe correlation of the panel blood test results with Gleason Score shows great promise in this regard.\nVolition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties.\nBased on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor.\nThis suggests the assays may provide better risk stratification than that available using PSA tests for men with actual or suspected PCA, leading to better patient management and fewer unnecessary biopsies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms. How might the false positive rate compare with current practice? Even if, as the company hopes, this blood test might reduce the total number of men sent to have biopsies who turn out to have low-grade tumors, could this test send some men to biopsy who would not have been subjected to it based on current practice?\nOn the other hand, what is the false negative risk; that is, the chance that identification of a high-grade tumor might be delayed because a man was not referred for a biopsy based on the results of this blood test?", "answer": 0}, {"article": "The group that received standard education lowered their scores by an average of 1 point.\nIn fact, they did better than their counterparts who were given conventional lessons on good sleep habits, the study authors said.\nBlack said the benefits of mindfulness training were on par with what's been found in studies of sleep medications and cognitive behavioral therapy -- a form of \"talk therapy\" that is often helpful for insomnia, for example.\nThe caveat, according to Spira, is that this study tested that specific program.\nThe program, Black said, did not specifically address sleep -- a topic that might only stir anxiety in people who are already worried about a lack of sleep.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions risks in the context of sleep medication, saying that sleeping pills \u201ccan have side effects that are particularly dangerous for older people \u2014 such as dizziness and balance problems that can lead to falls, and problems with attention and memory.\u201d By implication, the story is saying that the meditation showed no side effects. (For example, did it make it harder for any of the participants to sleep?) It would have been nice to have that issue clarified.", "answer": 1}, {"article": "\"You're killing the bad cells and regenerating with cells that are more functional.\"\n(CNN) How much -- or how little -- you eat could influence how long you live.\n\"It's not just about reducing calories\", says Longo.\n\"Five days is safe: going on for longer is difficult to do outside of a clinic,\" says Longo.\nThe idea of caloric control improving your health, and therefore your lifespan, is nothing new, but researchers are now hoping to accurately determine the type of diet that could make you live longer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story should have explained to readers at least a few known potential harms of fasting\u2013which are very real, especially for people with certain health conditions, including common ones like diabetes. All we get is a quote that hints it might be dangerous to fast for more than five days:\n\u201cFive days is safe: going on for longer is difficult to do outside of a clinic,\u201d says Longo.\nBut fasting for 5 days would clearly be harmful for many people.", "answer": 0}, {"article": "Ulcerative colitis, which affects about 38,000 people in the United States annually, is a chronic condition causing abdominal pain, intestinal ulcers, bloody diarrhea and weight loss.\nThe patient had no prior history of high blood pressure or cirrhosis, the drugmaker said.\nBoth 6 mg/kg and 130 mg doses of the intravenous treatment showed clinical remission in significantly more patients, compared with those on placebo, after eight weeks, the company said.\n\u201cMore than half of UC patients have not experienced remission with currently available treatment options,\u201d the study\u2019s lead investigator Bruce Sands said.\nTwo doses of Stelara, already approved for psoriasis, psoriatic arthritis and Crohn\u2019s disease, was tested in 961 patients with moderate-to-severe ulcerative colitis (UC) who had failed prior therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that one patient who received Stelara died from \u201cexcessive bleeding\u201d but that overall side effects were similar between Stelara and placebo patients. That\u2019s enough to earn a satisfactory rating here. However, it was fairly glaring to discuss a patient dying without explaining whether or not it was thought that this death was attributed to the treatment or the underlying disease.\nAlso the story would have been stronger if it had noted that Stelara affects the immune system, and can cause a host of other significant side effects. The story doesn\u2019t need to list every single risk, but a sentence addressing the risks would be worthwhile.", "answer": 1}, {"article": "\"Ideally, you won't need ultrasound, or at least you'll need less ultrasound.\"\nAlthough approved by the FDA, the femtosecond laser procedure is not widely used in the U.S., according to the American Academy of Ophthalmology.\n\"If you have a technique to soften the cataract, there appears to be less chance of damage [to the eye ],\" Salz says.\n\"There certainly seems to be a benefit to using the laser,\" says American Academy of Ophthalmology (AAO) spokesman James Salz, MD, clinical professor of ophthalmology at the University of Southern California in Los Angeles.\nMore than 1.5 million cataract surgeries are performed annually in the U.S. One in three mostly older Americans will have the surgery at some point in their lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not discuss potential harms of femtolaser surgery or mention any adverse effect data reported in the studies\u00a0being discussed.\u00a0(Given the brevity of the presentations, it is perhaps not surprising that potential harms were not mentioned.) While there are no data for the use of the femtolaser in cataract surgery, the risks associated with its use are well described when used in vision correction surgery and could have been mentioned here.", "answer": 0}, {"article": "\"I use all those parameters to tell a patient what his chances of a good outcome are,\" Andriole says.\nResearchers Say Common Test For Prostate Cancer May Not Work\n\nMore bad news on the prostate cancer front: A widely used test that's supposed to help doctors and patients predict the outcome of most prostate cancers is basically worthless.\nWhen these errors occur, the study says, doctors most often conclude the cancer is less serious than it really is.\nBut even when researchers allowed for these errors, they found the test doesn't predict how patients ultimately do.\n\"Our findings question the utility of our current staging system for localized prostate cancer,\" says Dr. Adam Reese of the University of California at San Francisco, lead author of the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that doctors \u2018erred 35% of the time\u2019 with clinical staging and this leads doctors to conclude that a given prostate cancer \u201cis less serious than it really is.\u201d\u00a0 However \u2013 this is only half of the story.\u00a0 There\u2019s also a significant harm that occurs from overtreatment of lesions that were never destined to be problematic. \u00a0To be balanced and complete, the story should have mentioned this as well because it is another important problem.\nFor example, a MedPageToday story addressed this issue:\u00a0 \u201cFor those men with prostate cancer found to have been staged incorrectly, the assigned clinical stage was too low 55.1% of the time \u2014 and too high in 44.9% of cases.\u201d", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe Brain Trauma Indicator was reviewed under the FDA\u2019s De Novo premarket review pathway, a regulatory pathway for some low- to moderate-risk devices that are novel and for which there is no prior legally marketed device.\n\u201cThe FDA\u2019s review team worked closely with the test developer and the U.S. Department of Defense to expedite a blood test for the evaluation of mTBI that can be used both in the continental U.S. as well as foreign U.S. laboratories that service the American military.\u201d\n\nThe Brain Trauma Indicator works by measuring levels of proteins, known as UCH-L1 and GFAP, that are released from the brain into blood and measured within 12 hours of head injury.\nThe FDA is permitting marketing of the Brain Trauma Indicator to Banyan Biomarkers, Inc.\nThese findings indicate that the test can reliably predict the absence of intracranial lesions and that health care professionals can incorporate this tool into the standard of care for patients to rule out the need for a CT scan in at least one-third of patients who are suspected of having mTBI.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms. In any screening test, there is always the harm of missing an injury that exists or finding a false positive that leads to unnecessary and sometime costly followup tests and treatments.", "answer": 0}, {"article": ".\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\n\"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease.\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\nAnother expert agreed that new treatment options for patients are sorely needed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes, \u201cSide effects among patients taking the drug were similar to the placebo group.\u201d Dr. Alessandro Di Rocco also agrees with this statement, since the \u201ccompound is apparently well tolerated without significant side effects.\u201d However, the story could have been more thorough in letting the reader know exactly what those side effects are.", "answer": 1}, {"article": "Badie and his team extracted immune cells from him, then engineered them to express proteins on their surface that would recognize and destroy glioblastoma tumor cells.\nIf the patient had not received the CAR T therapy, he likely would only have survived a few weeks after his cancer recurred, says Badie.\nThese results are the first encouraging sign that the immunotherapy that is helping more people with blood cancer might also be effective for people with solid tumors like brain cancers.\nBased on this man\u2019s case, his team is hoping to now inject not just the tumor site but also the ventricular space in the brain, since that may help control spread of the cancer.\nBut in a report published in the , researchers led by Dr. Behnam Badie from the City of Hope Beckman Research Institute and Medical Center say that the same immune-based therapy that is successful against blood cancers also helped a patient with advanced brain cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly notes that CAR-T cell therapy has potentially dangerous side effects when used the way it was in in this trial, and acknowledges surprise on the part of the investigators as to why the patient did not develop them. The story might have been stronger if it had noted that the treatment is well known for serious side effects in experiments on patients with other forms of cancer. (See our tips for\u00a0reporting accurately about the harms, side effects and risks of immunotherapy.)", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/12/national/a180226S32.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "\"It's automatically responsive to our body function, producing stimulation when needed,\" says Wang.\n\"One potential advantage of the new device over existing vagus nerve stimulators is that it does not require external battery charging, which is a significant advantage when you consider the inconvenience that patients experience when having to charge a battery multiple times a week for an hour or so.\"\nThis research was supported by grants from the National Institutes of Health (R01EB021336 and P30CA014520).\nUnlike gastric bypass, which permanently alters the capacity of the stomach, the effects of the new devices also are reversible.\nUW-Madison radiology professor Weibo Cai is also a senior author on the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss potential harms, even though the similar, approved device has caused a number of harms, such as:\n\u201cNausea, pain at the neuroregulator site, vomiting and surgical complications were among the serious adverse events reported in the clinical trial. Additionally, some patients experienced pain, heartburn, problems swallowing, belching, mild nausea and chest pain.\u201d\nThe release should have addressed the possibility that this experimental device could present similar risks.", "answer": 0}, {"article": "Drs.\nResearch at Group Health points to bupropion (Wellbutrin) as first choice for overweight and obese patients with depression\n\nSEATTLE--Group Health researchers have found that bupropion (marketed as Wellbutrin) is the only antidepressant that tends to be linked to long-term modest weight loss.\nSo smokers who take bupropion are likely to be trying to quit--and coping with the weight gain that often accompanies attempts to quit smoking.\nBut in some cases, an overweight or obese patient has reasons why bupropion is not for them--like a history of seizure disorder--and it would be better for them to choose a different treatment option.\nBupropion is often used to help patients stop smoking.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "With the exception of a mention that some people can\u2019t take buproprion (seizure disorder patients, for example), and the weight gain issue, the release makes no mention of the considerable side effects that accompany antidepressant use, or the often frustrating search patients and physicians must undertake to find an antidepressant that is both effective and tolerable for individual patients. Fatigue, insomnia, increased anxiety, headache and nausea are all fairly common when starting an antidepressant.", "answer": 0}, {"article": "Highlighting the significance of the findings, the study\u2019s senior author, George A. Macones, MD, the Mitchell and Elaine Yanow Professor and head of the Department of Obstetrics and Gynecology, said, \u201cThis study is a tremendous addition to the literature on preventing surgical-site infections after cesarean.\nThere are few circumstances when a single study should change our practice.\nBut according to Tuuli, the unique circumstances of a C-section \u2014 that bacteria come from both skin and vagina and that a woman\u2019s immune system is altered during pregnancy \u2014 mean the results of these studies may not apply.\nA new study from Washington University School of Medicine in St. Louis offers strong guidance on the best way to reduce the infection risk.\nThe study appears online Feb. 4 in The New England Journal of Medicine and coincides with a presentation at the Society for Maternal-Fetal Medicine\u2019s Annual Meeting in Atlanta.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t mention any harms associated with either of the antiseptics used in the study. If there were no skin reactions, or some with one but not the other, it would be good to note that. This is a minor omission.", "answer": 0}, {"article": "But for relapsed ovarian cancer, surgery is usually not an option.\nBut she stopped short of saying it should be eliminated, saying that in any event, patients would not accept that.\nThe finding is another in a series suggesting that early detection of cancer might not always lead to better outcomes for patients.\nThe group getting the test began chemotherapy a median of about five months earlier.\nDoctors are convinced that if the initial diagnosis can be made early, which is very difficult, the cancer can be treated by surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the major harm of CA-125 testing, which is that it could lead to unnecessary treatment in women who would not benefit from it.", "answer": 1}, {"article": "What does that mean for men today?\nToo much PSA, or prostate-specific antigen, in a man's blood can indicate that he has either a benign enlarged prostate or cancer.\nPSA tests are used to screen men for prostate cancer, but they're imprecise.\nBut Carter contends the findings suggest that men should consider getting a baseline PSA test around age 40, instead of the more usual 50, to use as a comparison for future changes.\nSome men have cancer despite a \"normal\" PSA count of 4 or below.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention that screening itself is associated with harms, such as physical pain from subsequent biopsies, anxiety, and problems related to a false positive (a false alarm) screening result.\u00a0 While the story does mention that many experts believe too many men are undergoing side effect prone treatments for prostate cancers which would never harm them,\u00a0 those treatments or side effects are\u00a0 not mentioned.\u00a0 The treatments\u00a0commonly include surgery or radiation, both of which can cause problems with impotence/erections, bladder control, and bowel functioning. The side effects are not inconsequential and happen to a significant number of men (sexual problems seem to occur in a majority of treated men).\u00a0 The reader doesn't have any context for how serious or frequent these may be.\u00a0 ", "answer": 0}, {"article": "Now Dr.\nIn this assessment, those getting insulin used more glucose in their brains; those taking placebos used less.\nIn the four-month study, the group randomly assigned to receive intranasal insulin twice a day either improved slightly or remained the same in tests of memory and assessments of their ability to handle day-to-day activities.\nA third also had scans to assess their brains\u2019 use of glucose.\nThe investigators first tried a single dose of insulin delivered via nasal spray to the brains of people with Alzheimer\u2019s disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story references potential adverse effects, and notes that this study was too short and small to reliably document the potential harms of treatment. However, it didn\u2019t mention the adverse effect data \u2014 limited though it may be \u2014 that was reported in the study. Adverse events were more common in the insulin-treated groups and were reported by 72% of patients receiving\u00a020 IU\u00a0of insulin,\u00a068% receiving\u00a040 IU, and\u00a057% receiving placebo.\u00a0The most commonly reported adverse event was a stuffy nose, but headaches and nosebleeds were also more common with insulin treatment.", "answer": 0}, {"article": "In one study, researchers found that people who have long telomeres, the small strips of DNA that cover the ends of chromosomes, have a 30 percent increased risk of developing colon cancer.\nSavings over time on a more accurate test done fewer times could justify the higher cost of the Cologuard test, Ahlquist said.\nAhlquist noted that the test still needs to be refined.\n\"Hopefully, this is a good start for a more reliable test.\"\nAhlquist noted that the cost of the test has not yet been established.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story kept piling up the accolades \u2013 \u201cone more advantage\u201d and then \u201canother benefit is\u2026\u201d but in the end the story was all benefits and no harms. The New York Times story, by comparison, addressed false positives.", "answer": 0}, {"article": "Broccoli has been linked to a growing list of health benefits, such as a reduced risk of cancer and osteoporosis. New research suggests consuming broccoli could also slow or reverse blood-vessel damage and atherosclerosis due to high cholesterol.\n\nThe study, in Experimental Biology and Medicine, found that a high-cholesterol diet combined with supplements containing sulforaphane, a natural compound in cruciferous vegetables such as broccoli and Brussels sprouts, significantly reduced levels of LDL, the so-called bad cholesterol,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At first glance, it\u2019s hard to imagine there are any dangers: Chemicals in broccoli are harmless, right? But as revealed by this very study\u2013that\u00a0sulforaphane has the capacity to significantly change blood lab levels\u2013these chemicals can work like medication. That means they\u00a0also may carry harms, too. In this case, specifically, it\u2019s for people taking the blood thinner Coumadin (warfarin), who must be very careful when eating broccoli and other vegetables rich in Vitamin K.", "answer": 0}, {"article": "\"What we've had available the last 16, 17 years has made a big difference,\" Richert says, \"and what we have coming onboard now, these are going to make even a larger difference.\nThe main benefit of the pills will be that they are easier to take.\nThese dangers are nothing new \u2014 the MS drug Tysabri was pulled from the market after some patients came down with rare brain infections.\nBut soon, it seems, they will have an alternative to this painful regimen: drugs that can be taken by mouth.\nThose painful welts are something he would happily do without \u2014 and the new pills could be the answer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential\u00a0 harms were listed but not quantified.\u00a0 How often do they occur?\u00a0 ", "answer": 0}, {"article": "For more information on stents, visit the U.S. National Library of Medicine.\n\"In this large-scale, practical randomized trial, the use of zotarolimus-eluting stents resulted in similar rates of major adverse cardiac events compared with sirolimus-eluting stents and in fewer major adverse cardiac events compared with paclitaxel-eluting stents at 12 months,\" the researchers concluded in their report.\nThe number of heart attacks and deaths was about the same in each group, but the rate of blood clots in the stents was significantly lower with sirolimus-eluting stents, Park's team also found.\nHowever, they said a limitation of their study is the one-year follow-up period, and noted that a longer, ongoing study pitting zotarolimus-eluting stents against sirolimus-eluting stents will provide more safety information.\n\"Similar to other comparative stent trials, the sirolimus-eluting stent seemed to come out ahead in safety and efficacy,\" said Fonarow, who is also a cardiology professor at the University of California, Los Angeles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s overlap between harms and benefits here because stents are designed to prevent harm. However, the study identifies the development of blood clots on the stent as a safety outcome (along with the numbers of heart attacks and death). While the article tells us that the rate of clots was significantly lower with one type of stent, it does not quantify the harms.", "answer": 0}, {"article": "Not so long ago, in 2000, the American Academy of Pediatrics recommended that allergenic foods be kept away from infants until they were at least a year old, and often older.\nThis is relatively new thinking.\nThat warning was especially strong for those with a family history of allergies.\nThe authors of the just-published study reviewed all of the available evidence on the topic and included 146 studies in their final analysis.\nBut, as an editorial published in the same issue of points out, in the next decade, food allergy prevalence nearly doubled in the United States.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "According to the news release, the study authors say that we need \u201ca careful assessment of the safety and acceptability of early egg and peanut introduction in different populations\u201d before rolling this out widely. What are these safety concerns? The story doesn\u2019t say.", "answer": 0}, {"article": "For the study, the researchers followed 57,872 women in B.C.\nThe study, published today in the British Medical Journal Open, found that low-income pregnant women who receive care from a midwife compared to a physician are less likely to go into early labour, to have a baby with a low birth weight, or to have a small-for-gestational age birth, meaning a fetus or infant that is smaller or less developed than normal for the number of weeks in pregnancy.\nMcRae said the findings add new evidence in support of midwifery care, and support the development of policies to ensure midwives are available and accessible, especially for low-income women.\nCompared to those who received care from an OB, low-income women receiving midwifery care had a 41 per cent reduction in odds for small-for-gestational age birth, the researchers found.\n\"Our findings show that women who are more vulnerable benefit from the care of a midwife, likely because they receive more time, counselling and education on how to care for themselves,\" said the study's lead author Daphne McRae, a post-doctoral research fellow at the UBC school of population and public health who conducted the study while she was a PhD student at the University of Saskatchewan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of midwifery care could include risks both for the health of the baby, as well as the health of the mother.\u00a0 Maternal health outcomes are not addressed in the study, and not mentioned in the release.", "answer": 2}, {"article": "According to the American Cancer Society, melanoma accounted for more than 68,000 cases of skin cancer in 2009, and 8,650 deaths.\nThe abstract was one of thousands of studies released on Thursday ahead of presentation at the American Society of Clinical Oncology (ASCO) next month in Chicago.\n\u201cThese findings may have implications for the use of ipilimumab therapy in the long-term management of advanced melanoma,\u201d the researchers reported in the abstract.\nThe study is the first to test ipilimumab in patients whose skin cancer had spread to the brain, and the findings, released in an abstract or brief summary, support its potential use in these patients, the researchers said.\nData from a second arm of the study is still being evaluated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not give any details about side effects. It is worth noting that the abstracts themselves fail to provide much details about treatment harms, which is one of the problems with basing a news story on medical meeting abstracts.", "answer": 0}, {"article": "Drugs such as ipilumumab can seem like breakthroughs to doctors because they help 15% of patients.\nAll improve survival by a few months.\nAnd none are risk-free.\nA few years ago, that would have been a very short list.\nFor the first time, however, patients such as Herry have options.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Adequate discussion of potential harms from a couple of the drugs.\u00a0 Excerpts:", "answer": 1}, {"article": "The use in spine surgery of bone-growth proteins like Medtronic Inc.\u2019s product Infuse has led to widespread nationwide increases in hospital charges ranging from 11% to 41% above conventional surgical costs, researchers found.\n\nThe researchers studied the results of a broad U.S. sample of 328,000 spine surgeries from 2002 through 2006. They report their findings this week in JAMA, the Journal of the American Medical Association.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the final paragraph, the story mentions that BMP is linked to more complications, particularly difficulty swallowing in surgeries done high on the spine.\nBut the story didn\u2019t explain how big were the potential harms.\u00a0 According to the results of the study, the use of BMP in anterior cervical fusion is associated with a 51.4% higher complication rate compared to patients who did not receive BMP (7.09% vs. 4.68%, respectively).\u00a0 However, these data were not presented in the story. ", "answer": 0}, {"article": "In an interview, Sakoda said, \"Metformin use was not associated with lung cancer risk when we looked at all patients with diabetes.\nNonsmokers who used metformin for five years or longer had a 52 percent reduction in lung cancer risk, but this finding was not statistically significant.\nThe researchers conducted this study to further clarify the association between metformin use and lung cancer risk.\nMetformin use for five or more years was associated with a 31 percent decrease in the risk for adenocarcinoma, the most common type of lung cancer diagnosed in nonsmokers, and an 82 percent increase in the risk for small-cell carcinoma, a type of lung cancer often diagnosed in smokers, but neither of these findings were statistically significant.\nMetformin use was not associated with lower lung cancer risk overall; however, the risk was 43 percent lower among diabetic patients who had never smoked, and the risk appeared to decrease with longer use.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the release about potential harms that may arise with the administration of metformin. The drug is known to produce harmful side effects in more than 10 percent of people taking it, largely affecting the stomach or bowel such as vomiting, diarrhea, and loss of appetite.", "answer": 0}, {"article": ", follow us on Twitter, Facebook, LinkedIn, and YouTube.\nWhen complications occurred, long-term shoulder functioning was not as good but even with the high complication rate, 72 percent of patients rated their satisfaction level as excellent or good.\nFurther surgery was required in six shoulders; in two cases, the RTSA procedure was considered a failure.\n\"In the absence of treatment alternatives, reverse total shoulder arthroplasty [RTSA] is a justifiable treatment for patients with a massive, irreparable rotator cuff tear before the age of 60,\" according to the report by Christian Gerber, MD, of the University of Zurich and colleagues.\nThe improvement was similar for patients with and without prior shoulder surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states, \u201cHowever, complications occurred in 39 percent of the shoulders. Further surgery was required in six shoulders; in two cases, the RTSA procedure was considered a failure.\u201d\u00a0 It adds that, \u201cWhen complications occurred, long-term shoulder functioning was not as good but even with the high complication rate, 72 percent of patients rated their satisfaction level as excellent or good.\u201d", "answer": 1}, {"article": "\u201cThere is a major cultural difference in how we deal with menopause symptoms,\u201d he mused.\nThe new study didn\u2019t find significant hormone changes in women who took soy supplements, and Wong said the compounds are probably safe for women.\n\u201cThe majority of them are showing no benefit,\u201d said William W. Wong, a nutrition researcher at Baylor College of Medicine in Houston who wasn\u2019t involved in the new work.\nThe work was supported by Frutarom Netherlands, which also donated the supplements.\nAt six months, their Kupperman scores \u2014 a measure of symptom severity that ranges from 0 to 63 \u2014 had dropped by more than 40 percent from an initial value of about 25 in the soy groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was a brief mention of harms that the National Institutes of Health list for soy supplements, but no mention of side effects experienced by women in the study.", "answer": 1}, {"article": "Lung cancer is the No.\nMetformin, an older and cheaper drug available generically, had a more powerful effect than newer drugs called thiazolidinediones, TZDs or glitazones, the researchers said.\n\u201cOur study, as well as other research, suggests an association between metformin and/or TZD use and the risk of developing lung cancer,\u201d said Dr. Peter Mazzone of the Cleveland Clinic in Ohio, who led the study.\n\u201cThis new information adds to the growing body of evidence that metformin may help prevent and inhibit the progression of lung cancer,\u201d Gutterman said.\nBut Dr. David Gutterman, president of the American College of Chest Physicians, said more research would be needed before this could be proposed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study may not have addressed the harms of these drugs during its chart review, but they do have well-known side effects, which could\u2019ve been mentioned.", "answer": 0}, {"article": "But in some people HPV leads to genital warts and cancers \u2013 notably, cervical cancer.\nGiven those drawbacks, it\u2019s not appropriate to draw too many conclusions from this study, says Dr. Diane Harper, a prominent HPV researcher at the University of Missouri \u2013 Kansas City\u2019s School of Medicine.\nThe study was not done as a randomized controlled trial, the gold standard for determining whether a drug works better than chance.\n\u201cSeveral therapeutic vaccines have shown great promise in phase 1 and then not panned out in phase 2,\u201d she noted in an e-mail.\nThe vaccine consists of three injections in the arm over three months, Kim said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states \u201cThe researchers did not observe any side effects.\u201d\u00a0 But the Philadelphia Inquirer reported: \u201cMost side effects of the vaccine were minimal and deemed unrelated to the treatment, the paper reported.\u201d", "answer": 0}, {"article": "Severe obesity is associated with serious physical and psychological conditions affecting quality of life.\n\u201cThe median BMI reduction of 10 kg/m2 with the lap band is a good result when compared to BMI reduction using the few medications available or lifestyle measures, which is around 1-3 kg/m2,\u201d says Dr Pe\u00f1a.\n\u201cLap band surgery is reversible and allows time for adolescents to mature to make a more informed decision on a permanent surgical procedure if required later on in life.\nThe research followed 21 severely obese teenagers between 14 and 18 years who had Laparoscopic Adjustable Gastric Banding (lap band surgery) in the South Australian Health Service.\nHowever there is no data available in Australian adolescents beyond 24 months post-surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study on which this release was based did reference \u201cminor complications\u201d and symptoms that required removal of the bands among some participants, the release ignores this information.", "answer": 0}, {"article": "Parkinson's is not considered an inflammatory disease, he said, adding: \"We might be missing something.\n\"It's intriguing [that the finding applied to] just ibuprofen and not aspirin or acetaminophen or other commonly prescribed medications for inflammation because it implies something more specific to ibuprofen that should be investigated,\" Tagliati said.\n\"So it narrows the focus to a subgroup of [anti-inflammatory drugs].\"\nTagliati called the study \"eye-opening.\"\nIn a six-year span, 293 were diagnosed with the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did at least mention that \"persistent use of ibuprofen can lead to gastritis, or inflammation of the stomach lining.\"", "answer": 1}, {"article": "Merck filed in February for FDA approval of Keytruda for both initial and secondary treatment of advanced urothelial cancer, the most common type of bladder cancer.\nThe Merck drug is awaiting U.S. Food and Drug Administration approval, but Tecentriq was approved by the agency last year, contingent on verification of its clinical benefit.\nMerck announced in October that the second-line bladder cancer study met its main goal and was stopped early.\nThe data, to be presented next month at a meeting of the American Society of Clinical Oncology, follow last week\u2019s announcement that rival drug Tecentriq, from Roche Holding AG, did not improve survival when used as a second-line treatment for bladder cancer in a trial.\nMerck said data from an open-label Phase 3 trial of 542 advanced bladder cancer patients showed median survival of 10.3 months for Keytruda patients and 7.4 months for patients given second-line chemotherapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only tells us that:\nSevere side effects were reported in 16.5 percent of the Keytruda patients, compared with nearly half of the chemotherapy group.\nBut what does severe mean? And how often did less severe side effects occur when patients were on Keytruda?\nAs we\u2019ve discussed in 6 tips for writing about immunotherapy, there\u2019s a tendency to underplay the harms of immunotherapy drugs.", "answer": 0}, {"article": "Air is suctioned through the side channels to emulate breathing.\nMore often than not, these studies produce mixed data that don\u2019t tell researchers much about whether it is safe and effective for humans.\nThe information is essential to reduce the risk for this side effect of oncology drugs.\n\u201cBiology is very complex.\u201d\n\nIncorporating the chips into drug testing could save millions of dollars and years of time on research.\nHe suspects that in the beginning the chips will be used to \u201ccomplement and supplement\u201d animal studies, but will eventually become routine practice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a tough one. The article does mention limitations, but doesn\u2019t specifically state that conceivably this chip technology could have unforeseen problems \u2014 that it may say everything is ok when it isn\u2019t and that could lead to harm. Given the early stage of this research, it would be prudent to include a caveat about potential for unknown or unpredictable downsides to the technology.", "answer": 0}, {"article": "The American Massage Therapy Association, the most respected name in massage therapy, is the largest non-profit, professional association serving massage therapists, massage students and massage schools.\nIndividuals should consult with a professional massage therapist to determine the best massage therapy approach for their specific needs.\nEVANSTON, Ill., Nov. 4, 2015 /PRNewswire/ -- People looking to fend off cold and flu as the winter months arrive should speak to a massage therapist about prevention strategies.\nImmediate massage benefits included reduced anxiety while the long-term impact increased serotonin values, natural killer cell numbers and lymphocytes,iii which work to strengthen the immune system and cognitive function during sickness.\nBy meeting or exceeding state training requirements, ascribing to a code of ethics and participating in continuing education, American Massage Therapy Association massage therapists are appropriate additions to any wellness regimen and create specialized approaches based on individual conditions, fitness and goals.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although massage is generally considered a \u201csafe\u201d therapy, it is still an intervention and not free from risk, particularly among those with musculoskeletal issues. Massage can cause soreness and also directly cause new injuries, exacerbate existing problems, distract patients from more appropriate care and mildly stress the body.\nSince harms were not mentioned at all in the news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "CHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\n\u201cThese results speak to a large swath of people residing in that part of the world.\n\u201cIt had an impact across a range of function, including intellectual function, executive function and fine motor function,\u201d factors that could affect a child\u2019s later academic success, Christian said.\nIron and folic acid deficiency are very common,\u201d she said.\n\u201cWhat we showed is prenatal iron and folic acid supplementation had a significant impact on the offspring\u2019s intellectual level and motor ability and ability during school age, which was a very exciting finding,\u201d she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any vitamin supplement taken in very high doses can be harmful and some acknowledgment of this should have been made here. Even citing the author or another expert about a lack of observed or known harm would have been sufficient.", "answer": 0}, {"article": "U.S. doctors do at least two stenting procedures these days for every coronary bypass operation.\nWhen doctors recommend surgery, these data suggest that that decision is a good one.\"\nBut Dr. Laura Mauri says in an accompanying editorial that the new study can't settle any debates.\nNow the biggest collection of cases so far comes out in favor of surgery on the all-important question of mortality.\nThe National Heart, Lung and Blood Institute, which funded the study with new \"stimulus\" money from the American Recovery and Reinvestment Act, is more bullish on the implications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story, along with the Associated Press we reviewed, failed to mention harms. We did appreciate, though, that NPR noted that \u201cdoctors and patients have voted with their feet in favor of the less-invasive procedure \u2014 clearing clogged arteries and propping them open with tiny scaffolds called stents.\u201d", "answer": 0}, {"article": "Dental caries (tooth decay) is caused by bacteria on the tooth surface feeding on carbohydrates, then making acids as waste.\nDental decay was low in both groups.\nDoing so can change the whole picture of caries control.\"\nPlease visit http://www.\nThose in the control group also reduced their risk to a lesser degree, simply by using over-the-counter products that also protect teeth and affect the bacteria.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms.", "answer": 0}, {"article": "And in an accompanying journal editorial, medical professors Dr. Bo Abrahamsen and Dr. Opinder Sahota wrote that due to study limitations, \"it is not possible to provide reassurance that calcium supplements given with vitamin D do not cause adverse cardiovascular events or to link them with certainty to increased cardiovascular risk.\nBut even when added to previous studies with similar findings, the new conclusions don't necessarily mark a death knell for calcium supplements, say the authors of a study released online April 19 in the BMJ.\nBut, as the current authors point out, more than half of the women in that study were already taking their own calcium supplements on top of what they had been prescribed for the trial, which may have clouded the results.\nThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women.\n\"The cautious way forward seems to be to encourage people to obtain their calcium from the diet, rather than from supplements, since food calcium has not been shown to carry this increased risk of heart disease,\" Reid added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story attempted to quantify the potential harms from calcium, but, because the numbers were presented only in relative terms, we feel readers will not be able to adequately assess for themselves whether they need to change their behavior. For example, the story says, \u201cwomen who were randomized to take calcium and vitamin D as part of the study protocol had a modest 13 to 22 percent increased risk of cardiovascular problems, particularly heart attacks.\u201d Then it says, \u201cThe case against calcium became stronger when researchers added in data from 13 other, unpublished trials involving almost 30,000 women. Now the increased risk for heart attack was 25 to 30 percent and, for a stroke, 15 to 20 percent.\u201d We\u2019re not sure why a 22 percent increased risk is considered \u201cmodest,\u201d while a 25 percent increased risk is cause for alarm. Some absolute numbers and even an explanation showing the number of women who would have to take calcium regularly in order to see one heart attack would have been good context.", "answer": 0}, {"article": "It was published in the December 2018 issue of the journal.\nThey verified that detailed quantification of the tested and retested tracer in those five patients with Alzheimer's and five older controls generated good and reproducible results.\nIn the second part of the study, researchers tested the optimal tracer, called F-18 RO948, with additional brain imaging in five patients with Alzheimer's and five older controls, with follow-up of previously seen patients to evaluate the potential progression of tau protein tangling after an average span of approximately 16 months.\nAccording to Wong, this body of work reveals that, as compared with the currently used Tau tracer, F-18 AV1451, the new tracer, F-18 RO948, does not bind randomly to other tissue, offering greater clarity into quantification of potential tau burden within the human brain.\nThese three most promising tracers were previously tested in nonhuman primates, and the results looked promising enough to test in people.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed. Are there any risks associated with injecting these molecular markers into a study participant or patient? Even if there aren\u2019t, that in itself is worth addressing. The release also doesn\u2019t address two other potential harms (which are common to most, if not all, diagnostics): the failure to identify someone who has Alzheimer\u2019s and the \u201cfalse positive\u201d misdiagnosis of people who do not have Alzheimer\u2019s. This is the difference between \u201csensitivity\u201d and \u201cspecificity.\u201d Missing someone who has Alzheimer\u2019s is problematic. And being told that one has a disease that one does not actually have can also have ramifications for future healthcare, with consequences both physical and financial.", "answer": 0}, {"article": ".\nIn the clinical study, surgeons treated patients according to the standard surgical procedure, but OCT data were collected from the margin of the tumor cavity and the margin of the removed tissue mass during surgery so that the results could be compared later.\nThe study found that the OCT device analysis identified the differences between normal and cancerous tissue with 92 percent sensitivity and 92 percent specificity.\nThey also found that the way that OCT spotted cancer in the removed tissue was closely correlated with the results from the postoperative pathology reports, which often came days later.\n\"For the first time, this study demonstrates the use of OCT for imaging tumor margins within the tumor cavity, in the patient, during surgery,\" Boppart said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did make clear that the OCT device was a light-only probe that carried no need for dyes or invasive procedures; it was \u201cswept\u201d across the tissue so that the microscopic tissue structures could be captured on video and analyzed or compared with the gold standard analyses in the path lab. But the release probably should have said whether the use of OCT added to time under anesthesia or was associated with little or no harm at all to patients.\u00a0In addition, there is the potential for harm in terms of an impact on cosmetic results if tissue is removed based on a positive reading that was found to be a false positive. One of the cases described in the study was a false positive.", "answer": 0}, {"article": "Tim Barham, the vice president of HBB, the maker of Lazy Cakes, said, \u201cWe look at the brownie as a supplement.\u201d\n\nNews reports have classified Lazy Cakes as dietary supplements, but last month, Douglas Karas, an F.D.A.\nBut she added, \u201cI don\u2019t want to go on the record saying this drug \u2018can\u2019 cause respiratory issues, that should be a \u2018may.\u2019 \u201d\n\nLazy Cakes appear harmless, even amusing, with swirly purple packaging; Kush Cakes have a tie-dye-printed wrapper.\nFor me, it\u2019s to get a good night\u2019s sleep.\u201d\n\nYet the products, intended for adults only, are being marketed as a novel way to relax in a stressed-out, wired world.\nStephanie Yao, a spokeswoman at the F.D.A., wrote in an e-mail that any item that uses melatonin \u201cas an additive may be subject to regulatory action.\u201d\n\nThat is why the makers of these new baked goods label them \u201cNot for food use.\u201d They want them to be considered dietary supplements, which do not need the F.D.A.\u2019s premarket approval and are not required to be proved safe or effective.\nAnd yet Tracy Evans, who owns a bar where musicians perform in Erie, Pa., that has sold hundreds of Lazy Cakes, said she instructs employees to tell partygoers, \u201cI highly recommend you wait to where you\u2019re going to be at the end of the night before eating.\u201d\n\nWhy?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that dessert makers \u201care marketing their products as a harmless way to promote relaxation.\u201d\nWhile harms are not quantified, it\u2019s clear from the story\u2019s discussions about regulatory questions why that\u2019s impossible to do right now. The harms mentioned are largely hypothetical in that there isn\u2019t good evidence documenting these problems.\nBut the story does a good job in painting, with broad strokes, what might go wrong if one uses these products.", "answer": 1}, {"article": "All rights reserved.\nAdditionally, the support from the medical community builds on a previously important review article about the use of peppermint oil in IBS.\nAmong the thirteen IBS options that Dr. Enck and the authors reviewed, only peppermint oil had the lowest NNT (number needed to treat) of 2-3 patients needed for one patient to benefit from the therapy.\nIn the section of the article discussing management options for IBS, Dr. Enck and the accompanying panel of researchers stated \"peppermint oil\u2026is beneficial in reducing IBS symptoms.\"\nThe publication has published a comprehensive review article exploring Irritable Bowel Syndrome (IBS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms, even though the trial of IBgard that is highlighted in the release specifically tracked adverse events including indigestion, flatulence and reflux. The article summarizing that trial knocked other brands of peppermint oil capsules for causing heartburn, nausea, anal burning and \u201cdose-dumping,\u201d which is the sudden release, rather than slow release, of the drug in the capsule.", "answer": 0}, {"article": "Steroids can cause severe weight gain, acne and the weakening of bones, among other side effects.\nMore patients on the drug had the required improvement in symptom severity.\n\u201cWe knew the drug was safe and biologically active,\u201d H. Thomas Watkins, chief executive of the company, said in an interview.\nIt also changed the measurement of success and lengthened the trial to give the drug more time to work.\nIn 2000, the company\u2019s share price soared to over $100 on anticipation that understanding the human DNA blueprint \u2014 the human genome \u2014 would lead to a cornucopia of drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not include any insight about potential harms or side effects that have been seen to date with the use of this drug.", "answer": 0}, {"article": "In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men.\nWhen compared to surrounding healthy tissues, it\u2019s hoped that contrast enhanced MRIs will reveal the shape and nature of any tumors present.\nHigher grade tumors correlate with higher restricted water volume in the cancer cells\u2019 large nuclei.\nBut many tumors do not significantly differ from surrounding healthy tissues with contrast enhanced MRI and so evade easy detection.\nGreater blood flow is often a requirement of growing cancer cells.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed. One conceivable concern is that \u201cprovid[ing] a better target for biopsies, especially for smaller tumors\u201d might lead to overdiagnosis \u2014 finding low-risk cancers that would never cause a problem. The patient is subsequently burdened with a cancer diagnosis and complication risks related to ensuing treatment/surveillance protocols.", "answer": 0}, {"article": "Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School.\n\"Proton radiotherapy is still not widely available in the U.S. or around the world, but it is increasingly recognized for its potential to reduce the side effects of treatment, particularly in the pediatric population,\" says Torunn Yock, MD, MCh, MGH Department of Radiation Oncology, lead and corresponding author of the report.\nTo investigate their hypothesis that proton therapy would reduce the incidence and severity of side effects without loss of treatment effectiveness, the researchers enrolled children and adolescents ages 3 to 21 - with an average age of around 6 \u00bd - who received proton therapy for medulloblastoma at the MGH from 2003 to 2009.\n\"At experienced centers, proton therapy has a proven track record of treatment success and safety.\"\n\"Our results indicate that proton therapy maintains excellent cure rates in pediatric medulloblastoma while reducing long-term side effects, particularly in hearing and neurocognitive function, and eliminating cardiac, pulmonary, gastrointestinal and reproductive effects,\" says Yock, who is an associate professor of Radiation Oncology at Harvard Medical School.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses some of the harms associated with the therapy and provides specific numbers\u00a0that are easy for readers to understand. It says, for example, \u201cOf 59 patients who enrolled, 12 died from their tumor during the study period and one from a traumatic brain injury. Significant hearing loss was seen in 12 percent of patients three years after treatment and in 16 percent at five years, which compares with around 25 percent reported in studies using photon radiotherapy.\u201d\nThe release didn\u2019t point out that all of the patients had additional treatments \u2014 including surgery and chemotherapy \u2014 so it\u2019s not possible to pinpoint years later where to place the blame for any hearing loss or cognitive deficits.\nWe think some of the harms from the therapy were given short shrift, but we address this in the \u201cQuality of Evidence\u201d measure.", "answer": 1}, {"article": "African-American women are more likely than white women to report hot flashes.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nThe study is the first to examine whether there are any racial differences in how well an antidepressant works in alleviating hot flashes.\nSince then, many women have been suffering through hot flashes and searching for effective alternatives.\nAn antidepressant can help alleviate hot flashes that plague many menopausal women, according to new federally funded research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the competing WebMD coverage at least mentioned the possibility that this drug could cause adverse effects, this blog post does not\u00a0acknowledge any potential downsides of treatment. We have a lot of good data on the adverse effects of antidepressants, and the story could easily have brought in\u00a0summary data from other studies, rather than relying simply on 8 week data from a relatively small number of women. Giving results from a single study, while ignoring data from hundreds of other relevant studies involving thousands of patients, is a frequent problem in reporting. See the WebMD review for a more thorough discussion of why this is important.", "answer": 0}, {"article": "In Canada, heart failure patients stay an average of almost 10 days for each hospital admission, accounting for 1.4 million hospital stays a year.\nThe CardioMEMS\u2122 HF System is designed to monitor heart failure patients whose condition is serious but who are not so ill that the technology cannot improve their outcome.\nThe first Canadian patient implanted with the heart monitor will be among 25 patients within the Ted Rogers Centre for Heart Research at the Peter Munk Cardiac Centre to be fitted with the device over the next nine months.\nThis technology is a way to directly measure how much fluid is in a patient, allowing us to intervene before they develop symptoms of congestion, before they end up in hospital.\nThis is a big game-changer.\u201d\n\nFunded by the Ted Rogers Centre for Heart Research, the device called CardioMEMS\u2122 HF System was successfully implanted by interventional cardiologists at the Peter Munk Cardiac Centre in March 2017.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No intervention is risk-free, especially ones that are invasive. On page 9 of the CardioMEMS user\u2019s manual, a slew of potential adverse effects is associated with this implantation procedure, including infection, bleeding, arrhythmias, blood clots, heart attacks, stroke and even death.\nSince the news release doesn\u2019t address harms, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "Crawford and his colleagues looked at a total of 80 patients broken into two groups.\n\"This type of osteochondral allograft transplantation has traditionally been used in younger active patients with cartilage disorders.\nHowever, seeing this type of success allows sports medicine physicians another option in older patients and serves as a predictable biologic joint preservation technique,\" said Crawford.\nSAN DIEGO, CA - Knee pain in active patients over 40 is often difficult to treat but according to researchers presenting their work today at the American Orthopaedic Society for Sports Medicine's (AOSSM) Annual Meeting in San Diego utilizing a special kind of allograft may be a step in the right direction.\nAOSSM is also a founding partner of the STOP Sports Injuries campaign to prevent overuse and traumatic injuries in kids.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed at all. No surgery is completely without risks, so this is not an acceptable oversight. For example, as of 2007, Orthopedics Today was still highlighting the fact that \u201cDisease transmission also remains a worry for surgeons using allografts.\u201d", "answer": 0}, {"article": "\u201cThat\u2019s something that we almost never see in someone who\u2019s manifested the degree of disease one needed to have in order to get into the study,\u201d Smith said.\nHigh blood sugar was also a key side effect in participants who already had diabetes, the study team notes, but adjusting diabetes medications solved that problem.\nHowever, while only 10 percent of patients who received the drug had double vision before the study, that rose to 50 percent by 24 weeks.\nMore people who received the drug had sizeable reductions in disease activity and reductions of 3 mm or more in eye bulge compared to the placebo group, the researchers note.\nThe duration of response to the autoimmune inflammatory disease, along with the quick response to initial therapy, suggests fewer infusions may be just as effective, \u201cbut future studies will sort that out,\u201d Smith said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that using the new drug brought on double vision among 50 percent of the patients by six months. Only 10 percent of the patients admitted double vision at the start of the trial.\u00a0 Also, the story states that \u201cHigh blood sugar was also a key side effect in participants who already had diabetes, the study team notes, but adjusting diabetes medications solved that problem.\u201d", "answer": 1}, {"article": "Food sources of vitamin D include milk, breakfast cereals and orange juice fortified with vitamin D, as well as some fatty fish, like salmon and mackerel.\nAlong with that evidence, recent lab research has shown that vitamin D may play an \u201cimportant role\u201d in the body\u2019s immune defenses against respiratory pathogens, Laaksi wrote in an email to Reuters Health.\nLaaksi said that larger clinical trials looking at different doses of vitamin D are still needed before the vitamin can be recommended for curbing the risk of respiratory infections.\n\u201cHowever,\u201d the researcher said, \u201cthere is a lack of clinical studies of the effect of vitamin D supplementation for preventing respiratory infections.\u201d\n\nFor the current study, Laaksi\u2019s team randomly assigned 164 male military recruits to take either 400 international units (IU) of vitamin D or inactive placebo pills every day for six months \u2014 from October to March, covering the months when people\u2019s vitamin D stores typically decline and when respiratory infections typically peak.\nThe findings, Laaksi said, offer \u201csome evidence\u201d of a benefit from vitamin D against respiratory infections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story cautions that vitamin D can cause problems including nausea, vomiting, constipation, poor appetite, weight loss and even higher blood pressure or heart rhythm abnormalities.", "answer": 1}, {"article": "\u201cIt can be the most interesting story in the world,\u201d he said.\nBut Dr. McDaniel, who does research into using plant-derived products to lengthen the life of cells, says he thinks the comparative data must be viewed with caution because the studies that yielded it are \u201cchallenging to do accurately, hard to interpret and not necessarily predictive of final products.\u201d\n\nSoon, consumers will judge whether Algenist products are a breakthrough.\nBut he cautioned that in-vitro testing does not demonstrate how a final formulation works off the shelf.\nDr. Ellen Marmur, the chief of the division of dermatologic and cosmetic surgery at Mount Sinai Medical Center in Manhattan, did say Algenist could fairly claim that alguronic acid offers protection against ultraviolet damage to cells, and that she might use the product as \u201ca nice sun protection on top of S.P.F.\nDr. Dana Sachs, an associate professor of dermatology at the University of Michigan, Ann Arbor, wrote in an e-mail after looking at Algenist\u2019s dossier that \u201cthe claims on cell regeneration and elastin synthesis are based on in vitro models, which is hard to extrapolate to in vivo, and again no statistical significance is presented, so this is a weak claim.\u201d\n\nDr. Day, who has a doctorate in biochemistry, said that statistical significance was found but not included in press materials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned in the story, which is too bad given that this product is apparently uNPRoven, both in labs and in the marketplace. Many would assume that there is no possible harm that could come from applying a natural product containing a seaweed compound. While that may indeed be true, there is no evidence to support that lack of any comments about potential harms. Since there are no data available about its use in premarket testing and the product has yet to reach the market, it would have been reasonable to point out that the potential harms of alguronic acid are unknown at the moment", "answer": 0}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nIn other words, it's not that the J-shaped spine is the ideal one \u2014 or the healthiest.\nAnd people who are thinner probably have less curvature\" \u2014 and thus a spine shaped more like J than than an S.\n\nAmericans are also much less active than people in traditional cultures, Mummaneni says.\nShe puts Gokhale's method in the same category as Pilates and yoga for back pain.\nIn fact, if you look at drawings from Leonardo da Vinci \u2014 or a Gray's Anatomy book from 1901 \u2014 the spine isn't shaped like a sharp, curvy S. It's much flatter, all the way down the back.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that an active lifestyle, and strong abdominal muscles, can reduce the risk of back pain. And there\u2019s a lot of evidence to support this. But not all exercises are created equal. Some exercises that people associate with abdominal strength may actually aggravate lower back pain. Full sit-ups can worsen back pain as can bilateral leg lengths. Also, poorly done Pilates or yoga can as well. All require some training. The same is true of a generally active life style \u2014 excessive squats, planks, core strengthening can worsen back pain. Some acknowledgement of that fact would have earned the story a Satisfactory rating here.", "answer": 0}, {"article": "So which one is right for you?\nBut according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk.\nWhile the American Cancer Society, the American College of Physicians and other gastroenterology experts recommend virtual screening every five years, the U.S. Preventive Services Task Force, a congressionally mandated but non-federal, independent group of medical experts, concluded the evidence wasn\u2019t strong enough to justify Medicare coverage of the service.\nPlus, Medicare does not currently reimburse patients for routine screening with virtual colonoscopy, but does cover evaluations with colonoscopy.\nVirtual colonoscopy is a good option for those who can\u2019t be sedated for colonoscopy, or who simply can\u2019t tolerate the scope.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that virtual colonoscopy \u201cinvolves exposure to a small amount of radiation. But according to Dr. Marc Gollub, director of CT and gastrointestinal radiology at Memorial Sloan-Kettering Cancer Center, \u201cthe radiation is much lower than a regular CT scan and has not been proven to be of any risk. It\u2019s similar to [the exposure from cosmic radiation] you might get on a long airplane flight.\u201d\nThe USPSTF states:\u00a0\u201cRadiation exposure resulting from CT colonography is reported to be 10 mSv per examination. The harms of radiation at this dose are not certain, but the linear no-threshold model predicts that 1 additional individual per 1000 would develop cancer in his or her lifetime at this level of exposure. The lifetime cumulative radiation risk from the use of CT colonography to screen for colorectal cancer should be considered in the context of the growing cumulative radiation exposure from the use of other diagnostic and screening tests that involve radiation exposure. On the other hand, improvements in CT colonography technology and practice are lowering this radiation dose.\u201d\nWe think that broader context should have been provided to readers.", "answer": 0}, {"article": "Keytruda thereby met its main goal of the study.\nSafety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients, Merck said in a release that included only summary \u201ctopline\u201d information from the results.\nPatients whose tumors had especially high levels of PD-L1 also went longer without a progression of disease than those taking docetaxel, Merck said.\nThose whose tumors expressed PD-L1, but not at high levels, did not show such a statistically significant benefit in progression-free survival.\n(Reuters) - Merck & Co\u2019s approved Keytruda lung cancer treatment provided superior overall survival to chemotherapy in a late-stage study of patients with advanced disease whose tumors produce a protein called PD-L1 associated with increased risk of the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When making decisions about health care treatment options, patients often consider three factors: cost, benefit, and quality of life (i.e., potential harms/side effects). Some patients may decide not to pursue treatment that may extend life for a short period of time if that treatment will also have a significant adverse effect on their quality of life. In short, discussion of potential harms is extremely important. The story notes only that \u201c[s]afety of Keytruda was consistent with what had been seen in previous trials among lung cancer patients.\u201d Given that potential side effects include hepatitis, hypothyroidism, and Type 1 diabetes mellitus, it would have been worth devoting an additional sentence or two to possible harms.", "answer": 0}, {"article": "'This is not the end': Using immunotherapy and a genetic glitch to give cancer patients hope\n\nNew shingles vaccine is highly effective \u2014 and in short supply\n\nResearchers use immune-cell 'army' to battle another tough cancer\nOthers said they are anxious to try an FDA-approved product.\nFDA Commissioner Scott Gottlieb said the approval was \u201ca reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies.\u201d The medication, tested in three randomized, placebo-controlled trials with more than 500 patients, was effective in reducing seizures, the FDA said.\nShlomo Shinnar, president of the American Epilepsy Society and a neurologist at Montefiore Medical Center in New York, has said the drug will be \u201ca very valuable addition\u201d to the limited options for treating severe childhood-onset epilepsy.\nThe drugmaker is testing other CBD treatments for glioblastoma and schizophrenia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The FDA release about the agency\u2019s approval lists the most serious side effects, many of which are common, including liver damage, depression, suicidal thinking, anorexia and insomnia. But the news story does not mention them.", "answer": 0}, {"article": "\u201cThat would be the quickest path to insolvency,\u201d he said.\nBut some also want Sarepta to make the drug available to more patients on a compassionate basis even before approval.\nIf eteplirsen gets to market, it would come nearly three decades after the 1986 discovery of the gene responsible for Duchenne.\nEteplirsen, which Sarepta says has shown no side effects so far, is vying with a similar drug being developed by GlaxoSmithKline to become the first medicine that works by directly countering the cause of the disease.\nEteplirsen could also be the first drug to reach the market for Sarepta since it was founded 32 years ago.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided some limited information on what is known about the potential harms, \u201cIt is also unclear how long the effects of the drug would last or if safety issues would arise with longer treatment.\u201d\u00a0 \u201cEteplirsen, which Sarepta says has shown no side effects so far,\u2026\u201d\u00a0\nThe company\u2019s press release noted: \u201cThe safety profile of eteplirsen was evaluated across all subjects through 48 weeks and there were no treatment-related adverse events, no serious adverse events, and no discontinuations.\u00a0Furthermore, no clinically significant treatment-related changes were detected on any safety laboratory parameters, including several biomarkers for renal function. \u201d We think that this information should have been included in the story, as it would have provided more meaningful details to back up the sparse comments on harms that were published.\u00a0 No, we don\u2019t expect a story to read like a journal.\u00a0 But we do draw a line between what we think is meaningful explanation to readers and what isn\u2019t.", "answer": 0}, {"article": "The Health System consists of Temple University Hospital (TUH), ranked among the \"Best Hospitals\" in the region by U.S. News & World Report; TUH-Episcopal Campus; TUH-Northeastern Campus; Fox Chase Cancer Center, an NCI-designated comprehensive cancer center; Jeanes Hospital, a community-based hospital offering medical, surgical and emergency services; Temple Transport Team, a ground and air-ambulance company; and Temple Physicians, Inc., a network of community-based specialty and primary-care physician practices.\nThe study is especially exciting because zileuton is already approved by the Food and Drug Administration for the treatment of asthma.\nThe study, published online in the journal Molecular Neurobiology, raises new hope for human patients affected by dementia.\nTheir superior performance suggested a successful reversal of memory deficiency.\nOther researchers contributing to the study include Phillip F. Giannopoulos and Jian Chiu at the Alzheimer's Center at Temple, LKSOM.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms in a mouse model do not necessarily translate to humans but we do know what the side effects profile looks like. \u00a0The harms include alteration of liver function, sleep and behavioral disorders \u2014 to name a few.", "answer": 0}, {"article": "People with poorly controlled diabetes, for example, may have breath that smells fruity due to an overproduction of chemicals called ketones; people with kidney or liver failure can have fishy breath.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nCleveland Clinic pulmonologist Peter Mazzone, MD, who is conducting lung cancer studies, says a breath test for cancer may be a reality in as little as five years if all goes well.\nDec. 5, 2012 -- A breath test similar to the one used to determine when a driver has had too much to drink shows promise as a screening tool for cancer .\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s too early to say exactly what harms might result from the use of this test clinically, but at the very least, we know that some patients would be unnecessarily flagged for\u00a0additional tests and procedures based on a false-positive test. The story should have mentioned this.", "answer": 0}, {"article": "Reiki, a therapy in which hands are placed lightly on the body or just above it, is increasingly being used to reduce cancer-related fatigue, anxiety, nausea and pain. Several studies suggest a benefit to patients, but scientists say more large, rigorous studies are needed.\n\nCancer patients\u2014due to the disease and to side effects of chemotherapy\u2014often suffer from severe mental and physical fatigue, doctors say. Anxiety, nausea and pain are also common. In recent years, many cancer centers have been offering Reiki, a form of...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the selling points of Reiki is how harmless it may be (lack of efficacy notwithstanding).\u00a0 The story could have addressed what might be the greater harm in people choosing Reiki for therapeutic benefit and forgoing other, proven treatment methods.\nWe\u2019ll again give the column the benefit of the doubt.", "answer": 1}, {"article": "\"At the end of the day, our findings might modestly over - or under-estimate the health burdens,\" he told us.\nNow, the task of estimating death or disease linked to diet is tricky.\nBut, here's the flip side: The researchers also found there's a significant risk in eating too little of certain healthy foods.\nNext \u2014 and I sympathize with all of you who love to eat these \u2014 high intake of red meat and processed meats such as bacon was linked to 8 percent of the deaths.\nIf you love foods that are associated with cardiovascular risks, you don't have to give them up entirely.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The likelihood of suffering harm from adopting any of this diet advice seems low, though concerns have been raised about the health effects of cutting sodium to very low levels. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Statins reduce cardiovascular risk and scientists believe it is because they decrease low-density lipoprotein, or LDL, the so-called bad cholesterol.\nIn many cases such big reductions were achieved even though the patients were already taking statins.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nIn the studies detailed on Sunday, both drugs reduced the bad cholesterol by about 60 percent, to about 50 milligrams per deciliter from about 120 at the start of the studies.\nWhether the results from these two small studies will be persuasive enough remains to be seen.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentioned the drugs could cause memory problems and that long-term safety must still be assessed. The story would have been stronger if it had mentioned the actual rates of memory problems found in the studies. Some mention of the side effects seen with monoclonal antibodies used for other purposes would also have been useful.", "answer": 1}, {"article": "\u2022 Swelling or thickening in part of the breast.\nAnd there are some lifestyle-related risk factors that can be controlled, such as hormone therapy after menopause, obesity, alcohol intake and physical inactivity, Evers said.\nIn some cases, women never develop any of these symptoms, Evers noted.\nTHURSDAY, Oct. 12, 2017 (HealthDay News) -- Breast cancer is the second leading cause of cancer death among women in the United States, and routine screenings remain the most reliable way to detect the disease early, a breast cancer expert says.\nThere are three tests often used to look for breast cancer, Evers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are potential and actual harms to screenings, including unnecessary biopsies and other tests, anxiety and false negatives. Again, while new technologies have reduced some of these harms, they are not zero. The story doesn\u2019t mention any.", "answer": 0}, {"article": "To test this theory, the Italian researchers compared 25 healthy infants who were randomly assigned to receive drops of Lactobacillus reuteri to 21 healthy infants randomly assigned to receive placebo drops.\nThe findings were published online today in Pediatrics.\nSome researchers question whether symptoms could be alleviated using probiotic therapy, or \"healthy\" bacteria to restore bacterial balance in the gut.\nAug. 16, 2010 -- A probiotic supplement may be an option for parents trying to soothe a colicky baby, according to a new study.\nColic affects up to 28% of infants and has no known cause or cure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Probiotics are generally regarded as safe for healthy children. Nevertheless,\u00a0the mechanism through which these bacteria work are not well understood, and there have been\u00a0reports of severe infections attributable to probiotics in\u00a0critically ill or immunocompromised patients.\u00a0We don\u2019t necessarily think the story needed to get into this level of detail about potential adverse effects,\u00a0but some comment about the general safety (or lack thereof) of this probiotic strain should have been provided", "answer": 0}, {"article": "No doubt you have heard that yogurt is teeming with bacteria--and no doubt you try not to think about that as you dig into a cup of the stuff. Yes, they're supposed to be good bacteria, ones that not only don't make you sick but actually improve your health. Still, a spoonful of critters with unlovely names like Lactobacillus reuteri, Lactobacillus rhamnosus and Bifidus regularis will never sound like a palate pleaser to even the most dedicated health nut.\n\nWhether or not you've ever developed a taste--or even a tolerance--for living things in your lunch, more are on the way. Food...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did provide potentially useful information about the kinds of people who should avoid consumption of probiotic containing foods. However, the story did not contain sufficient information about the nature of the evidence demonstrating this to be true. \u00a0Have there been any studies done comparing outcomes of people with \u2018weakened immune systems\u2019 (whatever that includes) who have and have not consumed probiotics?\nAnd while the story did mention that it is common for people who have begin to consume probiotic containing foods to experience uncomfortable bloating, it failed to report on more serious risks associated with probiotic use.", "answer": 0}, {"article": "\"No one has measured what we measured,\" says Lange of the MRI test he and Dr. Janet Lainhart from the University of Utah developed.\nPlus, the research needs to be expanded to many more study participants and tried on younger people with autism and those who are not as high-functioning as the subjects in this first trial.\nCurrently there's no biologic test for autism, so pediatricians look to see if a child is meeting certain developmental milestones as well as signs and symptoms of autism.\nStill he believes this is new study can help pinpoint the earliest markers of concern in developing brains.\nCarissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The same as with the Reuters story, CNN mentioned no harms in this story.\u00a0For those who have had the pleasure, you know how tight and confining the scanner \u201cchamber\u201d can be. Younger children frequently require deep sedation for a scan due to the tightness and to the loud banging that occurs during the scan. Although there is no radiation emitted, MRI scans are uncomfortable, loud and intimidating especially for younger children. The biggest harm, though, is the potential for false diagnoses, which should have been addressed.", "answer": 0}, {"article": "\u201cIt\u2019s one and done,\u201d he said.\nResearchers found that the severity of essential tremor reduced significantly over that time in the patients who underwent the treatment versus those who had a sham procedure.\nIn the study, published in the New England Journal of Medicine on Wednesday, 76 patients were treated with focused ultrasound, and their tremor was evaluated after the first, third, sixth, and 12th month.\nHe added that since these patients were only followed for a year, there isn\u2019t enough data available yet to determine the long-term efficacy of the treatment.\nNeurologist Dr. Bryan Ho, who is not involved in the trial, noted that tremor suppression remained sustained throughout the 12 months.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses adverse effects, and that\u2019s sufficient for a Satisfactory rating.\nWe do wish the story had quantified the harms that were measured in the study. The fourth paragraph says the procedure \u201cbrings lasting side effects in some patients\u201d and later the story quotes a physician who is not involved in the research as saying, \u201cIt\u2019s a pretty high incidence of side effects.\u201d But nowhere do exact numbers appear.\nRather than citing data from the study, the story quotes the physician as saying that \u201cover a third of patients actually experienced either gait disturbance or paresthesia,\u201d or numbness. This information isn\u2019t very useful because the story does not explain when these rates were measured. According to the study, three months after the procedure 36% of patients had gait disturbance and 38% had numbness. After 12 months, the numbers dropped, to 9 percent and 14 percent respectively.\nAlso worth mentioning is that one patient was reported to have permanent diminished sensation of the dominant thumb and index figure, which was categorized as a serious adverse event. That did not appear in the story.", "answer": 1}, {"article": "\"It was surprising, and exciting,\" Dr Belmer said.\nIt is commonly used there and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\"\nAlcohol is specifically very damaging for neurons.\n\"Other studies in mice have shown that tandospirone improves brain neurogenesis, but this is the first time it has been shown that it can totally reverse the neurogenic deficits induced by alcohol.\n\"This drug is relatively new and available only in China and Japan.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "When it comes to potential harms from using the drug, the release only offers the following:\u00a0 \u201cIt is commonly used there [in Asia] and shown to be highly effective in treating general anxiety and well tolerated with limited adverse effects.\u201d\u00a0 What are those limited effects?\u00a0 How often do they occur?\u00a0 Are they greater or lesser than the side effects of other drugs used in curbing heavy drinking?\nA caution on the the potential toxicity of the drug if taken with alcohol should have been included.", "answer": 0}, {"article": "The researchers found that women who consumed high levels of fiber (28 grams per day, on average) had a 24 percent lower risk of developing breast cancer before menopause, compared with women who ate low levels of fiber (14 grams per day, on average).\nOf course, the idea that high-fiber diets can help keep us healthy is not new.\nBut if you're skimping on fiber, the health stakes are high, especially if you're a teenage girl.\nThis new study provides some evidence of yet another potential benefit.\nA Diet High In Fiber May Help Protect Against Breast Cancer\n\nIf the advice to eat more fiber seems easy to ignore, you're not alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from incorporating additional fiber into one\u2019s diet. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "Bardwell hasn't worked since November because his condition, inherited, makes breathing so difficult.\nThe hope is that such stimulation will modulate nervous system responses, such as toning down the release of hormones that typically occur at times of stress and increasing the flow of blood.\nThe study calls for Torre to implant the system, done through small puncture holes in the lower back, in 20 patients with advanced heart failure, then conducting tests on them after one, two and three months to measure heart function.\nThe method, commonly used to treat pain, activates nerves that Methodist Hospital doctors think will improve the heart's ability to pump effectively, lowering blood pressure, reducing the amount of irregular heartbeats and stopping stress hormones from overreacting and causing cardiac damage.\nIf the experiment proves successful, it would provide an entirely different approach to heart failure, a chronic, progressive disease that affects nearly 6 million Americans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms were mentioned \u2014\u00a0unacceptable when the whole point of the study being covered is to ensure the safety of the new device.\u00a0Known complications of implanted neurostimulation devices include wound infections at the surgery site and breakdown of the device or hardware requiring reoperation. Since these devices have never been studied in advanced heart failure patients, we don\u2019t know if these issues might cause more serious problems\u00a0in these patients than they do in healthier populations where neurostimulation has been tried before.", "answer": 0}, {"article": "Children with ADHD have trouble paying attention, focusing and can be hyperactive.\n\"Measuring IgG levels in kids doesn't seem helpful,\" Ghuman said, but it does look as if the elimination diet may help some children.\nWhat's more, it didn't appear to matter if the children with challenged with a low- or high-IgG food.\n\"But, for this diet to work, you have to be very consistent with it, and you have to pay attention to nutrition.\nAnd, she added, that clinical practice shouldn't be changed based on the results of one study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither this story nor the WebMD story we reviewed mentioned that there were no adverse effects found from the study. We think that was worth mentioning given some of the understandable concerns raised by putting young children on any sort of restrictive diet.", "answer": 0}, {"article": "\u201cMost people in the world have access to a telephone,\u201d said Meltzer-Brody, who wasn\u2019t involved in the study.\nEven though the small study had several women drop out and lacked a control group of moms who received different treatment, the results are consistent with previous research that has proven peer counseling works, said Dr. Ruta Nonacs, a psychiatrist at the Center for Women\u2019s Mental Health at Massachusetts General Hospital in Boston.\n\u201cThis study, while small, suggests that peer phone counseling could be a very effective, widespread public health intervention.\u201d\nMothers who left the study said they no longer needed support, sought counseling from mental health professionals, or didn\u2019t have time for the phone calls.\n\u201cTraining peer counselors to do phone counseling is an effective, low-cost and non-stigmatizing way for new moms to get the help they need.\u201d\n\nParticularly for first-time mothers, postpartum depression can be hard to distinguish from the stress and fatigue that come with caring for a new infant around the clock, Letourneau said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention could be harmful, but the story does not address that possibility. The peer counselors might be less capable than professionals of detecting suicide risk, for example. Or, the counseling might provoke additional symptoms such as excessive anxiety.", "answer": 0}, {"article": "Anderson.\nWEDNESDAY, Sept. 29, 2010 (HealthDay News) -- Another study evaluating the value of mammograms for younger women finds that screening can lower the risk of dying from breast cancer for women in their 40s.\nLast year, the U.S. Preventive Services Task Force recommended that women in their 40s not at high risk for breast cancer could forego mammograms until they turned 50 and, even then, it said they only needed to undergo screening once every two years.\nThe benefits were greater in women aged 45 to 49, vs. those aged 40 to 44, the researchers said.\nTo further stir the pot, a Norwegian study released last week found that routine mammograms accounted for only about one-third of the decline in breast cancer death rates seen recently.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a poor job discussing any harms of screening women starting at age 40.\u00a0 We are not told if women 40-44 had more false positive and unncessary biopsies ,or unncessary breast cancer surgery or treatments\u00a0 for pre-cancerious lesions. We are also not told of the risks of additional radiation exposure on the risk future of breast cancers.\u00a0 We are not given the number needed to harm (NNH) for additional radiation exposure over 10 years of screening. ", "answer": 0}, {"article": "\"I was limping.\nResearchers at seven major universities and orthopedic surgery centers around the U.S. assigned 351 people with arthritis and meniscus tears to get either surgery or physical therapy.\nAfter six months, both groups had similar rates of functional improvement.\n\"There are patients who would like to get better in a 'fix me' approach\" and surgery may be best for them, said Elena Losina, another study leader from Brigham and Women's Hospital.\nPain scores also were similar.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only quoted a commentary in the journal that published the paper \u2013 referring to \u201cmillions of people are being exposed to potential risks.\u201d\u00a0 But the specific risks weren\u2019t qualified or quantified.\nThe paper itself reported:\n\u201cThere were no significant between-group differences in the frequencies of overall or specific adverse events. Over the 12-month period of follow-up, serious adverse events occurred in 3 participants assigned to arthroscopic partial meniscec-tomy and 2 participants assigned to physical therapy alone (including one death in each group); adverse events rated as mild or moderate in severity occurred in 15 participants in the arthroscopic-partial-meniscectomy group and 13 participants in the physical-therapy group. Total knee replacement (coded not as an adverse event but rather as an indication for discontinuation from the study) was performed in 5 participants assigned to arthroscopic partial meniscectomy and 3 participants assigned to physical therapy alone.\u201d", "answer": 0}, {"article": "Asthma has complicated Todd Anderson's life ever since he was 3 years old. Doing sports\u2014even stairs\u2014had been difficult. Cigarette smoke, pollen, disinfectants or a passing whiff of perfume could set off a severe asthma attack. \"It feels like your chest is clenching up like a fist,\" says Mr. Anderson, a 29-year-old music teacher in the New York City schools.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\n\n\nThe story does warn of risks. However, it doesn\u2019t tell readers how common they are. In fact, the researchers reported that 85 percent of patients reported at least one adverse event and that problems (including hospitalizations) occurred often enough in the first few weeks after treatment that it was only when researchers disregarded those treatment-related problems that they saw a net benefit during the first year. The researchers say their longer-term follow-up indicates patients report ongoing benefits according to some of the research measurements, but the story should have pointed out that the potential gains come only after enduring several weeks of recovery and elevated risk.\n", "answer": 0}, {"article": "The requested URL was not found on this server. That\u2019s all we know.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t give the details behind a physician\u2019s comment that \"there are relatively few downsides to trying statins\" and that statins are \u201crelatively safe.\" For the reader, who may not know much or anything about statins, what does that mean?\u00a0 What are the downsides?\u00a0 And how often do they occur? \nAlthough uncommon, statins may cause muscle soreness/damage or elevated liver enzymes.\nIn a shared decision-making environment, one would simply spell out the facts and let the reader/consumer/patient decide what \"relatively few\" and \"relatively safe\" means to them.\u00a0 ", "answer": 0}, {"article": "In a first-of-its-kind finding, a new stroke-healing gel helped regrow neurons and blood vessels in mice with stroke-damaged brains, UCLA researchers report in the May 21 issue of Nature Materials.\nThe mice with new neurons showed improved motor behavior, though the exact mechanism wasn't clear.\nThe gel was eventually absorbed by the body, leaving behind only new tissue.\nThe brain has a limited capacity for recovery after stroke and other diseases.\n\"Or the new tissue could be improving the performance of the surrounding, unharmed brain tissue.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned and are relevant.\nThe gel is a foreign substance being introduced into the brain. Did it trigger any kinds of reaction in the surrounding normal tissue? Did it cause any systemic symptoms?", "answer": 0}, {"article": "[3] Yokell et al.\nResults averaged across two adequate and well-controlled usability studies demonstrate more than 94% of users can correctly administer EVZIO without training, and 100% with training.\nEVZIO was the first naloxone product specifically designed, FDA approved and labeled for the emergency treatment of opioid overdose by individuals without medical training.\nRICHMOND, Va., March 29, 2016 /PRNewswire/ -- kal\u00e9o, a privately-held pharmaceutical company, today announced that EVZIO\u00ae (naloxone HCl injection) Auto-injectors have been reported to help save more than 1000 lives.\nEVZIO is small, easy-to-carry and easy-to-use to help patients and caregivers keep it on hand so they can take fast, confident action administering EVZIO during an opioid emergency.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release lists a number of adverse reactions that have been identified during use of naloxone hydrochloride in postoperative patients, including\u00a0hypotension, hypertension, ventricular tachycardia and fibrillation, dyspnea, pulmonary edema, and cardiac arrest.\nWhile we give the release credit for providing an extensive list of potential list of side effects, we question whether including a long laundry list of warnings under \u201cimportant safety information\u201d is sufficient to prevent accidents when untrained individuals are treating people who are suspected of opioid overdose. And yet this product is marketed for individuals without medical experience. In mentioning usability trials involving the product the release states that, on average, \u201cmore than 94% of users can correctly administer EVZIO without training, and 100% with training.\u201d We\u2019d like to know how many volunteers were involved and what is the effect of incorrectly administered Evzio.", "answer": 1}, {"article": "Cardiac hybrid imaging combines coronary computed tomography angiography (CCTA) and myocardial perfusion imaging with single photon emission tomography (SPECT) to provide information on both stenosis and perfusion.\nThe researchers hope to run a trial to show that hybrid imaging can have a positive impact on patient outcomes.\nNo additional imaging would be necessary if the results were normal.\nDr. Kaufmann said that hybrid imaging findings could help guide treatment decisions, such as whether or not a patient should have a revascularization procedure such as bypass or angioplasty.\nThe study supports CCTA use for an initial, noninvasive evaluation of patients with known or suspected stable coronary artery disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t address harms, which at a minimum involve exposure to an additional radiation-based imaging technique that could increase the risk for cancer.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story could have pointed out that because the significance of telomere length is unclear, people who take the test may either get a false sense of a security from learning they compare favorably to the general population or experience unnecessary anxiety if they get a lower-than-average result.", "answer": 0}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nBlindfolded, would you know the smell of your mom, a lover or a co-worker?\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The downsides of medical screening or diagnostic tools were left unmentioned. \u00a0This is an unfortunate lost opportunity to explain to readers that any diagnostic or screening technology, while potentially lifesaving, could potentially harm as well. What if, for example, it flags someone as sick when they\u2019re not \u2014 leading to unnecessary anxiety or treatment? And what if it detects a disease that would never cause the patient symptoms and yet the patient gets treated anyway? What if it misses someone who is sick and provides them with false reassurance?", "answer": 0}, {"article": "Serotonin imbalances have also been linked to depression.\n\u201cAnd if it\u2019s true for cancer care, then it could apply to other stressful medical conditions.\u201d\n\nBossis cautions that patients should not consume psilocybin on their own or without supervision by a physician and a trained counselor.\n\u201cIf larger clinical trials prove successful, then we could ultimately have available a safe, effective, and inexpensive medication \u2014 dispensed under strict control \u2014 to alleviate the distress that increases suicide rates among cancer patients,\u201d says Ross, also an associate professor of psychiatry at NYU School of Medicine.\nGuss says, \u201cThe randomization, placebo control, and double-blind procedures maximized the validity of the study results.\u201d\n\nOne of the key findings was that improvements in clinical evaluation scores for anxiety and depression lasted for the remainder of the study\u2019s extended monitoring period \u2014 specifically, eight months for those who took psilocybin first.\n\u201cOur results represent the strongest evidence to date of a clinical benefit from psilocybin therapy, with the potential to transform care for patients with cancer-related psychological distress,\u201d says study lead investigator Stephen Ross, MD, director of substance abuse services in the Department of Psychiatry at NYU Langone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is vague here, noting that patients \u201cexperienced no serious negative effects, such as hospitalization or more serious mental health conditions.\u201d But that doesn\u2019t mean they had no side effects. A look at the paper shows that 28 percent of patients, for example, suffered headaches or migraines and 14 percent had nausea. Did the benefits outweigh these effects? Many people might say yes. However, it\u2019s important for research institutions to describe the research \u2014 warts and all \u2014 and let people make informed decisions. If we think that\u2019s true for clinically available treatments, it should also apply to treatments in the earlier stages of testing.", "answer": 0}, {"article": "\"It's still new and it's quite different than previous genetic testing that's been available,\" says Norton.\nHe says the technology is so new that a lot of doctors have no experience with it, and consumers need to understand that.\nStudies have shown that the new fetal DNA tests do a better job, says Norton.\nSome worry that the companies' websites and marketing materials don't make the limitations clear enough.\nShe is concerned that some people might end a pregnancy without getting confirmatory testing and points to one study last year that found a small number of women did that.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cited several harms associated with the new screening tests, including the risk that some women may terminate a pregnancy based on the screening results alone without follow up diagnostic tests. It also noted that the tests can pick up minor genetic abnormalities that might previously have gone unnoticed.", "answer": 1}, {"article": "CT scans became popular because they offer a quick, relatively cheap and painless way to get 3D pictures so detailed they give an almost surgical view into the body.\nThe report estimates the percentage of cancers caused by CT scans -- currently 0.4 percent -- will increase to as much as 2 percent in a few decades because the number of scans has increased so dramatically, reports CBS News medical correspondent Dr. Jon LaPook.\nThe radiation and risk from one CT scan is low, but it carries a dose 50 to 100 times greater than a traditional X-ray, reports LaPook.\n\"There are some serious concerns about the methodology used,\" but the authors \"have brought to attention some real serious potential public health issues,\" said Dr. Arl Van Moore, head of the American College of Radiology's board of chancellors.\nBut they agree with the need to curb these tests particularly in children, who are more susceptible to radiation and more likely to develop cancer from it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article fails to flesh out the quantification of the effect under study, namely additional risk of cancers.\u00a0 While the source study reports on \"attributable risk\" of cancer and cancer-deaths due to CT scanning, it would be helpful for the viewer to know what this means in terms of numbers of cancers and risk to the individual.", "answer": 0}, {"article": "An estimated 12 million Americans suffer from food allergies, including about 2.2 million children.\nThe findings, presented on Sunday at a meeting of the American Academy of Allergy, Asthma and Immunology in Washington, suggest that a treatment for peanut allergy may be developed in two or three years, said Dr. Wesley Burks, the chief of the division of pediatric allergy and immunology at Duke University Medical Center, who helped conduct the research.\nA medically supervised daily dose of peanuts may help children with peanut allergies greatly increase their tolerance to the food, according to two new studies that raise the possibility of a cure for this potentially life-threatening condition.\nNearly half of the 150 deaths attributed to food allergies each year in the United States are caused by peanut allergies, according to Duke University.\nWhile drugs can be used to treat an allergic reaction, there are no approved treatments for food allergies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the last line, the story warns that the children in the studies, who were allergic to peanuts, were under close medical supervision and that \"parents should not try the approach at home.\"\nThis is a satisfactory warning about potential harms. But it should have appeared earlier. \u00a0 \nThe author should also have mentioned whether those in the study who \"did not tolerate\" the exposure treatment needed epinephrine or some other intervention to quell the allergic reaction. ", "answer": 1}, {"article": "What's more, \"people tended to measure the outcomes very differently,\" Matthews says.\nDublin City University's Anne Matthews, the review's lead researcher, says it was disappointing not to find more studies that were consistent in testing the same approaches.\nBut Matthews says reviewers found few high-quality studies about any treatment.\nThe studies in the review comprised more than 4,000 women who were up to 20 weeks pregnant.\nAnd there wasn't much hard data on psychological, social or economic outcomes, according to the report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that most of the studies included in the\u00a0review didn\u2019t include enough information about potential harms \u2014\u00a0\"something everyone would certainly want to know.\"\u00a0\u00a0We\u2019ll call this satisfactory, but we wish it had included at least some information about the harms that were mentioned, such as heartburn in patients taking ginger and drowsiness in patients taking anti-nausea medications.", "answer": 1}, {"article": "All the women had been successfully treated for early-stage breast cancer.\nDuring the next seven years, the cancer returned in 256 women (16.7 percent) in the special diet group and 262 women (16.9 percent) in the comparison group.\nThe government study found no benefit from a mega-veggie-and-fruit diet over the U.S. recommended serving of five fruits and vegetables a day -- more than most Americans eat.\nResearchers noted that none of the breast cancer survivors lost weight on either diet.\nHopes that a diet low in fat and chock-full of fruit and vegetables might prevent the return of breast cancer have been dashed by a seven-year experiment in more than 3,000 women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only provided the information that the two groups did not differ in terms of rates for breast cancer recurrence, not survival. The story did mention that neither of the groups lost more weight, so such a high-fiber diet is not a guarantee for weight loss.\u00a0 The story does not mention any harms of a diet high in fiber and low in fat. Possible \"side effects\" of such a diet might include bloating, gas, and diarrhea or loose stools.\u00a0 \n\u00a0\n", "answer": 0}, {"article": "The F.D.A.\nThey say that their ability to do either procedure makes them the most unbiased source of information for carotid disease patients.\nEveryone agrees that clinical evidence about the relative risks in different types of patients is only beginning to emerge.\nhas also tentatively approved a stent system from the Cordis division of Johnson & Johnson.\nBut with less than a third of the enrollment goal of 2,500 patients completed, doctors will have a long wait for esults.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "See above \u2013 the piece does not provide \nabsolute rates for harms or side effects for various treatment options.", "answer": 0}, {"article": "Paul is on Procter & Gamble's advisory board but holds no stock in the company and will not profit financially.\nChildren in all three groups got better, but those treated with the VapoRub saw the greatest improvement, and parents in this group also had improved sleep, the study found.\nTwenty of the 44 children in the vapor rub group suffered mild side effects including skin irritation and burning sensation of the eyes and nose.\nThe current study shows that Vaporub is more effective than placebo.\"\nAlthough Vicks VapoRub is often used to fight colds and congestion, there has never been proof of how well it works.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story reports that almost half of the children who were treated with VapoRub reported side effects including skin irritation or a burning sensation, while none of the children in the other groups reported any side effects.", "answer": 1}, {"article": "A female testosterone patch showed promise at boosting older women's enjoyment of sex, but concerns about the cancer risk of hormone therapies mean U.S. women won't be getting an equivalent of Viagra anytime soon.\n\nProcter & Gamble Co., the Cincinnati consumer-products giant, has worked since 1999 to secure U.S. approval for its Intrinsa patch, intended to increase sex drive and satisfaction in women after menopause.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports the potential health risks linked to the patch, primarily breast cancer.\nThe story does a nice job presenting the actual number of events (breast cancer), 3/264 in patch group and none in the placebo group, and goes on to mention that, although not statistically significant, it does support concerns about breast cancer risk. ", "answer": 1}, {"article": "Paul Delios of Saugus, Mass.\nHutcher says it's now about one in 1,000, which makes it less deadly than most major surgeries.\nA big reason the operation works is because it seems to suppress appetite.\nIt used to be that roughly one in 100 people died from this operation.\nIt's safer because of new surgical techniques which have also made it more effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment mentions some harms of the surgery, including death, depression and suicide. ", "answer": 1}, {"article": "MRI highlights angiogenesis, the formation of new blood vessels, especially those that feed cancerous tissues.\nWith the MRI screen, \"we found cancer in just over 3 percent of women [with a personal history], which was double [that found in those with a genetic or family history],\" she said.\nHowever, still more research is needed to clarify the role of MRI in this population, she said.\nBut it takes no position on MRI imaging for women who have had breast cancer, saying there is not enough evidence to recommend one way or the other.\n\"Women in the personal history group [who had MRI] were also less likely to be recalled for additional testing, and less likely to have a biopsy for a false positive finding,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story dismisses the potential harms of adding MRI scans. It paraphrases an expert as saying there is no downside to getting an MRI, \u201cexcept perhaps an increased risk of false positives and perhaps a need to pay out of pocket.\u201d As noted above, the out of pocket costs of ongoing scanning could cost a woman thousands of dollars. The researchers reported that 9 percent of the women with a history of breast cancer underwent biopsies following their MRI scans. Two out of three of those women were found to not have cancer. The story should have been more clear about this false positive rate.", "answer": 0}, {"article": ".\nIn an accompanying editorial, Omer Kucuk, MD, of the Winship Cancer Institute of Emory University, noted that the United States is the number 1 soy producer in the world and is in a great position to initiate changes in health policy encouraging soy intake.\n\"Because of this disparity, it remains unknown whether isoflavone consumption should be encouraged or avoided for breast cancer patients.\"\n\"For women with hormone receptor-negative breast cancer, soy food products may potentially have a protective effect.\n\"We now have evidence that soy foods not only prevent breast cancer but also benefit women who have breast cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does a competent job of explaining the concerns about soy\u2019s estrogenic properties and the fact that the study was designed to look at overall deaths from any cases among the patients, and not at quality of life or morbidity.\nA careful reader would be able to discern in the release that gobbling up soy supplements is not encouraged by the results of this study or the scientists who conducted it; and that there is a difference between saying something is \u201cnot detrimental\u201d in women treated with hormone therapy and that something is completely safe for all women with breast cancer.\nWe would have liked the release to include a statement noting that women with breast cancer should consult their physicians about their tumor\u2019s potential sensitivity to estrogen and to discuss dietary soy with them. This is particularly important since the release ends by quoting an editorial that encourages wide consumption of soy.", "answer": 1}, {"article": "\u201cA.A.\nA.A. and other 12-step programs \u201care not cure-alls,\u201d Dr. Kelly said, \u201cbut I would say at a minimum, they help.\u201d\n\nDr. Edward V. Nunes, a professor of clinical psychiatry at Columbia, said research had demonstrated that certain elements of A.A. were effective.\nDespite the largely negative findings, John F. Kelly, a clinical psychologist at Harvard, said he still believed that A.A. and other 12-step programs were effective.\nBut Sarah Zemore, of the Alcohol Research Group of the National Alcohol Research Center, said studies that observed the results of a treatment without setting up randomized control groups could also be informative.\nNone of the studies compared A.A. with no treatment at all, and the researchers said that made it more difficult to draw conclusions about effectiveness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of the harms of treatment, however, the story notes that A.A. and 12-step programs are not a panacea for alcohol dependence, as they do not work for everyone. The story does cite researchers in the field of addictions research and treatment who note that people often attend A.A.meetings as only one component of their treatment. ", "answer": 1}, {"article": "If your risk is lower it's harder to show a benefit.\"\nMost guidelines set forth by the major medical groups suggest starting a patient with an ACE inhibitor first, but the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) considers ACE inhibitors and ARBs to be equal.\nMost significantly, research showed a significant effect in reducing the risk of death with ACE inhibitors but not with ARBS.\nThe new analysis, published in Mayo Clinic Proceedings on Monday, involves a second look at 106 randomized trials with 254,301 patients that took place after 2000 and shows that during this time period patient outcomes on the two medications were remarkably similar.\nThe idea that ACE inhibitors are more effective than ARBs was based on comparing studies on ACE inhibitors going as far back as the 1980s and into the 1990s with newer studies on ARBs in the 2000s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does point to the greater occurrence of a dry cough as a result of taking ACE inhibitors compared to taking ARBs but a quick web search for both drug types shows a much larger list of possible side effects including dizziness, headaches, drowsiness, nausea, vomiting, diarrhea, low blood pressure, weakness,\u00a0and skin rash, as well as increased potassium levels and possible sexual dysfunction. A similar omission is present in a HealthDay story that explained the same research.\nCough is the most common side effect of ACEI that is not generally seen with ARBs. The one other one is angioedema which is more common with ACEI. Otherwise studies show that other side effects are probably similar. This isn\u2019t stated explicitly, but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nBut no cause-and-effect relationship has been established.\nAbout half of the patients undergo the procedure to control chronic throat or ear infections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms associated with the surgery. The harms, although rare, include infection and respiratory complications, and are more common in children with obstructive sleep apnea, the target population in this story.", "answer": 0}, {"article": "Medical-device makers, venture capitalists and surgeons are racing to turn a once-controversial weight-loss procedure into the next big thing in elective surgery.\n\nOnce dismissed by some surgeons as a gimmick, gastric banding -- in which a silicone band is wrapped around the upper stomach to restrict food intake -- is now the focus of a fierce competition pitting consumer-products giant Johnson & Johnson against Botox maker Allergan Inc. Venture-capital-backed outpatient centers are popping up to implant the bands. Growing...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned weight regain as well as some of the side effects that occur with the use of this device. \u00a0For a more complete discussion, it should have included information about how frequently these occur.", "answer": 1}, {"article": "The average age of patients was 19 years old.\n\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\n\u201cDeciding between a non-operative program or going forward with surgery can be a challenging decision for medical professionals treating shoulder injuries in young athletes,\u201d noted the study\u2019s lead author Tyler J. Marshall, MD, from Alabama Ortho Spine and Sports in Birmingham, AL.\n\u201cHowever, this study shows a substantial benefit for athletes undergoing surgery to prevent recurrent instability down the road.\u201d\n\nThe research data was collected between 2003 and 2013 from eight fellowship trained surgical practices, with patient ages ranging from 16 to 30 years old.\n\u201cPhysicians should counsel those with first time injuries on these benefits moving forward.\u201d\n\nThe American Orthopaedic Society for Sports Medicine (AOSSM) is a global leader in orthopaedic sports medicine education, research, communication and fellowship, and includes national and international sports medicine leaders.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not say whether there were any drawbacks associated with undergoing surgery. This quote from the lead author appears to acknowledge their existence:\u00a0\u201cWhile young athletes and parents may be wary of surgery, our study shows the advantages of this treatment approach,\u201d commented Marshall.\nBut it does not spell out what those drawbacks might be.", "answer": 0}, {"article": "Vegetable and canola oils, soybeans, flaxseed, walnuts and vegetables including spinach, kale and salad greens are also a source of omega-3 fatty acids.\nThe only people who should avoid DHA are patients on a blood thinner like Cumadin, he added.\nBoth types are thought to be beneficial.\nThe typical American diet doesn't contain enough of either.\nDHA has the added benefit of improving mood and reducing symptoms of depression, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that DHA has the potential to cause problems in people taking blood-thinning medication.", "answer": 1}, {"article": "An analysis of 106 randomized trials involving more than 250,000 patients examined the effects of newer angiotensin receptor blockers (ARBs) and older angiotensin-converting enzyme (ACE) inhibitors.\nMONDAY, Jan. 4, 2016 (HealthDay News) -- Newer blood pressure drugs are as safe and effective as older medications, new research suggests.\n\"The results of our analysis are especially important for patients, given that many ARBs are now also generic, which reduces their costs,\" he added.\nAccording to the new analysis, published online Jan. 4 in the Mayo Clinic Proceedings, the only difference between the medications is that ARBs are more easily tolerated.\nHowever, when trials were conducted at similar times, one drug was not more effective than the other, the findings showed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No specific harms are mentioned, just a reference to tolerability. A Washington Post story on the same study at least mentions the dry cough that ACE inhibitors can cause, information which would be most helpful to readers who have been prescribed these medications. Several other side effects could have and likely should have been mentioned, but we\u2019ll give the benefit of the doubt.", "answer": 0}, {"article": ".\nIn the study, pregnant women hospitalized with severe flu illness were half as likely to have been vaccinated as women hospitalized with milder illness (14 percent vs. 26 percent).\n\"Treating pregnant women who have influenza with antiviral drugs can have substantial benefit in terms of reducing length of stay in the hospital,\" said Sandra S. Chaves, MD, MSc, of the Centers for Disease Control and Prevention (CDC) and senior author of the study.\nFor expectant mothers hospitalized with flu, early treatment with the influenza antiviral drug oseltamivir may shorten their time in the hospital, especially in severe cases, suggests a new study published in The Journal of Infectious Diseases and available online.\nAmong pregnant women with severe flu illness who were treated early -- within two days of the start of symptoms -- the median length of stay was about five days shorter compared to hospitalized pregnant women with severe flu illness who were treated later (2.2 days vs. 7.8 days).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address potential harms at all and that is an important omission considering the strong disagreement over the drug\u2019s side effects and effectiveness. The Centers for Disease Control and Prevention (CDC) and the Mayo Clinic both stress that the risks associated with oseltamivir are far outweighed by the benefits of using it to treat flu during pregnancy. And studies (like this one from 2010 or this one from 2013) have found no evidence that oseltamivir hurts the pregnancy or the unborn child. However, the Cochrane Collaboration, which reviewed numerous trial data found \u201cThe use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children.\u201d\u00a0 The study itself even acknowledged that the health risk to fetuses is unknown. \u201c\u2026the study does not answer the question as to whether early treatment is associated with lower rates of important adverse outcomes such as stillbirths and maternal deaths,\u201d the study states in a section describing limitations.\nThe medical society was remiss in not acknowledging the unknown safety issues and that health experts are in disagreement over oseltamivir\u2019s safety and effectiveness.", "answer": 0}, {"article": "\u201cThere was no joy to life,\u201d she said.\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\nSo, that these results were so positive for something that\u2019s very safe is an impressive accomplishment.\u201d\n\nRecent studies have suggested that tai chi, with its slow exercises, breathing and meditation, could benefit patients with other chronic conditions, including arthritis.\nBut not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches.\nDr. Chenchen Wang, a Tufts rheumatologist who led the study, said she attributed the results to the fact that \u201cfibromyalgia is a very complex problem\u201d and \u201ctai chi has multiple components \u2014 physical, psychological, social and spiritual.\u201d\n\nThe therapy impressed Mary Petersen, 59, a retired phone company employee from Lynn, Mass., who said that before participating in the 2008 study, \u201cI couldn\u2019t walk half a mile,\u201d and it \u201churt me so much just to put my hands over my head.\u201d Sleeping was difficult, and she was overweight.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0A big point of the story is that tai chi would be a much less onerous therapy with no harmful side effects. It is difficult to imagine that twice-weekly tai chi, like any other form of moderate exercise, would be harmful, but, at a minimum, the story could have reported upon the study\u2019s adverse events registry. The journal article on which the story is based clearly discussed this. ", "answer": 0}, {"article": "The P-Cure team is committed to enabling all oncology centers and hospitals globally to establish cost-effective proton therapy services for the best possible care and cure,\u201d said Dr. Marash.\nThe P-Cure gantry-less system significantly reduces many factors associated with proton therapy including the capital cost of equipment and construction, the size of a single room center or multi-room expandable center and the time from center planning to treatment.\nBecause of the high capital costs, proton therapy is currently only available to less than one percent of patients who could potentially benefit from it.\nWith P-Cure, oncologists can develop a compact, gantry-less proton center for significantly less capital and operating costs, essentially making proton therapy more widely available and attainable.\nIn addition to the clinical benefits of P-Cure\u2019s solution, there are also significant economic advantages to treating patients in a seated position.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any harms associated with this therapy. As noted above, it makes passing and not numerically defined, reference to the potential harms of standard proton therapy, meaning radiation hitting parts of the body that don\u2019t need radiation treatment.\nThe release states indirectly who this wouldn\u2019t work for by giving the cancers that may be treated. The question of harm/benefit also depends on what the goal of the device. Is it to help patients already selected for proton beam therapy or to bring in patients who otherwise would be treated using conventional radiotherapy? Consideration of benefits and harms would differ, but neither is addressed.", "answer": 0}, {"article": "The hormone, a form of progesterone, prevents ovulation and thickens the cervical mucus, making it harder for sperm to reach and fertilize an egg.\nUnlike early IUDs no longer in use, \u201cmodern IUDs do not carry an increased risk of pelvic inflammatory disease after the first 20 days following insertion,\u201d Dr. Brooke Winner and her colleagues wrote in The New England Journal of Medicine.\nThese facts prompted a committee of the American College of Obstetricians and Gynecologists this month to urge its members to introduce women of all ages to the most effective and underused methods of reversible contraception: IUDs and hormonal implants.\nOnly about half of obstetrician-gynecologists offer the implant, the committee said, and many physicians use \u201coverly restrictive criteria\u201d when deciding whether to recommend an IUD, especially for adolescents and women who have not yet been pregnant.\nGreater LARC use can reduce birthrates among adolescents and, for women of all ages, a reliance upon abortion to prevent unwanted births, the experts wrote in the October issue of Obstetrics & Gynecology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists some of the potential side effects of long-acting implants or IUDs. These include \u201cirregular bleeding and cramping\u201d as short-term impacts. We\u2019ll give the benefit of the doubt, but we would have liked an additional comment by someone not connected to the committee report on whether there are any long-term studies underway about downstream potential impacts for women 5 or 10 years after using these. In addition, rare but potentially serious complications of copper IUDs, such as perforation (when the IUD pushes through the wall of the uterus), could have been mentioned.", "answer": 1}, {"article": "The study, conducted at the University of Texas M.D.\nPrevious research into diet and breast cancer has shown mixed results, but the authors of this study said the earlier ones were not rigorous.\nResearchers emphasized such nutrient-dense vegetables as dark, leafy greens, sweet potatoes and carrots and didn't count iceberg lettuce and french fries.\nThe findings, published in today's Journal of the American Medical Association, are a setback to the hope that better diets can prevent breast cancer recurrence.\nAnderson's department of health disparities and the study's principal investigator here.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms associated with fruit and vegetable consumption, something some might think is unnecessary.\u00a0 But, for comparison, another story by another news organization did quote the lead investigator as saying there were no harms found with eating fruits and vegetables above a certain threshhold. It could have been addressed in this story. ", "answer": 0}, {"article": "Researchers used CAR-T to treat a man with brain cancer to some success\n\nGlioblastoma is one of the deadliest cancers \u2014 an illness that responds to few treatment options, and often poorly. But a single case study that uses an experimental immunotherapy to treat these brain tumors might give oncologists a new way to approach the disease.\n\nThe therapy, called CAR-T, is controversial and has faced hurdles in clinical trials. It has shown great promise in treating blood cancers like leukemia and lymphoma \u2014 but has proven challenging in treating other forms of the disease, including solid tumors.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call, but we\u2019re leaning toward satisfactory.\nOn one hand, the STAT story\u00a0does acknowledge the downsides, so far, of CAR-T therapy, by referring to the adverse events as \u201cnotorious\u201d and providing a link for more information.\nOn the other hand, the story only mentions that severe side effects have occurred\u00a0without telling us any of\u00a0those side effects and what the side effects (if any) were for the one patient treated. Instead it says the patient\u2019s side effects were \u201cfairly innocuous\u201d and quotes a researcher early in the story saying \u201cit\u2019s amazing how safe it was.\u201d Yet, this hardly proves it\u2019s safe.\nSee our tips for\u00a0reporting accurately about the harms, side effects and risks of immunotherapy.", "answer": 1}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"Nivolumab is one of a new wave of immunotherapies that are beginning to have an impact across cancer treatment.\nPatients given chemotherapy reported feeling physically, socially and emotionally worse off, whereas those who were given nivolumab remained stable during the course of treatment.\nImportantly, fewer patients experienced serious side-effects from taking nivolumab than with conventional treatment - only 13 per cent compared with 35 per cent of patients who received chemotherapy.\nNivolumab will still have to go through approval by the European Medicines Agency and NICE before it is available for head and neck cancer patients on the NHS.\nAfter one year of the study, 36 per cent of patients treated with nivolumab were still alive compared with 17 per cent for the comparator arm.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As noted above, the release does address side effects, stating: \u201cfewer patients experienced serious side-effects from taking nivolumab than with conventional treatment \u2013 only 13 per cent compared with 35 per cent of patients who received chemotherapy.\u201d However, it doesn\u2019t explain what those \u201cserious side-effects\u201d might be. According to the website for one nivolumab drug, these side effects may include inflammation of the brain or nerve problems that lead to paralysis. Patients, families, and healthcare providers make decisions based on quality of life as well as length of life, and information like this is essential for anyone wanting to make informed decisions about treatment options. It\u2019s not enough to refer to \u201cserious side-effects,\u201d you need to explain what those side effects may include. Vague language does a disservice to the reader.", "answer": 0}, {"article": "Bernard M.Y.\nThis applied even if the patients already had low levels of low-density lipoprotein (LDL, or \"bad\") cholesterol, he noted.\nFor this reason, they noted that the incidence of severe muscle disease on 80 mg of Zocor might be an \"underestimate.\"\nThe reduction in LDL cholesterol from the higher dose ended up decreasing the risk of a major cardiac event by 6 percent, the researchers found, although the statistic in itself was not clinically significant.\nTwo died within a few weeks of developing the disorder, with one cause of death mentioning the muscle disorder as a contributing factor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story presented information about the increased incidence of myopathy and the more severe rhabdomyolysis observed with higher dosage statin use.\u00a0The story did, however, contain an error in referring to creatine kinase as an indicator of kidney damage. \u00a0It is an indicator of muscle damage.", "answer": 1}, {"article": "When diagnosed through screening, aortic aneurysms are carefully monitored for signs of enlargement, and surgical intervention often is needed to prevent rupture of the vessel.\nOf those who do get to a health facility alive, only about 50 percent survive.\nIt usually strikes without warning, killing approximately 50 percent of those who experience it before they reach a hospital.\nThe bottom line is that patients who used statins were more likely to survive during and after an elective endovascular procedure.\"\n\"Most patients with this disease are older and tend to have other health conditions such as high cholesterol.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Despite the horror show picture painted in the opening sentence, there is no explanation of the harms associated with statin therapy. Some discussion of the impact of giving statins to someone not already taking them would have added value to the release.", "answer": 0}, {"article": "Moderate-fat diet with one avocado a day lowered 'bad' cholesterol by 13.5 mg/dL\n\nThe researchers found that participants' levels of low-density lipoprotein (LDL) - referred to as the \"bad\" cholesterol - were an average of 8.3 milligrams per deciliter (mg/dL) lower after following the lower-fat diet without an avocado and 7.4 mg/dL lower after following the moderate-fat diet without an avocado, compared with their baseline average.\nOur Knowledge Center article on the health benefits of avocado reveals some of the other ways the food may be good for us, as well as the potential risks of avocado consumption.\nStill, the team believes their findings indicate that people should consider replacing saturated fatty acids in their diet with healthier fats from avocados and other sources.\nAlthough these findings demonstrate that an avocado a day alongside a moderate-fat diet has the potential to reduce bad cholesterol, the team notes that their research was a controlled feeding study.\nPrior to starting each diet, subjects ate what the researchers deem an \"average American diet,\" which was made up of 34% of calories from fat, 16% from protein, while around half of calories were from carbohydrates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that avocados are typically consumed in the U.S. as guacamole, which is often eaten with corn chips that are high in calories and sodium. We\u2019ll call that good enough for a satisfactory rating on this criterion. The story could have gone one step further, as NBC did, and note that consumers should compensate for the extra calories from avocados by reducing intake of\u00a0nutrient-poor calories. Otherwise they\u2019re likely to gain weight.", "answer": 1}, {"article": "Eat as you dare.\nAccording to Stewart, the meaning behind the numbers is clear.\nNow here\u2019s the interesting part: eating more foods thought to be less healthy \u2014 those typical of Western diets \u2014did not link to an increase in heart attacks, strokes, or deaths.\nThat said, Stewart notes his study has limitations, including a lack of strict guidelines about portion size and no measure of total calories.\n(Though diet names refer to regions, they are not precise.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because this is a story about a study of dietary habits, this is N/A.", "answer": 2}, {"article": "\"It's basically a piece of plumbing to bypass blockages,\" he said.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nDr. Bryan Becker, president of the National Kidney Foundation in the U.S., said about half of kidney patients could benefit from these vessels if further tests confirm they work.\nBut Mironov worried the vessels, which cost between $15,000 and $20,000, might be too expensive to be used widely.\nSome experts said the results suggested that doctors might one day be able to custom-produce blood vessels for patients with circulatory problems in their hearts or legs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the new approach made it \"easier and safer\" for dialysis.\u00a0 But such a statement can\u2019t be made definitively in a lead sentence of a story on such early research.\u00a0 Indeed, the story presented the picture of harms unevenly, stating that artificial vessels are \"prone to infection and inflammation,\" without explaining how often that happens.\u00a0 We don\u2019t think it helps reader comprehension to paint an existing approach with such a broad negative brush while painting the new and uNPRoven approach with such a broad positive brush. ", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.04.026.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\n\"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases,\" said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service.\nOphthalmologists at 10 sites nationwide tested the ring in a phase 2 clinical trial on patients with glaucoma or ocular hypertension.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release quotes the authors saying the device is \u201cwell-tolerated and safe\u201d with a retention rate of 89 percent at six months. It also pointed out that some patients experienced itchiness and redness, which it describes as common adverse effects for patients taking glaucoma medication, and that the ring became dislodged in 15 patients, requiring it be replaced so therapy could continue.\nWhile the release adequately covers the known risks, in a study this small it would be good to remind readers that the device has not yet been tested on a large and diverse group of patients who might have different results. We also wonder how the ring would work in practice. Would patients who have difficulty following a treatment regimen in the first place be prompt about getting to a physician\u2019s office promptly to have a ring replaced?", "answer": 1}, {"article": "Chemotherapy and other cancer therapies can wreak havoc on the taste buds and olfactory senses, depriving recipients of the intricate interplay between taste and smell that is critical to grasping flavors and enjoying foods.\n\"The prevailing symptom described by patients undergoing chemotherapy is a persistent metallic flavor or aftertaste, with or without food intake.\nThe substance is well-known as a first-line defense, aiding the body's immune response, but little is known about its ability to impact salivary proteins.\nAlthough TSA is widespread and a frequent complaint of cancer patients, until now, there have been no established therapies that reliably prevent or treat this problem.\nTheir most recent study builds on the previous body of work through the application of lactoferrin supplements in treating taste and smell abnormalities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of potential harms from lactoferrin.\nReaders might be curious about the potential for intoxication (animal studies have been inconclusive in this area) or intolerance.\nWebMD mentions:\n\u201cLactoferrin can cause diarrhea. In very high doses,\u00a0skin rash, loss of appetite,\u00a0fatigue, chills, and\u00a0constipation\u00a0have been reported.\u201d", "answer": 0}, {"article": "\"Proteins are constantly moving and changing shape,\" said Lapidus, a professor in the Department of Physics and Astronomy.\nThe medication also treats many of the symptoms associated with the disease such as tremors and poor muscle control.\nIn a proof-of-concept study, published in the journal Neurobiology of Disease, the drug nortriptyline, which has been used to treat depression and nerve pain, stopped the growth of abnormal proteins that can build up in the brain and lead to the development of the disease.\nThis type of therapy increases levels of dopamine, a natural chemical in the body that sends signals to other nerve cells and can significantly decrease in cases of Parkinson's.\nCollier is already looking for funding for the next phase of his research and hopes to lead a human clinical trial using the drug in the future.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The drug nortriptyline has side effects. These include nausea, rare allergic reactions and liver toxicity in some patients. The release should have made some reference to potential harms, even if these are not well-known for this new therapy yet.", "answer": 0}, {"article": "This was unheard of.\nEven that single dose of chemotherapy can be debilitating and toxic for some patients.\nIf the tumor did not respond after that first dose, patients would likely fail on the chemotherapy and would do better going straight to surgery.\nWolf hopes future research will reveal a way to tailor treatment without the need for the induction chemotherapy.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states: \u201cEven that single [initial] dose of chemotherapy can be debilitating and toxic for some patients.\u201d That\u2019s enough to earn it a marginal satisfactory mark here. The release would have been better if it had noted that radiation, surgery and chemotherapy all carry serious side effect risks. ", "answer": 1}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nThis amount of zinc is equivalent to what biofortified crops like zinc rice and zinc wheat can add to the diet of vulnerable, nutrient deficient populations.\nThis was a novel approach, different from the commonly used method of looking at zinc in the blood or using stunting and morbidity for assessing zinc status.\nOakland, CA (January 3, 2017) - A new study by researchers from the UCSF Benioff Children's Hospital Oakland Research Institute (CHORI) shows that a modest 4 milligrams of extra zinc a day in the diet can have a profound, positive impact on cellular health that helps fight infections and diseases.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We wish the news release mentioned that too much zinc is also harmful. According to the National Institutes of Health, increased zinc intake could lead to nausea, vomiting, loss of appetite, stomach cramps, diarrhea and headaches. When people take too much zinc for a long time, they sometimes have problems such as low copper levels, lower immunity and low levels of HDL cholesterol \u2014 sometimes referred to as the \u201cgood\u201d cholesterol.\nWhile this study was about food fortified with zinc, the news release was vague about how people should acquire their zinc, and this confusion could encourage people to reach for a bottle of zinc supplements.\nFor this reason, we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "To find out more about mercury in seafood, go to the Got Mercury?\nFor people who want to safely eat more seafood, the magazine recommended shrimp, scallops, sardines, salmon, oysters, squid and tilapia as the lowest-mercury seafood.\n\u201cSo why would the proposed 2015 dietary guidelines recommend that pregnant women eat more of it?\u201d\n\nBut Dr. Steve Abrams, a panel member involved in the seafood recommendations and medical director of the Neonatal Nutrition Program at Baylor College of Medicine, said that while women need to be aware of the types of fish they are eating, the evidence is strong that fish consumption by mothers is good for the brains of their babies.\nThe point is that you should have a variety of types of seafood and not limit yourself to one type, and variety includes canned tuna.\u201d\n\nAlice Lichtenstein, senior scientist and director of the Cardiovascular Nutrition Laboratory at Tufts University said the panel hasn\u2019t suggested that pregnant women eat more tuna.\nIn the report, the panel argues that albacore tuna is a \u201cspecial case.\u201d They noted that even when women ate double the recommended weekly amount of tuna, the benefits far outweighed the risks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does discuss the aforementioned 2005 study, which found that a baby\u2019s score on visual recognition memory tests was affected by the amount of mercury in the mother during pregnancy, so we\u2019ll give it a pass. However, the story would have been better if it had \u2014 even briefly \u2014 addressed the full suite of possible health risks associated with mercury exposure during pregnancy. Also, the story discusses the findings of the 2005 study by referring to mercury measured in parts per million, but discusses mercury levels in tuna in terms of micrograms per ounce. It would have been great if the story had used the same units of measurement in both cases, so that readers could understand the significance of the 2005 study\u2019s findings in regard to levels of mercury actually found in tuna. (A back-of-the-envelope calculation finds that if six ounces of tuna contains 60 micrograms of mercury, the mercury is present at a level of about 0.35 parts per million. But the story could have cited an expert.)\nIn addition, while the story does briefly discuss the advantages of eating fish, it does not really address the potential harms of not getting adequate amounts of omega-3 fatty acids or other nutrients found in tuna and other fish.", "answer": 1}, {"article": "But in either case, \"Something is better than nothing,\" Sayre said.\nIn a major change, the American Heart Association said Monday that hands-only CPR - rapid, deep presses on the victim's chest until help arrives - works just as well as standard CPR for sudden cardiac arrest in adults.\nSayre said the association took the unusual step of making the changes now - the next update wasn't due until 2010 - because three studies last year showed hands-only was as good as traditional CPR.\nBut less than a third of victims get this essential help.\nDr. Gordon Ewy, who's been pushing for hands-only CPR for 15 years, said he was \"dancing in the streets\" over the heart association's change even though he doesn't think it goes far enough.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The American Heart Assocation recommendations and the Circulation report provide contraindications for compression-only CPR, which the segment properly notes.\nThe report and recommendations cite no other risks of compression-only CPR. The published study cites the possibility that some unidentified subgroup of patients may benefit from traditional CPR, but says no research has demonstrated this.\nRib fractures are a potential harm, and the story could have mentioned this. Nonetheless, we\u2019ll give the story the benefit of the doubt on this criterion. \u00a0 ", "answer": 1}, {"article": "The decrease we saw was larger than is seen with the currently used medications,\" Lanctot said.\nTUESDAY, July 24, 2018 (HealthDay News) -- The active ingredient in pot that gets you high can calm agitation in people with advanced Alzheimer's disease, a small new study suggests.\nMarinol is now being tested for its usefulness in treating Alzheimer's symptoms, Lanctot said.\nPeople interested in trying it should reach out to one of the big clinical trials; Johns Hopkins is one of the centers testing Marinol.\n\"It's a milder form of TCH\" compared to whole-leaf marijuana, Lanctot said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A major strength of this news release is that it favors cautious, rather than hyped language.\nIt\u2019s clearly stated:\nAbout 45 percent of patients experienced sedation with nabilone, compared with 16 percent for placebo.\nWe very much appreciated how the story also anticipated that some readers might take the study findings as justification for self medicating with marijuana, and why that might be risky.", "answer": 1}, {"article": "Active older people resemble much younger people physiologically, according to a new study of the effects of exercise on aging.\nThe volunteers were all serious recreational riders but not competitive athletes.\nAs it turned out, the cyclists did not show their age.\nBut even in advance of those results, said Dr. Harridge, himself almost 50 and an avid cyclist, this study shows that \u201cbeing physically active makes your body function on the inside more like a young person\u2019s.\u201d\nMany older people require at least 7 seconds to complete the task, with those requiring 9 or 10 seconds considered to be on the cusp of frailty, Dr. Harridge said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include any comment about risks of injury or harms that might result from an active lifestyle riding miles on a bicycle.", "answer": 0}, {"article": "\u201cIt\u2019s a huge advancement in terms of expanding the types of medications we have to treat depression,\u201d Dr. Papakostas said.\nDr. Nelson, who was not involved in the Harvard study, said the results need to be replicated in a larger study, and that more information is needed on dosing, side effects and long-term treatment with SAMe, among other things.\n\u201cIt provides clues to new treatments, and it provides clues to understanding what causes depression as well as what goes on biochemically when people get better from depression.\u201d\n\nThe researchers studied the use of SAMe or a placebo in 73 adults with depression who were not responding to prescription antidepressant treatment.\nIn his editorial, Dr. Nelson notes that SAMe is typically not covered by insurance companies, and that although the cost is relatively low, it is still more than the drug co-payments required by most health plans.\nAfter six weeks of treatment, 36 percent of the patients taking a combination of SAMe and an antidepressant showed improvement, compared to just 18 percent of those taking the antidepressant and placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It only tells us that long-term safety in this setting is unknown. Since the study\u2019s benefits were presented, safety results should\u2019ve been mentioned too.\u00a0The study itself states that there were no serious adverse events, the SAMe and placebo groups had similar rates of discontinuation due to intolerance, and the SAMe group had a statistically significantly greater increase in blood pressure when lying down, an effect which \u201cif confirmed in future studies, may be of clinical relevance.\u201d\u00a0\nAt least, it could\u2019ve discussed if there are potential harms associated with SAMe in general. The editorial states that SAMe, like most antidepressants, carries a warning that it may induce mania in patients with bipolar disorder. This study was too short and too small to detect adverse events that emerge from longer-term use. ", "answer": 0}, {"article": "City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases.\nThe team of researchers chose to focus on low-dose \"baby\" aspirin, because not only is it inexpensive and readily available as potential means of prevention, but because there are already a lot of people already taking it for prevention of other diseases such as heart disease and even colon cancer.\nNow that we have some data separating low-dose from higher-dose aspirin, more detailed research can be undertaken to understand the full value of low-dose aspirin for breast cancer prevention,\" said Clarke.\"\nSuch regular use of low-dose aspirin reduced the risk by 20 percent of estrogen or progesterone receptor positive, HER2 negative breast cancer, which is the most common breast cancer subtype.\nBernstein added, \"Aspirin also reduces inflammation, which may be another mechanism by which aspirin taken regularly can lower risk of breast cancer developing or recurring.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms at all \u2014 and regular use of low-dose aspirin isn\u2019t for everyone. As the Mayo Clinic notes, people with some medical conditions are at greater risk of complications associated with daily aspirin therapy.\nIt\u2019s well known that daily aspirin use can cause serious gastrointestinal bleeding in some people, which is why experts recommend a careful risk-benefit calculation even where benefits are more conclusively established \u2014 as in the prevention of heart disease. It\u2019s irresponsible not to mention those risks in the context of a speculative benefit such as breast cancer prevention.  ", "answer": 0}, {"article": "Psoriasis affects about 5 million Americans, according to the U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).\nHe said that in an earlier trial of briakinumab, some unexplained major adverse cardiac events occurred.\nAt the time, Abbott withdrew its application for approval from the U.S. Food and Drug Administration pending further research.\n\"Cancer risk is extremely hard to define, and this study was not powered to detect any difference in the risk of developing a malignancy,\" said Bebo.\nFor people living with psoriasis, Bebo said the message from this study is that \"dramatic progress has been made from where we were just five years ago.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the competing WebMD story, this story quantified the serious infections and explained the two cancer cases seen in the briakinumab group.\u00a0 It also explained that an earlier trial of the drug showed \u201csome unexplained major adverse cardiac events.\u201d\u00a0 This was a more complete explanation than what WebMD provided.", "answer": 1}, {"article": "\"But we are optimistic that this new DNA Zika is a viable platform,\" Fauci said.\nThis kind of vaccine is much safer than ones that depend on live virus particles to foster immunity.\nBoth of these vaccines depend on new technology in which scientists learn the exact DNA of proteins on the surface of the virus and then create copies to be put in a vaccine.\nThree experimental vaccines being developed by researchers at Harvard\u2019s Beth Israel Hospital and the Walter Reed Army Institute of Research had already shown promise in mice \u2014 but monkeys are a much better model of how the medicines will work in humans.\nZika virus is most dangerous to pregnant women, because it can cause severe birth defects in babies if they are infected in the womb.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news story notes that the killed-virus vaccine is safer than another line of vaccines under development,\u00a0but it does not address the presence or absence of any side effects or potential harms/shortcomings of the new experimental vaccine if and when this vaccine is tested in humans. One extremely important safety concern, for example, will be how it affects pregnant women and fetuses.", "answer": 0}, {"article": "\"My wife's family is from southern Illinois, too, so it's home,\" Reavill says.\nBut because it's self-contained, the catheter theoretically should provide little margin for contamination that can lead to infection.\nA venous heart catheter inserted through the neck, the traditional approach, requires painstaking preparation of the insertion area and a \"pseudo-operative field,\" says Dr. Andrew Dennis, attending surgeon at Stroger Hospital's trauma and burn units and a clinical researcher.\nDennis adds that the catheter could prove useful in patients with sepsis, or blood poisoning, which strikes about 750,000 Americans every year.\nIt reduces risks to an \"absolute minimum\" by moving the catheter insertion to the arm, the judges said, replacing a complex wire-guided procedure through the neck, which is typically used to monitor the heart during a hospital stay for very ill patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms in the story. Placing a catheter into the central circulation and measuring pressure is not without the potential for harm.\u00a0 Although the risk of a catastrophic rare neck artery puncture may be avoided with the use of the arm approach, the risks of misplacement and infection may not be reduced.", "answer": 0}, {"article": "When Marin Mejia was pregnant with her son Owen, one such blood test that picks up DNA from mother and baby came back showing abnormal results.\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\nThe findings are published in the Journal of the American Medical Association.\nBut doctors told Mejia they needed to investigate what caused the irregular finding.\nMore testing showed she had anal cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the WSJ article, there was not even a hint that widespread use of these tests might pose harms as well as benefits, as well as higher costs and ethical dilemmas.", "answer": 0}, {"article": "\"But at the same time it's something we'll continue to look at, and hopefully confirm absence of risk.\"\nThe decision means that pediatricians are likely to recommend three doses of the oral vaccine for nearly every child at age 2 months, 4 months and 6 months, beginning almost immediately.\nThat test ruled out a safety problem similar to the one that felled RotaShield, an earlier rotavirus vaccine developed by Wyeth, a drugmaker in Madison, N.J.\nThe vaccine won approval from the Food and Drug Administration on Feb. 3, and some doctors have received supplies of it.\nMerck is selling the vaccine under the brand name RotaTeq.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author states that this vaccine appears to be safer than the previous one, however there is no evidence provided to support this claim. Although not statistically significant, there were more cases of intusussecption with the vaccine in the trials.", "answer": 0}, {"article": "Genetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\n\u201cAlthough these are early results, it appears that (prostate cancer) screening is reasonably accurate at predicting potentially aggressive prostate cancer among men at higher risk of the disease due to a genetic predisposition,\u201d said Ros Eeles, who led a research team from Britain\u2019s Institute of Cancer Research (ICR) and Royal Marsden hospital.\nEeles said the findings added to the increasing evidence that BRCA gene variation carriers develop more aggressive disease and supported the idea that men with genetic risks should be routinely screened for prostate cancer.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions several important potential drawbacks of PSA screening and correctly points out that many European countries do not routinely screen for prostate cancer. It also includes some important context, noting\u00a0\"a study in the United States last year found that routine prostate cancer screening had resulted in more than a million being diagnosed with tumors who might otherwise have suffered no ill effects from them.\"", "answer": 1}, {"article": "\"It should be relatively easy, as it seems that all that is needed is a year of treatment to see the effect,\" he said.\nCommenting on the study, Eric Jacobs, Strategic Director of Pharmacoepidemiology at the American Cancer Society, said that \"the lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing.\"\nThe findings in this study show that bisphosphonates are associated with a reduced risk of developing colorectal cancer, but they cannot confirm a causal effect -- that is, the study doesn't prove that the use of bisphosphonates is responsible for the lower risk of colorectal cancer.\n\"The adverse effects profile is of major importance if bisphosphonates are going to be recommended for cancer prevention in healthy people,\" the study authors cautioned.\nBisphosphonates used for osteoporosis have also been linked to a rare fracture of the thigh, according to the U.S. Food and Drug Administration.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give this story and the Reuters Health story credit for at least mentioning some of the risks of taking bisphosphonates. \u201cThe researchers noted, however, that the risks of using bisphosphonates include the possibility, in rare cases, of osteonecrosis of the jaw (destruction of the jawbone or jaw tissue). Bisphosphonates used for osteoporosis have also been linked to a rare fracture of the thigh, according to the U.S. Food and Drug Administration.\u201d But neither story quantified the harms in any way. This story also failed to point out, as the Reuters Health story did, that \u201cearlier study from the UK had found no link between bisphosphonate and colon cancer. Indeed, it found a higher risk of throat cancer in patients on the medication.\u201d\n", "answer": 0}, {"article": "Decongestants such as Sudafed work by shrinking swollen blood vessels in the nose.\nHere's what some top allergists say you need to know about these non-prescription options.\nOver-the-counter treatments should not take the place of professional care \u2014 especially if you have never been formally diagnosed with allergies, if you have additional medical problems or if your symptoms persist or worsen, Eghrari-Sabet and Sublett say.\nThe various sprays have never been studied head to head, so it's impossible to say whether they vary in effectiveness, she says.\nBut that does not mean they work for everyone, says James Sublett, a Louisville allergist and president of the allergy group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story goes into the side effects of steroid nasal sprays, antihistamines and decongestants. Although none of these harms are quantified, we\u2019ll give the story the benefit of the doubt.\nThe line that caught our attention was: \u201cLabels caution that some children using the sprays may experience slower growth.\u201d What kind of slower growth (mentally vs. physically)? How many children encountered this side effect? And is it worth the risk to ever use a steroid nasal spray? A few figures here would have been helpful to put this in perspective, because \u201cslower growth\u201d sounds like one of the more serious harms that someone could experience.", "answer": 1}, {"article": "Francisco Ponce, MD, Director of the Barrow Center for Neuromodulation, believes there are potential applications for Alzheimer's disease - the most common form of dementia - as well.\nWhile the study was relatively small, we believe the data suggest that DBS surgery targeting the fornix can be performed safely in this patient population.\n\"The first phase of this study was designed to evaluate the 90-day postoperative safety of this particular surgical method.\nAdverse effects such as headache and infection occurred in 11.9% (5 of 42) of the patients in this study, consistent with rates reported in other DBS trials.\nOverall, there were no programming-related adverse effects, unanticipated adverse device effects, reported neurological deficits or instances of mortality in the study population.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release only reports the mild adverse effects, including headache and infection, which occurred in 11.9 percent or 5 out of 42 patients. It was a glaring omission not to report serious side effects that required some of the patients to undergo corrective surgery following the procedure. According to the published study:\n\u201cTwenty-six (61.9%) patients experienced 64 AEs related to the study procedure, of which 7 were serious AEs experienced by 5 patients (11.9%). Four (9.5%) patients required return to surgery: 2 patients for explantation due to infection, 1 patient for lead repositioning, and 1 patient for chronic subdural hematoma.\u201d", "answer": 0}, {"article": "\u201cModels are models,\u201d Lin said.\nThis is a screening test that saves lives.\u201d\n\nThose gains come at some cost to health, though: For every life saved, she estimated, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them.\nIf the new analysis is correct, one of the influential PSA studies, called PLCO, reduced deaths from prostate cancer by 27 percent to 32 percent, not the zero percent that PLCO researchers themselves found.\nThe finding that assigned-to-screening men were no more likely to avoid death from prostate cancer might therefore have been because their screening behavior wasn\u2019t different enough from the \u201cunscreened\u201d (but in fact partly screened) men\u2019s, not because PSA screening doesn\u2019t save lives.\nAn analysis of two influential studies of prostate cancer screening concludes that the much-debated test \u201csignificantly\u201d reduces deaths from the disease, suggesting that current recommendations against routine PSA screening might be steering men away from a lifesaving procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drawing from information produced by the USPSTF, the article concluded that the gains in prostate cancer detection \u201ccome at some cost to health, though: For every life saved, five men will be told they have cancer when in fact their abnormal cells would never grow, spread, or harm them. In\u00a0other estimates, such \u201coverdiagnoses\u201d outnumber lives saved by 50-to-1.\u201d\nThe one harm that is often overlooked in widely-promoted screening programs is the psychological harm that perfectly healthy people may experience when they have had a \u201ccancer scare,\u201d and that even though their life is unlikely to be saved, the worry, anxiety, depression and angst do exact a substantial life-altering toll that goes unmeasured.", "answer": 1}, {"article": "All rights reserved.\nThe study hints at the potential for widespread health benefits from an upcoming nationwide ban, the authors and other experts say.\nDr. Mark Creager, former American Heart Association president, said the results echo previous studies \u201cand are consistent with the thinking of most scientists\u201d on potential benefits of these bans.\nThe results translate to 43 fewer heart attacks and strokes per 100,000 people, said lead author Dr. Eric Brandt, a Yale University cardiology fellow.\n\u201cPolicies such as these when adapted on a nationwide level will be good for our entire population,\u201d said Creager, director of Dartmouth-Hitchcock Medical Center\u2019s heart center in Lebanon, New Hampshire.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of harm/side effects does not seem relevant here.\nHowever, we did want to note: When trans fats were first introduced, they were supposed to be a healthy alternative to tropical oils with lots of saturated fat. Now that they are being removed, it\u2019s worth discussing what they will be replaced with and whether that change could have negative health consequences, too.", "answer": 2}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nRydapt was also approved today for adults with certain types of rare blood disorders (aggressive systemic mastocytosis, systemic mastocytosis with associated hematological neoplasm or mast cell leukemia).\nThe safety and efficacy of Rydapt for patients with AML were studied in a randomized trial of 717 patients who had not been treated previously for AML.\nRydapt should not be used in patients with hypersensitivity to midostaurin or other ingredients in Rydapt.\nIn addition, patients who received Rydapt in combination with chemotherapy in the trial went longer (median 8.2 months) without certain complications (failure to achieve complete remission within 60 days of starting treatment, progression of leukemia or death) than patients who received chemotherapy alone (median three months).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release effectively reports possible side effects experienced by AML patients receiving Rydapt, including \u201clow levels of white blood cells with fever (febrile neutropenia), nausea, inflammation of the mucous membranes (mucositis), vomiting, headache, spots on the skin due to bleeding (petechiae), musculoskeletal pain, nosebleeds (epistaxis), device-related infection, high blood sugar (hyperglycemia) and upper respiratory tract infection.\u201d\u00a0 It also warns women who are pregnant or breastfeeding to avoid taking Rydapt.\u00a0 It also points out that the FDA approved the use of Rydapt for other patients with \u201ccertain types of rare blood disorders\u201d and provides a list of possible side effects they might experience.", "answer": 1}, {"article": "\u201cThe length of statin use, both greater than six months and greater than five years of use was associated with reduction in colorectal cancer risk.\u201d\n\nThe group of statins that showed the greatest effect in reducing risk are classified as lipophilic: atorvastatin (Lipitor), fluvastatin (Lescol), lovastatin (Altocor, Altoprev, Mevacor), pitavastatin (Livalo), and simvastatin (Zocor),\n\nColorectal cancer is the third most common type of cancer in the U.S.; 102,900 new cases of colon cancer are diagnosed in men and women every year, and about 39,670 new cases of rectal cancer are diagnosed annually.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no mention of potential harms associated with the use of statin medication.\u00a0 That\u2019s a significant omission.\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070723/23healytip.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story was about a possible harm (increased cancer incidence) that the statin medications may result in.\u00a0 ", "answer": 1}, {"article": "\u201cThey look like teenager breasts.\u201d\nBut a baseline mammogram for a woman considering breast augmentation (or reduction) is a must, said Dr. Emily F. Conant, a radiology professor and the chief of breast imaging at the Medical Center.\nBut Dr. Stephen F. Sener, a professor of surgery at the Keck School of Medicine at the , wrote in an e-mail message: \u201cI\u2019ve seen enough injections of fat after mastectomies to tell you that fat necrosis is a real problem.\u201d It can result in a \u201cpalpable mass\u201d that needs to be biopsied to establish malignancy or infection, wrote Dr. Sener, the former president of the .\nThe company hopes that its Celution 800 system can \u201cdouble the cells that act as fertilizer, so it\u2019s possible to achieve a more predictable graft,\u201d said Tom Baker, the director of investor relations.\nLast month, new guidelines from the recommended that most women should start mammograms at 50, instead of 40, to try to reduce the number of tests, including biopsies for false positives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe body of the story details several potential complications including long-term fat loss that undoes any initial benefits, as well as the appearance of cysts, masses, nodules and scarring. The story also notes concern about fat grafts potentially interfering with breast cancer screening.\nHowever, the story should have at least referred to such problems higher in the story. It also neglected to mention reports of at least one death, as well as strokes and serious infections including septic shock, that were noted in the task force report.\n\n", "answer": 1}, {"article": "Barua is with the Kansas City (Mo.)\nWhile the new study results do seem to advocate for testosterone replacement therapy, Barua stresses the need for \"appropriate screening, selection, dosing, and follow-up of patients to maximize the benefit of testosterone therapy.\"\nDr. Rajat Barua, the paper's corresponding author, says the study is also noteworthy because of its finding that administering the right dose is critical: Treating \"low T\" but not restoring levels to normal doesn't appear to impart much benefit, at least in terms of cardiovascular risk.\nFor example, the new VA study excluded men with a history of heart attacks or strokes, although it did include those with existing heart disease.\n\"Patients who failed to achieve the therapeutic range after testosterone replacement therapy did not see a reduction in [heart attack] or stroke and had significantly less benefit on mortality.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions an FDA advisory about possible increased risk of heart attack and stroke with testosterone therapy. We\u2019ll call this acknowledgment of possible risks good enough for a Satisfactory rating, although many other possible risks exist including exacerbating sleep apnea, skin reactions, and promoting noncancerous growths of the prostate. One of the researchers is quoted as urging individuals to get appropriate screening from a health professional before considering\u00a0testosterone therapy, but the reader does not learn why this is important. Bottom line:\u00a0we know the overall mortality was lower in the group that was treated to a normal testosterone level, so serious adverse events , within the time frame of the study, do not appear to outweigh benefits. However, prostate cancer, for instance, is slow growing and might not have manifested within the time frame studied.", "answer": 1}, {"article": "How miserable is combing a child's hair, lock by lock, to pick off head lice? So miserable that some parents are buying $30 shampoos and other washes that promise to ward off the tiny, grayish bugs.\n\nThe parents get peace of mind that they are doing something. Conveniently for the product makers, there's no way to tell if they kept lice at bay, or if children wouldn't have gotten lice anyway. Makers say sales are growing fast.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "With its clear questioning of the evidence for lice control products, the story infers the harm of spending money on unproven products.", "answer": 1}, {"article": "Publicity in recent years about emotional, cognitive, and memory problems in aging football and hockey players who suffered multiple concussions during their careers has raised the anxiety level around the topic. A lawsuit by thousands of NFL players who claim the league did not keep them well enough informed about the long-term risks of concussion - dementia is one of them - is based in Philadelphia and has raised even higher the profile of what doctors call mild traumatic brain injury.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story illustrates how hard it can be for a parent to enforce cognitive rest.", "answer": 1}, {"article": "\u201cAfter all, the placebo is a well-known clinical phenomenon, and some of my patients report surprisingly favorable outcomes.\u201d\nThe improvements were small, and the studies were of varying quality, but preliminary evidence suggests that acupuncture, Chinese herbal medicine, Ayurvedic herbal medicine and a Korean topical cream may all have desirable effects, researchers conclude in the journal Sexual Medicine.\n\u201cTo our knowledge, this is the first systematic review to assess complementary and alternative medicine for premature ejaculation.\u201d\n\nAccording to the International Society for Sexual Medicine, premature ejaculation can be a lifelong problem, and this primary form of the problem is usually defined as ejaculation happening within one minute of initiating vaginal intercourse every time a man has ever had sex.\nSome studies, but not all, discussed side effects such as gastrointestinal discomfort, dizziness, mild pain and decreased libido.\nTogether, the two acupuncture studies found that the treatment slightly increased intravaginal ejaculatory latency time (IELT) by about half a minute compared to placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report helpfully mentioned that \u201csome studies, but not all, discussed side effects such as gastrointestinal discomfort, dizziness, mild pain and decreased libido. When they were reported, the adverse effects were generally mild.\u201d\nIt would have been useful to note that the off-label use of SSRIs also involves some rate of adverse effects and that some foreign-sourced herbal treatments have been found to be adulterated with compounds from prescription drugs, and that quality control of herbal treatments is sometimes a problem.", "answer": 1}, {"article": "\u2022 Khin NA, et.al.\nHowever, the study narrowly missed statistical significance for its primary efficacy endpoint.\nEsketamine nasal spray has an acceptable safety and tolerability profile, based on the adverse event data from both Phase 3 studies.\nData from other Phase 3 studies will be presented later in 2018.\nA bittering agent was added to placebo to simulate the taste of esketamine, to help mask the treatment assignment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release discusses adverse effects.", "answer": 1}, {"article": "Other immunotherapy approaches are in the pipeline, along with fancier versions of drugs to block the hormones that feed prostate cancer.\nThat's better than the only other approved treatment for such advanced cancers.\nSo it's not surprising there's a lot to be learned, and that it's pretty pricey.\nBut now the study that led to FDA approval is finally out in this week's New England Journal of Medicine.\nDeep in the data is further mystery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of any potential harms found in the studies. ", "answer": 0}, {"article": "And unfortunately there is no cure.\nBecause of the many unknowns about the chemical causes and triggers of IBS, the list of \u201cbad\u201d foods is exhaustive and elusive, and help from a dietician is highly recommended.\nIrritable bowel syndrome can be highly debilitating, if not virtually paralyzing, and affect work, sleep and personal and family relationships.\nMost treatments initially rely on medications that are often expensive, usually ineffective and frequently cause unwelcome side effects.\nMany practitioners and patients have turned to diet as a possible treatment, but many of the dietary recommendations have not been backed by clinical trials.The study, the largest of its kind, measured the degree of relief from low FODMAP, a frequently recommended diet, which stands for Fermentable Oligo-Di-Monosaccharides and Polyols.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While a dietary intervention may seem relatively harmless, there are notable risks. Potential nutritional deficiencies and changes in gut bacteria following a low FODMAP diet long-term have not been studied. Some people may also find it\u00a0 inconvenient to be on a restricted diet that prohibits consuming their favorite foods.", "answer": 0}, {"article": "\"Some will benefit in a very large way.\n...\nHow many lives?\nThis means some women will undergo needless surgery, radiation, or chemotherapy.\nSo should U.S. women continue to get routine mammograms?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "The Mount Sinai Hospital is in the \"Honor Roll\" of best hospitals in America, ranked No.\nThe research also determined that the best surgical approach for cochlear implant procedures did not involve drilling into the bone around the ear.\n\"The cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\" said Dr. Wanna.\nMore specifically, the non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\nDr. Wanna and the researchers also looked at the impact of two major surgical approaches used to insert the electrodes in the inner ear: \"round window\" (where surgeons open the membrane without bone removal or drilling in the inner ear) and \"cochleostomy\" (which requires drilling into the bone to get inside the inner ear).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Drilling into your ear to implant a device can involve harm. \u00a0As for harms, we learn of them only obliquely with this phrase: \u00a0\u201cthe non-wire electrodes were less traumatic, causing less injury and minimizing fractures inside the inner ear.\u201d \u00a0Are we to presume that the wire electrode implants can be \u201cmore traumatic?\u201d More detail was definitely needed here.\nThe favored \u201cround window\u201d approach is also considered safer given that the news release reports that \u201cthe cochleostomy approach causes fibrosis and scarring, leading to hearing loss over time,\u201d according to the lead researcher. \u00a0How much harm? We don\u2019t know.", "answer": 0}, {"article": "In May, British researchers reported that patients taking them have a higher risks of liver dysfunction, kidney failure, muscle weakness and cataracts.\nThe longer people took the highly popular cholesterol-lowering pills, the lower their risk of later developing colon cancer, the researchers told a meeting of the American College of Gastroenterology.\nSamadder\u2019s team did what is known as a meta-analysis, combining the findings of 22 scientific studies with more than 2.5 million volunteers.\nStatins are not risk-free.\nAnd U.S. health officials have been watching data that suggests some statins such as Merck & Co\u2019s blockbuster drug Vytorin may actually raise the risk of cancer, although they have saidf this is unlikely.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story mentioned potential harms associated with the use of statin medication though didn\u2019t provide any insight about how commonly these occur. Is it 1 in 10?\u00a0 1 in 100?\u00a01 in a million? \u00a0", "answer": 0}, {"article": "\"Anything we can do to get those rates up has the potential to save lives.\nDetection rates for the first doctor were about 67 percent while listening to music and 30 percent with no music.\nThe study authors suggested that the findings could help reduce the number of people affected by invasive colorectal cancer -- the third most common cancer diagnosed in men and women in the United States, according to background information in the news release.\nBetter detection of these so-called adenomatous polyps could save lives, the study authors noted, as survival rates for colorectal cancer are better than 90 percent if the disease is detected early.\nThe study was slated for presentation Monday at the American College of Gastroenterology's annual meeting in Washington, D.C. Because this study was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No foreseeable harms or side effects in listening to music during procedures.", "answer": 2}, {"article": "It matters.\nTen of 16 patients who had the BRAF gene mutation had a partial response to the drug, meaning the tumor shrank by at least 30 percent, while one had a complete response, with the tumor disappearing altogether.\nRecently, scientists reported that another experimental drug, ipilimumab, prolonged median survival in patients with metastatic melanoma from 6.4 months to 10 months.\nAmong 32 patients with BRAF-mutated melanoma in the second phase of the study, 24 had a partial response and two had a complete response.\nOne expert cautioned that it's too early to say whether the drug will actually prolong patient's lives, or if it might be helpful to patients in earlier stages of the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms in this story \u2014 somewhat shocking when you consider that safety assessment is the primary objective of phase\u00a0I research.\u00a0The suggestion that this drug may substantially increase the risk of another, less invasive type of skin cancer, certainly warrants some attention. The accompanying editorial in the NEJM commented: \"Overall, PLX4032 had moderate toxicity, with rash of grade 2 or 3, fatigue, and arthralgia being the major dose-limiting toxic effects. Somewhat unexpectedly, cutaneous squamous cell carcinomas developed in a significant percentage of patients.\"", "answer": 0}, {"article": "The study described in the article \"Effect of Foeniculum vulgare Mill.\nThe study outcomes are published online today in Menopause, the journal of The North American Menopause Society (NAMS).\nIn the end, fennel was concluded to be a safe and effective treatment to reduce menopause symptoms without serious side effects.\n(fennel) on menopausal symptoms in postmenopausal women: a randomized, triple-blind, placebo-controlled trial\" is one of the first clinical studies to examine the benefits of fennel for managing menopause symptoms, even though it had been previously studied and confirmed to manage premenopause symptoms.\nA new study confirms that it is also effective in the management of postmenopause symptoms such as hot flashes, sleeplessness, vaginal dryness, and anxiety, without serious side effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The jury remains out about the potential long-term effects of what some refer to as endocrine disrupters. Readers of this release are told there were no \u201cserious\u201d side effects, but not what the side effects were.\nNor was there any mention of the ongoing scientific debate about the safety of phytoestrogens. Concerns have been raised about tumor promotion in estrogen-sensitive tumors from phytoestrogens (although plant estrogen is actually very weak compared to estrogen used for pharmacologic purposes).", "answer": 0}, {"article": "This is a wonderful renewed hope of feeling better.\"\nFRIDAY, Jan. 1, 2010 (HealthDay News) -- Three-quarters of patients undergoing surgery for stubborn sinusitis saw significant improvements in their quality of life, new research shows.\nThe condition, marked by symptoms such as sinus pain and pressure, headache, stuffy nose and sneezing, can compromise quality of life more than even congestive heart failure, back pain or chronic obstructive pulmonary disease, the study authors said.\nThis second finding is probably explained by the fact that people going for second or further surgeries were probably sicker to begin with, Josephson said.\nMost of the remaining 25 percent also saw some improvement, just not as dramatic, said Dr. Timothy Smith, lead author of a study appearing in the January issue of Otolaryngology -- Head and Neck Surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the study authors did not report adverse effects of endoscopic sinus surgery, the news story should have mentioned that complications can include bleeding, bruising, swelling and infection. \u00a0Rare cases of vision problems, spinal fluid leaks and meningitis have also been reported.\u00a0 If you don\u2019t report harms and you don\u2019t report costs, you\u2019re not telling a very complete story. ", "answer": 0}, {"article": "Thousands of heart-failure patients die each year because they aren't able to get a transplanted organ. Now, many medical experts are touting the benefits of a new mechanical pump that gives a patient's own heart a new lease on life.\n\nPatients surgically implanted with the new pump, known as a left-ventricular assist device, or LVAD, had a survival rate of 58% after two years, according to a recent study. That's not as good as a heart transplant, which offers a survival rate of about 70% after 10 years. But it surpasses the...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story implies the likelihood of death after two years\u201342 percent. \nIt also cites potential harms that include inability to monitor blood pressure and potential damage to brain, kidneys and other organs. \nYet the story fails to mention other harms that were described in the New England Journal study: stroke [18 percent], infection [35 percent], sepsis [36 percent], transfusions and surgeries for bleeding, and replacements. After implantation, patients were in the hospital for an average of 27 days.\nThese are not insignifiant risks of harm. The story earns a satisfactory under this criterion only barely. ", "answer": 1}, {"article": "Dr Douglas Morrison, author of the paper from the Scottish Universities Environmental Research Centre at the University of Glasgow, commented: \"We developed inulin-propionate ester to investigate the role of propionate produced by the gut microbiota in human health.\nThis study illustrates very nicely that signals produced by the gut microbiota are important for appetite regulation and food choice.\nTo get the same increase from fibre alone, we would need to eat around 60g a day.\nAfter drinking the milkshakes, the participants in the current study underwent an MRI scan, where they were shown pictures of various low or high calorie foods such as salad, fish and vegetables or chocolate, cake and pizza.\nShe added that some people's gut bacteria may naturally produce more propionate than others, which may be why some people seem more naturally predisposed to gain weight.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Even if there were no direct harms/side effects of the supplements, it would have been useful to say so explicitly. It would also be useful to know if there\u2019s a risk from long-term use since there was the suggestion it might have an impact on the body\u2019s microorganisms. It also appears as if the MRI was a form of fMRI which may have carried some risks, however small.", "answer": 0}, {"article": "\"Current FDA-approved treatments for depression fail for millions of people because they don't work or don't work fast enough,\" said senior author Ruben Abagyan, PhD, professor of pharmacy.\nBut ketamine has not been tested in a large clinical trial, and all evidence of its antidepressant effects has come from anecdotes and small studies of fewer than 100 patients.\nFor financial and ethical reasons, ketamine has never been tested for its safety and effectiveness in treating depression in a large-scale clinical trial, but it reportedly works much more rapidly than standard antidepressants.\nAccording to Abagyan, it is possible that another factor common to patients taking ketamine was driving the antidepressant effect, such as the fact that ketamine also relieves pain.\nThat control group eliminated the possibility that people who take ketamine have less depression because they have less pain.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms from taking ketamine. A British Journal of Clinical Pharmacology study of ketamine for chronic pain devoted a lengthy discussion to side effects from clinical ketamine use, dividing them into central nervous system (CNS)-related, cardiovascular and hepatic (liver).", "answer": 0}, {"article": "Recently a well-known Seattle Seahawks player and four of his teammates are sitting out a week of training camp to receive a blood-healing treatment from a European supplier an IRAP-based treatment solution.\nThe cost of the USA-based IRAPjoint\u2122 treatment is $2,000 compared to the reported price of $10,000 for a foreign competitor.\nIt's a non-drug, non-surgical treatment derived from your own blood.\nOKLAHOMA CITY, Sept. 7, 2017 /PRNewswire/ -- Arthrokinex announces the release of IRAPjoint\u2122 therapy in the USA.\nTypically, the treatment process is painless and just takes a few minutes and consists of one injection per week for three weeks, followed by quarterly injections, as needed.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release mentioned no potential harms of the treatment, and emphasized multiple times the supposed safety of the treatment as a \u201cnon-drug, non-surgical treatment derived from your own blood.\u201d\u00a0\nBut just because it\u2019s from your body doesn\u2019t mean it\u2019s inherently safe\u2014further study would be necessary to determine the safety and risk of adverse reactions.\nThough probably safe if done in a sterile fashion, there is no information on the long-term impact of this treatment on the arthritic joint.", "answer": 0}, {"article": "Ginger, an herb, is found in supplements and in many foods such as ginger snaps and Asian dishes.\nHowever, more study needs to be done, and the researchers aren't yet recommending that people head to the supplements' aisle or start gobbling up more ginger at meal times.\nPrevious research in animals has suggested that ginger can reduce inflammation but isn't potentially toxic to the stomach like aspirin, Zick noted.\nAs for cost, she said that a month's supply of similar ginger supplements typically runs about $10 to $30.\nBut for now, she said, \"if you want to embrace ginger because you like the taste, go ahead,\" but there's no solid evidence that it prevents colon cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Barely satisfactory.\nThe story only says that previous animal research showed ginger \u201cisn\u2019t potentially toxic to the stomach like aspirin.\u201d\nWhat about in people?\nThe story states that the National Library of Medicine that ginger is \u201clikely safe\u2026although some people may develop side effects.", "answer": 1}, {"article": "The average age of children in the study was 7.\n\"This raises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\nThe findings suggest that a sniff test could be quite useful in the clinic, although the researchers emphasize that their test is in no way ready for that yet.\nThe researchers now plan to test whether the sniff-response pattern they've observed is specific to autism or whether it might show up also in people with other neurodevelopmental conditions.\nNow, researchers reporting in the Cell Press journal Current Biology on July 2 have found that people with autism spectrum disorder (ASD) don't make this natural adjustment like other people do.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The problem with any diagnostic tool, including very early-stage diagnostic concepts like this one, is that while they can offer accurate diagnoses \u2014 they may also provide an inaccurate diagnosis. This is particularly relevant, since the release quotes one researcher as saying the work \u201craises the hope that these findings could form the base for development of a diagnostic tool that can be applied very early on, such as in toddlers only a few months old.\u201d But here\u2019s the thing: in the event of a \u201cfalse positive\u201d diagnosis of ASD in a very young child, it may take months or years for the diagnosis to be disproven. That could cause unnecessary stress for the patient and family and \u2014 given the expense of ASD treatment for many families \u2014 could impose a significant economic burden as well. The\u00a0damage would be minimized by using the test, as any test should be, in the context of a good clinical evaluation.", "answer": 0}, {"article": "\"The cutting edge technology of IRE makes this a reality.\"\n\"The patients we have treated at The Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\" said Dr. Michael K. Stehling, an internationally recognized expert on image guided tumor ablation treatments and primary author of the study.\nThroughout the study, there were no cases of IRE-related incontinence, even when the lower urinary sphincter was included in the treatment field.\nCHICAGO, Dec. 2, 2015 /PRNewswire/ -- An analysis of clinical data from over 200 patients treated by Dr. Michael Stehling found that a new procedure that uses MR and ultrasound to guide treatment to the precise tumor location allows for faster recovery times and lower side effects in all stages of prostate cancer.\n\"The data from this study confirms what we see every day, we have a very attractive approach for patients who are concerned about quality of life challenges and are considering options for the treatment of localized and late stage prostate cancer,\" he said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes several different claims about the superiority of this treatment method to others \u2014 but never brings up the potential of harm.\n\u201cThe patients we have treated in the Prostata Center have had their cancers destroyed without the need for surgery, with a low incidence of side effects and in most cases have been back on their feet the next day,\u201d the release states. [Italics ours].\nThe word \u201cdestroyed\u201d is not typically used in medicine. Even if there is a \u201clow incidence\u201d of side effects, we would like to know what those rare side effects are.\nFurther, the news release provides no information about how side effects were measured (e.g., standardized measures completed by patients, physician assessments\u2013which is not considered reliable), how many men actually completed reports of complications, the median length of follow-up\u2013saying \u201cup to \u00a04 years\u201d is very imprecise. (They could have been followed just 6 months, 1 year, and so on.)\u00a0 Another problem is that the recurrence group\u00a0included\u00a0men who had already been treated with surgery or radiation\u2013which do cause erectile dysfunction and urinary incontinence. To interpret complication data the reader needs to know the level of urinary control and sexual function before the IRE treatment. The release also does not describe how recurrence was defined, whether all men were evaluated, and\u2013again\u2013the median length of follow up.", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the quoted source and the study authors cautioned that beta blockers carry some side effects and additional research is needed to determine if the drugs\u2019 benefits outweigh their risks for cancer patients. It specifically mentions risks for people with asthma. Other specific harms from beta-blockers for the general population include depression and diarrhea. Beta-blockers may also cause complications for people with diabetes.", "answer": 1}, {"article": "About the Society of Breast Imaging\n\nThe Society of Breast Imaging (SBI), established in 1985, is a professional medical organization dedicated to improving the practice of breast imaging and the quality of medical education in breast imaging.\nThis approach saves many more lives than screening started at a later age or with less frequent exams.\nRisk-based screening is a poor approach.\nFor information on mammography visit Mammography Saves Lives or the Society of Breast Imaging website.\nThe ACR and SBI believe women 40 and older should have access to mammograms and that Medicare and private insurers should be required to cover them for these exams.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Overdiagnosis and overtreatment aren\u2019t discussed, but these are real and significant issues with mammography.", "answer": 0}, {"article": "A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday.\n\nIn the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, dupilumab, compared with those getting a placebo.\n\nOther measures of lung function and disease control also improved, according to the study results, which were published online Tuesday in The New England Journal of Medicine and presented at the annual meeting of the American Thoracic Society in Philadelphia.\n\nDupilumab blocks the action of interleukin-4 and interleukin-13, two inflammatory chemicals made by the body that are believed to contribute to asthma. Sanofi and Regeneron say there are also preliminary signs dupilumab works against the skin condition atopic dermatitis, suggesting it can be blocking a biological pathway that contributes to multiple allergic conditions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of even potential harms in the story. Even the accompanying editorial raised one issue: \u201cGiven the appearance of increased eosinophilia in four patients in the dupilumab group, more safety data are also required.\u201d", "answer": 0}, {"article": "It\u2019s a conversation that could save their life,\" he said.\nBut as these antigens can be present in men without the cancer, it carries a risk of returning a false positive that can kick-start unnecessary, life-changing treatment.\nThe next steps should be to understand how this research can be developed into tests that could identify men who might be more likely to develop aggressive cancers, and how this could be rolled out to patients.\u201d\n\nDr. Iain Frame, the director of research at the charity Prostate Cancer UK, highlighted that men with a family history of prostate cancer are two-and-a-half times more likely to be diagnosed with the disease compared to a man with no family history.\nRosalind Eeles, an author of the study at the U.K.-based Institute of Cancer Research (ICR) who specializes in finding genetic variants that increase the risk of prostate cancer, told The Guardian the team is \u201cexcited by the test\u201d because it can be used by doctors to offer patients targeted screenings.\nThe resulting test hones in on these and the existing 100 known markers to pinpoint the 1 percent of men who are at six times greater risk of developing the condition, and the 10 percent of men who have a threefold greater risk of developing the disease, a study author told The Guardian.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned PSA tests. which detects antigens that can be present in men without the cancer and \u201ccarries a risk of returning a false positive that can kick-start unnecessary, life-changing treatment.\u201d\nHowever, the story didn\u2019t explain that a genetic test would not necessarily prevent these harms, without a better test to detect actual cancers. While men found to be at low risk might be spared additional testing, those with genetic markers for prostate cancer might be subject to more aggressive interventions that could harm them.", "answer": 0}, {"article": "Rates of \u201cno relief\u201d were highest with placebo treatments.\nOne limitation of the current study is that the smaller studies used in the analysis had a wide variety of designs and methods for testing the success of treatment, researchers note.\nAlthough the use of antidepressants is common among IBS patients, psychotherapy is not, the study authors note.\nStill, a psychological evaluation may make sense for IBS patients because it\u2019s possible their symptoms might be a byproduct of untreated depression, said Dr. Agnieszka Kulak-Bejda, a psychiatry researcher at the Medical University of Bia\u0142ystok in Poland who wasn\u2019t involved in the study.\nAnother drawback is that these studies weren\u2019t designed to prove how antidepressants or psychotherapy might directly improve IBS symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are also not addressed. This is particularly problematic for the sections of the piece that deal with antidepressants. For example, the story specifically mentions both tricyclic antidepressants (which have potential side effects ranging from constipation to sexual problems) and selective serotonin reuptake inhibitors (which can also pose health risks). We don\u2019t expect a story like this one to provide an exhaustive overview of risks associated with these classes of drugs, but we do think it should at least acknowledge that there are risks.", "answer": 0}, {"article": "\"I know scientists are supposed to be objective and dispassionate,\" Hendricks says.\nPerhaps this study will be a turning point in how our culture regards psychedelics and mental health.\nThe scientists recognize, too, that it's still unknown if classic psychedelics concretely led to a drop in psychological distress and suicidality; perhaps those who participated in the study and had reported using psychedelics in the past had personalities that made them less susceptible to distress and suicidality in the first place.\nOnly two population studies to date, this one included, specifically address the relationship between mental illness and psychedelics.\nThe study, published recently in the Journal of Pharmacology, analyzed data from an annual survey conducted by the National Survey on Drug Use and Health that measures substance abuse in relation to mental illness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u201cThe effects of psychedelics on the developing brain are still largely unknown, meaning they could still pose a threat to people with a predisposition to schizophrenia,\u201d says the story. But it does not add other possible drawbacks cited by the study, such as \u201cfeelings of anxiety, fear, panic and paranoia.\u201d Since potential harm is a big reason these drugs are not widely available, we think this was an issue worth discussing in more detail.", "answer": 0}, {"article": "A growing body of evidence suggests that weight-loss surgery is more effective than diet and exercise at getting rid of Type 2 diabetes.\n\nA small but rigorous randomized trial published Wednesday in JAMA Surgery provides the latest evidence showing the superiority of bariatric surgery over lifestyle changes in resolving the chronic condition involving high blood sugar.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a big hole. As noted earlier in this review, bariatric surgery is not without risk of complications, particularly in people with multiple morbidities and older age or very young age. It behooved the story to say something about this, including the risks and harms of untreated diabetes or diabetes and obesity in people who have tried everything and failed to resolve either condition.", "answer": 0}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\n\"The effect of pulsed radiofrequency is fast and without adverse events.\"\nIn 128 patients, the pRF treatment was delivered directly under CT guidance to the root of the nerve.\nThe use of pRF also could improve outcomes for patients set to receive corticosteroid injections.\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release leads with a phrase we find problematic: \u201cminimally invasive.\u201d For many readers this connotes a quick, \u201csafe and effective\u201d intervention as mentioned in the release. But \u201cminimally invasive\u201d can potentially have more complications than a prior \u201cmore invasive\u201d approach.\nNo instrumentation close to the spine or its nerve roots is risk-free. Nerve damage and infection are two potential complications that should have been mentioned.", "answer": 0}, {"article": "But this study doesn't tell us about long-term outcomes or what transpired over a long period of time,\" he said.\nPort noted that screening guidelines tend to be based on the ability of mammograms to save lives and how often they give a false positive result.\nAnd Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, noted that this was an observational study that only looked at the experience of one institution.\nAlso, because of the nature of the study and the small sample size in the young age group sub-analysis, Lichtenfeld said that \"this cannot be interpreted as a study telling us what age to start mammograms.\"\nClearly, the earlier a breast cancer is diagnosed, the less treatment that will be required.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story made no mention of the harms of earlier or more frequent screening, which have been documented time and time again. More screening can mean more false positives or more finding of breast changes that lead to more testing, such as biopsies, more costs, and more worry.", "answer": 0}, {"article": "Foods with fiber, such as fruits, vegetables and whole grains, can reduce cholesterol levels, while carbohydrates that are low in fiber tend to raise triglyceride levels and lower \"good\" HDL cholesterol levels.\nDespite the addition of several hundred calories a day to their diet, the apple-eating women didn't gain weight over the course of the study.\nWhat effects, if any, the prunes had on cholesterol levels were not mentioned in the study abstract.\nThe daily serving of dried apples contained about 240 calories, according to the study.\nThe researchers found that women eating dried apples lowered their total cholesterol by 14 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We can\u2019t think of any potential harms, and the story stated that \u201cDespite the addition of several hundred calories a day to their diet, the apple-eating women didn\u2019t gain weight over the course of the study. In fact, they lost an average of 3.3 pounds.\u201d ", "answer": 1}, {"article": "\u201cNo metal means the treated artery can pulse and flex naturally as demands on the heart change with everyday activities,\u201d said Gregg Stone of Columbia University Medical Center, who led clinical trials for Absorb.\n\u201cThere are no longer going to be permanent metal implants in the artery.\u201d\n\nAbsorb releases the drug everolimus to combat the growth of scar tissue that can form within a stent and cause the artery to narrow again, the U.S. Food and Drug Administration, which approved the stent, said.\nAbbott plans to roll out the device to about 100 hospitals in the next several months as it trains surgeons on the implant procedure before ramping up sales, said spokesman Jonathon Hamilton.\nAbsorb\u2019s appeal is that it allows the blood vessel to return to a natural state, free from a permanent metal implant.\nAbsorb will be priced at a \u201cmodest\u201d premium to Xience, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that one clinical study found a higher risk of heart attacks and blood clots in participants, complications that Abbott Labs apparently blames not on the stent but on surgeons\u2019 lack of experience in using it.\nA weakness here, though, as noted in the \u201cbenefits\u201d segment above, is that there apparently have been no clinical trials that have lasted long enough for the stents to dissolve (about three years) in order to assess harms. The story should make that clear to readers.", "answer": 1}, {"article": "\"Every day.\"\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nThis kind of surface stimulation has shown promise in small studies of patients with fibromyalgia and spinal cord injury.\nA small electrical current seems to work by affecting pain centers deep within the brain, somehow muffling the perception of pain.\nThe main side effect so far is slight scalp irritation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The segment says there is some tingling and a sunburn-like lingering effect linked to the treatment. \nWhile this is accurate, TDCS is relatively new and the real side effect profile is unknown at the moment.\u00a0 There may well be cognitive and motor reflex effects with repeated use.\u00a0 \nA simple statement that there may well be other unrecognized side effects would have put this into context. ", "answer": 0}, {"article": "Fibromayalgia is a condition marked by fatigue, disturbed sleep, and pain.\nHowever, a rheumatologist not connected to the study does not expect the new drug to be a ''game-changer.\"\n\"Bedtime treatment of fibromyalgia patients with low-dose cyclobenzaprine was safe and appears to be effective,\" says Seth Lederman, MD, president of TONIX Pharmaceuticals, which funded the study.\nCyclobenzaprine, marketed in higher doses by others as Amrix, Fexmid, and Flexeril, is already widely used ''off-label'' for patients with fibromyalgia, Lederman says.\nTONIX is developing a lower-dose version and improving the formula, Lederman says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does report that some participants had headaches, dry mouth and drowsiness, and that this drug sometimes makes people drowsy during the day. However, since there were only 18 participants who took the active ingredient, the story would have been better if it had alerted readers that much larger numbers of patients would need to be studied in order to quantify the likelihood of less common adverse events. ", "answer": 1}, {"article": "But the F.D.A.\nBut every major drug company has new experimental drugs it hopes will work, particularly if they are started early.\n\u201cThe 20 percent who had amyloid, though they were still statistically in the normal range, did worse on every memory test than the control group.\u201d\n\nWhat, Dr. Skovronsky asked, did that mean?\nIf so, could dementia be stalled if there were drugs to stop amyloid from accumulating?\n: How do you know that what you are seeing on scans is the same as the amyloid you see on autopsy?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No. There is nothing in this story about what it\u00a0would mean, for example, if everyone over a certain age started having their brains injected with radioactive dye on a regular basis. Everyone has a lifetime radioactive load limit, for one. What else might the dye do to people who have other chronic conditions or are taking medications?", "answer": 0}, {"article": "Patients getting canakinumab also suffered significantly more deaths from infections than those on placebo - but, on the positive side, they appeared to be at lower risk of cancer.\n\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\nThere was no significant difference in the rate of deaths from all causes between the placebo group and those on canakinumab.\n\u201cIn view of the additional oncology findings, we don\u2019t think you should just think about this as a cardiovascular drug,\u201d Narasimhan said.\nNovartis initially struggled with the sluggish launch of its last heart drug, the $4,500-per-year Entresto, so it is understandably concerned about the reception for canakinumab.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "From the get-go, readers are told there are risks to keep in mind. This was entirely absent from the TIME story we reviewed.\nThat said, we wish this Reuters story had discussed the harms more in-depth\u2013how frequent were they? How severe?", "answer": 1}, {"article": "Through a blood vessel in the groin, doctors snake a tube to a blocked heart artery.\nAbout 40 percent of patients in the study had a prior heart attack more than three months previously.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\nThe stunning results found that angioplasty did not save lives or prevent heart attacks in non-emergency heart patients.\nAfter an average of 4\u00bd years, the groups had similar rates of death and heart attack: 211 in the angioplasty group and 202 in the medication group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the study mentions the risk of clotting with drug-coated stents, this is not adequate information on harms. Furthermore, the study does not mention any possible harms of medication.", "answer": 0}, {"article": "\u201cMy nightmare was that nothing would be different from the placebo group, and there would be nothing of interest to talk about,\u201d he says.\nI think resveratrol is an engaging target that\u2019s very interesting and could be pharmacologically manipulated to develop a treatment.\u201d\n\nMORE: Red Wine Not That Healthy After All, Study Shows\n\nThe resveratrol group showed no change in the levels of a protein that builds up in the brains of Alzheimer\u2019s patients.\nIn what the authors describe as the largest and longest study of resveratrol in people with mild to moderate Alzheimer\u2019s disease, there\u2019s encouraging news that the component, which is found in red wine, grapes and dark chocolate, may keep the disease from progressing.\nHow resveratrol may be affecting the Alzheimer\u2019s disease process isn\u2019t clear yet.\nThat\u2019s likely because experts believe that as Alzheimer\u2019s progresses, more of the protein plaques form in the brain, and less of the protein is released to the rest of the body.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention side effects, but the study itself reported that adverse effects included nausea, diarrhea, and weight loss. In addition, there are some concerns that resveratrol may affect blood clotting, which would be important information for patients taking blood thinners. It\u2019s worth noting that this absence of potential harms in the story is particularly problematic, given that a key goal of the study was to determine whether high doses of resveratrol are safe. Moreover, weight loss is already a significant concern among Alzheimer\u2019s patients, so anything that would exacerbate that is definitely worth paying attention to.", "answer": 0}, {"article": "\u201cBefore we started living this life, I was clueless,\u201d she said.\nIn an e-mailed statement, FDA spokesperson Sandy Walsh confirmed that the FDA\u2019s decisions are all \u201cbased on an assessment of the available data and whether the benefits of the drug outweigh its risks.\u201d That data can include the experience of patients like Max, Rowan and Charlie.\nPTC Therapeutics founder and CEO Stuart Peltz says the statistics aren't a reason to reject the drug.\nMany of the clinical trials failed to satisfy the statistical requirement to prove a drug works\u2014at least not for the main outcome the company was looking at.\nThe NCHR also presented at the FDA meeting in September to discuss ataluren, urging the agency to not approve the drug without more research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text briefly mentions side effects associated with the drug, increases in blood pressure and cholesterol levels, an assertion contested by the drug\u2019s manufacturer, PTC Therapeutics. However, it would have been more helpful to quantify and more clearly describe these side effects, and tap independent experts for their viewpoints. We found the NCHR\u2019s testimony about the risks of combining this drug with other drugs these kids commonly take to be important, for example.", "answer": 0}, {"article": "\u201cI ran a treatment program for years, and we invested\u201d millions in treatment services.\nDoctors who treat smokers said that the study findings were not unexpected, given the haphazard way many smokers used the products.\nDr. Hurt said products like nicotine gum and patches \u201care absolutely essential, but we use them in combinations and doses that match treatment to what the individual patient needs,\u201d unlike smokers who are self-treating.\nThe use of replacement products made no difference, whether they were taken for the recommended two-month period (they usually were not), or with the guidance of a cessation counselor.\nOne subgroup, heavy smokers (defined as those who had their first cigarette within a half-hour of waking up) who used replacement products without counseling, was twice as likely to relapse as heavy smokers who did not use them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the stories mentioned the potential harms from taking nicotine, as opposed to quitting cold turkey. Nor did they mention the additional risks associated with continuing to smoke instead of making use of a more successful smoking cessation program that would actually help a smoker quit. As the leading risk factor for early death, smoking should be stopped as quickly and effectively as possible.", "answer": 0}, {"article": "MORE: The IUD Answer: Why The Best Form of Birth Control is the One No One Uses\n\nThe researchers followed 237 women who were using an implant like Implanon and Nexplanon and 263 women using the Mirena hormonal IUD.\nThat doesn\u2019t mean you should extend your own use of the contraceptives without talking to your doctor.\nThe study is still continuing, and it could be quite a long time before any changes to clinical recommendations are considered.\nThe benefit of being able to use the implant and IUD for a longer period of time is that it could reduce costs for individuals and insurance.\nThe study is still ongoing, and the researchers plan to recruit up to 800 women and ultimately test whether the IUDs and implants were effective for up to three years after their current FDA-approved duration.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s strongly implied that an unintended pregnancy is a potential harm of keeping\u00a0either one of these prescription devices longer than the FDA-approved length of time. But that\u2019s fairly self-evident. We think the story\u00a0should have addressed other potential harms that come with having an IUD in the first place such as infection, ectopic pregnancy, or expulsion.\u00a0This could have been addressed succinctly in one extra sentence.", "answer": 0}, {"article": ".\nHow the Study Was Conducted and Results: Patnaik, Shapiro, and colleagues enrolled 225 patients with a variety of types of advanced cancer in the phase I clinical trial designed to evaluate the safety and preliminary efficacy of abemaciclib.\nAmong these patients, the most common treatment-related adverse events were fatigue, diarrhea, nausea, vomiting, anorexia, weight loss, kidney dysfunction, and decreased red and white blood cell counts.\nLimitations: Patnaik explained that because this study included 225 patients with different types of cancer, confirmatory clinical trials in specific patient populations are necessary to precisely define the role of abemaciclib in cancer care.\nIn the dose escalation phase, the researchers determined that the maximum tolerated dose was 200 milligrams (mg) every 12 hours; the dose-limiting toxicity was grade 3 fatigue.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that \u201cthe most common treatment-related adverse events were fatigue, diarrhea, nausea, vomiting, anorexia, weight loss, kidney dysfunction, and decreased red and white blood cell counts.\u201d Although the release does not go into specific detail about the number of patients who reported side effects, or the degree of severity of the side effects, the list of harms seems adequate for a drug just beginning the clinical trial process.", "answer": 1}, {"article": "We have to really ask the question: 'How low do you go?'\nNabel stressed that while the death rate was higher in the intensive group, the rate in both groups was still lower than would be expected in patients at high risk receiving standard treatment.\nBecause some of the patients were taking the drug Avandia, which has been the focus of concern that it might increase the risk of heart attacks, the researchers specifically examined whether that was a factor.\nBut a special 10 member panel that was monitoring the study alerted the organizers that 257 patients r eceiving intensive treatment had died, compared with 203 receiving standard treatment, a difference of 54 deaths -- or 3 per 1,000 participants per year, officials said.\nThe patients were further divided into those who also received blood-pressure-lowering medication or drugs to improve their cholesterol levels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story was about the new finding that more intensive management of sugar levels in high risk patients increases mortality risk. Differences in death rates were given in absolute terms. ", "answer": 1}, {"article": "Most thyroid cancers can be treated successfully, but advanced cases can be difficult to treat, especially if they do not respond to radioactive iodine (RAI) therapy.\nAdditional information is available at http://abstract.asco.org/176/AbstView_176_165870.html.\nQ: What did you find?A: At the time we reported our results, six of the 22 patients remained on treatment.\nThis appears to be due to increased use of technology to detect thyroid nodules that may not otherwise been found previously.\nThe work is being presented at the American Society of Clinical Oncology (ASCO) Annual Meeting which begins tomorrow in Chicago.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is one sentence related to harms in the release, but it doesn\u2019t tell us what they are.\n\u201cThere were no treatment-related deaths or therapy discontinuations due to drug-related adverse effects.\u201d\nThe package insert lists the most common side effects as\u00a0fatigue, cough, nausea, diarrhea, constipation, anorexia, arthralgia (joint pain), pruritus (severe itching), and rash.", "answer": 0}, {"article": "But at this stage, the company itself has been careful not to promote its device directly to consumers since its F.D.A.\nPart of the reason the device has made inroads during these strapped times is that doctors don\u2019t buy it outright, but pay per use.\nThis time, each session is followed by a massage that supposedly speeds the release of fat.\nGordie Nye, the chief executive, sent an e-mail message declining to be interviewed for this article.\nThe fat enters the lymphatic system, and is eventually used as energy, Dr. Maloney said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to point out the potential harms of these devices.\u00a0\n The devices claim to be based on scientific principles involving the cellular destruction of lipids and their elimination from the body. This is serious metabolic stuff, presumably with serious potential risks. The story fails to acknowledge this. ", "answer": 0}, {"article": "\"So, yes, one of the limitations of this kind of study is always the question of its generalizability to other populations,\" he cautioned.\n\"Because there's very robust evidence showing the cardiovascular benefit of linoleic acid.\nSo, it's a very complex picture.\nBut he also suggested that his team's rigorous look back offered valuable insights into how nutritional science has evolved.\n\"But I don't think this is going to change AHA recommendations,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not Applicable. The primary focus of the story was addressing the potential harm of consuming too much linoleic acid. The story should have quantified these harms better, but since we\u2019ve already docked points above under Benefits, we\u2019ll grade this N/A here to avoid dinging it twice for the same flaw.\u00a0 We can\u2019t give it credit for a satisfactory score, though, for the same reason.", "answer": 2}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the drug is associated with \u201cfew significant side effects,\u201d however, the specifics of these side effects are not provided. Six patients in the advanced basel cell carcinoma study experienced 8 grade 3 adverse events, including fatigue, hyponatremia, muscle spasms, and atrial fibrillation. One patient withdrew from the study citing adverse effects.", "answer": 0}, {"article": "The higher a person's insulin levels are, the more likely they are to have or develop insulin resistance, which can increase blood sugar levels and diabetes risk.\nPeople who have a gastric bypass often have nutritional and vitamin deficiencies, Lenhard said.\nThe study authors had no part in which procedures the teens received.\nThe findings are important because many of the participants in this study likely already had some level of cardiac damage, such as thickened arteries or heart walls, says Geetha Raghuveer, a pediatric cardiologist at Children's Mercy Kansas City in Missouri who was not involved in the study.\nJust 5 percent had all four cardiac risk factors before their surgeries, but none had all of them three years later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the weight-reduction procedures \u201ccarry the same risks as any surgical procedure, such as infections, blood clots and bleeding\u201d as well as nutritional and vitamin deficiencies. It also states that gastric banding \u201chas low effectiveness and a risk of the band slipping down the stomach.\u201d Note: The most risky complications (problems arising from general anesthesia) were not mentioned.", "answer": 1}, {"article": "In Columbus, New York City and several other cities, ambulances take cardiac arrest patients whose hearts have been restarted by electric shock, but who remain unconscious, to hospitals that provide a cooling therapy that lowers the body temperature.\nThough it's not unusual to have debate over new therapies, the benefits of induced hypothermia is not a new discovery.\nAsked about outcomes, he said results won't be available until the program reaches one year.\nBut Dr. David Rosenbaum, director of MetroHealth's heart and vascular center, said there is not enough research data to justify a regional system.\nBut MetroHealth and Cleveland EMS officials say they aren't convinced the therapy is proven enough to rewrite the book on cardiac arrest treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms of treatment. \u00a0The story ended with a plea to provide people who would otherwise die, with something. \u00a0However since there was no discussion of outcomes with people who were and were not provided this treatment, it is not possible to know whether there are any harms of receiving this treatment. Survival with brain damage could be increased, which could be considered a harm worse than death in some cases.\u00a0 What do the data show? ", "answer": 0}, {"article": "\"It wasn't a huge, overwhelming difference,\" O'Neil said.\nA study coordinated by the MUSC Health Weight Management Center shows the scales tipping in Weight Watchers' favor instead of standard care when it comes to helping people with Type 2 diabetes.\nWhile the Weight Management Center has a high success rate at helping patients lose weight to fight diabetes, many people with the condition don't live near a specialized program and need help that's readily available.\nAfter a year, people in the Weight Watchers group had an average weight loss of about 4 percent of their starting weight, compared to 2 percent for the standard care group.\nThe Weight Watchers study is new evidence of what that help might include when it comes to a side effect of weight gain: Type 2 diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Most interventions pose some kind of potential harms and Weight Watchers is no exception. For some, particularly those without access to a dedicated dietitian as the study participants had, the amount of sodium in a WW points-based meal plan may be too high, or the vitamins insufficient to maintain nutritional needs.", "answer": 2}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\n\u201cTelephone-delivered psychotherapy is one way to overcome some barriers to mental health treatment that rural older adults face,\u201d the study concludes.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1154 and http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1306\n\nTelephone-based cognitive behavioral therapy was better at reducing worry, generalized anxiety disorder symptoms and depressive symptoms in older adults who live in rural areas, where access to mental health treatment may be limited, according to an article published online by JAMA Psychiatry.\nTelephone CBT consisted of up to 11 sessions (nine required) and focused on, among other things, anxiety symptom recognition, cognitive restructuring, relaxation, coping statements and problem solving.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentioned no possible harms from this approach, although in fairness, supportive telephone conversations are unlikely to carry much risk. \u00a0 However, we wonder about\u00a0situations where the telephone therapy sessions may not detect some problems that might surface during a face-to-face consultation.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions potential harms associated with older sunscreen formulations (e.g. ashy color, ineffective when exposed to light)\u2014but says nothing about potential harms of the newer versions that are the story\u2019s focus. Do they cause allergic or photoallergic reactions? Could they give sun-lovers unwarranted confidence in the lotions\u2019 prowess? In an apparent paradox, increased use of sunscreen has been associated with the spiraling incidence of skin cancer. Is this because sunscreens are used improperly (as the article suggests)? Or do sunscreens have inherent weaknesses as well? ", "answer": 0}, {"article": "\u201cIf there is a financial incentive\u201d for promoting the newer technique, he says, \u201cit is that more patients will want the anterior approach, so that the surgeon does more surgeries, and therefore collects more professional fees for that.\u201d\n\nWilliam Hamilton, who operates at the Anderson Orthopaedic Clinic at Inova Mt.\nFor this reason, new techniques are adapted slowly with extreme care, and in some cases, not at all.\u201d\n\nUnger adds that surgeons are naturally cautious and typically wait to see results from many studies before they switch methods.\nThey must get training in classes and cadaver labs, and the learning curve can be steep.\nUnger says that most surgeons have used the posterior approach for years, have fine results, and see no need to switch.\nSo when students leave and begin their practices, it\u2019s no longer foreign to them.\u201d\n\nHamilton, who has performed 1,100 anterior procedures and strongly supports the method, says that despite growing interest, \u201cit will take a generation of new surgeons\u201d before use of the anterior approach is widespread.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of harms in this story is by way of showing that the more \u201cinvasive\u201d method of hip surgery is more damaging to muscle and tissue. Again, the story is framed as a risk-free operation that most surgeons are ignoring and an awful, damaging technique that leaves people teetering like Charlie Chaplin.", "answer": 0}, {"article": "Uridine, which is produced by the liver and kidneys, is also found in some foods as a part of RNA, which helps make protein in the body.\nBut more research is needed before the drink could be made available to the public.\nThat makes it difficult to make a clear-cut statement about the value of the product, he said.\nThere is, however, a longer trial going on that might answer that question, Wurtman said.\nTo be effective, all three compounds must be given together, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only paraphrased the researchers saying \u201cthere were no serious side effects.\u201d That\u2019s not good enough.\u00a0 What did the data show?\u00a0 What was observed?\u00a0 In how many people?\u00a0 Then let readers or independent observers judge what is serious or not. At a minimum, the percentage of people in the trial with any side effects should be given.", "answer": 0}, {"article": "Some insurance plans cover EMDR.\nShe occupied herself with press inquiries and funeral arrangements.\nThe ordeal didn\u2019t end with the news of Nate\u2019s death.\nHenn was able to recall processed memories without feeling panic.\nBut after the whirlwind passed, unaddressed grief remained with her.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not broached.", "answer": 0}, {"article": "First, help with work or school such as assistance in deciding which classes or opportunities are most appropriate, given a person\u2019s symptoms.\nThe gains for those in typical treatment were apparent to doctors, but much less obvious.\nAbout half got the combined approach and half received treatment as usual.\nOver two years, both groups showed steady improvement.\nThe sprawling research team, led by Dr. John M. Kane, chairman of the psychiatry department at Hofstra North Shore-LIJ School of Medicine, randomly assigned 34 community care clinics in 21 states to provide either treatment as usual, or the combined package.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s conceivable that changing the standard of care for patients by reducing drug doses may carry some risk. Could some patients\u2019 symptoms be less-well controlled? Then again, drugs are very much overused in this area. And on average the study showed better symptom relief with the lower doses. No harms were documented in the study\u2013no increase in hospitalizations at least. \u00a0So while we can\u2019t give credit here, we won\u2019t ding the story either. We\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "With this information in hand, the researchers took the next step.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nHER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches.\nTo identify the patients in this study who carried the new HER2 mutation, the researchers required tissue from the tumor, a biopsy, from which they could extract and sequence the genetic material to determine the presence of the HER2 mutation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No side effects of the drug were mentioned. It was also glossed over that most of the patients in the trial did not seem to have any response to\u00a0neratinib. The release\u2019s only reference to harms was that \u201cNeratinib was well tolerated by most patients.\u201d Other research (including the peer-reviewed paper this release is based on) has shown diarrhea to be a significant side effect of neratinib.", "answer": 0}, {"article": "Hospice care is intensive palliative care including home nursing, but insurers and Medicare usually cover it only if the patient abandons medical treatment and two doctors certify that death is less than six months away.\n\u201cWe thought it made sense to start them at the time of diagnosis.\nIn practice, Medicare and private insurers do pay for some palliative care, said Dr. Gail Austin Cooney, a former president of the palliative medicine academy.\nThis trial was paid for by the American Society of Clinical Oncology and private philanthropy.\nAnd we were thrilled to see such a huge impact.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the competing coverage, we\u2019ll rule this one not applicable since the harms of palliative care are thought to be minimal.", "answer": 2}, {"article": "A study of more than 20,000 patients with traumatic injuries and at risk of bleeding to death found those who were treated with tranexamic acid were significantly less likely to die than those who got a placebo.\nAnd the result is a life saved.\nIt doesn't cost much.\nThe results were just published online by the medical journal The Lancet.\nThat improvement may not seem so dramatic, but drug is pretty easy to give -- an initial 10-minute infusion within 8 hours of injury, followed by a second infusion over 8 hours.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned there was no increase in deaths due to blood clots in the TXA group. We understand it\u2019s a blog brief \u2013 so this is sufficient. ", "answer": 1}, {"article": "\u201cIt cannot be simplified to a neat, effortless passage of the infant through the birth canal,\u201d he said.\nNow, in the first study of its kind, researchers on Monday confirmed that a mother\u2019s beneficial microbes can be transferred, at least partially, from her vagina to her baby after a C-section.\nThe procedure is not yet recommended by professional medical societies, said Dr. Sara Brubaker, a specialist in maternal and fetal medicine at N.Y.U.\nThe small proof-of-principle study suggests a new way to inoculate babies, said Dr. Maria Gloria Dominguez-Bello, an associate professor of medicine at New York University and lead author of the report, published on Monday in Nature Medicine.\nBut the first to reach an infant born by cesarean section come mostly from the environment \u2014 particularly bacteria from inaccessible or less-scrubbed areas like lamps and walls, and skin cells from everyone else in the delivery room.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that thus far the procedure \u201chas proved entirely safe,\u201d but we\u2019re talking about only four babies here!\u00a0The article assumes that all the bacteria in the mother\u2019s vaginal secretions are \u201cfriendly.\u201d \u00a0This is clearly not the case in all patients. Significant infections can be transmitted to the newborn from bacteria resident in the mothers vaginal secretions from less than friendly bacteria\u00a0including Chlamydia, Listeria and group B Strep to name a few. Suggesting that the procedure is not recommended but then pointing out that Dr. Brubaker had the procedure done for her newborn supports the notion that this is a harmless procedure \u2014 a potentially dangerous message.", "answer": 0}, {"article": "Flublok is an exact copy of the influenza virus coat protein and is not subject to the egg-adapted mutations associated with low vaccine effectiveness (see Skowronski et al.\nThis data satisfies both pre-specified criteria for non-inferiority and superiority of Flublok over the traditional egg-based quadrivalent inactivated vaccine.\nThe publication notes that approximately 9,000 people aged 50 and older were enrolled and randomized in an efficacy study designed to compare Flublok Quadrivalent to a traditional quadrivalent vaccine.\nFDA approved the quadrivalent formulation (\"Flublok Quadrivalent\") in October 2016 that will be commercially available for everyone over 18 years for the 2017/18 influenza season.\nFlublok contains three times more active ingredients than traditional vaccines and produced significantly higher immune responses to the A strains of influenza (especially H3N2) in the Flublok Quadrivalent study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a section on the safety of the new vaccine that offers substantial relevant information, as well as how to obtain more detailed information if desired.", "answer": 1}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nThere is no such screening tool currently in use.\nOne expert said the study is an important step but definitely needs follow-up work.\nBut she added that an ongoing study in the United Kingdom involving 200,000 women should more definitively determine the test's value.\nLu said the study isn't large enough to justify recommending yet.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions false positive results and unnecessary exploratory surgery as potential harms of the test.", "answer": 1}, {"article": "For more information, visit www.chronothera.com.\nTest group subjects had nicotine administered over a 30-hour time period via Chrono's prototype device that delivered nicotine according to Chrono's \"peaks and troughs\" profile.\nWhen compared to subjects treated with placebo, test subjects had a statistically significant and clinically meaningful reduction in cravings for all assessment methods (p=0.035; p=0.034 and p=0.016, respectively).\n\"Achieving statistical significance in a 24-subject trial is very striking and happens infrequently in biopharma; so these results are very encouraging,\" noted Wende Hutton, general partner at Canaan Partners and a member of Chrono's board of directors.\nAcross both groups, subjects showed no serious adverse events or study withdrawals due to an adverse event.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions that the subjects in the clinical trial did not have any adverse reactions to the device, and that a skin irritation assessment concluded there was no irritation or erythema. However, the study abstract provided by the news release issuer reported that 25% percent of the volunteers experienced itching.", "answer": 0}, {"article": "However, Swaminath wasn't fully sold on the notion.\nSwaminath pointed out that even the new study found that \"low- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\"\nThe study found that patients classified under the scoring system as low-risk did, in fact, have far fewer advanced abnormal growths that might develop into cancer, compared to patients classified as high-risk.\nImperiale's team noted that not all people deemed to be at \"average risk\" for colon cancer face the same risk of the disease, and so some might benefit more from invasive colonoscopy than others.\nNow, researchers say a special scoring system might point to those people at highest risk for colon cancer, who may need the test the most.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harm of a screening test such as this really is \u201cgetting it wrong\u201d in terms of predicting someone to be at low risk and finding them to have a higher risk polyp or malignancy. As noted above, the story cautions that \u201clow- to intermediate-risk patients still have a risk between of between 1.9 percent to 9.9 percent of harboring a polyp that can develop into cancer.\u201d", "answer": 1}, {"article": "Using the Clinformatics Data Mart, a database of one of the largest commercially insured populations in the U.S., Baillargeon and colleagues examined data of 450 men aged 40 to 63 with COPD who began testosterone replacement therapy between 2005 and 2014.\nThe paper is currently available in Chronic Respiratory Disease.\n\"The findings suggest that testosterone replacement therapy may slow the progression of disease in men with COPD.\"\nThe goal of the study was to find out whether testosterone replacement therapy reduced the risk of respiratory hospitalizations in middle-aged and older men with COPD.\n\"However, we are the first to conduct a large scale nationally representative study on this association.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are known dangers to TRT including raising the risk of prostate cancer but none of the risks are mentioned in the news release.", "answer": 0}, {"article": "Animals such as scorpions have venoms that block potassium and other ion channels.\nWhen the researchers treated rat models of the disease with iberiotoxin, they stopped the progression of the disease.\nIn addition, treatment with iberiotoxin did not induce side effects, such as tremors and incontinence, observed when treating with another channel blocker called paxilline.\nCurrent treatments target the immune cells involved in the disease and none are specific for FLS.\nA group of researchers led by Dr. Christine Beeton at Baylor College of Medicine has found that one of the hundreds of components in scorpion venom can reduce the severity of the disease in animal models, without inducing side effects associated with similar treatments.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release reported that treatment of rats with iberiotoxin \u201cdid not induce side effects, such as tremors and incontinence, observed when treating with another channel blocker called paxilline.\nThat\u2019s not quite right. The study itself says it only examined tremors and incontinence, and other adverse effects couldn\u2019t be ruled out.\nAlso, just because a particular adverse effect wasn\u2019t observed in rats doesn\u2019t mean it is safe for humans.", "answer": 0}, {"article": "Even better, she said, \u201cfor the first time I didn\u2019t feel any itch at all.\u201d\nMost patients who got the active drug, dupilumab, instead of a placebo reported that the itching began to wane within two weeks and was gone in a few months, as their skin began to clear.\nNearly 40 percent of participants getting the drug saw all or almost all of their rash disappear.\nOn Saturday, the results of two large clinical trials of a new drug offered hope to the estimated 1.6 million adult Americans with an uncontrolled, moderate-to-severe form of the disease, atopic dermatitis, which is a type of eczema.\nThe disease is characterized by an itching, oozing rash that can cover almost all of the skin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that patients receiving dupilumab reported slightly more cases of conjunctivitis, and swelling around the injection site, than those receiving the placebo injections. The story would have been more complete if it had also noted that a few patients saw their eczema get worse and that many also reported upper respiratory infections, though the rates were similar to those receiving placebo injections.", "answer": 1}, {"article": "But there were no significant differences in the reading rates of participants who had previous experience using the CCTV, compared to the reading rates of first-time CCTV users.\u201d\n\nAnother benefit is that many older adults feel stigmatized by using the traditional devices, because they identify them as having an impairment or disability.\nAnd that could help with stigmatization of the elderly and disabled.\n\u201cWhen we took previous experience into account, we found that participants who had used iPads before read on average 30 words per minute faster than those who were using the iPad for the first time.\nFor the study, the Concordia-based research team recruited 100 participants who ranged in age from 24 to 97.\n\u201cWhat was interesting to note was that it didn\u2019t matter what technology was used to do the magnification: an iPad worked just as well as a traditional device like a closed circuit television system (CCTV),\u201d he says.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release didn\u2019t address harms but we\u2019re not aware of any associated with assistive reading devices.", "answer": 2}, {"article": "1Wiseman JT, Guzman AM, Fernandes-Taylor S, et al.\nDr. Gunter said they were very successful in giving patients knowledge and access to technology so they could participate in the study.\nAlthough capturing specific numbers related to cost-savings was not part of this study, Dr. Gunter said it is an important area of focus for future studies.\nDuring the study, seven wound complications were detected and one false negative was found.\nShe said this is a model easily adaptable to other medical centers, whether through providing participants with a phone, having a rotating supply of phones at the hospitals for patients to borrow, or relying on a patient's personal device.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t explored. The app mentions that there was one false negative result among the 40 patients studied, but doesn\u2019t explain why this happened or what the consequence was.", "answer": 0}, {"article": "Twelve years ago, a car wreck took away Nathan Copeland's ability to control his hands or sense what his fingers were touching.\nBut they have relied entirely on vision to know whether the arm is going in the right direction or grasping an object with the proper amount of force.\nStill, the ability to receive touch sensation from a robotic arm has the potential to help not only thousands of people who are paralyzed, but also people with a wide range of physical disabilities, McLoughlin says.\nAt the moment, they are still too expensive, too bulky and too finicky to be used outside a laboratory setting.\nFor several years now, people have been able to control robotic arms using thoughts alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any harms that may lurk in future applications of surgical implants to communicate with a potential robotic arm.\u00a0The most obvious way to approach this would be to talk about risks of neurosurgery generally;\u00a0accidental destruction of healthy tissue, for example, or stroke. But there may be others related to the technology\u2013essentially there are a lot of unknowns when the patient test group is one individual.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061008/16healthwatch.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any effects, either positive or negative, of decreasing or eliminating cola consumption.", "answer": 0}, {"article": "Celgene\u2019s drug Abraxane prolonged the lives of patients with advanced pancreatic cancer by almost two months in a clinical trial, researchers reported Tuesday, signifying an advance in treating a notoriously difficult disease but not as big a leap as some doctors and investors had hoped.\n\n\u201cIt was not the breakthrough we were anticipating,\u201d said Dr. Andrea Wang-Gillam, an assistant professor and pancreatic cancer specialist at Washington University in St. Louis, who was not involved in the trial.\n\nStill, Dr. Wang-Gillam and others said any progress was welcome against metastatic pancreatic cancer, which has defied most treatments, with patients tending to live only about six months after diagnosis.\n\nPancreatic cancer is the fourth most common cause of cancer death, with 38,000 Americans expected to die this year, almost as many deaths as from breast cancer, according to the American Cancer Society. Yet there are only 45,000 new cases of pancreatic cancer a year compared with more than 230,000 new breast cancer cases.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One shortcoming of the story:\u00a0 no discussion of harms from Abraxane.\nHere is the data from the Calgene press release:\n\u201cThe most common grade \u2265 3 treatment-related adverse events in the study for ABRAXANE plus gemcitabine vs. gemcitabine alone were neutropenia (38% vs. 27%), fatigue (17% vs. 7%), and neuropathy (17% vs. 1%). In the ABRAXANE plus gemcitabine arm, the median time to neuropathy improvement was 29 days. There was no difference in serious life threatening toxicity (4% in each arm).\u201d", "answer": 0}, {"article": "\"Daniel's obstruction was both at the level of the soft palate and at the back of the tongue,\" Thaler says.\nAnd even then, success rates aren't high; they're effective only 20 to 30 percent of the time.\nSheiner is one of only about a half-dozen patients to have this robotic surgery for apnea.\nThe only surgery proved effective more than 90 percent of the time is a significant and highly invasive surgery.\nOftentimes, Aurora says, patients need a series of surgeries to completely treat apnea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only discusses success rates but doesn\u2019t mention any potential harms. What are the actual problems people encounter when having \u201ca series of surgeries to completely treat apnea\u201d or when they have the more \u201chighly invasive surgery\u201d?\u00a0 And what has been found even in the limited series of robotic procedures?", "answer": 0}, {"article": "While some people are helped by over-the-counter medications like ibuprofen, others need prescription medications that may cause side effects, such as dizziness.\nHowever, the price tag could be as much as $10,000 a year.\nFor 63-year-old Lynn Kaufman, the battle against migraines consumed her life.\n\u201cIf we can block CGRP, then we can abort a migraine attack,\u201d says Kudrow.\nMy entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes no discussion of the drawbacks of this new experimental class of drugs.\nAt the very least, we know that the need to take injections will be a turn off for some sufferers.", "answer": 0}, {"article": "\"Many patients who have a heart attack will go on to suffer heart failure,\" he said.\nThe study is a step forward in a field in which a lot of approaches have been tried in animals and preliminary human trials, but none has been approved for widespread clinical use for heart patients.\nThis method of intravenous injection means that the procedure theoretically could be performed in a doctor's office or clinic, increasing the accesibility to patients, Karp said.\nThe research, published in the Journal of the American College of Cardiology, were part of a phase I study that set out to show safety.\nThe phase I results from 53 patients are not definitive proof that the treatment is effective, but do suggest so, Hare said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story briefly mentions the potential for rejection, it fails otherwise to specify the potential side effects of the stem cell harvesting or infusion. This is surprising, given the fact that the Phase I trial is designed to prove safety. ", "answer": 0}, {"article": "\u201cThey seem credible to me, and they might hint that there are other mechanisms, besides just inflammation, linking the GI tract to the brain,\u201d he says.\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\n\u201cIt provides more scientific believability that something in the brain, at a very biological level, seems to be affected by this probiotic.\u201d\n\nNo serious side effects related to the probiotic were reported, suggesting that such a supplement could be a safe way to treat both stomach- and mood-related symptoms.\nOne explanation for the improved mood in the group taking probiotics could be that because their physical symptoms feel better, their mood gets better too.\nStudies have looked at various types of probiotics for IBS patients, the authors wrote, and a recent review found that seemed to work better for gastrointestinal symptoms than another common probiotic, .\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0states that no serious side effects of the probiotic were reported, and this is sufficient for Satisfactory rating.\nIdeally it would have provided additional\u00a0information about\u00a0what would\u00a0constitute\u00a0a \u201cserious\u201d side effect. With\u00a0the way the story is\u00a0worded, it\u2019s possible that other side effects were reported by study participants. This is important information to have in order to\u00a0compare to other treatments for depression or IBS.", "answer": 1}, {"article": "\"For many women with symptoms and especially with concerns about hormone replacement therapy, trying soy for six to 12 weeks to see if it relieves their symptoms could be a first line of treatment,\" says Melissa Melby, PhD, a professor of medical anthropology at the University of Delaware.\nThe study had no industry funding.\nTwo co-authors, not including Melby, have ties to the soy industry.\nNow, researchers who took another look at 19 published studies find that soy supplements may help, at least over time.\nApril 9, 2012 -- Taking soy to relieve hot flashes has received mixed reviews over the years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harm.", "answer": 0}, {"article": "of fat lost over 30 days.\nIn studies, clinically-tested, stimulant-free Capsimax was shown to significantly help improve body composition, promote thermogenesis and lipolysis, decrease appetite, accelerate metabolism and increase resting energy expenditure.\nThe study showed that supplementing with this low dose of Capsimax increased metabolic rate which calculated to an equivalent to burning an extra 116 calories per day.\nProprietary Capsimax is made using OmniBead Beadlet Technology to encapsulate the beneficial heat of concentrated highly-active, natural capsicum in a controlled-release coating--delivering effective levels of capsaicinoids without the oral and gastric burning sensation of unprotected red hot peppers.\nA recent paper, Capsaicinoids Enhance Metabolic Rate in Normal Healthy Individuals using a Novel Metabolic Tracker Breezing Device-An Open Label Placebo Controlled Acute Study, published in the journal Obesity Open Access discussed the findings of the Metabolic Rate (MR) Study, which demonstrated that an extract from red hot peppers boosted metabolic rate (Chen, et al., 2017).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that multiple studies have shown the supplement is safe, however, the safety hasn\u2019t been evaluated or demonstrated in this or other research we could find. A search of PubMed found only three studies involving\u00a0capsicum supplementation. All were short-term and none were designed to look at safety.\nWebMD\u00a0says that taking capsicum supplements\u00a0is generally safe for adults if taken for a brief period of time. However, taking large doses for a long period of time can lead to serious harms including liver or kidney damage.", "answer": 0}, {"article": "The mantra 'time is brain' still holds true.\"\nHowever, a pre-planned interim review of the treatment effectiveness after 200 patients were enrolled in the trial led the independent Data Safety Monitoring Board overseeing the study to recommend early termination of the trial, based on pre-defined criteria demonstrating that clot removal provided significant clinical benefit in the studied patients.\nAlmost half of the patients (48.6 percent) who had clot removal showed a considerable decrease in disability, meaning they were independent in activities of daily living 90 days after treatment.\nBut a milestone study with results published today in the New England Journal of Medicine shows that clot removal up to 24 hours after stroke led to significantly reduced disability for properly selected patients.\nTo select patients for the trial, the researchers used a new approach which used brain imaging and clinical criteria as opposed to just time alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any specific harms from either approach, nor what the rate of adverse effects was in either group. It\u2019s not enough to state only that there was no difference.\nThe release noted that there was \u201cno difference in mortality or other safety end points between the two groups of patients\u201d in the study (those undergoing clot removal and those getting medical only). But the release could have been much clear about specific \u201csafety end-points,\u201d complications of both the clot-removal procedure and drug therapy; and certainly more information about residual disability in both patient groups.", "answer": 0}, {"article": "She said: \"My first thought on diagnosis was that I wanted to survive, I gave little thought to long term or late effects of treatment.\nThe study worked with data on more than 10,000 patients, examining whether current methods of checking if anal cancer has spread to lymph nodes are giving experts an accurate picture of survival rates.\nBy identifying a unique phenomenon, these results will be taken into account by future work and ultimately could lead to better diagnosis of tumour stage and thus better treatment.\nThe results will be crucial to future large scale trials looking at optimum care for anal cancer patients.\nIt is crucial that we tackle what is becoming an increasingly common form of cancer through research studies like this.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes refers to the harm of over treatment and side effects, but never quantifies them. A quote from a patient refers to \u201cjoint pain and continence issues\u201d suffered by some patients but it\u2019s unclear which treatments were responsible.", "answer": 1}, {"article": "Surgeons sometimes fly blind when operating on hard-to-reach anatomical parts or hard-to-see conditions. For visual references inside the brain or body, they often rely on images and scans taken before an operation.\n\nA growing number of hospitals are equipping operating suites with magnetic resonance imaging, CT scanners and other technology that enables surgeons to scan a patient in real time, without having to move them from the operating table.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one\u2019s a close call that we ultimately ruled unsatisfactory. The story is enamored with the greater accuracy that \u201creal-time\u201d imaging should provide for surgeons, but it doesn\u2019t acknowledge that the scalpel cuts both ways. With increased visibility, there\u2019s a greater chance that these scans will turn up so-called \u201cincidental findings\u201d \u2014 problems that no one was looking for and that could well be meaningless to the patient (for example, a slow-growing tumor that would never pose a real risk to the patient). Cutting based on such findings may, in fact, increase morbidity and mortality.\nThe story does get credit for thoroughly explaining the potential risks associated with MRIs. However, the story does not address the risks associated with CT scans at all. CT scans require exposure to a significant amount of radiation, and patients can suffer allergic allergic reactions to the contrast dyes.", "answer": 0}, {"article": "Who and When: More than 140,000 U.S. women who had DCIS between 1998 and 2014; this study compared lumpectomy plus radiation vs. lumpectomy alone, lumpectomy vs. mastectomy, and lumpectomy plus radiation vs. mastectomy\n\nWhat (Study Measures and Outcomes): Use of radiation and/or extent of surgery (exposures); breast cancer mortality rates within 15 years (outcomes)\n\nHow (Study Design): This was an observational study.\nWhy The Research Is Interesting: Patients with DCIS are often treated with radiation after lumpectomy, although it has remained unclear whether this can reduce the risk of dying from breast cancer.\nRelated Material: The invited commentary, \"Systemic Effects of Radiotherapy in Ductal Carcinoma In Situ,\" by Mira Goldberg, M.D., and Timothy J. Whelan, B.M., B.Ch., of McMaster University, Ontario, Canada, also is available on the For The Media website.\nAuthors: Steven A. Narod, M.D., of Women's College Research Institute, in Ontario, Canada, and co-authors\n\nResults: A small improvement in breast cancer survival was associated with radiation plus lumpectomy for DCIS.\nStudy Limitations: Some data were missing; investigators didn't have information on tamoxifen use; treatments in the study population weren't randomly assigned; and the possibility remains that the decision to undergo radiotherapy was associated with other favorable prognostic factors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release briefly discusses harms. The release says patients who received radiation and lumpectomy had more \u201clocal\u201d recurrences of the cancer, but their overall survival was modestly better than patients who did not have radiation (a 0.27% reduction over 15 years).\nThe release should have given some mention to the harms of radiation treatment, particularly since the potential benefit of radiotherapy was very small.", "answer": 1}, {"article": "At 12 months in patients receiving torcetrapib, there was a 72 percent increased in good cholesterol and a 24.9 percent decrease in bad cholesterol.\nThe study said there were still many unanswered questions about Pfizer's pill, torcetrapib, the first in a new class of heart medicines known as a CETP inhibitors, which raise HDL, or good cholesterol, and lower LDL, or bad cholesterol.\nIt was unclear what the mixed bag of data presented at the American Heart Association's Scientific Session in Orlando would mean for CETP drugs under development by Merck and Roche, and another candidate in early-stage development by Pfizer.\nA long-awaited postmortem released this morning of Pfizer's (NYSE: PFE) failed heart drug held out hope for the discovery of a safe version of the revolutionary heart pill.\n\"In any case, it is premature to announce the death of CETP inhibitors on the bases of the torcetrapib experience alone.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the increased risk of death, heart disease and elevated blood pressure with the failed drug. However, in the absence of evidence, the story should not be suggesting that a more \"clean\" version of the drug would not have such harms.", "answer": 1}, {"article": "But it also lowered women's risk of dying from breast cancer by 11% and men's risk of dying from prostate cancer by 23%.\nNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding.\nStudies have also found that aspirin can help patients who have had (or are at high risk for) a heart attack or stroke, and of course it is a good drug to relieve pain.\nIt may also reduce your chances of dying from cancer, according to a study on long-term regular aspirin use and different kinds of cancer.\n(CNN) An aspirin a day may keep the doctor away.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states \u201cNot everyone can take aspirin, particularly if you are at high risk for ulcers and gastrointestinal bleeding. Studies have showed an increased risk of both when taking a daily aspirin.\u201d", "answer": 1}, {"article": "In a third type of weight-loss procedure, known as sleeve gastrectomy, surgeons remove part of the stomach.\nMONDAY, Feb. 21, 2011 (HealthDay News) -- When it comes to shedding pounds and improving or eliminating type 2 diabetes, gastric bypass surgery may be better than other surgical weight-loss procedures, two new studies find.\nBut obese patients should be careful to choose surgeons who have performed a high volume of these procedures before committing, said Dr. Guilherme M. Campos, lead author of one of two papers appearing in the February issue of the Archives of Surgery.\nMore of those undergoing lap-banding, however, needed repeat surgeries (13 percent vs. 2 percent).\nAn editorial accompanying the studies noted the results should be interpreted with caution since longer-term data is not yet available.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the LA Times, this story attached a number to the risk of complications observed during the study. It would have been interesting to see some discussion of the seriousness of these problems, as some data suggest that short-term\u00a0complications with gastric bypass are more grave than those with the band, while longer-term complications with the band may be more frequent and serious. This story mentioned that there were no deaths in either group in the bypass vs. band study, but as with the competing coverage, it didn\u2019t explain that there are well established differences in mortality risk associated with each procedure. We\u2019ll award a passing grade, but the story could have done better here.", "answer": 1}, {"article": "Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on Facebook, Twitter, LinkedIn, and YouTube.\nIn terms of toxicity, just over one-third of patients (34.5%) experienced radiation pneumonitis of any grade, with only two patients experiencing grade 3+ pneumonitis.\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\nForty percent of the tumors were adenocarcinomas, while 29 percent were squamous cell carcinomas and 31 percent did not have a biopsy.\nAt two years following definitive SBRT for lung cancer among elderly patients, survival rates were 73 percent for cancer specific survival (CSS) and 57 percent for overall survival (OS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that just over one-third of the 58 patients experienced radiation pneumonitis (inflammation of lung tissue), and that two had cases severe enough to possibly require oxygen or steroid treatment. However, the release does not mention other harms of this sort of radiation treatment, which can include fatigue lasting for several weeks, neuropathic pain, rib fractures and other problems. There is no mention of any measurements of these other radiation effects.", "answer": 1}, {"article": "Instead, they recruited 20 volunteers who were overweight or obese and assigned them to a week of either egg breakfasts or ready-to-eat cereal breakfasts.\nBoth types of breakfasts had the same number of calories, but the egg breakfasts contained \u201chigher protein quality,\u201d according to an abstract for the study, posted online here.\nThat\u2019s right \u2013 the folks who sell eggs paid for a study that comes to the shocking conclusion that eggs are an ideal breakfast food.\nThe folks who carried out this egg industry-funded research were from the Pennington Biomedical Research Center in Baton Rouge, La.\nNews flash: Eggs are really good for you.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In just a line, the story could have addressed whether eating an egg a day, as participants did during this study, is safe from a heart health standpoint (eggs contain a lot of cholesterol), but that\u2019s probably splitting hairs. We\u2019ll call this not applicable since there aren\u2019t really any harms from eating a reasonable amount of eggs. Most research from large cohort studies (Nurses\u2019 Health Study and Health Professionals Follow Up study) of diet have shown no increased risk of cardiovascular disease among regular egg eaters.\u00a0 Nonetheless, just as it popped into our reviewers\u2019 minds, we bet it popped into readers\u2019 minds as well \u2013 yet wasn\u2019t addressed.", "answer": 2}, {"article": "Attention, memory, and language improved.\nThe Mediterranean diet can improve your mind, as well your heart, shows a study published in the open-access journal Frontiers in Nutrition.\nThe main foods in the Mediterranean diet (MedDiet) include plant foods, such as leafy greens, fresh fruit and vegetables, cereals, beans, seeds, nuts, and legumes.\nThey envision that the utilization of a dietary pattern, such as the MedDiet, will be an essential tool to maintain quality of life and reduce the potential social and economic burdens of manifested cognitive declines like dementia.\nBy sticking to the Mediterranean diet the study showed that people had slowed rates of cognitive decline, reduced conversion to Alzheimer's, and improved cognitive function.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There appear to be minimal to no health debits stemming from the Mediterranean diet, assuming one eats in moderation.", "answer": 2}, {"article": "The F.D.A.\n\u201cThere are very few treatments in all of cardiovascular medicine that could claim that \u2014 I can think of heart transplant, and that\u2019s it.\u201d\n\nThe results were even more notable, he said, because the early versions of the devices were clunky, stiff and difficult to use.\nAnd new data from another large study by Edwards found that patients at intermediate risk did better with the newest version of its valve than would be expected with surgery in the first 30 days, when most deaths occur.\nThe consensus of the group, he said, was that \u201cnot every one of the 1,150 cardiac surgery programs or the 1,600 cath labs in the U.S. should be able to do it.\u201d\n\nIn June 2014, after another company, Medtronic, did similar studies, its device was approved, too, for high-risk patients.\nMore recent 2015 data from Medtronic indicates that its valve is better than surgery for high-risk patients, resulting in fewer deaths, at least in the first two years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article mentions several risks of the procedure such as stroke risk and paravalvular leak, but hard numbers are missing. How many patients undergoing TAVR or conventional valve surgery suffer strokes? How common is leakage? All the story provides are generalizations: \u201cThere is some question about whether the process of inserting the new valves loosens debris that can cause strokes. One large study found a higher stroke rate in patients receiving valves without surgery compared with those receiving valves with surgery. Another large study did not find this effect. The valves also tend to leak slightly around the edges. New designs are ameliorating this problem, but not solving it.\u201d\nWe\u2019ll reward the story here for at least mentioning some potential risks. But it is disappointing that such a lengthy report includes only one-sided, glowing patient reviews of TAVR. Why is there not a single account of any patient who suffered a stroke or other serious complication?\nTo the article\u2019s credit, it also raises the issue of limited evidence about the valves\u2019 durability: \u201cFor now, evidence of the procedure\u2019s effectiveness exists only for the sickest patients and there are only five years of data on how long the valves last.\u201d", "answer": 1}, {"article": "The page may no longer exist or may have moved to another web address. Try again to locate what you want by choosing a section from the navigation menu at left, viewing our Site Map or using the search box below.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that hypnosis comes with no known risks, unlike hormone replacement therapy.", "answer": 1}, {"article": "As a result, she was having trouble at work and in all other aspects of her life, Police recalled.\nThe study found that women taking the medicine had an average of five fewer hot flashes a week, compared with three fewer among women taking a placebo.\nHowever, he cautioned that its long-term effects aren't known.\nChemotherapy may induce early menopause, and drugs that reduce estrogen levels may make hot flashes worse, the research team noted.\nThe drug could be game-changing for certain women, said Dr. Alice Police, regional director of breast surgery at Northwell Health Cancer Institute in Sleepy Hollow, N.Y.\n\n\"This is a really important advance in survivorship and compassionate cancer care,\" added Police, who wasn't involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article says that side effects included constipation, mild diarrhea, dry mouth, dry eyes, episodes of confusion and difficulty urinating. It\u2019s not noted if these side effects were seen in both the low-dose and high-dose groups. There is also no indication of which side effects were most common or how many women experienced them.\nImportantly, though, the article does note that the long-term effects of the drug aren\u2019t known and that oxybutynin is in a class of drugs that \u201chave been linked with mental decline\u201d and that previous studies have found \u201cthe drugs may raise the risk for problems with short-term memory, reasoning and confusion, and may also hike the risk for dementia among older patients.\u201d\nInformation on ClincalTrials.gov about the trial suggests this study evaluated two doses in an effort to find an effective dose with fewer side effects.", "answer": 1}, {"article": "(\u201cEnjoyed\u201d?\nThe research in question involved mice, not women.\nThe Baylor scientists were able to correct for those variables.\nThe mice with running wheels voluntarily ran an average of more than six miles a night, decreasing to about two miles late in pregnancy.\nPregnancy experts, including those at the American College of Obstetricians and Gynecologists, recommend that most pregnant women get 30 minutes of exercise a day.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms of vigorous activity during pregnancy\u00a0were not discussed.", "answer": 0}, {"article": "Urothelial carcinoma is the most common type of bladder cancer and occurs in the urinary tract system, involving the bladder and related organs.\nThese are distinct programs intended to facilitate and expedite the development and review of certain new drugs in light of their potential to benefit patients with serious or life-threatening conditions.\nThe FDA granted the Tecentriq application breakthrough therapy designation, priority review status and accelerated approval for this indication.\nTherefore, today the FDA also approved the Ventana PD-L1 (SP142) assay to detect PD-L1 protein expression levels on patients' tumor-infiltrating immune cells and help physicians determine which patients may benefit most from treatment with Tecentriq.\nThis trial measured the percentage of patients who experienced complete or partial shrinkage of their tumors (objective response rate).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a description of side effects of this treatment. The most common ones included fatigue, decreased appetite, nausea, urinary tract infection, fever (pyrexia) and constipation. The release also mentions that patients taking the drug have an increased risk of infection and serious side effects that are \u201cimmune-mediated.\u201d We would have liked a bit more context on what this term means for patients.", "answer": 1}, {"article": "Cabozantinib, also known as XL184, is an oral drug designed to limit blood supply to tumors and to block two segments of a pathway used by cancer cells to grow and spread.\n\u201cMen with late-stage prostate cancer usually die from bone disease.\u201d\n\nAfter 12 weeks of treatment, 31 patients were randomly selected to receive either a placebo or cabozantinib.\nExcluding patients on placebo, the median survival without disease progression was 29 weeks.\nThe disease remained stable in 23 other patients, or 21 percent, and worsened in three.\nBut two ovarian cancer patients died from cabozantinib-related side effects - one from bowel fistula and one from intestinal perforation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said \u201cSide effects of cabozantinib included fatigue, high blood pressure and hemorrhage\u201d but it never explained how often these were seen.\u00a0 In 1% of patients?\u00a0 10%\u00a0 All of them? ", "answer": 0}, {"article": "If green coffee extract were a medication seeking approval from the Food and Drug Administration, these results would make it a viable candidate \u2014 more than 35% of subjects lost more than 5% of their body weight, and weight loss appeared to be greater while subjects were taking the pills than when they were on the placebo.\nThere were no signs of ill effects on any subjects, Vinson reported Tuesday.\nThe pilot study drew strong cautions from several scientists who weren't involved in the research.\nIt would be difficult to take without a lot of water, Vinson reported.\nOf the 16 volunteers, six wound up with a body mass index in the healthful range.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the HealthDay story on this criterion, quoting an expert on a specific concern about malabsorption within the gut \u2013 \u201ca condition that would lead to weight loss as well as malnutrition, heart arrhythmias and other problems.\u201d", "answer": 1}, {"article": "\"Men with low-risk prostate cancer who want to have a period of observation should consider using this drug.\"\nTUESDAY, Feb. 15, 2011 (HealthDay News) -- Men who have a low prostate-specific antigen (PSA) score when they're first tested may not need to be screened annually and probably don't need to undergo a biopsy, a new study suggests.\n\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\nA second study also being presented at the symposium found that a drug already used to treat enlarged prostate gland may delay the progression of low-risk, early prostate cancer among men who choose a wait-and-see approach to treatment.\nDutch researchers presenting the findings at the Genitourinary Cancers Symposium in Orlando, Fla., said that few men with a PSA below 3.0 ng/ml were likely to develop prostate cancer and die of the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential for harm associated with adopting any of the\u00a0aspects of prostate cancer testing and treatment covered in the story were not clearly or completely discussed.\nFor example \u2013 what are the consequences of a surgeon not being proficient with robotic surgery?\nWhat are the side effects for the medication Avodart? How often are they seen?", "answer": 0}, {"article": "\u201cThis M.R.I.\nMrs. Sugrue said the doctor urged her and her husband to resist doing an Internet search for glioblastoma because they would just read that it was a death sentence.\nDr. Boockvar said he thought that if he could just keep patients alive for two years, more advances might come along and give them time.\nBy mid-November, the researchers had treated five patients, including Mr. Sugrue; they first infused mannitol, waited five minutes and then sprayed in the Avastin.\nThey said they tried to follow his advice, but when the subject of prognosis came up in an interview, both had tears in their eyes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that the infusion method has not been proven safe\u2013indeed, that\u2019s what the current study is designed to find out. \nIn addition, the reporter cites the doctor\u2019s estimated risks of the treatment the featured patient faces: a 5 percent chance of becoming \"visibly weak\" and a 1 percent chance of left-side paralysis.\u00a0\n\u00a0", "answer": 1}, {"article": "\"A five-millimeter distance will make you either overexposed or underexposed,\u201d he explained.\nThe advantages of brachytherapy, also called \"accelerated partial breast irradiation,\u201d are shorter treatment time and a smaller area that is exposed to radiation.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nBrachytherapy also has fewer side effects such as radiation burns.\nBrachytherapy remains a mainstay of prostate cancer treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The most important potential harm of brachytherapy would be a lack of efficacy\u2013that is, a patient would choose it due to its greater convenience, despite what could be a lower success rate. Given the lack of long-term data on efficacy available, this is a significant shortcoming.\u00a0 \nThe article does not acknowledge other potential harms of brachytherapy when used for breast and prostate cancer.\u00a0\u00a0 ", "answer": 0}, {"article": "We're sorry, but we seem to have lost this page.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is almost a throw-away line in the study that says, \" A recent study estimated the epidemiologic impact of DWI-based diagnosis would result in reduced annual TIA incidence (33%) and increased stroke incidence (7%) in the United States.\" Reducing these \"mini-strokes\" by 33% would indeed be a dramatic change, given the number of people who suffer from them, but these are \"warning strokes,\" that can actually force people to change risky behaviors or begin taking the right medications to avoid an actual stroke. Those strokes may have actually climbed by 7% in the theoretical model of a world where diffusion scans were the norm. A 7% increase in strokes could mean an additional 55,650 people suffering a stroke each year, by our count. Again, these numbers would be nice to see in the story.\u00a0", "answer": 0}, {"article": "\"We're always searching for simpler things to do,\" Brooks said.\nBrooks said it would be nice to have a very simple, accurate screening test -- whether that means a breath test or blood or urine tests.\nIn the end, the researchers were able to correctly identify the cancer patients 76 percent of the time.\nBut many people are turned off by those tests.\nNow, a small pilot study suggests such a test could be developed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story mentioned that this test\u00a0would inevitably\u00a0produce\u00a0false-positive results that would lead to\u00a0needless invasive follow-up tests.", "answer": 1}, {"article": "Among them: engaging in regular physical activity, maintaining a healthy weight, and not smoking cigarettes.\nThe benefit, however, may not be as great as believed, says researcher Eric Jacobs, PhD, of the American Cancer Society.\nMany other strategies will also reduce the risk of cancer, he says.\nEven so, he says, \"our results provide additional support for the potential benefit of daily aspirin for [reducing] cancer mortality.\"\nA previous study by others found daily aspirin reduced cancer death risk by 37%.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story acknowledged that \u201ceven low-dose aspirin can lead to problems such as serious gastrointestinal bleeding.\u201d\n\u00a0", "answer": 1}, {"article": "For those with neglect, doctors typically prescribe cognitive rehabilitation, in which therapists teach skills and help the patient become more aware of the affected side of the body.\nThe researchers said that it\u2019s not clear what the amount of improvement they observed would mean for patients in their daily lives.\nIt\u2019s also not clear if the treatment might help most neglect patients, or if the findings only apply to certain groups, she told Reuters Health.\nBut researchers said it\u2019s still unclear what types of patients might benefit from the treatment and by how much.\nHe said that larger studies at multiple treatment sites are needed to determine how helpful magnetic stimulation can be in stroke recovery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention potential adverse effects of TMS or state whether any adverse effects were seen in the study.", "answer": 0}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nThe study is preliminary and doesn't prove cause and effect.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nBut the findings, presented at the American Academy of Dermatology annual meeting, raise an interesting possibility worthy of further study, experts agree.\nMarch 8, 2010 (Miami Beach, Fla.) -- Once again, cholesterol-lowering statin drugs have been shown to be good for more than the heart.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story failed to note any of the potential side effects of statins.", "answer": 0}, {"article": "They are often obtained through diet by eating fish.\nRamakrishnan said it's probably too soon to recommend routine use of DHA supplements for pregnant women, because the findings weren't \"dramatic.\"\nAt times, however, babies in the DHA group experienced longer duration of rashes and vomiting, the study authors noted.\nRamakrishnan said Mexican women tend to be deficient in DHA, much like many American women are.\nMONDAY, Aug. 1, 2011 (HealthDay News) -- When women take a supplement of the omega 3 fatty acid DHA during pregnancy, their babies have fewer cold symptoms and shorter illnesses, new research indicates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that the babies whose mothers had recevied prenatal supplementation with DHA had bouts with vomiting or rashes that lasted longer than the babies born to mothers in the control group.\nThe story mentioned that the women in the study had low DHA intake which was also the case for women in the US. \u00a0This appears to be an overstatement of the need for DHA supplementation for women in the US and the story should have touched on whether excessive DHA consumption might have potential consequences for pregnant women such as bleeding or problems with vitamin E levels.\nIn addition, the comments by Dr. Wu suggested that women use this supplement along with prenatal vitamins even though this particular study did not begin supplementing until 18-22 wks. A large randomized clinical published in JAMA showed some adverse outcomes among the female infants exposed in utero (not males), namely lower language scores and lower adaptive behavior scores.\u00a0 We don\u2019t know why the story chose to interview Dr. Wu, but perhaps her comments needed to be addressed by other expert perspectives as well.", "answer": 0}, {"article": "King said the training offered in the program was slightly different from the current Posit Science offering and that it was unclear whether speed training would help people who are already at risk for dementia.\n\u201cI do think we will know more after the paper is reviewed.\u201d\nEdwards also was a paid consultant for the company for part of 2008.\nThe program is now incorporated in Posit Science\u2019s BrainHQ.com brain training program.\nThe program got harder with each correct answer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to imagine any serious harms from using brain games, other than time lost.", "answer": 2}, {"article": "For more on chemotherapy, visit the American Cancer Society.\nWhat's more, blood analyses revealed that those in the fish oil group who had the biggest bump in bloodstream EPA concentrations also had the greatest muscle mass gains.\n\"But I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot,\" she added.\nSpecifically, nearly 70 percent of those in the fish oil group either kept their pre-chemo muscle mass or gained muscle.\n\"Because first of all they do have wasting from the cancer itself, which is very metabolically active and eats up your energy stores.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The independent perspective from the Texas dietitian did include this: \u201cBut I would caution that the amount of pure concentrated fish oil supplement the people in this study were given is a lot. Much much more than any recommended dietary allowance, along the lines of two to three servings of fish per week.\u201d\u00a0 But neither that comment nor any other line in the story explicitly mentioned the possibility of harm from the mega doses. Is it possible there could be interactions with drugs the lung cancer patients were taking?", "answer": 0}, {"article": "People in the early stages of dementia.\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nCAVEATS The study involved a relatively small number of participants and lasted a short time; a larger and longer study would be needed to adequately test effectiveness and safety.\nNonetheless, conclusive evidence about a treatment's effectiveness is rarely found in a single study.\nAlso, among those in the 40-milligram group, people carrying what is sometimes called the Alzheimer\u2019s gene (APOE-e4) showed more improvement than non-carriers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets credit here for pointing out, as part of the explanation of the study\u2019s limitations, that a longer and larger study would be necessary to determine whether the drug is safe as a treatment for Alzheimer\u2019s. The competing Fox News story simply took the lead researcher\u2019s word for it that there were no harmful side effects.\nThat improvement aside, the story still had a responsibility to report on the harms that were documented in the study, which included dizziness and congestion. The story didn\u2019t do that, which is why we\u2019re rating it unsatisfactory here.", "answer": 0}, {"article": "According to Kramer, \"This randomized study concludes that [aspirin's] use is not only effective for reducing the incidence of preeclampsia at term, but also preterm.\nThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\nACOG already recommends that women who are at high risk of preeclampsia take a low-dose baby aspirin beginning between 12 and 28 weeks of pregnancy.\nThe new study looked at an aspirin dose of 150 milligrams (mg) per day because some past studies with smaller daily doses of aspirin have produced conflicting results, according to Nicolaides.\nJust 13 women in the aspirin group developed preeclampsia, while 35 women in the placebo group developed the complication, the findings showed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cThere were no serious side effects for expectant mothers, or adverse events for the babies related to aspirin use during pregnancy, the researchers noted.\u201d To its credit, it also adds, \u201cHowever, as with all drugs, women should talk to their doctor about the use of aspirin in pregnancy before taking up this regimen, because aspirin does increase the risk for bleeding.\u201d", "answer": 1}, {"article": "Since 1998, the Food and Drug Administration has required that breakfast cereals, breads, rice, pasta and other grain products made with enriched flour come fortified with folic acid.\nMichael Dunn, the Brigham Young University food scientist who led the study, cannot comment on the test results while they're under FDA review, but he has previously called them encouraging.\nBut the FDA worries that this alkaline treatment could also \"affect the stability of added folic acid,\" the agency told The Salt in a statement.\n\"The story of folic acid is one of the great public health stories of \u2014 ever,\" says Dr. R.J. Berry, who works with the Division of Birth Defects and Developmental Disabilities of the Centers for Disease Control and Prevention in Atlanta.\n\"The FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses the FDA\u2019s worry that a chemical used on corn flour could interact with the corn masa flour. It quotes the FDA which says:\u00a0\u201cThe FDA is concerned that the breakdown of folic acid in corn masa flour could yield a substance that raises concerns about safety.\u201d It would have been nice for the story to explain more clearly what concerns are raised \u2014 this seems pretty vague \u2014 but we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "According to the U.S. Department of Agriculture\u2019s 2010 Dietary Guidelines, most Americans don\u2019t get enough fiber.\n\u201cIncreasing dietary fiber intake in the general public is of great public health significance,\u201d the Chinese team concludes.\nThat was after accounting for differences in risk factors like alcohol drinking, weight, hormone replacement therapy and family members with the disease.\nThe results \u201ccan identify associations but cannot tell us what will happen if people change their behavior,\u201d said John Pierce, a cancer research at the University of California, San Diego, who was not involved in the work.\nSo to get more clarity, the researchers combined 10 earlier studies that looked at women\u2019s diets and followed them over seven to 18 years to see who developed cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While there are hypothetically potential harms of too much fiber in the diet, this story in this context didn\u2019t need to drill down on them.", "answer": 2}, {"article": "National Jewish Health is the leading respiratory hospital in the nation.\nWhile it may seem counterintuitive to treat bacteria with more bacteria, experts say this approach seeks to restore the natural microbial balance of healthy skin.\nThe next steps involve testing those different combinations, ensuring they're safe and conducting a longer trial to see if the benefits of bacterial cream can truly provide a permanent solution for eczema patients.\nPowerful antibiotics are commonly prescribed for eczema, but they kill good bacteria on patients' skin along with the bad.\nCreams containing corticosteroids are also often prescribed to eczema patients, but they come with harsh side effects, and patients usually can't tolerate them for long periods of time.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms from using the lotion are mentioned.\nCould there be allergic reactions? If the lotion does, indeed, reduce the amount of Staph. aureus on the skin, are there consequences to that? Or consequences to changing the skin\u2019s microbial balance in general?\nAlso, many eczema patients are acutely aware that their skin is not just fragile, but also may have open sores; should a bacterial lotion be applied to broken skin? And does this put them at risk of a bacterial infection that can spread?", "answer": 0}, {"article": ".\nThey each slept alone, and the bedroom layout with furniture arrangement was kept consistent.\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\n\u201cThe exposure we are under while asleep is continuous .\nOn another night, the windows and door to the room were kept closed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There appear to be no immediate potential harms, but the story mentions indirect ones like extra noise or concerns about security.", "answer": 1}, {"article": "\u201cA whole world of freedom opens up [for these individuals] because you can move about a city like this (New York City) or anywhere much more easily, and the dogs can become your eyes,\u201d she said.\nThe quiz on Restasis.com can help individuals learn whether they\u2019re a candidate for the drug.\nIf you think you may be suffering from CDE, Tomei advised visiting your doctor to receive a diagnosis.\nSometimes, individuals with CDE have trouble opening their eyes, but Tomei said she went to the doctor and reported mild but incessant itchiness and dryness, and was diagnosed with CDE.\nOn Restasis.com, you can take the brand\u2019s \u201cdry eye quiz\u201d\u2014 for every quiz taken, Allergan has agreed to donate $1 to the organization.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nothing in this story discusses\u00a0any harms, but the product label tells us that \u201cIn clinical trials, the most common adverse reaction following the use of RESTASIS\u00ae was ocular burning (17%). Other reactions reported in 1% to 5% of patients included conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, and visual disturbance (most often blurring).\u201d \u00a0The label also says: \u201creported reactions have included: hypersensitivity (including eye swelling, urticaria, rare cases of severe angioedema, face swelling, tongue swelling, pharyngeal edema, and dyspnea); and superficial injury of the eye (from the vial tip touching the eye during administration).\u201d", "answer": 0}, {"article": "Her daughter took her grocery shopping.\nFor one, the treatment doesn't work for those who have had cataract surgery.\nThe treatment doesn't work for those who have had cataract surgery.\nBut if they're scanning the room to see exactly where the clock is, they use the other eye, which also has end-stage macular degeneration.\n\"In order to implant this device, we need to remove the natural lens, or the cataract, and then use a portion of the natural lens to position and support the telescope,\" says Williams.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The fourth sentence talks about the potential harms, a rarity for any health story. In fact, the whole second paragraph should be part of a template for most health writing.\u00a0\"Findings from the clinical trials show that the telescope does improve vision for the majority of patients. Still, there are some concerns about corneal damage, since the telescope is relatively large inside the eye. And the population who might benefit from the new device is somewhat limited. The treatment doesn\u2019t work for those who have had cataract surgery. And for those who catch the disease early on, there may be better options.\" One of our reviewers just printed that out and taped it to his computer screen.", "answer": 1}, {"article": "The research was published in the New England Journal of Medicine.\nIn a study published in the Annals of Neurology in 2010 researchers tested deep brain stimulation in six patients over the course of a year and found the treatment to be relatively safe.\nOne team has already tried deep brain stimulation in Alzheimer\u2019s patients.\nScientists are increasingly focused on ways to treat the memory-robbing disease, which affects more than 5 million Americans.\nIn Alzheimer\u2019s disease, this area of the brain is affected early on, when signs of dementia begin to appear.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While this story (unlike the HealthDay story we reviewed) at least mentions that deep brain stimulation is \u201cvery invasive,\u201d it should have listed at least some of the major risks of implanting electrodes into the brain connected to stimulation devices under a patient\u2019s skin, including bleeding, strokes and infections.\nA recent study of deep brain stimulation (DBS) involving 99 Parkinson\u2019s patients concluded that DBS\u00a0 \u201chas an adverse effect on executive functions with implications for daily life of the patients and their relatives.\u201d Almost 10% of those DBS patients had psychiatric events including a suicide attempt.", "answer": 0}, {"article": "Neuroblastomas are cancers that start in early nerve cells and commonly form in the tissue of the adrenal glands, near the kidneys.\n\"High-risk neuroblastoma can be resistant to traditional therapy, and survival can be poor.\nThis research is an excellent example of the collaboration between Nemours Children's Hospital and the University of Central Florida.\n\"This shows that nanoparticles can be an effective delivery vehicle for cancer drugs,\" said Professor Sudipta Seal, who directs of UCF's NanoScience Technology Center and Advanced Materials Processing Analysis Center, and is a collaborator on the study.\nThis research demonstrates a novel method of treating this tumor without the toxicity of aggressive therapy that can also have late effects on the patient's health,\" said Tamarah J. Westmoreland, MD, PhD, a pediatric surgeon at Nemours Children's Health System and senior author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned in the news release. Some scientists are concerned that nanotechnology may have toxic effects on the body, especially the lungs.\nDepending on the nanotechnology, other organs may also be at a risk for damage. In particular, some nanoparticles may affect the endocrine system, leading to changes in hormone levels, sexual characteristics, reproduction and development.\nThe news release talks only about the benefits of nanoscience research without any description of its potential harms. Consequently, we give it a Not Satisfactory rating.", "answer": 0}, {"article": "When Downing expressed concerns about the drug, she said the doctor blew her off: \"He said, 'What are you worried about?\nBy contrast, she said, the multiple screenings that Caroline received carefully evaluated the child as an individual and homed in on the kind of therapy that was best for her.\nShortly after Candace's death, the Food and Drug Administration placed black-box warnings on several antidepressants to say they elevated suicidal thinking among some children.\nCandace's treatment, Downing said, involved a one-size-fits-all approach to mental health that sees medications as a magic pill.\nDowning said she agreed to have her older daughter screened because the child was obviously in distress, but she told school officials that if an evaluation led to a prescription for medications, she would refuse to go along.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While indicating that the use of SSRI medication by adolescents has been associated with increased risk of suicide, the story provided no quantitative information about how likely this is to occur. \u00a0The story did mention the potential for over-prescribing of antidepressants. \u00a0However, it did not mention other potential harms such as stigma, mis-diagnosis, distracting from more important health problems, and treatment without adequate follow-up potentially leading to net harm.", "answer": 0}, {"article": "Newsday's coverage of the Class of 2019, led by Mariano Rivera and Mike Mussina.\nA hijab, a turban, a beard: What aren\u2019t you seeing?\nFrom a Catholic school uniform to a hijab, LIers talk about their religious clothing.\nHere\u2019s how he got out.\nAt 14, MS-13 was his family.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One expert is quoted saying, \u201cBut in general, the kind of exercise we\u2019re talking about is certainly not going to hurt.\u201d But suggestions for incorporating techniques such as walking backwards would seemingly come with some risk, especially in an unsupervised location.", "answer": 0}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\nThis compares to just 21 percent for PSA alone, the researchers told a meeting of the American Urological Association in San Francisco.\nThey said Gen-Probe\u2019s Progensa PCA3 test caught about half the actual cases of prostate cancer in men who had abnormal PSA levels or digital rectal exams, and had about a 20 percent \u201cfalse positive\u201d rate.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did include sufficient information to conclude that with this test, there were still both false positive and false negative results. \u00a0There was, however, no discussion about whether this test had any role in helping men who really didn\u2019t require treatment to avoid such treatment. ", "answer": 1}, {"article": "\"We estimate that use of [Brilinta] instead of [Plavix] for one year in 1,000 patients with acute coronary syndromes and who are planning to undergo an invasive strategy at the start of drug treatment would lead to 11 fewer deaths, 13 fewer myocardial infarctions, and six fewer cases of stent [clotting] without an increase in the rates of major bleeding or transfusion,\" conclude study researcher Christopher P. Cannon, MD, and colleagues.\nAnd in the new study, patients had less bleeding after stent installation.\nBoth drugs increase the risk of dangerous bleeding.\nBut there's a problem with Plavix, and with a newer, stronger drug in the same class called Effient.\nAnd since the drugs irreversibly bind to blood-clotting platelets, a patient has to stop taking these drugs for five to seven days before the body can make enough new platelets.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did discuss the main harm \u2013 the difference in bleeding \u2013 and that since\u00a0 ticagrelor must be taken twice a day, missing a dose can be very dangerous since the drug wears off so quickly.", "answer": 1}, {"article": "Anderson Cancer Center in Houston.\nThe study is a phase 2 study, meant to evaluate the vaccine's effectiveness and any side effects.\nPhase 3 studies are needed before the vaccine could be approved.\nThe study involved 217 breast cancer survivors who had gone through their treatment and were free of disease at the start of the trial.\nThe investigators found that in the vaccinated group, 86 percent of patients showed a significant response, compared with 27 percent of those in the \"control\" group who did not get the injection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study did not discuss any potential side effects of the current vaccine.", "answer": 0}, {"article": "Pimentel will also present the research on Sunday, May 17th, at Digestive Disease Week 2015 in Washington, D.C.\n\nPimentel and fellow researchers studied nearly 3,000 people, comparing IBS patients to those diagnosed with inflammatory bowel disease, celiac disease and those with no GI disease.\nFatigue and the stress of trying to plan one's life around visits to the bathroom can be debilitating.\n\"The fact that we can now confirm the disease through their blood, not their head, is going to end a lot of the emotional suffering I have seen these patients endure.\"\nThe new blood tests identify the presence and amount of specific antibodies reacting to the toxins.\nAn estimated 10 percent of the world's population suffers from the condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No test is 100% accurate. A wrong test result may lead doctors to causes that may not actually be the problem. As such it may lead to inappropriate treatments. That\u2019s a harm that should have been mentioned.", "answer": 0}, {"article": "A diet that includes tomatoes could lower the chance of having a stroke.\n\nA new study shows that men who had the highest levels of lycopene\u2014an antioxidant found in tomatoes\u2014had fewer strokes than men who had the lowest level of lycopene in their blood. Overall, the risk of strokes was reduced by 55%.\n\nThe study, based in Finland, will be published...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this not applicable as we did for the competing stories, but with the caveat: Lycopene supplements haven\u2019t been well studied and might cause adverse effects.", "answer": 2}, {"article": "According to the U.S. Centers for Disease Control and Prevention, high blood pressure affects 30 percent of American adults.\n\"I think it's really interesting physiology,\" added Penn, noting that the results would need to be repeated multiple times before a therapy based on it could be developed.\n\"I thought it was compelling, though single cases are always questionable\" to generalize.\nMONDAY, Jan. 24, 2011 (HealthDay News) -- Doctors administering deep brain stimulation to control a patient's severe pain report that they discovered the treatment consistently lowered the man's hard-to-control high blood pressure.\n\"This is a case report, and not a treatment for anything,\" he said, adding, \"There are risks to this procedure and one has to really look at the tradeoffs.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes passing reference to risks, but it doesn\u2019t mention any specific problems and doesn\u2019t discuss how commonly they occur with DBS. This is, after all, brain surgery, and there are a host of things that can go wrong, ranging from obvious problems such infections,\u00a0bleeding, and strokes,\u00a0to more subtle effects such as cognitive impairment. The story should have explored these. The competing WebMD story, while failing to quantify the harms, at least listed quite a few of the potential problems.", "answer": 0}, {"article": "We keep them at that temperature for the first 24 hours, at which time we re-warm them,\" Likosky explains.\nThe American Heart Association recommended more than a year ago using induced hypothermia for cardiac arrest patients who are stable.\nSays Likosky: \"If you cool the brain down, it may be that it uses less energy and (is) less likely to damage itself over that first 24 hours.\"\nThe idea is that cooling a comatose patient after a heart attack prevents brain damage.\n\"We know how to use it but we really don't know how it works,\" says cardiologist Mark Vossler.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms that might be associated with hypothermia treatment after a heart attack.\u00a0 There was no discussion of\u00a0conditions or medication use that might lessen or eliminate the benefit that this treatment might confer.\nAlthough one of the clinicians said \"ice packs can do the job\", there have been some studies to suggest that the percentage of surviving patients is lower in the group whose temperatures went too low.", "answer": 0}, {"article": "Load up on berries.\nBut he says it's important to point out that the women in this study weren't prime candidates for heart attacks anyway.\nIt's certainly not a perfect way to detect how certain foods may influence health, but it identifies important associations.\nAnd if they're out of season, like now, studies show frozen berries have similar levels of beneficial compounds.\nAnd when you eat a steady diet of them, they seem to have a number of positive health effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like both the HealthDay and TIME articles, the NPR story did not discuss potential harms. But all health interventions have harms, as well as benefits and costs. We looked the other way on costs but not on harms.", "answer": 0}, {"article": "For more information on bisphosphonates, visit U.S. Food and Drug Administration.\n\"As a whole, the study is negative,\" study author Dr. Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday news conference on the findings.\nAnderson Cancer Center, was not involved in the study but put it in perspective.\nSaid Coleman: \"Zoledronic acid cannot be routinely recommended for prevention of cancer returning, but it remains a very good drug for patients where the cancer has already spread to the bone.\"\nThe focus was on disease-free survival.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article accurately reported on the incidence of a serious side effect among the women taking zoledronic acid.", "answer": 1}, {"article": "March 7, 2011 -- Traditional Chinese acupuncture may be useful in reducing the severity of hot flashes and other symptoms of menopause, a new study suggests.\nThe rest were treated with \u201csham\u201d acupuncture needles that were blunted and did not penetrate the skin.\nHalf of them received traditional acupuncture treatment.\nThose in the comparison group were treated with shams needles at the same acupuncture points.\nTwenty-seven women received traditional Chinese acupuncture twice a week for 10 sessions from an experienced and licensed acupuncturist.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 only of benefits.", "answer": 0}, {"article": "\"These cells proliferated rapidly, and were susceptible to damage to their DNA - both factors that help them transition towards cancer,\" she said.\nAustralian researchers have discovered that an existing medication could have promise in preventing breast cancer in women carrying a faulty BRCA1 gene.\nIf confirmed in clinical studies, this would provide a non-surgical option to prevent breast cancer in women with elevated genetic risk.\nProfessor Lindeman, who is also a medical oncologist at The Royal Melbourne Hospital, said the discovery of RANK as a marker of cancer precursors was an important breakthrough, because inhibitors of the RANK signalling pathway were already in clinical use.\nCurrent cancer prevention strategies for these women include surgical removal of the breasts and/or ovaries, which can have serious impacts on people's lives.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms at all. Again, this is particularly problematic given that denosumab is already on the market and has well-documented potential harms. For example, the websites for both XGEVA and Prolia (denosumab\u2019s current trade names), note that the drug can cause a wide variety of problems, including (but not limited to): severe pain in muscles, bones and joints; serious infections that may require hospitalization; severe allergic reactions; osteonecrosis in the jaw; thigh fractures; and nausea.", "answer": 0}, {"article": "Game over?\nFirst, only about 1 in 20 men in the Swedish study had a prostate cancer diagnosis based on a high PSA level.\nFor this group, surgery saved one life for every seven men who had prostatectomies \u2014 considered a favorable ratio.\nThe study found 38 percent fewer prostate cancer deaths among men randomly assigned to the surgery group versus those in what the Swedes called the watchful-waiting group.\nBut Smith warns against assuming those results will settle the question of how men with early-stage prostate cancer should be treated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative information comparing the rate of all cause mortality in the two groups; it also indicated that more men in the group that didn\u2019t have surgery had hormone therapy. \u00a0To be balanced, the story should have indicated\u00a0that there are commonly occurring side effects from surgery to remove the prostate such as incontinence and sexual problems.\nThe competing HealthDay and AP stories, by comparison, did a better job of this.\nThe story would have been better if it had indicated that for men with prostate cancer, taking hormone therapy means that the cancer has progressed; further providing readers with insight about the absolute rates at which men in the two groups needed hormone therapy would have provided a more complete picture.", "answer": 0}, {"article": "And sometimes we have to make decisions about using drugs that are probably a little less effective but at the same time we have to take into account the financial standpoint,\" said Dr. Jay Brooks, chairman of hematology/oncology at Ochsner Health System in Baton Rouge.\nRead the full guideline at the American Society of Clinical Oncology.\nThe new guidelines replace previous guidelines issued in 2002, and subsequent updates in 2003 and 2004.\nAromatase inhibitors are not effective in this age group, the experts note.\nCrystal Denlinger, assistant professor of medical oncology at Fox Chase Cancer Center in Philadelphia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "\"Why throw away an important tool?\"\nA scientific review, published in August by the\n\n, highlighted the downside of doing breast self-exams: Women taught to perform the monthly ritual wind up having unnecessary biopsies.\nSelf-exams also appeal strongly to some younger women, whose main screening test is a manual exam done by a doctor or nurse.\n\"One danger of pushing breast self-exams on patients is that they may be falsely reassured by it and opt out of their mammograms,\" said Dr. Heidi Nelson, medical director of the\n\nin Portland.\nFurther, decades of research still have not produced good evidence that self-exams make any difference in breast cancer survival.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists the downsides of screening via a self-breast exam, namely,\u00a0 over treatment via biopsies for false positives and false reassurance that mammography is not needed. The story appropriately notes a woman\u2019s individual risk is a factor when choosing how and when to be screened. A woman at higher-risk may feel that\u00a0 monitoring tissue changes via self-breast exams is useful.\n\u00a0", "answer": 1}, {"article": "Doctors can slow macular degeneration with vitamins, laser surgery, stem cell treatments, and even implantable miniature telescopes.\nBut Dr. Grazia Pertile, director of ophthalmology at the Sacred Heart Don Calabria in Negrar, Italy and one of the Italian researchers, said in a written statement that her team's device could be \u201ca turning point in the treatment of extremely debilitating retinal diseases.\u201d\n\nShe\u2019s not alone in that assessment.\nRelated: This Revolutionary Gene-Editing Tool Could Change the World\n\nWhen the prosthesis was tested in rats, the animals' pupils constricted in response to exposure to light.\n\u201cThis is definitely a game changer,\u201d Dr. Kapil Bharti, an investigator at the National Eye Institute in Bethesda, Maryland who is not involved with the research, says.\nThe new prosthesis is designed to be implanted onto the back wall of the eye, where it absorbs light and transforms it into an electrical signal that stimulates the still-active retinal cells to restore vision.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article makes no\u00a0mention of harms. The story makes clear that the new devices have not been tested in humans, but there must be\u00a0data on the risks of implanting the\u00a0current devices, the FDA-approved artificial retinas mentioned in the article. A brief\u00a0mention of such\u00a0risks would help give readers a sense of the risk-benefit balance should these high-tech devices make it to the market in the coming years.", "answer": 0}, {"article": "Dong, an expert in vitamin D and a professor in the MCG Department of Population Health Sciences, says about 15 minutes daily in the \"young\" sun - between 10 a.m. and 2 p.m. - but before your skin starts to get pink, is the best source of vitamin D.\n\nFoods like milk, milk products like cheese and yogurt, fatty fish like mackerel and sardines, some greens like kale and collards and fortified cereals also are good sources.\nThe 4,000 upper-limit dose restored healthy blood level quicker - by eight weeks - and was also better at suppressing parathyroid hormone, which works against vitamin D's efforts to improve bone health by absorbing calcium, they reported.\nThe dose, now considered the highest, safe upper dose of the vitamin by the Institute of Medicine, reduced arterial stiffness the most and the fastest: 10.4 percent in four months.\nParticipants taking 4,000 international units - more than six times the daily 600 IUs the Institute of Medicine currently recommends for most adults and children - received the most benefit, says Dr. Anas Raed, research resident in the MCG Department of Medicine and the study's first author.\nAt 600 IUs, arterial stiffness actually increased slightly - .1 percent - and the placebo group experienced a 2.3 percent increase in arterial stiffness over the timeframe.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not delve into the side effects of taking high doses of vitamin D over a long period of time. These side effects include kidney stones, which should have been addressed. The study does note, though, that no side effects were reported in the trial.", "answer": 0}, {"article": "For more on heart failure, visit the American Heart Association.\nFor the study, Lenihan and his colleagues randomly assigned 40 patients to get an infusion of cimaglermin or a placebo.\nAccording to the results of a small phase 1 trial, a single intravenous infusion of the drug cimaglermin was safe and, at high doses, improved heart function for at least three months.\nThe improvement lasted 90 days, with the maximum increase in heart function reached in 28 days, the researchers found.\nOne patient who received the highest dose of cimaglermin developed abnormal liver function, which cleared up over a two-week period, Lenihan said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly points out that side effects included nausea and headaches, and that one participant did experience abnormal liver function after receiving the highest dose, a side effect that eventually cleared up.", "answer": 1}, {"article": "Allergan Inc. said that two large human tests of its Botox drug, best known for smoothing wrinkles, showed that periodic injections prevent headaches in adults who suffer from chronic migraines.\n\nEven though details of the study weren't released, the announcement, which surprised many physicians and investors, sent Allergan's shares soaring 11%, or $5.95, to $60.53 at 4 p.m. in New York Stock Exchange composite trading. Botox has been used to treat severe headaches for many years, but some researchers have long been skeptical...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study does not mention any potential harms of botox injection. While the procedure is safe, there are some risks that would be important to mention and consumers should also be told that they should seek out a practitioner who is skilled and experienced in providing the injections.", "answer": 0}, {"article": "\"Huge room exists for further improvement.\"\nMONDAY, Nov. 2, 2015 (HealthDay News) -- Despite the stereotype that Americans are eating more unhealthful foods that leave them vulnerable to assorted diseases, a new study suggests the opposite may be true.\nBut, she said, nutrition research like this has limitations because it relies on people's memories of what they ate.\nAs a result, she said, it's crucial to look at a variety of studies and see if trends hold up.\nChan School of Public Health in Boston, cautioned that it's not time to declare victory in the battle against unhealthy eating.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s certainly possible that attempts to promote healthier diets could result in unintended harms. For example, some might argue (erroneously, in our view), that a tax on sugar-sweetened beverages, intended to promote healthier drink choices, would be regressive (i.e. disproportionately costly to lower income consumers). But we think a discussion of such issues is beyond the scope of this article, so we\u2019ll rate it Not Applicable.", "answer": 2}, {"article": "Studies in mice, dogs, pigs, and monkeys have shown that so-called focused ultrasound waves can be used to heat tiny bubbles that then mechanically push open gaps in blood vessels, allowing drugs to leak out into the brain.\n\u201cIt really opens up a lot to the imagination.\u201d\n\nMost drugs are blocked from entering the brain by the \u201cblood-brain barrier,\u201d which protects against infection, but also makes it tricky to treat brain tumors, diseases like Alzheimer\u2019s, and mental illness.\n\u201cIf we feel like we have a safe method of getting drugs in there,\u201d he said, \u201cit will open up a whole new slew of clinical trials.\u201d\n\nMainprize said the patient, a \u201cremarkable woman,\u201d was chosen to go first, because of the status and large size of her tumor, because it was an area of the brain that the ultrasound machinery could easily reach, and because of her willingness to help the research.\nNew, safe doses of drugs will need to be determined, once medication is not being diverted by the blood-brain barrier, noted Dr. Gordon Li, a neurosurgeon at Stanford.\nSucceeding in getting drugs across the barrier is \u201ca huge achievement\u201d said Dr. Nathan McDannold, a radiologist at Boston\u2019s Brigham and Women\u2019s Hospital, who has been working to open the barrier with ultrasound since he first accomplished the feat 15 years ago in animals.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a single patient and the story does mention that \u201cno damage from the ultrasound was visible inside her brain.\u201d But breaching the blood brain barrier is a big deal and likely would entail harms, especially if done repeatedly as would need to be done in many clinical treatments. There\u2019s certainly a risk of bleeding as the news release mentions in a related Q&A. Some discussion of harms/tissue damage or lack thereof seen in animal studies would have been informative.\nThe story does contain information from someone who appears to be an independent voice\u2013Dr. Gordon Li\u2013cautioning the reader that the ability to get drugs into the brain now requires effort to determine \u201csafe doses\u201d of those drugs. \u00a0But that issue is given just a glancing blow \u2014 not enough for a Satisfactory grade here.", "answer": 0}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\n\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nThese vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nTwo HPV vaccines are now approved by the FDA: Cervarix and Gardasil.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides a single comment about the potential harms of the vaccine (\u201c\u2026thus far the vaccine appears to be safe.\u201d). Additional information concerning injection site reactions would have been useful. But we give the story credit for doing a good job of discussing the risks vs. benefits in the wider subject of universal vaccination of young men.", "answer": 1}, {"article": "\u201cFor now I think what this study does is to create another shade of gray in the understanding of gray matter,\u201d he said.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nDr. Nicholas Schiff, a neuroscientist at Weill Cornell Medical College in New York, said that the study provided \u201cknock-down, drag-out\u201d evidence for mental awareness, but that it was not clear \u201cwhether we\u2019ll see this in one out of 100 vegetative patients, or one out of 1,000, or ever again.\u201d\n\nIn a more recent exam, more than 11 months after her injury, the patient exhibited a sign of responsiveness: she tracked with her eyes a small mirror, as it was moved slowly to her right, and could fixate on objects for more than five seconds, said Dr. Steven Laureys, a neurologist at the University of Li\u00e8ge and an author of the study.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\nMs. Schiavo suffered far more profound brain damage than the woman in the study and was unresponsive for some 15 years, according to neurologists who examined her.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms of the imaging technique, either from the risks of the technique itself or from the implications of false positive or negative results. The article does imply that it isn\u2019t clear whether such findings would predict long-term cognitive improvement and the degree of improvement. However, little information is given about the test itself. It involves the use of a short-acting radioactive substance but is probably safe. The greater harm would be around providing false hope of recovery to family members.", "answer": 0}, {"article": "In type 1 diabetes, the immune system attacks and destroys insulin-producing cells within the pancreas.\n\"All our patients considered the [treatment] to be worthwhile and beneficial, though some patients experienced side effects,\" study head Weiqiong Gu, MD, of Ruijin Hospital in Shanghai, tells WebMD.\nThis is the latest of several stem cell studies to show promising results for the treatment of type 1 diabetes, Ratner notes.\nAs a result of the immune-system suppressing drugs, most of the patients in Gu's study experienced side effects including low white blood cell counts, fever, nausea, vomiting, hair loss, and suppression of bone marrow.\nWe need to better understand the biology behind the treatment and follow patients for long-term side effects,\" Robert E. Ratner, MD, chief scientific and medical officer of the American Diabetes Association, tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\nAs a result of the immune-system suppressing drugs, most of the patients in Gu\u2019s study experienced side effects including low white blood cell counts, fever, nausea, vomiting, hair loss, and suppression of bone marrow.\nMost of those side effects disappeared within two to four weeks, and unlike in previous studies of the experimental therapy, none of the patients developed infections, pneumonia, low sperm counts, or organ damage.\nStill, patients have to be followed for years to ensure they do not develop known long-term complications of immune-suppressing drugs, including tumors and infertility, Gu says.", "answer": 1}, {"article": "During the luteal phase, estrogen and progesterone levels are at their highest, which may help a woman keep addictive cravings at bay and reduce feelings of cigarette withdrawal.\nThey were asked to view photos both related and unrelated to smoking.\nAfter undergoing the brain scans they viewed the photos a second time and reported on a scale from zero to 100 if the pictures triggered cigarette cravings.\nWomen who want to quit smoking may find it easier if they time their efforts just right.\nNone of the study participants were enrolled in a smoking cessation program or were trying to quit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned, but it\u2019s also difficult for us to envision what they might be in this case, so we\u2019ll call it not applicable.", "answer": 2}, {"article": "This has major implications for how we now investigate and manage patients with suspected heart disease.\"\nThis suggests that including the scans in routine care would not lead to a surge in costly tests or additional heart surgery, the researchers say.\nAfter receiving the scan, the number of patients suffering a heart attack within five years dropped by 40 per cent, the study found.\nThe study had previously found that around a quarter of patients had their diagnoses reclassified after receiving the scan, prompting new treatments in many cases.\nCTA scans enable doctors to look at the blood vessels from the outside the body, without the need to insert tubes into the heart.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that CTA scans are \u201csafer\u201d than angiograms because CTAs don\u2019t require the insertion of tubes into the body.\nBut no other harms are mentioned and many readers may want to know about radiation exposure and allergic responses to the contrast dye used. \u00a0According to the study,\u00a0 those who did have a CTA scan ended up having more invasive coronary angiograms and coronary opening procedures in the months following the scan. These procedures carry considerable risks.", "answer": 0}, {"article": "Deep brain stimulation involves implanting electrodes in the brain, then connecting them to a pulse generator placed under the skin of the chest.\nOn a broader level, he noted, this study highlights an important point: \"Alzheimer's disease is more than just amnesia.\"\nIt's \"much too early\" for patients or caregivers to seek out DBS, said Fargo, who was not involved in the study.\nAnd there were \"signals\" that it was slowing down two of the patients' decline, said lead researcher Dr. Douglas Scharre, director of cognitive neurology at Ohio State University's Wexner Medical Center.\nInstead, he said, these findings suggest that deep brain stimulation is \"a reasonable route\" to study in larger clinical trials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t completely drop the ball, stating side effects \u201cincluded hot flashes, heart palpitations and burning sensations in the skin, which were reversed by adjusting the DBS settings.\u201d But any story on an implantable medical device should caution readers about the risks of surgery to both install and remove it and mention that medical devices are not required to undergo rigorous safety tests before they are allowed on the market. The lead\u2019s assertion that the device \u201cmay be safe\u201d neglects the inherent risks of implantable devices.\nThe story left out another known risk of deep brain stimulation: depression. All three subjects were treated with antidepressant medication. Although, as the study authors note, the DBS may not have caused the depression\u2013it is common in dementia, and treating it can improve people\u2019s cognitive and functional abilities. Such as described for patient \u201cLaVonne.\u201d", "answer": 0}, {"article": "Scientists working for Google\u2019s parent company Alphabet have used artificial intelligence to determine a person\u2019s risk of having a heart attack from their retinal scan.\nFurther tests are required before this latest method can be used within a clinical setting.\n\u201cMost cardiovascular risk calculators use some combination of these parameters to identify patients at risk of experiencing either a major cardiovascular event or cardiac-related mortality within a pre-specified time period, such as 10 years,\u201d the paper states.\n\u201cHowever, some of these parameters may be unavailable\u2026We therefore explored whether additional signals for cardiovascular risk can be extracted from retinal images, which can be obtained quickly, cheaply and non-invasively in an outpatient setting.\u201d\n\nRead more: Can smartphones replace your GP?\nThe researchers concluded: \u201cThe opportunity to one day readily understand the health of a patient\u2019s blood vessels, key to cardiovascular health, with a simple retinal image could lower the barrier to engage in critical conversations on preventive measures to protect against a cardiovascular event.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story offers no mention of potential harms that might arise from using this new approach and since it\u00a0would be\u00a0non-invasive, it is hard to imagine many.\u00a0 But the potential for incorrect assessments is always present as either false-positives or false-negatives and the harms from either of those can be considerable.", "answer": 0}, {"article": "UT Southwestern physicians provide medical care in about 80 specialties to more than 92,000 hospitalized patients and oversee approximately 2.2 million outpatient visits a year.\nIn addition to shorter treatment times, researchers found that side effects were not necessarily different compared to other forms of prostate cancer treatment.\nResearchers found a small risk of longer-term urinary and rectal complications, which is also comparable to conventional treatments.\nThe study - the first trial to publish five-year results from SBRT treatment for prostate cancer - found a 98.6 percent cure rate with SBRT, a noninvasive form of radiation treatment that involves high-dose radiation beams entering the body through various angles and intersecting at the desired target.\nOther clinical trials at the UTSW Department of Radiation Oncology are seeking to expand the application of SBRT to high-risk (Stage III) prostate cancer patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does include a paragraph about urinary side effects (among others) for patients in the trial. But the release deliberately seems to try to minimize these. (Editor added italics.)\n\u201cIn addition to shorter treatment times, researchers found that side effects were not necessarily different compared to other forms of prostate cancer treatment. In the short term, the side effects of SBRT can include urinary issues (urgency, frequency and burning) and rectal irritation, which are often temporary and reverse within four weeks of treatment. Researchers found a small risk of longer-term urinary and rectal complications, which is also comparable to conventional treatments. Decrease in erectile function was seen in 25 percent of patients, fewer than with conventional radiation or surgery, said Dr. Hannan.\u201d\nMany men might find a one-in-four chance of impotence a high price to pay for treatment for early-stage prostate disease. We have to complain that the release does not give us numbers for the harms \u2014 in any way that is meaningful and allows us to compare this new therapy to existing therapies.\nThe phrase \u201cnot necessarily different\u201d is not helpful. The phrase \u201ca small risk\u201d is not giving us a number we can use.\nAs noted above, a substantial proportion of the patients might not have needed treatment \u2014 so that even a \u201csmall risk\u201d of complications would be unacceptable. In the absence of a comparison group, no conclusions can be drawn as to whether this represents a less harmful active treatment option.", "answer": 0}, {"article": "Brain scans and spinal taps are helpful but they're not certain.\nThere is still plenty of lab work to be done, more rigorous research before it's proven a simple blood test can diagnose Alzheimer's, but those working on the test are hopeful it can be approved for use by 2009, adds Blackstone.\nToday only an autopsy can establish for sure that a patient had Alzheimer's.\nAccording to a paper published in the online edition of the British journal Nature Medicine, preliminary studies by a team of scientists led by a Stanford neurology professor show the test is yielding promising results in predicting which patients with mild memory loss are at high risk of developing Alzheimer's disease.\nIn a study of 259 blood samples, the test identified early markers for Alzheimer's with 90 percent accuracy, reports CBS News correspondent John Blackstone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Two harms of treatment, difficulty getting insurance when one has a prexising condition and not wanting to know that one was going to develop this disease, were mentioned in the broadcast.\nBut the story never addressed the issue of false positive test results \u2013 which could be a huge issue.\u00a0 Imagine being told erroneously that you test positive for Alzheimers disease! ", "answer": 0}, {"article": "Further,Dr.\nCrucially, this woman was in good health, suggesting that therapies aimed at blocking PCSK9 would not only be effective, but also safe.\nTwo of these drugs, in a category known as PCSK9 inhibitors, were approved by the Food and Drug Administration last summer for use by some individuals with extremely high cholesterol levels.\nMr. Brown had been part of a clinical trial testing the safety and effectiveness of one of the new PCSK9 inhibitors and, when the drugs were approved, Dr. Khera began working to get Mr. Brown approved by his insurance to be on the new regimen.\nTheir research led to the development by drug companies of evolocumab and alirocumab, the two approved PCSK9 inhibitors, which are delivered by monthly or semimonthly injections.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention potential harms at all. If anything, it does just the opposite, saying at one point that an observation of a woman with a genetic variation that naturally confers the effects of this class of drugs suggests that \u201ctherapies aimed at blocking [the protein targeted by these drugs] would not only be effective, but also safe.\u201d That\u2019s a good anecdote about the inspiration for the drug treatment, but it\u2019s problematic in a release that seems to focus almost exclusively on anecdotes. Particularly since the release does not tell readers that both evolocumab and alirocumab have potential adverse side effects. According to the press materials for evolocumab (Repatha), \u201cIn a 52-week trial, adverse reactions led to discontinuation of treatment in 2.2% of Repatha-treated patients.\u201d And the press materials for alirocumab (Praluent) note \u201cPraluent can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital.\u201d What\u2019s more,\u00a0there could be less common, but more serious adverse effects that will only come to light after large numbers of patients take these drugs for long time. There is nothing in the release that says for how long the drug was used. These potential health effects are worth noting \u2014 especially in a release that focuses solely on the use of a new class of drugs.", "answer": 0}, {"article": "If nothing else, \"The Business of Being Born,\" with its indelible image of a naked, exhilarated Ricki Lake cooing \"Hi there!\"\nWolf and other natural-birth advocates say we need a better idea of what normal birth looks like, as movies and TV usually depict the process as painful and bloody.\nThis, according to Lake, the executive producer of the film, and Abby Epstein, the film's director, is the right reaction: one of their messages is that C-sections should only be performed when needed to guarantee the well-being of the mother and infant, and should not be a first choice for healthy mothers.\nBut the image that viewers may find most shocking is that of a baby being cut out of a woman's abdomen via Caesarean.\nNew research into the risks associated with elective Caesareans supports their view.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quantifies the risk of death in C-section versus vaginal birth. The story could have done more to describe other, more common risks, such as wound complications and infections.", "answer": 1}, {"article": "\"We compare the colored glasses to being like a brace or cast but for the brain,\" he says.\nHowever, the researchers noted, they do not recommend wearing colored glasses while driving.\nIn addition to trying colored-lens sunglasses, the article suggests other ways to mitigate photophobia including wearing a wide-brimmed hat when outdoors, adjusting digital screen and device settings to an appropriate hue and brightness or purchasing filters for screens.\nWe believe the use of the colored glasses that provide photophobia mitigation has added benefits superior to dark sunglasses, especially for indoor lighting.\"\n\"While sunglasses can provide some relief, they are not very practical indoors or in low light environments,\" says Joe Clark, PhD, professor in the Department of Neurology and Rehabilitation Medicine at the UC College of Medicine and lead author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says that there were no reported side effects while wearing colored glasses. It recommends against wearing colored glasses while driving since \u201ccertain colors make seeing stop lights or emergency vehicle lights difficult.\u201d", "answer": 1}, {"article": "If a pill could prevent teenagers from taking dangerous risks, would you consider it for your children?\n\nI\u2019d be tempted. My skateboard- and bicycle-riding son was hit by a car\u2014twice\u2014when he was a teenager. I would have welcomed anything that could have averted those dreadful phone calls from the emergency room.\n\nWhile some bumps and scares...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the story.\u00a0The adverse effects of the drugs in question would be key information\u2013do they outweigh the benefits put forth in this story?", "answer": 0}, {"article": "Melanoma is the most lethal form of skin cancer, killing almost 9,000 people in the U.S. last year, according to the National Cancer Institute.\nAs a result, \u201cI wouldn\u2019t recommend (taking NSAIDs to reduce melanoma) just based on this\u201d new study, Asgari noted.\nFor one, you have to get the comparison right, she noted; there\u2019s always a concern that people without cancer who agree to participate in the study may be more health conscious to begin with, and it\u2019s this that protects them from cancer, not their use of NSAIDs.\nUnfortunately, the technique \u2014 comparing people with melanoma to those without - is fraught with potential problems, said Asgari.\n\u201cI think it\u2019s just too early\u201d to say NSAIDs offer any protection, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated: \u201cNSAIDs \u2013 which include aspirin, naproxen (marketed as Aleve), and ibuprofen (Advil) \u2014 have side effects, she noted, such as stomach bleeding.\u201d\u00a0 It didn\u2019t note whether study looked at side effects in those taking them for five years. Still, we\u2019ll rule this satisfactory for remembering to include some mention of potential harms.", "answer": 1}, {"article": ".\nOn that basis, the authors recommend that techniques such as the Boston modification of Robertson technique should be preferred by surgeons seeking to avoid pseudoptosis.\nOther advantages of the Boston modification of Robertson technique include decreased operative time and elimination of the \"triple point,\" the most common site of postoperative incision rupture.\nIn all patients, only one reduction technique was performed per patient.\nThe paper, The Sternum-Nipple Distance is Double the Nipple-Inframammary Fold Distance in Macromastia, is published Ahead-of-Print online in the Annals of Plastic Surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address the incidence of harms with either method.\nBased on our review of the literature on the topic, there are potential complications seen with both techniques including painful scars, wound dehiscence (a surgical complication in which a wound ruptures along a surgical incision), infection requiring antibiotics, and corrective surgery if the original surgery is unsuccessful.\nThe published study does note a variety of side effects and how often they occurred and also states there was no statistical difference between the rate of harms. This would have been good to mention in the release.", "answer": 0}, {"article": "In other words, they are the precursors to muscle, fat, bone, and tendon tissue.\nFurthermore, there were no life-threatening effects linked to the procedure used to administer them.\n\u201cThe recovery some patients showed was not just minimal, it was significant,\u201d said Steinberg, who has researched stem cell therapies for more than 15 years.\nIn Steinberg's study, it did not \u201ccause problems by differentiating into unwanted tissues or forming tumors.\u201d And even when the stem cells came from an unrelated donor, the participants did not experience a strong immune reaction.\n\u201cWhat surprised us most was the remarkable recovery some patients had,\u201d Dr. Gary Steinberg, professor and chair of neurosurgery at Stanford, told Medical Daily, \u201cWhile we had hoped for that, we didn\u2019t really expect it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly noted side effects.\u00a0 It\u2019s worth pointing out that the study only followed patients for about a year, and long-term effects are unknown and could be more severe.", "answer": 1}, {"article": "Dr Carol Routledge, from Alzheimer's Research UK, said: \"The diseases that cause dementia begin in the brain up to 20 years before any symptoms start to show, presenting a vital window of opportunity for us to intervene before widespread damage occurs.\nThe scans measure brain activity by tracking the uptake of a radioactive liquid injected into the blood.\nArtificial intelligence can be used to spot Alzheimer's six years before a patient would normally be diagnosed, a study shows.\nIt proved to be 100 percent accurate at detecting Alzheimer's disease many years before the patient was later diagnosed.\n\"This study highlights the potential of machine learning to assist with the early detection of diseases like Alzheimer's, but the findings will need to be confirmed in much larger groups of people before we can properly assess the power of this approach.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not mentioned. As with all screening tests, there is a risk of a false-positive or a false-negative result. Either can create anxiety, confusion, and incorrect medical treatment.\nRegarding the PET scan itself, the American College of Radiology lists the following:\nThe small circular opening of the scanner can elicit anxiety in some patients that may require sedation or stopping the scan.", "answer": 0}, {"article": ".\nHowever, \"this study suggests dry needling as an effective alternative to cortisone injection.\"\nThe study demonstrates that patients with GTPS can get similar results from dry needling as from a steroid injection.\nThe results showed that cortisone injection did not provide better outcomes than dry needling for either pain or function in patients with GTPS.\nDr. Brennan cautions that while this study uses a larger sample than most, further studies are warranted.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While no harms were reported in the study, the news release still should have mentioned typical side effects of dry needling such as temporary pain, bruising and post-treatment soreness. The release does mention the \u201cpotentially harmful effects of steroids\u201d but doesn\u2019t say what they are.\nThe concern over potential\u00a0complications from steroid injection seems to be magnified while any potential harms from dry needling is ignored.", "answer": 0}, {"article": "Visit sirweb.org.\nIn the first U.S. clinical trial on geniculate artery embolization (GAE), a minimally invasive, image-guided treatment that blocks key arteries in the knee to reduce inflammation and pain, resulted in a majority of study participants achieving significant pain reduction and improvements in range of motion, avoiding more invasive measures.\n\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nAs an outpatient treatment, GAE does not require open surgery or physical therapy, and takes 45-90 minutes to perform.\nWhile preliminary data shows that the treatment does work and is feasible, it has only been used in a clinical trial setting.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t discuss the potential harms associated with this procedure. The procedure is complex involving the catheterization of\u00a0 \u201cvery small arteries or capillaries within the lining of the knee,\u201d and carries inherent risks of penetrating those blood vessels. Potential complications include bleeding at the puncture site and pain. Long-term complications have yet to be determined but could include failure of the intervention to address the symptoms of knee OA, worsening of the pain in some individuals, and osteonecrosis (a bone disease that results from loss of blood supply to the bone). \u00a0Also yet to be established is the period of time it takes for healing to occur within the joints after the procedure.", "answer": 0}, {"article": "\"If someone said to my husband, 'I know this has been a rough road for you, and a big impact on your sex life, but if she stays on it another five years.\nThat's significant, given that tamoxifen is used by hundreds of thousands of women worldwide, says Gray, whose study was presented Wednesday at the annual San Antonio Breast Cancer Symposium.\nSome women will be glad to have another treament option, says breast cancer survivor Lillie Shockney, 59, administrative director of the Johns Hopkins Cancer Survivorhip Program in Baltimore.\nBecause the study didn't include AIs, doctors can't say how whether tamoxifen would benefit women who've taken them, Litton says.\nPatients and their partners need to have honest talks with doctors about how extended treatment will affect their relationship, she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag \u2013 but we\u2019ll give the story the benefit of the doubt.\nGood points:\nRoom for improvement:\nThe story provided only one woman\u2019s tale of side effects.\u00a0 It provided no estimate of how often these occur. And the Young Survival Coalition pointed out another age-specific concern in the statement it released:\nFinally, a particular concern with this study is the impact that this study may have on young women\u2019s family planning.\u00a0 Many young women already wait until they have completed their five-year course of Tamoxifen before trying to start a family.\u00a0 Will this study cause that delay to become 10 years?\u00a0 And, are the modest benefits shown in this study worth that?\u00a0 That is a very personal decision and again, we recommend speaking with your physician.", "answer": 1}, {"article": "[4] Quotes direct from author and cannot be found in text of Article.\nWhether this will help individuals improve self-awareness of their health status, however, or only lead to so-called cyberchondria, is a moot point.\nThe resource has been open to bona fide health researchers for 18 months.\nWe hope that our score might eventually enable doctors to quickly and easily identify their highest risk patients, although more research will be needed to determine whether it can be used in this way in a clinical setting.\n\"This is the first study of its kind which is based on a very large study sample, and is not limited to specific populations, single types of risk, or requiring laboratory testing.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The text does offer a brief cautionary note when it quotes from the commentary of a couple of UK scientists in The Lancet issue to the effect that \u201cwhether this will help individuals improve self-awareness of their health status\u2026or only lead to so-called cyberchondria, is a moot point.\u201d Cyberchondria refers to unfounded anxiety concerning the state of one\u2019s health brought on by visiting health and medical websites, so that term seems apt here. And \u201cmoot\u201d conveys the uncertainty surrounding outcomes as, again, the study can offer no evidence. We\u2019ll give a Satisfactory rating, though we wonder if it would have been more effective to say, \u201cit is unclear whether use of this information will lead to actions that will help or harm individuals.\u201d", "answer": 1}, {"article": "Error code 404. Something went\n\nwrong and we can't seem to find\n\nthe page you're looking for.\n\n Report a broken link.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no discussion of medical risks and hardships of surgery. Along with the usual risks posed by surgery, there\u2019s a risk that lymph node transfer could cause lymphedema to develop in the part of the body where healthy nodes were extracted, according to Breastcancer.org. For many women those drawbacks may outweigh the potential for an uncertain benefit.", "answer": 0}, {"article": "More: The hidden side of dementia: Families fight over care, end-of-life decisions, finances, estates\n\nDementia is a term used to broadly describe symptoms of cognitive decline; Alzheimer's disease is the most common cause of dementia.\nIf the vaccine proves safe and effective in humans, it could slice the number of dementia diagnoses in half, the study's senior author told USA TODAY.\nPrevious attempts to find an Alzheimer's vaccine either caused harmful side effects, such as brain inflammation, or used less effective approaches, she said.\nDoris Lambracht-Washington, a professor of neurology and neurotherapeutics at the University of Texas Southwestern Medical Center, said researchers believe the vaccine could extend lives by preventing the disease from developing.\nThere has been research in monkeys and rabbits as well, and the researchers hope the vaccine will progress to human trials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that the vaccine is \u201csafe in mice\u201d and alludes to the fact that it hasn\u2019t been proven safe in humans. It also mentions \u201charmful side effects, such as brain inflammation\u201d with a previous Alzheimer\u2019s vaccine attempt.\nFor that, we\u2019ll give the story credit. But we think it could have better served readers by explicitly cautioning that safety in mice doesn\u2019t translate to safety in humans.", "answer": 1}, {"article": "In AML, treatment involves intensive chemotherapy to try to kill the patient\u2019s leukemia cells and put the cancer into remission.\nThis information opens the door to using decitabine in a more targeted fashion to treat not just older patients, but also younger patients who carry TP53 mutations.\u201d\n\nFirst author John Welch, MD, PhD, an assistant professor of medicine, added: \u201cIt\u2019s important to note that patients with an extremely poor prognosis in this relatively small study had the same survival outcomes as patients facing a better prognosis, which is encouraging.\n\u201cThe value of this study is the comprehensive mutational analysis that helps us figure out which patients are likely to benefit.\nThe results of the current trial, he said, point to the inevitable need to replace large cancer clinical trials evaluating homogeneous drug treatments with smaller trials that involve subgroups of patients, with treatments targeted to their specific mutations.\n\u201cIt\u2019s exciting to think we may have a therapy that has the potential to improve response rates in this group of high-risk patients.\u201d\n\nThe research is supported by an AML-SPORE grant and the Genomics of AML Program Project grant, both from the National Cancer Institute at the National Institutes of Health (NIH), grant numbers P50 CA171963 and P01 CA101937.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t directly address harms from either decitabine or standard chemotherapy for AML. What are the common harms from chemotherapy and which of these side effects are reduced in decitabine? Because the focus of the release is on the trial results of a drug described as less toxic, we would have liked some context on what reduced toxicity means.", "answer": 0}, {"article": "More studies are needed, they said.\nSuch a marker would allow doctors to identify infants at high risk of developing autism before symptoms are present.\nCompletely different mechanisms may be at work for kids without an older sibling with autism, said Shen and Dimartino.\nIn a study published last month in Nature, 80 percent of infants diagnosed with autism as toddlers had an increased rate of growth in the surface area of their brains in their first year, compared to toddlers who were not diagnosed with autism.\nThe scans showed that 70 percent of high-risk toddlers diagnosed with autism at age 2 had an elevated amount of cerebrospinal fluid around their brains at 6 and 12 months, compared to toddlers who were not diagnosed with autism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of the harms inherent in MRIs for infants. Some of the harms of MRIs have to do with the sedation that is required, which, ironically, may harm the developing brain.\nAlso, as with any screening test, there are the harms of \u201cfalse-positive\u201d and \u201cfalse-negative\u201d results. In this case, a false-positive finding would result in a healthy baby being diagnosed with autism. And for a false-negative result, a baby with autism wouldn\u2019t be diagnosed.", "answer": 0}, {"article": "It's a substantial number of women,\" Lyman said.\nThe researchers noted that the study was limited to women with tumors known as T1 or T2, meaning they were relatively small, had no enlarged nodes that could be felt, and the cancer had not spread elsewhere.\nThe study, involving nearly 900 women who were treated at 115 sites across the country, found that those who did have their lymph nodes removed were no more likely to survive five years after the surgery than those who did not, the researchers reported in a paper published in the Journal of the American Medical Association.\nIn the new study, Armando Giuliano of the John Wayne Cancer Institute at Saint John's Health Center in Santa Monica, Calif., and colleagues analyzed data collected from 445 women who had their nodes removed and 446 who did not, along with radiation and chemotherapy.\nIn an accompanying editorial, Grant Walter Carlson and William Wood of Emory University in Atlanta called the study an \"important contribution\" that represents the latest development in breast cancer treatment, which has steadily been moving toward less-aggressive options, sparing women from unnecessary surgery and follow-up therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article accurately reported that the study found no benefit for the more aggressive full axillary lymph node dissection (ALND)\u00a0among the 900 women studied with T1 or T2 breast cancer.\u00a0 Because ALND poses risk of infection and lymphedema, more patients would be harmed by continuing the currently recommended treatment.\u00a0 While the article mentions the potential complications of ALND, it does not quantify the incidence of infection or of lymphedema after ALND. Women should be told how often this occurs.", "answer": 0}, {"article": "\"Normally when you make drugs, it's hard to say 'attack only that protein.'\nThe nanoparticles made their way smoothly to the target -- the tumor cell -- and cleaved the mRNA in just the right place, stopping production of the culprit protein.\nThe researchers injected the cargo-laden nanoparticles into the patients, much as you would administer a flu or any other type of shot.\nThe experiment proceeded just as planned, as biopsies later showed.\nThey did not inject directly into the tumor as many other researchers have done.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story paraphrased the researchers. \"The precision of the process is crucial to limiting side effects.\"\u00a0 But it never discussed what even the potential side effects of this approach might be.\u00a0 It would have been relatively easy for the story to have included a few words about the potential downsides, including \"off target\" side effects during an exaggerated immune response or the shuttinf off of non-targeted genes resulting in adverse outcomes. ", "answer": 0}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\n\u201cSleep deprivation makes this worse of course, and together with the clock, this conspires to impair our ability to sustain attention to task (e.g., driving), and avoid distraction, and react quickly to external stimuli like traffic lights, brake lights in front of you, road signs, etc,\u201d Mistlberger added by email.\nExposure to bright light didn\u2019t appear to improve reaction times or sleepiness.\nBut there are still things drivers can do now to stay safer on the road.\nFor the current study, researchers wanted to see if bright light might help reduce driving impairments related to sleep deprivation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Exposure to light in this way isn\u2019t harmful, so we\u2019ll rate this N/A. However, such a therapy could encourage people to skip on an intervention that would be more effective such as sleep. Or it could inure a false sense of security.", "answer": 2}, {"article": "Jamie Stagl worries that women with breast cancer don\u2019t get enough help coping with their diagnosis.\n\u201cThis is really a teachable moment.\u201d\n\nThe skills taught in the course are useful at many stressful moments, Porter said, not just when cancer is diagnosed.\n\u201cWhile I certainly wouldn\u2019t say that anyone could take a 10-week course and be set for life, I think anyone could take a 10-week course and be much better at coping with stress.\u201d\n\nNext, the study team, led by Michael Antoni of the University of Miami, hopes to show that an easier-to-manage five-week group class works as well as the 10-week one.\nIf a woman\u2019s stress level remains high indefinitely after diagnosis, she may have a worse outcome than if she can bring it back down, Stagl said.\nStagl doesn\u2019t know whether the women are still using the techniques they were taught \u2014 which include mindfulness, deep breathing, visual imagery, cognitive behavioral therapy, and learning how to ask for help from friends and family.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss possible harms associated with participating in this stress management program, although the harms are likely to be minimal.\u00a0In theory, the program could have heightened anxiety about the breast cancer diagnosis by focusing on it frequently over the 10 weeks of the group. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\u201cBut I am prepared to have it become more complicated.\u201d\nMore work will be needed to confirm what benefit betatrophin might have on diabetic patients before that might be possible, however.\nJohn Anderson, president of medicine and science for the American Diabetes Association, says \u201cIt\u2019s very promising and opens up new avenues of research, but we are a long way from replacing insulin, or a cure, or even knowing how this [hormone] will work in human tissue.\u201d\n\nThose concerns aren\u2019t lost on Melton, who also recognizes that more research is needed to confirm that betatrophin may benefit patients.\n\u201cThat\u2019s a huge difference.\u201d\n\nWhat\u2019s more, it appears the cells are relatively long-lasting, which could indicate they are robust enough to bring glucose levels in diabetics under control.\nIn theory, if the same results occur in people, it\u2019s possible that those on the verge of developing diabetes might never progress to develop the disease, since the high blood sugar levels that can cause damage to tissues and lead the body to become less responsive to insulin could be avoided.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story speculates extensively about the many benefits a treatment based on this preliminary research might confer. So we think it\u2019s only fair that the story at least mention the possibility that a\u00a0new treatment might also cause harm.\u00a0The researcher quoted in the story suggests that \u201canything that lowers blood sugar can make you healthier.\u201d Besides the obvious exception of hypoglycemia (which can be fatal),\u00a0recent experience with Avandia confirms that drugs which lower blood sugar can\u00a0sometimes have other undesirable\u00a0effects.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070107/15downs.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention potential harms of treatment, such as anxiety from positive test results and the possibility that patients will fail to follow up on a positive initial screen.\u00a0It also fails to define the potential harm of providing false reassurance \u2013 the risk of false negative results, which is failing to identify an affected infant, which would be of concern to women who are seeking accurate answers.", "answer": 0}, {"article": "This is really a game changer.\"\nIn fact, an interim review of the Partners data on effectiveness was so compelling that the trial was stopped early and the placebo arm was discontinued.\nThe risk of infection was reduced 63% overall, but for participants who actually got the drugs, that risk decreased by 78%.\nThe study, called TDF2, followed 1,200 uninfected heterosexual men and women between the ages of 18 and 39 years in Botswana, Africa.\nPreliminary results showed both treatments significantly reduced transmission in couples where one partner was already infected with the virus.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that the\u00a0primary source was a press statement (the results haven\u2019t been published yet), the story provided about as much information about potential harms as could be expected. In one of the studies, the story notes that the\u00a0safety monitors\u00a0saw no evidence of safety concerns. The story also notes that subjects taking the active drug in the the other study\u00a0reported nausea, vomiting and dizziness.", "answer": 1}, {"article": ".\nChildren taking the delayed-release stimulant did not have to wait for a morning dose to take effect and also benefited from improved symptoms later in the afternoon and evening, according to the study results published in Journal of Child and Adolescent Psychopharmacology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.\nThe article entitled \"Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder\" is coauthored by Steven Pliszka, MD, from The University of Texas Health Science Center at San Antonio and colleagues from Massachusetts General Hospital (Boston, MA), Westside Medical Family Practice (Clinton, UT), University of Tennessee Health Science Center (Memphis, TN), Meridien Research (Maitland and Bradenton, FL), Children's Development Center (Winter Park, FL), Ironshore Pharmaceuticals & Development (Grand Cayman, Cayman Islands), and Mount Sinai Medical Center (New York, NY), on behalf of the HLD200-108 Study Group.\nThe drug formulation, which consists of two layers of microbeads with an inner drug-loaded core, delays release of the active ingredient for 8-10 hours and then provides controlled extended release designed to cover the early morning into the evening.\nNew Rochelle, NY, September 25, 2017--A phase 3 study of children ages 6-12 years with attention deficit/hyperactivity disorder (ADHD) has shown that a delayed-release, long-acting formulation of the stimulant methylphenidate, when taken in the evening, led to significant improvement in ADHD symptoms and functional impairment first thing the next morning, compared to a placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses possible harms with use of this new formulation of the drug by saying, \u201cthe main adverse effects of appetite suppression and insomnia being those commonly reported for other formulations of methylphenidate.\u201d The study itself offers more detail and a breakdown of what proportion of participants experienced these effects but most were considered to be mild.", "answer": 1}, {"article": "An M.D.\nBecause it doesn't inflict the damage to healthy tissue caused by chemotherapy and radiation, immunotherapy's great appeal is its nontoxicity.\nThat's why immunotherapy's greatest successes will come when it can be used early in treatment, they say.\nNow, because drugs are mostly tested on patients whose cancer has resisted previous treatment, it's usually used on tumors advanced to often fatal stages.\nThe idea is simple: Instead of poisoning the cancer and causing grueling side effects, it signals the patient's immune system to attack malignant cells, much as the body does with viruses and bacteria.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story claims that \u201cimmunotherapy\u2019s great appeal is its nontoxicity\u201d and that a patient has had no side effects. This is not enough information on the harms of treatment.", "answer": 0}, {"article": "\"For example, we know that certain changes in the retina, like thinning tissue [due to cell loss] or weakening electrical activity, occur alongside loss of brain tissue and reduced brain activity in patients with neurological disorders like multiple sclerosis and Parkinson's disease.\nWe and other researchers are now investigating whether retinal changes are related to brain structure and function changes in schizophrenia.\"\n\"Our study should help generate further research into developing a test that clinicians - like psychologists, psychiatrists or nurses - can use in their offices to diagnose, treat and monitor the condition of people with schizophrenia.\"\nAlthough we know quite a bit about it, it's still not that well understood,\" said Steven Silverstein, professor of psychiatry at Rutgers Robert Wood Johnson Medical School and director of research at Rutgers University Behavioral Health Care (UBHC), who designed the study.\n\"However, since every prior study has found that people with schizophrenia exhibit reduced retinal wave forms and slowed retinal responses, our research shows that we closing in on an accurate test that is faster, less invasive, inexpensive and more accessible to patients.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "What\u2019s known about the safety of this device? And what about the chances of false positives or false negatives? The news release didn\u2019t say. It only quoted a researcher stating the test was performed to be \u201cas noninvasive and quick as possible.\u201d", "answer": 0}, {"article": "Anticipating wide interest in the psilocybin research from scientists, clinicians and the public, the journal solicited 11 commentaries to be co-published with the study results written by luminaries in psychiatry, palliative care and drug regulation, including two past presidents of the American Psychiatric Association, a past president of the European College of Neuropsychopharmacology, the former deputy director of the U.S. Office of National Drug Control Policy, and the former head of the U.K.\nA few participants reported headaches following the session.\nIn the other session, participants received a capsule with what is considered a moderate or high dose (22 or 30 milligrams per 70 kilograms).\nOne-third of the participants had transient increases in blood pressure.\nEach participant had two treatment sessions scheduled five weeks apart, one with a very low psilocybin dose (1 or3 milligrams per 70 kilograms) taken in a capsule and meant to act as a \"control\" placebo because the dose was too low to produce effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does a good job here, stating that \u201c15 percent of participants were nauseated or vomited, and one-third of participants experienced some psychological discomfort, such as anxiety or paranoia, after taking the higher dose. One-third of the participants had transient increases in blood pressure. A few participants reported headaches following the session.\u201d Well done.", "answer": 1}, {"article": "Saturated fat has been thought to promote cardiovascular diseases by raising the \"bad\" LDL cholesterol in the blood.\n\"These results indicate that most healthy people probably tolerate a high intake of saturated fat well, as long as the fat quality is good and total energy intake is not too high.\n\"But the alleged health risks of eating good-quality fats have been greatly exaggerated.\nThe researchers found strikingly similar health effects of diets based on either lowly processed carbohydrates or fats.\nEven the participants who increased their energy intake during the study showed substantial reductions in fat stores and disease risk.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not go into any detail on the potential downsides of a very-high-saturated fat diet.\nFor example: Would most people enjoy and be able to adhere to a diet that includes lots of butter, cream, and cold-pressed oils? Some would no doubt savor such a diet, but others might be turned off.", "answer": 0}, {"article": "\u201cSurgery puts the diabetes into remission.\nThe study was small, including just 10 patients who had the surgery and 11 patients who followed severely calorie-restricted diets.\nBut researchers say the preliminary findings could one day lead to diabetes treatments.\n\u201cCertainly weight loss by any means improves type 2 diabetes, but there is something else going on with gastric bypass surgery,\u201d study researcher Blandine Laferrere, MD, of Columbia University\u2019s St. Luke\u2019s and Roosevelt Hospital Center, tells WebMD.\nAnd the patients in both groups had lost just a fraction of the weight they needed to lose at the time of the analysis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the story did mention some of the common side effects that occur following gastric bypass surgery, it actually neglected to mention some of the serious side effects of surgery.\nIn addition, since the story was about the impact of gastric bypass surgery on diabetes, it also should have mentioned that resolution of diabetes is not guaranteed to be permanent and reoccurs in as many as 30 out of 100 people who had improvement.", "answer": 0}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a half-hearted attempt here. It says that new over-the-counter enzymes are made\u00a0by fungi and haven\u2019t been tested in humans. And it suggests that anyone with a fungal allergy should \u201cuse the products with caution.\u201d\u00a0It also passes along a company spokespersons\u2019 observation that \u00a0\u201conly occasional side effects\u201d are reported by customers taking one of their supplements.\nBut the company phone line\u00a0is hardly an accurate tool for assessing possible harms and side effects of these products. And vague warnings about possible allergic reactions don\u2019t qualify as useful information for decision-making.\u00a0If there are safety concerns with any of these products, the story should have spelled them out more clearly and described what the risks are.", "answer": 0}, {"article": "Veterans who received this pain-focused care while also being treated for addiction found that the intensity of their pain decreased, their ability to function increased, and their alcohol use went down, compared to veterans who received a less-focused approach.\n\"There's also a strong link between depression and pain.\nAnd the study's authors note that the ImPAT approach has the potential to be easily and inexpensively adopted by addiction treatment centers and groups worldwide, through team members trained in standard psychological techniques.\nANN ARBOR, Mich. -- It's a Catch-22 with potentially deadly consequences: People trying to overcome addiction can't get treatment for their pain, because the most powerful pain medicines also carry an addiction risk.\nIn an editorial accompanying the new paper, another addiction and pain specialist, William C. Becker, Ph.D. of Yale University and the Connecticut VA, notes that the new results are even more impressive because ImPAT was compared with another psychosocial approach.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address potential harms. But there don\u2019t appear to be potential harms associated with ImPAT, certainly none that stand out relative to other behavioral interventions. So we\u2019ll rate this not applicable.", "answer": 2}, {"article": "Men who only father daughters appear to be at greater risk of developing prostate cancer, according to a study published last week in the Journal of the National Cancer Institute.\nAnd now, a real pill for your unreal illness.\nIt was funded by an \"educational grant\" from Glaxo SmithKline, which makes Paxil.\nThe study was published this month in the American Journal of Psychiatry by researchers at Leiden University in the Netherlands and other Dutch centers.\nResearchers suggested that a combination of this talk therapy and medication might be especially effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential risks with the use of Paxil.", "answer": 0}, {"article": "In the early days of motherhood, women ideally build competency and confidence in their parenting.\nThe early results are \u201cpromising and exciting,\u201d said Dr. Allison Baker, a psychiatrist at Massachusetts General Hospital\u2019s Center for Women\u2019s Mental Health, but \u201cwe need to see replication of this data over a much wider range in terms of numbers.\u201d\n\nThe study is small and has not been peer-reviewed; Sage disclosed the results in a press release.\nOne of the drug\u2019s most promising features: It appears to work quickly \u2014 some women in the study started experiencing relief after 24 hours.\nThe company has not submitted study data to federal regulators and isn\u2019t at this point seeking approval of the drug, known as SAGE-547, for postpartum depression.\nSage Therapeutics, based in Cambridge, Mass., reported on Tuesday that 7 of the 10 women who took the drug in the trial experienced significant improvement in their depression within 60 hours of the injection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does report that the company said the only problems reported by patients were dizziness or a sedative effect (in both the treatment and placebo groups), it should have specifically cautioned readers that there could be other potential harms that cannot be identified by a one-month test in which only 10 patients received the active drug\u2013notably, if this drug can pass into breastmilk or affect babies in utero. Also, as noted above, the story fails to tell readers that the form of the drug used in this trial is given as an inpatient IV treatment, which carries risks.", "answer": 0}, {"article": "Women between 40 and 49 were screened every two years, and women 50 to 74 were screened roughly every three years.\n\u201cThis indicates that the long-term benefits of screening in terms of deaths prevented are more than double those often quoted for short-term follow-up.\u201d\n\nThe new data adds to evidence on the long-term benefits of regular mammography screening.\n\u201cI think for anybody who was beginning to have their faith shaken in the value of mammography, these data show mammography is quite valuable as a public health approach to reducing deaths from breast cancer,\u201d Smith said.\nBut the latest results from the Swedish study show the rate of false positive results was low.\nHe said the new findings do not speak to the frequency of screening issue, but they do make clear that screening works.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story briefly discussed a few of the harms associated with mammograms, specifically the stress and anxiety caused by false positive results; however, it should have also mentioned the harms associated with unnecessary treatment of cancers that may not cause problems or be life-threatening.  Also, focusing on this issue of the \u201cstress\u201d for women who receive a false positive result puts too much emphasis on these psychological harms. Counterposing \u201cstress\u201d to \u201clives saved\u201d, though valid, is not persuasive.\n\u00a0", "answer": 0}, {"article": "Without strong evidence for its efficacy, the American Congress of Obstetricians and Gynecologists does not include the treatment in its Practice Bulletin for Urinary Incontinence in Women. L. Elaine Waetjen, professor of obstetrics and gynecology at the University of California, Davis Medical Center, who has spent more than 15 years treating women for this problem, said that there is \"no scientific evidence that the O-Shot works for incontinence and there is also no clear biological mechanism for why it should treat this condition.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drawing blood and injecting blood components into the vagina and clitoris are not without potential risk of pain, infection or other unknown complications. This should have been made clear.", "answer": 0}, {"article": "\u201cIt made surgery go smoothly, and I didn\u2019t have any pain before or after.\nThe SAVI SCOUT Radar Localization System helps to decrease the time a woman is in the operating room, increase the success rates of lesion removal and reduce the amount of healthy breast tissue that is removed during the procedure.\nThe wire is placed into the breast to help guide the surgeon in removing the abnormality later that day.\nAfter the patient receives a local anesthetic, it can be placed into the breast using an extremely thin needle under image guidance days or weeks prior to surgery.\n\u201cWhen the marker was inserted near the lump, it was similar to a biopsy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not mention any potential harms from inserting the radar reflector. It mentions that it is performed on a day separate from the surgery, in a procedure similar to a needle biopsy.\u00a0 Uncommon but potential complications of a needle breast biopsy procedure include pain, syncope (fainting), bleeding, and infection.", "answer": 0}, {"article": "\u201cThis is a hot research area and everybody is so close together.\"\nNone of the subjects who received REGN727 discontinued the study because of adverse effects, and the subjects who received REGN727 had a striking reduction of 60 to 65% in LDL cholesterol, according to Stein.\nWith statins you get toxicity \u2013 with these drugs we don\u2019t see any side effects with the antibody.\u201d\n\nIn an accompanying editorial, authors Dr. Stephen G. Young, and Loren G. Fong, Ph.D. write: \u201cAt this point, the status of PCSK9 therapeutics appears to be full speed ahead.\nStein characterized the results of the trial as \u201cpretty dramatic.\u201d\n\nA PCSK9 inhibitor, Stein said, differs from statins \"because it's unlike any other drug.\nSoon, we can expect more human trials in which investigators will dissect the properties of different PCSK9 antibodies and assess the effect of these agents.\u201d\n\nHowever, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, Young and Fong caution that it will remain unclear how important this class of drugs will be.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that the researchers found that the drug was safe and \u201cNone of the subjects who received REGN727\u00a0discontinued the study because of adverse effects.\u201d While true, it does not give the whole picture.\u00a0 Here\u2019s what the investigators said:\n\u201cThe proportions of subjects who had at least one treatment-emergent adverse event were similar among subjects who received intravenous REGN727 and those who received placebo. As compared with subjects who received placebo, a higher proportion of subjects who received subcutaneous REGN727 had an adverse event in the single-dose and the multiple-dose studies. Headache was the most common adverse event.\u201d\nIt didn\u2019t include the caveat that the MedPage Today story did:\n\u201cGiven the small number of subjects and the short duration of exposure, our ability to evaluate the safety profile of REGN727 in these trials was limited,\u201d the researchers cautioned.\nBut it did report:\nHowever, without long-term safety data and evidence that PCSK9 inhibitors truly help prevent heart disease, (two editorial writers) caution that it will remain unclear how important this\u00a0class of drugs will be.", "answer": 1}, {"article": "Atrial fibrillation is a common heart abnormality that affects nearly 3 million American adults.\nThat's true even for people at low risk of a stroke who wouldn't normally be given blood thinners.\nThe researchers said that the key is to start blood thinners, such as warfarin, soon after atrial fibrillation is diagnosed.\nThe longer the delay in giving blood thinners, the more the risk for dementia, the researchers said.\nA score of zero to one usually means blood thinners aren't needed because the risk for stroke is low.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because blood thinners work by interfering with blood\u2019s ability to clot, users are at some risk of dangerous heavy bleeding. This issue doesn\u2019t\u00a0make an appearance in the story.", "answer": 0}, {"article": "\"Not every cancer cell becomes a metastatic cancer cell.\n\"This may help with prognosis and staging of the cancer and, in the future, with targets for breast cancer treatments,\" said study lead author Dr. Anthony Lucci, a professor of surgery at the University of Texas MD Anderson Cancer Center, in Houston.\nAnd in an accompanying comment article, Justin Stebbing, a professor in the department of surgery and cancer at Imperial College in London, said that \"despite increasing evidence supporting the use of [circulating tumor cells] as biomarkers, how this information can be integrated into present practice is uncertain.\"\nAccording to Lucci, circulating tumor cells are also showing promise in predicting melanoma prognosis, so the method may be \"effective in several different tumor systems.\"\nCommenting on the findings, Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, said, \"We are moving into a state where we're looking at a person's individual tumor and this is another way to do that, potentially leading to treatment.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quotes from experts not connected with the study give readers valuable perspective on the current usefulness of the test.\u00a0 Dr. Stephanie Bernik, chief of surgical oncology at Lenox Hill Hospital in New York City, notes that the presence of circulating tumor cells may not be sufficient predictive information.\nJustin Sebbing, a professor in the department of surgery and cancer at Imperial College in London, cautioned that it\u2019s currently uncertain \u201c\u2026how this information can be integrated into present practice.\u201d\nThe writer also notes that the American Society of Clinical Oncology does not recommend that clinicians measure circulating tumor cells in patients.\nThese three cautions should help readers understand that if accuracy is not established, use of a test to guide therapy decisions could lead people down the wrong path.", "answer": 1}, {"article": "In 2016, breast cancer accounted for 29 percent of all new cancers identified in the United States and was responsible for 14 percent of all cancer-related deaths.\nThe researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath, along with gas-chromatography mass spectrometry (GC-MS) to quantify substances found in urine.\nIn fact, typical mammography sensitivity, which is 75 to 85 percent accurate, decreases to 30 to 50 percent in dense tissue.\nIn addition, their revamped statistical analyses of urine samples submitted both by healthy patients and those diagnosed with breast cancer yielded 85 percent average accuracy.\n\"Our new approach utilizing urine and exhaled breath samples, analyzed with inexpensive, commercially available processes, is non-invasive, accessible and may be easily implemented in a variety of settings.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Screening methods typically include false positive results, which will require further testing that might include biopsy. The release did not mention this potential harm or any others from the proposed method of testing breath and urine.\nThis is not a 100% accurate test and there is no discussion on what happens when the test is wrong or why the test may not be accurate all of the time.", "answer": 0}, {"article": "I think it's important to understand that more is not necessarily better.\"\nVitamin D, in combination with calcium, is good for your bones.\nYou should consume modest amounts in your diet, if possible (and for most people that is quite possible), or in the form of supplements if you can't get enough via food and drink.\nBut somehow we've arrived at a point when some physicians are prescribing large doses of Vitamin D supplements for their patients in the hope of preventing cancer, cardiovascular disease, diabetes, autoimmune disorders and other maladies, despite a lack of evidence that this works, according to a new commentary in the Journal of the American Medical Association.\nI think there's a general perception that if some is good, more is better.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells readers that taking large doses of supplements (above 4,000 IUs) can increase your risk of kidney stones, calcification of blood vessels and cardiovascular disease. Vitamin D toxicity is rare, but given the current enthusiasm for supplementation, it\u2019s good for stories to voice some caution.", "answer": 1}, {"article": "Sept. 26, 2017.\nThe research, published Sept. 26 in the Journal of the American Medical Association, reports results from the clinical trial known as GIFT (Genetics Informatics Trial of Warfarin to Prevent Deep Venous Thrombosis).\nUnlike prior studies, GIFT took into account genetic variants in three genes for 11 days of warfarin therapy.\nOf the 789 patients who were dosed in the traditional manner, 116 experienced at least one adverse event (14.7 percent).\nOne group received warfarin dosing based on standard factors such as age, height and weight; the second group was dosed based on these clinical factors plus genetic variants.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although it does so in general terms, the release covers the essentials: the risk of using blood thinners like warfarin and the risks of not using them.", "answer": 1}, {"article": "\"Why does it work for some people and not others?\"\nOne big distinction between the two populations, though, is that breast cancer survivors do not have the option of hormone replacement therapy open to them because those hormones are linked to breast cancer.\nSome patients might wonder if acupuncture that's helpful for hot flashes among breast cancer patients might be helpful for the hot flashes associated with natural menopause.\nInterestingly, sham acupuncture came in second place for effectiveness, the researchers said.\n\"There is a component of behavior of doing a sham procedure, so it psychologically may trigger a different kind of reaction from patients versus taking the placebo pill.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Acupuncture is likely safe but we have no idea if the women who received it, the sham acupuncture or gabapentin experienced any adverse effects of those treatments.", "answer": 0}, {"article": "Additional UT Southwestern researchers include lead authors Dr. Wenfang Chen, Haley Hill, Alana Christie, and Min Soo Kim, as well as Eboni Holloman, Andrea Pavia-Jimenez, Farrah Homayoun, Dr. Yuanqing Ma, Dr. Nirav Patel, Dr. Guiyang Hao, Qurratulain Yousuf, Allison Joyce, Dr.\nResearchers surprisingly found a subset of tumors that do not respond to the drug, but were able to identify biomarkers that, once verified, would help determine which patients are more likely to benefit from HIF-2 therapies.\nIn the Nature study, researchers compared the two drugs head to head and found that the HIF-2 inhibitor was more active than sunitinib and that it was active against tumors progressing on sunitinib.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\nIn the study in Nature, investigators show that HIF-2 inhibition was able to control metastatic kidney cancer even after 7 lines of prior therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Other than explaining that some of the kidney cancers were \u2018resistant\u2019 to the drug\u2019s effects, we learn nothing about the potential adverse effects of the new treatment.\nWhile \u201cmice on sunitinib were sickly and lost weight,\u201d the mice on the new drug gained weight, according to the release. That is hardly sufficient information to know whether the new treatment was well tolerated. Perhaps weight gain was due to fluid retention.", "answer": 0}, {"article": "\"And in that case, I see this as just a waste of money.\"\nThe authors also noted that apart from an increased brain size among children diagnosed with autism, there are no apparent structural differences between the brains of autistic patients and patients who are not autistic.\nFor her part, Laura Bono, the Durham, N.C.-based former chair of the National Autism Association and member of the board of directors of the autism advocacy group \"Safe Minds,\" expressed a certain amount of hesitancy about the prospects for MRI-driven diagnoses.\nCommunication deficits between the two hemispheres of the brain were, in fact, uncovered by MRI scans -- differences that the team said were not found in the brains of people without autism.\nThe current effort, focused on patients already diagnosed with autism, used MRIs to locate areas of the brain where the left and right hemispheres do not communicate properly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does something worse than failing to quantify the potential harms of MRIs. It allows an autism activist to say, \"I\u2019m always glad to see there\u2019s more autism research underway, and there\u2019s certainly no risk to having an MRI.\" No risk? At the very least there is the potential for MRIs to lead to unnecessary procedures. A recent study showed, for example, that there was a direct correlation between the availability of MRIs in an area and the number of back surgeries. The study\u2019s authors concluded, \"if increased MRI availability is associated with increased early use of low back MRI as well as with subsequent use of low back surgery, both of which have questionable clinical benefit, then widespread MRI diffusion may put patients at risk of a decrease in the quality of care they receive.\" Another risk is for renal injury when MRI is performed with contrast dye.", "answer": 0}, {"article": "About 23 percent of the women reported taking a low-dose aspirin (81 milligrams), 18 percent took ibuprofen, 11 percent took full-strength aspirin (325 mg) and about 10 percent took a COX-2 inhibitor or another nonsteroidal anti-inflammatory drug (NSAID).\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\nThe research described in Quick Study comes from credible, peer-reviewed journals.\nMillions of people take a low-dose aspirin daily in hopes of reducing their chances of having a heart attack.\nMost of the participants were white.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that aspirin can increase risk for internal bleeding, and says that women should consult a doctor before beginning a daily-aspirin regimen. This is satisfactory\u2013but barely\u2013since the magnitude of this potential harm is not mentioned.", "answer": 1}, {"article": "Dr Francoise Soussaline, PhD, DSc, IMSTAR's president said: \"To bring a universal 'liquid biopsy' blood test for cancer to market, it must achieve a number of criteria, including high sensitivity and specificity and be fully automated with high throughput for a medical routine use.\nThe research team believes that the test could be the first screening tool to 'rule in, or rule out' cancer in patients under suspicion of the disease, alongside other traditional diagnostics methods.\nThis is a generic test for cancer in an individual, regardless of the underlying mechanism that's causing their cancer.\nHowever, in their two most recent clinical trials of the test involving over 700 blood samples from colorectal and prostate cancer patients (and further breast and lung cancer samples that were available), they were unable to distinguish those with cancer from healthy patients in 60 cases.\nScoring a minimum of 2,000 cells per slide, the IMSTAR Pathfinder\u2122 system was able to separate all individuals of the cancer group from the healthy control group with confirmed statistical significance.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release needed to provide more information on the risks that arise with cancer screening tests\u2013for example, of being told you have cancer when you do not; or the opposite, being told you\u2019re cancer-free when you actually have cancer. There is also the risk of overdiagnosis \u2014 finding and treating non-growing or slow-growing cancer that doesn\u2019t need to be treated.", "answer": 0}, {"article": "A drug derived from this bushy sea creature showed modest, preliminary promise as an Alzheimer's treatment.\n\nIn small Alzheimer\u2019s study, hints of modest benefit from unusual drug\n\nA little-known drug company announced modestly encouraging results for its experimental Alzheimer\u2019s drug on Monday, a rare but still preliminary glimmer of hope in a field that has been battered by failure after failure.\n\nA mid-stage study by a tiny company wouldn\u2019t usually attract much attention, but the results unveiled by Neurotrope BioScience have been eagerly anticipated because its drug \u2014 derived from a bushy, hermaphroditic sea creature \u2014 takes a novel approach.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the study might not have been long enough to detect serious risks with long term use. It says, \u201cIf it works, patients would likely have to take Bryostatin-1 for the rest of their lives. The main adverse event\u00a0was diarrhea.\u201d", "answer": 1}, {"article": "Adult brains contain oligodendrocyte progenitor cells (OPCs), which are stem cells that generate myelin-producing cells.\n\u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\nIn the current study, Dr. Tesar wanted to see if drugs already approved for other uses were able to stimulate OPCs to increase myelination.\nNCATS and Dr. Tesar have an ongoing collaboration and plan to expand the library of drugs screened against OPCs in the near future to identify other promising compounds.\nDr. Tesar and his colleagues caution that more research is needed before miconazole and clobetasol can be tested in multiple sclerosis clinical trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Dr. Tesar provides a cautionary note related to the potential harms of this approach; \u201cOff-label use of the current forms of these drugs is more likely to increase other health concerns than alleviate multiple sclerosis symptoms.\u201d Given the stage of research, we think this is sufficient to rate this criterion as satisfactory", "answer": 1}, {"article": "\u201cIn the next pregnancy, if you don\u2019t get it off, you may go from obese to very obese,\u201d Thornburg said.\nThere was no clear benefit among the women in the diet and exercise groups when the researchers looked at other complications, such as cesarean delivery, but it did look like there may be some benefit, they write.\nWhile the new study generally did not show fewer complications in the diet and exercise group, Dr. Loralei Thornburg told Reuters Health that it\u2019s good that there was no increase in complications.\nGaining too much weight is tied to an increased risk of complications for both mother and child, according to the researchers, who completed the review for The Cochrane Collaboration, an international organization that evaluates medical research.\nAfter including the new studies, the new review found \u201chigh-quality evidence\u201d to show diet, exercise or both can reduce the risk of excessive weight gain during pregnancy, write the researchers in The Cochrane Library.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one was borderline but ultimately deemed Not Satisfactory. The story addresses harms through quotes from an independent source who specializes in high-risk pregnancy. She says it \u201cwas very reassuring that [the paper says] there wasn\u2019t an increased risk of preterm birth with moderate exercise.\u201d However, we\u2019d note that the paper itself says that, while there was no difference between groups with regard to preterm birth overall, \u201cLimited evidence suggested that [the effect] may differ\u2026with a trend towards an increased risk for exercise-only interventions.\u201d That\u2019s not quite as reassuring as the source suggests, and we think the result deserved some discussion. In several places, the study authors noted that the issue of preterm birth needs more research so that safe guidelines can be established.\nA related concern is that there\u2019s no acknowledgment of the increased risk of low gestational weight gain seen in the diet and exercise groups or the associated harm that inadequate weight gain could potentially cause. Only the benefits of reducing excessive weight gain are discussed. To the story\u2019s credit, it does state the importance of talking to your doctor before starting a diet or exercise regimen.", "answer": 0}, {"article": "For more on obesity, visit the U.S. National Institutes of Health.\nCaution is vital when using any drug that has been approved for one condition for another, Sandon said.\nPsychological factors or lifestyle factors may play a role, he said.\n\"The important thing to keep in mind is that although we diagnose obesity on the basis of a mathematical formula -- a BMI of 30 and up -- the basis for obesity may differ from one individual to another.\"\n\"But for many people, this kind of drug might absolutely be of great help, by doing something that helps the regulation of these appetite hormones and the regulatory pathway,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nice job mentioning side effects in the third sentence, followed by a paragraph later in the story\u00a0that spells them out: \u201cBut patients in both drug groups faced a higher risk for side effects, including diarrhea, headache, fatigue, nausea/vomiting, concentration and memory difficulties, anxiety, and depression-related symptoms.\u201d\u00a0 While we wish the story had quantified how much higher the \u201chigher risk\u201d really was, we\u2019ll give it the benefit of the doubt for the things it did satisfactorily.", "answer": 1}, {"article": "He says he plays basketball with his granddaughter, works on his farm, and gets on the treadmill for 30 minutes three times a week.\nIt's early -- results are in for only the first 16 patients -- but the results already are drawing praise from experts not easily impressed by first reports.\nIt's the first time tissue-specific stem cells, other than bone-marrow cells, have been tested in humans, Hare says.\n\"Michael Jones, our first patient, could barely walk 30 feet [before treatment].\nThese adult stem cells already are committed to becoming heart cells, but they can transform into any of the three different kinds of heart tissues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that there were no side effects from the treatments. We would have liked to have seen more detail on how long the patients were followed (we\u2019re only told that 8 have been followed for one year) and the types of side effects one might expect with this type of therapy. The subjects underwent cardiac surgery during which time cardiac tissue was recovered and the stem cells were injected into the heart via a catheter.\u00a0 Each procedure carries the potential for harm.\u00a0 In reporting on such a small, short-term study, we think the potential for harm is worth at least a line. ", "answer": 0}, {"article": "\"It's a very important trial,\" added Dr. Angeles Alvarez Secord, associate professor of gynecologic oncology at Duke Comprehensive Cancer Center in Durham, N.C. \"I've been using [the IUD] clinically for several years now for this purpose in patients who desire future fertility and some patients who cannot undergo surgery or who are at high risk for surgical complications.\nNo adverse effects from treatment were noted, according to the researchers, who declared no conflicts of interest.\nHowever, all the women were alive and seemingly cancer-free by the end of the study after further treatment (either the IUD and GnRH treatment or a hysterectomy), the study reported.\nNine of the women in the study successfully delivered babies.\nThe IUD was removed at the end of the year if there was no evidence of cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story accurately notes that the study reported no adverse effects. The study\u2019s authors reported only on adverse effects that were sufficient to require suspension of treatment.", "answer": 1}, {"article": "\"That's about what you see with standard drug therapy,\" says researcher J. David Prologo, MD, assistant professor of interventional radiology at Case Western Reserve University\u2019s School of Medicine in Cleveland.\nBut other experts tell WebMD that questions about the long-term consequences remain.\nThe findings were presented here at the annual meeting of the Radiological Society of North America.\nA time to ejaculation of more than two minutes is normal, he tells WebMD.\nAlso unknown: whether men would opt for the treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were \u201cno side effects\u201d from the procedure, but then goes on to explain that three men reported that their erections weren\u2019t as firm after the procedure.\u00a0Call us picky, but wouldn\u2019t that count as a side effect? We were pleased to see some mention of the potential for nerve damage if the procedure needs to be repeated in order to maintain its effectiveness. But there should have been some\u00a0acknowledgment that this study\u00a0was\u00a0far too small to accurately assess potential harms of the procedure. A mixed bag, but enough concerns were raised to give the benefit of the doubt on this one.", "answer": 1}, {"article": "While the study offers insights on managing the disease, there's not enough evidence yet on whether HGH treatments could extend the lives of those with cystic fibrosis.\nThe disease also affects the pancreas, making it difficult for the body to absorb food, which significantly stunts growth and often leads to early deaths.\nThat growth also resulted in larger internal organs, particularly the lungs, making breathing easier.\nThe study, published Monday in the journal Pediatrics, was produced by the UConn/Hartford Hospital Evidence-based Practice Center and was funded by the U.S. Department of Health and Human Services.\nLungs are clogged with a thick mucus, which can lead to lung infections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "MS can cause many symptoms, including blurred vision, loss of balance, poor coordination, slurred speech, tremors, numbness, extreme fatigue, problems with memory and concentration, paralysis and blindness.\nThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\nA trial that compares stem cell transplants with other therapies to see whether stem cell transplants can become a treatment for patients who have progressive MS is about to start, added Racke, who co-authored an editorial that accompanied the study.\nMONDAY, Feb. 20, 2017 (HealthDay News) -- Stem cell transplants may halt the progression of aggressive multiple sclerosis (MS) in nearly half of those with the debilitating disease, but picking the right patients for the treatment is key, a new study suggests.\nBut the treatment can be risky because the patient's immune system has to be wiped out before the stem cells are transplanted, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on one potential adverse outcome: death. The story addresses this using clear, unambiguous language, which is good. In addition, the story notes: \u201cThose deaths are a major concern, one neurologist said, because MS is not in itself life-threatening.\u201d That\u2019s a key point to make. The story could have been stronger if it had addressed the potential for other, nonfatal outcomes, but we give it a satisfactory rating.", "answer": 1}, {"article": "U.S. guidelines recommend Americans consume less than 2.3 g of salt daily, or 1.5 g for certain people who are more at risk for high blood pressure or heart disease.\nThis gave the researchers enough data to be able to start drawing conclusions, they said.\nThe Cochrane review attracted sharp criticism from nutrition experts.\nBut even so, the scientists think they would need to have data from at least 18,000 people before they could expect to identify any clear health benefits.\nElaine Rush, a professor of nutrition at Auckland University of Technology in Australia, said that putting a spotlight on single trials and generalizing dietary advice for a single nutrient such as salt was \u201cnot helpful.\u201d\n\n\u201cWhat is helpful is for the food industry to reformulate products to reduce sodium and increase the nutrient quality of foods by using real ingredients,\u201d she said in an emailed comment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable in this story about reducing salt consumption.", "answer": 2}, {"article": "Legumes, beans, whole grains and some seeds have it, as do uncooked potatoes and unripe bananas.\n\u201cThe potential for a nutritional lifestyle intervention to counter obesity driven by high-carbohydrate food, though we don\u2019t know yet how significantly, is fascinating,\u201d Arciero says\u2014especially when it\u2019s as simple and delicious as reheating your pasta.\nThose benefits\u2014getting digested slower, being converted into fatty acids and sustaining colonies of gut bacteria\u2014set resistant starch apart.\nBut that\u2019s not the case with resistant starches, so named because they resist digestion.\nMost intriguing and surprising of all is that so many leftovers contain resistant starch.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re rating this N/A since it\u2019s about food choices. However, it is possible that the belief that a food contains resistant starch could paradoxically lead to that food\u2019s overconsumption.", "answer": 2}, {"article": "\u201cIt\u2019s life changing,\u201d Ms. Denlein said.\n\u201cIt\u2019s just a phenomenal tool.\u201d\n\nThere is a downside, though: \u201cInformation overload is a very serious problem\u201d for the doctors, said Dr. Lynne Warner Stevenson, director of the Heart Failure Program at Brigham and Women\u2019s Hospital in Boston and a professor at Harvard Medical School, who counts herself as a proponent of smart devices.\nThat meant that, with her device, Mrs. Elzo did not have to wait till her doctor could put a receiver directly on her chest.\nDr. Richard Page, president of the Heart Rhythm Society, said doctors wonder if they can be held liable if they do not look at all the data.\nStill, he said, the new technology \u201cis potentially transformative.\u201d\n\nFor researchers the information deluge leads to a different problem: how to analyze the data.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did mention the problem of potential information overload however there was no discussion of actual harm such as inappropriate shocks from implanted defibrillator devices, for example. \u00a0There was no questioning of the accuracy of the data potentially transmitted by devices.\nThis was a far too rosy picture \u2013 almost as if all the data was so terrific that the only downside could be the volume of terrific data.\u00a0 Other things can go wrong as past experience shows when you try to regulate the heart. ", "answer": 0}, {"article": "Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nWhile it may reduce the risk of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern because of the potential for delayed diagnoses of important cancers in men who may benefit from treatment, according to investigators reporting in The Journal of Urology\u00ae.\nHowever, the study also identified a drop of 28.1% in diagnoses of intermediate risk disease and 23.1% in high risk prostate cancer one year after the draft guideline, which could result in missing important opportunities to spare men with higher risk cancers from progressive disease and cancer death.\nThis study helped quantify the potential benefits (reduced harms of over diagnosis and overtreatment of low risk disease and disease found in elderly men) and potential harms (missed opportunities to diagnose important cancers in men who may benefit from treatment).\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harm of not screening is implied to be an increased risk for prostate cancer mortality because diagnoses of high-risk cancers could be delayed. We\u2019ll award a Satisfactory here, although we\u2019d note that we don\u2019t have high quality data supporting this supposition. The PIVOT trial of surgery vs. watchful waiting for men who were mostly screen-detected was negative. \u00a0Only post-hoc analyses showed a potential survival benefit for aggressively treating high-risk cancers. \u00a0One modeling study\u00a0suggested that screening can be associated with net gain of quality-adjusted life years\u2013though the 95% confidence interval also includes a net loss.\nAnother potential harm associated with screening are the adverse effects of treatment (whether necessary or unnecessary). The release notes that \u201cradiation therapy and surgery have a negative impact on quality of life,\u201d but this is somewhat euphemistic as we\u2019re talking about potential for incontinence, impotence, and biopsy-related sepsis as well as death. \u00a0There are hard numbers citing the rates of incontinence and impotence related to prostate surgery, so those certainly could have been cited here discussing harms.", "answer": 1}, {"article": "More women are undergoing genetic testing after a diagnosis of breast cancer, and improvements in both mastectomy and breast-reconstruction techniques have made the option of a double reconstruction less daunting.\nSeveral developments may be driving the trend toward prophylactic mastectomies, experts said.\nDoctors and patients\u2019 advocates urged women considering the procedure to go for counseling and take their time before making a decision, noting that other risk-reducing options were available, like tamoxifen therapy for estrogen receptor-positive breast cancer and the use of more sensitive magnetic resonance imaging screening for earlier detection.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The focus of the story discusses the recent increase in bilateral mastectomy after the diagnosis of cancer in one breast.\u00a0 This may be overtreatment for some women.\u00a0 The story notes that physicians should provide women with accurate information about the survival benefit of all treatments, including less invasive options for reducing the risk of a recurrence. ", "answer": 1}, {"article": "All rights reserved.\n\"We're not giving patients enough information to make their decision,\" said Dr. Peter Carroll, chairman of urology at the University of California, San Francisco.\nAdding the gene test put 100 men into that category, said another study leader, Dr. Matthew Cooperberg of UCSF.\nIn any category of risk it added independent information compared to the standard criteria we use today,\" Carroll said.\n\"I would suspect that having cancer and having to live with it would be very difficult for them,\" but it doesn't bother him, Smith said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained some of the potential limitations of the new testing approach.\n\u201cUnless you can be sure your biopsy has hit the most aggressive part that\u2019s in the prostate, you can\u2019t be sure\u201d how accurate your risk estimate is, explained Dr. Eric Klein, chief of urology at the Cleveland Clinic, who led early development of the Oncotype prostate cancer test.\n\u2026\nUCSF just got a federal grant to see how men choose treatments and whether this test might sway them.\n\u201cWe throw all these numbers at them. Are they really going to make a better decision?\u201d Cooperberg said.", "answer": 1}, {"article": "This is a way of getting closer to an answer,\" said Weiner.\nIt's an early test for those who already have cognitive concerns and who wonder whether Alzheimer's disease may be the cause.\nWith growing understanding that the changes of Alzheimer's disease may be decades in the making, the value of early detection is gaining adherents, said Weiner.\nAmong patients diagnosed with mild cognitive impairment, about 60% have amyloid plaques and will go on to develop dementia that is likely Alzheimer's disease, said Dr. Michael W. Weiner of the Department of Veterans Affairs' Center for Imaging of Neurodegenerative Diseases.\nWhile diagnosis by proton magnetic resonance spectroscopy is under study for early detection , accurate early detection by such noninvasive means is a ways away.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story hints at the potential harm of receiving a positive test result at a time when there are no effective treatment options for Alzheimer\u2019s. However, harms were not addressed directly enough to merit a satisfactory rating, in our opinion. As with any diagnostic test, this test may cause harm from a false-positive result, which may create unnecessary anxiety, or a false-negative reading, which may create a false sense of security and delay appropriate management steps. The test is also radioactive and contributes to the patient\u2019s lifetime radiation exposure and cancer risk. None of these downsides is discussed in the story.", "answer": 0}, {"article": "Biogen provided the researchers access to their data and statistical support.\nPatients who test JCV antibody-positive are typically either told to not to start natalizumab, or have had treatment stopped after two years, when risk was deemed to be too high.\nThere have been 756 PML cases reported worldwide as of January 2018, with a global incidence rate of 4.19 per 1,000 PML cases in people treated with natalizumab.\nNatalizumab is manufactured by Biogen Idec and Elan, and sold under the name Tysabri\u00ae.\nThe new research showed that extending dosing of natalizumab from every 4 weeks to every 5 to 12 weeks significantly reduced the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but potentially fatal brain infection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Other than progressive multifocal leukoencephalopathy (PML) \u2014 the side effect targeted in this study \u2014 the other side effects of natalizumab therapy are not mentioned. The most serious include liver toxicity, and infections from immunosuppression.\nFurthermore, although many other therapies which cause immunosuppression can lead to PML, it might have been helpful for readers to know that natalizumab has proven particularly worrisome in this regard. It\u2019s been pulled from the market in the past because of PML concerns, and it\u2019s recommended by many in the MS field to be used in very limited circumstances.", "answer": 0}, {"article": "\u201cBut even without that firm answer at this point I don\u2019t see the harm in supplementing.\u201d\nThe study, presented at the American Society of Reproductive Medicine annual meeting, was in mice, so more research needs to be completed before omega 3 foods or supplements become part of treatment for infertility.\n\u201cOur study shows that there may be some relationship between dietary factors and things like egg quality so one idea may be recommending supplementation with omega 3s to improve fertility.\u201d\n\nExactly how the healthy omega 3 fatty acids are helping the ovary to produce better quality eggs isn\u2019t clear yet.\nMore studies need to replicate and confirm the role that omega 3 fatty acids might play in fertility, but for now, Skaznik-Wikiel says that there isn\u2019t much harm in consuming more omega 3 fats.\n\u201cWe hope in the future to have more answers to be able to say firmly that yes, omega 3 fatty acids are the way to go [for women hoping to get pregnant,]\u201d she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the researcher\u00a0\u201csays there isn\u2019t much harm in consuming more omega 3 fats;\u201d it adds that high doses of omega 3s, in rare cases, increase the risk of hemorrhage in people prone to bleeding problems. That is just enough to merit a satisfactory rating.\nIt does not mention, however, that omega 3 supplements can cause allergic reactions in people with allergies to either fish or to the plants, seeds or nuts from which the supplements are derived. MayoClinic.org also notes that \u201cthere is not enough information at this time regarding the safety of fish oils when used in amounts greater than those found in foods during pregnancy and breastfeeding,\u201d which suggests that the risks of supplement use could be higher among the most likely audience for this story: women who have been trying to get pregnant.", "answer": 1}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\nIn the spinal cord - an area that's critical for walking -- they found a decrease in the expression of cholesterol synthesis genes.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\nThey compared gene expression changes between regions that correspond to different disabilities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not explain whether there are any harms from changing the gene expression in the mice, let alone what the potential harms might be in humans.", "answer": 0}, {"article": "Zeitzer said.\nZeitzer's latest study, published Monday in the Journal of Clinical Investigation , could make treatment easier by providing light exposure during sleep, before the trip, without changing or interrupting your routine.\nIn this latest study, Zeitzer and Raymond Najjar, a former postdoctoral scholar at Stanford now at Singapore Eye Research Institute, found that short flashes of light at night are more effective than continuous light exposure and could speed up the process of adjusting to a different time zone before a trip.\nThe treatment \"exploits biology in the eye\" to speed up the brain's adjustment to time changes, he said.\nThis study builds on previous research published in 2014, which found that light therapy works best at night because the body's circadian rhythms are more sensitive to light at night, even through closed eyelids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0were no harms expressed in the article, nor was the word \u2018harm\u2019 mentioned in the published study. This is where an outside expert may have shined some light. As an expert quoted in a Reuters article stated, \u201cMistiming light therapy can make jet lag worse.\u201d", "answer": 0}, {"article": "Among its raft of recommendations, the consensus statement says that:\n\u2022 Should aim to play for 150 minutes/week, or do less, but couple golf with other physical activity, and walk the course rather than ride a golf cart\n\u2022 Do warm-up/strengthening exercises to cut the risk of injury and use sun-cream and wear collared shirts/blouses to minimise the risk of skin cancer\n\u2022 Build on existing initiatives to promote inclusivity and develop environments and price structures that will be attractive to everyone\n\u2022 Develop a culture that will inspire more women and girls to play golf\n\u2022 Make every effort to promote equality and diversity, and boost accessibility\n\u2022 Promote sustainability through wildlife conservation and by restricting the use of water, energy, and pesticides\n\u2022 Provide additional facilities at clubs, such as a gym, walking routes, cr\u00e8ches and improve the focus on health and safety, with the provision of healthy foods, defibrillators, and speed limiters on golf carts, for example\n\u2022 Promote the benefits of regular physical activity, including golf, for people of all ages, genders, and income brackets\n\u2022 Work with industry and national associations to boost take up of the sport, particularly in groups where physical activity levels are low\n\u2022 Work with industry and regulatory bodies to get golf included in the Paralympics\n\n\"These outputs, if widely shared and adopted, will contribute to an improved understanding of golf and health, and aid these groups in making evidence-informed decisions and to improve health and wellbeing,\" the consensus statement concludes.\nMore people might be keen to take it up if golf were promoted as an enjoyable, lifelong outdoors activity that affords a sense of community and competitive challenge while providing some 'me time' as well as helping to fulfil recommended exercise quotas, says the statement.\nAnd it can boost older people's strength and balance.\nThis can put people off, says the statement.\nAnd the sport is often perceived as expensive, male dominated, difficult to learn, and not a game for the young or those on the lower rungs of the social ladder.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only potential harm from golf mentioned is an increased risk for skin cancer. It\u2019s an important inclusion that prompts us to give a barely passing grade.\nThis nebulous statement is also included: \u201cCompared with other sports, the risk of injury is moderate.\u201d (Rugby and mixed martial arts come to mind).\nWhat\u2019s not mentioned is a host of musculoskeletal injuries related to the repetitive and asymmetric nature of swinging a golf club.", "answer": 1}, {"article": "There were 812 deaths (32.2 percent) among heart failure patients not treated with Plavix and 709 deaths (28.1 percent) among heart failure patients treated with Plavix.\nA randomized study comparing conventional heart failure therapy with and without Plavix \"is needed urgently,\" the editorial writer concluded.\nThe study appears online March 23 and in the March 30 print issue of the Journal of the American College of Cardiology.\nMONDAY, March 22, 2010 (HealthDay News) -- The anti-clotting drug Plavix is of modest benefit in cutting the odds of death in patients with heart failure and heart attack who don't undergo angioplasty, a new study finds.\nHe said the benefit of the drug found in this study is \"of unquestionable practical importance,\" and added that the positive outcomes seen in a relatively short follow-up suggests potentially even better long-term survival.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion about any potential harms associated with the use of plavix. \u00a0", "answer": 0}, {"article": "Novel standard for research in malnutrition may save lives\n\nProfessor Henrik Friis, the senior author on the paper, points to the importance of the collaboration between university researchers and humanitarian organizations:\n\n\"It has been a new way to conduct research, that we tested the effect of nutritional supplements used mainly by aid agencies, employing very advanced research methods in remote rural areas where humanitarian organization are working, and not at the university hospitals.\nSo, I hope we can use the results to provide the best possible treatment for more vulnerable children.\nIf we can treat children with moderate acute malnutrition with the scientifically proven most effective food aid product, and thereby prevent severe acute malnutrition, then many lives can be saved\"\n\nDr Susan Shepherd, a paediatrician who heads ALIMA's Operational and Clinical Research, says:\n\n\"ALIMA is very proud of its participation in this study.\nThe study, published Monday 11 September in the open access medical journal PLOS Medicine, showed that corn-soy porridge should be replaced with a lipid-based nutrient supplement (LNS), a fortified peanut butter.\nStudies like Treatfood generate the evidence we need to make the best decisions with our patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Many people\u2019s first question upon reading about a peanut buttery kind of nutrient supplement might be whether it produced any allergic reaction or other side effects in infants. In fact, it didn\u2019t, but the news release doesn\u2019t tell us that.", "answer": 0}, {"article": "The seniors are focused and at ease in their daily ritual, and it's soothing to watch them.\nThe study authors say there's a usually a strong relationship between depression and heart failure, so the fact that tai chi helped cheer people up was an especially good sign.\nIn a quality of life questionnaire the researchers gave out, those who practiced tai chi scored significantly higher than those who hadn't been doing the movement.\nAccording to a Harvard Medical School newsletter, tai chi is increasingly seen as a form of 'medication in motion.'\nThe Archives of Internal Medicine study is the first large clinical trial to look at whether a tai chi program can do anything for people with heart failure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although evidence increasingly shows that patients with heart failure benefit from\u00a0physical activity, exercise is not without risk. Some patients with heart failure may experience worsening symptoms or cardiac arrhythmias related to exercise. There\u2019s also the potential for falls. The story should have noted that in this study, tai chi did not provoke any adverse events and seemed to be very safe for this group of patients with mostly mild heart failure.", "answer": 0}, {"article": "Seizures can be obvious, causing unconsciousness or convulsions, but often they trigger subtler changes in a person's perceptions or behavior -- like a short staring spell, confusion or an altered sense of taste or smell.\nThe findings, reported online May 2 in the journal Lancet Neurology, are based on only 15 patients, and the device worked far better in some than others.\n\"We just wanted to see if this is feasible, and this study shows that it is,\" said lead researcher Dr. Mark Cook, of the University of Melbourne and St. Vincent's Hospital in Australia.\nOver those four months, the implants worked fairly well for eight patients -- correctly giving the high-risk warning anywhere from 56 percent to 100 percent of the time.\nTwo patients ultimately had the implants removed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was careful to explain:\n\u201cBut any benefits need to be weighed against the risks. Besides false alarms and unnecessary anxiety, the implant itself can cause problems. In this study, three patients had serious complications, including one with an infection and one whose chest device moved and caused her pain. Two patients ultimately had the implants removed.\u201d", "answer": 1}, {"article": "One dose measured one-half teaspoon for children aged 2-5, one teaspoon for children aged 6-11 and two teaspoons for children aged 12-18.\n\"I would be reluctant to routinely recommend to all parents that they give honey, because in some rare cases children can have reactions to honey.\"\nUnlike older children, infants can't fight the bacteria.\nThe study comes at a time when parents are on the lookout for new ways to give sick children relief.\nHoney may suppress cough because its sweetness causes salivation that coats the throat, authors of the study suggested.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that honey may cause an allergic reaction and that, rarely, it contains bacteria.", "answer": 1}, {"article": "Philip Gehrman, a Penn clinical psychologist who was senior author, said the study proves that rapid treatment of depression is possible. But more research is needed to figure out why sleep deprivation works. His team is now conducting its own study. He's not hoping to use sleep deprivation as a treatment but thinks that pinpointing what it does to the brain will help doctors develop other, more sustained treatments.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not include the potential harms of sleep deprivation, which are extensive.", "answer": 0}, {"article": "\"We looked at all of these metabolites in concussed male adolescent patients and in non-concussed male adolescent patients and it turns out that the spectrum is really different,\" explains Daley, who is also Western's Associate Vice-President (Research) and a principal investigator at Western's renowned Brain & Mind Institute.\nOur research excellence expands knowledge and drives discovery with real-world application.\n\"With further research, we anticipate that our blood test will also aid clinicians in predicting concussion outcome, as well as aid rehabilitation after concussion.\"\nSince 1878, The Western Experience has combined academic excellence with life-long opportunities for intellectual, social and cultural growth in order to better serve our communities.\nEqually problematic are the decisions to stop play or activities, or when patients who have suffered a concussion can safely return to normal activities without risking further injury.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are mentioned, but they certainly exist. We encourage releases on diagnostic and screening tests to address the potential for false positive (over-diagnosis) or negative results (under-diagnosis) that could have an impact on patient care.", "answer": 0}, {"article": "In 37 years as a police officer, Edwin Michel coped with a plane crash, a sniper, wildfires and three bullet wounds.\n\nNothing much rattled him until he was diagnosed with prostate cancer in November 2016. His doctor said the cancer wouldn\u2019t kill him but Mr. Michel, now 76 years old, wasn\u2019t entirely reassured. He felt more confident after a genomics test later revealed his prostate cancer was very low risk. The test, known as Oncotype DX, takes a sample from a prostate biopsy and analyzes 17 genes in it to estimate how aggressive...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is always a risk of false positives or false negatives with such tests, but the story didn\u2019t address those risks. It did do a good job discussing the harms of overtreating prostate cancer.", "answer": 0}, {"article": "Our trial showed no difference between the two in protecting entire communities.\"\nDr. Mark Loeb, lead author of the study, says his team's findings challenge the ACIP's recommendations towards flu shots, or inactivated vaccines.\n\"The ACIP's decision was an unprecedented decision in influenza vaccine policy-making for children.\nThe original intention of the study was to show that nasal spray vaccines would provide better protection than flu shots, but Loeb says the conclusions of the study are now especially important, given the ACIP's recommendations.\nLoeb says his team will continue to study herd immunity with different vaccine formulations by vaccinating children.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release makes no mention of possible harms that my follow the use of either the influenza vaccine injections or nasal spray, even though there are well-known restrictions on whom should and should not receive the nasal spray, and potential negative reactions to the injections among some people.", "answer": 0}, {"article": "\u201cMore often than not, it\u2019s not clear-cut which way to go,\u201d explained Barry Rosenstein, professor of radiation oncology at Mt.\nThe next step, he said, is for group members to validate the predictive power of the markers his team found.\n\u201cAnd if we can do that, then there\u2019ll be enough confidence to put it into use in the clinic.\u201d\n\nEven better, he suggested, it may one day be possible to use drugs to target the SNiPs, or the biological processes they influence, as a way to prevent damage from therapy.\nSo what if it were possible to know before treatment which men might be more likely to suffer complications?\nThis early-stage study represents a big step toward doctors and their patients making that decision.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable; given that this is still an unproven strategy, there are no data for harms.", "answer": 2}, {"article": "To have a difference like that is amazing.\"\n\"From a public health perspective, that is potentially huge for prevention of HIV,\" Moskowitz said.\nOr, the reduced viral load may be the result of participants' better adherence to their antiretroviral drug therapy, which generally leads to a suppressed or undetectable viral load, Moskowitz said.\nThe HIV study is part of a larger body of positive affect research being conducted by Moskowitz.\nThe reduced viral load could be because of a stronger immune system, Moskowitz said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "If the researchers believe the intervention is without harm, the release needed to spell that out. Harms were also not measured or\u00a0disclosed in the study itself, but it\u2019s something we encourage news release writers and journalists to seek to clarify.", "answer": 0}, {"article": "\u201cWe were a little surprised,\u201d says Petersen.\nFor now, even if doctors identify patients around age 65 who might be at higher risk of developing cognitive impairment, there isn\u2019t much they can do to interrupt the process.\nAnd with rates of those diseases rising, experts say that more primary care physicians\u2014not neurology experts\u2014will have the task of identifying these patients early so they can take advantage of whatever early interventions might be available.\nBut they can direct them toward clinical trials of promising new drugs to address Alzheimer\u2019s dementia, which may slow the cognitive decline considerably.\n\u201cBut what\u2019s nice about it is that it\u2019s a nice non-cognitive, motor factor so it\u2019s looking at another aspect of brain function.\u201d\n\nMORE: This Alzheimer\u2019s Breakthrough Could Be a Game Changer\n\nPetersen suggests that every physician should get this information on their patients at age 65; that way, they can have a baseline against which to compare any changes as their patients age.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Being told you are at increased risk for developing cognitive impairment is potentially distressing news. But as with many new reports on screening for disease, absolutely no mention is made of the potential harms associated with the tests. \u00a0And what about the potential for false alarms? Unnecessary emotional anxiety, increased doctor visits, and drug interventions could potentially have a very negative impact on someone who is experiencing normal aspects of aging.", "answer": 0}, {"article": "Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care.\nSpironolactone is not approved for the treatment of acne by the U.S. Food and Drug Administration despite expert opinion supporting its use, and Barbieri says the findings of this study should be confirmed by a randomized controlled trial that directly compares the two treatment options.\nHe also noted spironolactone is less expensive, which may be relevant to patients with high deductibles or who are uninsured.\nHowever, those same anti-hormonal effects can help prevent acne outbreaks in women.\nSpironolactone, marketed under the name aldactone, is currently approved to treat high blood pressure, heart failure, and conditions that cause people to retain fluid.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss harms of the drug other than to say it \u201cmay have a better safety profile\u201d than oral antibiotics. Then again, it may not. Safety was not part of the study. There should be some language about spironolactone\u2019s known side effects, which include an allergic reaction and vomiting, among others listed by the National Library of Medicine.\nIn addition, there can be long-term consequences of lower androgens, such as decreased bone mass following continued use.\n\u00a0", "answer": 0}, {"article": "Drinking cow\u2019s milk produced at night may be a treatment for anxiety and insomnia, suggests an animal study in the Journal of Medicinal Food.\n\nA glass of milk at bedtime has long been touted as a sleep aid. But the study found that milk collected at night, or night milk, had enhanced sedative effects in mice compared with milk produced during the day. Night milk significantly decreased the rodents\u2019 physical activity, balance and coordination and increased sleep time compared with day milk, the research showed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Drinking milk is common enough that it hardly warrants an explanation of the associated harms.", "answer": 2}, {"article": "In 2015, he was ranked the No.\nThe researchers selected 69 as the lower age limit because Medicare coverage of the general population begins at age 65, and the exposure of interest was regular mammography screening in the four years immediately preceding breast cancer diagnosis.\nAlthough a number of randomized trials demonstrate the clear benefits of mammography screening in women up to age 74 on reducing mortality, data are sparse in women over the age of 74, especially minorities.\nAlthough many guidelines rely on self-reports, Hennekens and his collaborators from Baylor College of Medicine and Meharry Medical College, used the Surveillance, Epidemiology, and End Results (SEER) program file linked to the Medicare administrative claims file, which allowed them to identify screening mammography use from 1995 to 2009 from 64,384 non-Hispanic women (4,886 black and 59,498 white).\nIn a new study published in the American Journal of Medicine, Charles H. Hennekens, M.D., senior author and first Sir Richard Doll Professor and senior academic advisor to the dean in the Charles E. Schmidt College of Medicine at Florida Atlantic University, indicates that black and white women ages 75 to 84 years who had an annual mammogram had lower 10-year breast cancer mortality than corresponding women who had biennial or no/irregular mammograms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any harms that might come from more frequent or aggressive screening of older women. As experts at the University of California-San Francisco and Harvard explained following their 2014 review of studies conducted from 1990 to 2014 on risk factors for women 65 and older and the value of mammography for women 75 and older, \u201cDoctors should focus on life expectancy when deciding whether to order mammograms for their oldest female patients, since the harms of screening likely outweigh the benefits unless women are expected to live at least another decade.\u201d", "answer": 0}, {"article": "Measuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting\n\nMeasuring blood levels of the recently discovered hormone irisin may improve diagnosis rates of teenagers with polycystic ovary syndrome, according to research presented today at the 55th Annual European Society for Paediatric Endocrinology Meeting.\nThe findings may reduce the number of unnecessary treatments prescribed to otherwise healthy girls.\nThe findings suggest that irisin could be a marker for PCOS allowing the condition to be diagnosed more easily.\nThe cause of PCOS is unknown and there is currently no cure for the condition.\nLifestyle changes and different exercise-related signals that regulate the secretion of irisin could provide a potential option for the management of PCOS.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms are not discussed. While a blood test is a relatively low-risk procedure, this release could have mentioned the risk of under- or over-diagnosis leading to incorrect or no treatment based on reliance of this diagnostic test, if it makes it to the commercial stage.", "answer": 0}, {"article": "Before the introduction of whooping cough vaccine in the 1940s, more than 200,000 cases a year were reported in the U.S. By 1965, that number plummeted to fewer than 10,000 a year. But the disease made a comeback in the 1990s, as the newer \"acellular\" vaccine \u2014 containing only cellular material but not whole cells \u2014 was phased in. While it is safer and has fewer side effects than the old version, studies have found that its protective effects wane more quickly than originally expected.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a brief mention of side effects, so this skirts by as Satisfactory. However, it would have been helpful to explain that about 1 in 10 adults experience nausea, vomiting, or chills. Painful swelling in the injected arm that requires medical treatment is \u201crare,\u201d according to the CDC.\nThe reporter mentions there is no live bacteria, which is good, but probably should also have mentioned there is no thimerosal, a mercury-based preservative.", "answer": 1}, {"article": "Can a high-tech scan reveal whether Alzheimer's disease is the cause of your forgetfulness? Advocates of Positron Emission Tomography scans for the diagnosis of Alzheimer's say the scans significantly aid in the early and accurate diagnosis of the memory-robbing disease. Neurologists say PET is useful in distinguishing between Alzheimer's and a similar-acting dementia. However, opinions differ on whether the scans are useful in predicting the likelihood of Alzheimer's in people with only mild memory problems.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story hints at false alarms from the use of PET scans, this is insufficient information on the harms of scanning. What would a \u201cfalse alarm\u201d entail? What does it do to a person who receives this news? ", "answer": 0}, {"article": "But we don't know we're right yet.\"\nBut last summer, Biogen began presenting its results with aducanumab at scientific meetings, including the Alzheimer's Association International Conference in July.\nOfficials of Biogen, which is developing the drug, were also cautious about interpreting the results of the study, which included 165 patients in the early stages of Alzheimer's disease.\nBut it will take much larger studies to show for sure whether aducanumab really does slow down Alzheimer's disease, Reiman says.\nResults like those could also lead to the first approved drug to treat the underlying cause of Alzheimer's rather than just the symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is clear that the drug\u2019s effects on amyloid plaque are accompanied by potential harms:\nBut there\u2019s a downside. The process of removing plaque sometimes causes fluid to build up in the brain. In rare cases, it can also cause bleeding. These side effects are known as amyloid-related imaging abnormalities, or ARIA.\nWe\u2019re also told that about 20 participants dropped out of because of adverse effects.", "answer": 1}, {"article": "Amid a dry spell for breakthrough cancer drugs, recent U.S. approval of Eisai Co.'s Halaven represents some vindication for a small group of researchers who believe, contrary to recent pharmaceutical fashion, that molecules from nature hold promise against hard-to-treat diseases.\n\nThe Food and Drug Administration's approval of Halaven in November for treating late-stage breast cancer was a triumph of chemistry and tenacious research. Its path, extending nearly three decades from the first studies, demonstrates not only potential...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "\"Are you angry?\"\nThese results provide strong evidence for using advanced technology as a decision-support tool to help clinicians and caregivers identify and prevent suicidal behavior, says John Pestian, PhD, professor in the divisions of Biomedical Informatics and Psychiatry at Cincinnati Children's Hospital Medical Center and the study's lead author.\nThe study is published in the journal Suicide and Life-Threatening Behavior, a leading journal for suicide research.\nA new study shows that computer technology known as machine learning is up to 93 percent accurate in correctly classifying a suicidal person and 85 percent accurate in identifying a person who is suicidal, has a mental illness but is not suicidal, or neither.\nThose enrolled included patients who were suicidal, were diagnosed as mentally ill and not suicidal, or neither - serving as a control group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This isn\u2019t covered in the release, but a look at the study leaves open a concerning question for us. Suicide prevention work is sensitive work: It\u2019s tricky for caregivers and stressful for patients, and while the study notes an institutional review board approved the study, it doesn\u2019t make clear how or whether the patients were counseled or debriefed before or after the study intervention (i.e. asking them a bunch of open-ended questions and recording audio of them speaking). This should have been made clear in the study as well as the release. There is also the potential\u00a0harm of a false negative result \u2014 in which case caregivers may receive false reassurance regarding someone who is, in fact, suicidal.", "answer": 0}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\n\u201cSugar calories are not like other carbohydrate calories,\u201d said Dr. Robert Lustig, a co-author of the study and professor of pediatrics at Benioff Children\u2019s Hospital at the University of California, San Francisco.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study sought to hold number of calories constant in order to examine the impact of reduced sugar. \u00a0While many health experts would point out that substituting pizza and bagels does not meet the criteria for an overall healthy diet, that was not a concern of this design.", "answer": 2}, {"article": "For more on aspirin, visit the National Institutes of Health.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nAnd while cautioning that more research is necessary to build on this \"proof of principle,\" the authors suggested that people who embark on a long-term, low-dose aspirin regimen in their late 40s and 50s are probably the ones who stand to benefit the most.\nBut the long-term benefits on some specific cancers began to show five years after the studies ended.\nThe protective impact of low-dose aspirin on stomach and colorectal cancer death was not seen until 10 years out, and for prostate cancer, the benefits first appeared 15 years down the road.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential side effects of aspirin mentioned in the story \u2014 \u201cbleeding and stroke\u201d \u2014 are relegated to the last line of the story and are given nowhere near the prominence they deserve. For one thing, \u201cbleeding\u201d doesn\u2019t convey the seriousness of potentially fatal\u00a0gastrointestinal\u00a0hemorrhage that can result from daily aspirin. Second, the story didn\u2019t make any attempt to quantify these risks so that they can be balanced against benefits.", "answer": 0}, {"article": "\u201cBut how does the public deal with this information?\nBut others worry that more frequent testing could exacerbate what is already a major problem: most prostate cancers grow so slowly that they would have been harmless if left alone.\nThose at high risk because of their genetics might then choose to start prostate-cancer screening earlier than the usual age of about 50, using a blood test that looks for proteins secreted by prostate tumors.\nProstate cancer becomes more common as men age \u2014 autopsies of elderly men find that most had prostate cancer, whether they knew it or not.\nBut some said that if the test leads to more screening, it is not necessarily a good thing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did include mention of the harms that are associated with treatment of prostate cancer, namely impotence and incontinence, and that the treatment of prostate cancer may not be at all necessary because not all prostate cancers are life threatening. \u00a0As this is a very counter-intuitive thought (that not all cancers are deadly) it might have been emphasized more.\n\u00a0It is critical that people be aware that while a large clinical trial (the PIVOT study) is underway, it is not yet known whether aggressive treatment of early prostate cancer is effective or whether it may cause more harm than good. \u00a0So while the effectiveness of prostate cancer screening remains controversial,it\u2019s important to note that aggressive treatment of early prostate cancer remains controversial too. \u00a0", "answer": 1}, {"article": "The American Cancer Society estimates that in 2009, approximately 192,000 men were diagnosed with prostate cancer and approximately 27,000 men died of the disease.\nFor those methods, too, there was too little research to say with confidence which method was superior in preventing deaths from prostate cancer, the researchers said.\nIn part, that's because researchers found no randomized controlled trials -- considered the gold standard of research -- that compared radiation therapy with watching waiting, Ip said.\nTaken together, the review \"does point out that based on current evidence, doctors should not be telling their patients that this form of radiation is better than that form,\" Brooks said.\nProton beam therapy in particular is expensive, but according to this report, there isn't enough evidence to show it's any better than other option.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did state:\u00a0\u201cRetrospective studies, however, found that radiation treatments were associated with increased urinary or bowel problems, compared with no treatment or no initial treatment.\u201d\u00a0 We wish it had provided more detail, but we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "The study was published today, Friday, April 13, in the Journal of General Internal Medicine.\nThe study showed that screening patients using an expanded set of risk factors, which the USPSTF suggests but does not formally recommend, would identify most cases of prediabetes and type 2 diabetes.\nBut there has been little attention focused on this group's most recent diabetes screening guideline.\nBy following the limited guidelines and only screening patients who are overweight or obese, approximately 30 percent of Asians with prediabetes or type 2 diabetes would be identified.\nBy following this recommendation, 53 percent of patients who had prediabetes or type 2 diabetes would not be screened.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The considerable harms of overdiagnosis which include the risk of unnecessary followup tests and treatment that can cause adverse effects, are not mentioned. There are both benefits and harms associated with broad based screening programs.", "answer": 0}, {"article": "Abbott Laboratories is betting heart patients will benefit from a new type of arterial stent that dissolves away when it is no longer needed.\n\nStents are scaffold-like devices used to prop open clogged heart arteries. Most stents are made of metal. But Abbott's new device, called Absorb, is made from a plastic-like material called polylactide that is commonly used in surgical sutures. The Absorb scaffold\u2014Abbott doesn't call it a stent\u2014is designed to completely fade away in two years and to cease supporting arteries at six...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We liked the fact that the potential downsides of the bioabsorbable stent were included in the story.\u00a0The story notes that the bioabsorbable stent is thicker and may require patients to be on potent anti-clotting drugs, thus exposing the patient to a risk of bleeding. The story also notes that previous studies have shown a low rate of complications. We would have liked to have seen some information about the complications seen.", "answer": 1}, {"article": "Feb. 22, 2012 -- When women in their 40s get breast cancer , their tumors need less intense treatment and recur less often if they were first detected during routine mammogram screening.\nThese women will suffer the harms of early screening.\nThe women were carefully followed since their diagnosis in 1990 to 2008, says study co-leader Judith A. Malmgren, PhD, president of Seattle's HealthStat Consulting.\nEven the USPSTF accepts the fact that beginning breast cancer screening at age 40 saves lives.\nBut the picture isn't so clear for women in their 40s.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did at least mention the risk of false positives and how this could affect whether women would still be inclined to get mammograms as they get older.", "answer": 1}, {"article": "Naloxone is a prescription drug that can reverse the effects of prescription opioid and heroin overdose, and can be life-saving if administered in time.\n\u201cNaloxone is non-addictive, and expanding training on how to administer the drug can help basic emergency medical service staff reverse an opioid overdose and save more lives.\u201d\n\nNational Emergency Medicine Service Information System data for 2012 were reviewed to better understand factors associated with naloxone administration, including demographic data, 911 call information, and details about the scene of an injury or illness as reported by EMS staff.\nDepartment of Health and Human Services Secretary Sylvia M. Burwell has made addressing opioid abuse, dependence, and overdose a priority and work is underway at multiple HHS agencies on this important issue.\n\u201cNaloxone can be given nasally to a person suspected of overdose, allowing basic EMS staff to administer the drug without injection,\u201d said CDC Senior Health Scientist Mark Faul, Ph.D., M.A.\nHaving trained EMS staff to administer naloxone in rural areas will save lives.\u201d\n\nTo reduce opioid overdose deaths, particularly in rural areas, CDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release\u00a0does not say anything about the potential risks here. The fact that lower level EMS staff have been banned from administering this drug suggests that it could be dangerous. However, the reality is that the risks of intranasal naloxone are not significant, so this should have been mentioned. The risk of an intramuscular injection are also low \u2014 more or less the same as the risk of any injection (minor bleeding, hitting a nerve, etc). The release should have mentioned the lack of risk and perhaps provided context for the strict regulation of naloxone use (which again is more historical than rational).\nPart of what makes the release confusing is that it appears to be advocating for two things. It mentions multiple times that only staff with advanced training are allowed to administer the drug. And it says that \u201cNaloxone can be given nasally to a person suspected of overdose, allowing basic EMS staff to administer the drug without injection.\u2019 But then it also says that \u201cCDC recommends expanding training on the administration of naloxone to all emergency service staff, and helping basic EMS personnel meet the advanced certification requirements.\u201d Perhaps both statements are true, but the release does not make it clear whether the agency\u2019s strategy is focused on the training or the expansion to basic staff.", "answer": 0}, {"article": "Article reference: Thomas L. Jang, Neal Patel, Izak Faiena, Kushan Radadia, Dirk F. Moore, Sammy E. Elsamra, Eric A.\nAnother interesting finding from the research was that slightly more than half of men diagnosed with the disease did not receive combination therapies for their prostate cancer.\nThey found that 10 years after treatment, 89 percent of the prostate removal plus radiation group was still alive.\n\"Our study suggests that removing the prostate followed by adjuvant radiotherapy is associated with greater overall survival in men with prostate cancer.\"\n\"For high-risk prostate patients we started the use of aggressive radiation therapy after surgery 20 years ago,\" said Adam Dicker, Senior Vice President and Chair of the Department of Enterprise Radiation Oncology at Jefferson Health, who was not involved in the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a strength. The release stated: \u201cMen who received the combination of surgery and radiotherapy had higher rates of erectile dysfunction (28 percent vs 20 percent) and higher rates of urinary incontinence (49 percent vs 19 percent).\u201d\nThe news release also stated: \u201cThe risks of prostate removal, or prostatectomy, are well known and include higher chance of developing incontinence and erectile dysfunction. There are some risks associated with radiation treatment and hormone therapy, but they are less common, and are typically thought to have a lower impact on quality of life.\u201d", "answer": 1}, {"article": "\"The treatment I received on the trial changed my life.\nThe research, published in The Lancet Oncology, found that around half (49%) of patients treated with VTP went into complete remission compared with 13.5% in the control group.\nWith such an approach we should be able to achieve a significantly higher remission rate than in the trial and send nearly all low-risk localised prostate cancers into remission.\nBy contrast, VTP only caused short-term urinary and erectile problems which resolved within three months, and no significant side-effects remained after two years.\nAt the moment, men with low-risk prostate cancer are put under 'active surveillance' where the disease is monitored and only treated when it becomes more severe.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release states VTP \u201conly caused short-term urinary and erectile problems which resolved within three months, and no significant side-effects remained after two years.\u201d While it\u2019s good that harms were mentioned, it\u2019s a disservice to patients to downplay their impact with the word \u201conly.\u201d\nFurther, the news release does not give the proportion of patients on VTP who experience adverse events, which was 80 percent. Nor does it mention that 30 percent of VTP patients versus 10 percent of those in the active surveillance group had serious adverse events.\nFinally, the news release glosses over the fact that over 1/3 of subjects needed repeat treatment within 2 years and that men undergoing VTP appear likely to need to be on the same monitoring protocol as those on active surveillance (meaning they will need biopsies, which carry risks). VTP and prostate biopsies can cause harms.", "answer": 0}, {"article": "Watching her patients undergo bone marrow transplant ?\nGiving these cells when disease is in remission after transplant \"might actually be helping patients who have a high risk of relapsing to not relapse down the line,\" said Dr. Aude Chapuis, cancer physician and immunotherapy researcher at Fred Hutch, one of the study's leaders.\nBecause it was the first study of this particular approach, the researchers focused on a high-risk group -- AML patients undergoing bone marrow transplant who had certain genetic or disease characteristics that decrease the chance of long-term transplant success -- \"a hard population of patients,\" Chapuis said, many of whom \"were horribly sick.\"\nOf the 12 AML patients who received this experimental T-cell therapy after a transplant put their disease in remission, all are still in remission after a median follow-up of more than two years.\nThis is the team's first trial of this strategy, which was initially developed in the lab of Dr. Phil Greenberg, one of the study's leaders and the head of Fred Hutch's Program in Immunology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not only does the release omit side effects or other potential harms from this type of treatment, it emphasizes the harms of conventional treatment, thus presenting an unbalanced comparison. The conference abstract summarizing the research noted that adverse events included short-term flu-like symptoms that are common to certain types of immunotherapy, as well as temporary reductions in white blood cell counts. In addition to failing to mention these reported harms, the release did not alert readers to potential life-threatening risks of immunotherapy which sometimes do not become apparent until the therapies have been given to many people over many years.\nOf note: a similar experimental immunotherapy trial by the same company (with acute lymphoblastic leukemia rather than AML patients) was halted after some patients died, according to this conference recap. The growing awareness of potential hazards of immunotherapy was recently highlighted in this post on HealthNewsReview.org.\nThe release should have mentioned that the absence of life-threatening complications in this small trial does not prove the treatment is safe.", "answer": 0}, {"article": "\"It's something that has become almost a community standard.\nCurrent screening guidelines that recommend biopsies for men who have high PSA velocity but no other signs of prostate cancer -- such as a suspected abnormality during a digital rectal exam or high PSA level during a single test -- are leading to many unnecessary biopsies, the researchers said.\nHowever, the new study found that PSA velocity doesn't add any useful information beyond what physicians can already tell from other methods of prostate cancer screening, including the one-time PSA level test and digital rectal exams.\nThe thought was that since high PSA levels are correlated with prostate cancer, rapidly rising levels of PSA, called \"PSA velocity,\" from one year to another would also be an indicator of prostate cancer.\nBut when they factored in other things that can influence risk, including a family history of the disease, being older, being black, PSA level and results of a digital rectal exam, there was virtually no association between PSA velocity and biopsy outcome.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The competing AP story was much better on this point, reporting that using rising PSA levels, 1 in 7 men would have a prostate biopsy as compared with 1 in 20 men based solely on high PSA level. This suggests that change in PSA level results in 13/20 unnecessary prostate biopsies.\nThe story could have provided more detail on some of the possible complications resulting from prostate biopsies.\nIt did mention anxiety from tracking PSA levels over time. ", "answer": 0}, {"article": "Avastin is a so-called monoclonal antibody that works by blocking vascular endothelial growth factor A, which stimulates the growth of the tumor's blood supply.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\nThe funder was involved in study design, coordination of data collection, data analysis, data interpretation, and writing of the report, the journal noted.\n\"So, the researchers and sponsors are to be congratulated for doing this study.\nHowever, several issues remain to be determined, including the optimal dose and the role of maintenance therapy with Avastin, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story reported on the potential harms associated with the addition of this drug to a treatment regimen. \u00a0Without information about what a patient might gain \u2013 it is hard to know whether the risk of these harms is worth the potential benefit. And the story could have provided more details about the severity and impact of the harms.\u00a0 Nonetheless, we give it a satisfactory on this criterion. ", "answer": 1}, {"article": "\"It's just a matter of time.\"\nFeatherstone and Wendell say some dentists may be reluctant to embrace the preventive methods because they worry they'll lose money if they they do fewer costly procedures.\nAt this point, Featherstone says, two-thirds of dental schools in the U.S. teach some kind of disease management model based on a thorough risk assessment.\nBut if you catch decay early, Featherstone says, it can be reversed using fluoride treatments like varnish and concentrated toothpaste and gels.\nThe National Association of Dental Plans couldn't give a definitive answer about coverage, but calls to some individual carriers and dental offices suggest it depends entirely on the type of plan you have.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fluoride for dental health has been extensively studied for decades and is considered safe, so we\u2019ll file this rating as not applicable to the story.\nBut, as some dentists might point out, there is an argument to be made for discussing one known\u2013though minor\u2013risk: Some people living in areas with naturally high levels of fluoride in their water may experience tooth discoloration or other issues if they are given additional fluoride treatment.", "answer": 2}, {"article": "But all I need to do is add 5 and 5.\u201d\n\nEspecially in a time of concern over rising medical costs, \u201cwe should not simply use the highly sophisticated technology just because it\u2019s there,\u201d Falcone said.\n\u201cWe were surprised that (surgery with the robot) did not have better outcomes than (the surgeon alone), as we have always believed if you can see more and see better you can do more and do better,\u201d the authors write.\nBecause the robot lets the surgeon get a better picture of the inside of the body, the authors had expected that surgeries using the robot would go more smoothly than those without it.\nIn this case, the robot could turn what would have to be an open surgery into a simpler one.\nTo test this idea, they looked back at 78 minor surgeries that were done on women with endometriosis - half using the assistance of a robot, half without it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that there were no complications in either group and goes on to say that the robotic surgeries took longer, making it more likely that surgeons would make mistakes (although they did not, apparently, make any mistakes.) It says in passing that \"the incision is smaller (and) the manipulations are more controlled\" when a surgeon works without a robot, a counter-intuitive piece of information that merited at least an additional sentence of explanation, even in a story this short.", "answer": 1}, {"article": "In the new study of 24 patients, scores on a standard test measuring the disturbances of memory, language, attention, and other cognitive skills that are hallmark symptoms of Alzheimer's disease dropped an average of slightly more than five points in those treated with IVIG.\nThe IVIG treatment also appeared to slow the rate of brain shrinkage by about 45%, he tells WebMD.\nThat compares with a 15-point decline in patients who initially received placebo and switched to IVIG, says Norman Relkin, MD, of Cornell Weill College of Medicine in New York City.\nThe findings were presented at the American Academy of Neurology meeting.\nApril 14, 2010 (Toronto) -- A decades-old drug made from human plasma appears to slow the decline of mental skills in people with Alzheimer's disease, suggest results from a small preliminary study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states:\u00a0 \nWe wonder how well patients tolerate side effects of headaches, rashes and higher blood pressure. ", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\nHis team found that women who had been taking bisphosphonates \u2014 mainly the drug alendronate (Fosamax), which costs around $10 per month in the U.S. \u2014 for at least a year had a considerably lower risk of developing colon cancer later on.\nIndeed, it found a higher risk of throat cancer in patients on the medication.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story quantified the potential harms or any of the side effects found in the study itself. But this story did say, \u201c\u201dThe long-term effects are less well-known, however, and in rare cases it can cause bone death of the jaw, which would be important if healthy people were to take it.\u201d It also\u00a0was the only story to mention that an \u201cearlier study from the UK had found no link between bisphosphonate and colon cancer. Indeed, it found a higher risk of throat cancer in patients on the medication.\u201d", "answer": 1}, {"article": "AMD, the No.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\nThe next step in this research is to perform a clinical trial to determine the ability of this drug to prevent AMD.\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\nResearchers asked the question if people taking L-DOPA as a medicine are protected from AMD.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "At no point does the release mention any harmful effects from taking L-DOPA.\u00a0 And while patients might arguably be willing to face greater risks in order to retain their eyesight, it doesn\u2019t excuse the release for omitting relevant details. L-DOPA has been given to patients for years and the list of possible side effects \u2014 both physical and mental \u2014 is considerable. Patients reading stories or releases touting the possible treatment use of new drugs deserve to know the full story including possible negative effects of the drug\u2019s use.", "answer": 0}, {"article": "Prostate cancer patients had a 28 percent higher relative chance of having a fatal heart attack and a 21 percent increased chance of dying from heart disease.\n\"What we can do with these results is to raise a flag with hormone treatments,\" said Mieke Van Hemelrijck, a cancer epidemiologist at King's College in London and the study's lead researcher.\nStill, these risks were low in absolute terms: researchers estimated the hormone therapies would cause an extra 10 heart problems \u2013 like chest pain or a heart attack \u2013 a year for every 1,000 prostate cancer patients.\nThe research was announced Tuesday at a joint meeting of the European Cancer Organisation and the European Society for Medical Oncology in Berlin.\nThus, hormones that interfere with testosterone could be deadly.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story focuses on one potential harm of hormonal therapies given to men with prostate cancer. And while some specifics are included in the body of the story, the headline and lead of the story paint a much harsher picture of the potential risk than do the actual statistics reported by the researchers.", "answer": 1}, {"article": "\"That will be the subject of a larger study.\"\nAlthough the trial was primarily designed to look at safety, researchers scheduled to present the finding Wednesday at the American Heart Association's annual meeting in Chicago also report that anacetrapib raised HDL cholesterol by 138 percent and cut LDL, HDL's evil twin, almost in half.\nIn the new trial, anacetrapib actually showed a tendency toward fewer cardiovascular problems and fewer angioplasty or bypass procedures, although the study only lasted 18 months.\nTo assess the safety of the trial, investigators randomly chose 1,623 adults with coronary heart disease who were taking cholesterol-lowering statins to receive either anacetrapib or a placebo for 18 months.\nA large trial on torcetrapib was killed after investigators found an increased risk of death and other cardiovascular outcomes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports that anacetrapib did not show the type of harmful effects (including higher blood pressure and higher rates of cardiovascular problems and death) seen in trials of a similar drug, torcetrapib, which was pulled from testing. However, the story does not make it clear that this trial was designed to detect harms that were at least 25 percent more common in the treatment group than in the placebo group\u2026 so it was not powerful enough to rule out side effects that were less common than that threshold. ", "answer": 0}, {"article": "The study appeared online May 13 in The Annals of Rheumatic Diseases.\nA Swedish study suggests yet another health advantage of breast-feeding, this time for the mother: it reduces the risk of rheumatoid arthritis.\nThe authors acknowledge that it is difficult to separate the effect of breast-feeding from childbirth itself.\n\u201cBut even if you breast-feed for a month or two, it makes a difference.\u201d\n\nAlthough the mechanism is not clear, the scientists write that the protective effect may come from long-term changes in the mother\u2019s immune system induced by breast-feeding.\nResearchers compared 136 women with rheumatoid arthritis with 544 healthy women of similar age.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe study cites the health advantages of breast-feeding. Are there no potential harms or disadvantages? For example, there is some research to suggest that pregnancy and breast-feeding may increase flares of RA.\n", "answer": 0}, {"article": "Phentermine is commonly used as a short-term weight loss treatment, and was previously paired with fenfluramine to make the successful but now-discontinued weight loss drug Fen-phen.\nThe drug could be a good option for some people, but it's most likely not a silver bullet, said Dr. Melina Jampolis, CNNHealth's physician nutrition expert, who is not connected with the study.\nAccording to the report, there were specific concerns about each drug's safety individually; specifically Topamax, which is reported to cause some psychiatric and cognitive side effects and may cause clef palate birth defects if taken while pregnant.\nAmong the 2,487 study participants, nine became pregnant, and none of their children were born with cleft palates, the report said.\nAccording to the manufacturer's study, the two drugs, when taken together, and at controlled-release doses, were very safe.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story \u2013 while not quantifying harms \u2013 did a better job in discussing harms than the LA Times story, so we\u2019ll give it a satisfactory score. It reported:", "answer": 1}, {"article": "For more information, please visit http://www.\nLOS ANGELES - The supplement Aged Garlic Extract can reverse the buildup of deadly plaque in arteries and help prevent the progression of heart disease, according to a new study scheduled for publication in the Journal of Nutrition.\n\"This study is another demonstration of the benefits of this supplement in reducing the accumulation of soft plaque and preventing the formation of new plaque in the arteries, which can cause heart disease,\" said Matthew J. Budoff, MD, an LA BioMed lead researcher.\nThe research, conducted at LA BioMed, found a reduction in the amount of low-attenuation plaque, or \"soft plaque,\" in the arteries of patients with metabolic syndrome who took Aged Garlic Extract.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any harms that could arise from taking a garlic supplement although a quick web search shows potential negative side effects including nausea, vomiting and diarrhea. There are also some indications that garlic may lower blood pressure, increase bleeding,\u00a0and possibly irritate the intestinal lining, issues that should be of concern to some who might potentially take this supplement.", "answer": 0}, {"article": "FDNA scientists published a paper in January showing that their algorithm could better identify Down syndrome after being trained with a more diverse set of faces, and Muenke and Linguraru have also published papers this year demonstrating their algorithm\u2019s ability to identify genetic disorders correctly in children across a variety of ethnic backgrounds.\nTo continue to fix this problem, both the NIH and Face2Gene need help from more researchers who can upload more patients\u2019 faces \u2014 but that\u2019s easier said than done.\nThe algorithm the NIH uses \u2014 developed by scientists at Children\u2019s National Health System in Washington, D.C., \u2014 seems to work pretty well so far: In 129 cases of Down syndrome, it accurately detected the disorder 94 percent of the time.\nFace2Gene is meant to be more like a search engine for diseases \u2014 a means to an end.\nHowever, the app won\u2019t give clinicians a yes or no answer to the question of, \u201cDoes my patient have a genetic disorder?\u201d\n\nThat\u2019s intentional.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no explanation of harms here, but with any screening test (or \u201creference informational tool\u201d as Face2Gene calls itself), there is a risk of overdiagnosis or incorrect diagnosis, without confirmatory genetic testing. That could be devastating to parents of affected children for example. Even though the company says that the software should not be used as a diagnostic tool, the allure to do so \u201coff label\u201d is there.", "answer": 0}, {"article": "Autism is a complex brain disorder characterized by difficulties in social interaction and communication, ranging from mild to profound impairment.\nIt could be a boon for patients and their doctors by reducing reliance on time-consuming and emotionally trying assessments based on interviews and behavioral observation.\nThe accuracy of the scan in predicting autism was so high that the results were strongly significant, despite the small number of patients involved.\nThe speed of the test makes it some 20 times cheaper than traditional tests, which can take a team of doctors four to eight hours to conduct.\n\u201cWe would hope that it would work just as well ... there is no reason why not.\u201d\n\nThe ability to base a diagnosis on an objective biological test, rather than having to rely on personality traits, should mean patients get treatment more quickly, he added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As\u00a0discussed above, the story doesn\u2019t attempt to quantify the harm of false-positive or false-negative diagnoses. It also doesn\u2019t explore the potential harm of labeling someone with borderline symptoms as having autism.\u00a0In addition,\u00a0it has now become clear that MRI with contrast is associated with kidney damage.\u00a0Physicians now check kidney function in all patients prior to an MRI and must weigh the need for the images vs the very small (but tangible) risk of kidney damage.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/09/national/a005536S75.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nevirapine crosses the placenta. Studies in pregnant women have shown that nevirapine decreases the chance of passing HIV to a child during labor and at birth. Liver toxicity has been observed with long term use of nevirapine in combination with other HIV drugs, though this is not mentioned in the article. Additionally, other studies have shown 20-40% resistance to the drug after taking one dose as a protective measure in labor, yet there is no mention of the rate of resistance in the main study discussed in the article. Nevirapine may be \u201ceasy to take\u201d, but quantification of side effects noted in this and other studies discussed is omitted. Given there is only a 3% absolute reduction in transmission in one study cited, the risks of the drug for newborns and their mothers needs to be discussed. ", "answer": 0}, {"article": "Elevated sweat chloride confirms that an infant actually has CF.\nBut there are some obstacles that complicate clinical decision-making, explains Britz-McKibbin, because sweat chloride can result in ambiguous diagnoses in some borderline cases and does not reveal how the disease might progress for individual patients.\nTesting for these biomarkers could be done in cases in which the chloride sweat test result is unclear, say researchers.\nThe biomarkers also point to other underlying mechanisms that contribute to the progression of CF and could lead to better therapeutic interventions earlier in life.\nThe findings, published in the journal ACS Central Science, shed new light on the underlying mechanisms of CF and could lead to improved prognosis and better therapies for a disease which is quite variable, affecting different children in different ways, say researchers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms here involve errors in diagnosis. More specifically, the story does not address the specificity or sensitivity of the biomarker testing. And this is important. Specificity indicates how good a test is at ruling out people who don\u2019t have a problem. Sensitivity addresses how good a test is at positively identifying people who actually have the problem. False positives can result in unnecessary treatments and costs. False negatives can result in patients not getting treatments that could help them. And if it\u2019s still too early to tell what the specificity or sensitivity of the tests are, they need to address that.", "answer": 0}, {"article": "Atopic dermatitis is inherited and involves patches of highly itchy skin on any part of the body.\n\u201cWe do not know whether dupilumab will be effective in other patient populations,\u201d the editorial said, including patients that stay on their standard therapies and who do not have high levels of eosinophils.\nBut the editorial said effectiveness of dupilumab has been established in just a \u201climited subpopulation of patients with asthma\u201d because only 21 percent of those screened for enrollment in the study met its criteria.\nBut she cautioned that longer trials are needed to fully assess the drug.\nTrial results were also reported on Tuesday in the New England Journal of Medicine, along with an editorial that said results of the study appeared \u201ccompelling\u201d at first glance and superior to those seen in previous studies of other asthma drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The reporter takes it on the lead researcher\u2019s word that the \u201cdupilumab was well tolerated, with side effects similar to placebo. But she cautioned that longer trials are needed to fully assess the drug.\u201d We would have liked to have seen those side effect numbers. Similar to placebo? Does that mean 10 patients in the drug group had side effects and a dozen in the placebo group? Does it mean three and six? Just give us the numbers.\nImportantly, one subject receiving dupilumab developed angioedema, a serious and potentially life threatening allergic reaction presumably due to the drug.\nAnd even the accompany editorial in the New England Journal of Medicine drew attention to safety questions:\n\u201cGiven the appearance of increased eosinophilia in four patients in the dupilumab group, more safety data are also required.\u201d", "answer": 0}, {"article": "Pernilla Wittung-Stafshede stresses the importance of finding ways to combat these neurological conditions in the future:\n\n\"These diseases come with age, and people are living longer and longer.\nThere's going to be an explosion of these diseases in the future - and the scary part is that we currently have no cures.\n\"It will be very interesting to study how parvalbumin distributes within human tissues in more depth.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\n\"Because Nathalie had previously shown that parvalbumin passes into the body of the person eating fish, it made sense to study its interaction with human proteins.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release is dominated by suggestions that parvalbumin could help with Parkinson\u2019s and perhaps other neurodegenerative diseases including Alzheimer\u2019s, ALS and Huntington\u2019s but only at the very end do we learn it\u2019s been studied as a a cause of fish allergies.\nIs this the only harm? We don\u2019t know because harms aren\u2019t included.", "answer": 0}, {"article": "The researchers found that modest movement while seated elevated the metabolic rate more than sitting and more than standing, by 17 and 7 percent respectively, and had no detrimental effect on cognitive function.\nHaley Scott and Danel Voorhees are co-authors on the paper.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\nActive Ideas LLC, which offers the HOVR device used in study, funded the research.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms in the news release. It\u2019s likely that there aren\u2019t many, since low-impact seated activity is good for joints and can still burn some calories. But still, as we say in our review criteria:\u00a0if you\u2019re only hearing about the potential benefits of a test or treatment, run for the hills.", "answer": 0}, {"article": "For more information or to arrange an interview with Dr. Vuksan, please contact:\nBarley is higher in fibre, has twice the protein and almost half the calories of oats, which are important considerations for those with weight or dietary concerns.\nTORONTO, June 8, 2016 - Eating barley or foods containing barley significantly reduced levels of two types of \"bad cholesterol\" associated with cardiovascular risk, a St. Michael's Hospital research paper has found.\nMeasuring non-HDL and apoB provides a more accurate assessment for cardiovascular risk, as they account for the total 'bad cholesterol' found in the blood.\nHigh cholesterol and diabetes are major risk factors for cardiovascular disease and stroke, historically treated with medications.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are unlikely to be harms for most people if they increased their barley consumption, but upping their daily intake could also lead to gastrointestinal problems in some people. The recommended daily consumption of barley in Canada is 3 grams but the study recommends that it be increased to 6.5 to 7 grams daily. People diagnosed with Celiac disease have most likely already been advised that consuming barley (as well as other foods containing gluten) can cause complications.", "answer": 2}, {"article": "Professor Tim Newton from the Dental Institute at King's College London and lead author of the study said: \"People with dental phobia are most commonly given sedation to allow them to become relaxed enough for a short period of time to have their dental treatment performed.\nSome of the patients referred to us were found to be experiencing additional psychological difficulties, and needed further referral and management.\nThe latest study, published in the British Dental Journal, looked at the characteristics of 130 patients (99 women and 31 men) attending a psychologist-led CBT service and the outcomes of their treatment.\nNearly all patients (94%) reported a knock-on effect from problems with their teeth, mouth or gums on their daily living and quality of life.\nA proportion of the patients surveyed were found to have other psychological conditions - 37% had high levels of general anxiety and 12% had clinically significant levels of depression.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not address risks, but CBT carries few risks (if any). In addition, the release states that in this study, patients who needed additional therapy beyond CBT for mental health issues were referred for more assistance.", "answer": 1}, {"article": "; Walter Rocca, M.D.\n\u201cWomen with APOE e4, who have a greater genetic risk for Alzheimer\u2019s disease, particularly benefited from this therapy.\u201d\n\nMenopause is defined as occurring 12 months after a woman\u2019s last menstrual period and marks the end of menstrual cycles.\nA rapid decline in estrogen with menopause may be associated with an increased risk of Alzheimer\u2019s disease risk in women.\nThe Mayo Clinic study used data from the Kronos study to determine the effects of menopausal hormone therapy shortly after menopause, during the critical window of rapid estrogen depletion \u2014 five to 36 months past menopause.\nThe Women\u2019s Health Initiative study by the National Institutes of Health (NIH) reported that menopausal hormone therapy started in women 65 or older increased the risk of dementia.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Early in the text, the writer notes that one large, older study\u2014the Women\u2019s Health Initiative at NIH\u2014has found an association between use of estrogen and an increased risk of dementia among women 65 or older. The study highlighted here, in contrast, focuses on women five to 36 months past menopause, individuals predominantly in their 50s. The potential long-term effects of estrogen use by these younger women is not mentioned in the release.\nEstrogen carries a well-known small increase in risk for breast cancer and blood clots, which could have been briefly acknowledged. In addition, the National Library of Medicine states that estradiol, the form of estrogen used in transdermal patches, \u201cincreases the risk that you will develop endometrial cancer (cancer of the lining of the uterus [womb]). The longer you use estradiol, the greater the risk that you will develop endometrial cancer.\u201d Other minor side effects include head ache, breast pain and nausea, among others.", "answer": 0}, {"article": "\"These days it's possible for a food company to pay just about anybody to conduct a study,\" says Silverglade.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nBut that doesn't mean the claims are invented -- most are based in research.\nMost health beverage drinkers aren't as enthusiastic as the realtor from Alaska who posted the above testimonial.\nThe bottom line is that consumers shouldn't believe everything they read on labels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story perhaps could have mentioned that too much POM juice might contribute to obesity and related health risks such as type 2 diabetes. But we can\u2019t really fault it for not discussing\u00a0the harms of pomegranate juice, because there really aren\u2019t any direct adverse effects that have been well established.\u00a0(The same is not necessarily true for antioxidant supplements, which may well be harmful in some cases.) We\u2019ll call this one not applicable.", "answer": 2}, {"article": "Dr Allan Pantuck, the lead clinician of the study, added, \"With fixed dose therapy, patients are often switched to other drugs when they no longer respond to treatment.\n\"The implementation of CURATE.AI represents a game-changing shift in the way that combination therapy can be optimised at the single patient level, and we have shown that N-of-1 medicine can be a reality.\n\"Using CURATE.AI to dynamically modify drug doses and successfully treat a metastatic cancer patient represents a landmark breakthrough for the use of AI to truly personalise patient care.\nThis advance is expected to dramatically improve response rates for all combination therapies that are being developed for oncology as well as virtually all other diseases.\nOur clinical study has shown that dosing can profoundly affect the efficacy and safety of treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "AI is not perfect. AI programs can, and will, make mistakes. What might those mistakes mean in the context of cancer treatment? It\u2019s not clear, and the release doesn\u2019t address this. We know that clinical trials using \u201cCURATE.AI-guided\u201d therapies are underway, and that the patient highlighted in the news release is involved in a clinical trial. But we don\u2019t know how any of those trials are going. Will those trials identify any risks or potential harms? How will medication dosages be adjusted to reduce side effects? That remains to be seen, and the release should not simply ignore the issue. If this single patient\u2019s treatment was sufficient to warrant a news release, any potential harms (or even the absence of potential harms) should also be worth addressing.", "answer": 0}, {"article": "This is in line with some of our recent studies which indicate that the GI tract microbiome in Alzheimer's is significantly altered in composition when compared to age-matched controls, and that both the GI tract and blood-brain barriersbecome significantly more leaky with aging, thus allowing GI tract microbial exudates (e.g.\nProbiotics are known to give partial protection against certain infectious diarrheas, irritable bowel syndrome, inflammatory bowel disease, eczema, allergies, colds, tooth decay, and periodontal disease.\nIn mice, probiotics have indeed been shown to improve learning and memory, and reduce anxiety and depression- and OCD-like symptoms.\nFuture research, on more patients and over longer time-scales, is necessary to test if the beneficial effects of probiotics become stronger after longer treatment.\n\"In a previous study, we showed that probiotic treatment improves the impaired spatial learning and memory in diabetic rats, but this is the first time that probiotic supplementation has been shown to benefit cognition in cognitively impaired humans,\" says Professor Mahmoud Salami from Kashan University, the senior author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although probiotics are considered to be safe for people who are generally healthy, they have been linked to severe side effects in people with underlying medical problems. According to the National Institutes of Health, the populations most vulnerable to adverse effects from probiotics include the critically ill, infants, and people with weakened immune systems, which often includes elderly men and women. Since this study was conducted in individuals aged 60-95 years with an underlying health condition, safety should have been addressed in the news release. And yet, no explanation of risks or potential harms was provided.\nEvaluation of all treatments, including benign appearing supplements, should include an assessment of harm. ", "answer": 0}, {"article": "Both groups went to their V.A.\nAfter the study's first six months, 21 percent of the 5-FU group rated the side effects as \"severe,\" and 40 percent rated them as \"moderate.\"\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged.\nBut after six months and again at the end of the four-year trial, 87 percent of participants in the 5-FU group said they'd be willing to repeat the treatment if it proved effective in reducing skin cancer.\nAfter the first year, 20 of the 464 veterans in the control group developed a squamous cell carcinoma that required surgery, but only five of the 468 veterans who got 5-FU did, a statistically significant 75 percent reduction in the risk, according to the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release describes harms in the following paragraph:\nThe cream does have common side effects including reddened, more sensitive and often crusty skin, effects that resolve when the application of the cream stops, Weinstock acknowledged. After the study\u2019s first six months, 21 percent of the 5-FU group rated the side effects as \u201csevere,\u201d and 40 percent rated them as \u201cmoderate.\u201d", "answer": 1}, {"article": "\u2022 Kim TI, Lee YK, Park SG, et al.\nHowever, more research is needed to clarify the nature of the beneficial association between the EGCG and cognitive training intervention (ie, synergistic or additive).\"\nde la Torre and Dierssen's team showed that three months of EGCG treatment improved symptoms in individuals with Down syndrome, and in mice with a Down-syndrome-like condition characterized by overexpression of DYRK1A.\nParticipants who took the green tea extract also scored significantly better on assessments of visual recognition memory, inhibitory control, and adaptive behavior compared with those who took the placebo.\nAfter one year of treatment, functional brain scans (fMRI) showed that epigallocatechin-3-gallate (EGCG)-treated subjects had improved neuronal connectivity in certain brain regions.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although adverse effects were reported by by study participants (e.g bone and joint pain, headache, physical weakness and celiac disease), researchers commented in the study that these conditions were not related to treatment, since \u201cno differences were noted in adverse effects between the two treatment groups.\u201d\nBut if there are no side effects, then a simple acknowledgement that \u201cthere were no adverse effects\u201d would still be in order, and the release didn\u2019t provide this.", "answer": 0}, {"article": "For this case-control study, researchers recruited 5,307 colonoscopy patients, 60 percent of them men, at two Tennessee hospitals over a seven-year period ending in April 2010.\nA new study has found that consumption of omega-3 fatty acids from fish is associated with a reduced risk for one kind of colon polyp, but only in women.\nThe researchers found no effect in men, and no effect of omega-3 consumption on hyperplastic polyps, which are more likely to be benign.\nThe analysis appears online in The American Journal of Clinical Nutrition.\nAnimal studies have suggested that omega-3 fatty acids may have anti-cancer effects, but the results from human epidemiological studies have been inconclusive.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The harms of fish in the diet are not really in question, although some research has raised concerns about possible toxic effects of mercury found in some species.", "answer": 2}, {"article": "Newswise \u2014 Baltimore, Md.\nResearch has shown that thermal therapy can be especially useful in difficult-to-reach cancers in the abdomen and pelvic region.\nStudies have found that adding thermal therapy to standard treatments can significantly shrink tumors and can improve survival for some patients.\nProton therapy is performed on an outpatient basis and is a well-tolerated, non-invasive treatment that can reduce side effects.\nIt is a highly effective treatment for a wide range of localized tumors such as those found in the brain, base of the skull, head and neck area, eye tumors, tumors of the esophagus, lung, prostate, liver, breast, spinal cord, as well as gastrointestinal malignancies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the news release touts the potential benefits of both therapies, it says nothing about side effects or potential harms. According to the Mayo Clinic, possible side effects of proton therapy include fatigue, digestion problems and headaches. The National Cancer Institute lists possible side effects of hyperthermia, which include burns, blistering, vomiting, and and possible cardiac disorders.", "answer": 0}, {"article": "\"This is a multi-channel implantable device,\" Peckham explains.\nIt was the lowest point of Annette's life; the woman who once trained dogs to assist the disabled would now be relying on one herself.\nSo when the implant is turned on, it electrically stimulates the nerves in order to cause the muscles to move in motions, for example, to open and close the hands.\nWith the touch of a button, Annette turns on a device much like a pacemaker that's implanted in her chest.\nThat's what happened to Annette in 2002 when a car accident left her paralyzed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms or side effects. Because this is an invasive, implantable device, there are risks from the implantation alone. It is also unclear how long the device will last.", "answer": 0}, {"article": "\"But the real problem is the tonsils!\"\nMoran recalls.\nTyler still hears snoring at night, he says.\nAnd his snoring is gone.\nThen it fell out of favor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "The results have not previously been published or presented.\nThe field-friendliness and high specificity offered by the C-Tb test could allow for improved targeted treatment of M. tuberculosis-infected persons in also in resource-constrained settings, where IGRAs are too complicated to implement.\nThese phase III trial results demonstrate that C-Tb is safe, has comparable diagnostic performance to QFT-GIT and addresses the problem of false positive TST results in BCG vaccinated persons.\nThe cost of a C-Tb test is to be determined; however, it is expected to be significantly less than an IGRA.\nDr. Ruhwald said another advantage of C-Tb is that the measurement of infection, a 5mm or larger induration, is universal across patients with different risk factors, including HIV infection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0is no mention of potential harms with this new test, leaving readers to assume its safety. Although relatively minor, side effects have been noted in previous clinical trials including: \u201cLocal adverse reactions following C-Tb injection included transient itching and discomfort as expected components of the immune response.\u201d\nIn addition, as with most diagnostic tests, there is a risk of false-positive (over-diagnosis) or false-negative (under-diagnosis) results. This should have been mentioned along with data on the test\u2019s reliability. ", "answer": 0}, {"article": "Achillion\u2019s ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms from the drug. What were the drop out rates and adverse drug reaction rates? What was the severity of the reactions? The story does not address these issues.", "answer": 0}, {"article": "Assistant professor Mads Fiil Hjorth \n\nDepartment of Nutrition, Exercise and Sports, University of Copenhagen \n\nEmail: madsfiil@nexs.ku.dk \n\nTel.\nFor people with type 2 diabetes, the analysis found that a diet rich in healthy fats from plant sources would be effective for achieving weight loss.\nThese diets could also be effective independent of caloric restriction.\nThe study, \"Pretreatment fasting plasma glucose and insulin modify dietary weight loss success: results from 3 randomized clinical trials,\" found that fasting blood sugar and/or fasting insulin can be used to select the optimal diet and to predict weight loss, particularly for people with prediabetes or diabetes.\nThe latest findings, as published in AJCN, concluded that a personalized nutritional approach based on an individual's biomarkers will lead to improved weight loss and maintenance success.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It seems unlikely that personalizing a weight loss plan could cause significant harm. The most tangible downside is likely to be time and money wasted on a plan that might not be more effective than standard dietary advice. Still, a small risk of complications resulting from repeated blood draws or finger sticks is possible since glucose and insulin concentrations are measured from blood samples.", "answer": 2}, {"article": "Beta-blockers are usually taken to treat high blood pressure, heart arrhythmias and other cardiovascular conditions, though metoprolol (Lopressor or Toprol), propranolol (Inderal) and timolol (Blocadren) can also help with migraines.\nYou can read the new guidelines here, or check out the patient-friendly summary here.\nBOOSTER SHOTS: Oddities, musings and news from the \n\nhealth world Experts issue new guidelines for preventing migraines with drugs\n\nIt would seem that migraineurs would be eager to stop these headaches before they start.\nEach headache may last from four hours to two days.\nActually, odds are you wouldn\u2019t.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story was not specific enough on this point, it reminded readers that all drugs \u201ccan have side effects or interact with other medications.\u201d\u00a0 It didn\u2019t mention how serious they might be or how often they might occur. We\u2019ll give the story the benefit of the doubt however since the list of drugs is long and the incidence and severity of the side effects is complicated\n\u00a0", "answer": 1}, {"article": "The median age was 75 years (range 41to 94).\n\"This study is the largest series of its type to evaluate SBRT outcomes in patients aged 80 years and older,\" says Joel Goldwein, MD, Senior Vice President, Medical Affairs for Elekta.\nStudy results show no significant differences among the three age groups with respect to 2-year local recurrence, regional recurrence, distant metastases or the incidence of grade 3 or higher toxicity.\nThe results of our study clearly support the use of SBRT for elderly patients, especially those who may not be able to tolerate longer courses of radiotherapy or more invasive treatment options,\" says Meredith Giuliani, MBBS, FRCPC, MEd, a radiation oncologist in the Cancer Clinical Research Unit at Princess Margaret Cancer Centre, University Health Network in Toronto and lead study author.\n\"Older patients are often not considered for radiation therapy due to concerns about their ability to tolerate treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release. The study alludes to harms in a quote, saying:\n\u201cOlder patients are often not considered for radiation therapy due to concerns about their ability to tolerate treatment.\u201d\nOk. So this starts getting at the fact that the treatment itself is harmful. Why not go further and explain to readers and journalists what the risks are from the treatment and how the risks played out with this study?\nKnown harms from this treatment include fatigue lasting 4-6 weeks, neuropathic pain, rib fractures and other risks.\u00a0", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061105/13healy.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story minimizes the potential harms of screening. The story describes the radiation exposure from CT\u00a0as being equivalent to that of a mammogram. It is\u00a0not clear where this information comes from. CT scans generally have many times the\u00a0amount of radiation exposure of x-rays. There is also no discussion of the harms caused by false positives, which may lead to unnecessary biopsies, which may lead to further complications. ", "answer": 0}, {"article": "There are some caveats to the study.\nKeith Humphreys, a drug policy expert at Stanford University and one of the authors of the study, said this reveals an underappreciated policy lever for reducing drug overdoses: making sure patients prescribed to opioids aren\u2019t also prescribed to benzodiazepines, and vice versa.\nFinally, since the study looked at correlation (not causation), it\u2019s possible that it missed some other factor driving up overdose deaths among concurrent benzodiazepine and opioid users \u2014 perhaps, for whatever reason, these users may be more likely to misuse their drugs.\nThe study also only looked at legally prescribed opioid painkillers and benzodiazepines, missing the effects of concurrent use of illegally obtained pills or drugs.\nBut there\u2019s a catch: Such overdoses seem to be very closely tied to the opioid epidemic, with the majority of benzodiazepine overdose deaths involving both benzodiazepines and opioids.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions alternative treatments, but doesn\u2019t address potential harms of changing prescribing patterns. While reducing the risk of overdose may outweigh any potential negatives of taking patients off of a drug, it\u2019s still worth addressing any drawbacks.\nThe story\u00a0also does not explain how concurrent use of benzodiazepines and opioids cause harm (via the combined sedative effect which can lead to respiratory depression).", "answer": 0}, {"article": "Henderson E J et al.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\nScientists have discovered that a commonly prescribed dementia drug could hold the key to helping prevent debilitating falls for people with Parkinson's.\nRivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.\nAs part of the condition, they also have lower levels of acetylcholine, a chemical which helps us to concentrate - making it extremely difficult to pay attention to walking.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any harms or side effects but some commonly reported adverse events associated with rivastigmine include dizziness and nausea. It can also cause drowsiness and fatigue which in some patients might actually increase the risk of falling. In addition, this drug has potential interactions with commonly prescribed drugs for elderly patients (such as aspirin, some beta blockers, NSAIDs, and medications for urinary incontinence, among others). This is noteworthy because Parkinson\u2019s disease patients tend to be on multiple medications, increasing the likelihood of falls and of possible drug interactions.", "answer": 0}, {"article": "Mitochondria are the organelles within the body\u2019s cells that generate energy.\nDr. Evans described the study as \u201cvery important, because it is rare that we identify orally active molecules, especially natural molecules, that have such a broad-based, positive effect on a problem as widespread in society as metabolic disease.\u201d\n\nDr. Ronald Kahn, director of the Joslin Diabetes Center in Boston, said the research would focus attention on the sirtuins, a recently discovered group of enzymes that resveratrol is believed to affect.\nDr. Auwerx cites evidence that resveratrol does activate sirtuin, but Dr. Evans said the case was not yet fully convincing.\nDr. Ronald M. Evans, a leading expert on the hormonal control of metabolism at the Salk Institute, said that the report by Dr. Auwerx\u2019s team had \u201cshown very convincingly that resveratrol improves mitochondrial function\u201d and fends off metabolic disease.\nWhether much lower doses would benefit athletic performance is not clear, Dr. Evans said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that there were uncertainties about the safety of reservatrol in humans.\u00a0 In fact, to date, no clinical trials with this compound have been completed.\u00a0 At this time, a single trial looking at safety in colon cancer patients is recruiting subjects.\u00a0 The story should have emphasized the need for safety testing humans before any claims can be made. With some nutrients, such as Vitamin A, we know that small doses provide benefit, while large doses can be harmful.\u00a0 The story would have been strengthened by providing more sources with healthy skeptism to balance the overwhelming enthusiasm from other sources, many of whom had ties to the drug companies promoting the substance. ", "answer": 0}, {"article": "Side effects including shaking, headaches, vomiting and swollen gums\u2014as well as unwanted hair growth.\n\u201cThis research has been tested on human tissue, which is promising, but not on humans themselves, so there is still some way to go.\n\u201cIt is also important to realize that this is being proposed as a treatment for hair loss, not a cure as such.\u201d\n\nThis piece has been updated with a comment from the British Association of Dermatologists.\nDr. Hawkshaw said in a statement: \u201cThe fact this new agent, which had never even been considered in a hair-loss context, promotes human hair growth is exciting because of its translational potential: It could one day make a real difference to people who suffer from hair loss.\u201d\n\n\u201cClearly though, a clinical trial is required next to tell us whether this drug or similar compounds are both effective and safe in hair-loss patients.\u201d\n\nA British Association of Dermatologists spokesperson said in a statement the results were interesting.\nFor that reason new treatments are exciting as they give people more treatment options that may be effective.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The need to study the safety of WAY-316606 was mentioned, but should have been higher in the story. The story would have been stronger if it had mentioned whether the drug\u2019s safety has been studied previously, and what the results if any showed. It was a missed opportunity to highlight known harms of a drug already on market.", "answer": 0}, {"article": "People have been looking for something like this for years,\u201d said Dagan Wells of the Nuffield Department of Obstetrics and Gynaecology at Oxford University.\nBut it can happen later or earlier, making it difficult for women who want to develop a career before having babies to know how long to wait.\n\u201cThe possibility of an accurate predictor for menopause is very exciting.\nWells said Tehrani\u2019s team appeared to have hit upon a \u201cfairly accurate algorithm\u201d for predicting menopause.\n\u201cIt will be important to let patients know that fertility will have declined greatly in the years preceding the final ovulation.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no mention of any potential downsides of the testing. False positive results, for example, could cause unnecessary worry and anxiety and lead to needless fertility treatments.", "answer": 0}, {"article": ".\nInstead, these results show that endoscopic sleeve gastroplasty is another possibility that patients and health-care providers should consider when discussing options.\nWhen examining cost, researchers reported endoscopic sleeve gastroplasty resulted in the lowest-cost, with an average institutional procedure cost of $12,000, compared to $22,000 for laparoscopic sleeve gastrectomy and $15,000 for laparoscopic banding.\nResearchers found that patients who received endoscopic treatment had lower complications (1 percent) than those who received surgical treatment (10 percent for laparoscopic sleeve gastrectomy and 11 percent for laparoscopic banding).\nAt one-year follow-up, patients who chose laparoscopic sleeve gastrectomy surgery achieved the greatest percent total body weight loss at 29.28 percent, compared to 17.57 percent for endoscopic sleeve gastroplasty patients and 14.46 percent for laparoscopic banding patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is a close one. The release does state that \u201cresearchers found that patients who received endoscopic treatment had lower complications (1 percent) than those who received surgical treatment (10 percent for laparoscopic sleeve gastrectomy and 11 percent for laparoscopic banding).\u201d That\u2019s good. However, the release doesn\u2019t tell us what they mean by \u201ccomplications.\u201d Endoscopy, in general, is fairly low risk \u2014 but potential complications can include short-term pain and nausea, infection, organ tearing and bleeding.", "answer": 0}, {"article": "The 20-year project examined data from 2,560 men taking part in a randomised clinical trial to test the effects of statins versus a placebo.\n\u201cOur study lends support to LDL\u2019s status as a major driver of heart disease risk, and suggests that even modest LDL reductions might offer significant mortality benefits in the long-term.\nThey found that compared with the placebo, there was a 27% reduced risk of coronary heart disease, a 28% reduced risk of dying from coronary heart disease, and a 25% reduced risk of coronary \u201cevents\u201d such as a heart attack.\nStatins cut the risk of dying from heart disease by 28% among men, according to the longest study of its kind.\n\u201cThis legitimises current guidelines which recommend treating this population with statins.\u201d\n\nRay said people with lower levels of cholesterol, around 4mmol/L, who otherwise appear healthy, should also be treated with statins.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No side effects of statins are mentioned, but they\u2019re significant. Taken over many years, let alone decades, those risks become even more significant considerations. The most common side effect \u2014 29% of people on statins report experience it \u2014 is damage to muscles and muscle pain (e.g. soreness, tiredness, and weakness), according to the Mayo Clinic. However, those on placebo report a similar rate of muscle pain and damage. Other, less common side effects (for which there\u2019s also less evidence that statins may be responsible) include liver damage, increased blood sugar or type 2 diabetes, and memory loss/confusion.", "answer": 0}, {"article": "Former NASA astronaut Mark Kelly announced that he is running for John McCain's Senate seat in Arizona in the 2020 election.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There were a couple of openings for this story to better characterize the potential risks of this investigational procedure. At one point, the story says that the treatment \"doesn\u2019t come without risks,\"\u00a0but the only downside subsequently mentioned is that \"People will have to be trained to use the technique.\" Later,\u00a0an anchor says more directly, \"You are actually destroying some tissues in the lungs. Do they know anything about potential long-term complications?\" But the reporter responds that the treatment \"doesn\u2019t seem to limit pulmonary, lung function at all.\"\u00a0Faced with the\u00a0lack of any long-term data on how patients do with this procedure, we feel it would have been appropriate to at least discus the potential for adverse consequences or emphasize the uncertainty of the current evidence. Instead, the \"breakthrough\" framing came across as cheerleading. ", "answer": 0}, {"article": "When skin is exposed to sun, it makes vitamin D.\n\nStill, the doctor wanted to run a blood test to see if Rebecca Rosen had adequate vitamin D.\n\n\"So my wife said, 'Well, why do I need to have a vitamin D [test]?'\nBut the group is not expected to embrace the newer claims being made for vitamin D supplementation.\nForty years ago, he discovered the active form of the vitamin, 1,25-dihydroxyvitamin D. He has written several popular books on the subject and has another one, The Vitamin D Solution, coming out next month.\nUntil those results are in, Manson advises patients and doctors to view vitamin D claims as \"promising but not yet proven.\"\nThe evidence is strongest for colorectal cancer, she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0While Dr. Holick is quoted in this story as commenting that \u00a0\u00a0\"\u2026there is no downside to increasing your vitamin D intake\",\u00a0he is also a co-author on a 1992 paper in the New England Journal of Medicine documenting a series of deaths due to accidental overdose of vitamin D.\u00a0\u00a0 The story did not give any weight to the potential for problems with over-consumption of vitamin D.\n.\u00a0", "answer": 0}, {"article": "Age-related macular degeneration, or AMD, is the leading cause of vision loss among seniors, gradually eroding crucial central vision.\nWhile the study is too small to prove if lampalizumab really helps maintain vision, that\u2019s a bigger difference than the overall results suggested.\nIt turns out that nearly 6 in 10 of the study\u2019s participants carry a gene variation that makes part of the immune system go awry \u2014 a genetic flaw already known to increase the risk of getting macular degeneration in the first place.\nWhat\u2019s exciting for scientists came next, when researchers from drugmaker Genentech Inc. took a closer look at exactly who was being helped.\nThe current research sheds light on how that long-suspected immune culprit might be working, and is \u201cthe first suggestion that there may be a treatment for geographic atrophy coming up in the future,\u201d said National Eye Institute retina specialist Dr. Wai Wong, who wasn\u2019t involved in the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that there were no \u201csafety concerns\u201d noticed during the trial. We\u2019re not sure what that means\u2013does that mean there were zero side effects? Or just no life-threatening ones? When we looked at the study, we did see that the drug caused side effects, which might not meet the researchers\u2019 definition of a \u201csafety concern\u201d but could certainly be of interest to patients taking the drug.", "answer": 0}, {"article": "Hot flashes typically begin in the year or so before menopause and tend to abate in the years afterward.\nVincent's group recruited 103 women between the ages of 45 and 59 who reported that they had at least five hot flashes per day and were not using any other treatments for them.\nVincent said she and her colleagues were disappointed by the results of the study, which was funded by Mayo and prompted in part by the findings from the Women's Health Initiative (WHI), a federally funded study of more than 36,000 women ages 50 to 79.\nResearchers knew who was receiving sham treatment, but the women, who completed questionnaires detailing the extent of their hot flashes, did not.\nTo prove it is effective in reducing hot flashes, the Mayo team needed to demonstrate that it was superior to sham, or placebo, treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states that women in the study reported no adverse effects.", "answer": 1}, {"article": "The American Heart Association reports that more than 80 percent of smokers say they want to quit.\nStill, Laser Therapeutics\u2019 Camera said, the treatment won\u2019t work on everybody.\nTherefore, quitting leads to a quick drop in endorphin levels, he said.\nUsing acupuncture methods to treat addictions such as smoking is not new, White said, but there is still no clear evidence that treatment with needles has any therapeutic effects either.\nIn response, Laser Therapeutics is designing another study to address those comments, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address the potential harms of laser therapy, which was surprising given how careful the story is in other regards.", "answer": 0}, {"article": "\u201cThat\u2019s what\u2019s good about this program.\nSurprisingly, the older the patient, the greater the likelihood that she would text back, seeking more information.\nThe feasibility study was designed to see if texting could relieve some of the anxiety that comes with the fatigue, hair loss and other body changes that can accompany anticancer drugs.\nTexting did not affect the odds of developing symptoms of depression.\nThey also felt they had better communication with their doctors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There don\u2019t appear to be any harms associated with text messages, barring potential distraction while driving. Hence, this criterion doesn\u2019t apply.", "answer": 2}, {"article": "Prostate cancer is the most common cancer among men.\nNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\nOverall, about 95% of the men were cancer-free after a full year following the trial.\nIn this study, after 12 months, it\u2019s a 9-in-10 chance.\u201d\n\nThe men in the study were aged 45 to 80 with medium- to high-risk cancer, and would likely have undergone surgery or radiotherapy down the line.\nThe procedure was carried out under general anesthesia and most of the patients had hospital stays of less than 24 hours after the treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated that \u201cNone of the patients reported urinary incontinence a year after treatment, and only 1 in 10 suffered from poor erections.\u201d Again, this was not the whole story.\u00a0 17% of men developed urinary tract infections after the procedure and men required catheters for an average of 8 days.", "answer": 0}, {"article": "The study lasted a year, but \"we don't know what happens after that,\" Pryor said.\nPeople treated with the balloons lost an average of 7 percent of their weight, compared to less than 4 percent for those who received the sham device, the researchers found.\nWhether the weight loss will last over the long term isn't known, said lead researcher Dr. Aurora Pryor, director of the Bariatric and Metabolic Weight Loss Center at Stony Brook University in New York.\nThe device, called the Obalon Balloon System, was approved in September by the U.S. Food and Drug Administration.\nFor the study, Pryor and her colleagues randomly assigned nearly 400 obese patients to receive a real or sham device.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions these harms:\nAs for side effects, one patient had a bleeding stomach ulcer while taking high doses of pain pills after a knee replacement. Most patients (91 percent) suffered from stomach cramps and nausea, which nearly 100 percent said were mild or moderate.\nThe story would have been stronger if it had warned readers that a study that puts a device in only a couple of hundred people may miss problems that could appear after the device is placed in hundreds of thousands or even millions of patients. The documentation that the manufacturer will give patients lists several serious, even life-threatening, potential side effects, including intestinal and airway blockages. These potential risks should have been noted.", "answer": 1}, {"article": "Moffitt is the No.\nThe study was supported by funds received from the American Cancer Society and the DeBartolo Family Personalized Medicine Institute Pilot Research Awards in Personalized Medicine.\nThe researchers found that delaying surgery due to neoadjuvant radiation therapy was not a detriment to survival.\nThey included female patients in the analysis who were diagnosed between 1973 and 2011 with early-stage breast cancer.\nThese data are promising, but randomized clinical trials are needed to confirm the benefit of neoadjuvant radiation therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no comment in the release about potential harms, although the study itself addressed the potential negative impact on healing.", "answer": 0}, {"article": "\"It's phenomenal.\"\nBut the researchers and other brain-cancer doctors caution the research is at a very early stage.\nMuch more follow-up research is needed to better assess and hopefully improve the treatment's effectiveness, the researchers say.\nSome other researchers praised the results.\nThe treatment can cause a dangerous swelling in the brain that can lead to seizures and other complications, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported \u201csubstantial risks\u201d with the treatment, including \u201cdangerous swelling in the brain that can lead to seizures and other complications.\u201d It reported that one patient had a life-threatening blood clot in the brain that required surgery.\nThe story did not explain how many of the patients in the trial experienced the substantial risks. This was something NBC News handled better (see the review). We can look the other way on the benefits criterion, but the story should have given some estimate of how many people experienced harm from the treatment.", "answer": 0}, {"article": "Sept. 28, 2010 -- Intrauterine devices (IUDs) -- used to prevent pregnancy -- may also be an effective treatment for some patients with early-stage uterine cancer who want to preserve their fertility.\n\nIn a small, early study, carefully selected patients with cancer that had not spread beyond the inner lining of the uterus were treated with IUDs that released the hormone progesterone.\n\nThe treatment was found to be as effective as oral hormone therapy, which is the most widely used nonsurgical, fertility-sparing treatment for the cancer.\n\n\u201cOur results show promise for the treatment of younger endometrial cancer patients with early disease who desire pregnancy in the future,\u201d gynecologic oncologist Lucas Minig tells WebMD. \u201cBut patients must be screened very carefully to make sure their disease has not spread.\u201d", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the progestin IUD is well tolerated and there were no adverse events in the study, the story makes no mention of any potential harms.\u00a0 The adverse effect outcome measure reported in the study was effects or complications severe enough to suspend treatment. The concurrent GnRH analog treatment does have side effects (temporary menopausal symptoms) that may be important to some women, while not warranting suspension of treatment.", "answer": 0}, {"article": "According to the World Health Organization's 2008 figures, at least one in three of the world's adult population is overweight, and almost one in 10 people is obese.\nThe study notes physical activity is also an important part in preventing the risk factors for the metabolic syndrome.\nThe Mediterranean diet isn't just a little extra olive oil, noted Dr. Robert Eckel, an endocrinologist and past president of the American Heart Association.\n\"It's all these other components,\" Eckel said.\nThe syndrome is present when someone has three of those five risk factors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 The study itself didn\u2019t reflect on possible harms that might be associated with consumption of a\u00a0\u2018Mediterranean diet\u2019.", "answer": 2}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nA third control group of participants was contacted by the researchers every other week during the six weeks, but did not receive cognitive behavioral therapy.\nShe said the benefits of the online therapy include easy access to the treatment and flexibility in times for completing the sessions, which \"is really helpful for those juggling work and family demands.\"\nThe study was published in SLEEP, the official journal of the Sleep Research Society.\nKristi Pruiksma, a STRONG STAR collaborating investigator and clinical psychologist, served as a clinician on Taylor's study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no harms mentioned in the release. According to the scientific paper, \u201cAEs [adverse events] determined to be related to the research included one patient with an increase in insomnia after primary care physician reduced hypnotic medication and six patients with skin irritation from wearing the Actiwatch.\u201d While these appear to be minimal, releases should still try to address any potential harms.", "answer": 0}, {"article": "\u201cC.\nThe 116 patients used in this study may have been selected in part because they were ideal candidates for FMTs, Dr. Elizabeth Hohmann noted, but she said the paper is solid overall.\n\u201cWhat I like about this paper is that it validates the upper-GI route and demonstrates that you can get very good cure rates without doing a colonoscopy.\u201d\n\nThat\u2019s important because colonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body and can be complicated for the people most at risk for C. difficile infections, Hohmann noted\n\nKao\u2019s study also showed that people found FMTs far less unpleasant when the poop came in a pill.\nThough the procedures were done in a Canadian hospital, the FMTs delivered by colonoscopy cost nearly $500 USD more than the capsules, which cost about $300.\nTwo-thirds of the 57 patients who got the pills said their experiences were \u201cnot at all unpleasant,\u201d while just 44 percent of the 59 patients who received the FMT via a colonoscopy could say the same.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gets a satisfactory here for including the differences between the two methods of delivery: One source is quoted saying, \u201ccolonoscopies and the anesthesia required for the procedure can put a lot of stress on a person\u2019s body\u00a0and can be complicated for the people most at risk for C. difficile infections.\u201d\u00a0 It could have gone a step further and reminded readers that a colonoscopy is an invasive procedure with the inherent risks of infection and perforation that obviously aren\u2019t there when taking a pill. The story did not mention the other adverse events described in the paper such as nausea and vomiting, though.", "answer": 1}, {"article": "\u201cIt\u2019s very muddy now exactly how long we need to treat patients,\u201d George said.\nBased on the results, George and his team say, it would be necessary to treat 12 depressed patients with TMS in order to have one patient recover.\nGeorge said he and his colleagues would like to study whether giving people TMS intermittently instead of putting them on antidepressants would produce equally durable effects.\nAfter three weeks, 14 percent of patients in the real TMS group had recovered from their depression, compared to 5 percent of the sham TMS group; people who had the real treatment were four times as likely to get better as those who got the fake treatment.\nGeorge said he hopes that by better understanding where TMS should be delivered and by figuring out the best dose and duration of treatment, success rates closer to those of ECT might be achieved.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that people in the TMS and sham treatment groups were equally likely to experience side effects including headache, discomfort at the TMS site, and eye twitching. The story could have pointed out that we don\u2019t know much about long-term adverse effects of this treatment, and that a short-term study of 190 subjects has limited ability to identify rare but potentially serious adverse effects.", "answer": 1}, {"article": "Orthopedic surgeon George Theodore is about to blast her foot with powerful shock waves generated by sound.\n[Other centers use lower-energy shock waves over several treatments.]\nDuggal says he advises patients to try a combination of these measures for at least a year.\nSo the hope is that platelet injections will stimulate healing without the damaging effects of shock-wave therapy.\nDuggal says foot specialists don't really know what causes the pain of plantar fasciitis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of side effects is the report of some bruising for\u00a0two days afterwards. Potential risks of this treatment include discomfort soon after the procedure. And then there is the possibility that the procedure may make the condition\u00a0worse. Some information acknowledging the risks \u2014 even if they are minor and temporary \u2014 is always appropriate.", "answer": 0}, {"article": "Medical device makers have been working for years to develop a so-called artificial pancreas to deliver insulin to patients with type 1 diabetes, an autoimmune disease in which the body destroys its own ability to make insulin.\nThe ultimate goal is to create a device that can check patients blood day and night, during and between meals, and deliver insulin as required.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\nWhen we started, the technology wasn\u2019t very good and the functionality was limited, and it took a number of generations to move to the device that we have now.\nThe new system, which involves patients wearing a matchbox-sized monitor and a similar-sized pump with a tube to deliver insulin into the body, also halved the amount of time blood sugar dropped to worrying or dangerous levels, they said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gives no sense of what could go wrong if this technology malfunctions and delivers the wrong dose of insulin while someone is sleeping.\u00a0The consequences could be fatal. \u00a0", "answer": 0}, {"article": "\u201cWho doesn\u2019t want to maximize their cognitive ability?\nBut \u201csome of [the newer] compounds are things that some random editor found in a scientific article, copied the formula down and sent it to China and had a bulk powder developed three months later that they\u2019re selling.\n\u201cIt\u2019s the few who are getting ahead who are using supplements to do that.\u201d\n\nThe word \u201cnootropic\u201d was coined in 1972 by a Romanian scientist, Corneliu Giurgea, who combined the Greek words for \u201cmind\u201d and \u201cbending.\u201d Caffeine and nicotine can be considered mild nootropics, while prescription Ritalin, Adderall and Provigil (modafinil, a drug for treating narcolepsy) lie at the far end of the spectrum when prescribed off-label as cognitive enhancers.\nBut while some studies have found short-term benefits, Doraiswamy says there is no evidence that what are commonly known as smart drugs \u2014 of any type \u2014 improve thinking or productivity over the long run.\nBut when aficionados talk about nootropics, they usually refer to substances that have supposedly few side effects and low toxicity.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are addressed\u2013enough to be Satisfactory for this criteria. But the discussion is confusing. The story initially says nootropics have \u201csupposedly few side effects and low toxicity.\u201d Later it states:\nAs for newer nootropic drugs, there are unknown risks. \u201cPiracetam has been studied for decades,\u201d says cognitive neuroscientist Andrew Hill, the founder of a neurofeedback company in Los Angeles called Peak Brain Institute. But \u201csome of [the newer] compounds are things that some random editor found in a scientific article, copied the formula down and sent it to China and had a bulk powder developed three months later that they\u2019re selling. Please don\u2019t take it, people!\u201d\nIn contrast, consider these unequivocal cautions in a similar Mercury News story last fall, starting in the seventh paragraph:\nResearch into the cognitive benefits of nootropics is still in its early stages, and some experts worry about the long-term health effects of ingesting potent synthetic smart drugs, which are largely unregulated.\nSome users have reported side effects including headaches, upset stomach, insomnia, anxiety and depression.\nDr. Reid Blackwelder, past president of the American Academy of Family Physicians, said it concerns him that customers are ordering such drugs online without consulting a doctor, because some of the substances seem to have a powerful impact on the brain. And much of the research on the cognitive benefits of these substances is supported only by studies using animals, Blackwelder said.", "answer": 1}, {"article": "This didn't stop MS.\"\n\n\"But, this is extremely hopeful research,\" he added.\n\"And with the one oral option we have today, there has been a lot of concern over a possible risk for immune suppression and also an increased risk for cancer,\" added Zamvil, who was not a part of the current study team.\n\"We went 17 years with injectables before we got our first oral option, 'Gilenya', just last year.\nAnd it's also important to note that this is not a cure.\nMONDAY, April 11, 2011 (HealthDay News) -- A new oral medication for the treatment of multiple sclerosis (MS) shows promise in slowing disease progression, limiting brain atrophy and reducing MS relapses, a recently completed two-year clinical trial demonstrates.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cThe study found that to date, the new drug appears to be both safe and well-tolerated.\u201d It also says, \u201cAdverse events, including serious events, were comparable to those in the placebo group, according to the researchers. The incidence of liver enzyme elevation was higher in patients treated with laquinimod, according to Comi, but he added that the elevations were temporary, reversible and did not lead to any signs of liver problems.\u201d (That Comi paraphrasing also appears to be lifted directly from an American Academy of Neurology news release.) We would have liked to have seen some actual numbers attached to those adverse events. This is important context for readers.", "answer": 0}, {"article": "Army veteran Vivian Cooke has long struggled with debilitating depression.\n\u201cSo Botox basically inhibits the muscle and calms it down, so it becomes more difficult to feel those negative emotions.\u201d\n\nThe makers of Botox recently announced plans for the final phase of testing it as a treatment for depression.\nWhile Botox is commonly used for cosmetic purposes, doctors say the reasoning behind the treatment for depression may not be what you expect.\nFinzi notes previous studies show between 50 to 60 percent of patients may benefit from the treatment.\nBotox is currently FDA approved for cosmetic use to lessen frown lines, and for medical use to treat a number of conditions including chronic migraines, bladder incontinence, excessive underarm perspiration, and certain types of neck pain and eye issues.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible negative side effects. According to MayoClinic.com, possible side effects include \u201cpain, swelling or bruising at the injection site, headache or flu-like symptoms, droopy eyelid or cockeyed eyebrows, crooked smile or drooling, eye dryness or excessive tearing.\u201d In rare cases, the effect of botulinum toxin can spread to other parts of the body and cause botulism-like signs and symptoms.\nThere\u2019s another issue relating to potential harms that should have been mentioned here. Using botox to treat depression is still an off-label use, meaning that\u00a0its safety and efficacy as a treatment for depression have not been established by the FDA.", "answer": 0}, {"article": "It appears that abiraterone is able to shut down androgen production not only in the testes, but also from the adrenal gland and from within prostate tumors themselves.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nDe Bono reported the study findings in at this week's meeting of the European Society for Medical Oncology in Milan, Italy.\nThis study was presented at a medical conference.\nThe study was funded by Johnson & Johnson, which is developing the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms of hormone therapy \u2013 harms that may include osteoporosis, fractures, diabetes and heart disease.\u00a0 This is a significant oversight. ", "answer": 0}, {"article": "Their laboratory benches are literally down the hall from our patients and the oncologist's offices.\"\nDr. Kmiec noted that while his team is working to move into human trials, the CRISPR application being developed for lung cancer does not involve directly editing a patient's genome --only the genes in the tumor.\nDr. Kmiec said the lung cancer work reflects an approach adopted by the Gene Editing Institute to move cautiously in developing medical applications of gene editing.\nThe study reports that in both tissue culture and in a mouse, tumor growth stopped and there was a dramatic decrease in the volume of existing tumors when chemotherapy was combined with CRIPSP-Cas9, which was used to disable a tumor gene known as NRF2.\nDr. Kmiec said there are chemotherapies that have helped patients achieve remission or at least live longer and enjoy a better quality of life by significantly slowing the progress of the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release doesn\u2019t talk about specific harms but it does note that \u201cthe CRISPR application being developed for lung cancer does not involve directly editing a patient\u2019s genome \u2014 only the genes in the tumor.\u201d\nThe release calls this application a \u201crelatively conservative\u201d use of CRISPR and that it might \u201cprovide a level of safety and reliability that is reassuring for patients.\u201d\nThe release would have been better had it explained that there\u2019s potential for viral vectors that are used to carry genes into the body to infect healthy cells as well as cancer cells; the study cites a need for \u201cmore effective delivery methods of these genetic tools to lung tissue\u201d that would eliminate the potential for disrupting normal cells.\nIt would have been helpful to note why this is important: a germ line can be passed on to children while somatic mutations generally can not be passed on.", "answer": 0}, {"article": "It's crazy enough to laugh off.\nBut rather than stocking up on the sugar-rich chocolate bars at the checkout line, researchers believe the starting point is to look for ways to take the compound out of cocoa, make more of it and then use it as a potential treatment for current diabetes patients.\n\"These results will help us get closer to using these compounds more effectively in foods or supplements to maintain normal blood glucose control and potentially even delay or prevent the onset of type-2 diabetes,\" said study co-author Andrew Neilson, assistant professor of food science at Virginia Tech.\nThe new study, published in the Journal of Nutritional Biochemistry, finds beta cells work better and remain stronger with an increased presence of epicatechin monomers, compounds found naturally in cocoa.\nBut here's the thing: BYU researchers have discovered certain compounds found in cocoa can actually help your body release more insulin and respond to increased blood glucose better.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Aside from mentioning that chocolate has a lot of sugar in it, harms are not discussed in the news release. Not only is eating lots of chocolate (stuffed with fat and sugar) likely to increase, not decrease, a person\u2019s risk of developing diabetes, the research paper states that other cocoa components they tested made things worse by decreasing insulin secretion.", "answer": 0}, {"article": "\u201cI used to be so irritable because I was so uncomfortable,\u201d Joyce said.\nShe consulted an allergist at Weill Cornell Medicine/New York-Presbyterian Hospital, where a clinical trial involving immunotherapy toothpaste was taking place.\nJoyce, who lives in the Bronx, New York, signed on for the year-long study that required six of the 12 volunteers to brush their teeth for two minutes using two pumps of the toothpaste in either the morning or night, and the other six to use drops under their tongue.\nVolunteers using the toothpaste were also required to log their usage in a journal.\n\u201cBut now I don\u2019t really feel allergy symptoms anymore.\u201d\n\nTo find a prescribing doctor for Allerdent in your area or to find more information, visit Allovate.com.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms or the safety of the immunotherapy toothpaste in this story. \u00a0Does the product carry the risk of systemic reactions that one might see with allergy shots? Does the toothpaste make you drowsy like some antihistamines? There is no\u00a0statement that the product is FDA-approved, which might help readers gauge its merits.\u00a0 All we are given is the praise of one of the trial\u2019s participants and a comment from the product\u2019s inventor.", "answer": 0}, {"article": "They look impressive,\" said Dr. Gordon Weir of Joslin Diabetes Center in Boston.\nBurt, who wrote the study protocol, said the research was done in Brazil because U.S. doctors were not interested in the approach.\nIn addition, Ross said that the study should have had a comparison group to make sure the treatment was indeed better than standard diabetes care.\nFor now, the new treatment does not apply to the nearly 20 million Americans with Type 2 diabetes, reports CBS News medical correspondent Dr. Jon LaPook.\nWhile the procedure can be potentially life-threatening, none of the 15 patients in the study died or suffered lasting side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of the new treatment whatsover, including no mention of how serious these harms were or how frequently they occurred.\u00a0\u00a0 ", "answer": 0}, {"article": "New research analyzing more than 22,000 U.S. cases of aortic aneurysm repair is likely to hasten the trend toward more procedures being done with a device called a stent-graft instead of the typical surgery that requires up to eight weeks of recovery.\n\nThe study by doctors at Harvard Medical School and the federal Centers for Medicare and Medicaid Services found the death rate in surgery, 4.8%, was four times that of the 1.2% death rate in placing stent-grafts to seal off the aneurysm. Surgery tended to provide a more permanent...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story compared the percentage of patients dying during the two procedures as well as the percentage who would need re-treatment at a later point in time. \u00a0But the story did not mention that there is evidence that the endovascular repair in those who are not physically well enough to undergo the open procedure does not provide benefit in terms of mortality. Thus for a subset of patients, undergoing the procedure and accompanying recovery involves the harm of discomfort and risk without benefit.", "answer": 0}, {"article": "FRANKFURT (Reuters) - Merck KGaA said that its immunotherapy Bavencio, jointly developed with Pfizer, delayed the progression of kidney cancer when used in combination with Pfizer\u2019s Inlyta drug in a late-stage study.\n\nThe drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent, the German drugmaker said in a statement on Tuesday.\n\nThe trial will continue to show whether Bavencio plus Inlyta also prolongs patients\u2019 lives.\n\nWhile the company said the benefit was statistically significant, they did not specify the duration of progression-free survival. A detailed analysis would be submitted for presentation at a medical congress, it added.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t addressed. Again, this is unacceptable given that both drugs are already on the market. And these problems can be significant. The potential side effects associated with Bavencio include lung, liver and kidney problems. Potential side effects associated with Inlyta include heart failure and serious or fatal bleeding.", "answer": 0}, {"article": "Dr Sheraz Markar, an NIHR Clinical Trials Fellow from Imperial College London, under the supervision of Professor George Hanna, told the Congress: \"At present the only way to diagnose oesophageal cancer or stomach cancer is with endoscopy.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the oesophagus and stomach, and which do not.\nThis means that not only was the breath test good at picking up those who had cancer (sensitivity), it was also good at correctly identifying who did not have cancer (specificity).\nThis will assess the ability of the test to pick up cases within a group that is likely to contain only a small percentage of cancers.\nOver the next three years, the researchers will continue with a larger trial, using the test with patients who are being given an endoscopy for gastrointestinal symptoms but not yet diagnosed with cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the harms of such a breath test. If the release is going to discuss potential unproven benefits, it should also mention the potential harms of screening tests including false positives, false negatives leading to over- or under-diagnosis. \nChief among these harms would be falsely labeling healthy people as possibly having cancer and then subjecting them to invasive testing or even treatments that turn out to be unnecessary. Based on the statistics in the study abstract, an 81% specificity suggests that almost one-out-of-five people taking the test would be labeled as possibly having cancer when they don\u2019t. However, the 80% sensitivity suggests that at present about one-in-five people with cancer would be missed. (Computed tomography (CT) screening for lung cancer is about that). The numbers get much worse, as discussed above, when we consider using the test in the general population of people who aren\u2019t likely to have stomach cancer.", "answer": 0}, {"article": "Cancer cells remain elusive and tough to locate, but a new crop of nuclear-imaging tests promises to lead to more accurate prognosis and treatment.\n\nThe tests use imaging agents that combine radioactive isotopes with targeted molecules that can spot cancer at the cellular level. The ability to accurately locate the cancers helps physicians make better and earlier diagnoses\u2014and may eventually make possible targeted nuclear-medicine therapies that identify and kill cancer cells, but not the surrounding healthy cells.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The limitations and harms (from false positives, unnecessary biopsies, and unneeded surgery/radiation) from PSA screening and other current diagnostic procedures for prostate and other cancers are\u00a0pretty well known. It\u2019s unlikely that the newer nuclear imaging tests described in this article are without limitations and potential harms as well, including exposure to ionizing radiation, but there is no explicit/direct information about them. Also, finding low-risk cancers could pose psychological and physical harms from over diagnosis and over treatment.", "answer": 0}, {"article": "CAM2038 has the potential to alter the current treatment paradigm for opioid dependence,\" said Sharon Walsh, Ph.D, Professor of Behavioral Science and Director of the Center on Drug and Alcohol Research, University of Kentucky, \"Because of its long acting properties, CAM2038 may decrease patient and physician burden, improve access to treatment, and obviate public health concerns about illicit diversion of buprenorphine.\"\n\"Importantly, the fact that CAM2038 will be given in the clinic by health providers should address concerns about diversion of buprenorphine for illicit use.\n\"The current study demonstrated that weekly injections of CAM2038 produced significant and robust opioid blockade, a critical mechanism of efficacy for medications treating opioid dependence.\nFurthermore, CAM2038 was well tolerated across the course of treatment.\n\"We were pleased to be involved in the development of CAM2038 and are hopeful that it will serve as another safe and effective therapeutic option for patients with opioid use disorder.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms was offered beyond saying the drug was \u201cwell tolerated across the course of treatment.\u201d What does that mean? We do not know.\nWe do know that the drug is not wholly benign. Here are some side effects listed by the U.S. government\u2019s Substance Abuse and Mental Health Services Administration: nausea, vomiting, constipation, muscle aches and cramps, cravings, inability to sleep, distress and irritability and fever.\nUntil this is tested in a larger cohort, we do not know the potential array of side effects.", "answer": 0}, {"article": "In 2016, he was ranked the No.\nIn a commentary published in the current issue of the American Journal of Medicine, researchers from the Charles E. Schmidt College of Medicine at Florida Atlantic University reassure clinicians and their patients that varenicline, whose brand name is Chantix, is a safe and effective way to achieve smoking cessation and that failure to use this drug has caused preventable heart attacks and deaths from cardiovascular disease.\nIn their commentary, the FAU researchers emphasize that, until recently, the totality of randomized evidence on varenicline had been restricted to eight small trials, which did not demonstrate a hazard.\n\"The existing totality of evidence suggests an urgent need to increase the use of varenicline in the general population as well as in those with serious mental illness who on average die about 20 years earlier than the general population, in part, because their smoking rates may be as high as 75 percent,\" said Hennekens.\nSuch a large randomized trial was recently completed that included both apparently healthy individuals as well as those with severe mental illness.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes results of the EAGLES study, which aimed to address concerns about the potential for Chantix users to experience related neuropsychiatric problems. However, there are significant concerns with both the EAGLES study and with the FDA\u2019s subsequent decision to remove the \u201cblack box\u201d warning from Chantix. Rather than trying to recap all of those concerns in this space, we refer you to a detailed piece by Alan Cassels that was published on HealthNewsReview.org\u2019s blog in January. Suffice it to say, the EAGLES study did not settle the debate over the safety of Chantix \u2014 and that debate warrants some discussion in a release like this one.\nThis release describes harms from smoking and specifically the harms of under-treating smoking. But it doesn\u2019t discuss side effects of Chantix. While those side effects may be much less severe than combusted tobacco smoke that does not excuse their elimination from the news release. Ideally, people are provided enough information necessary for realistic, rational shared decision-making with their doctor about pharmaceutical medications, not false reassurance that there are no risks to this type of treatment.", "answer": 0}, {"article": "We suspect this strategy could benefit other cancer patient populations.\"\nThe high-dose vaccine (Fluzone High-Dose) was approved in 2009 by the FDA as a single dose for adults over 65.\nEven though patients with multiple myeloma and other plasma cell disorders may receive an annual flu vaccine, studies show that a one-time flu shot does not offer adequate immune response.\nThe booster strategy lowered the flu infection rate among patients to 6% versus an expected rate of 20%, and it improved protection against all flu strains covered by the vaccine in 66% of patients, said the study's first author Andrew Branagan, M.D., a postdoctoral associate in medicine (hematology).\nNew Haven, Conn. - Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any of the harms associated with the vaccine.\nWhile influenza vaccine is generally safe, there are some potential adverse reactions that are more common with the high dose formulation. According to a news release from Sanofi-Pasteur, the manufacturer of Fluzone, announcing updated prescribing information for Fluzone high-dose in patients 65 and older: \u201cThe most common local and systemic adverse reactions to Fluzone High-Dose vaccine include pain, erythema, and swelling at the injection site; myalgia, malaise, headache, and fever. Other adverse reactions may occur. Fluzone High-Dose vaccine should not be administered to anyone with a known hypersensitivity (eg, anaphylaxis) to any vaccine component, including egg protein, or to a previous dose of any influenza vaccine.\u201d", "answer": 0}, {"article": "According to the National Center for Health Statistics, an estimated 25.3 million Americans, or 11.2 percent of U.S. adults, experience chronic pain.\nSo it makes sense that Jay jumped at the chance to experience long-term pain relief with the help of a spinal-cord stimulator.\nThat aching back is hard to fix, but here are a few things to try\n\nThese real-life cyborgs hack their bodies with chips, magnets and other tech\nBut she shares a similarity with those characters: Her all-too-human body has been upgraded with a machine.\nBut the pain is far more controlled, and I can function much better at my current level of discomfort.\u201d\n\nAs the human and financial costs of the opioid crisis rise, spinal stimulation may become more popular, even though it\u2019s expensive.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a big oversight. There was no mention of the risks involved with having surgery in the vicinity of the spine, which could include serious complications such as infection, as well as device failure. The story should have cautioned that medical devices are not required to undergo rigorous safety trials before they are allowed on the market, as we cover in our medical device primer.", "answer": 0}, {"article": ".\nOur mission is to advance health and welfare by promoting progress and education in biological and biomedical sciences through service to our member societies and collaborative advocacy.\n\"Many would have predicted that tendon healing is inflammation-linked,\" said Thoru Pederson, Ph.D., Editor-in-Chief of The FASEB Journal, \"but that the anti-inflammatory roles of TSCs could be so potent, and so amplifiable, is a striking finding.\"\nIn vivo, the researchers evaluated inflammatory responses by TSCs, including infiltration of macrophages (white blood cells that consume damaged or dead cells) and expression of anti-/proinflammatory cytokines, at different time points.\nSubmit to The FASEB Journal by visiting http://fasebj.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Since the release\u2019s main source does reference the possibility of these findings leading to future treatment methods, the release really should offer some information about the possible harms of stem cell applications, which include immune reactions and even cancer.", "answer": 0}, {"article": "\u201cThis collaborative venue enabled two then-residents [Drs.\nEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\nIn a recent report on ongoing work to improve kidney tumor classification, published in the April issue of the journal Clinical Nuclear Medicine, the team reports that the sestamibi SPECT/CT test\u2014short for 99mTc-sestamibi single-photon emission computed tomography/computed tomography(CT) \u2014 adds additional diagnostic information in conjunction with conventional CTs and MRI and improves physicians\u2019 ability to differentiate between benign and malignant kidney tumors.\n\u201cSestamibi SPECT/CT offers an inexpensive and widely available means of better characterizing kidney tumors, and the identical test is now being performed as part of a large trial in Sweden, for which the first results have just recently been published and appear to confirm our conclusions.\u201d\n\nAlthough further study is needed to validate the accuracy of sestamibi SPECT/CT, this test appears to be a less expensive, faster, noninvasive alternative to surgery, says Michael A. Gorin, M.D., the other resident involved in developing this approach and now chief resident with The James Buchanan Brady Urological Institute of the Johns Hopkins University School of Medicine.\nReviewing sestamibi SPECT/CT scan results in conjunction with CT or MRI changed the initial rating levels from cancerous (score 3, 4, 5) toward benign (score 1 and 2) in 9 cases, and changed reviewers\u2019 score from likely cancerous (score 4) to definitely cancerous (score 5) in 5 cases, or about 10 percent of all cases.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does address harms in terms of reduced harms from adding the imagining technology to standard diagnostic tests:\n\u201cEven for patients whose tumors were not reclassified, the addition of sestamibi SPECT/CT increased physicians\u2019 ability to more confidently classify malignant tumors, which reduces the risk of misdiagnosis and unnecessary surgery for all patients, the researchers say.\u201d\nHowever, the potential harms from the test itself are not mentioned. Like CT, the test involves the use of ionizing radiation known to increase the risk of cancer. Though often minor, the contrast imaging agents (also called tracers or \u201cdye\u201d) injected prior to the test can cause allergic reactions, headaches, chest pain, dizziness, and other reactions.", "answer": 2}, {"article": "\u201cYou don\u2019t need any fancy equipment.\n\u201cThe basis of autism in the brain is very deep.\nFor the study, researchers at McLean and a team led by Dr. Janet Lainhart the University of Utah used an MRI that was tuned to pick up microscopic features of the brain\u2019s wiring \u2014 a technique known as diffusion tensor imaging.\nBy measuring six aspects of the brain\u2019s circuitry, the test was able to correctly pick out people who had been diagnosed with autism with 94 percent accuracy.\nHe said the findings, published in the journal Autism Research, were very preliminary, but if confirmed in several more and larger studies, they might replace current subjective tests now used to diagnose the disorder.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One would think from reading these stories that getting an MRI is as harmless as taking a shower. Neither this story nor the CNN story explained the real psychological and physical impacts of brain scans. For those who have had the pleasure, you know how tight and confining the scanner \u201cchamber\u201d can be. Younger children frequently require deep sedation for a scan due to the tightness and to the loud banging that occurs during the scan. Although there is no radiation emitted, MRI scans are uncomfortable, loud and intimidating especially for younger children. If this test is to become useful it would need to be conducted early in a child\u2019s life. This should have been conveyed to the reader.", "answer": 0}, {"article": "Compare that with a decrease of about 7 mg/dL for the low-fat diet, and about a 8 mg/dl drop from the moderate-fat diet.\nNew research finds that eating an avocado per day, as part of an overall diet rich in healthy fats, may help cut the bad kind cholesterol, known as LDL.\nTo put the difference in perspective, the avocado diet decreased LDL cholesterol about 14 milligrams per deciliter of blood.\nA mere half-cup of guacamole has about 200 calories all on its own.\nIt's also possible that the fiber in avocados plays a role in the cholesterol-lowering effect, she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that eating avocados is linked to decreases in LDL cholesterol levels, but also clearly notes that eating avocados in conjunction with tortilla chips (as guacamole lovers are wont to do) would lead to a significant increase in calorie consumption.", "answer": 1}, {"article": "But the evidence that pot smoking actually helps with spasticity has been anecdotal.\nThe new study, reported in the Canadian Medical Association Journal, included 30 MS patients with muscle spasticity that had failed to get better with standard medication.\n\u201cWhat effects that might have had on the results is unclear.\u201d\n\nCorey-Bloom said that should not have influenced the spasticity findings, since an independent researcher (who didn\u2019t know whether patients were smoking marijuana or the placebo) rated spasticity using a standard scale.\n\u201cSpasticity is a big problem for many people with MS, and the current medications don\u2019t necessarily work for everyone,\u201d said LaRocca, who was not involved in the new study.\n\u201cWe can\u2019t say anything about long-term effects,\u201d Corey-Bloom told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story included the important quote, \u201cWe can\u2019t say anything about long-term effects.\u201d\nAnd, short term, the story reported that the study found some patients had fatigue and dizziness.", "answer": 1}, {"article": "An estimated 25 million to 45 million Americans suffer from irritable bowel syndrome, or IBS, a gastrointestinal condition that can cause miserable symptoms.\nMaking it worse for many patients, there hasn't been a conclusive test to diagnose what's wrong with them.\nBut that could finally change with the introduction of two simple new blood tests for spotting the disease.\nShe got the new blood test to confirm her diagnosis, and when it came back positive, she said she felt a sense of relief knowing IBS wasn't all in her head.\n\"I'm not saying the symptoms went away,\" she said, but she \"started to feel more whole.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No test is 100 percent accurate, and a false positive test can lead to additional diagnostic testing that can cause harm as well as unnecessary treatments. The story could have mentioned this.", "answer": 0}, {"article": "About the University of Maryland School of Medicine\n\nThe University of Maryland School of Medicine was chartered in 1807 and is the first public medical school in the United States and continues today as an innovative leader in accelerating innovation and discovery in medicine.\nProton therapy did not make a difference in all of these side effects, but had significant effects on several.\nWhile most cancer patients are well served with today's state-of-the-art radiation therapy technology, up to 30 percent are expected to have a greater benefit from the new form of targeted proton beam therapy.\nThe treatment works well for many kinds of tumors, including those found in the brain, esophagus, lung, head and neck, prostate, liver, spinal cord and gastrointestinal system.\nThis technique can precisely direct radiation to the most difficult-to-reach tumors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "By focusing on proton therapy advantages, and offering little information on which side effects proton therapy does not ameliorate, the release effectively glosses over the fact that proton therapy can still cause a wide array of significant adverse side effects associated with radiation therapy.", "answer": 0}, {"article": "To resolve that possibility, a new trial is under way at 20 cancer centers, including M.D.\nAlmost all the patients mounted an immune response.\nThe trial's big surprise was that the chemotherapy didn't stop the vaccine from prompting a strong immune response and instead enhanced it.\nThe response was better with the highest dose of Temodar.\nHe appeared to be beating the cancer with the combination therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of whether the vaccine had any effects other than appearing to lengthen the time needed to observe cancer recurrence.", "answer": 0}, {"article": "These studies have been done with people, but other promising research has only been done with lab animals so far. In one 2009 study in the Journal of Medicinal Food, tart cherries helped fat rats. Not our favorite role models perhaps, but the obese beasties' risk of Type 2 diabetes and heart disease were reduced significantly, and parallel studies are now in the works with members of our own species, says lead author E. Mitchell Seymour: \"There are some interesting and potentially exciting results on the horizon. Stay tuned.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable. We don\u2019t know what the harms of eating cherries might be.", "answer": 2}, {"article": "In the Swiss research, animals took a drug that dissolved a barrier around the part of the brain where mammals store their fear memories. Afterward, they stopped being afraid of noises that were linked to electric shocks, which meant their bad memories had been erased, according to the Mail. Human brains, explains NYU neuroscience Prof. Joseph LeDoux, could actually \"overwrite\" memories with happier thoughts if the medication is developed for people, according to the Daily Mail.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No adverse effects were reported in the research; however, the story briefly mentions the ethical and medical concerns that may be associated with a drug that erases memory. ", "answer": 1}, {"article": "\"It's not a method that's going to suit everybody.\"\nEven so, the FPA advises that natural family planning is most effective if you\u2019re taught how to do it by a specialist teacher, and you monitor all three fertility indicators \u2013 temperature, menstrual cycle length, and cervical secretions.\nWithout temperature information an app can can guess at your ovulation day based on your average cycle length, but can't be sure when you actually have ovulated, and so you can't use it as a reliable form of birth control.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nFor starters, it can only protect against pregnancy, not STIs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The biggest harm to using this contraceptive method is getting pregnant. The article reminds readers that\u00a0another risk to using this method of birth control is it does not protect against sexually transmitted diseases, as condoms do. Otherwise, there is only the inconvenience of daily logging of one\u2019s temperature and entering menstrual cycle data.", "answer": 1}, {"article": "Restless leg syndrome (RLS) is a neurologic disorder causing unpleasant sensations and an urge to move the legs when at rest.\nPatients using the RLS device also reported an 82 percent decrease in sleep loss.\nThe eight-week clinical trial involved 30 otherwise healthy adults with moderate to severe restless leg syndrome.\nAdverse effects were reported by seven patients in the study.\nThe effects included pain (1), pins and needles sensation (2), irritability (3), spasm (1) and warm feet (1).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports the number of participants who had problems including \u201cpain (1), pins and needles sensation (2), irritability (3), spasm (1) and warm feet (1).\u201d", "answer": 1}, {"article": "Necator americanus, the New World hookworm, is as long and thin as a vermicelli noodle.\nIt was important that the participants be adults, because even relatively benign parasites can cause serious problems for children, pregnant women and others.\nAnd because of the risks associated with parasites, going around infecting people isn't a viable treatment option.\nThe study is the latest from a surprising field of research into the potentially positive sides of parasites, one of the most maligned groups in the animal kingdom.\nThe doctor wanted to know whether there might be a connection between the dramatic success of deworming programs around the world and the rise of immune system problems like asthma and celiac disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article provides some explanation of the potential harms of ingesting live hookworms for therapeutic purposes. It warns against readers \u201ctrying this at home,\u201d especially in the cases of young children and pregnant women. No statement is made about the potential harms of treatments derived from hookworm spit or similar compounds, but at least most readers probably won\u2019t leave this article with the impression that buying hookworms overseas and self-infecting is a great idea.", "answer": 1}, {"article": "\n\u2022 Read this story at www.uab.edu/news\n\u2022 The UAB News Studio is available for live or taped interviews with UAB experts.\nResults from inferior corneal staining tests \u2014 used by physicians to detect abrasions on the cornea \u2014 showed improvement in three of the four studies.\n\u201cIt is critical for eye care professionals to have a dialogue with patients who report symptoms because dry eye can be a progressive ocular surface disease.\u201d\n\nThe twice-daily eye drop solution of 5 percent lifitegrast ophthalmic solution is the only prescription eye drop indicated for the treatment of both signs and symptoms of dry eye, and it is the first new dry eye prescription drop approved in the last 13 years.\nThere are more than 30-plus new dry eye basic, translational and clinical studies being funded by the NEI/National Institutes of Health to further explore these lipids and proteins, with more than 50 papers being published monthly.\nKelly Nichols, O.D., Ph.D., a dry eye expert and dean of the University of Alabama at Birmingham School of Optometry, conducted research studies for the parent drug company to explore the efficacy and safety of lifitegrast in treating this eye condition that affects more than 16 million adults in the United States.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of possible harms caused by the drug. But the package insert\u00a0for the drug, also known as Xiidra, notes that they exist: \u201cThe most common side effects of Xiidra include eye irritation, discomfort, or blurred vision when the drops are applied to the eyes, and an unusual taste sensation (dysgeusia).\u201d\u00a0 It appears that some of the side effects are the same as the symptoms that the drug is supposed to\u00a0relieve.\u00a0 \u00a0", "answer": 0}, {"article": "\"It's my job to see that she gets what she needs to protect herself,'\" he says.\nThe vaccine promises to reduce the number of HPV related cervical cancers by more than 70 percent, CBS News correspondent Cynthia Bowers reports.\nThe FDA only approved Gardasil in June and already, there is talk of making the $360 vaccine mandatory for the 2 million American girls who enter the sixth grade every year.\nHe agrees Gardasil is a breakthrough, but says the final decision should be made by the parents.\nMillions of Americans have seen the ad blitz for Merck's new drug Gardasil.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not describe any potential harms of the vaccine.", "answer": 0}, {"article": "When people lose substantial amounts of weight, their physiology changes so that, although they may look normal, they have all the hallmarks of starvation.\nWould the subjects still show the metabolic changes of starvation?\nThe answer, published in the current issue of The Journal of Clinical Investigation, was that the leptin trick worked.\nLeptin reversed that, too.\nBut what if the researchers put people - fat and thin - on weight-reducing diets and gave them enough leptin to make their bodies think that they were still fat.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of any possible \nharms. What, if anything, happened after the study subjects stopped receiving leptin injections?", "answer": 0}, {"article": "\u201cHe said, \u2018Doc, give me what I got last time.\nUntil there are answers, Zarate of the mental health institute said ketamine should be a last-resort treatment for depression after other methods have failed.\nSome have lost jobs and relationships because of severe depression, and most find that ketamine allows them to function, Khare said.\n\u201cIt truly has revolutionized the field,\u201d changing scientists\u2019 views on how depression affects the brain and showing that rapid relief is possible, said Yale University psychiatrist Dr. Gerard Sanacora, who has done research for or consulted with companies seeking to develop ketamine-based drugs.\nKetamine\u2019s potential for almost immediate if temporary relief is what makes it so exciting, said Dr. Jennifer Vande Voort, a Mayo Clinic psychiatrist who has used ketamine to treat depression patients since February.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said ketamine can cause rapid increases in heart rate and blood pressure \u201cthat could be dangerous\u201d as well as hallucinations. It quoted one expert who said the drug \u201ccan be abused, so we have to be very careful about how this is developed.\u201d", "answer": 1}, {"article": "The research team, led by Cleveland Clinic's Eric Klein, M.D., conducted a multicenter prospective study of 261 men scheduled for prostate biopsy at five academic and community centers in the U.S. enrolled between August 2015 and December 2016.\n\"The methodology used in the IsoPSA assay represents a significant departure from conventional ways to define biomarkers in blood, and may be applicable to improving other cancer biomarkers,\" said Dr. Klein.\nThe study directly compared the clinical performance of a new test based on PSA, called IsoPSA, to PSA itself with patients already scheduled for prostate biopsy.\n\"Unfortunately, PSA is tissue-specific but not cancer-specific, leading to overdiagnosis and overtreatment of biologically insignificant cancers, which is widely recognized as a key limitation in its clinical utility.\"\nThe results show that if validated and adopted clinically, IsoPSA could significantly reduce the rate of unnecessary biopsies by almost 50 percent.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are no great harms associated with taking a blood test, but we do know there are harms associated with screening tests. They can lead to false positives, additional tests and over-treatment of low risk prostate (and other cancers) that might never have caused harm.\u00a0Patients may also suffer psychological effects\u00a0if they are confronted with false positive test results. The side effects of\u00a0treatment for these tumors can be serious \u2014 impotence, incontinence and bowel dysfunction. Though one could argue this new test may decrease those harms, it is unproven at this point.\nWe rate this one Not\u00a0Satisfactory.", "answer": 0}, {"article": "JACC is ranked No.\n\"Until now, the clinical community has focused on cardiovascular disease, which typically manifests in the later stages of life.\n\"This pioneering study represents a very important step in exploring the intersection of child development, cardiovascular health promotion and primordial prevention.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Because the interventions are largely educational and don\u2019t include drugs or therapies, we\u2019ll say that harms are unlikely. But is it theoretically possible that the intervention could have some unforeseen impact on these children that shows up years later? Fear of fat? Anorexia? We won\u2019t penalize the release for not raising the issue,\u00a0but saying something about downstream potential would have added depth and insight.", "answer": 2}, {"article": "Nearly two years later, Briana is back in school and playing with her dog, Goofy, and the family's seven parakeets.\nThe selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\nThe results of the larotrectinib trial in adult patients - a 75 percent response rate - were published last month in the New England Journal of Medicine.\nThe larotrectinib research was supported by Loxo Oncology Inc., the National Institutes of Health, the Cancer Prevention and Research Institute of Texas, the National Center for Advancing Translational Sciences, and Alex's Lemonade Stand Foundation.\nA next step in the research is a clinical trial involving a similar drug for those patients who developed resistance.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any of the specific harms from the drug.\nThis phase 1 safety trial demonstrated only that the drug is sufficiently safe to take to the next level of trials, not to use in practice.\nThe release mentions that \u201cnone of the patients with TRK fusions had to quit the study because of a drug-induced side effect.\u201d This is a key finding of the study and readers would have benefited from a more thorough explanation of the harms. There were seven patients enrolled without the genetic mutation. Four patients experienced a grade 3 (severe) adverse event. No patients experienced a grade 4 or 5 adverse (life threatening) event. These are important results of the study because they support future testing of the drug in larger pediatric populations.", "answer": 0}, {"article": "\"The earlier we get treatment started, the better.\nApproval of DaTscan followed two Phase 3 clinical trials in which 284 adult patients with tremors were studied.\nDuring an FDA advisory panel meeting, committee members were mostly positive about DaTscan, though one neurologist objected to the average $1,500 cost of a scan versus $150 for a month's supply of carbidopa or levodopa medications for a Parkinson's patient, according to Medscape Medical News.\nIt is the first \"radiopharmaceutical adjunct imaging agent\" approved by the Food and Drug Administration that helps physicians better evaluate patients who are thought to have Parkinson's disease or other parkinsonian syndromes.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not mention potential harms, including the potential cancer risk from radioactive iodine that is injected into patients as part of the DaTscan. The drug label warns that clinicians must use a blocking agent to prevent the patient\u2019s thyroid from taking up the radioactive iodine.\nThe story should have also reported that although adverse reactions were uncommon in clinical studies, some people did have hypersensitivity reactions such as rash and itching, and that less than 1 percent of patients reported mild to moderate headache, nausea, vertigo, dry mouth or dizziness. The story would have been better if it also noted that since the studies included fewer than 300 patients, side effects that occur only rarely might not have shown up.\nFDA-approved label for DaTscan:\nhttp://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000Lbl.pdf", "answer": 0}, {"article": "While the disease is rare, with about 3,100 new diagnoses and 330 deaths in the United States each year, it often goes undiagnosed until it affects vision. Sacks \u2014 known for books including Awakenings and The Mind's Eye, in which he tells the story of his own cancer \u2014 said his symptoms hit suddenly, wiping out a triangular chunk of the vision in his right eye.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no discussion of potential side effects or harms of this treatment approach, other than the patient\u2019s statement that he has had no side effects. He also called the\u00a0new intervention \u201ca breeze.\u201d\nIn truth, because the drug\u2019s safety is being evaluated\u00a0in this clinical trial, the researchers do not yet know what side effects might occur, a fact the story does not address. Also, there were likely some side effects measured in the animal studies.", "answer": 0}, {"article": "We can't find the page you're looking for. Try one of these options.\n\nAre you sure this is the right web address? Let us know.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release addresses the most common known side effects of the cooling system, which included cold-induced headaches, as well as neck and shoulder discomfort, chills and pain associated with wearing the cooling cap for an extended period of time.\nIt also mentioned another risk: the cold cap could cause chemotherapy drugs to \u201cmiss\u201d an isolated grouping of breast cancer cells in the scalp. However, the release points out that this is \u201cextremely rare.\u201d\nAlthough we would have liked some evidence-backed explanations on the latter harm, we feel the news release does a Satisfactory job here.", "answer": 1}, {"article": "\"This simple blood test was nearly as accurate as a state-of-the-art CT scan.\"\n\"This could ultimately change the way we diagnose concussions, not only in children, but in anyone who sustains a head injury,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\nResearchers plan to do more studies with the blood test, but they hope it will be commercially available within the next 5 years.\nMoreover, the study showed that the blood test detected symptoms of concussions, even when brain injuries were not visible on the CT scan.\n\"The idea is to get a point-of-care test that could be used on the field, to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play,\" said Papa.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is silent on the potential harms that could result from an easy-to-use biomarker test, especially one that has a 47% specificity (the ability of the test to correctly identify those without the condition). A test with only 47% specificity means that more than half of positive results will be \u201cfalse positives.\u201d\u00a0The release does not address these \u201cfalse positives\u201d at all \u2014 meaning instances in which the test diagnosed a patient as having brain injury when there was no injury. A false positive could result in additional testing, which may create a financial burden, and \u2014 in the case of a CT scan \u2014 poses health risks of its own. Second, the release refers to the possibility of using the blood test to make brain injury diagnoses \u201con the spot.\u201d Quoting one of the researchers who did the study, the release says: \u201cThe idea is to get a point-of-care test that could be used on the field to help the coaches, the trainers and the athletic directors, make a decision then and there about whether the child should go back to play.\u201d However, the journal article the release is reporting on notes that GFAP is detectable in the bloodstream \u201cwithin one hour of injury.\u201d The release does note that such a tool should only be used to \u201chelp\u201d adults make decisions about a child\u2019s health, but this still raises some significant questions. What if a coach, for example, takes a blood test before the GFAP has had time to become detectable in the blood stream? Would that give the coach a false sense of confidence that the child is fine and can re-enter the game?", "answer": 0}, {"article": "Nothing.\nThere are vaccines for several Neisseria meningitidis strains, but designing a vaccine to protect against the B strain was a particularly difficult nut to crack.\n\u201cMathematical modeling has shown that even a vaccine of moderate efficacy and duration could have a substantial effect on the transmission and prevalence of gonorrhea, if coverage in the population is high and protection lasts during the highest risk period,\u201d Kate Seib, of Australia\u2019s Institute for Glycomics, wrote in a commentary that accompanied the study.\nResearchers in Quebec say they saw the same phenomenon after a meningitis outbreak there, and previously published data from Cuba and Norway also hint of the vaccine\u2019s unexpected benefit.\nThe research, conducted in New Zealand, found that the gonorrhea rate among teens and young adults there who had received a meningitis B vaccine during an emergency campaign in the early 2000s was significantly lower than the rate seen in people of the same age who weren\u2019t vaccinated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Any vaccine has potential side effects, and these aren\u2019t mentioned. According to the CDC, more than half of the people who get meningitis B vaccines have mild problems such as headaches or soreness where the shot was given. Fainting, allergic reactions and shoulder pain are less common effects. Also, the vaccine appears to be only moderately effective, meaning people may get infected regardless.\nOverall, not much is known about this vaccine\u2019s safety\u2013whether it\u2019s being used for meningitis or gonorrhea. As Bloomberg News explained, many health experts decry the lack of data on the vaccine. Discussing this issue would have made the story stronger.", "answer": 0}, {"article": "As a result, sticky mucus builds up in a patient's lungs, causing infections and making it hard to breathe.\nOne of those chemicals ultimately became a successful drug, but it had to be modified so patients could take it by mouth, and so it would last the right length of time in a patient's body.\nThey have to have a particular mutation in the CF gene, or the drug is of little use.\nWhile not quite a cure, the drug is extremely effective for some CF patients.\nAt the time, scientists predicted that a genetic test for CF was just around the corner.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms in the story. We think that it\u2019s especially important to include information about harms when you feature a patient who describes the benefits of the drug by saying\u00a0\u201csomething huge had happened. It was just something I had never felt in my life before.\u201d\nThe prescribing information for the drug states: \u201cOverall, the most common adverse reactions in 353 patients with CF were headache (17%), upper respiratory tract infection (16%), nasal congestion (16%), nausea (10%), rash (10%), rhinitis (6%), dizziness (5%), arthralgia (5%), and bacteria in sputum (5%).\u201d", "answer": 0}, {"article": "Glover acknowledges that \"it's not a perfect solution.\nHe added that although the study proved the treatment's effectiveness and safety only in children, adults would probably benefit in the same way.\nOverall, participants experienced fewer side effects during the study than the researchers had anticipated.\nA little more than 11% of the children dropped out of the study due to severe side effects.\nTo test the experimental therapy, 66 research centers in 10 countries recruited 551 participants who ranged in age from 4 to 55 and who all had a peanut allergy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes harms through the profile of one patient: \u201cEllis experienced stomach cramps and vomiting multiple times during the study,\u201d and once she had an anaphylactic reaction which required medical attention. And this was a successful patient story.\nThe story also reports that 11% of participants dropped out of the study as a result of side effects.\nHowever, it left out important issues such as the higher dropout rate \u2014 around 20%, mainly due to adverse events \u2014 among those who received the treatment, and unknown long-term effects.", "answer": 1}, {"article": ".\nWhile study participants with the lower blood pressure goal appeared to have better cardiovascular outcomes overall, the researchers caution all other hypertension patients to talk to their doctor to determine whether this lower goal is best for their individual care.\nThe study shows that for adults aged 75 years and older with high blood pressure, a systolic blood pressure goal of less than 120 mm Hg reduced rates of cardiovascular events, such as heart attack and heart failure, as well as stroke, by 33 percent.\nThese additional results of the Systolic Blood Pressure Intervention Trial (SPRINT) appear in the current online issue of the Journal of the American Medical Association (JAMA).\nThe new analysis singles out adults aged 75 and older and confirms that those with high blood pressure also benefit from the lower pressure target similar to the larger group studied in the earlier research: non-diabetic adults aged 50 and older.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the possible adverse reactions to medications that lower blood pressure, although these are widely known.\u00a0 Nor does the release mention any adverse reactions among the study participants other than those that were used as endpoints for the study \u2014\u00a0myocardial infarctions, strokes and heart failure, for example.\nThe published research article notes that while treatment carried risk of side effects for both patient groups studied, the differences between the serious side effects (low blood pressure, fainting, acute kidney injury) encountered in each group weren\u2019t significantly significant.\nAnother issue not addressed in the release is that these patients were followed very closely by study staff and were examined initially every 3 months. In clinical practice, patients are often not seen that frequently which means that some patients might not get the level of monitoring needed to prevent or treat emerging complications.\nWe were pleased to see that the release cautioned patients to \u201ctalk to their doctor to determine whether this lower goal is best for their individual care.\u201d", "answer": 0}, {"article": "Xarelto already is approved for use by those with atrial fibrillation (irregular heartbeat) and by people who are having hip- or knee-replacement surgery.\n\"However, what is not reflected in the sponsor's analysis are minor bleeding events,\" FDA reviewer Dr. Karen Hicks wrote in the briefing documents.\nOf those patients, 136 had bleeding in the brain.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\n\"Carefully selecting patients for rivaroxaban therapy will be necessary to mitigate these bleeding risks.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No quantification of harms either \u2013 just vague \u201cincreased risk of potentially fatal bleeding.\u201d\nHow big a deal is this drug?\u00a0 The story never explains with any meaningful detail.\nThe story cites a talk at a recent conference that followed bleeding in patients in Xarelto or warfarin\u2026but never explained how many had bleeds on which drug \u2013 making the citation almost useless.", "answer": 0}, {"article": "\"They are a gateway out of smoking,\" says Etter.\n\"While ENDS may have the potential to benefit established adult smokers ... [they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures,\" says Tim McAfee, director the Office on Smoking and Health at the U.S. Centers for Disease Control and Prevention.\nBut others in the field of tobacco control disagree, stating that whilst people -- including youth -- may have tried e-cigarettes, the evidence is lacking for their regular use.\n\"The vast number of people using e-cigarettes are using them to stop smoking; [they're] about 60% more effective than going cold turkey or buying nicotine replacement therapy over the counter.\"\n\"[They may] expand their market to other customers who didn't use cigarettes but might consider nicotine use.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "On the harms possible from e-cigarettes, the story was not as thorough as it could have been. For example, there is a growing scientific literature on known harmful molecules in the vapor.\u00a0Nickel, for instance, is in some ENDS vapor and is known to be harmful in other inhaled scenarios. Concerns have also been raised about the quality of different brands of cartridges and the batteries used in some devices, which have in rare cases been reported to catch fire.\nBut we acknowledge that the story took the time to quote different experts by name and let them make their harms arguments, so we\u2019ll award a satisfactory rating. Jean-Francois Etter, professor of Public Health at the University of Geneva, urged people to see the benefit of e-cigarettes in cutting smoking as outweighing their harms. Another expert argues that while they may benefit adults who are trying to quit traditional smoking, \u201c[they] should not be used by youth and adult non-tobacco users because of the harmful effects of nicotine and other risk exposures. \u201d He adds that \u201cExposure to nicotine can harm adolescent brain development.\u201d", "answer": 1}, {"article": "The U.S. Preventive Services Task Force recommendations state that most women begin mammography at age 50.\nThe analysis was designed to look at new breast cancer screening guidelines from the American Cancer Society and the American Society of Breast Surgeons.\nBut the review of female patients between the ages of 40 and 44 found that 50 percent had an above-average risk for breast cancer, and therefore would be eligible to begin screening mammography at age 40, said lead researcher Dr. Jennifer Plichta.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\nSince the new guidelines lean heavily on knowing breast cancer risk, doctors need to redouble their efforts to make sure risk assessments are done for women in their early 40s, they concluded.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not discuss potential harms (outside of future breast cancer diagnosis) of women receiving a high score on the risk assessment. It is unfortunate because risk does not mean someone will absolutely get breast cancer and some women could receive false positive mammograms with attendant anxiety and risk of unnecessary follow-up tests and procedures.", "answer": 0}, {"article": "Primary pulmonary hypertension (PPH), a rare fatal lung disease, has been reported in patients who had taken a combination of phentermine and fenfluramine or dexfenfluramine for weight loss.\nSee Full Prescribing Information.\nThe limited usefulness of agents of this drug class (anorectics), including Lomaira, should be measured against possible risk factors inherent in their use.\nDosage should be individualized to obtain an adequate response with the lowest effective dose.\nThese are not all of the potential side effects of phentermine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release lists nine separate possible side effects of the use of the drug in question and then adds to that the statement that, \u201cThese are not all of the potential side effects of phentermine.\u201d\u00a0 It then offers seven additional paragraphs with cautions, contraindications and warnings pertaining to taking the drug, all under the heading of \u201cImportant Safety Information.\u201d\u00a0 Readers will at least be informed, if not alarmed, after reading.", "answer": 1}, {"article": "Accumulations of neurotoxic beta-amyloid protein can be detected with positron emission tomography, or PET scans, and analysis of cerebrospinal fluid, but these are invasive, inconvenient and costly, making them impractical for routine screening and follow-up evaluation.\nWith the imaging technology's ability to detect autofluorescence signal related to retinal beta-amyloid, these findings may lead to a practical approach for large-scale identification of the at-risk population and monitoring of Alzheimer's, the researchers say.\nThe article provides new insights into the disease's manifestations in the retina and information on the optical imaging system.\nThis clinical trial is reinforced by an in-depth exploration of the accumulation of beta-amyloid in the retina of Alzheimer's patients versus matched controls, and a comparison analysis between retina and brain pathologies.\nIn the new article, the researchers report on a 16-patient clinical trial to demonstrate the feasibility of identifying beta-amyloid in the eye using autofluorescence imaging.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is a reference to how other ways of detecting Alzheimer\u2019s are \u201cinvasive\u201d but there is nothing in the release about the possible harms associated with this diagnostic tool. A false-positive diagnosis of dementia or Alzheimer\u2019s would be one such harm.", "answer": 0}, {"article": "His spouse is the primary shareholder of Chapel Hill Doctors, which is an organization that was subcontracted by Wake Forest School of Medicine as a site for subject recruitment and treatment.\nWomen who had a reduction in their hot flashes saw a benefit beginning after about three to four weeks of weekly treatments.\u201d\n\nThe National Institutes of Health-funded study was designed to examine different patterns of responses to acupuncture.\nIn a study published in the Sept. 28 issue of the journal Menopause, scientists reported that about half the women in the study reduced the frequency of hot flashes, while half did not.\nOf the 170 women who received acupuncture, a small group of women (11.9 percent) had an 85 percent reduction in hot flashes by the eighth week of the study, Avis said.\n\u201cWomen bothered by hot flashes and night sweats may want to give acupuncture a try as a relatively low-cost, low-risk treatment,\u201d said Nancy Avis, Ph.D., lead author of the study and professor of Public Health Sciences at Wake Forest School of Medicine, a part of Wake Forest Baptist.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that 4 percent of study participants who received acupuncture actually had twice as many hot flashes (\u201ca 100 percent increase\u201d). That\u2019s good. The release also refers to acupuncture as \u201clow risk.\u201d But that doesn\u2019t mean no risk. According to the Mayo Clinic, acupuncture can cause soreness, minor bleeding or bruising \u2014 and that may be exacerbated for patients who are taking blood thinners. There are also more serious risks involved, particularly if an acupuncture therapist has not been properly trained. Those risks include infection and possible organ damage. Since the release explicitly says \u201cwomen bothered by hot flashes\u2026may want to give acupuncture a try,\u201d it is especially important to be up front about potential risks and the importance of finding a certified acupuncture practitioner (as well as where that certification should come from).", "answer": 0}, {"article": "Fish like salmon, herring and sardine are a common source of EPA-DHA, while ALA is found in vegetables including soybeans, flax seeds and walnuts.\nUnilever, whose margarine brands that contain omega-3 include Flora and I Can\u2019t Believe It\u2019s Not Butter, said the lack of benefit seen with EPA and DHA was surprising, considering the weight of evidence published to date.\n\u201cThe results indicate that more investigation is required into the efficacy of vegetable omega 3, but do not question the current authoritative dietary recommendations and advices for omega 3 intakes on which our products are based,\u201d the company said in a statement.\nDoctors, however, are unlikely to rush to change clinical practice.\nThe results of the study, which was supported by the Netherlands Heart Foundation, the National Institutes of Health, and Unilever, were also published in the New England Journal of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We always think harms should be addressed \u2013 even the absence of harms.\u00a0 Consumers need to be educated that no product making health claims is cost-free or harm-free.\u00a0 The story did not mention that there did not appear to be any differences among the various groups in terms of harms. \u00a0But since there were no differences, we\u2019ll simply rule this Not Applicable. ", "answer": 2}, {"article": "\"Many of the lifesaving drugs used in the treatment of heart attack patients work by inhibiting platelets and preventing blood clotting.\nThe serpent-medicine connection isn't new, one cardiologist noted, since venom typically kills by disrupting the blood's clotting mechanisms.\nThe snake's venom contains a protein called trowaglerix, the researchers explained.\nTHURSDAY, June 8, 2017 (HealthDay News) -- Scary pit vipers may need an image upgrade: Their venom might end up helping human heart patients, research suggests.\nStill, experiments in animals often don't translate to success in humans, so further research is needed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A source included a risk of blood thinners in general\u2013 that they can cause bleeding\u2013so the story gets a Satisfactory rating. But the story could have clarified that other potential harms are unknown at this point.", "answer": 1}, {"article": "Keep away from children.\nThere have been two clinical studies showing positive safety and effectiveness of the device in the increase of tear production completed with 145 aqueous deficient dry eye adult patients.\nThe direct clinical benefit of temporarily increasing tear production as a therapy for patients with dry eye disease was not assessed as part of these clinical trials.\nLast May, Allergan announced positive results from two pivotal trials for TrueTear\u2122 that showed an increase in tear production upon nasal neurostimulation in adults with aqueous tear deficiency.\nINDICATION \n\nTrueTear\u2122 provides a temporary increase in tear production during neurostimulation in adult patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We will give the release a satisfactory rating because it includes a list of adverse events and warns that there is no long term safety data. But the side effects are described only in percentages and there is no indication of the severity of the events. Other reports about the device indicate that the news release left out information about adverse events seen in other trials, as well as speculation about potential long term effects.\nAn article published in Clinical Ophthalmology, which describes an experiment that appears to be a precursor to \u201cStudy 2\u201d in the news release, describes three device-related adverse events, including one migraine headache in a patient with a history of migraines, along with two cases of nasal discomfort that lasted a day or two.\nAn article written by a doctor who said he tested the device reports that \u201cThe exact mechanism of action of OD-01 is still under investigation, because there is some suggestion that the device may produce long-term effects. One proposed mechanism is that neurostimulation works to kick-start the system through some form of lacrimal gland remodeling.\u201d Well, if use of the device could cause long term effects, including changes to the glands that produce tears, the release should have mentioned that potential.", "answer": 1}, {"article": "LONDON -- GlaxoSmithKline PLC said it has produced an effective bird-flu vaccine for humans and could begin producing the shots at year's end, leaving it to governments to decide whether to begin ordering the shots.\n\nGlaxo, the world's second-biggest drug maker by sales behind Pfizer Inc., called the findings a breakthrough but said it needs to gather additional data before it can answer several important questions, including how much of the vaccine it will be able to manufacture.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potentional harms of the vaccine.", "answer": 0}, {"article": "\u201cThere is a larger program we are putting into place.\u201d\nBYL719 plus fulvestrant cut risk of death or progression in those patients by an estimated 35 percent, Novartis said.\n\u201cThe results of SOLAR-1 are the most encouraging observed to date from a trial evaluating a PI3K inhibitor\u201d for patients with this kind of breast cancer, said Fabrice Andre, a professor at France\u2019s Institut Gustave Roussy.\n\u201cWe don\u2019t see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have the liver effects,\u201d he said.\nNovartis said earlier this year that this study, called SOLAR-1, of hormone receptor positive, HER2- breast cancer with mutations of the PIK3CA gene showed that YL719 helped patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article quotes the head of cancer drug development for Novartis as saying, \u201cWe don\u2019t see as much diarrhea, we do not have CNS (central nervous system) side effects, we do not have liver effects.\u201d\nWhat any of this means is not clear. As much diarrhea as compared to what? Were they expecting CNS or liver effects? Do other PI3K inhibitors have those side effects? None of that is spelled out.\nOnce again, we returned to the ESMO news release and abstract to learn more. This told us the most frequent side effects were hyperglycemia, nausea; decreased appetite and rash.", "answer": 0}, {"article": "\"This kind of training works no matter where you are in society.\"\nSherry L. Willis, the lead author of the study and a Pennsylvania State University professor of human development, said those who had the training also reported greater confidence in their ability to solve everyday problems, and this was especially true of the group that got the reasoning training.\nThe study did not indicate that mental training can hold off all cognitive decline permanently.\nIf anything, the study suggests, there is a bigger payoff to mental exercise, because the brief training sessions seemed to confer enormous benefits as many as five years later.\nAlthough it did not examine the effects of mental exercise on people who had begun to show signs of Alzheimer's or other brain disorders, previous studies have pointed toward the conclusion that anyone can benefit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of possible harms or comparisons of the harms between three cognitive training activities examined in this study.\u00a0 Perhaps there were none, but the story did not address the issue.\u00a0 The story included the example \"Knowing how to figure out directions and find a new route on a map, for example, could allow someone to retain mobility even after their night vision deteriorates\" though maintenance of this cognitive component might give someone false security about driving under conditions where they are physiologically not up to the tasks.", "answer": 0}, {"article": "He contended that kratom does not act on the brain's opioid receptors the way prescription painkillers and heroin do. But back in 2016, the Journal of the American Chemical Society reported that kratom indeed works this way. Last month, an FDA study found that 22 of the 25 of the most prevalent compounds in kratom do bind to opioid receptors, and so should be considered an opioid. The study also said most deaths did occur in people who used kratom in addition to other drugs, though in one case, only kratom was detected.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pushes back against misleading claims of safety and notes that kratom has been linked to at least 44 deaths. It also notes one confirmed instance of fatal kratom overdose, which contradicts one advocate\u2019s statement that \u201cyou can\u2019t take enough to hurt yourself.\u201d", "answer": 1}, {"article": "They didn\u2019t advise against using the devices.\nAt times, the devices malfunctioned, but other times, teens were careless or took risks, the study authors wrote.\nBut they called for more study to address safety concerns in teens and even younger children who use the popular pumps.\nThere were two possible suicide attempts by teens who gave themselves too much insulin, according to the analysis.\nIn the FDA study, appearing in the May issue of the journal Pediatrics, the reports of adverse events and deaths in adolescents using the pumps occurred from 1996 to 2005.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The overall focus of the original research and\u00a0this article was on the potential harms of insulin pump use by adolescents and the need to address safety concerns.\u00a0 Potential causes of adverse events related to patient use and education and device malfunction were appropriately described.\u00a0 This article could have been improved by including the importance of parental oversight in preventing adverse events, particularly since three of the five deaths occurred at times when there was no parental supervision.", "answer": 1}, {"article": "She recalled her boyfriend at the time searching the web for her diagnosis and saying: \u201cOh God, no.\u201d After that, she kept quiet about her diagnosis, worried it would drive friends away.\nIf there was a blood test for depression, it could just become part of a standard panel\u2014and thus help achieve earlier diagnoses, and in turn earlier treatment, across the board.\n\u201cAs the development costs of a test are very high, there is a risk that the test will not be commercially viable.\u201d For severe mental illnesses like schizophrenia, it\u2019s also the case that even if a test made it through development and hit the market, it may not be successfully integrated into psychiatric practice.\nThe uncertainty can lead to dangerous misdiagnoses.\nHaving this kind of tool would be invaluable\u2014with the current interview-based methods of diagnosis, subtle symptoms of schizophrenia are missed until too late, delaying treatment by months, or even years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no potential harms mentioned, and yet screening carries the potential for harm because of false positive and false negative rates that may lead to the wrong intervention.", "answer": 0}, {"article": "Aneurysms are weakening, or bulging, of blood vessels that can rupture and become life-threatening.\n\u201cPrior to gaining approval from the Food and Drug Administration, patients with many types of aneurysms and aortic conditions had limited treatment options,\u201d said Azizzadeh, director of Vascular Surgery at the Smidt Heart Institute at Cedars-Sinai.\n\u201cThis was a difficult surgery, but I knew I was in good hands,\u201d said Angelino, 85, of Culver City.\nCompared to other technologies, the stent graft can travel through smaller, curvy vessels and better adjust to a patient\u2019s anatomy.\n\u201cI feel very lucky to have benefited from this new and improved surgical technique and for the great doctors who cared for me.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms of the new procedure were mentioned. The lone patient who underwent the procedure called it \u201ca difficult surgery\u201d and anticipated feeling better after recovery but we\u2019re not told if the procedure was successful or how long recovery took.\nAs we\u2019ve written, minimally invasive is still invasive \u201cand thus pose potential harms associated with anesthesia, infection, and bleeding.\u201d", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070715/23knee.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article fails to mention the small but real risks of total knee replacement, which include blood clots in the leg and lungs, joint infections, and (rarely) death. Because of the risks, costs, and inconvenience of knee replacement, many people prefer nonsurgical remedies. While the story entertains the idea of knee replacement in younger people, such procedures are likely to require another operation during a person\u2019s lifetime \u2013 something not mentioned at all.\u00a0 \n", "answer": 0}, {"article": "The liquid is called silver diamine fluoride, or S.D.F.\nNow there\u2019s an alternative: an antimicrobial liquid that can be brushed on cavities to stop tooth decay \u2014 painlessly.\nBut studies show it can halt the progression of cavities and prevent them, and dentists are increasingly using it off-label for those purposes.\nIt\u2019s been used for decades in Japan, but it\u2019s been available in the United States, under the brand name Advantage Arrest, for just about a year.\nNobody looks forward to having a cavity drilled and filled by a dentist.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly discusses what is, by far, the most common side effect of SDF treatment \u2014 which is that the area of the tooth affected by the cavity becomes darkened after treatment. There are, however, other potential harms. A 2016 paper noted that 3 out of 1,493 patients in studies they reviewed developed \u201ca small, mildly painful white lesion in the mucosa,\u201d which disappeared after 48 hours. However, that\u2019s such a small effect size, that it\u2019s not clear whether the lesions were caused by SDF, so we don\u2019t fault this story for not mentioning it. There can be more significant adverse health effects if SDF is inhaled or swallowed \u2014 including respiratory problems, vomiting and diarrhea. But those effects are only relevant if SDF is not handled properly, so, again, we don\u2019t fault the story for not mentioning it.", "answer": 1}, {"article": "Blood and urine samples were taken from the children for analysis.\nAt this stage, the results presented are not strong enough to suggest that this method could be used for the diagnosis of autism.\nFor example, we don\u2019t know whether this technique can distinguish autism from ADHD, anxiety or other similar conditions.\nThey found the most reliable of the tests they developed was examining protein in blood plasma, which found children with ASD had higher levels of the oxidation marker dityrosine (DT) and certain sugar-modified compounds called advanced glycation end-products (AGEs).\nHowever, researchers believe their new tests could reveal yet-to-be-identified causes of ASD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although potential harms from blood or urine tests are quite minimal, the story suggests the research findings could lead to routine screening for autism.\nScreening tests are never completely benign; in particular \u2014 in this case \u2014 if a \u2018false positive\u2019 result led parents to believe their child had ASD when they did not \u2026 or \u2026 if a \u2018false negative\u2019 result offered false assurance that there was no ASD present.", "answer": 0}, {"article": "\"That makes for a powerful marketing advantage,\" Sullivan said.\nAll HSRx OTC drug products utilize natural ingredients in their formulations.\nAfter 24 hours treatment, the percentage of subjects with reduced acne count was 64% greater for those using HSRx 2121 than for subjects using the competing product.\nAfter 48 hours, the percentage of subjects with unsightly acne-associated redness was reduced nearly three times as much with HSRx 2121 as with the competing product.\nEach product is subjected to independently conducted clinical trials against a current market-leading product to demonstrate its ability to deliver superior treatment outcomes with reduced side effects.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not mentioned. Most OTC acne medications come with a warning to start slowly with small amounts until you know how your skin will react. Common side effects include dryness, redness, peeling, itching, burning, and rashes.", "answer": 0}, {"article": "In the U.K., women are advised not to drink at all during the first trimester of their pregnancy and to drink no more than a drink or two a week after that.\nIndeed, many of the women included in the \"light drinkers\" group had no more than a drink or two during their entire pregnancy.\nThe Kelly study appears in the Oct. 5 online issue of the Journal of Epidemiology and Community Health.\nMore than 11,500 children and their mothers were included in the study.\nMothers were first asked about their alcohol use when the kids were 9 months old.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to quantify the harms of drinking too much alcohol. The whole study was about whether alcohol harms kids, and this should have been quantified in some way.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThere are no previously approved therapies for TRAPS or HIDS/MKD.\nThe U.S. Food and Drug Administration today approved three new indications for Ilaris (canakinumab).\nIlaris was previously approved for another periodic fever syndrome called Cryopyrin-Associated Periodic Syndromes (CAPS) and for active systemic juvenile idiopathic arthritis.\nApprovals for the new indications were based on clinical studies, including safety, efficacy and pharmacokinetic data.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a discussion of harms warranting a borderline satisfactory rating. But the side effects information is similar to that found on product labeling \u2014 it follows the regulatory requirements concerning product labels \u2014 but provides no data on harms from the trials behind the drug\u2019s approval. It could have been more informative with a few more details.\u00a0 In addition, the information on harms appeared to be contradictory. One paragraph says common responses to the drug were minor reactions and susceptibility to colds; the next paragraph lists serious side effects.", "answer": 1}, {"article": "\u201cNow we know that electrical impulses to the olfactory bulb can provide a sense of smell \u2014 and that\u2019s encouraging.\u201d\n\nIn addition to Dr. Holbrook, authors on the International Forum of Allergy & Rhinology study include co-first author Sidharth V. Puram, MD, PhD, of Washington University School of Medicine, Reiner B.\n\u201cThe development of cochlear implants, for example, didn\u2019t really accelerate until someone placed an electrode in the cochlea of a patient and found that the patient heard a frequency of some type.\u201d\n\nSmell loss, or anosmia, has an estimated prevalence of 5 percent of the general population.\nIn the elderly, of whom there are estimates that greater than 50 percent of the population over the age of 65 has experienced smell loss, it can be difficult to get proper nutrition, as the sensation of flavor is closely tied to the sense of smell, and as flavor diminishes, appetite decreases in this population.\nThe findings described in the International Forum of Allergy & Rhinology report demonstrate this feasibility.\nThis breakthrough in human patients opens the door for a \u201ccochlear implant for the nose\u201d to be developed \u2014 though the study authors caution that the concept of an olfactory stimulator is more challenging than existing technologies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As with cost, it is far too early to create a laundry list of potential side effects associated with nerve stimulation to induce sensations of smell. However, there are things that could be said. For example, the study itself found that volunteers reported discomfort and occasional pain associated with the electrode stimulation. And the potential for inducing olfactory hallucination needs to be considered. \u00a0Dysosmia may be less desirable than anosmia.", "answer": 0}, {"article": "Symptoms of advanced Parkinson\u2019s disease include an impaired sense of balance, as well as tremors, poor mobility, slowness and stiffness.\nBergquist said he hoped the device could treat patients for whom the Levodopa drug, which turns into dopamine in the body and increases levels of the chemical, was not enough.\nAccording to the research institute, the experiments showed that the active noise stimulation improved both the patients\u2019 balance and the combined symptoms.\nThe research was led by Associate Professor Filip Bergquist, who said the simple device was similar to the TENS (Transcutaneous Electrical Nerve Stimulation) therapy which is used for pain relief, for example in child birth.\nThe plan is now for the device to be tested in a longer-term study, where patients will be using it at home.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms, though the study itself says that the intervention resulted in increased nausea in two patients.", "answer": 0}, {"article": "\"The band has a spotty history,\" Deveney said.\nThe procedure \"appears to result in relatively poor long-term outcomes,\" the researchers concluded.\nOne in six of the patients ended up deciding to have a gastric bypass procedure, and all of these patients demonstrated good outcomes following their subsequent surgery.\nThe current observations stem from a research effort led by Dr. Jacques Himpens, of the European School of Laparoscopic Surgery at the Saint Pierre University Hospital in Brussels, whose team assessed the status of 82 patients that had undergone the procedure known as \"laparoscopic adjustable gastric banding\" (LABG) more than a decade prior to the study launch.\n\"[I] therefore think patients will continue to ask for the procedure.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided quantitative information about the harms observed in the study population who had had gastric banding surgery. It says, \u201cHowever, 39 percent of the patients had experienced serious complications, including abnormal pouch expansion (9), band erosion (23) and band infection (1). Another 22 percent experienced relatively minor complications. Almost 50 percent had to have the bands entirely removed, while 60 percent needed to undergo subsequent surgery. The procedure \u201cappears to result in relatively poor long-term outcomes,\u201d the researchers concluded.\u201d", "answer": 1}, {"article": "After three months, seizure frequency declined by an average 45 percent in all participants.\nThis was in addition to their current drug therapy.\nAll participants in these studies knew they were taking the oil, which could have affected reports of its effectiveness.\n\"We don't know the real effect of the cannabidiol, and we won't until we complete the studies that are ongoing that are placebo-controlled and blinded,\" added Brooks-Kayal, who is also a professor of pediatrics, neurology and pharmaceutical sciences at the University of Colorado School of Medicine.\nCannabidiol is a major chemical component of marijuana, said Dr. Orrin Devinsky, a neurologist at NYU Langone Medical Center's Comprehensive Epilepsy Center in New York City and co-author of one of the studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The subheadline declares that \u201cdrug interactions remain a concern,\u201d and story includes reference to a study that found cannabidiol to interact \u201cbadly\u201d with anti-seizure medications currently approved for epilepsy treatment. It later specifies the drugs that may be affected. We think this nod in the direction of harms is sufficient for a Satisfactory rating, although we\u2019re concerned that the story mentions no other side effects from the treatment. A news release noted that \u201cAdverse events occurred in more than 10 percent of participants with the most common being somnolence, diarrhea and fatigue and led to discontinuation in 4 percent of patients.\u201d", "answer": 1}, {"article": "\"And that's exactly what's already underway, as we search for more aggressive and more successful treatments.\"\nHowever, the team did observe one appreciable difference: patients on gemcitabine were less likely to experience serious side effects as a result of their chemotherapy treatment than those on the fluorouracil/folinic acid treatment (7.5 percent versus 14 percent).\n\"In conclusion, gemcitabine did not result in improved overall survival compared with fluorouracil plus folinic acid in patients with [surgically removed] pancreatic cancer,\" the authors concluded in their report.\nThose who received fluorouracil and folinic acid chemotherapy had lived an average of 23 months.\nThe study authors noted that, currently, the prognosis for pancreatic cancer is very poor, with a five-year survival rate of less than 5 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms and tolerability are discussed, and the rates of serious side effects for each group are provided. Specific examples of those serious effects would\u2019ve been ideal, such as were provided in the JAMA editorial: \u201cmore stomatitis and diarrhea [were] observed in the fluorouracil and leucovorin group and more myelosuppression in the gemcitabine group.\u201d", "answer": 1}, {"article": "\u25a0 A woman who freezes eggs rather than embryos avoids potential custody problems if she and her partner split up.\nFreezing eggs now is no guarantee of a baby later.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\nShe owns her eggs, no question.\nIf you decide to try egg freezing, don\u2019t wait too long.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The sidebar has a list of bullets of \"things to consider before freezing your eggs\" that is, in essence, a list of potential harms. ", "answer": 1}, {"article": "A fourth drug, GlaxoSmithKline\u2019s and Biota Inc\u2019s Relenza, works by the same mechanism as Tamiflu.\nThere were some weaknesses in the study.\n\u201cTherapies for parainfluenza are urgently needed,\u201d Moscona, an expert on parainfluenza viruses, said in a statement.\nMoscona said tests were needed that would show the drug actually helped reduce disease symptoms in animals.\nThe rats were pre-treated with the drug an hour before they were infected with parainfluenza.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "       \n \nThe potential for harm is notably absent in the story. Now, the study design was such that toxicity could not be evaluated and as a  result it was not addressed in the publication. However, the story should\u00a0 have noted that the harms of the drug are unclear at the present time. \n ", "answer": 0}, {"article": "The American Society for Microbiology is the largest single life science society, composed of more than 30,000 scientists and health professionals.\nThe mice also functioned normally in tests for anxiety and motor function.\nComparing those profiles, the team found that in the treated cells, the virus triggered a strong antiviral response in the cells, which induced inflammation and eventually cell death.\nMice that got the ZIKV-LAV injected as well saw a significant delay in tumor development.\nCo-implanting the virus along with the GSCs also prolonged the median survival time of the treated mice to around 50 days, compared to around 30 days for the untreated mice who received GSCs alone.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that the treatment had \u201cno health effects on the mice, no weight loss, and no behavioral abnormalities such as loss of appetite, depression, lethargy, or self-injury. The mice also functioned normally in tests for anxiety and motor function.\u201d\nHowever, we interpret \u201charms\u201d to mean harms to humans. The release doesn\u2019t describe any potential harms to humans.", "answer": 0}, {"article": "Dr Weaver said: \"We have shown that all our patients in the study had their insulin doses reduced after taking metformin and have not suffered any serious adverse effect.\n\"For the first time, this study has shown metformin has additional benefit beyond improving diabetes control when given to patients with relatively well controlled Type 1 diabetes.\nExperts found that the stem cells of patients who took metformin were able to promote the repair of the blood vessels and there was an improvement in how vascular stem cells worked.\nHowever, for the first time, a clinical trial has revealed metformin can promote a patient's ability to repair their own damaged blood vessels by increasing vascular stem cells.\nMetformin may be used to lower Type 1 diabetic patients' risk of developing this complication.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of any side effects or harms to participants from the use of metformin, although a host of minor-to-moderate side effects\u00a0may be routinely seen with this drug. The research paper itself limits discussion of side effects to \u201cany major or severe episodes of hypoglycemia,\u201d which it defines as instances of low blood sugar \u201crequiring intervention of another person to resolve the event,\u201d or any episode of hypoglycemia \u201cresulting in a loss of consciousness.\u201d\u00a0Although none were reported, both instances seem substantively more serious than minor side effects. Gastrointestinal side effects, for example, are commonly reported by patients taking metformin. And there are some relatively commonly found metabolic adverse effects of metformin (metabolic acidosis) that could have been looked for to determine if there is an increased incidence in this \u2018vulnerable\u2019 group.", "answer": 0}, {"article": "Guidelines from the American Cancer Society and other organizations recommend that women age 30 and older are screened using Pap smears and tests for the human papillomavirus, or HPV.\n\u201cA woman should say, \u2018What screening tests are you doing on me?\u2019\u201d\n\nAnd if doctors want women to come back again next year, women should ask them why, Saraiya said.\nIn that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\nBut, he added, \u201ca single negative HPV test is very good at ruling out disease.\u201d\n\nEven when doctors use just a Pap test, Roland said, a woman who has had a few normal tests in a row can go two or three years before her next screening.\n\u201cSome of it is, don\u2019t go looking before you need to go looking because you\u2019ll find stuff that you\u2019d rather not find,\u201d said Castle, who was not involved in the new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job explaining that there can be harm from screening too often \u2013 something that often isn\u2019t explained in screening stories:\n\u201c\u2026any extra screening increases the chance of getting a \u201cfalse positive\u201d result on a test \u2014 meaning the test finds something that doesn\u2019t turn out to be cancer. In that case, women would need more invasive tests to rule out disease, Roland said, and risk \u201cundue harm\u201d from those procedures.\n\u201cSome of it is, don\u2019t go looking before you need to go looking because you\u2019ll find stuff that you\u2019d rather not find,\u201d said (one observer), who was not involved in the new study.", "answer": 1}, {"article": "GeneSight's test is covered by Medicare for patients under the care of psychiatrists and who have failed to achieve satisfactory results with at least one antidepressant. The company has coverage with some commercial payers and is working to widen that coverage, said Myriad Genetics spokesman Ron Rogers. The Genomind Genecept Assay is partly covered by Medicare and Medicaid. If the out-of-pocket cost for people with commercial plans is more than $300, Genomind will contact the client before processing the test. The company also has a financial assistance program for uninsured patients.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although harms from a cheek swab are unlikely there is a potential harm in framing the genetic testing results as guiding the choice of one antidepressant over another. Patients may focus solely on pharmaceutical options, to the exclusion of non-pharmaceutical ones.\nAntidepressants have well-documented side effects and drug interactions.", "answer": 0}, {"article": "Researchers said challenges in measuring the effectiveness of mammography screenings include increases in breast-cancer awareness and advances in treatment.\nThus, the relative reduction in mortality that was causally related to the screening program alone was 10 percent.\"\nThe publication notes that in 2002, the World Health Organization concluded that mammography screening for women between ages 50 and 69 reduced the death rate from breast cancer by 25 percent.\n\"Among women in the nonscreening group, there was an 18 percent reduction in the rate of death from breast cancer, as compared with the preceding 10-year period, presumably as a result of increased breast-cancer awareness, improved therapy, and the use of more sensitive diagnostic tools,\" the findings state.\nIt concluded the availability of mammography screening corresponded with a reduction in the rate of death from breast cancer, \"but the screening itself accounted for only about a third of the total reduction.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "The F.D.A.\nThe review for Medicare said there was insufficient evidence to judge whether Provenge would work if used off-label.\nThe analysis is part of a controversial review by the Centers for Medicare and Medicaid Services to determine whether to pay for Provenge, which costs $93,000 per patient and extended lives by about four months in clinical trials.\nBut the analysis for Medicare said that there were issues in how the trials were designed that made it difficult to assess how effective Provenge really was.\nSome analysts have assumed that Medicare will pay for Provenge when used for the patients specified in the drug\u2019s label \u2013 those with advanced prostate cancer that is resistant to hormone-deprivation therapy but who are experiencing no or minimal symptoms.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story does not mention harms. The clinical trials reported that patients treated with Provenge experienced infusion reactions and infections. The review for Medicare also noted that the FDA ordered further study of strokes in people who get Provenge.", "answer": 0}, {"article": "Laurie Fenton, president of the Lung Cancer Alliance, an advocacy group headquartered in Washington, said: \"We think this is a breakthrough for lung cancer.\nBut while the research clearly shows that the interval between diagnosis and death was longer in screened patients, it does not definitively show they lived longer -- a subtle difference with significant public health consequences.\nOthers, including researchers and policymakers in the government, say it is a question that will not be settled for five or six years, when other studies are complete.\nOf that group, 85 percent had small tumors that had not spread.\nUltimately, 535 were biopsied to see if they were lung cancer -- and 484 were.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that abnormal scans can lead to biopsies\u00a0and that the scans may pick up cancers that \"grow so slowly they will never pose a health problem.\"\u00a0 The story should have also mentioned radiation exposure as a potential harm and described the consequences of false positive test results.", "answer": 1}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nThe safety and efficacy of Dupixent were established in three placebo-controlled clinical trials with a total of 2,119 adult participants with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s).\nThe FDA granted the application for Dupixent Priority Review and Breakthrough Therapy designation.\nThe safety and efficacy of Dupixent have not been established in the treatment of asthma.\nOverall, participants who received Dupixent achieved greater response, defined as clear or almost clear skin, and experienced a reduction in itch after 16 weeks of treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gets an acceptable rating in this category since it mentions that the drug can cause serious allergic reactions and eye problems including conjunctivitis (pinkeye) and keratitis (inflammation of the cornea). It also cautions that people with asthma shouldn\u2019t use the drug since it hasn\u2019t been tested for safety in these patients.\nThe release should also have noted that regulators don\u2019t know if there are any long-term harms associated with Dupixent use. None of the trials exceeded 16 weeks.", "answer": 1}, {"article": "And tobacco kills one in 10 people worldwide, according to the World Health Organization.\nWhile the study shows that Chantix, which is known generically as varenicline, can be effective for some smokers, the group taking the pill also experienced more side effects such as nausea, abnormal dreams, insomnia, constipation, vomiting, and weight gain.\nThe U.S. Food and Drug Administration placed a black box warning - its most severe and restrictive warning - on the product in 2009, highlighting the drug\u2019s adverse neuropsychological effects.\n\u201cThis allows us to reach a much broader population of smokers who aren\u2019t willing to quit abruptly or set a quit date, and it shows that people can quit without going cold turkey,\u201d said lead study author Dr. Jon Ebbert, a professor in primary care and internal medicine at the Mayo Clinic in Rochester, Minnesota.\nOther treatments, such as nicotine patches and gum, can also help some smokers cut back gradually, she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends several paragraphs discussing potential side effects associated with Chantix \u2014 including the fact that the FDA has placed its black box warning on the drug in light of its possible neuropsychological effects. The story does not mention concerns related to possible cardiovascular health effects that were raised by the FDA in 2012.", "answer": 1}, {"article": "Finasteride blocks the conversion of testosterone to dihydrotestosterone, a hormone active mostly in the prostate and the scalp, and that all prostate cancers need to grow.\nAnd, he adds, the study did not look for a decline in death rates, and it is unlikely that any study ever will \u2014 it would take too long and be too expensive.\nWhile it might seem convoluted to offer a drug to prevent the consequences of overtreatment, that is the situation in the country today, others say.\nEven the effect on smaller tumors has important implications, said Dr. Ian M. Thompson, Jr., the study\u2019s principal researcher and a urologist at the University of Texas Health Science Center in San Antonio.\nWith this new analysis, many prostate cancer specialists, including Dr. Scardino, say their view of the drug has completely changed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did raise an important question about harms:\u00a0 \"Should healthy men take a drug for the rest of their lives to avoid getting and being treated for a cancer that, most often, would be better off undiscovered and untreated?Is it worth risking a chance that unanticipated side effects may emerge years later if millions of men with no prostate problems take this drug\u2026\"\u00a0 Although the balance of the story was out of whack \u2013 citing more proponents of using the drug than opponents \u2013 we\u2019ll give the story the benefit of the doubt on this criterion. ", "answer": 1}, {"article": "\"Our goal is to reach 100 percent.\"\nCompared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often.\nThat's why the American Cancer Society, which estimates there will be about 108,000 new cases of colon cancer and 40,700 new cases of rectal cancer this year, added the stool DNA test to its screening guidelines this spring.\nIt joins six other tests, including the traditional colonoscopy and the new CT colonography, or virtual colonoscopy.\nUnlike a traditional colonoscopy, one doesn't need to go through an extensive bowel cleaning through changes in diet and medication or take time off work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes a brief pass at discussing harms when it says: \"Compared to more invasive procedures, the test still might miss some polyps and cancers and may need to be repeated more often. If results are abnormal, a colonoscopy would still be required.\" But readers should be told how many cancers does the test miss (false negatives)? What is the rate of false positives\u2014and how many people will believe they have colon cancer, when in fact they don\u2019t? How many people will find themselves hospitalized with a serious complication caused by a follow-up confirmatory colonoscopy?\u00a0 ", "answer": 0}, {"article": "\"You start doing research on that type of tumor, and you're saying, 'Oh my God, you're history.'\nThe chemo failure was the latest in a string of personal setbacks.\nShe's been in the clinical trial for a year now, and continues to take Zelboraf (or vemurafenib generically) daily.\nThere are side effects, of course.\nMore doctors are taking advantage of the information to treat patients with a targeted approach.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article describes only one side effect of vemurafenib, the drug that targets the BRAF mutation in cancer. (\u201cShe\u2019s lost some peripheral vision, though she\u2019s been able to compensate.\u201d) However, the piece does link to the NIH-run MedlinePlus description of the drug, including a full list of side effects and other important information\u2013for a cursory online story, this is helpful and very responsible.", "answer": 1}, {"article": "We've had a lot of migrants from European nations, so they're fair-skinned ... and we do have a very intense sun here,\" Ziman said.\nIn turn people should talk to a health professional about any \"unusual or lasting changes to a mole, freckle or normal patch of skin.\"\n(CNN) Australian researchers have developed an experimental blood test they say is the first blood test capable of detecting melanoma -- an aggressive form of skin cancer -- in its early stages with a high degree of accuracy.\n\"We need to know how accurate it is, if it can save lives, and how it could work in practice.\nFor potential sufferers in remote areas, away from skin specialists, diagnosis can be especially tricky, he said, making a simple blood test an easy alternative to identify those at risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like many other stories about screening tests, the reader is not provided with any comments on the potential harms. Even with a 90% sensitivity and specificity (a high mark for such a test), there would be many\u00a0people with both false positive and false negative results. Read more about this issue in our primer:\u00a0Understanding medical tests: sensitivity, specificity, and positive predictive value\nThese cancers are frequently overdiagnosed, so a diagnostic test that finds a lot of low-risk cancers could be harmful by leading to overtreatment. Ideally, we want know that the test is leading to finding early-stage, high-risk cancers that require and would benefit from treatment.", "answer": 0}, {"article": "Suboxone works by taking the place of the opioids in the receptor - not only shutting off withdrawal symptoms but also blocking the effects of any new drugs.\nIt's an orange pill that's dissolved under the tongue.\nFor Brian, life now involves not only counseling and but a personal inventory as well.\n\"By the grace of God, I say it was a higher power.\nHas he had any use of prescription painkillers since he started the study?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The drug has considerable safety issues, yet the story didn\u2019t discuss any of them. ", "answer": 0}, {"article": "One in six American adults lives with high cholesterol, and millions have trouble getting it under control, according to the Centers for Disease Control and Prevention.\nNow, researchers believe a a new type of experimental drug may help change that.\nIn an editorial published along with the study, experts note that although the results are promising, more long-term research is needed to make definitive conclusions about the drug.\nResearchers analyzed 24 randomized control trials to assess the efficacy and safety of the new drugs, called PCSK9 antibodies, in adults with high cholesterol levels.\nThe results, published in the Annals of Internal Medicine, also show that the drugs have a significant effect on reducing heart attacks and overall mortality.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Every class of drugs has side effects, and there has been substantial concern about the possibility of neurocognitive side effects with this class of drugs. The fact that these drugs have to be injected under the skin could also potentially affect use and adherence to a medication regimen. We understand that this story is fewer than 300 words long, but there could have been a statement such as, \u201cMore study is needed to assess the potential side effects of this new class of drugs.\u201d", "answer": 0}, {"article": "But it\u2019s not proof,\u201d Broderick said.\nFurther, many practitioners think that newer clot-retrieving devices work better than the ones used in the three trials.\nWe wanted the superiority of endovascular treatment.\u201d\n\nWhether the findings will cause physicians to abandon the practice is uncertain.\nThe three studies reported this week (which will eventually be published in the New England Journal of Medicine) tested the hypothesis in a rigorous way.\nOne study took eight years to complete because it was so difficult to enroll patients willing to take the chance that they would be randomly assigned to get the older treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only mention of harm was this:\n\u201cmany practitioners think that newer clot-retrieving devices work better than the ones used in the three trials. Because endovascular procedures were shown to be no more dangerous than IV thrombolytics, physicians may continue to perform them and assume the outcomes can only get better.\u201d\nSince no benefit was seen with the invasive clot retrieving devices, we would have liked to have seen some additional information on the adverse events directly related to the placement of the device.", "answer": 0}, {"article": "You've seen high-definition televisions. Now some medical centers are marketing their high-definitioncolonoscopes, which they say will detect more pre-cancerous polyps. Several recent studies have found a small benefit to high-definition colonoscopy over the standard variety, but gastroenterologists say physician technique is more important in detecting polyps than equipment.\n\nColonoscopy, a screening test doctors recommend for most people starting at age 50, allows doctors to remove pre-cancerous growths before they become...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Something missing from the studies mentioned were any sort of placebo controls or comparisons to alternative screening techniques. Too much screening can lead to unnecessary surgeries that have their own risks. The story does say, \"the additional polyps found may result in more biopsies, raising costs.\" But it should have also talked about the potential downsides of screening and any potentail side effects from undergoing this procedure.", "answer": 0}, {"article": "Sonata uses a probe that is inserted through the cervix into the uterus. The probe not only allows the doctor to see the fibroid using ultrasound, but it also has a radio-frequency device at the tip. The doctor hits a foot pedal to send energy through the probe to heat the fibroid, shrinking it over time. The body absorbs the dead tissue, so it does not have to be surgically removed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Sonata is in the midst of an ongoing phase\u00a0II\u00a0clinical trial, designed to assess both effectiveness and safety of the procedure. But the story still makes a good effort to address risks and related concerns. For example, the story states that \u201csuch minimally invasive procedures require a lot of skill to perform safely\u201d and quotes an expert as saying \u201cYou need a really experienced surgeon\u2026.Will it translate to the average ob/gyn?\u201d In addition, the story notes that, while uterine fibroids are rarely malignant, in a small number of cases they can be cancerous \u2014 and \u201cbecause tissue is not removed with the Sonata method, it cannot be biopsied.\u201d\nWith a little more digging, the reporter might have found the Gynecological Surgery paper mentioned above. In that trial of 50 patients, there were 34 \u201cadverse events.\u201d Most were not severe, but incorporating some of that information would have made the story even stronger.", "answer": 1}, {"article": "Previous research has also suggested that fructans stimulate the growth of beneficial bacteria in the large intestine in a way that increases the body's absorption of minerals, including calcium and magnesium, which are needed for bone growth.\nBut drinking tequila won't help, the study authors noted.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\nThe National Osteoporosis Foundation has more about osteoporosis prevention.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not a word about potential harms.\u00a0 ", "answer": 0}, {"article": "Women are also more likely to experience a condition known as left bundle branch block, a pattern of disorganized electrical impulses that responds well when the left side of the heart is treated with a pacemaker.\n\u201cThis was far greater than expected.\nThe device also included a defibrillator used to shock dangerous heart beats back into normal rhythm.\n\u201cWe think this is the first (study) to show this.\u201d\n\nMoss said women have often been overlooked in studies of heart disease, which until recently were dominated by men.\n\u201cWe found there was a dramatic reduction not only in heart failure events, but a very dramatic reduction in death from any cause,\u201d Moss said in a telephone interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from the use of the device.", "answer": 0}, {"article": "When a hip bone breaks because of osteoporosis, the fracture usually involves either the ball at the top of the femur or the narrow neck just below the ball.\nThat's obviously a lot more benefit than risk.\nStill, the accumulating evidence that there is a risk of these serious, unusual fractures associated with bisphosphonates is getting a lot of attention in the medical community.\nFor instance, they started out with a history of more fractures, so the comparison isn't valid.\nThe idea is that perhaps they'd get the osteoporosis benefit without the risks of osteonecrosis and unusual fractures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "NPR does a good job of parsing the harm described in the JAMA article. Extra credit for including the notion of a \u201cdrug holiday\u201d that is a practical reaction from treating physicians to a confusing landscape of discoveries about these drugs.", "answer": 1}, {"article": "Bipolar disorder effects around 1 percent of the population worldwide and sufferers can experience moods that swing from one extreme to another, and have periods of depression and mania lasting several weeks or longer.\n\u201cIn mice, ebselen works like lithium,\u201d Churchill said.\nBut it is very toxic - at only twice the right dose it could kill a patient, Churchill said - and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\n\u201cNow we urgently need to see if it works like lithium in people.\u201d\n\nSome 60 years after it was first discovered, lithium - a mood stabiliser that can protect against both depression and mania, and reduce the risk of suicide - remains the most effective long-term treatment.\nChurchill worked with Sridhar Vasudevan to filter through a library of existing drugs - the U.S. National Institutes of Health Clinical Collection - that are considered safe but do not currently have a proven use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the side effects from lithium, saying, for example, \u201cBut it is very toxic \u2013 at only twice the right dose it could kill a patient, Churchill said \u2013 and its adverse side-effects mean many people stop taking the drug and relapse into episodes of mania and depression.\u201d We\u2019d rather have hard data \u2013 e.g., if 100 or 1,000 people with bipolar disorder took lithium for five years, how many would be expected to die from lithium toxicity?\u201d\nWe would have liked to have seen some side effect information for ebselen. Instead, the story states that the drug \u201cmay be a swift answer\u2026since it is already known to be safe.\u201d Data, please?", "answer": 0}, {"article": "Suits against tobacco companies have sought to force cigarette makers to pay for annual CT screens of former smokers.\nBut with the science uncertain, those claims have so far been rebuffed.\nBut Dr. Peter B. Bach, a pulmonologist at Memorial Sloan-Kettering Cancer Center in New York, said no one should rush out and get a CT scan yet because further analysis will better define whom the screening helped.\nHad the screening continued for 10 years, as many as 80 percent of lung cancer deaths could have been averted, she said.\n\u201cWhat we also have found is that low-dose CT scan gives information on cardiovascular disease, emphysema\u201d and other pulmonary diseases, Dr. Henschke said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe final paragraph of the story points out that there is a risk of harms from the radiation used for the CT scans and that the scans cause false positives and may lead to tests and treatments done on people who actually don\u2019t have dangerous tumors. We wish some attempt had been made to quantify these harms \u2013 even if it meant drawing from past research \u2013 but we\u2019ll give the story the benefit of the doubt.\n", "answer": 1}, {"article": "In 2016, he was ranked the No.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\nThe results released today from a randomized trial of a novel plaque identifying toothpaste, (Plaque HD\u00ae), show statistically significant reductions in dental plaque and inflammation throughout the body.\nIn addition, the product's proprietary formulation contains unique combinations and concentrations of cleaning agents that weaken the core of the plaque structure to help the subject visualize and more effectively remove the plaque.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms. While regular toothpastes come with a standard warning to keep away from young children and to avoid ingesting, we aren\u2019t told if the disclosing agents used in Plaque HD\u2019s \u201cTargetol technology\u201d pose any additional harms for people with sensitivity or mouth problems. It would be good to be told either way.", "answer": 0}, {"article": "\"The first time those three letters were uttered in a group setting, everyone's like, 'Oooo, that's scary, do we want to do that?'\nSo some scientists believe that by playing this game \u2014 Project Evo \u2014 you can improve a range of cognitive skills and, by extension, relieve a range of symptoms associated with cognitive disorders.\nHere, Ehlers touches on a broader controversy around games like Project Evo.\nIf the FDA gives its stamp of approval, doctors could prescribe the game.\nIn fact, the creators believe their game will be so effective it might one day reduce or replace the drugs kids take for ADHD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms. There is strong debate about whether recreational video games affect social development or behavior. Such games certainly can displace physical activity\u2026 playing outdoors\u2026 that is important to the health of children in particular. The story would have been better if it at least mentioned that video games may not be entirely benign.", "answer": 0}, {"article": "The new research, reported Oct. 10 in the journal Nature Communications, was led by Charles Brenner, PhD, professor and Roy J.\nThe study showed for the first time that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose.\n\"NAD+ is an abundant metabolite and it is sometimes hard to see the needle move on levels of abundant metabolites.\n\"Now that we have demonstrated safety in this small clinical trial, we are in a position to find out if the health benefits that we have seen in animals can be reproduced in people,\" says Brenner, who also is co-director of the Obesity Research and Education Initiative, professor of internal medicine, and a member of the Fraternal Order of Eagles Diabetes Research Center at the UI.\nThe next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults, but Brenner also has plans to test the effects of NR in people with diseases and health conditions, including elevated cholesterol, obesity and diabetes, and people at risk for chemotherapeutic peripheral neuropathy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are addressed. The news release said there were \u201cno serious side effects with any of the doses,\u201d though there were four cases of potential flushing we address under quality of evidence. But it should have pointed out that no safety data exists on long-term use. Nor is there data on the impact of taking this supplement along with other medications or in greater amounts than the tested doses. Also, the people in this study were all healthy, so it\u2019s unclear what impact this substance might have on people with health conditions. That\u2019s an important point since the researchers plan to study NR\u2019s effects on elevated cholesterol, obesity and diabetes as well as people at risk for chemotherapeutic peripheral neuropathy.\u00a0 Also, just because something occurs naturally in the human body doesn\u2019t mean it\u2019s safe.", "answer": 0}, {"article": "The combination of Yervoy and the newer Opdivo also reduced the risk of disease progression by 60 percent compared with Yervoy alone through 11 months of follow-up in previously untreated patients with advanced melanoma, researchers found.\nTwenty-two percent of those combination patients had a complete response, meaning no sign of tumor.\nBut after 11 months, more than half of the combination group had yet to see their disease worsen.\n\u201cThe response rates and the depth of responses are quite impressive,\u201d Dr. Stephen Hodi, director of the Melanoma Center at Dana-Farber Cancer Institute and co-lead author of the study, said in an interview.\nThat compared with 1 percent overall response rate and no complete responses for Yervoy alone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes, \u201cThe combination of the two drugs also led to far higher levels of side effects, such as colitis and inflammation of lung tissue, at 54 percent versus 24 percent for Yervoy alone. Patients were also more likely to stop taking the combination of drugs.\u201d\u00a0 That is useful information but a bit incomplete.\u00a0 The numbers reflect the percentage of patients who suffered grade 3 and 4 side effects and not just colitis and lung inflammation. \u00a0But the story missed the most significant potential harm of all: death. As the paper itself notes, out of fewer than 100 patients who received the drug combination, \u201cThree deaths were related to the combination therapy according to investigator assessment.\u201d That\u2019s worth mentioning.", "answer": 0}, {"article": "Dr. John Richmond disagrees.\n\"We have an epidemic of osteoarthritis of the knee and we have limited treatment options,\" says Dr. Richmond, who was not affiliated with the analysis but who reviewed the same data it was based on.\nDr. Richmond, who has independently reviewed the same research when the AAOS was drafting their recommendations to treat osteoarthritis of the knee, argues that despite infrequent instances of those side-effects, viscosupplementation remains a solid treatment choice for some patients.\nThe researchers in Switzerland reviewed the existing studies and concluded that viscosupplementation was associated with an increase in these and other adverse events.\n\"This is most effective in relatively younger patients, 40 to 50 to 60 year olds, and...in people with mild to moderate forms of the disease,\" says Richmond.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, the story states that the meta-analysis found \u201cpotential for harm.\u201d\u00a0 Further, it reported:\nThe most common side effects patients undergoing\u00a0viscosupplementation\u00a0may endure are flare-ups \u2013\u00a0 where the knee becomes hot and swollen within 24 hours after the injection \u2013 and effusions, where excessive joint fluid collects inside the knee.\u00a0 The researchers in\u00a0Switzerland reviewed the existing studies and\u00a0concluded\u00a0that\u00a0viscosupplementation was associated with an increase in these and other adverse events.\nBut there was no description of how often this was seen \u2013 making the issue almost useless to readers. Is it 1 in 100 patients?\u00a0 10 in 100?\u00a0 50 in 100?", "answer": 0}, {"article": "\u201cWe have the therapy.\nGao did not always believe the drug would ever make it out of the laboratory, because the field of gene therapy has been plagued with seemingly insurmountable obstacles, including the deaths of test subjects.\nAAVs are not quite as efficient as adenoviruses at getting genes into human cells, but they are much safer: The human immune system barely notices the virus\u2019s outer coat or \u201cdress,\u201d as Gao calls it.\nRegulators in the U.S. and Europe were highly skeptical of the safety and efficacy of such treatments.\nAt the time, only one gene therapy had been commercially approved in the world: a cancer drug in China.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This one is difficult to evaluate, since most of the current research relates only to animal studies. However, early in the story, the writer reflects on the well-publicized death of a clinical trial participant in 1999 that brought gene therapy trials to an abrupt halt in the United States.\u00a0 Other passages in the story also suggest caution,\u00a0as does a source later in the story, who notes that risk accompanies many therapies. These details are sufficient to indicate there could be significant harms if these methods move into human testing, and that\u2019s enough to rate as Satisfactory. However, it could have been made clearer that researchers\u00a0really don\u2019t know the harms yet.", "answer": 1}, {"article": ".\nShe and others say they know of no other physician in the Washington area who favors the radial approach.\nA member of the Institute of Medicine and a director of the Association of American Medical Colleges, Longnecker said he had never seen catheterization performed in this manner, and few of his physician friends who are not cardiologists had heard of it.\nThey are most common, Shah said, in \"little old ladies,\" who tend to have small arteries that can clamp shut.\nThe femoral artery, approximately the width of a pinkie, presents a direct route to the heart; to a physician, it's a straight stretch of freeway that can be navigated easily.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that arterial spasms tops the list of complications with this procedure and indicated that it was particularly problematic in \"little old ladies.\"\u00a0 Beyond this, the story did not give the reader any idea of how common this sort of problem was, making it difficult for readers to evaluate.", "answer": 0}, {"article": "UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.\nThe more than 50 participants in the study were divided into two groups, one of which received two years of supervised exercise training and the other group, a control group, which participated in yoga and balance training.\nPrevious studies from Dr. Levine's research program have shown substantial improvements in cardiac compliance in young individuals after a year of training, but surprisingly little change if the training was started after age 65.\nHowever, the researchers also found that the heart chamber in competitive masters-level athletes remains large and elastic, and that even four to five days of committed exercise over decades is enough for noncompetitive athletes to reap most of this benefit.\nIn the current study, researchers wanted to know if exercise can restore the heart's elasticity in previously sedentary individuals - especially if begun in late middle age.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does an excellent job of outlining the exercise regime employed in the study. However, it does not mention that the study specifically recruited subjects between the ages of 45 \u2013 64 who were sedentary. Given that one of the exercise sessions recommended in the study focuses on high-intensity interval training (HIIT) \u2014 and such training does come with potential risks for deconditioned individuals \u2014 it might have been advisable to mention that supervision for HIIT training should be strongly considered.", "answer": 0}, {"article": "It needs to be tested in large trials,\" he said.\nIn the 30 days after the procedure, 0.7 percent of the patients who had clots removed suffered a stroke, as did 0.3 percent of those who only had angioplasty, Jolly's team found.\nRemoving clots appears to have increased the risk of stroke in the month after clots were removed, the Canadian researchers report.\nFor the study, Jolly and colleagues randomly assigned 10,732 patients undergoing an angioplasty after a heart attack to have clots manually removed or to not have them removed.\nAmong all the patients, 6.9 percent who had clots removed, and 7 percent of those who didn't, died, had another heart attack or developed heart failure in the 180 days after the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story clearly states that there is no apparent benefit for clot removal and that there is some increased occurrence of strokes with the procedure. The absolute percentage of subjects who had a stroke in each group is also provided, so readers get a very clear picture of how often this occurs and the difference between the groups.", "answer": 1}, {"article": "Jan. 4, 2013 -- A new study from Australia may offer a new way of identifying people at risk of glaucoma years before vision loss happens.\nBut they added that blood pressure and other factors that can contribute to vessel size would need to be considered.\n\u201cWe call this disease a \u2018thief of vision\u2019 because most people with it have no idea that they have lost sight until it is too late to bring it back,\u201d Iwach says.\nThose with the narrowest vessels at the beginning of the study were four times more likely to have developed glaucoma a decade later.\nNone of the participants had glaucoma when they entered the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 There wasn\u2019t any discussion of potential harms and we can\u2019t think of any \u2013 besides the obvious one of unnecessary glaucoma screening in some cases.", "answer": 2}, {"article": "For more information, see www.scripps.edu.\nThe antibiotic has been prescribed by doctors for 60 years, and bacteria are only now developing resistance to it.\nThe next step in this research is to design a way to synthesize the modified vancomycin using fewer steps in the lab, as the current method takes 30 steps.\nEven if they found a solution to one of those, the organisms would still be killed by the other two.\u201d\n\nTested against Enterococci bacteria, the new version of vancomycin killed both vancomycin-resistant Enterococci and the original forms of Enterococci.\nThe original form of vancomycin is an ideal starting place for developing better antibiotics.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As noted above, the modified vancomycin hasn\u2019t been tested in human trials. As such, it\u2019s not clear what the potential harms may be. The release doesn\u2019t mention this. And there will almost certainly be potential harms, given that conventional vancomycin has a range of potential side effects, from nausea and diarrhea to kidney damage. Could risk of these potential harms decrease if the modified vancomycin can be used in smaller doses to address bacterial infection? If so, that\u2019s something the release could have addressed.\nWe also understand that some side effects would we a trade-off people might be willing to accept if it turns out the drug could prevent death or painful treatments that can come with an overwhelming bacterial infection. ", "answer": 0}, {"article": "Gestational diabetes increases the mother\u2019s chances for high blood pressure disorders of pregnancy and the need for cesarean delivery, and the risk for cardiovascular disease and type 2 diabetes later in life.\nAccording to the authors, comparatively few studies have examined whether the HbA1c test could help identify the risk for gestational diabetes, and these studies have been limited to women already at high risk for the condition.\nThe test is not currently recommended to diagnose gestational diabetes at any point in pregnancy.\nThe test approximates the average blood glucose levels over the previous 2 or 3 months, based on the amount of glucose that has accumulated on the surface of red blood cells.\nSimilarly, research is needed to determine whether lowering HbA1c with lifestyle changes, either in early pregnancy or before pregnancy, could reduce the risk for the condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The blood test itself is virtually harmless, and overall fairly reliable, but results can be skewed by a variety of unrelated diseases and lifestyle factors, resulting in false positives and negatives.", "answer": 0}, {"article": "The disease, transmitted through infected blood, can lead to liver cancer, scarring of the liver, known as cirrhosis, and death.\nThe greater possibility of a cure and fewer side effects, in turn, will lead more people who think they have hepatitis C to \"come out of the woodwork,\" said Schiff, who's familiar with the study findings.\nStill, the drug -- or others like it in development -- could add to the power of new drugs in the pipeline that are poised to cure many more people with hepatitis C, said Dr. Eugene R. Schiff, director of the University of Miami's Center for Liver Diseases.\nThe side effects, particularly of the treatment component known as interferon, can be \"pretty hard to deal with,\" said Nicholas A. Meanwell, a co-author of the study and a researcher with the Bristol-Myers Squibb pharmaceutical company.\nCombination treatments using these drugs will become the standard treatment for many people, he said, and boost cure rates into the range of 70 to 80 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the main side effect of BMS-790052 in early testing was headache. But considering that this was a phase 1 study designed primarily to collect information about drug safety, we think it\u2019s unfortunate that the story chose to emphasize a secondary test result \u2013reduction in viral load \u2014 and downplay potential safety issues.\u00a0\nThere is also no discussion of the potential harms associated with the\u00a0other experimental drugs that the story suggested would help treat\u00a0hepatitis C. If a story is going to pass long claims that unapproved drugs are\u00a0going to cure hepatitis\u00a0C, we feel it also needs to\u00a0provide\u00a0the full picture of the harms these treatments may entail. \u00a0", "answer": 0}, {"article": ".\nUsing an incision originally designed for another purpose, surgeons can gain direct access to the nerves involved in some types of chronic temporal headache, according to the report by ASPS Member Surgeon Dr. Ziv M. Peled of Peled Plastic Surgery, San Francisco.\nBefore and after surgery, headache symptoms were assessed using a standard score, the Migraine Headache Index (MHI).\nDeveloped by plastic surgeons who noticed that some migraine patients had fewer headaches after cosmetic forehead-lift, these procedures address \"trigger sites\" linked to certain headache patterns.\nHe comments, \"This is a straightforward technique and effective procedure that may make it easier for plastic surgeons to adopt and offer surgical options for patients with this debilitating condition.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release stated that \u201cNone of the patients experienced complications, and there was little or no visible scarring.\u201d\u00a0But the published study noted that neurapraxia (a temporary loss of nerve function) lasting several weeks was a risk. Although none of the 19 patients experienced complications, it would have nevertheless been helpful to describe possible risks in the news release. \nMost interventions carry risks, and the Gillies incision used in this procedure is no exception. Complications from the procedure could result in injuries to the wall of the eye and cosmetic deformities, as well as limitations in jaw movement.", "answer": 0}, {"article": "Research on a bacterial toxin first discovered in Adelaide has led to the development a new blood test for the early diagnosis of ovarian cancer - a disease which kills over 1000 Australian women and 150,000 globally each year.\nA paper published this month in Biochemical and Biophysical Research Communications has shown that the new test detected significant levels of the cancer glycan in blood samples from over 90% of women with stage 1 ovarian cancer and in 100% of samples from later stages of the disease, but not in any of the samples from healthy controls.\n\"Ovarian cancer is notoriously difficult to detect in its early stages, when there are more options for treatment and survival rates are better.\nThe team has now engineered a harmless portion of the toxin to enhance its specificity for the cancer glycan and used this to detect it in blood samples from women with ovarian cancer.\nProfessor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, said: \"Detection of this tumour marker may also play a role in a simple liquid biopsy to monitor disease stage and treatment.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As is so often the case with news releases about cancer screening tests, what usually gets highlighted is the sensitivity; in this case, that early stage cancers resulted in a positive test 90% of the time.\nBut what\u2019s not highlighted \u2014 and can cause significant emotional harm \u2014 is that 10% of the time\u00a0the test will be negative in someone who has cancer. That \u201cfalse-negative\u201d result provides false reassurance that there\u2019s no cancer present. In addition, there may be a small number of\u00a0\u201cfalse-positive\u201d tests leading to inappropriate procedures. Readers need to know how often false positive results occur with the test, and that\u2019s something a small study such as this can\u2019t confidently address.", "answer": 0}, {"article": "\"These are children who could have died from a teaspoon of milk before,\" Wood said.\nAfter about 10 months, all seven children on the placebo were still allergic, whereas none of the 13 on the peanut powder had reactions when they were challenged.\nAll the children are now receiving the treatment and are being followed to see if they remain desensitized and perhaps become \"tolerant,\" meaning they no longer need to consume daily doses of peanuts or peanut protein to maintain their ability to eat peanuts freely.\nFour of the children had to drop out because of allergic reactions, but six of nine children who underwent the treatment for 2 1/2 years have been able to stop the peanut powder and have now gone six to eight months without reacting to eating peanuts.\nThe researchers are tracking the remaining children in the study to see if any others achieve similar results and have followed up with a more stringent study in which 13 children received a similar treatment and seven received a placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that 4 individuals in a study of 33 had to withdraw from the study due to allergic reaction.\u00a0 \nThere was also a strong word of caution to readers NOT to try desensitization on their own. \u00a0 ", "answer": 1}, {"article": "Like ASA on Facebook, follow ASALifeline on Twitter and use the hashtag #ANES16.\n\u201cPostpartum depression can develop from a number of things including hormonal changes, psychological adjustment to motherhood, social support, and a history of psychiatric disorders.\u201d\n\nLabor pain may be more problematic for some women than others, the authors note.\nAdditional research is needed to identify which women are more likely to experience severe labor pain and who would benefit the most from effective labor pain-control strategies to help reduce the risk and affect of pain on postpartum recovery.\n\u201cWe found that certain women who experience good pain relief from epidural analgesia are less likely to exhibit depressive symptoms in the postpartum period.\u201d\n\nThe researchers controlled for factors already known to increase the risk for postpartum depression, including pre-existing depression and anxiety, as well as post-delivery pain caused by tissue trauma during childbirth.\nNewswise \u2014 CHICAGO \u2013 Epidural anesthesia may do more than relieve pain during labor; in some women it may decrease the likelihood of postpartum depression, suggests a preliminary study presented at the ANESTHESIOLOGY\u00ae 2016 annual meeting.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not told about any of the risks of epidurals.Those risks include a drop in blood pressure (which can complicate an otherwise normal pregnancy), severe headache (in less than 1% of women), slowing of labor due to lying on one side for too long (unless a \u201cwalking\u201d epidural is used, though the procedure is rare), shivering, backache, ringing of the ears, nausea, trouble urinating, and the increased likelihood of interventions like forceps and cesarean section (since it can be harder to push). Epidurals also require a catheter to drain urine, which significantly increase the risk of urinary tract infections.", "answer": 0}, {"article": "There was, however, a 70 percent reduction in chlamydia infections and cases of syphilis decreased by 73 percent.\nLike Molina and his co-authors, they said STI preventive use at this point is premature.\nBut such a strategy, which was tested in a population of men who had frequent unprotected sex with a number of male sex partners, could spark a controversy over the use of antibiotics and the general threat of growing antibiotic resistance.\n\u201cMy message with that study would be that we need to do more research to prevent STIs \u2014 because that\u2019s a concern.\nThe authors noted, however, that the study length was short and they can\u2019t tell if the strategy would work as well over the long term.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The body of the story spells out many of the potential harms, but the story would have been stronger if warnings had been included in the headline and lead paragraphs. The headline refers to \u201craising tough new questions\u201d and the second sentence in the story says the strategy \u201ccould spark a controversy.\u201d The potential harms would have been clearer to readers if the headline and lead had bluntly stated that routine use of doxycycline could undermine the effectiveness of antibiotics for a range of infections, not just the sexually transmitted diseases these researchers looked at.", "answer": 1}, {"article": "Probiotics are widely used to aid digestion and help restore gut bacterial balance after antibiotics.\nBut some researchers are investigating the beneficial bugs for conditions that have nothing to do with the digestive tract.\nThey are live microorganisms\u2014or \"good\" bacteria\u2014that when consumed in capsules or yogurt are said to confer a health benefit.\nOne of the fastest-growing dietary supplements, probiotics are now prominent on drug and big-box store shelves.\nPhoto: AP.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that probiotics are generally considered safe except for individuals with a compromised immune system. That\u2019s accurate.", "answer": 1}, {"article": "It's a barrier between enamel and the soft tissue that contains all the blood vessels and cells,\" Celiz explained.\nIf successful, a treatment like this could someday offer significant benefits for millions of dental patients each year.\nThough the work is still in its early stages, and has not yet been tested in people, the scientists won an award from the Royal Society of Chemistry for their idea: regenerative dental fillings.\nInstead of the current dental materials used on fillings, which are toxic to cells, the new approach harnesses stem cells instead.\nThe stem cell procedure is in the earliest stages of development, said Celiz.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential for risks when using stem cells to grow dental tissue.\u00a0As with many reports on new research, this story suffers from its optimism. \u00a0The new material has been tested in cell cultures and has yet to even make it to an animal model, so predicting harms is difficult but it is easy to come up with some concerns: Will this material be as durable as existing fillers? Has the material been tested for long-term safety? If the material fails, how will that impact a subsequent root canal? \u00a0Clearly these questions cannot be answered but\u00a0we think that any good story should point out the unknowns and not just the potential positives.", "answer": 0}, {"article": "More than half of the 35 million people living with HIV worldwide are women, and the vast majority live in sub-Saharan Africa.\nThese age differences are probably due in part to how the women used the drug, the researchers say.\nBut it\u2019s now known that, when taken properly, Truvada cuts new cases of HIV by at least 92%.\nOne of the new studies, published today in the New England Journal of Medicine, tested the ring in more than 2,600 women in four countries \u2014 Malawi, SouthAfrica, Uganda, and Zimbabwe \u2014 over nearly two years.\n\u201cA prevention tool like a ring could be used discreetly, a woman would have control over it, and it could allow her to keep herself safe from HIV without having to ask a male partner to take on prevention strategies,\u201d Baeten said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We would have liked to see some mention of whether there might be any harms associated with this. It is possible that long-term use might pose risks that don\u2019t show up in shorter studies. The story does not even say, \u201cWe don\u2019t know of any harms.\u201d", "answer": 0}, {"article": "Side effects of dopamine agonists can include euphoria, hallucinations, weight loss, nausea, insomnia, tiredness or weakness, dizziness and drowsiness.\n\"Up to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit,\" he noted.\n\"These are the only treatments approved by the [U.S. Food and Drug Administration],\" he added.\n\"Physicians and patients now have better information on the effectiveness and harms of two types of drug treatments for patients with at least moderately severe restless legs symptoms in which to guide treatment choices,\" said review author Dr. Timothy Wilt, core investigator at the Minneapolis VA Health Care System.\nThe report was published in the March 4 online issue of JAMA Internal Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists adverse effects commonly seen with both classes of medication discussed in the story. It adds, \u201cUp to 25 to 50 percent with even moderate to severe and longstanding symptoms stop taking these medications after more than a year due to either side effects or lack of benefit.\u201d", "answer": 1}, {"article": "Traditionally, highly sensitized patients in need of a kidney have languished on waiting lists because it's so hard to find a compatible donor.\nThose patients were all successfully treated with standard anti-rejection drugs, according to the researchers.\nResearchers found that the treatment -- dubbed IdeS -- quickly wiped out the dangerous antibodies, allowing all but one of 25 patients to have a successful transplant.\nIdeS patients still received additional treatment -- including a week of immune globulin and rituximab infusions.\nIdeS is still experimental, and the only way patients could receive it is through a clinical trial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article makes clear the patients were \u201csuccessfully treated\u201d if sensitizing antibodies returned, it does not give any information about side effects, from the enzyme infusion nor the anti-rejection drugs subsequently used.", "answer": 0}, {"article": "As a baker, he buys flour in 50 pound sacks.\nBut here's the challenge: How can people be motivated to eat healthier and move more?\nThat's promising, because there's evidence that a 7 percent body weight loss cuts the risk of developing diabetes by about 60 percent.\nAfter all, pulling off these changes is difficult\n\n\"I'm still on the journey to get to more optimal, health\" says Lonny Northrup, who lives in Utah.\nNot every Omada Health participant makes the progress they're aiming for.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not consider potential harms of the program, but because they do seem relatively minor, we\u2019ll rate this N/A.\nThings we did ponder related to risks of using the app: The study results implied that 25% of participants dropped out, but readers are not told why. Was following the program too difficult or not specific enough? Will this be simply one way for people trying to lose weight to fail and give up on improving their health? Do people get any portion of their money back if things don\u2019t work out?", "answer": 2}, {"article": "\"I hear a lot of moms say, 'I'm disappointed I had to have a C-section.'\nBetsey Snow of Anne Arundel Medical Center says the family-centered C-section represents a cultural shift, and her hospital is helping break new ground by adopting it.\nCamann says the gentle C-section is not a replacement for a vaginal birth; it's just a way to improve the surgical experience.\nWithout hard scientific data on outcomes and other concerns like infection control, many hospitals may be wary of changing their routines.\nShe says she'd like nothing more than to know that other women having C-sections are able to have the same amazing experience she had.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story did not address specific harms per se, it did mention that there was a lack of clinical studies on this topic \u2013 implying that nobody really understands the potential risks of this approach compared to a typical C-section. The piece also pointed out that infection control is a potential concern with family-centered C-sections, and that hospitals would be slow to change their routines without hard evidence on infection rates. We think that\u2019s enough to merit a satisfactory rating here.", "answer": 1}, {"article": "J Natl Cancer Inst.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\nMARLBOROUGH, Mass., April 26, 2016 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced that study results published today in a research letter in JAMA conclude that breast tomosynthesis (Hologic's Genius\u2122 3D MAMMOGRAPHY\u2122) exams reduce recall rates, and increase invasive cancer detection in women with both dense and nondense breasts.\nGenius\u2122 3D MAMMOGRAPHY\u2122 exams have been available in the U.S. since 2011, and are only available on the Hologic Selenia\u00ae Dimensions\u00ae mammography system.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There were no explanations of potential harms of integrating 3D mammography\u00a0into current breast cancer detection or that this technology does not appear to benefit women with extremely dense breasts. It is unclear if this technology could result in false positives (over-diagnosis) or what the negative predictive value of the test is (the probability that subjects with a negative screening test don\u2019t actually have the disease).\nIf these tests lead to over-diagnosis then women face the harms (and costs) of unnecessary treatment.", "answer": 0}, {"article": "Last year 61.5m prescriptions for antidepressants were issued in England.\nThat means that patients are tried on a succession of different drugs for 12 weeks or more and experience prolonged periods of ineffective treatment because their medication does not benefit them.\n\u201cSuch a finding and a test to back it up would be critical to advancing our understanding of the biological causes of depression.\nResearchers focused on two independent clinical groups of depressed patients on two biological markers that measure inflammation of the blood, as heightened levels are associated with poor response to antidepressants.\nCurrently it is impossible to establish who should or should not be given antidepressants, or combinations of them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions no potential harms. However, as with all screening tests, false-positive and false-negative results can be harmful in a number of ways.", "answer": 0}, {"article": "Pulses become more intense when arteries near the heart are worn down -- usually by lifestyle factors such as poor diet and drug use -- and can no longer \"cushion\" the blood flow coming from the heart.\nIf the findings are confirmed by larger studies, they could vastly improve the ability to detect dementia in middle age.\nThe test, which analyzes the pulse of blood vessels in the neck, could become part of routine testing for cognitive decline, according to the study by scientists at University College London (UCL), who presented their work Sunday at the American Heart Association's annual scientific conference.\nThe study's findings have been met with cautious optimism by dementia organizations.\nMore research is needed to determine whether neck scans should become a part of routine testing for dementia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The biggest risk with a screening test like this is incorrect results\u2013false positives and false negatives, which the story never explains. There is significant harm that can result if a person thinks they are at high risk of dementia when they aren\u2019t, or thinks they\u2019re at low-risk when they\u2019re high risk. These are otherwise known as a test\u2019s\u00a0sensitivity and specificity and they should have been discussed, especially how these unknowns will guide next steps for future research.", "answer": 0}, {"article": "Parkinson's disease is a degenerative condition that affects the central nervous system.\nThere are no harmful effects from berry consumption, and they lower the risk of hypertension too,\" Gao added.\nBut, berries are protective in both men and women,\" said the study's lead author, Dr. Xiang Gao, a research scientist at the Harvard School of Public Health and an associate epidemiologist at Harvard Medical School and Brigham and Women's Hospital in Boston.\nGao said it's not clear if there's a biological mechanism causing these differences, or another factor.\nAlso, recollections of dietary intake may be faulty, and it's possible that other properties of fruits and vegetables might have influenced the results, the authors said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends most of its time discussing the potential health benefits of berries. We\u2019re not aware of any harm attributable to berry consumption (provided they are the edible kind).\nAnd the story included this quote from the author:\n\u201cThere are no harmful effects from berry consumption, and they lower the risk of hypertension too,\u201d Gao added.", "answer": 1}, {"article": "'How exactly AIM2 does both of these functions is an exciting research area to pursue.'\n'However, our work is the first to identify AIM2's role in controlling proliferation of intestinal stem cells.\nShe said that the findings could have important applications for prevention, prognosis and treatment.\nHowever, AIM2's established function in the cell was not in the machinery of cancer, said one of the paper's first authors Si Ming Man, Ph.D., a postdoctoral fellow in Kanneganti's laboratory.\n'Since reduced AIM2 activity in colorectal cancer patients is associated with poor survival, it might be useful to detect the level of AIM2 expression in polyps taken from colonoscopy and use this as one of the biomarkers for prognosis,' Kanneganti said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This work is so far removed from clinical use in human subjects that it may be difficult to adequately assess potential risks for human patients. However, as noted above, the release does mention interferon treatment and transferring \u201cgood\u201d bacteria populations into human patients. Every treatment carries some risks, and those are worth discussing.\nThe human digestive system is awash in colonies of different bacteria, all striving to maintain dominance in their environment.\u00a0 An imbalance between these different strains can cause a host of intestinal problems ranging from simple discomfort to life-threatening conditions.\u00a0 The release\u2019s cavalier mention of possibly transferring \u201cgood bacteria\u201d does readers an injustice by ignoring risks.\u00a0 While fecal transplants have shown some success in early research, they do carry substantial risks, and while some colon cancer patients may be willing to accept that risk, the release should at least mention that it exists.", "answer": 0}, {"article": "Bleier said the device, which consists of a lead wire and a neurostimulator the size of a stopwatch, is implanted on top of a buttock muscle. Patients don't feel it when they sit down and you can't see its imprint under a tight pair of pants. Patients can try the stimulation for two weeks with the pacemaker outside the body before deciding whether to have it implanted, an outpatient procedure. Medicare pays about $21,500 for the device and treatment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned for either of the newer brand-name approaches mentioned \u2013 the drug Solesta or the device InterStim.\nThe Solesta website states:\nThe most common risks of treatment with SOLESTA are mild pain or discomfort in the rectum or anus, (experienced by about 27 out of 100 patients) and minor bleeding or spotting from the rectum following treatment (experienced by about 16 out of 100 patients). Some patients experienced a fever (7 out of 100), abdominal pain (3 out of 100), or diarrhea or constipation (6 out of 100) after treatment.\nMore serious risks including infection and inflammation of the tissues in the anus may occur, but these are not common. In clinical studies, about 4 of 100 subjects experienced infection and 3 of 100 subjects experienced inflammation.\nMedtronic\u2019s InterStim website states:\nThe InterStim Therapy system has risks similar to any surgical procedure, including swelling, bruising, and bleeding. Complications can include pain at the implant site, new pain, infection, lead (thin wire) movement, technical or device problems, undesirable changes in urinary or bowel function, and uncomfortable stimulation. Any of these situations may require additional surgery or cause your symptoms to return.", "answer": 0}, {"article": "But the F.D.A.\nBy contrast, he said by e-mail, Asclera \u201cis very safe for skin.\u201d\n\nAn injector\u2019s experience matters, because if the injection misses the vein, (or open sores) can occur.\nBut doctors say they should: these veins are not just a cosmetic problem, but can also lead to aches, pain, and heaviness from blood pooling in the legs.\nDr. Min said in an e-mail message that foam sclerotherapy was \u201cvery safe,\u201d but that \u201cit is associated with higher risks than liquid sclerotherapy.\u201d Foam injections have been blamed as the cause of blood clots in leg veins, he wrote, adding that one known stroke \u201cmay have been caused by foam sclerotherapy.\u201d\n\nBut foam sclerotherapy has been a big relief for some patients.\nVein specialists must first figure out which patients would benefit from sclerotherapy alone, and which need inner varicose veins treated before injections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t get specific as to how often harms should be expected with the various treatments discussed, but\u00a0it does mention some of the more common problems that can occur, including recurrence of the varicose vein or\u00a0the creation of new\u00a0varicose veins in the same area. Still, the story goes to significant\u00a0lengths to make readers think this is a benign procedure (including\u00a0a quote about one patient\u00a0feeling a \"a little tiny pinch\"), when long-term consequences of superficial vein ablation on risks of deep vein issues such as clots are unknown.\u00a0\u00a0Overall, because the story didn\u2019t give any sense of the scope of the problems \u2013 how often someone considering the various approaches may experience harms if they do \u2013 we must rule this unsatisfactory. ", "answer": 0}, {"article": "\"We have found the same thing with all of our trials.\"\nBoth the authors and other weight-loss experts were quick to note that the new findings did not answer the question of what is the best way for most people to shed weight.\nAll the participants reported eating about 2,000 calories a day when the study began.\nA careful read of the study shows \"no significant difference in weight loss between the Atkins and Ornish or LEARN diets after one year!\"\nAll also reported having cut their intake -- some by as much as 500 calories per day at two to six months -- but then gradually adding back many of those calories.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned a concern with the Atkins diet that it would result in increased LDL cholesterol but that the study did not find this to be the case.\nThe article on which the story was based reported on the reasons people did not complete the study; there were no serious medical harms found.", "answer": 1}, {"article": "Researchers at Brigham and Women's Hospital and Harvard Medical School set out to test melatonin's effects...\nWhat was lacking was clear evidence that taking melatonin in supplement form had the same sleep-inducing effect.\nDo melatonin supplements really help people sleep?\nThat's why there's so much interest in a study in the current issue of the journal Sleep.\nThere's no question that the hormone helps the brain tell a.m. from p.m.--regulating sleep cycles and circadian timing--when it is produced naturally by the body at night.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms from the use of melatonin were mentioned. (It may be problematic for those taking warfarin or individuals with epilepsy.)", "answer": 0}, {"article": "Unlike a heart attack, which happens when blood flow to a portion of the heart is blocked, cardiac arrest occurs when the heart\u2019s electrical system malfunctions, often due to irregular heart rhythms.\nThe study is observational and doesn\u2019t prove bystander CPR increases survival odds, the authors note in Circulation.\nThe biggest obstacle to bystander CPR remains that too few people know how to do it, said Dr. Peter Pons, an emergency physician in Denver and professor emeritus at the University of Colorado School of Medicine.\n\u201cIt is generally thought that the sooner this is implemented the better,\u201d Jacobs, who wasn\u2019t involved in the study, added by email.\n\u201cClearly, if someone has been motivated to learn and has been taught CPR, they will often assist,\u201d Pons, who wasn\u2019t involved in the study, said by email.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention studied here involves a last-ditch emergency effort to revive a person who is dying. There are some potential harms if the resuscitated person survives, and the story didn\u2019t mention those, but given the measured approach of this story and the nature of the research, we feel this one is N/A.", "answer": 2}, {"article": "DOI: 10.4172/2155-6105.1000290 \n\nhttp://www.\nHuman trials have reported no significant adverse respiratory effects associated with e-cigarette use for up to 1.5 years and a follow-up study of smokers with asthma who switched to vaping found significant improvements.\nThis is because smoking increases susceptibility to respiratory infections and stopping smoking can be expected to have a positive effect.\nIn addition to this, vaping may also provide some antimicrobial protection through the e-liquid ingredient propylene glycol, though further evidence is needed to confirm this.\nSome previous cell and animal studies have been interpreted as suggesting that vaping may increase vulnerability to infection, but these studies did not use realistic exposure levels.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release quotes a researcher saying it\u2019s \u201cmisinformation\u201d to tell smokers that vaping is dangerous. That\u2019s just not true. E-cigarettes contain nicotine, which can harm fetuses and adversely affect brain development. They also contain a host of other chemicals, including some potential carcinogens and lung irritants, which have not been adequately studied. The relative amount of harm from vaping versus smoking remains uncertain.", "answer": 0}, {"article": "Please use our search feature and update your bookmarks. Thank you!", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the only significant adverse event for those on estriol was irregular menses. It could have gone into more detail, perhaps, but this passes muster. The point is that estriol is essentially a weak form of estrogen that has been shown in previous studies to be fairly safe, and whatever risks exist are likely outweighed by benefits in women with MS.", "answer": 1}, {"article": "MDMA is believed to raise levels of the feel-good brain chemical serotonin and the so-called \"bonding hormone,\" oxytocin.\nConducting a study with an illegal drug is a complex process.\n(All of the participants received additional therapy sessions that did not involve the drug.)\nDon't try this experiment at home.\nThe others took a placebo but received the same therapy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It does not quantify the potential harms. It does, at least, mention a few of the dangerous effects of the drug. \"Don\u2019t try this experiment at home. Ecstasy use can cause depression, severe anxiety, and potential cognitive problems, according to the National Institute on Drug Abuse. And when purchased on the street it can be contaminated.\" The possibility of an overdose would have been a nice mention.", "answer": 0}, {"article": "The arms, thighs, abdomen, breasts, all lose texture and sag.\nBecause the surgery is still relatively new, there are few studies of complication rates.\nA small study published in January in the Annals of Plastic Surgery showed 27 percent of patients in one practice had complications including wound infections, fluid collections called seromas, collections of blood under the skin called hematomas and death of fat cells.\nWhile the surgical techniques used in contouring operations have been around for decades, bariatric patients present \"a unique challenge\" to plastic surgeons, says D'Amico.\nLast year more than 68,000 patients underwent body contouring after bariatric surgery, 77 percent more than five years ago, according to the American Society of Plastic Surgeons.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article details what are described as \u201chuge scars\u201d after surgery, along with \u201ca long and painful recovery\u201d. Contouring is described as \u201criskier\u201d and \u201crequiring longer recovery time\u201d than bariatric surgery, though again \u2013 there was no quantification provided. The artilce mentions that some patients will have revision done to improve upon the original contouring procedures. Again, no data were given on how common this really is, other than to say that it, in the view of one plastic surgeon, it has \u201cdramatically increased\u201d.", "answer": 0}, {"article": "However, contrary to the popularly held belief that a greater number of concussions are linked to CTE , no connection was found between levels of CCL11 and reported number of concussions.\nBut one of the biggest obstacles in understanding CTE has been the inability to diagnose it in the living.\nAn early step in the right direction\n\nMcKee also cautioned that this is still early research.\n\"The findings of this study are the early steps toward identifying CTE during life.\nNew research released Tuesday may make that possible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If a story is going to speculate about the potential clinical benefits of a new research finding (and this one does), the story should also discuss the harms. It\u2019s worth pointing out, for example, that any test such as\u00a0this would produce false-positive and false-negative results. Such results could cause unnecessary concern and anxiety and perhaps the loss of a lucrative career \u2014 or false reassurance that nothing is wrong when a degenerative process is underway.", "answer": 0}, {"article": "The findings are published in TheJournal of the American Medical Association.\nThe new study findings suggest Lexapro can provide an option for women reluctant to take hormone therapy.\n''We believe escitalopram provides an option for treating moderate to severe hot flashes that are disrupting people's lives and quality of life,\" says study researcher Ellen Freeman, PhD, a research professor in the department of obstetrics-gynecology and psychiatry at the University of Pennsylvania School of Medicine, Philadelphia.\nJan. 18, 2011 -- Low doses of the antidepressant Lexapro (escitalopram) cooled off hot flashes better than placebo in about 200 menopausal women, according to a new study.\nIn the study, Freeman found the antidepressant reduced both the number and severity of hot flashes compared to placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story wasn\u2019t thorough enough in its exploration of potential harms. The only adverse effect noted is the potential loss of libido discussed in the last line of the story. At one point, the story seems to dismiss the\u00a0potential for harm by noting that\u00a0 \u201cno serious adverse events were reported\u201d in the study.\u00a0However, minor adverse effects take on greater importance when a drug provides only a modest benefit over placebo \u2014 which is the case with this medication.\u00a0The study should have provided more detail on what harms were observed (even \u201cminor\u201d ones), and how frequently. Lexapro, when used for depression, commonly results in gastrointestinal disturbance such as nausea, vomiting, loose stools, and indigestion. A variety of\u00a0other adverse effects are possible, including include difficulty sleeping and headaches. It is quite conceivable that an increase in these\u00a0problems might outweigh the small benefit associated with the reduction in hot flashes, so the story\u00a0should have provided this information.\nAnother issue not addressed by the story is the potential for uncomfortable withdrawal symptoms when stopping this medication. This point is particularly relevant to make here because Lexapro hasn\u2019t been extensively studied in women who are healthy and don\u2019t have symptoms of depression. We know that some people with depression experience withdrawal symptoms after they stop taking the drug, but we don\u2019t\u00a0have much evidence on what happens to healthy non-depressed people when they stop taking it.\u00a0The risk of a discontinuation syndrome increases the longer\u00a0antidepressant therapy lasts, so an 8-week study may not capture the problems that women\u00a0may experience with longer-term use of Lexapro for relief of hot flash symptoms. The story could have mentioned that\u00a0women should never abruptly stop taking an antidepressant\u00a0medication like Lexapro, as this can increase the risk of\u00a0more severe withdrawal symptoms.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The concept of \u201charm\u201d does not appear to be relevant here. Individuals may find text messages to be annoying, of course, but the study itself notes that participants \u201coverwhelmingly\u201d reacted positively to the intervention. That doesn\u2019t make it into the story.", "answer": 2}, {"article": "\"What we are developing, and a lot of other companies too, are small molecule antiviral agents that specifically target the virus.\"\nA unique thing about the NS5A-targeting drug, according to Meanwell, is that laboratory studies show it to be effective against all HCV genotypes.\nBut the study provides the first clinical evidence that targeting the HCV protein NS5A may be an effective strategy for curing patients who are chronically infected with the HCV virus, says Nicholas A. Meanwell, PhD, who is executive director of chemistry with Bristol-Myers Squibb.\nThe research is so early that the drug hasn't been named.\nIn preliminary research published this week in Nature, researchers from Bristol-Myers Squibb -- the maker of the drug -- report that patients who took the drug showed dramatic reductions in viral load while exhibiting few side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says study participants who took the drug exhibited \"few side effects.\" But what were those side effects and how serious were they?\u00a0The story doesn\u2019t say. While the implication here is that the drug seems to be safe \u2014 a conclusion that we can\u2019t really draw based on a small, early phase test \u2014 the story does include a\u00a0cautionary quote from an expert about the need for additional testing to demonstrate safety.\u00a0It also noted that patients taking this drug might still need to be treated with interferon, which many individuals can\u2019t tolerate because of side effects. A close one, but we\u2019ll call it satisfactory.\u00a0\u00a0", "answer": 1}, {"article": "For more details and to read the full study, please visit the For The Media website.\nSix months after treatment, the YAG group reported significantly greater improvement in self-reported floater-related visual disturbance (54 percent) compared with sham controls (9 percent).\nA total of 19 patients (53 percent) in the YAG laser group reported significantly or completely improved symptoms vs 0 individuals in the sham group.\nChirag P. Shah, M.D., M.P.H., and Jeffrey S. Heier, M.D., of the Ophthalmic Consultants of Boston, randomly assigned 52 patients (52 eyes) to receive YAG laser vitreolysis (n = 36) in one session or a sham (placebo) laser treatment (control; n = 16).\nTo place an electronic embedded link to this article in your story Link will be live at the embargo time: http://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2017.2388\n\nPatients reported improvement in symptoms of eye floaters after treatment with a laser, according to a study published by JAMA Ophthalmology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in the release. Laser treatment can produce such irritants as \u201cdry eye\u201d and temporary visual halos, and a small number of patients have experienced increased eye pressure and the development of cataracts. These harms are apparently rare, but they deserve attention. The published study noted that there were few adverse effects and they were minor, but that the small sample size and length of follow-up were not adequate to make any firm statement about harms.", "answer": 0}, {"article": "In its statement, the panel said that \"for some adults ages 76 to 85, the benefits of screening are smaller, and the potential for harm greater.\nAll of the recommendations are specific to symptom-free people 50 years of age or older with an average risk colorectal cancer, the panel stressed.\nThere are varying amounts of proof supporting the effectiveness of each, and each method has its advantages and limitations, the panelists said.\nPeople with disorders or medical histories that raise their odds for colon cancer may need more rigorous screening, the USPSTF said.\nThis year about 134,000 people in the country will be diagnosed with the disease, and about 49,000 will die from it., the panel said\n\nThe USPSTF is an independent, volunteer panel of experts that makes recommendations about the effectiveness of specific preventive health services.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story should have mentioned some of the potential harms of screening, ranging from anxiety over a worrisome result to bleeding, colon perforation, sedation-related events and other problems. Also, since the story specifically included comments lauding colonoscopy, it should have also mentioned that colonoscopy accounts for most of the serious harms caused by colon cancer screening.", "answer": 0}, {"article": "For most people, \"the lower your blood pressure, the better you are.\nShe stressed that the study results should not be viewed as license to gorge on chocolate.\nUniversity of Cologne researcher Dr. Dirk Taubert, the study's lead author, said the blood pressure reductions with dark chocolate were small but still substantial enough to potentially reduce cardiovascular disease risks, although study volunteers weren't followed long enough to measure that effect.\nThe research involved just 44 people aged 56 through 73, but the results echo other small studies of cocoa-containing foods.\nIn the journal, none of the researchers report financial ties to any chocolate companies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although not explicit, this piece did allude to weight gain as a potential problem with advocating consumption of chocolate.\u00a0 It could have mentioned that with the portion of dark chocolate used in the study, no weight gain was seen during the 18 weeks of study.", "answer": 1}, {"article": "\u201cThe increased levels of testosterone explain the greater reported sexual satisfaction,\u201d he said.\nScientists at the University of Siena in Italy found that regular, early-morning use of a light box \u2013 similar to those used to combat Seasonal Affective Disorder or SAD - helped men increase testosterone and improved their sex lives.\nAndrea Fagiolini, a professor who led the study and presented it at the European College of Neuropsychopharmacology conference in Vienna on Monday, said the treatment may prove useful during the Northern hemisphere\u2019s darker winter months.\nLONDON (Reuters) - Exposure to bright light can raise testosterone levels and lead to greater sexual satisfaction in men with low sexual desire, according to the results of a small scientific trial.\nAfter taking baseline readings, they divided the men into two groups and gave one regular treatment with a bright light box, while the control, or placebo, group was treated with a light box adapted to give out significantly less light.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t mention any potential risks. Light therapy is generally safe, according to the Mayo Clinic, but mild side effects could include eyestrain, headaches, nausea, irritability, and agitation. Light therapy poses special risks for people with certain medical conditions or on medications such as antibiotics that can cause skin or eyes to be sensitive to light, and it can trigger mania in people with bipolar disorder.", "answer": 0}, {"article": ".\nResults of the technique, called deep transcranial magnetic stimulation (dTMS), will be presented Sunday at ENDO 2017, the Endocrine Society's 99th annual meeting in Orlando, Fla.\nUnlike deep brain stimulation, dTMS does not need an operation or implantation of electrodes.\nCurrently approved in the U.S. for treating major depression, dTMS is being studied in some countries for the treatment of other neuropsychiatric disorders, especially addiction.\nORLANDO--A new study finds that a noninvasive electromagnetic brain stimulation technique helps obese people lose weight, partly by changing the composition of their intestinal bacteria--the so-called gut microbiota.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Specific risks are not discussed, though it\u2019s mentioned that dTMS is currently approved in the U.S. for treating major depression and is being studied in other countries for treating neuropsychiatric disorders. Unlike deep brain stimulation, this technique does not require an operation or implantation of electrodes, so we can deduce that the potential harms are lower than other neurostimulation procedures. Nevertheless, a brief\u00a0mention of harms would give readers a sense of the risk-benefit balance should dTMS rise in popularity and availability in the coming years.", "answer": 0}, {"article": "Being around for my daughter, my son, my wife.\nSandoval is alive today because of an experimental form of immunotherapy called CAR-T.\nAbout eight months after a single treatment, 39 percent of patients had no evidence of cancer.\nNormally, our immune cells are good at killing invaders like bacteria but bad at fighting cancer.\n\u201cThat\u2019s actually quite remarkable knowing that at best only one out of 10 of these patients could have complete disappearance of their lymphoma with standard chemotherapy,\u201d Locke said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give this story a barely satisfactory rating because it does report that there were treatment-related deaths and side effects\u00a0including \u201cflu-like symptoms and confusion.\u201d But no other numbers or side effects are mentioned\u2013though there were many more\u2013and the story doesn\u2019t elaborate that CAR-T therapy can be fraught with unpredictable\u00a0problems.\u00a0Interviewing a patient who experienced these problems would have made the story more reflective of the true experience of receiving CAR-T.", "answer": 1}, {"article": "Surgery also typically involves significant breast tissue damage and disfigurement due to large incisions and removal of sizable breast mass.\nWe are confident that the ICE3 trial can prove certain women can be successfully treated less aggressively than in the past.\n\"There is growing awareness treatment should be based on individual tumor biology.\n\"For older patients the risks associated with invasive procedures and general anesthesia as well as the discomfort of long recoveries also makes this procedure particularly desirable.\nPotentially, it will usher in a new and gentler pathway for the treatment of a disease that affects one in every eight women annually.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The most we get is that patients felt \u201cminimal discomfort.\u201d But could ICE3 leave cancerous tissue behind without a clinician knowing? And are there any other side effects? We aren\u2019t told, and this seems strange given that the \u201ccosmetic\u201d benefits are so well-known and touted so frequently in the text. The National Cancer Institute does describe a few potential harms of cryoablation (which they classify as a type of cryosurgery), including hemorrhaging and bad interactions with chemotherapy. These probably should be mentioned in the release.", "answer": 0}, {"article": "Have a question?\nThat seems to be the same conclusion that other studies have drawn \u2014 the flu vaccine is modestly helpful, and doesn't hurt.\nOn the other hand, the evidence suggests that there's no harm in getting a flu shot, either.\nSo, as this Cochrane review notes, it's impossible to draw firm conclusions on the effectiveness of the flu vaccine for those over 65 because the data is so biased and poor.\nBeyond public health measures (making sure you have good hand hygiene and avoiding the office when you're sick), the flu shot is the best medical intervention we have for preventing infection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that the risks of negative reactions to getting a flu shot usually center on inflammation at the site of the injection, a comparatively minor side effect.\u00a0 It emphasizes that given such a minimal risk, there are very few harms for getting this protection, minimal though it may be in some years.", "answer": 1}, {"article": "Zinc lozenges appear to influence the common cold through the release of free zinc ions into the oro-pharyngeal region.\nBecause of the somewhat stronger binding, zinc gluconate has been proposed to be less suitable constituent for lozenges.\nNevertheless, he also considers that \"the current evidence of efficacy for zinc lozenges is so strong that common cold patients should be encouraged to try them for treating their colds, but the patients should ascertain that the lozenges do not contain citric acid or its salt citrate.\"\nPreviously zinc lozenges containing citric acid were shown to be ineffective in treating colds because citric acid binds zinc ions very tightly and no free zinc is released.\nAlthough the binding difference between zinc acetate and zinc gluconate is a fact, it is not evident whether that causes significant differences at the clinical level for treating the common cold.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release falls short in its description of harms of the recommended treatment. Sucking on zinc lozenges can have a number of minor but unpleasant side effects, like\u00a0leaving a metallic\u00a0taste in your mouth, and, less commonly, vomiting, stomach cramps, and diarrhea. The article warns that certain other ingredients in lozenges can cause zinc not to be absorbed. However,\u00a0it would have been better to spell out that zinc can interfere with the absorption of some classes of antibiotics, making those medications less effective as well.", "answer": 0}, {"article": "Medicare typically follows USPSTF guidelines in determining coverage and the Affordable Care Act specifies that USPSTF recommendations rated at the strongest levels must be used as a floor for coverage for private insurers.\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nLast month, National Institutes of Health Director Francis Collins wrote in the journal Lancet that \u201cit\u2019s a force for good.\u201d But Rita Redberg, a cardiologist at the University of California at San Francisco and editor of JAMA Internal Medicine, and others have been vocal about their belief that the drugs are overprescribed and that the side effects \u2014 which range from muscle pain and cataracts to possibly an increased risk for diabetes in women \u2014 should be taken more seriously.\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\nBut it puts a greater emphasis on age than the ACC and AHA did in determining who might benefit from the medication in preventing heart attack or stroke.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentions\u00a0\u201cmuscle pain and\u00a0cataracts [and] an increased risk for diabetes in women.\u201d This is sufficient, but the story would have been stronger if it had discussed frequency of these side effects, and mentioned the more serious (and thankfully more rare) risks of rhabdomyolysis and muscle breakdown.", "answer": 1}, {"article": "It\u2019s very apparent that he\u2019s dying.\u2019\u201d\n\nLandon began to refuse chemotherapy and turn into a \u201clittle psychopath,\u201d says Riddle.\nWhen Riddle made the decision to give her son cannabis, the information on its safety and efficacy was (and still is) limited to anecdotal accounts, a handful of case reports and lab studies published in obscure medical journals.\nBy the time Landon was nearing the end of his first stage of treatment, Riddle says her son was on the brink of death.\n\u201cCombined with other targeted therapies, which again, specifically target the leukemia, you give it a one-two punch and hopefully reduce side effects and improve efficacy of treatment,\u201d he says.\nMcKallip suggests cannabis could be used along with other treatments for leukemia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms of long term treatment with cannabis oil. Also, it does not clearly explain that early discontinuation of conventional treatment might increase the risk of relapse.", "answer": 0}, {"article": "The dorsal root ganglions are nerve cells, on both sides of each of the spine's vertebra, and are the gateway to pain between nerves in different parts of the body, spinal cord and brain.\nFive patients needed to have the wires implanted again, two patients had them removed because they were infected, and one had the device removed because of a complication.\nOne pain specialist not involved with the study saw the benefits of this procedure.\nAlso, the procedure isn't covered by all insurance companies, so out-of-pocket costs to patients can be very high.\nFor most patients, the device reduced pain by 33 percent, which was significant, the researchers reported.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said the procedure \u201cwas not without complications. Five patients needed to have the wires implanted again, two patients had them removed because they were infected, and one had the device removed because of a complication.\u201d\nThe story didn\u2019t describe the complication, which was a foot drop. It could have also gone a step further by cautioning that the FDA often does not require new medical devices to prove that they are safe or effective in order to be used in people.", "answer": 1}, {"article": "Delyth Morgan, chief executive at Breast Cancer Now, which funded the research, said: \u201cThis is a really crucial discovery.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\nFar too many women have to deal with the potentially devastating consequences of their breast cancer coming back and this research presents an important opportunity to improve the effectiveness of today\u2019s most commonly used treatments.\nCholesterol production by the tumour will not be the only reason why ER-positive breast cancers recur, but campaigners are excited by the possibilities for a treatment if further research corroborates these findings.\nBut about 12,000 of the 40,000 diagnosed oestrogen-receptor positive (ER-positive) cancers still recur every year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Statins are among the most commonly prescribed drugs in the U.S. but do carry risks including muscle damage, diabetes and memory loss. This isn\u2019t addressed in the story.", "answer": 0}, {"article": "Kappelmann, N et al.\nDr Khandaker and colleagues believe that anti-inflammatory drugs may offer hope for patients for whom current antidepressants are ineffective.\nAnti-inflammatory drugs similar to those used to treat conditions such as rheumatoid arthritis and psoriasis could in future be used to treat some cases of depression, concludes a review led by the University of Cambridge, which further implicates our immune system in mental health disorders.\n\"It's too early to say whether these anti-cytokine drugs can be used in clinical practice for depression, however,\" adds Professor Peter Jones, co-author of the study.\nPrevious work from the team found that children with high everyday levels of one of these markers are at greater risk of developing depression and psychosis in adulthood, suggesting a role for the immune system, particularly chronic low-grade systemic inflammation, in mental illness.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The researchers note that \u201csome existing drugs can have potentially serious side effects, which would need to be addressed.\u201d\u00a0 Because each of these drugs differ, consideration of the side effects of each would be something a patient should consider based on the benefits and evidence.\nThe side effects of anti-inflammatory medications can be serious. They may increase cancer risk and through suppression of the immune system, increase susceptibility to infection. The release would have been stronger had it offered more specifics about potential harms.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One of the weak points in this story \u2013 and in many of the stories we saw on this study, frankly \u2013 was that, while harms or complications were mentioned, they were not defined nor quantified.\u00a0 What harms?\u00a0 And how often do they occur? This story had a quote that \u201cI don\u2019t think we\u2019ve educated [people] well enough\u201d about the possible risks \u2013 but the story itself didn\u2019t do so.\nThe AP story, by comparison, at least mentioned \u201crisks that occur more often with older patients, including complications from sedation, accidental performation of the colon and bleeding.\u201d", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear that either product poses any particular harms. We\u2019ll rate this Not Applicable. However, it\u2019s worth mentioning that just like no one is sure if these devices help, we also don\u2019t know if they hurt. For example, using these products\u00a0may give false reassurance and lead individuals to stay glued to their devices even longer than they currently are \u2014 perhaps exacerbating an existing problem.", "answer": 2}, {"article": "Shares in Angle, which has a market cap of about 50 million pounds, rose 2.2 percent to 68 pence.\nThe test was nearly twice as successful in eliminating false-positives than current tests, he said.\nThe performance of the test would now be validated in another study designed to meet European CE Mark and US FDA regulatory requirements, he said.\nIt also had the potential to identify targets on the tumor that could be used to inform treatment strategies, he said.\nHeadline results from a study of 400 patients in Europe and the United States showed the test to detect cancerous cells in the bloodstream correctly identified cancer in up to 95 percent of cases, the company said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the rate of false positive diagnoses in the pilot studies described here were quite low, they still occurred.\u00a0 The story would benefit from directly addressing that and other possible debits of the test.", "answer": 0}, {"article": "Though CA125 is valuable to look for recurrence of cancer, it is not recommended for screening because it can surge, for example, during menstruation. However, guidelines from the American College of Obstetricians and Gynecologists and the National Comprehensive Cancer Network (NCCN) recommend a CA125 test plus vaginal ultrasound imaging for a woman with nonspecific symptoms that could signal ovarian cancer, such as bloating and pain. A CT or MRI scan may be added, although these are expensive. A biopsy is usually avoided because it could spread cancer cells.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re told that\u00a0experts fear that these tests could lead to unnecessary surgery or delayed diagnosis, and that\u2019s sufficient for a Satisfactory rating.\nThe story could have delved into a bit more of the specifics: What is the evidence\u00a0for these concerns? What are the false positive and false negative rates? These details are\u00a0useful\u00a0because the point of the story is that clinicians are not using these tests to try to improve outcomes of ovarian cancer patients. \u00a0Are the possible debits\u2013or\u00a0uncertainties driven by lack of clinical data\u2013contributing to these decisions?", "answer": 1}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\nBefore the treatment, patients had tried everything without success and were considering an operation, he says.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that no side effects were observed and that a small percent of patients had more pain after the injection.\nBu the story does not talk about the potential risks of ozone gas to individuals as well as the environment. Ozone is a toxic gas and one would expect that the benefit of its use as a medical treatment would need to be clearly demonstrated prior to recommending it as a routine treatment option. Even if that is done, one would want to know that this gas can be safely generated and administered without causing toxicity to those administering it and to the environment itself. In this context, the mention of no risks seen in the study needs to be taken with considerable caution.", "answer": 0}, {"article": "Autism is a group of complex brain developmental disorders characterized by impairments in social interaction, communication, and stereotypical and repetitive behaviours.\nThis is the first time a medical treatment has shown this type of benefit for children with autism and findings reinforce outcomes from a longer sustained program of research by this team.\nStudy co-author and co-director of the Brain and Mind Centre, Professor Ian Hickie noted the new results were a critical first advance in the development of medical treatments for the social deficits that characterize autism.\nOverall, the nasal spray was well tolerated and the most common adverse events were thirst, urination and constipation.\n\"We used some of the most widely used assessments of social responsiveness for children with autism,\" said autism expert, Associate Professor Adam Guastella of the Brain and Mind Centre.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release briefly describes the symptoms reported in the children taking part in the trial. The common side effects were thirst, urination and constipation.\nOur reviewers thought it should be pointed out that the risks and long-term effects of treating children with oxytocin are unknown.", "answer": 1}, {"article": "Hupin D, Roche F, Gremeaux, et al.\nBased on the results, Dr Hupin said that a revision of the recommendations for physical activity in the elderly may thus be warranted and beneficial - low dose physical activity can significantly reduce mortality.\nIn commenting on the results, Dr Hupin said several conclusions might be drawn but notably that the level of physical activity in the elderly was negatively associated with mortality rate in a \"dose-dependent\" way and that even a low level of exercise below current recommendations had some protective effect.\nDr Hupin emphasised that the widespread acceptance of this message would encourage more elderly people to include even \"low doses\" of physical activity in their usual daily activities, without experiencing high levels of fatigue or of pain.\nThe findings from this PROOF study were confirmed in a meta-analysis preformed by the same group and reported at this same EuroPRevent congress.3 This analysis, drawing on data involving almost 120,000 subjects, found that \"low-dose\" moderate-to-vigorous physical activity - of, say, 75 minutes per week or 15 minutes per day - significantly reduced mortality in the elderly.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Dr. David Hupin comments, \u201cThe level of physical activity in the elderly was negatively associated with mortality rate in a \u201cdose-dependent\u201d way.\u201d He also adds, \u201cEven a little [exercise] is good, and more may be better.\u201d\nBut exercise is painful for many older adults with arthritis or other physical ailments, and can also lead to falls, which aren\u2019t mentioned. We\u2019re not saying this is a major omission, as the release does emphasize the benefits of low doses that are less likely to cause harm. But it\u2019s still not up to our standard.", "answer": 0}, {"article": "''Currently, 20% to 25% of surgeries done for suspected lung cancer turn out to be benign diagnoses,\" says Steven Dubinett, MD, professor of medicine and pathology and director of the Lung Cancer Research Program at the Jonsson Comprehensive Cancer Center at the David Geffen School of Medicine, University of California, Los Angeles.\nIf perfected, the test could help spare patients the need to undergo invasive procedures such as biopsies when lung cancer is suspected, they predict.\nAccording to Dubinett, about one in 500 chest X-rays shows a lung nodule of ''indeterminant significance.\"\nWhen that occurs, the next step is to examine the suspicious area, with the physician ordering a biopsy or inserting a scope into the lungs to evaluate further.\nHe is the senior author on the study, presented at the American Association for Cancer Research-International Association for the Study of Lung Cancer's joint conference in Coronado, Calif.\n\nAbout 219,000 new cases of lung cancer were expected to be diagnosed in the U.S. in 2009, according to the American Cancer Society, and about 159,000 deaths were expected.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quantified harms are not as pertinent since this a blood test. However, one could infer indirect harms, the false positives and false negatives, from the data provided.", "answer": 2}, {"article": "\"Try a serving in a snack bag.\nWalnuts are especially heart healthy because they have more polyunsaturated fat than almonds, cashews, peanuts, pecans, pistachios, and macadamia nuts per serving.\nThe research shows the well-known cholesterol-lowering effect of eating walnuts works equally well in the elderly, even in the long term, the authors reported at the Experimental Biology conference in San Diego.\nIn a study by researchers from the Hospital Clinic of Barcelona and Loma Linda University, more than 700 older, healthy adults were asked to add either a handful of walnuts to their daily diets or to follow their normal diet without eating nuts.\nOther walnut studies presented at the conference, funded in part by the California Walnut Commission, suggested the omega-3 fatty acid-rich nut may also benefit gut bacteria and help reduce inflammation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned is that walnuts can cause weight gain because they are high in calories. Because walnuts are a common food, there are no real expected harms except for those who are allergic to them.", "answer": 1}, {"article": "The requested document is forbidden. Please try your operation again .", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Clearly elaborated.", "answer": 1}, {"article": "Antioxidants are found in different levels in fruits and vegetables, such as blueberries or broccoli.\n\u201cThis study does not demonstrate anything special about pomegranate juice,\u201d she told Reuters Health in an e-mail.\n\u201cPomegranate juice was shown in the last three years to contain the highest levels of polyphenols among a variety of products,\u201d Kristal said.\n\u201cWho the heck knows what the active ingredients are?\u201d\n\nMarion Nestle, a nutrition expert at New York University, said the effects might not be unique to pomegranate juice.\nBrosius was skeptical of the benefits, although he said the juice was unlikely to cause harm.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job.\u00a0 The story states that the \u201cteam had found no side effects, but added that kidney patients should be aware of the high potassium content in the juice, given the delicate balance of nutrients in their blood, and talk to their doctor if they consider drinking it.\u201d", "answer": 1}, {"article": "It's kind of trading in your MS for another autoimmune disease,\" Giovannoni said.\nStill, one MS specialist who reviewed the new study said patients need to be cautious about taking the drug.\nBut the authors of a new study believe giving it early may slow and even reverse some disease-related disability.\nThe decision to start Lemtrada should be made in the context of the risks, including infusion-associated reactions, infections, and autoimmune adverse events, she said.\nLemtrada is not for every patient with MS and the decision to use it should be carefully considered, said Dr. Dhanashri Miskin, an attending neurologist at Lenox Hill Hospital in New York City.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the risk of infections (including herpes), the need for monthly blood and urine tests for four years after the last dose, the risk of developing \u201canother autoimmune disease,\u201d such as\u00a0Graves\u2019 disease (a thyroid disorder) and a bleeding/bruising disorder called idiopathic thrombocytopenic purpura.\nWe\u2019d have preferred to see a statement that\u00a0long-term harms have not been determined, but this is otherwise a satisfactory description of the harms.\nAlso, the drug was initially refused approval by the FDA\u00a0for safety reasons, a very revealing\u00a0fact that would have provided patients with some context on how serious the side effects are.", "answer": 1}, {"article": "PAE reduced the symptoms of frequency and urgency of urination without causing side effects like incontinence, sexual dysfunction, retrograde ejaculation (ejaculation into the bladder), or bleeding.\nDespite the promising results of this small trial, experts said it was far too early to recommend PAE to patients.\nThe study was presented at the Society of Interventional Radiology annual meeting in Chicago.\n\u201cThe results are excellent.\u201d\n\nIn a small pilot study, most men were able to leave the hospital four to eight hours after the procedure, which is called prostatic artery embolization (PAE), researchers report.\nThe authors report that the dead tissue required surgical removal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention that one patient in the study had a serious complication that required surgery to repair the bladder. \u00a0However \u2013 since the study population was small and men were only followed for \u2018an average of nine months\u2019 after the procedure \u2013 the story could have been even more explicit and emphatic that it is too soon to know the harms associated with this procedure. It did include one independent expert\u2019s comments to that effect.\nMore bothersome: the story described the complications of TURP without informing the reader about how often they occur or bothering to note that other, widely available treatments that have been around for a decade or more have reduced risks of these complications.\nAny story whose first words are \u201ca minimally invasive procedure\u201d may paint an unjustified picture of guaranteed safety.\u00a0 Special caution should be taken to counter this.\nOne last point on harms:\u00a0 the major \u201charm\u201d that the study could not address (and the story ignored) is the possible eventual need for requiring additional treatment.", "answer": 0}, {"article": "A little bit of current may calm the tremors of Parkinson\ufffds disease, ease depression and epilepsy, and awaken those with terrible injuries.\nA glimpse of Mom must first register on your occipital lobes as a pattern of light and shadow.\nFrom there it is relayed to your memory center, where it is identified by comparison with every other face you've ever seen.\nA lateral X-Ray of the head of a 38-year-old man shows two Deep Brain Stimulation (DBS) leads with four electrodes attached to each implanted in the subcortical area of the brain called the thalamus.\nIt's harder than you think to say hello to your mother--at least in terms of the work your brain has to do.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms associated with deep brain stimulation.\u00a0 There are some minor or temporary problems that may occur as well as risk of brain hemorrhage. There is no mention of complications of foreign material in the brain, of stimulators\u00a0 housed in the chest, \"mild anesthesia\" and of the insertion of wires into the brain.\u00a0 \nHowever \u2013 in its description of the benefit for Parkinson\u2019s disease, the story mentioned that it was not beneficial for end-stage symptoms and indicated that the benefits of treatment were temporary for this degenerative condition.\u00a0 This provides an important perspective about limits of benefits.", "answer": 0}, {"article": "This study received funding from F. Hoffmann-La Roche Ltd.\n\nView the disclosures for the 2018 ASCO Annual Meeting News Planning Team.\nAt this interim analysis a statistically significant overall survival (OS) benefit was not observed (median OS was 14 months for atezolizumab plus chemotherapy vs. 13.9 months for chemotherapy alone).\nOutcomes for only two of the groups, however, are being reported in this presentation:\n\nOutcome data for the third treatment group, which received atezolizumab with a slightly different chemotherapy regimen (carboplatin and paclitaxel), are not yet available.\nKey Findings \n\n In this study, 29% of all patients, regardless of PD-L1 expression, had a reduced risk of disease worsening or death, compared with those who received chemotherapy alone.\nAlthough the difference between treatment groups is modest, a statistically significant improvement shows that, overall, people with advanced squamous lung cancer can benefit when immunotherapy is added to standard treatment, according to the authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Here again, the release and abstract include specific rates of treatment-related adverse events, but only buried deep in the text and without important context or explanation. It is not enough to glibly pass off higher rates of serious side effects as \u201cmanageable\u201d and \u201cconsistent with known safety risks.\u201d The release states that there were grade 3-4 adverse events in 68% of the patients receiving atezolizumab in addition to chemotherapy, compared to 57% of the patients receiving chemotherapy alone. But there is no explanation of what these numbers mean. Grade 3 usually means severe and a grade 4 adverse event is typically life-threatening. There is also no mention in the release itself of the finding that 20.4% of the immunotherapy patients suffered \u201cserious\u201d treatment-related adverse events, compared to 10.5% of those who received only chemotherapy.", "answer": 0}, {"article": "Brain imaging has become a popular subject of research in recent years as the technology to be able to scan, store and analyze the terabytes of information in the pictures has become more affordable.\n\"Why some toddlers with ASD get better and develop good language and others do not has been a mystery that is of the utmost importance to solve,\" Eric Courchesne, one of the study\u2019s authors and co-director of the University of California-San Diego's Autism Center, said in a statement.\nThe images of the children in the study -- MRIs of the brain -- were taken at 12 to 29 months while their language was assessed one to two years later at 30 to 48 months.\nNow scientists believe that they have a way to distinguish between those paths, at least in terms of language ability, in the toddler years using brain imaging.\nThere\u2019s no such thing as a blood test, cheek swab or other accepted biological marker so specialists must depend on parent and teacher reports, observations and play assessments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided no description of potential harms from this scanning approach. The chief potential harm would be a false positive or false negative scan. If the scan is wrong, that may trigger unnecessary additional anxiety or false reassurance for parents regarding their child\u2019s likely outcome. It may also lead parents and doctors to implement the wrong kind of therapy for autistic children. The researchers on this study have suggested that\u00a0non-verbal therapies may be more appropriate for the children whose scans suggest they are not \u201clanguage-ready\u201d (and vice-versa). But if the scan is wrong, these children may be offered the wrong kind of treatment \u2014 possibly leading to a worse outcome than if they hadn\u2019t been scanned at all.\nThe story also could have noted some of the challenges involved with getting MRI images on young children. MRI scanners make loud banging noises which can be frightening to children and sedation is sometimes required. \u00a0The researchers in this study were able to do the scans while the children were asleep, which didn\u2019t require sedating the children.", "answer": 0}, {"article": "She said that, \"though this study includes a small sample size followed for a short period of time, the results are promising in that TAK-875 appears to be effective for glycemic [blood sugar] control without significant risk for hypoglycemia or weight gain.\nAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said.\nHowever, like Wissner-Greene, Sood said that \"further investigation is warranted, especially including [heart disease] patients.\"\nThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\nThe patients were randomly assigned to receive either TAK-875 (303 patients), placebo (61 patients), or another diabetes drug called glimepiride (brand named Amaryl).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are numbers attached to the potential harms, but there is so little context that it would be hard for readers to make any sense of the numbers. It says, \u201cThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\u201d\u00a0 What does this mean, exactly?\u00a0 What specific types of side effects were experienced, and were some of them severe?", "answer": 0}, {"article": "...\n\"In the primary analysis of this study of adults with moderate to severe BED, lisdexamfetamine dimesylate treatment with 50 and 70 mg/d, but not 30 mg/d, demonstrated a significant decrease (compared with placebo) in weekly BE days per week at week 11.\nSimilarly, BE episodes decreased in the 50- and 70-mg/d treatment groups.\nResults also indicate the percentage of patients who achieved four-week BE cessation was lower with the placebo group (21.3 percent) compared with the 50-mg/d (42.2 percent) and 70-mg/d (50 percent) treatment groups.\nConsequently, many patients with BED are undertreated despite having functional impairments and difficulties in their social and personal lives.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no information about possible harm. In general, we might expect a news release about this kind of study to include the most common side effects found at rates considerably higher than placebo. Here those side effects include insomnia, dry mouth, and nausea. The rate on insomnia, which occurred in 14-15% of patients on drugs and <2% on placebo, is especially cogent, as it\u2019s a symptom that can really affect people\u2019s lives.", "answer": 0}, {"article": "Bone-health experts are making a new push to reduce rates of osteoporosis, with a particular focus on controlling the bone-wasting disease in men.\n\nAn important goal is to get greater numbers of men to be tested for osteoporosis when they come to a hospital or clinic with a fracture to the wrist, vertebrae or other bones that wasn\u2019t from a major accident or trauma. Doctors call this a fragility fracture\u2014one that results from a decrease in bone density.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no explanation of the potential harms from unnecessary screening, the intervention that\u2019s at the heart of this story. Unnecessary screening can produce false positive results that may lead to anxiety, unnecessary curtailing of activities, and needless treatment and follow-up that can cause harm. We acknowledge that the story does mention the harms from some specific bone density drugs. For example: \u201cBisphosphonates, sold under brand names such as Fosamax and Actonel, are highly effective. But because of some\u00a0possible, rare side effects\u2014an unusual type of fracture of the thigh bone and a deterioration of the jaw bone\u2014the medication often isn\u2019t prescribed for more than five years.\u201d But we\u2019d note that it isn\u2019t clear how one should extrapolate data on potential harms seen in post-menopausal women to men.", "answer": 0}, {"article": "\u201cWe\u2019re not talking about putting all these kids on statins,\u201d she said.\nIf a child was found with the disorder, parents were tested.\nFor every 1,000 people screened in the study, four children and four parents were identified as being at risk for early heart disease.\nOne in 270 children had the gene mutations; others were identified through cholesterol levels alone.\nNinety percent of them started taking preventive medicines after finding out.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of screening including false positives and negatives, overdiagnosis, overtreatment, inappropriate disease labelling and so on are not mentioned.", "answer": 0}, {"article": "When patients are in an abnormal irregular heart rhythm called atrial fibrillation, blood clots can form in the LAA, which can then circulate out through the bloodstream and cause stroke.\nThe researchers found that while results from the trials varied, the device did appear to be more cost-effective in the larger, longer-term trial.\nTo assess the cost-effectiveness of the device versus medication, the researchers developed a statistical model based on data from two key research trials, known as PROTECT AF and PREVAIL.\nHowever, longer-term results are needed to be completely certain of the device's value in clinical practice, he said.\n\"Based on that, the study may provide more certainty in terms of cost-effectiveness.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention possible drawbacks to use of the Watchman device.\nBut federal regulators have made clear that they have concerns. In a letter dated March 13, 2015, the Food and Drug Administration told the manufacturer, Boston Scientific, that its approval was\u00a0contingent upon the submission of periodic reports on the safety of the device.\n\u201cThe primary safety endpoint is treatment of the patient without the occurrence of life-threatening events as determined by the Clinical Events Committee, which would include events such as device embolization requiring retrieval, bleeding events such as pericardial effusion requiring drainage, cranial bleeding events due to any source, gastrointestinal bleeds requiring transfusion and any bleeding related to the device or procedure that necessitates an operation,\u201d the letter says.\nIt also notes that the device maker agreed to carry out a study to assess \u201cwhether the rates of safety and effectiveness during the early commercialization of the WATCHMAN device in the United States are consistent with the premarket findings.\u201d", "answer": 0}, {"article": "While mammography works on breast density, radiofrequency looks at contrasts between normal and diseased breast tissues.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nThe real-time imaging minimizes the chance of missing a breast tumor during scanning.\u201d Wu says it will even work through a bra.\nCosts are reduced and the electronics fit into a case the size of a lunchbox.\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are discussed. If it\u2019s too early to tell the rates of false positives, we need to know that. The article draws a picture of a tool with no potential downsides.", "answer": 0}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because this story puts forth the idea that certain foods (especially coffee and wine) are good for microbial diversity\u2013and that\u2019s a health claim\u2013there should be an acknowledgement that\u00a0these foods also can carry harms. There was no mention\u00a0of the size of the dose\u2013how much coffee? How much wine? And people may take that lack of dosing to mean whatever they want, including having more than is beneficial and veers into unhealthy or dangerous.", "answer": 0}, {"article": "\u201cIt\u2019s like a weather man using a computer model to see what the weather is rather than looking outside the window,\u201d Lee said in a telephone interview.\nMany groups, including the American Cancer Society, have stuck by their long-standing recommendations of a yearly breast exam for women starting at age 40, stressing that the breast X-rays have been proven to save lives by spotting tumors early, when they are most easily treated.\nBut Helvie and colleague Edward Hendrick of the University of Colorado wrote that \u201cthe USPSTF chose to ignore the science available to them and overemphasized the potential harms of screening mammography, to the serious detriment of U.S. women who follow their flawed recommendations.\u201d\n\nDr. Carol Lee who chairs the American College of Radiology\u2019s Breast Imaging Commission said the new study highlights the risk of setting policy based on the conclusions of one group of scientists.\nThose guidelines recommended against routine mammograms for women in their 40s and said women in their 50s should get mammograms every other year instead of every year.\nWhen they were issued, the task force\u2019s guidelines contradicted years of messages about the need for routine breast cancer screening starting at age 40, kicking off a fury of protest among breast cancer experts and advocacy groups who argued the recommendation of fewer screenings would confuse women and result in more deaths from breast cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not include information about the potential harms resulting from routine, annual mammography beginning at age 40.\u00a0 Readers, especially women who may decide to begin annual screening at age 40, need to be told about the possibility of false positives and unnecessary biopsies. Authors such as Welch and Esserman have referred to overdiagnosis and overtreatment.", "answer": 0}, {"article": "The researchers, Drs.\nThe earlier study also found that undergoing a radical prostatectomy lowered the risk of the cancer spreading, as well as the death rate from prostate cancer or any other cause.\n\"The management of early stage prostate cancer continues to require further randomized controlled studies, which are underway, to determine the true benefit of treatment versus expectant management,\" said Dr. Marc Danziger, an attending urologist at Lenox Hill Hospital in New York City, who was not involved with the study.\nAnna Bill-Axelson and Lars Holmberg of University Hospital, Uppsala, and colleagues, enrolled nearly 700 men with early prostate cancer under the age of 75 who were randomly selected either to undergo a radical prostatectomy or to stay in \"watchful waiting\" mode.\nBut the findings are not likely to be practice-changing, said Dr. Richard E. Greenberg, chief of urologic oncology at Fox Chase Cancer Center in Philadelphia, who was not involved with the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms associated with various approaches to treating prostate cancer as well as the increased risk of prostate cancer progression and death seen in the cohort of men who followed the watchful waiting approach were discussed.", "answer": 1}, {"article": "Needle-phobia, or trypanophobia, is a recognized medical condition that causes sufferers to avoid medical care.\nThe patch, which is lined with microscopic needles that dissolve into the skin, could provide a painless alternative to hypodermic needles and make visits to the doctor's office or clinic for a traditional flu shot a thing of the past.\nHe said his team is working on those diseases but is not as far along.\nBut he said it will be interesting to watch.\nThe microneedle technology may also be used for other vaccinations, such as polio and measles, said Prausnitz.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, but since these are likely to be minimal and we\u2019re at such an early stage in development, we\u2019ll call it not applicable. We think we\u2019re being lenient here (but we were with the AP story as well) because any new drug delivery system runs the risk of causing some harms and side effects \u2013 things that can\u2019t be known before human testing \u2013 and a point the story could have made. ", "answer": 2}, {"article": "Claudia Kawas, a geriatric neurologist at the University of California, Irvine, said a patient strode into her office soon after the FDA approved the procedure and asked for the \"Alzheimer's test.\" In one hand, he held an article about the approval of Amyvid. In the other, he had a document from a right-to-die group. If the test was positive, he told her, he would get his affairs in order and kill himself within 60 days.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports:", "answer": 1}, {"article": "The information entered on this page will not be used to send unsolicited email, and will not be sold to a third party.\nMoving forward, longer term, observational studies are needed to confirm the safety of fetal exposure to tenofovir treatment, says Pan.\nBased on the findings, the investigators recommend that women be tested for HBV viral load at week 28 of pregnancy.\n\u201cWe believe that these findings will not only save many lives, but could also help to eradicate hepatitis B nationally and abroad.\u201d\n\nThe study was conducted in five locations in China, where HBV infection is endemic.\nThe study focused on the most common way that children become infected with hepatitis B, an incurable viral infection that causes liver disease and cancer, which is through infection during the perinatal period.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release includes a discussion of harms. It states that \u201ctenofovir was well tolerated; only one participant treated with tenofovir voluntarily withdrew from the study due to nausea.\u201d\u00a0 It also says that researchers \u201cfound no significant differences between the tenofovir-treated group and the control group with regard to fetal development and infant growth.\u201d\u00a0 Lastly, it calls for longer term, observational studies to confirm the safety of fetal exposure to tenofovir treatment.", "answer": 1}, {"article": "The studies suggest that fewer physicians are recommending annual mammograms for women in their 40s, fewer patients in that age group are getting screened and that tumors found through routine mammography are more likely to be detected in early stages of cancer.\nBreast cancer ID'd more accurately by docs who see more scans\n\nPlecha's findings were not surprising to Moyer.\nThese cancers were more treatable because they were caught in earlier stages, Plecha said.\n\"There is a real, but rather modest benefit.\n\"I would still recommend screening mammograms starting at age of 40,\" because cancers caught earlier would be more curable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We wouid have like to have seen more discussion of the potential harms in 85% of biopsies being non-cancerous.\u00a0 But since the story did actually quantify the number of false positives, we\u2019ll give it the benefit of the doubt on this criterion.", "answer": 1}, {"article": "Melbourne based start-up Atmo Biosciences is set to commercialise this revolutionary technology.\nOf the one-in-five people worldwide who will suffer from a gastrointestinal disorder in their lifetime, almost a third remain undiagnosed due to a lack of reliable tests available to gastroenterologists.\nNew trials of a breakthrough swallowable sensor have revealed the device is 3,000 times more accurate than current technology used to diagnose many gut disorders.\n\"The rate of false positive and false negative diagnosis that breath tests give is a real problem in gastroenterology,\" Berean, who is also Chief Technology Officer at Atmo Bioscience, said.\nSuch an immune mechanism has never been reported before.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The published study mentions \u201cno reported adverse events,\u201d but the news release does not address harms.\nHarms are relevant since we\u2019re guessing many readers might be wary of swallowing an electronic transmitter and hope \u201cthis too shall pass\u201d (without incident).\nAnother harm that isn\u2019t mentioned is the risk of false-positive findings that may\u00a0lead\u00a0to unnecessary antibiotic treatment for some people. Such treatment poses risks to individual patients and contributes to the growing problem of antibiotic resistance.", "answer": 0}, {"article": "Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment.\nNewswise \u2014 Washington, DC (December 8, 2016) \u2014 A diet that emphasizes healthy foods rather than individual nutrients may help patients with chronic kidney disease live longer.\nAll content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects.\nThe findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN).\nThe article, entitled \u201cHealthy Dietary Patterns, Mortality and End-Stage Kidney Disease in CKD: A Meta-Analysis of Cohort Studies,\u201d will appear online at http://cjasn.asnjournals.org/ on December 8, 2016, doi: 10.2215/CJN.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not discuss any harms. Some of the \u201cclassic\u201d dietary recommendations have a small harm profile (potassium, protein), and this is also not discussed.", "answer": 0}, {"article": "He was not involved in the research.\nBut that test has caused controversy because it falsely detects cancer in about one out of four people, leading to further invasive procedures.\nIn its early stages, lung cancer has few symptoms, making it difficult for doctors to catch it early, when it's still treatable.\n\"The whole field is focused on using something that's readily available that does not involve an expensive surgery or scan that would allow us to find early cancers,\" says Ramalingam, who is developing technology that aims to replicate the ability of dogs to smell trace amount of chemicals produced by cancerous tumors.\nAug. 17, 2011 -- German researchers say that highly trained dogs are able to reliably sniff out lung cancer in human breath.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explicitly discuss harms from a potential \u201csniff\u201d test by dogs or machines imitating dogs.\u00a0 It does discuss contradictory research on whether cancer-sniffing dogs can achieve high accuracy. The obvious \u201charm\u201d of inaccuracy is that a patient goes untreated for cancer, or conversely, is exposed to invasive testing because of a false positive. Without early detection by dogs, patients are already getting exposed to tests such as computer tomography and bronchoscopy.", "answer": 0}, {"article": "Not a single cancer was undetected that became palpable,\" she said.\nAccording to Dr. Kuhl, the results suggest that MRI can serve as a useful supplemental screening tool for women at average risk, especially those with dense mammographic tissue, and that MRI is superior to supplemental ultrasound for this purpose.\nHowever, with breast cancer remaining a major cause of cancer death in women, there is good reason to pursue the search for improved screening methods, according to the study's lead author, Christiane Kuhl, M.D., chair of the Department of Radiology at RWTH Aachen University in Aachen, Germany.\nMRI screening has not been considered necessary for women at average risk, and there has been resistance to expansion of MRI into this population due, in part, to concern over higher costs.\nAccording to Dr. Kuhl, interval cancers exhibit an adverse biologic profile and are the main driver of breast cancer mortality.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not state any potential harms of MRI screening. False positives from MRIs aren\u2019t uncommon and can lead to anxiety and additional invasive testing. That\u2019s harmful for patients.\nWe\u2019d like to see news releases and stories start to acknowledge potential harms, particularly since the country is moving toward more universal breast cancer screening with MRI.\nOver the past few years, studies have been coming out noting concerns about the gadolinium (a heavy metal) contrast material that is used during breast MRI. The contrast is necessary to demonstrate areas of increased tissue vascularity (the state of blood vessel development and functioning). Recent reports note that gadolinium may deposit in the brain. We do not know the long-term significance of this. The FDA is studying the effects \u2014 if any\u2013 on \u201crepeated use of gadolinium-based contrast agents (GBCAs) for magnetic resonance imaging (MRI).\u201d", "answer": 0}, {"article": "\u201cIt\u2019s time for her to be a kid again and get her childhood back,\u201d Mr. Whitehead said.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\nHe hopes the new treatment will eventually replace bone-marrow transplantation, an even more arduous, risky and expensive procedure that is now the last hope when other treatments fail in leukemia and related diseases.\nThe researchers are not entirely sure why the treatment works, or why it sometimes fails.\nFor the patients who had no response whatsoever, the team suspects a flawed batch of T-cells.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes some of the adverse effects of treatment in great detail, and mentions that patients treated successfully have compromised immune systems and must undergo ongoing therapy\u00a0with immunoglobulins. The story could have noted that we have\u00a0little idea what kind of long-term challenges these patients might face as a result of the alterations made to their immune systems.", "answer": 1}, {"article": "Oral immunotherapy, swallowing small amounts of the allergen, has shown to be more effective than sublingual therapy, which involves putting even tinier quantities of milk under the person's tongue.\nThis is the first time the sublingual therapy has been studied in terms of its benefit as a precursor to the oral immunotherapy, Wood said.\nBut only one-third have longterm protection.\nStill, it did not eliminate all symptoms.\nThe big barrier to broadening the scope of the research is funding, Wood said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t quantify/explain the extent of \u201csignificant reactions during the treatments that make the therapy unfeasible\u201d in the new sublingual approach.", "answer": 0}, {"article": "\"It's a cheaper method for people who do want to get pregnant.\"\nBut Don't Think Of This As Birth Control Even though Clue\u2019s marketing director happened to find out she was pregnant from her Fitbit, the point of the study was to demonstrate that it's possible to use Fitbit as a conception tool, not as a pregnancy test, H\u00f6gqvist Tabor said.\nBut as Clue\u2019s and Ava\u2019s fertility research indicates, increasingly sophisticated sensors and algorithms could significantly open up wearables\u2019 capabilities \u2014 and make them that much more able to tackle bigger, complicated health issues.\nAnd while resting heart rate can be a tell-tale sign of ovulation, Lea von Bidder, CEO of Ava, says consumers shouldn\u2019t rely on that measurement alone if they\u2019re serious about getting pregnant.\nIf you\u2019re curious exactly what kind of increase in resting heart rate you should look out for, Clue hasn\u2019t revealed that information yet, but says it will publish that and other data in a paper later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s not clear what any potential harms might be in this case, though one possibility is that some women may delay taking steps to diagnose possible fertility problems in order to use this technology. Another possible \u201charm\u201d is the bother and cost of using this device by\u00a0women who would become pregnant anyway without any problem.\nWhile the story doesn\u2019t address those issues, we give kudos to the story for addressing another possibility: that women may use the technology to track their ovulation cycle in order to avoid becoming pregnant. The story tackles this issue head on.", "answer": 1}, {"article": "\"The duration and the severity of how they get sick is much less and they get healthy quicker,\" he said.\nThe Brennans' pediatrician, Dr. Lawrence Rosen, explains, \"Elderberry contains chemicals which are flavonoids which are anti-inflammatory agents.\"\nThat would be similar to prescription antiviral medications like Tamiflu or Relenza, which have been proven effective in much larger studies and approved by the FDA to shorten the duration of the flu.\n\"There is not enough research about whether [elderberry] works in children and there is also isn't enough information about the proper dose in children,\" Dr. Anna Minta of Johns Hopkins Children's Center told CBS News.\nThe University of Maryland Medical Center says European elder, also called black elder, is the variety most often used for medicinal purposes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the story credit here for making it clear that raw elderberries are poisonous. However, the story is about commercially-prepared elderberry extract, not raw berries. There was no discussion of possible harms of extracts. While the few clinical trials of elderberry extract did not report adverse events, the story could have at least noted that supplements are exempt from most FDA regulations. The lack of inspections and independent quality control checks means that consumers are almost entirely dependent on the internal procedures of manufacturers. Thus, there is no independent guarantee that the potentially poisonous elderberries are being properly prepared.", "answer": 1}, {"article": "But then the tide turned.\nSo the hypothesis is that intestinal worms could possibly reverse these problems, by damping down the immune system.\nThe bottom line: \"The proportion of patients who improved with the worms was no different than the proportion of patients who were improved with placebo,\" says Dr. Stephen Hanauer at Northwestern University Feinberg School of Medicine, who was involved with one trial.\nAt that point, the worms do something amazing: They suppress the immune system, says P'ng Loke, an immunologist at the New York University School of Medicine.\nHe talked to many people who were using an unlikely tool to treat their problems: parasitic worms that live in your gut \u2014 permanently.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says one person found that having worms in his body \u201cwasn\u2019t pleasant,\u201d and he experienced diarrhea and cramps. But potential risks are not adequately addressed. According to a story in The New York Times Magazine, for example, severe whipworm infection can result in anemia, clubbed fingers and stunted growth in children.", "answer": 0}, {"article": "This compared with 1.9 percent using mitoxantrone.\nThe primary endpoint of the so-called Tropic trial was overall survival.\nThe clinical trial results will be presented at the 2010 American Society of Clinical Oncology (ASCO) on June 6.\nThe FDA\u2019s review should happen in the third quarter, Sanofi said.\nFiling for approval in the EU has been completed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story mentioned that:", "answer": 1}, {"article": "About the UNM Comprehensive Cancer CenterThe University of New Mexico Comprehensive Cancer Center is the Official Cancer Center of New Mexico and the only National Cancer Institute-designated Cancer Center in a 500-mile radius.\nThe study showed that women in this age group were still protected from HPV infections.\nNewswise \u2014 WhatA research paper published in The Lancet Infectious Diseases reported that the human papillomavirus (HPV) vaccine is safe and efficacious across a wide age range of women.\nThey found that the vaccine protected the women against HPV infections during the follow-up period and that the women were protected from many types of HPV across a broad age range.\nWhenThe paper, \u201cEfficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study,\u201d was published in the June 28, 2016 online edition of The Lancet (www.thelancet.com/infection).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention harms, and that\u2019s a troubling omission in a summary of a study devoted to a drug\u2019s safety and efficacy. The published study states the following:\n\u201cSerious adverse events related to vaccination occurred in five (0\u00b72%) of 2877 women in the vaccine group and eight (0\u00b73%) of 2870 women in the control group.\u201d", "answer": 0}, {"article": "Both Prozac and Celexa belong to a class of antidepressants known as selective serotonin reuptake inhibitors, or SSRIs.\nTaking Prozac (fluoxetine) doubled the chances that a patient would show overall improvement, measured by their clinicians.\n\u201cIt takes the edge off,\u201d Hollander explains, noting that the findings were statistically significant and clinically meaningful.\nIt is not known if the differences between these studies are due to differences between the medications or other factors.\nWhen taking Prozac, Hollander says, \u201cPatients acknowledge experiencing less discomfort.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does say that, \u201cSide effects were mild to moderate and participants taking Prozac did not show increases in suicidal thoughts or ideas.\u201d\u00a0 It could have noted, though,\u00a0 that 12 weeks may not be long enough for side effects to emerge.", "answer": 1}, {"article": "High cholesterol levels can increase the risk of heart attack.\nHowever, the safety of selenium has not been studied, and the authors said the findings weren't significant enough to recommend supplementation of the trace mineral.\nMONDAY, May 16, 2011 (HealthDay News) -- A daily dose of the antioxidant selenium doesn't appear to elevate \"bad\" cholesterol levels, and may in fact prompt a very modest boost in \"good\" cholesterol, a new British study reveals.\nFor the study, published in the May 17 issue of the Annals of Internal Medicine, the authors focused on about 500 healthy British men and women aged 60 to 74 between 2000 and 2001.\nNoting that blood selenium levels were relatively low across the board at the study's launch, the authors found that selenium levels did rise as a result of supplementation, while those taking selenium also experienced a slight drop in both bad cholesterol (LDL) and overall cholesterol levels.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story was a little confusing\u00a0on this point. It initially says that\u00a0selenium\u2019s\u00a0safety \u201chas not been studied,\u201d but later quotes a researcher who says there is an increased risk for type 2 diabetes with selenium supplements in individuals whose\u00a0blood levels are already high. The story does note that there were no serious side effects in the selenium supplement users participating in this study, but it\u00a0could have qualified this by mentioning the relatively short duration of the study (6 months) and the potential for problems with longer-term use.\u00a0Too much\u00a0selenium can also, in rare cases, result in condition called selenosis, which\u00a0includes symptoms such as\u00a0gastrointestinal upsets, hair loss, white blotchy nails, garlic breath odor, fatigue, irritability, and mild nerve damage.\nA toss-up here, but since the story indicated that this was not a risk-free intervention and reported on the study findings as appropriate, we\u2019ll rule it satisfactory.", "answer": 1}, {"article": "While the function of sweating is to prevent overheating, those affected sweat even when the body does not need cooling.\n(Reuters) - Dermira Inc said its experimental topical therapy for excessive underarm sweating was successful in two late-stage studies, bringing it one step closer to providing an easy-to-use therapy for the often embarrassing condition.\nAbout two-thirds of the total 697 enrolled in the two trials for the company\u2019s topical treatment, DRM04, were treated with wipes containing DRM04, while the rest were not.\nDermira said it had expected to apply for marketing approval for the drug in the second half of 2017, subject to completion of the drug\u2019s long-term safety trial.\nIn the first trial, a significant improvement in the severity of sweating was seen in 52.8 percent of the patients treated with the drug, compared with 28.3 percent patients in the control group, on a scale designed by the company.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned, and given the lack of details on what the topical medication is made of, it would be difficult find out via independent research.", "answer": 0}, {"article": "Psoriasis is a skin condition that causes patches of skin redness and flaking.\n\"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today\u2019s approval provides patients with another treatment option for their psoriasis,\" said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nSiliq is also approved with a Medication Guide to inform patients of the risk of suicidal ideation and behavior, and that because Siliq is a medication that affects the immune system, patients may have a greater risk of getting an infection, or an allergic or autoimmune condition.\nBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Boxed Warning and the drug is only available through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Siliq REMS Program.\nNotable requirements of the Siliq REMS Program include the following:\n\u2022 Prescribers must be certified with the program and counsel patients about this risk.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We could have rated this release unsatisfactory on this criterion, since no numbers are given about the extent of the problems found in the trials. But we\u2019ll give it the benefit of the doubt because of the extent of discussion on potential harms \u2013 despite the absence of numbers.\nThe release mentions that completed suicides occurred in patients treated with Siliq during clinical trials, which is why the drug\u2019s label will include a boxed warning. Although the release states cause and effect hasn\u2019t been established, some patients \u2014 especially those with a history of depression \u2014 seemed to show an increased risk for suicidal ideation and behavior.\nThe release uses language that may confuse readers\u00a0about harms. In one place it says \u201cA causal association between treatment with Siliq and increased risk of suicidal ideation and behavior has not been established\u201d and in the next sentence claims that \u201cBecause of the observed risk of suicidal ideation and behavior, the labeling for Siliq includes a Black Boxed warning\u2026.\u201d\nPatients may also experience more infections, or allergic/autoimmune conditions, as Siliq targets the immune system. Other side effects associated with the drug include joint pain, headache, fatigue, diarrhea, throat pain, nausea, muscle pain, injection site reactions, influenza, low blood cell count and fungal infections, the news release adds.\nAlthough we would have liked to have seen some numbers indicating how often these side effects occurred, and clarity about whether or not they were observed, we believe the news release does an adequate job addressing harms, as a significant chunk is devoted to this issue. This is why we give it a Satisfactory rating here.", "answer": 1}, {"article": "\u201cNumerically this is hardly a major risk, just something we need to keep an eye on,\u201d Holman said.\nJanuvia, an oral medication known chemically as sitagliptin that helps lower blood sugar levels, had sales of about $4 billion in 2014, plus another $1.8 billion for the related combination product Janumet\n\nOn the study\u2019s main focus, after about three years 11.4 percent of Januvia patients had experienced cardiovascular death, non-fatal heart attack, non-fatal stroke or hospitalization for unstable angina versus 11.6 percent in the placebo group.\n\u201cWe can be reassured we can use this drug for glucose lowering without affecting the already high cardiovascular risk in people with type 2 diabetes,\u201d said Professor Rury Holman, the study\u2019s lead investigator, who presented the data at the American Diabetes Association meeting in Boston.\nMerck in April said the study, called Tecos, of 14,724 patients with type 2 diabetes and a history of heart disease demonstrated that adding Januvia to usual care did not increase major heart problems any more than adding a placebo, removing a cloud that has been holding back sales of the medicine and the company\u2019s share price.\nDeath from any cause occurred in 7.5 percent of Januvia patients versus 7.3 percent for placebo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is focused on the potential harms of the drug and it does a fairly good job explaining the differences between the risks for different bad outcomes from the drug and from a placebo. We give very high marks to the story for providing both comparisons using percentages but also using absolute numbers throughout. So, for example, the story said,\u201dThere were 228 such hospitalizations for Januvia and 229 in the placebo group, according to data also published in the New England Journal of Medicine.\u201d\nIt also does a nice job of explaining, at least in one instance, that some of the comparisons between the drug and placebo are not statistically significant. For example, the story said that, \u201cThere was also no significant difference between Januvia and placebo in infections, cancer, kidney failure or severe hypoglycemia, which is dangerously low blood sugar, researchers reported.\u00a0Acute pancreatitis, a concern with some diabetes drugs, was uncommon but higher with Januvia, 23 versus 12. That was not statistically significant.\u201d\nWith that being said, we wish the story had mentioned that three-year follow up may not be long enough to catch some potential harms. And while the pancreatitis issue was downplayed, a larger and longer study might have shown the concern to be statistically significant if the trend continued. An independent expert analyst may well have commented on such concerns, but no such expert was quoted.", "answer": 1}, {"article": "47(5) pp.\nResearchers say a single adverse event, a bleeding gastric ulcer, occurred in one balloon patient on high dose NSAIDs who had an outpatient knee replacement procedure.\n\u201cThis combination of lifestyle modification and balloon therapy provides a new low risk option for patients struggling with obesity.\u201d\n\nThe Obalon 6-Month Balloon System, a swallowable, gas-filled intragastric balloon for weight loss in adults with obesity for whom diet and exercise has failed, was approved in September by the U.S. Food and Drug Administration (FDA).\nUp to three balloons may be placed over the first three months, but the entire treatment period lasts six months.\nResults of the study were based on a double-blinded randomized, sham-controlled trial of 387 patients, about half of whom received treatment with the Obalon balloon and the other half with a sugar-filled sham capsule designed to look like the device.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the release reports that one trial participant had a gastric ulcer and almost all reported mild to moderate cramping and nausea, the release doesn\u2019t warn readers that this sort of balloon could cause serious, even fatal, complications including esophageal tears, intestinal blockages that require surgery, life threatening allergic reactions, heart attack, cardiac arrest or airway blockage. The FDA approved a package insert that lists these potential risks (see page 11 of the Patient Labeling). The release should have also mentioned the most important risks.", "answer": 0}, {"article": "To learn more about ASTRO, visit www.astro.org.\nNo patients experienced short-term grade 3+ urinary toxicity or grade 2+ gastrointestinal (GI) toxicity.\nNo patients experienced long-term grade 3+ urinary toxicity or grade 4 GI toxicity.\nWithin the six months following HDR therapy, seven patients (12.1%) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9%).\nSix patients (10.3%) experienced chronic grade 2 urinary toxicity and one patient (1.7%) experienced grade 3 chronic GI toxicity that subsequently resolved.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release provided detailed information on harms: \u201cWithin the six months following HDR therapy, seven patients (12.1%) experienced grade 2 urinary side effects, most commonly frequency/urgency (6.9%). No patients experienced short-term grade 3+ urinary toxicity or grade 2+ gastrointestinal (GI) toxicity. Rates were similarly modest for long-term side effects. Six patients (10.3%) experienced chronic grade 2 urinary toxicity and one patient (1.7%) experienced grade 3 chronic GI toxicity that subsequently resolved. No patients experienced long-term grade 3+ urinary toxicity or grade 4 GI toxicity.\u201d\nBut given that many oncology experts would consider the treatment unnecessary, any level of toxicity\u00a0could be considered unacceptable.\nThe lay reader would have benefited from a description of what \u201cgrade 2 or grad 3+\u201d levels of toxicity means.", "answer": 1}, {"article": "The key asset Pfizer wanted?\nA few weeks ago, the Food and Drug Administration granted Tesaro\u2019s drug fast-track approval status \u2014 and this new data will support its registration applications to both the FDA and the European Medicines Agency, Tesaro CEO Lonnie Moulder said.\nMore and more clinical trials will spring up to test PARP inhibitors in combination with other cancer treatments, such as immunotherapy, said Dr. Christina Annunziata, an investigator at the National Cancer Institute who studied the efficacy of Lynparza in ovarian cancer patients.\n\u201cAt this time, there\u2019s nothing available that has been approved by regulatory agencies for these women who have recurrence to their ovarian cancer.\u201d\n\nThe company aims to use its PARP inhibitor, rucaparib, to treat only patients with BRCA mutations who have had two or more chemotherapies.\nAt the European conference this weekend, Tesaro added a few more details to that data:\n\nThe study looked at 553 patients whose cancer responds to a certain type of chemotherapy, known as platinum chemo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention in the story about the side effects or harms traceable to either the three new drugs, or to the one approved drug also mentioned for the treatment of ovarian cancer.\u00a0 A quick web search yields a host of possible side effects, including nausea, anemia, fatigue, joint pain and many others. Especially with stories touting potential new drugs, information should be provided about potential harms the medications may present, not just the positive results of taking the drug.", "answer": 0}, {"article": "America needs to catch up.\nThe U.K.\u2019s new at-home HIV test won\u2019t reach all the undiagnosed or guarantee that the people who test positive wind up receiving the care they need from a doctor, but letting people check their status quickly and accurately is likely to produce cascading positive effects, as HIV-positive people find it easier to seek care for themselves, warn past partners about exposure, and reduce risk for future partners.\nOraQuick, on the other hand, is an oral-based at-home test that does let users see their results immediately, but it has an 8.3 percent chance of a false negative.\n(In contrast, BioSure\u2019s blood test has a much lower 0.2 percent chance that a person who is really HIV positive will test negative.)\nAdopting some version of the British at-home test could help Americans who have already been tested keep up their screening schedule.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is an egregious disregard of harms. Imagine the trauma of receiving a preliminary test indicating you may be infected with HIV, without any counseling or other support. A false positive test would inflict at least temporary anxiety, but if a person did not seek follow-up testing the trauma of an inaccurate test could be long-lasting. It\u2019s possible self-testing could harm people if it means they are less likely to seek care than if they had been tested in a setting that offers counseling. Also, the test may not detect infection that occurred within the previous three months, so a person who was recently infected, but gets a negative test result, may incorrectly believe he or she is uninfected and then expose others.\nSome of the challenges of home testing are covered in this review article.\u00a0(Dr. Ganguli is a co-author). In addition to the above, there is the issue of the test being used more by\u00a0the worried well and the affluent than by those at highest risk for the disease. In surveys, Americans report that they do not want to spend more than $15 on an HIV test.", "answer": 0}, {"article": "A capsule of Probiotic Immunity from New Chapter Inc., based in Brattleboro, Vt., contains 1 billion each of 10 different organisms, including Streptococcus salivarius subsp. thermophilus and Lactobacillus acidophilus, two species of bacteria often found in yogurt. Other ingredients include herbs such as cumin, ginger and spinach. Users are instructed to take two capsules each day, preferably one in the morning and one in the evening, on an empty stomach. You can buy a bottle of 90 capsules for about $20 at many health food stores.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The \u201cgenerally safe\u201d line is too vague for us.\u00a0 There are side effects and risks associated with probiotic use.", "answer": 0}, {"article": "For ongoing (or chronic) pain \u2014 a sore lower back, say, or the kind of degenerative arthritis that typically develops with age \u2014 ibuprofen still outperforms acetaminophen.\n(He advised people to see their doctor if they're taking any of these painkillers for more than a few days \u2014 particularly if they're on other drugs already.)\nTo be more exact, he said, \"I can't imagine why anybody would take acetaminophen.\"\nMoore has looked at all the evidence for what he calls \"infrequent tension headaches\" and found \"it is surprising how poor [the research] is and how little it tells us.\"\nFor ibuprofen, in its normal formulation at something around 400 mg or two tablets, about 50 percent have success.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story comprehensively describes the harms from each drug based on different uses and patient populations. We especially liked this quote:\u00a0\u201cDon\u2019t believe that just because something is over-the-counter, it\u2019s safe.\u201d", "answer": 1}, {"article": "Insulin may have a relationship with cancer.\nAt this point, no one knows if metformin is safe in non-diabetic populations but some clinical trials are starting to look at the issue, Lippman said.\nThis adds credence to the idea that metformin's value is in its ability to lower overall insulin levels in the body, Cantley said.\nOthers believed that the finding might influence the choice of drugs in people with diabetes.\nAnd when the drug was administered by injection, the improvement seen was 73 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At least the story noted, \"no one knows if metform in safe in non-diabetic populations but some clinical trials are starting to look at the issue.\" ", "answer": 1}, {"article": "Developed in the laboratory of UHN transplant surgeon Dr. Markus Selzner, with the help of UHN transplant surgeons Drs.\nOne way to address this gap by the transplant community worldwide has been to extend the criteria of those donor kidneys used for transplantation.\n\u201cThis technique will change the landscape of organ donation by improving organ preservation, allowing us to better assess and regenerate the donor organ on the device before we transplant it into a patient.\nSince the kidney did not \u201cstruggle\u201d after transplant, there is a greater likelihood that its long-term outcome will be better, he adds.\n\u201cThis new technology can help us answer the critical question, \u2018What\u2019s the best way to improve function and recover and repair the kidney before transplantation to get the best results for our patients?\u2019\u201d\n\nDr. Grant, who is also Professor of Surgery at the University of Toronto, emphasized that high-impact research projects such as this require strong collaborative teams \u2013 including researchers, surgical residents, nurses, Canadian Blood Services, perfusionists, colleagues at SickKids - working together on experimental and clinical trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Kidney transplantation poses a number of risks, from infection to rejection of the donor organ to the kidney failing to work normally. The release refers to the phenomenon known as \u201csleepy kidney,\u201d in which a newly transplanted organ takes some time before it begins functioning. However, it doesn\u2019t address other health risks in a meaningful way, not does it offer any insight into how the new technique may affect those risks. Could ex vivo organ perfusion reduce those risks? Increase those risks? We\u2019re not told.", "answer": 0}, {"article": ".\n\"I see the biggest impact of idarucizumab as providing reassurance to patients that if bleeding while taking dabigatran does occur, we can quickly reverse the dabigatran.\nResearchers say before idarucizumab was available, patients on dabigatran who needed emergency surgery were given purified clotting factors, which carry the risk of patients' clotting systems forming dangerous blood clots.\nAn interim analysis of the first 90 patients in a study called RE-VERSE AD (REVERSal Effects of idarucizumab in patients on Active Dabigatran) showed that idarucizumab effectively reversed dabigatran's anticoagulant effects, said Richard A. Bernstein, M.D., Ph.D., lead study author and director of the stroke program at Northwestern Memorial Hospital in Chicago, Illinois.\nThe new results are part of a large on-going phase III study testing idarucizumab in a range of patients who take dabigatran and have dangerous bleeding or need urgent surgery or other procedures that carry serious bleeding risks.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that idarucizumab \u201cdoesn\u2019t seem to carry with it any tendency to increase clotting,\u201d but does not tell readers anything else about potential harms. Could idarucizumab contribute to other problems? Readers don\u2019t know. Even if there are no health risks associated with idarucizumab, it\u2019s important to tell readers that. And, according to the Praxbind website, there are potential adverse effects.", "answer": 0}, {"article": "Women choosing to have both breasts removed face higher surgery costs and slightly higher risks of post-surgery complications and infections.\nResearch has found this procedure is equally effective, particularly with smaller tumors and often when used in combination with radiation.\nU researchers confirmed the trend using federal cancer data but could only speculate why.\nWhile these suspicions rarely end up as cancer, they do often result in follow-up tests such as biopsies and ultrasounds that can frighten patients, Leach said.\nThe survey results came a decade ago, however, when the safety of breast implants was a major issue, said Mayo\u2019s Dr. Lynn Hartmann.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report mentions slightly higher risks of surgical complications and infections. It would have been useful to specify how serious and frequent these outcomes are, but this is not a serious flaw. ", "answer": 1}, {"article": "\"In many of those cases we decide, 'OK, this lesion is too small to be treated with a filling.'\nIt's intended for patients whose decay has not gone beyond the tooth enamel.\nBut at the intermediate stages, dentists don't have many options.\nIcon was developed in Germany and has been available in the U.S. for just over a year.\nThat cringe-worthy sound may be on the way out.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story does not mention any harms from this product, so we would typically rate it as Unsatisfactory. However, a review article published last year on this sort of sealant also did not mention any side effects. The article did mention that there was a great deal of variation in how these products are used in different countries indicating that there is no clear consensus on how they should be used.\nReference:Sealants in Dentistry: Outcomes of the RCA Saturday Afternoon Symposium 2007Caries Research 2010;44:3\u201313http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=000271591&Ausgabe=253776&ProduktNr=224219&filename=000271591.pdf", "answer": 2}, {"article": "It doesn't make a whole lot of sense,\" he pointed out.\nWhile there are drugs for the secondary symptoms of autism, such as irritability and aggression, doctors have nothing yet for the core symptoms in the areas of language, social interaction and intellectual deficits.\nThe long-term effects of the hormone are also uncertain.\nAlthough there are many kinks to be worked out, experts feel the strategy holds promise to treat one of the core symptoms of autism spectrum disorder.\nAlso, scientists would need to come up with a different method of delivery, Young said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While harms are not quantified in the\u00a0published study\u00a0itself, this story does well to emphaszie the importance \u2014 and current lack \u2014 of safety data for an alluded-to use of oxytocin in children with autism. \nWe do know a good deal about the toxicity of oxytocin when given to women to induce labor and for a few hours. In addititon to possible severe allergic reactions, water intoxication is an important side effect.", "answer": 1}, {"article": "\"It's clear that these medications are beneficial,\" said Wadden, who has been a paid consultant to pharmaceutical companies as well as Weight Watchers. \"Unfortunately, there's a sense that they must not work if you have to take them indefinitely. But I think obesity medications should be used on a long-term basis for chronic weight management, just as I take a [cholesterol-lowering] statin and a blood-pressure medication for the long term.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms in the story\u2013although weight loss medications were discussed.", "answer": 0}, {"article": "\"It's not.\"\nTUESDAY, Nov. 1, 2011 (HealthDay News) -- Multiple sclerosis patients may eventually benefit from a novel treatment that takes aim at the abnormal behavior of a specific type of immune cell, preliminary research suggests.\nThe new therapy's potential is only in the early stages of exploration, cautions an international study team comprised of researchers from the United States, Canada, Switzerland and the Netherlands, in the report published in the Nov. 1 online edition of The Lancet.\n\"Our findings show that ocrelizumab rapidly suppresses inflammatory activity,\" noted the study authors, led by Dr. Ludwig Kappos from the University Hospital, Basel, Switzerland, in a journal news release.\nThat said, Dr. Moses Rodriguez, a professor of neurology and immunology at the Mayo Clinic in Rochester, Minn., disputed the premise that ocrelizumab is shaping up as anything new and innovative.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "What does \u201cappears to be safe\u201d and \u201cno serious adverse effects directly attributable to the drug\u201d mean?\nHere\u2019s what the study abstract stated:\u00a0 \u201cWe noted serious adverse events in two of 54 (4%; 95% CI 3\u00b70\u20144\u00b74) patients in the placebo group, one of 55 (2%; 1\u00b73\u20142\u00b73) in the 600 mg ocrelizumab group, three of 55 (5%; 4\u00b76\u20146\u00b73) in the 2000 mg group, and two of 54 (4%; 3\u00b70\u20144\u00b74) in the interferon beta-1a group.\u201d\nWhy didn\u2019t the story report this?\nWhat side effects were seen?\u00a0 Tell readers/patients and let them decide if they are serious or not.\u00a0 And how did researchers know that whatever was seen was not directly attributable to the drug?\nAnd what\u2019s the safety record been of the drug the Mayo expert described that has a longer track record?\nInsufficient information on harms.", "answer": 0}, {"article": "Ixekizumab works by blocking IL-17.\nAlthough any treatment that works by blocking the immune system\u2019s ability to mount an inflammatory response should be carefully monitored for its potential to render the body vulnerable to infectious disease, there were few observed differences in this category between recipients of placebo versus active drug given every four weeks, Genovese said.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\nWhile 19.5 percent of patients who received only the placebo injections were judged to have met the trial\u2019s specified clinical endpoint \u2014 at least a 20 percent reduction in the number of tender and swollen joints \u2014 the response rate among those getting the real drug every four weeks was 53.3 percent.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We learn that \u201cfew serious adverse events were reported for patients receiving the drug, or the placebo\u201d but a close reading of the actual abstract shows that 7 percent of patients taking the drug every two weeks (versus 3 percent on placebo) had serious adverse\u00a0events. If the absolute effects on benefits are reported why are not the absolute effects of the harms? We think it is important to at least list the major adverse events that occurred during the trial.", "answer": 0}, {"article": "Cocoa or cacao beans are not beans but the seeds of the fruit of the Theobroma cacao tree.\nFeb. 7, 2011 -- Giving your sweetie chocolate for Valentine's Day may show you care for their health as well as their heart.\nA new study suggests that dark chocolate and cocoa powder may be the next \"super foods\" thanks to their high antioxidant content.\nTwo groups of antioxidants in particular, polyphenols and flavonols, which are found in various fruits and seeds, have been the focus of much research due to their potentially healthy effects.\nFoods and fruits high in these antioxidants have been dubbed as \"super foods\" or \"super fruits\" by the media.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Starting with the headline, this story extols the\u00a0health-promoting\u00a0properties of the antioxidants found in chocolate, and it isn\u2019t until the last sentence that we receive\u00a0a hint of a warning about\u00a0potential downsides of chocolate, such as high saturated fat\u00a0and total calorie content.\u00a0The story states, somewhat euphemistically, that dark chocolate is a \u201cpotential superfood to be enjoyed in moderation.\u201d The story should have cautioned that you will have to limit yourself to\u00a0just\u00a0a small square of chocolate per day \u2014\u00a0a fraction of a standard chocolate bar, and much less than what the average person consumes as a snack \u2014\u00a0to achieve any potential health benefits. If you eat any more,\u00a0the weight gain caused by the additional calories will most likely negate any benefits from the health promoting antioxidants.", "answer": 0}, {"article": "The results showed that men who ate the most foods rich in flavonoids had a 35% lower risk of Parkinson\u2019s disease compared with those who ate the least.\nThis was an observational study and therefore can\u2019t establish cause and effect.\nThis study will be presented at a medical conference.\nNor is it clear why the results differed for men and women.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms aren\u2019t discussed but we don\u2019t know what they\u2019d be.", "answer": 2}, {"article": "Psoriasis is a chronic autoimmune-related skin condition in which thick, scaly patches appear on the skin.\nPatients who underwent surgery saw significant reductions in their disease severity scores at post-surgical follow-up -- according to a 0 to 10 rating scale -- with disease severity scores in patients with psoriasis dropping from 5.6 to 4.4, and scores falling from 6.4 to 4.5 for those with psoriatic arthritis.\nIt is estimated that as many as 20 percent of individuals with moderate to severe psoriasis develop psoriatic arthritis in their lifetime.\nResults were even more pronounced in those with severe disease activity, with scores falling from 7.7 before surgery to 5.7 after for patients with severe psoriasis, and from 8.2 to 4.8 after surgery for patients with severe psoriatic arthritis.\nThe researchers say excess weight loss may reduce the body-wide inflammation and pain triggered by extreme excesses of fat tissue.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Sadly, no harms related to bariatric surgery were mentioned, nor were the likelihood of complications due to the surgery and the rate of reversals that are often necessary.\nPsoriasis is an important problem but clearly bariatric surgery would not be a first-line treatment for the condition. The trade-offs in terms of risks of complications and required lifestyle changes after bariatric surgery are critical considerations for a patient hoping to reduce their psoriasis symptoms.", "answer": 0}, {"article": "Actinic keratoses are typically red, scaly skin lesions that can over time develop into a type of skin cancer.\nBecause the new gel is only used for a few days, any irritation is usually short-lived.\n\u201cThe shorter application period is what makes ingenol mebutate a breakthrough in the treatment of actinic keratosis,\u201d researcher Mark Lebwohl, MD, says in a news release.\nHalf got the new gel and the other half received an inactive placebo.\nThe short duration also makes people more likely to stay the course, another advantage, according to the study's authors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In an odd line, the story states \u201cBecause the new gel is only used for a few days, any irritation is usually short-lived.\u201d\u00a0 But it doesn\u2019t describe the irritation in any detail \u2013 nor\u00a0 how often it occurs.\u00a0 This isn\u2019t telling readers much of anything useful.", "answer": 0}, {"article": "Botox and Myobloc carry labels warning of possible adverse reactions near the injection site such as drooping eyelids, and of severe difficulty swallowing in patients with neuromuscular disorders.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nBotox's manufacturer, Allergan, thinks those older studies are more credible.\nNot surprisingly, these \"preclinical tests\" (that is, those performed before testing on humans) were especially rigorous for botulinum.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided a clear report on the potential harm to rats receiving Botox injection into whisker muscle. But the story went beyond a reasonable argument to suggest a link between the study results and harms to patients. \u00a0 While the implication of the study is that there is the potential of systemic effects following local treatment with botulism toxin, the story didn\u2019t really make clear what this meant.", "answer": 0}, {"article": "Instead, they used a weaker method comparing the before-and-after differences within each group.\nWhile some people will want to see and feel an impact, he said, for many the clinical claim alone suffices.\nSchalock told Reuters Health he has a \u201chard time seeing that statistically or scientifically they have proven it.\u201d\n\nThe fact that the company did the testing itself could also raise a red flag.\nOf more than a dozen researchers and dermatologists contacted about the quality of this study, only Schalock agreed to comment.\nBut a closer look reveals some shaky science, said Dr. Peter Schalock, a dermatologist at Massachusetts General Hospital in Boston who isn\u2019t affiliated with Laboratoires Inneov.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms found in the trials so far, but then the evidence in the trials so far is being called into question.\u00a0 We\u2019ll give the story credit for exposing the potential harm of consumers (and dermatologists) being misled by unsubstantiated claims. ", "answer": 1}, {"article": "The scans, called coronary computed tomography angiography or CCTA, produce a detailed image of the heart that reveals cholesterol buildups in the coronary arteries.\nIn an editorial, Dr. Michael S. Lauer of National Heart, Lung, and Blood Institute in Bethesda, Maryland, said the new study serves as a reminder of the downsides of screening.\nYet there\u2019s no evidence that treating people based on heart scan results does any good, said Dr. John McEvoy, of Johns Hopkins Ciccarone Center for the Prevention of Heart Disease in Baltimore, who led the new study.\n\u201cTesting might lead to more harm than good,\u201d McEvoy told Reuters Health, adding that heart scans may cost $600 or more.\nBy contrast, it\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the competing Wall Street Journal story, this story was clear about the potential harms: \u201cit\u2019s well known that the scans expose patients to a high dose of X-rays, which can increase their likelihood of developing cancer. And the dyes used to enhance the images cause kidney damage in a significant portion of people.\u201d", "answer": 1}, {"article": "The results were published in the journal Science Translational Medicine.\nNone of the patients experienced graft rejection or required long-term immune suppression -- two potential side effects with human donor corneal transplants.\nAug. 25, 2010 -- Corneas made in the lab using genetically engineered human collagen could restore sight to millions of visually impaired people waiting for transplants from human donors, researchers say.\n\u201cWe are still in the prototype stage, but this shows that regenerating a human cornea is possible.\u201d\n\nTwo years after having the corneas implanted, six of the 10 patients had improved vision .\nIn a newly released study, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that none of the patients \"experienced graft rejection or required long term immune suppression \u2014 two potential side effects with human donor corneal transplants.\" It could have discussed what it might mean for these patients if these grafts ultimately fail.\u00a0Does it prevent them from then undergoing a human corneal transplant, which has a more established record of long term success?", "answer": 1}, {"article": "For further information, please contact:\nThe previously unrecognized PMS/PMDD benefit of PS Plus came about when 2,000 volunteers received and consumed Lipogen's PS Plus for brain health and stress management.\nAt the end of the 2-month study, out of 220 women under the age of 40 who consumed the product regularly, 23 women (10.45%) reported that they noticed relief of premenstrual syndromes.\nAccording to the Medical University of South Carolina, current available treatments include SSRIs and other drug treatments that treat side effects and can cost from US$60.00 - US$535.00 per month.\n\"We also have begun an ongoing, double-blind, randomized, placebo-controlled clinical trial with daacro GmbH, Trier, Germany, to learn more how Lipogen's formulation can help alleviate PMS and PMDD symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no description of potential harms. The company CEO is quoted saying there are \u201cno reported side-effects.\u201d\nHowever, a look at a commonly used scientific database for CAM product ingredients reveals there are side effects associated with phosphatidilserine, the active ingredient found in the product. Those include nausea, gastric distress and insomnia. There also may be an increased risk for acquiring infectious diseases, such as bovine spongiform encephalopathy (mad cow disease) if the phosphatidilserine is derived from bovine cortex, according to the database site.", "answer": 0}, {"article": "This benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\n\"The new study is the first to establish a direct relationship between fish consumption, brain structure, and Alzheimer's risk,\" Raji says.\nAnd people who ate baked or broiled fish at least weekly and didn't lose brain cells were much less likely to develop Alzheimer's disease or mild mental impairment, says Cyrus Raji, MD, PhD, of the University of Pittsburgh School of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the competing HealthDay story, at least WebMD reminded readers:\n\u201cThe Environmental Protection Agency recommends that pregnant women, nursing mothers, and children avoid eating shark, swordfish, king mackerel, or tilefish and limiting albacore tuna to 6 ounces per week because of concern about levels of mercury in these fish.\u201d\n ", "answer": 1}, {"article": "Dr Iain Foulkes, Cancer Research UK's executive director of research and innovation, said: \"It's exciting to see how Cancer Research UK's partnerships with both academia and industry are bringing urgently needed new tests and treatments to patients.\nIf the Phase I trial proves successful, the compound must pass further stages of trial over the next few years before it becomes available to patients.\nThe trial is still ongoing, so results are not available yet.\nThe drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.\n\"Drugs such as these could help to shift the balance back in favour of the patients, potentially providing a new option to patients for who existing treatments no longer work.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential harms that might preclude this treatment from coming to market.\nFrom other examples of cancer drugs, it is most\u00a0likely that there\u00a0would be some undesirable effects and the release could have at least acknowledged that harms are unknown.\u00a0  ", "answer": 0}, {"article": "Stryker says that none of the problems underlying the recall or the warning letter from the F.D.A.\n\u201cPublished research shows squeaking is rare compared with other total-hip-related risks like infection, dislocation and leaving patients with uneven leg length.\u201d\n\nBut plaintiffs lawyers, who have already filed scores of lawsuits on behalf of ceramic hip patients, are gearing up to argue that squeaking is not a minor problem for many who experience it.\nBut Dr. Fabio Orozco, a surgeon at the Rothman Institute, a major orthopedics group in Philadelphia, said that a recently completed review of about 1,500 Rothman patients with ceramic hips had found that the squeaking condition occurred in 49 of them, or about 3 percent.\nWhile there have been no reported cases of serious mishaps, some surgeons fear that the ceramic material might shatter at some point, leaving a patient with so many inflammatory shards in the hip that a doctor could never find them all.\nNow that the squeaking has raised caution flags, researchers are weighing the noted durability of ceramic-on-ceramic hip joints like Stryker\u2019s Trident model against products with other combinations of materials.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news story focuses on one main harm\u2014squeaking in hip implants made of ceramic\u2014and provides estimates of its prevalence. A spokesperson for the hip maker points out that hip replacement has other potential risks as well, including infection, dislocation, and leg-length discrepancy. ", "answer": 1}, {"article": "Dr.\nPlum said that Epigenomics did not see its test as being necessarily in competition with the Exact Sciences test, because the blood-based test would be good alternative for people put off by stool testing.\n\u201cWith stool tests, you need a 90 percent specificity,\u201d said Dr. Bert Vogelstein, a cancer expert at Johns Hopkins University who is also an adviser to the company.\n\u201cIf widely used, and regularly, this test really does have the opportunity to eliminate colon cancer,\u201d said Dr. David A. Ahlquist, a colon cancer expert at the Mayo Clinic and an adviser to Exact Sciences.\nThe specificity of the Exact Sciences test is 88 percent, meaning that 12 percent of the time the patient will be given a false alarm.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The two tests the Times reported on were done on blood and on stool, which, in theory, should not harm anyone during the screening. But there is potential for harms as a result of screening. The story states that with the Exact Sciences DNA test \u201c12 percent of the time the patient will be given a false alarm.\u201d\u00a0 And, regarding the Epigenomics blood test, the story states that \u201cmore false positives could be generated so you could end up doing more harm than good.\u201d", "answer": 1}, {"article": "AstraZeneca PLC's cholesterol drug Crestor sharply lowered risk of heart attacks among apparently healthy patients in a major study that challenges longstanding heart-disease prevention strategies. The findings could substantially broaden the market for statins, the world's best-selling class of medicines.\n\nHeart experts said the findings, presented Sunday at the annual scientific meeting of the American Heart Association in New Orleans, could reshape cholesterol-treatment guidelines used for more than a decade to fight cardiovascular...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that there was an increased number of people taking Crestor who developed diabetes during the study.", "answer": 1}, {"article": "For the really Type A personality, here's a chance to measure how well you are relaxing. Makers of home biofeedback devices that monitor your heart rhythms say the devices teach you to combat emotional stress. Psychologists and psychiatrists say the gadgets appear to help their stressed-out patients but warn that there isn't yet strong scientific evidence that they work.\n\nBiofeedback has long been used to treat stress in psychologists' offices -- with an expert who leads the patient in relaxing breathing exercises and...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that no serious side effects have been reported.", "answer": 1}, {"article": "Cardiologist Debauche agrees.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\nCardiologist Douglas Zipes, past president of the American Academy of Cardiology, says the problems kids suffer are typically electrical, like abnormal heart rhythms, or structural, like a thickening of the heart muscle.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\nBoth of these problems are exacerbated during exertion when kids play sports.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nApart from a passing reference to costs, there is no discussion of the potential downsides to screening, which are numerous and include overtreatment of benign abnormalities, unnecessary exclusion of children from sports and other health-promoting physical activities, and creation of undue anxiety in children who have no reason to worry about their hearts.\u00a0\u00a0 \n1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n", "answer": 0}, {"article": "SIR Annual Scientific Meeting, March 17-22, 2018.\nResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\n\"Advanced stage liver tumors, including ones that have spread from other locations, have limited treatment options because the patients can be in poor health; further, the complex structure of the organ can make it difficult to target with standard approaches,\" said Steven S. Raman, M.D., professor of radiology, surgery and urology at the David Geffen School of Medicine, University of California, Los Angeles, and lead author of the study.\nThe authors note several limitations of the current study, including the preliminary nature of the results, as well as the number of patients tested.\nPatients were given escalating doses of T-VEC, up to the maximum FDA-approved dose for melanoma.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release stated, \u201cResearchers found the patients tolerated the treatment well with expected side effects, including temporary flu-like symptoms.\u201d\nSince this was a safety trial, we expected more detail on what those expected side effects were.\nWere \u201cexpected side effects\u201d the same as those observed in patients getting T-VEC for melanoma? Are the flu like symptoms the worst?", "answer": 0}, {"article": "NASHVILLE -- Sick with depression, Harriet Bruce spent her days lying in bed for months at a time.\nIt's an alternative to electroconvulsive therapy \u2014 shock treatments \u2014 for patients who have not responded to drugs or psychotherapy.\nThe devices cost around $100,000, Cochran said, who has treated 45 patients with the therapy.\nA clinical trial funded by the National Institutes of Health revealed a \"significant effect of treatment\" when patients received TMS treatment.\nIt can cost as much as $400 for a 37-minute session and require multiple treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t provide any specifics about potential harms of the treatment, \u00a0We are told, \u201c\u2026treatments are more effective than medications with far fewer side effects,\u201d \u00a0\u201c\u2026but for the most part, it is safer in general than taking a medicine. You\u2019ve got less seizure risk than taking a medicine. You\u2019ve got less side effects than taking a medicine.\u201d \u00a0Exactly what are the risks and how often do they occur? \u00a0Here is a listing of side effects from \u00a0the NIMH website:(http://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies.shtml )\n\u201cSometimes a person may have discomfort at the site on the head where the magnet is placed. The muscles of the scalp, jaw or face may contract or tingle during the procedure. Mild headache or brief lightheadedness may result. It is also possible that the procedure could cause a seizure, although documented incidences of this are uncommon. A recent large-scale study on the safety of rTMS found that most side effects, such as headaches or scalp discomfort, were mild or moderate, and no seizures occurred.\u00a0Because the treatment is new, however, long-term side effects are unknown.\u201d", "answer": 0}, {"article": "Got milk?\nNow that's trickier.\nAnd they consider themselves lucky.\nSusan Mueller, a mother of two in Ithaca, N.Y., bought shares in a dairy farm so she could pick up her raw milk and yogurt at a drop-off point closer to home.\nNo biggie--just zip to your local supermarket and pick up a carton.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned safety concerns associated with consumption of raw milk, especially by individuals who may have heightened vulnerability. \u00a0(The story also included comments from people who are fans of raw milk who claim these concerns are overblown.) However, this is one area where this story could have been improved. \u00a0Raw milk has the potential to make people quite ill, especially children (which was mentioned in the story) but also pregnant women, those whose immunity is compromised as well as the general public. \u00a0It should have included more information about infection rates among people consuming raw milk.", "answer": 0}, {"article": "\u201cThey should speak with their doctor.\u201d\nThis is not the first study to suggest Celebrex and similar drugs \u2014 known as COX-2 inhibitors - may reduce the risk of developing colon cancer, he said, but people need to balance that potential benefit with the higher risk of cardiovascular complications.\nOnly half of the people who originally agreed to participate in the study remained after 5 years, and it\u2019s unclear how this might affect the results, noted Chan, whose own research suggests aspirin could prevent deaths from colorectal cancer.\nBut to people who have no underlying cardiovascular problems and a particularly high risk of colon cancer - they were diagnosed with it before perhaps, or have a strong family history - regular screening may not be enough, Chan noted.\nAnd when participants stopped taking the pain pill Celebrex (celecoxib) out of concerns over side effects, they eventually developed more polyps than people who had remained on an inactive, or placebo, drug throughout the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "If we were tough on the \u201cevidence\u201d criterion grade, we go a little easy on this one.\nThe story notes that Celebrex users were more likely than the placebo group to develop polyps once they stopped taking the drug, and it quantifies this risk appropriately in absolute terms. However,cardiovascular risk \u2014 which is the main concern with this drug \u2014\u00a0is described only in\u00a0relative terms. The story states\u00a0that those treated with the drug had a 66% higher risk of serious cardiac disorders. Although we acknowledge that this is a picky point,\u00a0the story should have\u00a0reported the absolute rate of these problems in both groups and the associated difference in risk. This would have helped\u00a0readers understand how common cardiovascular events were in the study overall and how concerned they should be about the increased risk in the Celebrex group.\nNonetheless, because of the overall handling of harms and repeated mention of safety concerns, we\u2019ll give the story the benefit of the doubt.", "answer": 1}, {"article": "The ancient art of applying suction cups to the body has gotten a boost from several new studies that show it helps relieve a variety of painful conditions. But scientists say larger, more rigorous studies are needed.\n\nCupping, as the practice is called, was performed traditionally in China and other countries, and is now available from acupuncturists, and some chiropractors and massage therapists in the U.S. In the traditional method, called fire cupping, a ball of burning cotton is briefly placed inside a glass cup to heat...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Possible harms are never discussed in the story. The story does mention that cupping \u201cshouldn\u2019t be done on pregnant women, people with heart conditions or people with bleeding disorders,\u201d but why not? There are other possible harms, such as spread of resistant bacteria by not properly cleaning instruments.", "answer": 0}, {"article": "\u201cI would be with Ava during the day, and then when Jay got home, he would stay with Ava, and I would spend time with Audrey,\u201d she said.\nHer mother added, \u201cWe just need this to work and to stay working.\u201d\n\nNCI\u2019s Fry is careful not to make any promises about an extended remission.\nThat\u2019s a major achievement in a group whose cancer is emboldened by every treatment failure.\nIt is also far from clear that such a personalized approach \u2014 possibly costing hundreds of thousands of dollars \u2014 is economically viable on a large scale or will produce the lasting remissions that everyone hopes to see.\n[Brain cancer now the leading cause of cancer deaths in children]\n\nAt a six-month checkup, tests showed that the leukemia was back again.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses potential harms. Early on, the it notes that \u201ccomplications can be lethal,\u201d and refers to a study in which several patients died due to brain swelling. Much lower down, the story refers to one patient\u2019s \u201cintense immune reaction that followed treatment,\u201d involving a fever of 106 degrees Fahrenheit. Those aren\u2019t all the risks, but it\u2019s some of the major ones.", "answer": 1}, {"article": "\u201cI didn\u2019t know whether to laugh or cry,\u201d Quinn said.\nEverybody now has a donor, and that is a major advance.\u201d\n\nYet doctors and patients may not be aware there are choices other than conventional bone-marrow transplants, Jones said.\nUmbilical-cord stem cells, however, are sort of a blank slate because they haven\u2019t been exposed to much life \u2014 such as bacteria and viruses \u2014 and thus are more easily accepted even if they aren\u2019t a perfect match.\n\u201cThere are still lots of patients in need of transplants that are not getting them because of lack of matched donors, and that is unacceptable in the year 2016.\u201d\n\nJones estimates that about 7,500 transplants of donated stem cells were done in 2014 \u2014 primarily for leukemia and lymphoma but also for nonmalignant blood disorders such as sickle cell and aplastic anemia \u2014 but that more than 15,000 could easily be done annually if more doctors embraced the new methods now available.\nWhat eventually saved her, though, was an experimental transplant using stem cells from the blood of a baby\u2019s umbilical cord, an approach that can be used without perfectly matching blood types.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story nicely raises the risk of cord blood transplantation and the risk of standard cancer therapies throughout the piece. For example, it says, \u201cBecause each umbilical cord produces only a tiny number of stem cells, umbilical-cord transplants take longer to work than standard transplants, which makes patients more likely to get fatal infections. And if cells from several umbilical cords are used, the chances of immunity problems increase.\u201d\nWe do wish that the story made it clear earlier on that the new approach is preceded by intensive chemotherapy and the inherent side effects it entails.", "answer": 1}, {"article": "With knee-replacement surgery on the rise, more patients with two bad knees are opting for a controversial procedure that replaces both at the same time.\n\nSimultaneous bilateral knee replacement, as the surgery is known, is a subject of debate among orthopedic surgeons, with conflicting evidence about the risks and benefits. Proponents say it eliminates the need for a second hospital stay and grueling rehabilitation period, reduces time spent under anesthesia and costs less.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is pretty clear on this, noting early on that \u201crecent studies have found increased rates of complication such as blood clots that travel to the lung, an increased need for blood transfusions, and a higher risk of death with the bilateral procedure.\u201d Later the story refers to two different studies. One, published earlier this year, found \u201cincreased overall complications and risk of subsequent surgery within 30 days\u201d for patients who had the bilateral replacement. The other, published in 2014, found that \u201cbilateral patients were at increased risk of both minor and major in-hospital complications as well as death.\u201d Again, it would have been great to include links \u2014 or citations \u2014 for the relevant studies.", "answer": 1}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\nWe don\u2019t know what the harm would be, other than consumers pursuing a costly approach for which the evidence base is questioned.\n\u00a0", "answer": 2}, {"article": "Among other changes, they found that levels of human growth hormone, or HGH, surged after fasting \u2014 increasing 20 times in men and 13 times in women.\n\u201cWe were able to replicate the findings and show that people who fast routinely have a lower prevalence of coronary disease.\u2019\u2019\n\nThe downside of the study is that it didn\u2019t ask for specific details on the type and duration of fasting among the patients.\n\u201cBut what it does suggest is that fasting is not a marker for other healthy lifestyle behaviors.\nThat\u2019s the finding of a new study from doctors in Utah who looked at the relationship between periodic fasting and cardiovascular disease.\nIt appears to be that fasting is causing some major stress, and the body responds to that by some protective mechanisms that potentially have a beneficial long-term effect on risk of chronic disease.\u201d\n\nDr. Horne noted that patients shouldn\u2019t take up fasting without discussing it first with their doctor.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only discussion of potential harms of fasting was this: \u201cAny fast should include water because dehydration can raise risk for stroke.\u201d\u00a0 Over what period of time?\u00a0 What\u2019s the evidence base?\u00a0 In what kinds of people? What could happen if people at risk for cardiovascular disease, such as diabetics, fast?\nEven the previous line in the story suggests a broader issue than that when it said \u201cfasting is causing some major stress.\u201d\u00a0 What does that mean, and what are the broader implications for potential harms?", "answer": 0}, {"article": "\"Few would have expected such results.\"\nAfter an average of 4 1/2 years, the groups had similar rates of death and heart attack: 211 in the angioplasty group and 202 in the medication group \u2014 about 19 percent of each.\nAt the start of the study, 80 percent had chest pain.\nIn the study, only one-third of the people treated with drugs ultimately needed angioplasty or a bypass.\nThe stunning results found angioplasty did not save lives or prevent heart attacks in non-emergency heart patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned the percent of individuals in each group that initially had angina and then compared that with the percent affected at 3 and 5 years.\u00a0 It also mentioned the rates of heart attack and death in both treatment groups.\nWhile the story mentioned 1/3 of those in the medication-only group later went on to have a stent put in or had coronary bypass surgery, it could have compared this with the number of individuals in the stent and medication group who went on to either have an additional stent placed or had bypass surgery.\u00a0(30% vs. 20%)\u00a0", "answer": 1}, {"article": "She exercised.\nFor perspective, over the course of a lifetime, 1.5 percent of Americans will develop pancreatic cancer.\nEven more promising are the findings from the seven patients with early pancreatic cancer that were detectable through their protein levels.\n\u201cSomething like this could potentially flatten that curve and change the epidemiology of pancreatic cancer.\u201d\n\nStill, Donahue said, the method needs to be \u201cheavily vetted and validated.\nBut, by good fortune, the protein turns up in exosomes only when there is cancer, so its presence could be an early, and testable, marker for the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harm from screening and treatment is an important issue \u2014 these are major surgeries (which are best performed by skilled surgeons at high-volume centers) that are associated with mortality rates of around 4% and multiple morbidities. While the test was 100% sensitive and specific in the study, in the real world there will be false negatives and false positives\u2013and possibly indeterminate results. We also do not know whether there is any risk of overdiagnosis (detecting cancers that would never cause a problem).\nBut there was no mention in the story of the potential harms. The logical extension of the approach advocated in this piece is that all people should be screened for pancreatic cancer. If that is what the researchers and the other commentators in the piece believe, then they should also address the issue of unnecessary surgeries, side effects from treatments, and the anxieties caused by mass screening.\u00a0A more reasonable point of discussion in the piece might have been to suggest developing a screening protocol for populations known to be at risk. For example, people who smoke, are obese, or who have diabetes are all more likely to be diagnosed with pancreatic cancer. An\u00a0effective and cost-effective screening program would need to determine which people to target (including whether a person is healthy enough to undergo surgery) and at what age.", "answer": 0}, {"article": "I was very emotional!\"\nBut the vast majority of patients, 86 percent, did not have an allergic reaction.\nShe says the results aren't that surprising, since allergists had classified these patients as low-risk for reacting to the foods they were being tested for.\n\"We found that 14 percent of the patients challenged had mild or moderate allergic reactions,\" explains study author Carla Davis, an allergist and director of the Food Allergy Program at Texas Children's Hospital.\nShe says 2 percent of the reactions were more serious, requiring treatment with epinephrine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story explains, patients who experienced either mild or serious allergic reactions to the oral food challenge were treated with antihistamines or epinephrine respectively. For the 86% of patients who passed their food challenges with no adverse reactions, no harm was involved.", "answer": 1}, {"article": "\u201cCytokines are an alarm system in the body,\u201d said Dr. Curtis.\n(PHILADELPHIA) -- When patients present with neurologic symptoms such as severe headaches or seizures, the symptoms could suggest anything from infection, cancer, or an autoimmune disease of the brain or spinal cord, leaving physicians scrambling to find the cause in a short amount of time.\nThe differences in diagnosis can mean having mere hours to act or being able to take days or weeks to devise a treatment plan.\nWorldwide, meningitis and encephalitis affect more than four million adults and children each year.\nThe researchers then tested the cerebral spinal fluid (CSF) for the presence of 41 different cytokines and noticed that patients with confirmed infection of the central nervous system had a different cytokine fingerprint from those confirmed as having tumors or autoimmune disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Getting a \u201cspinal tap\u201d to extract a sample of CNF is nothing to sneeze at.\nAlso called a lumbar puncture, the roughly 45-minute procedure involves inserting a needle into a patient\u2019s lower back, navigating it between two spinal vertebrae, and barely slipping the tip into a sac near the spinal cord. This location allows a doctor to suck out the nervous system\u2019s fluid, which is shared from the brain case down through the spinal cord.\nBut during or after the procedure, there\u2019s up to a 25% chance that fluid will leak into nearby tissues and trigger headaches, according to the Mayo Clinic. Dizziness, nausea, and vomiting up to two days after the procedure can also occur, and the headaches can last as long as a week. Back pain can be an issue, too, as can bleeding at the site of the puncture.", "answer": 0}, {"article": "Where did this Ron DeSantis come from? Florida\u0092s governor surprises everyone but himself.\n\nA month into his term, Gov. Ron DeSantis has shattered assumptions that he would govern exclusively from the right. He has drawn unexpected praise from Republicans and Democrats.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While mentioning that one child with cirrhosis was able to reduce the number of medications he needed from 11 to 4, the story did not provide any information about side-effects and potential harms associated with liver transplantation. \u00a0In addition, the story indicated that this child had failed to lose weight after the transplant, though it failed to discuss that the high dose of steroids after transplant needed to avoid organ rejection likely contributed to this situation. \u00a0Lastly, as liver transplant just replaces the diseased liver but doesn\u2019t change the underlying circumstance that lead to the condition \u2013 the story should have discussed the potential future need for organ replacement.", "answer": 0}, {"article": "\u201cDuchenne muscular dystrophy (DMD) is a progressive and fatal genetic disorder of muscle degeneration.\nIt is not clear just how the drug is helping the mice, they reported in the Proceedings of the National Academy of Sciences, but they said it may be worth trying it as a treatment for muscular dystrophy.\nTests in mice genetically engineered to have a condition similar to Duchenne muscular dystrophy showed the drug could improve how the heart works, Joseph Beavoa of the University of Washington and colleagues at the University of North Carolina found.\nThe team, working with funds from the NIH and non-profit groups, tested Viagra in mice that had heart damage similar to that seen in muscular dystrophy.\nBecause of the involvement of the X chromosome, boys are far more likely to be affected than girls, who have two copies of the X chromosome and, thus, are likely to have a \u201cspare\u201d copy of the healthy gene.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story fails to mention any of harms of sildenafil, which include:\u00a0\u00a0\u00a0 * sudden severe loss of vision (see below for more information)\u00a0\u00a0\u00a0 * blurred vision\u00a0\u00a0\u00a0 * sudden decrease or loss of hearing\u00a0\u00a0\u00a0 * ringing in ears\u00a0\u00a0\u00a0 * erection that is painful or lasts longer than 4 hours\u00a0\u00a0\u00a0 * dizziness or lightheadedness\u00a0\u00a0\u00a0 * fainting\u00a0\u00a0\u00a0 * chest pain\u00a0\u00a0\u00a0 * worsening shortness of breath\u00a0\u00a0\u00a0 * itching or burning during urination\u00a0\u00a0\u00a0 * rashSildenafil may also interact with other prescription drugs.\nWhat\u2019s more, the story failed to note that the continual administration of sildenafil over many months used in this study (and the sort of life-long daily treatment that would be envisioned in human patients) is more like the way the drug is used in patients with pulmonary hypertension and completely different from the occasional doses of the Viagra brand form of the drug used by men to treat erectile dysfunction.", "answer": 0}, {"article": "Obesity is a risk factor for T2D, and both obesity and T2D increase CVD risk.\nA new study published in Nutrients shows that eating just 1.5 ounces of pecans - one small handful - every day may protect adults at risk for developing cardiovascular disease (CVD) and type 2 diabetes (T2D).\nThe study entitled \"A Pecan-Rich Diet Improves Cardiometabolic Risk Factors in Overweight and Obese Adults: A Randomized Controlled Trial\" is available online and will be presented at the American Society for Nutrition Annual Conference, Nutrition 2018 held in Boston this June.\nBoth the control diet and the pecan-rich diet were low in fruits, vegetables and fiber.\nWhile a growing body of evidence has linked tree nuts such as pecans to reduced risk of CVD, this is the first study to look at the effects of pecan consumption on factors other than blood lipid levels and specifically those related to T2D.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any possible harms from adding pecans to the diet. A brief mention of nut allergies and the high fat and calorie content of nuts would be appropriate in a release advocating daily pecan supplementation.", "answer": 0}, {"article": "Bladder cancer is the fourth most common cancer in men, but it is less common in women.\nThe RAZOR trial found that two years after surgery, 72.3 percent of patients in the robotic surgery group were alive, with no disease progression and essentially cured, compared with 71.6 percent in the open surgery group.\nSixty-seven percent of robotic surgery patients experienced adverse effects such as urinary tract infections and intestinal obstructions, compared with 69 percent in the open surgery group.\nResearchers wrote that the findings \"underscore the need for further high-quality trials to assess surgical innovation before this surgical technique is widely adopted in clinical practice.\"\nBut apart from the RAZOR trial, there have been no prospective, randomized multicenter trials to assess how robotic surgery compares to open surgery in cancer survival.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release reports that patients who had robot-assisted surgery spent more time in the operating room than those having open procedures (seven hours vs. six hours). It also reports overall rates of adverse effects (67 percent in the robot group vs. 69 percent in the open group), along with listing the most common problems: urinary tract infections and intestinal obstructions. It would have helped if the release had pointed out that these complication rates were not statistically different.", "answer": 1}, {"article": "In a similar study published in the journal Pediatrics in 2004, researchers recruited 100 children with upper respiratory tract infections who had been coughing for an average of over three days.\nIn this occasional series, the New York Times \u201cReally?\u201d columnist, Anahad O\u2019Connor, explores the claims and the science behind alternative remedies that you may want to consider for your family medicine cabinet.\nUltimately, the honey produced the greatest improvements when it came to better sleep and reduced cough frequency and severity.\nThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\nThe thinking is that sweet substances of any kind help soothe the back of the throat and break up mucus in the airways.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We appreciate that, at the end of the piece, it includes a section on risks. It says, \u201cThe Risks: According to the National Institute of Allergy and Infectious Diseases, honey may be useful in relieving coughing, but it should never be given to children under a year of age because in rare cases it can cause infantile botulism.\u201d We think a number here would have helped. How rare is rare? One in 1,000? One in 1 million? According to the Centers for Disease Control, there are about 110 cases of infant botulism annually. While the cause of the infection is not entirely clear, both honey and corn syrup have been implicated. SInce the story suggests that sweet substances might be useful, the addition of corn syrup to the risks would have been helpful to readers.(see:http://www.bt.cdc.gov/agent/botulism/clinicians/epidemiology.asp)", "answer": 0}, {"article": "The study is in the Sept. 22 issue of JAMA.\nThe drug is approved for treating pseudobulbar affect, a neurological disorder that involves involuntary crying, laughing and other emotional displays as its main symptom \u2014 not involuntary movement of the facial muscles.\nIn combination, they are used to treat pseudobulbar affect, a neurological disorder involving involuntary crying or other emotional displays.\nNow researchers report that a combination drug already in use for treating certain neurological problems may be a better remedy.\nDextromethorphan is a cough suppressant commonly found in over-the-counter cough medicines, and quinidine is a drug used to control heart rhythm disorders.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned, despite the fact that significant side effects occurred during the study, and in more than one or two people \u2014 most frequently falls, diarrhea, dizziness, and vomiting. The drug is also well known to have significant side effects on heart rhythm \u2014 hence the exclusion of patients with heart rhythm problems \u2014 and also to raise the levels of commonly used drugs such as digoxin and some of the SSRI class of anti-depressant/anti-anxiety drugs.", "answer": 0}, {"article": "This type of drug development program, which enrolled patients with different tumors but a common gene mutation, wouldn\u2019t have been possible a decade ago because we knew a lot less about such cancer mutations,\" said Dr. Gottlieb.\nThe FDA announced Monday that it had approved Vitrakvi (larotrectinib), a treatment for both adult and pediatric cancer patients.\nFor the second time, the U.S. Food and Drug Administration has approved a drug that, instead of targeting tumors by location\u2014breast cancer, prostate cancer, lung cancer\u2014attacks cancers according to specific genetic structures, known as biomarkers.\n\"Using our breakthrough therapy designation and accelerated approval processes, we support innovation in precision oncology drug development and the evolution of more targeted and effective treatments for cancer patients,\" the FDA stated.\n\"Accelerated approval\" means that the FDA has fast-tracked the process of getting drugs to patients before the usual clinical trials are completed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms. An FDA news release mentioned fatigue, nausea, cough, constipation, diarrhea, dizziness, vomiting, and elevated enzyme levels that might indicate liver damage. The FDA said patients should have regular liver tests and warned against treating women who are pregnant or breastfeeding because of potential harm to their fetus or baby.", "answer": 0}, {"article": "\u201cI knew starting a family was a few years off,\u201d said Gold.\nThe test has traditionally been offered to women who are struggling to get pregnant and helps assess the possible next steps, such as getting pregnant sooner or freezing eggs.\nSome doctors are now offering it as an option to healthy women to assess what they call their ovarian reserve.\nThis hormone is released by follicles in the ovaries and predicts the amount of possible eggs a woman has.\nThe test doesn\u2019t measure the quality of the eggs and it\u2019s not a guarantee of fertility.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms were not discussed, though they exist. To name a few, women may act upon the test results\u2013for example, undergoing invasive and expensive treatments like egg retrieval and freezing\u2013when those actions may have not been necessary. Or they may experience anxiety over test results that show low levels of the hormone, and consider themselves \u201cinfertile\u201d when that is not at all certain.", "answer": 0}, {"article": "Median length of stay was 6 days (range, 4-58) with a median follow-up of 25 months.\n\"This new analysis of IRE could help change the standard of care for Stage III pancreatic cancer patients whose only treatment options until now were chemotherapy or a combination of chemo-radiation therapy, which will only stabilize the disease and not destroy the tumor.\n\"The STAR data adds to the growing body of evidence that IRE ablation may represent a new treatment paradigm for patients with locally advanced pancreatic cancer,\" said Robert Martin, M.D., Ph.D., F.A.C.S., director of the Division of Surgical Oncology, and Professor, Department of Surgery, University of Louisville, James Graham Brown Cancer Center.\nThe centers that collaborated on the study included University of Louisville, Louisville, KY; Henry Ford Hospital, Detroit, MI; Cleveland Clinic, Cleveland, OH; Piedmont Hospital, Atlanta, GA; Swedish Medical Center, Denver, CO; and Cancer Treatment Centers of America, Atlanta, GA.\n\nFrom July 2010 to October 2014, patients with radiographic Stage III LAPC were treated with IRE and monitored under a multicenter, prospective IRB-approved registry.\nThe NanoKnife\u00ae IRE system is approved by the U.S. Food and Drug Administration for the surgical ablation of soft tissue.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are alluded\u00a0to, e.g. \u201c[19] percent sustained complications with a median grade of 2 (range 1-3),\u201d but they\u2019re not discussed or explained in sufficient detail. What\u2019s a \u201cmedian grade 2\u201d complication? It would have helped this release to cite, for example, the\u00a0American Cancer Society\u00a0on the side effects of\u00a0ablative therapies for pancreatic cancer. Generally, according the ACS, those harms can \u201cinclude abdominal pain, fever, nausea, infection, and blood clots in nearby blood vessels\u201d with a\u00a0potential for serious complications.", "answer": 0}, {"article": "The new surgery simply moves them to the side in order to fit the knee with titanium and plastic caps \u2014 creating a knee joint free of pain and arthritis.\nLess than two hours later the operation was over.\nO'Brien successfully charted the course and headed out of the hospital to a smooth recovery.\nO'Brien spent just a few hours in the hospital after surgery before she was well enough to go home.\nHer knee was wrapped in antibiotic plastic and tourniquets \u2014 to cut down on bleeding and the possibility of infection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential harms resulting from this procedure.", "answer": 0}, {"article": "At the start, about 12% said they didn\u2019t exercise, and the rest said they exercised anywhere from \u201cup to 30 minutes\u201d to \u201cmore than 4 hours\u201d a week.\n\u201cGiven that the intensity of exercise does not appear to be important,\u201d the authors wrote in their paper, \u201cit may be that the most effective public health measures are those that encourage and facilitate increased levels of everyday activities, such as walking or cycling.\u201d\n\nOf course, there are other benefits to more frequent and more intense bouts of exercise.\nIf their hypothesis is right, they say, 12% of depression cases could be prevented if everyone got just one hour of exercise a week.\nRegular exercise may prevent many cases of future depression, according to a new Australian study, and researchers say that as little as one hour a week can make a real difference.\nIt\u2019s also possible, they add, that exercise may trigger changes in self-esteem, the release of mood-boosting endorphins and the production of certain proteins.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this N/A since the risks associated with light exercise are fairly minimal. However, we think it\u2019s always a good idea to discuss the potential harms of an intervention. In this case, the story implies that very light and infrequent exercise provides this benefit. Does this encourage people to exercise less and to then lose out on other health benefits of more exercise? Injuries are also an issue for those going from no to some exercise.", "answer": 2}, {"article": "For more information, please visit www.proove.com or call toll free 855-PROOVE-BIO (855-776-6832).\nPeer-reviewed clinical studies show that the Proove Opioid Risk\u00ae profile accurately identifies patient risk for opioid abuse.\nStudy author, Gregory A. Smith, M.D, former Director of Pain Management at Harbor UCLA, explains, \"Having used this technology for 6 years, this data provides further evidence that clinicians can use Proove Opioid Risk\u00ae for ruling out patients unlikely to exhibit aberrant behaviors, and identifying high-risk patients for alternative therapies.\"\nThis study evaluated 186 patients, comparing 94 Medicaid patients at an addiction treatment facility with confirmed cases of opioid abuse, and 92 healthy patients with no history of opioid use.\nFurthermore, the sensitivity of the \"moderate risk\" cut-off score was 98%, while the specificity of the \"high risk\" score was 100%.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms from the test are not explained. The primary medical risks from the use of such a test would stem from inaccurate identification of an individual\u2019s risk of addiction. This could lead to individuals identified as being at low risk potentially being less careful about their use of opioids, leading to addiction; conversely, inaccuracy could identify an individual as being at higher risk when, in fact, they were at low risk and would benefit from being prescribed opioids.", "answer": 0}, {"article": "\"This may simply indicate that some of the causes for preterm birth may not pre-exist before the pregnancy,\" Graves said.\nThe false positive rate -- referring to tests that wrongly indicated premature birth -- was 20 percent.\nThe test may cost $150 to $250, Graves said.\nThe test wasn't as effective at 24 weeks of gestation.\nWu said the study results are promising, but more research is needed to confirm that the test is reliable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It mentioned that the false positive rate was 20%, so we\u2019ll give it a passing grade. We wish, though, that it had included some expert comment on the significance of a false positive rate that high.", "answer": 1}, {"article": "Among the materials that his predecessor had left behind was a latex bald cap.\nIn fact, previous research has found that when everything goes well, the guidance system produces targeting errors of about 2 millimeters but, in about one operation out of seven, the target error is much larger, forcing the surgeon to redo the registration process.\nThey determined that the cap outperformed the headband by 76 percent when the forces were applied to the headband and by 92 percent when they were applied to the markers.\n\"Actually, we do have a solution to this problem but it involves drilling and attaching the markers directly to the skull...which we don't like to do because it is painful and it's a step backwards from the majority of what we are doing,\" said Assistant Professor of Otolaryngology Paul Russell, who is collaborating with the engineers on the project.\nThey designed three tests to determine how well this \"granular jamming cap\" performed relative to the current headband in reducing targeting error:\n\u2022 They \"bumped\" both them from a number of different directions with a tennis ball filled with plastic particles swinging on the end of a string.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions that the cap is \u201cnoninvasive\u201d but doesn\u2019t say whether there are any potential harms. Silicone allergies are purportedly rare, but they do exist.\nThe news release is silent on the issue of potential harm which is movement from anatomic landmarks. We aren\u2019t sure that the lower error rate seen with the coffee cap is really an advantage. \u00a0An earlier publication from the group concluded:\nOur results show that our granular jamming fixation prototype reduces registration error by 28%-68% (depending on bump direction) in comparison to a standard Brainlab reference headband.. Indeed the method appears to be better than the headband approach but it is unclear how it performs in comparison to anchored fiducial markers.", "answer": 0}, {"article": "Dr. Steve Hicks, senior author of the study and an assistant professor of pediatrics at Penn State College of Medicine, said the \"five microRNAs in saliva could predict with approximately 85% accuracy which concussed children would have symptoms one month later.\n(CNN) A saliva test may someday be able to diagnose a concussion and predict how long symptoms last, according to a study published Monday in the JAMA Pediatrics.\n'Way too early to know'\n\nHowever, the editorial authors, Dr. William P. Meehan III of Micheli Center for Sports Injury Prevention at Boston Children's Hospital in Massachusetts and Dr. Rebekah Mannix of Brain Injury Center at Boston Children's Hospital, noted that \"the relatively small sample size in this study requires larger-scale studies to determine the reliability\" of the results.\nIn the study, those who had used anti-inflammatory medications were the ones with longer-term symptoms.\nPossibly, then, the drugs may be a potential 'confounding' variable, they wrote, meaning that medication may influence test results and symptoms, adding an element of confusion to the study and its possible interpretation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not directly address potential harms. The harms with screening tests are false-negative results\u2013in this case, concluding a child doesn\u2019t have a concussion when she really does\u2013and false-positive results\u2013concluding a child needs treatment when she doesn\u2019t.", "answer": 0}, {"article": "Too many people give up on treatments like Rogaine and low-level-light devices before they\u2019ve had a chance to work, Dr. Senna said.\nFor now, Maryanne Senna, a dermatologist and the director of the Hair Academic Innovative Research Unit at Massachusetts General Hospital in Boston, said the best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\nOne is how much emphasis the company places on compliance, the major stumbling block in the efficacy of any treatment, said Dr. Senna, an author of studies on the subject.\nThat\u2019s the most Mr. Skjoth will say about it.\nClients must also use the company\u2019s shampoo, conditioner and styling products, forsaking all others \u2014 a psychological as well as a financial buy-in, Dr. Senna said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms of this mystery substance aren\u2019t addressed. The story quotes a dermatologist who says \u201cthe best she can tell patients who ask \u2014 and a lot of them do \u2014 is that Harklinikken won\u2019t do any harm.\u201d But how does a dermatologist \u2014 or anyone \u2014 really know since the company won\u2019t say exactly what\u2019s in its product?", "answer": 0}, {"article": "The Ache: In cold and flu season, pathogens spread when people are crammed into close quarters, such as airplanes and cars.\n\nThe Claim: Personal air purifiers worn around the neck clean the air in the wearer\u2019s breathing zone of viruses and bacteria as well as allergens, say companies that sell them.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does mention that the devices can produce ozone which, in some concentrations, can be harmful.\u00a0 It also cites one case where a similar device exploded during an air flight, mentioning that no one was seriously injured.\u00a0 It seems fair to consider the story satisfactory for this criterion.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070311/19clot.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did explain that the use of MRI technology might result in 'false signals'.\u00a0 It should have explained that this means that some patients who did not have clots that could cause a cardiopulmonary embolus\u00a0would have been treated as if they did.\u00a0 There was no discussion about the harms associated with this treatment; nor was there any discussion of the mental anguish that might accompany the diagnosis in the absence of the condition.\nSimilarly \u2013 the story included no discussion of the possible harms associated with the Angiojet.\u00a0 Although it appears, from the summary of safety and effectiveness data filed with the FDA, that the risks of bleeding complications, heart attacks, and death are less with the Angiojet than with the treatments for large deep vein thrombosis with which it was compared, there was no discussion of the harms associated with this device in the story.", "answer": 0}, {"article": "New Zealand's scrubby manuka trees with their creamy blossoms used to be chopped down for farmland.\nThe South African Medical Journal reported in 2006 on a trial among gold miners in which honey worked as well as, and was more cost-effective than, a standard gel on shallow wounds and abrasions.\nThe European Journal of Medical Research reported in 2003 that honey had an 85 percent success rate in treating infected post-op Caesarean wounds, compared with a 50 percent success rate for conventional interventions.\nRose Cooper, a microbiologist and honey expert at the University of Wales Institute at Cardiff, remains cautiously optimistic that the increased use of honey dressings will help better information to emerge.\nAndrew Jull, a research fellow at the University of Auckland's Clinical Trials Research Unit and principal investigator in a trial in New Zealand of 368 patients into the use of honey as a therapy for leg ulcers, says that while \"there is reasonable evidence for manuka honey's antibacterial effect\" in the lab, \"there is still need for in vivo testing.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms of using honey. Reports indicate that topical use of honey can cause a burning or stinging sensation and there is some concern about infection.", "answer": 0}, {"article": "Still, little is known about its cause.\nThe many potential preventive health benefits of breastfeeding should also be communicated openly to the general public, not only to mothers, so breastfeeding can be more socially accepted and facilitated.\n\u201cBecause the primary goal of public health is prevention of morbidity, health care professionals should be taught the potential health benefits of breastfeeding and given tools to assist mothers with breastfeeding, whether themselves or with referrals to others who can help.\nBreast milk is meant to exclusively supply all the nutritional needs of infants and current recommendations include exclusively breastfeeding for the first six months of life to optimize growth, development and health.\nIn addition, more high-quality studies are needed to clarify the biological mechanisms underlying this association between breastfeeding and lower childhood leukemia morbidity,\u201d the study concludes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re on the fence here. We\u2019re not suggesting that breastfeeding causes serious harm to mother or child, except perhaps in some cases of infectious disease transmission. However, breastfeeding isn\u2019t always the peaceful scene of contentedly suckling infant often portrayed in the media. Cracked nipples, nipple pain, engorgement, mastitis (breast infections) are not uncommon and can reduce breastfeeding success. In addition, breast milk is low in vitamin D, and exclusive breastfeeding may increase the risk of rickets. Some acknowledgment of these issues could potentially encourage steps to prevent and address these problems, which would be beneficial.", "answer": 0}, {"article": "Attorney James Tuffin followed his usual daily routine last week: He ran five miles and drove to his office on suburban Long Island. In between, he stopped at Advanced Radiation Centers in North Hills, N.Y. There, he drank a quart of water, lay down on a treatment table and watched as a high-tech linear accelerator rotated around him for 90 seconds, blasting his cancerous prostate with radiation.\n\n\"On a good day, I'm in and out in a half-hour,\" says Mr. Tuffin, 54 years old, who was midway through his scheduled 45...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only harm of treatment mentioned was that the patient interviewed for the story feels a little sleepy in the afternoon after treatment. \u00a0However the experience of a single individual cannot be considered sufficient information on the possible harms associated with a treatment.", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms were mentioned.\nThe FDA said side effects of Gilenya in pediatric trial participants were \u201csimilar to those seen in adults,\u201d with the most common being headache, liver enzyme elevation, diarrhea, cough, flu, sinusitis, back pain, abdominal pain and pain in extremities.\nThe FDA added there are other serious risks with the drug including slowing heart rate, infections including a rare brain infection, vision problems, swelling and narrowing of the blood vessels in the brain, respiratory problems, liver injury, increased blood pressure and skin cancer, as well as potential harm to a developing fetus.", "answer": 0}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of side effects that may accompany long-acting contraceptive methods, nor of those associated with the birth control pill/patch/ring.\u00a0While effectiveness in preventing pregnancy is a paramount concern, women also weigh side effects in making a decision about which method to use.", "answer": 0}, {"article": "Researchers from Leeds Metropolitan University in the U.K. steeped thyme, marigold, and myrrh in alcohol to make what's called a tincture, and then tested them on the bacteria that cause acne.\nBut some U.S. dermatologists are quick to caution that while intriguing, this research is still preliminary, and thyme-tinged acne treatments are not yet ready for prime time.\nThey all had greater antibacterial effect after five minutes compared to lab specimens exposed to plain alcohol, but thyme was the most potent.\nLargely due to its anti-inflammatory and anti-bacterial properties, the herb thyme -- which is found with other herbs in the produce section of most food stores -- may well earn itself a place in the skin care section of your local drug store.\nThe new findings were presented at the Society for General Microbiology's Spring Conference in Dublin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No human testing was apparently done.\u00a0 In point of fact, it\u2019s far too early for the story to talk about either benefits or harms.", "answer": 2}, {"article": "The W.H.I.\nfindings have been seriously misunderstood and misinterpreted,\u201d and millions of women for whom the benefits clearly outweigh the risks are needlessly being denied treatment.\nfindings, many new analyses and studies have prompted experts to rethink the wisdom of avoiding hormone replacement, especially for women within a few years of menopause whose personal and family history do not place them at high risk of breast cancer.\nMost of the 27,347 women entering the study were already in their 60s and 70s, already a decade or more past menopause.\nBut now, new research suggests that the benefits of short-term hormone treatment to control life-disrupting menopausal symptoms outweigh the risks \u2014 as long as the treatment is started at or near menopause.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is trying to compensate for bad communication in years past, and so we believe it should meet a high standard when communicating the perspective it says is \u201cnew.\u201d\nHere is one harms statement that could use more careful writing and more numbers. The italics were added by us:\n\u201cIn an analysis in 2013 in the American Journal of Public Health, Dr. Philip M. Sarrel and his co-authors calculated that, based on reduced death rates among women taking only estrogen in the W.H.I. study, avoiding hormone replacement resulted in the premature deaths of 18,601 to 91,610 women in the decade after the study\u2019s release.\u201d\nThere is a lot of leeway between 18,000 and 90,000. The claim of deaths due to misinformation begs for a more accurate description of the equation used in the 2013 paper, as well as limitations of the analysis. It would also be\u00a0important to explain why this recommendation differs from that of the independent U.S. Preventive Services Task Force, which still recommends against the use of HRT for the prevention of chronic diseases. Their recommendation includes a\u00a0detailed description of harms and benefits on their web site.\nThe entire story is about the \u201charm\u201d possibly done by the warning years ago that hormone replacement therapy had been hyped inaccurately as a cure-all. But the story is remarkably silent on the potential \u201charm\u201d that still exists from hormone replacement for some women under some circumstances. The point that every woman should calculate her own personal risk versus benefits with her physician seemed buried.", "answer": 0}, {"article": "Schafer Cardiovascular Research Fund, the Johns Hopkins Magic That Matters Research Fund for Cardiovascular Research, grants from the National Center for Advancing Translational Sciences (UL1-TR-000040 and UL1-TR-001079), and contracts from the National Heart, Lung, and Blood Institute (HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168 and N01-HC-95169).\nIn the study, published on Jan. 10 in Circulation, the researchers say these calcium scores allow physicians to go beyond the traditionally calculated risk factors to determine which blood pressure treatment strategy may be most appropriate for a particular patient.\nThe scans use radiation, so there is a very small cancer risk for susceptible individuals.\nThus, even though their calculated heart disease risk is relatively low and their blood pressure is below traditional cutoffs for treatment, the researchers say people in this category with calcium over 100 are high risk and may benefit from more aggressive blood pressure treatment.\nPreviously, the appropriate blood pressure treatment for these patients used risk calculations and some guesswork, potentially leaving many vulnerable to heart disease or taking drugs they don't need.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states: \u201cThe scans use radiation, so there is a very small cancer risk for susceptible individuals.\u201d While the mention of cancer risk is laudable, we aren\u2019t clear what\u2019s meant by \u201csusceptible individuals.\u201d Also, it does not mention that CT scans are not recommended for pregnant women due to possible risk to the fetus. In addition, harms can also arise from medications prescribed to treat these calcium scores.", "answer": 1}, {"article": "Half of the group engaged in resistance training twice a week, while the other half continued to live their lives normally without systematic training.\n\"Over the past six years, we have been pursuing the idea that physical training has effects on more than just the symptoms, and this study provides the first indications that physical exercise may protect the nervous system against the disease,\" says one of the researchers behind the study, Associate Professor Ulrik Dalgas from the Department of Public Health at Aarhus University.\nOn the other hand, the study indicates that systematic physical training can be a far more important supplement during treatment than has so far been assumed.\nA bigger and more in-depth on-going study will help to clarify this, and may also lead to improved treatment options, says Ulrik Dalgas.\n\"For the past 15 years, we have known that physical exercise does not harm people with multiple sclerosis, but instead often has a positive impact on, for example, their ability to walk, their levels of fatigue, their muscle strength and their aerobic capacity, which has otherwise often deteriorated.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release points out that MS patients were advised against exercise in the past for fear of exacerbating the condition. But only positive effects correlated with the study are addressed in the release, with no mention of potential harms. Weight training and other types of exercise have the potential to cause injury, which might be more likely in MS patients with reduced muscle function, impaired balance, or other issues. Consequently, we give the news release, a Not Satisfactory rating here.", "answer": 0}, {"article": "Children slept in the MRI machine while researchers read them bedtime stories.\nBefore bringing it to clinics, researchers need to make sure this test isn't detecting other developmental delays such as dyslexia, he noted.\nAnd when it is ready for prime time, it probably won't be applicable to all children with autism.\nThis allowed the investigators to see which parts of the brain were being activated in typical children versus children with autism.\nThe test involved using functional MRI to measure brain responses to spoken words in sleeping children.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It makes a pass at this by saying the screening may inadvertently detect other brain problems and lead to misdiagnoses,\u00a0but it\u00a0doesn\u2019t develop the theme. Although fMRI does not use ionizing radiation, the procedure is long and the subject\u2019s head need to be restrained for the scans to be taken,\u00a0 In addition, the scan itself produces a good deal of noise (loud thumping)\u00a0requiring the subject to wear protective earphones.\u00a0 And, the test will take up to one hour to complete. ", "answer": 0}, {"article": "Women with BRCA1 and BRCA2 mutations who had their ovaries and fallopian tubes removed had similar results.\nThe study shows the benefits of genetic tests that give women with a family history of cancer the chance to take steps to increase their chances of survival, they said.\n\u201cThis is the first study to prove women survive longer with these preventive surgeries and shows the importance of genetic testing when there is a family history of early breast or ovarian cancer,\u201d Dr. Virginia Kaklamani of Northwestern University in Chicago wrote in a commentary about the study published in the Journal of the American Medical Association.\nShe said primary care physicians, gynecologists and women \u201cneed to be more aware that these tests exist.\u201d\n\nDr. Sandhya Pruthi, a breast cancer expert at the Mayo Clinic in Rochester, Minnesota, who counsels women with BRCA mutations, said the study adds more evidence that the surgery can help save lives, but the choice is never easy.\nNo woman who had a mastectomy developed breast cancer during the three years of follow-up testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story mention psychological issues facing women who undergo mastectomy and early menopause that results from ovary removal, but the brief reference to harms and lack of important details understates the trauma, side effects and complications that preventive surgery causes women.\u00a0 There are also potential harms from the increased surveillance, for example, with ensuing biopsies. ", "answer": 0}, {"article": "Cervical cancer is the fourth most common cancer in women, with more than 500,000 new cases occurring annually worldwide.\nThis work was supported by the National Institutes of Health (1R01CA195500, 1R01CA193380).\nBy using both methods to visualize the cervix, the researchers will be able to make a direct comparison.\nAsiedu is also working to automate the screening process.\nThe device also includes a channel through which contrast agents used for the cervical cancer screening procedure can be applied.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No possible harms are described. While it is difficult to imagine how this device could cause direct harm, screening and diagnostic tests always involve the possibility of harm from false-negative and false-positive tests. A brief mention of this was warranted.", "answer": 0}, {"article": "\u201cLet\u2019s talk about your test results,\u201d my neurologist said.\n\nShe looked as if she had good news. Instead, it was shocking.\n\nThe carotid artery on the left side of my neck, one of the brain\u2019s two main sources of blood and oxygen, was clogged with fatty plaque, the doctor said. The artery was almost completely blocked.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will rate the story as satisfactory because it does clearly point out that the surgery is hazardous, sometimes triggering a stroke, and that some patients die soon after the procedure. However, the story reports stroke and death rates at the lower end of the ranges reported in medical literature. The story says a major task force report estimated the risk of stroke and death within 30 days after surgery as less than 3 percent overall, but up to 5 percent at some hospitals. However, the lower figure in that task force report uses data only from clinical trials, which typically involve highly skilled surgeons and have better outcomes than typical clinical care. That report also said that some observational data indicates a risk of stroke and death of almost 7 percent at some hospitals. The evidence review mentioned above concludes that the 30-day risk of stroke and death is 7 percent in clinical trials of carotid endarterectomy.\nThe story does warn readers that few hospitals and surgeons publish their individual results.\nThe story would have been stronger had it mentioned that there are harms that can occur if we started screening anyone, regardless of whether they had symptoms. As the USPSTF explains, \u201cFor the general primary care population, the magnitude of benefit is small to none. Adequate evidence indicates that both the testing strategy for carotid artery stenosis and treatment with [surgery or stenting] can cause serious harms.\u201d", "answer": 1}, {"article": "Kilmer McCully of the V.A.\nThe findings follow a number of disappointing studies testing vitamins and other dietary supplements for health reasons.\nAlthough the new studies did show that the vitamins cut homocysteine levels, that did not translate into a reduction in the risk for heart attacks or strokes.\nIn the second study, Kaare Harald Bonaa of the University of Tromso in Norway and colleagues researchers gave 3,749 patients who had had a heart attack within the previous week the vitamins or a placebo for more than three years on average.\nAlthough homocysteine levels among those taking the supplements fell, they were no less likely to die from a heart attack or stroke, the researchers found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of any harms associated with consumption of vitamin B supplements, although such harms would occur from vitamin B intake unlike that studied, so this gets a satisfactory grade. ", "answer": 1}, {"article": "The U.S. National Cancer Institute has more about colon and rectal cancer.\nWhile the study found an association between NSAID use and a reduced risk of colorectal cancer, it did not prove a cause-and-effect.\n\"The results of our study help to further clarify the importance of different durations of NSAID use over time for the risk for dying from colorectal cancer,\" Coghill noted in the news release.\nStudy participants were enrolled in the Women's Health Initiative, which \"represents a large and well-characterized cohort [group] of postmenopausal women, and the medication data collected in this cohort made it possible for us to investigate multiple types, durations and strengths of NSAID use,\" Coghill explained.\nThe researchers confirmed 2,119 cases of colorectal cancer and 492 deaths due to the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of potential harms of prolonged aspirin use, such as stomach bleeding and gastrointestinal ulcers.", "answer": 0}, {"article": "George Bray, an obesity researcher at Pennington Biomedical Research Center in Baton Rouge who has also studied this topic and who wrote the accompanying editorial in JAMA, says that other studies \"show that you can do well on any diet as long as you stick to it.\nOn a low-glycemic index diet, you would avoid highly processed carbs such as white bread, white rice, many snack foods, prepared breakfast cereals, sugary desserts and sugary beverages, she says.\nThe authors note a downside to the low-carb diet: It appears to raise some risk factors for heart disease.\nThe study, funded by the National Institutes of Health, was designed to see if changing the type of diet people consumed helped with weight maintenance because dieters often regain lost weight.\nA new study is raising questions about the age-old belief that a calorie is a calorie.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that the low-carb diet raised some risk factors for heart disease.", "answer": 1}, {"article": "Santarelli describes gantenerumab as a drug engineered to bind itself to plaques known as amyloid-betas, which accumulate as Alzheimer's progresses.\nTherefore, it's not known if reducing the amount of them will slow or stop the disease.\nThe study is published in the online edition of Archives of Neurology.\nThe experimental compound, known as gantenerumab, is being developed by Roche, the Swiss pharmaceutical company.\nWhat is not entirely known at this point, though, is if these plaques cause Alzheimer's or are by-products of the disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than its HealthDay competition in that WebMD actually told us how many people experienced harms in the study.", "answer": 1}, {"article": "High blood pressure increases the risk for heart attack, stroke and kidney problems.\nTUESDAY, March 13, 2018 (HealthDay News) -- A pill that combines three blood pressure-lowering drugs improves people's chances of lowering their high blood pressure, researchers report.\n\"Based on our findings, we conclude that this new method of using blood pressure-lowering drugs was more effective and just as safe as current approaches,\" lead author Ruth Webster said in a news release from the American College of Cardiology.\nAmong those who took the so-called \"triple pill\" for six months, 70 percent had achieved their blood pressure targets, compared with 55 percent of those who received their usual care.\nThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reports: \u201cThe rate of side effects was no greater among those who took the three-in-one pill than among the usual care group.\u201d\nWhat were those side effects, how severe were they, and at what rate did they occur? The story doesn\u2019t say.\nWhile the news release doesn\u2019t say what specific side effects were observed, there are array of potential side effects with blood pressure medication that the story could have mentioned, such as nausea and fatigue.", "answer": 0}, {"article": "\"This is an important area of research.\nThe study found that the advanced version of TCD ultrasound was able to differentiate between healthy and concussed athletes 83 percent of the time.\nEach of the concussed athletes had their brain blood flow measured with the advanced ultrasound headset within an average of six days after the injury.\n\"While such changes may be detected with MRI, we believe there may be a less expensive and portable way to measure these changes with a transcranial Doppler (TCD) device.\"\nThis is in contrast to traditional TCD ultrasound measurements like change in cerebral blood flow reactivity which differentiated between the two 60 percent of the time, average blood flow speed which differentiated 55 percent of the time and blood flow resistance which differentiated 53 percent of the time.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Possible harmful effects, most notably false positive and false negative results, of the ultrasound procedure are not mentioned. A false positive could result in unnecessary follow-up tests and treatments while a false-negative result could lead to an athlete resuming on-field play too soon, greatly increasing their risk of head injury complications and severity.", "answer": 0}, {"article": "After radiation treatment, patients often experience severe, lifelong swallowing, eating, and nutritional issues.\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee.\n\u201cAnd while traditional chemoradiation has demonstrated good tumor control and survival rates for patients, too often they encounter unpleasant outcomes that can include difficulty swallowing solid foods, impaired nutrition, aspiration and feeding tube dependence,\u201d said Dr. Burtness.\n\u201cToday, many younger patients are presenting with HPV-associated squamous cell carcinoma of the oropharynx,\u201d said Dr. Burtness.\n\u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not quantify whether there is any reduction in progression-free survival or \u201ccure\u201d rate with reduced radiation. The release also does not quantify what is meant by the words \u201creduced radiation.\u201d Is it half of normal doses, or reduced frequency but the same dose?\nThere may be potential harms in reducing a therapy aimed at a cure, but the release does not address this except in vague terms:\n\u201cWe found there are some patients have very high cure rates with reduced doses of radiation,\u201d said Barbara Burtness, MD, Professor of Medicine (Medical Oncology), Yale Cancer Center, Disease Research Team Leader for the Head and Neck Cancers Program at Smilow Cancer Hospital, and the chair of the ECOG-ACRIN head and neck committee. \u201cRadiation dose reduction resulted in significantly improved swallowing and nutritional status,\u201d she said.", "answer": 0}, {"article": "The main campus also includes University Hospitals Rainbow Babies & Children's Hospital, ranked among the top children's hospitals in the nation; University Hospitals MacDonald Women's Hospital, Ohio's only hospital for women; and University Hospitals Seidman Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center.\nThe new results were part of a multi-center randomized, placebo-controlled phase 3 clinical trial for TX004HR, an investigational bio-identical 17\u03b2-estradiol applicator free vaginal softgel capsule.\nThe majority of women taking either TX004HR or placebo (85.4 - 92.1 percent) found the product easy to use.\n\"We still have to find better ways to educate the millions of women suffering with VVA about the symptoms, however, so that more of them know it is common, decide to discuss treatment with their healthcare professional, and seek symptom relief with appropriate treatment.\"\nThe survey, which included 731 respondents with a 96 percent response rate, sought to quantify participants' satisfaction with the application method and overall treatment delivery system.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Neither the news release nor the original study on which it reported provided any detailed information about the safety of the investigational drug, other than to say that the estrogen product used has been shown to be \u201csafe and effective.\u201d\nThe product being discussed may offer a lower dose of estrogen than other currently available alternatives, but nonetheless, full disclosure requires some discussion of potential risks.", "answer": 0}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nAfter three months, 37 percent of participants in the acupressure group reported a 50 percent reduction in pain intensity.\nOnly 25 percent of women in the control group reported a similar reduction in pain intensity at both the 3-month and 6-month marks.\nAcupressure-based features - with instructions on how to administer self-acupressure shortly before and during menstruation - were only made available to the intervention group.\nAfter six months, this proportion had increased to more than half of the women in this group (58 percent).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release leaves the impression that there were no ill effects, but the study summary itself notes that some women in the acupressure group experienced bruising, nausea, dizziness or chest pressure.\nAccording to the study, 15 participants experienced an adverse effect.", "answer": 0}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states, \u201cWomen taking estrogen in pill form saw an increase in HDL or \u201cgood\u201d cholesterol and a decrease in LDL or \u201cbad\u201d cholesterol, but an increase in triglycerides.\u201d But what does that mean? Would an increase in triglycerides be harmful to one\u2019s health? The article does not mention any other adverse effects, but it may have been beneficial to reinforce the notion that the study lacks the absolute numbers and statistical power to claim, \u201cNo significant differences in adverse events.\u201d", "answer": 0}, {"article": "Lowering A1C levels helps reduce the risk of long-term complications from diabetes such as eye, kidney and heart disease.\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\n* Average reductions of 0.8 pct seen in levels of A1C\n\nCHICAGO, June 29 (Reuters) - Medtronic Inc\u2019s (MDT.N) insulin pump and monitoring device controlled blood glucose levels better than multiple daily injections in patients with Type 1 diabetes, according to a large post-market study.\nBergenstal said patients who are not achieving their goals with multiple daily injections should consider using a pump and sensor.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story does not mention any potential harms of insulin pumps, even though the researchers reported that two patients were hospitalized because of infections at the site of the pump insertion.", "answer": 0}, {"article": "Infections are also a problem when doctors put tubes into the body.\n\u201cPreventing one infection will pay for thousands of these screenings,\u201d Dr. Henri Verbrugh of Erasmus, a coauthor of the study, said in a telephone interview.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\nThe rate for 413 volunteers given placebo treatment was 7.7 percent.\nIn a commentary, Dr. Richard Wenzel of the Virginia Commonwealth University in Richmond said the chlorhexidine-alcohol mixture should replace the older disinfectant when scrubbing people for surgery, and the nasal disinfection technique should primarily be used for people undergoing cardiac surgery, receiving an implant, or whose immune system is likely to be affected.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harms of the drugs, potential false positives from screening, deaths during the study, and impact of such a prophylactic protocol on antibiotic resistance are not discussed.\u00a0 \nThe\u00a0study publication\u00a0mentions adverse reactions due to local irritation of the nose or skin, which resolved after treatment was discontinued.\u00a0 \nWe believe harms always warrant at least a brief mention. ", "answer": 0}, {"article": "UW-Madison establishes state\u2019s first and only addiction hotline for providers\n\nIn what is believed to be a national first, the University of Wisconsin-Madison, in conjunction with UW Health, has established a new resource for Wisconsin primary-care physicians and other providers to help them successfully manage patients with...\nThe new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\nThe Wisconsin Partnership Program at the University of Wisconsin School of Medicine and Public Health has awarded $750,000 to 15 community-driven projects to catalyze innovative ideas to improve health equity in Wisconsin.\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the news release does note that the study population was limited to post-menopausal women due to the effect of Lupron on sex steroid production, it does not mention potential harms associated with the drug combination among post-menopausal women or possible interactions with other drugs that may be used by this population. The study itself found that\u00a077 of 109\u00a0patients or (71%) experienced at least one adverse event. Three serious adverse events (2 cases of gastrointestinal hemorrhage and one case of deep vein thrombosis) were judged to be potentially related to the drug.\nEmphasis on or exaggeration of potential benefits, coupled with minimizing or totally ignoring harms, have been hallmarks of a majority of the ~2,000 news stories that we\u2019ve reviewed in the past 9 years. \u00a0News releases could help turn news stories in a different, more helpful, more complete direction. \u00a0That\u2019s our hope and expectation with this new feature of reviewing health care news releases.", "answer": 0}, {"article": "Collaborating with Hayes, Schmidt offered the animals kaolin clay, then compared how much they ate normally and with the addition of the AChEIs.\n\"We know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and this will limit their compliance,\" he said.\nThe findings sparked the CIRNA clinical trial, which has to date studied 33 smokers ages 18 to 60.\nFinally, the researchers asked the study subjects to do their best to not smoke for seven straight days, a time during which the participants still took either galantamine or a placebo.\nUniversity of Pennsylvania researchers Rebecca Ashare and Heath Schmidt saw potential for a permanent cessation solution in a class of FDA-approved medications used to improve cognitive impairments from Alzheimer's disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that people may become ill when taking the AD drugs. A source is quoted in the release says, \u201cWe know from the literature that upward of 30 percent of patients will report nausea and vomiting [when taking these drugs], and that this will limit their compliance.\u201d", "answer": 1}, {"article": "The rate was 26 percent lower in counties with screening.\nThe study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nAlthough this story does not go into detail about the potential harms of screening mammography, it does include comments from independent experts who point out that the scans do lead to the diagnosis and treatment of women whose tumors would never have become life-threatening.", "answer": 1}, {"article": ".\nFurther studies, including the planned prospective multi-institutional study referenced in this press release, as well as patient data covering longer periods of time post-treatment, could lead to different or contrary results from those expressed during ASTRO or in the poster presentation.\nThis press release contains forward-looking statements.\nThe other sample received a lower, more conventional biologically effective dose (maxBED10 <90), using non-adaptive therapy.\nForward looking statements with respect to predicted improved survival described in the poster presentation and video, are based on current expectations from the presented retroactive study and involve inherent risks and uncertainties about the potential health and medical benefits of MR-guided Radiation Therapy for the treatment of patients with locally advanced pancreatic cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release provides specific results regarding experiences of both groups with regard to toxicity from radiotherapy.", "answer": 1}, {"article": "Others mixed them with applesauce and cinnamon in a blender or chopped them up and added them to meatloaf, hamburger, and spaghetti sauce.\nThe new study, funded in part by the California Walnut Commission, enrolled 117 men aged 21 to 35 who ate a typical Western diet.\nBefore and after the experiment, the men\u2019s semen quality was analyzed by a researcher who did not know which ones had eaten walnuts.\nIn the new study, most of the walnut eaters snacked on the shelled whole nuts straight out of the package, Robbins says.\nEating 2.5 ounces of walnuts a day -- a little more than half a cup -- for 12 weeks improved sperm quality in healthy young men, researchers report.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Eating walnuts isn\u2019t harmful per se, but they are\u00a0packed with fat and protein,\u00a0and so they\u00a0should be eaten in moderation. The\u00a0amount participants in this study were eating (2.5 oz per day)\u00a0provides about 450 calories and is more than the amount of nuts that is generally recommended for daily consumption (1.5 oz).\u00a0It could\u00a0lead to weight gain if\u00a0not counterbalanced by\u00a0decreased intake of other\u00a0foods. The story\u00a0should have mentioned this.\u00a0 Of course the California Walnut Commission, which partially funded this study, would love to see people eat as many walnuts as possible.\u00a0 Why was the studied designed with this level of walnut consumption?", "answer": 0}, {"article": "Cortisol is known as the \u201cstress hormone\u201d because it is released in response to acute stress to help the body react and cope.\nSimmons said the results did not mean all children with elevated cortisol levels would go on to develop behavioural problems or mental illness, with many other social, environmental and genetic factors also involved.\nThe tests could also be unpleasant and invasive for children, given blood tests require a needle and saliva tests require the child to fast beforehand.\nThe greater number of traumatic events a child had experienced, such as divorce, injury, moving house, severe illness or the death of a family member, the higher the hair cortisol concentrations were, the researchers found.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None were mentioned.\u00a0The other side of the early identification/screening coin is that labeling a child with a mental illness early on and with minimal evidence also has adverse effects with regards to self-image and development.", "answer": 0}, {"article": "The task becomes more difficult, especially for people with early stages of dementia, as the dots move around, changing their direction, speed and intensity.\n\u201cI think it\u2019s a really potentially valuable tool,\u201d said Leslie Algase, an internist who tends about 2,000 patients in Rochester, at least 30 percent of whom are older than 65.\nThe test, which has been around since 1975, offers only a broad indication of cognitive abilities and fails to pick up borderline problems, she said.\nBut the alternative involves referring patients for a battery of neuropsychiatric tests that can take hours to complete and cost $1,000 or more.\nThe Pittsford, N.Y.-based company\u2019s FDA application included data from a comparative study involving 401 people recruited from 13 communities for older adults.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the FDA approved this test on the basis of \u201clittle risk.\u201d But we really aren\u2019t told anything about what those risks are. Here\u2019s what the FDA had to say: \u201cThe risk of a false positive result may result in result in the clinician conducting a more detailed and extensive medical work-up to determine if a subject actually has cognitive impairment that would not be expected for his/her age and educational level. The risk of a false negative result would also be considered minimal. Clinicians would still be responsible for conducting a diagnostic work-up for patients presenting with cognitive impairment symptoms regardless of the Cognivue device result.\u201d\nOne thing both the story and FDA neglect to mention is that a\u00a0false positive can produce patient/family anxiety regarding a devastating condition with no effective treatments. We\u2019re not sure that qualifies as \u201clittle.\u201d", "answer": 0}, {"article": "Floaters become more common with age, and although some people simply get used to them, others are bothered by them or their vision is impaired.\nFor her part, Goldberg said that although \"there was significant improvement in patients' symptoms following treatment, and no significant complication was seen,\" these findings are early and \"it is difficult to predict the long-term safety of this laser procedure.\"\nThey explained that, currently, there are three management options for floaters: patient education and observation; surgery; and a laser procedure known as YAG vitreolysis.\nThe new study involved 52 patients with floaters who received one session of either the YAG laser treatment or a \"sham\" placebo laser treatment.\nHowever, Shah and Heier said there are few published studies on the laser treatment's effectiveness in treating floaters.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses harms by saying, \u201cThere were no differences between the two groups in harmful side effects, according to the study.\u201d\nBut that\u2019s not enough\u2013What are the potential risks? The small size of the study (52 patients) makes it hard to exclude the possibility of side effects. As with any new surgery, doctors will have to learn how to do the procedure. Would you want to be an eye doctor\u2019s first patient to get the new procedure?", "answer": 0}, {"article": "This page either does not exist or is currently unavailable.\n\nFrom here you can either hit the \"back\" button on your browser to return to the previous page, or visit the ABCNews.com Home Page. You can also search for something on our site below.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "\u201cEveryone was hoping vitamin D would be kind of a panacea,\u201d Dr. Black said.\nAnd there is evidence that excess calcium can increase the risk of heart disease, the group wrote.\nIt is not clear how or why the claims for high vitamin D levels started, medical experts say.\nAfter reviewing the data, the committee concluded that the evidence for the benefits of high levels of vitamin D was \u201cinconsistent and/or conflicting and did not demonstrate causality.\u201d\n\nEvidence also suggests that high levels of vitamin D can increase the risks for fractures and the overall death rate and can raise the risk for other diseases.\n\u201cThe number of vitamin D tests has exploded,\u201d said Dennis Black, a reviewer of the report who is a professor of epidemiology and biostatistics at the .\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that, contrary to the claims of many advocates for increased supplemental vitamin D, there is evidence that\u00a0high levels of vitamin D may\u00a0have adverse\u00a0effects, such as increased risk for fractures and an increase\u00a0in the overall death rate. The story also explained that too much calcium has been linked to increased risk of kidney stones and, more tentatively, heart disease.", "answer": 1}, {"article": ".\nBy activating the bitter taste receptors in the uterus, the bitter substances relaxed the contracted uterine muscle tissue more completely than the current drugs used to prevent preterm labor in humans.\nThis could be good news for those trying to prevent preterm labor: New research published online in The FASEB Journal suggests that exposing bitter taste receptors in the uterus to certain substances can stop many unwanted contractions that occur during premature labor.\n\"The bitter taste receptors that we have found on uterine muscle could be one more piece of the puzzle to understand the onset of labor, both at term and preterm, and develop new therapeutics for preterm labor.\"\nThey then exposed the tissue to bitter substances.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms of preterm birth are explained, but nothing is said about the possible harm of the drug \u2014 even to pregnant mice and fetuses.", "answer": 0}, {"article": "Researchers studied 27 men, 21 years old and older.\n\"This study shows that if we treat the gum disease, it can improve the symptoms of prostatitis and the quality of life for those who have the disease,\" said Nabil Bissada, chair of Case Western Reserve's Department of Periodontics and the new study's corresponding author.\nThe researchers reported their findings in the Dentistry article, \"Periodontal Treatment Improves Prostate Symptoms and Lowers Serum PSA in Men with High PSA and Chronic Periodontitis.\"\nSymptom scores on the IPSS test also showed improvement.\nThose with the highest levels of inflammation benefited the most from the periodontal treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release clearly assumes readers will understand there is potential harm from untreated gum or prostate disease and that is probably reasonable. It might have described the risks and limitations of repeated PSA screening and biopsies (which can lead to false-positive results and unecessary treatment), but we don\u2019t think that was an essential part of this analysis. Nonsurgical treatment of periodontal disease has a low potential for harm, something the release could have mentioned. The release does point out the risk to heart patients and pregnant women of untreated periodontal disease.", "answer": 1}, {"article": "The found the chronic poor sleepers became sick more often: those who slept for five hours or less each night were 4.5 times more likely to catch the cold than people who slept seven hours or more.\nIn fact, sleep was more important than any other factor, including age, stress or income level, in predicting who would get sick after being exposure to the cold virus, the researchers say.\nPeople who regularly sleep six hours or less each night are four times more likely to get a cold than people who sleep just an hour longer, a new study finds.\nThe actigraphy measured sleep in a much more accurate way than information researchers get from self-reports, he says.\nIf you're loading up on vitamin C and zinc to stave off the sniffles, you should try an earlier bedtime instead.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites the increased risk of getting a cold with not enough sleep \u2014 with the attendant sometimes debilitating symptoms that are all-too-familiar to many. But mainly the story is advocating for more sleep \u2014 and could there be risks to getting more sleep or trying to stay in bed for 8 hours if you\u2019re only hardwired to sleep for 6 hours? That\u2019s unclear, but the story could have clarified that although more sleep is associated with fewer colds, that doesn\u2019t necessarily mean that increasing your amount of sleep will reduce the number of colds you get. Proving that would require a different study. We\u2019ll give the benefit of the doubt here.", "answer": 1}, {"article": "In addition to He and Dibaba, other contributors included Pengcheng Xun, a faculty member in IU's Department of Epidemiology and Biostatistics; Kuninobu Yokota of The Jikei University School of Medicine in Tokyo, Japan; and Emily White of the University of Washington in Seattle.\nIndiana University researchers have found that magnesium intake may be beneficial in preventing pancreatic cancer.\nPrevious studies have found that magnesium is inversely associated with the risk of diabetes, which is a risk factor of pancreatic cancer.\nThe study also found that the effects of magnesium on pancreatic cancer did not appear to be modified by age, gender, body mass index or non-steroidal anti-inflammatory drug use, but was limited to those taking magnesium supplements either from a multivitamin or individual supplement.\n\"While more study is needed, the general population should strive to get the daily recommendations of magnesium through diet, such as dark, leafy greens or nuts, to prevent any risk of pancreatic cancer.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release encourages people to add magnesium through their diets and through supplementation but doesn\u2019t tell them what the recommended daily allowance is. In the United States, the current magnesium recommended intakes are 400-420 mg/day for men and 310-320 mg/day for women.\nExceeding the recommended levels of magnesium through supplementation can cause side effects. Although these are not likely to be life-threatening, excessive intake of supplemental magnesium is harmful to\u00a0 individuals with impaired kidney functions. In addition, magnesium can interfere with certain medications so patients should always consult with their doctor before adding a supplement.\nFrom WebMD: \u201cDoses less than 350 mg per day are safe for most adults. When taken in very large amounts, magnesium is POSSIBLY UNSAFE. Large doses might cause too much magnesium to build up in the body, causing serious side effects including an irregular heartbeat, low blood pressure, confusion, slowed breathing, coma, and death.\u201d", "answer": 0}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lays out a few harms of hormone blockers \u2014 which it notes is also called chemical castration in men \u2014 including hot flashes, breast growth and sexual problems.", "answer": 1}, {"article": "\"We talk with older folks and many say, 'I can't exercise, but maybe I can become more physically active.'\n\" Study participants were advised to \"start low and go slow,\" and some were even able to get rid of their canes after six months of exercise, which Gill says they found particularly rewarding.\nThe study followed participants for about 2.7 years, and found that the physical activity program cut the amount of time that people spent with a \"major mobility disability\" \u2014 defined as being unable to walk a quarter mile \u2014 by 25 percent compared to the education program.\nThe exercise program pretty closely followed the government's recommendations for all adults, including older ones: 150 minutes of moderate-intensity or 75 minutes of vigorous-intensity exercise per week, plus two strength sessions that hit all the major muscle groups.\n(Canes were OK.)\n\nHalf of the participants got a health education program involving regular in-person sessions and some stretching exercises, while the other group was told to aim for 150 minutes of aerobic activity as well as strength, flexibility and balance training both at the study's facilities and at home.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story basically recommends physical activity for the elderly, which most experts would support. But the study in question focused on \u201csedentary people between 70 and 89 years old who had some functional limitations, but who could walk about a quarter of a mile in 15 minutes or less, unassisted by another person or a walker. (Canes were OK.)\u201d\u00a0 There is obviously a great deal of variation in a population that broad and many included in that age bracket may also have balance, pain or stability\u00a0issues that might preclude jumping into a similar program.\u00a0\u00a0We would have been happier if the story focused early on any new program of physical activity being clearly linked to an initial consult with the person\u2019s physician.\u00a0 While the story does mention at the end that the authors of an accompanying editorial advised physicians that, \u201cPrescribing exercise may be just as important as prescribing medications \u2014 perhaps even more important in some cases,\u201d that seemed insufficient compared to the consequences of physical-activity-induced injury among the elderly.", "answer": 0}, {"article": "The brain\u2019s synapses control how much of these chemicals are released, and drugs like Zoloft effectively prevent the little serotonin being produced from reabsorbing back into the nerve cells from which they were released, resulting in a higher concentration of serotonin.\nThe most common, not surprisingly, are headaches.\nThis article is featured in Newsweek's Special Edition: Nature's Remedies\u2014Heal Your Body.\nThis article was excerpted from Newsweek's Special Edition: Nature's Remedies\u2014Heal Your Body.\nAt this point, specific symptoms can be targeted depending on the patient\u2019s needs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are a feature of this story.", "answer": 1}, {"article": "When the researchers factored in other diet habits, exercise levels and major risk factors for stroke \u2014 like high blood pressure and diabetes \u2014 heavy olive oil use was tied to 41 percent reduction in the odds of stroke.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nWhat\u2019s needed, he said, are clinical trials where people are randomly assigned to use olive oil or not, then followed over time to see who suffers a stroke.\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\nSuch clinical trials are considered the \u201cgold standard\u201d of medical evidence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.", "answer": 2}, {"article": "Aging is never easy, particularly during menopause. But for 30 years women could at least depend on estrogen and progestin supplements, a comforting hormonal hand to hold that would not only ease the uncomfortable symptoms of getting older but also keep skin supple and hair lustrous. Doctors even encouraged women well into their 70s to take the treatments, on the basis of studies showing that they protected against heart disease and cushioned bones against osteoporosis-related fractures.\n\nIt seemed almost too easy--and it was. In 2002 the quick pharmaceutical fix was all but snatched away when a large government study found that...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story adequately describes the harms of hormone therapy, which include a higher\u00a0risk of heart disease, stroke and breast cancer (but see \"quantification of benefit\" criterion below).", "answer": 1}, {"article": "\"They do research online, are more informed and sometimes go to the doctor demanding, 'I think I need an MRI.'\nThere is just no single reason why people get chronic headaches, although we do know that migraines have a genetic component and usually a trigger.\nOn top of that, exposure to radiation in tests like CT scans adds up over time and can increase the risk of certain cancers.\nMafi's study did not include patients with tumors or other serious problems that can cause headaches.\n\"\n\nAnd while an informed patient is a good thing, Mafi says sometimes the patient gets it wrong.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A strong point of this story is that it does explore the potential harm from unnecessary diagnostic tests. We applaud the mention, as too few stories address this phenomenon, but the facts that are presented to help the audience understand why a test would be harmful are somewhat confusing. The story says:\nMafi\u2019s study did not include patients with tumors or other serious problems that can cause headaches. He only looked at otherwise healthy patients who suffered chronic headaches. And in these cases, repeated diagnostic testing can lead to further unnecessary procedures like biopsies.\u00a0On top of that, exposure to radiation in tests like CT scans adds up over time and can increase the risk of certain cancers.\nIn other words, diagnostic tests could find something like a tumor that is causing a headache or early bleeding in the brain prior to an aneurysm, for example. But those people weren\u2019t part of this study so we have no way to make a true comparison to people who had a test and found a problem versus people who had an unnecessary test.\nThe story should have explained the exclusion of patients with tumors more clearly. The patients here are chronic headache patients, as opposed to people who have developed headache as a new symptom or a new type of headache. Depending on their presentation, the latter two may need a series of tests.", "answer": 1}, {"article": "Silicone breast implants were pulled off the market in 1992 amid concerns that leaks from the implants could lead to cancer or autoimmune disease.\nMoreover, that data are limited to just the last two or three years \u2014 not enough, Wolf says, to make any real claims about the long-term safety of the implants.\nBack then they contained a runny liquid silicone.\nSo you have to at least expect that sometime in your life, you are going to need a reoperation.\nBut ultimately she decided she didn't want to go through more surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discussed common problems, but was silent on:\nHalf the story on harms just isn\u2019t good enough in this case.\n", "answer": 0}, {"article": "Lower blinds and turn off lights so your room is as dark as possible.\nHe applied for funding of the research a few years ago, to no avail.\nI suspect it's part of the picture, along with lack of exercise and dietary indiscretion.\"\nOkay, so just how long are we supposed to stay asleep?\n\"It's such an intriguing idea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 Harms don\u2019t seem to apply in this case. ", "answer": 2}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nDoctors can then \"walk through\" the colon and explore many different angles.\nThis new wave of radiology-based colonoscopy could improve those odds further.\nDr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions radiation exposure and the potential for the need for a follow up colonoscopy if a suspicious lesion is found. In reality almost one third of routine colonoscopies identify a suspicious lesion that is either removed or is biopsied. That means that roughly one in three people undergoing a bowel preparation for a CT colonoscopy will need to undergo a second round for removal or biopsy of a suspicious lesion. That is a significant downside that should have been emphasized in the story.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/03/29/national/w155455S59.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In presenting the lack of harms associated with even the high doses of antigen needed to trigger the desired immune response, the article included an important caveat about elderly individuals typically faring worse than the healthy young people tested.", "answer": 1}, {"article": "Renal vein surgery can often be managed with minimally invasive laparoscopic techniques, but this is not typically advisable for an IVC thrombus (a fibrous clot), which is surgically far more complex with potentially fatal complications that can occur in the course of removing the thrombus and reconstructing the IVC.\n\"Using robotic nephrectomy, our complication rate and lack of mortalities compare reasonably with open series with no grade III to V complications, according to the Clavien system, in any patient, including no deaths.\"\nExperts from nine leading U.S. medical centers report here on their combined experience of 32 cases since 2008.\nHowever, despite the complex and critical nature of these procedures, our series demonstrates favorable outcomes and reproducibility by surgeons with adequate robotic experience.\"\nDr Abaza added, \"While complications were relatively minor in our series, it is evident that complications are not entirely avoidable.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives a nod to harms in a comment by the lead surgeon who describes complications from the procedure as \u201crelatively minor\u201d but it could have just as well have said \u201crelatively serious\u201d for all the insight the phrase gave us about harms and risks from the robotic surgery. The surgeon also is quoted saying \u201ceven with a minimally invasive approach, the surgical management of severe cancers in mostly elderly patients will likely involve complications.\u201d Again, we are not told what those complications are and their impact on the patient.", "answer": 0}, {"article": "The full results from the feasibility study are expected to be published early 2016.\nHowever, yoga has been predominantly evaluated for breast cancer, and research on its role in alleviating prostate cancer patients' side effects has been lacking, largely due to the perception that men would not be willing to participate in this form of holistic exercise.\nNational statistics indicate that 72 percent of those who practice yoga are female, and only 18 percent of practitioners are over the age of 55.\nMost yoga participants reported a sense of well-being at the end of each class, and upon finishing the yoga program and concluding their study involvement, many patients requested and received an at-home practice routine to fit their needs, Ben-Josef said.\nFatigue that stems from cancer or cancer treatments has been found to lower patients' quality of life even more than pain, and studies have shown that anywhere from 60 to 90 percent of patients receiving radiation therapy report this symptom.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not say whether anyone felt that yoga may have caused any harms. Injuries from the practice of physical yoga (as opposed to meditative) are, in fact, quite common, although most are minor and include pulled muscles and sprains but can extend to more serious injuries such as a ruptured disk in the lower back.", "answer": 0}, {"article": "Overweight people on low-carbohydrate and Mediterranean diets lost more weight and got greater cardiovascular benefits than people on a conventional low-fat diet, according to a study that endorses alternative diets published in a major medical journal.\n\nThe study, which tracked 322 Israelis for two years, surprisingly found that a low-carb diet, often associated in the U.S. with high levels of meat consumption -- was better than a low-fat diet in boosting blood levels of \"good\" cholesterol, or high-density lipoproteins...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article addressed the safety issue of of the three diets, which was a main outcome of the research study.\u00a0 There had been concern among medical and health professionals that low carbohydrate diets like the Atkins Diet, which allow large amounts of meat and cheese, could cause harmful increases in LDL (\"bad cholesterol\") and increase the risk of heart disease.\u00a0 An important message of this article is that alternative dietary approaches can be safe and beneficial to reduce serious health risk of overweight and obesity.", "answer": 1}, {"article": "PD-1 or PD-L1 inhibitors work by blocking a mechanism of tumors that allows them to evade detection by cancer-fighting cells.\nKeytruda, when compared to chemotherapy, enabled certain patients with esophageal cancer to live longer, helping the drug meet the main goal of the late-stage study, Merck said.\n\u201cThis marks the sixth tumor type where Keytruda has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,\u201d said Roy Baynes, chief medical officer of Merck Research Laboratories.\n(Reuters) - Merck & Co\u2019s blockbuster drug Keytruda met the main goal of a late-stage trial testing the treatment in patients with cancers of the digestive tract, the U.S. drugmaker said on Wednesday.\nKeytruda, among a class of medicines called PD-1 inhibitors, is Merck\u2019s top selling drug and has already been approved to treat several forms of cancer including skin and lung cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "When you\u2019re simply passing along information spoonfed to you by a drug company, you\u2019re not likely to explain or quantify the potential harms. \u00a0And, indeed, Reuters didn\u2019t even nod in the direction of discussing harms.\nMerck\u2019s news release unhelpfully said the \u201csafety profile of Keytruda in this trial was consistent with that observed in previously reported studies.\u201d\nIn our 6 tips for writing about immunotherapy, we note that harms of immunotherapy drugs \u2014 which can include serious adverse effects such as diarrhea and pneumonitis \u2014 are often downplayed", "answer": 0}, {"article": "First published on July 1, 2008 at 12:00 am\nDr. Bonventre wrote that the study had \"a predominance of male patients,\" so there is a question of whether its results can be applied to female patients.\nIn an accompanying editorial, Dr. Joseph V. Bonventre of Harvard Medical School wrote that he had concerns about the change of therapy offered to patients in the study.\n\"When a patient transitions from one therapy to another, the dialysis dose is unlikely to be equivalent,\" he said, adding that results could be affected by different methods in the high-intensity and low-intensity groups.\nAnd, he said, the results cannot be simply applied to patients with chronic kidney disease, who then have acute kidney injury, since the study excluded any patients with advanced chronic kidney disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that \"There was no difference in death rates in both groups, and both also had similar rates of recovering kidney function and other organ failure.\" \nBut the story did not provide a clear picture of the view from patient perspective about how the two treatment approaches differed.", "answer": 1}, {"article": "After adjusting for age, diabetes, hypertension and other factors, men who took a daily aspirin or another Nsaid reduced their risk of moderate or severe urinary symptoms by 27 percent, and their risk of an enlarged prostate by 49 percent.\nThe study, published online by The American Journal of Epidemiology, had limited data on dosage, but scientists believe that even low doses of anti-inflammatory drugs reduce the risk of urological problems.\nDr. Lieber acknowledged that the study was observational and not a placebo-controlled trial.\n\u201cAt least half the patients I see are taking a daily aspirin for other health reasons,\u201d said Dr. Michael M. Lieber, an author of the study and a Mayo Clinic urologist.\nTaking aspirin every day may lower the risk for prostate enlargement, a new study has found.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does not mention any harms of using daily aspirin (like bleeding). ", "answer": 0}, {"article": "It was funded by the government of France.\nResearchers found that even though people on the FOLFIRINOX had a longer average survival rate of 11.1 months, versus the gemcitabine group with 6.8 months, the quality of life for patients on FOLFIRINOX was not as good.\nTherefore investigators recommended that only patients who are younger than 76 years old, and who do not suffer from other health problems use FOLFIRINOX.\nAfter six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\nInvestigators concluded that although the FOLFIRINOX did improve survival rates over gemcitabine, the toxicity of the drug combination caused numerous negative side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was badly incomplete and confusiong in reporting on harms.\nFirst, it inaccurately reported that \u201cthe quality of life for patients on FOLFIRINOX was not as good\u2026.After six months, only 31% of patients on FOLFIRINOX reported a decent quality of life, compared with 66% of those on gemcitabine.\u201d\u00a0 That\u2019s wrong.\u00a0 The researchers reported:\u00a0\u201cAt 6 months, 31% of the patients in the FOLFIRINOX group had a definitive decrease in the scores on the Global Health Status and Quality of Life scale versus 66% in the gemcitabine group. Significant increases in the time until definitive deterioration in the quality of life were also noted in the FOLFIRINOX group for all functional and symptom scales.\u201d\u00a0 So quality of life was BETTER, not worse in the Folfirinox group.\nAnd the reporting of harms was oddly incomplete.\u00a0 The story stated:\u00a0\u201cAt least 5% of patients on the drug combination suffered from low white blood cell counts, fatigue, serious diarrhea, a loss of feeling in their feet and hands, as well as hair loss.\u201d\nWhy did the story report that statistic instead some of these easily explained in the journal article:\n75 of those in the Folfirinox group (46%) had neutropenia compared with 35 in the Gemcitabine group (21%) 21 of those in the Folfirinox group (13%) had diarrhea compared with 3 in the Gemcitabine group (2%) 15 of those in the Folfirinox group (9%) had sensory neuropathy compared with 0 in the Gemcitabine group \u00a0 ???", "answer": 0}, {"article": "Bright-colored berries have long been a part of any healthy diet, owing mainly to the anthocyanins that give them their vibrant color and act as antioxidants to fight off damage to cells.\nWhen we\u2019re making choices in our 20s, we may think that a burger and fries is great, but the message is that there are alternatives that make a difference for the rest of your life.\n\u201cAlthough we know about the effects of antioxidants and flavonoids, and their effects in wine and chocolate, it is interesting to look at their effects in such a large group of women over a long period of time,\u201d says Dr. Suzanne Steinbaum, director of women and heart disease at Lenox Hill Hospital in New York City, who was not involved in the study.\nThe benefits for the heart of eating strawberries and blueberries can build up over a lifetime, according to the latest research.\nThat means that regular consumption of berries might be a relatively easy way to lower a woman\u2019s risk of having a heart attack later in life, possibly even insulating her from heart problems.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Like both HealthDay and NPR, TIME also did not discuss potential harms. But all health interventions have harms, as well as benefits and costs.\nWe looked the other way and gave a N/A score for no discussion of costs, but we can\u2019t do so with harms.", "answer": 0}, {"article": "I called him to be sure.\nThat\u2019s because the FDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\nAnd there\u2019s another major problem with the use of many antidepressants in children: They may increase suicidal thoughts and behavior.\nIf we are to answer these big unknowns regarding the safety of antidepressants in young patients (critical, because therapy and medication are more effective together than in isolation), we need more data.\nNew research out of Oxford helps confirm this and then some: The researchers\u2019 meta-analysis on how commercially available antidepressants compare with a placebo showed that just one of the 14 antidepressants examined was significantly better than a placebo in treating depression in children and adolescents.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes some harms and uncertainty associated with antidepressant use in young people whose brains are not fully developed, including an increased risk of suicide.\nBut, unfortunately, the story goes\u00a0beyond the evidence, and includes erroneous information.\nThe story says: \u201cSince 2004, the FDA has advised\u00a0that antidepressants not be prescribed to individuals under 24 due to the increased risk in suicidality.\u201d This is not true\u2013the FDA did not make such a blanket statement\u2013they note the increased risk of suicidality, but leave it up to physicians to weigh the possible risks vs possible benefits.\nIt also says: \u201cFDA has deemed that Prozac has demonstrated benefits that outweigh one of the suspected downsides of antidepressants in kids and teens: disrupting brain development.\u201d But, FDA doesn\u2019t address brain development in their evaluation of drugs.\nThe story then says: \u201cresearch on antidepressants suggest they negatively affect brain plasticity\u00a0and memory\u201d and cites two rather dated animal studies that that don\u2019t seem well described by the story.\u00a0\u00a0Antidepressants do seem to affect brain plasticity, but in a good way, as opposed to stress. We\u2019re aware of no adverse effects on memory documented in humans with antidepressant treatment (although depression adversely affects memory).\nAlso, the reference the author cites for antidepressants sparking a chemical reaction to increase the risk of suicide is about psychosis, not suicide, at least as far as we can tell from the abstract.", "answer": 0}, {"article": "For more information, visit fredhutch.org or follow Fred Hutch on Facebook, Twitter or YouTube.\nBecause of the data from this clinical trial, avelumab (brand name Bavencio) has become the first systemic therapy approved by the FDA for MCC, and the first treatment of any kind approved for metastatic MCC.\nAvelumab is the first FDA-approved treatment for metastatic MCC and the first disease that the drug has ever been approved to treat.\nUntil now, there were no systemic therapies approved by the Food and Drug Administration for this cancer, and no approved therapies once the cancer had spread.\nDr. Paul Nghiem, affiliate investigator of the Clinical Research Division at Fred Hutch, and the George F. Odland Endowed Chair in Dermatology at the University of Washington School of Medicine, is a senior investigator on the clinical trial that led to the FDA approval and the senior author on the Lancet Oncology article that preceded the approval.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The same study named in the release shows that multiple patients had side effects from the drugs. These are not mentioned in the release.\nThe side effects occurred in two patients who developed lymphopenia (abnormally low white blood cells), one who had an increase in blood creatine phosphokinase which could indicate muscle inflammation or damage, and other disorders.\nThere were also \u201cserious treatment-related adverse events\u201d in five patients, including enterocolitis [inflammation of the small intestine and the colon], infusion-related reaction, aminotransferases [enzymes related to the liver] increased, chondrocalcinosis [calcium deposits in cartilage], synovitis [joint inflammation], and interstitial nephritis [inflammation of the kidneys].", "answer": 0}, {"article": "\u201cToday I\u2019d say he has \u2018autism light,\u2019 \u201d he added.\nStill, Dr. Barkley cautioned that he had yet to see credible evidence confirming claims that such benefits can be long lasting, much less permanent.\nWhen it comes to to the actual devices, Dr. Kerson, at the International Society for Neurofeedback and Research, cautioned that they should never be used without experienced supervision.\nWilliam E. Pelham Jr., director of the Center for Children and Families at Florida International University, called neurofeedback \u201ccrackpot charlatanism.\u201d He warned that exaggerated claims for it might lead parents to favor it over proven options like behavioral therapy and medication.\nBut Dr. Barkley says he was persuaded to take another look after Dutch scientists published an analysis of recent international studies finding significant reductions in impulsiveness and inattention.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give the story the benefit of the doubt on this criterion because it did at least mentions that there are potential harms, but the story would have been better if it had given more detail about the type and frequency of harms. It should have also clearly noted that risks exist even when a treatment is supervised by a skilled practitioner.One of the potential harms raised is this uNPRoven treatment may be favored over proven options like behavioral therapy and medication. \u00a0The story mentioned readily available neurofeedback packages while at the same time had stern warning from a society spokesperson that people can have seizures or anxiety attacks if they use equipment that they get from ebay and use without supervision. No information about how commonly problems such as these occur. ", "answer": 1}, {"article": "More adults and kids taking Prozac, known generically as fluoxetine, had at least a 50 percent improvement in scores on depression tests after six weeks compared to those assigned to take a placebo pill.\nStill, not everyone in the studies improved \u2014 on average, about five people had to be treated with one of the drugs for one person to feel better, and the benefits seemed to be diminished among some of the oldest patients.\n\u201cDefinitely it doesn\u2019t look like antidepressants are placebos,\u201d he concluded.\nStill, Gibbons said that the improvement in symptoms for the average patient wasn\u2019t insignificant.\nAbout 9,000 participants were included.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was at least the acknowledgement that these drugs do carry side effects \u2013 but none was specified nor quantified.", "answer": 0}, {"article": "It is the inception of an entirely new way of treating ED that has never been seen before,\u201d he said.\nHe also noted that men who take certain drugs for heart disease cannot use the popular pills.\n\u201cED is largely a vascular disease and that\u2019s why Medtronic was interested in this,\u201d said Dr. Jason Rogers of UC Davis Medical Center, one of the researchers of the company-sponsored trial.\nThere were no adverse events reported up to three months later, but Rogers acknowledged that risks may become evident much later.\nInitial findings showed two-thirds of men who underwent the 1- to 2-hour procedure improved by at least 4 points on the 30-point Internal Index of Erectile Dysfunction scale, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, the story explained that there were no adverse events reported up to three months later but that risks may become evident much later. That\u2019s an appropriate and important reminder.\nBut the story didn\u2019t go far enough in providing available context.\u00a0 The coronary stents are well known to have problems with clotting \u2013 generating a new generation of more expensive \u201ccoated\u201d stents and the need for prolonged treatment with expensive oral medications to prevent clotting. The story could have addressed this \u2013 extrapolating that coronary artery complications could occur in penile arteries is not unreasonable. However, the trade-offs of stent risks \u2013 protecting the heart vs. protecting erectile dysfunction are quite different (and implicitly equating them smacks of another element of disease-mongering).", "answer": 0}, {"article": "That's a message Bacon hopes resonates.\nIn a study recently published in BMJ Open Respiratory Research, experts from Concordia University, the H\u00f4pital du Sacr\u00e9-Coeur de Montr\u00e9al and several other institutions* analyzed the exercise habits of 643 participants who had been diagnosed with asthma.\nResults were overwhelmingly clear: those who engaged in optimal levels of physical activity on a regular basis were nearly two-and-a-half times more likely to have good control of their symptoms, compared with those who did no exercise.\nTraditionally, people with the condition have been discouraged from exercising because of a belief that it triggers shortness of breath and attacks.\nIt's something to keep in mind during winter months, when fitness levels tend to drop along with the temperature, and cold air provides another trigger for asthma symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release points out some precautions people need to take before exercising. The study\u2019s lead author explains that patients should use \u201creleaver medication\u201d (sic) before they exercise and adds they should take the time to cool down afterward. He also says people could exercise indoors during the winter months, since cold air provides another trigger for asthma symptoms. It would have also been helpful to note that any physical activity triggers asthma symptoms in some people. In these cases, patients may have to take medicines before they exercise. The National Heart, Lung and Blood Institute recommends easing into physical activity with a warm-up period and also wearing a mask or scarf over the mouth when exercising in cold weather. More detail would have been appreciated here, but we feel the news release had enough for a Satisfactory rating.", "answer": 1}, {"article": "\"What was unique about this study is the very large number of children studied,\" Dawson noted.\nThe U.S. National Institute of Neurological Disorders and Stroke has more about autism.\nEEG revealed that the children with autism had a reduced short range connectivity, indicating poor function of local brain networks.\n\"The hope is that early behavioral intervention can help mitigate these functional impairments, helping to form the connections that natural develop in typical children.\"\nIn the new study, Dr. Frank Duffy and Dr. Heidelise Als compared EEG measurements of nearly 1,000 children with and without autism.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Nor is it clear what the potential harms might be. The rise in autism diagnoses has been controversial in part because once a child is put \u201con the spectrum\u201d they may be treated differently by the educational system, not to mention other kids.\nIf EEG is used inappropriately and \u2018overdiagnosis\u2019 is a concern, this could be a problem.", "answer": 0}, {"article": "\"So many people say `how can cancer screening be harmful?'\nThe prostate study sought a better way to use PSA tests, which are troublesome because PSA can be high for many reasons besides cancer, and doctors don't know which cancers need treatment or whether screening saves lives.\nTwo big studies suggest possible new ways to screen healthy people for cervical or prostate cancers, but a third disappointed those hoping for a way to detect early signs of deadly ovarian tumors.\nLooking 27 years later, researchers saw that 44 percent of cancer deaths occurred in men whose initial PSAs had been in the top 10 percent when they were 44 to 50 years old.\nThe results don't apply to using these tests on women with symptoms of ovarian cancer or abnormal physical exams.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is one of the strengths of the piece, that it takes harms head-on in a screening story, instead of assuming that early screening could do nothing but prevent disease and death. The story does a good job quantifying the harms for some of the screenings mentioned and, for others, explains that the studies did not address harms. It says in its third bullet point,\u00a0\u201cScreening women with no symptoms for ovarian cancer with a blood test and an ultrasound exam is harmful. It didn\u2019t prevent deaths and led to thousands of false alarms, unneeded surgeries and serious complications.\u201d Later, the story becomes more specific, saying, \u201cAfter 13 years, there were no major differences in ovarian cancers found or deaths from the disease. Screening found only 212 cancers while giving 3,285 false alarms that led to 1,080 unneeded biopsy surgeries and 163 serious complications.\u201d", "answer": 1}, {"article": "\"It is very big.\n\"We have developed and continue to develop a broad range of technologies that are evolving what we know about cancer and cancer care.\"\nIt has the potential to turn cancer into a chronic disease, because we can monitor patients individually and respond with treatment to the genetic makeup of their cancer.\"\n\"Researchers have been working on this and similar technologies for some time, and others have predicted a day when we will be able to diagnose cancers before they are otherwise visible by current techniques,\" said Dr. Len Lichtenfeld, the group's deputy chief medical officer.\n\"The challenging goal of sorting extremely rare circulating tumor cells from blood requires continuous technological, biological and clinical innovation to fully explore the utility of these precious cells in clinical oncology,\" Toner said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms, not even the obvious possibility that this sort of test could detect cells that don\u2019t actually present a serious health threat or aren\u2019t susceptible to treatment. It perpetuates the myth that early detection is always beneficial and turns a blind eye to the harms of overtreatment.\nBy comparison, see what Dr. Susan Love said on the ABC News website:\n\u201cHaving the cells in the bloodstream does not necessarily mean that the cancer will spread and kill you. Just because you find them does not mean you know what to do with the information. \u2026We all have cancer cells in our body that are dormant,\u201d Love said. \u201cWe need to be careful not to over react to the presence of cancer cells when the treatment may actually be worse than the cure.\u201d \n\u00a0", "answer": 0}, {"article": "In fact, my life has changed completely thanks to this research.\"\n\n\u2022 People who have had Type 2 diabetes for up to 10 years can reverse their condition\n\nA new study from Newcastle University has shown that people who reverse their diabetes and then keep their weight down remain free of diabetes.\nA previous study led by Professor Taylor, published in 2011, showed that diabetes could be reversed by a very low calorie diet.\nIf a person gains more weight than they personally can tolerate, then diabetes is triggered, but if they then lose that amount of weight then they go back to normal.\nThe research is part of a growing body of evidence showing that people with Type 2 diabetes who successfully lose weight can reverse their condition because fat is removed from their pancreas, returning insulin production to normal.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms that might arise from this approach. There are risks that come with very low calorie dieting \u2014 which was done for 8 weeks according to the release. Potential harms of extreme dieting should have been mentioned including whether there were any health issues in the 30 patients over the six months study period.\nThe most common side effect of very low calorie dieting is gallstones, according to the National Institute of Diabetes and Digestive and Kidney Diseases. Minor, short-lasting side effects include fatigue, constipation, nausea and diarrhea. The Institute recommends that patients following a very low calorie diet that results in rapid weight loss should be monitored by a doctor.", "answer": 0}, {"article": "Emergency contraceptive pills have been available in the United States for more than a decade.\nIf it is approved, it should be clearly labeled as an abortifacient, which would limit its distribution, the American Association of Pro Life Obstetricians & Gynecologists said in a letter to the FDA earlier this month.\n\u201cThere is a medical need for an efficient emergency contraceptive product which acts consistently over a prolonged time period,\u201d HRA Pharma said in a separate document released by the FDA.\nThe agency\u2019s reviewers also said the company\u2019s studies showed no unexpected side effects in women, although reports of nausea, headache and abdominal pain were common.\nData shows the one-pill treatment, called ella and made by French drugmaker HRA Pharma, is effective when taken as many as five days after unprotected sex, Food and Drug Administration staff reviewers said in documents released ahead of a public meeting on the drug scheduled for Thursday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that the FDA found no unexpected adverse events and describes the side effects of the drug including nausea, headache and abdominal pain as \"common.\" The package insert for EllaOne describes these side effects as affecting more than 10% of users. It would have been helpful if the story had cited that stat. ", "answer": 1}, {"article": "\u201cBut now in this paper, we identify a particular pathway that was not associated with inflammation before.\nTo the age-old question \u201cIs coffee bad for you?\u201d, researchers are in more agreement than ever that the answer is a resounding \u201cno.\u201d A new study published in the journal found that older people with low levels of inflammation \u2014 which drives many, if not most, major diseases \u2014 had something surprising in common: they were all caffeine drinkers.\n\u201cThe more caffeine people consumed, the more protected they were against a chronic state of inflammation,\u201d says study author David Furman, consulting associate professor at the Institute for Immunity, Transplantation and Infection at Stanford University.\nCaffeine inhibits this circuit and turns the inflammatory pathway off, the researchers say.\nPeople who drank more than five cups of coffee a day showed extremely low levels of activity in the inflammatory gene pathway.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t addressed at all \u2014 and there are potential harms associated with drinking, as the story says, \u201cmore than five cups of coffee a day.\u201d As the Mayo Clinic notes: \u201cEven among adults, heavy caffeine use [more than around four cups of coffee per day] can cause unpleasant side effects [including fast heartbeat and muscle tremors]\u2026.Some people are more sensitive to caffeine than are others. If you\u2019re susceptible to the effects of caffeine, just small amounts \u2014 even one cup of coffee or tea \u2014 may prompt unwanted effects, such as restlessness and sleep problems.\u201d", "answer": 0}, {"article": "Also, scar tissue often builds up around intravenous wires, a process that can make removing and replacing them difficult or dangerous.\nIn the study published Wednesday, Dr. Bardy and others reported that the new device had undergone several successful initial trials, including one in which it was used for a year in about 60 patients.\nBut Dr. Bardy estimated that the device could work in about 25 percent of patients who now get a defibrillator.\nBefore the device can be sold here, Cameron Health will have to submit more extensive human trial data to the F.D.A.. Dr. Bardy said a larger study of the device has just begun in this country and overseas and that it will most likely take a year or more to assemble data from it for the agency\u2019s review.\nDr. Bardy said the cost of the new device is about the same as a standard defibrillator.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nAlthough the researchers pointed out in their journal article that \u201cthe initial experience includes several cases of problems such as lead migration, lead dislodgement, and inappropriate sensing,\u201d the story does not refer to any potential harms.", "answer": 0}, {"article": "Cancerous tumors tend to be stiffer than surrounding tissues or cysts, whereas benign lesions are more compressible.\nDr. Eliot L. Siegel, vice chairman of the radiology department at the University of Maryland School of Medicine in Baltimore and the study's lead author, said in the news release that \"dermatologists tend to biopsy any lesions that seem visually suspicious for disease.\"\nIn another study scheduled to be presented at the meeting, researchers found that high-frequency ultrasound with elastography can help distinguish between cancerous and benign skin lesions, which could improve the efficiency of skin cancer diagnosis.\nTUESDAY, Dec. 1, 2009 (HealthDay News) -- When used with ultrasound, elastography helps distinguish between cancerous and benign breast lesions, which reduces unnecessary biopsies, U.S. researchers have found.\nThey also calculated the elasticity ratio of the lesions and adjacent normal skin and used laboratory analysis to confirm their diagnoses.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned no harms of elastography, which are similar to conventional ultrasonography. Excessive false positive results could lead to needless biopsies in the case of both skin and breast lesions.\u00a0 Alternatively, false negative results of the new test could lead to undiagnosed breast or skin cancer.\u00a0 The story focuses on the reduced likelihood of biopsy in both cases failing to comment on the potential downside. ", "answer": 0}, {"article": "In 2005, she was told she was having a boy, and she chose a name, bought boy clothes and told everyone.\nOne potential worry is that women might abort fetuses of an undesired sex.\nLab fees and shipping costs, which vary, bring the total expense to $265 to $330.\nFor the blood tests, women prick their fingers and send blood samples to labs.\nMost tests that were highly accurate were conducted on a mother\u2019s blood, not urine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Yes, the story lists potential harms. These range from inaccuracy, because the tests are unregulated and the laboratories don\u2019t have to meet medical standards, to the potential for abortions based on fetal gender.", "answer": 1}, {"article": "\u201cWhy would we?\nSo far, most of the focus in that direction has been on rigorously assessing orthotics and prosthetics for other conditions, like scoliosis, with less work on shoe orthotics for otherwise healthy athletes.\nSeamus Kennedy, president and co-owner of Hersco Ortho Labs in New York, said there was an abundance of evidence \u2014 hundreds of published papers \u2014 that orthotics can treat and prevent \u201cmechanically induced foot problems,\u201d leading to common injuries like knee pain, shinsplints and pain along the bottom of the foot.\nBeing generous about studies with design flaws that could overstate effects, Dr. Nigg and his colleagues concluded that custom-made orthotics could help prevent and treat plantar fasciitis, a common injury to a tendon at the bottom of the foot, and stress fractures of the tibia, along the shin.\nThe key measure of success, said Jeffrey P. Wensman, director of clinical and technical services at the Orthotics and Prosthetics Center at the University of Michigan, is that patients feel better.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article focused largely on the potential upside of shoe inserts\u2014and didn\u2019t explicitly address potential harms from the use of orthotics.\u00a0It mentioned that inserts could increase muscle work requirements but didn\u2019t discuss the significance of this point in terms of pain and function.\nSome of the potential harms\u2014 such as exacerbating injury risk and/or pain and dysfunction\u2014are obvious. There are more subtle harms as well, such as creating the expectation among athletes that they cannot safely exercise, perform normal daily activities, and work\u00a0 without the aid of an orthotic.\n\u00a0\n", "answer": 0}, {"article": "The outcomes are getting better and better.\"\nThe current study showed that an alternative schedule of high-dose methotrexate was superior.\nPrior to the release of the initial study results, which were first presented last year at the annual meeting of the American Society of Clinical Oncology (ASCO), the standard of care for high-risk ALL patients in North America was escalating methotrexate.\nThe investigators found that patients in either arm responded very well overall to treatments, but those in the high dose group had a significantly better outcome, by 5 to 6 percent, which translated into a significantly decreased relapse rate for these patients.\nPrevious studies by the Children's Oncology Group showed that in standard risk ALL patients--those with low white blood cell counts or under 10 years of age--decadron prevented relapse in both the spinal fluid and in the bone marrow.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this category a satisfactory rating largely due to the release including information that patients 10 and older receiving dexamethasone \u201cwere at much higher risk for a debilitating bone condition called osteonecrosis,\u201d although we would have been happier if that greater risk would have been quantified. However, the published study explains that there were toxicity problems beyond that of dexamethasone and the release would have been stronger including that information as well.", "answer": 1}, {"article": "They are most commonly treated with regular infusions of clotting factor.\n\"This work is very exciting and promising,\" said Nichols, who added, \"The FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\nBased on previous work by Margaritis, the UNC team identified dogs for this gene therapy study.\nBoth Nichols and Margaritis agreed: \"The table is now set to propose clinical trials that would treat people who suffer from FVII deficiency.\"\nBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses harms in a couple of places, as in this excerpt:\n\u201cThe FVII-deficient dogs tolerated the initial gene therapy infusions very well and have had no adverse side effects over several years of follow up.\u201d\nand in a quote by the lead researcher:\n\u201cBased on kidney function, liver function, and blood measurements in the dogs, the treatment was safe, and did not elicit unwanted immune responses.\u201d\nBut as this study was done in canines, we would have liked a bit more detail on how harms might\u00a0 manifest in human clinical trials.", "answer": 1}, {"article": "Both are reasonable options.\u201d\nResearchers randomly assigned 241 women with urinary incontinence to daily medicine and a placebo injection, or a Botox injection and a daily placebo pill.\nSignificantly, those who took Botox were more likely to have their symptoms completely disappear.\nThe scientists, writing online on Oct. 4 in The New England Journal of Medicine, found that both treatments significantly reduced incontinence episodes.\nDry mouth was much more common in those who took the medicine; urinary infections and incomplete emptying of the bladder were more common in those given Botox.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does detail the side effects of dry mouth, urinary infections and incomplete emptying of the bladder, but these are never quantified. But language like \u201cmuch more common\u201d or \u201cmore likely\u201d is unhelpful in its lack of specificity.\u00a0 The paper itself revealed:\nDry mouth occurred in significantly more participants in the anticholinergic group than in the onabotulinumtoxinA group (46% vs. 31%, P=0.02). Intermittent catheterization was recommended according to protocol criteria at scheduled visits in the onabotulinumtoxinA group only (in 5% of the participants at 2 months, 3% at 4 months, and 1% at 6 months). However, additional women in both groups performed catheterization off-protocol . More women in the onabotulinumtoxinA group than in the anticholinergic group had a urinary tract infection (33% vs. 13%, P<0.001).\nMaybe 15 percentage point differences\u00a0 or 20 percentage point differences are things we should tell readers about and let them judge.", "answer": 0}, {"article": "The FDA recently warned people with peanut allergies to avoid foods containing ground cumin, after traces of peanut powder were found in the ground spice.\nAt the end of a year, 50 percent of those wearing the high-dose 250 microgram patch were able to tolerate consuming at least one gram of peanut protein.\nIt could be several more years before the patch will be available for consumers.\n\u201cAnd the patch may be a way of doing this that is safer.\u201d\n\nThe patch study's results are promising, although researchers need to continue following the participants for another year, Sampson said.\nThe same dose worked for nearly 54 percent of kids, 6 to 11.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story handles this aspect well, by noting side effects of the patches and explaining the difficulties experienced by two participants forced to drop out of the study.", "answer": 1}, {"article": "The women ranged in age from 18 to 86.\nBut previous studies suggest more than 50 percent of these biopsies are unnecessary and can result in pain, worry, infertility and higher health care costs.\n\"When developing a new cancer screening test, we want something in the range of 90 to 95 percent sensitivity, which is competitive with the effectiveness of tests developed and now marketed in Europe,\" says Guerrero-Preston.\n\"If further studies confirm these findings, we see a significant use of urine screening as a way to quickly and inexpensively determine if a biopsy is warranted, or if physicians can use a 'watch and wait' approach before intervening,\" says Guerrero-Preston.\nThe next step, the researchers report, was to verify that the four-gene test worked using freely circulating DNA from blood and urine, rather than DNA taken directly from cervical tissue.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does make\u00a0it clear that this small urine test study correctly identified those without cancer 83% of the time, a considerable improvement over the false positive rate of the more traditional Pap test.\nBut the real risk of this new test is that it may indicate a false negative \u2014 suggesting all is well \u2014 when it isn\u2019t. Under the best of scenarios, the new test gets it wrong 10 in 100 times. When applied to a more usual practice setting, it gets it wrong 15 to 25 in 100 times. Here getting it wrong may mean missing an advanced pre-cancerous lesion or even a cancerous one. One can argue that even 1 in a 100 times is too much, but in developing countries this may be better than current practice. However, we don\u2019t believe the risk of false negatives has been clearly or addressed.", "answer": 0}, {"article": "\u2022 Dried seaweed can be added to food as powder, granulate or pieces in pastries, egg dishes, mashed potatoes, dressings, or sprinkled on vegetables or fish dishes.\nIt can even enhance the flavor of the food, they argue.\nIn the article the authors offer suggestions to how both individual consumers and the food industry can use seaweed to make our everyday meals healthier.\nThe men's reaction was that the bread tasted acceptable as long as the seaweed content was kept under 4%.\n\"It is difficult to determine how much seaweed a person should consume to benefit from its good qualities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There are some vague references to harms in a list of bullet points at the end of the release. We do not think this satisfies the criteria but, instead, creates more confusion. It says:\nWhat is one to make of that?", "answer": 0}, {"article": "\"But it is heartening that we now have scientific proof that this can work.\nAnd because hormone treatment for breast cancer typically makes the hot flash experience even worse, Razzini added, acupuncture could be a useful tool for helping such patients \"stay on their therapy and improve their quality of life.\"\nRazzini didn't know how much American patients might have to pay for such treatment, but added, \"Compared to other effective treatments such as antidepressants, (acupuncture) should be less expensive, and, for sure, more safe and feasible.\"\nNoting that hot flashes are a fact of life for many women with breast cancer, the investigators found that pairing lifestyle advice with weekly acupuncture sessions dramatically improved the women's quality of life.\nThose in the acupuncture group also seemed to have a generally higher overall quality of life in terms of both physical and mental health, with no serious side effects, the study authors said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t mentioned at all. The Mayo Clinic notes that risks associated with acupuncture range from soreness to infection to organ injury. Further, the clinic warns that some patients are at higher risk than others, such as patients who have pacemakers or bleeding disorders.", "answer": 0}, {"article": "Those medications can produce adverse side effects like gastrointestinal distress and fractures of the femur.\nAt the time the study was submitted for publication, \u201cwith more than 90,000 hours of yoga practiced largely by people with osteoporosis or osteopenia, there have been no reported or X-ray detected fractures or serious injuries of any kind related to the practice of yoga in any of the 741 participants,\u201d Dr. Fishman and his colleagues wrote.\nOf the 741 people who joined his experiment from 2005 to 2015, 227 (202 of them women) followed through with doing the 12 assigned yoga poses daily or at least every other day.\nEven if bone density did not increase, improvements in posture and balance that can accrue from the practice of yoga can be protective, Dr. Fishman said.\nSo in 2005, Dr. Fishman began a small pilot study of yoga moves that turned up some encouraging results.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides insight into the downsides of bisphosphonate therapy but says nothing about the potential dangers of yoga. It is true that, done correctly, yoga is not likely to produce significant injuries. However, the subjects in the study were not supervised nor was their positioning for each of the poses determined. Incorrect alignment can cause joint strain and joint and injury. In fact, the Times itself has previously reported that yoga can wreck your body!", "answer": 0}, {"article": "\"To make any form of health care work and to truly power economic mobility, we have to get healthy,\" says Levin.\nFor clinicians concerned about spending extra time in and outside of the exam room, the study authors encourage time-strapped health care providers to refer patients to registered dietitians who can help with the transition to a plant-based vegetarian diet.\nTaking small steps, like those proposed by the National Cholesterol Education Program Adult Treatment Panel 3, which include assessing heart disease risk, making lifestyle and dietary recommendations, and assessing the need for future follow-up appointments and pharmaceutical interventions, could prevent approximately 20,000 heart attacks, 10,000 cases of coronary heart disease, and save almost $3 billion in medical costs each year.\nThe meta-analysis appears as an online advance in Nutrition Reviews.\nThe 2015 Dietary Guidelines for Americans highlights a healthy vegetarian diet as one of three healthful eating plans to follow.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms but does suggest registered dietitians and the menus found in federal recommended dietary guidelines could help people transition to a plant-based diet. There is mounting evidence that plant-based diets may be associated with reduced risk for many health conditions, as long as one eats a balanced diet and in moderation. We\u2019ll rate this one Not Applicable.", "answer": 2}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\n\u201cThe results clearly remove any doubts about anti-VEGF drugs\u2019 efficacy in treating DME.\nOne year after starting treatment, all participants had improved vision.\nHowever, one drug, aflibercept, provided greater improvement for people with more severe vision loss when treatment was initiated.\nThose with mild vision loss (20/32 to 20/40) at baseline in all three treatment groups gained on average almost two lines on an eye chart.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nothing is reported about adverse effects either locally in the eye or systemically. While these drugs are standard treatments, a line about potential for infection or other potential harms should have been included. Information about completion rates and reasons for dropouts would also have been welcome.", "answer": 0}, {"article": "\u201cIt\u2019s a mixed bag,\u201d Elliott says.\nFor one thing, he says, dry needling as performed by a physical therapist is not rooted in ancient Chinese medicine \u2014 there\u2019s no talk about redirecting the body\u2019s energy flow by placing needles at certain points in the body.\nTestimonials like that are a big reason dry needling has caught on with some physical therapists, athletes and other patients, Briggs says.\nIn rare cases, deep needling can lead to a punctured lung or injuries to nerves and blood vessels, and acupuncturists fear non-specialists will be more likely to make such mistakes, Burgoon says.\nHe says many acupuncturists do exactly what the physical therapists describe, with the same kind of needles.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We like that the story called out risks specifically, which is something we don\u2019t see often. It says, \u201cNeedling can produce minor bleeding and some soreness, but in trained hands, and with the use of sterile needles and gloves, \u201cit\u2019s a very safe procedure,\u201d Briggs says.\u00a0In rare cases, deep needling can lead to a punctured lung or injuries to nerves and blood vessels, and acupuncturists fear non-specialists will be more likely to make such mistakes, Burgoon says.\u201d\nThe story would have been stronger if it had quoted a source with no vested interest in discussing risks. Also, it\u2019s worth pointing out that these risks are real whether \u201ctrained hands\u201d do the procedure or not.", "answer": 1}, {"article": "In addition, people can obtain folic acid from breads, cereals and other grain products enriched with folic acid, as well as folic acid supplements.\nNone of the other factors they examined accounted for their finding, Nilsson's team noted.\n\"It's one of those things that's no harm, no foul.\nHowever, there is no scientific evidence that taking folate supplements will be beneficial, Armstrong noted.\n\"These results provide new information that points to the importance of keeping a closer watch on folate status in childhood and adolescence.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable. The story could have mentioned the potential for excessive folic acid intake to interfere with vitamin B12 uptake which, though unlikely in a teen population, could mask symptoms of B12 deficiency. But we\u2019ll give it the benefit of the doubt on this.", "answer": 2}, {"article": "Nearly 800,000 Americans suffer a stroke every year, with about a sixth of them dying of it and many more left disabled.\n\u201cGiven the observational design of the study, findings from this study cannot prove that it\u2019s chocolate that lowers the risk of stroke,\u201d Susanna Larsson from Karolinska Institutet in Stockholm told Reuters Health in an email.\nThe results add to a growing body of evidence linking cocoa consumption to heart health, but they aren\u2019t a free pass to gorge on chocolate.\nNEW YORK (Reuters Health) - A sweet tooth isn\u2019t necessarily bad for your health\u2014 at least not when it comes to chocolate, hints a new study.\nFor those at high risk, doctors recommend blood pressure medicine, quitting smoking, exercising more and eating a healthier diet \u2014 but so far chocolate isn\u2019t on the list.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Close call here, but the story goes a step further than WebMD when discussing the possible\u00a0adverse effects of consuming too much chocolate. In addition to warning that chocolate has a lot of fat, sugar and calories, it explicitly notes that eating too much of it\u00a0\u201ccould be counterproductive.\u201d WebMD offers no comparable warning and suggests that eating more chocolate than\u00a0was\u00a0consumed in this study would\u00a0result in similar\u00a0health benefits.", "answer": 1}, {"article": "Obstructive sleep apnea occurs when the soft tissues of the mouth and airway, especially the tongue, block air flow into the lungs.\nFor Kothare, the out-of-pocket expense for the device, the risks of surgery, plus the potential for the mechanism \u2014which moves the tongue forward \u2014 to break, doesn\u2019t make it a viable option for everyone.\nThe main side effect from the device is that people can wake up with a sore tongue.\nI thought since I'm older so that's what it is.\u201d\n\nIt wasn\u2019t until a mother-daughter vacation that Turner\u2019s daughter noticed something interesting when her mother slept.\n\u201cAnd then the doctors looked piece by piece, and realized that what I have is sleep apnea.\u201d\n\nTurner\u2019s nightly interrupted breathing increased her chances of heart attack or stroke by three to four times, according to Dr. Robson Capasso, associate professor of Otolaryngology Head and Neck Surgery at Stanford University.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the main side effect from the device is \u201cthat people can wake up with a sore tongue.\u201d We\u2019ll give this a barely passing satisfactory. (What about people who may have suffered adverse reactions or complications from surgery?)", "answer": 1}, {"article": "ASTHMA According to conventional wisdom, asthma and other allergic diseases like hay fever are made worse by dirty environments. Recent evidence has suggested, however, that children exposed to dirt and germs early in life may have a lower risk of developing asthma and other allergies. Studies have found that the children of farmers -- who presumably are exposed to a ... (Full article: 838 words)", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Fainting and abnormal potassium levels were mentioned as harms of treatment, though there was no indication of how common these harms might be. Another harm not mentioned was that it is known from other studies that labeling someone as \u2018hypertensive\u2019 can severely affect their quality of life (self perception). ", "answer": 1}, {"article": "The fibers within the tendons fray.\nBut this is not the case for those getting cortisone shots, he wrote; they \u201ctend to lag behind significantly at those time frames.\u201d In other words, in some way, the cortisone shots impede full recovery, and compared with those adopting a wait-and-see policy, those getting the shots \u201care worse off.\u201d Those people receiving multiple injections may be at particularly high risk for continuing damage.\nThe reviewers determined that, for most of those who suffered from tennis elbow, cortisone injections did, as promised, bring fast and significant pain relief, compared with doing nothing or following a regimen of physical therapy.\nThe evidence for cortisone as a treatment for other aching tendons, like sore shoulders and Achilles-tendon pain, was slight and conflicting, the review found.\nIn other words, is reducing soreness now worth an increased risk of delayed healing and possible relapse within the year?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\nThe article provided adequate detail on the main harms associated with steroid injections: disruption of the long-term healing process and relapse into pain and disability. It might have been useful to also mention other potential side effects and potential harms related to steroid injections.\n", "answer": 1}, {"article": "In the study, men taking an angiotensin receptor blocker had a 24 percent lower incidence of dementia than those taking other cardiovascular drugs.\nThere are potential hazards, such as too-low blood pressure that can lead to damaging falls, Wolozin said.\nThe new report describes an observational study, one that lacks the strict controls that are needed for convincing proof.\nThe risk was nearly halved for those taking both angiotensin-targeting drugs.\n\"You only know for sure when you have done clinical prospective trials.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "One harm was mentioned \u2013 \"There are potential hazards, such as too-low blood pressure that can lead to damaging falls.\"\u00a0 That\u2019s an incomplete listing, but we\u2019ll give the story the benefit of the doubt in at least nodding in the direction of potential harms. ", "answer": 1}, {"article": "There's much room for improvement, Shimoide says.\nBut a major problem facing kampo medicine is herbal product quality.\nThere have been cases in which poisonous plants found their way into the herbal mix, resulting in kidney damage, for example.\nMarch 5, 2012 (Orlando, Fla.) -- A traditional Chinese herbal remedy known as kampo helped to relieve daily asthma symptoms in nearly all of more than 200 people studied, Japanese researchers report.\nThe study did not look at possible side effects of kampo herbs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained:\nThe study did not look at possible side effects of kampo herbs. But a major problem facing kampo medicine is herbal product quality. There have been cases in which poisonous plants found their way into the herbal mix, resulting in kidney damage, for example.", "answer": 1}, {"article": "About the American College of Surgeons\n\nThe American College of Surgeons is a scientific and educational organization of surgeons that was founded in 1913 to raise the standards of surgical practice and improve the quality of care for surgical patients.\nFor the study, researchers analyzed data in the National Inpatient Sample (NIS) database of more than 75,000 adults who underwent either laparoscopic or open fundoplication for GERD between 2000 and 2013.\nAlong with discovering that the use of laparoscopy for the surgical treatment of GERD has increased significantly in the last decade, the researchers also found that, on average, the minimally invasive approach reduced length of hospital stay by approximately two days, and open operations were more than $9,000 more expensive than minimally invasive procedures.\n\"Patients with GERD have an incompetent lower esophageal sphincter, which allows gastric acid to go back up into the esophagus,\" said lead study author Francisco Schlottmann, MD, a surgeon at the Center for Esophageal Diseases and Swallowing, University of North Carolina, Chapel Hill.\nThe study showed that the rate of laparoscopic procedures increased from 24.8 percent in 2000 to 84.3 percent in 2013.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release names complications associated with both types of surgery for GERD, while stating that patients undergoing laparoscopic procedures encountered fewer of them: \u201cpostoperative blood clots, wound complications, surgical site infection, esophageal perforation (which can be life threatening), bleeding, cardiac failure, and death.\u201d", "answer": 1}, {"article": "Behind that common piece of advice is a complex series of physiological processes that calm the body, slow the heart and help control pain.\n\nBreathing and controlling your breath is one of the easiest ways to improve mental and physical health, doctors and psychologists say. Slow, deep and consistent breathing...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that deep breathing may cause people with asthma or panic disorders to hyperventilate and that a different breathing pattern is often recommended for these patients. The story could have mentioned exercise or psychological techniques for reducing stress and improving health, many of which are supported by stronger evidence.", "answer": 1}, {"article": "Learn more about Parkinson's disease and its symptoms at the Parkinson's Disease Foundation.\nThe data are compelling evidence that statins are not detrimental for people with or at risk of Parkinson's disease, he said.\nHowever, the risk reduction was modest and may have been due to chance, the authors said, noting that more research is warranted, especially because statins can cause adverse side effects.\nMONDAY, March 12, 2012 (HealthDay News) -- People taking popular cholesterol-lowering drugs called statins may have a slightly lower risk than others of developing Parkinson's disease, new research suggests.\nThe researchers can't say exactly how -- or even if -- statins reduce the risk of Parkinson's.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story credit for noting the potential side effects of statins up high.\u00a0 And later it reported:\nThere was a concern that statins could be harmful as they might lower the level of coenzyme Q10 in the blood. Co-Q10, an antioxidant, is thought to have benefits for people with Parkinson\u2019s disease.\nBut we wish the story had gone the extra step of actually quantifying the harms from this study or other studies.\u00a0 And it could have cited the recent FDA update on the risks associated with statins.", "answer": 0}, {"article": "Tissue plasminogen activator, known as tPA, can dramatically reverse stroke symptoms in those whose strokes are caused by blood clots and blockages, which account for an estimated 85 percent of all strokes.\n\"These results will be useful for centers that offer 24-hour access to acute stroke patients.\n\"Like any imaging technique, it has a certain accuracy but it won't be perfect.\n\"Really pinpointing the time of onset is so crucial for us.\nThe study, reported online Nov. 2 and in the December issue of the journal Radiology, reinforces results from similar research, Oppenheim said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any possible harms associated this application of MRI technology.\u00a0 Although the harms would likely be small, the harm that may arise from incidental findings is worth noting.\u00a0 The more you scan \u2013 something being proposed in this study \u2013 the more you find, including things you didn\u2019t need to find. That\u2019s worth at least a line.", "answer": 0}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\nThe other 13 people in the study had previously received a type of immunotherapy before the study.\nAll 22 people in the study had an advanced stage of inoperable or metastatic melanoma.\nUnfortunately, this therapy still only works in a subset of patients,\" said Dr. Deborah Wong, assistant clinical professor of medicine at the Geffen School of Medicine and an oncologist at the Ronald Reagan UCLA Medical Center, who was also an author of the paper.\nThe study was funded by Dynavax Technologies Corp., which provided SD-101.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a dose-escalation study that was conducted to determine the safest dose. This means the focus was symptoms and side effects. And the news release states that. Yet, none of the symptoms or side effects patients in the study experienced are described in the news release. This is a major deficiency of this release.", "answer": 0}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nThe findings come as the American Academy of Pediatrics debates updating its recommendations regarding circumcision among newborns.\nAnd there's more to consider, Perera said.\nThe American Academy of Pediatrics has more on circumcision.\nThe academy now takes a neutral stance.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 0}, {"article": "Vitamin D is found in certain foods and beverages such as fortified milk and cereals, and fatty fish such as salmon.\nGrowing evidence has suggested that vitamin D, found in fortified milk, may lower one\u2019s risk of MS. Now, researchers with the Harvard School of Public Health in Boston have shown that it\u2019s possible this protective benefit could begin while a baby is developing in the womb.\nIt revealed that women born to mothers who had the highest intake of vitamin D had a much lower risk of developing MS as an adult.\n\"We also found the risk of MS among daughters whose mothers were in the top 20% of vitamin D intake during pregnancy was 45% lower than daughters whose mothers were in the bottom 20% for vitamin D intake during pregnancy.\"\nAmong the nurses studied, 199 developed MS over the 16-year study period.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know if any of the mothers who reported a high intake of vitamin D experienced adverse effects; however, it\u2019s worthwhile to mention that excessive intake of vitamin D supplements is associated with harms, including nausea, vomiting, constipation, and weakness. Additionally, information about how to safely get enough sun exposure to convert vitamin D to its active form would have been helpful.", "answer": 0}, {"article": "Graphic artist Colleen Kelly decided in 2000 that she had nothing to lose by enrolling in an experimental study of VNS.\nThe company's Web site says that \"preliminary imaging studies suggest that VNS Therapy affects many areas of the brain implicated in mood regulation.\"\nThe device has also attracted attention on Capitol Hill, where the Senate Finance Committee has spent two years looking into decision-making at the FDA.\nA report by Harvard Pilgrim Health Care, an influential mental health insurer in Boston, called it \"experimental, investigational and unproven.\"\nLast July, a top FDA official, citing the lack of alternatives for severely depressed patients, overruled unanimous opposition by 20 members of his staff and approved the device as a depression treatment for adults who had failed four other treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Very thorough discussion of potential harms. The story mentions cardiovascular problems that can be life-threatening. It says the device must be replaced every five years or so when the battery runs low. The story also profiles a patient who \u201cfrequently lost her voice while she was talking and felt a persistent constriction in the back of her throat. Both are common side effects of VNS treatment.\u201d It states that \u201cWorsening depression and suicide attempts were reported by one-third of patients in one study funded by Cyberonics, according to data presented to the FDA.\u201d The story also suggests that while the device generator may be removed from the chest of a person who wants to stop VNS use, the \u201celectrodes in her neck must remain forever; doctors tell VNS patients that removing them is too risky because tissue grows around them As a result, VNS recipients cannot undergo a full body MRI or therapeutic ultrasound.\u201d", "answer": 1}, {"article": "March 21, 2011 -- Long-term results for Lap-Band weight loss surgery are relatively poor, according to a new study from Belgium.\nEven so, a majority of the patients in their small study said they were satisfied with the procedure.\nThe critics also point out that both the device itself and the expertise of surgeons placing it have improved greatly since the patients in the study had their bands placed, in the years 1994 through 1997.\nThe average weight loss was below what experts consider good results.\nBut a spokesman for the company that manufactures Lap-Band says the study is flawed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job providing information about the common harms, along with the percentage of individuals affected.", "answer": 1}, {"article": "A new study raised questions about the benefits of a relatively common procedure for heart patients\u2014implanting tiny devices that prop open clogged arteries to relieve chest pain.\n\nThe 200-patient study conducted by U.K. researchers found that patients with stable chest pain, or angina, who received stent devices experienced no significant improvement in exercise time on a treadmill, compared with similar patients who received no stents during sham procedures.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms of the procedure, which should be a factor in weighing the risks and benefits of any intervention.", "answer": 0}, {"article": "Other researchers contributing to this study include: Robert L. Coleman, M.D., Alpa M. Nick, M.D., Pedro T. Ramirez, M.D., Lois M. Ramondetta, M.D., Diana Urbauer, Jack L. Watkins, all from MD Anderson; Susan K. Lutgendorf, Ph.D. from University of Iowa; Sanjeev Kumar, M.B., B.S.\nWith further research, they may also prove beneficial in conjunction with other treatment regimens and across other cancer types.\nThen they potentially could be used as an adjuvant therapy during surgical recovery and chemotherapy to decrease tumor growth, delays in wound healing and metastasis.\nThis was not true for patients who took SBBs.\nFurther examination revealed that NSBB users had improved overall survival regardless of the presence of such prognostic factors or comorbidities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms at all. Side effects can range from diarrhea to depression, may trigger asthma attacks in asthmatic patients, and can cause complications for patients with diabetes. Some of these side effects may seem relatively inconsequential when compared to EOC mortality, but they\u2019re worth mentioning.", "answer": 0}, {"article": "\"The issue is, can you detect these in patients that don't have advanced cancer?\" Venook said. \"The answer is, we don't know.\" The numbers tested by the MD Anderson researchers -- 251 patients with pancreatic cancer (five of whom had very early lesions), 32 with chronic pancreatitis and 120 healthy controls -- aren't nearly large enough to draw such conclusions. And getting a clear answer, Venook said, would probably require lengthy and expensive studies on very large populations.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article, like others covering the study that we reviewed, ignored the potential harms from screening tests. In the real world, all screening tests carry the risk of false negatives, false positives and inconclusive results that could lead to more invasive tests and over-aggressive treatments.", "answer": 0}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a close call. On one hand,\u00a0the story does address harms from false-positive tests: \u201cJust as important, the tests were remarkably good at avoiding false-positive signals, which would needlessly alarm women and lead to riskier and more-invasive tests to confirm a diagnosis. For both types of cancer, the PapSeek test\u2019s \u201cspecificity\u201d \u2014 its ability to accurately recognize the absence of disease \u2014 approached 100%.\u201d\nYet\u00a0the story glossed over the high false-negative rates and how a patient might (incorrectly) interpret a result \u2014 i.e. by testing negative, they may wrongly believe they do not have a uterine or ovarian cancer.", "answer": 0}, {"article": "Wolters Kluwer reported 2016 annual revenues of \u20ac4.3 billion.\n\"Our study demonstrates the high functional disability experienced by migraine patients, compared to those with other pain conditions, \" comments ASPS Member Surgeon William Gerald Austen, Jr, of Massachusetts General Hospital.\nThe PSEQ has been used to study treatment outcomes in patients with a wide range of pain conditions.\nDr. Austen and colleagues conclude, \"Chronic pain questionnaires such as the PSEQ add to our understanding of functional outcome after surgery and put pain in migraine surgery patients in perspective to better-known pain conditions.\"\nIt provides information not only on pain scores, but also on functional disability and ability to cope with pain when performing normal daily activities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This is perhaps one of the most egregious omissions of the news release: not mentioning any potential harms of a surgery that directly impacts the nerves and muscles of the face. While the method of this surgery is not included in the news release, a look at the Mass General web page where the lead author works describes the surgery as a \u201crelease\u201d of nerves in the eye, forehead, back of head, and nasal regions. Depending on the extent of the surgery, a patient may be required to undergo anesthesia in an operating room. The risks are not mentioned on this page either, but a look at the risks of the similar brow-lift procedure shows that complications may include facial nerve damage or paralysis, infection, and scarring.", "answer": 0}, {"article": "Nearly 175,000 Americans will be diagnosed with lung cancer this year.\nSays Henschke: \"This is a way of finding it early and taking it out early, because it is a much better chance of being cured from the disease.\"\nIf Lazarus hadn't had any studies, says Dr. Harvey Pass of the NYU Medical Center in New York, the tumor would have grown causing pain, cough bleeding and maybe not have been able to be surgically removed.\nThat's because standard chest X-rays too often can't spot it until it's too late, reports.\nBut doctors decided to use a more sophisticated test \u2014 a CT scan that can detect tumors as small as a kernel of rice.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms \u2013 such as radiation exposure, the harms of biopsies and the consequences of a false positive result.", "answer": 0}, {"article": "Those in the lower group ate an average of 0.5 meals per week.\nFurther, the protective association of seafood was even stronger among individuals with a common genotype (APOE-\u03b54) that increases the risk of developing Alzheimer's disease.\nThe age-related memory loss and thinking problems of participants in the study who reported eating seafood less than once a week declined more rapidly compared to those who ate at least one seafood meal per week.\n(Chicago) - Eating a meal of seafood or other foods containing omega-3 fatty acids at least once a week may protect against age-related memory loss and thinking problems in older people, according to a team of researchers at Rush University Medical Center and Wageningen University in the Netherlands.\nThe study group also completed annual food frequency questionnaires, allowing the researchers to compare participants' reported seafood intake with changes in their cognitive abilities as measured by the tests.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study population in this specific study was made up of older adults (mean age of 81.4 years old). There are few, if any, risks associated with eating one seafood meal per week for older adults. However, the release might have warned that both the FDA and the EPA, while encouraging pregnant and breastfeeding women to consume two to three servings of fish weekly, now recommend that they choose fish that is low in mercury (which include salmon, shrimp, pollock, tuna (light canned), tilapia, catfish, and cod).", "answer": 2}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\n\"In addition to the clinical outcomes, we now have a clear understanding of the mechanisms through which limited BCG vaccine doses can make permanent, beneficial changes to the immune system and lower blood sugars in type 1 diabetes.\"\nLong-term follow-up of participants in clinical trials of a generic vaccine to reverse advanced type 1 diabetes finds significant clinical benefits, including restoration of near-normal blood sugar levels.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\nAn extension and expansion of that trial with long term follow-up, the current results are based on data from 282 human study participants - 52 with type 1 diabetes who participated in the BCG clinical trials and 230 who contributed blood samples for mechanistic studies.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms of the vaccine are mentioned.\nIt\u2019s been given to humans since the 1920s and side effects, including allergic reaction to this live vaccine, have been well documented. It should be avoided in anyone with decreased immune function.\nOf note, a\u00a0 point is made that in those study subjects who received the vaccine, there were \u201cno reports of severe hypoglycemia.\u201d", "answer": 0}, {"article": "One patient with ovarian cancer had a complete response that lasted 89 weeks, one patient with gastroesophageal cancer had a partial response that lasted 16 weeks, and four patients (two with colon cancer, one with prostate cancer, and one with ovarian cancer) had stable disease.\nAmong the six patients who received the lowest dose of the vaccine, 5 million dendritic cells per injection, no clinical benefit was seen.\nAmong the 11 patients who received either 10 million or 20 million dendritic cells per injection, six had clinical benefit.\nAccording to Berzofsky, the main scientific limitation of the study is that it is a relatively small, phase I clinical trial with no placebo control.\nIn the dose escalation portion of the phase I clinical trial, patients were injected with the vaccine on weeks 0, 4, 8, 16, and 24 after enrollment in the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only harm mentioned in the release was some injection site discomfort. The release also mentioned that the patients were tested to see if there was cardiotoxicity (heart dysfunction or muscle damage) and none was found.", "answer": 1}, {"article": "\u2018What insanity is that?\u2019 Hundreds of NC children are being killed or injured by guns.\n\nDid you realize that in the past five years, hundreds of teens and youth have been killed or hurt by gunfire in North Carolina? Here\u2019s what some say you can do about it.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The AP report provides no details on potential harms. The New England Journal of Medicine study reported mostly minor side effects of the vaccines and one serious complication attributed to the nasal spray\u2014hospitalization for acute inflammation of the tissue surrounding the heart and great vessels (acute pericarditis). It's also worth noting that pericarditis has also been reported (rarely) with the inactivated vaccine.", "answer": 0}, {"article": "\"In these types of studies you think of things like this,\" Haber said, \"but how real it is, is something we're going to have to see.\nUsing electrical impulses to stimulate a part of the brain critical for memory function significantly improved patients' navigational ability, reflecting improved spatial memory, the small study from the University of California, Los Angeles (UCLA) suggests.\nCurrently, deep brain stimulation is used to control the tremors associated with Parkinson's, symptoms of obsessive-compulsive disorder and some other psychiatric conditions, including depression.\nHaber noted that the brain damage that occurs with epilepsy, which can produce memory problems, is different than that resulting from Alzheimer's disease, in which the formation of amyloid plaques and neurofibrillary tangles are believed to contribute to nerve cell deterioration.\nSix patients showed a 64 percent reduction in \"excess path length\" -- the ideal path between destinations, which indicated better performance -- for locations that had been learned during periods of deep brain stimulation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even though the researchers did not report any harms to participants in this study, the story should have mentioned that while similar treatments are considered safe enough in the right circumstances, implanting electrodes and electrical stimulation devices can cause bleeding, strokes, infections, mood changes, movement disorders, sleep problems and other harms.\nA recent study of deep brain stimulation (DBS) involving 99 Parkinson\u2019s patients concluded that DBS\u00a0 \u201chas an adverse effect on executive functions with implications for daily life of the patients and their relatives.\u201d Almost 10% of those DBS patients had psychiatric events including a suicide attempt.\n\u00a0", "answer": 0}, {"article": "Doctors in Seattle cured a late-stage cancer patient after tinkering with his body's defenses against infection, leading to cautious optimism about treating late-stage melanoma, a deadly skin cancer.\n\nThe surprising result, published in this week's issue of the New England Journal of Medicine, is the latest hopeful finding from the 30-year-old field of \"adoptive immunotherapy,\" which theorizes that the body can be taught to fight off its own cancers.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention potential harms of the immunotherapy it describes. Immunotherapy frequently causes a flu-like syndrome. Among the potential complication are devastating infections. The published case study hints at these, observing that the patient\u2019s initial reaction to the therapy was \u201ctransient lymphopenia, low-grade fever, and myalgia.\u201d Other adverse events commonly reported after immunotherapy include diarrhea, rash, adrenal insufficiency, and liver test abnormalities.", "answer": 0}, {"article": "Dr. Matthew Brams, M.D., Clinical Assistant Professor at Baylor College of Medicine and principal investigator for study 305, added: \"The study of SHP465 in children and adolescents is an essential next step to progressing the clinical program.\nAdverse events were generally mild to moderate in severity and similar to those observed in previous SHP465 studies and with other amphetamine compounds.\nTreatment-emergent adverse events \u2265 5% for SHP 465-305 were decreased appetite, headache, insomnia, irritability, nausea, weight decrease and dizziness.\nSHP465 was also superior to placebo in the key secondary efficacy analysis on the clinical global impression improvement scale (CGI-I), with an LS mean difference from placebo at Week 4 of -0.8 (95% CI: -1.1 to -0.5, p<0.001), indicating a significantly higher proportion of patients were rated improved on the CGI-I rating scale.\nThe primary efficacy analysis of study 305 demonstrated that SHP465, administered as a daily morning dose, was superior to placebo on the change from baseline in ADHD-RS-IV (ADHD rating scale) total score, with a Least Squares (LS) mean difference from placebo at Week 4 of -9.9 (95% CI: -13.0 to -6.8, p<0.001), suggesting a significant improvement in ADHD symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The adverse effects are clearly listed and equated with those of other amphetamine drugs. The adverse effects that occurred in more than 5 percent of the subjects included decreased appetite, headache, insomnia, irritability, nausea, weight decrease and dizziness and were similar to those observed with other amphetamine compounds.", "answer": 1}, {"article": ".\nThose people taking the drug also saw reduced cholesterol levels and waist size, changes that have been linked to lessening cardiovascular risk factors such as blood pressure.\nPeople taking the Arena pill experienced significantly more weight loss, at least 5 percent of their weight over 12 weeks, than people taking a placebo, according to the report filed in the journal Obesity.\nBut one of the two components of that drug made by Wyeth, fenfluramine, also hit a second target in the heart, which was linked to heart valve problems.\nThe drug also proved to be highly selective, meaning it hit the intended targets inside the body and did not cause troubling side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although mentioning the heart valve problems which were seen to occur with the use of a different weight loss medication, there was no mention in this story of the side effects (headache, nausea, and dizziness) which were seen to occur with this medication during the relatively short period of time it was used. \u00a0The story also failed to mention whether weight re-gain was common after use of the medication was stopped. Harm is of particular concern with obesity drugs, particularly given the experiences with Fen-Phen which had a similar mechanism of action.", "answer": 0}, {"article": "In those procedures, doctors either extract a small amount of the fluid that surrounds the fetus (amniocentesis) or they take a sample of the placenta (chorionic villus sampling).\nWhile it\u2019s available over the Internet, she said her team had only looked at hospital-based test performance.\n\u201cRemember, gender is not a disease.\u201d\n\nThe test looks for small pieces of the male sex chromosome in the mother\u2019s blood, which would mean she is carrying a baby boy.\nRosser, however, chalked that up to the ethical issues it raises.\n\u201cBut it should only be used by families that are at risk for sex-linked diseases.\u201d\n\nBianchi said she owns stock in Verinata Health, a company that is developing cell-free fetal DNA tests for Down syndrome, although that company had no role in the new study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give this a barely passing grade, because the story does quote one ethicist raising doubts about how parents may use the test.\u00a0She points out: \u201cRemember, gender is not a disease.\u201d Reuters does not use the word \u201cabortion.\u201d Seems to be a bit light on the harms side of the social equation.", "answer": 1}, {"article": "July 14, 2010 -- An experimental weight loss drug that targets the brain\u2019s hunger center was shown to be safe and effective for helping dieters shed pounds in a two-year study, researchers say.\nAll the participants were counseled about diet and exercise.\nThe study appears in the July 15 issue of the New England Journal of Medicine.\nThe company hopes to win FDA approval to market the new drug later this year.\nHe says that all the patients in the study were monitored closely for heart valve irregularities, and no difference was seen in the two treatment groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Stronger points: \nWeaker points:\u00a0", "answer": 1}, {"article": "Human monoclonal antibodies are naturally occurring human antibodies that are genetically altered in a laboratory, cloned in large numbers and introduced into the patient to target disease sites.\nMONDAY, Nov. 5, 2012 (HealthDay News) -- An experimental drug may help patients who can't tolerate statins lower their cholesterol, a new Australian study suggests.\nMore trials need to be done of this unique treatment, she added.\n\"The most interesting aspect of this study is use of a novel approach using monoclonal antibodies -- a subtype of antibodies -- in the management of elevated LDL cholesterol,\" said Dr. Kenneth Ong, acting chief of cardiology at the Brooklyn Hospital Center.\n\"Of note is the reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will score this story as meeting the minimum requirement of this criterion because the story did briefly note that \u201cthe reduction in the number of myalgias (muscle pains) for patients compared to the number of myalgias experienced by people taking statins,\u201d which would imply to alert readers that the number wasn\u2019t zero. However, the point of the trial was to find a way around side effects that statins cause some patients, so it is irksome that the story fails to point out that a trial this small probably wouldn\u2019t have detected the statin-caused problem, and that much larger trials will be needed to rule out similarly uncommon problems with this new drug.", "answer": 1}, {"article": "Professor Norman Ratcliffe said, \"There is currently no accurate test for prostate cancer, the vagaries of the PSA test indicators can sometimes result in unnecessary biopsies, resulting in psychological toll, risk of infection from the procedure and even sometimes missing cancer cases.\nAn accurate urine test would mean that many men who currently undergo prostate biopsy may not need to do so.\"\nOur aim is to create a test that avoids this procedure at initial diagnosis by detecting cancer in a non-invasive way by smelling the disease in men's urine.\nThe research team is now looking to fund a full clinical trial.\nThe results of the pilot study using the GC sensor system indicate that it is able to successfully identify different patterns of volatile compounds that allow classification of urine samples from patients with urological cancers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release speculates about potential benefits, but never acknowledges that the test might have downsides similar to the PSA test. False-positive results could lead to unnecessary biopsies and take a psychological toll on men who are tested \u2014 the release should have mentioned this.", "answer": 0}, {"article": "I couldn't get anything done,\" Ham said.\nThere are some promising findings involving rats and one 2014 JAMA study showing that states with medical marijuana laws had nearly 25 percent fewer opioid-related overdose deaths than those without, but even a co-author on that study said it would be wrong to use the findings to make the case for cannabis as a treatment option.\nIt would also be wrong to portray marijuana as completely safe, they say, because it can also be addictive.\nBut there's a problem: There is very little research showing marijuana works as a treatment for such addictions.\nCannabis could have limited benefits as a treatment alternative, said Harvard Medical School's Dr. Kevin Hill, who last year authored the JAMA study that found benefits in using medical marijuana to treat chronic pain, neuropathic pain and spasticity related to multiple sclerosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are some known or suggested harms of chronic marijuana use, yet there was not much\u00a0mention of those harms in this story. \u00a0The one harm mentioned is a significant one: marijuana also can\u00a0be addictive.\nHowever, the article didn\u2019t mention others risks of inhaling marijuana, such as lung disease,\u00a0as well as effects on motivation, and other cognitive\u00a0issues, especially when the dose isn\u2019t being well controlled when smoked.", "answer": 0}, {"article": "They were then monitored for 24 hours.\nBut researchers say this is the first study to look at the effects of adding beet juice to a heathy person\u2019s diet without making any other diet or lifestyle changes.\nIn this case, Coles says it may be partially explained by the fact that the women in the study tended to be older, and many were on prescription medications, such as oral contraceptives.\nThe study shows that within hours of drinking it, beet juice lowered systolic blood pressure (the top number in a blood pressure reading) by an average of 4-5 points among a small group of healthy men .\n\u201cThat effect might be even greater over the long term if they are drinking it day upon day.\u201d\n\nResearchers say that drop may seem small, but on a public health level a reduction like that would equate to a 10% reduction in deaths due to heart disease .\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss potential harms. We\u2019re not aware of any harms associated with drinking beet root juice, but there are concerns that getting too much nitrate could have have toxic effects, such as increasing the risk for cancer. (That\u2019s why nutritionists often advise against eating meats cured with nitrates such as hot dogs.) The story could also have warned of possible adverse effects from supplements that contain nitrate or nitrite salts, which can be highly toxic.\u00a0There is no information on Medlineplus.gov about beetroot. \u00a0Medication interactions are also possible. Harm is always possible, even with nutritional supplements. We stand by our same hard line as with the \u201ccosts\u201d criterion above.\u00a0 All interventions have potential harms; some discussion is warranted.", "answer": 0}, {"article": "\u201cI couldn't even imagine first of all, not having the pain,\" she said.\nA new, non-invasive knee procedure could bring some relief for patients suffering from debilitating chronic pain, for whom surgery is not an option.\nThe treatment, recently approved by the Food and Drug Administration, is called \u201ccooled radio frequency ablation\u201d and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don\u2019t make them a good candidate for surgery.\n\"But let\u2019s say a patient is younger, instead of going for a total knee replacement early, which might have to be repeated later on, Coolief can postpone the need for the total knee replacement,\" Ross told NBC News.\nWhile it reduces pain, it can't stop the progression of osteoarthritis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Risks are identified.\nHowever, we think it would have been worth pointing out that there is little scientific\u00a0literature about applying this old technology to a new\u00a0part of the body. So, it\u2019s unclear what the eventual risks are.\nAlso, the article is not quite clear what radiofrequency ablation is doing: killing nerves, for at least 6 months. There could be permanent loss of nerve sensation, or maybe the nerves will grow back years later, either normally or in an altered state (which has happened in some other medical and surgical situations).", "answer": 1}, {"article": "There are also a number of drop-based products.\nAcross the studies, which included a total of 2,971 adults and children with grass-pollen allergies, immunotherapy reduced symptoms by about 20 percent to 30 percent, on average.\nThe researchers, led by Dr. Gabriele Di Lorenzo of the University of Palermo, describe the benefits as \u201cmodest.\u201d\n\nIn an email, Di Lorenzo told Reuters Health that the findings suggest that sublingual immunotherapy is \u201chighly effective in many, but not in all patients.\u201d He said that more work is needed to identify which patients might be most likely to benefit.\nOn the other hand, Nelson said, allergy shots appear to outperform the oral versions, with a symptom reduction about twice that of sublingual immunotherapy.\nFor the new study, reported in the Journal of Allergy and Clinical Immunology, Italian researchers combined the results of 19 clinical trials conducted since 1995 on the effectiveness of immunotherapy tablets and drops against hay fever caused by grass pollen.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>1clip_themedata.thmx\"/>1clip_colorschememapping.xml\"/>\n\n\n\n \nThe story provides a list of the most common side effects associated with sublingual immunotherapy; however, a more complete report would have also mentioned more serious, albeit rare, reactions. It would also be useful for readers to know that in the 1518 patients who received sublingual immunotherapy, there were 3286 reported adverse events (2.6 per person), compared to 1570 reported adverse events in the placebo group (1.34 per person). Furthermore, 54 (3%) patients in the sublingual immunotherapy group dropped out of the studies due to adverse events, compared to 12 (1%) in the placebo group.\n", "answer": 0}, {"article": "1 Yiou et al.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\n\"The CaverStem\u2122 procedure involves obtaining a small amount of bone marrow from the patient, purifying the stem cells using a closed system device that is FDA cleared, and then administering these cells in the same procedure into the patient's penis,\" said Thomas Ichim, Ph.D, Chief Scientific Officer and Co-Founder of the Company.\nThe goal of this procedure is to regenerate blood vessels and smooth muscle, parts of the penis that are not functioning properly in this patient population.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention any potential harms of the stem cell treatment. Although stem cell clinics often tout the safety of stem cells because they come from within the patient\u2019s own body, that does not mean that there are no risks to stem cell procedures. Only one stem cell procedure (a blood-derived stem cell treatment used for treating cancer and blood-illnesses) is currently approved by the FDA. All other stem cell therapies in the U.S. are experimental and unregulated by the government, including this\u00a0CaverStem procedure. On his blog, UC Davis stem cell scientist Paul Knoepfler reminds patients seeking stem cell therapy that every medical procedure has side effects. \u201cDifferent kinds of stem cells have variable risk profiles,\u201d writes Knoepfler, \u201cbut if someone tells you that the stem cell treatment they are selling has no risks then that is a big red flag and I would walk away.\u201d\nGiven the small number of men tested and the limited duration of follow-up, it is difficult to deem that this is a safe treatment.", "answer": 0}, {"article": "They then moved each patient's head forward and shook it from side to side for about 15 seconds.\nIn some cases, the cause is unclear.\nPreventative medication was given to 20 of the 35 people with the newly detected type of vertigo.\nThirty-five study participants had this form of vertigo.\nThe others' outcomes were not revealed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story focuses on the diagnosis of a suspected new form of vertigo so possible false diagnoses are a possible harm. And, the unnamed medication likely carries side effects.", "answer": 0}, {"article": "At the end of the day I don't know that this will be the best technology out there, but it is a step forward to allow continued innovation in this area,\" Foreman said.\nAnother concern was that doctors could misinterpret the device's feedback, particularly error messages when a mole cannot be scanned.\nThe company's study was not intended to show that screening with the device saves lives, only that it can help improve a doctor's ability to spot melanoma.\n\"The diagnosis of melanoma is the most serious one a dermatologist makes, and we have sleepless nights worrying about it,\" said Pariser, who consulted for the device's maker, Mela Sciences Inc. of Irvington, N.Y., on its presentation to FDA.\nMelaFind correctly identified about 10 percent of non-cancerous growths, which was better than doctors in the study who were correct less than 4 percent of the time, on average.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s a bit confusing, but the story explains that the device also makes the wrong call too often, giving too many false positives. \u201cHowever, the device did not raise an alarm about non-melanoma growths only about 10 percent of the time; that was still better than doctors in the study who correctly ruled out melanoma in less than 4 percent of such cases, on average.\u201d Just presenting the false positive and false negative rates would have been more helpful to readers.", "answer": 1}, {"article": "Too much coffee may make it harder to conceive and can increase the risk of miscarriage.\nHowever, coffee alone may not be the answer according to some experts.\n\"Each person needs to think about how they metabolize caffeine or coffee.\"\nOur hope is that much will be learned from the sharing of useful information and personal experiences based on the medical and health topics of the blog.\nWe receive many comments on this blog each day; not all are posted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "At least this story did what the WebMD story didn\u2019t do in discussing some of the potential harms from drinking a lot of coffee. ", "answer": 1}, {"article": "An Online Program May Help Prevent Depression In Some People\n\nWorking through a self-help program online can prevent or delay major depression disorder in people who are vulnerable, a study finds.\n\"And of course, I'm surprised about what happens now; that a health insurance company offers the intervention to its members.\nIt's also not clear if this kind of program could be scaled up.\nAt the next session, participants reflect on their experiences.\nStill, Buntrock seems pleased with the results, especially since the German insurance company BARMER GEK that sponsored the trial is now providing it to its customers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not address potential harms, but there are few potential harms associated with the relevant interventions\u2013other than temporary discomfort, stress or anxiety that can come along with addressing difficult feelings. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "\"I think there\u2019s no one answer,\u2019\u2019 Goldstein said.\nMichael Sand, director of clinical research at Boehringer, said the company intends to pursue regulatory approval based on the late-stage study findings.\nSales of the drug could reach $100 million, according to analysts with market research firm Decision Resources.\nThe drug, which is being developed by the giant German drug maker Boehringer Ingelheim, could become the first treatment approved by U.S. regulators for women who suffer from hypoactive sexual desire disorder.\n\"I\u2019m hoping this will help the women who need it.\u2019\u2019\n\nOne expert, Andrew Goldstein who runs the Sexual Wellness Center in Annapolis, Md., described a \"huge\u2019\u2019 unmet need for a medical treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No adverse effects of the drug were reported in the story.\u00a0 Safety data reported indicates that potential side effects include dizziness, nausea, fatigue, somnolence, and insomnia. ", "answer": 0}, {"article": "Journal of Child and Adolescent Psychopharmacology.\nIf nothing else, it might allow people who would be reluctant to take medication more treatments to choose from.\nBoth findings reaffirm the potential that mindfulness therapy could bring to the table.\n\"Increasingly, patients and families are asking for additional therapeutic options, in addition to traditional medication-based treatments, that have proven effectiveness for improved symptom reduction.\nBut a team of researchers from the University of Cincinnati set out to explore other treatment options that focus more on the mind and less on pharmaceutical solutions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t address harms. However, that may be because there are few (if any) risks associated with cognitive therapy for anxiety disorders. We\u2019ll rate this not applicable.", "answer": 2}, {"article": "According to the Centers for Disease Control and Prevention, about 610,000 Americans die of heart disease each year, accounting for 1 in 4 deaths.\nThose who would benefit from the regimen, according to the U.S. Preventive Services Task Force, must meet a strict list of criteria -- including a high risk of heart disease and a low risk of bleeding side effects.\nFor people in this group, taking low-dose aspirin daily can help reduce the risk of heart attack, stroke, and colorectal cancer.\"\nWhen it comes to dosing, experts say sticking to a low-dose baby aspirin is best.\nThe task force looked at the most up-to-date research on both the benefits and harms of taking aspirin for the primary prevention of both heart disease and colorectal cancer to arrive at their recommendations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained, and that\u2019s sufficient to rate as Satisfactory.", "answer": 1}, {"article": "A growing number of doctors are offering an expensive laser procedure they say zaps away a common fungus that causes ugly, discolored nails. Published data on laser treatment for nail fungus is scant, but early results suggest it is a reasonable option for people who don't want the side effects of oral medications.\n\nOnychomycosis, or fungal infection of nails\u2014most often on the toes\u2014affects about 12% of Americans, according to the American Academy of Dermatology. Some people are genetically prone to it. Others, including swimmers...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a reasonable job in describing the side effects seen with Lamisil, a drug approved for this use. Unfortunately it does so with a bit of an apparent bias, \u201c\u2026.If you are willing to risk side effects, \u2026\u201d in its discussion. Although the laser treatments are generally well tolerated, some people have mild pain and a sense of warmth. We would have been willing to give the benefit of the doubt but the suggestion that there are absolutely no side effects associated with the laser treatment leads us to rule this unsatisfactory.", "answer": 0}, {"article": "The median age was 70, with a range of 50 to 88.\nQuality of life was not adversely affected by surgery at any time in patients who, prior to surgery, had performance status of 1 or 2; a tumor volume greater than 600 ml.\nThe study is titled \u201cQuality of Life in Patients Undergoing Pleurectomy and Decortication for Malignant Pleural Mesothelioma.\u201d The surgeries were performed by Dr. Vigneswaran at University of Chicago Medicine, where he practiced before recently joining Loyola.\nImproved quality of life was observed in the first month after surgery and was maintained at late follow-up in all patients.\nFollowing surgery, all patients were surveyed at 1 month, 4-5 months, 7-8 months and 10-11 months.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "All interventions carry risks, and the news release does not mention any potential harms that may accompany major surgery. These include complications related to anesthesia \u2014 including blood clots and pneumonia, infection at the incision site, fluid build-up under the skin, bleeding, scarring and nerve damage.\nAs mentioned in the \u201cbenefits\u201d section, the news release also does not point out the patient subgroups who did not experience a marked improvement in their quality of life.\nFor these reasons, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "AMG145, along with other PCSK9 inhibitors being developed by companies like Pfizer, Regeneron Pharmaceuticals Inc in partnership with Sanofi and Roche, is a man-made antibody.\nThe trial, presented here at the annual scientific meeting of the American Heart Association, included 168 patients with heterozygous familial hypercholesterolemia, in which a defective gene inherited from one parent impairs the ability to properly metabolize LDL.\nThe most common side effects seen in the trial were injection-site reactions, cold-like symptoms and headache.\nThe new drug, given by injection every four weeks, is part of a promising new class of biotech medicines known as PCSK9 inhibitors designed to target a protein that prevents the body from removing artery blocking LDL cholesterol from the bloodstream.\nThe Phase II trial found that after 12 weeks, patients treated with a low dose of AMG145 had a 43 percent reduction in LDL, while those given a higher dose had a drop of 55 percent.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story meets the minimum requirement of this criterion by reporting some of the side effects seen in this drug trial. However, it should have noted that the trial was too small to see less common side effects. Indeed, a trial this small would be unlikely to detect the muscle pain and weakness that cause serious problems for some similar patients when they take statin drugs to reduce cholesterol and heart-related risks.", "answer": 1}, {"article": "During an 18-month-long randomized, double-blind trial, 80 postmenopausal women with osteoporosis received daily injections of either placebo, a single unit of growth hormone or a 2.5-unit dose of growth hormone.\n, ahead of print.\n\"The findings indicate the beneficial effects of growth hormone remained long after the treatment ceased,\" Krantz said.\nThe women were between the ages of 50 and 70 when they were recruited for the decade-long study.\nAfter 18 months, the women who received the placebo halted the injections.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention potential harms at all. Given the wide range of potential side effects from growth hormone use \u2014 from headache and joint pain to weight gain and weakness \u2014 this is a significant oversight.", "answer": 0}, {"article": "They ran the test at about 15 weeks gestation.\nSuch a \u201cmetabolic fingerprint\u201d test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\n\u201cA high caliber predictive test would allow women who are identified at high-risk for pre-eclampsia to seek obstetric care by specialists and to be monitored more vigilantly,\u201d Eleni Tsigas, executive director of the Pre-eclampsia Foundation, said in a statement.\nThe cost of treating mothers with pre-eclampsia is $45 billion a year in the United States, Europe, Asia, Australia and New Zealand, the researchers said.\n\u201cIf we can bring the rates of maternal deaths in undeveloped countries down to the rates in developed countries, by being able to determine which women are at the greatest risk for developing pre-eclampsia, then it has that potential to save thousands of lives,\u201d Baker said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The preliminary nature of the research makes it difficult to accurately assess potential risks associated with the diagnostic test. At the same time, high in the story the lead author touts the huge potential benefits of the research. \"Such a \"metabolic fingerprint\" test could save the lives of thousands of women, Philip Baker of the University of Alberta in Canada, who helped lead the study, said in a statement.\" With all screenings and \"early warning sign\" tests there are opportunities for overtreatment and potentially harmful treatment, this should have been addressed in some fashion. For example, the main treatment right now for preeclampsia is magnesium sulfate. As the Preeclampsia Foundation, which is quoted in this story, points out on its website, \"Nevertheless, magnesium sulfate, is not a benign drug and must be used by a skilled health care provider with appropriate support facilities. Overdoses can and do occur.\"", "answer": 0}, {"article": "Old friendships fell apart.\nHis book is likely to spark even greater interest \u2014 and funding \u2014 in TMS as a non-medicinal way to treat symptoms associated with disabilities like autism, epilepsy, ADHD, and dementia.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nA recent paper by the BIDMC team concluded that TMS, while appealing and worth further study, is not yet recommended as an autism treatment.\nStill, there are a number of clinics currently offering TMS as an autism treatment, a practice that concerns many researchers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0does describe harms that affected the man highlighted in this piece. While that\u2019s important for understanding his story, the descriptions provided do not help the reader determine how common these harms may be nor\u00a0the severity of the negative aspects identified. Studies of TMS for the treatment of other disorders\u2013for example, depression\u2013could have been cited to establish common risks and side effects.", "answer": 0}, {"article": "Past studies have found that compared with people without fibromyalgia, those with the disorder have higher rates of stressful life events, such as childhood abuse, marital problems and high levels of job stress.\nPart of that, according to the researchers on the new study, may be because standard treatments do not specifically address the role psychological stress and emotions can play in triggering people\u2019s pain.\nNone of the women in the control group had a comparable improvement.\nSchubiner also acknowledged that this general \u201cmodel\u201d for understanding and addressing fibromyalgia pain is controversial.\nAnother difference is that, right now, only a small number of healthcare providers practice affective self-awareness, according to Schubiner.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll grade this one not applicable because the story didn\u2019t mention any potential harms of psychotherapy \u2013 which is understandable since these are generally thought to be small.\u00a0 But there are some theoretical risks which the story could have mentioned.\u00a0 ", "answer": 2}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes potential harms from the vaccines: \u201cThe level of serious adverse events was higher in the placebo group than either vaccine group, and \u2018most of the serious adverse events were attributed to malaria.'\u201d", "answer": 1}, {"article": "But that is not what we found.\u201d\nBut the fact that the fewest recurrences were seen in men who took the highest statin doses is compelling, says senior investigator Stephen J. Freedland, MD, of the Duke Prostate Center.\nThose who took the highest doses saw their recurrence risk drop by half.\n\u201cStatin users may see their doctors more often and may be more health conscious in general, and it has been suggested that this could explain the observed reduction in risk,\u201d Freedland tells WebMD.\nThe research does not prove that taking cholesterol-lowering drugs directly slows the growth and progression of prostate cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms. Statins do have side effects, contrary to their glowing press. And, although the story does say that more study is needed, it makes no mention of the fact that cancer patients may be taking a host of other drugs that could interact poorly with statins.", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article explains possible harms from using the devices by soliciting opinions from the Heimlichs, the namesake of the famous Heimlich maneuver:\n\u201cAny action that delays use of the Heimlich maneuver or complicates the rescue can be deadly.\u201d\nTo balance this perspective, the article also discusses the use of these devices as a backup to other standard procedures:\nThe LifeVac and the Dechoker are both intended to be used if standard rescue treatments fail, the companies say. One person can get the device while another person starts the Heimlich maneuver, suggests Sean Pittman, Dechoker\u2019s director of strategic development.", "answer": 1}, {"article": "Unlike the more common obstructive sleep apnea, in which the airway partially collapses and causes pauses in breathing, central sleep apnea (CSA) occurs when the brain fails to control breathing during sleep.\nAt the six month evaluation, the device reduced CSA events per hour by half or more for 35 of the 68 members (51 percent) of the treatment group.\nAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\nTen were excluded due to non-study related medical issues or deaths, exiting the study or missing visits.\nAbraham, along with lead author Dr. Maria Rosa Costanzo at Advocate Heart Institute in Naperville, IL, led the study at 31 hospitals in the United States, Germany and Poland.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contains this short phrase \u201cwithout causing serious side effects\u201d in reference to potential harms. We find that inadequate considering that CSA is serious condition that occurs in already very ill people. Presumably, they would be susceptible to a range of risks for side effects from the surgical placement of the device.\nThe release also states that 10 study enrollees were \u201cexcluded due to non-study related medical issues or deaths, exiting the study or missing visits,\u201d and \u201cAbout a third of patients in the treatment group reported therapy-related discomfort that was resolved with some reprogramming of the device.\u201d\nWe think a discussion on why some patients exited the study (was it due to intolerance?) and some details on \u201ctherapy-related discomfort\u201d were warranted here.", "answer": 0}, {"article": "But it was a small study, and \"it will take another year or two to get enough cases to nail down the predictive index,\" Veltri said.\nThe study included 71 men originally diagnosed as having small, low-grade and low-stage prostate cancer, the kind whose ultimate aggressiveness is often in doubt.\nMen in the trial had periodic blood tests that measured three different forms of PSA, including pro-PSA, a molecule in which two of the amino acids that make up the protein have been clipped off.\nAnother report at the same meeting described use of a microchip to detect tumor cells in the blood of people with prostate cancer.\nThe Hopkins work was described as \"outstanding\" by Dr. William J. Catalona, director of the prostate cancer program at Northwestern Memorial Hospital's Robert H. Lurie Comprehensive Cancer Center, who pioneered the use of the standard PSA test and helped develop the new version of the test.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did not provide insight about the individuals who were incorrectly diagnosed in the study reported on. \u00a0What percentage of men had aggressive tumors that the test failed to detect? \u00a0And what percentage of men received treatment because the test identified them as having aggressive tumors but actually did not need to be treated?", "answer": 0}, {"article": "In the first study, published Monday in the journal Cancer Epidemiology, Biomarkers and Prevention, scientists found that men who took a daily dose of acetaminophen (Tylenol) for five years had a 38% lower risk of developing prostate cancer, compared with other men.\nThat\u2019s what the findings of two new studies published this week suggest.\nMen who took acetaminophen for less than five years saw no protective benefit.\n\u201cThe important point was the intensity of the activity,\u201d Erin Richman, a postdoctoral fellow at UCSF, said in a statement.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No drug \u2013 not even acetaminophen \u2013 is without risk.\u00a0 So, when the story starts in cavalier fashion \u2013 \u201cPop a Tylenol\u2026\u201d it should also find time and space somewhere to mention that popping pills comes with some risk \u2013 especially given that the safe daily maximal dose of acetaminophen has been lowered in recent years.", "answer": 0}, {"article": "People who experience them see or hear things that are not there (hallucinations) and/or have false beliefs (delusions).\nThe effectiveness of Nuplazid was shown in a six-week clinical trial of 199 participants.\nNo drug in this class is approved to treat patients with dementia-related psychosis.\nAs with other atypical antipsychotic drugs, Nuplazid has a Boxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis.\n\u201cNuplazid represents an important treatment for people with Parkinson\u2019s disease who experience these symptoms.\u201d\n\nAn estimated 50,000 Americans are diagnosed with Parkinson\u2019s disease each year, according to the National Institutes of Health, and about one million Americans have the condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that Nuplazid has a \u201cBoxed Warning alerting health care professionals about an increased risk of death associated with the use of these drugs to treat older people with dementia-related psychosis.\u201d Other harms observed in the very brief (6-week) trial are swelling due to the accumulation of excessive fluid in the tissue, nausea\u00a0 and confusion. The release would have been stronger had it given us an idea of how common or rare these side effects are.", "answer": 1}, {"article": "The latest advances in Alzheimer\u2019s disease involve people who don\u2019t appear to show any signs of cognitive decline yet.\nIdeally, for example, isolating those with MCI might help doctors to focus in on a group of patients who might be at higher risk of developing Alzheimer\u2019s and therefore might need more intensive and regular testing.\nThe results aren\u2019t conclusive enough yet for doctors to start using them to distinguish people who are more likely to develop Alzheimer\u2019s, but that\u2019s the goal, says Sapkota.\nExperts now believe that the biological processes behind the neurodegenerative condition begin years, if not decades, before memory problems and confusion become noticeable.\nBy comparing their saliva components, the scientists found that each of the three groups showed slightly different patterns of compounds, which could form the basis of a relatively easy and non-invasive way to determine which people are at higher risk of developing more serious degenerative brain conditions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Direct harms from a simple saliva test seem improbable at best, given its non-invasive nature.\u00a0 But the competing HealthDay story pointed out that even a saliva test could produce false positives that could cause real anxiety in patients, something that clearly could harm them.\u00a0There is also the potential for false negative results, which would falsely reassure patients about their status. Even an accurate positive finding could cause harm, since it would inform people about their risk of a future condition without giving them the ability to do much about it.", "answer": 0}, {"article": "Anorexia has one of the highest mortality rates of any psychiatric disorder and is among the most common psychiatric disorders in girls aged between 15 and 19 years.\nImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur, the researchers said.\nThis success, in a small study designed as a pilot to test the safety of the technique, suggests larger trials will confirm the effectiveness of the deep brain stimulation (DBS) device, the researchers wrote in the medical journal The Lancet.\nCommenting on the results of this small trial, Janet Treasure and Ulrike Schmidt of King\u2019s College London\u2019s Institute of Psychiatry said the technique looked promising and would give hope to patients with especially pernicious forms of anorexia.\nThe devices were activated 10 days later and researchers measured changes in the patients\u2019 mood and anxiety to help find the correct level of stimulation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story minimizes potential harms, stating \u201cImplanting the DBS device requires minimally invasive surgery which can be completely reversed if problems occur.\u201d\u00a0 There was no other discussion of potential harms.\nIn fact, the researchers reported:\n\u201cDBS was associated with several adverse events, only one of which (seizure during programming, roughly 2 weeks after surgery) was serious. Other related adverse events were panic attack during surgery, nausea, air embolus, and pain.\u201d", "answer": 0}, {"article": "The American Academy of Family Physicians outlines medicines used to treat patients with acute coronary syndrome.\n\"Of note, there is little reason to ever use aspirin 325 mg except in the acute setting of a heart attack or stroke,\" he added.\nIn this latest analysis of PLATO findings, researchers found that patients who took Brilinta with low-dose aspirin were 16 percent less likely than those who took Plavix with low-dose aspirin to have a heart attack or stroke, or to die within a year.\nThe data and conclusions of the research should be viewed as preliminary until published in a peer-reviewed journal.\nThe panel's recommendation was based in part on prior findings from this study, called the Platelet Inhibition and Patient Outcomes (PLATO) trial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In the setting of heart attacks, the major harms of the drugs are related to their benefits \u2014 how well they prevent future cardiovascular tragedies. However, all the drugs in this article, including aspirin, impart a risk of bleeding, which is part of the comparison in PLATO and this follow-up analysis. It was good that the article gives a mention, albeit a brief one in the quote from Dr. Berger, of the increased risk of bleeding with higher doses of aspirin.\u00a0", "answer": 1}, {"article": "Caught early, lung cancer can be cured surgically, but it causes vague symptoms and usually is not diagnosed until it has spread.\n\u201cWe will have what breast cancer has now, which is a lot of survivors.\u201d\n\nThe researchers have some caveats.\nThe researchers waited until an independent panel could document a 20 percent reduction in cancer deaths, or could determine that there was no significant benefit.\nDr. Bruce Johnson of the Dana Farber Cancer Institute in Boston, who is on the board of the American Society of Clinical Oncology, said he doubted most people would see the findings as a green light to smoke.\nHer ideas were controversial to start with and widely disregarded when other researchers found her work had been paid for by a tobacco company.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story misses the mark completely in its handling of the potential harms of the test.\u00a0It does provide the important caveat that \u201cCritics of the scans fear that smokers may not be motivated to quit if they believe screening can save their lives if they do get cancer.\u201d\u00a0\u00a0It fails to note the relatively high false positive rate (25% to 60%) and the implications on unnecessary additional testing. This is especially disappointing because the NCI press release provided the information.", "answer": 0}, {"article": "In the absence of FY26, cancer cells switch from using their defective mitochondria to using metabolic activity in their cytoplasm to generate energy.\n\u201cIt is clear that a new generation of drugs is necessary to save more lives and our research points to a highly effective way of defeating cancerous cells\u201d.\nThe researchers argue that the drug could be cheaper to produce, less harmful to healthy cells than existing treatments and has been shown to be active against cancer cells which have become resistant to platinum-based drugs.\nSimilar results were obtained by the National Cancer Institute USA in tests conducted on 60 cell lines.\nThe research could also lead to substantial improvements in cancer survival rates, suggests co-researcher Dr Isolda Romero-Canelon:\n\n\u201cCurrent statistics indicate that one in every two people will develop some kind of cancer during their life time, with approximately one woman dying of ovarian cancer every two hours in the UK according to Cancer Research UK and two deaths every hour from bowel cancer.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story promises so much of this compound, including that it could be\u00a0less harmful to healthy cells than existing treatments. But it\u2019s hard to know what side effects might exist because the drug has apparently never been tested in animals or humans. The release does mention the many side effects associated with existing chemotherapies, but we wish there had been a caution: \u201cThere may be side effects with FY26 that remain to be discovered.\u201d", "answer": 0}, {"article": "Kymriah is a leukemia treatment made by pharmaceutical giant Novartis.\nOne-time-only treatments for rare genetic disorders are still unique, he noted.\nThis is the first to correct an inherited genetic mutation.\n\"Spark Therapeutics is charging as much for Luxturna as they think they can get away with.\"\nThe drug will be available in the United States in early spring, with an estimated 1,000 to 2,000 people in the US standing to benefit from this treatment, according to Spark.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned potential harms of the therapy. We do think the story should have mentioned that we don\u2019t know much about the long-term effects and safety of using this technology, however.", "answer": 1}, {"article": "\"My reaction was, 'Well, you smoked for 30 years.\nAnd it is mainly a disease of older people.\nAnd, after five years, almost 9 out of 10 patients were alive and cancer free.\nHe was senior author of a study published in the Journal of Clinical Oncology in October.\nSeventy today is not the same as it was 20 years ago, Lichtenfeld says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article admits the conventional wisdom is that older patients don\u2019t tolerate surgery for lung cancer, but from headline to the final sentence\u00a0the NPR story is about older lung cancer patients thriving, based on a personal story and and experts\u2019 opinions. There is no meaningful discussion of the harms of surgery.", "answer": 0}, {"article": "Acute myeloid leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow.\nBased on these results the company expects to submit a New Drug Application (NDA) for VYXEOS with the U.S. Food and Drug Administration (FDA) later this year and submit a Marketing Authorization Application (MAA) with the European Medicines Agency (EMA) in the first quarter of 2017.\nEWING, N.J., March 14, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (Nasdaq: CPXX) today announced positive results from the Phase 3 trial of VYXEOS\u2122 (cytarabine: daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as 7+3.\nIn the intent-to-treat population, Grade 3 or higher, non-hematologic adverse events were similar across all organ systems, including cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.\nInformation on ongoing trials is available at www.clinicaltrials.gov.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release noted that serious harms from the drug were comparable to the standard therapy and listed the adverse events including infections, febrile neutropenia, bleeding, cardiac, gastrointestinal, general systems, metabolic disorders, musculoskeletal, nervous system, respiratory, skin and renal.\nOne word of caution about the harms. The study was not blinded (according to its listing on ClinicalTrials.gov) and these adverse effects may have been subjectively\u00a0found, potentially biasing the results. \u00a0We are not given enough information about this in the news release.  ", "answer": 1}, {"article": "Researchers around the world are seeking ways to regenerate damaged hearts, spines and skin with stem cells. At an operating table here recently, Kotaro Yoshimura leaned over a 51-year-old woman and put stem cells to use for a different purpose: cosmetic breast surgery.\n\nDr. Yoshimura jabbed the underside of the woman's left...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does an excellent job listing the potential harms of the procedure.\u00a0 The story gives appropriate caveats that this stem cell and fat grafting is relatively unstudied in women with a history of breast cancer, a population possibly more vulnerable to long-term harms of fat injections in the breast area. The story notes the potential need for multiple revision surgeries if the fat transfer does not take.\u00a0 The story notes that women looking for increased bresat volume beyond 1 cup size would likely not be candidates.\u00a0 The story appropriately lists potential long-term harms, including obscured mammograms due to nercrosis and calcifications from the fat. ", "answer": 1}, {"article": "Among the women who initially had no heart disease and did not take any dietary supplements, 3.4 percent had heart attacks, compared to 2.6 percent of the women who took multivitamins plus other supplements; this translated to a 27 percent lower heart attack risk with vitamins.\n\u201cEven if we have controlled for many of those factors that are associated with a healthy behavior we cannot exclude the possibility that we might measure a healthy lifestyle via multivitamin use.\u201d\n\nIn industrialized countries, Rautiainen and her team note in the American Journal of Clinical Nutrition, multivitamin use is widespread.\nWhile conventional wisdom holds that taking vitamins could help prevent heart disease, the researchers add, there\u2019s actually little evidence to back up this claim.\n\u201cIt is very important to keep in mind that multivitamin users tend be \u2018healthier\u2019 in general.\nFor the women without heart disease at the study\u2019s outset, taking a multivitamin for less than five years reduced heart attack risk by 18 percent compared with non-users of supplements.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of possible harms associated with the use of multivitamins. \u00a0In an era where so very many foods are fortified with various nutrients, the consumption of yet another source of micronutrients may not be without potential down sides.", "answer": 0}, {"article": "There will also be the matter of cost.\nMuscle weakness is a potential concern in MS patients, LaRocca noted, since that problem often comes with the disease itself.\nThe new study, published in the journal Neurology, tested the effects of Botox injections on MS-related arm tremors, which affect up to two-thirds of people with MS.\nResearchers found that when they gave injections to 23 patients, the treatment typically eased their tremors and improved their writing ability.\nRight now, there\u2019s no good way to treat MS arm tremors, said Nicholas G. LaRocca, vice-president of healthcare delivery and policy research at the National MS Society.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated:\nMuscle weakness was the most common side effect in this study, van der Walt said. It affected 42 percent of the study patients, though it went away within two weeks.\nMuscle weakness is a potential concern in MS patients, LaRocca noted, since that problem often comes with the disease itself.", "answer": 1}, {"article": "In the study, published in the Annals of Internal Medicine, researchers reviewed 83 studies on the two methods.\nResearchers say needle biopsy has fewer complications and a shorter recovery time than open surgical biopsy, but some women and doctors may have concerns about the accuracy of the procedure compared with traditional open surgery methods of breast cancer diagnosis.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nWomen suspected of having breast cancer after initial screening are usually referred for a biopsy to determine whether the lesion is cancerous.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions \"complications\" and \"side effects\" but does not discuss exactly what these include with either procedure.\u00a0 Surgical biospy is more invasive and risks include infection, scars and slower\u00a0 wound healing compared with CNB.\u00a0 Women who have CNB and are diagnosed with breast cancer have fewer surgeries than women diagnosed via surgical biopsy.\u00a0 Women at higher risk of developing breast cancer (genetic factors, prior pre-cancerous lesions or biopsies, older age)\u00a0may feel more confident of their results via surgical biopsy v. CNB.\u00a0\u00a0", "answer": 0}, {"article": "That's been the brass ring.\"\nResearchers who were not involved in the study praised the work, saying the findings were promising and could lead to the first effective treatment for the central problems affecting people with autism.\nWhile cautioning that more research is needed on children and additional patients to make sure oxytocin is safe and effective, advocates for families with children with autism welcomed the findings.\nBut Sirigu was among those who said the finding should encourage more research on the potential benefits of oxytocin itself, especially for children.\nBecause oxytocin does not last long in the body and produces its effects for a relatively brief period, some experts said the findings were more likely to encourage drug companies to develop alternative substances that had the same benefits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study was of relatively short duration and no side effects were reported. The story does note that more research in children particularly is needed on the safety of oxytocin.\u00a0However, the story could have noted that oxytocin is not without side effects based on usage in adults. ", "answer": 1}, {"article": "Because about half of deaths in people with diabetes are caused by heart disease, reducing heart risk is considered essential to their care.\nNovo, the world\u2019s biggest diabetes company, had said in March that Victoza cut heart risks \u201csignificantly\u201d in the study but the scale of the benefit was only disclosed on Monday.\nMads Krogsgaard Thomsen, Novo\u2019s chief science officer, said the results should encourage doctors to use Victoza earlier, since they could now see it offered \u201clife-expanding\u201d treatment.\nThe Victoza trial, known as Leader, had been designed to show Novo\u2019s drug did not increase heart risk, so its superiority is welcome news for the company, especially as Sanofi\u2019s (SASY.PA) rival Lyxumia failed to show heart benefits in an earlier test.\nThere was also concern that Victoza did not appear to lower heart risks in American patients monitored in the study, despite doing so in other parts of the world and producing a solid result globally.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of mentioning the side effects of Victoza, even pointing towards whether effects were statistically\u00a0significant. One omission was that the story did not mention the higher incidence of gallstone disease, a side effect that was highlighted as significant in the paper.", "answer": 1}, {"article": "Letters being mailed to study participants advise them to discuss with their doctors whether they should have additional scans or not.\nThe NCI still is compiling rates of false alarms and other risks from the study.\nMany smokers already had sought out spiral CTs, even though the American Cancer Society hasn't recommended the test - citing a lack of clear evidence that they work - and most insurance doesn't cover the $300 to $400 cost.\nIt found 20 percent fewer deaths from lung cancer among those screened with spiral CTs than among those given chest X-rays, the NCI said Thursday, a difference significant enough that it ended the study early.\nWhile the spiral CTs emit less radiation than standard CT scans used to diagnose disease, researchers also will analyze whether the radiation exposures from three scans changes a smoker's lifetime risk of other radiation-related cancers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story points out that such scans can produce false positive results, lead to further tests and treatments that don\u2019t always benefit patients and have their own risks, and that CT scans expose people to radiation that may raise the risk of other types of cancer.\u00a0 It explains that the NCI is \u201cstill compiling the rates of false alarms and other risks\u201d\u00a0but estimates could have been drawn from past research.\n", "answer": 1}, {"article": "In a healthy brain, microglia act as chemical rubbish collectors, surveying the local environment, clearing up unwanted compounds, but in Alzheimer\u2019s these cells can lose this function and switch into an inflammatory state in which they secrete toxic compounds instead.\n\u201cIf humans behave similarly to mice in response to this treatment, I would say the potential is just enormous, because it\u2019s so non-invasive, and it\u2019s so accessible,\u201d said Li-Huei Tsai, director of the Picower Institute for Learning and Memory at MIT, and the paper\u2019s senior author.\nThe authors caution that a \u201cbig if\u201d remains over whether the findings would be replicated in humans \u2013 and whether cognitive deficits as well as visible symptoms of the disease would be improved.\nAfter being given one hour of flickering light each day for a week, the scientists saw a 60% reduction of harmful amyloid plaques in the brains of the mice.\nThe latest intervention, scientists predict, should be quicker and cheaper to confirm in humans than pharmaceuticals, which typically take more than a decade to develop and assess for safety before the clinical efficacy is even examined.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This potential treatment is still in mouse trials, so there\u2019s not a lot that can be said at this point about potential harms. The author quotes the researchers, who pointed out that the lights as they were used in the trial \u201cwould not be offensive at all for people to have in the background.\u201d", "answer": 2}, {"article": "The study is in the Clinical Journal of the American Society of Nephrology.\nOld age is not necessarily a barrier to kidney donation.\nGenerally, guidelines classify donors older than 50 as \u201cextended criteria donors,\u201d but shortages have led to using these donors more frequently.\nItalian researchers retrospectively studied 647 kidney transplants, grouping the donors according to whether they were in their 50s, 60s, 70s or 80s.\nA new study has found a kidney transplanted from a deceased 79-year-old can be as effective as one from a person 30 years younger.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Kidney transplants vary in success rates according to many factors. There is no mention of harms that might come to a patient from receiving a kidney from a much older deceased donor. Or the harms that an older donor might face compared with a younger donor.", "answer": 0}, {"article": "Weight training or cardio?\n\"A lot of older adults will walk as their exercise of choice,\" said Kristen Beavers, assistant professor of health and exercise science at Wake Forest and lead author of the study.\nThis is the latest study from the Cooperative Lifestyle Intervention Program (CLIP-II), a single-blind, randomized controlled trial.\nThese results may be even more important for older adults who gain and lose weight with frequency, because seniors typically don't regain muscle - they regain fat mass - which is \"all the more reason for older adults to try and preserve muscle mass during weight loss,\" Beavers said.\nLosing weight is generally recommended for those with obesity, but preserving muscle - while losing fat - is particularly important for older adults in order to maximize functional benefit, Beavers said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not address harms. We believe the release should have encouraged seniors, especially those with documented cardiovascular disease, to be assessed by a physician before starting a new exercise program.\nThis example of an exercise readiness questionnaire covers some of the considerations that seniors should discuss with a physician prior to embarking on a new exercise regimen.", "answer": 0}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/02/15/national/a141001S34.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Article failed to mention that calcium and vitamin D supplementation increased the risk of kidney stones. Although the experts quoted were clear that the trial was not a ringing endorsement for the use of these supplements to reduce fracture rate, they also cast the use of these supplements in a light more positive than the current study suggested.", "answer": 0}, {"article": "For instance, it only became apparent after about five years for esophageal, pancreatic, brain, and lung cancer; about 10 years for stomach and colorectal cancer; and about 15 years for prostate cancer.\nThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\nThe investigation also showed that the benefits of taking aspirin increased over time.\nThe fall in the risk of death broke down according to individual types of cancer: Reductions in pancreatic, stomach, and brain cancers were difficult to quantify because of smaller numbers of deaths, the authors say.\nParticipants were also followed up after 20 years, by which point 1,634 of the original participants had died as a direct result of cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike the NPR Shots story, this one failed to provide a clear number about harms. It says, \u201cPrevious research has linked aspirin with reductions in heart attacks and strokes, but doctors have been wary when recommending whether people should take daily doses of aspirin because of the risk of gastric bleeding. Rothwell says, \u201cThe size of the effect on cancer I think is such that it does more or less drown out those sorts of risks.\u201d\u201d ", "answer": 0}, {"article": "Instead of shrinking as expected, as part of the normal aging process, the memory center in the brains of seniors maintained their size and, in men, grew modestly after two years in a program that engaged them in meaningful and social activities, new Johns Hopkins Bloomberg School of Public Health-led research suggests.\nExperience Corps is a national program, however it can be costly and isn't available everywhere.\nShe says the program increases involvement in so many different kinds of activities that retired people may not have engaged in otherwise.\nCarlson says it's not entirely clear which elements of Experience Corps account for the improved memory function and increased brain volumes.\nThey also conducted memory tests.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Due to the nature of the intervention\u00a0 \u2013 which was volunteering in a school setting \u2013 it\u2019s difficult to imagine harms occurring. There was no mention of harms in the release, but we won\u2019t penalize the release for that omission.", "answer": 2}, {"article": "Straiton didn\u2019t respond to emails seeking comment.\nResults of the current study reaffirm that a minimally-invasive procedure can be a viable option, even for elderly people who are high-risk surgical patients, said Dr. Samir Kapadia, a cardiovascular medicine researcher at the Cleveland Clinic in Ohio.\nPatients in the study had minimally-invasive surgery that fixes the problem by inserting a replacement valve to send blood around the damaged valve while leaving it in place.\nThe results offer fresh evidence that transcatheter aortic valve replacement can help ease symptoms like shortness of breath and fatigue that limit the ability to handle physical exertion, said Dr. David Cohen, director of cardiovascular research at Saint Luke\u2019s Mid America Heart Institute in Kansas City, Missouri.\n(Reuters Health) - People who get minimally-invasive surgery to replace damaged heart valves have an easier time completing daily tasks and a better quality of life after the procedure, a research review suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story portrays this procedure as minimally invasive and less risky than traditional surgery, but does not describe any risks.\nAlthough TAVR is considered to be lower risk than surgeries that cut open the heart, it\u2019s long-term durability is unknown because the procedure has only been approved in the U.S since 2011.\nMinimally invasive TAVR is still risky. The rate of death within 30 days ranges from 1 to 4%, for example, and it increases the risk of a stroke or heart attack, in addition to other potential vascular and valvular complications, according to UpToDate.com.", "answer": 0}, {"article": "Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.\nBut another experiment got the researchers more excited.\n\u201cThe patients walk in the door and they have something wrong with them \u2014 we don\u2019t know what.\nThe researchers have patented their findings through the universities but Bild said myo-inositol supplements are cheap and freely available.\nAnd, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "       \n \nUnfortunately, the story does not mention harms or lack thereof associated with myo-inositol. And are there any harms from collecting cells from the windpipe with a brush? The story didn\u2019t address this question. \n ", "answer": 0}, {"article": "Rosie Dow, Head of Sing with Us at Tenovus Cancer Care and co-author of the research, added: \"This research is so exciting, as it echoes everything all our choir members tell us about how singing has helped them.\nWe do this where it is needed most - right at the heart of the community.\nThe full research paper can be found at http://ecancer.\nWe have been building a body of evidence over the past six years to show that singing in a choir can have a range of social, emotional and psychological benefits, and now we can see it has biological effects too.\nInternational students constitute approximately 50% of our student body.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention harms but it\u2019s very unlikely there\u2019s any harm in this activity.", "answer": 2}, {"article": "Heart defects and other health problems are also common, according to the March of Dimes.\nIf larger clinical trials confirm the results, the test could become standard practice, Patsalis said.\nIt also can identify Down syndrome in the 11th week of pregnancy, early enough for a woman to end her pregnancy if she chooses, Patsalis said.\nDr. Brian Skotko, clinical fellow in genetics at Children's Hospital Boston and a spokesman for the National Down Syndrome Society, said this study has widespread implications for the incidence of Down syndrome.\nIn a small study, an experimental blood test identified a gene mutation associated with Down syndrome with 100 percent accuracy, according to the Cyprus scientists.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms \u2013 of sensitivity and specificity issues still not determined after such a small study.", "answer": 0}, {"article": "\"We have no right as parents or as physicians or adults to strap them down and chop off a normal part of their body.\nSome think the academy's position is long overdue, and that the group should have gone even further and more forcefully recommended circumcision.\nAt that time, the group, which represents about 60,000 pediatricians nationwide, concluded that there was no clear evidence for or against circumcising newborns.\nChapin and other critics argue that the scientific evidence is questionable.\nThey liken the procedure to female genital mutilation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The only specific harm mentioned in the story was critics\u2019 comparison to genital mutilation.\nBut the story didn\u2019t cite what the AAP wrote in its statement:\n\u201cComplications are infrequent; most are minor, and severe complications are rare.\u201d\nOr what appears on the AAP website:\n\u00a0", "answer": 0}, {"article": "The main attraction of an insulin pill, aside from avoiding injections, is that it comes much closer to the path of natural insulin, which is produced in the pancreas and goes directly to the liver.\nThere were no reported serious adverse side effects and no issues with hypoglycemia, or dangerously low blood sugar, the company said.\nThose who received the oral insulin had a mean night-time glucose reduction of nearly 6.5 percent compared with a placebo.\nOramed said it plans to publish more detailed data from the study once it has had time to analyze the full results.\nThe 28-day study involved patients whose type 2 diabetes was not adequately controlled by metformin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story states that there were \u201cno reported serious adverse side effects and no issues with hypoglycemia, or dangerously low blood sugar.\u201d", "answer": 1}, {"article": "Those who drank between one-third and 1 drink per day five to seven days a week were almost 50 percent more likely to be in good health when they got older compared with those who did not imbibe.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\nThat was after accounting for other factors, such as smoking.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cautions that higher levels of alcohol intake are not protective, remedying an important\u00a0deficiency in the competing WebMD coverage. But\u00a0it\u00a0doesn\u2019t really address the\u00a0uncertainty about whether moderate alcohol intake might increase the risk for some diseases such as breast cancer or pose other potential harms. As such, it doesn\u2019t fulfill the criterion.", "answer": 0}, {"article": "\"People say, 'What's the harm in screening?'\nIt did find enough new data to recommend for the first time against screening for older men.\nThe new review of the scientific literature found no evidence to alter that assessment for younger men.\nBut they drew strong criticism from others who are convinced that routine screening is necessary.\n\"And we know that the therapy produces significant harms.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Without quantifying the frequency, the story mentioned the common side effects of treatment for prostate cancer.", "answer": 1}, {"article": "Severely premature babies are more likely to live if they receive intensive-care treatments rather than palliative care to keep them comfortable, according to a U.S. government-funded study published Thursday.\n\nWhether babies born at the extreme edge of viability, generally considered to be 22, 23 or 24 weeks of gestation, should be aggressively medically treated is a controversial issue among pediatric experts. These infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We particularly like how the article treated this criterion. It is made clear early in the story that aggressive medical treatment in premature babies may be a double-edged sword, since \u201cthese infants often don\u2019t survive and, even if they do, many have substantial long-term health problems.\u201d\nWe also like the fact that the article differentiates between survival and a \u201cfunctional, fully participatory life.\u201d An independent pediatrics professor, Dr. Elizabeth Rogers, is quoted as saying she wouldn\u2019t change her clinical practice based on the research because \u201cthe risks of poor outcome outweigh the possibility of a really good outcome for families,\u201d especially for babies born at an early gestational age.", "answer": 1}, {"article": "Bathing-suit season is here and with it, anxiety over cellulite. A new laser device that burrows under the skin is getting praise from some doctors who say it gives more dramatic and longer-lasting results than previous treatments, but others caution that more research is needed.\n\nCellulite is a dimpled, uneven appearance of skin caused by fat underneath. It affects some 85% of women and about 5% of men. Until recently, the main treatments to battle cellulite have been external treatments such as creams and radio-frequency and...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were mentioned:\nCellulaze leaves tiny scars\u2014about two millimeters long\u2014which fade with time, surgeons say. Typically, compression garments are recommended for at least two or three weeks to prevent fluid buildup. And there will be bruises, so patients typically need to wait three to six weeks before venturing out in a bathing suit, surgeons say.\nThe procedure can cause a buildup of fluid in the area that has been treated, which can last for months and needs to be drained regularly by a doctor.\nIn a written statement, Cynosure says \u201ca few\u201d patients in early trials had the buildups, called seromas, adding that they need to be drained to prevent infections and other complications. The company says it has since lowered the recommended laser dosage and it isn\u2019t aware of any seromas since the device hit the U.S. market.\nBut none of these harms was quantified, so the scope of the potential harm wasn\u2019t clear.\u00a0 What does it actually mean when the story uses vague terms such as \u201ctypically\u201d\u2026\u201dcan cause\u201d\u2026\u201da few patients\u201d ?", "answer": 0}, {"article": "A drug called tissue plasminogen activator (tPA) dissolves clots and restores blood flow.\nThose parts of the brain soon start to die.\nIn fact, one in three people who suffer a mild stroke are disabled three months later, Khatri says.\nFeb. 10, 2011 (Los Angeles) -- Giving clot-busting drugs to people with mild strokes could prevent more than 2,000 of them from becoming disabled each year, researchers say.\nIt's been assumed that people with mild strokes \"generally [do] well and the risk of tPA treatment, which includes a slight but significant risk of life-threatening bleeding in the brain, would not be worth the benefit,\" she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not good enough.\u00a0 The story only says the drug isn\u2019t without risks, chiefly brain bleeding.\u00a0 How often does this occur?\u00a0 This is a big issue. If even one of the 4 people whose records show they got tPA in this analysis had problems after hospital discharge, that could throw any potential benefit out the window.", "answer": 0}, {"article": "Older adults with mild cognitive impairment have less severe memory loss than those with Alzheimer's but often go on to develop the disease.\nThe team cautioned that while eating baked and broiled fish appears to exert some cognitive benefit, other lifestyle and socioeconomic factors may play a role.\nTo assess the impact of fish on cognitive health, the authors focused on 260 mentally healthy elderly individuals drawn from the Cardiovascular Health Study, sponsored by the U.S. National Heart, Lung, and Blood Institute.\nBut fish and chips lovers, take note: No cranial benefit was evident with respect to consumption of fried fish.\nThey also completed the U.S. National Cancer Institute Food Frequency Questionnaire.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not as good as the competing WebMD story, which stated:\n\u201cThe Environmental Protection Agency recommends that pregnant women, nursing mothers, and children avoid eating shark, swordfish, king mackerel, or tilefish and limiting albacore tuna to 6 ounces per week because of concern about levels of mercury in these fish.\u201d\n ", "answer": 0}, {"article": "63 senior respondents of a mean age of 80 were studied during 3 consecutive weeks.\nIn conclusion, melatonin can be of great value for aged people suffering from hypertension as an adjuvant substance complementing basic medication as it is able to stabilize circadian BP, heart rate profiles and their phase relationships.\nIncreased blood pressure and reduced robustness of circadian rhythms are frequently reported in elderly subjects.\nNone of these effects was found in 34 placebo treated seniors, thus ruling out the possibility that rhythms could be improved just because of regular schedule and presence of medical personal who took measurements.\nMelatonin ws effective in synchronizing disrupted circadian rhythms of BP, heart rate and body temperature, making these circadian rhythms smoother and less irregular.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is clearly a downside to any supplement use, particularly in older people who may already be on multiple interacting medications.\nAlthough melatonin is probably safe for many adults, according to the University of Maryland Medical Center, a physician should be consulted before taking melatonin if you\u2019re already taking medications for high blood pressure, antidepressants and blood thinners, among others.\nA Web MD article states that melatonin can worsen symptoms in those suffering from bleeding disorders, diabetes, and seizures, and, perversely, may increase blood pressure levels in individuals taking medication to control those levels. Given the availability of melatonin supplements, ignoring the downsides for individuals with these common health problems is significant.", "answer": 0}, {"article": "The answer?\nThere are no laboratory tests to diagnose migraines, depression, bipolar disorder and many other ailments of the brain.\nAlthough the technique's potential to identify brain disorders and diseases was noted years ago, fcMRI-based diagnostic tests have yet to make their way into doctors' offices.\nIt's exciting to think that these individual differences may be related to personality, cognitive ability, or psychiatric or neurological disease.\nThe consistency of the fcMRI scans makes them a promising diagnostic tool.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention is made of discomforts or potential dangers associated with MRIs.", "answer": 0}, {"article": "Most people turning to surgery for weight loss are probably concerned with how many pounds they can expect to shed.\nThe cost of the surgery was about $30,000, which exceeds the savings observed directly.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nAlso, at two years after surgery, data were available for less than half the patients.\nWhile mortality in the hospital was 0.3 percent, some 21 percent of patients had to be admitted to the hospital again for one reason or another within a year of their operations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThe story does report that some patients died and 21 percent had to be readmitted to a hospital within a year after surgery.\u00a0 Since the story was about the study, we\u2019ll give it a satisfactory score for reporting the harms reported in the study.\u00a0 But such stories could (and we wish would) always include even a line about other side effects and complications of stomach-reduction surgery, which include nutritional deficiencies, gallstones, stomach ulcers, hernias, food intolerance, kidney stones, low blood sugar, blood clots, leaks in stomach staples, pneumonia, dumping syndrome (nausea, vomiting, diarrhea, dizziness and sweating caused by food moving too quickly through the small intestine) and other problems.\n", "answer": 1}, {"article": "However, \"I don't want women who chose mastectomy to think they did the wrong thing,\" Hwang said.\nThe study was observational, Hwang stressed.\nThe others died of other causes.\nThe study is scientifically sound in many ways, Kruper said.\nAges ranged from 39 to 80.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of possible harms from either treatment. \u00a0In particular, there was no mention of the possible long-term dangers of radiation.", "answer": 0}, {"article": "\"However, there are gaps in knowledge about what is the best way to alleviate pain during vaccination.\"\nFor babies under age 1 year, lidocaine cream, combined with a small amount of sugar given by mouth and infant soothing, can help relieve pain from routine vaccinations, according to a study in CMAJ (Canadian Medical Association Journal).\n\"The effects of consistent pain management on the development of preprocedural anxiety (fear), hypersensitivity to pain and compliance with future vaccination warrant future investigation,\" they recommend.\n\"We found that, when used consistently during vaccine injections in the first year of life, only liposomal lidocaine combined with parental video instruction and orally administered sucrose showed a benefit on acute pain when compared with placebo, video alone, and video and sucrose together,\" wrote the authors.\nThe study was conducted by researchers at SickKids, the University of Toronto, York University and several Toronto-based pediatricians.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms weren\u2019t addressed at all. While lidocaine is most often used to numb sunburn, bug bites, and other skin pain, the Mayo Clinic\u00a0describes it as a last resort for relieving topical pain in kids under the age of 3. Lidocaine can be toxic when ingested by children when used for oral pain relief during teething. The FDA has tracked some cases of seizures and even death linked to use of the drug.", "answer": 0}, {"article": "Miner continued.\nAlthough the fight against cancer often appears to be an overwhelmingly intransigent problem, significant progress is being made regarding the development of additional tools for cancer detection, such as the ONCOblot Test.\nSerum samples that were collected from asbestos-exposed individuals prior to the development of mesothelioma as part of a cancer surveillance program were tested for ENOX2 protein presence to determine how long in advance of clinical symptoms that the mesothelioma-specific ENOX2 protein transcript variants could be detected.\nDallas, Texas -February 4, 2016 - MorNuCo Laboratories of West Lafayette, Indiana, and their ONCOblot\u00ae Test recently completed a retrospective clinical trial focusing on the early detection of malignant mesothelioma, with the exciting results that the ONCOblot\u00ae test detected a molecular marker that is indicative of the presence of mesothelioma, 4-10 years in advance of clinical symptoms appearing.\nIn this study, the serum presence of a mesothelioma-specific form of the ENOX2 protein (a recently identified marker of malignancy) was found within the serum of asbestos-exposed individuals an average of 6.2 years in advance of clinical symptoms by using the ONCOblot tissue of origin cancer detection test.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the ONCOblot test itself involves just drawing a blood sample, the results of the test could produce life-threatening harms if it overdiagnoses people. In other words, a person told they have tested positive for these biomarkers for mesothelioma might start treatment too early or unnecessarily. Mesothelioma treatment is notably damaging. Let\u2019s put the study into perspective: there were a total of 32 people enrolled (17 with known malignant mesothelioma and 15 without). Hardly a large enough sample size on which to make the claims made. Although as we noted previously, early detection does offer a small survival advantage, it comes at a cost. The American Cancer Society notes that chemotherapy for mesothelioma can cause hair loss, mouth sores, loss of appetite, nausea and vomiting, diarrhea, increased risk of infections, easier bruising or bleeding, fatigue and long-lasting nerve damage. Radiation treatment also can cause many of the same problems, as well as lung damage. Combining radiation and chemotherapy often makes side effects worse.\nIt won\u2019t be known whether starting treatment earlier offers any benefits to people at risk for mesothelioma, but it is certain that treating more people earlier would cause more treatment-related harm.", "answer": 0}, {"article": "But by then, more than two-thirds of the young people in both groups had dropped out, making it difficult to interpret differences between them.\nWeight gain is a common side effect of Zyprexa.\nIn the first year of a two-year trial, 5 of the 31 of those on medication developed full-blown psychosis, compared with 11 of 29 of those who were taking dummy pills.\nSome left the study without explaining why; others moved; and 10 of those on medication quit the study because they felt the drug was not working, could not make the appointments or did not like the side effects, among other reasons.\n\"This might discourage people, and legitimately so, from using this drug for prevention because of the weight gain, but hopefully it won't discourage study\" of other drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions primary harms of treatment as weight gain seen in this short-term trial, but there is no mention of the long term side effects or safety of Zyprexa. Diabetes and complications of the metabolic syndrome have been noted in many patients taking newer anti-psychotic medications like Zyprexa. This may be a result of the significant weight gain from the drugs. The FDA has issued an additional warning about patients developing hypoglycemia and diabetes as a result of taking Zyprexa: http://www.fda.gov/medwaTCH/SAFETY/2004/zyprexa.htm", "answer": 0}, {"article": "The iron in the blood increases infants' iron storage, and iron is essential for healthy brain development.\nBut Rabe said these infants may actually benefit most from the practice.\nRabe's editorial accompanied the study published Tuesday in the journal JAMA Pediatrics.\nThese babies often need more blood volume to help with blood pressure, breathing and circulation problems, Rabe said.\nAnother potential risk is a condition called polycythemia, a very high red blood cell count, said Dr. Scott Lorch, an associate professor of pediatrics at the University of Pennsylvania Perelman School of Medicine and director of the Center for Perinatal and Pediatric Health Disparities Research at Children's Hospital of Philadelphia.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hooray for this story including two potential harms and reporting with experts outside of the study authors. The story calls the potential for harms \u201cunclear\u201d and that is one of way of giving the reader some balance even if there isn\u2019t much information available. Both jaundice and polycythemia are listed as potential harms.", "answer": 1}, {"article": "Follow her on Twitter @drfernstrom.\nWhile the study has many limitations because it doesn\u2019t take into account genetic or lifestyle factors that are proven important in both heart disease risk and longevity, it suggests that blood cholesterol levels are only one factor.\nThe new report, which analyzed 40-year-old data from the Minnesota Coronary Experiment, found no association between lower cholesterol levels and longer life, suggesting that reducing the amount of saturated fat in the diet isn\u2019t enough to reduce risk of death from heart disease.\nIn fact, the study found that the lower the cholesterol, the greater the risk of death.\nBut that\u2019s a misleading association because a variety of illnesses can also cause drop in cholesterol, which is unrelated to diet.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The intervention in the study (eating more unsaturated fat)\u00a0is unlikely to cause adverse side effects, risks, or\u00a0complications, so we\u2019re rating this\u00a0N/A.\u00a0The story did point out the surprising association between lower cholesterol levels and increased risk of death, though that could have been\u00a0explained more clearly.", "answer": 2}, {"article": "Chronic inflammation is known to contribute to the development and progression of several diseases, including some cancers.\nHalf of the study participants were randomly selected to receive 2,000 IU of vitamin D daily for the duration of the year-long trial, and the other half received an identical-appearing placebo, or dummy vitamin.\nTo explore this question, Duggan and colleagues recruited 218 healthy, overweight older women who had lower-than-recommended levels of vitamin D (less than 32 ng/mL).\nBiomarkers of inflammation were measured at the beginning and end of the study.\n\"We were quite surprised to see that vitamin D had an effect on an inflammation biomarker only among women who lost at least 5 percent of their baseline weight,\" Duggan said.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Because some of the participants were vitamin D-deficient and the dose of vitamin D provided was modest (2000 IU/d), this was a tough call. But supplementation is often so misunderstood, overhyped and oversold that some statement cautioning readers to pay attention to the specifics of this study and not apply its recommendations to everyone seems prudent.", "answer": 0}, {"article": "Jean-Charles Sanchez says.\nIt will display the word \"positive\" or \"negative\" and send the result to the patient's or caregiver's smartphone via Bluetooth.\nYet 90% of these patients will be able to return home safely, as no trauma has been detected.\nHis team has developed a rapid diagnostic test (POCT) called TBIcheck, inspired by the principle of pregnancy testing: by placing a single drop of blood on the well of a small 5cm plastic case, the patient knows within 10 minutes whether there is a risk of mild trauma, namely whether or not his H-FABP level is higher than 2.5 nanograms per millilitre of blood.\nIn case of doubt when reading the result, a small reader, the Cube Reader, can be installed on TBIcheck.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention harms, such as missing an injury due to a false negative or having a false positive result that leads to unnecessary and potentially expensive follow-up tests and treatments.\nWith 100% sensitivity there will be no false negatives, but that is a suspect result. It\u2019s not clear what actions are (or are not taken) as a result of this test so it is hard to assess potential harms.", "answer": 0}, {"article": "(Health.com) -- People who consume lots of foods rich in vitamin B12 -- such as fish and fortified cereals -- may be at lower risk of developing Alzheimer's disease than people who take in less of the vitamin, a small study conducted in Finland suggests.\nHealth.com: 9 foods that may help save your memory\n\nOver the next seven years, 17 study participants were diagnosed with Alzheimer's disease.\nMaria Carillo, Ph.D., the senior director of medical and scientific relations at the Alzheimer's Association, a nonprofit research and advocacy group, urges caution in interpreting the new findings, especially given that so few study participants developed the disease.\nAnd he worries that the results may spur doctors to recommend B12 injections to their patients -- a preventive treatment that he says is unfounded and already overused.\n\"The role of supplementation remains unclear.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "tears.\nHe points out that in The New England Journal of Medicine study, only 8 percent of the patients in the first surgical group subsequently tore a meniscus, a fragile pillow of cartilage that can rip if a knee gives way.\nIn the current study, most of the group members who had reconstructive surgery reported that their injured knees felt healthy after two years and that they had returned to activity \u2014 not, in most cases, at the same level as before their injuries, but they were active.\nSeveral top-flight orthopedic surgeons I contacted say that they remain convinced that surgery leads to a better long-term outcome for certain patients, particularly if they want to return to pivoting sports.\nBut large-scale, randomized controlled studies, the gold standard of medical research, may be difficult to orchestrate, in part because people with shredded A.C.L.\u2019s can balk at being denied surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Several of the outcomes in this study straddle the line between benefit and harm (or lack of harm), so please see the \"Benefit\" criterion below, too.\u00a0Overall,\u00a0this story\u00a0covers the authors\u2019 key safety messages from the\u00a0published NEJM article, particularly as they refer to the rates of adverse events between the two groups. The piece says in general terms\u00a0that ACL surgery has risks like any surgery.\u00a0It would\u2019ve been better to include some more details.\u00a0A mention, if not quantification, of specific risks would\u2019ve added more balance to the discussion. The study\u00a0itself did consider surgical and anesthetic adverse events in its analysis. \nIt also could have been clearer about the uncertainty about the lack of long-term outcomes. We don\u2019t know how the two treatment groups will compare in terms of development of arthritis and future surgeries (e.g., more meniscectomies) farther out than 2 years. The challenge is that such long-term outcomes may be decades off in this young population.", "answer": 1}, {"article": "Treatment typically involves the use of inhaled steroids and bronchodilators to open airways and make breathing easier.\nOthers got a sham acupuncture treatment, in which the needles did not enter their skin.\nThe study appears online in the Archives of Internal Medicine.\nIn a new study of 68 people with COPD, some got acupuncture, along with their daily medication, for three months.\nMany people with COPD have problems getting optimal nutrition because of their condition.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Dr. Tong-Joo Gan of Duke University hints that there are few downsides to acupuncture, but the story does not specifically point out any harms or side effects from acupuncture. Probably the key point is at the very end where the acupuncturists say don\u2019t try acupuncture first.", "answer": 0}, {"article": "We aim to answer these questions with future research.\"\nUnlike conventional methods of HIV prevention, such as condoms or anti-HIV drugs, the implant takes advantage of some people's natural immunity to the virus.\nThe tool, a vaginal implant, decreases the number of cells that the HIV virus can target in a woman's genital tract.\n\"What we don't know yet is if this can be a stand-alone option for preventing HIV transmission or if it might be best used in conjunction with other prevention strategies.\nWhen the T cells stay resting and do not attempt to fight the virus they are not infected and the HIV virus is not transmitted between people.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that the news release opens with\n\u201cScientists at the University of Waterloo have developed a new tool to protect women [emphasis added] from HIV infection\u201d\nit might lead some interested women to ask about side effects.\nThe question of harms is never addressed. That\u2019s a huge oversight given that the device is implanted and there are many risks associated with such procedures: pain, bleeding, infection, the device becoming dislodged, follow-up surgeries to remove the implant.\nNo potential risks are mentioned.\nIn addition, if the device is not effective in comparison to existing preventive strategies then there\u2019s a potential harm in relying on the device and acquiring HIV.", "answer": 0}, {"article": "Vitamin D is called the \"sunshine vitamin\" because human bodies produce it when the sun's ultraviolet rays strike the skin.\nHowever, colon cancer patients shouldn't try to boost vitamin D levels beyond the normal range, one expert said.\nMONDAY, Jan. 12, 2015 (HealthDay News) -- Higher vitamin D levels in patients with advanced colon cancer appear to improve response to chemotherapy and targeted anti-cancer drugs, researchers say.\nThe report, scheduled for presentation this week at the Gastrointestinal Cancers Symposium in San Francisco, adds more weight to suspicions that vitamin D might be a valuable cancer-fighting supplement.\nBut vitamin D also influences cellular function in ways that could be beneficial in treating cancer, Ng said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes it clear that patients should not take supplements to increase vitamin levels if they are already normal, thus preventing harms from oversupplementation. However, we wish the story had specifically mentioned potential side effects of high dose vitamin D.", "answer": 1}, {"article": "She said these types of studies weren't done on Exubera.\n\"Afrezza is an ultra-rapid-acting insulin, and clinical studies have shown us that it has the potential to change diabetes therapy, because in the body, Afrezza looks like the insulin that's normally in a person's body,\" said Andrea Leone-Bay, vice president of pharmaceutical development for MannKind Corp., manufacturer of Afreeza.\nThe new drug, Afrezza, which is awaiting approval from the U.S. Food and Drug Administration, works faster, keeps blood sugar levels at a closer to normal level and has less risk of causing low blood sugar levels (hypoglycemia) than currently available injectable insulins, researchers say.\nTUESDAY, March 23, 2010 (HealthDay News) -- A new form of inhaled insulin appears to help people with diabetes who must use insulin, with fewer potential risks than an earlier form of inhaled insulin that is no longer on the market.\nFrom the beginning, concerns surfaced about the effects the drug might have on the lungs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "All the claims are qualitative. That alone would earn an unsatisfactory rating, but the article goes further. Harms are not only presented without quantities, they are described in a vague, unclear, and overly optimistic way. We\u2019re told, in general, that the safety studies \"came out clean.\" That\u2019s overly simplistic without any further detail; even placebos are associated with harms in studies. Then there are the specific issues.\n First, consider the potential cancer risks. The only data described are, it seems, from short-term animal studies. The cancer risks that hung over Exubera were not revealed until after it was yanked from the market, and ultimately the association to Exubera wasn\u2019t definitive. To say that Afrezza holds an advantage over Exubera for these reasons based on short-term animal data is unsubstantiated.\n\nSecond, pulmonary function. The pulmonary function problems for Exubera are detailed as one of its major flaws, with the implication that they contributed to its ultimate failure. In the second-to-last paragraph, the VP acknowledges that Afrezza \"may have\" pulmonary harms; however, \"once people stopped taking Afrezza, this effect went away.\" In several\u00a0studies\u00a0of Exubera, lung function declines were also reversible after people stopped taking it. Without providing any evidence, the article\u2019s general coloring of Afrezza safety being superior to that of Exubera is speculative and wholly inappropriate.", "answer": 0}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nMM36 was also associated with improvement in patient-reported outcomes, most notably rapid and sustained itch relief, with Visual Analog Scale scores showing improvement from moderate to mild within the first week (36.4% mean change; p=.0011).\nThese effects were sustained through week 8 of the study.\nThe randomized, double-blind, vehicle-controlled study in 121 patients showed that MM36 demonstrates a statistically significant effect on the primary endpoints versus vehicle as measured by improvement in IGA score (Investigators Global Assessment) and percentage change in EASI score (Eczema Area and Severity Index).\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The published research report clearly reports that some subjects experienced a worsening of symptoms, or no real change, but the release fails to mention any data on side effects. According to the study, the harms were about the same in the high dose group and the placebo, but were greater in the low dose group (and that difference was statistically significant).", "answer": 0}, {"article": "Lung cancer is the most common cause of cancer death in the U.S. for men and women.\nThe new compound seems promising in mouse models, the researchers say, adding they hope it proves effective in clinical trials and is better tolerated than drugs now used.\nMuch work lies ahead in determining whether the compound and related ones will prove to be effective therapies, but the researchers say their discovery demonstrates the power of screening specially designed compounds against cancers \"with certain genetic quirks.\"\nThe researchers say their new compound shows how fast lung cancer research and development are moving forward.\nThe researchers say the framework of the new compound is different from that of other cancer drugs and acts against a protein that carries a structural defect, according to a news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No potential harms are discussed, nor is it mentioned that the safety profile in humans has yet to be established. The article would have done well to continue the Dr. Eck quote from the\u00a0press release\u00a0to include his acknowledgment that \"we still have much to learn about their potential liabilities,\" referring to this new class of compounds.\nThe \"hope\" that the compound will have fewer harms than currently available drugs appears to be based largely on in vitro\u00a0data.", "answer": 0}, {"article": "The other three people served as the control group.\nStopping that autoimmune attack appears to be crucial to any treatment that hopes to cure or reverse type 1 diabetes.\nThe researchers have dubbed this \"Stem Cell Educator Therapy,\" because while exposed to the stem cells, the lymphocytes seem to relearn how they should behave.\nIf we can control the autoimmunity, we may reverse the diabetes.\nAlthough the treatment didn't wean anyone off insulin completely, average blood sugar levels dropped significantly, which would reduce the risk of long-term complications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "To claim a treatment is safe after testing it in only a dozen patients at a single hospital in China is to ignore the long history of treatments that appeared to be beneficial after initial tests, then later revealed serious, even lethal, harms. Even though the researchers declare the treatment to be safe in their journal article, journalists should be skeptical of such broad claims that are based on such slim evidence. There is a vast gulf between stating that 12 individuals did not appear to be harmed during a 40-week trial and proclaiming that a treatment would be safe for millions of patients over the course of decades.", "answer": 0}, {"article": "\u201cHe wanted to be at home with his dog.\nSo after considerable discussion, Mr. Hladik decided to skip the three weekly trips to a renal center, along with the resulting fatigue and dietary and travel restrictions.\nHis doctors managed his heart disease and hypertension with drugs.\nHe wanted to be able to go to the beach.\u201d\n\nA nephrologist at the University of North Carolina School of Medicine, Dr. Hladik understood better than most how kidney dialysis could consume a patient\u2019s days.\nHe died at home in November, a year and a half after saying no to dialysis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are explained in terms of the side effects of the dialysis, the pain, nausea and feeling \u201cdizzy, washed out.\u201d \u00a0It was good that the article explained that the harms of dialysis are also measured in other ways: the disruption to a person\u2019s life, the need to travel and go in and out of facilities, and the effects on their independence, which can be debilitating for older people.", "answer": 1}, {"article": "Espey agreed.\nWEDNESDAY, Jan. 9, 2013 (HealthDay News) -- Women with heavy menstrual bleeding may find some relief using an intrauterine device, or IUD, containing the hormone levonorgestrel, according to new research.\n\"If women suffer with heavy periods and do not want to get pregnant -- as the levonorgestrel intrauterine system is a contraceptive -- then having the levonorgestrel intrauterine system is a very good first-line treatment option that does not require taking regular, daily oral medications,\" said the study's lead author, Dr. Janesh Gupta, professor of obstetrics and gynecology at the University of Birmingham and Birmingham Women's Hospital in England.\nResults of the study, which was funded by the United Kingdom's National Institute of Health Research, appear in the Jan. 10 issue of the New England Journal of Medicine.\n\"This study really adds to the evidence that shows how useful this intrauterine system is for heavy menstrual bleeding,\" said Dr. Eve Espey, professor of obstetrics and gynecology at the University of New Mexico School of Medicine in Albuquerque.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The explanation of side effects was not satisfactory. \u00a0There are a list of side effects on the manufacturer\u2019s website that were not mentioned in the story.\nAs correctly stated in the story, the most common side effect of Mirena is irregular bleeding. Since the purpose of the study was to compare overall effectiveness and side effects of Mirena vs. other medical therapies, it was adequate to the study\u2019s purpose to simply state that serious adverse effects were no different between the groups. But the story provides little detail provided about adverse effects of the other therapies, as well as Mirena. It would be useful to the reader to have a better sense of the kinds of side effects associated with both types of treatment.\n\u00a0", "answer": 0}, {"article": "\"In most cases, a recall doesn't mean you have cancer,\" says Hubbard, a biostatistician at the Group Health Research Institute in Seattle.\nThose false-positives may cause inconvenience and anxiety, and biopsies can cause pain and scarring, the researchers note.\nThe task force says the decision to start regular, biennial mammograms before age 50 should be an individual choice based on each patient's situation.\nThe study wasn't really designed to answer the question of which screening regimen is best, study researcher Rebecca Hubbard, PhD, says.\nInformation about the women and their mammograms came from the Breast Cancer Surveillance Consortium, funded by the National Cancer Institute.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The piece states that the researchers noted that \u201c\u2026false positive recalls may cause inconvenience & anxiety and biopsies can cause pain and scarring.\u201d", "answer": 1}, {"article": "Cannabidiol, or CBD, is a compound in the cannabis plant that does not contain psychoactive properties that induce a high.\nSide effects \u2013 experienced by 93.4 percent of patients in the CBD group and 74.6 percent of those treated with placebo \u2013 were generally reported as mild or moderate in severity.\nEight participants from the CBD group withdrew from the trial due to side effects compared to one participant in the placebo group.\nFor the study, 120 children and adolescents with Dravet Syndrome between the ages of 2 and 18 years were randomized across 23 sites in the United States and Europe to receive either CBD 20 mg/kg or placebo added to their existing treatment over a 14-week period.\nThe study included a liquid pharmaceutical formulation of CBD, called Epidiolex, which is manufactured by GW Pharmaceuticals and has not been approved by the U.S. Food and Drug Administration.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release is clear in mentioning the side effects of the use of this drug in the study: \u201cSide effects \u2013 experienced by 93.4 percent of patients in the CBD group and 74.6 percent of those treated with placebo \u2013 were generally reported as mild or moderate in severity. The most common side effects in the CBD group were vomiting, fatigue and fever. Eight participants from the CBD group withdrew from the trial due to side effects compared to one participant in the placebo group.\u201d", "answer": 1}, {"article": "\"I say, 'Go for it!'\nTo avoid poking through to the brain or into the orbit of an eye, there's a device around the patient's head with a guidance system that tells Metson, in three dimensions, exactly where his sharp instruments are on a CT scan of Butler's head.\nShe'd consider a second operation, but Metson says usually that's advised only for patients with nasal polyps that regrow -- not a problem she has.\nThat's because surgery doesn't touch the root cause of chronic sinusitis.\nJudy Foreman, another of Metson's patients, offers an example of both how surgery can help -- and why patients' expectations shouldn't be too high.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story refers off-handedly to the possibility of\u00a0\"poking through to the brain or into the orbit of an eye,\" but it fails to explain that these events are very rare but real risks of the surgery. While extremely unlikely, it\u2019s possible for surgeons to accidentally\u00a0damage\u00a0the optic nerve, resulting in blindness, or to puncture the base of the skull, resulting in cerebrospinal fluid leakage. Other less serious,\u00a0but more common complications are also possible. The story didn\u2019t mention\u00a0any of them.", "answer": 0}, {"article": "\u201cI was cute as button \u2014 and there was my double chin,\u201d she said.\nBy middle age, Ms. Gallagher, 51, the owner of a pet-sitting business in Torrance, Calif., was avoiding mirrors and considering liposuction, but she worried about the effects of anesthesia and the recovery time.\nThen she discovered another option: a series of fat-reducing injections intended to slim down a double chin.\nEven as a pigtailed child, Ashley Gallagher was self-conscious about a certain fullness in her face.\nAs an adult, she faithfully performed facial exercises purported to tighten the area under the chin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a great job in not only providing a listing of potential harms, it also provides information on their frequency and impact on the subjects in the clinical trials.", "answer": 1}, {"article": "HER2+ breast cancer is more likely to affect younger women and also more likely than other breast cancers to metastasize specifically to the brain.\nThe 50 women treated had progressed despite a median 5 previous treatment regimens.\nTwenty-seven percent of these heavily pretreated patients saw clinical benefit from the drug, with at least \"stable disease\" at 24 or more weeks after the start of treatment.\nBecause the drug is taken in pill form and has a very favorable side effect profile, Borges points out that it is relatively patient-friendly, allowing women to avoid treatments in infusion centers and also many of the side-effects associated with chemotherapies.\nBorges has been a major driver of the drug's development from its invention at Array Biopharm in Boulder, CO and now through clinical trials of the drug, which is licensed to Cascadian Therapeutics of Seattle, WA.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "According to the original study, 30% of the patients had to have their treatments \u201cinterrupted,\u201d usually due to effects on liver function, although the study says the drug treatment was \u201calmost always\u201d re-initiated, and no one had to be removed from the drug entirely. None of these problems was mentioned in the news release, which also offers no specific information about the frequency or severity of side effects.", "answer": 0}, {"article": "\u201cThe findings were exciting,\u201d she said.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nIn coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\nAfter 12 weeks of daily yoga and coherent breathing, the subjects\u2019 depressive symptoms significantly decreased and their levels of gamma-aminobutyric acid, a brain chemical that has calming and anti-anxiety effects, had increased.\nIf you have never practiced breathing exercises before, you may have to work up to this practice slowly, starting with inhaling and exhaling to the count of three and working your way up to six.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. The National Center for Complementary and Integrative Health says relaxation techniques such as deep breathing exercises \u201care generally considered safe for healthy people, although there have been a few reports of\u00a0negative experiences such as increased anxiety. People with serious physical or mental health problems should discuss relaxation techniques with their health care\u00a0providers.\u201d\nIt\u2019s also possible that some people with serious disorders may not seek other proven treatments in the belief that deep breathing will help them.", "answer": 0}, {"article": "JACC is ranked No.\n\"Our findings highlight the link between worsening depression and cardiovascular risk and support routinely assessing depression in patients to determine heart disease risk.\nThis research also demonstrates the positive effects of exercise for all patients, including those with depressive symptoms,\" said study author Arshed A. Quyyumi, M.D., co-director of the Emory Clinical Cardiovascular Research Institute in Atlanta.\nThey also looked a several early indicators of heart disease.\n\"There are many patients with heart disease who also experience depression - we need to study whether encouraging them to exercise will reduce their risk of adverse outcomes.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t delve into harms but we\u2019ll rate this Not Applicable since the release doesn\u2019t give us any specifics on the types of exercise the study volunteers took up. Some exercises are riskier than others.", "answer": 2}, {"article": "Chan\u2019s project aims to find out who will.\nSome will have a gene that puts them at risk of the condition or will come from a family with a history of Alzheimer\u2019s.\nBy identifying potential patients far earlier than is possible at present, researchers hope it should then become easier in the long term to develop treatments aimed at halting or slowing their condition.\n\u201cIf we can develop drugs and administer them earlier, for instance before the disease has spread beyond the entorhinal cortex, then this would have the potential to prevent the onset of dementia.\u201d\n\u201cThe aim of the study is very simple: can we detect changes in brain function before people are aware that they have them?\u201d\n\nResearchers recently pinpointed the significance of a tiny area of the brain known as the entorhinal cortex, which acts as a hub in a widespread brain network that controls navigation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The big risk here, as with any screening test, is incorrect results. Even if the study hasn\u2019t happened yet, and important data sets like sensitivity and specificity can\u2019t yet be quantified, they should be addressed in the story. What are sensitivity and specificity? Sensitivity measures how often a test correctly generates a positive result for people who have the condition that\u2019s being tested for. Specificity measures a test\u2019s ability to correctly generate a negative result for people who don\u2019t have the condition that\u2019s being tested for. In other words, there are two possible harms inherent in diagnostic and risk assessment tools: the failure to identify someone who has Alzheimer\u2019s; and the \u201cfalse positive\u201d misdiagnosis of people who do not have Alzheimer\u2019s. Either mistake can have significant costs \u2014 financial and personal \u2014 for patients.", "answer": 0}, {"article": "The quality of what you get can differ from one practitioner to another,\" said Manber.\nMONDAY, Feb. 22, 2010 (HealthDay News) -- Women who experience depression during pregnancy may have another treatment option, new research suggests.\nAnd, she cautioned, suicidal thoughts are never normal and are a sign that you should seek help.\nBut, she cautioned that \"acupuncture is not a substitute for the appropriate use of antidepressant therapy especially in women with a prior history of response to antidepressants.\"\nDr. Shari Lusskin, director of reproductive psychiatry at the New York University Langone Medical Center, echoed that sentiment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study reported some cases of pain at needle insertion sites and bleeding, but the story didn\u2019t mention this.\u00a0 Even with a treatment that is generally very safe, women should be aware of any risks.", "answer": 0}, {"article": "One study suggests that the new guidelines are better at identifying who is truly at risk of a heart attack and should be given statins than the older guidelines are.\n\u201cThere is no longer any question as to whether to offer treatment with statins for patients for primary prevention, and there should now be fewer questions about how to treat and in whom,\u201d said an editorial that accompanied the publication of the studies in JAMA, a journal of the American Medical Association.\nThe other suggests that treating people based on the new guidelines would be cost-effective, even with the tremendously increased use of statins.\nBut they could help dispel some of the criticism of the new guidelines and strengthen the position of those who contend treatment should be extended to more people.\nThe new studies are not large clinical trials that will definitively settle the matter of whether to expand drug treatment to millions more people in hopes of preventing cardiovascular disease, the leading killer of Americans.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We thought that NBC did a better job detailing some of the potential harms from statin use, but we give the Times credit here for framing the story as a discussion of risks vs. benefits and making it clear that experts critical of the new guidelines believe that they \u201cwould lead millions of additional people to take statins, exposing them to potential side effects such as\u00a0muscle pain\u00a0or damage with little to gain.\u201d", "answer": 1}, {"article": "OraVerse is a formulation of a decades-old drug, phentolamine mesylate, which is used to treat severe episodes of hypertension.\nDr. Papas, an adviser to Novalar and an investigator in its clinical trials, said she thought the drug would appeal especially to those receiving cosmetic dentistry \u201cwho like to look good when they leave the dentist\u2019s office.\u201d\n\nNovalar said its surveys showed great interest in the product among consumers and among dentists, some of whom said they would mark up the price of the drug as a source of profit.\nIn the clinical trials there were no serious side effects, Novalar said.\nThose patients would be expected to have lingering pain, and should not get Oraverse, Dr. Moore said.\nNovalar said the label of OraVerse would also contain the warnings, but note that OraVerse is given in a different manner.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article says that when used for high blood pressure the drug can cause heart attacks and occlusion of blood vessels in the brain. \nBut the report does not challenge the drugmaker\u2019s claim that those side effects would not apply for this use of th drug. And again, since the data is unpublished it is a leap of faith to accept this conclusion. ", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nAs this study was conducted on animals, results cannot yet be implied for humans.\nThis is the first study that evaluates whether walnut consumption can cause changes to micro-ribonucleic acids (miRNA), the nucleotides that are involved in altering gene expression.\nTumor growth rate was also significantly slower in the walnut group compared to the control group.\nThe CWC is mainly involved in health research and export market development activities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The limited study did not appear to investigate potential harms, and the release didn\u2019t comment on them. For humans, consumption of too many calorie-dense walnuts could precipitate weight gain. But the equivalent of two ounces a day doesn\u2019t sound like it could be very harmful. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "The new research provides more evidence of the need for new regional centers of care, in order to minimize the time it takes to transport a patient to hospital capable of providing stent therapy, according to Dr. William J.\n\u201cThey are destined to be in a nursing home or to be dead and when we re-establish blood flow \u2014 often times right there on the table \u2014 they get better.\u201d\n\nStent retriever therapy is a new procedure experts call the most major advance in stroke treatment in two decades.\nI felt like I was in a dream state until I finally ran off the road.\u201d\n\n911 calls to police that morning reported a drunk driver on the road and when Reisch crashed, the paramedics were quickly on the scene.\nFirst responders asked Reisch to smile and immediately recognized his drooping mouth as a sign of a stroke.\nAt the hospital, the first-line therapy, a powerful blood-thinning medication called tissue plasminogen activator or tPA could not dissolve the blood clots in Reisch\u2019s brain.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of potential harms from any aspect of the treatment studied. This is a major oversight in any story, but especially one dealing with a surgical procedure.", "answer": 0}, {"article": "Among parents of children with autism, Mr. Frank said, \"some will say, 'Come on, who are you kidding?'\nNo cause for autism has been found, and debates rage as to whether the brain development disorder is purely genetic or caused in part by environmental factors, including air and food-borne chemicals.\nDr. Faber noted that Ms. Slimak's clean room work -- like much of the research on toxicity in autism -- \"hasn't been written for the main [scientific] literature\" but instead has been written mostly for the Internet.\nBut by exposing children to a clean atmosphere and toxic-free diet, doctors will also try to slowly release chemicals from the children's bodies, through their skin, urine and stool.\nMany people with these disorders also have unusual ways of learning, paying attention and reacting to sensation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article doesn\u2019t discuss the very real risks of the proposed experiment and does not seek out any disinterested expert resource.\u00a0 A hallmark of autism spectrum disorders is problematic social interaction.\u00a0 One can speculate that transfer of affected children out of the home and into a hospital \"clean-room\" runs counter to the effort to improve socialization that is a current, mainstream treatment for the disorders.", "answer": 0}, {"article": "\"When a body gets used to having a chronic headache suppressor, the patient can experience a rebound in the absence of that suppressor.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\nDr. Richard Lipton, director of the Montefiore Headache Center in New York City, described the findings as \"very dramatic.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of any harms in the story.\u00a0Lead author Dr. Kenneth Mandato commented on the nasal spray as being \u201csafe, convenient and innovative.\u201d Such statements without any mention of the drug\u2019s potential harms gave the story an overly positive spin. Side effects of lidocaine include flushing or redness of the skin and bleeding at the application site. And while the procedure may be \u201d simple\u201d and \u201cminimally invasive\u201d to an interventional radiologist, anyone who\u2019s had these catheters wending into their sinus cavities may not agree.", "answer": 0}, {"article": "Feb. 3, 2011 -- Children with attention deficit hyperactivity disorder (ADHD) should be offered a special ADHD diet to see if eliminating certain foods might reduce their symptoms, Dutch researchers say.\nU.S. experts had some caveats, saying that the results of the study, which included 100 children, should be repeated in other populations to see if the findings hold up.\n''I am of the opinion that every child deserves this diagnostic intervention,\" researcher Lidy Pelsser, PhD, of the ADHD Research Centre in Eindhoven, the Netherlands, tells WebMD.\nThe diet studied, known as the restricted elimination diet (RED), can work, the researchers say, because they believe ADHD symptoms in some children might be affected by eating specific foods.\nIn five weeks of trying the diet, Pelsser says, parents will know if their child is responding or not; if not, they can move on to other treatments.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t mention that there were no adverse effects found from the study. We think that was worth mentioning given some of the understandable concerns raised by putting young children on any sort of restrictive diet. We do appreciate, too, that this story at least mentioned in passing concerns about malnutrition.", "answer": 0}, {"article": "\u2022 Retrograde menstrual flow: During a period, when a woman is shedding her uterine lining, some of that tissue can flow through her fallopian tubes and into her pelvis, which researchers think may cause endometriosis.\nThat\u2019s not to mention cost: The drug\u2019s price is listed at $850 per month.\nThe drug\u2019s side effects also concerned her, as did the lack of knowledge about its long-term impact.\nIt\u2019s sometimes mistaken or dismissed for regular period pain.\nSoon, it seems, women like Dunham with endometriosis pain will have a new option for relief.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The text does an impressive job of sharing information about the debits of the drug, including bone loss and symptoms of menopause.", "answer": 1}, {"article": "Current methods for determining if a prostate has become cancerous include a physical examination of the prostate (known as a digital rectal examination or DRE), MRI scans, a biopsy or tests to determine levels of the chemical prostate-specific antigen (PSA) in the blood.\n\u201cIt is therefore doubly exciting to hear of the new techniques in diagnostic imaging.\nWe can now see with much greater accuracy what tissue is cancerous, where it is and what level of treatment it needs.\nHowever, to make it applicable to prostate cancer a special probe had to be developed by the team.\n\u201cThe technique has picked up cancers which MRI did not reveal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of any harms that might come from use of this new approach.\u00a0 And while the story claims that the new technique \u2014 shear wave elastography (SWE)\u00a0\u2014 is non-invasive, there are clear harms that can come from false negatives or false positives with any screening technique.", "answer": 0}, {"article": "Plaque psoriasis is an autoimmune condition that causes cells to build up on the surface of the skin, forming thick red patches and flaky silver-white scales.\nBecause of these events, the labeling for Siliq will include a Boxed Warning, and the drug will only be available through a restricted REMS (Risk Evaluation and Mitigation Strategy) program.\nThe drug also comes with a more serious warning, as well.\nHe adds that the data on Siliq suggests that it is not only effective in treating psoriasis, but that many patients experience improvement in anxiety and depression, as well.\nIn the three clinical trials considered for drug approval, more than 50% of patients who used Siliq achieved total skin clearance\u2014the ultimate goal of psoriasis treatments\u2014within a year.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a strong point for the story. In the\u00a0second paragraph, it states that the drug will be sold with a \u201cblack box warning\u201d because of \u201can association with suicidal thoughts and behaviors\u201d among those who took it. It goes further, later on, by saying, \u201cThe most common side effects of the drug were joint and muscle pain, headache, fatigue, diarrhea, throat pain, nausea, flu, low white blood cell count, fungal infections and reactions at the injection site.\u201d\nAs well, the story spends at least two additional paragraphs discussing the link between use of the drug and suicide, and finally, it cites its effect on the immune system and how it should not be taken by people with some chronic conditions, such as Crohn\u2019s disease.\n(For more on the checkered history of this drug\u2019s side effects as noted in\u00a0clinical trials, see this same criterion in our news release review for the FDA approval of Siliq.)", "answer": 1}, {"article": "\"The results can now be immediately put to clinical use to the considerable benefit of the patients.\"\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer,\" says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery.\nThe results of the study show that patients with delayed surgery develop fewer complications with equally good oncological outcomes.\nThese hypotheses have now been tested in a study in which rectal cancer patients were randomly assigned to three different treatment arms:\n\u2022 Delayed surgery with short-course (5x5 Gy) radiotherapy followed by surgery after 4-8 weeks.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a close call. The news release refers to harms/adverse effects from radiotherapy at least four times but does not name even one potential harm, so we\u2019re rating it unsatisfactory for the omission. \nAccording to the study, the most common postoperative complication was infection, which occurred in 18 percent of patients. The study also mentions bowel obstruction and pelvic abscesses. About 7 percent of patients whose surgery was delayed were hospitalized for radiation toxicity.\nThe news release (and the abstract of the journal article) avoid a thornier question. Could delaying surgery after radiation treatment of rectal cancer increase the chance that rectal cancer will come back? The study found rectal cancer recurred in 2.8% of patients an average of 19 months after delayed surgery and in 2.2% of patients an average 33 months after\u00a0surgery at the usual time. The small\u00a0difference seems to\u00a0favor the usual\u00a0timing of surgery. The authors take a scientifically valid\u00a0position that if the difference in rate between options could have happened up to 5 percent of the time by random chance, then the new\u00a0option is \u201cnoninferior\u201d to the standard treatment, as is the case here.\u00a0It is quite possible that cancer outcomes are slightly worse for the new timing of treatments, but justified by a much bigger improvement in complication rate. The absolute difference in local cancer recurrence is only 0.6% (with a large margin of possible error) whereas surgical complications were reduced by an absolute 12% (41 vs. 53%).\nThe study notes that one potential drawback of delaying surgery is that it delays the start of chemotherapy in\u00a0 regimens that include chemotherapy after a tumor has been removed. But it says chemotherapy could be more effective if administered before surgery, so a delay would present an opportunity to administer chemo. Whether that would help patients would need to be determined by another research study.", "answer": 0}, {"article": "Lucinda Bateman is a doctor at the Fatigue Consultation Clinic in Salt Lake City who specializes in chronic fatigue syndrome.\nShe's skeptical about the Lancet study, pointing out that patients improved only moderately, and not much more than those who were counseled about pacing themselves.\nShe says some patients get caught in a \"push and crash\" cycle.\nBateman takes also issue with CBT's implication that chronic fatigue syndrome is psychosomatic.\nIts cause is still unknown, but over the years, researchers have identified various brain, immune system and energy metabolism irregularities involved.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no attempt to quantify harms, even though harm rates were mentioned in the study. It does talk about the potential harms, though, in quoting a physician who treats chronic fatigue patients in Salt Lake City.", "answer": 0}, {"article": "About half were given the probiotic product twice daily for three weeks; children in the comparison group were given a dairy product without the probiotic.\nIt seemed logical that probiotics, live microorganisms that are often called \u201cfriendly\u201d or \u201cgood\u201d bacteria, might work for children.\nBut in a new study the kids who consumed the fermented dairy product did no better, based on number of stools produced, than youngsters in a comparison group.\nThe finding is significant, the researchers say, because probiotics have helped some adults with constipation.\nThe study examined 159 children with constipation for at least two months with a defecation rate of less than three times per week.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story didn\u2019t discuss any harms that might occur from the use of probiotics. \u00a0Are there specific groups for which these products could be dangerous? \u00a0And if constipation is as serious as the story suggested, is there harm in first attempting self management with ineffectual products?", "answer": 0}, {"article": "\u201cIt\u2019s like you\u2019re possessed,\u201d said Lorie Novak, who has suffered from chronic migraines since childhood.\nBut the companies\u2019 fortunes are intertwined, he said, and \u201cthe class only wins if headache care in America improves.\u201d\n\nAiming to prevent migraines before they start\n\nThere\u2019s plenty of room for improvement.\nA genetic test would be \u201cthe Holy Grail of personalized medicine,\u201d said Rob Lenz, Amgen\u2019s global development lead for neuroscience, but no one has made one yet.\nAnd long-term safety remains a major question mark.\nThat medication, Topamax, has been dubbed dubbed \u201cSleepomax\u201d by doctors and patients because it\u2019s also a heavy sedative.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "None of the companies has reported \u201cserious side effects,\u201d according to the story, which does go on to note that the studies so far have been short-term, 12-week trials and that an understanding of the impact of the drugs \u201cwill take years.\u201d\nHowever, we find this lacking. Even if there weren\u2019t \u201cserious\u201d side effects, readers still want to know what the potential downsides are, and surely there were noted side effects that would have to be weighed against the benefits.", "answer": 0}, {"article": "So, for example, a person who is actively using opioids and can't manage the withdrawals may be better suited for buprenorphine, while someone coming from a facility where he or she has detoxed and who doesn't want to use opioids may be better suited for naltrexone.\nOnce on either of the medications, people fared equally well.\nWhat was important, Lee said, was for opioid addicts as well as treatment providers to understand that addiction isn't one-size-fits-all.\nWithout the opioids, people can go into withdrawal, all contributing to a cycle of dependency.\nAddiction \"is an incredibly deadly disease,\" said Komaromy, an addiction specialist at the University of New Mexico Health Sciences Center.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Both Vivitrol and Suboxone have side effects that are not compared\u2014or even mentioned\u2014in this story.", "answer": 0}, {"article": "\"This is outside the box. I've never used it this far out,\" Metz said. \"My radar is up if I see [such an injury] again. As we get more follow-up from David, it will be important to publish this case so people will be aware.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article mentioned overuse of the treatment, there wasn\u2019t an explicit mention of the type of harms associated with using hyperbaric therapy.", "answer": 0}, {"article": "For more about penis size, visit Psychology Today.\nThese devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\n\"All procedures aimed to increase the penile girth should be considered unsafe, leading to potentially poor cosmetic and functional results,\" Gontero added.\nLong-term vacuum treatments did not appear effective, producing no significant physical changes after six months, Gontero said, but did provide a degree of psychological satisfaction.\nTHURSDAY, April 21, 2011 (HealthDay News) -- For men who believe size matters -- and that their penises don't measure up -- success can be found in certain non-surgical penile lengthening treatments, a new study analysis by Italian researchers contends.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms are mentioned here, and we appreciate that. We do think, though, that some hard numbers should have been put to the risks associated with more of the enhancement procedures. We give it a pass, though, for at least providing harms data for the penile extenders that are touted as the method with the biggest benefit. It says, \u201cMore than 70 of them used penile extenders, with six experiencing minor problems such as bruising, pain and itching. These devices yielded average flaccid length increases of between 0.2 inches and 1 inch, Gontero said, and men achieving better results noted their satisfaction.\u201d", "answer": 1}, {"article": "When the lights went up, Nadella welcomed both Lawton and engineer Zhang on stage, thanking them for showing that thanks \"developers can have impact.\"\n\"Rather, its technology has the potential to help Parkinson\u2019s patients manage symptoms that impede regular functions.\n\"Once these symptoms can be identified and measured, it\u2019s possible to develop technology and devices that help humans manage their symptoms.\nThe goal of further research is to determine whether Emma Watch could help other people with similar Parkinson\u2019s symptoms.\"\nBut at Build 2017 in Seattle Wednesday, Microsoft went for the waterworks at the conclusion of CEO Satya Nadella's keynote address: it showcased a prototype watch that temporarily eliminated the arm shaking that often plagues those suffering from the neurological disease Parkinson's.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms are discussed, and there\u2019s no study to suggest what those might be. But presumably the physical harms here would be minimal, given that thousands if not millions of people wear vibrating smart watches without any known ill effects.", "answer": 2}, {"article": "The bone cells don't have the ability to lay down new bone.\"\nThe editorial pointed out, however, that Forteo should not be used in patients whose cancer has already spread to the bone, as it might prompt even more spread.\nAccording to an editorial accompanying the study, this complication occurs in about 5 percent of cancer patients who are taking a high-dose bisphosphonate (Zometa or Aredia) to control or prevent spread of malignancy to the bone.\nBut, she pointed out, Forteo is not yet approved for this indication, so \"we can't recommend it next week.\"\nBut the two papers in the Oct. 16 online issue of the New England Journal of Medicine report success with teriparatide (Forteo) in rebuilding bone.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In our opinion, the risks of Forteo are not described in sufficient detail. It does note that Forteo may prompt further spread of bone cancer, but what about the more common side effects? The Forteo prescribing information, for example, lists a number of more common side effects, and it includes\u00a0a black box warning with a broader caution about bone cancer, concluding that this drug should only be prescribed for patients in whom the potential benefits outweigh the risks.\n While this particular study observed no significant differences regarding adverse events, including no serious adverse events, the article should have noted, as the investigators do, that the study was too small to accurately assess safety. Absent such a discussion, the article might be read as implying a green light for safety.", "answer": 0}, {"article": "Eli Lilly announced promising data on its efforts to have its Cymbalta depression treatment also used as pain medicine, saying a study showed the drug \"significantly\" reduced chronic lower-back pain.\n\nLilly has been looking at the potential of Cymbalta for relieving the discomfort of fibromyalgia and osteoarthritis pain as well as back pain. The company's results of late have been boosted by the antidepressant, whose second-quarter sales jumped 26% to $654.4 million.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Absolutely no discussion of potential harms, which is unacceptable for a story based on a drug that already has a known risk profile and for which new claims are being made. ", "answer": 0}, {"article": "To learn more about breast cancer surgery, visit the American Cancer Society.\nBut the MarginProbe is another tool that might help reduce the odds of needing a subsequent surgery, she said.\nLooking at the volume of tissue excised, the researchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control-group patients, Boolbol said.\nIf the results are repeated in larger studies, it could be a welcome addition to doctors' techniques, she said.\nWith the new device, the wait time is about five minutes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story simply \u2013 but inadequately \u2013 stated that \u201cresearchers said not much more tissue was removed when the device was used compared to tissue removed in the initial and subsequent surgeries among the control group patients.\u201d\nIt would be useful to have a more quantitative sense of how much more tissue was removed using the MarginProbe device. What does \u201cnot much more\u201d mean?\u00a0 Would it mean the same thing to all women? That would help the reader balance the benefit of avoiding a second surgery against the risk of removing more breast tissue when the device is used, which could negatively affect\u00a0the appearance of the breast after surgery.", "answer": 0}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\nThe team found that a suitable combination of mild electrical stimulation (MES) with heat shock (HS) activated HSP72 more efficiently.\n\"This device is very easy to use since it simply attaches to the abdomen, and it has a low-impact on the patient.\nThe first trial showed that activation of the HSR produced a large therapeutic effect.\nThe researchers developed a belt-type medical device that uses a special type of rubber to transmit MES and HS at the same time.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The belt device is claimed to be well tolerated, but no details on potential harms are given. The release notes: \u201cThe team found that a suitable combination of mild electrical stimulation (MES) with heat shock (HS) activated HSP72 more efficiently.\u201d What is the electrical stimulus and how uncomfortable is it? \u00a0Exactly what is a delivery of heat shock? What temperature is used? And finally is the device battery operated or is it a plug in? \u00a0All of these unanswered questions seem relevant to understanding the device.", "answer": 0}, {"article": "Jan. 6, 2010 -- A new imaging technique that measures the random motion of water within the brain may prove useful for detecting early signs of Alzheimer's disease.\n\"This type of brain scan appears to be a better way to measure how healthy the brain is in people who are experiencing memory loss,\" Carlesimo says in a news release.\nBut it is increasingly clear that DTI can also be used to identify very small structural changes in the gray matter of the brain, which is critical for learning and memory, researcher Giovanni A. Carlesimo, MD, PhD, of Italy's Tor Vergata University tells WebMD.\n\"This might help doctors when trying to differentiate between normal aging and diseases like Alzheimer's.\"\nIn a study published in the Jan. 19 issue of Neurology, Carlesimo and colleagues found that DTI scanning predicted declines in memory performance with more accuracy than traditional MRI.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did not mention that 13% of the individuals in the study were unable to complete the test due to claustrophobia and that for 17% of the individuals tested, there were technical difficulties which made their test results unusable.\u00a0 \u00a0\n", "answer": 0}, {"article": "Because about one-half of the deaths in people with type 2 diabetes are caused by cardiovascular disease, reducing cardiovascular risk is considered essential to diabetes care.\n\u201cThe big news here is that the drug reduced cardiovascular stuff.\nLilly shares jumped as much as 9 percent after data from the trial was released Thursday at a medical meeting in Stockholm.\nHe has not prescribed Jardiance and similar drugs as frequently as treatments like Januvia, but expects that may change based on the new data.\nThe vast majority of those patients could be candidates for Jardiance, which costs over $4,000 per year, Morningstar analyst Damien Conover said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article didn\u2019t mention any harms associated with Jardiance, a type of SGLT2 inhibitor. Some mention of potential adverse effects is always appropriate in stories about new drugs.", "answer": 0}, {"article": "\"What is unique about this study is that we had an unprecedented opportunity to examine the relationships between caffeine intake and dementia incidence in a large and well-defined, prospectively-studied cohort of women.\"\nAmong a group of older women, self-reported caffeine consumption of more than 261 mg per day was associated with a 36 percent reduction in the risk of incident dementia over 10 years of follow-up.\nIntake was estimated from questions about coffee, tea, and cola beverage intake, including frequency and serving size.\nThose who consumed above the median amount of caffeine for this group (with an average intake of 261 mg per day) were diagnosed at a lower rate than those who fell below the median (with an average intake of 64 mg per day).\nDriscoll and her research colleagues used data from 6,467 community-dwelling, postmenopausal women aged 65 and older who reported some level of caffeine consumption.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Nary a mention of the potential risks of caffeine, particularly in an older population. Caffeine is associated with\u00a0headaches, tachycardia (rapid heart rate), and anxiety to name a few.", "answer": 0}, {"article": "\u201cMany babies with Down syndrome appear normal on an ultrasound,\u201d she says.\n\u201cThis test looks very promising, but it is also very expensive,\u201d\n\nWhile there are risks attached to amniocentesis and CVS screens, these are minimized when the test is performed by a skilled obstetrician, she says.\nJoyce Fox, MD, the chief of medical genetics at Cohen Children's Medical Center in New Hyde Park, N.Y., definitely sees a role for a test such as the one described in the new study.\n\u201cWe are not quite there yet, but it may become a real possibility for finding out real information without having to risk a pregnancy.\u201d\n\nFor example, \u201cIf this comes back negative, you don\u2019t need an amniocentesis, but if it comes back positive, we would probably still do an amniocentesis to confirm the results,\u201d she says.\nIt is not a diagnostic test for Down syndrome, she says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does quantify potential harms in one way by noting, \u201cThere were no false-negative results with the new test.\u201d We wish the story also spoke about false positives. False positives are certainly part of the stress and harms from any screening test that need to be considered. In this case, it appears the false positives were low but not negligible.", "answer": 1}, {"article": "\"Here, fertility is very important to many young women,\" he said.\nTUESDAY, Oct. 6, 2015 (HealthDay News) -- Cancer patients who have ovarian tissue removed and stored for later transplantation have a chance at a successful pregnancy, a new study finds.\nOf 32 women who had ovarian tissue frozen and transplanted in this study, 10 women -- or 31 percent -- had a child, she said.\nSimultaneous advances in cancer treatment and reproductive medicine have made these scientific leaps possible, he said.\n\"So some of these women will still be able to have more children and avoid menopausal symptoms,\" she said, noting two more pregnancies have been reported to her laboratory since the study's publication.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story just barely mentions the risk \u2013 which it says is not increased \u2013 of a return of cancer. Since that\u2019s likely the main concern with this procedure, we\u2019ll go ahead and award a Satisfactory. But we\u2019d add that women who have\u00a0their own ovarian tissue removed and then reimplanted in a new surgery could potentially have complications of\u00a0those procedures (all surgeries carry some risk). No such complications are addressed in the study that\u2019s the basis for this story, and it\u2019s not clear if adverse effects (beyond cancer recurrence) were tracked by the study authors. We wish the story had asked about, and covered, those potential harms.", "answer": 1}, {"article": ".\nAllowing the lozenge to dissolve instead of swallowing it seemed to provide a therapeutic effect.\n\"Much of the variation in the published study findings can be explained by the daily dose of zinc administered in the zinc lozenges,\" said Hemila, who funded the research himself.\nWhile surprised to note how strong the correlation was between daily doses of zinc and its effect on colds' duration, he said he and his colleagues still don't know why it seems to work.\nThe study is published in The Open Respiratory Medicine Journal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story suggests that, \u201cNo prior studies showed zinc lozenge use \u2014 even up to 150 mg per day \u2014 might cause harm aside from bad taste or constipation\u201d We give it a pass since it does note the major side effects seen.", "answer": 1}, {"article": "The experimental gadget, Nerivio Migra, is a patch with a battery, electrodes and a computer chip that can wirelessly communicate with mobile devices.\nAt higher pulse widths than this device used, people might feel their muscles contract.\nIt\u2019s designed to stimulate nerves under the skin in the arm and block pain signals from reaching the brain.\nOne shortcoming of the current study is that researchers didn\u2019t examine how long the pain relief lasts beyond two hours, Schoenen said by email.\nAt the highest level of stimulation, 58 percent of the people who started out with moderate to severe pain reported little or no pain after treatment.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects are minimal but worth mentioning \u2014 and this story doesn\u2019t lay them out. Some users can be allergic to the sticky pads of a TENS system, and those with heart conditions, metal implants, epilepsy, or other\u00a0neurological conditions might be poor candidates for it.", "answer": 0}, {"article": "One of the most frustrating aspects of brain injuries is that they can be difficult to diagnose; emergency rooms can sometimes miss subtle symptoms, leading to improper treatment and potentially catastrophic consequences. Now, researchers are close to identifying so-called biomarkers that may soon make it possible to pinpoint brain injuries with a simple blood test.\n\nPresence of these biomarkers\u2014proteins produced by an injured brain\u2014could end up determining the future treatment of the estimated 1.4 million athletes, car-crash...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s too early to quantify harms, as it\u2019s not clear there\u2019s a physical test yet, no matter a final roster of biomarkers.\nYou might say the potential harms of a blood test are low, but what about the odds that the test will screw up? Not all tests are created equally, and some test results can be equivocal, inconsistent, or wrong. That\u2019s why we need to study the test\u2019s reliability in the DOD trial. We don\u2019t know\u00a0how many people with severe brain damage will slip past this test (its sensitivity) and how many it will wrongly diagnose (its specificity). Poor sensitivity or specificity cause harms when warning signs are missed and when people get treatments or follow-up tests, sometimes invasive ones, they don\u2019t need.", "answer": 2}, {"article": "Men who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\nTomatoes are not the only food that is rich in this antioxidant.\nDuring that time, 67 men had a stroke.\nThe findings appear in the Oct. 9, 2012, issue of Neurology.\nThe new study included slightly more than 1,000 men from Finland aged 46 to 65.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re not aware of any harms from eating tomatoes.", "answer": 2}, {"article": "Obstructive sleep apnea (OSA) is marked by interruptions in breathing while asleep; it is common among children with enlarged tonsils or adenoids.\nThere are many other causes of bedwetting, Lakshmanan said.\nThose who did not stop wetting the bed after the surgery were more likely to be born prematurely, be male, be obese or have a family history of bedwetting, the investigators noted.\nHowever, half of the 417 children in this latest study who had sleep apnea and were bedwetters stopped wetting the bed after they had their tonsils or adenoids removed.\nPremature birth was the greatest predictor of continued bedwetting after surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a big omission in the story. Any story about surgical procedures needs to address the potential harms from surgery.The basic risks of surgery, including infections, bleeding, and complications of anesthesia should have been mentioned.", "answer": 0}, {"article": "Oct. 17, 2010 -- Women aged 65 and older are advised to undergo bone mineral density (BMD) screening every two years, but those with normal results at age 67 may be able to wait 10 years before their next screening test, a new study suggests.\nResearchers analyzed bone mineral density data from 5,035 women aged 67 or older who had their BMD tested at least twice during the 15-year study period.\nTheir findings are based on the women's T-score, which is a measure of bone density.\n\"Our study found it would take about 16 years for 10 percent of women in the highest bone density ranges to develop osteoporosis.\nThe new findings are slated to be presented at the annual meeting of the American Society for Bone Mineral Research in Toronto.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story did not quantify any harms associated with bone density testing, with osteoperosis or with waiting too long to have ones bones tested.", "answer": 0}, {"article": "Melanoma is the most serious, and often deadly, form of skin cancer.\nThe study was conducted at 14 sites in the United States and Australia and included 162 patients who received different dose combinations of the drugs: two daily 150 milligram (mg) doses of dabrafenib plus one 2 mg dose of trametinib; the same dabrafenib dose with a 1 mg dose of trametinib; or treatment with dabrafenib alone.\nBy targeting different points in the same growth-factor pathway, the kinase inhibitor drugs dabrafenib and trametinib postponed the development of drug resistance in patients with BRAF-positive metastatic melanoma, the study authors said.\nBut the response is temporary in most cases, and tumor growth resumes in six or seven months, the researchers explained.\n\"We investigated this (drug) combination because of research we and others have conducted into the molecular underpinnings of resistance to BRAF inhibitor therapy,\" study lead author Dr. Keith Flaherty, of the Massachusetts General Hospital Cancer Center, said in a hospital news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u2019s discussion of harms tends to\u00a0downplay their importance.\u00a0It quotes an expert who says there were no \u201cuntoward side effects\u201d with the combination treatment, and\u00a0it reports that\u00a0skin rashes and rates of squamous cell carcinoma were\u00a0\u201csimilar to that typically seen in patients taking only one of the drugs.\u201d\nThat\u2019s one take, we suppose, but the study itself reported much higher rates of drug induced fevers and chills\u00a0in the combination groups, which was serious enough to require hospitalization in 19% of low-dose and 26% of high-dose combination group patients (compared with 2% of monotherapy patients). Other\u00a0side effects reported more frequently in the\u00a0combination groups were\u00a0fatigue (in 53% of patients), nausea (44%), vomiting (40%), and diarrhea (36%).\u00a0Those certainly sound like \u201cuntoward\u201d side effects to us.", "answer": 0}, {"article": "COLUMBIA, Mo.\n\"Prostate cancer, unfortunately, is a common cancer, and more than 27,000 men are estimated to have died from the disease in 2015,\" said Naveen Pokala, M.D., an assistant professor in the Division of Urology at the MU School of Medicine and lead author of the study.\nThe study, \"Survival Outcomes in Men Undergoing Radical Prostatectomy after Primary Radiation Treatment for Adenocarcinoma of the Prostate,\" recently was published by Clinical Genitourinary Cancer, a peer-reviewed journal on the detection, diagnosis, prevention and treatment of genitourinary cancers.\nUsing the Surveillance, Epidemiology and End Results (SEER) program database, Pokala and his research team studied 364 patients who underwent a salvage radical prostatectomy surgery after unsuccessful radiation treatments.\n\"By studying a national database of prostate cancer cases, we found that a procedure known as salvage radical prostatectomy can greatly increase a man's chance of survival when traditional radiation therapy has failed to eradicate the cancer.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention or explain any harms that might be associated with these surgeries. This strikes us as especially disappointing because some of the side effects of surgery are known to influence patient decisions about treatment. The two side effects that get the most attention are incontinence and impotence.\nThe researcher is quoted acknowledging the fear that patients have, but does not offer any measures for post-surgical outcomes related to quality of life. We found that disappointing.\n\u201cBecause radical prostatectomy is a complex surgery, there can be a reluctance to undergo the procedure,\u201d Pokala said. \u201cHowever, this study shows that it is a viable treatment option. This can bring a renewed hope and peace of mind to men living with prostate cancer.\u201d\nHarms for either surgery or radiation alone such as urinary, bowel, and sexual dysfunction, can adversely affect quality of life. The literature suggests that salvage prostatectomy can cause even more worrisome complications such as damage to pelvic structures, blood clots, and bleeding. \u00a0Unfortunately, these data are not available in the SEER database so the authors could not assess\u2013an important\u00a0limitation of the study.", "answer": 0}, {"article": "...\nYet some doctors say the study was far from rigorously performed, and so badly run that its marginally positive results are meaningless.\nEven the study's lead author says the research should not be used to recommend chelation therapy, and he acknowledges that its findings could have been due to chance.\nThe trial, known as the Trial to Assess Chelation Therapy, or TACT, has been dogged by accusations of safety and ethical problems from its beginnings 10 years ago.\nThat could lead to a bias in favor of chelation, Atwood says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that chelation is risky and\u00a0dangerous, and\u00a0notes that at least 30 patients have died from off-label chelation therapy since the 1970s. But then it quotes the\u00a0director of the National Heart, Lung, and Blood Institute calling the study a \u201cbreakthrough\u201d \u2013 not for proving that chelation works, but for \u201cestablishing that this chelation therapy regimen can be administered in a safe manner in the context of a clinical trial.\u201d Without some data or an explanation, readers are going to have a hard time\u00a0reconciling these\u00a0contradictory views about the safety of chelation. And since the NHLBI quote ends the piece, it\u2019s the take-home that may have the biggest influence on readers.", "answer": 0}, {"article": "Omega-3s prevent and fight cancer by turning on genes associated with the immune system and blocking tumour growth pathways, said Ma.\nOmega-3s from fish pack a stronger punch than flaxseed and other oils when it comes to cancer prevention, according to a first-ever University of Guelph study.\nBesides certain foods containing EPA and DHA, supplements and functional foods, such as omega-3 eggs or DHA milk, can offer similar cancer prevention effects, he added.\nBased on the doses given in the study, Ma said humans should consume two to three servings of fish a week to have the same effect.\nALA is plant-based and found in such edible seeds as flaxseed and in oils, such as soy, canola and hemp oil.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Some fatty and farm fish contain significant levels of mercury, PCBs, and other contaminants and experts recommend limiting their consumption and avoiding them entirely if you\u2019re pregnant. That isn\u2019t mentioned. The release also conveys an endorsement of fish oil tablets, which can have side effects such as heartburn, nosebleeds, hot flushes, leg cramps, nausea and bad breath.", "answer": 0}, {"article": "DOI: 10.1016/j.ophtha.2016.01.036.\nResearchers noted that the findings only pertain to consuming the nutrient through food and not vitamin supplements.\nThe research is also the first to show that diet and lifestyle may play a greater role than genetics in cataract development and severity.\nThese results make the study the first to suggest that genetic factors may be less important in progression of cataract than previously thought.\nHow vitamin C inhibits cataract progression may have to do with its strength as an antioxidant.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release makes no mention of harms that may come with increasing the amount of Vitamin C one consumes in their diet. While mega doses of Vitamin C supplements are known to be harmful, this release and study stress that the focus here is on obtaining Vitamin C through food sources.", "answer": 2}, {"article": "Check back soon for further information.\nCSL, which is one U.S. vaccine supplier, found the same side effects in its study that people experience with regular flu vaccine, which is no surprise since this shot is merely a recipe change from the annual standby.\nIn a study of 240 adults, half younger than 50 and half over, one shot prompted the same kind of immune response indicating protection that is seen with regular flu vaccine.\nBut scientists had feared that people of all ages would need two shots about a month apart because the new H1N1 strain is so genetically different from normally circulating flu strains that most of the population has little if any immunity.\nAustralian and U.S. researchers said Thursday that one dose of the new swine flu vaccine looks strong enough to protect adults \u2013 and can begin protection within 10 days of the shot.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe story says that the participants in the H1N1 flu vaccine trials reported side effects similar to those seen with seasonal flu vaccination; that is, almost half had some soreness or rash at the injection site or a headache.\n However, the story should have pointed out that these small and very brief trials don\u2019t reveal whether the new H1N1 flu shots may be linked to the sort of rare cases of Guillain-Barre diseases that were seen during the rushed attempt to vaccinate people against a variety of swine flu in 1976.", "answer": 1}, {"article": "An experimental spray improved sex for some men who regularly experience premature ejaculation, according to the results of two studies set to be presented Tuesday at a urology conference.\n\nMen who applied the aerosol spray, a mixture of the anesthetics lidocaine and prilocaine, reached orgasm a mean of 3 minutes 18 seconds after beginning sex, compared with about 56 seconds for those who got a placebo spray. The 539 men completing the two studies, who were randomly assigned to the real drug or the fake version, had an average...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It talks about the potential side effects, but it limits that discussion to what the study found in a very small group of men. Are there long term effects from lidocaine exposure that have been found in other studies? Does the body build up resistance to lidocaine? This isn\u2019t a short term problem that can be solved with a few weeks of therapy. It is\u00a0usually a\u00a0life long problem, and the story should be framed that way both in discussing the benefits and the harms.", "answer": 0}, {"article": ".\nAs this study has shown in a randomized, double-blind, double-dummy, placebo-controlled manner, exogenous testosterone therapy with Androgel can clearly decrease sperm production and potentially impact fertility,\" said Dr. Kim.\nThe findings, which are published in BJU International, could change the way men are treated for low testosterone.\nEdward Kim, MD, urologist at the University of Tennessee Medical Center and Professor at the University of Tennessee Graduate School of Medicine in Knoxville, and his colleagues compared such a drug, called Enclomiphene citrate, with testosterone replacement therapy (Androgel) in overweight men with low testosterone, or hypogonadism.\n\"This study confirmed that Enclomiphene can maintain spermatogenesis while restoring testosterone levels to normal.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release\u00a0did not include any mention of adverse events from the trial in question. \u00a0We always look for an explicit discussion of potential harms. Excerpts from the\u00a0journal manuscript:\n\u201cThere were 53 (21%) men in the studies who had adverse events\u00a0considered by the investigators to be possibly, probably, or definitely related to the study drug. None of these were severe and none were serious\u2026.\nOther than a\u00a0road traffic death, the only death was in the ZA-304 study. This was a 59-year-old Caucasian with secondary hypogonadism who was treated in a \u2018blinded\u2019 fashion with 12.5 mg enclomiphene citrate for 34 days before an ischaemic stroke\u2026.His high number of risk factors and limited exposure made it highly unlikely that the study medication was the cause of his death in the opinion of the investigator.\u201d\nRegarding the researchers\u2019 statement that none of the adverse events were severe or serious, we always think that\u2019s in the eye of the beholder \u2014 the patients, who, of course, are not heard from.\nBut what we\u2019re reviewing is the news release, which is silent on potential harms.\nOur reviewers noted that the FDA has issued a safety alert to add information to labeling about a possible increased risk of heart attacks and strokes in patients taking testosterone. If enclomiphene raises testosterone levels it\u2019s hard to accept the investigator (with a possible financial conflict) dismissing the possibility that the drug caused the stroke.", "answer": 0}, {"article": "There were about 68,000 new cases of melanoma and about 8,700 deaths last year in the United States, up from 48,000 cases and 7,700 deaths in 2000, according to the American Cancer Society.\nIn the latest trial, a big one was liver damage.\nThe new trial of this drug, by contrast, involved patients who were getting treated for the first time.\n\u201cIf it weren\u2019t for the trial I wouldn\u2019t be here,\u201d she said.\n(The drug\u2019s name comes from V600E mutation in RAF.)\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good job explaining signifcant potential harms of both drugs \u2013 something competitors didn\u2019t do at all.", "answer": 1}, {"article": "For nine months, the developing fetus is attached to its mother by the umbilical cord.\nThen, moments after birth, that cord is severed.\nCutting the cord is a momentous event in a baby's life.\nIron is essential to the developing brain, he said, and deficiencies during early months \u2014 perhaps linked to early clamping \u2014 could affect nerve and muscle control, making it harder for the child to later control a pen or interact comfortably with peers.\nShe said the decision about when to clamp should be made between the doctor and parents, depending on the delivery, the health of the baby and the mother's condition.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not talk about potential harms to the newborn, such as jaundice, although it does mention the original rationale for quick cord-clamping, to limit the blood loss to the mother.", "answer": 0}, {"article": "Currently, people who do not have HIV but are at substantial risk of getting it--because they have multiple sexual partners, for example, or an HIV-infected partner--can receive antiviral medications to prevent disease, a strategy called pre-exposure prophylaxis (PrEP).\nIn an effort to accomplish this, the investigators are looking into modified variants of the antibodies with prolonged activity, so that they would need to be given less often in the PrEP setting.\nThe study of 10-1074, an early-stage clinical trial, included 19 individuals who were infected with HIV and 14 who were not.\nThe investigators found that among 13 HIV-infected people who received the highest dose of 10-1074, 11 showed a rapid decline in the amount of virus.\nAlthough these patients were found to have some resistant virus in their blood, further research in the lab showed that those viruses were still sensitive to other broadly neutralizing antibodies, including 3BNC117, that target different parts of the pathogen.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t include a discussion of actual safety results of the study drug, although this is the primary goal of the study. \u00a0Was this safe? \u00a0Were there any adverse events? The discussion about \u201cresistant virus\u201d found in some patients is not well described. Was this a resistance identified at the beginning of the trial or related to use of 10-1074?", "answer": 0}, {"article": "Previous studies have shown that nitrites \u2014 also found in high concentrations in celery, cabbage, and other leafy, green vegetables like spinach \u2014 widen blood vessels, but researchers say this was the first to find that nitrites also increase blood flow to the brain .\nThe high-nitrate breakfast included 16 ounces of beet juice.\nAn hour later, an MRI scan recorded brain flow in each person\u2019s brain.\nThen they were sent home with lunch, dinner, and snacks that conformed to their assigned diets.\nAnd blood tests before and after breakfast confirmed nitrite levels in the body.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of potential harms from consuming high concentrations nitrates.", "answer": 0}, {"article": "But another found that the stroke rate was 22 percent lower in people who ate chocolate once a week, and a third reported that death from stroke was 46 percent lower in those who ate 50 grams of chocolate once a week.\nBut the findings, based on a review of existing research, aren't conclusive, and they don't prove that chocolate is good for your heart.\nFor now, said registered dietitian Katie Clark, \"caution should be taken not to promote chocolate as a health food,\" even though it's fine in moderation.\nBut Keith-Thomas Ayoob, an associate professor at Albert Einstein College of Medicine in New York City who studies nutrition, said chocolate does have its benefits.\nFor one thing, it's possible that some factor other than chocolate could be helping lower the risk of stroke.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did discuss the possible harms of higher LDL cholesterol \"or perhaps higher incidence of cardiovascular disease\" from chocolate. But it didn\u2019t provide any evidence.\u00a0 Nonethless we\u2019ll give it the benefit of the doubt. ", "answer": 1}, {"article": "\u201cI tell my patients, \u2018buyer beware,\u2019\u201d Shepard said in an email.\n\u201cStudies like this highlight that medicine is still an art - we do not have perfect answers, and we have to individualize for each patient.\u201d\n\nThe study was sponsored by IBSA Institut Biochimique SA, a pharmaceutical company based in Lugano, Switzerland, that makes the chondroitin sulfate supplements used in the test.\n\u201cHowever, it should not replace other therapy such as quad strengthening exercises, and weight loss, which we know will provide benefit.\nIn addition, U.S.-based studies of chondroitin have had mixed results, said Shepard, who wasn\u2019t involved in the study.\nI tell them to try chondroitin for one month as a trial and if they like it and feel better with it, then keep taking it.\u201d\n\nIf chondroitin doesn\u2019t work for them, he suggests taking an NSAID \u201cperiodically,\u201d and to be aware of the side effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that chondroitin is not associated with the dangerous side effects seen with NSAIDs, but we were left wondering: What were the\u00a0adverse events seen with this supplement?", "answer": 0}, {"article": "Involuntary muscle spasms (spasticity) are common symptoms of MS.\nSide effects varied greatly and depended on the amount needed to limit spasticity, the researchers write.\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms.\nThe researchers say that many existing therapies for this condition are difficult to obtain, ineffective, or associated with intolerable side effects.\n\"Considering the distress and limitations spasticity brings to individuals with MS, it is important to carefully weigh the potential for side effects with the potential for symptom relief, they say in the news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Absolutely no numbers were provided to give a sense of the scope of the potential harms of taking the extracts.\u00a0\u00a0 All the story said was, \"Side effects vary greatly.\"\u00a0 What were they?\u00a0 How many people had them?\u00a0 ", "answer": 0}, {"article": "Co-authors are Erin Van Blarigan, ScD, of the departments of Urology, and Epidemiology and Biostatistics at UCSF; Howard Sesso, ScD, MPH; Edward Giovannucci, MD, ScD; Meir Stampfer, MD, DrPH, and Julie Batista, ScD, all of Harvard T.H.\n\"It's interesting that vigorous activity had the highest potential impact on prevention of lethal prostate cancer.\nThese lifestyle habits align with other recommendations to prevent diabetes and heart disease.\"\nReducing intake of processed meats would cut the risk by 12 percent, they reported.\nCases were confirmed through medical records and pathology reports, and cause of death was determined by death certificate and medical record, and secondarily by next of kin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms. But the lifestyle choices at issue here are (for the most part) so broadly defined that it would be difficult to say what the harms would be. What harms are associated with eating tomatoes, avoiding processed meats, or not smoking? We\u2019ll rate this one not applicable.", "answer": 2}, {"article": "The F.D.A.\nPatients in both groups of the study could also take other drugs, such as beta blockers, as their doctors saw fit.\nNovartis is considering trying so-called risk-sharing with some health plans, meaning it might charge more if the drug really does keep people out of the hospital and less if it doesn\u2019t.\nThat represented a relative risk reduction of 20 percent using a measure known as the hazard ratio.\nBlacks and those with a previous history of the condition were at increased risk, it said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story addresses both common side effects and severe ones, while also noting which patients may be at increased risk of those side effects. The coverage would have been even stronger with some mention of the rate at which these problems occurred.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/061015/23addict.b.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story did mention concerns about anxiety and depression; how often these occur and whether the drug increases their prevelance\u00a0are relevant peices of information. It would have been useful to hear how often these side effects occur. ", "answer": 1}, {"article": "\u201cWe can offer people hope from the start.\u201d\nNearly half of people in the study who were given a six-month diet plan and lost an average of 30 pounds went into remission and no longer had diabetes.\nMost importantly, 46% of the people in the diet group went into remission with their diabetes, compared to just 4% in the control group.\nAfter a year, most of the people in the diet group lost about 22 pounds, compared to two pounds in the control group.\nIn the study, Dr. Roy Taylor, professor of medicine and metabolism at Newcastle University, and his colleagues randomly assigned nearly 300 people to either a weight management program or their usual treatments, including diabetes medications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of the very restricted diet were not mentioned. Were there any problems resulting from months on the liquid diet? Did subjects have trouble adhering to the restrictions?\nThere were quite a few side effects during treatment. According to the study, during the intervention, most common side effects/complaints were constipation (56%), headache (45%), increased cold sensitivity (44%), dizziness (42%). These tended to dissipate over time.", "answer": 0}, {"article": "First published on June 22, 2006 at 12:00 am\nBut Dr. George Merriam, a professor of medicine at the University of Washington, cautioned that much more study is needed to determine whether the medication should become widely available to help counteract the effects of aging.\nDr. Julia Zehr, a Michigan State University researcher who led the study, said the findings suggest that biological factors may influence those behaviors, not just the psychological effect of changes in body composition during puberty.\nA tablet that stimulates the production of growth hormone may help older adults improve their physical functioning and lower their body fat percentage, a researcher said yesterday.\nThe government has approved use of growth hormone for a limited array of conditions in adults and children, Dr. Merriam said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that further study of growth hormone in otherwise healthy older adults is needed due to a lack of safety information, however none of the potential harms are mentioned. We do not know the long-term effects of growth hormone in older adults; however, it may pose an increased risk of prostate cancer for older men and decrease longevity (Vance, M. L. (2003). Can growth hormone prevent aging? N Engl J Med, 348(9), 779-780.).", "answer": 0}, {"article": "Prostate cancer begins when cells in a man\u2019s prostate gland mutate and start to grow uncontrollably.\n\u201cThe side effects of traditional treatment were not worth it to me, and I wasn\u2019t afraid to try the most cutting-edge technology.\nIt is the first trial of its kind in the world.\n\u201cThe side effects of current prostate cancer treatments can be extremely traumatic.\n\u201cIn fact, the first patient in the trial was actually riding a bike within a week of his treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only harms discussed are those in relation to competing treatments.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/061210/18vitamin.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story failed to mention that excess vitamin D is stored in the body and that excessive intake can be fatal.", "answer": 0}, {"article": "Tuberculosis is a chronic bacterial infection that's spread through the air and usually infects the lungs, although other organs of the body can be involved.\nThe test, known as the \"Xpert MTB/RIF\" test for Mycobacterium tuberculosis and resistance to rifampin (RIF), appears to be more than 97 percent accurate and is even able to diagnose drug-resistant TB, researchers said.\nThe test diagnosed tuberculosis in 99.2 percent of the patients, the researchers found.\nThe machine costs around $30,000, but would be priced under $20,000 in poor countries, he told the AP.\nFurther trials of the new test are planned, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the new test apparently does a very good job\u00a0of ruling out individuals who don\u2019t have TB, the study reported that 5 out of 609 patients without TB received a false-positive TB diagnosis. These individuals may be subjected to additional tests and treatments that have the potential to cause harm. The story didn\u2019t mention this. ", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The side effects of Erbitux are accurately presented.", "answer": 1}, {"article": "The Lancet.\n\"If the SCOOP screening strategy was taken up in exactly the same way as in the study in all UK women aged 70-85 years, we estimate that the strategy could prevent up to 8000 hip fractures per year in the UK.\nCommunity screening for osteoporosis could prevent more than a quarter of hip fractures in older women, according to new research.\n\"A hip fracture can be devastating with a loss of independence and less than one third of patients make a full recovery.\nThe study suggests that one hip fracture could be prevented for every 111 women screened and early analysis suggests the approach is likely to be cost-effective.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Given that this news release addresses effectiveness of a community screening effort rather than a treatment, harms are likely to be few. However, we think potential harms deserved some attention.\nHarms could arise from medication complications \u2014 which for bisphosphonates (the most commonly used drug class for treating osteoporosis) can paradoxically include atypical fractures. This is a risk calculator, so we\u2019re not as concerned about over-diagnosis. The expectation is that the risk information should be incorporated into discussions of treatment options. The bigger concern would be under-diagnosis \u2014 how many fractures occur in women whose FRAX score is low and then don\u2019t go on to bone density scanning (DXA) so the opportunity to diagnose and treat osteoporosis is lost.", "answer": 0}, {"article": ".\nIf the test is negative, its accuracy will allow doctors to wait and watch a lesion.\nBut now, according to a study published Sunday in the New England Journal of Medicine, there appears to be a new, much less invasive way of determining whether a growth is malignant.\nThat has left only two ways to determine whether the abnormality is cancerous: inserting a needle through the chest wall and into the tumor, or surgically opening a patient's chest to find it (and remove it if necessary).\nIf it shows a malignancy, a biopsy still would be needed to confirm the cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that the additional maneuvering of the bronchoscope to collect cells for the genomic testing adds less than a minute to a bronchoscopy procedure. But it doesn\u2019t make clear that bronchoscopy itself carries some risks (mainly of infections). In addition, a company news release reports that the test has a relatively low specificity of 47%, which means there will be many false positive results. The story doesn\u2019t explore this beyond saying that there will still be biopsies. These false positives will result in unneeded surgical or needle biopsies in those who turn out not to have cancer.\u00a0Any story about a new test \u2013 rather than dwelling on \u201caccuracy\u201d \u2013 should explain both the sensitivity and specificity of the test.", "answer": 0}, {"article": "Espiritu started work at Henry Ford just as the program was starting, and she remembers the initial staff meetings: \"There was a lot of, 'How can you do this?\nThe story of the health system's success is a story of persistence, confidence, hope and a strict adherence to a very specific approach.\nEach lists things she can do when she feels depression coming on.\nShe says with the treatment she's received at Henry Ford, she's learned to live, even thrive, with bipolar disease.\nBefore the zero suicide plan went into effect, says psychiatrist Doree Ann Espiritu, acting head of the zero suicide program at Henry Ford, you might make a contract with a patient where the patient agrees not to commit suicide.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story looks at an overarching strategy for identifying and treating depression; screening patients to identify those at risk and then pursuing \u201cappropriate care.\u201d While individual drugs or other treatment options can have potentially adverse side-effects, the story does not attempt to evaluate specific courses of treatment. For that reason, exploring the potential harms associated with individual treatment options doesn\u2019t seem relevant in this case.", "answer": 2}, {"article": "Red and purple fruits owe their colors to...\nIt pays researchers to study the benefits of pomegranate juice, gives doctors information on positive studies and, of course, sells pomegranate products.\nAlthough it's a challenge to eat the raw fruit without getting a mouthful of seeds and astringent pith, pomegranates are everywhere now in the form of juice, concentrates and extracts, all heavily promoted for better health.\nMuch of the popularity is the work of a California-based company, Pom Wonderful.\nBut is it especially healthful?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article failed to mention any harms or ill-effects that might be associated with ingestion of pomegranate or pomegranate-containing products. There are several case reports of pomegranate allergies in the medical literature.", "answer": 0}, {"article": "\u2022 Paulsen AJ, Cruickshanks KJ, Fischer ME, et al.\nThe demonstration of efficacy by Seciera\u2122 at 12 weeks is earlier than other drugs approved for dry eye in the same class.\nBased on published data, the efficacy and safety endpoints in these trials compared favorably to other formulations of cyclosporine A with the advantage of early onset.\nAfter 12 weeks of treatment, as compared to vehicle, Seciera\u2122 showed statistically significant improvement in the primary end point, Schirmer's score (a measurement of tear production) (p<0.0001).\nAdverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release does acknowledge harms by saying, \u201cAdverse events reported in the trial were mild to moderate in nature and similar to other approved drugs in the category,\u201d that offers no useful information for readers as to what those adverse events are, or how troublesome they might be to those using the product. The U.S. National Library of Medicine lists these possible side effects from cyclosporine ophthalmic: \u201cburning, itching, stinging, redness, or pain of the eyes, overflow of tears, red eyes.eye discharge, blurred vision or other vision changes, feeling that something is in the eye.\u201d", "answer": 0}, {"article": "Pulse pressure is the difference between systolic and diastolic (bottom number) in blood pressure readings.\nThe researchers conclude that mangos may be a heart-healthy fruit that may help play a role in reducing the risk of cardiovascular disease.\nMango consumption helped relax blood vessels in as little as two hours after intake.\nMangos contain a mix of polyphenols, including mangiferin, quercetin, gallotannins, and gallic acid, that have been the focus of previous investigations exploring the potential health-protecting properties of mangos.\n\"This is the first study to demonstrate positive vascular effects of mango intake in humans,\" said lead researcher Robert Hackman, with the UC Davis Department of Nutrition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Mangoes are a fruit. Eating fruit is generally a good idea \u2014 as long as it is part of a balanced diet. The \u201cbalanced diet\u201d part is missing from the release. Mangos are not inherently unhealthy, but they do contain a significant amount of sugar. So, if one is going to increase one\u2019s mango consumption, that should be offset by reducing other sources of sugar in the diet. Adding two cups of mangoes a day at 214 calories is not insignificant unless calories are cut back elsewhere in the diet. To be clear, we don\u2019t think mangoes need a warning label \u2014 but a simple note that mango consumption should be incorporated into a balanced diet would have been valuable.\n\u00a0", "answer": 0}, {"article": "By far, the lowest incidence of colorectal cancers was seen in pesco-vegetarians, people who eat fish at least once a month but eschew all other types of meat. Compared to omnivores, pesco-vegetarians were 43% less likely to be diagnosed with these cancers during the course of the study.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are really no harms to discuss when addressing these dietary changes, particularly given the extremely broad definitions of the vegetarian diet in the relevant study. Not applicable.", "answer": 2}, {"article": "Moffitt is the No.\nThe researchers report that the dendritic cell vaccines were well-tolerated and patients only experienced low-grade toxicities.\nThey also show that the vaccine was able to stimulate an immune response in the majority of the patients.\nImportantly, the immune responses among the patients were similar, regardless of the route of vaccine administration.\nThe Moffitt researchers assessed the effectiveness of the vaccine by determining the percentage of patients who had detectable disease within surgical specimens after resection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release states that the vaccines were \u201cwell-tolerated and patients only experienced low-grade toxicities. The most common adverse events were fatigue, injection site reactions, and chills.\u201d\u00a0 The release would have been better if it had told us how often these side effects occurred in the patient volunteers.", "answer": 1}, {"article": "For more information, click here.\nThe balloon remains in the patient\u2019s stomach for six months and is then removed the same way it was inserted, through the mouth.\nThe objective of the Orbera system is the make the patient feel partially satiated so they eat smaller, but more nutritious portions.\nThe most common side effect of installing the balloon is nausea that lasts a few days.\nChattoo also offers patients a nutritionist and trainer with the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story spends more time playing down potential risks than it does addressing what risks are posed by Orbera. Risks are summed up with a line that says: \u201cThe most common side effect of installing the balloon is nausea that lasts a few days.\u201d It also says that patients are kept under \u201cmild to moderate\u201d sedation when Orbera is put into the stomach. The story adds that Orbera eliminates \u201crisks involved with more invasive options,\u201d effectively playing down the risks associated with sedation. The story also doesn\u2019t address risks such as \u201cvomiting, abdominal or back pain, acid reflux, influence on digestion of food, blockage of food entering the stomach, bacterial growth in the fluid filling the balloon which can lead to infection, injury to the lining of the digestive tract, stomach or esophagus,\u201d etc. \u2014 all of which are discussed on Orbera\u2019s website.\nHowever, the most problematic line in the story related to harms states: \u201ceven if the balloon were to pop, the saline would be absorbed and pose no harm to the patient. The balloon would be removed in the same way it is at the six month mark.\u201d Readers might think that this mean a popped balloon in the stomach is a trivial event. However, Orbera\u2019s directions for use \u2014 which are also available online \u2014 note that \u201cBowel obstructions have been reported due to deflated balloons passing into the intestines and have required surgical removal. The risk of obstructions may be higher in patients who have diabetes, a dysmotility disorder, or who have had prior abdominal or gynecological surgery, so this should be considered in assessing the risk of the procedure. Bowel obstruction can result in death.\u201d Not necessarily such a trivial event after all.", "answer": 0}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\n\"Therefore, in this project we studied the recently developed alternatives to oily fish or supplementation, namely chicken meat and eggs, naturally enriched with sustainable algae-based omega-3 PUFA.\n\"This science has demonstrated the importance of food nutrients to promote good health and prevent ill health.\nWe are also focusing our research efforts on producing sustainable and nutrient rich pork, beef and milk, with scientifically proven health claims.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give the release a Not Applicable in this category since the study involved eating a moderate amount of chicken and eggs in their normal diet.\u00a0 Based on what little the release actually tells us about the trial, it\u2019s hard to see where people would be harmed from eating this amount of these particular foods.", "answer": 2}, {"article": "For more information, visitwww.asmbs.org.\nThetreatment involves patients swallowing a capsule that quicklydissolves in the stomach to reveal a deflated gastric balloon inside.With a thin catheter attached to the device, but long enough toremain outside the patient\u2019s mouth, a physician fills the balloonwith fluid (550 mL) to about the size of a grapefruit.\nThe catheteris then removed, while the balloon remains in the stomach for fourmonths.\nSimilar to othergastric balloons, the most common adverse events reported were nauseaand vomiting.\nii iii\n\nMetabolic/bariatricsurgery has been shown to be the most effective and long lastingtreatment for morbid obesity and many related conditions and resultsin significant weight loss.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives only a very brief mention of harms, citing nausea and vomiting as the most common adverse events reported. However, with a catheter patients might experience irritation in their esophagus or stomach (which could lead to bleeding or ulcers) or infection from bacteria surrounding the balloon. A concern for this type of balloon, which is intended to deflate, would be improper deflating and obstruction of the intestine \u2014 a potentially serious complication.", "answer": 0}, {"article": "This signal is passed to a computer that decodes it, and the resulting instruction is then sent to a sleeve he wears on his forearm that stimulates the muscles that move his wrist and fingers.\nFor starters, the device that records the brain signals will need to be much smaller so it's fully implanted under the paralysed person's skin.\nThat's why the device requires training every time Burkhart uses it.\nDr Jonas Zimmerman, a neuroscientist at Brown University in the US, who was also not involved with the study, echoed Jackson's point.\nThere are still many challenges to be overcome to bring this work out of the lab and into the lives of the millions of people who are paralysed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even if the technology is experimental and only tested on one patient, the\u00a0story should have included some discussion of risks of the implantation surgery and the implant itself.", "answer": 0}, {"article": "Breast MRI currently is used to screen women at high risk of breast cancer and as a diagnostic adjunct to mammography.\nShould the results hold in larger trials, the model has potential advantages in the clinic beyond its ability to reduce unnecessary biopsies in women with BI-RADS 4 lesions.\nThe examination relies on gadolinium-based contrast agents that need to be injected intravenously.\nThe new approach is not intended to replace current contrast-enhanced breast MRI protocols in general, Dr. Bickelhaupt emphasized, but to expand the spectrum of options available for answering specific clinical questions.\nThe software algorithm makes the assessment reader-independent, ensuring that its accuracy is maintained across different imaging facilities.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No specific description is provided of potential harms. One potential harm is that this technique still misses some malignant lesions.", "answer": 0}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nDavidovitch makes it clear that this kind of surgery is not one-size-fits-all.\nThose who have risk factors must plan on staying overnight in the hospital, not going right home.\nBut it's not the surgical approach alone that allows some of his patients to go home the same day -- it's a combination of what happens before, during and after surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We will give the story a Satisfactory rating on this criterion because it includes comments from a surgeon who warns about the risk of serious complications during the first night after surgery.\nHowever, the most prominent voice in the story is a surgeon who dismisses those concerns by saying, \u201cif the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital. It really doesn\u2019t make sense.\u201d\nWe\u2019re not given any information or data that proves this \u201cdoesn\u2019t make sense,\u201d though.\nWe also think potential harms that could have been included are falling at home due to dizziness, or otherwise not being adequately prepared for managing under major surgery.", "answer": 1}, {"article": "Catheter ablation involves inserting a thin tube into a blood vessel, usually through a site in the upper leg or neck, and then threading it though the body until it reaches the heart.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\nThe procedure has been used to treat arrhythmias for years.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nDubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story did mention several of the harms associated with the use of this device along with the incidence with which they were observed.", "answer": 1}, {"article": "The American Cancer Society has more on lymphoma.\nResearch presented at meetings should be considered preliminary because it has not been subjected to the rigorous scrutiny given to research published in medical journals.\nBut the study couldn't prove that more exercise actually caused death risk to drop.\n\"Therefore, since physical activity behaviors can be modified, physicians should counsel patients and survivors on the importance of physical activity and encourage them to maintain and, if possible, increase their level of physical activity.\"\n\"Importantly, our study shows a survival benefit in patients who increase their level of physical activity,\" Pophali said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "In general, we feel that it is important to discuss potential risks even if those risks are minimal. In this case, you\u2019re talking about a group of people with a very serious illness taking very serious drugs\u2013what should they know about the risks of increasing their physical activity?", "answer": 0}, {"article": "BLOOMINGTON, Ind.\nThe majority of the ADHD medicines used in the study were stimulants such as Adderall, an amphetamine, and Ritalin, or methylphenidate.\nThe results, based upon nearly 3 million people with ADHD in the United States, are reported in the American Journal of Psychiatry.\n\"While concerns about prescribing medications to treat ADHD that have the potential for abuse are understandable, this study provides further evidence that the use of these medications is not associated with increased risk of substance use problems in adolescence or adulthood,\" Quinn said.\n\"The results also highlight the importance of careful diagnosis and compliance with treatment.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not make any mention of potential side effects of stimulants used to treat ADHD. Common side effects include headache, upset stomach, increased blood pressure, dizziness, decreased appetite, insomnia and dry mouth.", "answer": 0}, {"article": "\u201cThe difference is, the length of stay is cut in half,\u201d he said.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nLiao said the robotic surgery was the right choice for Holmes, the bypass patient.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention negative outcomes that may be associated with the daVinci machines. It does not indicate whether complication rates are higher, lower or equal.\u00a0 \nThe story also fails to mention the potential harm if the machine is used to justify a hospital\u2019s investment or support surgical revenues regardless of whether it\u2019s the best use for a particular patient. ", "answer": 0}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nResponse by others in the field was positive but not effusive.\nAnd cancer sometimes returns even after that much time has elapsed.\nNeither Rosenberg nor others would describe the two patients as cured.\nAt least five years would need to pass before such a declaration would be considered.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no mention of harms or side-effects that have been experienced with this form of treatment. ", "answer": 0}, {"article": "Ultraviolet light can alter chromophores so they no longer absorb color, but UV light can damage the retina.\nMuch more research and development work remains, Dr. Kessel said, but the goal is a relatively simple procedure that would last half an hour at most and use largely automated equipment in mobile clinics.\nLine Kessel, an ophthalmologist at Glostrup Hospital of the University of Copenhagen in Denmark, and colleagues have come up with what they say is a promising alternative to replacement surgery.\nTo make cataract treatment available to more people around the world, a less-invasive, less-expensive technique is needed.\nIn their approach, described in the open-access journal PLoS ONE, they \u201cbleach\u201d the lens with a laser.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "You can\u2019t say much about potential harms when all that\u2019s been reported is an experiment on 9 human organ donor lenses.\u00a0 But the story didn\u2019t even capture what the authors wrote:\u00a0", "answer": 0}, {"article": "U.S.\nTo management's knowledge, USRM has completed more clinical treatments than any other stem cell company in the world.\nThe healed tear could not be penetrated by the probe.\nExcept as required by law, we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.\nThe paper outlines the case study of a 56-year-old male with a chronic meniscus injury.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "While the release\u2019s statements (mentioned above) refer to positive outcomes and mention no adverse effects, readers can\u2019t draw any conclusions about the safety of the procedure, given it\u2019s a single case study and a short-term follow-up.", "answer": 0}, {"article": "AsthmaNet is a nationwide clinical research network created by the NHLBI in 2009.\n\"Results from this randomized controlled study showed that in young children with mild asthma, acetaminophen used as needed was not associated with increased asthma flares or more asthma symptoms.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\nThe study did not detect any worsening of asthma in the children treated with acetaminophen compared with those receiving ibuprofen.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Another major study question was whether frequent acetaminophen use in children with mild persistent asthma worsens symptoms. This was measured by asthma exacerbation rate, number of days of asthma control, need for \u201crescue\u201d medication and unscheduled medical visits for asthma, as the news release points out. As mentioned above in the \u201cQuantify Benefits\u201d section, this release\u00a0does not lay out any supporting quantitative data for these benchmarks. It only states, \u201cThe study did not detect any worsening of asthma in the children treated with acetaminophen compared with those receiving ibuprofen.\u201d\nFor these reasons, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "Lovaza is an omega-3 drug FDA-approved for the treatment of severe high triglycerides at the dose of 4 milligrams daily.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nThe study included 266 healthy postmenopausal women with high breast density detected by routine mammograms.\nThese findings may help to support future research looking at the direct effect of omega-3 supplementation on breast cancer incidence in obese women.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This release fails to mention harms at any point and, while a widely consumed, readily available supplement like omega-3 fatty acids isn\u2019t likely to cause major problems, it is not free from side effects that are worth mentioning. The research paper itself points to more than a half-dozen participants in the study who withdrew because of adverse effects including hot flushes, leg cramps and\u00a0nausea. Readers rightly deserve to know possible negative impacts found in research studies.", "answer": 0}, {"article": "The Merck drug boceprevir and Vertex Pharmaceutical\u2019s similar drug telaprevir are expected to win FDA approval within months, following phase III trials showing that both drugs boosted cure rates to around 70% when used with standard therapy.\nAdding one of the drugs to the current two-drug regimen of peginterferon and ribavirin will make the treatment of hepatitis C more complex, but it will also cure a lot more people, hepatitis C specialist Donald M. Jensen, MD, of the University of Chicago Medical Center, tells WebMD.\nThe drugs will be used in patients with HCV genotype 1 -- the hardest to treat form of the viral infection.\nResults from two phase III boceprevir trials are published in the New England Journal of Medicine.\nMarch 30, 2011 -- Two highly anticipated hepatitis C drugs are poised to usher in a new era in the treatment of the viral disease as early as this summer, experts say.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The study points out that a major side effect of the new drugs is anemia, and more than 40% of patients in the boceprevir studies required erythropoietin to combat it; however, the story should have noted that over 20% of patients in the control groups also became anemic. In addition, there was a high drop-out rate in the two trials, which should have been mentioned. Why did so many drop out? \n ", "answer": 0}, {"article": "\"And I need the help.\"\nBarbara Troupin of Vivus, the company that is developing Qnexa, says the drug appears to do a lot more than just help people lose weight.\nWe're talking about medications to help those who are struggling with the health impact of obesity,\" Nadglowski says.\nFerguson has been helping to organize a series of meetings involving public health experts, anti-obesity advocates, government officials and others to try to figure out what the FDA should do.\nYou recall the fen-phen episode where a significant number of people got heart-valve defects,\" says Janet Woodcock, a top FDA official.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story sidebar notes \u2013 from the FDA briefing documents: \u201cThe review noted continued concerns that Qnexa can increase the risk for several possible side effects, including increased heart rate, birth defects and thinking problems such as memory lapses and confusion.\u201d\nIt also included these caveats:\n\u201cThere\u2019s been a long history with obesity drugs that we\u2019ve had to take off the market. You recall the fen-phen episode where a significant number of people got heart-valve defects,\u201d says Janet Woodcock, a top FDA official.\nWoodcock argues that the agency has to be extra-careful with weight-loss drugs, because chances are it won\u2019t just be obese people taking them.\n\u201cWhen you\u2019re talking about a drug where it could go into literally tens of millions of Americans, there has to be attention to safety,\u201d Woodcock says.\nWhat might look like a rare problem now could turn into another public health disaster, she says.", "answer": 1}, {"article": ".\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\nThe research, \"Pasta Consumption in American Children and Adolescents is Associated with Greater Daily Intake of Shortfall Nutrients as Defined by the 2015 Dietary Guidelines, Improved Diet Quality and Lower Added Sugar Intake,\" was conducted by Nutritional Strategies, Inc. on behalf of the National Pasta Association.\nThe study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\nThey are:\n\n-Better overall diet quality (as measured by USDA's Healthy Eating Index-2010 scale) -Greater intake of key shortfall nutrients like dietary fiber, folate, iron, magnesium and vitamin E -No significant associations were seen with body weight, waist circumference and body mass index\n\nPasta has long been celebrated as one of America's favorite foods and is advocated by nutritionists for its good nutrition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any harms from increased pasta consumption. The problem is not with pasta\u2019s nutrients but with potentially filling up on high-calorie pasta and excluding other healthy foods (not named in the release) from your diet.", "answer": 0}, {"article": "Georgetown University Medical Center (GUMC) is an internationally recognized academic medical center with a three-part mission of research, teaching and patient care (through MedStar Health).\nTurner says the study also found that resveratrol was safe and well tolerated.\nTurner, who treats patients at MedStar Georgetown University Hospital, cautions that the findings cannot be used to recommend resveratrol.\nResveratrol and similar compounds are being tested in many age-related disorders including cancer, diabetes and neurodegenerative disorders.\nThe researchers obtained brain MRI scans on participants before and after the study, and found that resveratrol-treated patients lost more brain volume than the placebo-treated group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release mentions resveratrol\u2019s most common side effects, which include nausea, diarrhea and weight loss. It would have been helpful to know how commonly these effects occurred. It also lists loss of brain volume as an effect, but states it could interpreted as either a benefit (since it could have reduced inflammation) or harm.", "answer": 1}, {"article": "Neurosurgeons performing EDAS reroute arteries from the scalp and the membranes that cover the brain and place these arteries under the skull near areas of the brain at risk of stroke.\nTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\nThe trial, led by Nestor R. Gonzalez, MD, professor of Neurosurgery and director of the Neurovascular Laboratory at Cedars-Sinai, enrolled 52 patients with severe brain atherosclerosis, also known as intracranial atherosclerotic disease, or ICAD, who showed symptoms of either a recent stroke or a mini-stroke, called a transient ischemic attack.\nWhile this Phase IIa trial selected patients from previous studies as the control group, the Phase III study would enroll new ICAD patients for both the control and experimental groups, he explained.\nAfter one year, 9.6 percent of the patients treated with the surgery experienced another ischemic stroke or died, compared with 21.2 percent of patients in a matched control group who received only intensive medical management.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addresses harms criteria with the following statement:\u00a0 \u201cTwo of the EDAS patients had small wound openings that required additional surgical interventions, but there were no intracranial hemorrhages or other serious adverse events, the researchers reported.\u201d\nWhile we\u2019ll award a borderline satisfactory, we wish that the release had cautioned that a study of 52 people is incapable of identifying harms that might occur with a larger and broader sample of patients.", "answer": 1}, {"article": "CT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer.\n\u201cThis is consistent with overdiagnosis of pulmonary embolisms that may have caused very little harm, may not have caused death,\u201d said Dr. Renda Soylemez Wiener of Boston University, who worked on the study.\nAccording to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\n\u201cI think doctors should think carefully about the pretest probability of a pulmonary embolism before they order this test,\u201d Wiener told Reuters Health.\nUsing national data, the researchers found the rate of so-called pulmonary embolisms, or PEs, nearly doubled with the introduction of a new powerful diagnostic test more than a decade ago.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained: \u201cthe blood-thinning drugs used to treat blood clots increase the risk of bleeding in the brain or gastrointestinal tract, for example. According to the new results, such complications rose from three to five per 100,000 people hospitalized with PE per year after doctors began using chest CT scans.\u201d It also reported: \u201cCT scans expose patients to radiation, for example, which can increase the likelihood of developing cancer. And the dyes used to enhance the scan also cause kidney damage in a significant portion of people.\u201d", "answer": 1}, {"article": "Tobacco use accounts for some 85 percent of lung cancer cases in the U.S., and one estimate puts a smoker\u2019s lifetime absolute risk of developing lung cancer between 12 percent and 17 percent.\nThat previous finding was \u201cvery good news in the field,\u201d said Dr. Bruce Johnson of the Dana Farber Cancer Institute, who treats lung cancer patients and reviewed the results for Reuters Health.\nAnd for lung cancer, doctors know there is a high false-positive rate and have a set protocol to follow in order to determine which lesions are dangerous, added Johnson.\nThe high so-called \u201cfalse positive\u201d rate is an issue, said Dr. James Hanley of McGill University, who also reviewed the findings for Reuters Health, but many mammograms also find lesions that turn out to be benign.\nHer ideas were controversial to start with, especially when other researchers found her work had been paid for by a tobacco company.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nWhile too many news reports take a \u201cwhy not?\u201d attitude toward medical screening tests, this story confronts some of the potential harms. It refers to a recent report that more than one in five \u201cinitial lung CT scans show suspicious lesions that turn out not to be cancer, but lead to needless invasive follow-up procedures and radiation exposure, as well as stress and anxiety for patients and their families.\u201d", "answer": 1}, {"article": "\"The ice ball forms very rapidly, \" Lee said.\nHe also knew that the cancer happened to be a spot where the small instruments couldn't reach it, the operation might have to be much more extensive.\nBesides being tiny, Guiles said they offer the advantage of flexibility.\nThat was what happened to Davis, who had gone to a hospital for a kidney stone.\nOnly one incision is required because Lee and other doctors can use a device called a trocar, which has holes for each instrument and the endoscope.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential \"mishaps\" but what does that mean? How often do they occur? How often will the surgeon need to revert to open surgery? What are the long-term risks?", "answer": 0}, {"article": "The risk of lung cancer death was 30 percent lower, the risk of colorectal cancer death was 40 percent lower and the risk of esophageal cancer death was 60 percent lower, the study reported.\n\u201cThis is important as a proof of principle that a single simple compound like aspirin can reduce the risk of cancer substantially,\u201d said the study\u2019s lead author, Dr. Peter M. Rothwell, professor of neurology at the University of Oxford.\nAs part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n\u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did say, \u201cBut even as some experts hailed the new study as a breakthrough, others urged caution, warning people not to start a regimen of aspirin without first consulting a doctor about the potential risks, including gastrointestinal bleeding and bleeding in the brain (hemorrhagic strokes).\u201d It could have put a number to these harms, as the NPR Shots story did. ", "answer": 0}, {"article": "Those are also symptoms of a deficiency of B12, a key nutrient needed to make red blood cells and DNA and keep the nervous system working right.\n\nVitamin B12 deficiency is officially considered rare, affecting about 1 in 1,000 Americans, according to a 2005 study. But the incidence...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Irwin Rosenberg was quoted as stating that taking too much vitamin B12 is unlikely to cause harm. \u00a0However \u2013 there are specific conditions where the use of injectable vitamin B12 can be problematic (e.g. in those with Leber\u2019s disease or allergy to cobalt) and any regular injections are associated with risk of blood borne infection.", "answer": 0}, {"article": "For Patients and the General Public:", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although highlighted in the NEJM paper describing the neratinib trial, the news release doesn\u2019t mention that 38% of patients receiving the drug experienced severe diarrhea, requiring a change to the trial protocol.\nA related NEJM editorial also noted that a\u00a0phase 3 trial including trastuzumab, pertuzumab and neratinib (compared to standard of care trastuzumab and pertuzumab) could result in significant side effects when added to chemotherapy, and they raise concerns of over-treatment of a large number of patients.", "answer": 0}, {"article": "The U.S. Food and Drug Administration said Tuesday it has approved Cotellic, a drug produced by Swiss biotech company Roche, for use in combination with the vemurafenib medication as a treatment for advanced melanoma.\n\nThe drugs are intended to target the illness after it has spread to other parts of the body or can\u2019t be removed by surgery.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story states both the severe and mild side effects of taking this drug. We\u2019ll rule this Satisfactory since there was a good-faith attempt to address the criterion. However,\u00a0while the array of side effects are listed they are not quantified. We do not know what proportion of those taking the medication get each side effect. Nor do we know how severe they are, or how many stopped the medicine die to the side effects. More detail would have been welcome.", "answer": 1}, {"article": "That's the tantalizing premise behind Deplin, a prescription form of the B-vitamin folate. Although it has been on the market since 2006, Deplin is generating growing buzz at psychiatric conferences and among clinicians and patients, particularly those who haven't responded to antidepressants or did for a while only to have their depression return.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes that patients receiving Deplin during a short-term study reported no increase in side effects compared with those receiving a placebo. However, the story did not mention that there are potential harms associated with the administration of synthetic folate that would not show up in a small, short-term study such as this one.\u00a0There are concerns, for example, that too much folate might increase the risk for colorectal cancer or hasten cognitive decline in individuals with poor vitamin B-12 status. At the very least, the story should have noted that current studies are not capable of identifying potential adverse effects of long-term Deplin therapy.", "answer": 0}, {"article": "Asked if he's suggesting that it's some kind of a rejuvenation drug that would turn a 70-year-old into a 35-year-old, Westphal tells Safer, \"That might be pretty hard to do.\nIt's normally inactive, but when it is active, Sinclair believes it triggers a survival mechanism that extends life.\nSinclair says he was aware of research into red wine and certain health benefits.\nresearch company.\nEveryone from plastic surgeons to your friendly snake oil salesman have been promising a ticket to eternal youth for some time, so the prospect of a prescription pill based on red wine that could trigger a longevity gene sounds too good to be true.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any harms, potential or known.", "answer": 0}, {"article": "Alzheimer's disease is the most common cause of dementia, and two out of three Alzheimer's cases are women.\nThe study explored the association between postmenopausal hormone replacement therapy, Alzheimer's disease, dementia and cognition in two nation-wide case-control studies and two longitudinal cohort studies.\nBushra Imtiaz's doctoral thesis Hormone therapy and the risk of dementia, cognitive decline and Alzheimer's disease is available for download at: http://epublications.\nThe newest results were published recently in Neurology and Maturitas and the earlier results in the Journal of Alzheimer's disease.\nThe study also showed that the postmenopausal removal of ovaries, uterus or both was not significantly linked to the risk of Alzheimer's disease, irrespective of the indication of surgery or hormone therapy use.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of the harms associated with hormone replacement therapy. These are well documented in multiple studies and include a heightened risk of breast cancer and other types of cancer.", "answer": 0}, {"article": "A California company has developed a genetic test that can predict whether patients treated for early-stage colon cancer are likely to suffer a recurrence of the disease, the third leading cause of cancer deaths in the U.S.\n\nThe results of the test, based on an analysis of seven different genes found in colon-cancer tumors, yield a score that tells whether patients are at low, intermediate or high risk of having the disease come back after it is removed through surgery.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Because the study failed to prove that the Oncotype DX test could identify the patients most likely to benefit from chemotherapy, the risk is that the test would be used for this purpose anyway.\u00a0\nThis triggers the risk of \"false reassurance\"\u2013that a resassuring test result would lead to no aggressive treatment yet a bad outcome.\u00a0 \nThe story fails to warn about the potential risks of clinical over-use and over-reliance on a test that may not improve survival rates. ", "answer": 0}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\nMarybeth Thorsgaard, a Medtronic spokeswoman, said the company was close to completing a clinical trial involving the use of Infuse in anterior cervical fusion.\nThe products\u2019 use in cervical fusion procedures is a small component of their total sales, which reached an estimated $760.3 million in 2008, with Medtronic\u2019s share the larger one, according to Millennium Research Group, a consulting firm in Toronto.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe harms associated with the use of bone-growth proteins in fusions to treat upper spine pain are the headline of the story \u2013 and the study it is based on. The story specifically notes that patients have reported life-threatening complications, including difficulty breathing and swelling of the neck.\nThe story would have been better if it had included some explanation of the number needed to treat in order to see an additional case of harm.", "answer": 1}, {"article": "\"We try to time the pattern to stimulation so that it's integrated with their ability.\nOnce we got it fine-tuned and I got walking, I thought it was amazing.\nTraining with the system improved McGlynn's speed when it was turned off to 23 yards per minute, indicating therapeutic benefit.\nMcGlynn's gait became noticeably more symmetrical and energetic, the researchers said.\nBoth men gained strength and endurance through repeated use of the systems and fine-tuning by the researchers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There\u2019s no mention of potential harms, such as the risk of infection from implanted electrodes.", "answer": 0}, {"article": "For more information about Hebrew SeniorLife, visit http://www.\nThey graded the severity of these calcium deposits using scans done for osteoporosis screening.\nBOSTON -- Researchers from Hebrew SeniorLife's Institute for Aging Research, University of Western Australia, University of Sydney, and Edith Cowan University have discovered that bone density scans, typically used to determine fracture risk, could also be an aid in identifying cardiovascular disease.\nResearchers analyzed the bone density scans of over 1000 older women from Australia for the presence of calcium deposits in the large artery in the abdomen called the aorta.\n\"We found that that the presence of calcifications increased the likelihood of having cardiovascular disease such as heart attacks, and even the likelihood of cardiovascular deaths and mortality in general.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned.\nA bone density scan is a non-invasive and safe test, but the news release is silent on the issue of harms from false-positive or false-negative results \u2014 either of which could lead to over- or under-treatment.", "answer": 0}, {"article": "They found that rats with strokes who received DBS had more proteins in the brain that are associated with brain plasticity\u2014and twice as many synapses or connections between nerve cells compared to rats with strokes who did not undergo DBS.\nAnd experts aren\u2019t even entirely sure why it works for Parkinson\u2019s in the first place.\nSince the procedure is experimental, there may be some unknown risks as well.\nThat\u2019s why doctors at the Cleveland Clinic will test deep brain stimulation (DBS)\u2014a procedure in which electrodes are implanted in the brain to provide small electric pulses as a way to help people recover control of their movements.\n\u201cWhen we are treating stroke, we are really trying to make movement come back.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Near the end, the story does mention that \u201cDBS is a type of brain surgery, and comes with risks like bleeding, infection and need for more surgeries\u201d so it earns a Satisfactory rating. It also points out some harms may be unknown. But we would have been happier if the risks were not buried in the last paragraph of the story by which point, odds are, some\u00a0people would have stopped reading.", "answer": 1}, {"article": "Almost never?\nConsider, for example, the many posts on The New York Times\u2019 Well blog on the topic (walking versus running, the \u201cright dose of exercise,\u201d \u201cwalk hard, walk easy\u201d), all of which focus on the relative benefits of walking versus jogging versus running.\nSecond, the optimal walking/jogging exercise is light to moderate jogging.\nWhat is a bit surprising about this chart is that running faster or farther doesn\u2019t seem to reduce death rates any more than running slowly and, in fact, in both cases is slightly worse.\nEven if we dismiss the possibility that running harder is worse, it is probably useful to note that running harder or farther doesn\u2019t seem to be better.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Even moderate jogging carries health risks \u2014 more for some people than others. Running can cause joint problems, shin splints, and aggravate lower back strains, among other things (it\u2019s done all three things for at least one of our reviewers). And people with heart disease, arthritis, asthma, diabetes, lung disease, kidney disease or other serious ailments should consult a physician before embarking on an exercise regime \u2014 even a low-impact one \u2014 because they are at higher risk of incurring more serious health problems. Any story that effectively encourages readers to engage in moderate exercise several times a week (which is laudable), should also caution readers about the potential risks involved and how to begin such an exercise regime safely.", "answer": 0}, {"article": "NEW YORK (Reuters Health) - In a small study, people who had chronic pain as a result of damage to the nervous system reported feeling less pain, as well as less depression and anxiety, when they smoked marijuana compared to when they smoked a drug-free placebo.\nWare agreed that more research is needed.\n\u201cThe trial did not last long ... so the authors cannot really say whether any response would be sustained,\u201d Dr. Henry McQuay, who studies pain and pain relief at the University of Oxford, wrote in an editorial accompanying the study.\nIn the second, third and fourth rounds of treatment, most - but not all - patients were able to tell when they had been on either the highest THC dose or the placebo.\nFor that reason, the finding that marijuana may actually help improve patients\u2019 sleep, she said, is \u201cparticularly noteworthy.\u201d\n\nThe cannabinoid family, which includes marijuana, is \u201cemerging as an interesting new class of drugs for pain management,\u201d Ware said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Neither story actually quantified the harms, but they both noted there were side effects. This story did a better job, though, by noting that the only dose that seemed to work also seemed to produce the most side effects and by raising the issue of long-term safety concerns. It also was the only story to answer the question that readers surely would have when reading about an illegal narcotic being used as medicine. Did these patients feel high as a result? This story says that most did not. Because of the additional information and context, the rating here is satisfactory.", "answer": 1}, {"article": "Studies of adults find that social jet lag is associated with higher BMI, insulin resistance, depression, and a higher likelihood to engage in dangerous behaviors like smoking.\nThere are some limitations to mention about the new meta-analysis.\nBut it\u2019s not a foregone conclusion that later start times will ensure teens sleep more.\nBut even if later school start times only improve sleep time, that\u2019s a positive step for public health.\nLater start times could lead teens to go to bed even later.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are some drawbacks\u00a0associated with delaying school start times, and the story does a good job of discussing them.", "answer": 1}, {"article": "\u201cUsing these multiple, possible endpoints was something unique to this study,\u201d Jaffe said.\n\u201cSince each of these signs can be associated with different types of uveitis, the study\u2019s results broaden the applicability of treatment for patients.\u201d\n\nThe study authors note, however, that patients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\nPatients in the adalimumab group were also significantly less likely to experience treatment failure during the duration of the study (80 weeks) and they were at lower risk of treatment failure due to each of the four signs.\nJaffe said the study\u2019s results are significant not only because they indicate adalimumab delays treatment failure, but also because the investigation considered several signs as causes for treatment failure.\n\u201cThe hope is that by delaying or eliminating recurrences, the symptoms will be minimized or eliminated.\u201d\n\nThe researchers found that median time to treatment failure was 24 weeks in the adalimumab group and 13 weeks in the placebo group.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harms covered in the study were glossed over in the release, in particular by this sentence: \u201c[P]atients in the adalimumab group reported serious adverse effects, such as respiratory tract infections and allergic reactions, more frequently than those in the placebo group.\u201d\nGiven what was left out, we\u2019ll mark this one unsatisfactory.\nWhat\u2019s not mentioned is that 16% patients in the adalimumab group dropped out compared to less than 7% in the placebo group. We also learned that some of the adverse events that triggered dropout weren\u2019t included in the release: \u201cAdverse events leading to discontinuation of participation in the trial were more common in the adalimumab group and included choroidal neovascularization, blurred vision, reduced visual acuity, fatigue, malaise, and suicidal ideation.\u201d\nSomething simple\u00a0that the release could have characterized about the\u00a0adalimumab treatment\u2019s harms, but didn\u2019t: it had three times the rate of \u201cadverse events\u201d and twice as many serious adverse events.\nIncluding any of these numbers \u2014 and some of the harms that taking corticosterids like prednisone can cause (the best we get is \u201cmany unwanted side effects\u201d) \u2014 would have put the harms and benefits of the adalimumab treatment into clearer context.", "answer": 0}, {"article": "Independent committees look at the details of the patients and how well they are doing in drug trials like these.\nIt worked at least as well if not better than the chemo, so the researchers have stopped the study to give everyone a chance to take Keytruda, Merck, the company that makes the drug, said.\n\"Having seen patients benefit who failed existing therapies, now doing well on these new therapies, is fantastic.\"\nThe drug, Keytruda, is the same drug that former president Jimmy Carter says helped stall advanced melanoma that had spread to his brain.\nThe researchers wanted to see how it worked against the standard chemotherapy cocktails.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says about the whole class of drugs to which Keytruda belongs, \u201cThe new drugs are less toxic and more precise than standard chemotherapy. But they are not free of side-effects. Some are severe and can damage the lung, colon, liver, kidneys, hormone-producing glands and the brain, the FDA says.\u201d", "answer": 1}, {"article": "Nov. 8, 2011 -- A vaccine for breast and ovarian cancer that has spread to other parts of the body shows promise, according to a preliminary study of 26 patients.\nOverall, however, the limited success in some patients and the complete success in one is good news, he says.\n\"It gives us encouragement that we may be on to something here.\"\nResults of the vaccine were not as good in the other 25 patients.\n\"In January, it will be four years [for her],\" he tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions side effects in a satisfactory way.", "answer": 1}, {"article": "Foods to avoid\n\n Dairy: Milk, ice cream, yogurt, cottage and ricotta cheeses (except for lactose-free versions)\n\n Fruits: Apples, peaches, pears, watermelon, cherries, figs\n\n Vegetables: Garlic, onions, leeks, asparagus, cauliflower or large servings (more than \u00bd cup) of broccoli and Brussels sprouts\n\n Grains: Wheat (except in sourdough bread), rye, barley\n\n Legumes and nuts: Cashews, kidney beans, soy beans and soy milk\n\n Sweeteners: Honey, fructose, xylitol, agave syrup\n\nFoods to include \n\n Dairy and dairy substitutes: Kefir, almond milk, coconut milk\n\n Fruits: Bananas, blueberries, grapes, oranges, strawberries\n\n Vegetables: Carrots, green beans, bell peppers, potatoes, tomatoes\n\n Grains: Rice, oats, gluten-free bread (but check labels for high-FODMAP ingredients)\n\n Legumes and nuts: Peanuts, pecans, walnuts\n\n Sweeteners: Cane sugar, aspartame, stevia\nWhen patients do make their way to Kate Scarlata, a Boston area registered dietitian who specializes in the diet, the first thing she tells them is that it \u201cis a dietary experiment.\nShe credits the diet, along with medication, with a big reduction in her symptoms, but says \u201cit has not been a miracle cure.\u201d\n\nThe diet has generated enough interest to prompt some food companies to introduce low-FODMAP products \u2014 hoping for a market surpassing that for gluten-free foods, according to some industry reports.\nIn 2014, IBS treatment guidelines from the American College of Gastroenterology said the diet showed promise, but that the quality of evidence was \u201cvery low.\"\n\u201cPhysicians are largely administering the diet by giving patients sheets of paper with foods to exclude,\u201d Chey says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that the diet is restrictive, in the sense that it asks patients to eliminate a wide array of foods eaten in a normal diet (before cautiously adding them back later in the process). It also hints that because of all the unknowns with this relatively new, not-fully-researched diet, \u201cit\u2019s not known if the diet leads to any nutritional deficiencies or keeps working in the long run \u2014 especially for patients who get little support from doctors or dietitians.\u201d", "answer": 1}, {"article": "New research is helping Pfizer Inc. build a case for getting an important drug in its portfolio approved to treat a mysterious pain condition that could offer a big additional source of sales.\n\nThe New York drug maker said Tuesday that Lyrica, already on the market to treat certain types of pain, reduced painful symptoms among sufferers of fibromyalgia, a chronic and controversial condition that may affect as many as six million Americans. And today, it will unveil results from another study that it says shows Lyrica has a lasting...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story presented information about one side effect, dizziness, it did not do an adequate job address potential harms associated with treatment.\nFrom the company's own website, it was possible to learn that:\nThe most common adverse events occurring during all controlled clinical trials for patients taking LYRICA vs those taking a placebo were dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and thinking abnormal (primarily difficulty with concentration/attention).\nThese might be important to patients or investors. \u00a0", "answer": 0}, {"article": "Menstrual cramps, known by the medical name dysmenorrhea, typically begin just before or at the start of a woman's menstrual period and can last several days.\nThe study was published Feb. 27 in the Archives of Internal Medicine.\nAnd since the study period lasted only two months, there was no way to tell whether such a high dose produced any toxic long-term effects.\nGraham and Rabin agreed that much larger trials should be done before they would recommend vitamin D3 use to any of their patients for cramp relief.\nThe 300,000 IU dose of vitamin D3 given in the study also far exceeds the daily intake of 600 IUs recommended for American women of reproductive age, both Graham and Rabin said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did not talk about any harms related to high doses of Vitamin D.\n\u00a0", "answer": 0}, {"article": "CHICAGO\u2014Using whole-brain radiation to treat cancer that has spread to the brain is a treatment that for many patients is worse than the disease, a new study suggests.\n\nResearchers said the technique, when used after a more precise radiotherapy to kill the cancer, resulted in more memory loss and other cognitive deficits than treating with radiotherapy alone. While the more aggressive treatment was better at preventing recurrence of tumors in the brain, it didn\u2019t extend survival.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The potential harm in this case would be that, by avoiding whole-brain radiation, a patient may shorten his or her life. The story addresses this. For example, the story does a good job of articulating differences in overall survival for those who received whole-brain radiation and targeted therapy versus those who only received targeted therapy \u2014 and it gets bonus points for explaining that the observed differences in survival time were not statistically significant. The story also quotes one source as saying that there are some circumstances in which whole-brain radiation may still be beneficial.", "answer": 1}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It seems that harms to the mice were not discussed in the research paper (not surprising as the mice were all killed as part of the study) that\u2019s the basis for the story. A brief search didn\u2019t turn up anything overly concerning regarding the harms of ginger, but then again, it\u2019s not clear what the dosage given to the mice would translate to in human terms. A high-enough dose of anything can be dangerous. But while it might have been helpful to mention harms to humans attributed to powdered ginger, this may also have propagated the questionable notion that the findings are applicable to humans. We\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "\"Women should recognize that CAD comes with some potential risks,\" Fenton said.\nHowever, among the women who did have invasive cancer, computer-aided detection was linked with a greater likelihood of finding the cancer while it was stage 1 or 2 compared to stage 3 or 4, they found.\n\"The good news is the use of CAD was related to finding invasive cancers at smaller sizes and earlier stages than before the CAD era,\" said Kopans, also a member of the American College of Radiology's Breast Imaging Commission.\n\"But the [overall] rate of invasive breast cancer diagnosis was no different with or without CAD,\" Fenton said.\nDr. Daniel Kopans, a professor of radiology at Harvard Medical School and senior radiologist in the breast imaging division at Massachusetts General Hospital, said the study provides additional information to doctors and women, but has some limitations.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Beginning with the headline \u201cAre Pricey Computer-Aided Mammograms Worth It?\u201d and continuing throughout the piece, the potential problems with CAD are noted. \u00a0The article includes several quotes from Dr. Joshua Fenton, lead author of the study, on three key problems with CAD. \u00a0Dr. Fenton observed that \u201cthe (overall) rate of invasive breast cancer diagnosis was no different with or without CAD.\u201d \u00a0 In addition, \u201cCAD was also associated with increased diagnostic testing among women who turned out not to have breast cancer.\u201d \u00a0These women had additional mammography, or ultrasound, or biopsies. \u00a0Finally, because CAD led to increased diagnosis of DCIS, Dr. Fenton observed that \u201cIf you are an older woman, (there is) the risk of over-treatment of noninvasive lesions.\u201d", "answer": 1}, {"article": "You have to be really low on your iron storage before you're going to flag as anemic.\"\nIn addition to timing, further research will be needed to determine which blood test for iron deficiency without anemia is accurate, cost-efficient and practical for routine doctor's office use.\nPhysicians should consider blood testing of female adolescents for iron deficiency within a few years of starting menses, according to two studies by Penn State College of Medicine researchers.\nAmong iron-deficient adolescent women there is a future risk of maternal iron deficiency and negative effects on infant health.\nTaken together, the studies suggest that risk factors and assessments should not be used to determine which young women should receive testing for iron deficiency.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Screening is not without harms. The release does not mention any potential harms or downsides from identifying more teens with iron deficiency, or pre-anemia. Would a positive screen result in iron supplementation or a change in eating habits? Some research has suggested that mild iron deficiency is protective.\nIron supplementation is associated with constipation and too much iron is harmful to the liver, heart and other organs. A harm to society might be more financial drain on an already strained health care system if widespread screening were adopted.", "answer": 0}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nThe researchers say there\u2019s enough evidence to warrant a larger study on the effects of yoga on mental health, and it should be considered as part of treatment for more disorders.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\nWe thought it\u2019s time to see if we could pull all [the literature] together \u2026 to see if there\u2019s enough evidence that the benefits individual people notice can be used to help people with mental illness.\u201d\n\nTheir findings suggest that yoga does in fact have positive effects on mild depression and sleep problems, and it improves the symptoms of psychiatric disorders like schizophrenia and ADHD among patients using medication.\nDespite all of this, the vast majority of studies looking at the benefits of yoga are all small studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While it\u2019s not an invasive treatment and seems to be safe for most people, yoga can cause harm.\u00a0The story, however, doesn\u2019t address this possibility or state whether the studies included in the review assessed potential adverse effects\u00a0of treatment.", "answer": 0}, {"article": "\u201cThis is literally on the cutting edge of where the field is,\u201d Dr. DeKosky said.\nIt is very powerful.\u201d\n\nA lot of work lies ahead, researchers say \u2014 making sure the tests are reliable if they are used in doctors\u2019 offices, making sure the research findings hold up in real-life situations, getting doctors and patients comfortable with the notion of spinal taps, the method used to get spinal fluid.\nAnd when \u2014 researchers optimistically are saying \u201cwhen\u201d these days \u2014 drugs are shown to slow or prevent the disease, the thought is that people will start having brain scans or spinal taps for Alzheimer\u2019s as routinely as they might have colonoscopies or mammograms today.\nFor now, Dr. DeKosky said, the days when Alzheimer\u2019s could be confirmed only at autopsy are almost over.\nBut, he said, there needs to be an education campaign to make people feel more comfortable about having them.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThis rating is a close call. The story does highlight concerns about testing people for a disease for which there is no effective treatment. It also obliquely refers to the risk of erroneous results mislabeling people as destined to develop Alzheimer\u2019s Disease. However, the story includes comments from experts who downplay the risks to spinal taps without noting the number of people who experience severe pain, bleeding, infections or other problems. The discussion of potential harms seems imbalanced. ", "answer": 0}, {"article": "The newest scientific report for the U.S.D.A.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nFinally, while the coffee may be healthy, that\u2019s not necessarily true of the added sugar and fat that many people put into coffee-based beverages.\nI grant you that pretty much none of the research I\u2019m citing above contains randomized controlled trials.\nI can\u2019t think of any other product that has this much positive epidemiologic evidence going for it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story warns that adding sugar and fat to coffee may negate any potential health benefits. The story also mentions \u201cjitteriness\u201d and the fact pregnant women should limit consumption, but doesn\u2019t describe the potential harms of excess caffeine in pregnancy that have been well described in the literature. And there are a number of studies suggesting that caffeine seems to trigger symptoms in people with anxiety disorders. More generally, what about the research on the ill effects of coffee on insomnia,\u00a0or urinary incontinence.\u00a0or dependence? \u00a0What about withdrawal headaches and the problems of \u201cstopping\u201d coffee drinking? \u00a0We\u2019ll give the benefit of the doubt here as we usually do on borderline calls, but the exploration of harms was not nearly as thorough as the coverage of benefits.", "answer": 1}, {"article": "Iowa Democrats may have saved the caucuses\n\nIf the proposed Democratic plan is adopted, the Iowa Democratic caucuses will be both familiar and new and may well endure as first in the nation.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No mention of harms. ", "answer": 0}, {"article": "He was not involved in the study.\n\u201cOur trial took a very commonly used multivitamin that has basically low levels of all the different essential vitamins and minerals.\u201d\n\nThe findings suggest that the biggest health benefit may come from a broad combination of dietary supplements, he said.\n\u201cThere have been some other trials that have tested combinations, often at high doses, of certain vitamins and minerals,\u201d said Dr. Howard Sesso, one of the study\u2019s authors and an associate epidemiologist at Brigham and Women\u2019s Hospital in Boston.\n\u201cThis is indeed a landmark study,\u201d said Cory Abate-Shen, a professor of urological oncology at Columbia University Medical Center who was not involved in the trial.\nResearchers said they planned to continue to follow the study group to monitor the effect of vitamin intake over time, and said additional studies would be needed to see if there were similar benefits for women or younger men.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story said that taking a multivitamin \u201cappears to have no dangerous side-effects,\u201d\u00a0which we\u2019ll call good enough for a satisfactory. In addition, it describes the results of previous studies that have suggested harm from other vitamin formulations. However, it didn\u2019t emphasize that the study was conducted in relatively healthy non-smoking\u00a0men, and that\u00a0certain vitamins may cause problems for people who\u00a0smoke or who are taking medications. The AP explained this nuance.", "answer": 1}, {"article": "Like rheumatoid arthritis, osteoarthritis is a chronic, degenerative joint disease.\nStudy researcher Gabriel Chodick, MD, called the risk reduction \"important and meaningful,\" but he says more research is needed to confirm the association.\nThe study appears in the September issue of the journal PLoS Medicine.\n\"But one important message is that people who have been prescribed them should adhere to treatment.\n\"It would certainly be premature to suggest taking statins to prevent rheumatoid arthritis ,\" he tells WebMD.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nEven though the authors of the research study commented on the risks of statin use in order to place this potential additional use into context, this story failed to include any mention of the potential harms.", "answer": 0}, {"article": "The other is that, for tens of thousands of years, parasites and other infections unusual in modern society were a major problem in humans. The body developed a defense mechanism - inflammation - to fight them. Now, there aren't as many of these infectious diseases for our bodies to deal with, but we still have this defense mechanism. It has begun to target other things, such as allergens in the environment. Immunotherapy helps teach the body to better tolerate these harmless parts of our environment.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article duly notes the most common side effect of the newer sublingual drops treatment and the rare risk of serious side effects from allergy shots. The article could have been strengthened by including information on the side effects of OTC and prescription drug treatments.", "answer": 1}, {"article": "Computed tomography coronary angiography (CTCA), is a high-resolution X-ray of the heart that can be used to diagnose the reason for angina, or chest pain, symptoms and clarify what other treatments might be needed.\nIf a doctor is faced with a patient who is already on an aspirin and statin with an unconfirmed and questionable clinical diagnosis of angina due to coronary heart disease, he said, then CTCA would be useful because finding normal heart anatomy means that more invasive testing can be avoided, treatment could be stopped and quality of life improved.\nThis reflects the fact that the cause of the symptoms had been unknown before and in addition they now have heart artery disease that needs treatment, Newby said.\nWhen the CTCA results revealed something less than a blockage, so-called nonobstructive disease, as the cause for the patient\u2019s chest pain, patients\u2019 quality of life got worse in the following weeks and months.\n\u201cIn my opinion, CTCA does have added value in the diagnostic process (improved decision making), it is less invasive than coronary angiography (CAG), and can provide more clarity in the cardiac symptoms experienced by patients,\u201d Mommersteeg concluded.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story includes a cautionary quote about the type of patient who might end up feeling worse after CTCA testing. The story would have been better if it noted that this type of scan can inadvertently find suspicious shadows, especially in the lungs, which may then lead the patient into further, possibly invasive, testing. The story could have also included some reference to concern about harms from X-ray radiation.", "answer": 0}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nResearchers stress the findings are preliminary and that men with the cancer should not reach for the aspirin bottle in an attempt to improve their health.\nAspirin and other anticlotting medications carry risks of their own, chiefly bleeding, Zietman says.\nHowever, they need to be confirmed, and the optimal dose, timing, and duration of use needs to be worked out, he says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story mentions that the drugs carry risks, including bleeding. However, the story should have been clear that such bleeding can be lethal in some cases and that these drugs also raise the risk of prostate cancer patients suffering complications during treatments.\u00a0", "answer": 0}, {"article": "\"We should offer all women the possibility of a cure.\"\nUp to half of women with advanced-stage ovarian cancer might be cured, compared to the current 20 per cent survival rate, argues Dr. Steven Narod, senior scientist at Women's College Research Institute, who calls for a new standard of treatment for women with late-stage ovarian cancer.\nDr. Narod, who is also a Tier 1 Canada Research Chair in Breast Cancer, recommends that doctors should consider adopting a standard model of care for all women diagnosed with advanced-stage ovarian cancer:\n\u2022 Chemotherapy should be offered after the surgery, rather than before.\nThe possibility of a 50 per cent cure rate would be a significant improvement over the current 20 per cent survival rate resulting from more conventional treatment options offered to patients, which consist of a combination of different methods including: chemotherapy before surgery; post-operative chemotherapy delivered intravenously to the whole body (as opposed to localized into the abdomen); and surgery that leaves minimal residual disease in the abdomen, rather than removing all visible cancer cells.\nChemotherapy before surgery might provide a false assurance that there's no more residual cancer, whereas microscopic tumour may remain after the surgery, leading to cancer recurrence and possibly, death.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms. For example, there is no discussion of the risks associated with aggressive surgery to remove ovarian cancer tumors. As the Mayo Clinic notes on its site, ovarian cancer surgery \u201cgenerally involves removing both ovaries, the fallopian tubes, the uterus as well as nearby lymph nodes and a fold of fatty abdominal tissue (omentum) where ovarian cancer often spreads.\u201d All surgery poses some risk, and this surgery is extensive. Chemotherapy also poses risk. In addition, the release stresses a specific order in which treatment should be given. It states \u201cwomen should be first treated with aggressive surgery to remove all clinically-detectable cancer cells, followed by targeted chemotherapy to the abdomen (intraperitoneal chemotherapy).\u201d While the surgery first technique may well have greater chances of survival, reducing tumor bulk with chemotherapy first reduces the peri-operative complications. This trade-off is not discussed.\nWhen a news release is explicitly advocating for a very specific standard of treatment, it\u2019s important to articulate the risks as well as the potential benefits, so that healthcare providers and patients can make informed decisions.", "answer": 0}, {"article": "\u201cThe acupuncture protocol we have tested appears effective,\u201d lead researcher Dr. Rachel Manber, of Stanford University in California, told Reuters Health in an email.\nAnother 49 women received control acupuncture and 49 received massage.\nAntidepressant medications are one treatment option, but there are safety concerns.\nAll completed a standard measure of depression severity at the outset and again after four and eight weeks of treatment.\nSSRIs include drugs like sertraline (Zoloft), paroxetine\n\nBecause of the potential for harm from medications, many pregnant women with depression may prefer psychotherapy or other non-drug options.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Furthermore, a study from the University of Rochester, published in March in Environmental Health Perspectives, found that men with shorter anogenital spans had lower sperm counts, poorer quality sperm, lower sperm concentrations and lower motility.\nBut one urologist said the the finding is too preliminary to introduce into clinical practice, however.\nOne expert who's done her own research in this area applauded the study.\n\"Together the two studies make a strong case that this simple measure (the anogenital distance) reflects early genital development and predicts semen quality and fertility,\" she said.\nWEDNESDAY, May 11, 2011 (HealthDay News) -- It may be possible to assess a man's fertility by checking his \"anogenital distance,\" the gap between his scrotum and anus, a new study suggests.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\u00a0 But this story promotes a \u201csimple\u2026noninvasive way to test testicular function and reproductive potential in adult men.\u201d\u00a0 So presumably one would act on the basis of what this simple test shows.\u00a0 That opens questions about the sensitivity and specificity of this approach \u2013 neither of which are addressed and both of which raise issues of potential harm, overtesting and overtreatment for the man.\nMaybe not so \u201csimple\u201d as described.", "answer": 0}, {"article": "\"That's about 20 pounds,\" Smith said.\n\"Among those who remained, lorcaserin produced relatively modest weight loss when combined with diet and exercise counseling, and that weight loss was maintained in over half of the participants only so long as they kept taking the drug.\n\"In this long-term study of lorcaserin for treating patients for obesity, there was good weight loss, outstanding safety profile and the drug was extremely well-tolerated,\" said lead researcher Dr. Steven Smith from the Translational Research Institute for Metabolism and Diabetes in Winter Park, Fla.\n\n\"As patients are looking for additional options and physicians are looking for new tools, [lorcaserin] provides us with a look into the future for what's going to be available for helping patients lose weight,\" he added.\nFDA briefing documents posted online Tuesday acknowledged Qnexa's effectiveness in helping patients lose weight, but said the review panel should take into account a number of potential nervous system and psychiatric side effects, the Associated Press reported.\nA potential player in fighting the obesity epidemic, lorcaserin is a new type of weight-loss drug that works by acting on serotonin, a chemical associated with feelings of well-being and feeling full, and does not appear to increase blood pressure or cause any other heart problems, according to the researchers, whose work was sponsored by the drug manufacturer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mixed bag \u2013 but we\u2019ll give this a barely satisfactory score. This story is the only one of the three that we reviewed on this study that buries the fen-phen connection. And none of them take the time to spell out how much damage fen-phen really caused. As with the other stories, it breezes past any side effects or other long-term problems by saying, \"(the) team noted that for those taking lorcaserin, there was no increase in heart valve problems as had been seen with the discredited diet drug Fen-Phen. However, common side effects included headache, dizziness and nausea.\" Although, unlike the other stories, it points out about a competing drug, \"FDA briefing documents posted online Tuesday acknowledged Qnexa\u2019s effectiveness in helping patients lose weight, but said the review panel should take into account a number of potential nervous system and psychiatric side effects, the Associated Press reported.\" \nBut, again, connected with our \"Evidence\" criterion comments above, was the study rigorous enough to answer tough questions about safety? We wish the story had explored this more deeply. Can we be sure this drug is safe, since so many prior weight loss drugs fell down on this point?", "answer": 1}, {"article": "A healthy cholesterol level is less than 200 mg/dL, according to the American Heart Association, while 200 to 239 mg/dL is considered \u201cborderline high.\u201d\n\nIn the groups taking 100 and 200 micrograms of selenium daily, total cholesterol dropped an average of 8.5 mg/dL and 9.7 mg/dL, respectively, compared to the group taking a placebo pill.\nWhile Guallar said the results are \u201cgood news\u201d in showing that high selenium intake is probably not a risk for high cholesterol, he wanted to add a note of caution.\nLast week, a review of prior studies suggested that selenium probably doesn\u2019t help prevent cancer, but might be linked to an increased diabetes risk at high doses (see Reuters Health story of May 11, 2011.)\nStill, the finding is \u201creassuring\u201d because previous research had linked high selenium with higher cholesterol levels, said study author Dr. Eliseo Guallar, from the Johns Hopkins Bloomberg School of Public Health in Baltimore.\nThe authors reported no serious side effects associated with selenium during the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that high levels of selenium have been linked with\u00a0increased risk of type 2 diabetes. It notes that no serious side effects were reported with selenium use in this particular study, but it\u00a0should have qualified this by mentioning the relatively short duration of the study (6 months) and the potential for problems with longer-term use. It might also have noted that selenium supplements have the potential to cause a rare syndrome called selenosis when taken at very high doses.", "answer": 1}, {"article": "The item you've requested, /cgi-bin/article.cgi?f=/n/a/2006/01/17/national/a130050S19.DTL&type=health, was not found.\n\u2022 the item no longer exists, or\n\u2022 there has been an error on the site.\n\nIf you feel the address you entered is correct you can contact us, mentioning the error message received and the item you were trying to reach.\n\nWe apologize for any inconvenience. From here, you can:\n\u2022 use the menu bar above\n\u2022 select an item from our site index below", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\nmentions harms and the frequency of surgical complications in this study, however, the discussion is limited when compared to\nthe discussion of untreated hernias. Does not mention the harm that a hernia can recur even with the surgery (1.4% in this\nstudy.) The most significant harm reported may be the one case of nerve injury, which was not mentioned in the story. While\nthe story states 20% had complications, three of them life-threatening, readers could have used more detail.", "answer": 0}, {"article": "Post-traumatic stress disorder (PTSD) is a term for a broad range of psychological symptoms that can develop after someone experiences or witnesses a traumatic event.\nPTSD is caused by an overactive fear memory, and the new research shows that doxycycline can reduce the fear memory response in healthy volunteers.\nThis is called 'reconsolidation', and we now plan to test the effect of doxycycline on reconsolidation of fear memories.\nThe study, published in Molecular Psychiatry, was a pre-registered, placebo-controlled, double-blind randomised controlled trial in 76 healthy volunteers.\nMatrix enzymes are found throughout the body, and their over-activity is involved in certain immune diseases and cancers.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "One of the investigators is quoted acknowledging the challenges inherent in using drugs like doxycycline to prevent PTSD, but there is no mention in the release about the many serious adverse side effects and drug interactions that come with the use of tetracycline antibiotics.\nDoxycycline has been tried\u00a0long-term for aortic aneurysms (as a matrix metalloproteinase or MMP inhibitor, the same reason it was tried here)\u00a0and as an antibiotic for acne, recurrent urinary infections and other conditions. Although generally considered safe to use, over a long term it can cause allergic rashes, antibiotic resistance, changes in friendly gut bacteria,\u00a0possible weight gain and other problems.", "answer": 0}, {"article": "The Ache: Common cholesterol-lowering drugs called statins can have unpleasant side effects, including muscle aches and weakness.\n\nThe Claim: An extract from a bitter, fragrant citrus fruit called bergamot, commonly known as a flavoring in Earl Grey tea, can lower cholesterol with minimal side effects, some scientists say. It also boosts good cholesterol, reduces fatty deposits in the liver and lowers blood sugar, they add.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story noted that mild heartburn was the only side effect seen in the study, and that larger long-term studies are needed to establish safety. \u201cI would tell a patient the caveat is, \u2018If you want to try it, you need to be aware that we don\u2019t really know its side effects,'\u201d a researcher says.\nWe\u2019d also add that the herbal supplement industry is not regulated or controlled in the same way as the pharmaceutical industry, i.e. there are fewer restrictions and enforcement, so relying on supplements to treat a condition can pose additional risks from potentially poor-quality or contaminated products.", "answer": 1}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nIn a study published in The Lancet on Thursday, researchers found that a class of inexpensive, existing generic called aromatase inhibitors, which suppress hormones, reduce recurrence rates by 30 percent as compared with tamoxifen.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nResearchers at Sheffield University found that in postmenopausal women during the first 10 years after diagnosis of breast cancer, the drug could reduce the risk of death by 18 per cent.\nUsing the two drugs together as a one-two punch may be even more powerful.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t really addressed in this report, except for the last sentence, which states the \u201cmain side effect of aromatase inhibitors is an increase in bone loss and fractures.\u201d\nBut aromatase inhibitors also carry the risk of exacerbating menopausal symptoms (including sexual side effects and sleep problems) and of serious muscle and joint pain, which has caused some women to stop taking the drug in the past.\nBisphosphonates long term can cause bone fractures (paradoxical \u2013 they build bone but not always normal bone) and rarely can cause jaw osteonecrosis (\u201cbone death\u201d). This is more common after dental work, but can also happen sporadically and is devastating.\nSince these details are missing in the report, we give it a \u201cNot Satisfactory\u201d rating here.", "answer": 0}, {"article": "\u201cWe\u2019ll also advance key parts of our tobacco plan very soon,\u201d he said.\n\u201cThere is no other single action our country can take that would prevent more young people from smoking or save more lives,\u201d said Matthew L. Myers, president of Campaign for Tobacco-Free Kids.\nThe FDA will seek public input and scientific research on the role that flavors such as menthol play in tobacco addiction, and for the regulation of premium cigars, Gottlieb said.\nThe FDA is seeking additional research and data for public review, Gottlieb said, as it tries to develop a nicotine product standard.\nThe comment period will be open through mid-June, said Mitch Zeller, director of FDA\u2019s Center for Tobacco Products.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did not mention possible harms of introducing low-nicotine cigarettes, namely that it might encourage current smokers to smoke more to get their usual dose or make people think the cigarettes aren\u2019t as harmful, so they aren\u2019t as cautious about intake. In that scenario, smokers would be inhaling more of the toxic smoke that causes damage to the lungs. We think it\u2019s important to share with readers if researchers have looked into this, and if it\u2019s indeed a concern, as NPR did.", "answer": 0}, {"article": "RA Nash et al.\nThe treatment carries some risks, and many participants experienced the expected side effects of HDIT/HCT, such as infections.\nFive years after receiving the treatment, called high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT), 69 percent of trial participants had survived without experiencing progression of disability, relapse of MS symptoms or new brain lesions.\n\u201cIf these findings are confirmed in larger studies, HDIT/HCT may become a potential therapeutic option for patients with active relapsing-remitting MS, particularly those who do not respond to existing therapies,\u201d said Daniel Rotrosen, M.D., director of NIAID\u2019s Division of Allergy, Immunology and Transplantation.\nThree participants died during the study; none of the deaths were related to the study treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does the bare minimum here, stating:\n\u201cThe treatment carries some risks, and many participants experienced the expected side effects of HDIT/HCT, such as infections. Three participants died during the study; none of the deaths were related to the study treatment.\u201d\nStill, we think more could have been said about the side effects of chemotherapy. For example, How many patients experienced them and how bad were they? And the news release does not say how long treatment and recovery takes. The process by which the deaths were categorized is not given and leads to uncertainty about whether these patients may\u00a0have died as a result of the immuno-suppression of their bone marrow.", "answer": 1}, {"article": "[3] Quote direct from author and cannot be found in text of Article.\nThe study, published in The Lancet, also found that grip strength is a stronger predictor of death than systolic blood pressure, and the authors suggest that it could be used as a quick, low-cost screening tool by doctors or other healthcare professionals to identify high-risk patients among people who develop major illnesses such as heart failure and stroke.\nThese associations persisted even after taking into account differences in other factors that can affect mortality or heart disease such as age, education level, employment status, physical activity level, and tobacco and alcohol use.\nThe current study followed 139691 adults aged between 35 and 70 years living in 17 countries from The Prospective Urban-Rural Epidemiology (PURE) study for an average (median) of four years.\nBut until now, information on the prognostic value of grip strength was limited, and mainly obtained from select high-income countries.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As mentioned in the section on benefits, the release does not explain how the test results might be used. If the intent is to steer people identified as being at higher risk toward more testing or treatment, then the release should have mentioned the risk of doing more harm through overtreatment.\u00a0", "answer": 0}, {"article": "A study of a proposed diabetes drug, Januvia, from Merck & Co. showed it lowered a key measure of blood sugar when taken in combination with another common diabetes drug.\n\nThe study, due to be presented Thursday at the European Association for the Study of Diabetes in Copenhagen, involved 1,056 patients diagnosed with Type 2 diabetes who hadn't previously been treated with diabetes medications.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story describes a serious side effect of low blood sugar and tells readers that the number of low blood sugar episodes with the new drug is lower than that for older drugs. Yet, this could be a serious complication and the actual rate of this complication is not reported. The story does describe actual rates of some side effects for the new drug when combined with an existing drug (metformin). These included diarrhea (10% of participants) and nausea (8% of participants). The story describes sore throat, headache, and runny nose as \u201cless common,\u201d with no quantification. Yet the story does not mention side effects for the new drug individually, so readers don\u2019t know whether these side effects reported may be related to the existing drug metformin. The story also claims that there appear to be no big safety problems, which is probably a premature statement given the relatively long lag time often needed to see safety problems. ", "answer": 0}, {"article": "Master said each participant was asked to carry an accelerometer to record movements and an iPod Touch loaded with an app that would ping them prompts at intervals during each day to report any symptoms they were feeling. They also completed activity questionnaires and summaries. In addition, they wore a device called an ActiGraph to monitor sleep.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story mentions the heightened risk of further damage from activity in the days and weeks after a concussion, and the unknowns/uncertainties of this risk.", "answer": 1}, {"article": "The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center -- which are recognized as one of the nation's top \"Honor Roll\" hospitals by U.S. News & World Report -- Chester County Hospital; Lancaster General Health; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751.\n\"Having dense breast tissue makes it more difficult to detect a cancer on a mammogram,\" said the study's lead author, Susan Weinstein, MD, an associate professor of Radiology and the director of breast MRI at Penn Medicine.\nHowever, screening ultrasound examinations have higher rates of false positives, meaning more cases of positive screenings where no cancer is present.\n\"Based on the literature and our results, women with dense breast tissue who desire supplemental screening, these results suggest that AB-MR may be a better option than other supplemental screening tests such as whole breast ultrasound.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the study authors mentioned that whole breast screening ultrasound produces high rates of false positives, there was no information provided about the rate of false positives for the abbreviated breast MRI.", "answer": 0}, {"article": "The results were striking.\nRather than proving that acupuncture does not work, in other words, the study may suggest that it works even when administered poorly.\nThe results came out with no difference between the groups.\u201d\n\nThe MD Anderson research and other recent acupuncture studies have fueled speculation that the prick of a needle, whether from real acupuncture or a sham version, can influence the way the body processes and transmits pain signals.\nResearchers from MD Anderson Cancer Center in Houston found that among 455 patients with painful knee arthritis, acupuncture delivered no more relief than a sham treatment.\nStill another study, this one financed by the National Institutes of Health and published in 2004, found that acupuncture significantly reduced pain and improved function in knee arthritis patients compared with a sham treatment or routine knee care.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "      \n\n\n \n\n \nThe article didn\u2019t discuss or quantify potential harms associated with acupuncture. However, potential adverse effects would not likely serve as an obstacle to wider utilization of this treatment. When performed with sterile disposable needles by competent practitioners, acupuncture appears to be a relatively safe treatment approach.\n ", "answer": 0}, {"article": ".\nNAC is available over the counter and does not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician's supervision.\nAlthough these early, promising findings show that NAC reduced PTSD symptoms, craving, and depression, NAC should not be used as a monotherapy or substitute for evidence-based behavioral treatment, but instead be seen as an adjunct therapy that enhances it.\nIn the eight-week randomized controlled trial led by Back and Kalivas, 35 veterans with PTSD and SUD, all of whom were receiving cognitive behavioral therapy (CBT) for their SUD, were randomized to either 2400 mg/day of NAC or placebo.\nAlthough selective serotonin reuptake inhibitors have been approved by the FDA for treatment of PTSD, pharmacological treatments for co-occurring PTSD/SUD have yielded suboptimal results.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release explains that the drug used \u201cdoes not cause side effects at the doses used in the study, but it degrades quickly when stored, is contraindicated in patients with asthma, and can cause nausea at higher doses and so should always be obtained and administered under a physician\u2019s supervision.\u201d However, the published study notes a higher incidence of adverse events in the N-acetylcysteine treated group that in those treated with placebo (66.7% vs. 47.1%). N-acetylcysteine can cause \u201cnausea, vomiting, and diarrhea or constipation. Rarely, it can cause rashes, fever, headache, drowsiness, low blood pressure, and liver problems,\u201d according to WebMD.", "answer": 0}, {"article": "\u201cTo me, the take-home message is that we don\u2019t have a perfect test, unfortunately,\u201d Dr. Paik said.\nShe said the findings raised questions of whether women who were Her2-negative should be tested again.\nDr. Soonmyung Paik, who presented the second study at the cancer conference, said the problem might lie not in sloppy testing but rather in the cutoff used to determine which women get Herceptin.\nDr. Paik, who is with the National Surgical Adjuvant Breast and Bowel Project, said that about 40 percent of women had intermediate levels of Her2.\nSome experts were skeptical, saying the number of patients in the two studies was too small to draw firm conclusions.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harms of treatment (i.e. slight increased risk of heart failure in some women).\u00a0 The story also mentions that even women diagnosed as positive are not guaranteed benefit from the drug.", "answer": 1}, {"article": "The research is published in the journal Nature Biotechnology.\nWhat remains to be seen is whether the researchers have picked the right proteins that might turn off the disease in humans, he says.\nWhen researchers attach specific proteins to the particles, they say they're able to teach the body not to attack its own tissues.\n\u201cThis technology could be very effective,\u201d says Timothy Coetzee, PhD, chief research officer for the National Multiple Sclerosis Society.\nIf the approach succeeds in human studies, it may one day lead to more targeted treatments not only for multiple sclerosis but also for other kinds of autoimmune disorders, including type 1 diabetes and rheumatoid arthritis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unfortunately, the story bounces from an older approach, using white blood cells, to the use of microparticles.\u00a0 So, it is easy to get the wrong impression of results.\u00a0 Harms were not addressed in the results of the study using microparticles.\u00a0 Dr. Miller\u2019s quote, \u201c\u201dThere [were no side effects], there was no re-triggering of disease, and we actually showed that immune responses in patients were decreased,\u201d were related to the ongoing and unpublished study using white cells as carriers.", "answer": 0}, {"article": "Another sensor, just approved by the F.D.A.\nLike the pump, the sensor requires injecting a tiny catheter (less than an inch long) into the midsection of the body, and changing it every three days to avoid infection.\nThe sensor doesn\u2019t control the pump but allows a diabetic to make quicker, presumably better decisions.\nEven with the help of an expert trainer from MiniMed, I found that injecting the catheter took much more dexterity than injecting one for a pump.\nSo imagine my enthusiasm when I learned last fall that the Food and Drug Administration had finally approved the first implantable sensor to continuously measure glucose, beeping or vibrating a warning whenever levels head too high or too low.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Through one man\u2019s story-telling, harms are described and included malfunctions with the machine leading to recalibration or inserting new catheters, trouble relying on machine recommendations for insulin dosages, potential for infection at the injection site, and inconvenience of being awakened or disturbed by the beeping or buzzing alarm. Of course, it\u2019s not clear whether these are the only harms, but they seem reasonable. The story could be improved by reporting on actual harms reported in clinical trials. ", "answer": 1}, {"article": "\"Nothing happens,\" he told Stahl.\nKanzius thought he had discovered a way to attack cancer cells without the collateral damage caused by standard treatments like chemotherapy and radiation.\nSo he wondered: if he injected a cancerous tumor with some kind of metal, would radio waves heat up the metal and cook the cancer cells to death, and only the cancer cells?\nDr. Curley thought there was so much promise in Kanzius' invention, he began conducting his own research with the machine, using tiny bits of gold nano-particles that are so small, thousands of them can be injected into a single cancer cell.\nIt was that relentlessness of leukemia that had given Kanzius the idea to build his radio wave machine in the first place.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n \nThe underlying premise of this device is that it cooks cancer cells by heating metallic nanoparticles. If the nanoparticles used in this approach collect in normal tissue, those tissues could also be cooked by the radio waves.\n The researchers wrote in an article in the journal Cancer in 2007 that while rabbits in their tests did not appear to suffer any irreversible toxic effects, the safety of this approach in humans \u201ccannot be assumed.\u201d The portrayal of this experimental device as lacking potential harms is inaccurate.", "answer": 0}, {"article": "Jay Konduros used to rush home several times a year after accidentally cutting or bumping himself.\nStill, he noted, the study has some limitations.\nOther experts also were impressed by the results.\nThe treatment also \u201cnearly universally eliminated\u201d the need for preventive infusions of clotting factor a few times a week, the scientists said.\n\u201cOne of the key things is, how long will the treatment last?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does not address harms directly\u2013and should have\u2013it does note that one of the worrying side effects of gene therapy\u2014spurring the body to attack itself\u2014was not present in this study.", "answer": 0}, {"article": "We need to be proactive in our approach.\"\nWhile dislocations only occur in about 1 percent of patients after hip replacement, certain individuals may be at a higher risk.\nHowever, no guidelines currently exist to aid clinicians in deciding when to use these more flexible implants, which are often more expensive than conventional implants, may not be medically necessary, and may carry added risks if implanted unnecessarily.\nSome newer hip implants are designed with dual mobility cups that allow for increased range of motion, which helps reduce dislocation risk.\nThis led researchers to further develop a risk prediction tool to better identify which patients undergoing a hip replacement may be at higher risk for dislocation, and then implement a treatment algorithm to help reduce that risk.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not mention any risks associated with hip replacement surgery in general, nor does it address potential harms specific to dual mobility cups, which are described in the release as the recommended approach to reduce risk for dislocations. The release notes that dual mobility cups may carry risks \u201cif implanted unnecessarily\u201d but doesn\u2019t describe or quantify those risks. Of note, there is some concern that this type of replacement joint may release higher levels of metal ions than conventional joints when implanted in younger, more active patients.\nAs presented, the only downside of these newer devices are the increased cost. It would be helpful to know if there are any other risks. Newer devices may have some risk simply due to not having long-term experience with them. Current hip replacement devices have been shown to work for 20+ years. It will take considerable time to know whether the same may hold for these newer devices.", "answer": 0}, {"article": "Botox is now being used by men, some of whom did not even run for President. The number of men in the U.S. who paid to get a series of tiny injections in their face nearly tripled from 2001 to 2007--to 300,000, or about 7% of the total Botoxed population. And despite the recession, those numbers aren't going down yet; one of the many things the laid-off cannot afford is to look their age.\n\nMen usually get Botox to remove those two vertical lines between their eyebrows that make them look angry and confused and thus, one could argue, masculine. They...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention the potential harms of Botox treatment, which include a droopy eyelid, muscle weakness, headache, headache, respiratory infection, flu-like symtoms and redness and pain at the injection sites.\u00a0 \nThe risk of these side effects may be reduced if the treatment is provided by a licensed dermatologist. This should have been stated.\u00a0 ", "answer": 0}, {"article": "An experimental drug has proved effective at treating an aggressive form of breast cancer in patients who aren't responding to the widely used drug Herceptin, giving hope to women with otherwise limited treatment options, said drug maker GlaxoSmithKline PLC, presenting the results Saturday at the American Society of Clinical Oncology meeting in Atlanta.\n\nWhen taken with a standard chemotherapy treatment in a clinical study, the new drug, Tykerb nearly doubled the time to 8.5 months before the average patient's breast cancer...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Cardiac side effects are reported as less serious than those seen in patients who were treated with Herceptin and chemotherapy. However, this comparison with Herceptin is not a fair one. In trials of Herceptin, the incidence of cardiac problems was about 4% at 3 years, so the reduction to 2.5% with lapatinib appears to be an improvement, but there is not enough information in this story on length of time patients took lapatinib and Herceptin to get those figures (and whether those are statistically different). Although long-term cardiac problems are less of an issue for metastatic patients, this side effect is potentially a big issue for early-stage breast cancer patients \u2013 a group of women for which this drug is already being tested as an alternative to Herceptin. ", "answer": 0}, {"article": "Joslin has one of the largest diabetes training programs in the world, educating 150 M.D.\n\u201cThis was a clear benefit associated with the anti-VEGF medication,\u201d said Dr. Sun, who as the DRCR.net nationwide Protocol Working Investigator was instrumental in the study\u2019s development.\nA separate clinical trial, now getting underway, will examine whether anti-VEGF injections given at an earlier stage of diabetic eye disease can help prevent people from developing both DME and the sight-threatening PDR stage of the disease at all, Dr. Aiello said.\nSlightly more than half (53 percent) of eyes in the laser group received Lucentis injections to treat DME.\nThe trial results \u201cprovide crucial evidence for a safe and effective alternative to laser therapy against PDR,\u201d said NEI Director Paul A. Sieving, M.D., Ph.D.\n\n\u201cPatients who received Lucentis showed a little bit better central vision, much less loss of their side vision, and substantially less risk for surgery than patients who received laser treatment,\u201d said Lloyd Paul Aiello, M.D., Ph.D., director of the Beetham Eye Institute at Joslin Diabetes Center and Professor of Ophthalmology at Harvard Medical School.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions that one study volunteer in the Lucentis group developed an eye infection and stated that \u201cserious systemic adverse events,\u201d namely cardiac arrest and stroke, occurred at similar rates among the two groups undergoing the two different procedures. We\u2019ll rate that satisfactory for the disclosure although the release might have gone even further by mentioning the other side effects named in the study including inflammation and elevated intraocular pressure which occurred in both treatment groups.", "answer": 1}, {"article": "But, that's an entirely different problem, compared with atrial fibrillation,\" he said.\nWith apixaban, patients can use a standard dose that doesn't need monitoring and adjusting, Ansell said.\nThe study was funded by Bristol-Myers Squibb and Pfizer, the makers of apixaban.\nAlso, unlike warfarin, apixaban has few interactions with other drugs or foods, he added.\nFor the trial, more than 18,000 patients with atrial fibrillation and a heightened risk for stroke were randomly assigned to receive either apixaban or warfarin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provided good insight about possible problems associated with apixabane in patients with coronary artery disease who were simultaneously taking two blood thinners in addition to apixabane.", "answer": 1}, {"article": "Atrial fibrillation (also called AFib or AF) is a quivering or irregular heartbeat (arrhythmia) that can lead to blood clots, stroke, heart failure and other heart-related complications.\nBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\nThe results must be replicated in larger studies before Botox injections are routinely used to prevent AF after bypass surgery, researchers said.\nTo avoid bias, neither patients nor doctors knew whether the injections contained Botox or saline.\n\"Atrial fibrillation is also always associated with lengthened hospitalization and that means increased healthcare costs.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The story appropriately points out that there were no additional harms seen in the group injected with the botulinum toxin compared to those who received saline other than those associated with the surgery.\n\u201cNo complications from the Botox injections were reported,\u201d according to the release. \u201cBut complications from the bypass surgery were similar in both groups, including time in intensive care and on a breathing machine, and infection rate.\u201d", "answer": 1}, {"article": "Doctors diagnose Alzheimer\u2019s by excluding other causes of memory loss, such as stroke, tumors and heavy drinking.\n[ID:nN13273900] These proposed rules included measurements of cerebral-spinal fluid.\nAnd they may also help identify early signs of the disease in healthy people, the team reported in the Archives of Neurology.\nThey can also administer simple paper-and-pencil tests.\nWhen they looked to see how accurate these signatures were at spotting the disease, they found 90 percent of those with Alzheimer\u2019s had the disease pattern in their spinal fluid.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\nThe story does not mention any potential harms of either the spinal tap procedure itself or from the interpretation of the test results. The spinal tap harms include pain and bleeding. The harms of the test could include insurance or employment discrimination, as well as the consequences of mistaken diagnoses.", "answer": 0}, {"article": "Heart disease is still the leading killer of Americans \u2014 790,000 people have heart attacks each year \u2014 and stenting is a mainstay treatment in virtually every hospital.\nOther estimates are far higher.\nThe devices are lifesaving when used to open arteries in patients in the throes of a heart attack.\nSometimes patients get stents when they have no pain at all, just blockages.\nTheir study focused on the insertion of stents, tiny wire cages, to open blocked arteries.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story briefly mentions there are potential harms, including death.", "answer": 1}, {"article": "\"There were times when I would yell at myself: 'I can't do this.\nIt is hard to know who will be able to improve reading skills over time, and how much extra help is necessary.\nRebecca Branstetter, psychologist who blogs at Notes from the School Psychologist, says this dyslexia brain scan could provide useful information, but it doesn't highlight environmental factors -- such as the quality of instruction in the child's classroom -- that could contribute to reading problems.\nHere's another insight about dyslexia: men with the condition may have enhanced visual-spatial abilities, according to a study in the journal Learning and Individual Differences.\nBecause of this, Weiner said, three-dimensional letters and numbers, perhaps made out of plastic or clay, help a dyslexic child grasp the shapes better.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nMRI brain scans are generally considered to present little physical risk, so the issue here is really the potential negative effects of the information the test produces. At least the story raises that issue by including comments from parents who worry that this sort of scanning could further stigmatize children who have trouble reading or writing. ", "answer": 1}, {"article": "And exercise does seem to be protective -- even if you don't lose all the weight, it absolutely has beneficial effects,\" she said.\nThe study speaks both to the benefits of bariatric surgery and to the tremendous toll obesity takes on health.\nOther effects included improving patients' physical quality of life, improving their insulin levels and ability to use glucose - which may reduce their risk for diabetes - and even altering the composition of their gut bacteria.\nTen percent of study participants who had not had a hysterectomy showed precancerous changes in the lining of the uterus, and all of those resolved with weight loss.\nWhile the study speaks to the transformative effect bariatric surgery can have, Modesitt urged people to avoid gaining weight in the first place and for those seeking to lose weight to exercise and eat more healthily before turning to surgery.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms or risks in the release. Bariatric surgery has many well-documented short- and longer-term risks.\u00a0According to the Mayo Clinic, risks associated with the procedure may include excessive bleeding, infection, blood clots, and leaks in the gastrointestinal system, to name a few. Long term risks of the procedure include bowel obstruction, vitamin deficiencies and malnutrition, and stomach perforation.", "answer": 0}, {"article": "\u201cIt\u2019s an important part of this challenge,\u201d Frank said.\nThe review also only looked at patients who volunteered to taper off opioids, meaning this research does not prove that involuntarily pulling patients off the drugs will lead to similar outcomes.\nMaybe the opioids themselves caused problems that negatively impacted function or quality of life, \u201csuch as constipation, fatigue, poor sleep, and depressed mood.\u201d It\u2019s possible that opioid dose reduction also resolved what\u2019s known as opioid-induced hyperalgesia, \u201ca paradoxical response in which patients receiving opioids become more sensitive to painful stimuli.\u201d\n\nOr, the researchers suggested, the observational studies simply showed reverse causation \u2014 \u201cthat is, patients successfully tapered opioids because pain severity decreased.\u201d\n\nThe findings do not mean that doctors can now simply yank patients off opioids and expect them to get better.\nCrucially, the studies also looked at what happened when these reductions in opioid doses were paired with alternative treatments, including alternative medicines like acupuncture, interdisciplinary pain programs, and medication-assisted treatment for addiction.\nA new study published in the Annals of Internal Medicine, however, offers a cause for optimism: Reviewing the research so far, it found that it may be possible to reduce doses for patients in long-term opioid therapy and improve their pain outcomes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms are addressed right away: Come off opioids too quickly, and patients can suffer by having little recourse to deal with chronic pain. Some even resort to illicit drugs or commit suicide.\u00a0One of the study\u2019s authors is also quoted as recommending doctors and patients to exercise caution if tapering is being attempted, and another explains that not all patients respond the same way (and do poorly with tapering).", "answer": 1}, {"article": "LONDON (Reuters) - Scientists in Britain have developed a type of HIV test using a USB stick that can give a fast and highly accurate reading of how much virus is in a patient\u2019s blood.\nBut in some cases the drugs stop working - sometimes because virus has developed resistance to them - and the first sign of that would be a rise in a patient\u2019s so-called \u201cviral load\u201d.\n\u201cWe have taken the job done by this equipment, which is the size of a large photocopier, and shrunk it down to a USB chip.\u201d\n\nThe test, which uses a mobile phone chip, requires a drop of blood to be placed onto a spot on the USB stick.\nIt could be particularly useful in remote settings to help HIV patients manage their treatment more effectively, since current tests to detect virus levels take at least three days and involve sending a blood sample to a laboratory.\nAny HIV in the sample triggers an acidity change, which the chip transforms into an electrical signal.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The physical harms are pretty obvious, as the story\u2019s comparison to a diabetes blood sugar test makes clear: Patients need to get a spot of blood onto the sensor. But the more important harm isn\u2019t discussed here, where a simple \u201cthis isn\u2019t ready for the field\u201d statement would have covered. More than 11 in 100 HIV-positive people getting a false-negative test is not very comforting; they could be misled to think their anti-retroviral therapy is still working when it might not be.", "answer": 0}, {"article": "Jan. 25, 2010 -- A low-carbohydrate diet may have health benefits that go beyond weight loss.\nResearchers say studies have already shown that the two weight loss methods are effective at promoting weight loss, but it's the first time the health effects of each have been compared head to head.\n\"It's important to know you can try a diet instead of medication and get the same weight loss results with fewer costs and potentially fewer side effects,\" Yancy says.\nA new study shows that a low-carbohydrate diet was equally good as the weight loss drug orlistat (the active ingredient in Alli and Xenical) at helping overweight and obese people lose weight, but people who followed the low-carb diet also experienced a healthy drop in their blood pressure levels.\n\"If people have high blood pressure and a weight problem, a low-carbohydrate diet might be a better option than a weight loss medication.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Similar to the HealthDay piece, the story provides no information about the potential adverse effects of orlistat or a low-carbohydrate diet.", "answer": 0}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\nPublished online by the New England Journal of Medicine and being presented this week at a Presidential session of the European Cancer Congress (ECC), the findings of CheckMate-025 provide definitive evidence that an immune checkpoint inhibitor is a valid treatment strategy for patients with advanced RCC, and supports a paradigm change in the standard of care treatment, according to the authors.\nBased on the CheckMate-025 findings, earlier this month (September 16) the FDA granted Breakthrough Therapy Designation to nivolumab for the potential indication of metastatic RCC.\nIn addition to demonstrating increased overall survival, the researchers showed a higher objective response rate - the number of patients who respond to the treatment - with nivolumab.\nMore than 12 months later, 31% and 27% of patients treated with nivolumab and everolimus, respectively, continued to show a response.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release says only that there were \u201cfewer treatment-related adverse events, including fatigue and nausea, and improved quality of life with nivolumab.\u201d But that\u2019s not really a satisfactory accounting of the harms of treatment. As the\u00a0article in the NEJM notes, \u201cTreatment related adverse events of any grade occurred in 319 of the 406 patients (79%) treated with nivolumab and in 349 of the 397 (88%) treated with everolimus.\u201d The release should have given readers more insight into what these harms are and how often they occur.", "answer": 0}, {"article": "FDA approves first drug aimed at women with inherited breast cancer\n\nU.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.\n\nThe Food and Drug Administration on Friday approved AstraZeneca PLC\u2019s Lynparza for patients with inherited BRCA gene mutations who have undergone chemotherapy.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states: \u201cPossible side effects are less severe than for chemotherapy, but serious problems can include blood and bone marrow cancers. Common side effects include nausea, fatigue, respiratory infections and blood count problems.\u201d\nAlthough this would be a rare concern, the FDA also says: \u201cLynparza can cause harm to a developing fetus; women should be advised of the potential risk to the fetus and to use effective contraception. Women taking Lynparza should not breastfeed as it could cause harm to a newborn baby.\u201d", "answer": 1}, {"article": "A 2007 study of Chinese women in Shanghai found that middle-aged women who ate large amounts of white rice and other refined carbohydrates were also at increased risk for diabetes compared to their peers who ate less.\nNext time you order takeout wonton soup and a spicy Number 82, you might want to make sure it comes with brown rice.\nA serving is half a cup of cooked rice.\nSuch food studies can be unreliable, since they rely on self-reported surveys.\nThe study, which was published in The Archives of Internal Medicine and used data from two Harvard nurses\u2019 health studies and a separate study of health professionals, isn\u2019t the first to point a finger at foods like white rice as a culprit in Type 2 diabetes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 No harms discussed, but both of these food choices are safe and likely to be well tolerated. ", "answer": 2}, {"article": "A total of 117 clusters (or \"rings\") were identified, each made up of an average of 80 people.\nIn addition to showing high efficacy among those vaccinated, the trial also shows that unvaccinated people in the rings were indirectly protected from Ebola virus through the ring vaccination approach (so-called \"herd immunity\").\nAmong the 5,837 people who received the vaccine, no Ebola cases were recorded 10 days or more after vaccination [3].\nAs part of this agreement, Merck committed to ensure that 300,000 doses of the vaccine are available for emergency use in the interim, and to submit the vaccine for licensure by the end of 2017.\nThe study found that the vaccine was safe and induced an immune response that peaked at 28 days, but decreased during the six months post injection.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release also accurately quantifies the harms associated with this vaccine, noting that more than half of those vaccinated reported mild side effects, including short-term headaches, fatigue and muscle pain. The release also\u00a0identified two serious negative reactions (a high fever and an allergic reaction) associated with the vaccination and a flu-like illness that might have been a result of the vaccine.\u00a0This is a particularly strong point of the release in that many releases on drug/vaccine studies don\u2019t quantify the adverse event rates very clearly or completely.", "answer": 1}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nParticipants in the active arm of the study received 248 milligrams of elemental magnesium per day over six weeks, while those in the control arm received no treatment.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release made no mention of potential harms of magnesium supplements although it notes the treatment is safe on two\u00a0occasions. \u00a0The actual results, however, were not quite as straightforward. The authors noted in the published study, \u201cThe most common reason for a negative response was that \u201cmagnesium did not help mood\u201d (46%), followed by side effects (20%). The most common side effect, diarrhea, was reported by 8 participants. In addition, the published study notes that people with gastrointestinal disorders or\u00a0kidney disease could not participate in the study since high levels of magnesium are not safe for these patients.\u00a0", "answer": 0}, {"article": "Former smokers who had accumulated 30 pack-years were included only if they had stopped smoking within the previous 15 years.\nDr. Otis W. Brawley, chief medical officer of the American Cancer Society, said he was stunned to hear a radio advertisement for an Atlanta screening center cite the study just a few days after the government had announced the results.\nBut now cancer and screening experts are worried that the limited findings will be used by private screening centers to promote the test to a broader group than was studied.\nBut because the study was stopped early, a full analysis of the harms caused by screening scans is still months away.\nIn the study, even experienced radiologists at major cancer centers had a high rate of false positives, suggesting that the rate would be even higher in the real world.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was clear on this:\nIn a rarity for such a story, \u201cdownsides\u201d was even in the headline.\u00a0 The third paragraph read:\u00a0 \u201cBut now cancer and screening experts are worried that the limited findings will be used by private screening centers to promote the test to a broader group than was studied. That, in turn, could lead to thousands of unnecessary lung scans, causing excess radiation exposure and unnecessary biopsies and surgery.\u201d", "answer": 1}, {"article": "The additional benefit in terms of body composition came as a surprise for the research team.\nVitamin D supplementation is routinely recommended for babies until they can get an adequate amount through their diet.\nIn addition, Health Canada advises parents and caregivers to avoid direct sunlight and avoid use of sun block creams in young infants.\nWhile there were no significant differences in body composition across the different dosage groups, the researchers found children who had vitamin D stores above the threshold recommended by the Canadian Paediatric Society (CPS) averaged around 450 grams less body fat at 3 years of age.\nA healthy intake of vitamin D in the first year of life appears to set children up to have more muscle mass and less body fat as toddlers, according to a new study published in the journal Pediatric Obesity.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no warning that in rare cases vitamin D overdoses can cause calcium to rise to harmful levels, which can weaken bones and cause kidney stones and other problems. Some of the reported cases have been linked to manufacturing errors which meant the drops given to children contained far more vitamin D than listed on the label.", "answer": 0}, {"article": "Other possible complications of shingles include pneumonia, hearing problems, blindness and encephalitis.\nHere\u2019s how it compares to its predecessor Zostavax, which over all reduces the risk of shingles by 51 percent and of PHN by 67 percent.\nWhat makes Shingrix so much better is the inclusion of a substance called an adjuvant that boosts the body\u2019s immune response to the vaccine.\nBut for about 15 percent of people, shingles does not end there.\nIt also reduces the risk of PHN by 86 percent, and it appears to be longer lasting than Zostavax, which starts to lose its protection after three years.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The author tells her personal story and a few common harms. She notes that \u201cthe shot itself is painful and can cause a sore arm for a day or two. Some people develop immune-related side effects like headache, fever or an upset stomach that last less than three days, according to the manufacturer, GlaxoSmithKline. My only reaction beyond local soreness was an acid stomach for a day or two.\u201d\nThis is a good start, but the story didn\u2019t recognize that significant adverse effects are actually more common than the benefits, making the story imbalanced.\nThe study shows that the severity of the side effects of the vaccine were much more intense than what the Times implies. In it, 17% of the patients injected with the vaccine, versus 3% on placebo, had \u201cgrade 3\u201d symptoms. These are defined as symptoms that \u201cprevented normal everyday activities.\u201d The absolute rate therefore is 14% or a NNH (number needed to harm) of seven. While the author of the Times story might not have been that sore after the vaccine, according to the data in the trial, for every seven persons injected with the vaccine, one person will have \u201cgrade 3\u201d symptoms and have difficulty functioning in everyday activities.", "answer": 0}, {"article": "\u201cI wouldn\u2019t use the word excited too much,\u201d said Anthony Fauci, director of the NIH\u2019s National Institute of Allergy and Infectious Diseases.\nIn a trial on the RV144, 31 percent of people who got the vaccine did not develop HIV \u2014 too small a number to be useful.\nInterestingly, in the early human study, the immune response was comparable to the rhesus monkey one, which gave the researchers hope that the vaccine might be similarly effective in people.\nBefore this, studies of the mosaic vaccine in rhesus monkeys showed a 66 percent efficacy rate, meaning 66 percent of monkeys that got the shot were protected from the virus.\nBut with the new HVTN trial, researchers hope some tweaks to the vaccine might boost the efficacy rate.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the Ad26 vaccine was the \u201cbest tolerated\u201d of several approaches, but doesn\u2019t tell us what may have occurred in people who didn\u2019t tolerate it so well. The potential indirect harms of\u00a0a vaccine program could also have been mentioned. The vaccine is expected to work only about 50 to 60 percent of the time, according to the researchers. If people feel less pressure to employ other proven measures to control HIV (condoms, etc) because of the vaccine, then it\u2019s possible some harm could occur due to false reassurance.", "answer": 0}, {"article": "\u201cWhy not open it late?\nAlthough angioplasty is not open surgery, it is an invasive procedure with risks, and the researchers wanted to know if there was any reason to put these patients through it when they seemed to be on the road to recovery.\nIf anything, those who had angioplasty seemed to fare a bit worse than those who did not, but the differences were not statistically significant and might have been because of chance, Dr. Hochman said.\nThe study was also published online yesterday by The New England Journal of Medicine and will appear in the Dec. 7 issue.\nLike a lot of things in medicine, however, when you actually test it in an organized way, in a randomized, controlled trial, you find out it doesn\u2019t work.\u201d\n\nHe added, \u201cIt will change what I do.\u201d\n\nIn an editorial accompanying the study in the journal, two other cardiologists say that late angioplasty may still be worthwhile for some patients.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms associated with the use of drug coated stents were presented in this story.\u00a0 The reader needed to infer that a harm associated with stents was the propensity of the artery to \"close again\".\u00a0 Ideally, a story should mention both the frequency and severity of adverse effects.\u00a0 But since the focus of this story was on a study showing that the rates of heart attack and death were comparable for different approaches\u00a0 (\"either heart medicines only or balloon treatment and stents with heart medicines\"), we consider this as satisfactory. \n\u00a0\n\u00a0", "answer": 1}, {"article": "Two new just-released studies offer fresh insights into the best way to lose weight and keep it off. Jennifer Corbett Dooren has details on The News Hub. Photo: Bloomberg\n\nA diet based on healthy carbohydrates\u2014rather than a low-fat or low-carbohydrate diet\u2014offers the best chance of keeping weight off without bringing unwanted side effects, a study published Tuesday in the Journal of the American Medical Association suggests.\n\nStudy participants following a low-glycemic-index diet, which is similar to a Mediterranean diet and focuses on fish, fruit, vegetables, nuts and whole grains, also saw improved cholesterol levels and other important markers that lower the risks of developing heart disease...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned that despite burning more calories, the low-carb group had increases in some markers of cardiovascular disease.", "answer": 1}, {"article": "Researchers found that each picomolar increase in blood vitamin B12 level was associated with a 2% reduction in the risk of Alzheimer's disease among the elderly.\nBlood levels of folate, another nutrient believed to lower homocysteine levels, were not linked to Alzheimer's disease risk.\nThe seven-year study followed 271 Finnish people ages 65 to 79 who did not have any symptoms of Alzheimer's disease at the start of the study.\nDuring the study, published in Neurology, 17 people developed Alzheimer\u2019s disease.\n\u201cLow levels of vitamin B12 are surprisingly common in the elderly.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "Instead, the chief usefulness of the \"ALVAC-AIDSVAX\" vaccine is likely to be what it can teach virologists about what is happening in the immune system when a person is even somewhat protected from HIV.\nThe results were barely significant on statistical grounds, perplexing for scientific reasons and unanticipated by most researchers.\nOther researchers were less sanguine about the study but did not want to be quoted by name as being skeptical when only a few details of the results have been released.\nThat the vaccine is at least nominally a success comes as a surprise.\nIt is unlikely -- but not impossible -- that any country would consider it effective enough to be used as a public health measure against HIV.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Were any harms \u2013 besides the lack of protection in most trial participants \u2013 reported in the Thai trial?\u00a0 We don\u2019t know from the story.\u00a0 ", "answer": 0}, {"article": "Such screening is increasingly used in research.\n\u201cThe papers indicate that amyloid imaging is important to be sure that the drugs are being tested on people who have amyloid,\u201d said Dr. Roger Rosenberg, the director of the Alzheimer\u2019s Disease Center at the University of Texas Southwestern Medical Center at Dallas, who wrote an editorial about the studies.\nExperts say previous trials of anti-amyloid drugs on people with dementia failed because their brains were already too damaged or because some patients, not screened for amyloid, may not have had Alzheimer\u2019s.\nThe findings also confirm that amyloid screening, by PET scan or cerebral spinal fluid test, can help identify people for clinical trials of drugs to prevent Alzheimer\u2019s.\nTwo linked studies, published Tuesday in JAMA, also support the central early role in Alzheimer\u2019s of beta amyloid, the protein that creates plaques.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were expressed through the quote from Mount Sinai Hospital\u2019s Dr. Samuel Gandy, who said giving preventative medication to people at a young, healthy age \u2014 as early as age 30 \u2014 would be exposing them to possible drug side effects for decades.\nThe article also notes that some experts cautioned against early screening of pre-symptomatic people because no drug exists to prevent or treat Alzheimer\u2019s. This is important to point out, since it would be very distressing for most people to learn that they have incipient Alzheimer\u2019s and that they have no current way to treat it.", "answer": 1}, {"article": "\"I just didn't want to do that for my children.\nWhile surgical decisions are up to patients, the findings of this study should help them decide what to do, she says.\nIt confirms what smaller studies have suggested in the past: Women who have a family history of breast cancer can greatly reduce their chances of getting the disease by having a double mastectomy.\nThe study findings are extremely reassuring to Rebbeck -- no breast cancer diagnoses among women who had double mastectomies after three years of follow-up.\n\"We found mastectomy provided huge risk reduction of subsequent breast cancer diagnosis and death.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nThis story does not mention any of the harms of treatment. Although it could be assumed that readers understand that mastectomy and ovary removal are traumatic, this story does not inform them about other substantial harms, such as premature menopause. Indeed, most of the women included in this study had decided not to have surgery, presumably because of concerns about the heavy consequences. While the results of this study may lead many women with BRCA1/2 mutations to reevaluate the balance of benefits and harms, the story should have offered at least some overview of the reasons the decision to undergo these preventative procedures is so difficult.\n", "answer": 0}, {"article": "The study also looked at folic acid use later in pregnancy but found no correlation between that and the chances of a child developing an autism spectrum disorder.\nThe fact that autism cases have been on the rise in the U.S. even after folic acid supplementation became mandatory is a puzzle, according to three researchers from the Centers for Disease Control and Prevention\u2019s Division of Birth Defects and Developmental Disorders.\nThe researchers also found that the popularity of folic acid supplements rose as time went on.\nIn an editorial that accompanies the JAMA study, they write that the discrepancy \u201cmay be attributable to changes in diagnosis and surveillance but also may reflect a concurrent real increase in the risk of ASDs attributable to as-yet undescribed risk factors and exposures.\u201d They also note that data from the National Health Examination and Nutrition Survey published in 2009 show that the typical American consumes only 150 mcg of folic acid per day even with mandatory fortification.\nAs a result, a cup of enriched white long-grain rice now contains 797 micrograms of folic acid, for example, and a cup of Cheerios has 493 mcg, according to this report from the Harvard Women\u2019s Health Watch.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a tough call.\nThe US Preventive Services Task Force and other expert bodies state that there is no evidence of potential harm from recommended levels of folic acid supplementation. But there are hypothetical, yet plausible concerns about harmful effects of getting too much folic acid, especially an increase in cancer risk. This is why many countries have not embraced mandatory folic acid fortification of the food supply. The story could have mentioned this.\nThe point is that there are always potential harms.\u00a0 This is not a risk-free substance.\u00a0 Stories may not always find the time/space to delve into hypothetical/plausible potential harms, but we wish they would.", "answer": 0}, {"article": "Breast MRI is the most sensitive technique for the detection of breast cancer, with widespread application in the screening of high-risk patients and pre-surgical planning.\nOf the 2,021 patients, 285, or 14 percent, had additional cancer detected on MRI that was hidden from view on mammography.\nResearchers said that in some cases MRI findings of additional cancers not seen on mammography may necessitate a change in treatment.\nThe Society is based in Oak Brook, Ill. (RSNA.org)\nTo learn more, Dr. Iacconi and colleagues reviewed records from 2,021 patients with newly diagnosed breast cancer who underwent biopsy after preoperative MRI.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A quote near the top of the release notes that some women may be overtreated. But the release provides no specifics about what that means. In the case of an MRI-detected additional cancer, it could mean an unnecessary mastectomy. We\u2019ll give a borderline satisfactory rating here, although more detail would have been welcome.", "answer": 1}, {"article": "The caveat is that VX-770 is designed to counter one specific genetic mutation that accounts for about 4 percent of cases of cystic fibrosis.\nmay have a profound effect on the disease.\u2019\u2019\nMany do not live past age 40.\nShe said other results of the trial were encouraging.\nThe drug also reduced the frequency of disease exacerbations that required treatment with antibiotics.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 1}, {"article": "Sunlight's ultraviolet (UV) rays can damage the DNA in skin cells, increasing the risk for skin cancer.\nIt doesn't involve any high-priced new pharmaceuticals -- the key may be an over-the-counter vitamin supplement that costs less than $10 a month.\nWiese thinks the vitamin study sounds promising.\nBut she said more reserach is needed to see if everyone benefits from it.\nResults of the study are being presented at the annual meeting of the American Society of Clinical Oncology later this month.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019re told via the study\u2019s author that twice-daily nicotinamide is \u201csafe,\u201d but that it\u2019s \u201cnot something we\u2019d recommend at this stage for the general population.\u201d The author\u2019s\u00a0claims to safety can\u2019t be verified without a look at the actual study data (which haven\u2019t been published yet), but since the references we\u2019ve consulted generally support the idea that adverse effects are minimal, we\u2019ll give the benefit of the doubt.", "answer": 1}, {"article": "Two new devices\u2014one that deflates fat cells, one that destroys them\u2014have just been cleared for \"body contouring\" in doctors' offices by the Food and Drug Administration.\n\nZeltiq grabs onto love handles and belly pouches and freezes the fat cells inside, causing them to self-destruct over several months. Zerona...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was discussion of hypothetical harms that might results from eliminating a cache of subcutaneous fat.\u00a0\u00a0It flags this early on by saying, \"Eliminating fat cells without also eating less or exercising more may make fat crop up elsewhere and ultimately do more harm than good.\" However, the story does not\u00a0provide\u00a0any data about whether\u00a0the harms considered have been demonstrated to occur.", "answer": 0}, {"article": "In this study, the average age of the men and women was 52.\nWEDNESDAY, Aug. 31, 2016 (HealthDay News) -- Weight-loss surgery helps people drop a significant amount of weight, and now a new study confirms that much of the weight appears to stay off for at least 10 years.\nFor example, the study included mostly men, so the findings may not apply to women.\nThe study helps address a knowledge gap about long-term outcomes of bariatric surgery, said Dr. Jon Gould, chief of general surgery at the Medical College of Wisconsin in Milwaukee.\nIn addition, women who undergo bariatric surgery are typically in their 30s through their 50s, he said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of harms. Bariatric procedures can lead to an array of complications that are worth considering. And on the flip side, it\u2019s worth noting that research also has\u00a0indicated that\u00a0bariatric surgery can both extend quantity and quality of life when compared to not having surgery.", "answer": 0}, {"article": "His \"tactile imaging system\" capitalizes on the fact that cancerous lumps tend to feel harder and less movable than harmless abnormalities such as fluid-filled cysts or fibrous nodules. The fist-sized, $1,000 machine \u2014 with an elastomer probe, a light, and a camera \u2014 acts like ultrasensitive fingertips. It measures the size, elasticity, and mobility of a breast lump, then a computer program converts the data into a score from 1 to 5, with scores under 2 likely to be benign.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No information is included about possible over-diagnosis that may occur if this device is used to determine if very small lumps that are possibly benign or malignant.\u00a0 Recent studies have focused on the harm done by over-diagnosis and the resulting over-treatment of DCIS and early breast cancers.", "answer": 0}, {"article": "Some 10 million Americans currently suffer from bone thinning, according to the National Osteoporosis Foundation.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\nPark-Wyllie and colleagues tapped into data on more than 205,000 Ontario women at least 68 years old who had taken the bone drugs.\nAfter taking bone drugs for five years, about one in 1,000 women went on to suffer a thigh fracture over the next year.\nOverall, 716 women suffered the unusual type of thighbone fracture after starting the bone drugs, and nearly 10,000 had typical hip fractures.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a good job of telling the reader how few women suffered the unusual thigh fracture. They further give some context by explaining how those on the drugs reduced their harm from more-typical fractures by 24 percent.", "answer": 1}, {"article": "Nov. 22, 2010 -- Exercising to piano music may help improve balance and prevent falls among the elderly.\n\nA new study shows older men and women who participated in a piano-music-based exercise program were less likely to suffer a fall than those who didn't. Those who exercised to piano music also showed improvements in balance and the manner or style of walking.\n\n\u201cEach year, one-third of the population 65 years and older experiences at least one fall, and half of those fall repeatedly,\u201d write researcher Andrea Trombetti, MD, of University Hospitals and Faculty of Medicine of Geneva, Switzerland, and colleagues in the Archives of Internal Medicine. \u201cExercise can counteract key risk factors for falls, such as poor balance, and consequently reduce risk of falling in elderly community-dwelling individuals.\u201d\n\nResearchers say a large proportion of falls in elderly people occur while walking, so improving gait and balance can have a major impact on fall prevention.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\nThe story does not mention harms.\n\u00a0\nWhile the researchers reported that there were no adverse events during the trial, it is possible that exercise classes could lead to falls or sports injuries, so the story should have addressed this point.", "answer": 0}, {"article": "\u201cIt\u2019s a breakthrough.\n\u201cHowever, if the mechanism is fundamental, you might expect to see effects when an intervention is based on it.\u201d\n\nPrevious experiments had already hinted that the hypothalamus, an almond-sized part of the brain in humans, played some role in the ageing process, but what it was remained unclear.\nHaving proved that it was neural stem cells that were important for ageing, the scientists ran further tests to work out what the cells were doing.\nTo test whether the decline in stem cells was causing ageing, and not itself a result of old age, the researchers injected mice with a toxin that wiped out 70% of their neural stem cells.\nThe next step is to create human neural stem cells in the lab for testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story makes no mention of the potential harms that might arise from this approach. Since this has never been tested in humans, we have no idea what they risks are. The story needed to point this out.\nTheoretically, the stem cells would have to be delivered into human brains via injections, which would make the intervention incredibly risky and possibly a non-starter. In the original paper, the stem cells were injected into the hypothalamus of the mice using viruses as \u201cvectors.\u201d The researchers used lentiviruses, which are used often as vectors for research, but can be deadly in humans. Some discussion of this hurdle also was warranted.", "answer": 0}, {"article": "\u2022 Ovarian cysts may occur but usually disappear.\nVarious known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.\nWhen Kyleena is removed, menstrual periods should return.\nAfter using Kyleena for a while, the number of bleeding and spotting days is likely to lessen.\nFor some women, periods will stop altogether.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release goes into this at length, which is good. What would have been even better would have been for the release to compare the likelihood of potential side effects for Kyleena with the likelihood of side effects for other products on the market.", "answer": 1}, {"article": "A qualified claim means there is evidence supporting the claim, but it is not conclusive.\nThe Food and Drug Administration allowed the new item, developed by a physician, to make the claim just months after the nation\u2019s top allergy experts reversed longstanding advice on preventing peanut allergies, dropping recommendations to withhold all peanut-containing foods in early childhood in favor of early, frequent exposure, starting with peanut powder or extract for infants beginning to eat solid food.\nThe product, called Hello, Peanut, can be mixed into pur\u00e9ed baby food to expose infants to peanuts starting around five months old.\nA new powdered peanut product is the first food item allowed to claim it may reduce peanut allergies in infants, though parents of susceptible babies are urged to consult a doctor before trying it.\nWhile many foods like whole grains, nuts and supplements carry qualified health claims stating that they may reduce the risk of diseases like cancer or heart disease, this is the first time a food product label will be allowed to make a qualified claim that it reduces the risk of an allergy, officials said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story covers directions for Hello, Peanut!\u2019s use in great detail, and also emphasizes that if a baby develops a reaction, parents should discontinue use and contact their pediatrician. The story also discusses potential harms of the product specifically in terms of unintended use. Quoted sources worry that consumers might mistake the product as a cure for peanut allergies as opposed to a preventative tactic. Feeding the product to a child with an existing peanut allergy would likely cause an allergic reaction.", "answer": 1}, {"article": "These findings provide hope for people who thought, 'This is as good as my recovery is going to get' and for the medical community who have yet to find a way to objectively measure a patient's recovery,\" he said.\nPrevious studies have shown that cortical thickness and rsFC can be potential markers for training-induced brain changes.\nChanges in cortical thickness and functional connectivity also correlated to an individual's ability to switch between tasks quickly and consistently to achieve a specific goal.\nIndividuals in the strategy-based reasoning training showed a greater change in cortical thickness and connectivity compared to individuals who received the knowledge-based training.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Harms are not discussed. While presumably there is little risk from participating in brain training, cognitive training can have its downsides. Harms such as the time investment, frustration over speed or lack of progress, costs, etc. could have been mentioned.", "answer": 0}, {"article": "Each person's genome, or complete set of DNA, is like a word that's the length of 3 billion characters; but spelled with only the letters A, T, C or G. Traditional DNA sequencing techniques decode sections of DNA 700 characters at a time, while NGS takes advantage of parallel computing capabilities, enabling scientists to decode millions of DNA fragments.\nThe earlier the diagnosis, the earlier we can direct therapies at the child.\nIn fact, there is no national surveillance here, but the CDC estimates that 1 in 323 American children have the condition.\nIf successful, the researchers say the type of blood test in development also may be useful for other disorders, such as infant leukemia.\nNew and better ways to identify infants with CP are needed so that interventions can start earlier for more children.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of potential harms that might arise from the use of such a test. A blood draw is a low risk procedure; the real potential harm comes from over- or under-diagnosis and that should have been clarified.", "answer": 0}, {"article": "Coronary angioplasty is a procedure in which arteries are opened to increase blood flow to the heart.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\nIndependent of the length of stay, the wrist approach costs about $900 less than the groin approach, on average.\nAccording to Amin, improved technology has allowed wrist access to become a viable route to the coronary arteries, even for complex cases, and should be considered for more patients.\nOf the study\u2019s patient population receiving PCI, 9 percent received the procedure in which doctors used wrist access.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does not discuss any possible downsides associated with the new technique. Although the disadvantages of using the wrist rather than the groin approach\u00a0are minor and perhaps not clinically relevant for most people, it would have been better for the release to at least mention them.", "answer": 0}, {"article": "\"Now I feel relieved.\"\n\"I think it's a very good vaccine, and it's a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people,\" said Sumaya, also a member of CDC's Advisory Committee on Immunization Practices.\nTseng's team wanted to test the vaccine's real-world performance, so they compared 75,761 vaccinated members of the Kaiser Permanente health plan to 227,283 members who elected not to have the shot.\nIn vaccinated individuals, the rate of shingles was 6.4 cases per 1,000 people in a year while it was twice that -- 13 per 1,000 -- in the unvaccinated population, the investigators found.\nWhile less reliable than some childhood vaccines, which are usually 90 percent effective in preventing certain illnesses, the shingles vaccination is still worthwhile, said Dr. Ciro Sumaya, professor of health policy and management at Texas A&M Health Science Center School of Rural Public Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThis story briefly refers to this vaccine providing protection against shingles \u201cwithout many side effects.\u201d While many stories would stop there (if they even acknowledged the potential for side effects), this report goes further to include the comment from an independent source that \u201cI think it\u2019s a very good vaccine, and it\u2019s a safe vaccine, but obviously there needs to be continuing surveillance of usage of the vaccine to make sure there are no adverse effects that are seen in one in a 100 million cases versus one in five or 10,000 people.\u201d ", "answer": 1}, {"article": "What does that mean?\nHelping patients think differently about pain and encouraging them to move in ways they previously feared appears to ease pain and improve function, researchers say.\nWhereas back pain studies involving exercise and drugs have shown changes to the brain's gray matter, the program in this study found no brain changes, Malfliet said.\n\"People with chronic neck and/or back pain should be educated about their pain, [and] should be reassured,\" said lead researcher Anneleen Malfliet.\nIn general, they also had less disability, a reduced fear of moving, and improvement in mental and physical outlook, according to the study authors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although physical therapy and a 12-week program of education about the origins of pain designed to reshape people\u2019s understanding of the pain pathway are not likely to cause harm, it would have been useful to know if any experimental treatment subjects dropped out, failed to finish the program, or felt worse than those in the control group. There is also the potential in such studies for \u201cvictim blaming,\u201d or imposing the onus of attitude change on pain patients. Some of the comments of the principal investigator in the article (i.e. patients \u201cshould learn to put pain into the right perspective and\u2026avoid fear of moving\u201d) may impose additional burdens on some pain patients.", "answer": 0}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nSome study limitations should be considered.\n\"These results add to the large body of evidence that outline the many benefits of a healthy diet for women.\nThere are numerous possible active properties in walnuts that may be contributing factors in providing health benefits.\nFor more industry information, health research and recipe ideas, visit http://www.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "As we stated in a recent review of a news release about walnuts and heart health, a brief mention of nut allergies and the high caloric content of nuts would be appropriate.", "answer": 0}, {"article": "\"After his implant, he just blossomed,\u201d Naberhaus said.\nThey sound different, but that's better than not hearing them at all.\u201d\n\nPriddy said that from his experience as a cochlear implant recipient, he has learned many valuable lessons about himself and the world around him.\nBut Priddy adapted quickly to his second implant and can now talk on the telephone all he wants.\nHe was nervous about this because, being left-handed, he favors his left ear and was worried that he wouldn't be able to do one of his favorite pastimes: talking on the telephone.\nBut the risks are low, he said, and most people who are good candidates for the implant will react positively to it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says the harms of surgery are few\u2014mainly the dashed hopes of those it doesn\u2019t help and the chance that some people may need a reoperation if the first implant stops working. It\u2019s not completely clear that if the surgery fails, a partially deaf person is likely to be permanently deaf. Can it cause infections or facial paralysis or affect a person\u2019s taste? Yes, it can\u2014but readers will have to do their own research to find out. ", "answer": 0}, {"article": "Milo A. Puhan, MD, is director of the Epidemiology, Biostatistics and Prevention Institute and professor of epidemiology and public health at the University of Zurich.\nAs I showed in a commentary in the Journal of the American College of Cardiology, when combined with a statin, aspirin\u2019s net benefit in primary prevention is almost completely lost.\nThe recommendations were published Monday in the Annals of Internal Medicine.\nThis information is essential for making rational guidelines for aspirin in primary prevention.\nVerheugt: Even doctors are confused\n\nBy Kirsten Bibbins-Domingo: Taking aspirin is easy, but deciding whether or not to take aspirin for prevention is complex.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As above, Hennekens gave a description of the absolute harms involved in aspirin, particularly related to gastrointestinal bleeding, and several of the other sources also discussed this important harm.", "answer": 1}, {"article": "Bipolar disorder carries one of the highest rates of suicide of any mental illness, alongside schizophrenia and alcohol and drug addiction.\nThe researchers\u2019 analysis bore out one of the two main criticisms of lithium, but found the other to be baseless.\nBut lithium\u2019s reputation is largely misplaced and based on the experiences of patients from the 1960s to the 1980s who were given too large a dose of the drug, he added.\nBut as with all areas of mental health there is still more research to be done.\nPeople rightly have suspicions about it.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does a reasonable job in outlining the side effects seen with the four drugs in question and provides them in context.", "answer": 1}, {"article": "\u201cPeople who smoke a pack of cigarettes a day are chronically inflaming their lungs,\u201d he says.\n\u201cThis all makes sense to me.\u201d Studies have already shown, for example, that inflammation may be a factor in prostate cancer and colon cancer.\nPerhaps more intriguing are additional results that Ridker reported, related to cancer.\nBut whether anti-inflammatory agents, like canakinumab, or even over-the-counter drugs like aspirin, should be part of standard cancer treatment isn\u2019t clear yet.\nBut it\u2019s never been clear exactly how much inflammation adds to heart disease risk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Hardly a word about the real and unknown harms of the drug, which are more carefully outlined in a Reuters piece. The TIME article emphasizes the positive news\u2013that anti-inflammatory drugs like the one described in the trial may well represent the future of substantial reductions in heart disease and cancer mortality. But there are caveats that needed much attention not paid in this story.", "answer": 0}, {"article": "Alpha-carotene is part of a group of antioxidants known as carotenoids, which also includes beta-carotene and lycopene.\nAlthough previous studies have suggested eating more fruits and vegetables is associated with a lower risk of disease, studies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\nNov. 22, 2010 -- Eat your veggies and you may live longer, a study suggests.\nResearchers found that people with the highest levels of the antioxidant alpha-carotene in their blood had a 39% lower risk of death from any cause, including heart disease and cancer, than those who had the lowest levels of the antioxidant during the 14-year study.\nResearchers wanted to see if other carotenoids may also play a role in reducing the risk of disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nWhile it seems almost silly to worry about potential harms of eating more fruits and vegetables, the story does not include caveats that would help readers see how misinterpretation of the study results might cause harm. The story mentions that \u201cstudies have not shown that taking beta-carotene supplements reduces the risk of dying from heart disease or cancer.\u201d It should have pointed out that an earlier round of observational studies of fruit and vegetable intake similar to this one produced rampant enthusiasm for beta-carotene, but then actual experiments had to be cut short because some participants taking the supplements had higher rates of lung cancer. Any story about potential benefits of specific components of foods should clearly remind readers that in some cases supplements containing these same components have been shown to be useless or even hazardous.", "answer": 0}, {"article": "Corticosteroids are involved in a wide range of physiological processes in the body, including regulating metabolism, blood pressure and helping the body to cope with physical stress.\nThe new treatment - expected to have fewer side effects than existing therapies - could help people with disorders of the adrenal gland whose bodies are unable to produce a class of steroids called corticosteroids.\nThe researchers say that, with further research, these findings may one-day lead to improved therapies for other conditions that respond to steroid treatment, including asthma and rheumatoid arthritis.\nDr Mark Nixon, of the BHF Centre for Cardiovascular Science at the University of Edinburgh, said: \"The discovery of this selective corticosterone pump in fat cells could lead to a completely new approach in our search for safer steroid medications.\"\nThe researchers tested the therapy in a small group of patients with Addison's disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the research article from which this release stems notes that \u201cadverse effects will need to be compared not only for metabolism and obesity but also for immune suppression and osteoporosis,\u201d the release makes no mention of possible harms.", "answer": 0}, {"article": "MRI uses a powerful magnetic field and pulses of radiowave energy to create images.\nThough that difference is well established among radiologists, the new study may be of assistance in the general medical community, including general cardiologists, because \"it summarizes the advantages of CT at this point in time,\" he said.\nIndeed, CT appears to be better for assessment of coronary artery disease, matched against not only MRI but other methods, such as echocardiography, he said.\nDr. Ricardo Cury, director of cardiac MRI and CT at Baptist Cardiac & Vascular Institute in Miami and a consultant radiologist at Massachusetts General Hospital, said that the \"meta-analysis demonstrates a knowledge that we have accumulated for the past several years.\"\nIndeed, CT and MRI are not contenders in clinical practice but are used for different reasons to make different assessments, Schoepf said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story highlights the presumed advantages of CT scans, there isn\u2019t a single word about potential harms. That includes the radiation exposure leading to risks for cancer, which are acknowledges in the introduction to the\u00a0published study. (According to the most recent estimates, the risks may be in the neighborhood of one case of cancer for every 800 individuals scanned.)\u00a0The story also leaves out\u00a0the specificity results of this research, ignoring the rates of false positives and their potential harms.", "answer": 0}, {"article": "\"It's like 'Star Trek.'\nToday, the artificial retina is primarily for sufferers of retinitis pigmentosa, but it could expand to other diseases, like dry age-related macular degeneration, Mech said.\nThose factors do not prevent Campbell from dreaming.\nAnd while some patients like Campbell do well with the implant, there are some who struggle.\nCampbell's doctors try to temper her excitement and that of other study participants.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story fails to mention any potential harms, including risks of the surgery and whether remaining vision, or retinal and surrounding tissue, could be damaged. ", "answer": 0}, {"article": "A complex and expensive pacemaker-defibrillator can significantly improve the chance for survival among the tens of thousands of heart-failure patients with only mild symptoms, according to a major, multiyear clinical study.\n\nThe research, regarded as likely to change medical practice, showed that the device to \"resynchronize\" the hearts of such patients lowered the death rate by 29% in such patients over 40 months, compared to those who had a standard defibrillator implanted.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says, \u201cBut the study showed an increase in the number of device- or implantation-related complications within 30 days of implant: 118 among 888 patients with the new device, compared to 61 of 898 in the standard defibrillator group.\u201d This is beyond what the LA Times did, and we think it is adequate for this score.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070408/16healy.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article focuses on the associations between hormone use, heart disease, and the ages at which women begin using hormones. It does not mention other known harms of hormone use. For example, the statement, \"This new analysis tells us that hormones have no or very little risk for women when started within 10 years of menopause\" is not accurate; there IS an increased risk of breast cancer if used for more than a few years.\u00a0", "answer": 0}, {"article": "Early opposition to Gardasil was based on concerns it could encourage sexual activity in the young.\n\"This is certainly a wonderful, good step in addition to our screening processes\" in helping eradicate cervical cancer, said Dr. Monica Farley, who heads the advisory panel.\nGardisil is likely to be approved in early June, After that, the vaccine will move into the hands of the Centers for Disease Control, which will have to decide if it should be a mandatory vaccine or just a recommended vaccine, CBS News correspondent Elizabeth Kaledin reports.\nHowever, this vaccine should not be considered a replacement for the standard screening test: the pap smear, adds Kaledin.\nAlso, the drug does not protect against infection from the many other virus strains not included in the vaccine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention harms, and this is a very important omission. To do this right, you would need to immunize 70 million people. Varicella vaccine has a serious event rate of about 4%. If this vaccine is in the same ballpark, there would be 2.8 million people with serious reactions. Some discussion of possible harms is necessary. ", "answer": 0}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Story says \"few eye-related complications\" were reported in the Lucentis group, but didn\u2019t say what few means or what they were.\u00a0 We don\u2019t think that\u2019s quite adequate. ", "answer": 0}, {"article": "\"It's an important step along the way,\" Dr. Hadley said.\nBut Dr. Ravussin and Dr. Hadley cautioned that the study was preliminary, and that it did not prove that calorie restriction could make people healthier or add years to their lives.\nAmong the main findings of Dr. Ravussin's study was that calorie restriction led to decreases in insulin levels and body temperature.\nDr. Ravussin's study included men and women, ages 27 to 49, who were overweight but not obese.\nPart of the reason for the study, Dr. Ravussin said, was to find out whether people could stand calorie restriction.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This article does a good job of highlighting the weight regain that occurs when peoples\u2019 adherence to a dietary program that provides all the food ends. However, there was no mention of potential side-effects or harms of long-term calorie restriction such as decreased testosterone, muscle mass or bone density.", "answer": 0}, {"article": "Elevated blood pressure is major risk factor for stroke.\nThough the study looks promising, experts say that we can't necessarily give all of the credit to lycopene.\nIt seems the jury is still out, but researchers suggest we eat healthy as they continue to search for answers.\nLycopene has attracted a lot of attention in recent years because it's such a powerful antioxidant.\nIf we don't eat enough lycopene-packed foods, experts suspect too many free radicals get left in the body, damaging blood vessels by helping to form fatty deposits.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know of any harms that can result from eating tomatoes,\u00a0so we\u2019ll rule this not applicable. However, the story could have cautioned against trying to get lycopene from supplements,\u00a0which could have unknown side effects and harms.", "answer": 2}, {"article": "Powers said, \"I think what's going to happen is that we will develop systems of rapid triage and rapid transport.\nThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\nAll of these studies showed that the device can safely and effectively stop a stroke by removing blood clots, he added.\nThat last point is especially important, because the stent retrieval device will not fit into the smaller blood vessels that branch out further into the brain, Powers said.\nThe tool, called an endovascular stent retrieval device, is made up of wire mesh that resembles a tiny ring of chicken wire, Powers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article meets the standard by including this sentence: \u201cThe major risk of using the device is that it could tear an artery and cause bleeding in the brain, particularly since it will be used on people who have already received very potent blood thinners, Kandzari said.\u201d\nIt also notes, \u201cclinical trials have shown that the risk of brain bleeding for people who received tPA and then went through mechanical clot removal is no greater than for people who just receive the blood thinner.\u201d Some caution about the fact that we don\u2019t know if that risk will be as low when the procedure is rolled out more widely (as opposed to being used in a highly controlled study environment) would have been welcome.", "answer": 1}, {"article": "It attacks and breaks down a naturally-occurring protein in the body which normally prevents cancer cells from spreading.\nThe culprit gene, called WWP2, is an enzymic bonding agent found inside cancer cells, the researchers explained in their study, published in the journal Oncogene Monday.\nSurinder Soond, who worked on the study, said it was a \u201cnovel and exciting approach to treating cancer and the spread of tumors which holds great potential.\u201d\n\n\u201cThe challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene,\u201d said Andrew Chantry of UEA\u2019s school of biological sciences, who led the research.\nChantry said in a telephone interview the findings mean drugs could be developed in the next 10 years that could be used to halt the aggressive spread of many forms of cancer, including breast cancer, brain, colon and skin cancer.\nIn tests in the laboratory, the UEA team found that by blocking WWP2, levels of the natural inhibitor protein were boosted and the cancer cells remained dormant.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of possible harms that might come from blocking a gene. The story calls the gene a \u201crogue\u201d and a \u201cculprit\u201d but does little to explain what it does. It says it is both inside cancer cells and outside them, destroying \u201ca naturally-occurring protein in the body which normally prevents cancer cells from spreading.\u201d As anyone who has been through cancer treatment knows, knocking out cancer cells through radiation and chemotherapy can take a heavy toll on a person. People can die from infections and other complications. One question might have helped answer the harms question: \u201cWhen you blocked this rogue gene, what happened to all of the normal cells around the cancer cells?\u201d\u00a0Anything that alters cell function in tumors could have powerful effects on normal tissue, too. The researchers noted in their article that they have yet to \u201cestablish normal and disease expression patterns of all three WWP2 isoforms\u201d. If they don\u2019t yet fully understand the normal form and function of WWP2, the potential for unanticipated effects is a serious concern that the story should have addressed.", "answer": 0}, {"article": "In the U.S., cancers of the upper digestive tract are relatively uncommon.\nIn this study, about 10 percent of all participants had a false-positive finding on the stool test.\nSo for their study, the researchers followed nearly 2,800 adults who all volunteered to have iFOBT, a colonoscopy and an upper endoscopy to check for problems in the upper digestive tract.\nThe findings, reported in the Canadian Medical Association Journal, give some extra weight to fecal occult blood testing (FOBT) as a valid option for early detection of colon cancer.\n\u201cIt is a strong support to iFOBT as an effective screening tool.\u201d\n\nThe researchers also found that iFOBT had \u201cspecificity\u201d for colon cancer of close to 90 percent, meaning the test would accurately give a negative result to almost 90 percent of people who did not have colon cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Unlike many stories on screening tests, this one included information on false positive findings and the need for further testing. Story was careful to include the fact that in the study 10% of all participants had a false-positive finding on the stool test.", "answer": 1}, {"article": "The greatest risk was found for drugs that target gonadotropin-releasing hormone: 159.4 cases of diabetes per 1,000 person-years, compared with 87.5 for men who did not have androgen deprivation therapy, as well as a 35 percent increased risk for sudden cardiac death, a comparable increase in heart attack risk and a 22 percent increased risk for stroke.\n\"We are beginning to realize that there can be significant problems in terms of cardiovascular risk.\n\"It does save lives or delay progression for men with metastatic prostate cancer so the trade-offs there are reasonable.\n\"We're not suggesting that men who need hormone deprivation therapy should not have it.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0The story included quantitative information about the harms associated with androgen deprivation therapy. However, it mixed uses of relative risks and absolute risks within the same sentence, which we think can only confuse readers. Excerpt:\u00a0\nWe urge journalists to use absolute risk throughout every story.\u00a0 See our primer on this topic.\u00a0 \nNonetheless, we\u2019ll give the story the benefit of the doubt on this one.\n", "answer": 1}, {"article": "GHRH, a hormone produced by the hypothalamus in the brain, is linked to the insulin system, but also has a host of other effects.\nWhat\u2019s more, the hormone, which was provided free by the manufacturer in the study, today costs $700 for a single shot, Baker said.\n\u201cThey wanted to know where they could get (the hormone) after the study was over.\u201d\n\nBut that\u2019s jumping the gun, she warned, because the treatment is still experimental and GHRH is not approved to treat mental decline.\nIt\u2019s unclear how the test differences will translate into real life, said Baker.\n\u201cOn self-report, many of the folks in the active group reported they felt better,\u201d Baker, who led the study, told Reuters Health.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with the benefits, we wish the story had quantified the side effects observed in the study, but since side effects were acknowledged and since the following caveat was included, we\u2019ll give it a satisfactory score on this criterion:\n\u201c\u2026more work is needed to gauge the long-term consequences of GHRH injections. It\u2019s possible health problems could show up down the road, and the mental boost may be short-lived.\n\u201cIs it going to work in the long run and is it going to be safe? That is still unknown,\u201d said Petersen. \u201c", "answer": 1}, {"article": "\u201cIt\u2019s just not a good operation,\u201d he asserted.\nBut he also questioned the value of weight-loss surgery, in general, for severely obese people who do not have medical conditions that stand to improve or resolve after surgery.\nThe average weight loss seen with either gastric bypass or duodenal switch will improve or reverse obesity-related ills like diabetes, sleep apnea and knee arthritis, according to Livingston, who wrote an editorial published with the study.\nThe study involved 850 U.S. veterans who underwent some form of weight-loss surgery, at an average age of about 50, and more than 41,000 vets who had only non-surgical care.\nThe study, published in the Annals of Internal Medicine, followed 60 severely obese patients who were randomly assigned to either gastric bypass surgery or a more extensive procedure known as duodenal switch.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story shines in its details about the delicate weighing of risk vs. benefits for weight-loss surgery in general, and then for the duodenal vs. gastric bypass method in particular. Some readers might find it confusing that the story includes two separate publications about weight-loss surgery. The story leads with the small study comparing duodenal with gastric bypass, published in the Annals of Internal Medicine, but then delves into a larger Veterans Administration study from the Journal of the American Medical Association that looked at the longer-term results of all surgeries for obesity. We salute Reuters for providing the context and the controversy within medical practice, and quoting a principal investigator on the VA study, Edward Livingstone, who wrote an editorial that appeared in the Annals beside the duodenal paper.", "answer": 1}, {"article": "LOS ANGELES (Reuters) - Scientists for the first time have used gene therapy to successfully destroy cancer tumors in patients with advanced disease \u2014 a goal that has taken 20 years to achieve.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\nAbout two weeks after the gene therapy, patients began to experience \u201ctumor lysis syndrome\u201d \u2014 chills, nausea and fever \u2014 caused by the break-down products of dying cancer cells.\nFurther study will show whether the latest results \u201creflect an authentic advance toward a clinically applicable and effective therapy or yet another promising lead that runs into a barrier that cannot be easily overcome,\u201d Urba said in an NEJM editorial.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story gave short shrift to potential harms. The WebMD story stated more plainly that patients suffered debilitating side effects and, in one case, had to be treated with steroids that may have hindered the effectiveness of the cancer therapy.", "answer": 0}, {"article": "Type 1 diabetes is an autoimmune disease in which the body's immune system mistakenly attacks the insulin-producing beta cells in the pancreas.\nWithout replacement insulin, people with type 1 diabetes couldn't survive.\nTHURSDAY, April 14, 2011 (HealthDay News) -- In the latest research to test the concept of an artificial pancreas for the management of type 1 diabetes, British researchers report that they were able to improve blood sugar control and reduce the risk of dangerous low blood sugars overnight.\nBut, replacing insulin isn't easy.\nSeveral weeks later, the participants came back for another meal and switched overnight regimens.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No risks or harms from statins are mentioned in this story. Statins are a well tolerated class of drugs with a relatively low risk profile, but all drugs carry risks and have side effects. When you start talking about extending statin use to a much larger percentage of the population, those risks become magnified. We felt that some mention of risks was warranted.", "answer": 0}, {"article": "They rated themselves as healthier and were less likely to report problems with mobility, pain, daily activities, social interactions and feelings of depression and anxiety, among other factors that can compromise well-being.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\nShe bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery\u2019s ability to reverse the often devastating effects of being extremely overweight on health and quality of life.\nMatched with comparable patients who did not have surgery, those who did fared much better physically, emotionally and socially.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells readers that bariatric surgery \u201cis also much safer nowadays than it was even a decade ago.\u201d It also refers to the \u201cwell-documented safety and effectiveness of bariatric surgery.\u201d But there are still potential harms, such as bleeding, infection and \u2014 in rare cases \u2014 surgical problems that can be fatal. After surgery, there also is the long-term risk of nutritional deficiencies.\nIf a story aims to offer a complete picture of bariatric surgery it needs to address all aspects, including risks. And if the risks are low, articulate how low those risks are. This allows readers to make more informed decisions about their personal health.", "answer": 0}, {"article": "\u201cI even busted out the old \u2018before\u2019 and \u2018after\u2019 pictures,\u201d he said.\nOne advantage of Latisse is that it needs to be applied only once a day (Rogaine needs to be applied twice; Propecia is taken once daily), and does not seem to cause reactions in people who are allergic to minoxidil.\nThough some users of Latisse have experienced skin discoloration, Dr. Bauman said he had never seen any such reaction on the scalp of his patients.\nRogaine, which is also available over the counter now, costs about $25 a month, and a month\u2019s supply of Propecia runs about $75.\nIt is, however, expensive: a month\u2019s supply of Latisse can cost up to $150, and that is in amounts appropriate for use merely on the eyelashes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned harms in passing but did not quantify them. We wish it would have. The problem here is that we are talking about off label use, but, at a minimum, some of the harms related to the other, more established products could have been quantified. Instead, the story gives the harms question short shrift, saying, \u201cOne advantage of Latisse is that it needs to be applied only once a day (Rogaine needs to be applied twice; Propecia is taken once daily), and does not seem to cause reactions in people who are allergic to minoxidil.\u201d", "answer": 0}, {"article": "\"It's an outpatient procedure, and no physical therapy is required before or after this procedure,\" he said.\nDr. Suresh Vedantham, president of the Society of Interventional Radiology, called the new procedure \"very promising,\" given that it focuses on the inflamed knee lining that causes the pain.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nThe small pilot study -- the first U.S. clinical trial of this procedure -- involved 20 patients with moderate to severe arthritis pain.\nThose eight patients averaged a 58-point decrease in pain, as measured on a 100-point visual scale used to estimate pain, Bagla said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story quoted the lead researcher saying \u201cthere were no adverse events related to this treatment\u201d and no side effects were expected because the procedure \u201conly blocks additional blood flow to the knee, rather than cutting it off altogether.\u201d\nIn a preliminary study such as this with almost no follow-up, we think the above statement is inappropriate. There is so little known about it to say \u201cno side effects are expected\u201d is hubris, and the story should have pointed that out.", "answer": 0}, {"article": "The research needs to be duplicated, Hertz-Picciotto tells WebMD.\nTaking prenatal vitamins was found even more protective for mothers and children who had a high-risk genetic makeup .\nThe groups included:\n\nMothers reported their use of prenatal vitamins or other supplements before, during, and after pregnancy.\nChildren who had the high-risk COMT gene form were seven times as likely to have autism as children without it whose mothers did take the vitamins.\nThe mothers with the high-risk form of MTHFR had a 4.5 times higher chance of a child developing autism, she says, than mothers without this high-risk form who did take the prenatal vitamins.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There\u00a0should have been some discussion of\u00a0the possible downsides of\u00a0getting too high a dose of certain vitamins, and that more is not necessarily better when it comes to supplements.\u00a0Especially now that many foods are fortified with folic acid, there is some concern about women receiving folic acid doses that could overwhelm the body\u2019s systems for metabolizing this vitamin, which\u00a0could lead to\u00a0unknown adverse effects on the fetus. Some women also report gastrointestinal problems, including nausea and constipation, when taking prenatal vitamins.", "answer": 0}, {"article": "Is this stuff working?\"\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\nThe standard scan, which looks for blood sugar usage, has gotten good results in tests with a variety of tumors including breast, prostate, colorectal and esophageal cancers, said Dr. Steven Larson of the Memorial Sloan-Kettering Cancer Center in New York.\nThe hope is that, over time, FLT PET would prove reliable for giving a faster answer on whether an experimental treatment is working.\nThe researchers reported that just one week after treatment began, they could tell with 93 percent certainty which patients would eventually respond to the drug and which would not.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report should have mentioned the radiation doses used in PET scans. While these are not large\u2013about the amount of a typical X-ray\u2013they are worth noting. \nPET scans are not indicated for women who are pregnant.\u00a0 \nIf multiple PET scans were to become part of a treatment or diagnositic protocol the radiation dose could become significant. \nIn addition, there is no mention of the possibility that a scan might erroneously identify a treatment as ineffective, causing an unwarranted and harmful change in the treatment approach.", "answer": 0}, {"article": "Federally funded Head Start, which is free for 3- to 5-year-olds living in poverty, helps children prepare for kindergarten.\n\"This paper importantly suggests that some of the best strategies for controlling weight and promoting health may have little directly to do with either,\" said Katz, who wasn't involved in the study.\nMONDAY, Jan. 12, 2015 (HealthDay News) -- School readiness isn't the only benefit young children can gain from Head Start.\nThe report was published Jan. 12 online in the journal Pediatrics.\nWhether those children were in another preschool program wasn't stated.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms were mentioned in this article. However, it is difficult to ascertain possible risks or harms in a case like this.", "answer": 2}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story does not quantify the harms of either the diet plans or of obesity.", "answer": 0}, {"article": "The hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nAlthough EllaOne is not available in the U.S., an FDA advisory panel recently voted that it should be.\nIt is effective for up to five days after unprotected sex.\nAs of now, EllaOne is used in Europe as a morning-after pill because it blocks the effects of key hormones -- namely progesterone -- involved in ovulation.\nFibroids may cause severe abdominal pain, heavy bleeding, and interfere with fertility in some women.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the potential harm of elevated liver function test results. However, it does not explain\u00a0 that women commonly experience abdominal pain, headaches and nausea with this drug.", "answer": 0}, {"article": "Most experts believe that the build up of beta amyloid proteins, which accumulate as plaque, is responsible for Alzheimer's.\nThe other study, which involved looking at more than 2,000 MRI scans from 262 patients, found 36 cases of amyloid-related imaging abnormalities (ARIA) may have been linked to the bapineuzumab.\nBut only 8 of those 36 cases involved symptoms, and they were more likely to be found in patients with APOE-e4 who were taking higher doses of the drug.\nSalloway's study looked at the drug's safety in 194 Alzheimer's patients, most of whom had mild- to-moderate Alzheimer's and participated in a long-term (78 weeks or longer) study.\nNinety-one percent of participants had side effects, about a quarter of which were attributable to bapineuzumab.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story indicated that some patients taking the higher does of the drug experienced\u00a0headache, memory loss, hallucinations, reduced coordination or other symptoms. \u00a0From the information in the story, it appeared that 8% (21/262) of patients participating in a second study using the lower dose of the medication had some anomalies on MRI scan but no reported symptoms.", "answer": 1}, {"article": "Male condoms and oral pills dominate the $5.5 billion contraceptive market in the United States.\nAmphora was found to have an 86 percent efficacy rate in avoiding pregnancies and no serious side-effects were observed in the study, which evaluated about 1,400 healthy women belonging to the age group 18-35 years, Evofem said.\n\u201cOur research and current understanding of women suggests the time is now for there to be a new non-hormonal category in contraception,\u201d Chief Executive Saundra Pelletier said on a conference call with analysts.\nThe company plans to resubmit the marketing application for Amphora in the second quarter next year and if approved, plans to launch the product in January 2020.\n\u201cThese results pave the way for Amphora\u2019s disruption of the contraception market as a novel, highly effective, non-hormonal and woman-controlled method that finally answers women\u2019s long-awaited desire to avoid hormones,\u201d Roth Capital Partners analyst Yasmeen Rahimi said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll give this a just-passing satisfactory score because side effects were briefly mentioned: \u201cno serious side effects were observed in the study.\u201d Still we\u2019d like to see mention of less serious side effects, especially for a birth control intervention, because they\u2019re often a significant factor in women\u2019s choices.", "answer": 1}, {"article": "\u201cThey showed it was safe and tolerable treatment at least for this small number of people,\u201d Fargo said.\nSha says it\u2019s not clear what might be found in plasma from young people that might help the symptoms of Alzheimer\u2019s.\nAnd, McCracken says, the company is working to figure out just what it is in the plasma that might affect aging and disease.\nAlkahest plans to move forward with formal clinical trials in 40 volunteers next year, said Joe McCracken, vice president for development at the company.\nThis does not mean that blood transfusions could treat Alzheimer\u2019s disease, researchers cautioned.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There are no mentions of harms anywhere in this story. Transfusions are invasive procedures and carry with them certain unpredictable risks.\u00a0 While the story does say at the end that any eventual product would be cleansed of components that mandate blood-type matching, there is no other discussion related to potential harms.", "answer": 0}, {"article": "\"For research, there's a lot of value,\" Knopman says.\nThat would be good for the Alzheimer's Association and the National Institute on Aging, which sponsored the work on the new criteria.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nThe goal in all this, according to the Alzheimer's Association, is to increase opportunities for earlier diagnosis and treatment.\nBut, the guidelines say, the tests are to be used only for research, and not for diagnosing Alzheimer's in the general public.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nAs the story makes clear, lab tests and brain scans looking for signs of Alzheimer\u2019s are not ready for clinical use, so it is reasonable to defer discussion of the potential harms of such tests. The story does mention that the revised guidelines do \u201cleave one wondering if a lot more worry will be generated by the notion of \u201cpreclinical Alzheimer\u2019s,\u201d when science and medicine can\u2019t offer anything to ease those fears.\u201d", "answer": 1}, {"article": "Parkinson's disease is a neurological disorder that can cause tremors, stiffness, slowness of movement, trouble balancing, problems walking and difficulty coordinating movement.\nAccording to Dr. Paul Wright, chairman of neurology at North Shore University Hospital in Manhasset, New York, and Long Island Jewish Medical Center in New Hyde Park, New York, the importance of this study is that it brings to light that there are new biomarker tests that can delineate between these neurological diseases.\n\"This can be very challenging, especially during the early stages of the diseases and if the responsible doctor is not a neurologist specialized in movement disorders,\" said Dr. Oskar Hansson, lead author of the new study, a neurologist and an associate professor at Lund University in Sweden.\nThough other symptoms will show up eventually and help in diagnosing the patient, in the meantime, the patient will be receiving the wrong medicines.\nWhen validating a new biomarker for disease, \"one should always analyze at least two different (groups of patients and controls) to make sure that the results are reproducible,\" said Hansson, who added that participants should also include both early- and late-stage patients established at different clinics.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms of the experimental test were not discussed. One important potential harm here is that there may be a much higher false-positive or false-negative rate once you use this test in the general public. For now, it\u2019s only been tested in controlled situations where the health status of the study participant was known.", "answer": 0}, {"article": "THC interacts with receptors in the brain\u2019s endocannabinoid system, which is involved in many physiological functions, including pain, mood, memory and appetite.\nHowever, when treated with THC, the older groups improved at the task, while the young mice fared far worse.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\nWith a cannabinoid like THC, which does have adverse effects in certain individuals, there would be worries about the chronic dosing of this kind of medicine.\n\u201cThis paper is addressing a possible role for that compound in memory and cognition, which is relevant to disorders such as Alzheimer\u2019s and other dementias.\u201d\n\nHe said that while it is important to remember the study was carried out on mouse models, the differences in the effect of the drug on younger animals versus older animals tells us a lot about our understanding of the differences between old and young brains.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The report might have mentioned if any or all of the test mice sustained any ill effects (physically or mentally) but it did quote a scientific expert about the potential adverse effects for humans using cannabinoids.", "answer": 1}, {"article": "In 2008, about 8,000 U.S. men were diagnosed with metastatic prostate cancer.\nThe new study seems to make a powerful argument in favor of PSA testing.\nBut he would not yet have symptoms or detectable metastatic disease, so he'd be diagnosed with earlier-stage disease.\nHe's subtracted forever from the men whose first diagnosis was late-stage disease, even though screening could not save his life.\nMessing says this misses the point of his study, which appears in the online July 30 issue of the journal Cancer.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story lists some of the potential harms of screening at the very end.", "answer": 1}, {"article": "Toni Weiser is a veteran of skin-cancer removals. The 75-year-old retired teacher in Santa Fe, N.M., says she\u2019s had at least eight basal and squamous cell cancers scraped, frozen and surgically excised from her arms, face and shoulders.\n\nWhen a basal-cell cancer reappeared on Mrs. Weiser\u2019s nose last year, her dermatologist suggested a new, painless, nonsurgical treatment and she eagerly agreed. After 16 treatments with a small radiation device held millimeters from her nose, the tumor was gone. \u201cI felt nothing\u2014just some mild...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Radiation treatment can cause secondary cancers and other problems. The story mentions this and clearly explains that the incidence of such cancers is low. But, as noted above, existing studies do not track patients long enough to make a determination of harms feasible.", "answer": 1}, {"article": "They do, however, strongly urge further research.\nIt may be that fish oil works better in young people with pre-psychotic conditions than in older people with more established psychiatric disorders.\nIt's also not clear how fish oil might prevent psychiatric disorders.\nFish oil pills have no serious side effects.\nIt's not clear whether the fish oil pills help people with established psychosis.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As the story indicates, fish oil supplements are not associated with serious side effects, unlike antipsychotic drugs that can lead to weight gain and sexual dysfunction.\u00a0 The story might have noted that some people taking fish oil supplements have reported mild gastrointestinal side effects (e.g. diarrhea). ", "answer": 1}, {"article": "Other studies have shown that metformin can cut diabetics\u2019 risk of pancreatic and breast cancers, and the latest finding now suggests it may defend the body against smoking-induced lung tumors.\nThe findings were so strong the team now wants to test it in smokers to see if it can keep then from developing tumors.\n\u201cThis important laboratory study, together with prior laboratory and epidemiology research, suggests that metformin may be useful in cancer prevention and treatment,\u201d said Dr. Michael Pollak of McGill University in Montreal, who wrote a review on metformin research in the same journal.\n\u201cAlthough smoking cessation is the most important step for current smokers, over half of lung cancer cases are diagnosed in former smokers, raising the importance of identifying those at highest risk and identifying effective preventive treatments,\u201d Dennis, whose findings were published in the journal Cancer Prevention Research, said in a statement.\nThey treated the mice with metformin either orally or with an injection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no discussion of harms.\u00a0 We don\u2019t know what harms there might be in mice on metformin, but we shouldn\u2019t have to wonder!\u00a0 After all, we weren\u2019t the ones writing about \"strong\" benefits of metformin in mice! ", "answer": 0}, {"article": "Despite a similar number of reported cases of breast cancer among African-American and European-American women, African-Americans experience a more aggressive clinical course and a 40 percent higher death rate than European-Americans among premenopausal and menopausal breast cancer patients.\n\"We found that African-American breast cancer patients responded better to neoadjuvant chemotherapy than European-American patients.\n\"We found that, in general, African-American breast cancer patients exhibit increased likelihood for tumor recurrence, particularly to regional and distant sites, after receiving any combination of adjuvant therapy (treatment following surgery) compared to European-American breast cancer patients.\nThis higher incidence of tumor recurrence can contribute to a poorer prognosis,\" said Nikita Wright, first author of the study and a senior Ph.D. student in Dr. Ritu Aneja's laboratory in Georgia State's Biology Department.\nCo-authors of the study include Jun Xia, Sergey Klimov, Pranay Neema, Dr. Dora Il'yasova, Dr. Padmashree C. G. Rida, Dr. Remus Osan and Dr. Aneja of Georgia State; Dr. Guilherme Cantuaria and Dr. Mildred Jones of the Northside Hospital Cancer Institute; Dr. Uma Krishnamurti, Dr. Xiaoxian (Bill) Li and Dr. Michelle D. Reid of Emory University; and Dr. Meenakshi Gupta of West Georgia Hospitals.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not discuss any harms of\u00a0providing cancer treatment in this order\u2013chemo first, surgery second.\u00a0 We\u2019re not aware that neoadjuvant chemotherapy is more harmful than standard treatment but it\u2019s a valid question and the release would have been more helpful had it clearly stated that one way or the other.", "answer": 0}, {"article": "The goal is to find what's right for you.\"\nMore than 20 percent of Americans have significant symptoms of depression or anxiety each year, but only around 20 percent of people with a mental health problem get adequate treatment.\nMost apps designed for mental health typically offer a single strategy to feel better or provide too many features that make them difficult to navigate.\nThe 96 participants who completed the research study reported that they experienced about a 50 percent decrease in the severity of depressive and anxiety symptoms.\nPeople also may enroll in a study in which they will be paid to provide even more feedback.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although there\u2019s little harm associated with using any app on the face of it, relying on an app instead of seeking professional help could be harmful. The release should have acknowledged this, and done a better job of explaining who is most likely to be helped by a smartphone app and which individuals have symptoms severe enough to warrant seeking professional medical assistance. There are many different types of depression that range in severity. The National Institute of Mental Health describes several \u2014 seasonal affective disorder, persistent depressive disorder, major depressive disorder, psychotic depression, postpartum depression.\u00a0 ", "answer": 0}, {"article": "Giving babies and toddlers antibiotics when doctors are certain they have ear infections can help speed up their recovery, supporting current treatment guidelines for children between the ages of 6 months and 23 months.\nOne of the strengths of both studies, Rosenfeld said, is that the researchers took the time to make a solid diagnosis.\nIn treatment outcomes for pain, there was no difference, he notes.\nThese 2 new studies were designed to provide the research to fill the gap, and clarify treatment recommendations for babies and toddlers.\nHe, too, has been eagerly awaiting the results of these 2 studies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although we\u2019re tempted to give this story a pass for providing a detailed list of potential harms and a better explanation of why limiting antibiotic use can be beneficial (it can \u201cincrease the chance the future use of antibiotics will be effective\u201d), the expectation here is that the story will provide a quantitative estimate if available. These figures were easily obtainable from the original studies, and should have been provided.", "answer": 0}, {"article": "The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices.\nEpclusa carries a warning for patients and health care providers that serious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\nEpclusa also carries a warning not to use with certain drugs that may reduce the amount of Epclusa in the blood which could lead to reduced efficacy of Epclusa.\nThe safety and efficacy of Epclusa was also evaluated in a clinical trial of 267 subjects with decompensated cirrhosis (moderate to severe cirrhosis), of whom 87 subjects received Epclusa in combination with ribavirin for 12 weeks, and 94 percent of these patients had no virus detected in the blood 12 weeks after finishing treatment.\nFor patients with moderate to severe cirrhosis (decompensated cirrhosis), Epclusa is approved for use in combination with the drug ribavirin.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that the most common side effects of Epclusa are headache and fatigue. It also explains that Epclusa carries a warning that \u201cserious slowing of the heart rate (symptomatic bradycardia) and cases requiring pacemaker intervention have been reported when amiodarone is used with sofosbuvir in combination with another HCV direct-acting antiviral.\u201d The FDA also warns that certain drugs may reduce the amount of Epclusa in the blood which would reduce its effectiveness.", "answer": 1}, {"article": "\u201cWomen, when they undergo menopause, lose bone and gain body fat.\nBut how do mice models translate to human treatments?\nThat would then lead\u2014if all goes well\u2014to the first human trials in three to four years.\u201d\n\nAt present, the researchers are focusing on the adiposity, rather than bone loss, for drug development: \u201cI think obesity is a more prevalent disease\u2014but osteoporosis at the tail end can be tagged on.\n\u201cWe would then hopefully go to the next phase of preclinical testing, which would be to look at side effects, toxicology etc.\nBut it could also be a unique drug because it lowers body fat and makes bones stronger.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not tell readers whether the antibody experiment had any adverse effects on the health of the mice, much less what potential there may be for harms in humans. Again, we know that there have been no human studies yet, so it is impossible to say what potential harms have been found in human subjects. However, it is worth \u2014 at the very least \u2014 specifically acknowledging this point. And one could do more, such as asking about the various roles that the FSH plays in the human body (which likely vary across sex, age range, etc.).", "answer": 0}, {"article": "One evening, they found themselves at Del Posto, a chic Italian restaurant.\nIn neither study did patients actually live longer, and there was a high rate of side effects, including high blood pressure and internal bleeding.\nAnother breast cancer specialist, Dr. Edith Perez, deputy director of the Mayo Clinic Cancer Center in Jacksonville, Florida, says many chemotherapy drugs, such as Gemzar -- which is substantially less expensive than Avastin -- have previously been approved without showing they can lengthen survival.\nThe move was based on preliminary studies that found the drug increased the time that patients went without symptoms getting worse.\nGilbert says the combination stopped her illness in its tracks.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that Avastin is associated with serious side effects, such as high blood pressure and internal bleeding; however, it did not provide data on how many women in each treatment arm experienced these side effects. ", "answer": 0}, {"article": "test found a small cancer, and he does not want to take a chance that it will grow slowly and not cause him problems.\nBut if a man has been screened year after year, it can be hard to suggest he stop because he may not live much longer.\nYet changing medical practice can be difficult.\nAnd doctors, he added, have many inducements to screen.\n\u201cIt is harder to get rid of an aberrant behavior than to adopt a new one.\u201d\n\nDr. Andriole said the very concept of not screening is difficult.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article does address the harms of overdiagnosis and treatment, though does not provide quantitative data. We\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "FcMBL binds to pathogens and pathogen-released fragments, known as Pathogen-Associated Molecular Patterns (PAMPs) by recognizing carbohydrate molecules on their surface.\nNow, a Wyss Institute team led by Donald Ingber reports in eBioMedicine that it has filled this void with a rapid and specific diagnostic assay that could help physicians decide within an hour whether a patient has a systemic infection and should be hospitalized for aggressive intervention therapy.\n\"In a cohort of emergency room patients with suspected sepsis, we saw that the assay picked up infection within an hour in 85% of patients who exhibited clinical symptoms of sepsis, and equally importantly, it did not falsely predict infection in healthy subjects or patients with inflammation triggered by other causes, such as trauma.\nThe potential of this assay to detect pathogen materials was demonstrated in both animal studies and a prospective human clinical study, whose results also suggest that it also could serve as a companion diagnostic to monitor the success of antibiotic and dialysis-like sepsis therapies.\nAnd it can more specifically identify patients who have excessive inflammation due to systemic infection, rather than other causes,\" said Donald Ingber, M.D., Ph.D., the Wyss Institute's Founding Director, the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children's Hospital, and Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This test may have harms that warrant mention. It is possible that this test could mislead doctors, just as any test that isn\u2019t perfect could. It wasn\u2019t 100 percent sensitive. So the 15 percent who had a normal test but turned out to have sepsis could have been sent home inappropriately. Or antibiotics could have been delayed where they otherwise might not have. Similarly, it wasn\u2019t 100 percent specific either, so some patients may have received treatments they didn\u2019t need or weren\u2019t given ones that they should have been. A researcher is quoted saying that he envisions this as an add-on to current tests, but until it is studied prospectively in real practice settings, one can\u2019t be sure if it will help more than it may harm.", "answer": 0}, {"article": "In an email, Gunter said she frequently prescribes high-frequency TENS (pulses between 50 and 120 hertz at a low intensity) to treat patients who suffer through their periods: \"I have done so for more than 15 years.\nAnd while he claims that Livia is more effective at treating period pain than the cheaper, already available TENS units (he said \"its frequency and wave shape are unique and optimized especially for relieving menstrual pain\"), without publicly available studies comparing the two, all we have to go on is his word.\nGunter's main question about Livia is whether it will be significantly different from the already available and effective TENS devices, which usually cost around $35.\nIn fact, there's enough research that the Cochrane Collaboration was able to put together a review of the evidence.\nFor now, it's only possible to preorder the device (at a cost of $85) and wait six months for it to ship.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We would normally look for some statement about potential harms but in this case we don\u2019t think the requirement is applicable: TENS, when used according to directions, have a low harm profile.", "answer": 2}, {"article": "The California Walnut Commission offices are located at 101 Parkshore Dr., Ste.\nBeyond finding that tree nuts lower total cholesterol, triglycerides, LDL cholesterol and ApoB, researchers also found that consuming at least two servings (two ounces) per day of tree nuts, such as walnuts, has stronger effects on total cholesterol and LDL.\nIn addition to providing omega-3s, walnuts also deliver a convenient source of fiber (2 grams per ounce) and protein (4 grams per ounce).\nMore than two decades of research has shown that walnuts may help lower cardiovascular risk factors by decreasing LDL (bad) cholesterol by 9-16%2 and diastolic blood pressure by 2-3 mmHg2, as well as reducing total cholesterol2,3,4, raising HDL cholesterol2,3, reducing inflammation as measured by C-reactive protein5, and improving arterial function2.\nAdditionally, results showed that tree nut consumption may be particularly important for lowering the risk of heart disease in individuals with type 2 diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A brief mention of nut allergies and high caloric content of nuts might be appropriate here since walnuts are being recommended as a daily health supplement for people with Type 2 diabetes. Diabetics and cardiovascular disease are often comorbidities of being overweight.", "answer": 0}, {"article": "\"In our study there are now almost 200 newborns following UFE,\" Dr. Pisco said.\nSuch patients have a fibroid recurrence rate of more than 60 percent after myomectomy, making UFE an important option.\nThe procedure was repeated in 28 patients whose fibroids had not been fully treated, as shown by MRI, and 11 of those patients subsequently got pregnant.\nFor the new study, Dr. Pisco and colleagues assessed pregnancy rates in 359 women with uterine fibroids who were unable to conceive and who underwent either conventional or partial UFE.\nDr. Pisco suggested that UFE may become the first-line treatment for women with fibroids who wish to conceive, particularly for those with numerous or very large fibroids.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release cites concerns that UFE \u201cmay cause inadequate blood flow to the endometrium, or lining of the uterus, and the ovaries\u201d as the reason the procedure isn\u2019t more widely used. This is a bit hard to interpret by the layperson and it isn\u2019t until later in the release\u00a0that we learn this essentially means there are risks of infertility associated with conventional UFE.\nThe release should have spelled out the known complications, which, in addition to infertility, include pelvic pain, fever and vaginal discharge, all of which are usually temporary. Death from an embolism (an artery blocked by blood or an air bubble or some other foreign body) following the procedure has been reported but is extremely rare.\nAlso, one of the reported findings\u00a0is fairly misleading:\nComplication rates were 14.6 percent for partial UFE and 23.1 percent for conventional UFE.\nThe original research article discloses that this observed difference is not significantly significant.", "answer": 0}, {"article": "Those consuming higher doses saw some of the insulin resistance benefits and a drop in triglycerides, but not a significant increase in HDL.\n\"Therefore, the findings from the current study apparently shouldn't be generalized to different sorts of chocolate candies or white chocolates, of which the content of sugar/food additives could be substantially higher than that of the dark chocolate.\"\n\"We found that cocoa flavanol intake may reduce dyslipidemia (elevated triglycerides), insulin resistance and systemic inflammation, which are all major subclinical risk factors for cardiometabolic diseases.\"\nPROVIDENCE, R.I. [Brown University] -- To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We think that you can\u2019t have a release that talks about how \u201ctempting\u201d the results of a new chocolate-is-good-for-you story without talking about the countervailing wind that is the high calorie count of so many chocolate products. If everyone starts having a chocolate milkshake at lunch after reading this study, our obesity epidemic is going to be even worse.\nThe release included a quote from the study author who noted that \u201cthe findings from the current study apparently shouldn\u2019t be generalized to different sorts of chocolate candies or white chocolates, of which the content of sugar/food additives could be substantially higher than that of the dark chocolate.\u201d\nBut that didn\u2019t go far enough. We think there was an opportunity here to discuss the real health implications of adding cocoa flavanols to the diet in whatever form it might take.\nOnly 37% of all releases we\u2019ve reviewed are graded satisfactory on harms. The discussion on an intervention\u2019s harms needs to start somewhere, and a news release is often the headwaters of the news stream.", "answer": 0}, {"article": "\u2022 None 6 things you can do right now to help prevent the flu \n\n\n\nThe drug uses a different approach to fight the flu than other medications.\nThe drugmaker plans to apply for approval in the U.S. this summer; however, the drug likely wouldn't be available here until next year.\nThe experimental drug worked three times faster than another antiviral drug, Tamiflu, the company told the Journal.\nBoth Japanese and American flu patients were included in the trial.\nThe experimental drug, however, kicks into action earlier, working to block the virus from hijacking cells in the first place, the Journal said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a significant oversight of the story.", "answer": 0}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nMRI measurements of brain activity in the subjects suggested that the difference was related to a surge in negative emotions.\nCAUTIONS: The study included only male healthcare providers, so it might not be generalizable to a broader population.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story does mention excessive drinking as a harm (it could raise blood pressure), it does not mention any of the other potential adverse effects.", "answer": 0}, {"article": "For enquiries out of hours, please call 07595 963 613.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\nWomen in the palbociclib plus fulvestrant group took a median of 9.5 months to progress, as measured by CT and MRI scans, compared with 4.6 months in the placebo group.\nIn the trial, researchers from 144 research centres in 17 countries followed 521 women allocated to receive either palbociclib and fulvestrant, or a dummy pill and fulvestrant.\nMany women (81 per cent on the palbociclib arm) had a drop in their white blood cell count, but this rarely led to serious symptoms.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release downplays a number of side effects named in the journal article. According to the news release, the drug combination apparently has few severe side effects. The news release identifies a drop in white blood cell count as a common, but non-severe, side effect. But when we looked at the study\u2019s table of side effects we found a considerable number of grade 3 or 4 (more serious) adverse events. Some of this is confusing to interpret. For example, the study says that grade 3 or 4 adverse events\noccurred in 251 (73%) of 345 patients in the fulvestrant plus palbociclib group and 38 (22%) of 172 patients in the fulvestrant plus placebo group. The most common grade 3 or 4 adverse events were neutropenia [low white blood cell count] (223 [65%] in the fulvestrant plus palbociclib group and one [1%] in the fulvestrant plus placebo group), anaemia (ten [3%] and three [2%]), and leucopenia (95 [28%] and two [1%]).\nThe study later says,\n\u201cSerious adverse events (all causalities) occurred in 44 patients (13%) of 345 in the fulvestrant plus palbociclib group and 30 (17%) of 172 patients in the fulvestrant plus placebo group.\u201d\nThe study may be drawing a distinction between \u201cserious\u201d and \u201csevere\u201d events and including or not including grade 3 events in these different tallies. Regardless, the\u00a0release misleads by omission when it calls severe side effects \u201crare\u201d while not mentioning these relatively common less-severe effects. And that\u2019s leaving aside the issue of grade 1 and 2 side effects that appeared to be quite common and more frequent in the experimental treatment group. The study notes, for example, that \u201cInfections, fatigue, nausea, anaemia, thrombocytopenia,\u00a0alopecia, rash, and stomatitis, among others, were also\u00a0more common in the palbociclib group.\u201d", "answer": 0}, {"article": "Packaged in powder form and mixed with liquid, alginate expands in the stomach to form a thick gel, mimicking the effect of a large meal.\nAmong people who stuck with the trial, those on the fiber supplement lost 15 pounds, on average, compared to 11 pounds in the placebo group.\nBy the end of the trial, sixteen people had dropped out of the study, including 10 out of 48 from the seaweed group, according to findings published in the American Journal of Clinical Nutrition.\nFor Mette Kristensen, one of the study\u2019s authors, the message seems clear: \u201cIf you actually comply with the treatment, you do have the improvement in weight loss.\u201d\n\nHowever, effects on blood pressure were less promising.\nFive people taking the fiber gel left the study due to problems with stomach bloating, nausea and diarrhea.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was clear about the unpleasant nature of the supplement \u2013 and how it contributed to study dropouts. And the story mentioned concerns about long term safety \u2013 with some study participants having bloating, nausea, and diarrhea.\u00a0 The story also noted that blood pressure did not drop as much in the supplement group as with placebo, perhaps due to the sodium content of the supplement.", "answer": 1}, {"article": "\u201cIt\u2019s something you don\u2019t have to figure out,\u201d he said.\n\u201cA lot of rehydrating beverages have additives, whereas the coconut water \u2014 it\u2019s super clean.\u201d\n\nCoconut oil and milk, though, are receiving mixed reviews.\nI was meeting with a cardiologist recently, and he said he doesn\u2019t advise (coconut oil) for any clients.\u201d\n\nThe fat issue is complicated by the types of fatty acids found in coconut, versus other saturated fats.\nWhile most other saturated fats contain \u201clong- chain\u201d fatty acids, most coconut fats are \u201cmedium-chain.\u201d\n\nThis is advantageous for coconuts because the medium-chain fatty acids are broken down more rapidly by enzymes, said Little.\nIn addition, coconut fats are high in lauric acid, which many believe acts as an antimicrobial, helping prevent viruses, fungi and parasites.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story attempted to do one thing helpful for readers. It provided a comparison, of sorts, of different coconut parts. It says, for example, that \u201d\nOne tablespoon of coconut oil contains 120 calories and 14 grams of fat, 12.5 grams of which is saturated. A tablespoon of butter, by comparison, contains 102 calories and 11.5 grams of fat; 7.3 of those grams are saturated.\u201d But it provides no context about what this means. We read this and assumed that we should avoid all coconut oil products and stick with butter, but the story hypes coconut oil and coconut milk so much that readers are likely to miss this nuance.\n\u00a0\nOne quote in the story refers to calories, but the matter of high-calorie food of any sort, including coconut oil, contributing to obesity is not explained.", "answer": 0}, {"article": "It tends to relieve depression, which is common among people with epilepsy.\nThe device is appealing because it doesn't require surgery, doesn't have side effects and is very easy to use, Rees says.\nThe trigeminal nerve stimulator, in contrast, never penetrates the skin and is powered by an external device about the size of a large cell phone, DeGiorgio says.\nThe device causes \"a slight tingling sensation\" on her skin, she says.\nAnd DeGiorgio says he's found an interesting benefit to trigeminal nerve stimulation.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story goes on at some length to talk about the side effects from drugs, yet allows the researcher/inventor to make the claim that there are no side effects from this device. With all the framing about the promise of the approach, we would hope for more discussion of what\u2019s not known about safety profile after such limited experience to date. Even an additional line would suffice. We only hear the one positive patient\u2019s experience.", "answer": 0}, {"article": "Chronic idiopathic constipation is a diagnosis given to those who experience persistent constipation and for whom there is no structural or biochemical explanation.\nThe safety and efficacy of Trulance were established in two 12-week, placebo-controlled trials including 1,775 adult participants.\nParticipants in the trials were required to have been diagnosed with constipation at least six months prior to the study onset and to have less than three defecations per week in the previous three months, as well as other symptoms associated with constipation.\n\u201cNo one medication works for all patients suffering from chronic gastrointestinal disorders,\u201d said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA\u2019s Center for Drug Evaluation and Research.\nIf severe diarrhea occurs, patients should stop taking Trulance and contact their health care provider.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We rate this Satisfactory because the release includes the restrictions on pediatric use and the risk of severe diarrhea. The release would have been even better if it had mentioned how often the volunteers experienced side effects and the full scope of side effects.", "answer": 1}, {"article": "Doctors who have turned surgery into a popular treatment for obesity are setting their sights on a burgeoning new market: diabetes patients.\n\nA growing amount of research suggests that bariatric surgery, which shrinks the stomach and sometimes reroutes the intestines, has a lasting effect on the most common form of diabetes, and not just because patients lose weight. Studies have found that more than 75% of patients with this type of diabetes who undergo the surgery see their disease disappear. They can go on to live diabetes-free...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The reporter makes clear the serious risks of surgery, including death rate, and their\u00a0frequency not well-known. \nIt would have been useful to include the risks of death and serious side effects\u00a0for the more invasive intestinal surgery likely to be used on diabetics. The story states that one reason for the decline in bariatric surgery risks generally is\u00a0increased use of the\u00a0less invasive procedure. ", "answer": 1}, {"article": "The biopharma company Amarin is making some heart-medicine history Monday with its proprietary, prescription formulation of fish oil, called Vascepa.\n\nIn a stunning clinical trial result that upends years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids, Amarin\u2019s Vascepa significantly reduced the risk of deaths, heart attacks, strokes, and other serious cardiovascular events compared to a placebo.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story says the company reported a \u201cside effect profile consistent with the drug\u2019s currently approval label\u201d, it did not tell readers what that means. The most important adverse event reported in other studies of Vascepa is joint pain, affecting up to about one in 25 patients. The story does not mention warnings about possible allergic reactions in people allergic to seafood or interactions with anti-clotting drugs, which many heart patients take.", "answer": 0}, {"article": "No serious adverse events were reported.\nLarger and longer studies are now needed to prove that the twice-daily pill can also reduce severe asthma attacks, known as exacerbations.\nPills for asthma used to be standard treatment 40 or 50 years ago, but those older products were often associated with worrying side effects.\nNovartis believes the medicine could be filed for regulatory approval in around 2019.\nFevipiprant, which is being developed by Novartis, reduced a biological marker of asthma nearly five-fold in the 12-week trial involving 61 patients, researchers said on Saturday.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that that no serious adverse events were reported in the trial. It would have been useful to note that 12 weeks is too little time to determine how an asthma drug might affect patients over decades of use.", "answer": 1}, {"article": "NEW YORK -- Scientists acknowledged that an HIV vaccine recently tested in Thailand may be less effective than they originally suggested, but said it still provided valuable leads for further research.\n\nWhen first publicly disclosing the outcome of the vaccine trial in September, researchers said the vaccine had lowered the risk of infection by about 31%. That result was modest but statistically significant. Coming after two decades of failed HIV-vaccine trials, the announcement was welcomed by researchers around the world.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Given that this is a follow-up report focused on newly released data, a discussion of the potential harms of the vaccine is not necessary.", "answer": 2}, {"article": "The Harvard Medical School affiliates share a clinical staff that delivers inpatient care at Boston Children's Hospital and most outpatient care at Dana-Farber Cancer Institute.\nAlthough adding Ezh2-targeting agents to the standard drug regimen for CML has the potential to dramatically shorten the treatment period for many patients, ethical considerations may lead to the agents' first being tested in patients who don't respond to Gleevec and similar drugs, either initially or after drug resistance develops, Orkin remarks.\n\"The vast majority of patients with CML do remarkably well on imatinib [Gleevec] and similar drugs: The disease is well controlled and side effects are tolerable,\" says Stuart Orkin, MD, the study's senior author and a pediatric hematologist/oncologist at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.\nAlthough second- and third-line targeted therapies can often return the disease to remission, some patients don't benefit from these drugs or develop severe side effects.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Side effects are mentioned for imatinib, but never detailed. And this is a major oversight that would have benefited the\u00a0crux of the release (i.e. a need for alternatives to imatinib-like drugs). One 2010 study\u00a0assessed a flotilla of side effects, including muscle cramps, nausea, diarrhea, headaches, abdominal pain, joint pain, and more in greater than 10% of patients who take it for CML. But it also notes\u00a0a rare few can be \u201csinister\u201d in less than 1% of patients: heart\u00a0damage, kidney failure, muscle degeneration, secondary cancers, and even\u00a0cerebellar edema, which can cause fainting, seizures, and even put someone into a coma.\nThe side-effects of Ezh2 inhibitors also aren\u2019t noted since it seems\u00a0the most promising one is still in clinical trials. Since the new drug hasn\u2019t been tested in humans there is really no way to gauge side effects but all cancer drugs have them, often very serious ones as noted above.", "answer": 0}, {"article": "\u201cCAR-T is not the EpiPen,\u201d he said.\nAnd although checkpoint inhibitors are off the shelf, with every patient getting the same drug, CAR T-cell therapy is customized to an individual.\nThe article that appeared in the New England Journal of Medicine in August 2011 created a \u201cfirestorm,\u201d June said \u2014 one that brought them new resources.\nAnd childhood leukemia is just the start for a field that has attracted intense interest in academia and industry.\nYet along with the enthusiasm come pressing questions about safety, cost and the complexity of the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes: \u201cThe revved-up immune system [that results from the CAR T-cell treatment] becomes a potent cancer-fighting agent but also a dangerous threat to the patient. Serious side effects abound, raising concerns about broad use.\u201d The story then goes on to discuss those potential harms more thoroughly.\nOrdinarily, this would be sufficient for a Satisfactory rating. But given the severity and frequency of serious, life-threatening events, the story needed numbers: What percentage of patients in the trial experienced a serious immune reaction? How many died?\nThere are also plenty of unknowns with a new cancer treatment, such as lack of data on long-term prognosis.", "answer": 0}, {"article": "\"Weight loss was similar but substantial in both groups we studied, but blood pressure improved more in the low-carb dieters,\" said study author Dr. William Yancy Jr., an associate professor of medicine at Duke University Medical Center and a staff physician at the Department of Veterans Affairs Medical Center in Durham, N.C.\n\n\"There are options out there.\nWhat often makes the difference in whether or not a diet is successful, she said, is whether or not there's a counseling and support component to the plan.\nYancy said the blood pressure and cholesterol drops might have been even more impressive if people had stayed on their medications, but as they lost weight and normalized these readings, the doctors took them off blood-pressure and cholesterol drugs.\nAnd, she said, these studies show that you don't necessarily need to get to your \"ideal body weight\" to make substantial improvements to your health.\nThe low-carb diet began with a carbohydrate intake of less than 20 grams of carbohydrates a day.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any of the known\u00a0adverse effects\u00a0of orlistat, which include gastrointestinal\u00a0upset that can limit the drug\u2019s tolerability.\u00a0It could also have mentioned some of the concerns (such as potential for nutrient deficiencies)\u00a0that many health professionals have about diets that are high in meat\u00a0and protein and very low in carbohydrate.", "answer": 0}, {"article": "And general practice physicians missed cancers 60 percent more often than gastroenterologists.\nCanadian researchers note that their finding should be a heads-up to clinicians performing the exam, as well as to patients preparing for it.\nBoth groups could do things to improve the detection rate, they said.\nGiven the wide variation in colonoscopy training, the researchers call for standardizing it, including credentialing and re-credentialing.\n\u201cThis is very different from a population undergoing screening.\u201d\n\nColonoscopy would probably miss a smaller percentage of cancers in such a large population, Lieberman said, because the rate would be lower.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not quantify potential harms from colonscopies, such as colon perforation.", "answer": 0}, {"article": "About the University of Pittsburgh School of Medicine\n\nAs one of the nation's leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition.\nThe safety profile of mepolizumab did not differ from placebo in either trial.\nThe exacerbation rate in the low eosinophil group treated with the biologic did not differ from placebo.\nThe time to the first exacerbation also was higher with mepolizumab than placebo, but only in the high eosinophil group.\nPatients included in the trials were still having flare-ups despite a year of a standard treatment known as \"triple inhaled therapy\" that includes bronchodilators and glucocorticoids.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t describe any possible side effects from the use of mepolizumab, even though there are several. They include headaches, back pain, fatigue and flu symptoms, urinary tract infections, abdominal pain, itching, eczema, and muscle spasms.\nTo its credit the release does say that the side effects encountered from the drug and the placebo were similar. \u201cThe safety profile of mepolizumab did not differ from placebo in either trial,\u201d it says.", "answer": 0}, {"article": "CHICAGO (Reuters) - U.S. researchers have developed tiny nanoparticle robots that can travel through a patient\u2019s blood and into tumors where they deliver a therapy that turns off an important cancer gene.\nBut getting the treatment to the right target in the body has presented a challenge.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\n\u201cThis is the first study to be able to go in there and show it\u2019s doing its mechanism of action,\u201d said Mark Davis, a professor of chemical engineering, who led the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says this was a phase 1 clinical trial \u2013 the main purpose of which is to determine safety of an experimental intervention.\u00a0 Yet the story says the lead investigator could not say if there were any safety concerns.\u00a0 Huh?\u00a0 We can understand not leaping to conclusions after tests on just three tumor samples (although, as noted,\u00a0 the story tended to do anyway), but shouldn\u2019t the story have at least probed for potential safety concerns with this approach?\u00a0 \nIn fact, the use of siRNA in experiments like this is in its infancy and as such little is known about the existing side effect profile.\u00a0 High on the list is the potential for the agent to have unexpected and non specific effects called off-targeting.\u00a0 Off-targeting is the potential largest liability of the approach, possibly resulting in inadvertent turning off or on of non-targeted genes.\u00a0 This collateral damage is a significant challenge to the use of siRNA even with nano-directed treatments.\u00a0 A more balanced story would have noted the potential downside of the approach.", "answer": 0}, {"article": "ZURICH (Reuters) - Roche\u2019s Tecentriq immunotherapy combined with other drugs boosted lung cancer patients\u2019 survival versus an older cocktail, the Swiss company said as it seeks an edge on Merck and Bristol-Myers Squibb.\nThis could help Roche make the case that its cocktail is suitable for broad patients groups, not just those with specific biomarkers.\nWhile Roche did not provide specific overall survival data, the headline result helps its bid to catch up to better-established immunotherapies from Merck and Bristol-Myers Squibb and its shares rose about 1 percent in early trading.\nShe also said the survival benefit was observed across key subgroups, including those with varying levels of a protein called PD-L1 that can help tumors avoid detection.\n\u201cFacing biosimilar competition... we see Tecentriq sales coming timely to support Roche\u2019s profitability going forward.\u201d\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Again, there is no information in the story about side effects, patient exclusions, or other potential harms of Tecentriq or the chemotherapies included in the cocktail.\nAlso, the common talking point around immunotherapy includes the claim that it is less toxic than traditional chemotherapy, so why would a person take both, instead of just one or the other? What does that do to the side effect profile?", "answer": 0}, {"article": "Critically ill children in intensive care are unable to eat independently.\nThe study shows that receiving little to no nutrition during the first week in intensive care makes children recover faster.\nThe researchers examined whether fasting or receiving very small amounts of feeding during the first week in the paediatric intensive care unit was better for the children than full feeding through an IV.\nPrevious research by Professor Van den Berghe and her team (2011 and 2014) had already shown that early artificial feeding should be avoided to treat adults in intensive care.\nThese findings provide strong evidence against current practice and can thus be expected to change paediatric intensive care worldwide.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study report goes into substantial background detail about potential harms of malnutrition and overfeeding, and the release \u2014 although without specific data \u2014 more or less describes the concerns. The release could have been strengthened even more if it had informed readers about the rigorous informed consent obtained from parents, and the efforts to maintain basic nutrient levels in all the children.", "answer": 1}, {"article": "Sigmund Freud often included one of his dogs in psychoanalysis sessions.\nAnd that\u2019s just as important.\u201d\n\nFocusing too much on scientific support sometimes feels like a form of \u201cphysics envy,\u201d Beck added, \u201cwhere you try to quantify everything without appreciating it.\u201d\n\nBut there are good reasons for rigorous research on animals and mental health.\nBut the evidence to date is problematic, according to Crossman\u2019s review and others before it.\nMore generally, Serpell said, the popular idea that pets make you happier \u201cis not a harmless distortion.\nIn other words, people are recognizing that anecdote isn\u2019t enough.\u201d\n\nUsing animals in mental health settings is nothing new.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call for us: Harms are discussed, but briefly and anecdotally. The brief portion comes in the same quote mentioned above, noting that the body of evidence regarding therapy animals \u201csometimes has shown positive short-term effects, often found no effect and occasionally identified higher rates of distress\u201d (emphasis added). A little more information there would be welcome.\u00a0There\u2019s also the issue of immunosuppressed patients coming into contact with therapy animals, and possible harm to the animals, who could be over-worked or subjected to aggressive or harmful treatment from even well-meaning people.\nStill, some harms are at least acknowledged.", "answer": 1}, {"article": "Dr. Sonia Friedman is an associate professor of medicine at Harvard Medical School.\nThe researchers randomly assigned more than 1,700 people with ulcerative colitis to one of three phase 3 trials.\nIn the first trial, nearly 19 percent of the patients taking Xeljanz experienced a remission of their condition in eight weeks.\nThe first two trials looked at more than 1,100 patients with moderate to severe ulcerative colitis who had failed with conventional treatment or treatment with newer \"tumor necrosis factor antagonist\" drugs, such as Remicade (infliximab).\nXeljanz targets certain proteins involved in the body's inflammatory and immune responses that other so-called biologic drugs don't, the researchers said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Over the course of three paragraphs, the story discusses a variety of adverse health effects experienced by patients participating in the clinical trials, including infections, nonmelanoma skin cancer, \u201cheart problems,\u201d and an increase in cholesterol levels.\nAs with benefits, the story compares the number of adverse health events in those taking Xeljanz with the number of adverse events in those taking placebo \u2014 which is useful for helping readers place the risk in context.", "answer": 1}, {"article": "Fish-oil supplements don't appear to help pregnant women prevent post-partum depression or boost the baby's brain development as previously believed, according to a large trial published Tuesday in the Journal of the American Medical Association.\n\nThe 2,400-woman, randomized study complicates the advice for pregnant women. It adds to a body of mixed research on some potential benefits of the popular omega-3 fatty acid known as DHA, or docosahexaenoic acid. DHA, which can move from the mother to the baby during pregnancy, accumulates...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There was no broad discussion of safety or side effects.\u00a0 But one issue was raised that was not in the NYT story:\u00a0\n\"Women in the fish-oil group had lower rates of pre-term births, particularly births earlier than 34 weeks of gestation. But, there was a trade-off: More women who took the supplement needed their labor to be induced or had caesarean sections because the babies stayed in the womb longer, said Dr. Makrides.\"\nBecause it at least nodded in the direction of a specific potential harm issue, this story gets a satisfactory score on this criterion.", "answer": 1}, {"article": "Oct. 28, 2010 -- A new, consumer-friendly test for colon cancer, once approved, could persuade more Americans to undergo screening for the deadly cancer, according to researchers presenting their findings on the test's effectiveness at a cancer conference in Philadelphia.\nThe research was presented at the American Association for Cancer Research's special conference, Colorectal Cancer: Biology to Therapy.\nAt the meeting, Ahlquist presented the results of the first clinical evaluation study, which enrolled 1,100 patients.\nThe test can be done at home without dietary restrictions or bowel preparation.\nPatients must often take time off work and need transportation home from the procedure.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of potential harms.", "answer": 0}, {"article": "An infarct, a kind of stroke, happens when the passage of blood is slowed or completely blocked by clotting.\nThe bottom line for dementia is that fish oil may help in the very early stages, but more research must be done to confirm this, he said.\nIn general, dietary patterns are consistent for at least seven or eight years, Scarmeas said.\nIt is possible that the diet protects the brain vessels themselves, irrespective of other problems such as high blood pressure, Scarmeas said.\nThe next step would be to have controlled experiments concerning food and dementia in which participants are randomly assigned to follow a diet, Cole said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0There was no discussion of harms, but we\u2019re not sure of any from this diet \u2013 so we judge this criterion Not Applicable in this case. ", "answer": 2}, {"article": "Kychman is an advisor to Boehringer Ingelheim and serves on their speakers' bureau, services for which he is compensated.\nSome 15% of women on flibanserin, and 7% of those on placebo, stopped treatment due to side effects.\nIn the 24-week \"Bouquet\" studies (each of the Boehringer Ingelheim-funded studies is named after a flower), there were few drug-related side effects.\nWhile HSDD is a controversial diagnosis -- some experts see it as the medicalization of what is for many women a relationship issue -- the 1,378 premenopausal women enrolled in the clinical trials were suffering distress over their lack of sexual desire.\nThe findings come from phase III clinical trials that drugmaker Boehringer Ingelheim hopes will convince the FDA to approve flibanserin for the treatment of hypoactive sexual desire disorder (HSDD).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0provided statistics on common side effects including\u00a0daytime sleepiness, dizziness, fatigue, anxiety, dry mouth, nausea and insomnia.\u00a0 These side effects resulted in 15% of those\u00a0taking flibanserin vs 7% taking placebo withdrawing from the study.", "answer": 1}, {"article": "Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.\nFollowing the procedure, typical side effects include temporary redness, swelling, blanching, bruising, firmness, tingling, stinging, tenderness, cramping, aching, itching, or skin sensitivity, and sensation of fullness in the back of the throat after submental area treatment.\nDuring the procedure you may experience sensations of pulling, tugging, mild pinching, intense cold, tingling, stinging, aching, and cramping at the treatment site.\nIn the U.S., the CoolSculpting procedure is FDA-cleared for the treatment of visible fat bulges in the submental area, thigh, abdomen and flank, along with bra fat, back fat, underneath the buttocks (also known as banana roll), and upper arm.\nYou should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "CoolSculpting.com states the procedure is proven to be a safe and effective. However, there are risks associated with this treatment. The addendum to the release does contain information about potential harms so we rate this as Satisfactory.\nAccording to CoolSculpting\u2019s patient safety document, subjects may have redness, blanching, bruising, tingling and stinging immediately after the procedure. One to two weeks after treatment, patients could also experience cramping, numbness, skin sensitivity and \u201csensations of fullness.\u201d In addition, cold exposure to certain nerves may cause tongue deviation, lower lip weakness, dry mouth and a decrease in saliva production. Some rare side effects include late-onset pain, first and second degree frostbite, fainting, nausea, dizziness, nodules in the treatment area and hyperpigmentation. Some patients have even experienced \u201cparadoxical adipose hyperplasia,\u201d meaning they experience the reverse reaction and end up with more fat cells in the area.", "answer": 1}, {"article": "The resource you are looking for might have been removed, had its name changed, or is temporarily unavailable.", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of potential harms.", "answer": 0}, {"article": "\"It is not going to be reimbursed by insurance, at least for the first generation and certainly for the foreseeable future,\" he said.\nBut the device can only be used for six months at a time, and it is not likely to be an alternative for people who require lap-band surgery, stomach stapling or other forms of bariatric surgery, said Dr. Mitchell Roslin, chief of obesity surgery for Lenox Hill Hospital in New York City.\nPatients who did not receive the device lost about half that amount of weight -- just over 3 percent of their total body weight, the FDA said.\nIn the clinical trial, the 187 participants who used the device lost an average of more than 14 pounds, or about 7 percent of their total body weight.\nThe device doesn't change the stomach's natural anatomy, according to the FDA.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that\u00a0nausea that made some patients drop out of the study, and explained that\u00a0gastric ulcers were seen in the stomachs of more than one-third of patients. Since the device appeals to a consumer who \u201cdoes not qualify\u201d for medical obesity treatment and has only temporary benefit, we believe the story should have quoted at least one critic.\nGiven that the patients in this study are those who \u201cdo not qualify\u201d for the medical management of obesity, one might raise questions about the ethics of\u00a0an intervention that isn\u2019t medically indicated. Given the temporary nature of the device, the risks should\u00a0be expected to\u00a0outweigh the benefits \u2013 especially since the benefits in turn, unless marked behavior changes are permanently undertaken, will, by definition, be temporary. This can be viewed as\u00a0an extreme intervention in the name of non-medically necessary weight loss \u2013 the kind of approach that runs the risk of encouraging people to pursue all sorts of nonsensical, and, at times, dangerous diets and interventions.", "answer": 1}, {"article": "Today, the United States is the third largest pear-producing country in the world, and Oregon and Washington comprise the nation's largest pear growing region with 1,600 growers producing 84% of all fresh pears grown in the United States.\nA new study, 'Fresh Pear Consumption is Associated with Better Nutrient Intake, Diet Quality, and Weight Parameters in Adults: National Health and Nutrition Examination Survey 2001-2010,' published in Nutrition and Food Science, revealed new information regarding the health benefits of pear consumption.1 Of particular interest given the high rates of obesity in the United States, the study found that adult pear consumers had a lower body weight than non-pear consumers and they were 35 percent less likely to be obese.\nIn addition to discovering a correlation between fresh pear consumers and lower body weight, the study found that pear consumption was associated with higher diet quality (as defined by the Healthy Eating Index).\nThe epidemiologic study, led by Carol O'Neil of the Louisiana State University Agricultural Center, used a nationally representative analytic sample to examine the association of fresh pear consumption with nutrient intake, nutrient adequacy, diet quality, and cardiovascular risk factors in adults.\n\"We believe fiber intake may have driven the lower body weights that were seen in this study because there was no difference in energy intake or level of physical activity found between the fresh pear consumers and non-consumers.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The study looked at a possible association between pear eating and obesity but the protocol did not have a way to determine harms of eating or not eating the fruit. In any case, it\u2019s hard to imagine any.", "answer": 2}, {"article": "Staying sexually active\u2014and considering sexuality an important part of life\u2014may be linked to higher cognitive functioning as people age, according to a study in the March issue of the American Journal of Geriatric Psychiatry.\n\nOlder men and women who were satisfied with their sexual relationships and considered sexuality an essential component of aging performed better on tests of cognitive function than those who felt sexuality and intimacy were unimportant, the research showed.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Older adults are susceptible to sexually transmitted diseases like anyone else. Increased sexual activity might increase those risks.\nWe acknowledge that we\u2019re holding the bar high here, but unapologetically, especially with recent studies showing rising rates of STDs in seniors.", "answer": 0}, {"article": "Aromatase inhibitors block an enzyme that the body needs to produce estrogen.\nBut because the absolute benefits were not huge, and because the drug did cause side effects, it makes sense to consider this for women at the highest risk of a recurrence of breast cancer, he said.\nStill, said Dr. Richard Schilsky, who serves as the chief medical officer of ASCO and who was not involved in the study, \u201cthere\u2019s a substantial benefit\u201d to continuing aromatase inhibitors out to 10 years to lower the chance of cancer developing in the other breast.\nPut another way, the risk of cancer returning in the original or the opposite breast was 34 percent lower in women on 10 years of letrozole compared with those who stopped after five.\nDr. Debra Patt, a breast cancer specialist at Texas Oncology who was not involved in the study, called the difference of a few percentage points in the risk of recurrence (95 percent vs. 91 percent) \u201csubstantial.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "First, we applaud the story for recognizing\u00a0the difference between absolute and relative benefits.\nBut because the absolute benefits were not huge, and because the drug did cause side effects, it makes sense to consider this for women at the highest risk of a recurrence of breast cancer, he said.\nThe story also clearly understands that the absolute benefit of the treatment must be weighed against the side effects:\nAromatase inhibitors cause side effects in some women, especially night sweats, hot flashes, and sexual dysfunction. Women receiving five more years of letrozole also had greater loss of bone in their hip, worse osteoporosis, and more fractures.\nOne thing that would have made this even stronger: Including the rates of the different side effects.", "answer": 1}, {"article": "It is funded by the Agency for Healthcare Research and Quality.\nThe authors focused specifically on comparing second generation antidepressants, such as Wellbutrin, Lexapro and Prozac with cognitive behavioral therapy, which includes several in-person or phone sessions with a therapist to examine how actions and thoughts can impact depression.\nAfter conducting a full review of the scientific literature available, the researchers examined 11 randomized controlled trials with 1,511 patients that compared a second generation antidepressant with cognitive behavioral therapy.\n\"Major depressive disorder is a disabling and prevalent form of depression, experienced by more than 16 percent of U.S. adults during their lifetime,\" said Arlene Bierman, M.D., Director, Center for Evidence and Practice Improvement, at the Agency for Healthcare Research and Quality, which funded the study.\nA recent evidence review of several alternatives to medication found that using cognitive behavioral therapy as the first treatment for depression can be equally effective as using a second generation antidepressant.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions harms from both CBT and antidepressants. While promoting the advantages of CBT over medications, the release discusses some harms from antidepressants (\u201cconstipation, diarrhea and dizziness\u201d) but didn\u2019t touch on the more serious harms associated with SSRIs, particularly when going through withdrawal.", "answer": 1}, {"article": "Fader no longer holds that role.\nShe notes that using trastuzumab to selectively treat uterine serous carcinoma that express HER2/neu is part of a broader trend at Johns Hopkins and other cancer centers to use the tools of tailored therapy, or precision medicine, based on the molecular and genetic makeup of tumors and patients.\nThe results of the trial, published online ahead of print on March 27 in the Journal of Clinical Oncology, show that the drug extended the length of time to tumor progression by four to eight months in the seven-year trial.\nAdding the monoclonal antibody drug trastuzumab--already used to treat certain breast cancers--to the chemotherapy regimen of women with a rare form of uterine cancer lengthens the amount of time their tumors are kept from growing, according to Johns Hopkins Medicine researchers conducting a small phase II trial of the regimen, testing its safety and value.\nFader cautions that a larger study of the drug combination, or other combinations, is needed to confirm the findings and potentially extend survival even more.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms were not addressed. This trial was relatively small, with only 58 patients, and the relevant journal article notes that the trastuzumab \u201cwas well tolerated\u201d by study participants. However, because trastuzumab is already in clinical use for treating other cancers, we know that it is associated with some risks. And those risks are not insignificant. For example, Herceptin\u2019s manufacturers note that the drug \u201ccan result in sub-clinical and clinical cardiac failure\u201d \u2014 and that is in addition to more common, but less severe, adverse reactions.\nAlthough practices vary, patients need to be monitored with an echocardiogram while on trastuzumab.\nSometimes patients with existing heart problems may be precluded from getting this drug. The abstract, but not the release, addressed risks but only in part, when it states: \u201cToxicity was not different between treatment arms, and no unexpected safety signals emerged. Conclusion: Addition of trastuzumab to carboplatin-paclitaxel was well tolerated and increased progression-free survival.\u201d", "answer": 0}, {"article": "\"One day I turn to my wife and I'm like, 'I feel calm today.\nBut Papolos has found that the condition does respond to ketamine.\nSince then, doctors have prescribed ketamine \"off label\" to thousands of depressed patients who don't respond to other drugs.\nAnd it may also explain why ketamine helps people who have symptoms associated with several different psychiatric disorders.\nJohnson & Johnson expects to seek approval for its nasal spray esketamine later this year, though the approval would be limited to use in a clinical setting.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is no discussion of harms in the story. The Johnson & Johnson news release cited in the story lists a number of side effects: \u201cThe most common treatment-emergent adverse events (>10%) reported in the esketamine group were metallic taste, nausea, vertigo, dizziness, headache, drowsiness, dissociation, blurred vision, paraesthesia (tingling sensation) and anxiety.\u201d\nA recent journal article that was not mentioned in this story reported side effects so severe that all the participants quit taking an inhaled form of ketamine.", "answer": 0}, {"article": "Repeated treatments also resulted in a higher likelihood of remission or a longer time to relapse, with an overall response and remission rate of 68.8 percent for the patients receiving ketamine treatment.\nAs part of the double-blind, placebo-controlled trial, an active control treatment which causes sedation similar to ketamine, was used to substitute for one of the treatment sessions.\n\"Not only was ketamine well-tolerated by participants, with none experiencing severe or problematic side effects, but giving the treatment by a simple subcutaneous injection (a small injection under the skin) was also shown to be an acceptable method for administering the drug in a safe and effective way.\"\nMany medications may cause more side effects or have lower efficacy as the brain ages,\" said co-author Dr Duncan George from UNSW Sydney.\n\"These findings take us a big step forward as we begin to fully understand the potential and limitations of ketamine's antidepressant qualities,\" said lead author UNSW Professor Colleen Loo, who is based at Black Dog Institute.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Although the release doesn\u2019t say how widespread side effects were in the study population, it does mention some of the side effects and it\u2019s clear to readers that ketamine is not a trouble-free drug.", "answer": 1}, {"article": "\u201cYou have to show that there\u2019s a return on investment.\u201d\nAnd researchers at Washington University School of Medicine found that compared with a control group, bronchial thermoplasty patients saw their asthma attacks drop by a third, their emergency room visits fall by 84 percent, and the number of days they lost from work and school drop by 66 percent.\nAfter the procedure, the airways no longer are so prone to constricting, studies show.\n\u201cIt\u2019s not going to get rid of asthma, but it is going to reduce symptoms and hospitalizations and make patients more functional in their daily life.\u201d For now, the procedure is only for severe asthmatics, who \u2014 unlike a vast majority of asthma patients \u2014 cannot keep flare-ups at bay with standard medications, said Dr. Kyle Hogarth, an assistant professor of medicine at the University of Chicago who was involved in clinical studies of the treatment.\nSome patients report temporary coughing, mucus and other respiratory symptoms brought on by irritation of airways.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story refers to 5-year studies suggesting that the procedure is safe, and suggests that short-term problems consist of\u00a0\u201ctemporary coughing, mucus and other respiratory symptoms brought on by irritation of airways.\u201d This understates the severity of adverse effects\u00a0seen\u00a0while patients are receiving active treatment. In the trial mentioned above, 16 patients\u00a0in the bronchial thermoplasty group had to be hospitalized for asthma-related complications during treatment,\u00a0compared with only 2 patients in the control group.", "answer": 0}, {"article": "\"Shireen had the idea, 'Why can't I just test my food and figure out what's in it?'\nThe company plans to deliver the product by the middle of next year after they've tested it more thoroughly, Sundvor.\nWe had this shared experience; Shireen has several food allergies and I also have several food intolerances.\n\"So we do not need FDA clearance for the device because we are not using it to diagnose or manage disease.\nRestaurants, office parties, potlucks, meals while traveling -- they're a minefield for people with celiac disease and gluten sensitivity who can suffer from stomach pain and upset, swollen joints, and other debilitating health problems when they ingest even a little bit of gluten.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Without any evidence one way or the other about the \u201cmini chemistry test\u2019s\u201d accuracy, it\u2019s hard to know if there might be any false positive or negative readings, and thus any harms from eating food that has more gluten than the test user thinks. The story doesn\u2019t discuss this.", "answer": 0}, {"article": "But when it recurs and becomes metastatic, it's very difficult to treat,\" she explained.\nAmong them, she said, were the small size of the study group, \"imbalances at baseline\" favoring the iniparib group, and the \"unconventional\" chemotherapy regimen.\nThis may not seen like very long in either group, but for this serious a cancer, it is impressive, the researchers noted.\nThe findings were enough to generate the interest of Dr. Lisa A. Carey, the co-author of an accompanying editorial.\nIn her editorial accompanying the study, Carey agreed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "While the researcher believed the drug was well-tolerated, the article should have included information about demonstrated side effects, even minor ones.\u00a0 The author also should have noted if the study was powered to detect differences since the study cohort was so small.", "answer": 0}, {"article": ".\n\"This study shows that, for women who need or choose to avoid medications, electro-acupuncture may be an option because it has minimal risks, but blinded controlled trials are needed,\" says Dr. JoAnn Pinkerton, NAMS executive director.\nA new study shows that electro-acupuncture may be effective in providing some relief.\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\nThe study is being published online in Menopause, the journal of The North American Menopause Society (NAMS).\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release makes no mention of potential harms or side effects from the use of electro-acupuncture, which like traditional acupuncture, is considered to be of relatively low risk.\u00a0 But neither is without risk entirely, given that infection is possible along with bleeding or other injury.\u00a0 Electro-acupuncture is not suggested for people with heart problems, strokes, seizures or epilepsy, nor should it be used by patients with cardiac pacemakers since the small current used can disrupt the function of these devices. These risks should have been included in the release.", "answer": 0}, {"article": "\"Sadly,\" they write, \"we are left in a conundrum.\nIn a related commentary in the journal, a pair of doctors from the University of Washington School of Medicine note that the estimates of overdiagnosis of breast cancer are \"frustratingly broad\" \u2014 from less than 10 percent to 50 percent or more of women who get screened.\nAnd yet, a new study published in JAMA Internal Medicine has found something that may seem counterintuitive: More breast cancer screening didn't actually save lives.\nBut this isn't the first study to call into question the benefits of mammography and whether women are too often the victims of overdiagnosis.\nWe have to find a better way to screen women for breast cancer\n\nThe medical community has known about overdiagnosis and overtreatment for years, documenting the problem in a range of cancers \u2014 in breast, prostate, lung, and thyroid (which you can see in the chart above).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is mainly about harms and the fact that increased breast cancer screening was not associated with lower mortality rates in the study \u2014 suggesting that there is a high rate of overdiagnosis of breast cancer. \u201cThe trouble with overdiagnosis is that while the cancers doctors find wouldn\u2019t have harmed their patients, the treatment and stress that result from the diagnosis probably will,\u201d the story says. The story adds that estimates of the scope of the problem are \u201cfrustratingly broad \u2014 from less than 10 percent to 50 percent or more of women who get screened. In other words, we don\u2019t actually know how bad the problem is.\u201d", "answer": 1}, {"article": "For more information on breast cancer, visit the American Cancer Society.\nBut their work was done in a laboratory, not in humans, she noted.\nIf so, human trials might follow.\nEating bitter melon could also have a beneficial effect, Ray said.\n\"We didn't see any death in the normal cells,\" she said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Not applicable.\u00a0 You can\u2019t talk about harms from an agent that\u2019s only been tested in a petri dish.\u00a0 But, then again, you really can\u2019t say much at all. Yet they made a news story out of this. ", "answer": 2}, {"article": "\u201cBut there\u2019s never before been data saying how harmful stopping shortly before surgery can be.\nTaking statins the day of a coronary artery bypass operation may significantly improve survival, a study in the Annals of Thoracic Surgery found.\nResearchers looked at 3,021 heart surgery patients, most of whom were taking cholesterol-lowering statins.\nAfter controlling for many preoperative health and behavioral characteristics, they found that compared with other patients, those who took statins on the day of surgery had a 48 percent reduced risk of dying in the next 30 days.\n\u201cWe already knew that people on statins before surgery had a decreased risk of death,\u201d said a co-author, Dr. Yi Deng, an assistant professor of anesthesiology at Baylor College of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms of taking a statin are not addressed, even though they carry side effects, and these effects may have been a reason people stopped taking them before surgery.\nAlso, as\u00a0implied in the news release from The Society of Thoracic Surgeons, patients may have been told to stop their statins by a doctor\u2013why is that sometimes the case? Was it because of a potential perceived harm? This context isn\u2019t provided.\n(It appears, for example, that drug labels for statins used to recommend stopping them before surgery because of the risk of muscle breakdown, known as rhabdomyolysis. There\u2019s some indication that doctors have been slow to catch up with newer guidelines that state statin use should be continued.)", "answer": 0}, {"article": ".\nThe results showed that the blood test was able to detect brain injuries with 94 percent accuracy, nearly as effective as state-of-the art CT scans.\nNeither scenario gives doctors and objective way to determine the severity of the injury.\nWhen cross-checked with scans, the blood test was able to detect mild to moderate traumatic brain lesions with up to 97 percent accuracy in patients 18 years and older.\n\"Symptoms of a concussion, or a mild to moderate traumatic brain injury, can be subtle and are often delayed, in many cases by several days,\" said Linda Papa, MD, MSC, an emergency medicine physician and NIH funded researcher at Orlando Health and lead author of the study.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release did not mention any potential harms of this screening tool. Just to mention one hypothetical case, it is possible that caregivers relying on the blood levels alone may err and fail to test in other ways for brain injury. In general, medical tests have two potential harms. The first is that the test does not demonstrate the presence of injury when in fact there is one. This would lead to under-diagnosis. The second is the test demonstrates the presence of injury when it does not exist. That would lead to over-diagnosis. While obvious, the report should have included some caveats to its otherwise glowing comments.", "answer": 0}, {"article": "However, prostate cancer is one of the few cancers that\u2019s not strongly linked to smoking (and falling cigarette consumption over the past 40 years is a major reason for falling cancer rates).\nIt\u2019s saying that, for most men, the (albeit small) risk of sexual dysfunction and urinary leakage from eventual treatment is not worth it, given the even smaller chance that PSA testing could save your life.\nAs for the new paper this week, which suggests that three times as many men would be diagnosed each year with metastatic prostate cancer if it weren\u2019t for PSA testing, that study is published in the journal Cancer \u2014 and its numbers deserve a little explanation.\nOn the first issue, there is still some uncertainty.\nBut a new study this week reflects the continued view of many physicians \u2014 that screening does help to catch tumors earlier.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "WebMD\u2019s story quantified the potential harms in a more helpful way.\nWe also take issue with the statement that it is an \u201calbeit small risk of sexual dysfunction and urinary leakage from eventual treatment.\u201d\nThe discussion of harms was incomplete.", "answer": 1}, {"article": "\u2018\u2018I\u2019ve had chemotherapy.\nMany women with early-stage breast cancer can skip chemotherapy without hurting their odds of beating the disease \u2014 good news from a major study that shows the value of a gene-activity test to gauge each patient\u2019s risk.\nIn the study, women who skipped chemo based on the test had less than a 1 percent chance of cancer recurring far away, such as the liver or lungs, within the next five years.\n\u2018\u2018These patients who had low risk scores by Oncotype did extraordinarily well at five years,\u2019\u2019 said Dr. Hope Rugo, a breast cancer specialist at the University of California, San Francisco, with no role in the study.\n\u2018\u2018There is no chance that for these patients, that chemotherapy would have any benefit.\u2019\u2019\n\nDr. Karen Beckerman, a New York City obstetrician diagnosed with breast cancer in 2011, said she was advised to have chemo but feared complications.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We give the story the benefit of the doubt here. It mentions that adding chemo exposes patients \u201cto side effects and other health risks,\u201d but it doesn\u2019t detail what those effects are. Two other people mentioned in the story refer to \u201ccomplications\u201d and chemo being \u201cnot pretty,\u201d but the story does not elaborate on these comments. The National Cancer Institute lists a slew of side effects from undergoing cancer treatment, such as bleeding, fertility problems and hair loss.\nOn the flip side, researchers mentioned it\u2019s possible that patients in the low risk group could experience relapses in the future, and it\u2019s unclear if early administration of chemo would have helped in these cases. We address this point in the \u201cQuality of Evidence\u201d section, since researchers addressed this as a study limitation in their paper.", "answer": 1}, {"article": "Healthy cartilage that covers the bone surfaces in the knee joint transfers these high loads from the lower leg to the upper leg.\nThe case report highlights the journey a 39-year-old female endurance runner took from the end of her post-knee surgery rehabilitation to taking part in her sport again.\nAn eight week return to running programme using the anti-gravity treadmill was individually designed by Dr Hambly.\nThe team individually tailors rehabilitation programmes to support people in returning to sport and exercise activities after injury or surgery.\nNews releases can also be found at http://www.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release does not mention any potential harms.", "answer": 0}, {"article": "\"It's been a miracle to me,\" Wolfe said.\nAddiction specialists not involved in the study said the findings are promising, although side effects such as trouble concentrating, tingling and itching caused about one in five people to drop out of the study.\nThe study, published in today's Journal of the American Medical Association, was funded by the maker of the drug, Johnson & Johnson Inc.'s Ortho-McNeil Neurologics.\nThe study followed 371 heavy drinkers for 14 weeks.\nBy the end of the study, 27 of the 183 people, or 15 percent, who took Topamax had quit drinking entirely for seven weeks or more.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did mention some of the unpleasant side effects that people taking the drug experienced; although it did not provide information about how frequently they occurred, it mentioned that 20% of the people dropped out of the study which provides a composite of sorts.\u00a0 ", "answer": 1}, {"article": "Along with obesity, high levels of blood fats can lead to heart disease and other health problems, including diabetes.\nNeal's data show that may not be the case.\nThe next update of the recommendations is expected in spring 2011.\nThat allowed Neal and his team to determine how many children who actually had high cholesterol would have been missed if they had been screened based on federal guidelines.\nAmong the 5,798 children who would not have been screened, nearly 10% had elevated LDL cholesterol levels (above 130 mg/dL), according to the study, published in the August issue of Pediatrics.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nThe story mentions neither the potential harms of statin drug treatment that have been reported in studies of adults nor the fact that the safety of these drugs has not been studied in children.", "answer": 0}, {"article": "Previous studies have found that aspirin users enjoyed a lower risk of colon cancer; a trial published earlier this year concluded that people who take a daily aspirin have as much as a 46% lower risk of colon, lung and prostate cancers, compared with non-users.\n\u201cGiven the high skin cancer incidence and the widespread and frequent use of NSAIDs, a preventive effect of these agents may have important public health implications,\u201d the authors, led by Sigrun Alba Johannesdottir from Aarhus University Hospital in Denmark, wrote.\nIt\u2019s not the first study to show a potential anticancer effect of aspirin and other similar painkillers \u2014 a class of medications known and nonsteroidal anti-inflammatory drugs, or NSAIDs.\nHowever, the researchers didn\u2019t have information on other key skin cancer risk factors like exposure to UV radiation.\nBut taking aspirin and aspirin-like drugs isn\u2019t without consequences: they may have harmful side effects on the stomach and digestive tract, causing bleeding and dangerous ulcers.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that aspirin and NSAIDs can cause bleeding and are associated with adverse cardiovascular effects. However, maybe these important caveats should have come sooner than paragraph eight of a nine-paragraph story. Moreover, the story could have provided some sense as to how frequently these adverse events occur and if they are common enough to counterbalance the apparent decrease in cancer associated with these drugs.", "answer": 1}, {"article": "The difference?\nMany women in the Women\u2019s Health Initiative study were well past menopause, were obese or were smokers and therefore already at risk of heart disease and stroke.\nDr. Noushin A. Firouzbakht, an obstetrician-gynecologist at Texas Health Harris Methodist Hospital Fort Worth, says that despite the alarm provoked by the Women\u2019s Health Initiative study, much was learned, especially about the ideal candidate for hormone replacement.\nBut in 2002, when concerns were raised by a set of studies by the Women\u2019s Health Initiative of the National Institutes of Health showing hormones correlated with elevated breast cancer, heart disease and stroke risk, women and their doctors hit the brakes.\nThe doctors emphasized not just the medical benefits, but that the treatment can enable and boost a woman\u2019s overall day-to-day existence, too.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states that conclusions of the Women\u2019s Health Initiative have been discredited by subsequent studies but fails to state any of these studies or acknowledge potential side effects of HRT. \u00a0The article instead points out some of the limitations of the Women\u2019s Health Initiative, but we don\u2019t think \u201cdiscredit\u201d is appropriate in this case.\u00a0 It was further analysis of the WHI data \u2013 not new studies \u2013 that showed that risks are different in the younger postmenopausal women (women in their 50s) compared with the older population.", "answer": 0}, {"article": "I relived the parts of me I had lost.\nThe current protocol calls for patients to take MDMA two or three times, each a month apart, interspersed with psychotherapy.\nThe drug floods the brain with hormones and neurotransmitters that evoke feelings of trust and well-being, users report.\nResearchers say this allows patients to re-examine traumatic memories.\nIn follow-up psychotherapy, patients process emotions and insights brought up during the MDMA session.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article states:\nSide effects including anxiety, headache, fatigue, muscle tension, and insomnia, were generally minor and limited to the days following the MDMA sessions.\nReaders might have concerns regarding the long-term consequences of pharmaceutical grade MDMA, but this is unknown. The article does make it clear that the MDMA-assisted psychotherapy model used in the study only involves taking the drug on 2-3 occasions.\nAlso, the article anticipates that some people may (and already do) turn to street sources of MDMA (aka \u201cEcstasy\u201d or \u201cMolly\u201d) to self medicate. It\u2019s made clear that this could could be dangerous, or even fatal, since street sources can be laced with other psychoactive drugs.", "answer": 1}, {"article": "\"Compared to childhood vaccines, people would [probably] think 55% is not too impressive, because many childhood vaccines are in the range of 80% to 90% [effective],\" says researcher Hung Fu Tseng, PhD, MPH, a research scientist at Kaiser Permanente Southern California.\nAnother new study, published in the American Journal of Preventive Medicine, finds that by 2008, less than 7% of U.S. adults aged 60 and older had gotten the vaccine, which has been available just since 2006.\nHowever, he tells WebMD, the 55% risk reduction ''is pretty high compared to other adult vaccines.\"\nThe new study is published in the Journal of the American Medical Association.\nAbout a million episodes of shingles, sometimes debilitating, occur in the U.S. annually, Tseng says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story reports that earlier research identified side effects of the vaccine, including redness and pain at the injection site. But an inquiring story would have asked about side effects in the new study.\n", "answer": 1}, {"article": "One large egg has about 70 calories, and it contains about 6 grams of protein, 5 grams of fat, and 186 milligrams of cholesterol.\nMay 11, 2012 -- Starting your day off with an egg may help curb your appetite better than cereal, new research suggests.\nThe research was funded by the American Egg Board, and will be presented at the19th European Congress on Obesity in Lyon, France.\nIn a small study, it took longer for people who ate eggs for breakfast to show signs of hunger than it did for those who had a bowl of ready-to-eat cereal.\n\"This study shows that diets with higher protein quality may enhance satiety, leading to better compliance and success of a weight loss diet,\" researcher Nikhil Dhurandhar, PhD, says in a news release.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this not applicable, as the potential harms of eating eggs are minimal. In just a line, though, the story could have addressed whether eating an egg a day, as participants did during this study, is safe from a heart health standpoint (eggs contain a lot of cholesterol). Most research from large cohort studies (Nurses\u2019 Health Study and Health Professionals Follow Up study) of diet have shown no increased risk of cardiovascular disease among regular egg eaters.\u00a0 Nonetheless, just as it popped into our reviewers\u2019 minds, we bet it popped into readers\u2019 minds as well \u2013 yet wasn\u2019t addressed.", "answer": 2}, {"article": "\u201cIt\u2019s a tough disease because we don\u2019t have a way to bring vision back once it\u2019s lost,\u201d he said.\nOther studies indicate that antioxidants in tea could have similar effects, he noted.\nCoffee, or caffeine in general have previously been linked to increased glaucoma risk, although recent studies don\u2019t agree, Coleman and her colleagues write.\n\u201cExercising, eating healthy and trying novel ways to improve your health is something you should definitely explore and bring up with your physician.\u201d\n\nEnvironmental factors could play a role in glaucoma risk as well, said Dr. Ahmad Aref at the University of Illinois at Chicago.\n\u201cThis makes sense, but we\u2019ll see if it holds up in future studies.\u201d\n\nFuture studies should look at the habits, activities and nutrition that affect lifestyle and glaucoma risks, said Idan Hecht of Tel-Aviv University in Israel, who wasn\u2019t involved in the research.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Only potential harm to be considered would be those people who respond to this study by abusing caffeinated tea thinking that more consumption might offer more protection from glaucoma. Excess caffeine can have deleterious health effects. Not including this unlikely scenario in the story seems reasonable.", "answer": 2}, {"article": "\u201cI\u2019m amazed,\u201d she said.\nIt\u2019s not clear why just one in five patients benefits, said Dr. Annick Desjardins, who worked on the study team.\nIt\u2019s no miracle cure \u2014 only about 20 percent of patients with gliomas were helped \u2014 but some are alive six years later, the team reported in the New England Journal of Medicine.\n\u201cSimilar to many immunotherapies, it appears that some patients don\u2019t respond for one reason or another, but if they respond, they often become long-term survivors,\u201d Desjardins said.\nThese patients have a \u201cdismal\u201d prognosis, the Duke team wrote in the New England Journal of Medicine.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Better than the NPR story that we also reviewed, NBC did a good job of spelling out harms, stating 19% of patients had \u201cnotable adverse events\u201d and more than a quarter experienced brain damage affecting speech and communication. Again, though, we think it\u2019s better to give readers the absolute number of adverse events \u2013 how many out of how many?", "answer": 1}, {"article": "For more on stroke, visit the National Stroke Association.\nBleeding into the brain, the most serious side effect of either drug, occurred in 1 percent of patients, regardless of which drug they received, Campbell said.\nAmong more than 200 stroke victims, TNKase (tenecteplase) was about twice as effective as alteplase in restoring blood flow to the brain, and it also resulted in less disability, the scientists found.\nIn this study, patients were given the drugs within 4.5 hours after the onset of a stroke, Campbell said.\nThe researchers specifically looked to see which drug was better at restoring blood flow to clot-blocked blood vessels in the brain, and which drug resulted in patients having better outcomes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentioned a feared complication of clot-busting stroke drugs: often-fatal brain bleeds, which it said occurred in 1% of patients regardless of which drugs they received. It did not say that one of the two patients in the study who had a brain bleed died from it.", "answer": 1}, {"article": "By using dynamic contrast magnetic resonance imaging (MRI) to image the brain\u2019s glymphatic pathway, a complex system that clears wastes and other harmful chemical solutes from the brain, Stony Brook University researchers Hedok Lee, PhD, Helene Benveniste, MD, PhD, and colleagues, discovered that a lateral sleeping position is the best position to most efficiently remove waste from the brain.\nDr. Benveniste cautioned that while the research team speculates that the human glymphatic pathway will clear brain waste most efficiency when sleeping in the lateral position as compared to other positions, testing with MRI or other imaging methods in humans are a necessary first step.\n\u201cThe study therefore adds further support to the concept that sleep subserves a distinct biological function of sleep and that is to \u2018clean up\u2019 the mess that accumulates while we are awake.\nTheir finding is published in the Journal of Neuroscience.\nNewswise \u2014 Stony Brook, NY \u2013 Embargoed for August 4 @ 5:00 PM EST, 2015 \u2013 Sleeping in the lateral, or side position, as compared to sleeping on one\u2019s back or stomach, may more effectively remove brain waste and prove to be an important practice to help reduce the chances of developing Alzheimer\u2019s, Parkinson\u2019s and other neurological diseases, according to researchers at Stony Brook University.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The harm of changing one\u2019s sleeping pattern is not addressed. While there are people with certain health conditions that can\u2019t sleep on their side, it doesn\u2019t seem like an applicable criteria for rating this release.", "answer": 2}, {"article": "Kalajian, A. Aldoukhi, A.J.\nA vitamin D3 producing UV LED device could be used on skin areas that experience less exposure to sunlight such as upper legs and arms and abdomen and back thus minimizing risk for developing non-melanoma skin cancer.\nThis device for making vitamin D is ideally suited for patients with fat malabsorption syndromes including inflammatory bowel disease and gastric bypass surgery.\nThe research shows that RayVio's UV LEDs could be used for treating patients that are vitamin D deficient.\nTyler Kalajian and his research team, led by Dr. Michael F. Holick, Ph.D., M.D., and supported by Boston University School of Medicine and a Boston University Ignition Award, found that skin samples exposed to RayVio's UV LED for just 0.52 minutes produced more than twice as much vitamin D3 as samples exposed to 32.5 minutes of sunlight.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release gives a nod to harms, although only to discuss how it would reduce risk compared with sunlight exposure. It states: \u201cA vitamin D3 producing UV LED device could be used on skin areas that experience less exposure to sunlight such as upper legs and arms and abdomen and back thus minimizing risk for developing non-melanoma skin cancer. The UV LED device also emits a much narrower band of UVB light and thereby decreasing likelihood of skin damage that can occur when the skin is exposed to higher wavelengths of UV radiation.\u201d\nAlmost all interventions are associated with potential harms, and light therapy is no different. Although light therapy is considered generally safe, it may cause eyestrain, headache, nausea, irritability or agitation, and mania, euphoria, hyperactivity or agitation associated with bipolar disorder. Specifically, UV light can cause eye and skin damage, as well as increase one\u2019s risk of skin cancer.\nSince harms from UV LED aren\u2019t addressed in this news release, we give it a Not Satisfactory rating here.", "answer": 0}, {"article": "(Reuters Health) - Waning eyesight may hasten the pace of cognitive decline in older people, suggests a U.S. study.\nThe good news, Whitson added, is that poor vision is one of the few risk factors for cognitive decline that is potentially modifiable.\nPoor eyesight and weakening mental function are common in older people and related to one another, but the question of whether vision influences cognition, or vice versa, has not been clear, the study team writes in JAMA Ophthalmology.\nA person\u2019s vision at their previous check-up was related to their mental function at the following check-up.\n\u201cTaking care of your vision is important in order to maintain good cognitive function,\u201d she said in a telephone interview.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the debits of traditional eye exams are minor, more substantive \u201cfixes\u201d of vision problems mentioned in the story (such as cataract surgery) do bring with them possible risks.", "answer": 0}, {"article": "Watch Sanjay Gupta MD Saturday at 4:30pm and Sunday at 7:30am ET.\n\"There is a large group in the middle called intermediate risk, which may be as much as 50% of the population,\" said Dr. Erin Michos, a cardiologist at the Ciccarone Center for the Prevention of Heart Disease at Johns Hopkins University\n\nA good candidate for a coronary calcium scan, she says, would be a 50-year-old man with slightly elevated cholesterol and a father who had a heart attack.\nAgatston thinks the coronary calcium scan should be routinely scheduled at age 50, like a colonoscopy, or earlier for people with family histories of heart disease.\nAgatston says relatively new imaging tests give real-time pictures showing whether plaque is building up in key blood vessels, alerting doctor and patient to an increased risk of a potentially deadly heart attack.\nThese new tests give patients a chance to make major changes in their diet and lifestyle, and give doctors an opportunity to treat them with medication.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "As with costs, this story mentions harms, yet generally misleads readers. While the story emphasizes potential long-term benefits of screening, there is no mention of the downstream risks of tests and treatments triggered by the initial screening scans. For example, someone found to have a high coronary calcium score may be referred for an invasive coronary angiography exam, which in rare cases can cause serious injury or death. This story fails to point out the typical downsides of screening, especially for low-risk individuals who are less likely to gain important benefits.", "answer": 0}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\nThey were all taking part in the Physician\u2019s Health Study, a giant, ongoing research project that follows thousands of male doctors over their lives.\nIt\u2019s really not a shocking discovery, Chavarro says.\nSo-called Mediterranean-style diets, with plenty of fresh vegetables and fruit, olive oil instead of saturated fat, whole grains and more fish than meat, ward off these same diseases.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We won\u2019t flag the story for not discussing the potential harms a Mediterranean style of eating \u2014 which don\u2019t really merit much discussion.", "answer": 2}, {"article": "Face the light but do not stare at the light.\nAnd because it has few side effects, researchers are studying whether light therapy can help with depression during pregnancy and be used to treat elderly people with dementia.\n\u201cStudies have also shown that light influences serotonin and epinephrine pathways in the brain, the same neurotransmitter systems known to be affected in people with general depression.\u201d\n\nBut while part of the appeal of light therapy is that it can be self-prescribed, using a light box is not as simple as it may appear.\n\u201cIf you can fix the drift, you can fix the depression.\u201d\n\nLight therapy may even help with major nonseasonal depression, experts say, and with sleep disorders.\nPatients generally sit in front of the light box, which can be as small as 9 by 11 inches and 5 inches deep, with the bright light emanating from the square surface, in the morning.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story stated \u201cSide effects include headaches and hypomania.\u201d And it included the warning: \u201cUsing a light box is not as simple as it may appear. Experts recommend consulting with a knowledgeable health care provider.\u201d\nAnother point the story could have raised is that a person with a disorder that does not respond to light may self-diagnose and fail to seek more effective therapy or advice.", "answer": 1}, {"article": "And while I was willing, part of me dreaded it.\nDr. Lauren Streicher, medical director of the Center for Sexual Medicine at Northwestern Memorial Hospital in Chicago, said the results cited in the Dutch study are averages, and while Addyi doesn't work for everyone, many of her patients have benefited from it.\nShe says she's written Addyi prescriptions for about 10 women, and three or four have emailed her back to say it's worked.\nSome doctors and patients who've been using Addyi say the drug has been helpful.\n(CNN) A new review of the \"little pink pill\" for women with low sexual desire says the drug doesn't work very well -- but some doctors and patients who've been using the treatment disagree.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We learn the drugs have side effects but nothing about the fainting, falls and somnolence that are known side effects of the drug.\nThe patient with the testimonial is\u00a0quoted saying: \u201cI should be able to choose whether the side effects are worth the benefit.\u201d\nWe agree. But we also agree that anyone reading this article should get a sense of what those side effects are likely to be\u00a0and how often they occur.", "answer": 0}, {"article": "But in the study group overall, more-inflammatory diets were not linked to fracture and - in fact - the researchers found a modestly lower risk of lower-arm and total fracture in women with the highest dietary inflammation scores.\nThis was despite the fact that they started off with lower bone density overall.\nBecause the study was observational, it's not possible to definitively link dietary patterns and bone health and fracture outcomes.\n\"I think this gives us yet another reason to support the recommendations for a healthy diet in the Dietary Guidelines for Americans.\"\nThe study, led by Tonya Orchard, an assistant professor of human nutrition at The Ohio State University, appears in the Journal of Bone and Mineral Research.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of harms in the release but it\u2019s hard to envision harms that could occur from an improved diet.", "answer": 2}, {"article": "Coffee or tea?\nWe've heard a lot about the health benefits of tea, especially green tea.\nGood clinical studies are few, however, and although I and other physicians tell our patients to drink green tea, there hasn't been any definitive proof of the value of that advice.\nThat's why I was so interested in a report last week in the Journal of the American...\nIt is high in polyphenols--compounds with strong antioxidant activity that in test-tube and animal models show anticancer and heart-protective effects.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "A claim is made in the article that by enjoying tea of the best quality, you are probably doing more good than harm. The article did not mention any potential harms associated with consumption of green tea, even if that would be to say that there are no known risks associated with green tea consumption.", "answer": 0}, {"article": "\u201cWith medicine, you always want to optimize a patient\u2019s outcome,\u201d Shastri said.\nPlus, the American Society for Reproductive Medicine (ASRM) committee opinion on IVM states that implantation rates for IVM\u2014between 5.5 and 21.6 percent\u2014 are a more reliable indicator of IVM success and are lower than expected for women of the same age who use IVF.\nThey also note that the technology hasn\u2019t been widely used and that there are no studies looking at the outcomes of birth defects or developmental delays.\nFor starters, since there is less time involved with IVM, women who are undergoing chemotherapy, radiation or plan to have surgery may be good candidates.\nAlthough IVF is considered the standard of care, experts say some women may benefit from IVM.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the article notes that for \u201csome women\u201d the hormone injections required for IVF (and presumably IVM as well) can be \u201cdownright dangerous,\u201d it doesn\u2019t say exactly how they are dangerous, what the dangers are, or what the dangers are of the rest of the IVF/IVM procedure in terms of fetal outcomes\u00a0or biological/psychological tolls on women.", "answer": 0}, {"article": "All rights reserved.\nApproval as an initial treatment likely would boost that sharply.\nTykerb had sales of $189 million last year.\nIt targets cancer cells more than healthy ones, Roychowdhury said.\nThe British pharmaceutical company's Tykerb was approved here two years ago as part of a treatment for most women with advanced breast cancer that wasn't stopped after chemotherapy and other drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story says that Tykerb can damage the liver and harm a fetus.\u00a0 But that\u2019s an incomplete listing.\u00a0 Tykerb can cause rare but very serious problems with heart failure and pulmonary toxicity. The drug can also cause diarrhea, skin rash, swelling, redness, pain and or peeling of the skin on the hands and feet, anemia, nausea and vomiting \u2013 along with a host of less common side effects. The story was way off in this regard. ", "answer": 0}, {"article": "While smoking is a public health scourge, the nicotine in cigarettes may have some promise in treating another growing problem, mild cognitive impairment (MCI), which can be a precursor to Alzheimer\u2019s disease or other forms of dementia.\nThe authors conclude, \u201cThis initial study provides evidence for nicotine-induced cognitive improvement in subjects with MCI; however, whether these effects are clinically important will require larger studies.\u201d\n\nThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\nThe research was funded by the National Institute on Aging, but some of the authors also receive pharmaceutical industry funding and one reported funding from Philip Morris.\nThe study was led by Dr. Paul Newhouse of Vanderbilt University and published in Neurology.\nHowever, when clinical experts rated overall general change in the patients, they did not see a significant difference between the two groups.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story reported:\u00a0 \u201cThe study found no problematic side effects associated with the nicotine patch and none of the patients had withdrawal symptoms when it was stopped.\u00a0 However, patients on nicotine did lose a few pounds, which is a known side effect.\u201d The study also reported a small drop in systolic blood pressure in subjected treated with nicotine \u2013 an unusual finding which the story did not report.\nWe like that the story, unlike the MSNBC piece, noted that \u201cnicotine might enhance the cancer-causing properties of other substances.\u201d", "answer": 1}, {"article": "As a result, we set out to conduct a systematic search of all the scientific literature.\"\nIn a systematic review of the available scientific literature a team from Cardiff University's School of Medicine found a significant reduction in mortality and cancer spread by patients who took a low-level dose of aspirin in addition to their cancer treatment (average study follow-up length over 5 years).\nPatients receiving cancer treatment could increase their chance of survival by up to 20% and help stop their cancer from spreading by taking a low-dose of aspirin, new research suggests.\nA mutation - known as PIK3CA - was present in about 20% of patients, and appeared to explain much of the reduction in colon cancer mortality by aspirin.\n\"There is a growing body of evidence that taking aspirin is of significant benefit in reducing some cancers,\" said Professor Peter Elwood who led the research published in the journal PLOS ONE.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The only risk of harm in the release is a passing mention of intestinal bleeding in cases of colorectal cancer.\nBriefly mentioning the handful of other risks would have greatly improved this release. Even small doses (80-325 mg) of aspirin can reduce the body\u2019s ability to clot wounds, and consequently promote bleeding. Giving aspirin to patients being treated for cancer may be presumed to increase bleeding risk, especially if the patient has low platelets as a result of chemotherapy.\nSome people are also allergic to aspirin, which can complicate asthma. A regular dose of aspirin can also increase the risk of bleeding stomach ulcers.\nImportantly, 21 out of 36 studies included in the meta-analysis of aspirin and the three cancer types had no data on bleeding.", "answer": 0}, {"article": "Source: Brightling C, et al.\nThe drug, known as Fevipiprant (QAW039), was shown to reduce asthma symptoms as well as inflammation, and it improved lung function and repaired airway linings.\n\u201cMost treatments might improve some of these features of disease, but with Fevipiprant improvements were seen with all the types of tests.\n\u201cA unique feature of this study was how it included measurements of symptoms, lung function using breathing tests, sampling of the airway wall and CT scans of the chest to give a complete picture of how the new drug works,\u201d said Brightling in the press release.\nBy measuring the sputum eosinophil \u2014 the inflammation marker that shows how white blood cells increase during asthma attacks \u2014 the researchers were able to track the effects of the drug.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No serious adverse effects were reported in trial participants who took fevipiprant, a fact the story does not mention. The story also should have mentioned\u00a0mentioned that it remains to be seen whether fevipiprant is safe over decades of continuous use, which is typical for as asthma drug, as well as for patients of various ages and health conditions.", "answer": 0}, {"article": "\"Although we do not know why the men who took saunas more frequently had greater longevity (whether it is the time spent in the hot room, the relaxation time, the leisure of a life that allows for more relaxation time, or the camaraderie of the sauna), clearly time spent in the sauna is time well spent,\" Redberg wrote.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story squeaked by on this one by pointing out that there are some sudden deaths associated with sauna use, usually in relation to alcohol use. But the story also mentions that previous studies have suggested that sauna bathing might have some harmful effects. We wonder what those effects were, and why we should trust the new study\u2019s assurance that there are no such effects.", "answer": 1}, {"article": "\u201cWhen people engage in risky behaviors like driving or smoking, they\u2019re encouraged to take measures that minimize their risk, like wearing a seatbelt or choosing cigarettes with filters.\n\u201cAlthough no substitute for systematic lifestyle improvements, including healthy diet, regular exercise, weight loss, and smoking cessation, complimentary statin packets would add, at little cost, one positive choice to a panoply of negative ones,\u201d the scientists write in their paper.\nBut a few experts say you might want to ask your server to hold the statin at this point.\nWhile statins might combat some of the toll that fatty foods take on cholesterol, there\u2019s a lot they can\u2019t negate: \u201csodium content is high, fibres are absent, and caloric load gargantuan,\u201d Messerli said of the fast food the authors looked at.\nTaking a statin is a rational way of lowering some of the risks of eating a fatty meal.\u201d\n\nStill, Peter Weissberg, medical director at the British Heart Foundation (BHF) health charity, said Francis\u2019 idea should not be taken too literally.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "It\u2019s hard to ding the story for not actually calculating the potential harms, given that the piece is based on an editorial. In all, we think the story did a fair job pointing out the problems with using statins as a subsitute for exercise and a healthy diet. It could have at least mentioned some of the side effects of long-term statin use.", "answer": 1}, {"article": "So for many of these women, these medications are life-saving and life-altering.\"\nThe FDA advisory pointed to a single study showing a six-fold increased risk of a condition called persistent pulmonary hypertension in newborns whose mothers were taking antidepressants.\n\"The risk increase of taking antidepressants late in pregnancy, if present, is much more modest than previous studies have found,\" says Krista Huybrechts, Ph.D., an epidemiologist at Brigham and Women's Hospital.\nDr. Economy warns patients about the potential risks like withdrawal in the newborn and a small risk of heart defects, but says for many women, the worst time to stop their medications is at the end of pregnancy when postpartum depression becomes a concern.\nBut now a new, large-scale study finds that the risk is negligible -- much lower than previously believed, reports CBS Boston's Dr. Mallika Marshall.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The harms mentioned by this story include PPHN, newborn withdrawal from antidepressants, and \u201ca small risk of heart defects.\u201d This is responsible \u2013 and enough for a Satisfactory rating. The story could have gone further by quantifying these harms and mentioning the potential harms of untreated depression, which aren\u2019t noted in the story.\u00a0As noted by the study author in the competing HealthDay story: \u201cUntreated depression or anxiety during pregnancies has been linked to different adverse health outcomes, such as miscarriage, preterm birth, pre-eclampsia and smaller newborns,\u201d Huybrechts said.", "answer": 1}, {"article": "It is a bold move, but bold moves are what our patients deserve.\"\nMore than improving the results of the initial treatment, the MASTER study will treat patients for the necessary time to confirm elimination of minimal residual disease and then discontinue therapy.\nUp until now, existing therapies have been developed on trials that assigned treatment for a defined duration of time, irrespective of depth or speed of response, often followed by maintenance therapy for indefinite duration and with potentially adverse impact on risk of complications and cost.\nAs it stands, patients with billions of cancer cells in their bodies and patients with true disease eradication will both appear to be in complete remission using current methods to measure disease response to therapy.\nPatients will be monitored for relapse at the molecular level, before disease becomes again symptomatic.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "There is no mention of risks or harms of the experimental approach, but part of the function of a phase 2 trial is to evaluate harms. Not only does each drug in the experimental cocktail include its own risks (including increased risk of heart attack and stroke, nerve damage, blood clots, low white blood cell and platelet counts, fatal spikes in blood pressure), but the effect of the combination of drugs could exacerbate the harms or even create new ones. While multiple myeloma patients may be aware of and acknowledge the risks of individual drugs as part of standard treatment, the unknowns of the experimental drug combination should have been pointed out in the release.", "answer": 0}, {"article": "Then they took tests involving memorizing words.\nDr. Fl\u00f6el said the memory improvement might be linked to a decrease in insulin and inflammation in the calorie-restricted participants, who lost four to seven pounds.\nThe study, published Monday in The Proceedings of the National Academy of Sciences, appears to be the first to link calorie-restricted diets with improved memory in people.\nStudies with animals have shown memory improvement, but there is debate about the impact of calorie restriction on humans\u2019 cognitive function.\nEating fewer calories may lead to better memory, a new study says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions that some earlier studies found that caloric restriction was linked to memory decline. \nBut it fails to mention one very important practical warning relevant to the study populations: That older patients are at increased risk for malnutrition, and should not restrict their caloric intake without medical superivision.\u00a0\nFurther, it\u2019s not known whether caloric restriction is safe for slightly overweight or normal weight adults regardless of age.\u00a0 ", "answer": 0}, {"article": "Source: Australian Bureau of Statistics, 2016, National Health Survey: First results, 2014-15, ABS cat.\n\u201cThis study shows that the new MedDairy works better than a generic low-fat diet, ensuring better health outcomes for people at risk of cardiovascular disease.\u201d\n\nImportantly, the MedDairy diet also meets additional calcium requirements recommended by Australia\u2019s national health bodies.\nThe results show that the dairy-supplemented MedDiet (MedDairy) significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function.\nNewswise \u2014 Thousands of people can take heart as new research from the University of South Australia shows a dairy-enhanced Mediterranean diet will significantly increase health outcomes for those at risk of cardiovascular disease \u2013 and it\u2019s even more effective than a low-fat diet.\nSimilarly, the Mediterranean diet (MedDiet) has been shown to deliver significant health benefits.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t address harms from a dairy enriched diet.\nSince the release is encouraging greater dairy consumption, including up to 4 servings of cheese a day, it would be important to mention that there are potential harms from consuming more saturated fats found in many dairy products.", "answer": 0}, {"article": "It\u2019s there.\nAnd it needs to be strong enough and elastic enough that it actually affects the recoil of the skin.\u201d\n\nThat, he said, \u201cis the challenge I put to them.\u201d\n\nDr. Robert Langer, a biomedical engineer who is a professor at M.I.T.\nWhy, Dr. Anderson asked the company executives, couldn\u2019t there be a polymer to put on skin?\nOne of the first applications, said Dr. Barbara A. Gilchrest, a dermatology professor who is part of the research team, was on undereye bags, a condition that plagues so many middle-aged and older people.\n\u201cWhen we move skin, it doesn\u2019t snap back to what it used to be.\u201d\n\nWhat if there was a way to restore the elastic nature of skin?\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions harms indirectly by citing a lack of irritation or allergic reactions among those test subjects that used it. This at least clarifies the findings about some of the obvious potential harms, so we\u2019ll rate this Satisfactory.\nBut, we do think the the story could have pointed out that long-term effects are still unknown. For example, what happens if you get some of this in your eye?", "answer": 1}, {"article": "According to Hazinski, one easy way to remember the rhythm is that it is roughly equivalent to the beat of the 1977 Bee Gees' disco hit \"Stayin' Alive.\"\nHe said the latest research on CPR supports the notion that in the critical minutes before an ambulance or defibrillation device arrives, it is very important to provide uninterrupted, deep chest compressions.\nThe Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\nOnly about 6 percent of victims whose hearts stop outside of a hospital survive.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The news article explains that when CPR is performed with chest compressions only (without mouth-to-mouth resuscitation) the main harm is rib fractures induced by energetic chest thumping. ", "answer": 1}, {"article": "Standard therapies include over-the-counter pain meds, corticosteroid spinal injections, and/or invasive spine surgery that sometimes involves disk removal and vertebrae fusion.\nAnd the new research suggests the treatment could prove a boon to back pain patients for whom standard therapies have failed to do the trick.\nHe noted that because \"the majority of people with back pain improve with time and exercise alone,\" it remains an open question as to whether the pRF procedure really cured the condition.\nThe therapy is not new, having first received U.S. Food and Drug Administration approval in the 1980s.\n\"Best case, I think [pRF] could be an option for people if they [have already] failed therapy and medication,\" said Park.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss the harms of this treatment. It\u2019s full of language \u2014 \u201ca simple zap to the spine,\u201d \u201cscalpel-free,\u201d \u201cnoninvasive,\u201d \u201cless risky\u201d \u2014 that might mislead readers into being falsely assured.\nA procedure that introduces instruments close to the spine and makes contact with major nerve roots carries risks of infection and nerve damage. Those should have been mentioned.\nThe story does say that \u201cdiagnostic uncertainty can undermine the ability of surgery to get at the true source of a patient\u2019s pain.\u201d However, we think the story should have underscored the point that low back pain is often treated unnecessarily. Even if a herniated disk shows up in imaging \u2014 which is common \u2014 it might not be the cause of a patient\u2019s pain. That opens the possibility that some patients will undergo a procedure that won\u2019t help them, but could do harm.", "answer": 0}, {"article": "In the case of microablative fractional CO2 laser surgery, a series of microscopic laser beams using fractionated energy penetrate the skin to remove old and damaged skin cells, intended to rebuild the vaginal pathway.\n\"Until more data are available, all treatment options, including lubricants, vaginal moisturizers, and FDA-approved vaginal and systemic hormone therapies, should be discussed with women who suffer from GSM to determine the best treatment option for them.\"\nAlthough there is ongoing debate regarding the safety and effectiveness of vaginal laser surgery, a new study suggests that it may be effective, especially after multiple treatments.\nCLEVELAND, Ohio (October 8, 2018)--Microablative fractional CO2 lasers are energy-based devices designed to help manage troublesome menopause symptoms such as painful sex, dryness, itching/burning, urinary frequency, and incontinence.\nStudy results are published in the article \"Microablative fractional CO2 laser for the genitourinary syndrome of menopause: up to 12-month results.\"\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "Not mentioned and extremely relevant based on this June, 2018 publication by the FDA:\nFDA warns against use of Energy-based devices to perform vaginal \u2018rejuvenation or vaginal cosmetic procedures\nThis includes \u201cprocedures intended to treat vaginal conditions and symptoms related to menopause, urinary incontinence, or sexual function\u201d\nSide effects listed include: \u201cvaginal burns, scarring, pain during sexual intercourse, and recurring/chronic pain.\u201d", "answer": 0}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\nSix months later, \u201cformer smokers showed significant improvements on all measures, indicating that treatment with iloprost may reduce the risk of developing lung cancer among former smokers,\u201d the researchers said.\n\u201cOral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,\u201d they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.\nThis was seen even among patients who did not have the EGFR genetic mutation that Tarceva targets, they reported in Lancet Oncology.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No harms of iloprost or erlotinib are mentioned.\u00a0In the\u00a0iloprost study, 11% of subjects receiving the drug reported serious adverse events. That\u2019s a pretty big omission. ", "answer": 0}, {"article": "\u201cAnd we shouldn\u2019t expect it to come off overnight.\u201d\nResearchers found that the drug could lead to consistent and sustained loss of more than 5 percent of weight in nearly 40 percent of patients at risk for heart attacks, strokes and death from cardiovascular disease without increasing the likelihood of such events, according to a report published recently in the New England Journal of Medicine.\nThere are probably a few reasons for this, including cost, if not covered by insurance, and a perception that these agents are not safe in light of the history with weight loss agents.\u201d\n\nIn fact, a 2017 report that examined the medical records of 2.2 million patients found that fewer than one in 50 patients who were eligible for a diet pill prescription received one.\n\u201cMost prior studies of weight loss only followed patients for a year, and a few out to two years,\u201d said the study\u2019s lead author, Dr. Erin Bohula, an assistant professor of medicine at Harvard Medical School and a cardiologist and investigator with the TIMI Study Group at Brigham and Women\u2019s Hospital in Boston.\nWeight loss drugs are recommended supplements to diet and exercise \u2014 included, for example, in 2013 guidelines by the American Heart Association, the American College of Cardiology and the Obesity Society, Bohula said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story kept referring to weight loss drugs as a group, the story focused mostly on lorcaserin, including a\u00a0three-year study that showed lorcaserin didn\u2019t increase the risk of bad heart events versus a placebo in patients at high risk of heart disease. However, the story didn\u2019t mention side effects and uncertainty about long-term use of that drug.\nAn accompanying editorial to the lorcaserin study said that the drug \u201cmay best be used on a cautious basis according to the needs of individual patients,\u201d and mentioned uncertain safety of its long-term use as well as side effects such as headache, fatigue, dizziness, diarrhea, and nausea that led some patients stop using it.\nOther research has raised concern about an increased risk of depression and other side effects that might outweigh lorcaserin\u2019s benefits.", "answer": 0}, {"article": "The United States recommends that men and women over age 31 eat 420 and 320 milligrams of magnesium daily, respectively.\n\u201cIt\u2019s a diet that\u2019s rich in fruits, vegetables and grains.\nMost of the studies allowed the researchers to rule out other factors, such as family history.\n\"It's again the diet per se, not any one individual component of the diet.\"\nAbout 6,500 of them, or three percent, had a stroke in the time they were followed.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms weren\u2019t discussed, but we\u2019re not sure there any substantial harms of a diet rich in leafy green vegetables, nuts and beans worth mentioning.", "answer": 2}, {"article": "A biopsy involves the removal of tissue or fluids to test for disease.\nIn addition, image-guided biopsies are more accurate, Quencer said.\nTUESDAY, Aug. 17, 2010 (HealthDay News) -- Less invasive biopsies done with the help of imaging to guide the needle now make up the majority of biopsies being done, a new study finds.\nMoreover, by 2008, 67 percent of these biopsies were being done through the skin with the help of CT scans, ultrasound and MRI, Kwan's group found.\nIn fact, the use of these minimally invasive biopsies increased from 59 percent to 67 percent of all biopsies between 1997 and 2008, a trend which is likely to continue, one expert noted.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\"Minimally invasive\" does not equate to \"no harm.\"\u00a0 Yet no discussion of potential harms \u2013 either in traditional biopsies or in the minimally-invasive variety made it into the story.\u00a0 No medical intervention with any level of invasiveness is without harm.\u00a0 So potential harms must be discussed to make the story complete. ", "answer": 0}, {"article": "A minimally invasive procedure designed to shrink prostate tissue with a series of nine-second blasts of steam offers men a new treatment for urinary symptoms commonly associated with enlarged prostates.\n\nThe procedure, called Rez\u016bm (pronounced \u201cresume\u201d) and developed by NxThera Inc. of Maple Grove, Minn., became widely available in the U.S. in the second half of 2016. Thermal energy in the form of steam is applied to the prostate with a needle. As it cools it releases heat energy into the tissue, killing cells and shrinking...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story discusses a few\u00a0potential side effects, at least to the same extent as discussed in the related journal article \u2014 namely, the need to wear a catheter for a few days after treatment, and issues in some patients related to ejaculatory volume. It also talked about the need for more long-term data.\nThat said, it would have been helpful to specifically address other potential treatment side effects\u2013bleeding, infection, etc.", "answer": 1}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nA co-author of the 2013 study linking heavy coffee drinking to higher mortality called the new one \u201cvery good,\u201d especially since it controlled for the deadly effects of smoking, which the earlier one did not.\nThis is another observational study, where researchers look for associations between people\u2019s freely-chosen diet and other lifestyle decisions and subsequent health outcomes.\nThis same Nurses Health Study, for instance, infamously found a correlation between post-menopausal hormone therapy and lower risk of cardiovascular disease and death, here and here.\nIt might mean instead that a third factor \u2014 another behavior, socioeconomic status, even personality or genetics \u2014 might go hand in hand with Behavior A and be the true cause of Outcome B.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This STAT story explained the slightly increased risk of death in those participants in the current study who drank\u00a0very high\u00a0amounts of coffee,", "answer": 1}, {"article": "\"It is not inconceivable that in the near future you will see the I-Portal goggle used on every sideline in America,\" Hoffer said.\nWith these findings, it appears the I-Portal goggle may be a solution.\nThe research findings published by PLOS ONE help support their objective.\nAnother benefit for this research was that \"this next generation test has the considerable advantage of not requiring baseline testing,\" said study co-author Carey Balaban, Ph.D., of the University of Pittsburgh.\n\"This is the first paper demonstrating an objective method of diagnosing mTBI that relies on physiologic parameters,\" said Hoffer, who is professor of otolaryngology at the University of Miami Miller School of Medicine.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release did not mention any potential harms that may be associated with the goggles. Almost every health care intervention carries risks, although the severity may vary. The main potential harms are those\u00a0arising from a false positive or false negative test. This could lead to unnecessary treatment or exclusion from play in the first case or no treatment for an injury in the second and potential for much more severe effects from a second head injury. \nSince harms weren\u2019t even addressed, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": ".\nThe current results demonstrate the importance of prompt imaging and treatment of patients with clot-caused stroke, even in those who wake up having experienced a stroke or who for other reasons are not identified in the first few hours after the onset of symptoms.\nIt is already well-established that the benefit of clot removal declines each hour during the first 6 hours after symptoms are detected.\nThe international DAWN trial previously demonstrated that patients with a small area of irreversible brain damage and a large area of brain at jeopardy of being lost if the clot remains are more likely to recover with minimal disability if the clot is removed up to 24 hours after symptoms begin or were noticed.\nThe association has strict policies to prevent these relationships from influencing the science content.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release skimmed over the harms associated with the procedure. As discussed in a previous review, there are adverse effects attributable to this procedure, including the risk of tearing an artery which could cause bleeding in the brain.", "answer": 0}, {"article": "\"There was no significant difference,\" Boden said.\nThe procedure costs about $50,000 and is considered safe, though it does carry some risks.\nBut Boden said that the study did include patients with moderate to severe heart disease and that many such patients undergo the procedure in the belief it will protect them against heart attacks.\nBut the findings indicate that for a patient whose condition is stable, medical therapy is just as effective at reducing the major risks.\nThose concerns had led doctors to curtail their use of the newer devices, and the new findings are expected to have a similar effect on angioplasty overall.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story states the procedure is considered \"safe\" but that it does carry some risks.\u00a0 However, what those risks are and their frequency or severity is not discussed.\u00a0 ", "answer": 0}, {"article": "For decades, researchers have searched unsuccessfully for ways to automatically coordinate insulin delivery with real-time changes in blood sugar to essentially create an artificial pancreas that maintains target blood sugar levels with minimal effort.\n\"This is hugely promising and very significant research,\" he tells WebMD.\n\"Nighttime is the time of day that strikes fear into patients and parents of children with diabetes.\"\nAaron J. Kowalski, PhD, of the Juvenile Diabetes Research Foundation, which was involved in funding the research, says the study represents an important step forward in the search for a clinically feasible artificial pancreas to improve outcomes and quality of life among insulin-dependent diabetes patients.\nFeb. 4, 2010 - It has been called the Holy Grail of treatment for insulin-dependent diabetes, and it may be close to reality.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story emphasizes the upside but makes no mention of what could go wrong with an automated system.\u00a0The potential adverse effects of a malfunction, such as hypoglemic shock and death,\u00a0are\u00a0serious.", "answer": 0}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThe study makes that last point very clear.\nThat doesn't tell the whole story.\nThat touched off a lot of celebrating.\nSome insurers might pay, but some might balk.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Several clear points were made about harms:", "answer": 1}, {"article": "A new, detailed mammography exam catches more cancers while causing fewer false alarms, according to the company that sells it. The downside, some physicians say, is that it costs more and delivers twice as much radiation as traditional mammograms.\n\nTomosynthesis, or three-dimensional mammography, has been available in the U.S. since February from Hologic Inc., Bedford, Mass. In just a few months, radiologists say they are finding cancers they would have missed with the standard exam.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article did discuss the potential harm due to the increase in radiation exposure, but was then followed by a quote from the VP of breast health at the company making the device dismissing some of the concern related to the increase in radiation.\nThe article did not mention rates of false positives or false negatives with the new imaging.\u00a0\u00a0It could be that it finds lots of new things\u00a0that\u00a0lead to many more biopsies but not all cancer (i.e. they report the recall rate, but what about the biopsy rate for traditional vs. 3-D?)\nSo despite the headline that addresses false positives, the story doesn\u2019t give any evidence on that question.", "answer": 0}, {"article": "\"Now they tell me, 'You never say 'What?'\nImplanting the Esteem is a three-hour outpatient procedure done under general anesthesia.\nFor patients with profound hearing loss, a cochlear implant is a better option, he said.\nUnlike a hearing aid, which amplifies sounds, Esteem is a prosthetic inner-ear stimulator.\nMerlo's doctor, ear surgeon Sam Marzo of Loyola University Medical Center in Maywood, has performed 40 Esteem implants since he was trained by its manufacturer, Envoy Medical Corp. in St. Paul, Minn., in 2010.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides no information about potential harms of the surgery (requiring general anesthesia) or of the device once implanted.\u00a0 The study reported ongoing adverse events related to the device and the surgery including dizziness, taste disturbances, facial weakness/paralysis, ear pain, tinnitus (ringing in the ear) and middle ear effusions (build up of fluid).", "answer": 0}, {"article": "\"The robot is the way to go,\" Jackson said.\nHe said that experienced cardiac surgeons who have mastered conventional bypass surgery are the best candidates for learning to use robots because they have the skills and confidence to get themselves out of difficult situations that may arise.\nSrivastava said it is true that the normal sense of touch is missing from robotic work, and that is a shortcoming, but it can be overcome with practice.\nMany who trained to use robots to do coronary bypass run out of patience after three or four procedures, Jeevanandam said, which is why he decided to hire Dr. Sudhir Srivastava, who performed hundreds of robotic bypasses while working at a center in Odessa, Texas.\nIf he can train several cardiac surgeons and their teams at the University of Chicago to do robotic coronary bypass procedures, Srivastava said it will change the face of bypass surgery because consumers who hear the benefits of avoiding a cracked sternum will demand the minimally invasive approach.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article fails to compare key risks\u2013of death, complications, need for additional surgeries,\u00a0infection rates, etc.\u2013of robot-assisted to conventional surgeries. Again, since the article raises the comparison between stenting and robotic surgery, these risks should have been compared too. Because the story uses anecdotes that suggest better outcomes and fewer side effects, the reporter should have looked for data to compare those anecdotes to.", "answer": 0}, {"article": "Dr. Gregg Fonarow is a professor of cardiology at the University of California, Los Angeles.\nThe study investigators found that 27 percent of patients with two or more risk factors for stroke were not on blood thinners, but one-third of low-risk patients were taking them.\n\"Catheter ablation is a valid alternative for the management of atrial fibrillation with a satisfactory success rate,\" said study lead researcher Dr. Elena Arbelo.\n\"Of concern is that complication rates are still higher than desirable for this procedure, and there was suboptimal use of stroke-preventing anticoagulation [anti-clotting] therapy after the procedure,\" added Fonarow, who was not involved with the study.\nIt causes 20 to 30 percent of all strokes and can decrease quality of life due to palpitations, shortness of breath, tiredness, weakness and psychological distress, the study authors explained.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story points out the caveats that should be remembered when considering ablation.\u00a0 It explains some of the complications that can occur, and that the procedure may only be a short-term fix.\nHowever, there was definitely a missed opportunity to dig more deeply, and report the scope of the harms as clearly as the benefits. For example, the story didn\u2019t explain 1 out of 10 people had to go back for a repeat procedure during the study. Nor that there were 280 in-hospital complications (7.8%) and 577 complications over the 12 month follow-up (16.3%). Some of the complications were quite serious, including 47 perforations of the surrounding heart tissue.", "answer": 1}, {"article": "In the 1970s, the FDA required warnings on drugs containing progesterone, as 17-HP does, because of an increased risk of birth defects.\nEveryone in this field is mindful of the long-running tragedy of vaginal and other cancers and male urinary disorders that resulted from the last drug thought to prevent premature birth \u2013 a synthetic estrogen called diethylstilbesterol, or DES.\nInterestingly, the drug is not new \u2014 it's just taken a long and circuitous route to approval.\nNor is it for women who have other conditions that raise their risk of preterm birth, such as high blood pressure or infection.\nThe FDA is apparently satisfied that 17-HP is safe, but it's requiring its sponsors KV Pharmaceuticals and TherRx to conduct further studies of women who have taken it and children exposed during pregnancy.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Good discussion of concerns and ongoing monitoring of the drug\u2019s safety.", "answer": 1}, {"article": "And I am completely pain free.\"\nMore than half of all hip-replacement surgeries performed this year are expected to be on people under 65, with the same percentage projected for knee replacements by 2016.\nIn the past, many doctors assumed implants would wear out in about 10 or 15 years, and they urged young patients to put off surgery as long as possible to minimize the risk of needing a costly and difficult revision surgery\u2014or even two.\nLast year, one manufacturer, Smith & Nephew , won clearance from the Food and Drug Administration to market its latest technology as a \"30-year knee\" based on tests mimicking 30 years of wear.\nThe fastest-growing group is patients 46 to 64, according to the American Academy of Orthopaedic Surgery.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article included only general references to the harms associated with knee and hip replacement. It did not specify rates of mortality, blood clotting, infection, and other potential adverse events associated with primary and revision knee and hip replacement operations. These are important issues in this age group since early joint replacement will likely involve more problematic revision procedures down the road. Detailing the complications and adverse events that can be expected in revision procedures would have helped balance the article.\n", "answer": 0}, {"article": "This, too, is suggested by sense and common experience, as it is affirmed by the science reported here,\" Katz said.\nTUESDAY, March 29, 2011 (HealthDay News) -- If you're looking to lose those extra pounds, you should probably add reducing stress and getting the right amount of sleep to the list, say researchers from Kaiser Permanente's Center for Health Research in Portland.\nThose in the second phase of the trial continued their diet and exercise program.\nThe important message is that weight loss should not be looked at with tunnel vision, Katz said.\nLower stress by itself predicted more weight loss during the first phase of the trial, they added.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story was reporting on the impact of getting adequate amounts of sleep on weight loss. \u00a0While there was no overt discussion of the harm of obtaining adequate amounts of sleep, there doesn\u2019t appear to be any harm involved in adequate sleep.", "answer": 1}, {"article": "\u201cIt all depends on how you approach risk,\u201d Dr. Zelen said.\nThe study, published Thursday in The , looked at what happened in before and after 1996, when the country began rolling out mammograms for women ages 50 to 69 along with special breast cancer teams to treat all women with breast cancer.\nBut, cancer experts said, no one would do such a study today when mammograms are generally agreed to prevent breast cancer deaths.\nMarvin Zelen, a statistician at the Harvard School of Public Health and the Dana-Farber Cancer Institute, who was a member of the research team said even though the mammography benefit is small, if he were a woman he would get screened.\n\u201cIt shows the relative impacts of screening versus therapy in an era in which therapy has been improving.\u201d\n\nDr. Otis Brawley of the said in a statement that the investigators used \u201ccareful methodology.\u201d The society, Dr. Brawley said, \u201cbelieves that the total body of the science supports the fact that regular mammography is an important part of a woman\u2019s .\u201d\n\nDr. Carol Lee, a radiologist at and chairwoman of the breast imaging commission of the American College of Radiology, said the new study affirmed that mammography saves lives.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe story notes that screening mammography exposes women to false alarms scares as well as the risks and harms of treating tumors that actually would not have become life-threatening.", "answer": 1}, {"article": "\"It's not prevention,\" Ms. Visco said.\nAnother issue is that the message from the cancer institute seemed to play down a shortcoming of raloxifene that cancer doctors consider important.\nBut since there is no way to predict who will actually get cancer, everyone has to be treated, meaning that 980 will be exposed to the drug's risks but will get no cancer benefit.\nTo Dr. Norton, the most important conclusion to be drawn from the study is that more research on breast cancer prevention is needed.\nThe concern is that many women would have to take tamoxifen or raloxifene for a few to benefit.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides sufficient information on the harms of raloxifene compared to tamoxifen. The story does explain that one downside of raloxifene is that it does not appear to reduce the risk of ductal carcinoma in situ (DCIS), which tamoxifen does. There is one error in the story \u2013 about 50% of DCIS will progress to invasive cancer, not 10% as stated in the story.", "answer": 1}, {"article": "That\u2019s the good news.\nIn an editorial accompanying the study, Emily Jungheim and Graham Colditz of Washington University School of Medicine in St. Louis wrote that the findings indicate that while there \u201cmay still be a role for short-term use of unopposed estrogen for treating some women with menopausal symptoms ... this role may be vanishing as existing and emerging data continue to be better understood.\u201d\n\nRowan Chlebowski, one of the researchers who worked on the analysis, stressed that the study only looked at women who were taking estrogen alone.\nIn the new analysis, researchers analyzed data collected from 7,645 women who were in the part of the study examining the effects of taking estrogen alone an average of 10.7 years, after the study was halted because of the evidence the drugs were harming women.\nThe researchers found that the risk for heart disease during the follow-up period was similar to that seen while the women were taking the hormone.\nWomen who took a combination of estrogen and progestin face increased risk for breast cancer, previous studies have shown, Chlebowski said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\nThe Post tries but fails to do justice to the mixed picture of longer-term outcomes for women who took estrogen-only therapy. There is no quantitative statement about the risks, or the benefits. Some of the findings are misstated: \u201cRisk for heart disease during the follow-up period was similar to that seen while women were taking the hormone.\u201d The point of the study is that there was no increased risk in heart disease in estrogen-alone users (as opposed to findings with estrogen/progestin arm); and longer followup confirmed no increase. As stated, the story seems to imply there was an increased risk for heart disease that did not diminish during followup.", "answer": 0}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The first line of the story says that this cream \"promises instant anti-impotence with no side effects.\" It also quoted a researcher:\u00a0 \"Our initial studies show that it is safe to use multiple times.\"\nWhat does that mean? \nThe story should have at least briefly mentioned that \"safety\" in ten rats does not automatically equate to safety in people. \u00a0\nAll drugs have side effects. \u00a0\u00a0", "answer": 0}, {"article": "Commenting, Professor Andreas Meyer-Lindenberg, Central Institute of Mental Health, Mannheim and member of the ECNP executive board, said: \"This work builds on previous studies that have shown a critical role of excessive activity of subregions of the temporal lobe in the generation of voice hallucinations in schizophrenia.\nTo move this into treatment, controlled trial such as the one by Dollfus and coworkers are important.\nTMS uses magnetic pulses to the brain, and has been shown to be effective in several psychiatric conditions.\nHowever, there is a lack of controlled trials to show that TMS works effectively with AVH sufferers.\nSecondly, we have shown that treatment with high frequency TMS makes a difference to at least some sufferers, although there is a long way to go before we will know if TMS is the best route to treat these patients in the long-term\".\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "TMS is generally regarded as a low-risk treatment. That does not, however, make it a no-risk treatment. According to the Mayo Clinic, the use of TMS to treat depression can have side effects ranging from headache and lightheadedness to (in rare cases) seizures and hearing loss. We don\u2019t think the release needs to include a laundry list of potential risks, but it does need to address the risk of potential harms in some meaningful way \u2014 even if it is only to highlight that there is a low risk of significant harms.", "answer": 0}, {"article": "Stay in touch on Linkedin, on Twitter @EpicSciences or on Facebook.com/EpicSciences.\nAdditionally, the authors validated the test within a prognostic risk group, to ensure that the biomarker effect was due to the biomarker rather than other clinical variables.\nA full LCD for the test is expected in the upcoming months and would support Medicare reimbursement for applicable patients considering ARSI or taxane therapies.\nImportantly, patients negative for AR-V7 who were treated with ARSi therapy had superior OS relative to those treated with taxanes (media OS, 19.8 vs. 12.8 months).\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No harms are mentioned. The potential risks of blood tests are minor, although the potential of a false result could have serious consequences if it leads to a patient getting an ineffective or potentially harmful treatment.", "answer": 0}, {"article": "A new generation of treatments for severe eczema is on the horizon, which doctors say could help millions more patients gain relief from chronic outbreaks of the oozing, itchy and sometimes debilitating rashes that come with the disease.\n\nAt least two new eczema medicines could be approved by the U.S. Food and Drug Administration in 2017, and a half-dozen more drugs are being tested in clinical trials.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "There is a small bit of information on harms at the bottom of the story for one of the two drugs: pain at the site where the ointment is applied in a small number of individuals. This squeaks by with a Satisfactory rating.\nBut, a reader will be hard pressed to find any information about the possible long-term harms of the injectable drug of interest here\u2013this is concerning because these types of drugs are known to have serious\u00a0side effects like increased infection or even cancer risk, as this Nature Review\u00a0article notes.\u00a0We\u2019re not looking for an exhaustive list, but some acknowledgment that possible long-term harms are plausible and haven\u2019t been studied would have been helpful.", "answer": 1}, {"article": "\u201cThis wakes up the immune system and says, \u2018Hey!\n\u201cAnd Amgen\u2019s not a company that likes to price gouge.\u201d\n\nSchmidt said Imlygic\u2019s market potential as a standalone drug is \u201cvery, very modest.\n\u201cAfter that, there were no side effects.\u201d\n\nSuch muted side effects point to a major benefit of this new approach, doctors and patients said.\nApproved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus \u2014 called Imlygic, which was developed in part in a Massachusetts lab \u2014 is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.\n\u201cIt\u2019s a low-toxicity treatment, and for the right patients you see quite stunning results,\u201d said Robert Coffin, a virologist who created Imlygic at BioVex, the Woburn-based company he founded.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is a close call, but we think the story downplays the significance of the harms attributable to these drugs. The story quotes a researcher who calls one drug \u201clow-toxicity\u201d and lists 3 adverse effects, but does not say with what frequency they occurred. According to the linked study, 11% of patients developed grade 3 (severe) and 4 (life-threatening) adverse events related to the treatment. We don\u2019t think that\u2019s what readers have in mind when they hear \u201clow-toxicity.\u201d", "answer": 0}, {"article": "The participants were separated into groups by age at the time of last visit or death, gender and ethnicity.\nBecause of this, there is a large consensus that preventing this kind of toxicity would be an effective treatment strategy.\nThe UTMB research team and others have shown previously that this enzyme plays a central role in the harmful effects of the A\u03b2 oligomers and that elevated calcineurin is found in the nervous system of Alzheimer's patients.\nHowever, the question of whether such a strategy would prevent the onset and progression of Alzheimer's in people is challenging because treatment with a calcineurin-blocking agent suppresses the immune system.\nCompelling evidence shows that toxic protein aggregates called A\u03b2 oligomers selectively target and disrupt the points of communication between brain cells, impairing memory in people suffering from the disease.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The news release does point out that preventive treatment with anti-rejection drugs suppresses the immune system. \u00a0But exactly what does that mean? \u00a0What are the implications of this effect? The release does not provide any description of the potential problems that could occur. And that is not the only issue with these drugs. Both tacrolimus and cyclosporine have an extensive its of side effects.", "answer": 0}, {"article": "Visit the U.S. Centers for Disease Control and Prevention for more on urinary tract infections.\nNow, researchers report that a new program shows it might be possible to reduce both catheter use and its associated infections.\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\nIncluded in the program are:\n\u2022 Daily checks to see if a catheter is still needed.\nThe researchers found that catheter infection rates in the new program dropped 14 percent overall in general wards (non-ICU).\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Harms aren\u2019t discussed in this story, but improved caretaker education on when and when not to use a catheter, and how to insert one while reducing the risk of infection, doesn\u2019t seem to warrant it.\u00a0\u00a0Although there may be some harms from this \u201cbundle,\u201d the study itself was not set up to look for them.", "answer": 2}, {"article": "POPGis one of several lipids found in the fluid that lines the air sacs of the lungs.\nResearchers say that until now, the function of POPG has been unclear.\nTherefore, together with the results of this study, researchers say the compound merits further research as a treatment for RSV infection in humans.\n\"While these are still early studies, several characteristics of POPG make me believe that it has real potential as both an antiviral and anti-inflammatory treatment.\"\nIt is also inexpensive and easy to use.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "You can\u2019t quantify the harms of something that hasn\u2019t advanced beyond the lab and has not yet been done in humans.\u00a0 Of course, you can\u2019t say much at all at this stage, which raises the question of why the story was published now in a consumer health section that is labeled, \"Health & Parenting.\"\u00a0 ", "answer": 2}, {"article": "Doctors spin a few tablespoons of a patient's own blood, separating out the platelets.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\nThe hope is that the same technology that allowed Bornstein to get back on the field so quickly can now be used to treat injuries in weekend warriors as well.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nIt's called Platelet Rich Plasma therapy \u2014 or PRP.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story only said\"\u00a0 \"reported side effects were minor. The biggest complaint so far?\u00a0 Needles hurt.\"\u00a0 Let viewers judge which side effects were minor by naming them and listing how often they happened.\u00a0 Even more important, though, the story should have emphasized that really nothing can be said about side effects when the very preliminary experimental approach is still undergoing clinical trials. ", "answer": 0}, {"article": "Use of osteoporosis drugs, once heavily advertised by celebrity spokeswomen, has dropped by more than 50% in recent years amid reports of such serious side effects as sudden bone fractures.\n\nYet many experts say the benefits of the drugs, known as bisphosphonates, far outweigh the risks for many users.\n\nAn analysis in the New England Journal...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions potential harms in its lead sentence, referring to \u201csuch serious side effects as sudden bone fractures.\u201d As noted above, the entire story is essentially about comparing the benefits and risks of bisphosphonate use for treating osteoporosis. The story does a good job of discussing potential (and serious) side effects such as sudden fracture of the femur and osteonecrosis of the jaw. However, the story doesn\u2019t mention the less serious (but more common) side effects such as heartburn or other gastrointestinal problems.", "answer": 1}, {"article": "Breast cancer strikes more than 180,000 women each year in the United States and kills more than 40,000, making it the most common form of cancer after skin cancer and second leading cancer killer among women.\nWhile welcomed by some patient advocates and doctors, the $1,625 test raises concerns among others.\nPreviously, the only tests for breast cancer risk were for relatively rare genes, leaving most women with no way to assess their individual genetic predisposition.\nSome questioned its reliability, while others worried that the results could either lull women into a false sense of complacency or needlessly alarm them, prompting them to take unnecessary tests or even undergo unneeded surgery.\nThe test by Decode Genetics of Reykjavik, Iceland, a respected pioneer in genetic research, promises to determine a woman's risk through a simple blood sample or cheek swab.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story provides appropriate caveats for women who are considering this test. Namely, a lower than average score might suggest a woman could forgo screening.\u00a0 Women with a higher than average risk score could experience unnecessary anxiety and possibly choose treatments they do not need (such as prophylactic mastectomy).\u00a0 ", "answer": 1}, {"article": "\u201cThe finding doesn\u2019t reflect how hormones are used in the U.S. at the moment,\u201d Dr. Colditz said.\nBut there were surprising differences in the risks and benefits of estrogen use on heart risk when comparing the youngest and oldest women in the study.\nWhile most women in the hormone study were taking combination hormone therapy, women without a uterus took estrogen alone or a placebo for about six years and were followed for nearly 11 years.\n\u201cThis study differentiates estrogen alone from estrogen and progestin in a very big way.\nA major caveat in interpreting the new estrogen data is that the study used conjugated equine estrogens, which are estrogen compounds derived from the urine of pregnant mares and marketed by Wyeth Pharmaceuticals under the brand Premarin.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nKudos to the The Times for parsing risk carefully. Among these: estrogen alone carries different risks than estrogen-with-progestin,\nestrogen-alone for older women is much riskier than for younger women and risks for women who still have a uterus (unlike those who have had a hysterectomy) are also different. Last, but still important, the form of estrogen used in the study is not typically used now, so conclusions about benefits cannot be assumed to follow to the current form (estradiol.)", "answer": 1}, {"article": "Cytology-based screening, known as the Pap test or Pap smear, is used to detect abnormal cells.\nThe HPV test captures the known cancer causing viruses, but there are gynecologists who believe that there may be unknown cancer causing viruses and so continue to do the Pap smear (plus HPV testing).\nDraft guidelines from the US Preventive Services Task Force recently recommended either primary HPV testing every five years or the Pap test every three years for women 30 to 64, and did not recommend cotesting.\nA new paper in the Journal of the National Cancer Institute finds that testing for cervical cancer using HPV testing in addition to the Pap smear is unlikely to detect cancer cases that wouldn't be found using HPV testing alone.\nResearchers were searching for realistic performance data to quantify the additional benefit of the Pap test component of cotesting, as the costs of intensive screening of all women using two screening tests are substantial.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t directly explain the harms of cancer screening. The release addresses the harm of omitting one test, but this wasn\u2019t enough to meet our standard.\u00a0The release states that HPV is \u201cmore sensitive than the Pap test for detecting precancer.\u201d But it doesn\u2019t discuss the flip side, which is that many pre-cancers may not go on to become cancer even though all are treated.", "answer": 0}, {"article": "Although no one can pinpoint a reason for the link with certainty, \"essentially we think that alcohol may be having an effect by reducing the immune response, which leads to joint inflammation, and also that it may have a mild pain-killing effect,\" said Maxwell.\nNor do the study authors advise drinking as a cure for arthritis.\n\"This actually isn't a new concept.\n\"We would also remind patients to observe recommended government limits for alcohol consumption,\" he added.\nGuy Fiocco, assistant professor of internal medicine at Texas A&M Health Science Center College of Medicine and director of rheumatology at Scott & White in Temple, Texas.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of harms of alcohol consumption. ", "answer": 0}, {"article": "Learn more about alcoholism and how it is treated at the U.S. National Institute on Alcohol Abuse and Alcoholism.\nChantix costs roughly $3 per pill.\nThe study was funded by the U.S. National Institute on Drug Abuse and the U.S. National Institute on Alcohol Abuse and Alcoholism.\nExactly how this drug curbs drinking is not fully understood, but its use may increase blood pressure, heart rate and feelings of sadness and nausea, thereby blunting the pleasurable effects of alcohol, the researchers said.\nMore research is needed, he noted, but \"this medication may be helpful for people with a drinking problem who are also smokers.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does report that Chantix carries a \u201cblack box\u201d warning and that there are concerns about depression, suicidal thoughts, and the risk of heart attacks and strokes.", "answer": 1}, {"article": "Injections could result in harmful thickening of the blood, however, especially if above-normal blood levels of the hormone result.\nStill, this study will not answer the question of whether it is safe to use the hormone for years, even decades, which would be necessary to maintain any benefits.\nAlthough testosterone can cause overgrowth of the prostate, studies have not shown harm to urinary function, Dr. Morgentaler said.\nWe need the same kind of study for testosterone as the Women\u2019s Health Initiative \u2014 several thousand men followed for maybe 10 years.\nCurrently, we\u2019re in limbo as to how to advise patients.\u201d\n\nHe acknowledged that the need for such a study for men is \u201cless compelling\u201d because, in contrast to women, who experience an abrupt drop in estrogen at menopause, often with disruptive symptoms, hormone decline in aging men is far more gradual, and symptoms, when they occur, are commonly viewed as normal signs of aging, not hormone deficiency.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story\u00a0notes that a recent study was halted because of an unexpectedly high rate of cardiac problems in the testosterone group. It also mentions the possibility that testosterone therapy can result in thickening of the blood and may increase the risk of prostate cancer.\nThe story isn\u2019t precise about\u00a0how often these harms occur, and it also\u00a0didn\u2019t mention\u00a0some of the \"minor\" side effects associated with testosterone use, including acne, hair loss on the scalp, hair growth on the face, increased breast size, and testicular atrophy.\nA close one here. Overall, we felt the story called appropriate attention to the harms and did not try to minimize them \u2014 enough\u00a0to earn a satisfactory.\u00a0\u00a0\u00a0\u00a0", "answer": 1}, {"article": "Researchers measured concentrations of three proteins previously identified as potential biological indicators, or biomarkers, for Alzheimer's and MCI: amyloid-beta, tau, and phospho-tau.\nIn one study, this protein signature was also seen in spinal fluid samples from all patients with mild cognitive impairment who progressed to Alzheimer's disease within five years.\nLow levels of the amyloid protein amyloid-beta 1-42, along with high levels of total tau and elevated phospho tau 181 (P-tau 181), identified Alzheimer's disease in three independent study groups, Hugo Vanderstichele, PhD, of the Belgian biotech company Innogenetics, tells WebMD.\nAug. 9, 2010 -- Researchers have identified a protein \"signature\" in the spinal fluid of patients with Alzheimer's disease, which could represent an important advance in its diagnosis.\n\"Using this approach, which was totally independent of diagnosis, we were able to identify patients with Alzheimer's disease,\" Vanderstichele says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\nWhile noting that many people are reluctant to undergo spinal taps, this story includes only comments that downplay the potential harms, including pain or bleeding. The story fails to discuss the potentially serious consequences of using this sort of test before symptoms appear, such as insurance or employment discrimination.\nFinally, the story downplays that importance of the relative lack of specificity of the method. While testing of apparently healthy older people for the presence of the markers may be appealing, the reality is that based on the study up to a third of those may be falsely labeled as having the disease. This may subject a significant number of older Americans to the potential side effects of newer treatments to say nothing of the financial impact of a third of the population in this age group.", "answer": 0}, {"article": "Reductions were seen of 35 percent at 10 weeks, and just over 22 percent at one year, for those given real acupuncture, compared with 24.5 percent and 5 percent, respectively, for those given sham acupuncture, the researchers said.\nThe report was published online Feb. 15 in the journal Acupuncture in Medicine.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\nHowever, although taking less pain medication, acupuncture patients were using higher levels of antidepressants after one year, which may have artificially boosted the positive results, he said.\nStill, Shrikhande said, \"the findings in this study help demonstrate that acupuncture is a safe and effective treatment for chronic pain patients.\"\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This story made no mention of potential harms from the use of acupuncture although the research paper clearly\u00a0identified some \u201cmild adverse events\u201d affecting participants. These included headaches, pain and bruising at the acupuncture sites, and an aggravation of some fibromyalgia symptoms. While these are far from serious harms, readers deserve to know that they are possible outcomes.", "answer": 0}, {"article": "Editor: Jadwiga Wedzicha, MD, professor of respiratory medicine at the National Heart and Lung Institute (Royal Brompton Campus), Imperial College London, UK.\nThe authors believe that future trials of vitamin C supplementation in pregnant smokers should determine whether the benefits are greater if the supplementation starts earlier and continues postnatally in the babies themselves.\nIn \u201cOral Vitamin C (500 mg/day) to Pregnant Smokers Improves Infant Airway Function at 3 Months: A Randomized Trial,\u201d Cindy T. McEvoy, MD, MCR, and her co-authors report that at three months of age, the infants whose mothers took 500 mg of vitamin C in addition to their prenatal vitamin had significantly better forced expiratory flows (FEFs).\nThose levels rose in study participants who received vitamin C to become comparable to women who do not smoke.\n\u201cFinding a way to help infants exposed to smoking and nicotine in utero recognizes the unique dangers posed by a highly advertised, addictive product and the lifetime effects on offspring who did not choose to be exposed.\u201d\n\nIn a previous study, the authors had shown that 72 hours after birth, babies of mothers who smoked had better lung function if their mothers were randomized to vitamin C (500 mg/day) during their pregnancies compared to those born to mothers who smoked and were randomized to placebo.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release doesn\u2019t mention any potential harms from vitamin C use.\u00a0Since some readers may take license with these preliminary findings \u2014 and think more vitamin C is better (ie. improve their infant\u2019s lung function) \u2014 the potential harms of vitamin C should have been included.\nPeople can have allergic reactions to vitamin C at even low doses. At higher doses it can be problematic in people with kidney disease, and could be detrimental to fetuses.", "answer": 0}, {"article": "As we cut calories and lose weight, our resting metabolic rate eventually slows and our bodies become less efficient at shedding mass in a process known as adaptive thermogenesis.\nWhile frustrating, it\u2019s one of our natural survival mechanisms to prevent potential starvation.\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\nBut, Varady believes it\u2019s probably safe to enjoy a slice of cake or bowl of ice cream during the break.\nHowever, it\u2019s important not to think of them as cheat days.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We\u2019ll rate this N/A since it\u2019s hard to imagine harm from restricting a third of normal calories for two week cycles over 16 weeks.", "answer": 2}, {"article": "Autism spectrum disorder (ASD) includes a range of conditions, including Asperger syndrome, that affect a person\u2019s social interaction, communication, interests and behaviour.\nHowever, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nHowever strengths included the relatively large population-based sample size and the advanced analytical methods used to gauge the robustness of findings.\nThey point to several study limitations, such as the potential for confounding and difficulty assessing type, timing and dose of supplements.\n\u201cTogether, the three analyses appear to point toward a potential inverse association between multivitamin use with ASD with intellectual disability,\u201d say the authors.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "No mention of potential harms \u2014 or lack of harms, if that\u2019s the case \u2014 from taking multivitamins or extra iron were mentioned in the release.", "answer": 0}, {"article": "Texas rep expects Trump to make case for a border wall at State of the Union\n\n\"We're going to keep working to secure the border, and not blink until we either get it done or the voters get to speak in 2020\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although uterine cancer and blood clots are mentioned as harms of treatment, there is no mention of how often they occur. Other harms such as cataracts and stroke are not mentioned.", "answer": 0}, {"article": "Anal Cancer Fund, and a philanthropic donation.\nThe study revealed encouraging correlations between immunologic biomarkers and responses to treatment.\nImmune monitoring of pre-treatment samples showed a significantly higher percentage of CD3 and CD8 T-cells as well as other indicators, all which point to correlations between immunologic biomarkers and responses to treatment.\nStudy results showed a decrease in frequency of CD8 T-cells in post-treatment tumor samples among responder-patients.\nOf note, patients who scored as responders had higher frequency of CD8 T-cells and PD-L1 CD45 immune cells in pre-treatment samples.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This news release makes no mention of potential harms. According to the Chemocare.com website, more than 30 percent of patients on nivolumab may experience fatigue, low white blood cells, low sodium, shortness of breath, musculoskeletal pain, decreased appetite and cough.", "answer": 0}, {"article": "I wouldn\u2019t wish it on my worst enemy, but I have to go through with it.\u201d\n\nDr. Lowy explored the entire cavity from the diaphragm to the pelvis.\nThe therapy has even been featured on an episode of the TV series \u201cGrey\u2019s Anatomy.\u201d\n\nBut Dr. Ryan, a gastrointestinal oncologist, suggested in an interview that the procedure was being extended to because \u201cyou can\u2019t make a living doing this procedure in appendix cancer patients.\u201d\n\nHe debated the procedure publicly at the recent annual meeting of the American Society of Clinical Oncology.\nBut doctors added it may be if it is described merely as chemotherapy.\nBut 8 percent who got the surgery and Hipec died from the treatment itself.\nBut Dr. Alan Venook, a colon cancer specialist at the , said that a couple of patients referred by him had \u201cdied miserable deaths.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explains that one study showed that \u201c8 percent who got the surgery and Hipec died from the treatment itself.\u201d\u00a0 And it stated:", "answer": 1}, {"article": "First the science.\n\u201cFor now, there is no magical cream that can make you look younger.\u201d\n\nOlivo will work first to develop the product to deliver drugs to the skin \u2013perhaps allergy or eczema medication, or long-lasting sunscreen, MIT said.\nThere are hundreds of skin products that do this now, but this one sticks better and doesn\u2019t pucker the skin, the team reports.\nThe stuff can just be peeled off, or taken off with makeup remover, the researchers said.\n\u201cCreating a material that behaves like skin is very difficult,\u201d added Dr. Barbara Gilchrest, a dermatologist at the Massachusetts General Hospital who worked on the study.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story tells us that\u00a0\u201cRepeated daily wear resulted in no report of irritation or other adverse events resulting from the XPL use.\u201d That\u2019s at least a nod toward discussing potential harms, so we\u2019ll consider this Satisfactory.\nBut, we think the story would be stronger if it had been more specific about what \u201crepeated\u201d meant. We\u2019re also wondering about things that could inevitably occur with regular use, like the product getting into the eyes.", "answer": 1}, {"article": "That heat can then be used to interrupt the troublesome brain connections responsible for the tremor.\n\u201cThe degree of tremor control was very good overall in the study, but the most important aspects were the significant gains in disabilities and quality of life \u2013 that\u2019s what patients really care about,\u201d Elias said.\nThe paper outlines the results of an international clinical trial, led by Jeff Elias, MD, of the University of Virginia Health System, that evaluated the scalpel-free approach called focused ultrasound for the treatment of essential tremor (ET), a condition that afflicts an estimated 10 million Americans.\n\u201cThis study represents a major advance for neurosurgery, treatment of brain disease and specifically the treatment of ET,\u201d Elias said.\nThe essential tremor research has been supported by InSightec, the Focused Ultrasound Foundation and the BIRD (US-Israel Binational Industry Research and Development) Foundation.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions harms in this statement: \u201cThe most commonly reported side effects were gait disturbances and numbness in the hand or face; in most instances, these side effects were temporary but some were permanent.\u201d\u00a0 But that is by no means enough. More than a third of the patients in the study developed gait problems or numbness, or both, that in some cases persisted for 12 months. Others developed ataxia, unsteadiness and weakness that was persistent. The release seems to go overboard in downplaying these adverse effects and amplifying the positive outcomes. Releases should never cherry-pick the data from a study.", "answer": 0}, {"article": "\u201cSometimes serious addiction needs to be coaxed down the stairs one at a time, not thrown off the top floor,\u201d said Dr. Abrams, who was not involved in the study.\nThe study was funded by Pfizer, the drug company that makes Chantix, a treatment that costs about $250 a month.\nStill, some researchers not involved in the study said the topic required more work.\nAbout 1,500 patients at 61 clinics in the United States and abroad participated in the study.\nThe practice is common for smoking cessation therapies, said Robert West, director of tobacco studies at University College London, who was among the study\u2019s authors.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story specifically focuses on the use of varenicline, which goes by the trade name Chantix, but does not mention any of the possible adverse health effects associated with the drug. These possible side effects include changes in mood, suicidal thoughts, and cardiovascular problems \u2014 all of which are worth mentioning.", "answer": 0}, {"article": "In clinical trials of asthma patients, the most common side effects were headache, flu, abdominal pain and cough.\nMerck says the information is on the company's Web site, though one must go to the fourth page of a product labeling file to find it.\nTheir labeling does not contain language about suicide.\nShe's now writing letters to every patient who takes Singulair, urging them not to over-react.\nHis mom now believes that Singulair cost him his life.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story is fundamentally about alleged harmful side effects of the drug, so this criterion is clearly established. ", "answer": 1}, {"article": "Age-related macular degeneration (AMD) is a condition that affects older people.\nIt provides an image that has been magnified more than two times, the FDA says in a news release.\n\"This innovation has the potential to provide many people with an improved quality of life,\" Jeffrey Shuren, MD, JD, director of the FDA's Center for Devices and Radiological Health, says in the news release.\nTraining would also be needed to verify that there is sufficient peripheral vision in the untreated eye.\nIt is intended for use in only one eye because the other eye is used for peripheral vision, the FDA says.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did quantify the harms:\u00a0 \"the IMT is large enough to pose a threat to the cornea of the eye, leading to extensive loss of cells essential for maintaining the clarity of the cornea. In the study, 10 eyes had unresolved corneal edema, or swelling, caused by trapped fluid. Five such cases resulted in corneal transplants. The FDA says the five-year risk for unresolved corneal edema, corneal decompensation, and corneal transplant are 9.2%, 6.8%, and 4.1%, respectively.\"", "answer": 1}, {"article": "UCLA's Bhat noted another limitation in the study: \"These are all genetic cataracts.\nShe said, even without answers to the question of whether it will work in aging eyes, it creates hope for children with congenital issues.\nIf it takes months to get to an outcome, it's not superior to the lens technologies we have now.\nBhat was not involved in the new research, but said it's \"extremely exciting\" because it offers an alternative to \"an extraordinarily invasive\" procedure.\nShe said the new procedure, which coaxes stem cells to regenerate normal tissue in the body, offers promise.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story doesn\u2019t discuss short- or long-term harms that may arise from this new approach.\u00a0It may be too soon for researchers to determine potential long-range harms from this approach, but saying that would have offered readers some perspective.", "answer": 0}, {"article": "Inside the brightly lit storefront in Brooklyn, N.Y., business was brisk as employees combed, washed and blow-dried little heads.\n\n\u201cDo I have a lot of lice?\u201d a boy asks the woman combing his hair slathered in Pantene conditioner.\n\nIt\u2019s the busiest time of the year for companies like Lice Busters, a family-run business Dalya Harel started in...", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article notes that various organizations and experts consider the chemical/medicinal treatments to be highly safe as well as effective.", "answer": 1}, {"article": "The website for LipoFuze says that the supplement \"increases the metabolic mechanism in your body.\" The site also says the green tea and caffeine will \"rev up your metabolism\" and \"increase energy, focus and physical performance.\" The site features testimonials it says are from users who claim they have lost huge amounts of weight with the help of LipoFuze. One man says he dropped more than 100 pounds, although it's unclear how long that took. A woman says she lost 40 pounds in less than a year, including 20 pounds in her first month.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story ends with a Duke fitness expert warning that \u201ctoo much caffeine \u2014 such as the high doses found in Zantrex \u2014 could cause jitteriness, anxiety, spikes in blood pressure and rapid heartbeats in some people.\u201d", "answer": 1}, {"article": "\"Transcendental Meditation has been reported to have health benefits and has been evaluated in a number of studies,\" said Dr. Gregg Fonarow, professor of cardiology at the University of California, Los Angeles.\nEven though the findings in this study were statistically significant, the new study was too small to be conclusive, Fonarow said.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nAnd it's not something you can learn by yourself.\nBut a cardiology expert said that although the study adds to evidence supporting meditation, it doesn't prove a cause-and-effect relationship between the practice and better health outcomes.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Same observation we made in reviewing the TIME.com story: An important indirect harm is that of \u201copportunity costs.\u201d\u00a0 Training and ongoing programming in TM is expensive especially given the mean household income of the participants \u2013 less than $18,000 annually.\u00a0 The story didn\u2019t address this.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions the most serious harm of the treatment, an increased risk\u00a0of atrial fibrillation. Other risks include post-infusion reactions, including fever,\u00a0headache, flu-like symptoms and joint pain.", "answer": 1}, {"article": "\"We know that art therapy can work, music therapy can work.\nThe researchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\n\"Tablet use as a nonpharmacologic intervention for agitation in older adults, including those with severe dementia, appears to be feasible, safe, and of potential utility,\" said Vahia.\nThe study also found that the tablets demonstrated significant effectiveness in reducing symptoms of agitation, particularly--but not exclusively--among patients with milder forms of dementia.\nVahia cited several examples of the tablet's potential to improve a patient's condition.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release addressed harms by saying \u201cresearchers found that tablet use was safe for every patient, regardless of the severity of their dementia, and that with proper supervision and training, the engagement rate with the devices was nearly 100 percent.\u201d", "answer": 1}, {"article": "We really need to know that before we can apply this therapy,\u201d Miller said.\nMice don\u2019t live very long, and it\u2019s not clear if human patients would need repeat treatments.\nIt\u2019s also clear the approach would not repair any damage already done by the disease, so the best candidates would be patients having their very first symptoms.\nAnd while mice are different from humans in many ways, their immune systems are quite similar.\nWhat\u2019s great about the approach, Miller says, is that it can be used to treat any autoimmune disease.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not explore potential harms, which is too bad. As the story points out, mice do have much shorter life spans than humans, and if humans have to be on this type of therapy for the long-term there are many potential risks involved.", "answer": 0}, {"article": "Dec. 20, 2010 -- Scientists using brain scanning technologies say they have been able to predict with 90% accuracy which children with dyslexia will be able to improve reading skills over a period of a few years.\n\nResearchers say their findings reveal activity in specific brain regions during reading that could eventually lead to new treatments for people with dyslexia.\n\n\u201cAt this time, we cannot say which treatment type will each child benefit from,\u201d study researcher Fumiko Hoeft, MD, PhD, an imaging expert at Stanford University, tells WebMD in an email. \u201cBut with more research, and if researchers combine it with intervention studies, then we should be able to identify brain patterns that are predictive of responding to one type of intervention or another.\u201d\n\nShe says in a news release that the study \u201cgives us hope that we can identify which children might get better over time\u201d and that the findings represent \u201ca huge step forward.\u201d\n\nThe discovery of brain regions involved in the learning disorder \u201cmay provide a mechanism for enduring improvement that promotes relatively successful reading development,\u201d according to the study, published in the Dec. 20 issue of the Proceedings of the National Academy of Sciences.", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\n\n\n\nThe story demonstrates an all too familiar bias with regard to screening tests; there are no down sides.\u00a0 A couple of words of caution (again the CNN story got it right) about the implications of testing and test results would have been useful.\u00a0 If, for example, the fMRI and DTMRI scans are as accurate as this study indicates, might treatment be withheld from children who do not have the brain scan results that promise likely improvement?", "answer": 0}, {"article": "It can dominate the lives of patients and their families, leading to excessive overeating, choking, and stomach rupture, along with slowed metabolism and psychiatric disorders.\n\u201cThis is the first demonstration of a clinical benefit against two of the major issues that affect this patient population.\nThomas E. Hughes, chief executive of Zafgen, said the Boston company will use the data to prepare a \u201crisk-mitigation\u201d plan to help persuade the Food and Drug Administration to lift its so-called clinical hold on the late-stage trial, allowing it to resume.\nOur intention is to provide a plan for moving forward with an emphasis on patient safety.\u201d\n\nThe clinical results did not address a key issue for patients and regulators: whether Beloranib triggered the blood clotting that resulted in two patient deaths last year.\n\u201cAs of today, we have no evidence to suggest that Beloranib by itself can cause blood clots,\u201d Hughes said.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The article discloses the possible side effects of beloranib related to blood clotting along with the caveat that Prader-Willi patients are predisposed to clotting issues. Two deaths out of 100 patients is a significant issue, even if they can\u2019t be linked definitively to the drug, so it\u2019s good that this is a focal point. But the story mentions no other adverse effects that were observed in the study, and it should have. We\u2019ll give the benefit of the doubt and hope for improvement next time.", "answer": 1}, {"article": "\u201cShe couldn\u2019t get over the background buzzing,\u201d Dr. Kaufman said.\nAnother concern is that patients who require high doses of stimulation drain the battery quickly, requiring surgery to replace the device.\nThe syndrome may follow 5 percent of all injuries, according to the Reflex Sympathetic Dystrophy Association, an advocacy group for people with chronic pain.\nStill, most patients accept this vibrating version of white noise, says Dr. Richard North, a retired neurosurgery professor at Johns Hopkins who developed several patents related to the technology, although he no longer receives royalties.\nDoctors say simple adjustments to the device may solve that problem.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story notes some annoyances and potential problems with the device (e.g. the \u201cbuzzing\u201d vibration and the need for reoperations to replace dead batteries), but neglects to mention others. For example, the authors of the 2007 trial noted that electrode migration occurred in some 10% of patients and infections in 8%. A 2004 review by a leading group of pain experts noted that complications occur in about one-third of patients. Additional problems included pain near the site where the device is implanted, tears of the membrane that surrounds the spinal cord (the dura), and malfunctioning equipment. (Pain 2004;108:137-47)\u00a0 ", "answer": 0}, {"article": "\"We're looking right now through a small keyhole at a very very large room, and we really don't know yet how big it will be.\"\nIn December, the Food and Drug Administration approved Opdivo to treat advanced melanoma, a type of skin cancer that used to be considered a death sentence.\nThe trial compared Opdivo to Docetaxel, a type of chemo used for patients whose cancers have recurred after treatment.\nIn addition to melanoma and lung cancer, this brake-release approach has been shown effective in early trials against bladder, kidney, head and neck cancers, and some blood cancers.\nJanne, also a professor at Harvard Medical School, said more research is needed before lung cancer patients should be routinely treated with Opdivo, Keytruda or similar drugs.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story does not mention any potential harms associated with Opdivo, despite the fact that the Bristol-Myers Squibb release notes a variety of possible adverse side effects (and that 41 percent of patients receiving Opdivo had adverse reactions). These possible side effects included immune-mediated pneumonitis (i.e., lung inflammation \u2014 including fatal cases), hypothyroidism, colitis, and hepatitis, among others.", "answer": 0}, {"article": "Pacemakers zap the heart with low levels of electricity when the heartbeat becomes too fast, too slow or too irregular.\nIn the new study, researchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it.\nStill, a new company-funded study shows that \"this is now a possibility\" that could reduce infections and the severity of pacemaker surgery, said study author Dr. Vivek Reddy, director of the Cardiac Arrhythmia Service at Mount Sinai Hospital in New York City.\nDr. Saman Nazarian, a cardiologist and assistant professor of medicine at Johns Hopkins Hospital, said the findings are promising and \"the new technology has enormous potential.\"\nAnd the existing version of the device won't work for most pacemaker patients because it lacks some key features.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story explained that:\n\u201cresearchers implanted the pacemaker in 32 people for the first time through a puncture in the skin; in 10 patients, they had to reposition it. \u2026one patient died of a stroke while convalescing after suffering a heart injury during implantation and another had the pacemaker replaced with a defibrillator.\u201d\nOne independent expert in the story said the new device \u201cmay pose special risks of its own.\u201d\nAnother said, \u201cWhen the battery of the implanted leadless pacemaker is exhausted, a new implant is necessary, with all the potential risks associated with this. It is not known if it will be feasible to safely retrieve the old device. If the old device is left in place, it is not known what the long-term effects of this will be.\u201d", "answer": 1}, {"article": "However, Owens said, \u201cit\u2019s hard to do all of that in your head.\nThe problem with the old-fashioned way, he told Reuters Health in an email, is that there are many pieces of information about a patient to consider.\nA researcher not involved in the work said it was a \u201cnice study\u201d that is a first step toward showing that tailored guidelines could have benefits.\nAnd right now, there is a way to go before most doctors will have those systems in place.\nThis gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know what the harms would be of the idealized \u201ctailored medicine\u201d approach described in the piece.", "answer": 2}, {"article": "None did.\nAlthough the scans looked promising, the companies needed to show that what they revealed was the same as what a pathologist would see on autopsy.\nNeither the radiologists nor the pathologists knew whether the patients had dementia.\nAnd the data showed that the scans were completely accurate in ruling out Alzheimer\u2019s pathology: unlike doctors, they never said people had Alzheimer\u2019s pathology when they did not.\nIn addition, the company scanned the brains of 76 younger people who would not be expected to have plaque in their brains.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "\u00a0Although the story did mention that the test involved a radioactive tracer, there was no information about the level of radioactivity exposure involved in the test or whether there were any adverse events reported with the use of this particular dye.", "answer": 0}, {"article": "PHILADELPHIA - Patients with atrial fibrillation (AF), a rapid irregular heartbeat caused by pooling blood in the heart which can lead to heart failure and stroke, are often treated with an ablation, a minimally invasive procedure used to remove the tissue which causes the pooled blood.\n\"It is extremely common for patients with AF to seek treatment that does not involve the use of chronic oral anticoagulants therapy, as there are other risks associated with their long term use,\" said co-author Francis E. Marchlinski, MD, FHRS, director of Electrophysiology for the University of Pennsylvania Health System and Richard T. and Angela Clark President's Distinguished Professor in the Perelman School of Medicine at the University of Pennsylvania.\nHowever, a new study shows the use of novel anticoagulants for AF prescribed on an \"as-needed basis\" guided by diligent pulse monitoring, can be a safe and effective alternative to lowering overall risk of stroke.\nResearchers followed the participates for approximately 23 months, during which time 28 patients started taking the blood thinner at least once for a suspected or detected AF episode, and only 10 patients transitioned back to chronic oral anticoagulation therapy for recurrent AF.\nPatients were provided with novel oral anticoagulants and were instructed to start taking the medication if they suspected or detected an AF episode lasting longer than one hour.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release mentions the bleeding harms that come with taking anticoagulants, a harm that increases with chronic use. However, the release suggests that the therapy was proven safe when that wasn\u2019t clearly established.", "answer": 1}, {"article": "In a statement, Dr. Lesley Russell, Cephalon's chief medical officer, said:\n\nThe most common side effects for Nuvigil, include diarrhea, headache, insomnia and nausea, according to Cephalon.\nDon't Stay Up Waiting For A Pill To Fight Jet Lag\n\nWhile jet lag may not be health crisis exactly, it sure can be a pain.\nWell, the Food and Drug Administration.\nCephalon soldiered on, giving FDA more data.\nThe medicine is already approved to fight narcolepsy and sleepiness related to shift work.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Solid job reviewing most common side effects and links to other, rare but life threatening problem.", "answer": 1}, {"article": "The beneficial effects of traditional acupuncture, according to the researchers, did not appear to be associated with changes in levels of hormones that trigger menopause and its associated symptoms.\nThe findings were published online March 7 in Acupuncture in Medicine.\nAfter 10 weeks, the women in the traditional acupuncture group had significantly less severe hot flashes and mood swings than those who'd gotten the fake treatment.\nThe research included 53 postmenopausal women, with about half receiving traditional Chinese acupuncture twice a week and the others given sham acupuncture treatments.\nThere were no differences between the two groups in terms of vaginal dryness and urinary tract infection.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "No discussion of any potential harms \u2013 only a discussion of benefits.", "answer": 0}, {"article": "medical personnel.\nThose of us who coach or care for young athletes know by now that an athlete who falls or collides with something during play or seems dazed, dizzy, loses consciousness or complains of head pain should be tested for a concussion, which occurs when the brain is physically jostled within the skull.\nInterestingly, uninjured athletes are almost always faster at reading the numbers during games or practices, because physical exertion sharpens the kind of visual performance being tested.\nIt is still too early to say, however, whether the King-Devick test can replace other, more conventional concussion evaluations for young athletes, including the standardized assessment, despite its shortcomings in this study, Dr. Galetta cautioned.\nresearchers knew that in recent years, trainers working with athletes in sports such as boxing and mixed martial arts, where concussions are common, had begun supplementing the Standardized Assessment with a simple vision exam, known as the King-Devick test, during which someone reads slightly jumbled lines of numbers printed on three cards as quickly as possible.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Quoting a researcher, the story suggests that parents and coaches should \u201cabsolutely consider\u201d using the test. However, the small number of young athletes tested and the testing that occurred under the supervision of research personnel (who won\u2019t be on the sidelines of youth sports games to train parents and volunteers doing this test on their own) all suggest that it would be inappropriate to state that this test has in any way been shown to be safe.\u00a0Only testing in a large number of students with potential injuries, across a range of ages, backgrounds and sports, with attention to measuring cognitive outcomes in a uniform fashion could lead to this test being demonstrated to be\u00a0the\u00a0same or better than current practice. In addition, we\u2019d note that a potential harm of this test is that it could give parents and coaches a false sense of security. There is no evidence that any of this actually prevents\u00a0young athletes from developing long-term cognitive impairment. While this is true for current practice as well as for this new test, seeing children getting tested on the sidelines more frequently might give false reassurance. One could argue that the safest thing\u00a0for a concerned parent is to avoid contact sports that are prone to involve head injuries.", "answer": 0}, {"article": "Human embryonic stem cells are controversial because their creation usually entails the destruction of human embryos, although Advanced Cell Technology is working on a technique to avoid that.\nAfter a year, roughly 95 percent of the patients in all the arms of the trial maintained their vision, meaning their ability to read an eye chart declined by no more than 15 letters, or three lines.\nStill, even starting the trial could be a boost to Advanced Cell, which often makes headlines but has struggled to raise money.\nDr. Peter J. Francis, an associate professor at the Oregon Health and Science University, which will be a site for the trial, says the eye is a good place to test stem cell therapy because it is accessible.\nAlso, he said, there is less chance of rejection of the implanted cells because the eye is shielded somewhat from the body\u2019s immune system.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story cites a company assurance that the new drug is \u201cequally safe\u201d compared with\u00a0its\u00a0FDA-approved competitor. To which we respond:\u00a0How safe is that?\u00a0\u00a0Injecting\u00a0substances into the eye\u00a0is associated with rare but potentially serious risks such as infections of the interior eye. There\u2019s also some evidence that\u00a0Lucentis\u00a0is associated with increased risk of stroke. Does the new drug carry the same\u00a0risks? The story should have provided more details. \u00a0 With over 2000 patients in the trials the company could have reported on the minor and major complications that were observed in the 2 trials.", "answer": 0}, {"article": "What would happen if screening for male infertility was just about as easy as taking a pregnancy test in your home bathroom?\nSeveral other home-based tests are already on the market, but Boston researchers say their version can analyze additional aspects of the sample, checking how well the sperm move (known as motility) as well as their concentration.\nThough it\u2019s as common as female infertility, it often goes unrecognized due to factors like cultural stigma, the high cost and time required for testing, and access to laboratory facilities.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nThe smartphone-based test involves several distinct parts: one, a disposable device on which to place the sample, including a disposable microchip that handles the sample; two, an optical attachment that connects to a smartphone; three, an app that guides the user through each step of testing.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Potential harms aren\u2019t discussed, and there\u2019s a significant one: a man receiving a false-negative test (he believes his sperm count is too low, when it\u2019s actually normal) or a false-positive (his sperm count is low, but a test tells him it\u2019s normal) \u2014 and telling his partner this incorrect information. For a\u00a0couple that\u2019s trying desperately to conceive, that could be crushing news or deceptive false-hope. Any news story about a new screening test should discuss the false-negative and false-positive rates.\nFor example, a story at LiveScience\u00a0captures these well, telling readers that about 98% of people with no training could detect abnormal sperm samples from a fertility clinic with the new device. The sensitivity of the test\u2019s ability to actually detect a sample with a low sperm count was 99.3%, but only 89.4% of normal-sperm-count samples were correctly read by the device. This means more than 10% of men with a normal sperm count might be lead to believe their numbers are abnormal.", "answer": 0}, {"article": "The journal is abstracted and indexed in Biological Abstracts, Current Awareness in Biological Sciences, Chemical Abstracts, Current Contents, Excerpta Medica, Index Medicus, Nutrition Abstracts and Science Citation Index.\nBased on four-month intervention data, the annual projected body weight increase in the prebiotic group would be 3 kilograms (6.6 pounds), within the expected healthy range, whereas the projected increase in the placebo group was 8 kilograms (17.6 pounds), almost triple the expected yearly weight increase.\nImportantly, the researchers show that the prebiotic induced specific gut bacterial shifts compared to placebo.\n\"Powdered fiber, mixed in a water bottle, taken once a day is all we asked the children to change, and we got, what we consider, some pretty exciting results -- it has been fantastic,\" added Raylene A. Reimer, PhD, RD, professor and researcher in the Faculty of Kinesiology at University of Calgary, who led the study.\nThis is the first randomized controlled study to assess comprehensive changes in gut microbial composition with prebiotic intervention in children who are overweight and obese.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "A quote indirectly suggests that the prebiotics are \u201cnon-invasive\u201d but that doesn\u2019t tell us a lot. Bloating and gas are often at least a temporary problem. It would have been useful to know how well children in the study tolerated the supplement.\nAnd if the parents of children with obesity are not changing their diet (avoiding high fructose corn syrup, excessive prepared foods, and overfeeding), and letting the supplement do the work, that\u2019s not teaching kids to eat healthily, which is an unintended consequence.", "answer": 0}, {"article": "Tobias Hartmann, the project's coordinator, said, \"We have known for a while that diet can reduce the risk of developing dementia.\n\"This is exciting because it shows that in the absence of effective drug options, we really have found something that can help slow down some of the most distressing symptoms in very early AD (pre-dementia); especially in those who started the intervention early.\nThe study did not find a significant benefit in broad cognitive function (the study primary endpoint).\nProject coordinator Professor Tobias Hartmann, Saarland University Germany, explained that this is the most likely reason the primary endpoint was not met.\nThe primary outcome parameter was selected to assess the effect on cognitive function (a broad measure of thinking) during 24 months intake of Fortasyn Connect compared with a control product.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "We don\u2019t know the possible risks associated with drinking an amalgam of different food products. And this release provides no insights. Previous studies have suggested that the nutritional product is well tolerated and did not appear to cause any harms. That being said, we think that this should have been noted in the report.", "answer": 0}, {"article": "Send your questions to Julia via the submission form or @juliaoftoronto on Twitter.\nIn many ways, Sarah is a perfect case study in how to think about the benefits and risks of running versus walking.\nAll this research, while illuminating, didn\u2019t offer up any clear conclusions on whether running or walking was better for you overall.\nAnd a lot of running (i.e., ultramarathon training) can well be harmful, while the same is never true for walking.\nSo the answer to the running versus walking question will probably vary from person to person.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The\u00a0story does a very good job of quantifying the potential risks of running and of comparing the likelihood of injury from running to those for walking.", "answer": 1}, {"article": "\"Previous patients got sick, but it wasn't clear at the time whether it was due to the T cells or an infection,\" said pediatric oncologist Stephan Grupp, who oversaw Emily's care at Children's Hospital of Philadelphia. \"Now we know the main reason they were sick was the cells. But now we can intervene. She taught us.\"", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although it discusses the potentially catastrophic side effects of acute treatment,\u00a0the story did not explain that these patients have compromised immune systems following treatment and need ongoing therapy with immunoglobulins for an unknown amount of time. That\u2019s a considerable omission.\nThe New York Times story, which we also reviewed, did a better job on this.\n\u00a0", "answer": 0}, {"article": "Instead, they pass through to the large intestine, where they draw water into the gut and start to ferment.\nUnless you have specific symptoms that a low-FODMAP diet alleviates, Gibson says, \u201cenjoy your FODMAPs!\u201d\n\u201cFollowing strictly the low-FODMAP diet is associated with changes in the microbiota that many would not equate with good health,\u201d says Gibson, who stresses that a low-FODMAP diet should be used to reduce specific symptoms, not as a way to improve health.\nBut there\u2019s a problem with a low-FODMAP diet.\nIf your gut can handle FODMAPs, foods that contain a lot of them can be very good choices \u2014 partly because the fermentation helps your gut biome and partly because the way FODMAPs are digested means you\u2019re absorbing fewer calories than indicated on a FODMAP-rich product\u2019s label.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "This is the strongest aspect of the story and the area where readers are likely to find some value. The story explains that the low-FODMAP diet has drawbacks, since foods high in FODMAPS are thought to stimulate growth of certain bacteria associated with digestive health. We\u2019d add that anything that restricts consumption of fruits and vegetables has the potential to reduce the quality of your diet and potentially impact your health. This is especially true for children. The story rightfully\u00a0stresses that a low-FODMAP diet should be used \u201cto reduce specific symptoms, not as a way to improve health.\u201d", "answer": 1}, {"article": "Hemoglobin A1c levels dropped from 6.5% to a normal level of 6.1%.\nAnd during Victoza treatment, patients needed less and less insulin.\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\nPatients who continued treatment for 24 weeks had further decreases in insulin doses, and lost an average of 10 pounds.\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story pays appropriate attention to potential harms. It notes that the weight loss caused by the drug could be detrimental to thin patients, and that the drug causes\u00a0abdominal pain, nausea, and vomiting.\u00a0\u00a0The study author notes\u00a0that adverse effects cause about 5% of type 2 diabetes patients to stop taking the drug. The story probably should have mentioned that the drug is administered by injection, something which can\u2019t be very appealing to type 1 diabetics who\u00a0may already be giving themselves multiple injections daily or, as in this study, are using insulin pumps that only require a needle to be inserted every few days.", "answer": 1}, {"article": "\"What we found is that kids get home from school around 4 p.m.\nThe researchers conclude that afterschool programs and schools can replace energy dense, unhealthy snacks with peanuts to provide a healthier alternative for children (researchers in the study ensured students did not suffer from nut allergies).\nThe snack was administered after school as students were boarding the school bus to go home.\nFollowing the 12-week intervention, students spent 12 more weeks maintaining the healthy snacking habit.\nParticipants in the study were part of a larger longitudinal study on a school-based obesity intervention program.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release notes that care was taken not to give these snacks to children who had nut allergies.", "answer": 1}, {"article": "\"Because cancer cells are different to healthy ones, they produce a different mixture of chemicals.\nThis study suggests that we may be able detect these differences and use a breath test to indicate which patients are likely to have cancer of the esophagus and stomach, and which do not,\" he explained.\nIn the longer term this could also mean earlier diagnosis and treatment, and better survival,\" Markar said.\n\"At present the only way to diagnose esophageal cancer or stomach cancer is with endoscopy.\n\"A breath test could be used as a noninvasive, first-line test to reduce the number of unnecessary endoscopies.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The test itself\u2013if an exhaled breath is all it involves\u2013is unlikely to carry immediate harms. But with any lab test used to detect disease, the potential harm is if the test fails the patient\u2013by either flagging them as having cancer when they don\u2019t, or flagging them as not having cancer when they do. The first scenario can cause anxiety and lead to extra, unnecessary testing, and the second means the cancer is going untreated. We always hope to see a nod to this in any story about testing, and it\u2019s why we often say \u201cthere is no such thing as a simple medical test.\u201d", "answer": 0}, {"article": "In postpartum depression, the GABA pathway may play a key role in regulating hormones that researchers believe can lead to PPD.\nThe reduction of symptoms in the patients receiving brexanolone injection was maintained throughout the last study visit at Day 30.\nNewswise \u2014 CHAPEL HILL, NC \u2013 UNC researchers say the results from the multi-site phase 2 and 3 trials of brexanolone injection are not only promising, but could change the way postpartum depression (PPD) is treated.\nA unique dose group of brexanolone 60 \u00b5g/kg/hr in one of the studies was not included in the integrated efficacy analysis, but was included in integrated analyses of safety.\nSage Therapeutics is the developer of brexanolone injection and sponsor of the trials.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "The release contains one somewhat vague sentence on harms.\nThe most common (\u226510% of subjects) adverse events following during brexanolone injection administration were headache, dizziness and somnolence.\nReaders would also be interested in details on whether the drug is safe for nursing infants. That\u2019s not mentioned.", "answer": 1}, {"article": "Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 35,000 e-book titles and many iconic reference works, including Gray's Anatomy.\nThe authors, from Cleveland Clinic in the US, say considering radiosurgery earlier on could make a big difference to patients' lives.\nBy considering it earlier as a treatment option, doctors could help improve the lives of patients with TN more quickly.\nIn the research, radiosurgery helped improve the quality of life for patients with trigeminal neuralgia and reduced their depression, which is often exacerbated by the side effects of other treatments.\nThe team plans to analyze the impact of other treatment options and carry out a cost-based analysis to establish the best treatment options for TN.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "It would be most useful to know why radiosurgery is typically a \u201csecond line treatment to be used following the medication\u201d and so one wonders if this is due to the harms involved with this type of surgery which can include fatigue, skin problems, and difficulty swallowing, none of which are mentioned in the news release. At a minimum, if there weren\u2019t any side effects among the patient volunteers, the release could have stated that there weren\u2019t any. Additionally, since the treatment involves radiation and radiation can promote cancer, the study should have mentioned this and why or why not it is an issue with this specific treatment.", "answer": 0}, {"article": "Using the sensor to pinpoint chemical variations, the team found they could not only distinguish between healthy and malignant breath but also identify the four different common tumor types.\nLONDON (Reuters) - An \u201celectronic nose\u201d could be used as a simple breath test to detect lung, breast, bowel and prostate cancers, Israeli scientists said Wednesday.\n\u201cIf we can confirm these initial results in large-scale studies, this new technology could become a simple tool for early diagnosis of cancer along with imaging,\u201d said Abraham Kuten of Technion Israel Institute of Technology.\nTheir findings, published in the British Journal of Cancer, build on earlier research published by scientists at the same institute last year showing that a sensor made with gold nanoparticles could detect lung cancer in breath.\nWhile more work is needed to develop the technology, the early success could lead to the development of a cheap, easy-to-use and portable test to help diagnose cancer earlier.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "", "answer": 2}, {"article": "Kidney stones are small, hard mineral deposits that form inside the kidneys, affecting up to 12 percent of men and seven percent of women.\n\"HCA shows promise as a potential therapy to prevent kidney stones,\" the researchers wrote.\n\"HCA may be preferred as a therapy over CA (potassium citrate).\"\nThis finding could lead to the first advance in the treatment of calcium oxalate stones in 30 years.\nHCA was also tested in human subjects, as seven people took the supplement for three days, allowing researchers to determine that HCA is excreted through urine, a requirement for the supplement to work as a treatment.\n", "question": "Does the news release adequately explain/quantify the harms of the intervention?", "explanation": "This was a tough call. The release notes that some people are unable to tolerate the side effect of citrate and it says that safety studies of hydroxycitrate are needed, but there is no discussion of what potential harms the proposed treatment might pose.", "answer": 0}, {"article": "Dr. Jeffrey Tice, an internist at the University of California, San Francisco, who wrote an editorial accompanying the study, said: \"With hormones, we really were thinking we were preventing a lot of diseases and it was good for the long term.\nOf 10 studies on antidepressants, for instance, the researchers judged only two of the studies to be good, and the rest fair or poor.\nThe researchers found that on average, antidepressants and Catapres each appeared to reduce hot flashes by about one per day, and Neurontin by about two per day.\nFor the other antidepressants, Prozac and Celexa, and for the plant extracts, there was no statistically significant evidence that they worked for hot flashes.\nNone of the drugs or extracts are approved by the Food and Drug Administration to treat hot flashes \u2014 only hormones are approved for that purpose \u2014 but doctors are free to prescribe medicines for any use they see fit, and many recommend the drugs or plant products for hot flashes, based on study findings and their patients' experiences.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Mentions side effects of the non-hormonal treatment under study, as well as the risks associated with hormone replacement therapy. There is no mention of the incidence of these side effects. However, this was a meta-analysis of 43 studies, so side effects varied by medication and each study. ", "answer": 1}, {"article": "So what's going on?\nBut when they looked at the mortality rates in nonsmokers who had never had cancer or heart disease, it also became associated with a higher BMI over time.\nBut the BMI, which is a general measure of body fat, has proven useful for thinking about the health of large groups of people, as in this study.\nAnd all of the people in this study are white, so that's a limitation.\nThat means a person who is 5-foot-8 could weigh 180 pounds and be in that epidemiological sweet spot, according to the NIH's online BMI calculator.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story did a good job describing why some people with low BMI might be at higher risk of dying\u2013 i.e., they may be suffering from cancer or another disease that could cause weight loss.", "answer": 1}, {"article": "\"Here in the U.S., we do things differently,\" he said.\nEven though the ephedra-containing herbal is not readily available in the United States, the M-Y herbal formula is available in many countries besides China, including Korea, Japan, India and Germany, the study authors noted.\nCao and Wang, who specialize in infectious diseases and clinical microbiology, said the herbal recipe -- known as maxingshigan-yinqiaosan (M-Y) -- is easily accessible throughout China and much less expensive than Tamiflu (oseltamivir).\n\"The pandemic influenza 2009 gave us the opportunity to evaluate a standard Chinese herb formula\" designed to target the flu, they added.\nAll three approaches helped to resolve fever sooner than no intervention whatsoever, the authors said, noting it appeared that fever dissipated fastest when M-Y and Tamiflu were given together.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story mentions adverse effects that have been associated with ephedra, one of the constituents of the herbal treatment being tested. It also says that minimal side effects were seen in all treatment groups of this\u00a0study. The story could have\u00a0commented on other possible side effects of herbals, such as potential\u00a0interactions with other medications.", "answer": 1}, {"article": "\"Our idea was to ask, 'What are the most important proteins we could find in Alzheimer's patients?'\nWhile much of the scientific work, including that at Stanford, is promising, Goldstein said all the technologies are a long way from being available in clinics.\nAlthough the studies were small in scale, researchers said the experiment proved that the concept of screening for chemical signals was promising and that the first Alzheimer's blood test might be within reach after further large scale studies.\nBut he said that a test showing the likelihood that the disease will develop will help patients and family members prepare for what lies ahead.\n\"This study shows that the chemical fingerprint found in the blood of these patients was pretty reliable.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "Although the story did acknowledge that there are very few medical treatments for patients once they are diagnosed with Alzheimers\u2019s, it failed to address the burden of such knowledge for the patient and the patient\u2019s family.\u00a0 There could be insurance ramifications, there should likely be\u00a0a consulting component to go hand in hand with the test, and there is the possibility of false positive results.\nThe story did not do an adequate job of addressing the potential harms of this test.", "answer": 0}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nOne woman, a doctor who had been in therapy for years to manage bouts of disabling anxiety, recently began seeing Gaea Logan, a therapist in Austin, Tex., who incorporates mindfulness meditation into her practice.\nThe question, said Linda Barnes, an associate professor of family medicine and pediatrics at the Boston University School of Medicine, is not whether mindfulness meditation will become a sophisticated therapeutic technique or lapse into self-help clich\u00e9.\nOthers, like Dr. Linehan, insist that patients in severe mental distress are the best candidates for mindfulness.\n", "question": "Does the story adequately explain/quantify the harms of the intervention?", "explanation": "The story alludes to the harms of mindfulness mediation for some patients who have had fewer than 3 episodes of depression (according to one study). The story also notes the general harms of a new practice becoming a fad when there are few standardized training programs, and it has not been studied long enough for all conditions for which it is currently being promoted. ", "answer": 1}]